PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Holguin, F; Bleecker, ER; Busse, WW; Calhoun, WJ; Castro, M; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Israel, E; Jarjour, NN; Moore, WC; Peters, SP; Yonas, M; Teague, WG; Wenzel, SE				Holguin, Fernando; Bleecker, Eugene R.; Busse, William W.; Calhoun, William J.; Castro, Mario; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Moore, Wendy C.; Peters, Stephen P.; Yonas, Michael; Teague, W. Gerald; Wenzel, Sally E.			Obesity and asthma: An association modified by age of asthma onset	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe; asthma; obesity; Severe Asthma Research Program	BODY-MASS INDEX; AIRWAY INFLAMMATION; CLUSTER-ANALYSIS; HETEROGENEITY; PHENOTYPES; SEVERITY	Background: Studies of asthma phenotypes have identified obesity as a component of a group characterized by a high proportion of subjects with adult-onset asthma. However, whether age of asthma onset modifies the association between obesity and asthma is unknown. Objectives: We sought to compare the associations between body mass index (BMI) categories with physiological, inflammatory, and clinical parameters across age of asthma onset phenotypes; and to compare the rate of BMI change in relation to asthma duration, by age of onset asthma phenotypes. Methods: From the Severe Asthma Research Program, we defined age of asthma onset as early (< 12 years of age) and late (>= 12 years of age). Comparisons of BMI categories were done within age-of-onset groups, and obesity was also compared across these groups. Multivariable logistic regression analysis was done to evaluate the association between BMI categories with health care use and respiratory symptoms and multivariable linear regression for the association between duration of asthma and weight gain (BMI change per year). An interaction between obesity and age of asthma onset was included in the multivariable analyses. Results: The study population consisted of 1049 subjects, and the median age for asthma onset was 10 years (interquartile range, 4-25 years); 48% had late-onset asthma (>= 12 years of age), and 52% had early-onset asthma (< 12 years of age). Compared with obese subjects with late-onset asthma, obese subjects with early-onset asthma had more airway obstruction, bronchial hyperresponsiveness, and higher odds ratios of ever having 3 or more previous oral steroid tapers per year or intensive care unit admissions for asthma per preceding year (interactions between obesity and age of asthma onset were P =.055 and P =.02, respectively). In subjects with early-onset asthma but not in subjects with late-onset asthma, there was a significant association between increasing BMI and duration of asthma after adjusting for confounders. The interaction between asthma duration and age of asthma onset was a P value of less than .01. Conclusion: Asthmatic subjects are differentially affected by obesity based on whether they had asthma early (< 12 years of age) or later in life. These results highlight the need to understand obesity as a comorbidity that affects specific clinical phenotypes and not all asthma subjects alike. (J Allergy Clin Immunol 2011;127:1486-93.)	[Holguin, Fernando] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA 15260 USA; [Bleecker, Eugene R.; Moore, Wendy C.; Peters, Stephen P.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA; [Busse, William W.; Jarjour, Nizar N.] Univ Wisconsin, Madison, WI 53706 USA; [Calhoun, William J.] Univ Texas Galveston, Div Pulm & Crit Care Med, Galveston, TX 77555 USA; [Castro, Mario] Washington Univ, St Louis, MO USA; [Erzurum, Serpil C.] Cleveland Clin, Cleveland, OH USA; [Fitzpatrick, Anne M.] Emory Univ, Asthma Clin Res Program, Atlanta, GA 30322 USA; [Gaston, Benjamin] Univ Virginia, Dept Pediat, Div Resp Med, Charlottesville, VA USA; [Israel, Elliot] Harvard Univ, Dept Med, Boston, MA USA; [Yonas, Michael] Univ Pittsburgh, Dept Family Med, Pittsburgh, PA 15260 USA; [Teague, W. Gerald] Univ Virginia, Dept Pediat, Div Resp Med, Charlottesville, VA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); Cleveland Clinic Foundation; Emory University; University of Virginia; Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia	Holguin, F (corresponding author), UPMC, Asthma Inst, UPMC Montefiore 9NW,3459 5th Ave, Pittsburgh, PA 15213 USA.	holguinf@upmc.edu		Fitzpatrick, Anne/0000-0002-2933-5926; Calhoun, William/0000-0001-7075-712X	National Institutes of Health [HL-069174]; National Institutes of Health (NIH; National Institute of Allergy and Infectious Diseases [NIAID]; National Heart, Lung, and Blood Institute [NHLBI]; Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception; Asthmatx; Amgen; Genentech; Merck; Aerovance; Biota; Ception Therapeutics; NIH(NHLBI); NIH (NIAID and NHLBI); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146, UL1TR000454, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069174] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH; National Institute of Allergy and Infectious Diseases [NIAID](United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute [NHLBI](United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; Asthmatx; Amgen(Amgen); Genentech(Roche HoldingGenentech); Merck(Merck & Company); Aerovance; Biota; Ception Therapeutics; NIH(NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH (NIAID and NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL-069174.; Disclosure of potential conflict of interest: W. W. Busse has served on the advisory boards for Centocor and Merck; has consulted for AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, GlaxoSmithKline, (GlaxoSmithKline) Amgen, Pfizer, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH; National Institute of Allergy and Infectious Diseases [NIAID] and National Heart, Lung, and Blood Institute [NHLBI]), Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. M. Castro has consulted for Electrocore, NKTT, Schering, Asthmatx, and Cephalon; has served on an advisory board and given talks for Genentech; has given talks for AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received research support from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the NIH, and GlaxoSmithKline; and has received royalties from Elsevier. A. M Fitzpatrick has received research support from the NIH (NHLBI and National Institute of Nursing Research). B. Gaston has served on an advisory board for Gilead. E. Israel has consulted for Abbott, Amgen, Cowen & Co, GlaxoSmithKline, Icagen, MedImmune, Merck, NewMentor, NKT Therapeutics, Ono Pharmaceuticals US, Schering-Plough, and TEVA; has received research support from Aerovance, Amgen, Biota, Ception Therapeutics, Genentech, MedImmune, the NIH, and Novartis; and has provided legal consultation or expert witness testimony on the topic of asthma. N. N. Jarjour has consulted for Asthmatx and Genentech and has received research support from GlaxoSmithKline, Merck, Genentech, and MedImmune. S. P. Peters has received research support from the NIH(NHLBI). W. G. Teague has given talks for Merck and Genentech and has received research support from the NIH (NIAID and NHLBI) and the American Lung Association. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835, DOI 10.1164/ajrccm.164.10.2105033; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Dizier MH, 2001, EUR J HUM GENET, V9, P867, DOI 10.1038/sj.ejhg.5200732; Fahy JV, 1998, CLIN EXP ALLERGY, V28, P1047, DOI 10.1046/j.1365-2222.1998.00330.x; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Holguin F, 2010, J ASTHMA, V47, P55, DOI 10.3109/02770900903318330; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kazaks A, 2005, J ALLERGY CLIN IMMUN, V116, P929, DOI 10.1016/j.jaci.2005.06.005; Lessard A, 2008, CHEST, V134, P317, DOI 10.1378/chest.07-2959; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Srivastava A, 2001, GENET EPIDEMIOL, V21, pS154, DOI 10.1002/gepi.2001.21.s1.s154; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Sutherland TJT, 2008, AM J RESP CRIT CARE, V177, P970, DOI 10.1164/rccm.200711-1738OC; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Todd DC, 2007, CLIN EXP ALLERGY, V37, P1049, DOI 10.1111/j.1365-2222.2007.02748.x; van Veen IH, 2008, ALLERGY, V63, P570, DOI 10.1111/j.1398-9995.2007.01597.x; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	25	252	258	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1486	U249		10.1016/j.jaci.2011.03.036	http://dx.doi.org/10.1016/j.jaci.2011.03.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21624618	Bronze, Green Accepted			2022-12-18	WOS:000291048500026
J	Bilsborough, J; Leung, DYM; Maurer, M; Howell, M; Boguniewcz, M; Yao, L; Storey, H; LeCiel, C; Harder, B; Gross, JA				Bilsborough, J; Leung, DYM; Maurer, M; Howell, M; Boguniewcz, M; Yao, L; Storey, H; LeCiel, C; Harder, B; Gross, JA			IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; pruritus; IL-31; IL-31 receptor A; keratinocytes; macrophages; skin-homing T cells	ACTIVATION-REGULATED CHEMOKINE; MACROPHAGE-DERIVED CHEMOKINE; ALLERGIC DISEASES; CYTOKINE RECEPTOR; THYMUS; KERATINOCYTES; EXPRESSION; TARC	Background: IL-31 is a newly discovered T-cell cytokine that, when overexpressed in mice, results in pruritus and skin dermatitis resembling human atopic dermatitis (AD). Objective: We sought to investigate the expression of IL-31 and IL-31 receptor A (IL-31RA) in skin biopsy specimens and peripheral blood cells from patients with AD and healthy individuals. Methods: Expression of IL-31 and IL-31RA was evaluated in skin biopsy specimens from patients with AD and healthy individuals by means of immunohistochemistry and RT-PCR. IL-31 protein production by skin-homing cutaneous lymphocyte antigen (CLA)-positive T cells was also assessed. Results: IL-31RA protein was expressed by keratinocytes and infiltrating macrophages in skin biopsy specimens from patients with AD. Comparisons between skin from patients with AD and healthy skin showed IL-31RA expression at higher levels on epidermal keratinocytes in AD samples. Infiltrating cells, more numerous in skin from patients with AD compared with that of healthy individuals, expressed IL31 mRNA. Histomorphometric analysis of these cells indicated they were of the lymphocytic lineage, with the majority of cells staining positive for CLA and CD3. IL31 mRNA and protein expression is largely restricted to CD45RO(+) (memory) CLA(+) T cells in peripheral blood of patients with AD and healthy volunteers. Moreover, circulating CLA(+) T cells from patients with AD, but not from patients with psoriasis, are capable of producing I higher levels of IL-31 compared with CLA(+) T cells from healthy individuals. However, the average levels of IL-31 were not significantly different between patients with AD and healthy individuals. Conclusion: We provide evidence that IL-31 expression is associated with CLA(+) T cells and might contribute to the development of AD-induced skin inflammation and pruritus.	ZymoGenet Inc, Dept Autoimmun & Inflammat, Seattle, WA 98102 USA; ZymoGenet Inc, Dept Genet, Seattle, WA 98102 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Zymogenet Inc.; Zymogenet Inc.; National Jewish Health	Bilsborough, J (corresponding author), ZymoGenet Inc, Dept Autoimmun & Inflammat, 1201 Eastlake Ave E, Seattle, WA 98102 USA.	bilsborj@zgi.com		Bilsborough, Janine/0000-0001-6349-0957				Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 1997, J IMMUNOL, V159, P4611; Antunez C, 2004, CLIN EXP ALLERGY, V34, P559, DOI 10.1111/j.1365-2222.2004.1933.x; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Horikawa T, 2002, INT IMMUNOL, V14, P767, DOI 10.1093/intimm/dxf044; Kakinuma T, 2002, CLIN EXP IMMUNOL, V127, P270, DOI 10.1046/j.1365-2249.2002.01727.x; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Nakamura M, 2003, BRIT J DERMATOL, V149, P718, DOI 10.1046/j.1365-2133.2003.05586.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Santamaria-Babi LF, 2004, EUR J DERMATOL, V14, P13; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x	27	252	303	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					418	425		10.1016/j.jaci.2005.10.046	http://dx.doi.org/10.1016/j.jaci.2005.10.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461143	Bronze			2022-12-18	WOS:000235687300024
J	Hunt, J				Hunt, J			Exhaled breath condensate: An evolving tool for noninvasive evaluation of lung disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled breath condensate; exhaled biomarkers; pH; cytokines; hydrogen peroxide; nitrogen oxides; oxidant	HYDROGEN-PEROXIDE; EXPIRED BREATH; OXIDATIVE STRESS; NITRIC-OXIDE; INCREASED NITROTYROSINE; CYSTIC-FIBROSIS; AIR; 8-ISOPROSTANE; CHILDREN; MARKER	Exhaled breath condensate (EBC) contains aerosolized airway lining fluid and volatile compounds that provide noninvasive indications of ongoing biochemical and inflammatory activities in the lung. Rapid increase in interest in EBC has resulted from the recognition that in lung disease this easily sampled fluid has measurable characteristics that differ prominently from health. These assays have provided evidence of airway and lung redox deviation, acid-base status, and degree and type of inflammation in acute and chronic asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, occupational diseases, and cystic fibrosis. Characterized by, uncertain and variable degrees of dilution, EBC does not provide precise assessment of individual solute concentrations within native airway lining fluid. However, it can provide useful information when concentrations differ substantially between health and disease or are based on ratios of solutes found in the sample. Because they can be used to measure the targets of modern therapy, EBC assays are likely to become integral components of future clinical studies, and after further technical work is accomplished, they might be used to diagnose and monitor therapy in individual patients.	Univ Virginia, Div Pediat Resp Med, Charlottesville, VA 22908 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hunt, J (corresponding author), Univ Virginia, Div Pediat Resp Med, Box 800386, Charlottesville, VA 22908 USA.							Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; Antczak Adam, 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P119; BALDWIN SR, 1986, LANCET, V1, P11; Balint B, 2001, EUR RESPIR J, V17, P1201, DOI 10.1183/09031936.01.00072501; Becher G, 1997, Pneumologie, V51 Suppl 2, P456; Carpenter CT, 1998, CHEST, V114, P1653, DOI 10.1378/chest.114.6.1653; Corradi M, 2001, AM J RESP CRIT CARE, V163, P854, DOI 10.1164/ajrccm.163.4.2001108; Cunningham S, 2000, EUR RESPIR J, V15, P955, DOI 10.1034/j.1399-3003.2000.15e24.x; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813, DOI 10.1164/ajrccm.154.3.8810624; DOHLMAN AW, 1993, AM REV RESPIR DIS, V148, P955, DOI 10.1164/ajrccm/148.4_Pt_1.955; Effros RM, 2002, AM J RESP CRIT CARE, V165, P663, DOI 10.1164/ajrccm.165.5.2101018; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; FAIRCHILD CI, 1987, AM IND HYG ASSOC J, V48, P948, DOI 10.1080/15298668791385868; FERRUS L, 1980, RESP PHYSIOL, V39, P367, DOI 10.1016/0034-5687(80)90067-5; GONCHAROVA VA, 1989, SOV MEDITISINA, V5, P22; Groves WA, 1996, AM IND HYG ASSOC J, V57, P257, DOI 10.1202/0002-8894(1996)057<0257:IOOVLT>2.0.CO;2; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; Ho LP, 1999, EUR RESPIR J, V13, P103; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; HUNT J, 2000, AM J RESP CRIT CARE, V161, pA104; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; Iakovleva O A, 1990, Ter Arkh, V62, P102; Jobsis Q, 1998, EUR RESPIR J, V12, P483, DOI 10.1183/09031936.98.12020483; Jobsis Q, 2000, EUR RESPIR J, V16, P95, DOI 10.1034/j.1399-3003.2000.16a17.x; Jobsis Q, 1997, EUR RESPIR J, V10, P519; Jobsis RQ, 2001, MEDIAT INFLAMM, V10, P351; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Loukides S, 1998, AM J RESP CRIT CARE, V158, P991, DOI 10.1164/ajrccm.158.3.9710031; LOUKIDES S, 2002, AM J RESP CRIT CARE, V163, pA723; McRae K., 2001, Journal of Heart and Lung Transplantation, V20, P184, DOI 10.1016/S1053-2498(00)00379-X; Montuschi P, 2000, THORAX, V55, P205, DOI 10.1136/thorax.55.3.205; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Nowak D, 2001, FREE RADICAL BIO MED, V30, P178, DOI 10.1016/S0891-5849(00)00457-3; Papineni RS, 1996, J AEROSOL MED, V10, P105, DOI 10.1089/jam.1997.10.105; PSATHAKIS KE, 2001, AM J RESP CRIT CARE, V163, pA557; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; SCHEIDELER L, 1993, AM REV RESPIR DIS, V148, P778, DOI 10.1164/ajrccm/148.3.778; SIDORENKO GI, 1980, TERAPEVT ARKH, V52, P65; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322	42	252	263	1	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					28	34		10.1067/mai.2002.124966	http://dx.doi.org/10.1067/mai.2002.124966			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110814				2022-12-18	WOS:000176870300006
J	BROIDE, DH; GLEICH, GJ; CUOMO, AJ; COBURN, DA; FEDERMAN, EC; SCHWARTZ, LB; WASSERMAN, SI				BROIDE, DH; GLEICH, GJ; CUOMO, AJ; COBURN, DA; FEDERMAN, EC; SCHWARTZ, LB; WASSERMAN, SI			EVIDENCE OF ONGOING MAST-CELL AND EOSINOPHIL DEGRANULATION IN SYMPTOMATIC ASTHMA AIRWAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; MAST CELL; EOSINOPHIL; HISTAMINE; TRYPTASE; MAJOR BASIC PROTEIN; EOSINOPHIL DERIVED NEUROTOXIN	MAJOR BASIC-PROTEIN; ANTIGEN CHALLENGE; MEDIATOR RELEASE; HISTAMINE-RELEASE; BRONCHOALVEOLAR LAVAGE; BRONCHIAL-ASTHMA; MILD ASTHMA; TRYPTASE; DEXAMETHASONE; GRANULE	To assess whether mast cell and eosinophil (EOS) degranulation occurs in the airway of subjects with moderately symptomatic asthma, we have measured levels of performed mast cell-derived mediators (histamine and tryptase) and EOS-derived mediators (major basic protein and EOS-derived neurotoxin) in bronchoalveolar lavage fluid (BALF) obtained from patients with symptomatic (N = 14) and asymptomatic asthma (N = 9) and patients without asthma (N = 6). Both the FEV1 (1.52 +/- 0.33 L:55% +/- 15% of predicted FEV1) and the forced expiratory flow at 50% (FEF50) (1.11 +/- 0.62 L/sec: 26% +/- 14% of predicted FEF50) in the patients with symptomatic asthma were significantly lower than the corresponding values for FEV1 (3.16 +/- 0.45 L:86% +/- 10% of predicted FEV1) and the FEF50 (4.04 +/- 1.54 L/sec:71% +/- 25% of predicted FEF50) in the patients with asymptomatic asthma. Levels of histamine (4.8 +/- 5.0 ng/ml versus 0.2 +/- 0.2 ng/ml) (p = 0.05), EOS-derived neurotoxin (420.6 +/- 959.4 ng/ml versus 12.6 +/- 7.7 ng/ml) (p = 0.05), major basic protein (31.4 +/- 46.6 ng/ml versus < 9 ng/ml) (p = 0.05), and percent EOSs (10.6% +/- 7.0% versus 1.1% +/- 0.9% of BAL cells) (p = 0.0006) were all significantly elevated in BALF from symptomatic compared to asymptomatic patients with asthma. The elevated levels of tryptase (13.2 +/- 14.8 ng/ml versus 3.9 +/- 3.9 ng/ml) in BALF from symptomatic compared to asymptomatic patients with asthma approximated, but did not reach, statistical significance. Spontaneous histamine release from BAL mast cells of symptomatic patients with asthma was 46% +/- 5% compared to 5% +/- 2% in asymptomatic patients with asthma. In response to antihuman IgE, histamine release from BAL mast cells recovered from asymptomatic patients with asthma increased to 25% +/- 10%, whereas in BAL mast cells of symptomatic patients with asthma, no anti-IgE potentiation of histamine release occurred. This study suggests that mast cell and EOS degranulation is ongoing in the airway of patients with moderately symptomatic asthma.	MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55905 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV RHEUMATOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV ALLERGY, RICHMOND, VA 23298 USA; ALVARADO HOSP, DEPT MED, DIV PULM MED, SAN DIEGO, CA USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV IMMUNOL, RICHMOND, VA 23298 USA	Mayo Clinic; Mayo Clinic; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	BROIDE, DH (corresponding author), UNIV CALIF SAN DIEGO, MED CTR,DEPT MED,DIV ALLERGY & IMMUNOL,H-811-G, 225 DICKINSON ST, SAN DIEGO, CA 92103 USA.			Broide, David/0000-0001-8405-9090	NIAID NIH HHS [AI 17268, AI 29974, AI 20476] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268, R29AI029974, P50AI020476] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P360, DOI 10.1016/S0091-6749(05)80099-5; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOWEN DL, 1988, INFLAMMATION BASIC P, P877; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHRISTIANSEN SC, 1989, AM REV RESPIR DIS, V139, P1125, DOI 10.1164/ajrccm/139.5.1125; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; DAERON M, 1982, J IMMUNOL, V129, P1212; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GUO C-B, 1990, Journal of Allergy and Clinical Immunology, V85, P172; JARJOUR N N, 1989, American Review of Respiratory Disease, V139, pA328; LANG DM, 1986, J ALERGY CLIM IMMUNO, V77, P517; LEE TC, 1984, J BIOL CHEM, V259, P5526; MARQUARDT DL, 1983, J IMMUNOL, V131, P934; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1987, AM REV RESPIR DIS, V135, P562; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SHALIT M, 1988, J IMMUNOL, V141, P821; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SVEDMYR N, 1982, EUR J RESPIR DIS, V63, P48; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	41	252	257	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					637	648		10.1016/0091-6749(91)90158-K	http://dx.doi.org/10.1016/0091-6749(91)90158-K			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1717532				2022-12-18	WOS:A1991GL04900013
J	BARNARD, JH				BARNARD, JH			STUDIES OF 400 HYMENOPTERA STING DEATHS IN UNITED-STATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BARNARD JH, 1967, J ALLERGY, V40, P107, DOI 10.1016/0021-8707(67)90104-9; BARNARD JH, 1966, NEW YORK STATE J MED, V66, P1206; BARNARD JH, 1970, J ALLERGY, V45, P92; BURKE DM, 1954, AMA AM J DIS CHILD, V88, P772, DOI 10.1001/archpedi.1954.02050100774011; HERRERA N, 1962, NY ST J MED, V62, P3560; JELLINGER K, 1961, KLIN WOCHNSCHR, V73, P81; KAILIN E, 1962, PERSONAL COMMUNICATI; MEANS ED, 1972, T AM NEUROL ASSOC, V97, P308; OCONNOR R, 1964, ANN ALLERGY, V22, P385; PATTERSON R, 1960, JAMA, V173, P303; WILLIAMS W H Jr, 1951, J S C Med Assoc, V47, P187	11	252	261	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					259	264		10.1016/0091-6749(73)90044-4	http://dx.doi.org/10.1016/0091-6749(73)90044-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4746790				2022-12-18	WOS:A1973R208700002
J	Pieper, K; Grimbacher, B; Eibel, H				Pieper, Kathrin; Grimbacher, Bodo; Eibel, Hermann			B-cell biology and development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; B lymphocyte; immunodeficiency; development; humoral immunity; autoimmunity; tolerance	X-LINKED AGAMMAGLOBULINEMIA; AUTOSOMAL-RECESSIVE FORM; CANNABINOID RECEPTOR 2; COMMON VARIABLE IMMUNODEFICIENCY; ANTIBODY-DEFICIENCY SYNDROME; CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; LIVED PLASMA-CELLS; MARGINAL ZONE; BONE-MARROW	B cells develop from hematopoietic precursor cells in an ordered maturation and selection process. Extensive studies with many different mouse mutants provided fundamental insights into this process. However, the characterization of genetic defects causing primary immunodeficiencies was essential in understanding human B-cell biology. Defects in pre-B-cell receptor components or in downstream signaling proteins, such as Bruton tyrosine kinase and B-cell linker protein, arrest development at the pre-B-cell stage. Defects in survival-regulating proteins, such as B-cell activator of the TNF-alpha family receptor (BAFF-R) or caspase recruitment domain-containing protein 11 (CARD11), interrupt maturation and prevent differentiation of transitional B cells into marginal zone and follicular B cells. Mature B-cell subsets, immune responses, and memory B-cell and plasma cell development are disturbed by mutations affecting Toll-like receptor signaling, B-cell antigen receptor coreceptors (eg, CD19), or enzymes responsible for immunoglobulin class-switch recombination. Transgenic mouse models helped to identify key regulatory mechanisms, such as receptor editing and clonal anergy, preventing the activation of B cells expressing antibodies recognizing autoantigens. Nevertheless, the combination of susceptible genetic backgrounds with the rescue of self-reactive B cells by T cells allows the generation of autoreactive clones found in patients with many autoimmune diseases and even in those with primary immunodeficiencies. The rapid progress of functional genomic research is expected to foster the development of new tools that specifically target dysfunctional B lymphocytes to treat autoimmunity, B-cell malignancies, and immunodeficiency. (J Allergy Clin Immunol 2013; 131: 959-71.)	[Pieper, Kathrin; Grimbacher, Bodo; Eibel, Hermann] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany; [Pieper, Kathrin] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany	University of Freiburg; University of Freiburg	Eibel, H (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Engesser Str 4, D-79106 Freiburg, Germany.	hermann.eibel@uniklinik-freiburg.de		de la Rosa (nee Pieper), Kathrin/0000-0003-4809-3157	German Cancer Research fund [108935]; Federal Ministry of Education and Research [BMBF 01 EO 18 0803]; American Academy of Allergy, Asthma Immunology; European Community; Marie Curie Excellence Grant; German Cancer Research Fund	German Cancer Research fund; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); American Academy of Allergy, Asthma Immunology; European Community(European Commission); Marie Curie Excellence Grant(European Commission); German Cancer Research Fund	K. P. and H. E. are supported by the German Cancer Research fund through grant 108935. B. G. and H. E. are supported by Federal Ministry of Education and Research through grant no. BMBF 01 EO 18 0803.; Disclosure of potential conflict of interest: K. Pieper and H. Eibel have received grants from the German Cancer Research Fund. B. Grimbacher has received a speaker's honorarium from the American Academy of Allergy, Asthma & Immunology and has received grants from the European Community 6th and 7th Framework Programmes, the Marie Curie Excellence Grant, and the German Cancer Research Fund.	Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Balazs M, 2002, IMMUNITY, V17, P341, DOI 10.1016/S1074-7613(02)00389-8; Basu S, 2011, J IMMUNOL, V187, P5720, DOI 10.4049/jimmunol.1102195; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Becker-Herman S, 2011, J EXP MED, V208, P2033, DOI 10.1084/jem.20110200; Benson MJ, 2008, J IMMUNOL, V180, P3655, DOI 10.4049/jimmunol.180.6.3655; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bortnick A, 2012, J IMMUNOL, V188, P5389, DOI 10.4049/jimmunol.1102808; BRINK R, 1995, EUR J IMMUNOL, V25, P1980, DOI 10.1002/eji.1830250727; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; Burnet FM, 1949, PRODUCTION ANTIBODIE; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Cassese G, 2003, J IMMUNOL, V171, P1684, DOI 10.4049/jimmunol.171.4.1684; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Chan TD, 2012, IMMUNITY, V37, P893, DOI 10.1016/j.immuni.2012.07.017; Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; Darce JR, 2007, J IMMUNOL, V179, P7276, DOI 10.4049/jimmunol.179.11.7276; Derry JM, 1994, CELL, V79, P922; Dobbs AK, 2007, J IMMUNOL, V179, P2055, DOI 10.4049/jimmunol.179.4.2055; Ehrlich P, 1900, P R SOC LONDON, V66; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Ferrari S, 2007, J EXP MED, V204, P2047, DOI 10.1084/jem.20070264; Good-Jacobson KL, 2012, J IMMUNOL, V188, P4217, DOI 10.4049/jimmunol.1102885; GOODNOW CC, 1991, NATURE, V352, P532, DOI 10.1038/352532a0; GOODNOW CC, 1989, COLD SPRING HARB SYM, V54, P907, DOI 10.1101/SQB.1989.054.01.106; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Granados EL, 2002, J CLIN INVEST, V110, P1029, DOI 10.1172/JCI200215658; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; Hashimoto S, 1996, BLOOD, V88, P561, DOI 10.1182/blood.V88.2.561.bloodjournal882561; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Hutcheson J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4086; Isnardi I, 2008, IMMUNITY, V29, P746, DOI 10.1016/j.immuni.2008.09.015; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Jiang C, 2011, J IMMUNOL, V186, P6136, DOI 10.4049/jimmunol.1001931; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kanegane H, 2007, GENES IMMUN, V8, P663, DOI 10.1038/sj.gene.6364431; Kavli B, 2005, J EXP MED, V201, P2011, DOI 10.1084/jem.20050042; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Khan WN, 2009, J IMMUNOL, V183, P3561, DOI 10.4049/jimmunol.0800933; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Manz RA, 1998, INT IMMUNOL, V10, P1703, DOI 10.1093/intimm/10.11.1703; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Melamed D, 1997, P NATL ACAD SCI USA, V94, P9267, DOI 10.1073/pnas.94.17.9267; Melchers F, 2005, NAT REV IMMUNOL, V5, P578, DOI 10.1038/nri1649; Mihalci SA, 2010, J IMMUNOL, V185, P1045, DOI 10.4049/jimmunol.1001120; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Muppidi JR, 2011, J EXP MED, V208, P1941, DOI 10.1084/jem.20111083; Nair JR, 2011, J IMMUNOL, V187, P1243, DOI 10.4049/jimmunol.1100016; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Ng YS, 2004, J EXP MED, V200, P927, DOI 10.1084/jem.20040920; Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185; Njau MN, 2012, J IMMUNOL, V189, P2758, DOI 10.4049/jimmunol.1102728; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; Pereira JP, 2009, NAT IMMUNOL, V10, P403, DOI 10.1038/ni.1710; Pereira JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009277; Peron S, 2008, J EXP MED, V205, P2465, DOI 10.1084/jem.20080789; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Racine R, 2011, J IMMUNOL, V186, P1011, DOI 10.4049/jimmunol.1002836; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Reimold AM, 1996, J EXP MED, V183, P393, DOI 10.1084/jem.183.2.393; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rizzi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010838; Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHLOMCHIK M, 1987, J EXP MED, V165, P970, DOI 10.1084/jem.165.4.970; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; SRINIVASAPPA J, 1986, J VIROL, V57, P397, DOI 10.1128/JVI.57.1.397-401.1986; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Stohl W, 2012, ARTHRITIS RHEUM-US, V64, P2328, DOI 10.1002/art.34400; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; ten Boekel E, 1998, IMMUNITY, V8, P199; Teng G, 2007, ANNU REV GENET, V41, P107, DOI 10.1146/annurev.genet.41.110306.130340; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Todd EM, 2011, J IMMUNOL, V187, P3015, DOI 10.4049/jimmunol.1101033; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Tonegawa S, 1987, Tanpakushitsu Kakusan Koso, V32, P239; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Wang Y, 2002, AM J MED GENET, V108, P333, DOI 10.1002/ajmg.10296; Warde Nick, 2010, Nat Rev Rheumatol, V6, P246, DOI 10.1038/nrrheum.2010.53; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Wehrli N, 2001, EUR J IMMUNOL, V31, P609, DOI 10.1002/1521-4141(200102)31:2<609::AID-IMMU609>3.0.CO;2-9; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Weller S, 2008, J EXP MED, V205, P1331, DOI 10.1084/jem.20071555; Weller S, 2012, BLOOD, V120, P4992, DOI 10.1182/blood-2012-07-440776; Westerberg L, 2005, BLOOD, V105, P1144, DOI 10.1182/blood-2004-03-1003; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715; Willenbrock K, 2005, EUR J IMMUNOL, V35, P3002, DOI 10.1002/eji.200535134; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yatomi Y, 2000, BLOOD, V96, P3431; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231; YUAN D, 1984, J IMMUNOL, V132, P1566; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zikherman J, 2012, NATURE, V489, P160, DOI 10.1038/nature11311; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333; Ziring D, 2006, IMMUNOGENETICS, V58, P714, DOI 10.1007/s00251-006-0138-x	150	251	263	2	87	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					959	971		10.1016/j.jaci.2013.01.046	http://dx.doi.org/10.1016/j.jaci.2013.01.046			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23465663	Bronze			2022-12-18	WOS:000317187200002
J	Fox, AT; Sasieni, P; du Toit, G; Syed, H; Lack, G				Fox, Adam T.; Sasieni, Peter; du Toit, George; Syed, Huma; Lack, Gideon			Household peanut consumption as a risk factor for the development of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; children; food allergy; peanut allergy; sensitization; peanut consumption; cutaneous exposure; environmental exposure	FOOD CHALLENGES; NUT ALLERGY; FOLLOW-UP; EXPOSURE; CHILDREN; IGE; FEATURES; ANTIGEN; INFANCY; ATOPY	Background: Most children with peanut allergy (PA) react on first known oral exposure to peanut. Recent data suggest cutaneous exposure as a route of sensitization. Objectives: This study aimed to establish the relevant route of peanut exposure in the development of allergy. Methods: Questionnaires were administered to children with PA and to high-risk controls (with egg allergy) and controls without allergy. Questionnaires were completed before subjects were aware of their PA status, avoiding recall bias. Questionnaires recorded maternal peanut consumption during pregnancy, breast-feeding, and the first year of life. Peanut consumption was determined among all household members, allowing quantification of environmental household exposure (household peanut). Results: Median weekly household peanut in the 133 PA cases was significantly elevated (18.8 g) compared with 150 controls without allergy (6.9 g) and 160 high-risk controls (1.9 g). There were no differences in infant peanut consumption between groups. Differences in maternal peanut consumption during pregnancy (and lactation) were significant but become nonsignificant after adjusting for household peanut. A dose-response relationship was observed between environmental (nonoral) peanut exposure and the development of PA, which was strongest for peanut butter. Early oral exposure to peanut in infants with high environmental peanut exposure may have had a protective effect against the development of PA. Conclusions: High levels of environmental exposure to peanut during infancy appear to promote sensitization, whereas low levels may be protective in atopic children. No effect of maternal peanut consumption during pregnancy or lactation is observed, supporting the hypothesis that peanut sensitization occurs as a result of environmental exposure. (J Allergy Clin Immunol 2009;123:417-23.)	[Fox, Adam T.; du Toit, George; Lack, Gideon] Kings Coll London, MRC, London, England; [Sasieni, Peter; Syed, Huma] Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med, London, England	University of London; King's College London; University of London; Queen Mary University London	Lack, G (corresponding author), St Thomas Hosp, Dept Pediat Allergy, Lambeth Palace Rd, London SE1 7EH, England.	gideon.lack@kel.ac.uk	Fox, Adam/O-3547-2015	Fox, Adam/0000-0002-3533-9798; Lack, Gideon/0000-0001-7350-4021; Sasieni, Peter/0000-0003-1509-8744; Du Toit, George/0000-0002-0321-2928	Food Standards Agency [T07043]; Aimwell Foundation; Medical Research Council [G0400503B] Funding Source: researchfish	Food Standards Agency; Aimwell Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by it research grant from the Food Standards Agency (United Kingdom; T07043). This grant supported the project costs, including the salary of A.T.F. over the study duration. G.L.'s salary was supported in part by the Aimwell Foundation.	Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Committee on Toxicity of Chemicals in Food, 1998, PEAN ALL; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Ewan PW, 1996, BRIT MED J, V312, P1074; Fox AT, 2006, S AFR J CLIN NUTR, V19, P154; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; HUSBY S, 1994, J IMMUNOL, V152, P4663; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; NGAN J, 1978, J IMMUNOL, V120, P861; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Venter C, 2006, J HUM NUTR DIET, V19, P129, DOI 10.1111/j.1365-277X.2006.00677.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	30	251	253	7	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					417	423		10.1016/j.jaci.2008.12.014	http://dx.doi.org/10.1016/j.jaci.2008.12.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203660				2022-12-18	WOS:000263495000020
J	Crystal-Peters, J; Neslusan, C; Crown, WH; Torres, A				Crystal-Peters, J; Neslusan, C; Crown, WH; Torres, A			Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; administrative claims analysis		Background: Although asthma and allergic rhinitis commonly occur together, the nature of the association has yet to be determined. Treatments for one condition could potentially alleviate the coexisting condition. Objective: Patients with both allergic rhinitis and asthma were studied to test the hypothesis that treating allergic rhinitis reduces health care utilization for co-morbid asthma. Methods: A retrospective cohort study was carried out with 1994-1995 MarketScan claims data. The cohort was limited to patients with both allergic rhinitis and asthma, aged 12 to 60 years, who were continuously enrolled and had no evidence of chronic obstructive pulmonary disease. Allergic rhinitis treatment and asthma-related events (hospitalizations and emergency department visits) were identified. An incidence density ratio (IDR) associated with exposure to allergic rhinitis treatment was calculated. A multivariate Poisson regression was estimated, and the parameter estimates were transformed into IDRs for each explanatory variable. An allergic rhinitis treatment indicator was included in all regressions. Results: The study sample population consisted of 4944 patients with allergic asthma, approximately 73% of whom were treated for their allergic rhinitis. Asthma-related events occurred more often for the untreated group compared with the treated group, 6.6 % compared with 1.3 %. An IDR of 0.49 for the treatment group (P =.001) indicates that the risk of an asthma-related event for the treated group was about half that for the untreated group. Conclusion: In summary, those who were treated for allergic rhinitis have a significantly lower risk of subsequent asthma-related events (emergency department visits or hospitalizations) than those who were not treated.	MEDSTAT Grp, Washington, DC 20008 USA		Crystal-Peters, J (corresponding author), MEDSTAT Grp, 4401 Connecticut Ave NW,Suite 400, Washington, DC 20008 USA.							Altemeier WA, 2000, PEDIATR ANN, V29, P391, DOI 10.3928/0090-4481-20000701-03; ALTEMEIER WA, 2001, PEDIATR ANN, V29, P398; *AM AC ALL ASTHM I, FAST FACTS STAT ASTH; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, pS424, DOI 10.1016/S0091-6749(98)70236-2; Bykowsky M, 2000, J S C Med Assoc, V96, P229; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS352, DOI 10.1016/S0091-6749(98)70218-0; Fireman P, 2000, ALLERGY ASTHMA PROC, V21, P45, DOI 10.2500/108854100778248935; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; HALPERN M, 1996, AM J RESP CRIT CARE, V153, pA860; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; Lemanske RF, 1998, J ALLERGY CLIN IMMUN, V101, pS392, DOI 10.1016/S0091-6749(98)70228-3; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; RoweJones JM, 1997, ALLERGY, V52, P20, DOI 10.1111/j.1398-9995.1997.tb04818.x; Selvin S., 1996, STAT ANAL EPIDEMIOLO; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, pS605, DOI 10.1067/mai.2000.106150; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; *STAT CORP, 1997, STAT STAT SOFTW REL; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	21	251	263	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					57	62		10.1067/mai.2002.120554	http://dx.doi.org/10.1067/mai.2002.120554			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799366				2022-12-18	WOS:000173739300009
J	MAY, CD				MAY, CD			OBJECTIVE CLINICAL AND LABORATORY STUDIES OF IMMEDIATE HYPERSENSITIVITY REACTIONS TO FOODS IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80220	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BOCK SA, IN PRESS; Bryan W T, 1971, Otolaryngol Clin North Am, V4, P523; FISHMAN WH, 1970, METHODEN ENZYMATISCH, P886; GALANT SP, 1973, CLIN ALLERGY, V3, P363, DOI 10.1111/j.1365-2222.1973.tb01343.x; HAWKINS D, 1972, J IMMUNOL, V108, P310; HENSON PM, 1971, J IMMUNOL, V107, P1535; HULLIGER L, 1967, LANCET, V1, P1304; LOVELESS MH, 1950, J ALLERGY, V21, P489, DOI 10.1016/0021-8707(50)90097-9; Maslansky L, 1971, Conn Med, V35, P5; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MAY CD, 1970, P SOC EXP BIOL MED, V133, P758; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X	13	251	253	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					500	515		10.1016/0091-6749(76)90194-9	http://dx.doi.org/10.1016/0091-6749(76)90194-9			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	61222				2022-12-18	WOS:A1976CH21000007
J	Wahn, U; Tabar, A; Kuna, P; Halken, S; Montagut, A; de Beaumont, O; Le Gall, M				Wahn, Ulrich; Tabar, Ana; Kuna, Piotr; Halken, Susanne; Montagut, Armelle; de Beaumont, Olivier; Le Gall, Martine		SLIT Study Grp	Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinoconjunctivitis; grass pollen allergy; optimal dose; sublingual tablet; sublingual immunotherapy; children; adolescents	DOUBLE-BLIND; FOLLOW-UP; RHINITIS; ASTHMA; CHILDREN; SYMPTOMS; COLLABORATION; METAANALYSIS	Background: The efficacy and safety of the 300-index of reactivity (IR) dose of 5-grass-pollen sublingual immunotherapy (SLIT) tablets (Stallergenes, Antony, France) have been demonstrated for the treatment of hay fever in adults. Objective: We sought to assess the efficacy and safety of this tablet in children and adolescents with grass pollen-related allergic rhinitis. Methods: In this multinational, randomized, double-blind, placebo-controlled study, 278 children (5-17 years of age) with grass pollen-related rhinoconjunctivitis (confirmed by means of a positive grass pollen skin prick test response and serum-specific IgE measurement) received once-daily SLIT tablets or placebo. Treatment was initiated 4 months before the estimated pollen season and continued throughout the season. The primary outcome was the rhinoconjunctivitis total symptom score (RTSS), a sum of 6 individual symptom scores: sneezing, runny nose, itchy nose, nasal congestion, watery eyes, and itchy eyes. Secondary end points included rescue medication intake, individual scores, and safety. Results: The intent-to-treat population included 266 children (mean age, 10.9 +/- 3.22 years). The RTSS for the 300-IR group was highly significantly different from that of the placebo group (P = .001). The 300-IR group showed a mean improvement for the RTSS of 28.0% over that seen with placebo and a median improvement of 39.3%. Significant differences between the 300-IR and placebo groups were also observed regarding rescue medication score and proportion of days using rescue medication during the pollen season (P = .0064 and P = .0146, respectively). Adverse events were generally mild or moderate in intensity and expected. No serious side effects were reported. Conclusion: Five-grass-pollen SLIT tablets (300 IR) reduce both symptom scores and rescue medication use in children and adolescents with grass pollen-related rhinoconjunctivitis. (J Allergy Clin Immunol 2009;123:160-6.)	[Wahn, Ulrich] Charite Campus Virchow Klinikum, Berlin Childrens Hosp, D-13353 Berlin, Germany; [Tabar, Ana] Hosp Virgen del Camino, Secc Alergia, Pamplona, Spain; [Kuna, Piotr] Med Univ Lodz, Div Internal Med Asthma & Allergy, Barlicki Univ Hosp, Lodz, Poland; [Halken, Susanne] Odense Univ Denmark, Dept Pediat, Odense, Denmark; [Montagut, Armelle] Delta Consultants, Meylan, France; [de Beaumont, Olivier; Le Gall, Martine] Stallergenes SA, Dept Med, Antony, France	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; Medical University Lodz; University of Southern Denmark; Stallergenes Greer	Wahn, U (corresponding author), Charite Campus Virchow Klinikum, Berlin Childrens Hosp, Augustenburger Pl 1, D-13353 Berlin, Germany.	ulrich.wahn@charite.de		Halken, Susanne/0000-0003-0161-8278; Kuna, Piotr/0000-0003-2401-0070	Stallergenes	Stallergenes	Supported by Stallergenes.	Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blaiss MS, 2004, CURR MED RES OPIN, V20, P1937, DOI 10.1185/030079904X13266; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Carr WW, 2008, ALLERGY ASTHMA PROC, V29, P14, DOI 10.2500/aap2008.29.3074; Cox L, 2008, CURR ALLERGY ASTHM R, V8, P102, DOI 10.1007/s11882-008-0019-5; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Hrabina M., 2008, Clinical and Experimental Allergy Reviews, V8, P7, DOI 10.1111/j.1472-9733.2008.00126.x; Hrabina M, 2007, INT ARCH ALLERGY IMM, V142, P11, DOI 10.1159/000095994; Ibanez MD, 2007, PEDIAT ALLERG IMM-UK, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Malling HJ, 1998, ALLERGY, V53, P461; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Moingeon P, 2008, INT ARCH ALLERGY IMM, V146, P338, DOI 10.1159/000121468; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Roeder E, 2008, PEDIAT ALLERG IMM-UK, V19, P197, DOI 10.1111/j.1399-3038.2007.00648.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	33	250	255	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					160	166		10.1016/j.jaci.2008.10.009	http://dx.doi.org/10.1016/j.jaci.2008.10.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19046761	Bronze			2022-12-18	WOS:000262793900026
J	Bush, RK; Prochnau, JJ				Bush, RK; Prochnau, JJ			Alternaria-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alternaria; asthma; allergens; aerobiology	HUMANIZED MONOCLONAL-ANTIBODY; NUTRITION EXAMINATION SURVEY; SCHOOL-AGE-CHILDREN; 2ND NATIONAL-HEALTH; HOUSE-DUST MITE; FUNGAL ALLERGENS; CHILDHOOD ASTHMA; MOLECULAR-CLONING; IGE ANTIBODY; RISK-FACTOR	Acute, severe asthma attacks can be precipitated by a variety of stimuli including exposure to aeroallergens, viral respiratory infections, pollutants, and occupational chemicals. Alternaria is a major aeroallergen in many parts of the world. Sensitivity to Alternaria has been increasingly recognized as a risk factor for the development and persistence of asthma, asthma severity, and potentially fatal asthma exacerbations. We present the case of a patient with IgE-mediated sensitivity to Alternaria who developed an acute, life-threatening asthma attack during the peak Alternaria season. We describe the aerobiology, pathophysiobiology, diagnosis, and treatment options for patients with Alternaria-induced asthma.	William S Middleton VA Hosp, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bush, RK (corresponding author), William S Middleton VA Hosp, 2500 Overlook Terrace, Madison, WI 53705 USA.							ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114, DOI 10.1159/000237521; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; Bush RK, 2002, MED CLIN N AM, V86, P1113, DOI 10.1016/S0025-7125(02)00036-6; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; BUSH RK, 2001, ENV ASTHMA, P69; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2003, MIDDLETONS ALLERGY P, P1175; CANTANI A, 1988, ALLERGOL IMMUNOPATH, V16, P1; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Esch R, 2003, MIDDLETONS ALLERGY P, P539; Floyer J., 1745, VIOLENT ASTHMA VISIT, V3rd Edn; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564, DOI 10.1164/ajrccm.160.2.9809038; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6, DOI 10.1001/jama.1930.02710270008002; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; JARJOUR NN, 2003, MIDDLETONS ALLERGY P, P1257; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kenyon N, 2001, CLIN REV ALLERG IMMU, V20, P271, DOI 10.1385/CRIAI:20:3:271; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; Seear M, 1997, AM J RESP CRIT CARE, V155, P364, DOI 10.1164/ajrccm.155.1.9001337; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; VIJAY HM, 1999, ALLERGENS ALLERGEN I, P113; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2491::AID-IMMU2491&gt;3.0.CO;2-R; Werner HA, 2001, CHEST, V119, P1913, DOI 10.1378/chest.119.6.1913	51	250	259	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					227	234		10.1016/j.jaci.2003.11.023	http://dx.doi.org/10.1016/j.jaci.2003.11.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767434				2022-12-18	WOS:000188885700007
J	Bresciani, M; Paradis, L; Des Roches, A; Vernhet, H; Vachier, I; Godard, P; Bousquet, J; Chanez, P				Bresciani, M; Paradis, L; Des Roches, A; Vernhet, H; Vachier, I; Godard, P; Bousquet, J; Chanez, P			Rhinosinusitis in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; computed tomography; severe asthma; eosinophils; oral corticosteroids	COMPUTED-TOMOGRAPHY; CHRONIC SINUSITIS; INFLAMMATION; NASAL; ABNORMALITIES; EOSINOPHILIA; ANATOMY; SURGERY; CT	Background: Chronic rhinosinusitis is a common comorbidity of asthma, However, sinonasal Involvement in severe steroid-dependent asthma is still undefined. Objective: The aim of the study was to evaluate chronic rhinosinusitis In 35 patients with severe steroid-dependent asthma by using a clinical score and coronal computed tomography (CT) scanning. Methods: Thirty-five subjects (16 female subjects) with severe asthma requiring daily doses of oral corticosteroids were compared with 34 patients (19 female patients) with mild-to-moderate asthma, Sinonasal involvement was studied by using clinical and CT scores. Airflow obstruction, therapy requirement, and asthma triggering factors were carefully assessed, Results: The proportion of patients with symptoms of rhinosinusitis was similar in both groups of asthmatic subjects (74% in patients with severe steroid-dependent asthma and 70% in patients with mild-to-moderate asthma), All subjects with steroid-dependent asthma versus 88% of subjects with mild-to-moderate asthma had abnormal CT scan results, The clinical (P <.05) and CT scan (P <.0005) severity scores were higher in the subjects with severe steroid-dependent asthma, In both groups the CT scan scores were correlated to the clinical scores (P <.0001 and (P<.006), but only in the mild-to-moderate group were both scores correlated with high significance (P <.002 and P <.0005) to the absolute number of blood eosinophils. Conclusion: Frequency of rhinosinusitis in patients with mild-to-moderate or severe steroid-dependent asthma is similar; however, sinonasal involvement, as evaluated by clinical symptoms and CT scan imaging, is significantly greater in the patients with severe steroid-dependent asthma than in those with mild-to-moderate asthma.	CHU Montpellier, Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France; CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier 5, France; CHU Montpellier, Hop Arnaud de Villeneuve, Serv Radiol, F-34295 Montpellier 5, France	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Chanez, P (corresponding author), CHU Montpellier, Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France.		Vachier, Isabelle/AAV-5731-2020; Bousquet, Jean/O-4221-2019	Vachier, Isabelle/0000-0003-2730-5165; chanez, pascal/0000-0003-4059-0917				[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BABBEL RW, 1991, SEMIN ULTRASOUND CT, V12, P526; Bachert C., 1997, Acta Oto-Rhino-Laryngologica Belgica, V51, P209; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Bhattacharyya N, 1999, LARYNGOSCOPE, V109, P1055, DOI 10.1097/00005537-199907000-00008; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CALHOUN KH, 1991, JAMA-J AM MED ASSOC, V265, P3152; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; de Benedictis FM, 1999, CHEST, V115, P550, DOI 10.1378/chest.115.2.550; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; DUVOISIN B, 1991, NEURORADIOLOGY, V33, P403, DOI 10.1007/BF00598612; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; GLEICH GJ, 1991, LUNG, P581; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Hoover GE, 1997, J ALLERGY CLIN IMMUN, V100, P185, DOI 10.1016/S0091-6749(97)70223-9; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; LUND VJ, 1991, J LARYNGOL OTOL, V105, P832, DOI 10.1017/S0022215100117463; Messerklinger W, 1967, Acta Otolaryngol, V63, P176, DOI 10.3109/00016486709128748; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V272, P852; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P147, DOI 10.1177/019459988609400203; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; Vachier I, 1998, AM J RESP CRIT CARE, V158, P963, DOI 10.1164/ajrccm.158.3.9710085; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; *WHO NHLBI, 1995, PUBL WHO NHLBI; ZIMMERMAN B, 1987, J ALLERGY CLIN IMMUN, V80, P268, DOI 10.1016/0091-6749(87)90029-7; Zinreich SJ, 1998, AM J MED SCI, V316, P2, DOI 10.1016/S0002-9629(15)40365-9; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863, DOI 10.1177/01945998901030S505; 1995, ANN OTOL RHINOL LARY, V104, P7	38	250	257	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					73	80		10.1067/mai.2001.111593	http://dx.doi.org/10.1067/mai.2001.111593			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149994				2022-12-18	WOS:000166533300013
J	INGRAM, JM; SPORIK, R; ROSE, G; HONSINGER, R; CHAPMAN, MD; PLATTSMILLS, TAE				INGRAM, JM; SPORIK, R; ROSE, G; HONSINGER, R; CHAPMAN, MD; PLATTSMILLS, TAE			QUANTITATIVE ASSESSMENT OF EXPOSURE TO DOG (CAN-F-1) AND CAT (FEL-D-1) ALLERGENS - RELATION TO SENSITIZATION AND ASTHMA AMONG CHILDREN LIVING IN LOS-ALAMOS, NEW-MEXICO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; DOG; CAT; DUST MITE; ALLERGEN; ALTITUDE	HOUSE-DUST MITE; D-I; ENVIRONMENTAL EXPOSURE; IGE ANTIBODIES; UNITED-STATES; P-I; AEROALLERGENS; POPULATION; PREVALENCE; CHILDHOOD	Background: Our objective was to identify the allergens associated with asthma among schoolchildren in an area of the United States where dust mite growth is expected to be pool: Los Alamos, N.M., was chosen because it has low I rainfall and is at high altitude (7200 feet), making it very dry. One hundred eleven children (12 to 14 years old) from the middle school who had been previously classified according to bronchial hyperreactivity to histamine (BHR) were studied. Methods: Sera were assayed for IgE antibodies to mite, cat dog, cockroach, Russian thistle, and grass pollen, with both CRP system fluoroimmunoassay (Kabi Pharmacia, Uppsala, Sweden) and conventional RAST. Allergens were measured in dust samples from 109 homes with true-site assays for mite (Der p I and Der f I), cat (Fel d Ij, dog (Can f Ij, and cockroach (Bla g 2). Results: Concentrations of dog and cat allergens were elevated in almost all houses with pets but were also high in a significant proportion of the houses without pets. Levels of mite allergen were less than 2 mu g/gm in 95% of the houses, and cockroach was undetectable in all but two of the houses. Among the 21 with BHR who had symptoms, 67% had IgE antibody to dog and 62% had IgE antibody to cat. For these allergens IgE antibody was strongly associated with asthma (p < 0.001). By contrast, the presence of IgE antibody to mite, cockroach, or gas pollen wets not significantly associated with asthma. Conclusion: The high prevalence of IgE antibody to cat and dog allergens among these children is in keeping with the presence of cat and/or dog allergen in most of the houses. Furthermore, sensitization (as judged by IgE antibodies) to cat and clog allergens was strongly associated with asthma. On the other hand, no clear relationship was found between sensitization ol symptoms and the current level of allergen in individual houses. The results show that in this mite-and cockroach-free environment sensitization to domestic animals was the most significant association with asthma.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV ASTHMA & ALLERG DIS, CHARLOTTESVILLE, VA 22908 USA; GREAT ORMOND ST HOSP CHILDREN, RESP UNIT, LONDON, ENGLAND	University of Virginia; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Platts-Mills, Thomas/0000-0002-1263-329X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565, U01AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-34607, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; LIN RY, 1993, ANN ALLERGY, V71, P33; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MOYER DB, 1985, ANN ALLERGY, V55, P680; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OHMAN JL, 1987, J ALLERGY CLIN IMMUN, V79, P955, DOI 10.1016/0091-6749(87)90246-6; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; ROSE G, 1994, J ALLERGY CLIN IMMUN, V93, P229; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P32; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SMITH JM, 1969, BRIT MED J, V2, P723, DOI 10.1136/bmj.2.5659.723; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1995, IN PRESS AM J RES CR; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P181	28	250	253	3	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					449	456		10.1016/S0091-6749(95)70286-5	http://dx.doi.org/10.1016/S0091-6749(95)70286-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560654				2022-12-18	WOS:A1995TA09500003
J	LAM, S; WONG, R; YEUNG, M				LAM, S; WONG, R; YEUNG, M			NONSPECIFIC BRONCHIAL REACTIVITY IN OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LAM, S (corresponding author), UNIV BRITISH COLUMBIA, VANCOUVER GEN HOSP, DEPT MED, VANCOUVER V5Z 1M9, BC, CANADA.							[Anonymous], 1965, LANCET, V1, P775; BOUHUYS A, 1970, J CLIN INVEST, V49, P106, DOI 10.1172/JCI106209; CADE JF, 1971, AUST NZ J MED, V1, P22, DOI 10.1111/j.1445-5994.1971.tb02256.x; CHANYEUNG M, 1976, AM REV RESPIR DIS, V114, P1027; CHANYEUNG M, 1976, CAN MED ASSOC J, V114, P433; CHANYEUNG M, 1978, CAN MED ASSOC J, V118, P1271; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CHANYEUNG M, UNPUBLISHED; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P1; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DEVRIES, 1964, BRONCHITIS, V2, P167; GANDEVIA B, 1963, BRIT J IND MED, V20, P204; ITKIN IH, 1967, 10 P ASP EMPH C, P243; OREHEK J, 1976, B EUR PHYSIOPATH RES, V12, P565; PAIN MCF, 1972, MED J AUSTRALIA, V1, P522, DOI 10.5694/j.1326-5377.1972.tb46926.x; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5	21	250	250	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					28	34		10.1016/0091-6749(79)90158-1	http://dx.doi.org/10.1016/0091-6749(79)90158-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	758339				2022-12-18	WOS:A1979GE11000004
J	Chan, K; Puck, JM				Chan, K; Puck, JM			Development of population-based newborn screening for severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SCID; newborn screening; TREC; T-cell receptor excision circle; T-cell maturation; early intervention; primary immunodeficiency; cost-effectiveness; bone marrow transplant; dried blood spots	STEM-CELL TRANSPLANTATION; THYMIC FUNCTION; GENE-THERAPY; MUTATIONS; CD45; AGE; EXPRESSION; DISEASES; INFANT; OUTPUT	Background: Severe combined immunodeficiency (SCID) is a treatable, inherited lack of cellular and Immoral immunity caused by diverse mutations in several different genes and leading to death in infancy unless immune reconstitution is provided. Currently no population screening exists for SCID, but early diagnosis would improve outcome. Objective: Because all patients with SCID make few or no T cells, we asked whether the absence of T-cell receptor excision circles (TRECs), DNA episomes in newly formed T cells, could identify SCID regardless of genotype. Methods: DNA isolated from dried blood spots was assayed by real-time PCR to quantitate TRECs. Control PCR was performed on a segment of the P-actin gene. After pilot studies with adult and cord blood control subjects, blood from SCID patients was spotted onto filters and tested, followed by screening of actual blood spots from the Maryland Newborn Screening Program. Finally, newborn blood spots were recovered and tested from 2 infants after their diagnosis of SCID. Results: In contrast to filters from the newborn screening program, which had a mean of 1020 TRECs in two 3-mm punches, samples from 23 infants with SCID had < 30 TRECs. The newborn screening filter was retrieved from a state laboratory for one of these infants plus another infant who had died of SCID previously; although both samples had detectable R-actin DNA, neither had TRECs. Conclusion: TRECs are a stable analyte that can identify T-cell lymphopenia in newborn dried blood spots so that infants with SCID can receive early, life-saving treatment.	NHGRI, NIH, Bethesda, MD 20892 USA; Yale Univ, Sch Med Epidemiol & Publ Hlth, New Haven, CT 06520 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yale University	Puck, JM (corresponding author), NHGRI, NIH, 49 Convent Dr,Bldg 49,Room 4A14, Bethesda, MD 20892 USA.	JPuck@mail.nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000010] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; ALTMAN PL, 1961, BLOOD OTHER BODY FLU, P126; [Anonymous], 1999, PRIMARY IMMUNODEFICI; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Belmont J.W., 2003, METABOLIC MOL BASES, P4751; Bertrand Y, 2002, BONE MARROW TRANSPL, V29, P759, DOI 10.1038/sj.bmt.1703531; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Buckley RH, 2002, IMMUNOL REV, V185, P206, DOI 10.1034/j.1600-065X.2002.18517.x; Carpenter KH, 2002, CLIN CHIM ACTA, V322, P1, DOI 10.1016/S0009-8981(02)00135-3; Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a; Centers for Disease Control and Prevention (CDC), 2004, MMWR-MORBID MORTAL W, V52, P1; Chinen J, 2004, J ALLERGY CLIN IMMUN, V113, P595, DOI 10.1016/j.jaci.2004.01.765; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cooper Max D, 2003, Hematology Am Soc Hematol Educ Program, P314; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; de Villartay JP, 2003, CURR OPIN IMMUNOL, V15, P592, DOI 10.1016/S0952-7915(03)00101-8; Dobrowolski SF, 2003, MOL GENET METAB, V78, P100, DOI 10.1016/S1096-7192(02)00231-7; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Fanos JH, 2001, AM J MED GENET, V98, P46, DOI 10.1002/1096-8628(20010101)98:1<46::AID-AJMG1008>3.3.CO;2-B; Gilroy RK, 2004, BLOOD, V103, P1171, DOI 10.1182/blood-2003-04-1187; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; HACIENBEYABINA S, 2002, NEW ENGL J MED, V288, P669; Hazenberg MD, 2001, J MOL MED, V79, P631, DOI 10.1007/s001090100271; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kalman L, 2004, GENET MED, V6, P16, DOI 10.1097/01.GIM.0000105752.80592.A3; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; Kung C, 2000, NAT MED, V6, P343; Levy HL, 2000, ANNU REV GENOM HUM G, V1, P139, DOI 10.1146/annurev.genom.1.1.139; Markert ML, 2003, BLOOD, V102, P1121, DOI 10.1182/blood-2002-08-2545; MERYASH DL, 1981, NEW ENGL J MED, V304, P294, DOI 10.1056/NEJM198101293040510; Mwaba P, 2003, LANCET, V362, P1459, DOI 10.1016/S0140-6736(03)14693-4; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Pignata C, 1996, AM J MED GENET, V65, P167, DOI 10.1002/(SICI)1096-8628(19961016)65:2<167::AID-AJMG17>3.0.CO;2-O; Puck JM, 1997, BLOOD, V89, P1968; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Schonland SO, 2003, BLOOD, V102, P1428, DOI 10.1182/blood-2002-11-3591; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Tangsinmankong N, 1999, J ALLERGY CLIN IMMUN, V103, P1222, DOI 10.1016/S0091-6749(99)70207-1; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; Wagener JS, 2003, CURR OPIN PEDIATR, V15, P309, DOI 10.1097/00008480-200306000-00015; Wilcken Bridget, 2003, Paediatr Respir Rev, V4, P272, DOI 10.1016/S1526-0542(03)00084-8; WILSON JMG, 1968, WHO CHRON, V22, P473; ZHANG YH, 1994, BIOCHEM MED METAB B, V52, P27, DOI 10.1006/bmmb.1994.1030	51	249	265	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					391	398		10.1016/j.jaci.2004.10.012	http://dx.doi.org/10.1016/j.jaci.2004.10.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696101	Green Published			2022-12-18	WOS:000227043600029
J	Kaplan, AP				Kaplan, AP			Chronic urticaria: Pathogenesis and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chronic urticaria; skin; anaphylaxis; hives; autoimmune	FC-EPSILON-RI; CHRONIC IDIOPATHIC URTICARIA; AFFINITY IGE RECEPTOR; HISTAMINE-RELEASE; HELICOBACTER-PYLORI; ALPHA AUTOANTIBODIES; BASOPHILS; DIPHENHYDRAMINE; AUTOIMMUNITY; CYCLOSPORINE	Patients previously designated as having chronic idiopathic urticaria are now divided into 2 groups: 40% to 50% with chronic autoimmune urticaria, and the remainder with chronic idiopathic urticaria. Patients in both groups may have concomitant angioedema (approximately 40%). The autoimmune subgroup has an association with antithyroid antibodies and is caused by IgG antibody to the a subunit of the IgE receptor (35% to 40%), usually reactive with unoccupied IgE receptors, or IgG antibody to IgE (5% to 10%). Complement activation augments histamine secretion by release of C5a. The IgG subclasses that appear to be pathogenic are IgG(1), IgG(3), and, to a lesser degree, IgG(4), but not IgG(2). Histology of chronic urticaria (both subtypes) reveals a perivascular non-necrotizing infiltrate of CD4(+) lymphocytes consisting of a mixture of T(H)1 and T(H)2 subtypes, plus monocytes, neutrophils, eosinophils, and basophils. These cells are recruited as a result of interactions with C5a, cell priming cytokines, chemokines, and adhesion molecules. Suggested therapy for patients with severe disease involves the use of high-dose hydroxyzine or diphenhydramine when nonsedating antihistamines are ineffective, supplemented by H-2 antagonists and leukotriene antagonists. The most severe patient may require protracted treatment with low-dose alternate-day steroid or cyclosporine. Cyclosporine can be steroid-sparing when side effects are encountered or when use of steroids is relatively contraindicated. Careful monitoring of blood pressure, BUN, creatinine, and urinalysis is required.	Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med Allergy & Clin Immunol, Charleston, SC USA	Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Pulm Med, Suite 812-CSB,96 Jonathan Lucas St, Charleston, SC USA.	kaplana@musc.edu						Becker H, 1998, HAUTARZT, V49, P907, DOI 10.1007/s001050050846; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; CASOLMO V, 1993, J IMMUNOL, V151, P5562; Confino-Cohen R, 2002, J ALLERGY CLIN IMMUN, V109, P349, DOI 10.1067/mai.2002.121314; Di Campli C, 1998, DIGEST DIS SCI, V43, P1226, DOI 10.1023/A:1018851623109; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 2003, ALLERGY, V58, P802, DOI 10.1034/j.1398-9995.2003.00195.x; Ferrer M, 2002, INT ARCH ALLERGY IMM, V129, P254, DOI 10.1159/000066772; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; FRADIN MS, 1991, J AM ACAD DERMATOL, V25, P1065, DOI 10.1016/0190-9622(91)70308-O; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Grattan CEH, 1997, CLIN EXP ALLERGY, V27, P1417, DOI 10.1111/j.1365-2222.1997.tb02986.x; GRATTAN CEH, 1988, BRIT J DERMATOL, V119, P179, DOI 10.1111/j.1365-2133.1988.tb03199.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Haas N, 1998, INT ARCH ALLERGY IMM, V115, P210, DOI 10.1159/000023902; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hidvegi B, 2001, INT ARCH ALLERGY IMM, V126, P167, DOI 10.1159/000049508; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; Horn MP, 2001, FASEB J, V15, P2268, DOI 10.1096/fj.00-0890hyp; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Kaplan AP, 1999, CAN J ALLERGY CLIN I, V4, P286; Kaplan Ap, 2003, ALLERGY PRINCIPLES P, P1537; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2003, J ALLERGY CLIN IMMUN, V112, P218, DOI 10.1067/mai.2003.1605; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Lee KH, 2002, J INVEST DERMATOL, V118, P658, DOI 10.1046/j.1523-1747.2002.01733.x; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; Liutu M, 1998, INT J DERMATOL, V37, P515, DOI 10.1046/j.1365-4362.1998.00328.x; LOPEZ LR, 1984, J ALLERGY CLIN IMMUN, V73, P600, DOI 10.1016/0091-6749(84)90518-9; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Pachlopnik JM, 2004, J AUTOIMMUN, V22, P43, DOI 10.1016/j.jaut.2003.09.007; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Poon E, 1999, BRIT J DERMATOL, V140, P667; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SCHUYDER B, 1999, INT ARCH ALLERGY IMM, V119, P60; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; TORBI E, 1997, ALLERGY, V52, P312; VASECCHI R, 1998, ACTA DERM-VENEREOL, V78, P440; Verster JC, 2003, J ALLERGY CLIN IMMUN, V111, P623, DOI 10.1067/mai.2003.63; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939; Wedi B, 1998, INT ARCH ALLERGY IMM, V116, P288, DOI 10.1159/000023958; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Ying S, 1999, J IMMUNOL, V163, P3976; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	58	249	272	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					465	474		10.1016/j.jaci.2004.02.049	http://dx.doi.org/10.1016/j.jaci.2004.02.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356542				2022-12-18	WOS:000223799600001
J	Adelroth, E; Rak, S; Haahtela, T; Aasand, G; Rosenhall, L; Zetterstrom, O; Byrne, A; Champain, K; Thirlwell, J; Della Cioppa, G; Sandstrom, T				Adelroth, E; Rak, S; Haahtela, T; Aasand, G; Rosenhall, L; Zetterstrom, O; Byrne, A; Champain, K; Thirlwell, J; Della Cioppa, G; Sandstrom, T			Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; allergy; IgE; anti-IgE; recombinant humanized mAb-E25	MONOCLONAL-ANTIBODY; ASTHMATIC SUBJECTS; IMMUNOTHERAPY; RHINOCONJUNCTIVITIS; CORTICOSTEROIDS; ACTIVATION; RESPONSES; RECEPTOR; TRIALS; LUNG	Background: Allergic rhinitis is a common condition often requiring treatment. Objective: We evaluated whether recombinant humanized (rhu)mAb-E25, a recombinant humanized construct of a murine antibody that binds to circulating IgE, could control symptoms and reduce intake of concomitant medication in seasonal allergic rhinitis (SAR) induced by birch pollen if given subcutaneously in a dose schedule predicted to reduce serum free IgE levels below 25 ng/mL. Methods: We randomly assigned 251 adult subjects with a history of SAR and a positive skin test response to birch pollen to receive 300 mg of rhumAb-E25 or placebo given 2 or 3 times during the season, depending on baseline IgE levels. The primary efficacy variable was the subject's average daily nasal symptom severity score (sneezing, itching, runny, and stuffy nose) from diary data collected over the double-blind treatment period. Secondary efficacy variables included the average number of rescue antihistamine tablets per day, the proportion of days with any SAR medication use, and rhinoconjunctivitis-specific quality of life (QOL), Results: Significant between-treatment differences in favor of rhumAb-E25 were observed in average daily nasal symptom severity scores, the average number of tablets of rescue antihistamines per day, the proportion of days with any SAR medication use, and all domains of QOL. Serum-free IgE levels were markedly lower in rhumAb-E25-treated subjects and were associated with clinical effectiveness. Recombinant humanized mAb-E25 was well tolerated. No anti-rhumAb-E25 antibodies mere detected. Conclusion: Compared with placebo, rhumAb-E25 was safe and effective in controlling birch pollen-induced SAR symptoms, with Less concomitant medication use and improved QOL. This study shows the therapeutic potential of anti-IgE antibody in SAR.	Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden; Sahlgrens Hosp, Dept Allergy, Gothenburg, Sweden; Helsinki Univ Hosp, Dept Allergy, Helsinki, Finland; Kongsberg Sykehus, ENT Clin, Kongsberg, Norway; Huddinge Hosp, Dept Resp Med & Allergy, Stockholm, Sweden; Linkoping Univ Hosp, Allergy Ctr, S-58185 Linkoping, Sweden; Novartis Horsham Res Ctr, Horsham, W Sussex, England	Umea University; Sahlgrenska University Hospital; University of Helsinki; Helsinki University Central Hospital; Linkoping University; Novartis	Adelroth, E (corresponding author), Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden.							AGRESTI A, 1996, INTRO CATEGORICAL DA, P188; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BOUSQUET J, 1993, CLIN EXP ALLERGY, V23, P484; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Burney P, 1996, EUR RESPIR J, V9, P687; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023, DOI 10.1164/ajrccm.160.3.9810012; FOUCARD T, 1991, ALLERGY, V46, P20; Frick O.L., 1987, BASIC CLIN IMMUNOL, P197; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MABRY RL, 1993, AM J OTOLARYNG, V14, P379, DOI 10.1016/0196-0709(93)90110-S; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; PRESTA LG, 1993, J IMMUNOL, V151, P2623; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; WUTRICH B, 1989, INT ARCH ALLER A IMM, V90, P3	28	249	260	2	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					253	259		10.1067/mai.2000.108310	http://dx.doi.org/10.1067/mai.2000.108310			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932067				2022-12-18	WOS:000088708100006
J	GOSSET, P; TSICOPOULOS, A; WALLAERT, B; VANNIMENUS, C; JOSEPH, M; TONNEL, AB; CAPRON, A				GOSSET, P; TSICOPOULOS, A; WALLAERT, B; VANNIMENUS, C; JOSEPH, M; TONNEL, AB; CAPRON, A			INCREASED SECRETION OF TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-6 BY ALVEOLAR MACROPHAGES CONSECUTIVE TO THE DEVELOPMENT OF THE LATE ASTHMATIC REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TUMOR NECROSIS FACTOR; INTERLEUKIN-1-BETA; INTERLEUKIN-6; ALVEOLAR MACROPHAGES; LATE ASTHMATIC REACTION; ASTHMA	PLATELET-ACTIVATING FACTOR; COLONY-STIMULATING FACTOR; BRONCHIAL-ASTHMA; HUMAN-MONOCYTES; GROWTH-FACTORS; NEUTROPHILS; IGE; EOSINOPHILS; RAT; PROVOCATION	The late asthmatic reaction (LAR), consecutive to bronchial allergen challenge, is characterized both by the influx of various cells in proximal and distal airways and by the enhancement of bronchial hyperresponsiveness. However, the exact conditions for the development of the inflammatory reaction during the LAR remain to be specified. Since monokines play a key role in inflammatory processes, particularly in the lung, the production of tumor necrosis factor-alpha (TNF-alpha), interleukin; 1-beta (IL-1-beta) and interleukin-6 (IL-6) by alveolar macrophages (AM), collected 18 to 20 hours after exposure to allergen, was evaluated in 15 allergic subjects with asthma submitted to a challenge test with Dermatophagoides pteronyssinus (N = 6) or with wheat flour (N = 9) and in three healthy subjects. After bronchial provocation test, four patients presented no bronchial response (group 1), and six patients, a single early reaction (group 2). In contrast, five patients developed successively an immediate plus a late response (group 3). The monokine production was compared to that from nine allergic subjects with asthma studied at baseline (group 0) and from 11 unchallenged healthy subjects (control subjects). Measurements of cytokines were evaluated for TNF-alpha and IL-1-beta by a specific immunoradiometric assay, whereas IL-6 levels were appreciated by the proliferation of 7TD1 cells. No detectable amounts of TNF-alpha, IL-1-beta, and IL-6 were in bronchial alveolar lavage fluid, even after a tenfold concentration. In contrast, a significant increase of TNF-alpha (10,642 +/- 3127 U/ml) and IL-6 (1250 +/- 427 U/ml) concentrations was noted in AM supernatants from patients exhibiting an LAR (group 3) compared to cells recovered from groups 2, 1, and 0 and to challenged or unchallenged control subjects (805 +/- 244, 995 +/- 521, 1269 +/- 524, 688 +/- 85, and 445 +/- 74 pg of TNF-alpha per milliliter, respectively; 190 +/- 64, 114 +/- 91, 242 +/- 95, 80 +/- 9, and 54 +/- 19 U/ml of IL-6 per milliliter, respectively). No modification of IL-1-beta contents could be detected between the different groups. A significant correlation was detected between concentrations of TNF and IL-6 (r = 0.92; p < 0.001). These results demonstrate TNF-alpha and IL-6 secretion by AM consecutively to the development of LAR in allergic subjects with asthma, confirming that AMs are activated after allergen challenge. The release of monokines suggests that AMs not only participate in the ongoing inflammatory process occurring in the bronchial tree but also in the more distal airways of patients exposed to the allergen and developing an LAR.	INST PASTEUR,CNRS 624,INSERM,UM167,CIBP,F-59019 LILLE,FRANCE; CHR LILLE,HOP CALMETTE,SERV PNEUMOL & IMMUNOALLERGOL,F-59037 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	GOSSET, P (corresponding author), INST PASTEUR,CJF 90-06,BP 245,F-59019 LILLE,FRANCE.		Gosset, Philippe/C-6174-2018; Tsicopoulos, Anne/C-2260-2019	Gosset, Philippe/0000-0002-4043-6429; Tsicopoulos, Anne/0000-0002-1579-2763				AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CANNISTRA SA, 1987, J CLIN INVEST, V79, P1720, DOI 10.1172/JCI113012; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON M, 1981, J IMMUNOL, V126, P2087; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DEBS RJ, 1988, J IMMUNOL, V140, P3482; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUBOIS C, 1989, J IMMUNOL, V143, P964; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; GOSSET P, 1988, AM REV RESPIR DIS, V138, P40, DOI 10.1164/ajrccm/138.1.40; GOSSET P, 1989, J ALLERGY CLIN IMMUN, V83, P222; GUERNE PA, 1990, J IMMUNOL, V144, P499; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; HUTSON PA, 1990, AM REV RESPIR DIS, V141, P535, DOI 10.1164/ajrccm/141.3.535; JOSEPH M, 1983, NATURE, V303, P810, DOI 10.1038/303810a0; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; OHNO I, 1990, AM J RESP CELL MOL, V3, P285, DOI 10.1165/ajrcmb/3.4.285; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; RANKIN JA, 1984, J IMMUNOL, V132, P1993; RICH EA, 1989, AM REV RESPIR DIS, V139, P1010, DOI 10.1164/ajrccm/139.4.1010; ROSENBLUM MG, 1989, CRIT REV IMMUNOL, V9, P21; ROUBIN R, 1987, CLIN EXP IMMUNOL, V70, P484; TONNEL AB, 1983, LANCET, V1, P1406; VALONE FH, 1988, J IMMUNOL, V141, P3945; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; WARREN JS, 1988, AM J PATHOL, V130, P489; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	42	249	252	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					561	571		10.1016/0091-6749(91)90149-I	http://dx.doi.org/10.1016/0091-6749(91)90149-I			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918723				2022-12-18	WOS:A1991GL04900004
J	Hruz, P; Straumann, A; Bussmann, C; Heer, P; Simon, HU; Zwahlen, M; Beglinger, C; Schoepfer, AM				Hruz, Petr; Straumann, Alex; Bussmann, Christian; Heer, Pius; Simon, Hans-Uwe; Zwahlen, Marcel; Beglinger, Christoph; Schoepfer, Alain M.		Swiss EoE Study Grp	Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Hruz, Petr; Straumann, Alex; Beglinger, Christoph] Univ Basel Hosp, Dept Gastroenterol & Hepatol, Basel, Switzerland; [Bussmann, Christian] Kantonsspital, Dept Pathol, Luzern, Switzerland; [Zwahlen, Marcel] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland; [Schoepfer, Alain M.] Univ Lausanne Hosp, CHUV, Dept Gastroenterol & Hepatol, Lausanne, Switzerland	University of Basel; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital; University of Bern; University of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hruz, P (corresponding author), Univ Basel Hosp, Dept Gastroenterol & Hepatol, Basel, Switzerland.	phruz@uhbs.ch	Simon, Hans-Uwe/AAU-7410-2020; Zwahlen, Marcel/AFF-8559-2022	Simon, Hans-Uwe/0000-0002-9404-7736; Zwahlen, Marcel/0000-0002-6772-6346; Hruz, Petr/0000-0003-2767-0445				Ahuja V, 2010, J DIGEST DIS, V11, P134, DOI 10.1111/j.1751-2980.2010.00429.x; Croese J, 2003, GASTROINTEST ENDOSC, V58, P516, DOI 10.1067/S0016-5107(03)01870-4; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Kapel RC, 2008, GASTROENTEROLOGY, V134, P1316, DOI 10.1053/j.gastro.2008.02.016; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Prasad GA, 2009, CLIN GASTROENTEROL H, V7, P1055, DOI 10.1016/j.cgh.2009.06.023; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Vanderheyden AD, 2007, ARCH PATHOL LAB MED, V131, P777; Veerappan GR, 2009, CLIN GASTROENTEROL H, V7, P420, DOI 10.1016/j.cgh.2008.10.009	9	248	257	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1349	1350		10.1016/j.jaci.2011.09.013	http://dx.doi.org/10.1016/j.jaci.2011.09.013			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22019091				2022-12-18	WOS:000298342700027
J	Dykewicz, MS; Hamilos, DL				Dykewicz, Mark S.; Hamilos, Daniel L.			Rhinitis and sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; sinusitis; rhinosinusitis; allergic; fungal sinusitis; nasal polyposis	CHRONIC RHINOSINUSITIS; ALLERGIC RHINITIS; NONALLERGIC RHINITIS; BRONCHIAL RESPONSIVENESS; EOSINOPHILIA SYNDROME; COMPUTED-TOMOGRAPHY; MOMETASONE FUROATE; EPITHELIAL-CELLS; AMPHOTERICIN-B; NASAL POLYPS	Rhinitis and sinusitis are among the most common medical conditions and are frequently associated. In Western societies an estimated 10% to 25% of the population have allergic rhinitis, with 30 to 60 million persons being affected annually in the United States. It is estimated that sinusitis affects 31 million patients annually in the United States. Both rhinitis and sinusitis can significantly decrease quality of life, aggravate comorbid conditions, and require significant direct medical expenditures. Both conditions also create even greater indirect costs to society by causing lost work and school days and reduced workplace productivity and school learning. Management of allergic rhinitis involves avoidance, many pharmacologic options, and, in appropriately selected patients, allergen immunotherapy. Various types of nonallergic rhinitis are treated with avoidance measures and a more limited repertoire of medications. For purposes of this review, sinusitis and rhinosinusitis are synonymous terms. An acute upper respiratory illness of less than approximately 7 days' duration is most commonly caused by viral illness (viral rhinosinusitis), whereas acute bacterial sinusitis becomes more likely beyond 7 to 10 days. Although the mainstay of management of acute bacterial sinusitis is antibiotics, treatment of chronic sinusitis is less straightforward because only some chronic sinusitis cases have an infectious basis. Chronic rhinosinusitis (CRS) has been subdivided into 3 types, namely CRS without nasal polyps, CRS with nasal polyps, and allergic fungal rhinosinusitis. Depending on the type of CRS present, a variety of medical and surgical approaches might be required. (J Allergy Clin Immunol 2010;125:S103-15.)	[Dykewicz, Mark S.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med Res,Dept Inter, Allergy & Immunol Unit,Sect Pulm Crit Care Allerg, Winston Salem, NC 27157 USA; [Hamilos, Daniel L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA	Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Dykewicz, MS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med Res,Dept Inter, Allergy & Immunol Unit,Sect Pulm Crit Care Allerg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dykewicz@wfubmc.edu			Merck; Flight Attendant Medical Research Institute	Merck(Merck & Company); Flight Attendant Medical Research Institute	Disclosure of potential conflict of interest: M. S. Dykewicz is an advisor for Alcon, Boehringer Ingelheim, and Ista; is on the speakers' bureau for Merck and Sanofi-Aventis; is on the Board of Directors for the American Board of Allergy and Immunology; is on the Board of Directors and is a member of the Rhinitis Committee for the American Academy of Allergy, Asthma & Immunology; and is Vice Chair and on the Committee on Rhinitis and Sinusitis for the American College of Allergy, Asthma & Immunology. D. L. Hamilos has received research support from Merck and the Flight Attendant Medical Research Institute and has served an as expert witness on the topics of anaphylaxis and occupational asthma.	Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948, DOI 10.1016/S0091-6749(99)70073-4; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Alobid I, 2004, CURR ALLERGY ASTHM R, V4, P208, DOI 10.1007/s11882-004-0028-y; Anon JB, 2004, OTOLARYNG HEAD NECK, V130, P1, DOI 10.1016/j.otohns.2003.12.003; Barbero GJ, 1996, OTOLARYNG CLIN N AM, V29, P27; Baroody Fuad M, 2007, Clin Allergy Immunol, V20, P103; Benitez P, 2006, LARYNGOSCOPE, V116, P770, DOI 10.1097/01.mlg.0000205218.37514.0f; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bernstein Joel M, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P39, DOI 10.1097/00020840-200502000-00010; Berrettini S, 1999, ALLERGY, V54, P242, DOI 10.1034/j.1398-9995.1999.00813.x; Bhattacharyya N, 2003, AM J RHINOL, V17, P27, DOI 10.1177/194589240301700106; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Chambers DW, 1997, LARYNGOSCOPE, V107, P504, DOI 10.1097/00005537-199704000-00014; COREY JP, 1992, OTOLARYNG CLIN N AM, V25, P225; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Danese M, 1997, J RADIOL, V78, P651; DRAKELEE AB, 1982, INT ARCH ALLER A IMM, V69, P268, DOI 10.1159/000233182; Ebbens FA, 2006, J ALLERGY CLIN IMMUN, V118, P1149, DOI 10.1016/j.jaci.2006.07.058; Ellegard EK, 2006, IMMUNOL ALLERGY CLIN, V26, P119, DOI 10.1016/j.iac.2005.10.007; Ellis AK, 2006, CURR ALLERGY ASTHM R, V6, P215, DOI 10.1007/s11882-006-0037-0; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Gilbert C, 2005, DRUG SAFETY, V28, P707, DOI 10.2165/00002018-200528080-00005; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P1; Hamilos DL, 1996, ALLERGY ASTHMA PROC, V17, P293, DOI 10.2500/108854196778662200; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Harvey RJ, 2007, RHINOLOGY, V45, P3; Heppt W, 2004, CLIN EXP ALLERGY, V34, P1105, DOI 10.1111/j.1365-2222.2004.01990.x; Hickner JM, 2001, ANN INTERN MED, V134, P498, DOI 10.7326/0003-4819-134-6-200103200-00017; Hopkins C, 2007, OTOLARYNG HEAD NECK, V137, P555, DOI 10.1016/j.otohns.2007.02.004; Jakobsen J, 2000, ACTA OTO-LARYNGOL, P158; Jang YJ, 2006, AM J RHINOL, V20, P634, DOI 10.2500/ajr.2006.20.2899; Jani AL, 2005, J ASTHMA, V42, P1, DOI 10.1081/JAS-200044744; Jones NS, 1997, CLIN OTOLARYNGOL, V22, P47, DOI 10.1046/j.1365-2273.1997.00862.x; Jones NS, 2004, CURR ALLERGY ASTHM R, V4, P187, DOI 10.1007/s11882-004-0025-1; Kay DJ, 2001, AM J RHINOL, V15, P249, DOI 10.1177/194589240101500406; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; Knipping S, 2007, OTOLARYNG HEAD NECK, V136, P57, DOI 10.1016/j.otohns.2006.08.025; Kramer MF, 2004, AM J OTOLARYNG, V25, P173, DOI 10.1016/j.amjoto.2003.12.004; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; Lee JT, 2006, AM J RHINOL, V20, P278, DOI 10.2500/ajr.2006.20.2857; Lohrmann C, 2006, J COMPUT ASSIST TOMO, V30, P122, DOI 10.1097/01.rct.0000191134.67674.c6; Lusk RP, 1996, OTOLARYNG CLIN N AM, V29, P75; Malekzadeh S, 2002, OTOLARYNG HEAD NECK, V127, P190, DOI 10.1067/mhn.2002.126800; Marple BF, 1998, AM J RHINOL, V12, P263, DOI 10.2500/105065898781390037; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; MONERETVAUTRIN DA, 1990, ANN ALLERGY, V64, P513; Moore EJ, 2001, AM J RHINOL, V15, P355, DOI 10.1177/194589240101500601; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Ponikau JU, 2005, CURR ALLERGY ASTHM R, V5, P472, DOI 10.1007/s11882-005-0028-6; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Psaltis AJ, 2007, LARYNGOSCOPE, V117, P2030, DOI 10.1097/MLG.0b013e31812e01ab; Ramadan Hassan H, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P183; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; Rosbe KW, 1998, AM J RHINOL, V12, P167, DOI 10.2500/105065898781390208; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Rosenwasser L, 2007, ALLERGY ASTHMA PROC, V28, P10, DOI 10.2500/aap.2007.28.2977; RoweJones JM, 1997, CLIN OTOLARYNGOL, V22, P167, DOI 10.1046/j.1365-2273.1997.00003.x; RUPP GH, 1982, PEDIATRICS, V70, P437; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; Schiavino D, 1997, ALLERGY ASTHMA PROC, V18, P363, DOI 10.2500/108854197778558061; Schreiber S, 2009, EUR ARCH OTO-RHINO-L, V266, P17, DOI 10.1007/s00405-008-0770-1; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; STRINGER SP, 1993, LARYNGOSCOPE, V103, P6; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Watelet JB, 2004, AM J RHINOL, V18, P267, DOI 10.1177/194589240401800502; Werler MM, 2002, AM J EPIDEMIOL, V155, P26, DOI 10.1093/aje/155.1.26; ZOHAR Y, 1990, J OTOLARYNGOL, V19, P345	90	248	266	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S103	S115		10.1016/j.jaci.2009.12.989	http://dx.doi.org/10.1016/j.jaci.2009.12.989			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176255				2022-12-18	WOS:000280170600010
J	Pascual, RM; Peters, SP				Pascual, RM; Peters, SP			Airway remodeling contributes to the progressive loss of lung function in asthma: An overview	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; airway; remodeling; inflammation	SMOOTH-MUSCLE-CELLS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ENDOTHELIAL GROWTH-FACTOR; ALLERGEN CHALLENGE; SIGNAL TRANSDUCER; BASEMENT-MEMBRANE; GENE-EXPRESSION; DENDRITIC CELLS; MODERATE ASTHMA; FATAL ASTHMA	Airway inflammation, airflow obstruction, and bronchial hyperresponsiveness are characteristic phenotypic features of asthma. Clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects experience an accelerated and progressive loss of lung function over time. Histopathologic studies of the asthmatic airway have demonstrated stereotypic changes that might explain the loss of lung function that many patients with asthma experience. The notion of airway remodeling in asthma postulates that the alteration of the structure and function of key airway constituents, including airway smooth muscle, epithelium, blood vessels, and mucus glands, might explain, at least in part, the progressive loss of lung function that is observed clinically. Inflammation driven by CD4(+) lymphocytes and mediated by effector cells, particularly the eosinophil, appears to modulate the function of mesenchymal cells, including fibroblasts and myofibroblasts, changing the composition of the airway wall matrix. Changes in the airway epithelium might alter the function of the underlying smooth muscle and the composition of the matrix and could drive inflammation. Alterations in the structure and function of airway smooth muscle change the mechanical properties of the airway wall and might also affect the function of other airway constituents. A variety of experimental models have identified candidate mechanisms and mediators for these observed changes, which are thus potential therapeutic targets. However, clinical studies to date have been disappointing, and it remains to be seen whether targeted therapies will prevent the progressive loss of lung function seen in asthma.	Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	Pascual, RM (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpascual@wfubmc.edu			NHLBI NIH HHS [HL067663, HL074225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074225, P50HL067663, P01HL067663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babu KS, 2003, EUR RESPIR J, V21, P1046, DOI 10.1183/09031936.03.00069202; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663, DOI 10.1164/ajrccm.162.2.9907151; BAI TR, 1991, AM REV RESPIR DIS, V143, P441, DOI 10.1164/ajrccm/143.2.441; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Bleecker Eugene R, 2004, Chest, V126, p93S, DOI 10.1378/chest.126.2_suppl_1.93S; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241, DOI 10.1165/ajrcmb.23.2.3999; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Cho SH, 2004, EXP BIOL MED, V229, P138, DOI 10.1177/153537020422900202; Cho SH, 2000, J IMMUNOL, V165, P3154, DOI 10.4049/jimmunol.165.6.3154; Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cohn L, 1998, J IMMUNOL, V161, P3813; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hite RD, 2005, AM J PHYSIOL-LUNG C, V288, pL610, DOI 10.1152/ajplung.00273.2004; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Kelly EA, 2003, CURR OPIN PULM MED, V9, P28, DOI 10.1097/00063198-200301000-00005; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; KRAFT M, 1995, CHEST, V107, pS162, DOI 10.1378/chest.107.3_Supplement.162S; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Ma XF, 2002, AM J PHYSIOL-LUNG C, V283, pL1181, DOI 10.1152/ajplung.00389.2001; MACKLEM P T, 1989, European Respiratory Journal, V2, p516S; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; MARUNO K, 1995, AM J PHYSIOL-LUNG C, V268, pL1047, DOI 10.1152/ajplung.1995.268.6.L1047; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Mautino G, 1999, J ALLERGY CLIN IMMUN, V104, P530, DOI 10.1016/S0091-6749(99)70319-2; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; Page K, 2000, AM J RESP CELL MOL, V23, P436, DOI 10.1165/ajrcmb.23.4.3953; Panettieri RA, 2003, RESP PHYSIOL NEUROBI, V137, P277, DOI 10.1016/S1569-9048(03)00153-8; Pascual RM, 2001, AM J PHYSIOL-LUNG C, V281, pL1425, DOI 10.1152/ajplung.2001.281.6.L1425; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; Solway J, 1997, AM J RESP CELL MOL, V17, P144, DOI 10.1165/ajrcmb.17.2.f137; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Whicker S D, 1988, Pulm Pharmacol, V1, P25, DOI 10.1016/0952-0600(88)90007-5; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	87	248	255	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					477	486		10.1016/j.jaci.2005.07.011	http://dx.doi.org/10.1016/j.jaci.2005.07.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159612				2022-12-18	WOS:000235686500001
J	Pepe, C; Foley, S; Shannon, J; Lemiere, C; Olivenstein, R; Ernst, P; Ludwig, MS; Martin, JG; Hamid, Q				Pepe, C; Foley, S; Shannon, J; Lemiere, C; Olivenstein, R; Ernst, P; Ludwig, MS; Martin, JG; Hamid, Q			Differences in airway remodeling between subjects with severe and moderate asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; structural changes; subepithelial fibrosis; airway smooth muscle; human bronchial biopsies; tissue morphometry	SMOOTH-MUSCLE-CELLS; CLINICAL PHENOTYPES; EXPRESSION; MYOFIBROBLAST; ENDOTHELIN-1; HYPERPLASIA; CYTOKINES; RELEASE	Background: Airway remodeling in asthma comprises a range of structural changes. Several studies have suggested an association between these changes and disease severity. The relationship between the extent of remodeling and lung function is not well defined. Objective: We sought to contrast the structural changes in the airways of well-defined groups of subjects with severe and moderate asthma and to correlate the extent of remodeling with disease severity. Methods: Endobronchial biopsy specimens were obtained from 15 subjects with severe and 13 subjects with moderate asthma. Epithelial integrity, cell-layer areas, subepithelial fibrosis, and the distance between epithelial and airway smooth muscle (ASM) layers were measured by means of image analysis. Collagen was identified by using Van Giesen stain, and ASM was defined by using smooth muscle alpha-actin immunostaining. Specific immunostains were performed for the evaluation of RANTES, IL-8, and eotaxin expression as markers of ASM phenotype. Results: ASM area was greater in subjects with severe (0.24 +/- 0.03 mm(2)) than in subjects with moderate (0.05 +/- 0.01 mm(2)) asthma (P < .001). The distance between the epithelial and ASM layers was less in the severe group (0.12 0.01 mm) than in the moderate group (0.24 +/- 0.02, P < .001). A trend toward greater subepithelial fibrosis in subjects with severe asthma did not reach statistical significance. IL-8 and eotaxin expression, but not RANTES expression, were increased in the ASM of subjects with severe asthma compared with in subjects with moderate asthma. Conclusion: Smooth muscle alteration is the key structural change that distinguishes severe from moderate asthma, and phenotypic change in ASM might contribute to the difficulty in obtaining adequate control in some subjects with severe asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Div Resp, Montreal, PQ H2X 2P2, Canada; Hop Sacre Coeur, Montreal, PQ, Canada	McGill University; McGill University; Universite de Montreal	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca		Martin, James/0000-0001-7574-5363				Ayres JG, 1998, THORAX, V53, P315, DOI 10.1136/thx.53.4.315; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bento AM, 1998, ALLERGY ASTHMA PROC, V19, P353, DOI 10.2500/108854198778612672; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chung KF, 1999, EUR RESPIR J, V13, P1198; Cohen MD, 1997, AM J RESP CELL MOL, V16, P85, DOI 10.1165/ajrcmb.16.1.8998083; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; GIAID A, 1993, LANCET, V341, P1550; HANSEL TT, 2001, CURR ALLERGY ASTHM R, V2, P164; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Morishima Y, 2001, AM J RESP CELL MOL, V24, P1; Nakagawa T, 2004, CLIN REV ALLERG IMMU, V27, P1, DOI 10.1385/CRIAI:27:1:001; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814, DOI 10.1152/jappl.1997.83.6.1814; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC	33	248	255	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					544	549		10.1016/j.jaci.2005.06.011	http://dx.doi.org/10.1016/j.jaci.2005.06.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159622				2022-12-18	WOS:000235686500012
J	Trasande, L; Thurston, GD				Trasande, L; Thurston, GD			The role of air pollution in asthma and other pediatric morbidities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; particulate matter; lead; sulfur dioxide; carbon monoxide; nitrogen oxides; children's environmental health	DIESEL EXHAUST PARTICLES; LOW-BIRTH-WEIGHT; EMERGENCY-ROOM VISITS; SOUTHERN CALIFORNIA; INFANT-MORTALITY; SULFUR-DIOXIDE; RESPIRATORY SYMPTOMS; HOSPITAL ADMISSIONS; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE	A growing body of research supports the role of outdoor air pollutants in acutely aggravating chronic diseases in children, and suggests that the pollutants may have a role in the development of these diseases. This article reviews the biologic basis of children's unique vulnerability to highly prevalent outdoor air pollutants, with a special focus on ozone, respirable particulate matter (PM2.5 [< 2.5 mu m in diameter] and PM10 [< 10 mu m in diameter]), lead, sulfur dioxide, carbon monoxide, and nitrogen oxides. We also summarize understanding regarding health effects and molecular mechanisms of action. Practitioners can significantly reduce morbidity in children and other vulnerable populations by advising families to minimize pollutant exposures to children with asthma, or at a broader level by educating policymakers about the need to act to reduce pollutant emissions. Management of children with asthma must expand beyond preventing exposures to agents that directly cause allergic reactions (and therefore can be diagnosed by means of skin tests) and must focus more attention on agents that cause a broad spectrum of nonspecific, generalized inflammation, such as air pollution.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Dept Community & Prevent Med, Ctr Childs Hlth & Environm, New York, NY USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	New York University; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Thurston, GD (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	thurston@env.med.nyu.edu	Trasande, Leonardo/ABE-6339-2020	Trasande, Leonardo/0000-0002-1928-597X	NIEHS NIH HHS [P42 ES 07384, ES 00260] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, P42ES007384] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; ANDERSON HR, 1999, AIR POLLUTION HLTH, P461; [Anonymous], NAT SCAL AIR TOX ASS; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; BATES D, 2002, CITIZENS GUIDE AIR P; Berkowitz GS, 2003, JAMA-J AM MED ASSOC, V290, P595, DOI 10.1001/jama.290.5.595-b; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539, DOI 10.1136/oem.56.8.539; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; BOBAK M, 2000, ENV HLTH PERSPECT, V108, P539; Cloutier MM, 2002, CHEST, V122, P1571, DOI 10.1378/chest.122.5.1571; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; DUGGAN M J, 1985, Public Health Reviews, V13, P1; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; Fanucchi MV., 2000, AM J RESP CRIT CARE, V161, pA615; FANUCCHI MV, 1997, COMPREHENSIVE TOXICO, V8, P203; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8, DOI 10.5271/sjweh.272; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Goldman LR, 2001, PEDIATRICS, V108, P197, DOI 10.1542/peds.108.1.197; GRAY R, 1991, CANCER RES, V51, P6470; GRISCOM NT, 1978, RADIOL CLIN N AM, V16, P367; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Hajat S, 1999, THORAX, V54, P597, DOI 10.1136/thx.54.7.597; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; IARC, 1989, IARC MON EV CARC RIS, V46, P458; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888, DOI 10.1136/oem.54.12.888; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; KAVLOCK R, 1979, TOXICOL APPL PHARM, V48, P19, DOI 10.1016/S0041-008X(79)80004-6; KIMBROUGH R, 1995, PEDIATRICS, V95, P550; KOENIG JQ, 1992, J ALLERGY CLIN IMMUN, V89, P789, DOI 10.1016/0091-6749(92)90432-2; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lanphear BP, 1998, ENVIRON RES, V79, P51, DOI 10.1006/enrs.1998.3859; Lanphear BP, 1997, ENVIRON RES, V74, P67, DOI 10.1006/enrs.1997.3726; Lederman SA, 2004, ENVIRON HEALTH PERSP, V112, P1772, DOI 10.1289/ehp.7348; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Lin MC, 2001, J TOXICOL ENV HEAL A, V64, P637, DOI 10.1080/152873901753246232; LINN WS, 1990, ARCH ENVIRON HEALTH, V45, P24, DOI 10.1080/00039896.1990.9935920; LINN WS, 1988, ARCH ENVIRON HEALTH, V43, P399, DOI 10.1080/00039896.1988.9935858; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.2307/3433245; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCDONNELL WF, 1990, LONG TERM AMBIENT OZ, pA80; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473, DOI 10.1136/oem.56.7.473; *NAT AC SCI, 1984, TOX TEST NEEDS PRIOR; *NAT ASTHM ED PREV, 1996, AM REV RESPIR CRIT 2, V154, pS119; *NAT RES DEF COUNC, 2001, NO BREATH AISL DIES; National Research Council (US) Committee on Pesticides in the Diets of Infants and Children, 1993, PEST DIETINF CHILD; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175, DOI 10.1080/10473289.2000.10463998; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.2307/3434038; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.2307/3433341; Peters A, 1997, EUR RESPIR J, V10, P872; Petroeschevsky A, 2001, ARCH ENVIRON HEALTH, V56, P37, DOI 10.1080/00039890109604053; Plopper CG, 2000, ENVIRON HEALTH PERSP, V108, pA252, DOI 10.1289/ehp.108-a252; PLUNKETT LM, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P79; PORNSCHEIN RL, 1987, TRACE SUBSTANCES ENV, V20, P322; PRYOR WA, 1991, OXIDATIVE DAMAGE & REPAIR, P496; *PUBL HLTH SERV, 1952, 95 PUBL HLTH SERV; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Saintot M, 1999, ARCH ENVIRON HEALTH, V54, P34, DOI 10.1080/00039899909602234; SALDIVA PHN, 1994, ENVIRON RES, V65, P218, DOI 10.1006/enrs.1994.1033; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Shannon MW, 2004, PEDIATRICS, V114, P1699, DOI 10.1542/peds.2004-2166; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; SPIELBERG SP, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P104; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; TRASANDE L, 2005, IN PRESS ENV HLTH PE; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; U.S. Environmental Protection Agency, 1998, CHEM HAZ DAT AV STUD; *US EPA, 1998, CHEM COMM INF SYST C; *US EPA, 2003, 410R97002 EPA; *US EPA, 2004, AIR TOX HLTH EC EFF; *US EPA, 2001, 454K02001 EPA; *US EPA, 2002, EPA6008909057F; *US EPA, 2003, EPA454R03005; *US EPA, 2001, 454K01002 EPA; *US EPA, 2003, 410R99001 EPA; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.2307/3433580; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Wiley J. A, 1991, STUDY CHILDRENS ACTI; Wiley J.A., 1991, ACTIVITY PATTERNS CA; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35, DOI 10.1046/j.1365-3016.1999.00150.x; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608, DOI 10.1289/ehp.97105608; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407, DOI 10.1080/00039896.1995.9935976	102	248	252	2	66	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					689	699		10.1016/j.jaci.2005.01.056	http://dx.doi.org/10.1016/j.jaci.2005.01.056			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805986				2022-12-18	WOS:000228373400005
J	Johnston, NW; Johnston, SL; Duncan, JM; Greene, JM; Kebadze, T; Keith, PK; Roy, M; Waserman, S; Sears, MR				Johnston, NW; Johnston, SL; Duncan, JM; Greene, JM; Kebadze, T; Keith, PK; Roy, M; Waserman, S; Sears, MR			The September epidemic of asthma exacerbations in children: A search for etiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; viral infections; rhinovirus; school return; inhaled corticosteroid; leukotriene receptor antagonist	RESPIRATORY-INFECTIONS; RHINOVIRUS INFECTIONS; HOSPITAL ADMISSION; CHILDHOOD ASTHMA; AIR-POLLUTION; ALLERGENS; FREQUENCY; EXPOSURE; VIRUSES; SCHOOL	Background: Predictable peaks of asthma exacerbation requiring hospital treatment, of greatest magnitude in children and of uncertain etiology, occur globally after school returns. Objective: We wished to determine whether asthmatic children requiring emergency department treatment for exacerbations after school return in September were more likely to have respiratory viruses present and less likely to have prescriptions for control medications than children with equally severe asthma not requiring emergent treatment. Methods: Rates of viral detection and characteristics of asthma management in 57 (of 60) children age 5 to 15 years presenting to emergency departments with asthma in 2 communities in Canada between September 10 and 30, 2001, (cases) were compared with those in 157 age-matched volunteer children with asthma of comparable severity studied simultaneously (controls). Results: Human picornaviruses were detected in 52% of cases and 29% of controls (P=.002) and viruses of any type in 62% of cases and 41% of controls (P =.011). Cases were less likely to have been prescribed controller medication (inhaled corticosteroid, 49% vs 85%; P <.0001; leukotriene receptor antagonist, 9% vs 21%; P =.04). Conclusion: Respiratory viruses were detected in the majority of children presenting to emergency departments with asthma during the September epidemic of the disease and in a significant minority of children with asthma in the community. The latter were more likely to have anti-inflammatory medication prescriptions than children requiring emergent treatment. Such medication may reduce the risk of emergency department treatment for asthma during the September epidemic.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 4A6, Canada; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London, England; Brant Community Healthcare Syst, Brantford, ON, Canada	McMaster University; McMaster University; Imperial College London	Johnston, NW (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	njohnsto@sympatico.ca	Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; Blaisdell CJ, 2002, J ASTHMA, V39, P567, DOI 10.1081/JAS-120014921; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; DEKLUIJVER J, 2002, AM J RESP CRIT CARE, V168, P1174; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Gern JE, 2002, AM J MED, V112, p19S; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Harju T, 1997, EUR J PEDIATR, V156, P436, DOI 10.1007/s004310050632; Johnston NW, 2001, AM J RESP CRIT CARE, V163, pA359; Johnston SL, 2003, AM J RESP CRIT CARE, V168, P1145, DOI 10.1164/rccm.2309004; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; LONGINI IM, 1984, INT J EPIDEMIOL, V13, P99, DOI 10.1093/ije/13.1.99; Makela MJ, 2003, J ALLERGY CLIN IMMUN, V112, P861, DOI 10.1067/mai.2003.1768; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; MELETH S, 1997, CAN RESP J, V4, P263; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Monteil MA, 2000, J ASTHMA, V37, P677, DOI 10.3109/02770900009087306; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; POTTER PC, 1984, S AFR MED J, V66, P397; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; STORR J, 1989, ARCH DIS CHILD, V64, P103, DOI 10.1136/adc.64.1.103; STRACHAN D, 2002, COLLATION COMPAR DAT; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33, DOI 10.1111/j.1746-1561.2002.tb06509.x; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323	36	248	254	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					132	138		10.1016/j.jaci.2004.09.025	http://dx.doi.org/10.1016/j.jaci.2004.09.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637559	Green Published, Bronze			2022-12-18	WOS:000226267000019
J	Samee, S; Altes, T; Powers, P; de Lange, EE; Knight-Scott, J; Rakes, G; Mugler, JP; Ciambotti, JM; Alford, BA; Brookeman, JR; Platts-Mills, TAE				Samee, S; Altes, T; Powers, P; de Lange, EE; Knight-Scott, J; Rakes, G; Mugler, JP; Ciambotti, JM; Alford, BA; Brookeman, JR; Platts-Mills, TAE			Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: Assessment of response to methacholine and exercise challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; helium; magnetic resonance imaging; imaging; ventilation; lungs	COMPUTED-TOMOGRAPHY; HE-3 GAS; DISEASE; AIRWAYS; HEALTH	Background: Imaging of gas distribution in the lungs of patients with asthma has been restricted because of the lack of a suitable gaseous contrast agent. Hyperpolarized helium-3 (HHe3) provides a new technique for magnetic resonance imaging of lung diseases. Objective: We sought to investigate the use of HHe3 gas to image the lungs of patients with moderate or severe asthma and to assess changes in gas distribution after methacholine and exercise challenge. Methods: Magnetic resonance imaging was performed in asthmatic patients immediately after inhalation of HHe3 gas. In addition, images were obtained before and after methacholine challenge and a standard exercise test. Results: Areas of the lung with no signal or sharply reduced HHe3 signal (ventilation defects) are common in patients with asthma, and the number of defects was inversely related to the percent predicted FEV1 (r = 0.71, P < .002). After methacholine challenge (n = 3), the number of defects increased. Similarly, imaging of the lungs after exercise (n = 6) showed increased ventilation defects in parallel with decreases in FEV1. The increase in defects after challenge in these 9 asthmatic patients was significant both for the number (P < .02) and extent (P < .02) of the defects. The variability and speed of changes in ventilation and the complete lack of signal in many areas is in keeping with a model in which the defects result from airway closure. Conclusion: HHe3 magnetic resonance provides a new technique for imaging the distribution of inhaled air in the lungs. The technique is suitable for following responses to treatment of asthma and changes after methacholine or exercise challenge.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Dept Internal Med,Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Dept Internal Med,Div Asthma Allergy & Immunol, POB 801355, Charlottesville, VA 22908 USA.		Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL059022, R01HL066479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 66479, R44 HL 59022] Funding Source: Medline; NIAID NIH HHS [AI 20565] Funding Source: Medline; NIEHS NIH HHS [P01 ES/AI 50989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806, DOI 10.1164/ajrccm.159.3.9805103; de Lange EE, 1999, RADIOLOGY, V210, P851, DOI 10.1148/radiology.210.3.r99fe08851; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179, DOI 10.1164/ajrccm.162.1.9806079; Kauczor HU, 1997, JMRI-J MAGN RESON IM, V7, P538, DOI 10.1002/jmri.1880070314; King GG, 1999, AM J RESP CRIT CARE, V159, P992, DOI 10.1164/ajrccm.159.3.9805064; MCFALL J, 1996, RADIOLOGY, V200, P553; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; *NAT ASTHM ED PREV, 1997, NIH PUBL; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Parker JA, 1996, J NUCL MED, V37, P1906; WOOLCOCK AJ, 1972, AM REV RESPIR DIS, V106, P692, DOI 10.1164/arrd.1972.106.5.692; WOOLCOCK AJ, 1972, AUST NZ J MED, V2, P294, DOI 10.1111/j.1445-5994.1972.tb03078.x	19	248	253	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1205	1211		10.1067/mai.2003.1544	http://dx.doi.org/10.1067/mai.2003.1544			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789218				2022-12-18	WOS:000183424700006
J	Martin, RJ; Kraft, M; Chu, HW; Berns, EA; Cassell, GH				Martin, RJ; Kraft, M; Chu, HW; Berns, EA; Cassell, GH			A link between chronic asthma and chronic infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic asthma; mycoplasma; Chlamydia; polymerase chain reaction; airways	MYCOPLASMA-PNEUMONIAE INFECTION; CHLAMYDIA-PNEUMONIAE; RESPIRATORY VIRUSES; AIRWAYS; INFLAMMATION; GENE; PCR; ASSOCIATION; DIAGNOSIS; TRACT	Background: Asthma is a prevalent disease with marked effects on quality of life and economic societal burden. However, the cause of asthma and its pathophysiology are not completely defined. Recently, the possibility that chronic infection may play a role has been suggested. Objective: We sought to define the association between Mycoplasma and Chlamydia species and chronic asthma, Methods: We performed a comparison study of asthmatic patients and normal control subjects. Fifty-five patients with chronic stable asthma were compared with 11 normal control subjects by using PCR, culture, and serology for Mycoplasma species, Chlamydia species, and viruses from the nasopharynx, lung, and blood. Bronchoalveolar lavage cell count and differential, as well as tissue morphometry, were also evaluated. Computer-generated scoring for the degree of chronic sinusitis in asthmatic patients was additionally evaluated. Results: Thirty-one of 55 asthmatic patients had positive PCR results For Mycoplasma (n = 25) or Chlamydia species (n = 6), which were mainly found on lung biopsy specimens or in lavage fluid. Only 1 of 11 normal control subjects had positive PCR results for Mycoplasma species. The distinguishing phenotype between asthmatic patients with positive and negative PCR results was the significantly greater number of tissue mast cells in the group with positive results. Conclusion: A significant number of patients with chronic stable asthma demonstrate the presence of Mycoplasma species, Chlamydia species, or both in their airways, with the distinguishing feature of increased mast fell number. These findings need further delineation but may help us to understand the pathophysiology of asthma and new treatment options.	Univ Colorado, Natl Jewish Med & Res Ctr, Dept Med, Hlth Sci Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Denver, CO USA; Northwestern Univ, Sch Med, Dept Radiol, Chicago, IL 60611 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Northwestern University; University of Alabama System; University of Alabama Birmingham	Martin, RJ (corresponding author), Univ Colorado, Natl Jewish Med & Res Ctr, Dept Med, Hlth Sci Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BLOCK S, 1995, PEDIATR INFECT DIS J, V14, P471, DOI 10.1097/00006454-199506000-00002; BOWDEN JJ, 1994, AM J RESP CRIT CARE, V150, P1391, DOI 10.1164/ajrccm.150.5.7524980; Cassell G. H., 1994, P491; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Corne JM, 1999, J VIROL METHODS, V82, P9, DOI 10.1016/S0166-0934(99)00073-7; Dakhama A, 1999, AM J RESP CRIT CARE, V159, P1316, DOI 10.1164/ajrccm.159.4.9807085; EMRE U, 1994, ARCH PEDIAT ADOL MED, V148, P727, DOI 10.1001/archpedi.1994.02170070065013; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; GAYDOS CA, 1994, J CLIN MICROBIOL, V32, P903, DOI 10.1128/JCM.32.4.903-905.1994; GIL JC, 1993, ANN ALLERGY, V70, P23; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; Hahn DL, 1998, ANN ALLERG ASTHMA IM, V81, P339, DOI 10.1016/S1081-1206(10)63126-2; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; KAWANO M, 1990, VIROLOGY, V174, P308, DOI 10.1016/0042-6822(90)90081-2; KERN DG, 1993, CHEST, V104, P208, DOI 10.1378/chest.104.1.208; KOK T, 1994, J VIROL METHODS, V50, P87, DOI 10.1016/0166-0934(94)90166-X; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lorber B, 1996, ANN INTERN MED, V125, P844, DOI 10.7326/0003-4819-125-10-199611150-00010; Lorber B, 1999, ANN INTERN MED, V131, P989, DOI 10.7326/0003-4819-131-12-199912210-00101; Macek V, 1999, Can Respir J, V6, P37; Marin J, 2000, J INFECTION, V41, P69, DOI 10.1053/jinf.2000.0688; MARMION BP, 1993, CLIN INFECT DIS, V17, pS90, DOI 10.1093/clinids/17.Supplement_1.S90; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; *NAT ASTHM ED PREV, 1997, NAT I HLTH PUBL; *NAT HEART LUNG BL, 1992, NAT I HLTH PUBL; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Routes JM, 2000, J ALLERGY CLIN IMMUN, V105, P391, DOI 10.1016/S0091-6749(00)90093-9; SOKAL RR, 1981, BIOMETRY, P704; WILLIAMSON J, 1992, EPIDEMIOL INFECT, V109, P519, DOI 10.1017/S0950268800050512; WILLIAMSON J, 1994, J INFECT DIS, V170, P1052, DOI 10.1093/infdis/170.4.1052; YANO T, 1994, AM J RESP CRIT CARE, V149, P1348, DOI 10.1164/ajrccm.149.5.8173777	34	248	261	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					595	601		10.1067/mai.2001.113563	http://dx.doi.org/10.1067/mai.2001.113563			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295645				2022-12-18	WOS:000168190100007
J	STARK, BJ; SULLIVAN, TJ				STARK, BJ; SULLIVAN, TJ			BIPHASIC AND PROTRACTED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas								ANSELL G, 1980, INVESTIGATIVE RADI S, V15, P32; BATSON JM, 1960, NEW ENGL J MED, V262, P590, DOI 10.1056/NEJM196003242621202; BECKER EL, 1968, TXB IMMUNOPATHOLOGY, P76; BERNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259; BLEECKER ER, 1983, CURRENT THERAPY ALLE, P78; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; DELAGE C, 1972, Journal of Forensic Sciences, V17, P525; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GREENBERGER P, 1980, INVEST RADIOL, V15, P40; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; IDSE O, 1968, B WORLD HEALTH ORGAN, V38, P159; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KERN RA, 1953, AM J MED SCI, V226, P357, DOI 10.1097/00000441-195310000-00001; LEMANSKE R, 1983, J ALLERGY CLIN IMMUN, V71, P136, DOI 10.1016/0091-6749(83)90313-5; LOCKEY RF, 1974, MED CLIN N AM, V58, P147, DOI 10.1016/S0025-7125(16)32184-8; MATHEWS KP, 1956, J ALLERGY, V27, P1, DOI 10.1016/0021-8707(56)90033-8; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; POPA VT, 1984, ANN ALLERGY, V53, P151; PORTER J, 1977, LANCET, V1, P587; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHONING B, 1982, KLIN WOCHENSCHR, V60, P1048, DOI 10.1007/BF01716970; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P227, DOI 10.1016/0091-6749(85)90048-X; SLAVIN RG, 1964, J ALLERGY, V35, P499, DOI 10.1016/0021-8707(64)90081-4; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SULLIVAN TJ, 1983, CURRENT THERAPY ALLE, P62; Valentine M, 1979, ASTHMA OTHER ALLERGI, P467; WASSERMAN SI, 1983, ALLERGY PRINCIPLES P, P689; WELCH H., 1958, Antibiotics Annual, P296; WENDEL GD, 1985, NEW ENGL J MED, V312, P1229, DOI 10.1056/NEJM198505093121905; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	34	248	250	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				76	83		10.1016/0091-6749(86)90117-X	http://dx.doi.org/10.1016/0091-6749(86)90117-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722636				2022-12-18	WOS:A1986D299600012
J	Wiegman, CH; Michaeloudes, C; Haji, G; Narang, P; Clarke, CJ; Russell, KE; Bao, WP; Pavlidis, S; Barnes, PJ; Kanerva, J; Bittner, A; Rao, N; Murphy, MP; Kirkham, PA; Chung, KF; Adcock, IM				Wiegman, Coen H.; Michaeloudes, Charalambos; Haji, Gulammehdi; Narang, Priyanka; Clarke, Colin J.; Russell, Kirsty E.; Bao, Wuping; Pavlidis, Stelios; Barnes, Peter J.; Kanerva, Justin; Bittner, Anton; Rao, Navin; Murphy, Michael P.; Kirkham, Paul A.; Chung, Kian Fan; Adcock, Ian M.		COPDMAP	Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ozone; inflammation; airway smooth muscle; mitochondria; chronic obstructive pulmonary disease; airway hyperresponsiveness; oxidative stress; antioxidant; proliferation; MitoQ	ENERGY-METABOLISM; ASTHMA FEATURES; OZONE; COPD; BETA; HYPERRESPONSIVENESS; FRAGMENTATION; MECHANISMS; EXPRESSION; RESPONSES	Background: Inflammation and oxidative stress play critical roles in patients with chronic obstructive pulmonary disease (COPD). Mitochondrial oxidative stress might be involved in driving the oxidative stress-induced pathology. Objective: We sought to determine the effects of oxidative stress on mitochondrial function in the pathophysiology of airway inflammation in ozone-exposed mice and human airway smooth muscle (ASM) cells. Methods: Mice were exposed to ozone, and lung inflammation, airway hyperresponsiveness (AHR), and mitochondrial function were determined. Human ASM cells were isolated from bronchial biopsy specimens from healthy subjects, smokers, and patients with COPD. Inflammation and mitochondrial function in mice and human ASM cells were measured with and without the presence of the mitochondria-targeted antioxidant MitoQ. Results: Mice exposed to ozone, a source of oxidative stress, had lung inflammation and AHR associated with mitochondrial dysfunction and reflected by decreased mitochondrial membrane potential (Delta Psi m), increased mitochondrial oxidative stress, and reduced mitochondrial complex I, III, and V expression. Reversal of mitochondrial dysfunction by the mitochondria-targeted antioxidant MitoQ reduced inflammation and AHR. ASM cells from patients with COPD have reduced Delta Psi m, adenosine triphosphate content, complex expression, basal and maximum respiration levels, and respiratory reserve capacity compared with those from healthy control subjects, whereas mitochondrial reactive oxygen species (ROS) levels were increased. Healthy smokers were intermediate between healthy nonsmokers and patients with COPD. Hydrogen peroxide induced mitochondrial dysfunction in ASM cells from healthy subjects. MitoQ and Tiron inhibited TGF-beta-induced ASM cell proliferation and CXCL8 release. Conclusions: Mitochondrial dysfunction in patients with COPD is associated with excessive mitochondrial ROS levels, which contribute to enhanced inflammation and cell hyperproliferation. Targeting mitochondrial ROS represents a promising therapeutic approach in patients with COPD.	[Wiegman, Coen H.; Michaeloudes, Charalambos; Haji, Gulammehdi; Narang, Priyanka; Clarke, Colin J.; Russell, Kirsty E.; Bao, Wuping; Barnes, Peter J.; Kirkham, Paul A.; Chung, Kian Fan; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London SW3 6LY, England; [Pavlidis, Stelios] Janssen Res & Dev, High Wycombe, Bucks, England; [Kanerva, Justin; Bittner, Anton; Rao, Navin] Janssen Res & Dev LLC, San Diego, CA USA; [Murphy, Michael P.] MRC, Mitochondrial Biol Unit, Cambridge, England	Imperial College London; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Wiegman, CH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Dovehouse St, London SW3 6LY, England.	c.wiegman@imperial.ac.uk	Adcock, Ian/L-3217-2019; Bao, Wuping/AAX-5674-2020; Chung, Kian Fan/B-1872-2012; Murphy, Michael/C-2120-2009	Chung, Kian Fan/0000-0001-7101-1426; Knox, Alan/0000-0002-5906-4143; brightling, chris/0000-0002-9345-4903; Barnes, Peter/0000-0002-5122-4018; Adcock, Ian/0000-0003-2101-8843; Wiegman, Coen/0000-0001-9161-0581; Michaeloudes, Charalambos/0000-0002-4107-4028; Murphy, Michael/0000-0003-1115-9618	MRC-ABPI COPD-MAP consortium [G1001367/1]; Wellcome Trust [093080/Z/10/Z]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London; MRC [MC_U105663142, G1001367] Funding Source: UKRI; Medical Research Council [MC_U105663142, G1001367] Funding Source: researchfish	MRC-ABPI COPD-MAP consortium(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The MRC-ABPI COPD-MAP consortium (G1001367/1) funded the clinical aspects of this project; in this regard we are also grateful to Professor M. Polkey (RBHFT) for his support for these aspects. Gene arrays were performed by Janssen Research & Development. I.M.A. and P.J.B. are supported by Wellcome Trust grant 093080/Z/10/Z. C.H.W. is a RCUK Research Fellow. This project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health.	Agarwal AR, 2012, AM J PHYSIOL-LUNG C, V303, pL889, DOI 10.1152/ajplung.00219.2012; Aravamudan B, 2014, AM J PHYSIOL-LUNG C, V306, pL840, DOI 10.1152/ajplung.00155.2013; Aravamudan B, 2013, EXPERT REV RESP MED, V7, P631, DOI 10.1586/17476348.2013.834252; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Camougrand N, 2001, RESP PHYSIOL, V128, P393, DOI 10.1016/S0034-5687(01)00314-0; Chang PJ, 2012, J ALLERGY CLIN IMMUN, V130, P877, DOI 10.1016/j.jaci.2012.07.017; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Chung KF., 2005, P AM THORAC SOC, V2, P71; Chung Kian Fan, 2005, Proc Am Thorac Soc, V2, P347, DOI 10.1513/pats.200504-028SR; Eiswerth ME, 2005, J ENVIRON MANAGE, V77, P56, DOI 10.1016/j.jenvman.2005.02.010; Enesa K, 2008, J BIOL CHEM, V283, P18582, DOI 10.1074/jbc.M801312200; Frezza C, 2014, INT J BIOCHEM CELL B, V48, P11, DOI 10.1016/j.biocel.2013.12.013; Hara H, 2013, AM J PHYSIOL-LUNG C, V305, pL737, DOI 10.1152/ajplung.00146.2013; Hirota N, 2013, CHEST, V144, P1026, DOI 10.1378/chest.12-3073; Hoffmann RF, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-97; Hollingsworth John W, 2007, Proc Am Thorac Soc, V4, P240, DOI 10.1513/pats.200701-023AW; Ichimaru Y, 2012, AM J PHYSIOL-LUNG C, V302, pL325, DOI 10.1152/ajplung.00453.2010; Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419; Koshiba T, 2013, BBA-MOL CELL RES, V1833, P225, DOI 10.1016/j.bbamcr.2012.03.005; KUTSUZAWA T, 1995, AM J RESP CRIT CARE, V152, P647, DOI 10.1164/ajrccm.152.2.7633721; Leo S, 2008, ANN NY ACAD SCI, V1147, P264, DOI 10.1196/annals.1427.019; Li F, 2011, EUR RESPIR J, V37, P933, DOI 10.1183/09031936.00021110; Li F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080782; Mabalirajan U, 2008, J IMMUNOL, V181, P3540, DOI 10.4049/jimmunol.181.5.3540; Mabalirajan U, 2009, J APPL PHYSIOL, V107, P1285, DOI 10.1152/japplphysiol.00459.2009; Mabalirajan U, 2009, J IMMUNOL, V183, P2059, DOI 10.4049/jimmunol.0900342; Mailloux RJ, 2013, TRENDS BIOCHEM SCI, V38, P592, DOI 10.1016/j.tibs.2013.09.001; Michaeloudes C, 2011, AM J RESP CRIT CARE, V184, P894, DOI 10.1164/rccm.201011-1780OC; Michaeloudes C, 2011, AM J PHYSIOL-LUNG C, V300, pL295, DOI 10.1152/ajplung.00134.2010; Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008; Osiewacz HD, 2013, GERONTOLOGY, V59, P413, DOI 10.1159/000348662; Peng RD, 2013, AIR QUAL ATMOS HLTH, V6, P445, DOI 10.1007/s11869-012-0180-9; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Pryor WA, 2006, AM J PHYSIOL-REG I, V291, pR491, DOI 10.1152/ajpregu.00614.2005; Rahman I, 2012, CURR OPIN PHARMACOL, V12, P256, DOI 10.1016/j.coph.2012.01.015; Ricciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Sohal SS, 2013, EXPERT REV RESP MED, V7, P275, DOI [10.1586/ERS.13.26, 10.1586/ers.13.26]; Sugiura H, 2008, ANTIOXID REDOX SIGN, V10, P785, DOI 10.1089/ars.2007.1937; Taylor CT, 2010, ARTERIOSCL THROM VAS, V30, P643, DOI 10.1161/ATVBAHA.108.181628; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Triantaphyllopoulos K, 2011, AM J PHYSIOL-LUNG C, V300, pL691, DOI 10.1152/ajplung.00252.2010; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Wiegman CH, 2014, CLIN SCI, V126, P425, DOI 10.1042/CS20130039; Williams AS, 2007, J APPL PHYSIOL, V103, P1189, DOI 10.1152/japplphysiol.00172.2007; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; WUYAM B, 1992, EUR RESPIR J, V5, P157	48	247	260	0	52	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					769	780		10.1016/j.jaci.2015.01.046	http://dx.doi.org/10.1016/j.jaci.2015.01.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25828268	hybrid, Green Published			2022-12-18	WOS:000360913300029
J	Lynch, SV; Wood, RA; Boushey, H; Bacharier, LB; Bloomberg, GR; Kattan, M; O'Connor, GT; Sandel, MT; Calatroni, A; Matsui, E; Johnson, CC; Lynn, H; Visness, CM; Jaffee, KF; Gergen, PJ; Gold, DR; Wright, RJ; Fujimura, K; Rauch, M; Busse, WW; Gern, JE				Lynch, Susan V.; Wood, Robert A.; Boushey, Homer; Bacharier, Leonard B.; Bloomberg, Gordon R.; Kattan, Meyer; O'Connor, George T.; Sandel, Megan T.; Calatroni, Agustin; Matsui, Elizabeth; Johnson, Christine C.; Lynn, Henry; Visness, Cynthia M.; Jaffee, Katy F.; Gergen, Peter J.; Gold, Diane R.; Wright, Rosalind J.; Fujimura, Kei; Rauch, Marcus; Busse, William W.; Gern, James E.			Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; allergen exposure; microbial exposure; inner city	HOUSE-DUST MITE; CHILDHOOD ASTHMA; INNER-CITY; IMMUNE DEVELOPMENT; VIRUS-INFECTION; DOG OWNERSHIP; UNITED-STATES; LUNG-FUNCTION; BIRTH-COHORT; CAT ALLERGEN	Background: Wheezing illnesses cause major morbidity in infants and are frequent precursors to asthma. Objective: We sought to examine environmental factors associated with recurrent wheezing in inner-city environments. Methods: The Urban Environment and Childhood Asthma study examined a birth cohort at high risk for asthma (n = 560) in Baltimore, Boston, New York, and St Louis. Environmental assessments included allergen exposure and, in a nested case-control study of 104 children, the bacterial content of house dust collected in the first year of life. Associations were determined among environmental factors, aeroallergen sensitization, and recurrent wheezing at age 3 years. Results: Cumulative allergen exposure over the first 3 years was associated with allergic sensitization, and sensitization at age 3 years was related to recurrent wheeze. In contrast, first-year exposure to cockroach, mouse, and cat allergens was negatively associated with recurrent wheeze (odds ratio, 0.60, 0.65, and 0.75, respectively; P <= .01). Differences in house dust bacterial content in the first year, especially reduced exposure to specific Firmicutes and Bacteriodetes, was associated with atopy and atopic wheeze. Exposure to high levels of both allergens and this subset of bacteria in the first year of life was most common among children without atopy or wheeze. Conclusions: In inner-city environments children with the highest exposure to specific allergens and bacteria during their first year were least likely to have recurrent wheeze and allergic sensitization. These findings suggest that concomitant exposure to high levels of certain allergens and bacteria in early life might be beneficial and suggest new preventive strategies for wheezing and allergic diseases.	[Lynch, Susan V.; Boushey, Homer; Fujimura, Kei; Rauch, Marcus] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Wood, Robert A.; Matsui, Elizabeth] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Bacharier, Leonard B.; Bloomberg, Gordon R.] Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Kattan, Meyer] Columbia Univ, Med Ctr, Div Pediat Allergy & Immunol, New York, NY USA; [O'Connor, George T.; Sandel, Megan T.] Boston Univ, Sch Med, Ctr Pulm, Chapel Hill, NC USA; [Calatroni, Agustin; Lynn, Henry; Visness, Cynthia M.; Jaffee, Katy F.] Rho Inc, Chapel Hill, NC USA; [Johnson, Christine C.] Div Allergy & Immunol Henry Ford Hlth Syst, Detroit, MI USA; [Gergen, Peter J.] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Gold, Diane R.; Wright, Rosalind J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; [Busse, William W.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA	University of California System; University of California San Francisco; Johns Hopkins University; St. Louis Children's Hospital; Washington University (WUSTL); Columbia University; Rho; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison	Wood, RA (corresponding author), Johns Hopkins Univ, Sch Med, 600 North Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu		Bacharier, Leonard/0000-0003-0432-2704; Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Allergy and Infectious Diseases; National Institutes of Health [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I]; National Center for Advancing Translational Sciences, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992 02]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533, UL1RR025771, UL1RR024992, M01RR000071, UL1RR024156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496, P01AI089473, UM1AI114271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023515] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This project has been supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract numbers NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN272201000052I. Additional support was provided by the National Center for Advancing Translational Sciences, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992 02.	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Chen CM, 2007, J ALLERGY CLIN IMMUN, V119, P1148, DOI 10.1016/j.jaci.2007.02.017; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Corver K, 2006, PEDIAT ALLERG IMM-UK, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; DeSantis TZ, 2007, MICROB ECOL, V53, P371, DOI 10.1007/s00248-006-9134-9; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Fujimura KE, 2012, J MICROBIOL METH, V91, P231, DOI 10.1016/j.mimet.2012.08.016; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Haapakoski R, 2013, J INVEST DERMATOL, V133, P964, DOI 10.1038/jid.2012.356; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hazen TC, 2010, SCIENCE, V330, P204, DOI 10.1126/science.1195979; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Huang YJ, 2010, J ALLERGY CLIN IMMUN, V127, pe1; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jose Lopez-Sanchez M, 2008, ENVIRON MICROBIOL, V10, P3417, DOI 10.1111/j.1462-2920.2008.01776.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Pelletier AJ, 2006, PEDIATRICS, V118, P2418, DOI 10.1542/peds.2006-1193; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Phipatanakul W, 2008, ALLERGY, V63, P1512, DOI 10.1111/j.1398-9995.2008.01679.x; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593, DOI 10.1016/S1081-1206(10)61139-8; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ries M, 2013, J LEUKOCYTE BIOL, V94, P123, DOI 10.1189/jlb.0612278; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Vujkovic-Cvijin I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006438; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Yasui H, 2004, CLIN DIAGN LAB IMMUN, V11, P675, DOI 10.1128/CDLI.11.4.675-679.2004	57	247	254	2	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					593	+		10.1016/j.jaci.2014.04.018	http://dx.doi.org/10.1016/j.jaci.2014.04.018			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24908147	Green Accepted			2022-12-18	WOS:000341372400011
J	Marri, PR; Stern, DA; Wright, AL; Billheimer, D; Martinez, FD				Marri, Pradeep Reddy; Stern, Debra A.; Wright, Anne L.; Billheimer, Dean; Martinez, Fernando D.			Asthma-associated differences in microbial composition of induced sputum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microbiome; Proteobacteria; metagenomics; sputum	NONPARAMETRIC-ESTIMATION; EXACERBATIONS	Background: It is increasingly evident that microbial colonization of the respiratory tract might have a role in the pathogenesis of asthma. Objective: We sought to characterize and compare the microbiome of induced sputum in asthmatic and nonasthmatic adults. Methods: Induced sputum samples were obtained from 10 nonasthmatic subjects and 10 patients with mild active asthma (8/10 were not using inhaled corticosteroids). Total DNA was extracted from sputum supernatants and amplified by using primers specific for the V6 hypervariable region of bacterial 16s rRNA. Samples were barcoded, and equimolar concentrations of 20 samples were pooled and sequenced with the 454 GS FLX sequencer. Sequences were assigned to bacterial taxa by comparing them with 16s rRNA sequences in the Ribosomal Database Project. Results: All sputum samples contained 5 major bacterial phyla: Firmicutes, Proteobacteria, Actinobacteria, Fusobacterium, and Bacteroidetes, with the first 3 phyla accounting for more than 90% of the total sequences. Proteobacteria were present in higher proportions in asthmatic patients (37% vs 15%, P<.001). In contrast, Firmicutes (47% vs 63%, P=.17) and Actinobacteria (10% vs 14%, P=.36) were found more frequently in samples from nonasthmatic subjects, although this was not statistically significant. Hierarchical clustering produced 2 significant clusters: one contained primarily asthmatic samples and the second contained primarily nonasthmatic samples. In addition, samples from asthmatic patients had greater bacterial diversity compared with samples from nonasthmatic subjects. Conclusion: Patients with mild asthma have an altered microbial composition in the respiratory tract that is similar to that observed in patients with more severe asthma. (J Allergy Clin Immunol 2013;131:346-52.)	[Marri, Pradeep Reddy; Billheimer, Dean; Martinez, Fernando D.] Univ Arizona, BIO5 Inst, Tucson, AZ 85721 USA; [Stern, Debra A.; Wright, Anne L.; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA; [Billheimer, Dean] Univ Arizona, Stat Consulting Lab, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Martinez, FD (corresponding author), BIO5 Inst, 1657 E Helen St, Tucson, AZ 85721 USA.	Fernando@arc.arizona.edu			Southwest Environmental Health Sciences (SWEHSC) training grant [ES007901]; National Heart, Lung, and Blood Institute [HL 56177, HL 14136]; SWEHSC [ES006694]; National Institutes of Health (NIH); NIH; Association of American Medical Colleges; University of Vermont; American Medical Colleges; CRS [HL56177]; Abbott; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177, U10HL098112, P50HL014136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	Southwest Environmental Health Sciences (SWEHSC) training grant; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); SWEHSC; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association of American Medical Colleges; University of Vermont; American Medical Colleges; CRS; Abbott(Abbott Laboratories); Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by Southwest Environmental Health Sciences (SWEHSC) training grant ES007901 (to P. R. M.). Part of this study was supported by National Heart, Lung, and Blood Institute grants HL 56177 and HL 14136 (to F. D. M. and A. L. W.) and SWEHSC grant ES006694 (to D.B.).; D. A. Stern has been supported by one or more grants from and/or has one or more grants pending with the National Institutes of Health (NIH). A. L. Wright has been supported by one or more grants from and/or has one or more grants pending with NIH, has received one or more payments for lecturing from or is on the speakers' bureau for the Association of American Medical Colleges and the University of Vermont, and has received one or more payments for the development of educational presentations for Association of American Medical Colleges. F. D. Martinez has been supported by one or more grants from CRS (HL56177), has consultancy arrangements with MedImmune, has received one or more grants from or has one or more grants pending with the NIH, has received one or more payments for lecturing from or is on the speakers' bureau for Abbott and Merck, and has received one or more payments for travel/accommodations/meeting expenses from Abbott and Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; CHAO A, 1984, SCAND J STAT, V11, P265; Chao A, 2003, ENVIRON ECOL STAT, V10, P429, DOI 10.1023/A:1026096204727; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Gedalia A, 2004, PEDIATR REV, V25, P425; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Hugenholtz P, 2008, NATURE, V455, P481, DOI 10.1038/455481a; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Lazarevic V, 2009, J MICROBIOL METH, V79, P266, DOI 10.1016/j.mimet.2009.09.012; Lemon KP, 2010, MBIO, V1, DOI 10.1128/mBio.00129-10; Maffey AF, 2010, PEDIATR PULM, V45, P619, DOI 10.1002/ppul.21236; Martin RJ, 2006, CLIN CHEST MED, V27, P87, DOI 10.1016/j.ccm.2005.10.004; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Stern DA, 2004, CLIN EXP ALLERGY, V34, P1563, DOI 10.1111/j.1365-2222.2004.02088.x; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	26	247	266	3	57	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					346	+		10.1016/j.jaci.2012.11.013	http://dx.doi.org/10.1016/j.jaci.2012.11.013			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23265859	Green Accepted			2022-12-18	WOS:000314661500010
J	Williams, LK; Peterson, EL; Wells, K; Ahmedani, BK; Kumar, R; Burchard, EG; Chowdhry, VK; Favro, D; Lanfear, DE; Pladevall, M				Williams, L. Keoki; Peterson, Edward L.; Wells, Karen; Ahmedani, Brian K.; Kumar, Rajesh; Burchard, Esteban G.; Chowdhry, Vimal K.; Favro, David; Lanfear, David E.; Pladevall, Manel			Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Medication adherence; inhaled corticosteroids; asthma; patient compliance; asthma exacerbations	MEDICATION ADHERENCE; COMBINATION THERAPY; OUTCOMES; ADULTS; BUDESONIDE; CHILDREN; PERSISTENCE; MANAGEMENT; STEROIDS; RECORDS	Background: Asthma is an inflammatory condition often punctuated by episodic symptomatic worsening, and accordingly, patients with asthma might have waxing and waning adherence to controller therapy. Objective: We sought to measure changes in inhaled corticosteroid (ICS) adherence over time and to estimate the effect of this changing pattern of use on asthma exacerbations. Methods: ICS adherence was estimated from electronic prescription and fill information for 298 participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity. For each patient, we calculated a moving average of ICS adherence for each day of follow-up. Asthma exacerbations were defined as the need for oral corticosteroids, an asthma-related emergency department visit, or an asthma-related hospitalization. Proportional hazard models were used to assess the relationship between ICS medication adherence and asthma exacerbations. Results: Adherence to ICS medications began to increase before the first asthma exacerbation and continued afterward. Adherence was associated with a reduction in exacerbations but was only statistically significant among patients whose adherence was greater than 75% of the prescribed dose (hazard ratio, 0.61; 95% CI, 0.41-0.90) when compared with patients whose adherence was 25% or less. This pattern was largely confined to patients whose asthma was not well controlled initially. An estimated 24% of asthma exacerbations were attributable to ICS medication nonadherence. Conclusions: ICS adherence varies in the time period leading up to and after an asthma exacerbation, and nonadherence likely contributes to a large number of these exacerbations. High levels of adherence are likely required to prevent these events. (J Allergy Clin Immunol 2011;128:1185-91.)	[Williams, L. Keoki; Ahmedani, Brian K.; Chowdhry, Vimal K.; Favro, David; Lanfear, David E.; Pladevall, Manel] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki; Lanfear, David E.] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Peterson, Edward L.; Wells, Karen] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Kumar, Rajesh] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; [Pladevall, Manel] Res Triangle Inst Hlth Solut, Barcelona, Spain	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Research Triangle Institute	Williams, LK (corresponding author), Henry Ford Hosp, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org		Kumar, Rajesh/0000-0002-1962-7108	Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases [R01AI079139, R01AI061774]; National Heart, Lung, and Blood Institute (NHLBI) [R01HL079055]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK064695]; National Institutes of Health (NIH); NHLBI/NIH [R01HL078885, R01HL088133, K23HL093023-01]; Flight Attendant Medical Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023, R01HL079055, R01HL078885, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079139, R01AI061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER	Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Flight Attendant Medical Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the Fund for Henry Ford Hospital, the American Asthma Foundation, and the National Institute of Allergy and Infectious Diseases (R01AI079139 and R01AI061774); the National Heart, Lung, and Blood Institute (NHLBI; R01HL079055), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK064695), National Institutes of Health (NIH; to L.K.W.). E.G.B. receives funding through the NHLBI/NIH (R01HL078885 and R01HL088133) and the Flight Attendant Medical Research Institute. R.K. also receives funding through the NHLBI/NIH (K23HL093023-01). These funding agencies did not have a role in the study design, analysis, drafting of the manuscript, or revision of the manuscript.; L. K. Williams has received research support from the National Institute of Allergy and Infectious Diseases, the National Heart Lung and Blood Institute (NHLBI), and the National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health), as well as the American Asthma Foundation. R. Kumar has received research support from the NHLBI. The rest of the authors declare that they have no relevant conflicts of interest.	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bender B, 2008, J ALLERGY CLIN IMMUN, V122, P490, DOI 10.1016/j.jaci.2008.05.041; Bender BG, 2006, J ALLERGY CLIN IMMUN, V118, P899, DOI 10.1016/j.jaci.2006.07.002; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Breekveldt-Postma NS, 2008, PHARMACOEPIDEM DR S, V17, P411, DOI 10.1002/pds.1552; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; Clerisme-Beaty EM, 2011, J ALLERGY CLIN IMMUN, V127, P406, DOI 10.1016/j.jaci.2010.11.038; Cochrane GM, 1996, DRUGS, V52, P12, DOI 10.2165/00003495-199600526-00004; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Habib ZA, 2009, PHARMACOEPIDEM DR S, V18, P437, DOI 10.1002/pds.1722; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jin Y, 2010, J ALLERGY CLIN IMMUN, V126, P618, DOI 10.1016/j.jaci.2010.06.007; Lasmar L, 2009, ALLERGY, V64, P784, DOI 10.1111/j.1398-9995.2008.01877.x; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Milgrom Henry, 1997, Current Opinion in Pediatrics, V9, P590, DOI 10.1097/00008480-199712000-00008; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miller MR, 2005, EUR RESPIR J, V26, P153, DOI 10.1183/09031936.05.00034505; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Paris J, 2008, ANN ALLERG ASTHMA IM, V101, P482, DOI 10.1016/S1081-1206(10)60286-4; Pladevall M, 2004, DIABETES CARE, V27, P2800, DOI 10.2337/diacare.27.12.2800; RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69, DOI 10.1164/ajrccm/149.2_Pt_2.S69; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; SAS Institute Inc, 2008, STAT AN SYST SAS STA; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Stern L, 2006, ANN ALLERG ASTHMA IM, V97, P402, DOI 10.1016/S1081-1206(10)60808-3; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Wells K, 2008, AM J RESP CRIT CARE, V178, P1194, DOI 10.1164/rccm.200808-1233OC; Wilke RA, 2011, CLIN PHARMACOL THER, V89, P379, DOI 10.1038/clpt.2010.260; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; 2000, N ENGL J MED, V343, P1054	43	247	254	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1185	U500		10.1016/j.jaci.2011.09.011	http://dx.doi.org/10.1016/j.jaci.2011.09.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22019090	Green Accepted			2022-12-18	WOS:000298342700005
J	EBNER, C; BIRKNER, T; VALENTA, R; RUMPOLD, H; BREITENBACH, M; SCHEINER, O; KRAFT, D				EBNER, C; BIRKNER, T; VALENTA, R; RUMPOLD, H; BREITENBACH, M; SCHEINER, O; KRAFT, D			COMMON EPITOPES OF BIRCH POLLEN AND APPLES - STUDIES BY WESTERN AND NORTHERN BLOT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BIRCH POLLEN; APPLES; IGE CROSS-REACTIVITY; MONOCLONAL ANTIBODY; CDNA BET-V-I	BETULA-VERRUCOSA; ALLERGIC PATIENTS; CROSS-REACTIVITY; IGE ANTIBODIES; MAJOR ALLERGEN; VEGETABLES; FRUITS; RNA; HYPERSENSITIVITY; SENSITIVITY	Eighty-three sera from patients with birch-pollen allergy were investigated for IgE antibodies against apple allergens by means of immunoblotting. In immunoblots, 81 patients (97.6%) exhibited IgE directed against the major allergen of birch, Bet v I (17 kd), and these patients also demonstrated IgE binding to apple allergens in the molecular weight range 17 to 18 kd. Inhibition studies by preincubation of sera with birch-pollen extract led to complete blocking of IgE binding to this 17 to 18 kd protein, whereas preincubation with apple extract could not diminish IgE binding to Bet V I. Furthermore, a 17 kd protein in apple extract could be detected by immunoblotting with a Bet v I-specific monoclonal antibody. Northern blotting with a Bet v I cDNA clone as a probe revealed cross-hybridization of birch and apple allergen coding nuclei acids under conditions of high stringency, suggesting significant homology of the nuclei acid level. Our results support the concept that antigens in birch pollen and apples share allergenic epitopes leading to IgE cross-reactivities that may cause clinical manifestations when a special threshold level of specific IgE antibodies is reached.	UNIV VIENNA,INST GEN & EXPTL PATHOL,WAHRINGERSTR 13,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN CHEM & LAB DIAGNOST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MICROBIOL & GENET,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; ARNTZEN FC, 1989, J ALLERGY CLIN IMMUN, V83, P66, DOI 10.1016/0091-6749(89)90479-X; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; DANIEL P, 1989, MOL PLANT MICROBE IN, V6, P325; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISTENSKY B, 1988, PLANT MOL BIOL, V11, P713, DOI 10.1007/BF00017470; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; LATHI A, 1980, ALLERGY, V35, P297; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWENSTEIN H, 1983, ALLERGY, V38, P577, DOI 10.1111/j.1398-9995.1983.tb04143.x; PETTENBURGER K, 1990, EPITOPES ATOPIC ALLE, P65; RUMPOLD H, 1990, EPITOPES ATOPIC ALLE, P26; SOMSSICH IE, 1988, MOL GEN GENET, V213, P93, DOI 10.1007/BF00333403; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; WALTER MH, 1990, MOL GEN GENET, V222, P353, DOI 10.1007/BF00633840	29	247	250	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					588	594		10.1016/0091-6749(91)90152-E	http://dx.doi.org/10.1016/0091-6749(91)90152-E			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1717531				2022-12-18	WOS:A1991GL04900007
J	Campbell, KS; Hasegawa, J				Campbell, Kerry S.; Hasegawa, Jun			Natural killer cell biology: An update and future directions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cell; killer cell immunoglobulin-like receptors; innate immunity; immune memory; antibody-dependent cellular cytotoxicity; cancer; viral infection; hematopoietic stem cell transplantation; immunomodulatory drugs; IFN-gamma	MHC CLASS-I; INNATE LYMPHOID-CELLS; NK-CELLS; INHIBITORY RECEPTORS; SELF-MHC; MOLECULAR-MECHANISMS; BORTEZOMIB TREATMENT; PERIPHERAL-BLOOD; PHASE-1 TRIAL; KIR ANTIBODY	Natural killer (NK) cells constitute a minor subset of normal lymphocytes that initiate innate immune responses toward tumor and virus-infected cells. They can mediate spontaneous cytotoxicity toward these abnormal cells and rapidly secrete numerous cytokines and chemokines to promote subsequent adaptive immune responses. Significant progress has been made in the past 2 decades to improve our understanding of NK cell biology. Here we review recent discoveries, including a better comprehension of the "education'' of NK cells to achieve functional competence during their maturation and the discovery of "memory'' responses by NK cells, suggesting that they might also contribute to adaptive immunity. The improved understanding of NK cell biology has forged greater awareness that these cells play integral early roles in immune responses. In addition, several promising clinical therapies have been used to exploit NK cell functions in treating patients with cancer. As our molecular understanding improves, these and future immunotherapies should continue to provide promising strategies to exploit the unique functions of NK cells to treat cancer, infections, and other pathologic conditions.	[Campbell, Kerry S.; Hasegawa, Jun] Fox Chase Canc Ctr, Res Inst, Cell Dev & Host Def Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Campbell, KS (corresponding author), Fox Chase Canc Ctr, Res Inst, 333 Cottman Ave, Philadelphia, PA 19111 USA.	kerry.campbell@fccc.edu	Campbell, Kerry S./T-1381-2019		National Institutes of Health [CA083859, CA06927]; Health Research Formula Fund (CURE) grant from the Pennsylvania Department of Health; Daiichi Sankyo Co, Tokyo, Japan; National Institutes of Health; Pennsylvania Department of Health; Bristol Meyers Squibb; Daiichi Sankyo Co.; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA083859] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Health Research Formula Fund (CURE) grant from the Pennsylvania Department of Health; Daiichi Sankyo Co, Tokyo, Japan(Daiichi Sankyo Company Limited); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; Bristol Meyers Squibb(Bristol-Myers Squibb); Daiichi Sankyo Co.(Daiichi Sankyo Company Limited); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by National Institutes of Health grants CA083859 (to K.S.C.) and CA06927 (FCCC) and a Health Research Formula Fund (CURE) grant from the Pennsylvania Department of Health. The department specifically disclaims responsibility for any analyses, interpretations, or conclusions. J.H. was supported by Daiichi Sankyo Co, Tokyo, Japan.; K. S. Campbell has received grants from the National Institutes of Health, the Pennsylvania Department of Health, and Bristol Meyers Squibb; has consultant arrangements with Bristol Meyers Squibb; has a patent for genetically modified human natural killer cell lines; and has received royalties from Springer Press. J. Hasegawa has received financial and travel support from Daiichi Sankyo Co.	Altvater B, 2009, CLIN CANCER RES, V15, P4857, DOI 10.1158/1078-0432.CCR-08-2810; Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arai S, 2008, CYTOTHERAPY, V10, P625, DOI 10.1080/14653240802301872; Armeanu S, 2008, CLIN CANCER RES, V14, P3520, DOI 10.1158/1078-0432.CCR-07-4744; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Benson DM, 2012, BLOOD, V120, P4324, DOI 10.1182/blood-2012-06-438028; Benson DM, 2011, BLOOD, V118, P6387, DOI 10.1182/blood-2011-06-360255; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Beziat V, 2013, BLOOD, V121, P2678, DOI 10.1182/blood-2012-10-459545; Binyamin L, 2008, J IMMUNOL, V180, P6392, DOI 10.4049/jimmunol.180.9.6392; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Brodin P, 2009, BLOOD, V113, P2434, DOI 10.1182/blood-2008-05-156836; Brown ACN, 2012, BLOOD, V120, P3729, DOI 10.1182/blood-2012-05-429977; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Chalifour A, 2009, IMMUNITY, V30, P337, DOI 10.1016/j.immuni.2008.12.019; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Cichocki F, 2010, J IMMUNOL, V185, P2009, DOI 10.4049/jimmunol.1000855; Cooley S, 2007, BLOOD, V110, P578, DOI 10.1182/blood-2006-07-036228; Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Curti A, 2011, BLOOD, V118, P3273, DOI 10.1182/blood-2011-01-329508; Davies GE, 2007, GENES IMMUN, V8, P245, DOI 10.1038/sj.gene.6364381; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Fang M, 2010, J EXP MED, V207, P2369, DOI 10.1084/jem.20100282; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Foley B, 2012, BLOOD, V119, P2665, DOI 10.1182/blood-2011-10-386995; Furukawa H, 1999, HUM IMMUNOL, V60, P32, DOI 10.1016/S0198-8859(98)00097-4; Gross CC, 2010, J IMMUNOL, V185, P2918, DOI 10.4049/jimmunol.1000761; Haas P, 2011, BLOOD, V117, P1021, DOI 10.1182/blood-2010-02-269381; Hanke T, 2001, EUR J IMMUNOL, V31, P3370, DOI 10.1002/1521-4141(200111)31:11<3370::AID-IMMU3370>3.0.CO;2-2; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214; Horst D, 2011, CURR OPIN IMMUNOL, V23, P96, DOI 10.1016/j.coi.2010.11.005; Hsu AK, 2011, BLOOD, V117, P1605, DOI 10.1182/blood-2010-04-278432; Hsu KC, 2007, TISSUE ANTIGENS, V69, P42, DOI 10.1111/j.1399-0039.2006.759_5.x; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Jamieson AM, 2004, J IMMUNOL, V172, P864, DOI 10.4049/jimmunol.172.2.864; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kim S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI 10.1073/pnas.0712229105; Klingemann H, 2013, TRANSFUSION, V53, P412, DOI 10.1111/j.1537-2995.2012.03764.x; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Koepsell SA, 2013, TRANSFUSION, V53, P404, DOI 10.1111/j.1537-2995.2012.03724.x; Kohrt HE, 2011, BLOOD, V117, P2423, DOI 10.1182/blood-2010-08-301945; Koka R, 2003, J EXP MED, V197, P977, DOI 10.1084/jem.20021836; Korbel DS, 2009, J IMMUNOL, V182, P6426, DOI 10.4049/jimmunol.0804224; Krieg S, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00388; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Li L, 2010, CANCER GENE THER, V17, P147, DOI 10.1038/cgt.2009.61; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108; Lundqvist A, 2011, J CANCER, V2, P383, DOI 10.7150/jca.2.383; Lundqvist A, 2009, BLOOD, V113, P6120, DOI 10.1182/blood-2008-11-190421; Mace EM, 2010, BLOOD, V116, P1272, DOI 10.1182/blood-2009-12-261487; MacFarlane AW, 2006, CURR TOP MICROBIOL, V298, P23; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; McDaniel Jessica M, 2012, Adv Hematol, V2012, P513702, DOI 10.1155/2012/513702; McQueen KL, 2007, HUM IMMUNOL, V68, P309, DOI 10.1016/j.humimm.2007.01.019; Miller JS, 2007, BLOOD, V109, P5058, DOI 10.1182/blood-2007-01-065383; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Muller T, 2008, CANCER IMMUNOL IMMUN, V57, P411, DOI 10.1007/s00262-007-0383-3; Ni J, 2012, J EXP MED, V209, P2351, DOI 10.1084/jem.20120944; O'Connor GM, 2011, J IMMUNOL, V187, P2162, DOI 10.4049/jimmunol.1002906; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Orange JS, 2006, CURR OPIN ALLERGY CL, V6, P399, DOI 10.1097/ACI.0b013e3280106b65; Orr MT, 2010, NAT IMMUNOL, V11, P321, DOI 10.1038/ni.1849; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Pelak K, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001208; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Prlic M, 2003, J EXP MED, V197, P967, DOI 10.1084/jem.20021847; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Raulet DH, 1997, IMMUNOL REV, V155, P41, DOI 10.1111/j.1600-065X.1997.tb00938.x; Romagne F, 2009, BLOOD, V114, P2667, DOI 10.1182/blood-2009-02-206532; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Saleh A, 2004, IMMUNITY, V21, P55, DOI 10.1016/j.immuni.2004.06.005; Schonberg K, 2011, BLOOD, V117, P98, DOI 10.1182/blood-2010-03-273656; Schuster S, 2012, J LEUKOC BIOL; Seidel UJE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00076; Seliger B, 2006, INT J CANCER, V118, P129, DOI 10.1002/ijc.21312; Sola C, 2009, P NATL ACAD SCI USA, V106, P12879, DOI 10.1073/pnas.0901653106; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Stringaris K, 2010, BIOL BLOOD MARROW TR, V16, P1257, DOI 10.1016/j.bbmt.2010.03.004; Sun JC, 2012, J EXP MED, V209, P947, DOI 10.1084/jem.20111760; Sun JC, 2011, J EXP MED, V208, P357, DOI 10.1084/jem.20100479; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Uherek C, 2002, BLOOD, V100, P1265, DOI 10.1182/blood.V100.4.1265.h81602001265_1265_1273; Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3; Velardi A, 2002, TRENDS IMMUNOL, V23, P438, DOI 10.1016/S1471-4906(02)02284-6; Venstrom JM, 2012, NEW ENGL J MED, V367, P805, DOI 10.1056/NEJMoa1200503; Vey N, 2012, BLOOD, V120, P4317, DOI 10.1182/blood-2012-06-437558; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Vivian JP, 2011, NATURE, V479, P401, DOI 10.1038/nature10517; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wehner R, 2011, J INNATE IMMUN, V3, P258, DOI 10.1159/000323923; Zhang JH, 2011, CELL MOL IMMUNOL, V8, P1, DOI 10.1038/cmi.2010.38; Zhu D, 2008, CANCER IMMUNOL IMMUN, V57, P1849, DOI 10.1007/s00262-008-0512-7	115	246	270	3	78	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					536	544		10.1016/j.jaci.2013.07.006	http://dx.doi.org/10.1016/j.jaci.2013.07.006			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23906377	Green Accepted			2022-12-18	WOS:000323612000003
J	Hamilos, DL				Hamilos, Daniel L.			Chronic rhinosinusitis: Epidemiology and medical management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Rhinosinusitis; sinusitis; nasal polyposis; epidemiology; medical management; treatment	ALLERGIC FUNGAL RHINOSINUSITIS; PLACEBO-CONTROLLED TRIAL; CHRONIC HYPERPLASTIC SINUSITIS; MESSENGER-RNA EXPRESSION; QUALITY-OF-LIFE; NASAL POLYPOSIS; DOUBLE-BLIND; SYSTEMIC CORTICOSTEROIDS; ASPIRIN DESENSITIZATION; INTRANASAL BUDESONIDE	Chronic rhinosinusitis (CRS) affects 12.5% of the US population. On epidemiologic grounds, some association has been found between CRS prevalence and air pollution, active cigarette smoking, secondhand smoke exposure, perennial allergic rhinitis, and gastroesophageal reflux. The majority of pediatric and adult patients with CRS are immune competent. Data on genetic associations with CRS are still sparse. Current consensus definitions subclassify CRS into CRS without nasal polyposis (CRSsNP), CRS with nasal polyposis (CRSwNP), and allergic fungal rhinosinusitis (AFRS). Evaluation and medical management of CRS has been the subject of several recent consensus reports. The highest level of evidence for treatment for CRSsNP exists for saline lavage, intranasal steroids, and long-term macrolide antibiotics. The highest level of evidence for treatment of CRSwNP exists for intranasal steroids, systemic glucocorticoids, and topical steroid irrigations. Aspirin desensitization is beneficial for patients with aspirin-intolerant CRSwNP. Sinus surgery followed by use of systemic steroids is recommended for AFRS. Other modalities of treatment, such as antibiotics for patients with purulent infection and antifungal drugs for patients with AFRS, are potentially useful despite a lack of evidence from controlled treatment trials. The various modalities of medical treatment are reviewed in the context of recent consensus documents and the author's personal experience. (J Allergy Clin Immunol 2011; 128:693-707.)	Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hamilos, DL (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.	dhamilos@partners.org						Aazami A, 2009, IRAN J ALLERGY ASTHM, V8, P199, DOI 08.04/ijaai.199203; Adams P F, 1999, Vital Health Stat 10, P1; Al-Qudah M, 2008, INT J PEDIATR OTORHI, V72, P817, DOI 10.1016/j.ijporl.2008.02.006; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Alobid I, 2006, RHINOLOGY, V44, P8; Anand VK, 2004, ANN OTO RHINOL LARYN, V113, P3, DOI 10.1177/00034894041130S502; Asero R, 2001, ANN ALLERG ASTHMA IM, V86, P283, DOI 10.1016/S1081-1206(10)63299-1; Aukema AAC, 2005, J ALLERGY CLIN IMMUN, V115, P1017, DOI 10.1016/j.jaci.2004.12.1144; Bachert C, 2005, DRUGS, V65, P1537, DOI 10.2165/00003495-200565110-00006; Bachert C, 2010, CURR ALLERGY ASTHM R, V10, P194, DOI 10.1007/s11882-010-0096-0; Bassichis BA, 2001, OTOLARYNG HEAD NECK, V125, P487, DOI 10.1067/mhn.2001.119585; Benitez P, 2006, LARYNGOSCOPE, V116, P770, DOI 10.1097/01.mlg.0000205218.37514.0f; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Berrettini S, 1999, ALLERGY, V54, P242, DOI 10.1034/j.1398-9995.1999.00813.x; Bhattacharyya N, 2009, AM J RHINOL ALLERGY, V23, P392, DOI 10.2500/ajra.2009.23.3355; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; Briggs RD, 2004, LARYNGOSCOPE, V114, P126, DOI 10.1097/00005537-200401000-00022; Cheng AG, 2009, OTOLARYNG HEAD NECK, V141, P86, DOI 10.1016/j.otohns.2009.03.020; Cherry WB, 2008, AM J MED, V121, P185, DOI 10.1016/j.amjmed.2007.09.022; Christian DL, 1998, AM J RESP CRIT CARE, V158, P532, DOI 10.1164/ajrccm.158.2.9709023; Cryer J, 2004, ORL-J OTO-RHIN-LARYN, V66, P155, DOI 10.1159/000079994; Dahl M, 2004, J EXP MED, V199, P1391, DOI 10.1084/jem.20040111; Danese M, 1997, J RADIOL, V78, P651; DelGaudio JM, 2005, LARYNGOSCOPE, V115, P946, DOI 10.1097/01.MLG.0000163751.00885.63; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Durmus R, 2010, ACTA OTO-LARYNGOL, V130, P1053, DOI 10.3109/00016481003621546; Ebbens FA, 2009, LARYNGOSCOPE, V119, P401, DOI 10.1002/lary.20064; Elliott KA, 2006, AM J RHINOL, V20, P1; Ferguson BJ, 2005, AM J RHINOL, V19, P452, DOI 10.1177/194589240501900506; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441, DOI 10.1016/S0030-6665(00)80018-3; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; FOKKENS W, 2007, RHINOL S, V20, P1; Ghegan MD, 2007, AM J RHINOL, V21, P560, DOI 10.2500/ajr.2007.21.3082; Gosepath J, 2001, ARCH OTOLARYNGOL, V127, P316, DOI 10.1001/archotol.127.3.316; Gosepath J, 2008, ACTA OTO-LARYNGOL, V128, P778, DOI 10.1080/00016480701724896; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; Hamilos D, 2004, ANN OTO RHINOL LARYN, V113, P27, DOI 10.1177/00034894041130S508; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P1; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P299; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Harvey R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006394; Hauptman G, 2007, OTOLARYNG HEAD NECK, V137, P815, DOI 10.1016/j.otohns.2007.07.034; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Hochstim CJ, 2010, OTOLARYNG HEAD NECK, V143, P697, DOI 10.1016/j.otohns.2010.07.017; Huang WH, 2006, LARYNGOSCOPE, V116, P288, DOI 10.1097/01.mlg.0000197316.36698.c4; Hutcheson PS, 2010, AM J RHINOL ALLERGY, V24, P405, DOI 10.2500/ajra.2010.24.3533; Ikram Mubasher, 2009, Ear Nose Throat J, V88, pE8; Javer AR, 2007, J OTOLARYNGOL, V36, P1, DOI 10.2310/7070.2006.0084; Jones NS, 1997, CLIN OTOLARYNGOL, V22, P47, DOI 10.1046/j.1365-2273.1997.00862.x; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Karaman M, 2009, AM J RHINOL ALLERGY, V23, P2, DOI 10.2500/ajra.2009.23.3253; KATLE EJ, 2011, EUR ARCH OTORHINOLAR; Kennedy D W, 1992, Laryngoscope, V102, P1; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; Kienast K, 1996, Eur J Med Res, V1, P533; Koskinen OM, 1999, EUR RESPIR J, V14, P1363, DOI 10.1183/09031936.99.14613639; Landsberg R, 2007, OTOLARYNG HEAD NECK, V136, P252, DOI 10.1016/j.otohns.2006.09.010; Lavigne F, 2002, LARYNGOSCOPE, V112, P858, DOI 10.1097/00005537-200205000-00015; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Li Y, 2008, ORL-J OTO-RHIN-LARYN, V70, P113, DOI 10.1159/000114534; Lieu JEC, 2000, ARCH OTOLARYNGOL, V126, P940, DOI 10.1001/archotol.126.8.940; Lim M, 2008, AM J RHINOL, V22, P381, DOI 10.2500/ajr.2008.22.3189; Lion A, 2003, CHEST, V124, P1781, DOI 10.1378/chest.124.5.1781; Lotvall J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-163; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Lund VJ, 2004, RHINOLOGY, V42, P57; Lusk RP, 1996, OTOLARYNG CLIN N AM, V29, P75; Mafee Mahmood F, 2007, Clin Allergy Immunol, V20, P185; Mainz JG, 2011, AURIS NASUS LARYNX, V38, P220, DOI 10.1016/j.anl.2010.09.001; MAJIMA Y, 2011, AURIS NASUS LARYNX; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Micheletto C, 2004, ALLERGY, V59, P289, DOI 10.1046/j.1398-9995.2003.00351.x; Ozmen S, 2008, LARYNGOSCOPE, V118, P890, DOI 10.1097/MLG.0b013e318165e324; Parikh A, 2001, RHINOLOGY, V39, P75; Patiar S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005232.pub2; Pauli C, 2007, LARYNGO RHINO OTOL, V86, P282, DOI 10.1055/s-2007-966094; Pearlman AN, 2009, AM J RHINOL ALLERGY, V23, P145, DOI 10.2500/ajra.2009.23.3284; Pleis John R, 2009, Vital Health Stat 10, P1; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ragab S, 2001, CLIN EXP ALLERGY, V31, P1385, DOI 10.1046/j.1365-2222.2001.01160.x; Ragab SM, 2004, LARYNGOSCOPE, V114, P923, DOI 10.1097/00005537-200405000-00027; Ramadan HH, 2002, OTOLARYNG HEAD NECK, V127, P546, DOI 10.1067/mhn.2002.129816; Reh DD, 2009, AM J RHINOL ALLERGY, V23, P562, DOI 10.2500/ajra.2009.23.3377; Robinson S, 2006, AM J RHINOL, V20, P625, DOI 10.2500/ajr.2006.20.2907; Rollin M, 2009, RHINOLOGY, V47, P75; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; Sachanandani NS, 2009, ARCH OTOLARYNGOL, V135, P303, DOI 10.1001/archoto.2008.555; Sanclement JA, 2005, LARYNGOSCOPE, V115, P578, DOI 10.1097/01.mlg.0000161346.30752.18; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P260, DOI 10.1111/j.1365-2222.2007.02889.x; Schaefer D., 1999, Rhinology (Utrecht), V37, P56; Schapowal A. G., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P235; Scheinberg Philip A, 2002, Ear Nose Throat J, V81, P648; Schubert Mark S, 2007, Clin Allergy Immunol, V20, P263; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Senior BA, 1999, OTOLARYNG HEAD NECK, V121, P66, DOI 10.1016/S0194-5998(99)70127-0; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; Singhal D, 2010, AM J RHINOL ALLERGY, V24, P169, DOI 10.2500/ajra.2010.24.3462; Skorpinski EW, 2008, ANN ALLERG ASTHMA IM, V100, P529, DOI 10.1016/S1081-1206(10)60061-0; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Sobol SE, 1998, J OTOLARYNGOL, V27, P252; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; SPEKTOR DM, 1989, ENVIRON HEALTH PERSP, V79, P167, DOI 10.2307/3430545; Stankiewicz JA, 2002, OTOLARYNG HEAD NECK, V126, P623, DOI 10.1067/mhn.2002.125602; Stewart RA, 2008, OTOLARYNG HEAD NECK, V139, P682, DOI 10.1016/j.otohns.2008.07.010; Stjarne P, 2009, ARCH OTOLARYNGOL, V135, P296, DOI 10.1001/archoto.2009.2; Subramanian HN, 2002, AM J RHINOL, V16, P303, DOI 10.1177/194589240201600605; Tammemagi CM, 2010, ARCH OTOLARYNGOL, V136, P327, DOI 10.1001/archoto.2010.43; Tichenor WS, 2008, J ALLERGY CLIN IMMUN, V121, P917, DOI 10.1016/j.jaci.2007.08.065; Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Vanlerberghe L, 2006, B-ENT, V2, P161; Vaughan WC, 2002, OTOLARYNG HEAD NECK, V127, P558, DOI 10.1067/mhn.2002.129738; WALD ER, 1995, J PEDIATR-US, V127, P339, DOI 10.1016/S0022-3476(95)70061-7; Wallwork B, 2006, LARYNGOSCOPE, V116, P189, DOI 10.1097/01.mlg.0000191560.53555.08; Wang XJ, 2000, JAMA-J AM MED ASSOC, V284, P1814, DOI 10.1001/jama.284.14.1814; Wang XJ, 2005, ARCH OTOLARYNGOL, V131, P237, DOI 10.1001/archotol.131.3.237; Whatley WS, 2006, AM J RHINOL, V20, P251, DOI 10.2500/ajr.2006.20.2855; WIGHT RG, 1992, CLIN OTOLARYNGOL, V17, P354, DOI 10.1111/j.1365-2273.1992.tb01012.x; Wise SK, 2008, OTOLARYNG HEAD NECK, V138, P38, DOI 10.1016/j.otohns.2007.10.020; Wise SK, 2006, AM J RHINOL, V20, P283, DOI 10.2500/ajr.2006.20.2849; WOLFF RK, 1986, ENVIRON HEALTH PERSP, V66, P223, DOI 10.2307/3430237	131	246	255	0	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					693	709		10.1016/j.jaci.2011.08.004	http://dx.doi.org/10.1016/j.jaci.2011.08.004			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21890184				2022-12-18	WOS:000296538100001
J	Van Crombruggen, K; Zhang, N; Gevaert, P; Tomassen, P; Bachert, C				Van Crombruggen, Koen; Zhang, Nan; Gevaert, Philippe; Tomassen, Peter; Bachert, Claus			Pathogenesis of chronic rhinosinusitis: Inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; remodeling; inflammation; Staphylococcus aureus; IgE; eicosanoids	AUREUS ENTEROTOXIN-B; STAPHYLOCOCCUS-AUREUS; NASAL POLYPS; IGE; PROSTAGLANDIN; PHAGOCYTOSIS; RESPONSES; PROTEIN	Chronic rhinosinusitis (CRS) is a heterogeneous group of inflammatory diseases of the nasal and paranasal cavities either accompanied by polyp formation (CRSwNP) or without polyps (CRSsNP). CRSsNP and CRSwNP are prevalent medical conditions associated with substantial impaired quality of life, reduced workplace productivity, and serious medical treatment costs. Despite recent research evidence that contributes to further unveiling the pathophysiology of these chronic airway conditions, the cause remains poorly understood and appears to be multifactorial. A diverse spectrum of alterations involving histopathology, inflammatory cell and T-cell patterns, remodeling parameters (eg, TGF-beta), eicosanoid and IgE production, microorganisms, and epithelial barrier malfunctions is reported in the search to describe the pathogenesis of this heterogeneous group of upper airway diseases. Furthermore, novel evidence indicates considerable heterogeneity within the CRSwNP subgroup determining the risk of comorbid asthma. The characterization of specific disease subgroups is a challenging scientific and clinical task of utmost importance in the development of diagnostic tools and application of individualized treatments. This review focuses on recent evidence that sheds new light on our current knowledge regarding the inflammatory process of CRS to further unravel its pathogenesis. (J Allergy Clin Immunol 2011;128:728-32.)	[Van Crombruggen, Koen; Zhang, Nan; Gevaert, Philippe; Tomassen, Peter; Bachert, Claus] Ghent Univ Hosp, Upper Airway Res Lab, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Bachert, C (corresponding author), Ghent Univ Hosp, Upper Airway Res Lab, Dept Otorhinolaryngol, De Pintelaan 185, B-9000 Ghent, Belgium.	claus.Bachert@ugent.be	Gevaert, Philippe/ABA-4588-2021; Bachert, Claus/J-8825-2012; Tomassen, Peter/B-8013-2009; Gevaert, Philippe/AAP-1892-2020; Zhang, Nan/AAQ-3944-2020	Tomassen, Peter/0000-0002-0698-6574; Gevaert, Philippe/0000-0002-1629-8468; 				Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Fokkens WJ, 2009, IMMUNOL ALLERGY CLIN, V29, P677, DOI 10.1016/j.iac.2009.07.002; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Kim YM, 2010, CLIN IMMUNOL, V137, P111, DOI 10.1016/j.clim.2010.05.013; Kowalski ML, 2011, ALLERGY, V66, P32, DOI 10.1111/j.1398-9995.2010.02379.x; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Li XY, 2010, J ALLERGY CLIN IMMUN, V125, P1061, DOI 10.1016/j.jaci.2010.02.023; Okano M, 2011, CLIN EXP ALLERGY, V41, P171, DOI 10.1111/j.1365-2222.2010.03584.x; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Perez-Novo CA, 2008, J INFECT DIS, V197, P1036, DOI 10.1086/528989; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Sachse F, 2010, ALLERGY, V65, P1430, DOI 10.1111/j.1398-9995.2010.02381.x; Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Crombruggen K, 2010, RHINOLOGY, V48, P54, DOI 10.4193/Rhin09.078; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	24	246	251	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					728	732		10.1016/j.jaci.2011.07.049	http://dx.doi.org/10.1016/j.jaci.2011.07.049			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21868076				2022-12-18	WOS:000296538100004
J	Savenije, OE; Granell, R; Caudri, D; Koppelman, GH; Smit, HA; Wijga, A; de Jongste, JC; Brunekreef, B; Sterne, JA; Postma, DS; Henderson, J; Kerkhof, M				Savenije, Olga E.; Granell, Raquel; Caudri, Daan; Koppelman, Gerard H.; Smit, Henriette A.; Wijga, Alet; de Jongste, Johan C.; Brunekreef, Bert; Sterne, Jonathan A.; Postma, Dirkje S.; Henderson, John; Kerkhof, Marjan			Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; preschool children; latent class analysis; phenotype	1ST 6 YEARS; LUNG-FUNCTION; PRESCHOOL-CHILDREN; ASTHMA; LIFE; POLYMORPHISMS; SENSITIZATION; PREVALENCE; SYMPTOMS; RISK	Background: Asthma has its origins in early childhood, but different patterns of childhood wheezing vary in their associations with subsequent asthma, atopy, and bronchial hyperresponsiveness (BHR). Novel wheezing phenotypes have been identified on the basis of analyses of longitudinal data from the Avon Longitudinal Study of Parents And Children (ALSPAC). It is unclear whether these phenotypes can be replicated in other birth cohorts. Objective: To compare wheezing phenotypes identified in the first 8 years of life in the ALSPAC study and the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) study. Methods: We used longitudinal latent class analysis to identify phenotypes on the basis of repeated reports of wheezing from 0 to 8 years in 5760 children from the ALSPAC study and 2810 children from the PIAMA study. Phenotypes were compared between cohorts. Associations with asthma, atopy, BHR, and lung function were analyzed by using weighted regression analyses. Results: The model with the best fit to PIAMA data in the first 8 years of life was a 5-class model. Phenotypes identified in the PIAMA study had wheezing patterns that were similar to those previously reported in ALSPAC, adding further evidence to the existence of an intermediate-onset phenotype with onset of wheeze after 2 years of age. Associations with asthma, atopy, BHR, and lung function were remarkably similar in the 2 cohorts. Conclusion: Wheezing phenotypes identified by using longitudinal latent class analysis were comparable in 2 large birth cohorts. Study of genetic and environmental factors associated with different phenotypes may help elucidate the origins of asthma. (J Allergy Clin Immunol 2011;127:1505-12.)	[Savenije, Olga E.; Kerkhof, Marjan] Univ Groningen, Dept Epidemiol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 RB Groningen, Netherlands; [Granell, Raquel; Sterne, Jonathan A.] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Caudri, Daan; de Jongste, Johan C.] Erasmus MC Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; [Smit, Henriette A.; Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Wijga, Alet] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Bristol; University of Bristol; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Utrecht University	Kerkhof, M (corresponding author), Univ Groningen, Dept Epidemiol, Univ Med Ctr Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands.	m.kerkhof@epi.umcg.nl	Sterne, Jonathan/Z-3106-2019; Granell, Raquel/AAY-4846-2020; Koppelman, Gerard/AAG-9187-2020; Granell, Raquel/AAB-5256-2022	Sterne, Jonathan/0000-0001-8496-6053; Granell, Raquel/0000-0002-4890-4012; Koppelman, Gerard/0000-0001-8567-3252; brunekreef, bert/0000-0001-9908-0060	Dutch Asthma Foundation [3.4.01.26, 3.2.06.022, 3.4.09.081, 3.2.10.085CO]; ZonMw (a Dutch organization for health research and development) [912-03-031]; Ministry of the Environment; UK Medical Research Council [0401540]; GlaxoSmithKline; Netherlands Asthma Foundation; Top Institute Pharma; AstraZeneca; MRC [G0902125, G0401540] Funding Source: UKRI; Medical Research Council [G0902125, G9815508, G0401540] Funding Source: researchfish	Dutch Asthma Foundation; ZonMw (a Dutch organization for health research and development)(Netherlands Organization for Health Research and Development); Ministry of the Environment(Ministry of the Environment, Japan); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); GlaxoSmithKline(GlaxoSmithKline); Netherlands Asthma Foundation; Top Institute Pharma; AstraZeneca(AstraZeneca); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The PIAMA study is supported by the Dutch Asthma Foundation (grant nos. 3.4.01.26, 3.2.06.022, 3.4.09.081, and 3.2.10.085CO), the ZonMw (a Dutch organization for health research and development; grant no. 912-03-031), and the Ministry of the Environment. The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for ALSPAC. R. G. was supported by the UK Medical Research Council (grant no. 0401540).; J. Henderson receives research support from the UK Medical Research Council. G. H. Koppelman receives research support from GlaxoSmithKline and the Netherlands Asthma Foundation. D. S. Postma has consultant arrangements with Nycomed and receives research support from Top Institute Pharma and AstraZeneca. J. A. Sterne receives research support from the Medical Research Council-UK. R. Granell receives research support from the Medical Research Council-UK. The rest of the authors have declared that they have no conflict of interest.	Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Brussee JE, 2004, AM J RESP CRIT CARE, V169, P209, DOI 10.1164/rccm.200306-800OC; Bush A, 2009, AM J RESP CRIT CARE, V179, P637, DOI 10.1164/rccm.200902-0206UP; De Meer G, 2001, THORAX, V56, P362, DOI 10.1136/thorax.56.5.362; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Henderson A J, 2008, Chron Respir Dis, V5, P225, DOI 10.1177/1479972308097327; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Henderson J, 2009, ARCH DIS CHILD, V94, P333, DOI 10.1136/adc.2008.143636; Holloway JW, 2008, J ALLERGY CLIN IMMUN, V121, P573, DOI 10.1016/j.jaci.2008.01.007; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kapitein B, 2008, EUR RESPIR J, V32, P1203, DOI 10.1183/09031936.00020108; Kiley J, 2007, CURR OPIN PULM MED, V13, P19; Kurukulaaratchy RJ, 2002, RESP MED, V96, P163, DOI 10.1053/rmed.2001.1236; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Mai XM, 2007, ARCH DIS CHILD, V92, P881, DOI 10.1136/adc.2006.110692; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Melen E, 2006, CLIN EXP ALLERGY, V36, P1391, DOI 10.1111/j.1365-2222.2006.02577.x; Muthen L., 2017, MPLUS; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Patel SP, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-57; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Pembrey M, 2004, EUR J ENDOCRINOL, V151, pU125, DOI 10.1530/eje.0.151U125; Rusconi Franca, 2005, Epidemiol Prev, V29, P47; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Saglani S, 2007, CURR OPIN ALLERGY CL, V7, P83; Sandin A, 2004, PEDIATR ALLERGY IMMU, V15, P316, DOI 10.1111/j.1399-3038.2004.00166.x; SELEUX G, 1996, J CLASSIF, V13, P195; Sembajwe G, 2010, EUR RESPIR J, V35, P279, DOI 10.1183/09031936.00027509; Sharma S, 2010, AM J RESP CRIT CARE, V181, P328, DOI 10.1164/rccm.200907-1009OC; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Spycher BD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008533; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; SUBSTRATA LS, 2009, J IMMUNOL, V183, P2793; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wilson NM, 2004, PEDIATR PULM, V38, P75, DOI 10.1002/ppul.20049; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; ZAPLETAL A, 1977, Zeitschrift fuer Erkrankungen der Atmungsorgane, V149, P343	46	246	251	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1505	U285		10.1016/j.jaci.2011.02.002	http://dx.doi.org/10.1016/j.jaci.2011.02.002			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21411131	Bronze			2022-12-18	WOS:000291048500029
J	Francis, JN; James, LK; Paraskevopoulos, G; Wong, C; Calderon, MA; Durham, SR; Till, SJ				Francis, James N.; James, Louisa K.; Paraskevopoulos, Giannis; Wong, Cheukyee; Calderon, Moises A.; Durham, Stephen R.; Till, Stephen J.			Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; IL-10; late-phase response; IgG4; IgA; early-phase response	FACILITATED ALLERGEN BINDING; HUMAN MAST-CELLS; FC-EPSILON-RI; CYTOKINE PRODUCTION; HAY-FEVER; GAMMA-RII; T-CELLS; IGE; RHINITIS; MUCOSAL	Background: Grass pollen immunotherapy is an effective treatment for seasonal allergic rhinitis that provides the opportunity to study the induction and maintenance of allergen-specific immune tolerance. Objectives: We investigated the relationship between clinical responsiveness, regulatory cytokine production, and antibody responses to allergen during 1 year of immunotherapy. Methods: Eighteen subjects with severe seasonal allergic rhinitis were randomized double-blind to receive active or placebo injections of an alum-adsorbed grass pollen vaccine (Alutard SQ). Subjects underwent repeated testing of early- and late-phase skin responses to intradermal allergen, and cellular responses to grass pollen allergen were tested. Sera were tested for allergen-specific IgG4, IgA, and inhibitory activity in biologic assays of IgE responses. Results: Grass pollen immunotherapy was effective in reducing overall symptom scores (P <.05) and conjunctival reactivity (P <.05). In the active group significant IL-10 production occurred early at low allergen doses and at a similar time as inhibition of late skin responses at 2 to 4 weeks. Serum allergen-specific IgG4, IgA, and inhibitory antibody activity for basophil histamine release and IgE-facilitated allergen binding to B cells occurred later, at 6 to 12 weeks, at higher allergen doses and preceded inhibition of early skin responses. Conclusion: IL-10 responses occur early but at immunotherapy doses that are not clinically effective. Later induction of inhibitory antibodies, including IgG4 and IgA, might be required for efficacy through modulation of IgE-mediated events.	[Francis, James N.; James, Louisa K.; Paraskevopoulos, Giannis; Wong, Cheukyee; Calderon, Moises A.; Durham, Stephen R.; Till, Stephen J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London SW7 2AZ, England	Imperial College London	Till, SJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	stephen.till@imperial.ac.uk	James, Louisa/C-9831-2010	James, Louisa/0000-0002-2252-4636; Till, Stephen/0000-0003-4518-3093	Medical Research Council [G0400503B] Funding Source: researchfish; MRC [G0601303, G0200485] Funding Source: UKRI; Medical Research Council [G0200485, G0601303] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akdis CA, 2000, FASEB J, V14, P1666; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Sihra BS, 1997, THORAX, V52, P447, DOI 10.1136/thx.52.5.447; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VAREZCUESTA E, 2006, ALLERGY S82, V61, P1; Vercelli D, 1998, INT ARCH ALLERGY IMM, V116, P1, DOI 10.1159/000023918; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; White P, 1998, CLIN EXP ALLERGY, V28, P266	36	246	254	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1120	1125		10.1016/j.jaci.2008.01.072	http://dx.doi.org/10.1016/j.jaci.2008.01.072			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18374405				2022-12-18	WOS:000255961700007
J	Diaz-Sanchez, D; Garcia, MP; Wang, M; Jyrala, M; Saxon, A				Diaz-Sanchez, D; Garcia, MP; Wang, M; Jyrala, M; Saxon, A			Nasal challenge with diesel exhaust particles can induce sensitization to a neoallergen in the human mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel exhaust particles; allergic sensitization; IgE regulation; pollution; atopy	KEYHOLE LIMPET HEMOCYANIN; IGE PRODUCTION; IN-VIVO; CYTOKINE PRODUCTION; ANTIGEN; IMMUNIZATION; INFLAMMATION; EXPRESSION; ASTHMATICS; RESPONSES	Background: Diesel exhaust particles (DEPs) increase in vivo IgE and cytokine production at the human upper respiratory mucosa, exacerbating allergic inflammation. Objective: We examined the ability of DEP exposure to lead to primary sensitization of humans by driving a de novo mucosal IgE response to a neoantigen, keyhole limpet hemocyanin (KLH), Methods: Ten atopic subjects were given an initial nasal immunization with 1 mg of KLH followed by 2 biweekly nasal challenges with 100 mu g of KLH. Identical nasal KLH immunization was then performed on 15 different atopic subjects, but DEPs were administered 24 hours before each KLH exposure. Results: Exposure to KLH alone led to the generation of an anti-KLH IgG and IgA humoral response, which was detected in nasal fluid samples. No anti-KLH IgE appeared in any subjects. In contrast, when challenged with MH preceded by DEPs, 9 of the 15 subjects produced anti-KLH-specific IgE. KLH-specific IgG and IgA at levels similar to that seen with KLH atone could also be detected. Subjects who received DEPs and KLH had significantly increased IL-4, but not IFN-gamma, levels in nasal lavage fluid, whereas these levels were unchanged in subjects receiving KLH alone. Conclusion: These studies demonstrate that DEPs can act as mucosal adjuvants to a de novo IgE response and may increase allergic sensitization.	Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Dept Med, Hart & Louise Lyon Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Diaz-Sanchez, D (corresponding author), Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Dept Med, Hart & Louise Lyon Lab, 52-175 Ctr Hlth Sci, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, U19AI034567, U01AI034567, R21AI015251] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34567, AI15251] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRDSALL HH, 1983, CLIN EXP IMMUNOL, V53, P497; DAVIES RJ, 1995, INT ARCH ALLERGY IMM, V107, P428, DOI 10.1159/000237068; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Engwall E, 1972, J IMMUNOL, V109, P129; FALCONER AE, 1992, CLIN EXP IMMUNOL, V89, P495; Fujieda S, 1998, CLIN CANCER RES, V4, P1583; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Ichinose T, 1997, TOXICOLOGY, V122, P183, DOI 10.1016/S0300-483X(97)00096-6; KERKVLIET NI, 1993, TOXICOL APPL PHARM, V119, P248, DOI 10.1006/taap.1993.1066; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; MACY E, 1988, FASEB J, V2, P300; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V79, P639; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658, DOI 10.1136/oem.53.10.658; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; Schuyler M, 1997, IMMUNOLOGY, V91, P167, DOI 10.1046/j.1365-2567.1997.00234.x; SIDELL N, 1990, J INVEST DERMATOL, V95, P597, DOI 10.1111/1523-1747.ep12505593; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; WEISSMAN DN, 1994, AM J RESP CELL MOL, V11, P607, DOI 10.1165/ajrcmb.11.5.7946390; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372	25	246	252	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1183	1188		10.1016/S0091-6749(99)70011-4	http://dx.doi.org/10.1016/S0091-6749(99)70011-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588999				2022-12-18	WOS:000084289200010
J	Fajt, ML; Wenzel, SE				Fajt, Merritt L.; Wenzel, Sally E.			Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma phenotypes; biologic therapies; eosinophils; IgE; IL-4; IL-5; IL-13; T(H)2/type 2 inflammation	NECROSIS-FACTOR-ALPHA; ANTI-IGE ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ATOPIC-DERMATITIS; IL-4 RECEPTOR; AIRWAY HYPERRESPONSIVENESS; EOSINOPHILIC ASTHMA; PERSISTENT ASTHMA; CLUSTER-ANALYSIS	Traditionally, asthma and allergic diseases have been defined by broad definitions and treated with nonspecific medications, including corticosteroids and bronchodilators. There is an increasing appreciation of heterogeneity within asthma and allergic diseases based primarily on recent cluster analyses, molecular phenotyping, biomarkers, and differential responses to targeted and nontargeted therapies. These pioneering studies have led to successful therapeutic trials of molecularly targeted therapies in defined phenotypes. This review analyzed randomized double-blind, placebo-controlled trials of molecularly targeted therapies in defined allergic disease and asthma phenotypes. IgE was the first successful biological target used in patients with allergic disease and asthma. This review shows that therapies targeting the canonical type 2 cytokines IL-4, IL-5, and IL-13 have shown consistent efficacy, especially in asthmatic patients with evidence of T(H)2/type 2 inflammation ("type 2 high"). As of yet, there are no successful trials of targeted therapies in asthmatic patients without evidence for type 2 inflammation. We conclude that further refinement of type 2 therapies to specific type 2 phenotypes and novel approaches for patients without type 2 inflammation are needed for asthma and allergic disease treatment.	[Fajt, Merritt L.; Wenzel, Sally E.] Univ Pittsburgh, UPMC UPSOM, Asthma Inst, Dept Med,Div Pulm Allergy & Critical Care Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fajt, ML (corresponding author), Univ Pittsburgh, UPMC UPSOM, Asthma Inst, Dept Med,Div Pulm Allergy & Critical Care Med, 3459 Fifth Ave,NW 628 Montefiore, Pittsburgh, PA 15213 USA.	fajtml@upmc.edu		Wenzel, Sally/0000-0002-4242-0164	Amgen; AstraZeneca; GlaxoSmithKline; Pfizer; Boehringer Ingelheim; Novartis; ICON; Sanofi Aventis; Genentech	Amgen(Amgen); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Novartis(Novartis); ICON; Sanofi Aventis(Sanofi-Aventis); Genentech(Roche HoldingGenentech)	S. E. Wenzel has received grants and personal fees from Amgen, AstraZeneca, GlaxoSmithKline, Pfizer, and Boehringer Ingelheim; has received personal fees from Novartis and ICON; has received grants from Sanofi Aventis and Genentech; and receives royalties from UpToDate. M. L. Fajt declares no relevant conflicts of interest.	Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 2014, FULL PRESCR INF XOL; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BROWN HM, 1958, LANCET, V2, P1245; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2011, J ALLERGY CLIN IMMUN, V127, P398, DOI 10.1016/j.jaci.2010.09.043; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002; Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1067/MAI.2002.130051; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Gouvis-Echraghi R, 2012, J ALLERGY CLIN IMMUN, V130, P1005, DOI 10.1016/j.jaci.2012.07.007; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Holloway JI, 2014, MIDDLETONS ALLERGY P, P343; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Iyengar SR, 2013, INT ARCH ALLERGY IMM, V162, P89, DOI 10.1159/000350486; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Kamin W, 2010, PEDIAT ALLERG IMM-UK, V21, pE160, DOI 10.1111/j.1399-3038.2009.00900.x; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kim DH, 2013, CLIN EXP DERMATOL, V38, P496, DOI 10.1111/j.1365-2230.2012.04438.x; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, NAT ASTH ED PREV PRO; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Prazma CM, 2014, THORAX, V69, P1141, DOI 10.1136/thoraxjnl-2014-205581; Del Pozo MER, 2011, J INVEST ALLERG CLIN, V21, P416; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Slager RE, 2012, J ALLERGY CLIN IMMUN, V130, P516, DOI 10.1016/j.jaci.2012.03.030; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Tsabouri S, 2014, J ALLER CL IMM-PRACT, V2, P332, DOI 10.1016/j.jaip.2014.02.001; Rensen ELJ, 2009, ALLERGY, V64, P72, DOI 10.1111/j.1398-9995.2008.01881.x; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790	117	245	252	1	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					299	311		10.1016/j.jaci.2014.12.1871	http://dx.doi.org/10.1016/j.jaci.2014.12.1871			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25662302	Bronze			2022-12-18	WOS:000349372300001
J	Commins, S; Steinke, JW; Borish, L				Commins, Scott; Steinke, John W.; Borish, Larry			The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IL; cytokine; IL-10-related cytokines	IFN-LAMBDA; T-CELLS; POTENTIAL ROLE; RECEPTOR; CYTOKINE; INTERLEUKIN-20; ASTHMA; PROLIFERATION; MDA-7/IL-24; INDUCTION	Cytokines are involved in virtually every aspect of immunity and inflammation. A cascade of responses evolves after cytokine activation, although optimal function might ultimately involve several complementary cytokines. Understanding the function of individual cytokines is complicated because their role can vary depending on the cellular source, target, and phase of the immune response. In fact, numerous cytokines have both proinflammatory and anti-inflammatory potential, with the contrasting outcome observed being determined by the immune cells present and their state of responsiveness to the cytokine. These issues make the study of cytokine biology daunting, particularly so for IL-10 and IL-10-related genes. The IL-10 superfamily is highly pleiotropic. These genes are linked together through genetic similarity and intron-exon gene structure. Significant commonality exists not only through shared receptors but also through conserved signaling cascades. However, its members mediate diverse activities, including immune suppression, enhanced antibacterial and antiviral immunity, antitumor activity, and promotion of self-tolerance in autoimmune diseases.	[Commins, Scott; Steinke, John W.; Borish, Larry] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Beime Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia	Borish, L (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Beime Carter Ctr Immunol Res, Box 801355, Charlottesville, VA 22908 USA.	lb4m@virginia.edu						Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Chae SC, 2006, EXP MOL MED, V38, P302, DOI 10.1038/emm.2006.36; Chen WY, 2006, ARTERIOSCL THROM VAS, V26, P2090, DOI 10.1161/01.ATV.0000232502.88144.6f; DELPRETE G, 1993, J IMMUNOL, V150, P353; Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935; Dumoutier L, 2004, J BIOL CHEM, V279, P32269, DOI 10.1074/jbc.M404789200; Gallagher G, 2004, INT IMMUNOPHARMACOL, V4, P615, DOI 10.1016/j.intimp.2004.01.005; Ghislain JJ, 2001, J INTERF CYTOK RES, V21, P379, DOI 10.1089/107999001750277853; Hor S, 2004, J BIOL CHEM, V279, P33343, DOI 10.1074/jbc.M405000200; Hsieh MY, 2006, GENES IMMUN, V7, P234, DOI 10.1038/sj.gene.6364291; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Ikeuchi H, 2005, ARTHRITIS RHEUM-US, V52, P1037, DOI 10.1002/art.20965; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Lasfar A, 2006, CANCER RES, V66, P4468, DOI 10.1158/0008-5472.CAN-05-3653; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; Mennechet FJD, 2006, BLOOD, V107, P4417, DOI 10.1182/blood-2005-10-4129; Mumm JB, 2006, J INTERF CYTOK RES, V26, P877, DOI 10.1089/jir.2006.26.877; Naka K, 2005, J GEN VIROL, V86, P2787, DOI 10.1099/vir.0.81124-0; Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005; Scumpia PO, 2005, CRIT CARE MED, V33, pS468, DOI 10.1097/01.CCM.0000186268.53799.67; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Taylor A, 2007, J ALLERGY CLIN IMMUN, V120, P76, DOI 10.1016/j.jaci.2007.04.004; Whittington HA, 2004, AM J RESP CELL MOL, V31, P220, DOI 10.1165/rcmb.2003-0285OC; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2007, J IMMUNOL, V178, P5973, DOI 10.4049/jimmunol.178.9.5973; Zheng MZ, 2007, CANCER IMMUNOL IMMUN, V56, P205, DOI 10.1007/s00262-006-0175-1	31	245	263	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1108	1111		10.1016/j.jaci.2008.02.026	http://dx.doi.org/10.1016/j.jaci.2008.02.026			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18405958				2022-12-18	WOS:000255961700005
J	Klion, AD; Bochner, BS; Gleich, GJ; Nutman, TB; Rothenberg, ME; Simon, HU; Wechsler, ME; Weller, PF				Klion, Amy D.; Bochner, Bruce S.; Gleich, Gerald J.; Nutman, Thomas B.; Rothenberg, Marc E.; Simon, Hans-Uwe; Wechsler, Michael E.; Weller, Peter F.		Hypereosinophilic Syndromes Workin	Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophil; hypereosinophilic syndromes; Churg-Strauss Syndrome; eosinophil-associated gastrointestinal disease; treatment	CHURG-STRAUSS-SYNDROME; EOSINOPHILIC ESOPHAGITIS; INTERFERON-ALPHA; ANTI-INTERLEUKIN-5 ANTIBODY; SYSTEMIC MASTOCYTOSIS; FOLLOW-UP; IMATINIB; THERAPY; RESISTANCE; VASCULITIS	Hypereosinophilic syndromes are a heterogeneous group of uncommon disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in a wide variety of clinical manifestations. Although corticosteroids are the first-line therapy for many of these disorders, approaches to the treatment of patients who do not tolerate or are unresponsive to corticosteroids are poorly standardized. A multidisciplinary group of 37 clinicians and scientists participated in a workshop held in May 2005 in Bern, Switzerland to discuss current and future approaches to therapy for 3 eosinophil-mediated disorders: hypereosinophilic syndrome, Churg-Strauss syndrome, and eosinophil-associated gastrointestinal disease. The goal of the workshop was to summarize available data regarding treatment of these disorders to identify the most promising therapies and approaches for further study. There was consensus among all of the participants that the identification of markers of disease progression to assess treatment responses is a research priority for all 3 disorders. Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized.	NIH, Parasit Dis Lab, Bethesda, MD 20892 USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT USA; Univ Utah, Dept Med, Salt Lake City, UT USA; Cincinnati Childrens Hosp, Ctr Med, Dept Pediat, Cincinnati, OH USA; Univ Bern, Dept Pharmacol, Bern, Switzerland; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins Medicine; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Cincinnati Children's Hospital Medical Center; University of Bern; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Klion, AD (corresponding author), NIH, Parasit Dis Lab, Blsg 4,Rm 126,4 Ctr Dr, Bethesda, MD 20892 USA.	aklion@niaid.nih.gov	Wechsler, Michael/B-3979-2013; Simon, Hans-Uwe/AAU-7410-2020; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; Simon, Hans-Uwe/0000-0002-9404-7736; Klion, Amy/0000-0002-4986-5326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000439, ZIAAI000805, ZIAAI000439, Z01AI000805] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bain BJ, 2004, AM J HEMATOL, V77, P82, DOI 10.1002/ajh.20088; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Butterfield JH, 2005, ACTA HAEMATOL-BASEL, V114, P26, DOI 10.1159/000085560; CHURG J, 1951, AM J PATHOL, V27, P277; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Druilhe A, 2003, APOPTOSIS, V8, P481, DOI 10.1023/A:1025590308147; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gayraud M, 1997, BRIT J RHEUMATOL, V36, P1290; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; Hellmich B, 2005, ANN NY ACAD SCI, V1051, P121, DOI 10.1196/annals.1361.053; Hochhaus A, 2004, LEUKEMIA, V18, P1321, DOI 10.1038/sj.leu.2403426; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood-2003-08-2798; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Lane Suzanne E, 2005, Curr Rheumatol Rep, V7, P270, DOI 10.1007/s11926-005-0036-5; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Markowitz JE, 2003, GASTROENTEROL CLIN N, V32, P949, DOI 10.1016/S0889-8553(03)00047-5; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; McNagny K, 2002, J EXP MED, V195, pf43, DOI 10.1084/jem.20020636; Metzler C, 2005, ANN RHEUM DIS, V64, P1242, DOI 10.1136/ard.2004.032664; Metzler C, 2004, CLIN EXP RHEUMATOL, V22, pS52; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Pardanani A, 2003, BLOOD, V101, P3391, DOI 10.1182/blood-2002-10-3103; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; Pitini V, 2003, BLOOD, V102, P3456, DOI 10.1182/blood-2003-07-2393; Pitini Vincenzo, 2004, Br J Haematol, V127, P477, DOI 10.1111/j.1365-2141.2004.05206.x; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Roufosse F, 2004, ALLERGY, V59, P673, DOI 10.1111/j.1398-9995.2004.00465.x; SAKAMOTO K, 1992, AM J PEDIAT HEMATOL, V14, P348; Schandene L, 2000, BLOOD, V96, P4285; Sefcick A, 2004, BRIT J HAEMATOL, V124, P558, DOI 10.1046/j.1365-2141.2003.04801.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Ueno NT, 2002, BRIT J HAEMATOL, V119, P131, DOI 10.1046/j.1365-2141.2002.03771.x; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656	47	245	264	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1292	1302		10.1016/j.jaci.2006.02.042	http://dx.doi.org/10.1016/j.jaci.2006.02.042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750989				2022-12-18	WOS:000238332300014
J	Blanca, M; Torres, MJ; Garcia, JJ; Romano, A; Mayorga, C; de Ramon, E; Vega, JM; Miranda, A; Juarez, C				Blanca, M; Torres, MJ; Garcia, JJ; Romano, A; Mayorga, C; de Ramon, E; Vega, JM; Miranda, A; Juarez, C			Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin test; penicillin allergy; natural evolution; selective reaction	PENICILLIN ALLERGY; IMMEDIATE HYPERSENSITIVITY; IGE ANTIBODIES; CLINICAL-EXPERIENCE; CROSS-REACTIVITY; LONG-TERM; ANAPHYLAXIS; DETERMINANTS; EXPOSURE	Background: Subjects with immediate reactions to penicillins and positive skin test responses may lose sensitivity if penicillin is avoided. The longer the interval between the reaction and the skin test, the greater the likelihood of having a negative result. Objective: We sought to study prospectively the evolution of skin test sensitivity in a group of subjects allergic to penicillin with positive skin test responses to different penicillin determinants. Methods: Skin tests were performed with major and minor determinants of benzylpenicillin (BPO/MDM), amoxicillin (AX), and ampicillin-at the initial evaluation and repeated 1, 3, and 5 years later if the responses were still positive. Subjects were divided into 2 groups. Group A consisted of patients with a positive skin test response to benzylpenicilloyl or minor determinant mixture, and group B consisted of those with a selective response to amoxicillin and good tolerance to benzylpenicillin. Results: In group A (n = 31) after 1 year, 25 patients continued to have positive responses and 6 began to have negative responses; after 3 years, 18 continued to have positive responses, 5 began to have negative responses, and;2 were lost to follow-up; and after 5 years, 12 continued to have positive responses, 5 began to have negative responses, and 1 was lost to follow-up. In group B (n = 24) 12 had positive responses, and 12 had negative responses after 1 year; 6 had positive: responses, 5 had negative responses, and 1 was lost to followup after 3 years; and no patients had positive responses, 5 had negative responses, and 1 was lost to follow-up after 5 years. Survival analysis showed significant differences between groups (log-rank test = 12.8; P < .0003). Conclusion: Patients with a selective response to amoxicillin tended to lose sensitivity faster than those who responded to several penicillin determinants, supporting the existence of at least 2 distinct types of IgE response in patients allergic to beta-lactam.	Carlos Haya Hosp, Allergy Lab, Dept Internal Med, Res Unit Allerg Dis, Malaga 29010, Spain; UCSU, Allergy Unit, Dept Internal Med & Geriatr, CI, Rome, Italy; IRCCS Oasi Maria S, Troina, Italy	Hospital Carlos Haya	Blanca, M (corresponding author), Carlos Haya Hosp, Allergy Lab, Dept Internal Med, Res Unit Allerg Dis, Avd Carlos Haya S-N, Malaga 29010, Spain.		Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017; Mayorga, Lina/FBO-7730-2022; Mayorga, Cristobalina/D-7167-2018; Romano, Antonino/D-3102-2017	Torres, María José/0000-0001-5228-471X; Mayorga, Cristobalina/0000-0001-8852-8077; Romano, Antonino/0000-0001-9742-9898				ANTONY SJ, 1993, J FAM PRACTICE, V37, P499; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; BLANCA M, 1992, J IMMUNOL METHODS, V153, P99, DOI 10.1016/0022-1759(92)90311-G; Blanca M, 1996, CLIN EXP ALLERGY, V26, P335; BRAVO CM, 1995, ALLERGY, V50, P539; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; DEWDNEY JM, 1984, J ROY SOC MED, V77, P866, DOI 10.1177/014107688407701013; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; IGEA JM, 1992, ANN ALLERGY, V68, P515; KRAFT D, 1977, CLIN ALLERGY, V7, P21, DOI 10.1111/j.1365-2222.1977.tb01420.x; KRAFT D, 1976, BRIT J DERMATOL, V94, P593, DOI 10.1111/j.1365-2133.1976.tb05156.x; LEVINE BB, 1976, MANUAL CLIN IMMUNOLO, P637; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; MORENO F, 1995, INT ARCH ALLERGY IMM, V108, P74, DOI 10.1159/000237121; MOSS RB, 1984, J PEDIATR-US, V104, P460, DOI 10.1016/S0022-3476(84)81117-8; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297; PARKER PJ, 1991, J ALLERGY CLIN IMMUN, V88, P213, DOI 10.1016/0091-6749(91)90331-H; Patriarca G, 1996, J INVEST ALLERG CLIN, V6, P162; Romano A, 1997, CLIN EXP ALLERGY, V27, P1425, DOI 10.1111/j.1365-2222.1997.tb02987.x; Romano A, 1997, ALLERGY, V52, P89, DOI 10.1111/j.1398-9995.1997.tb02550.x; SCHWARTZ HJ, 1984, ANN ALLERGY, V52, P342; SILVIUDAN F, 1993, J ALLERGY CLIN IMMUN, V91, P694, DOI 10.1016/0091-6749(93)90188-L; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; VANDELLEN RG, 1981, J ALLERGY CLIN IMMUN, V68, P169, DOI 10.1016/0091-6749(81)90179-2; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x	31	245	254	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				918	924		10.1016/S0091-6749(99)70439-2	http://dx.doi.org/10.1016/S0091-6749(99)70439-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329829				2022-12-18	WOS:000080470200030
J	HIRSCHWEHR, R; VALENTA, R; EBNER, C; FERREIRA, F; SPERR, WR; VALENT, P; ROHAC, M; RUMPOLD, H; SCHEINER, O; KRAFT, D				HIRSCHWEHR, R; VALENTA, R; EBNER, C; FERREIRA, F; SPERR, WR; VALENT, P; ROHAC, M; RUMPOLD, H; SCHEINER, O; KRAFT, D			IDENTIFICATION OF COMMON ALLERGENIC STRUCTURES IN HAZEL POLLEN AND HAZELNUTS - A POSSIBLE EXPLANATION FOR SENSITIVITY TO HAZELNUTS IN PATIENTS ALLERGIC TO TREE POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; HAZEL POLLEN; HAZELNUT; IGE EPITOPES; RECOMBINANT TREE POLLEN ALLERGENS; BET V-I; PROFILIN	BIRCH-POLLEN; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; CROSS-REACTIVITY; BETULA-VERRUCOSA; IGE ANTIBODIES; EXTRACTS; PROTEINS; HYPERSENSITIVITY; VEGETABLES	It is known that most patients with type I allergy to tree pollens also suffer from intolerance to nuts. To identify allergenic structures common to hazel pollen and hazelnuts, cross-reactivity of patients' IgE was investigated. With use of immunoblotting, serum IgE from 25 patients displaying type I allergic reactions to tree pollens and intolerance to hazelnuts (group I) bound to the 17 kd major hazel pollen allergen Cor a I (100%) and to the 14 kd hazel pollen profilin (16%). IgE binding to proteins of comparable molecular weights in hazelnut extracts was found (18 kd and 14 kd), suggesting that proteins similar to Cor a I and hazel profilin might be also expressed in hazelnuts. In contrast, only four sera (22%) from 18 patients (group II) with tree pollen allergy but without any case history of nut hypersensitivity showed IgE binding to the 18 kd protein of hazelnut extract, and none of these sera exhibited IgE reactivity to the hazelnut profilin. To characterize the hazel pollen and hazelnut allergens, purified recombinant Bet v I (major birch pollen allergen) and purified recombinant Bet v II (birch profilin), respectively, were used for IgE-inhibition experiments. Bin&ng of IgE from patients (with nut allergy) to the blotted hazelnut allergens could be blocked by preincubation of patients' sera with the recombinant proteins. Furthermore, the 18 kd protein of hazelnut extract was purified and induced specific release of histamine from basophils of a patient suffering nut hypersensitivity but not from a healthy control donor. A rabbit antibody raised against celery profilin identified the 14 kd proteins in hazel pollen and hazelnuts as profilin. Our experiments suggest a protein with IgE binding properties similar to the major allergens from pollens of hazel, Cor a I, and of birch, Bet v I, as predominant allergens in hazelnuts, and show that the plant pan-allergen profilin can be detected in both hazel pollen and hazelnut extracts.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,AKH,INST CLIN CHEM & LAB DIAGNOST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,AKH,DEPT INTERNAL MED 1,DIV HEMATOL & HEMOSTASEOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna			Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Ferreira, Fatima/AAB-4321-2019; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Ferreira, Fatima/E-4889-2011; Sperr, Mast/V-4767-2019	Valent, Peter/0000-0003-0456-5095; Ferreira, Fatima/0000-0003-0989-2335; Gamperl, Susi/0000-0003-0456-5095; Ferreira, Fatima/0000-0003-0989-2335; Sperr, Mast/0000-0002-7778-5219; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365				ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ENDLER AT, 1987, CANCER INVEST, V5, P127, DOI 10.3109/07357908709018467; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FERREIRA F, IN PRESS MOL BIOL IM; FLORVAAG E, 1988, ANN ALLERGY, V61, P392; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; IPSEN H, 1990, EPITOPES ATOPIC ALLE, P3; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; LOWENSTEIN H, 1983, ALLERGY, V38, P577, DOI 10.1111/j.1398-9995.1983.tb04143.x; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEDERGAARD L, 1992, MOL IMMUNOL, V6, P703; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1992, ALLERGY S, V12, P276; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VALLIER P, IN PRESS CLIN EXP AL	33	245	252	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				927	936		10.1016/0091-6749(92)90465-E	http://dx.doi.org/10.1016/0091-6749(92)90465-E			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1281178				2022-12-18	WOS:A1992KD19000009
J	PLATTSMILLS, TAE; HAYDEN, ML; CHAPMAN, MD; WILKINS, SR				PLATTSMILLS, TAE; HAYDEN, ML; CHAPMAN, MD; WILKINS, SR			SEASONAL-VARIATION IN DUST MITE AND GRASS-POLLEN ALLERGENS IN DUST FROM THE HOUSES OF PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Chapman, Martin/0000-0002-0845-3632	PHS HHS [A120565] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aalberse R C, 1975, Dev Biol Stand, V29, P197; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1978, J MED ENTOMOL, V14, P484; BEUG HJ, 1960, Z HAUT GESCHLECHTSKR, V29, P267; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, IN PRESS J ALLERGY C; COOKSON J B, 1975, Clinical Allergy, V5, P375, DOI 10.1111/j.1365-2222.1975.tb01876.x; FERNANDEZCALDAS E, 1986, J ALLERGY CLIN IMMUN, V77, P197; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; Hughes, 1976, MITES STORED FOOD HO; KERN A, 1921, MED CLIN N AM, V5, P751; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; MARSH DG, 1975, ANTIGENS, V3, P271; MAUNSELL K, 1968, LANCET, V1, P1267; MCCULLOUGH JA, 1986, J ALLERGY CLIN IMMUN, V77, P130; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1980, ANN ALLERGY, V45, P347; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; Platts-Mills TAE, 1984, ASTHMA PHYSL IMMUNOP, P297; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPIEKSMA FTM, 1969, HOUSE DUST ATOPY HOU, P44; TOVEY E, 1979, CLIN ALLERGY, V9, P253, DOI 10.1111/j.1365-2222.1979.tb01551.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WOODS RA, 1986, J ALLERGY CLIN IMMUN, V77, P130	38	245	249	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					781	791		10.1016/0091-6749(87)90211-9	http://dx.doi.org/10.1016/0091-6749(87)90211-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571770				2022-12-18	WOS:A1987H434900014
J	Zaba, LC; Suarez-Farinas, M; Fuentes-Duculan, J; Nograles, KE; Guttman-Yassky, E; Cardinale, I; Lowes, MA; Krueger, JG				Zaba, Lisa C.; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Nograles, Kristine E.; Guttman-Yassky, Emma; Cardinale, Irma; Lowes, Michelle A.; Krueger, James G.			Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNF; psoriasis; etanercept; gene; T(H)17; T(H)1	INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; TUMOR-NECROSIS-FACTOR; T-CELL-CLONES; DENDRITIC CELLS; SKIN-LESIONS; DOUBLE-BLIND; KERATINOCYTE; MACROPHAGES; ARTHRITIS; INFLAMMATION	Background: TNF inhibitors have revolutionized the treatment of psoriasis vulgaris as well as psoriatic and. rheumatoid arthritis and Crohn disease. Despite our understanding that these agents block TNF, their complex mechanism of action in disease resolution is still unclear. Objective: To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment. Methods: In a clinical trial using etanercept TNF inhibitor to treat psoriasis vulgaris (n = 15), Affymetrix gene arrays were used to analyze gene profiles in lesional skin at multiple time point's during drug treatment (baseline and weeks 1, 2,4, and 12) compared with nonlesional skin. Patients were stratified as responders (n = 11) or nonresponders (n = 4) on the basis of histologic disease resolution. Cluster analysis was used to define gene sets that were modulated with similar magnitude and velocity over time. Results: In responders, 4 clusters of downregulated genes and 3 clusters of upregulated genes were identified. Genes downmodulated most rapidly reflected direct inhibition of myeloid lineage immune genes. Upregulated genes included the stable dendritic cell population genes CD1c and CD207 (langerin). Comparison of responders and nonresponders; revealed rapid downmodulation of innate IL-1 beta and IL-8 sepsis cascade cytokines in both groups, but only responders downregulated IL-17 pathway genes to baseline levels. Conclusion: Although both responders and nonresponders to etanercept inactivated sepsis cascade cytokines, response to etanercept is dependent on inactivation of myeloid dendritic cell genes and inactivation of the T(H)17 immune response. (J Allergy Clin Immunol 2009;124:1022-30.)	[Zaba, Lisa C.; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Nograles, Kristine E.; Guttman-Yassky, Emma; Cardinale, Irma; Lowes, Michelle A.; Krueger, James G.] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10065 USA	Rockefeller University; Rockefeller University	Krueger, JG (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave,Box 178, New York, NY 10065 USA.	jgk@rockefeller.edu	Nograles, Kristine/V-3648-2019; Zaba, Lisa/Q-9681-2019; Suarez-Farinas, Mayte/I-3558-2012; Lowes, Michelle A/G-9585-2016	Suarez-Farinas, Mayte/0000-0001-8712-3553; Zaba, Lisa/0000-0001-9036-5465; Lowes, Michelle A/0000-0003-4256-478X	Clinical and Translational Science [UL1RR024143]; National Institutes of Health Medical Scientist Training [GM07739, K23 AR052404-01A1]; Doris Duke Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102, UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR052404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	Clinical and Translational Science; National Institutes of Health Medical Scientist Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by a Clinical and Translational Science Award, grant no. UL1RR024143. L.C.Z. is supported by National Institutes of Health Medical Scientist Training Program (MSTP) grant no. GM07739, and M.A.L. by K23 AR052404-01A1 and the Doris Duke Foundation. Amgen supported this study by an unrestricted research grant to Rockefeller University. J.G.K. was a visiting lecturer at Amgen and received a small honorarium.	Basso AS, 2009, CELL RES, V19, P399, DOI 10.1038/cr.2009.26; Chang JCC, 1997, ARCH DERMATOL, V133, P703, DOI 10.1001/archderm.133.6.703; Chomarat P, 2003, J IMMUNOL, V171, P2262, DOI 10.4049/jimmunol.171.5.2262; CLARK IA, 1981, INFECT IMMUN, V32, P1058, DOI 10.1128/IAI.32.3.1058-1066.1981; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; D'Haens Geert, 2006, Curr Gastroenterol Rep, V8, P506, DOI 10.1007/s11894-006-0041-5; Diluvio L, 2006, J IMMUNOL, V176, P7104, DOI 10.4049/jimmunol.176.11.7104; Gottlieb AB, 2007, CURR MED RES OPIN, V23, P1081, DOI 10.1185/030079907X182112; Gottlieb Alice B, 2004, Dermatol Ther, V17, P401, DOI 10.1111/j.1396-0296.2004.04043.x; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; GREEN S, 1976, P NATL ACAD SCI USA, V73, P381, DOI 10.1073/pnas.73.2.381; Haider AS, 2008, J IMMUNOL, V180, P1913, DOI 10.4049/jimmunol.180.3.1913; HOFFMAN MK, 1986, LYMPHOKINE RES, V5, P255; Kasperska-Zajac A, 2005, INFLAMMATION, V29, P90, DOI 10.1007/s10753-006-9004-0; Koczan D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2419; Krueger G, 2004, ARCH DERMATOL, V140, P218, DOI 10.1001/archderm.140.2.218; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Nair RP, 2008, J INVEST DERMATOL, V128, P1653, DOI 10.1038/sj.jid.5701255; Nestle FO, 2005, E SCHERING RES FDN W, V50, P203; Nickoloff BJ, 2006, J AM ACAD DERMATOL, V54, pS143, DOI 10.1016/j.jaad.2005.10.059; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; ORTEGA C, 2009, J LEUKOC BIOL; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; PRINZ JC, 1994, EUR J IMMUNOL, V24, P593, DOI 10.1002/eji.1830240315; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toichi E, 2006, J IMMUNOL, V177, P4917, DOI 10.4049/jimmunol.177.7.4917; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; WEINSHENKER BG, 1989, J AM ACAD DERMATOL, V20, P1132, DOI 10.1016/S0190-9622(89)80200-2; Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194	35	244	246	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1022	1030		10.1016/j.jaci.2009.08.046	http://dx.doi.org/10.1016/j.jaci.2009.08.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895991	Green Accepted			2022-12-18	WOS:000272108000023
J	Garcia-Ara, C; Boyano-Martinez, T; Diaz-Pena, JM; Martin-Munoz, F; Reche-Frutos, M; Martin-Esteban, M				Garcia-Ara, C; Boyano-Martinez, T; Diaz-Pena, JM; Martin-Munoz, F; Reche-Frutos, M; Martin-Esteban, M			Specific IgE levels in the diagnosis of immediate hypersensitivity to cows' milk protein in the infant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cows' milk hypersensitivity; infant; specific IgE; skin prick test; predictive values; challenge test	FOOD HYPERSENSITIVITY; NATURAL-HISTORY; ALLERGY; CHALLENGES; CHILDREN; TESTS	Background: A milk-free diet with substitute formula should be established when immediate symptomatic hypersensitivity to cows' mills protein (CMP) is diagnosed, and therefore an accurate diagnosis is very important. Objective: This study aims to find the optimal cutoff values for specific IgE antibody levels that discriminate between allergic and tolerant infants by using cows' milk and its principal proteins as allergens. Methods: A prospective study was carried out on 170 patients under 1 year old (mean, 4.8 months). These patients were seen consecutively over a 4-year period in our outpatient clinic and for the first time because of a reaction suggesting immediate hypersensitivity after ingestion of cows' milk formula. A clinical history, prick test with cows' milk and its proteins (alpha -lactalbumin, beta -lactoglobulin, and casein), determination of specific IgE antibodies with the CAP system FEIA for the same allergens as for the prick test, and a challenge test according to the diagnostic protocol were performed in all of the children. A study of validity of the prick test (cutoff point, 3 mm) and CAP system by using different cutoff points in the specific IgE, values for cows' milk and its proteins were also analyzed. Results: Prevalence of immediate symptomatic hypersensitivity to CMP in this study was 44%. When both the whole milk and its principal milk proteins were used in the prick test, the negative predictive value was very high, and a negative value excluded allergy in 97% of the patients. When the different cutoff points of the specific IgE for milk were analyzed, 2.5 KUA/L, had a positive predictive value of 90% and 5 KUA/L had a positive predictive value of 95%. Conclusions: When diagnosing immediate hypersensitivity to CMP in infants, negative skin test responses exclude allergy in most of the patients, if the prick test response is positive, specific IgE levels for cows' milk may be helpful. If these values are 2.5 KUA/L or greater, the challenge test should not be performed because of its high positive predictive value (90%).	Hosp Univ La Paz, Serv Alergia Infantil, Madrid, Spain	Hospital Universitario La Paz	Garcia-Ara, C (corresponding author), C Alfredo Marquerie 18,4,C, Madrid 28034, Spain.							Bindslev-Jensen C, 1998, ALLERGY, V53, P72, DOI 10.1111/j.1398-9995.1998.tb04966.x; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P86; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Businco L, 1993, Pediatr Allergy Immunol, V4, P101, DOI 10.1111/j.1399-3038.1993.tb00077.x; *EX COMM AM AC ALL, 1992, J ALLERGY CLIN IMMUN, V90, P263; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; KAIRISTO V, 1995, SCAND J CLIN LAB INV, V55, P43, DOI 10.3109/00365519509088450; NORGAARD A, 1992, ALLERGY, V47, P503, DOI 10.1111/j.1398-9995.1992.tb00673.x; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P6	17	244	252	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					185	190		10.1067/mai.2001.111592	http://dx.doi.org/10.1067/mai.2001.111592			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150010	Bronze			2022-12-18	WOS:000166533300030
J	GERGEN, PJ; TURKELTAUB, PC; KOVAR, MG				GERGEN, PJ; TURKELTAUB, PC; KOVAR, MG			THE PREVALENCE OF ALLERGIC SKIN-TEST REACTIVITY TO 8 COMMON AEROALLERGENS IN THE UNITED-STATES POPULATION - RESULTS FROM THE 2ND NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GERGEN, PJ (corresponding author), NATL CTR HLTH STAT,ALLERGEN PROD LAB,CTR BLDG,ROOM 2-58,3700 EW HIGHWAY,HYATTSVILLE,MD 20782, USA.		turkeltaub, paul/AAG-6160-2019; turkeltaub, paul/U-7729-2019; Holloway, John/B-5424-2009	Holloway, John/0000-0001-9998-0464; turkeltaub, paul/0000-0002-7350-1469				APPEL SJ, 1961, PENN MED J, V64, P621; BANDELE EO, 1983, J NATL MED ASSOC, V75, P511; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BLOCH KJ, 1984, J ALLERGY CLIN IMMUN, V74, P482, DOI 10.1016/0091-6749(84)90382-8; BOWMAN KL, 1935, J ALLERGY, V7, P39; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CHAMBERS VV, 1958, J ALLERGY, V29, P249, DOI 10.1016/0021-8707(58)90009-1; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; Cserhati E, 1983, Acta Paediatr Hung, V24, P189; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; CYPRESS BK, 1983, DHHS PHS831732 PUBL; DAWSON B, 1969, LANCET, V1, P827; EPSTEIN WL, 1981, J ALLERGY CLIN IMMUN, V68, P20, DOI 10.1016/0091-6749(81)90118-4; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FROSTAD AB, 1977, INT ARCH ALLER A IMM, V55, P35, DOI 10.1159/000231905; GERGEN PJ, 1986, DHHS PHS861685 PUBL; GILCHREST BA, 1982, J INVEST DERMATOL, V79, P11, DOI 10.1111/1523-1747.ep12510417; GLEICH GJ, 1974, INT C SERIES, V323, P44; GREGG I, 1977, ASTHMA; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HAAHTELA T, 1980, ALLERGY, V35, P433, DOI 10.1111/j.1398-9995.1980.tb01790.x; HAAHTELA T, 1979, ALLERGY, V34, P413, DOI 10.1111/j.1398-9995.1979.tb02011.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; HIGGINS JE, 1977, INT STAT REV, V45, P51; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAY MMB, 1979, INT C SERIES, V469, P442; LANDIS JR, 1976, COMPUT PROG BIOMED, V6, P196, DOI 10.1016/0010-468X(76)90037-4; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; MCDOWELL A, 1981, DHHS PHS811317 PUBL; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; PASCUAL HC, 1977, ANN ALLERGY, V39, P325; Pearson RSB, 1937, Q J MED, V6, P165; PEDERSEN PA, 1981, ALLERGY, V36, P175, DOI 10.1111/j.1398-9995.1981.tb01833.x; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; SHERRY MN, 1968, ANN ALLERGY, V26, P335; SMITH JM, 1983, ALLERGY PRINCIPLES P, P771; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; TAN WC, 1979, ANN ALLERGY, V43, P44; TIPTON WR, 1983, PEDIATR CLIN N AM, V30, P785; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; [No title captured]; 1969, CURRENT POPULATI P23, V28; 1976, NATIONAL CTR HLTH ST	58	244	253	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					669	679		10.1016/0091-6749(87)90286-7	http://dx.doi.org/10.1016/0091-6749(87)90286-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	K9930	3680811				2022-12-18	WOS:A1987K993000006
J	Lanier, B; Bridges, T; Kulus, M; Taylor, AF; Berhane, I; Vidaurre, CF				Lanier, Bob; Bridges, Tracy; Kulus, Marek; Taylor, Angel Fowler; Berhane, Indrias; Vidaurre, Carlos Fernandez			Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; omalizumab; IgE; allergic; anti-IgE; exacerbation; child; pediatric	QUALITY-OF-LIFE; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; ANTIBODY OMALIZUMAB; FLUTICASONE; MONTELUKAST; SAFETY; METAANALYSIS; ADOLESCENTS; MANAGEMENT	Background: Many children with asthma continue to experience symptoms despite available therapies. Objective: This study evaluated the efficacy and safety of omalizumab, a humanized anti-IgE mAb, in children with moderate-to-severe persistent allergic (IgE-mediated) asthma that was inadequately controlled despite treatment with medium-dose or high-dose inhaled corticosteroids (ICSs) with or without other controller medications. Methods: A randomized, double-blind, placebo-controlled trial enrolled children age 6 to < 12 years with perennial allergen sensitivity and history of exacerbations and asthma symptoms despite at least medium-dose ICSs. Patients were randomized 2:1 to receive omalizumab (75-375 mg sc, q2 or q4 wk) or placebo over a period of 52 weeks (24-week fixed-steroid phase followed by a 28-week adjustable-steroid phase). Results: A total of 627 patients (omalizumab, n = 421; placebo, n = 206) were randomized, with efficacy analyzed in 576 (omalizumab, n = 384; placebo, n = 192). Over the 24-week fixed-steroid phase, omalizumab reduced the rate of clinically significant asthma exacerbations (worsening symptoms requiring doubling of baseline ICS dose and/or systemic steroids) by 31% versus placebo (0.45 vs 0.64; rate ratio, 0.69, P = .007). Over a period of 52 weeks, the exacerbation rate was reduced by 43% versus placebo (P < .001). Omalizumab significantly reduced severe exacerbations. Over a period of 52 weeks, omalizumab had an acceptable safety profile, with no difference in overall incidence of adverse events compared with placebo. Conclusion: Add-on omalizumab is effective and well tolerated as maintenance therapy in children (6 to < 12 years) with mode rate-to-severe persistent allergic (IgE-mediated) asthma whose symptoms are inadequately controlled despite medium to high doses of ICSs. Q Allergy Clin Immunol 2009;124:1210-6.)	[Lanier, Bob] Univ N Texas, Dept Pediat, Ft Worth, TX 76132 USA; [Bridges, Tracy] Asthma & Allergy Clin Georgia, Albany, GA USA; [Kulus, Marek] Med Univ Warsaw, Dept Pediat Resp Dis & Allergy, Warsaw, Poland; [Taylor, Angel Fowler; Berhane, Indrias; Vidaurre, Carlos Fernandez] Novartis Pharmaceut, E Hanover, NJ USA	University of North Texas System; University of North Texas Health Science Center; Medical University of Warsaw; Novartis	Lanier, B (corresponding author), Univ N Texas, Dept Pediat, 6407 Southwest Blvd, Ft Worth, TX 76132 USA.	boblaniermd@askdrbob.com	Kulus, Marek/W-4821-2018	Kulus, Marek/0000-0002-5360-4372	Novartis Pharma AG	Novartis Pharma AG	Supported by Novartis Pharma AG.	Adams NP, 2006, RESP MED, V100, P1297, DOI 10.1016/j.rmed.2006.04.015; Allen DB, 2002, PEDIATR PULM, V33, P208, DOI 10.1002/ppul.10040; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Bousquet J, 2002, CLIN THER, V24, P1, DOI 10.1016/S0149-2918(02)85002-0; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chipps B, 2006, CURR MED RES OPIN, V22, P2201, DOI 10.1185/030079906X148643; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; CORREN J, 2009, CLIN EXP ALLERG 0317; Ekins-Daukes S, 2002, BRIT MED J, V324, P1374, DOI 10.1136/bmj.324.7350.1374; *ENV PROT AG, 402F04019 EPA; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; Gelfand EW, 2008, ALLERGY ASTHMA PROC, V29, P99, DOI 10.2500/aap.2008.29.3090; Global Initiative for Asthma, NIH PUBL, V02-3659; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; HOLT S, 2001, BRIT MED J, V323, P1, DOI DOI 10.1136/BMJ.323.7307.253; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kelly HW, 2008, PEDIATRICS, V122, pE53, DOI 10.1542/peds.2007-3381; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Larsen GL, 2001, DM-DIS MON, V47, P34; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; National Heart Lung and Blood Institute, 2007, NIH PUBL; NG D, 2004, COCHRANE DB SYST REV; *NIH, NIH PUBL; Ostrom NK, 2005, J PEDIATR-US, V147, P213, DOI 10.1016/j.jpeds.2005.03.052; Paul EF, 2002, SOCIETY, V39, P7, DOI 10.1007/s12115-002-1000-x; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Randell Tabitha L, 2003, Paediatr Drugs, V5, P481, DOI 10.2165/00148581-200305070-00005; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; *XOL, XOL OM FULL PRESCR I; *XOL, 2007, XOL OM PROD INF SUMM	41	243	260	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1210	1216		10.1016/j.jaci.2009.09.021	http://dx.doi.org/10.1016/j.jaci.2009.09.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910033				2022-12-18	WOS:000273071500011
J	Sicherer, SH; Furlong, TJ; Maes, HH; Desnick, RJ; Sampson, HA; Gelb, BD				Sicherer, SH; Furlong, TJ; Maes, HH; Desnick, RJ; Sampson, HA; Gelb, BD			Genetics of peanut allergy: A twin study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; hypersensitivity; food allergy; genetics; twin studies	ATOPIC DISEASES; FAMILY; FOOD	Background: The role of genetics in the etiology of peanut allergy is unknown, For complex genetic traits, twin studies can provide information on the relative contribution of genetic factors to a disease, as the relative confounding effects of environmental factors are markedly decreased. Objective: This study was performed to search for evidence that genetic factors influence peanut allergy by comparing the concordance rate for this allergy among monozygotic and dizygotic twins. Methods: Twin pairs with at least one member with peanut allergy were ascertained through the Food Allergy Network by advertisements in the organization's newsletters and Web site. Individuals with peanut allergy or parental surrogates were interviewed by telephone. A full atopic history was obtained, and peanut allergy and zygosity were determined using previously validated questionnaires. Heritability of peanut allergy was determined using univariate genetic model fitting by maximum likelihood with the Mr statistical modeling software package. Results: Seventy-five twin pairs were recruited. Seventeen pairs were excluded because of unconvincing peanut allergy histories (9 pairs, including 4 of uncertain zygosity) or because one twin had reportedly never ingested peanut (8 pairs). The median age of the 58 remaining twin pairs was 5 years (range 1 to 58 years), Seventy individuals had peanut allergy, In addition to convincing histories of peanut allergy, 52 (74%) had been tested (skin prick testing with or without radioallergosorbent assay) and all had positive reactions to peanut. Twenty-nine of the 70 had experienced >1 reaction to peanut; 29 of 70 had multisystem reactions. Among the monozygotic pairs (n = 14), 9 were concordant For peanut allergy (pairwise concordance, 64.3%) and among dizygotic pairs (n = 44), 3 were concordant for peanut allergy (pairwise concordance, 6.8%; chi(2) = 21,38, P < .0001), Heritability of peanut allergy was estimated at 81.6% (95% confidence interval 41.6% to 99.7%) with model fitting using a population prevalence of peanut allergy of 0.4%, Conclusions: The significantly higher concordance rate of peanut allergy among monozygotic twins suggests strongly that there is a significant genetic influence on peanut allergy.	CUNY Mt Sinai Sch Med, Div Allergy Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Virginia Commonwealth Univ, Dept Human Genet, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA; Food Allergy Network, Fairfax, VA USA; Katholieke Univ Leuven, Ctr Phys Dev Res, Louvain, Belgium	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; KU Leuven	Sicherer, SH (corresponding author), CUNY Mt Sinai Sch Med, Div Allergy Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, Box 1198,1 Gustav L Levy Pl, New York, NY 10029 USA.				NHLBI NIH HHS [HL60688] Funding Source: Medline; NIAID NIH HHS [K23 AI 01709-01] Funding Source: Medline; NICHD NIH HHS [HD28822-08] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; CAVALLISFORZA LL, 1971, GENETICS HUMAN POPUL, P565; EAVES LJ, 1978, HEREDITY, V41, P249, DOI 10.1038/hdy.1978.101; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; HRUBEC Z, 1973, AM J HUM GENET, V25, P15; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; NEALE MC, 1999, MX STAT MODELING; Rasanen M, 1998, ALLERGY, V53, P885, DOI 10.1111/j.1398-9995.1998.tb03996.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1	19	243	258	5	41	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				53	56						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887305				2022-12-18	WOS:000088393300007
J	ZEISS, CR; PATTERSON, R; PRUZANSKY, JJ; MILLER, MM; ROSENBERG, M; LEVITZ, D				ZEISS, CR; PATTERSON, R; PRUZANSKY, JJ; MILLER, MM; ROSENBERG, M; LEVITZ, D			TRIMELLITIC ANHYDRIDE-INDUCED AIRWAY SYNDROMES - CLINICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,CHICAGO,IL 60611	Northwestern University; Northwestern University								BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MELAM H, 1970, J ALLERGY, V45, P46; PATTERSO.R, 1965, J CLIN INVEST, V44, P140, DOI 10.1172/JCI105120; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PAULY JL, 1973, J LAB CLIN MED, V82, P500; PEPYS J, 1974, ANN NY ACAD SCI, V221, P27, DOI 10.1111/j.1749-6632.1974.tb28195.x; PLOTZ CM, 1956, AM J MED, V21, P893, DOI 10.1016/0002-9343(56)90104-8; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; SCHATZ M, 1976, CLIN EXP IMMUNOL, V24, P33; ZEISS CR, 1973, J IMMUNOL, V110, P414	15	243	244	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					96	103		10.1016/0091-6749(77)90033-1	http://dx.doi.org/10.1016/0091-6749(77)90033-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	68964	Bronze			2022-12-18	WOS:A1977DR44800002
J	Caubet, JC; Kaiser, L; Lemaitre, B; Fellay, B; Gervaix, A; Eigenmann, PA				Caubet, Jean-Christoph; Kaiser, Laurent; Lemaitre, Barbara; Fellay, Benoit; Gervaix, Alain; Eigenmann, Philippe A.			The role of penicillin in benign skin rashes in childhood: A prospective study based on drug rechallenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; virus; skin rash; children; penicillin; beta-lactam; cephalosporin; oral challenge; skin test; blood allergy test	NONIMMEDIATE REACTIONS; DIAGNOSIS; ALLERGY; ANTIBIOTICS; CHALLENGE; HISTORY	Background: Delayed-onset urticarial or maculopapular rashes are frequently observed in children treated with beta-lactams. Many are labeled "allergic" without reliable testing. Objective: Determine the etiology of these rashes by exploring both infectious and allergic causes. Methods: Children presenting to the emergency department with delayed-onset urticarial or maculopapular rashes were enrolled. Acute and convalescent sera were obtained for viral screening along with a throat swab. Subjects underwent intradermal and patch skin testing for beta-lactams 2 months after presentation. Anti-beta-lactam blood allergy tests were also obtained. All subjects underwent an oral challenge test (OCT) with the culprit antibiotic. Results: Eighty-eight children were enrolled between 2006 and 2008. There were 11 (12.5%) positive intradermal and no positive patch tests. There were 2 (2.3%) positive blood allergy tests. There were 6 (6.8%) subjects with a positive OCT, 2 were intradermal-negative, and 4 were intradermal-positive. No OCT reactions were more severe than the index event. Most subjects had at least 1 positive viral study, 54 (65.9%) in the OCT negative group. Conclusion: In this situation, beta-lactam allergy is clearly overdiagnosed because the skin rash is only rarely reproducible (6.8%) by a subsequent challenge. Viral infections may be an important factor in many of these rashes. OCTs were positive in a minority of intradermal skin test-positive subjects. Patch testing and blood allergy testing provided no useful information. OCTs should be considered in all children who develop a delayed-onset urticarial or maculopapular rash during treatment with a beta-lactam. (J Allergy Clin Immunol 2011;127:218-22.)	[Caubet, Jean-Christoph; Gervaix, Alain; Eigenmann, Philippe A.] Univ Hosp Geneva, Dept Child & Adolescent, Geneva, Switzerland; [Kaiser, Laurent; Lemaitre, Barbara] Univ Hosp Geneva, Virol Lab, Div Infect Dis, Geneva, Switzerland; [Kaiser, Laurent; Lemaitre, Barbara] Univ Hosp Geneva, Div Lab Med, Geneva, Switzerland; [Kaiser, Laurent; Lemaitre, Barbara] Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland; [Fellay, Benoit] Cantonal Hosp Fribourg, Cent Labs, Fribourg, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Eigenmann, PA (corresponding author), Hop Univ Geneve, Dept Pediat, 6 RueWilly Donze, CH-1211 Geneva, Switzerland.	Philippe.Eigenmann@hcuge.ch	Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826; Kaiser, Laurent/0000-0002-0857-2252	Geneva University Hospitals [06- I 7]; Swiss National Foundation [3200B 101670]; Swiss National Foundation	Geneva University Hospitals; Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss National Foundation(Swiss National Science Foundation (SNSF))	Supported by a Geneva University Hospitals Research & Development Award #06- I 7 and in part by a Swiss National Foundation research grant (3200B 101670).; L. Kaiser has received research support from the Swiss National Foundation. P. A. Eigenmann has received speakers' honoraria from Phadia. The rest of the authors have declared that they have no conflict of interest.	ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; BIERMAN CW, 1972, J AMER MED ASSOC, V220, P1098, DOI 10.1001/jama.220.8.1098; Blanca M, 2000, ALLERGY, V55, P998, DOI 10.1034/j.1398-9995.2000.00628.x; Blanca-Lopez N, 2009, ALLERGY, V64, P229, DOI 10.1111/j.1398-9995.2008.01903.x; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Cherry JD, 2009, FEIGIN CHERRYS TXB P, P755; Cohen AD, 2001, INT J DERMATOL, V40, P41, DOI 10.1046/j.1365-4362.2001.00081.x; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Fernandez TD, 2009, CURR OPIN INFECT DIS, V22, P272, DOI 10.1097/QCO.0b013e3283298e62; Garbino J, 2009, THORAX, V64, P399, DOI 10.1136/thx.2008.105155; Goldberg A, 2008, ANN ALLERG ASTHMA IM, V100, P37, DOI 10.1016/S1081-1206(10)60402-4; HOPESIMPSON RE, 1969, PROG MED VIROL, V11, P354; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; Jappe U, 2007, ALLERGY, V62, P1474, DOI 10.1111/j.1398-9995.2007.01518.x; Langley JM, 2002, CLIN INVEST MED, V25, P181; Machin D, 1997, BLACKWELL SCI, P132; MacLaughlin EJ, 2000, ARCH FAM MED, V9, P722, DOI 10.1001/archfami.9.8.722; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; Ponvert C, 2007, ALLERGY, V62, P42, DOI 10.1111/j.1398-9995.2006.01246.x; Romano A, 2000, Paediatr Drugs, V2, P101, DOI 10.2165/00148581-200002020-00003; Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x; Stur K, 2007, J INVEST DERMATOL, V127, P802, DOI 10.1038/sj.jid.5700648; Tapparel C, 2009, EMERG INFECT DIS, V15, P719, DOI 10.3201/eid1505.081286; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Vega Alonso T, 2003, Aten Primaria, V32, P517, DOI 10.1157/13054673	25	242	245	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					218	222		10.1016/j.jaci.2010.08.025	http://dx.doi.org/10.1016/j.jaci.2010.08.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21035175	Green Published, Bronze			2022-12-18	WOS:000285917300031
J	Shore, SA; Schwartzman, IN; Mellema, MS; Flynt, L; Imrich, A; Johnston, RA				Shore, SA; Schwartzman, IN; Mellema, MS; Flynt, L; Imrich, A; Johnston, RA			Effect of leptin on allergic airway responses in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway responsiveness; bronchoalveolar lavage; cytokines; IgE; leptin; ovalbumin	BODY-MASS INDEX; MURINE ASTHMA MODEL; IMMUNE-RESPONSES; CELL ACTIVATION; GENE-PRODUCT; OBESE GENE; HYPERRESPONSIVENESS; WEIGHT; PROLIFERATION; EXPRESSION	Background: Epidemiologic data indicate that the incidence of asthma is increased in obese patients. Objective: Because the serum levels of the satiety hormone and proinflammatory cytokine leptin are increased in obese individuals, we sought to determine whether leptin can augment allergic airway responses. Methods: We sensitized and challenged BALB/cJ mice with ovalbumin. Alzet(R) micro-osmotic pumps were implanted in the mice to deliver a continuous infusion of either saline or leptin (1.75 mug/g/d). Two days later, the mice were challenged with either aerosolized saline or ovalbumin once per day for 3 days. We measured airway responsiveness, performed bronchoalveolar ravage, and obtained blood to measure serum leptin and IgE 24 or 48 hours after the last challenge. Results: Leptin infusion increased serum leptin concentrations, which were increased further after ovalbumin sensitization and challenge. Ovalbumin challenge increased bronchoalveolar lavage fluid cells and cytokines, serum IgE, lung cytokine mRNA expression, and responses to inhaled, aerosolized methacholine. It is important to note that the changes in methacholine responsiveness and IgE were augmented in leptin- versus saline-infused mice. Conclusions: These results indicate that serum leptin is increased during allergic reactions in the airways and may play a role in the relationship between obesity and asthma.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Shore, SA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Bldg 1,Room 311,665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu		Johnston, Richard/0000-0003-0686-5139	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009, T32HL007118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07118, HL33009] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; BRUNO A, 2002, AM J RESP CRIT CARE, V165, pA559; Bryson JM, 1999, AM J PHYSIOL-ENDOC M, V276, pE358, DOI 10.1152/ajpendo.1999.276.2.E358; Busso N, 2002, J IMMUNOL, V168, P875, DOI 10.4049/jimmunol.168.2.875; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen Y, 1999, AM J EPIDEMIOL, V150, P255, DOI 10.1093/oxfordjournals.aje.a009996; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; Creutzberg EC, 2000, AM J RESP CRIT CARE, V162, P1239, DOI 10.1164/ajrccm.162.4.9912016; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Kanehiro A, 2002, J IMMUNOL, V169, P4190, DOI 10.4049/jimmunol.169.8.4190; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Makimura Hideo, 2003, BMC Physiol, V3, P5, DOI 10.1186/1472-6793-3-5; Malendowicz LK, 2000, ENDOCR RES, V26, P141, DOI 10.3109/07435800009066158; Mancuso P, 2002, J IMMUNOL, V168, P4018, DOI 10.4049/jimmunol.168.8.4018; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Morimoto I, 2000, NEUROENDOCRINOLOGY, V71, P366, DOI 10.1159/000054557; Murad A, 2003, FASEB J, V17, P1895, DOI 10.1096/fj.03-0068fje; Mykoniatis A, 2003, GASTROENTEROLOGY, V124, P683, DOI 10.1053/gast.2003.50101; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; O'Donnell CP, 1999, AM J RESP CRIT CARE, V159, P1477, DOI 10.1164/ajrccm.159.5.9809025; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602, DOI 10.1164/ajrccm.164.4.2001016; Shore SA, 2002, ASTHMA COPD BASIC ME, P79; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; TEPPER JS, 1997, AM J RESP CRIT CARE, V155, pA160; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; Umemoto Y, 1997, BLOOD, V90, P3438, DOI 10.1182/blood.V90.9.3438; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	45	242	259	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					103	109		10.1016/j.jaci.2004.10.007	http://dx.doi.org/10.1016/j.jaci.2004.10.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637554				2022-12-18	WOS:000226267000014
J	Hoshino, M; Nakamura, Y; Sim, JJ; Shimojo, J; Isogai, S				Hoshino, M; Nakamura, Y; Sim, JJ; Shimojo, J; Isogai, S			Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BASEMENT-MEMBRANE; MONOCLONAL-ANTIBODIES; METHACHOLINE; INHIBITOR; TENASCIN; RESPONSIVENESS; COLLAGENASE; IMBALANCE; DISEASE; IV	Background: Bronchial asthma is characterized by airway structural changes, including mucosal inflammation and subepithelial collagen deposition. An imbalance between the matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) is thought to play a critical role in the synthesis or degradation of the extracellular matrix of the airway architecture, However, the relationship between subepithelial basement membrane thickness and these enzymes in asthma has not been determined. Objective: We compared the thickness of collagen and tenascin deposition and the expression of MMP-9 and TIMP-1 in bronchial biopsy specimens from subjects with asthma and control subjects, Methods: Bronchial biopsy specimens were obtained from 25 subjects with asthma and 10 healthy control subjects to estimate the extent of collagen and tenascin deposition in subepithelial reticular basement membrane by immunohistochemical staining. Using a computer-assisted image analysis system, He quantitated expression of both epithelial and submucosal MMP-9 and TIMP-1. The numbers of inflammatory cells were also determined. Results: Subjects with asthma exhibited greater thickness of collagen III (P < .01), collagen V (P < .01), and tenascin (P < .01) deposition in reticular basement membrane than did control subjects. The proportions of epithelium and submucosa immunoreactive to MMP-9 and TIMP-1 were significantly higher in the subjects with asthma than in the control subjects (each P < .001). Submucosal expression of MMP-9 was significantly higher than that of TIMP-1 in subjects with asthma (P < .01). Significant correlations were found between the number of myofibroblasts and thicknesses of collagen III (r(s) = 0.70, P <,001), collagen III (r(s) = 0.67, P < .001), and tenascin (r(s) = 0.58, P < .01) in subjects with asthma. On the other hand, the number of eosinophils was correlated with degree of mucosal expression of MMP-9 (r(s) = 0.43, P < .05) and TIMP-1 (r(s) = 0.69, P < .001). In subjects with asthma, a significant inverse correlation was found between subepithelial fibrosis and FEV1 (type III collagen, r(s) = -0.89, P < .001; type V collagen. r(s) = -0.90, P < .001; tenascin, r(s) = -0.88, P < .001), and airway responsiveness (type III collagen, r(s) = -0.59, P < .01; type V collagen, r(s) = -0.47, P < . 05; tenascin, r(s) = -0.18, P < .05). Conclusion: These findings suggest that collagen III, collagen V, and tenascin deposition in basement membrane in subjects with bronchial asthma are associated with increased expression of MMP-9, which may be produced by eosinophils, and that airway remodeling in subjects with asthma may he related to air-flow obstruction and airway hyperresponsiveness.	Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, Tokyo, Japan		Hoshino, M (corresponding author), Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, 6-11-1 Omori Nishi, Tokyo, Japan.		Nakamura, Yutaka/AAE-1546-2019	Nakamura, Yutaka/0000-0001-8717-1475				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DELACOURT C, 1995, AM J RESP CRIT CARE, V152, P765, DOI 10.1164/ajrccm.152.2.7633740; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; EHRISMANN RC, 1986, CELL, V47, P131; EMONARD H, 1990, CELL MOL BIOL, V36, P131; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; HOWEEDY AA, 1990, LAB INVEST, V63, P798; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KODAMA S, 1987, COLLAGEN REL RES, V7, P341; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAMBERT RK, 1991, J APPL PHYSIOL, V71, P666, DOI 10.1152/jappl.1991.71.2.666; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MARTRISIAN LM, 1990, TRENDS GENET, V6, P121; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; MERKER HJ, 1994, MICROSC RES TECHNIQ, V28, P95, DOI 10.1002/jemt.1070280203; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OCONNOR CM, 1994, THORAX, V49, P602, DOI 10.1136/thx.49.6.602; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; ROCHE WR, 1989, LANCET, V1, P520; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; ZUCKER S, 1993, CANCER RES, V53, P140	33	242	252	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					783	788		10.1016/S0091-6749(98)70018-1	http://dx.doi.org/10.1016/S0091-6749(98)70018-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819295				2022-12-18	WOS:000077033400012
J	ROUSSET, F; ROBERT, J; ANDARY, M; BONNIN, JP; SOUILLET, G; CHRETIEN, I; BRIERE, F; PENE, J; DEVRIES, JE				ROUSSET, F; ROBERT, J; ANDARY, M; BONNIN, JP; SOUILLET, G; CHRETIEN, I; BRIERE, F; PENE, J; DEVRIES, JE			SHIFTS IN INTERLEUKIN-4 AND INTERFERON-GAMMA PRODUCTION BY T-CELLS OF PATIENTS WITH ELEVATED SERUM IGE LEVELS AND THE MODULATORY EFFECTS OF THESE LYMPHOKINES ON SPONTANEOUS IGE SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STIMULATORY FACTOR-I; HUMAN B-CELLS; RECOMBINANT HUMAN INTERLEUKIN-4; NORMAL HUMAN-LYMPHOCYTES; LOW AFFINITY RECEPTOR; IFN-GAMMA; MONOCLONAL-ANTIBODY; INVITRO SYNTHESIS; IL-4; CD23	Interleukin-4 (IL-4) has been demonstrated to induce IgE synthesis by peripheral blood mononuclear cells (PBMNCs) of healthy donors. In this study, we demonstrated that IL-4 also can enhance spontaneous IgE synthesis by PBMNCs of allergic/atopic patients and patients with Buckley's or hyper-IgE syndrome. Spontaneous IgE production by PBMNCs of these patients was suppressed by interferon (IFN)-gamma or IFN-alpha in a dose-dependent fashion. Despite high serum IgE levels, no IL-4 could be detected in the serum of the patients, but indirect evidence was obtained indicating that enhanced IL-4 production in vivo may be associated with the high serum-IgE levels in these patients. Spontaneous IL-4 production was measured in PBMNC cultures of 4/21 patients tested. Furthermore, spontaneous IgE synthesis by PBMNCs of three other patients of seven tested in vitro was partly blocked by anti-IL-4 antiserum. In addition, levels of soluble CD23 (which is specifically induced by IL-4) were strongly elevated in sera of patients. Finally, activation of PBMNCs of the patients resulted in levels of IL-4 and of IFN-gamma synthesis that were higher and lower, respectively, than levels produced by PBMNCs of healthy control donors tested in parallel. Collectively, our data indicate that spontaneous IgE synthesis in vitro can be modulated by IL-4, IL-5, IFN-gamma, and IFN-alpha. In addition, our data suggest that enhanced IL-4 and reduced IFN-gamma production is associated with the elevated serum IgE levels observed in these patients.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304; UNICET,IMMUNOBIOL RES LAB,DARDILLY,FRANCE; HOP DEBROUSSE,F-69005 LYONS,FRANCE; HOP HOTEL DIEU,LYONS,FRANCE; HOP ST ELOI,MONTPELLIER,FRANCE	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; CHU Lyon; Universite de Montpellier; CHU de Montpellier			Robert, Jacques/B-2179-2008	Robert, Jacques/0000-0003-4380-1476				BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1988, EUR J IMMUNOL, V18, P117, DOI 10.1002/eji.1830180118; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; CHRETIEN I, 1988, J IMMUNOL, V141, P3128; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P67, DOI 10.1016/0022-1759(89)90120-8; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DEFRANCE T, 1988, J IMMUNOL, V141, P2000; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DELESPESSE G, 1988, IMMUNOL INVEST, V17, P363, DOI 10.3109/08820138809049845; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DEVRIES JE, 1989, IMMUNOL REV, V109, P119; FAVRE C, 1989, MOL IMMUNOL, V26, P17, DOI 10.1016/0161-5890(89)90015-1; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GILLIS S, 1978, J IMMUNOL, V120, P2027; KAWABE T, 1988, J IMMUNOL, V141, P1376; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Ring J, 1989, Curr Probl Dermatol, V18, P79; ROUSSET F, 1988, J IMMUNOL, V140, P2625; SARFATI M, 1988, J IMMUNOL, V141, P2195; SARFATI M, 1984, IMMUNOLOGY, V53, P207; SARFATI M, 1984, IMMUNOLOGY, V53, P197; SAVELKOUL HFJ, 1988, J IMMUNOL, V141, P749; SOUILLET G, 1989, LANCET, V1, P1384; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; YANG XD, 1988, EUR J IMMUNOL, V18, P1699, DOI 10.1002/eji.1830181107; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388	41	242	245	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				58	69		10.1016/0091-6749(91)90213-8	http://dx.doi.org/10.1016/0091-6749(91)90213-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1825101				2022-12-18	WOS:A1991EX98500008
J	GLEICH, GJ				GLEICH, GJ			THE LATE PHASE OF THE IMMUNOGLOBULIN-E - MEDIATED REACTION - A LINK BETWEEN ANAPHYLAXIS AND COMMON ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT MED,ALLERG DIS RES LAB,ROCHESTER,MN 55905	Mayo Clinic	GLEICH, GJ (corresponding author), MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, P50AI011483, R01AI009728, R37AI009728, R37AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11483, AI-15231, AI-9728] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1979, ALLERGY, V34, P121, DOI 10.1111/j.1398-9995.1979.tb01372.x; Ackerman S., 1982, Advances in host defense mechanisms. Volume 1: Phagocytic cells., P269; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BAUR X, 1980, ALLERGY, V35, P383, DOI 10.1111/j.1398-9995.1980.tb01783.x; BLACKLEY C, 1959, EXPT RES CAUSES NATU, P77; BROSTOFF J, 1979, LANCET, V1, P1268; BROWN SJ, J IMMUNOLOGY; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; Cooke RA, 1922, J IMMUNOL, V7, P219; DAHL R, 1978, ALLERGY, V33, P120, DOI 10.1111/j.1398-9995.1978.tb01520.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DESSEIN AJ, 1981, J EXP MED, V153, P423, DOI 10.1084/jem.153.2.423; DESSEIN AJ, 1982, ADV HOST DEFENSE MEC, V1, P243; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOLOVICH J, 1981, CAN MED ASSOC J, V124, P1557; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; DVORACEK JE, 1979, J ALLERGY CLIN IMMUN, V63, P210; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GLEICH GJ, 1980, CLIN IMMUNOLOGY, V2, P1316; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HAYES JA, 1976, BRONCHIAL ASTHMA MEC, P347; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; JAN K, 1980, CLIN ALLERGY, V10, P25, DOI 10.1111/j.1365-2222.1980.tb02076.x; Kabe J, 1974, Allerg Immunol (Leipz), V20-21, P393; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MACDONNELL KF, 1976, BRONCHIAL ASTHMA MEC, P679; MITCHELL EB, 1982, LANCET, V1, P127; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P499, DOI 10.1111/j.1476-5381.1951.tb00661.x; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1968, EXCERPTA MED INT C S, V162, P221; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SHAMPAIN MP, AM REV RESPIR DIS; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Stalenheim G, 1979, Monogr Allergy, V14, P264; STALENHEIM G, 1973, IMMUNOCHEMISTRY, V10, P501, DOI 10.1016/0019-2791(73)90221-8; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VAUGHAN WT, 1924, SOUTH MED J, V17, P749; WASSERMAN SI, 1980, ENVIRON HEALTH PERSP, V35, P153, DOI 10.2307/3428985; WASSERMAN SI, 1980, INT J DERMATOL, V19, P7, DOI 10.1111/j.1365-4362.1980.tb01984.x; WLADISLAVOSKY-WASERMAN P, 1982, Journal of Allergy and Clinical Immunology, V69, P148; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	62	242	243	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					160	169		10.1016/0091-6749(82)90037-9	http://dx.doi.org/10.1016/0091-6749(82)90037-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	6125535				2022-12-18	WOS:A1982PG38400002
J	Mertes, PM; Alla, F; Trechot, P; Auroy, Y; Jougla, E				Mertes, Paul Michel; Alla, Francois; Trechot, Philippe; Auroy, Yves; Jougla, Eric		Grp Etud Reactions Anaphylactoides	Anaphylaxis during anesthesia in France: An 8-year national survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; anesthesia; epidemiology; sex; children; neuromuscular blocking agents; latex; antibiotics	ADVERSE DRUG-REACTIONS; REVISED NOMENCLATURE; EPIDEMIOLOGIC SURVEY; IGE ANTIBODIES; ALLERGY; RADIOIMMUNOASSAY; SENSITIZATION; PREVALENCE; PREVENTION	Background: More attention should be paid to rare serious adverse events such as anaphylaxis to increase the safety of anesthesia. Objective: To report the results of an 8-year survey of anaphylaxis during anesthesia in France. Methods: Data from patients who experienced anaphylaxis between January 1, 1997, and December 31, 2004, were analyzed. Estimated incidences were obtained by combining this database with data from the French pharmacovigilance system by using a capture-recapture method. The number of patients exposed to the offending agents was obtained from data collected during the national survey of anesthesia practice. Results: A total of 2516 patients was included. A diagnosis of IgE-mediated reaction was established in 1816 cases (72.18%). The most common causes were neuromuscular blocking agents ([NMBAs]; n = 1067; 58.08%), latex (n = 361; 19.65%), and antibiotics (n = 236; 12.85%). The median annual incidence per million procedures was higher for females 154.9 (5th-95th percentile, 117.2-193.1) than for males 55.4 (5th-95th percentile, 42.0-68.0). It reached 250.9 (5th-95th percentile, 189.8-312.9) for women in cases of allergic reactions to NMBAs. In children, a diagnosis of IgE-mediated reactions was obtained in 122 cases (45.9%). The most common causes were latex (n = 51; 41.8%), NMBAs (n = 39; 31.97%), and antibiotics (n = 11; 9.02%). In contrast with adults, no female predominance was observed. Conclusion: The incidence of allergic reactions during anesthesia, estimated on a national basis, is higher than previously estimated. These results should be taken into account in the evaluation of the benefit-to-risk ratio of the various anesthetic techniques in individuals. The similar incidence of reactions according to sex before adolescence suggests a role for sex hormones in the increase of anaphylaxis observed in women. (J Allergy Clin Immunol 2011;128:366-73.)	[Mertes, Paul Michel] CHU Nancy, Hop Cent, Serv Anesthesie Reanimat Chirurg, INSERM,Grp Choc,U911, F-54035 Nancy, France; [Alla, Francois] Ctr Hosp Univ Nancy, Hop Cent, INSERM, Serv Epidemiol,CIC EC, F-54035 Nancy, France; [Trechot, Philippe] CHU Nancy, Hop Cent, Ctr Pharmacovigilance Nancy, F-54035 Nancy, France; [Auroy, Yves] Hop Instruct Armees Val de Grace, Serv Anesthesie Reanimat, Paris, France; [Jougla, Eric] Natl Inst Hlth & Med Res, INSERM, CepiDc, Le Vesinet, France	CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Nancy; Val-de-Grace Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mertes, PM (corresponding author), CHU Nancy, Hop Cent, Serv Anesthesie Reanimat, 29 Ave Lattre de Tassigny, F-54035 Nancy, France.	pm.mertes@chu-nancy.fr	alla, francois/D-2295-2014; Roland, Pascale PNR Nicaise/J-4587-2017	alla, francois/0000-0002-5793-7190; Lucas, Michaela/0000-0001-8881-9990; Abuaf, Nisen/0000-0002-1277-0593				Adkinson NF, 2002, J ALLERGY CLIN IMMUN, V109, pS461, DOI 10.1067/mai.2002.122214; Arnold R, 2010, BIOMETRICS, V66, P644, DOI 10.1111/j.1541-0420.2009.01289.x; Auroy Y, 2009, ANAESTHESIA, V64, P366, DOI 10.1111/j.1365-2044.2008.05792.x; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Clergue F, 1999, ANESTHESIOLOGY, V91, P1509, DOI 10.1097/00000542-199911000-00045; Cremer R, 2002, EUR J PEDIATR SURG, V12, pS19; De Queiroz M, 2009, PEDIATR ANESTH, V19, P313, DOI 10.1111/j.1460-9592.2009.02955.x; Fisher Malcolm, 2004, Novartis Found Symp, V257, P193; FISHER MM, 1993, ANN FR ANESTH, V12, P97, DOI 10.1016/S0750-7658(05)81016-0; Fisher MM, 2004, DRUG SAFETY, V27, P393, DOI 10.2165/00002018-200427060-00004; Fishman, 1996, MONTE CARLO CONCEPTS; Florvaag E, 2005, ACTA ANAESTH SCAND, V49, P437, DOI 10.1111/j.1399-6576.2004.00591.x; Florvaag E, 2009, IMMUNOL ALLERGY CLIN, V29, P419, DOI 10.1016/j.iac.2009.04.002; Gerber BO, 2006, AAPS J, V8, pE160, DOI 10.1208/aapsj080119; GUEANT JL, 1991, ALLERGY, V46, P452; GUILLOUX L, 1992, J ALLERGY CLIN IMMUN, V90, P153, DOI 10.1016/0091-6749(92)90066-B; Haller G, 2009, ANESTHESIOLOGY, V110, P1158, DOI 10.1097/ALN.0b013e3181a1093b; Jensen-Jarolim E, 2008, ALLERGY, V63, P610, DOI 10.1111/j.1398-9995.2008.01645.x; Johansson SGO, 2010, ALLERGY, V65, P498, DOI 10.1111/j.1398-9995.2009.02193.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; JonvilleBera AP, 1996, THERAPIE, V51, P169; Laake JH, 2001, ACTA ANAESTH SCAND, V45, P1196, DOI 10.1034/j.1399-6576.2001.451004.x; Lang TJ, 2004, CLIN IMMUNOL, V113, P224, DOI 10.1016/j.clim.2004.05.011; Laxenaire MC, 1999, ANN FR ANESTH, V18, P796, DOI 10.1016/S0750-7658(00)88460-9; LAXENAIRE MC, 1990, ANN FR ANESTH, V9, P501, DOI 10.1016/S0750-7658(05)80222-9; Laxenaire MC, 2001, BRIT J ANAESTH, V87, P549, DOI 10.1093/bja/87.4.549; Laxenaire MC, 1996, ANN FR ANESTH, V15, P1211, DOI 10.1016/S0750-7658(97)85882-0; LAXENAIRE MC, 1985, INT ANESTHESIOL CLIN, V23, P145, DOI 10.1097/00004311-198511000-00010; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lugardon S, 2006, BRIT J CLIN PHARMACO, V62, P225, DOI 10.1111/j.1365-2125.2006.02633.x; Mertes PM, 2010, MED CLIN N AM, V94, P761, DOI 10.1016/j.mcna.2010.04.002; Mertes PM, 2008, CURR PHARM DESIGN, V14, P2809, DOI 10.2174/138161208786369704; Mertes PM, 2007, ANESTH ANALG, V104, P471, DOI 10.1213/01.ane.0000253671.90500.0b; Mertes PM, 2007, ANESTHESIOLOGY, V107, P245, DOI 10.1097/01.anes.0000270721.27309.b3; Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91; Mertes PM, 2004, ANN FR ANESTH, V23, P1133, DOI 10.1016/j.annfar.2004.10.013; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Mitchell VL, 2007, CLIN EXP ALLERGY, V37, P276, DOI 10.1111/j.1365-2222.2007.02658.x; MOORE N, 1985, LANCET, V2, P1056; *PAN HOSP, 2004, MAPI; Pirmohamed M, 2003, BRIT J CLIN PHARMACO, V55, P486, DOI 10.1046/j.1365-2125.2003.01847.x; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; SACHS RM, 1986, AM J MED, V81, P49; Seeger JD, 1996, AM J HEALTH-SYST PH, V53, P178, DOI 10.1093/ajhp/53.2.178; Tsong Y, 1995, J Biopharm Stat, V5, P95, DOI 10.1080/10543409508835100; Uemura Y, 2008, HUM IMMUNOL, V69, P149, DOI 10.1016/j.humimm.2008.01.017; Wilson W, 2007, J AM DENT ASSOC, V138, P739, DOI 10.1161/CIRCULATIONAHA.106.183095; WUBBEN I, 2010, QUAL SAF HEALTH CARE, V19, P1; Zaitsu M, 2007, MOL IMMUNOL, V44, P1977, DOI 10.1016/j.molimm.2006.09.030; 2002, ANN FR ANESTH REA S1, V21, pS7	52	241	250	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					366	373		10.1016/j.jaci.2011.03.003	http://dx.doi.org/10.1016/j.jaci.2011.03.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21497888	Bronze			2022-12-18	WOS:000293280800018
J	James, LK; Shamji, MH; Walker, SM; Wilson, DR; Wachholz, PA; Francis, JN; Jacobson, MR; Kimber, I; Till, SJ; Durham, SR				James, Louisa K.; Shamji, Mohamed H.; Walker, Samantha M.; Wilson, Duncan R.; Wachholz, Petra A.; Francis, James N.; Jacobson, Mikila R.; Kimber, Ian; Till, Stephen J.; Durham, Stephen R.			Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; IgE; IgG4; facilitated antigen presentation; CD23	GRASS-POLLEN IMMUNOTHERAPY; FC-GAMMA-RIIB; IGG ANTIBODIES; B-CELLS; MONOCLONAL-ANTIBODIES; CONTROLLED TRIAL; T-CELLS; RHINITIS; BINDING; INHIBITION	Background: Grass pollen immunotherapy for allergic rhinitis is a disease-modifying treatment that results in long-term clinical tolerance lasting years after treatment discontinuation. Active treatment is associated with generation of inhibitory grass pollen-specific IgG antibodies capable of blocking allergen-IgE interactions. Objectives: We sought to investigate the involvement of IgG-associated inhibitory antibodies with long-term clinical tolerance after discontinuation of grass pollen immunotherapy. Methods: We conducted a 4-year study in which patients who had moderate-to-severe allergic rhinitis underwent a randomized, double-blind, placebo-controlled discontinuation of subcutaneous grass pollen immunotherapy. All subjects received grass pollen immunotherapy injections for 2 years (n = 13), followed by a further 2 years of either active (n 5 7) or placebo (n = 6) injections. Clinical outcomes included seasonal symptoms and use of rescue medication. Serum specimens were collected at baseline and after 2 and 4 years for quantification of allergen-specific IgG antibodies. Sera were also tested for IgG-dependent inhibitory bioactivity against IgE-allergen binding in cellular assays by using flow cytometry and confocal microscopy to detect binding of IgE-grass pollen allergen complexes to B cells. Results: Clinical improvement was maintained after 2 years of discontinuation. Although immunotherapy-induced grass pollen-specific IgG1 and IgG4 levels decreased to near-preimmunotherapy levels during discontinuation, inhibitory bioactivity of allergen-specific IgG antibodies was maintained unchanged. Conclusion: Grass pollen immunotherapy induces a subpopulation of allergen-specific IgG antibodies with potent inhibitory activity against IgE that persists after treatment discontinuation and that could account for long-term clinical tolerance. (J Allergy Clin Immunol 2011;127:509-16.)	[Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, MRC, London SW7 2AZ, England; [Kimber, Ian] Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England	Imperial College London; University of Manchester	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, MRC, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.durham@imperial.ac.uk	Shamji, Mohamed/AAD-1788-2019; Walker, Samantha/B-9740-2013; Shamji, Mohamed/AAU-8811-2020; James, Louisa/C-9831-2010	Walker, Samantha/0000-0001-5503-8258; Shamji, Mohamed/0000-0003-3425-3463; James, Louisa/0000-0002-2252-4636; Till, Stephen/0000-0003-4518-3093; Jacobson, Mikila/0000-0002-2921-6169	Immune Tolerance Network; Asthma UK; Health Foundation; London Law Trust; Biotechnology and Biological Sciences Research Council (BBSRC); ALK-Abello; MRC [G0200485, G0601303] Funding Source: UKRI; Medical Research Council [G1000758, G0200485, G0601303, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Immune Tolerance Network; Asthma UK; Health Foundation; London Law Trust; Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); ALK-Abello; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by grants from the Immune Tolerance Network (S.R.D.), Asthma UK (S.R.D. and S.J.T.), the Health Foundation (S.J.T.), and the London Law Trust (L.K.J.), and a Biotechnology and Biological Sciences Research Council (BBSRC) studentship case award (M.H.S.).; S. M. Walker has received consulting fees and research support from ALK-Abello. S. R. Durham has received lecture fees and research support from ALK-Abello and has consulted for ALK-Abello, Circassia, and Greer Laboratories. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; AALBERSE RC, 1983, J IMMUNOL, V130, P722; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Chanez P, 1996, ALLERGY, V51, P850; DJURUP R, 1984, ALLERGY, V39, P51, DOI 10.1111/j.1398-9995.1984.tb01933.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; LAMBIN P, 1993, J IMMUNOL METHODS, V165, P99, DOI 10.1016/0022-1759(93)90111-J; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; Satoguina JS, 2008, EUR J IMMUNOL, V38, P3101, DOI 10.1002/eji.200838193; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Svenson M, 2003, MOL IMMUNOL, V39, P603, DOI 10.1016/S0161-5890(02)00198-0; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; White P, 1998, CLIN EXP ALLERGY, V28, P266; Wilson AM, 2003, BRIT J CLIN PHARMACO, V55, P354, DOI 10.1046/j.1365-2125.2003.01776.x; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	38	241	250	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					509	U1837		10.1016/j.jaci.2010.12.1080	http://dx.doi.org/10.1016/j.jaci.2010.12.1080			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281875				2022-12-18	WOS:000286808000027
J	Boyano-Martinez, T; Garcia-Ara, C; Diaz-Pena, JM; Martin-Esteban, M				Boyano-Martinez, T; Garcia-Ara, C; Diaz-Pena, JM; Martin-Esteban, M			Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg white-specific IgE antibodies; egg allergy; prognostic factors; natural history	NATURAL-HISTORY; FOOD ALLERGY; ATOPIC-DERMATITIS; MILK ALLERGY; HYPERSENSITIVITY	Background: It is thought that the natural evolution of food allergy has a good tolerance prognosis. However, there are few follow-up studies that determine the exact probability of tolerance to a given food or that analyze prognostic factors that can help us to understand the evolution of a child who begins life with a food allergy. Objective: We sought to determine the likelihood that children younger than 2 years of age with allergy to egg would eventually have tolerance to it and to analyze several prognostic predictors using egg white-specific IgE level as the main variable. Methods: We performed a prospective study of 58 children younger than 2 years of age with egg allergy, who were studied periodically until tolerance developed or until the end of the study. During the follow-up period, open challenge tests were carried out according to previously established criteria to verify tolerance to egg. Factors such as egg white-specific IgE level, serum total IgE level, symptoms after egg ingestion, size of skin prick test reactions to egg white, atopic dermatitis, and sex were analyzed as prognostic markers. Kaplan-Meier survival curves were used to calculate cumulative tolerance probability. Predictor influence and relative prognostic importance were estimated with the Cox proportional regression model. Results: The median time from the appearance of the first symptoms to tolerance was 35 months. Cumulative tolerance probability was 16% at 12 months of follow-up, 28% at 24 months, 52% at 36 months, 57% at 48 months, and 66% at 60 months. The relative weight of prognostic factors, expressed as the hazard ratio, was 50.95 for symptoms and 3.74 for the size of skin prick test reactions, with both being independent effects. The hazard ratio was 1.173 for every 0.1-unit decrease in the concentration log (decimal logarithm) of specific IgE level, with this effect being associated with tolerance only in children with cutaneous symptoms. Conclusions: Half of the children younger than 2 years of age with egg allergy will tolerate the food at 35 months of follow-up, and the proportion could be 66% after 5 years. At that age, the main predictors were the symptoms experienced after egg ingestion, followed by the size of skin prick test reactions. In addition, the specific IgE antibody level is an important prognostic marker in children who only had cutaneous symptoms.	Hosp Univ La Paz, Serv Alergia Infantil, Madrid, Spain	Hospital Universitario La Paz	Boyano-Martinez, T (corresponding author), C Ginzo de Limia 55,9 C, Madrid 28034, Spain.							ARA MCG, 1996, ALLERGOL IMMUNOPA S1, V24, P31; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; EGGLESTON PA, 1987, ANN ALLERGY, V59, P179; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; MARTINEZ MTB, 1987, AN ESP PEDIAT, V26, P241; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Oehling A, 1998, ALLERGY, V53, P139, DOI 10.1111/j.1398-9995.1998.tb04985.x; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3	13	241	248	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					304	309	UNSP 1/87/126081	10.1067/mai.2002.126081	http://dx.doi.org/10.1067/mai.2002.126081			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170273				2022-12-18	WOS:000177509800017
J	Meltzer, EO; Malmstrom, K; Lu, S; Prenner, BM; Wei, LX; Weinstein, SF; Wolfe, JD; Reiss, TF				Meltzer, EO; Malmstrom, K; Lu, S; Prenner, BM; Wei, LX; Weinstein, SF; Wolfe, JD; Reiss, TF			Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						montelukast; loratadine; cysteinyl leukotriene receptor antagonist; H-1-receptor antagonist; seasonal allergic rhinitis	QUALITY-OF-LIFE; LEUKOTRIENES; EFFICACY; SYMPTOMS; ASTHMA	Background: Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist, administered alone or concomitantly with loratadine, an H-1-receptor antagonist, in seasonal allergic rhinitis. Objective: The purpose of this study was to determine the effect of concomitant use of montelukast and loratadine in the treatment of seasonal allergic rhinitis. Methods: In this multicenter (N = 12) double-blind, randomized, parallel-group, placebo-controlled 2-week trial, 460 men and women, aged 15 to 75 years, with spring seasonal allergic rhinitis were randomly allocated to receive 1 of the following 5 treatments: montelukast 10 or 20 mg, loratadine 10 mg, montelukast 10 mg with loratadine 10 mg, or placebo, once daily in the evening. The primary end point was daytime nasal symptoms score (average of congestion, rhinorrhea, itching, and sneezing). Other end points were eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations (patient's and physician's), and rhinoconjunctivitis quality-of-life scores. Results: Concomitant montelukast with loratadine improved the primary end point significantly (P < .001) compared with placebo and each agent alone. Compared with placebo, montelukast with loratadine also significantly improved eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations, and quality of life. Montelukast alone and loratadine alone caused modest improvements in rhinitis end points. All treatments were similarly well tolerated. Conclusions: Concomitant montelukast with loratadine provided effective treatment for seasonal allergic rhinitis and associated eye symptoms with a safety profile comparable with placebo.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Merck Res Labs, Dept Pulm Immunol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biostat, Rahway, NJ 07065 USA; Allergy Associates Med Grp Inc, San Diego, CA USA; Allergy & Asthma Specialists, Huntington Beach, CA USA; Santa Clara Valley Res Ctr, Allergy & Asthma Associates, San Jose, CA USA	Merck & Company; Merck & Company	Malmstrom, K (corresponding author), Merck Res Labs, Dept Pulm Immunol, RY 32-621,POB 2000, Rahway, NJ 07065 USA.							Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207, DOI 10.1159/000237289; Busse WW, 1996, CLIN EXP ALLERGY, V26, P868, DOI 10.1111/j.1365-2222.1996.tb00621.x; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Fireman P, 1997, AM J RHINOL, V11, P95, DOI 10.2500/105065897782537142; HAY DWP, 1995, TRENDS PHARMACOL SCI, V16, P304, DOI 10.1016/S0165-6147(00)89059-8; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; Knapp H R, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P279; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; OKUDA M, 1988, ANN ALLERGY, V60, P537; REICIN AS, 1998, AM J RESP CRIT CARE, V157, pA416; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; SIMONS FER, 1996, HISTAMINE H1 RECEPTO; Suonpaa J, 1996, ANN MED, V28, P17, DOI 10.3109/07853899608999069	22	241	256	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					917	922		10.1067/mai.2000.106040	http://dx.doi.org/10.1067/mai.2000.106040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808172	Bronze			2022-12-18	WOS:000087185000010
J	LAM, S; CHAN, H; LERICHE, JC; CHANYEUNG, M; SALARI, H				LAM, S; CHAN, H; LERICHE, JC; CHANYEUNG, M; SALARI, H			RELEASE OF LEUKOTRIENES IN PATIENTS WITH BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LAM, S (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,2775 HEATHER ST,VANCOUVER V5Z 3J5,BC,CANADA.							ABRAHAM WM, 1986, PROSTAGLANDINS, V31, P457, DOI 10.1016/0090-6980(86)90108-5; ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BERNSTEIN IL, 1987, J ALLERGY CLIN IMMUN, V79, P320, DOI 10.1016/0091-6749(87)90148-5; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; CLOUD M, 1987, J ALLERGY CLIN IMMUN, V79, P256; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GIN W, 1985, AM REV RESPIR DIS, V132, P1199; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAMMOND CV, 1982, INT ARCH ALLER A IMM, V67, P284, DOI 10.1159/000233032; HOLGATE ST, 1986, EUR J RESPIR DIS, V144, P34; HOLROYDE MC, 1981, LANCET, V2, P17; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LEE TH, 1987, J ALLERGY CLIN IMMUN, V79, P256; LEWIS RA, 1982, INT J IMMUNOPHARMACO, V4, P85, DOI 10.1016/0192-0561(82)90055-8; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MITA H, 1983, PROSTAGLANDINS, V31, P869; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SALARI H, 1986, IMMUNOLOGY, V58, P322; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHELHAMER JH, 1983, CHEST S, V81, P36; SIMONSSON B, 1982, ACTA PHYSL SCAND, V98, P131; SOFER NA, 1983, J INVEST DERMATOL, V80, P115; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	34	241	243	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					711	717		10.1016/0091-6749(88)91043-3	http://dx.doi.org/10.1016/0091-6749(88)91043-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356850	Bronze			2022-12-18	WOS:A1988N065000012
J	LOWMAN, MA; REES, PH; BENYON, RC; CHURCH, MK				LOWMAN, MA; REES, PH; BENYON, RC; CHURCH, MK			HUMAN MAST-CELL HETEROGENEITY - HISTAMINE-RELEASE FROM MAST-CELLS DISPERSED FROM SKIN, LUNG, ADENOIDS, TONSILS, AND COLON IN RESPONSE TO IGE-DEPENDENT AND NONIMMUNOLOGIC STIMULI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, CTR BLOCK, SOUTHAMPTON S09 4XY, ENGLAND	University of Southampton								BARNES PJ, 1986, BRIT J PHARMACOL, V88, P741, DOI 10.1111/j.1476-5381.1986.tb16246.x; BARRETT KE, 1986, J IMMUNOL, V137, P2001; BEAVEN MA, 1983, J PHARMACOL EXP THER, V224, P620; BEFUS D, 1985, INT ARCH ALLER A IMM, V76, P232, DOI 10.1159/000233697; BENYON RC, 1987, J IMMUNOL, V138, P861; BIENENSTOCK J, 1986, 12 P INT C ALL CLIN, P150; BLOOM GD, 1967, ACTA PHYSIOL SCAND, V71, P270, DOI 10.1111/j.1748-1716.1967.tb03734.x; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CHURCH MK, 1981, BRIT J PHARMACOL, V74, pP979; CHURCH MK, 1983, INT ARCH ALLER A IMM, V72, P188, DOI 10.1159/000234865; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; EBERTZ JM, 1986, AGENTS ACTIONS, V18, P455, DOI 10.1007/BF01964946; ENERBACK L, 1986, MAST CELL DIFFERENTI, P1; EVANS DP, 1973, LIFE SCI 2-BIOCH GEN, V12, P327, DOI 10.1016/0024-3205(73)90366-4; FEWTRELL CMS, 1982, J PHYSIOL-LONDON, V330, P393, DOI 10.1113/jphysiol.1982.sp014347; FLINT KC, 1985, CLIN SCI, V68, P427, DOI 10.1042/cs0680427; FOREMAN JC, 1984, J ALLERGY CLIN IMMUN, V74, P127, DOI 10.1016/0091-6749(84)90274-4; FOREMAN JC, 1982, BRIT J PHARMACOL, V77, P531, DOI 10.1111/j.1476-5381.1982.tb09328.x; FOX CC, 1985, J IMMUNOL, V135, P483; GROSMAN N, 1981, AGENTS ACTIONS, V11, P196, DOI 10.1007/BF01967614; HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092; HOLGATE ST, 1987, ALLERGY INFLAMMATION, P29; IHLE JN, 1983, J IMMUNOL, V131, P282; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; JOHNSON AR, 1973, P SOC EXP BIOL MED, V142, P1252; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KITAMURA Y, 1986, 12 P INT C ALL CLIN, P154; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LAGUNOFF D, 1972, J INVEST DERMATOL, V58, P296, DOI 10.1111/1523-1747.ep12540314; LEE T D G, 1985, Clinical Immunology Reviews, V4, P143; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MORRISON DC, 1975, INT ARCH ALLER A IMM, V49, P172, DOI 10.1159/000231392; ORR TSC, 1977, SCAND J RESPIR DIS, P1; PEARCE FL, 1982, PROGR MED CHEM, V19, P59, DOI 10.1016/S0079-6468(08)70328-X; PEARCE FL, 1985, INT ARCH ALLER A IMM, V77, P274, DOI 10.1159/000233808; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHMUTZLER W, 1985, INT ARCH ALLER A IMM, V77, P177, DOI 10.1159/000233778; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, IN PRESS MAST CELLS; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; WIESNERMENZEL L, 1981, ACTA DERM-VENEREOL, V61, P465, DOI 10.2340/0001555561465469; WOODBURY RG, 1982, IMMUNOLOGY, V46, P487	48	241	246	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					574	579		10.1016/0091-6749(88)90199-6	http://dx.doi.org/10.1016/0091-6749(88)90199-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181	2450114				2022-12-18	WOS:A1988M618100015
J	Akdis, M; Blaser, K; Akdis, CA				Akdis, M; Blaser, K; Akdis, CA			T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						T regulatory cells; immunotherapy; tolerance; allergy; IgE; T cells; histamine; IL-10; TGF-beta	GROWTH-FACTOR-BETA; DENDRITIC CELLS; BEE VENOM; NONALLERGIC INDIVIDUALS; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; IMMUNOTHERAPY; ANTIGEN; ASTHMA; HISTAMINE	The identification of T regulatory (T-Reg) cells as key regulators of immunologic processes in peripheral tolerance to allergens has opened an important era in the prevention and treatment of allergic diseases. Both naturally occurring CD4(+)CD25(+) T-Reg cells and inducible populations of allergen-specific IL-10-secreting T(R)1 cells inhibit allergen-specific effector cells in experimental models. Allergen-specific T-Reg cell responses contribute to the control of allergic inflammation in several ways. Skewing of allergen-specifie effector T cells to a T-Reg phenotype appears to be a crucial event in the development of a healthy immune response to allergens and successful outcome in allergen-specific immunotherapy. The increased levels of IL-10 and TGF-beta produced by T-Reg cells can potently suppress IgE production while simultaneously increasing the production of the noninflammatory antibody isotypes IgG4 and IgA, respectively. T-Reg cells directly or indirectly suppress effector cells of allergic inflammation, such as mast cells, basophils, and eosinophils, and contribute to remodeling in asthma and atopic dermatitis. In addition, mediators of allergic inflammation that trigger cyclic AMP-associated G protein-coupled receptors, such as histamine receptor 2, might play a role in peripheral tolerance mechanisms against allergens. Current strategies for drug development and allergen-specific immunotherapy exploit these observations with the potential to provide core for allergic diseases.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 2004, ALLERGY, V59, P897, DOI 10.1111/j.1398-9995.2004.00587.x; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1293, DOI 10.1046/j.1365-2222.2002.01470.x; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987, DOI 10.1152/ajpgi.1997.273.5.G987; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Duvernelle C, 2003, PULM PHARMACOL THER, V16, P181, DOI 10.1016/S1094-5539(03)00051-8; EBNER C, 1995, J IMMUNOL, V154, P1932; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fischer P, 2005, ANN TROP MED PARASIT, V99, P53, DOI 10.1179/136485905X13339; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Goleva E, 2004, J ALLERGY CLIN IMMUN, V114, P183, DOI 10.1016/j.jaci.2004.04.001; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Haczku A, 1999, AM J RESP CRIT CARE, V159, P1638, DOI 10.1164/ajrccm.159.5.9711040; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jordan MS, 2000, EUR J IMMUNOL, V30, P136, DOI 10.1002/1521-4141(200001)30:1<136::AID-IMMU136>3.3.CO;2-S; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.11.041; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Lim HW, 2004, J CLIN INVEST, V114, P1640, DOI 10.1172/JCI22325; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Peek EJ, 2005, AM J RESP CELL MOL, V33, P105, DOI 10.1165/rcmb.2005-0100OC; PIRQUET V, 1908, MUNCHEN MED WOCHEN, V34, P1297; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60, DOI 10.1165/ajrcmb.25.1.4396; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; Shim JY, 2003, CLIN EXP ALLERGY, V33, P52, DOI 10.1046/j.1365-2222.2003.01567.x; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; WALKER C, 1991, J IMMUNOL, V146, P1829; Wilson S, 2000, Drug Des Discov, V17, P105	71	240	263	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					961	968		10.1016/j.jaci.2005.09.004	http://dx.doi.org/10.1016/j.jaci.2005.09.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275361				2022-12-18	WOS:000235686700002
J	Berges-Gimeno, MP; Simon, RA; Stevenson, DD				Berges-Gimeno, MP; Simon, RA; Stevenson, DD			Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; asthma; rhinitis; desensitization; nonsteroidal anti-inflammatory drugs; aspirin desensitization treatment	RHINOSINUSITIS-ASTHMA; IMPROVEMENT	Background: Aspirin desensitization treatment is an option to decrease disease activity and reduce the need for systemic corticosteroids in patients with aspirin-exacerbated respiratory disease (AERD). Objective: This study was designed to determine whether the clinical courses of patients with AERD improved as early as 6 months after starting aspirin desensitization and to compare this with follow-up evaluations after at least a year. Methods: Between 1995 and 2000, 172 patients with AERD were admitted to our General Clinical Research Center, were desensitized to and treated with aspirin, were discharged to their home communities, and participated in follow-up interviews and written assessments of their clinical courses. Results: By the first 6 months of aspirin treatment, there were significant reductions in sinus infections and numbers of short courses of prednisone and improvements in sense of smell and general assessment of nasal-sinus and asthma symptoms (P <.0001). These results persisted for I to 5 years (P <.0001). Mean prednisone doses decreased from 10.8 mg/d to 8.1 and 3.6 mg/d at 6 months and greater than 1 year, respectively. Of the 172 patients, 24 (14%) discontinued aspirin treatment because of side effects, and 115 (67%) responded to aspirin treatment. After eliminating those who discontinued aspirin treatment because of side effects, the improvement rate was 115 (78%) of 148 patients. Of the 126 patients who completed a year or more of aspirin treatment, 110 (87%) experienced improvement. Conclusion: Aspirin desensitization followed by daily aspirin is efficacious by at least the first 6 months of treatment and continues to be effective for up to 5 years of follow-up.	Scripps Clin, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clin, 10666 N Torrey Rd, La Jolla, CA 92037 USA.		Berges-Gimeno, María Pilar/AAB-7399-2019	Berges-Gimeno, María Pilar/0000-0002-0313-4122	NCRR NIH HHS [M01RR00833] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Kennedy D W, 1992, Laryngoscope, V102, P1; Mastalerz L, 1997, ALLERGY, V52, P895, DOI 10.1111/j.1398-9995.1997.tb01248.x; McFadden EA, 1997, AM J RHINOL, V11, P263, DOI 10.2500/105065897781446702; Nakamura H, 1999, ACTA OTO-LARYNGOL, V119, P592; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Widal M, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2; 1997, NIH PUBLICATION, V4051	18	240	246	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					180	186		10.1067/mai.2003.7	http://dx.doi.org/10.1067/mai.2003.7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532116				2022-12-18	WOS:000180465500028
J	vanderVeen, MJ; vanRee, R; Aalberse, RC; Akkerdaas, J; Koopelman, SJ; Jansen, HM; vanderZee, JS				vanderVeen, MJ; vanRee, R; Aalberse, RC; Akkerdaas, J; Koopelman, SJ; Jansen, HM; vanderZee, JS			Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; peanut allergy; cross-reactivity; glycoproteins; carbohydrate determinants	GRASS-POLLEN ALLERGEN; VEGETABLE FOODS; MAJOR ALLERGEN; SKIN-TESTS; BEE VENOM; N-GLYCANS; ANTIBODIES; PURIFICATION; PROFILIN; EPITOPE	Background: In our outpatient population, approximately one third of patients sensitized to grass pollen were found to have significant serum levels of anti-peanut IgE in the RAST, without positive peanut skin prick test (SPT) response and without peanut-related allergic symptoms. It was suggested earlier that poor biologic activity of IgE antibodies directed to cross-reactive carbohydrate determinants (CCD) of glycoproteins might explain these discrepancies. Objective: In this study we investigated the biologic activity of IgE directed to CCD. Methods: Sera of 32 patients allergic to grass pollen with significant levels of anti-peanut IgE, a negative response on peanut SPT, and no symptoms of peanut allergy were tested for the presence of anti-CCD IgE. Eleven of these patients with greater than 3.0 IU/ml anti-peanut IgE (patients 1 to II) were selected together with four control patients allergic to peanut, on the basis of a positive response on peanut SPT and a history of peanut allergy (patients 12 to 15). Inhibition of the peanut RAST was performed by using proteinase K-treated grass pollen extract as a CCD source. Basophil histamine release assays (BHRAs) were performed with peanut extract and the isolated peanut major allergens Ara h 1 and Are h 2. In addition, intracutaneous tests with peanut extract were performed. Results: In 29 (91%) of 32 patients with discrepant peanut RAST and SPT responses, anti-CCD IgE (greater than or equal to 0.1 IU/mL) was detected. In patients 1 to II almost complete inhibition of the peanut RAST with CCD was found (94.3% +/- 5.5%; mean +/- SD). In contrast, in the patients allergic to peanut only partial inhibition (59%) was found in one subject (p = 0.002, Mann-Whitney test). In the BHRAs and the intracutaneous tests of patients with discrepant peanut RAST and SPT results, reactivity was found only at high concentrations of peanut allergens. When related to specific IgE levels, reactivity to peanut allergens in the BHRAs of these patients was found to be at least a factor of 1000 less when compared with reactivity to control inhalant allergens. Conclusion: We conclude that cross-reactive IgE directed to carbohydrate determinants of glycoproteins, as found in grass pollen-sensitized patients, has poor biologic activity. It fan therefore cause positive RAST results without apparent clinical significance.	UNIV AMSTERDAM,DEPT PULMONOL,ACAD MED CTR,NL-1100 DE AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT ALLERGY,AMSTERDAM,NETHERLANDS; NETHERLANDS ORG APPL SCI RES NUTR & FOOD RES INST,ZEIST,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Organization Applied Science Research			van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring/HGU-9235-2022; van der Zee, Jaring S/M-8462-2013	van der Zee, Jaring S/0000-0002-8698-6039				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; AALBERSE RC, 1976, PROTIDES BIOL FLUIDS, P725; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; DEJONG EC, UNPUB CLIN EXP ALLER; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HINO K, 1995, J BIOCHEM-TOKYO, V117, P289, DOI 10.1093/jb/117.2.289; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; Lerouge P, 1996, PLANT PHYSIOL BIOCH, V34, P263; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOEWENSTEIN H, 1983, ALLERGY, V38, P577; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Ohsuga H, 1996, J BIOL CHEM, V271, P26653, DOI 10.1074/jbc.271.43.26653; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; PETERSEN A, 1995, ELECTROPHORESIS, V16, P869, DOI 10.1002/elps.11501601144; Schafer T, 1996, ALLERGY, V51, P372; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265	39	240	244	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					327	334		10.1016/S0091-6749(97)70245-8	http://dx.doi.org/10.1016/S0091-6749(97)70245-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314344				2022-12-18	WOS:A1997XX47900009
J	Jackson, DJ; Sykes, A; Mallia, P; Johnston, SL				Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.			Asthma exacerbations: Origin, effect, and prevention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma exacerbations; viral infection; virus; allergy; allergen; pollutant; bacteria	BUDESONIDE/FORMOTEROL COMBINATION THERAPY; BRONCHIAL EPITHELIAL-CELLS; INDOOR NITROGEN-DIOXIDE; MILD PERSISTENT ASTHMA; NECROSIS-FACTOR-ALPHA; HUMAN RHINOVIRUS C; DOUBLE-BLIND; RISK-FACTORS; MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE	Asthma is the most common chronic respiratory disease, affecting up to 10% of adults and 30% of children in the Western world. Despite advances in asthma management, acute exacerbations continue to occur and impose considerable morbidity on patients and constitute a major burden on health care resources. Respiratory tract viruses have emerged as the most frequent triggers for exacerbations in both children and adults; however, the mechanisms underlying these remain poorly understood. More recently, it has become increasingly clear that interactions might exist between viruses and other triggers, increasing the likelihood of an exacerbation. In this article we begin with an overview of the health, economic, and social burden that exacerbations of asthma carry with them. This is followed by a review of the pathogenesis of asthma exacerbations, highlighting the various triggers responsible and multiple interactions that exist between them. The final section first addresses what preventative measures are currently available for asthma exacerbations and subsequently examines which of the new treatments in development might lessen the burden of exacerbations in the future. (J Allergy Clin Immunol 2011;128:1165-74.)	[Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, London W2 1PG, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mech Asthma, London W2 1PG, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Ctr Resp Infect, London, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Imperial Coll Healthcare NHS Trust, London, England	Imperial College London; Imperial College London; University of London; King's College London; Imperial College London	Johnston, SL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Jackson, David/AAG-8818-2020; kamuchaki, sarah/E-7315-2017; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200	MRC [G0601236]; MRC Centre [G1000758]; Predicta FP7 Collaborative Project [260895]; Wellcome Trust; ERC [233015]; National Institutes of Health Research; Asthma UK; Medical Research Council [G0700552, G0601236, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212, CL-2008-21-014] Funding Source: researchfish; MRC [G0700552] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Predicta FP7 Collaborative Project; Wellcome Trust(Wellcome TrustEuropean Commission); ERC(European Research Council (ERC)European Commission); National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported in part by MRC project grant G0601236, MRC Centre grant G1000758, the Predicta FP7 Collaborative Project grant 260895, and the Wellcome Trust-sponsored Centre for Respiratory Infection (CRI). D.J.J. is supported by ERC FP7 Advanced grant 233015 (to S.L.J.), A.S. is supported by an MRC Clinical Training Fellowship, A.S. and P.M. are National Institutes of Health Research Clinical Lecturers, and S.L.J. holds the Asthma UK Clinical Chair (CH1155).; S.L. Johnston is a consultant for AstraZeneca, Centocor, and Sanofi-Pasteur; is a consultant for and shareholder in Synairgen; has received research support from the European Research Council, Medical Research Council Clinical Training Fellowship, National Institutes of Health Research, Asthma UK, Medical Research Council, Predicta FP7 Collaborative Project, and the Wellcome Trust-sponsored Centre for Respiratory Infection. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami Lara J, 2011, Natl Health Stat Report, P1; ALLEGRA L, 1994, EUR RESPIR J, V7, P2165, DOI 10.1183/09031936.94.07122165; *AM LUNG ASS, TRENDS ASTHM MORB; [Anonymous], COCHRANE DATABASE SY; Asthma Insight and Management (AIM) Survey, ASTHMA INSIGHT MANAG; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2010, BMJ-BRIT MED J, V341; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Bueving HJ, 2005, CURR OPIN ALLERGY CL, V5, P65, DOI 10.1097/00130832-200502000-00012; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2011, J ALLERGY CLIN IMMUN, V127, P130, DOI 10.1016/j.jaci.2010.11.014; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Christy C, 2004, ARCH DIS CHILD, V89, P734, DOI 10.1136/adc.2003.030999; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cosentini R, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-48; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; CUSTOVIC A, 2007, ALLERGY CLIN IMMU S2, P270; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edwards MR, 2011, EMBO MOL MED, V3, P306, DOI 10.1002/emmm.201100143; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grant E N, 1999, Curr Opin Pulm Med, V5, P27, DOI 10.1097/00063198-199901000-00005; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hansel NN, 2008, ENVIRON HEALTH PERSP, V116, P1428, DOI 10.1289/ehp.11349; Hartert TV, 2002, ANN ALLERG ASTHMA IM, V89, P467, DOI 10.1016/S1081-1206(10)62083-2; He R, 2010, ANN NY ACAD SCI, V1183, P13, DOI 10.1111/j.1749-6632.2009.05128.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jang YJ, 2006, EUR RESPIR J, V27, P12, DOI 10.1183/09031936.06.00008005; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2006, J ALLERGY CLIN IMMUN, V117, P1233, DOI 10.1016/j.jaci.2006.03.035; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Kaufman EH, 2011, J ALLERGY CLIN IMMUN, V127, P462, DOI 10.1016/j.jaci.2010.10.029; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kolbe J, 2002, THORAX, V57, P317, DOI 10.1136/thorax.57.4.317; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Legg JP, 2005, PEDIATR INFECT DIS J, V24, P611, DOI 10.1097/01.inf.0000168747.94999.aa; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lieberman D, 2003, AM J RESP CRIT CARE, V167, P406, DOI 10.1164/rccm.200209-996OC; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Mallia P, 2011, AM J RESP CRIT CARE, V183, pA3728; Mann JK, 2010, ENVIRON HEALTH PERSP, V118, P1497, DOI 10.1289/ehp.0901292; Massanari M, 2009, CLIN PEDIATR, V48, P859, DOI 10.1177/0009922809339054; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; MILLER TP, 1992, CHEST, V102, P515, DOI 10.1378/chest.102.2.515; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Namazy JA, 2005, CURR OPIN PULM MED, V11, P56, DOI 10.1097/01.mcp.0000148568.20273.f5; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; *OFF ENV HLTH HAZ, 2005, HLTH EFF EXP ENV TOB; Ohta K, 2009, RESPIROLOGY, V14, P1156, DOI 10.1111/j.1440-1843.2009.01633.x; Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752; Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906; Papi A, 2011, EUR RESPIR J, V37, P5, DOI 10.1183/09031936.00145710; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Ramsay CF, 2011, THORAX, V66, P7, DOI 10.1136/thx.2010.135038; Rees P John, 2007, Arch Dis Child Educ Pract Ed, V92, pep127; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schmaling KB, 2002, J ASTHMA, V39, P501, DOI 10.1081/JAS-120004916; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Skevaki CL, 2009, CLIN EXP ALLERGY, V39, P1700, DOI 10.1111/j.1365-2222.2009.03307.x; Stanford RH, 2008, CURR MED RES OPIN, V24, P3141, DOI [10.1185/03007990802462990, 10.1185/03007990802462990 ]; Stokes JR, 1998, EUR RESPIR J, V11, P324, DOI 10.1183/09031936.98.11020324; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Tahan F, 2007, EUR RESPIR J, V29, P91, DOI 10.1183/09031936.00029206; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Walters JAE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001288.pub3; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002; Weiss KB, 2010, ANN ALLERG ASTHMA IM, V105, P174, DOI 10.1016/j.anai.2010.04.018; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC	135	239	247	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1165	1174		10.1016/j.jaci.2011.10.024	http://dx.doi.org/10.1016/j.jaci.2011.10.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22133317	Green Published			2022-12-18	WOS:000298342700003
J	Guttman-Yassky, E; Nograles, KE; Krueger, JG				Guttman-Yassky, Emma; Nograles, Kristine E.; Krueger, James G.			Contrasting pathogenesis of atopic dermatitis and psoriasis-Part I: Clinical and pathologic concepts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; pathogenesis; therapy	ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION; REGULATORY T-CELLS; EPIDERMAL BARRIER; HYGIENE HYPOTHESIS; IMMUNOLOGICAL BASIS; ADAPTIVE IMMUNITY; ALLERGIC DISEASES; DENDRITIC CELLS; CYCLOSPORINE-A	Atopic dermatitis and psoriasis are 2 of the most common inflammatory skin diseases. They are similar in that they are complex inherited diseases involving genes that encode immune components and structural proteins that regulate differentiation of epidermal cells. Each disease is characterized by proliferation of epidermal keratinocytes and abnormal cornification or terminal differentiation in the epidermis; skin lesions contain immune infiltrates of T cells, dendritic cells, and other types of leukocytes. We review similarities between the diseases and differences in epidermal barrier defects and immune cells. We also propose mechanisms of pathogenesis based on differences in the balance of immune cell subsets that could cause the phenotypes that distinguish these diseases. The first part of this 2-part review focuses on the clinical and pathologic features of the diseases; the second part discusses differences in immune cell subsets between atopic dermatitis and psoriasis and recent therapeutic strategies. (J Allergy Clin Immunol 2011;127:1110-8.)	[Guttman-Yassky, Emma; Nograles, Kristine E.; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Guttman-Yassky, Emma] Weill Cornell Med Coll, Dept Dermatol, New York, NY USA	Rockefeller University; Cornell University	Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA.	eguttman@rockefeller.edu	Nograles, Kristine/V-3648-2019		Amgen; Centocor; Merck; Eli Lilly	Amgen(Amgen); Centocor; Merck(Merck & Company); Eli Lilly(Eli Lilly)	Disclosure of potential conflict of interest: E. Guttman-Yassky and K. E. Nograles have declared that they have no conflict of interest. J. G. Krueger has consulted for Amgen, Anacor Pharmaceuticals, Centocor, Gateway Pharmaceuticals, Idera Pharmaceuticals, and Pfizer; has performed investigations for Boehringer Ingelheim, Eli Lilly, and Merck; has served on an advisory board for Janssen; and has received research support (through Rockefeller University) from Amgen, Centocor, Merck, and Eli Lilly.	Ahern DJ, 2005, CURR OPIN ALLERGY CL, V5, P531, DOI 10.1097/01.all.0000191239.20632.ab; Akiyama M, 2010, BRIT J DERMATOL, V162, P472, DOI 10.1111/j.1365-2133.2009.09582.x; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Barnes KC, 2010, CURR OPIN ALLERGY CL, V10, P427, DOI 10.1097/ACI.0b013e32833de6ee; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Bieber T, 2009, CURR ALLERGY ASTHM R, V9, P291, DOI 10.1007/s11882-009-0041-2; Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bos JD, 2010, EXP DERMATOL, V19, P325, DOI 10.1111/j.1600-0625.2009.01024.x; Brown SJ, 2008, SEMIN CUTAN MED SURG, V27, P128, DOI 10.1016/j.sder.2008.04.001; Chang Timothy T, 2002, Am J Clin Dermatol, V3, P175, DOI 10.2165/00128071-200203030-00004; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Chien YH, 2007, CLIN REV ALLERG IMMU, V33, P178, DOI 10.1007/s12016-007-0041-8; Christophers E, 2003, J INVEST DERMATOL, V120, pXVII, DOI 10.1046/j.1523-1747.2003.12111.x; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; de Cid R, 2009, NAT GENET, V41, P211, DOI 10.1038/ng.313; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Di Nardo A, 1998, ACTA DERM-VENEREOL, V78, P27; Elder JT, 2009, GENES IMMUN, V10, P201, DOI 10.1038/gene.2009.11; Elder JT, 2010, J INVEST DERMATOL, V130, P1213, DOI 10.1038/jid.2009.319; Elias PM, 2008, AM J PATHOL, V173, P689, DOI 10.2353/ajpath.2008.080088; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Finkelman FD, 2010, J ALLERGY CLIN IMMUN, V125, P312, DOI 10.1016/j.jaci.2009.12.936; Fonacier LS, 2010, J ALLERGY CLIN IMMUN, V125, pS138, DOI 10.1016/j.jaci.2009.05.039; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Grammatikos AP, 2008, ANN MED, V40, P482, DOI 10.1080/07853890802082096; Guttman-Yassky E, 2007, BRIT J DERMATOL, V157, P1103, DOI 10.1111/j.1365-2133.2007.08135.x; Guttman-Yassky E, 2011, J ALLERGY C IN PRESS; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Harding Clive R, 2004, Dermatol Ther, V17 Suppl 1, P6, DOI 10.1111/j.1396-0296.2004.04S1001.x; Harper EG, 2008, J INVEST DERMATOL, V128, pS185; Hayek B, 2004, 23 EAACI C JUN 12 16, V224, P744; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Heidenreich R, 2009, INT J EXP PATHOL, V90, P232, DOI 10.1111/j.1365-2613.2009.00669.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, pe9; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hijnen DJ, 2007, DERMATITIS, V18, P163, DOI 10.2310/6620.2007.06025; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V126, P200, DOI 10.1016/j.jaci.2010.06.006; Holt PG, 2003, VACCINE, V21, P3432, DOI 10.1016/S0264-410X(03)00345-1; Incorvaia C, 2008, CLIN EXP IMMUNOL, V153, P27, DOI 10.1111/j.1365-2249.2008.03718.x; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; Jensen J, 2004, J INVEST DERMATOL, V122, pA76; Jensen JM, 2009, GIORN ITAL DERMAT V, V144, P689; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Madison KC, 2003, J INVEST DERMATOL, V121, P231, DOI 10.1046/j.1523-1747.2003.12359.x; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; Mauro C, 2006, J BIOL CHEM, V281, P2631, DOI 10.1074/jbc.M502181200; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Nograles KE, 2010, SEMIN CUTAN MED SURG, V29, P3, DOI 10.1016/j.sder.2010.03.001; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nograles KE, 2009, NAT CLIN PRACT RHEUM, V5, P83, DOI 10.1038/ncprheum0987; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Park SY, 2010, ANN DERMATOL, V22, P349, DOI 10.5021/ad.2010.22.3.349; Parronchi P, 2000, INT ARCH ALLERGY IMM, V121, P2, DOI 10.1159/000024291; Pershagen G, 2000, PEDIATR ALLERGY IMMU, V11, P26, DOI 10.1034/j.1399-3038.2000.00507.x; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; Proksch E, 2009, J DTSCH DERMATOL GES, V7, P899, DOI 10.1111/j.1610-0387.2009.07157.x; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; REEVES WH, 1991, SEMIN DERMATOL, V10, P217; Renz H, 2006, CHEM IMMUNOL ALLERGY, V91, P30; Roberson EDO, 2010, TRENDS GENET, V26, P415, DOI 10.1016/j.tig.2010.06.006; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rottem Menachem, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P223, DOI 10.1097/01.moo.0000122312.13359.eb; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Sehra S, 2008, CRIT REV IMMUNOL, V28, P15, DOI 10.1615/CritRevImmunol.v28.i1.20; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Snyder RA, 2010, AM J CLIN DERMATOL, V11, P19, DOI 10.2165/1153416-S0-000000000-00000; Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019; Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164; Thomsen SF, 2007, ALLERGY ASTHMA PROC, V28, P535, DOI 10.2500/aap2007.28.3041; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Tschachler E, 2007, CLIN DERMATOL, V25, P589, DOI 10.1016/j.clindermatol.2007.09.021; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; van den Biggelaar AHJ, 2009, J ALLERGY CLIN IMMUN, V124, P544, DOI 10.1016/j.jaci.2009.03.040; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Wilsmann-Theis D, 2008, EUR J DERMATOL, V18, P172, DOI 10.1684/ejd.2008.0357; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; Zaiac M, 2010, AM J CLIN DERMATOL, V11, P27, DOI 10.2165/1153418-S0-000000000-00000; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015; Zhang XJ, 2009, NAT GENET, V41, P205, DOI 10.1038/ng.310; Zhang Y, 2006, ARCH DERMATOL RES, V297, P425, DOI 10.1007/s00403-006-0641-9; Zhao Y, 2007, J INVEST DERMATOL, V127, P1878, DOI 10.1038/sj.jid.5700817	115	239	247	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1110	1118		10.1016/j.jaci.2011.01.053	http://dx.doi.org/10.1016/j.jaci.2011.01.053			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21388665				2022-12-18	WOS:000290018600003
J	Pauli, G; Larsen, TH; Rak, S; Horak, F; Pastorello, E; Valenta, R; Purohit, A; Arvidsson, M; Kavina, A; Schroeder, JW; Mothes, N; Spitzauer, S; Montagut, A; Galvain, S; Melac, M; Andre, C; Poulsen, LK; Malling, HJ				Pauli, Gabrielle; Larsen, Tina H.; Rak, Sabina; Horak, Friedrich; Pastorello, Elide; Valenta, Rudolph; Purohit, Ashok; Arvidsson, Monica; Kavina, Alexander; Schroeder, Jan W.; Mothes, Nadine; Spitzauer, Susanne; Montagut, Armelle; Galvain, Sylvie; Melac, Michel; Andre, Claude; Poulsen, Lars K.; Malling, Hans-Jorgen			Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recombinant allergens; immunotherapy; Bet v 1; allergic rhinitis; IgE; IgG4; allergy; allergen	TREE POLLEN; V 1; IMMUNOTHERAPY; RESPONSES; EXTRACTS; MUCOSAL; DISEASE	Background: Recombinant DNA technology has the potential to produce allergen-specific immunotherapy vaccines with defined composition. Objective: To evaluate the effectiveness of a new recombinant birch pollen allergen vaccine in patients with birch pollen allergy. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was undertaken to compare the following 3 vaccines in 134 adults with birch pollen allergy: recombinant birch pollen allergen vaccine (rBet v 1a), licensed birch pollen extract, natural purified birch pollen allergen (nBet v 1), and placebo. Patients received 12 weekly injections followed by monthly injections of the maintenance dose containing 15 mu g Bet v 1 for 2 years. Results: Significant reductions (about 50%) in rhinoconjunctivitis symptoms (rBet v 1, P = .0002; nBet v 1, P = .0006; birch extract, P = .0024), rescue medication (rBet v 1, P = .0011; nBet v 1, P = .0025; birch extract, P = .0063), and skin sensitivities (P < .0001) were observed in the 3 actively treated groups compared with placebo during 2 consecutive pollen seasons. Clinical improvement was accompanied by marked increases in Bet v 1-specific IgG levels, which were higher in the rBet v 1-treated group than in the birch and nBet v 1-treated groups. New IgE specificities were induced in 3 of 29 patients treated with birch pollen extract, but in none of the 32 rBet v 1-treated or 29 nBet v 1-treated patients. No severe systemic adverse events were observed in the rBet v I-treated group. Conclusion: The rBet v 1-based vaccine was safe and effective in treating birch pollen allergy, and induced a highly specific immune response. (J Allergy Clin Immunol 2008;122:951-60.)	[Pauli, Gabrielle; Purohit, Ashok] Univ Hosp, Strasbourg, France; [Larsen, Tina H.; Poulsen, Lars K.; Malling, Hans-Jorgen] Natl Univ Hosp, Copenhagen, Denmark; [Rak, Sabina; Arvidsson, Monica] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Horak, Friedrich; Kavina, Alexander] Univ Hosp Vienna, Vienna, Austria; [Pastorello, Elide; Schroeder, Jan W.] Osped Niguarda Ca Granda, Milan, Italy; [Valenta, Rudolph; Mothes, Nadine] Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria; [Spitzauer, Susanne] Med Univ Vienna, Inst Med & Clin Lab Diagnost, Vienna, Austria; [Montagut, Armelle] Delta Consultants, Meylan, France; [Galvain, Sylvie; Melac, Michel; Andre, Claude] Stallergenes SA, Dept Med, F-92183 Antony, France	CHU Strasbourg; Sahlgrenska University Hospital; University Hospital Vienna; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Medical University of Vienna; Medical University of Vienna; Stallergenes Greer	Andre, C (corresponding author), Stallergenes SA, Dept Med, 6 Rue Alexis Tocqueville, F-92183 Antony, France.	candre@stallergenes.fr	Poulsen, Lars K/J-3065-2019; m, m/GZB-2153-2022; PASTORELLO, ELIDE ANNA/E-3897-2017	Poulsen, Lars K/0000-0002-1730-847X; Valenta, Rudolf/0000-0001-5944-3365; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783	Stallergenes, France; ALK-Abello and Allegropharma; Siemens	Stallergenes, France; ALK-Abello and Allegropharma; Siemens(Siemens AG)	Supported by Stallergenes, France.; Disclosure of potential conflict of interest: C. Andre, S Galvain, and M. Melac are employed by Stallergenes. G. Pauli has received honoraria from Stallergenes. S. Rak declared a relevant conflict of interest with ALK-Abello, Stallergenes, and Siemens and has received research support from ALK-Abello and Allegropharma. A. Montagut has served as an expert witness for biostalistics. L. K. Poulsen has received research support from Siemens and has served as an expert witness for Novozymes. The rest of the authors have declared that they have no conflict of interest.	Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Borsutzky S, 2004, J IMMUNOL, V173, P3305, DOI 10.4049/jimmunol.173.5.3305; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Castro AJ, 2003, INT ARCH ALLERGY IMM, V131, P164, DOI 10.1159/000071482; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COMTOIS P, 1988, REV FR ALLERGOL, V28, P279, DOI 10.1016/S0335-7457(88)80046-7; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gastaminza G, 2003, CLIN EXP ALLERGY, V33, P470, DOI 10.1046/j.1365-2222.2003.01644.x; *GINA, 2007, GLOB STRAT ASTHM MAN; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Malling HJ, 1998, ALLERGY, V53, P461; Mothes-Luksch N, 2006, 25 C EUR AC ALL CLIN, P294; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Noon L, 1911, LANCET, V1, P1572; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Pree I, 2007, J IMMUNOL, V179, P5309, DOI 10.4049/jimmunol.179.8.5309; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x	33	239	253	3	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					951	960		10.1016/j.jaci.2008.09.017	http://dx.doi.org/10.1016/j.jaci.2008.09.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	19000581				2022-12-18	WOS:000260940100014
J	CLARK, NM; FELDMAN, CH; EVANS, D; LEVISON, MJ; WASILEWSKI, Y; MELLINS, RB				CLARK, NM; FELDMAN, CH; EVANS, D; LEVISON, MJ; WASILEWSKI, Y; MELLINS, RB			THE IMPACT OF HEALTH-EDUCATION ON FREQUENCY AND COST OF HEALTH-CARE USE BY LOW-INCOME CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									COLUMBIA UNIV,BABIES HOSP N,COLL PHYS & SURG,DEPT PEDIAT,630 W 168TH ST,NEW YORK,NY 10032; UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH BEHAV & HLTH EDUC,ANN ARBOR,MI 48109	Columbia University; University of Michigan System; University of Michigan					NHLBI NIH HHS [1-HR-7-2973, R18-HL-28907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL028907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLARK NM, 1980, HEALTH EDUC QUART, V7, P278, DOI 10.1177/109019818000700403; CLARK NM, 1984, J SCHOOL HEALTH, V54, P143, DOI 10.1111/j.1746-1561.1984.tb08796.x; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; CLARK NM, 1981, HEALTH EDUC QUART, V8, P166, DOI 10.1177/109019818100800203; CREER T, 1976, REHABIL LIT, V38, P226; DAVIS DJ, 1972, J ALLERGY CLIN IMMUN, V49, P323, DOI 10.1016/0091-6749(72)90130-3; ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7; FIREMAN P, 1981, PEDIATRICS, V68, P341; GREEN LW, 1977, HEALTH EDUC QUART, V5, P161, DOI 10.1177/109019817700500206; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; KARETZKY MS, 1977, J ALLERGY CLIN IMMUN, V60, P383, DOI 10.1016/0091-6749(77)90070-7; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; LEVINE PH, 1973, ANN INTERN MED, V78, P195, DOI 10.7326/0003-4819-78-2-195; LEWIS CE, 1984, PEDIATRICS, V74, P478; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MILLER LV, 1972, NEW ENGL J MED, V286, P1388, DOI 10.1056/NEJM197206292862605; PLESS I, 1975, CHRONIC CHILDHOOD DI, P147; PLESS I, 1974, CHRONIC CHILDHOOD IL; ROBBINS SM, 1973, CLIN PEDIATR, V12, P550, DOI 10.1177/000992287301200914; ROSENBERG S, 1971, HSMHA HLTH REP, V85, P793; WRIGHT L, 1970, POSTGRAD MED, V47, P173, DOI 10.1080/00325481.1970.11697529; 1979, NIH79387 PUBL, P397; 1984, PHS861745 PUBL, V13	23	239	243	0	16	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				108	115		10.1016/0091-6749(86)90122-3	http://dx.doi.org/10.1016/0091-6749(86)90122-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	D2996	3088085				2022-12-18	WOS:A1986D299600017
J	ROBERTSON, DG; KERIGAN, AT; HARGREAVE, FE; CHALMERS, R; DOLOVICH, J				ROBERTSON, DG; KERIGAN, AT; HARGREAVE, FE; CHALMERS, R; DOLOVICH, J			LATE ASTHMATIC RESPONSES INDUCED BY RAGWEED POLLEN ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, HAMILTON, ONTARIO, CANADA; ST JOSEPHS HOSP, DEPT PEDIAT, HAMILTON, ONTARIO, CANADA; ST JOSEPHS HOSP, DEPT MED, HAMILTON, ONTARIO, CANADA	McMaster University; McGill University; McMaster University; McGill University; McMaster University								BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; ITKIN IH, 1966, J ALLERGY, V37, P187, DOI 10.1016/0021-8707(66)90113-4; LITTLE DC, 1973, CAN MED ASSOC J, V108, P1120; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PEPYS J, 1969, LANCET, V1, P1181; SMITH RD, 1954, J ALLERGY, V25, P36, DOI 10.1016/0021-8707(54)90047-7; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; TAYLOR G, 1971, BRIT J IND MED, V28, P143; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182; WILSON AF, 1971, J ALLERGY, V47, P107; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	20	239	242	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	4					244	254		10.1016/0091-6749(74)90067-0	http://dx.doi.org/10.1016/0091-6749(74)90067-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3236	4414060				2022-12-18	WOS:A1974U323600007
J	Wood, RA; Camargo, CA; Lieberman, P; Sampson, HA; Schwartz, LB; Zitt, M; Collins, C; Tringale, M; Wilkinson, M; Boyle, J; Simons, FER				Wood, Robert A.; Camargo, Carlos A., Jr.; Lieberman, Philip; Sampson, Hugh A.; Schwartz, Lawrence B.; Zitt, Myron; Collins, Charlotte; Tringale, Michael; Wilkinson, Marilyn; Boyle, John; Simons, F. Estelle R.			Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; prevalence; epinephrine	EMERGENCY-DEPARTMENT VISITS; EPIDEMIOLOGY; ALLERGY; HOSPITALIZATIONS; MULTICENTER; POPULATION; MANAGEMENT; TRENDS	Background: Although anaphylaxis is recognized as an important life-threatening condition, data are limited regarding its prevalence and characteristics in the general population. Objective: We sought to estimate the lifetime prevalence and overall characteristics of anaphylaxis. Methods: Two nationwide, cross-sectional random-digit-dial surveys were conducted. The public survey included unselected adults, whereas the patient survey captured information from household members reporting a prior reaction to medications, foods, insect stings, or latex and idiopathic reactions in the previous 10 years. In both surveys standardized questionnaires queried anaphylaxis symptoms, treatments, knowledge, and behaviors. Results: The public survey included 1,000 adults, of whom 7.7% (95% CI, 5.7% to 9.7%) reported a prior anaphylactic reaction. Using increasingly stringent criteria, we estimate that 5.1% (95% CI, 3.4% to 6.8%) and 1.6% (95% CI, 0.8% to 2.4%) had probable and very likely anaphylaxis, respectively. The patient survey included 1,059 respondents, of whom 344 reported a history of anaphylaxis. The most common triggers reported were medications (34%), foods (31%), and insect stings (20%). Forty-two percent sought treatment within 15 minutes of onset, 34% went to the hospital, 27% self-treated with antihistamines, 10% called 911, 11% self-administered epinephrine, and 6.4% received no treatment. Although most respondents with anaphylaxis reported 2 or more prior episodes (19% reporting >= 5 episodes), 52% had never received a self-injectable epinephrine prescription, and 60% did not currently have epinephrine available. Conclusions: The prevalence of anaphylaxis in the general population is at least 1.6% and probably higher. Patients do not appear adequately equipped to deal with future episodes, indicating the need for public health initiatives to improve anaphylaxis recognition and treatment.	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA; [Lieberman, Philip] Univ Tennessee, Coll Med, Dept Internal Med, Memphis, TN USA; [Lieberman, Philip] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA; [Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23284 USA; [Zitt, Myron] SUNY Stony Brook, Dept Med, Stony Brook, NY USA; [Collins, Charlotte; Tringale, Michael] Asthma & Allergy Fdn Amer, Landover, MD USA; [Wilkinson, Marilyn] Abt SRBI, Silver Spring, MD USA; [Boyle, John] ICF Int, Calverton, NY USA; [Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Sect Allergy & Clin Immunol, Winnipeg, MB R3T 2N2, Canada	Johns Hopkins University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Manitoba	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Tringale, Mike/0000-0003-3139-6637	Asthma and Allergy Foundation of America	Asthma and Allergy Foundation of America	Supported by the Asthma and Allergy Foundation of America.	Allen KJ, 2012, IMMUNOL ALLERGY CLIN, V32, P35, DOI 10.1016/j.iac.2011.11.008; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Campbell RL, 2012, J ALLERGY CLIN IMMUN, V129, P748, DOI 10.1016/j.jaci.2011.09.030; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Gibbison B, 2012, ANAESTHESIA, V67, P833, DOI 10.1111/j.1365-2044.2012.07159.x; Harduar-Morano L, 2010, J ALLERGY CLIN IMMUN, V126, P98, DOI 10.1016/j.jaci.2010.04.017; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	28	238	244	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					461	467		10.1016/j.jaci.2013.08.016	http://dx.doi.org/10.1016/j.jaci.2013.08.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24144575	Bronze			2022-12-18	WOS:000332397100021
J	Shore, SA; Terry, RD; Flynt, L; Xu, AM; Hug, C				Shore, Stephanie A.; Terry, Raya D.; Flynt, Lesley; Xu, Aimin; Hug, Christopher			Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung; airway responsiveness; IL-13; IL-5; eosinophil; IgE; adiponectin receptor 1; adiponectin receptor 2; T-cadherin; adipocyte	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; MONOCYTE-DERIVED MACROPHAGES; E-DEFICIENT MICE; PLASMA-PROTEIN; OBESE MICE; INSULIN-RESISTANCE; WEIGHT-REDUCTION; ASTHMA SEVERITY; ADIPOSE-TISSUE	Background: Epidemiologic data indicate an increased incidence of asthma in the obese. Objective: Because serum levels of the insulin-sensitizing and anti-inflammatory adipokine adiponectin are reduced in obese individuals, we sought to determine whether exogenous adiponectin can attenuate allergic airway responses. Methods: We sensitized and challenged BALB/cJ mice with ovalbumin (OVA). Alzet micro-osmotic pumps were implanted in the mice to deliver continuous infusions of buffer or adiponectin (1.0 mu g/g/d), which resulted in an approximate 60% increase in serum adiponectin levels. Two days later, mice were challenged with aerosolized saline or OVA once per day for 3 days. Mice were examined 24 hours after the last challenge. Results: OVA challenge increased airway responsiveness to intravenous methacholine, bronchoalveolar lavage fluid cells, and T(H)2 cytokine levels. Importantly, each of these responses to OVA was reduced in adiponectin- versus buffer-treated mice. OVA challenge caused a 30% reduction in serum adiponectin levels and a corresponding decrease in adipose tissue adiponectin mRNA expression. OVA challenge also decreased pulmonary mRNA expression of each of 3 proposed adiponectin-binding proteins, adiponectin receptor 1, adiponectin receptor 2, and T-cadherin. Conclusion: Our results indicate that serum adiponectin is reduced during pulmonary allergic reactions and that adiponectin attenuates allergic airway inflammation and airway hyperresponsiveness in mice. Clinical implications: The data suggest that adiponectin might play a role in the relationship between obesity and asthma.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Boston, MA 02115 USA; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Childrens Hosp, Div Pulm, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Hong Kong; Harvard University; Boston Children's Hospital	Shore, SA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Bldg 1,Room 311,665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu	Xu, Aimin/D-3291-2013	Xu, Aimin/0000-0002-0668-033X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077499, P01HL033009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013307, P30ES000002] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 077499, HL 33009] Funding Source: Medline; NIEHS NIH HHS [ES 00002, ES 013307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835, DOI 10.1164/ajrccm.164.10.2105033; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Degawa-Yamauchi M, 2005, OBES RES, V13, P662, DOI 10.1038/oby.2005.74; Engeli S, 2003, DIABETES, V52, P942, DOI 10.2337/diabetes.52.4.942; Fallo F, 2004, EUR J ENDOCRINOL, V150, P339, DOI 10.1530/eje.0.1500339; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Furukawa K, 2004, BIOCHEM BIOPH RES CO, V317, P831, DOI 10.1016/j.bbrc.2004.03.123; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Kanehiro A, 2002, J IMMUNOL, V169, P4190, DOI 10.4049/jimmunol.169.8.4190; Kappes A, 2000, HORM METAB RES, V32, P548, DOI 10.1055/s-2007-978684; Kawanami D, 2004, BIOCHEM BIOPH RES CO, V314, P415, DOI 10.1016/j.bbrc.2003.12.104; Kern PA, 2003, DIABETES, V52, P1779, DOI 10.2337/diabetes.52.7.1779; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Makimura H, 2002, AM J PHYSIOL-ENDOC M, V283, pE1266, DOI 10.1152/ajpendo.00227.2002; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Milan G, 2002, OBES RES, V10, P1095, DOI 10.1038/oby.2002.149; Nawrocki AR, 2004, CURR OPIN PHARMACOL, V4, P281, DOI 10.1016/j.coph.2004.03.003; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Simard B, 2004, OBES SURG, V14, P1381, DOI 10.1381/0960892042584021; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamaguchi N, 2005, FEBS LETT, V579, P6821, DOI 10.1016/j.febslet.2005.11.019; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723	56	238	254	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					389	395		10.1016/j.jaci.2006.04.021	http://dx.doi.org/10.1016/j.jaci.2006.04.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890763				2022-12-18	WOS:000239877700014
J	Wachholz, PA; Soni, NK; Till, SJ; Durham, SR				Wachholz, PA; Soni, NK; Till, SJ; Durham, SR			Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antigen presentation; IgG; CD23; immunotherapy; B cell	BEE VENOM IMMUNOTHERAPY; CD4+ T-CELLS; PHL P 1; MESSENGER-RNA; IL-4; INTERLEUKIN-4; BASOPHILS; RESPONSES; EPITOPES; SHIFT	Background: Among atopic individuals, levels of allergen-specific IgG antibodies have been inversely associated with the degree of allergen sensitization. Additionally, allergen-specific IgG antibodies are markedly increased by allergen injection immunotherapy. These observations have led to proposals that allergen-specific IgG antibodies might have protective properties in atopic individuals. Objective: We hypothesized that after grass pollen immunotherapy, these antibodies disrupt IgE-dependent allergen processing by antigen-presenting cells. Methods: We have developed a novel flow cytometric assay based on detection of allergen-IgE binding to the low-affinity IgE receptor on B cells to examine the blocking effects of sera collected from 18 patients who participated in a double-blind, controlled trial of grass pollen immunotherapy for 1 year. Results: In all 10 patients who received active therapy, there was induction of activity that inhibited allergen-IgE binding to B cells (P = .02, vs placebo subjects), as well as subsequent allergen presentation to T cells. This activity copurified with IgG and was allergen specific, because sera taken from patients treated with grass pollen immunotherapy but who were also birch pollen sensitive did not inhibit IgE-birch pollen allergen binding to B cells. Conclusion: We conclude that allergen-specific IgG antibodies induced by immunotherapy can disrupt formation of allergen-IgE complexes that bind to antigen-presenting cells and facilitate allergen presentation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; ALK Abello, Horsholm, Denmark	Imperial College London; ALK-Abello AS	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Till, Stephen/0000-0003-4518-3093				AHLSTEDT S, 1977, INT ARCH ALLER A IMM, V55, P400, DOI 10.1159/000231951; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BHEEKHA ER, 1995, IMMUNOLOGY, V86, P343; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Jarzab J, 2000, J INVEST ALLERG CLIN, V10, P24; Jeannin P, 1998, J IMMUNOL, V160, P3555; JUTEL M, 1995, J IMMUNOL, V154, P4187; KALMAKOFF J, 1977, J IMMUNOL METHODS, V14, P73, DOI 10.1016/S0022-1759(97)90024-7; KIMURA I, 1985, CLIN ALLERGY, V15, P1, DOI 10.1111/j.1365-2222.1985.tb02248.x; KOLBE L, 1995, IMMUNOLOGY, V84, P285; LIN KL, 1991, ANN ALLERGY, V67, P63; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MAURER D, 1995, J IMMUNOL, V154, P6285; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Michils A, 1997, CLIN EXP ALLERGY, V27, P1036, DOI 10.1111/j.1365-2222.1997.tb01255.x; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; MOQBEL R, 1995, J IMMUNOL, V155, P4939; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; WOODHEAD JS, 1989, J BIOLUM CHEMILUM, V4, P611, DOI 10.1002/bio.1170040180; YU Y, 1995, ALLERGY, V50, P119, DOI 10.1111/j.1398-9995.1995.tb05067.x	41	238	260	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					915	922		10.1016/S0091-6749(03)02022-0	http://dx.doi.org/10.1016/S0091-6749(03)02022-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610480				2022-12-18	WOS:000186553300013
J	Toda, M; Leung, DYM; Molet, S; Boguniewicz, M; Taha, R; Christodoulopoulos, P; Fukuda, T; Elias, JA; Hamid, QA				Toda, M; Leung, DYM; Molet, S; Boguniewicz, M; Taha, R; Christodoulopoulos, P; Fukuda, T; Elias, JA; Hamid, QA			Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; skin biopsy; fibrosis; cytokines; collagen; remodeling	GROWTH-FACTOR-BETA; HUMAN-LUNG FIBROBLASTS; ATOPIC-DERMATITIS; MESSENGER-RNA; AIRWAY INFLAMMATION; IN-VITRO; ASTHMA; EOSINOPHILS; INTERLEUKIN-11; STIMULATION	Background: In atopic dermatitis (AD) there is evidence of tissue fibrosis involving a number of structural changes, including papillary dermal fibrosis and epidermal hyperplasia. These changes are suggested to be the result of chronic inflammation of the skin. Several remodeling-associated cytokines, including transforming growth factor (TGF) beta1, IL-11, and IL-17, have been shown to be increased in allergic diseases, including asthma. Objective: We investigated TGF-beta1, IL-11, and IL-17 expression in skin biopsy specimens recovered from acute and chronic skin lesions from patients with AD, as well as from uninvolved skin of patients with AD and skin from healthy volunteers. We also examined the correlation between the expression of these cytokines and the extent of total, type 1, and type III collagen deposition. Methods: We evaluated the expression of TGF-beta1, IL-11, and IL-17 by means of immunohistochemistry. Collagen deposition was assessed by means of immunohistochemistry and van Gieson staining. Results: TGF-beta1 expression was markedly enhanced in both acute and particularly chronic lesions (P < .001). Although IL-11 expression was significantly increased only in chronic lesions (P < .0001), IL-17 was preferentially associated with acute lesions (P < .005). Although collagen type III deposition was not significantly different among the groups, type I collagen deposition was significantly increased in chronic AD lesions (P < .0005). There was a significant correlation between IL-11 and type I collagen deposition, as well as the number of eosinophils in skin specimens from patients with AD (r(2) = 0.527, and r(2) = 0.622, respectively; P < .0001). Conclusion: These results suggest that TGF-beta 1, IL-11, and IL-17 are involved in the remodeling of skin lesions in patients with AD. However, IL-11 and IL-17 are preferentially expressed at different stages of the disease. Type I collagen appeared to be the major subtype involved in this repair process.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Fac Sci Pharmaceut & Biol, INSERM, U456, Rennes, France; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06510 USA; Dokkyo Univ, Dept Pulm Med & Clin Immunol, Tokyo, Japan	McGill University; National Jewish Health; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University; Dokkyo Medical University	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00051] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; BRADDING P, 1997, AIRWAY WALL REMODELL, P29; Coker RK, 1997, AM J PATHOL, V150, P981; DERYNCK R, 1982, CYTOKINE HDB, P593; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; ELIAS JA, 1994, J IMMUNOL, V152, P2421; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GIAID A, 1993, LANCET, V341, P1550; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Katoh N, 2002, CLIN EXP IMMUNOL, V127, P283, DOI 10.1046/j.1365-2249.2002.01740.x; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; Leng SX, 1997, INT J BIOCHEM CELL B, V29, P1059, DOI 10.1016/S1357-2725(97)00017-4; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1996, ATOPIC DERMATITIS PA, P113; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MOLET S, 2000, AM J RESP CRIT CARE, V161, P742; MOLET S, 1999, EUR RESPIR J, V14, P1939; *NIH NHLBI, 1997, NIH PUBL; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PLEDGER WJ, 1982, ANN NY ACAD SCI, V397, P1, DOI 10.1111/j.1749-6632.1982.tb43411.x; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; RAGHOW R, 1989, CHEST, V99, pS61; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; ROCHE WR, 1999, LANCET, V353, P520; Rochester CL, 1996, J IMMUNOL, V156, P4449; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; UITTO J, 1979, J CLIN INVEST, V64, P921, DOI 10.1172/JCI109558; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297; WILSON JW, 1997, AIRWAY WALL REMODELL, P65; WONG DTW, 1991, BLOOD, V78, P2702; YOO ZB, 1995, J IMMUNOL, V155, P5483; ZHANG K, 1995, AM J PATHOL, V147, P352; ZHENG T, 1994, J IMMUNOL, V153, P4742	46	238	266	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					875	881		10.1067/mai.2003.1414	http://dx.doi.org/10.1067/mai.2003.1414			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704372				2022-12-18	WOS:000182258500032
J	ZEIGER, RS; HELLER, S; MELLON, MH; WALD, J; FALKOFF, R; SCHATZ, M				ZEIGER, RS; HELLER, S; MELLON, MH; WALD, J; FALKOFF, R; SCHATZ, M			FACILITATED REFERRAL TO ASTHMA SPECIALIST REDUCES RELAPSES IN ASTHMA EMERGENCY ROOM VISITS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDREN; HOSPITALIZATION; EDUCATION; PROGRAM	Facilitated asthma-specialist care delivered by allergists was compared to generalist care on the rate of relapse of asthma emergency room (ER) visits and hospitalizations and on asthma control in a prospective, controlled study of San Diego Kaiser Health Plan members with asthma. Subjects with asthma between the ages of 6 and 59 years presenting for acute ER care for asthma were systematically assigned by alternating, consecutively, the day of their ER visit to receive either (1) facilitated referral to an asthma specialist within the allergy department and concomitant comprehensive ongoing asthma care (intervention group, n = 149) or (2) continued outpatient management from generalist physicians (control group, n = 160). The course of their asthma was evaluated blindly during the subsequent 6 months by review of medical records, initial and follow-up questionnaires, and spirometry. Compared to the control group, the intervention group noted (1) a 75% reduction in the number of, and percent of, subjects with asthma awakenings per night (p less-than-or-equal-to 0.0001), (2) an almost 50% reduction in asthma ER relapses (p = 0.017) resulting from a reduction in the frequency of multiple relapses (p = 0.005), and (3) a greater use of inhaled corticosteroids (p < 0.00001) and cromolyn (p = 0.002). Thus, facilitated referral of subjects with asthma to specialists in asthma therapy after acute ER therapy appears to reduce asthma ER relapses and to improve asthma outcome.	KAISER PERMANENTE MED CTR,DEPT ALLERGY IMMUNOL,SAN DIEGO,CA	Kaiser Permanente				Zeiger, Robert/0000-0001-5788-5063				BUCKNALL CE, 1988, LANCET, V1, P748; CREER T L, 1990, Pediatric Asthma Allergy and Immunology, V4, P41, DOI 10.1089/pai.1990.4.41; FREUND DA, 1989, J ALLERGY CLIN IMMUN, V84, P401, DOI 10.1016/0091-6749(89)90428-4; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; RICHARDS W, 1989, PEDIATRICS, V84, P111; SHIELDS MC, 1990, AM J PUBLIC HEALTH, V80, P36, DOI 10.2105/AJPH.80.1.36; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; WILLERT C, 1985, J PEDIATR-US, V106, P707, DOI 10.1016/S0022-3476(85)80340-1; 1962, AM REV RESPIR DIS, V85, P762; 1990, MMWR, V39, P493	14	238	241	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1160	1168		10.1016/0091-6749(91)92162-T	http://dx.doi.org/10.1016/0091-6749(91)92162-T			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045618				2022-12-18	WOS:A1991FR06600016
J	KIDD, JM; COHEN, SH; SOSMAN, AJ; FINK, JN				KIDD, JM; COHEN, SH; SOSMAN, AJ; FINK, JN			FOOD-DEPENDENT EXERCISE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,ALLERGY & IMMUNOL SECT,MILWAUKEE,WI 53226; VET ADM MED CTR,MARCUS CTR IMMUNOL & ALLERGY RES,WOOD,WI 53193	Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BLUMBERG MZ, 1978, ANN ALLERGY, V41, P99; CORRIGAN AB, 1972, MED J AUSTRALIA, V2, P363, DOI 10.5694/j.1326-5377.1972.tb47352.x; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GREEN LH, 1976, ANN INTERN MED, V84, P704, DOI 10.7326/0003-4819-84-6-704; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; KAUPPINEU K, 1980, CONTACT DERMATITIS, V6, P279; LEVIT F, 1977, NEW ENGL J MED, V297, P1127; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MAY CD, 1981, NEW ENGLAND SOC ALLE, V2, P198; ORANGE RP, 1978, ALLERGY PRINCIPLES P, P162; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SOTER N A, 1982, Journal of Allergy and Clinical Immunology, V69, P103; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; 1980, LANCET, V2, P1344	17	238	245	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					407	411		10.1016/0091-6749(83)90070-2	http://dx.doi.org/10.1016/0091-6749(83)90070-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6833679	Bronze			2022-12-18	WOS:A1983QL12100009
J	WASSERMAN, SI				WASSERMAN, SI			MEDIATORS OF IMMEDIATE HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV RHEUMATOL ALLERGY,ALLERGY SECT,SAN DIEGO,CA 92103	University of California System; University of California San Diego					NIAID NIH HHS [AI-17268] Funding Source: Medline; PHS HHS [00431] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED T, 1980, J APPL PHYSIOL, V49, P826, DOI 10.1152/jappl.1980.49.5.826; ALHENCGELAS F, 1982, PROSTAG OTH LIPID M, V24, P723, DOI 10.1016/0090-6980(82)90040-5; ANWAR ARE, 1977, NATURE, V269, P522, DOI 10.1038/269522a0; APPLEGREN LE, 1982, J BIOL CHEM, V257, P531; ARMOUR CL, 1982, EUR J PHARMACOL, V82, P229, DOI 10.1016/0014-2999(82)90519-2; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V69, P39; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; AUSTEN KF, 1982, POSTGRADUATE COURSE; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BESSIN P, 1983, EUR J PHARMACOL, V86, P403, DOI 10.1016/0014-2999(83)90190-5; BLANK ML, 1981, LIFE SCI, V29, P769, DOI 10.1016/0024-3205(81)90031-X; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLANK ML, 1981, J BIOL CHEM, V256, P175; BOOJINOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BOSWELL RN, 1978, J IMMUNOL, V120, P15; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BURKE JA, 1982, FED PROC, V41, P823; BURKE JA, 1982, J PHARMACOL EXP THER, V221, P235; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CENTER DM, 1983, J ALLERGY CLIN IMMUN, V71, P29, DOI 10.1016/0091-6749(83)90543-2; CENTER DM, 1979, CLIN EXP IMMUNOL, V35, P112; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CHIU H, 1972, HISTOCHEM J, V4, P135, DOI 10.1007/BF01004972; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COLEMAN JW, 1981, IMMUNOLOGY, V44, P859; COMBS JW, 1965, J CELL BIOL, V25, P577, DOI 10.1083/jcb.25.3.577; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DVORAK AM, 1982, BLOOD, V59, P1279; DVORAK HF, 1977, J IMMUNOL, V119, P38; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; EADY RAJ, 1981, CLIN EXP DERMATOL, V6, P355, DOI 10.1111/j.1365-2230.1981.tb02318.x; EADY RAJ, 1978, LANCET, V1, P336; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P294; FINDLAY SR, 1981, AM J PHYSIOL, V241, pC130, DOI 10.1152/ajpcell.1981.241.3.C130; FRAKI JE, 1975, ARCH DERMATOL FORSCH, V253, P261, DOI 10.1007/BF00561152; GALLI SJ, 1979, CELLULAR MOL CLIN AS, P1; GOETZL E J, 1978, Journal of Immunology, V120, P526; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1977, J CLIN INVEST, V59, P179, DOI 10.1172/JCI108617; GOETZL EJ, 1979, ADV INFLAMMAT RES, V1, P157; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HALONEN M, 1980, AM REV RESPIR DIS, V122, P915; HALONEN M, 1981, AM REV RESPIR DIS, V124, P416; HAMMARSTROM S, 1981, BIOCHEM BIOPH RES CO, V101, P1109, DOI 10.1016/0006-291X(81)91562-X; HAMMARSTROM S, 1981, J BIOL CHEM, V256, P9579; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HENDERSON WR, 1983, BIOCHEM BIOPH RES CO, V110, P266, DOI 10.1016/0006-291X(83)91290-1; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HUMPHEREY CM, 1982, LAB INVEST, V46, P422; HUMPHREY DM, 1982, LAB INVEST, V47, P227; ISHIZAKA T, 1976, J IMMUNOL, V116, P747; ISHIZAKA T, 1981, BIOCH ACUTE ALLERGIC, P213; JAKSCHIK BA, 1982, J BIOL CHEM, V257, P5346; JAKSCHIK BA, 1980, BIOCHEM BIOPH RES CO, V95, P103, DOI 10.1016/0006-291X(80)90710-X; JONES DG, 1974, CLIN EXP IMMUNOL, V16, P213; JONES TR, 1982, CAN J PHYSIOL PHARM, V60, P638, DOI 10.1139/y82-087; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LAI FM, 1983, LIFE SCI, V32, P1159, DOI 10.1016/0024-3205(83)90122-4; LAMPE M, 1977, ARCH DERMATOL RES, V258, P69, DOI 10.1007/BF00582869; LEE CW, 1982, P NATL ACAD SCI-BIOL, V79, P4166, DOI 10.1073/pnas.79.13.4166; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LOTNER GZ, 1980, J IMMUNOL, V124, P676; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P607, DOI 10.1083/jcb.11.3.607; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARQUARDT DL, 1982, WESTERN J MED, V137, P195; MARQUARDT DL, J IMMUNOL; MCMANUS LM, 1980, J IMMUNOL, V124, P2919; MCMANUS LM, 1981, LAB INVEST, V45, P303; MCMANUS LM, 1981, J CLIN INVEST, V67, P903, DOI 10.1172/JCI110108; MEIER HL, 1979, J ALLERGY CLIN IMMUN, V63, P191; MEIER HL, 1980, ADV ALLERGY APPLIED, P652; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; METCALFE DD, 1980, J INVEST DERMATOL, V74, P210, DOI 10.1111/1523-1747.ep12541737; METCALFE DD, 1979, J CLIN INVEST, V64, P1537, DOI 10.1172/JCI109613; METCALFE DD, J IMMUNOL; METZGER WJ, 1983, CLIN RES, V31, P164; MILLS DCB, 1974, THROMB RES, V5, P401, DOI 10.1016/0049-3848(74)90176-5; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; NEWBALL HH, 1980, ANAPHYLACTIC ACTIVAT; OERTEL HL, 1981, J IMMUNOL, V127, P1398; OFLAHERTY JT, 1981, INFLAMMATION, V5, P193, DOI 10.1007/BF00914443; OMINI C, 1981, PHARMACOL RES COMMUN, V13, P633, DOI 10.1016/S0031-6989(81)80051-3; ORANGE RP, 1971, J EXP MED, V134, pS136; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PINCKARD RN, 1980, J ALLERGY CLIN IMMUN, V65, P196; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; PLAUT M, 1973, J IMMUNOL, V111, P389; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1982, J BIOL CHEM, V257, P7229; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; ROCKLIN RE, 1981, J CLIN IMMUNOL, V1, P73, DOI 10.1007/BF00915479; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; ROUBIN R, 1982, EUR J IMMUNOL, V12, P141, DOI 10.1002/eji.1830120208; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; RUZICKA T, 1983, J ALLERGY CLIN IMMUN; SAMUELSSON B, 1979, PROSTAGLANDINS, V17, P785, DOI 10.1016/0090-6980(79)90052-2; SAMUELSSON B, 1980, ALLERGY, V35, P375, DOI 10.1111/j.1398-9995.1980.tb01782.x; SATOUCHI K, 1981, ARCH BIOCHEM BIOPHYS, V211, P683, DOI 10.1016/0003-9861(81)90504-X; SATOUCHI K, 1981, J BIOL CHEM, V256, P4425; SCHECHTER NM, 1983, J BIOL CHEM, V258, P2973; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SCHLEIMER RP, 1983, FED PROC, V42, P1380; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; SCHWARTZ LB, CLIN REV ALLERGY MAS; SCHWARTZ LB, 1981, J BIOL CHEM, V256; SELIGMANN BE, 1983, J IMMUNOL, V130, P1902; SHAW JO, 1981, J IMMUNOL, V127, P1250; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOK DE, 1981, BIOCHEM BIOPH RES CO, V101, P222, DOI 10.1016/S0006-291X(81)80034-4; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; STECHSCHULTE DJ, 1973, J IMMUNOL, V111, P1585; STEEL LK, 1981, J BIOL CHEM, V256; STEINHOFF MM, 1980, BIOCHIM BIOPHYS ACTA, V618, P28, DOI 10.1016/0005-2760(80)90050-8; STIMLER NP, 1981, AM J PATHOL, V105, P64; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TING S, 1981, J ALLERGY CLIN IMMUN, V68, P65, DOI 10.1016/0091-6749(81)90125-1; TING S, 1981, J IMMUNOL, V127, P5577; TOUQUI L, 1983, BIOCHEM BIOPH RES CO, V110, P890, DOI 10.1016/0006-291X(83)91045-8; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; TRZECIAKOWSKI JP, 1982, J PHARMACOL EXP THER, V223, P774; TURNBULL LW, 1977, IMMUNOLOGY, V32, P57; UENO A, 1982, PROSTAGLANDINS, V23, P865, DOI 10.1016/0090-6980(82)90130-7; VALONE FH, 1978, J IMMUNOL, V120, P102; VALONE FH, 1983, IMMUNOLOGY, V48, P141; VARGAFTIG BB, 1982, EUR J PHARMACOL, V82, P121; WARREN K, 1983, J ALLERGY CLIN IMMUN, V71, P206, DOI 10.1016/0091-6749(83)90101-X; WASSERMAN MA, 1977, PROSTAGLANDINS, V13, P255, DOI 10.1016/0090-6980(77)90007-7; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WASSERMAN SI, 1977, J BIOL CHEM, V252, P7074; WEBB DR, 1982, BIOCHEM BIOPH RES CO, V104, P1617, DOI 10.1016/0006-291X(82)91438-3; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; WELLER PF, 1981, FED PROC, V40, P1023; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P4298, DOI 10.1021/bi00613a029; WOODMAN O L, 1983, European Journal of Pharmacology, V86, P125; WYKLE RL, 1982, FEBS LETT, V141, P29, DOI 10.1016/0014-5793(82)80008-2; WYKLE RL, 1981, BIOCHEM BIOPH RES CO, V100, P1651, DOI 10.1016/0006-291X(81)90708-7; WYKLE RL, 1980, J BIOL CHEM, V255, P256; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YASAKA T, 1982, J IMMUNOL, V128, P1939; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405; YURT RW, 1977, J BIOL CHEM, V252, P518	185	238	240	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					101	115		10.1016/0091-6749(83)90512-2	http://dx.doi.org/10.1016/0091-6749(83)90512-2			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6193157	Bronze			2022-12-18	WOS:A1983RD95900001
J	Subramanian, H; Gupta, K; Ali, H				Subramanian, Hariharan; Gupta, Kshitij; Ali, Hydar			Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						G protein-coupled receptor; MRGPRX2; mast cells; host defense peptides; neuropeptides; drug-induced pseudoallergy; chronic urticaria; asthma	AIRWAY SMOOTH-MUSCLE; FC-EPSILON-RI; SUBSTANCE-P RECEPTOR; HISTAMINE-RELEASE; PEPTIDE LL-37; HUMAN BETA-DEFENSIN-2; INNATE IMMUNITY; KERATINOCYTE MIGRATION; RHINOVIRUS INFECTION; CUTANEOUS RESPONSES	Mast cells (MCs), which are granulated tissue-resident cells of hematopoietic lineage, contribute to vascular homeostasis, innate/adaptive immunity, and wound healing. However, MCs are best known for their roles in allergic and inflammatory diseases, such as anaphylaxis, food allergy, rhinitis, itch, urticaria, atopic dermatitis, and asthma. In addition to the high-affinity IgE receptor (FceRI), MCs express numerous G protein-coupled receptors (GPCRs), which are the largest group of membrane receptor proteins and the most common targets of drug therapy. Antimicrobial host defense peptides, neuropeptides, major basic protein, eosinophil peroxidase, and many US Food and Drug Administration-approved peptidergic drugs activate human MCs through a novel GPCR known as Mas-related G protein-coupled receptor X2 (MRGPRX2; formerly known as MrgX2). Unique features of MRGPRX2 that distinguish it from other GPCRs include their presence both on the plasma membrane and intracellular sites and their selective expression in MCs. In this article we review the possible roles of MRGPRX2 on host defense, drug-induced anaphylactoid reactions, neurogenic inflammation, pain, itch, and chronic inflammatory diseases, such as urticaria and asthma. We propose that host defense peptides that kill microbes directly and activate MCs through MRGPRX2 could serve as novel GPCR targets to modulate host defense against microbial infection. Furthermore, mAbs or small-molecule inhibitors of MRGPRX2 could be developed for the treatment of MC-dependent allergic and inflammatory disorders.	[Subramanian, Hariharan; Gupta, Kshitij; Ali, Hydar] Univ Penn, Sch Dent Med, Dept Pathol, 240 S 40th St, Philadelphia, PA 19104 USA; [Subramanian, Hariharan] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	University of Pennsylvania; Michigan State University	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Pathol, 240 S 40th St, Philadelphia, PA 19104 USA.	alih@upenn.edu	Subramanian, Hariharan/AHC-5755-2022		National Institutes of Health [HL085774, AI108585, HL121073]; American Heart Association [12POST9260009]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085774, R00HL121073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI108585, R01AI124182] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R21OD017843] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grants HL085774 and AI108585 (to H.A.). This work was also supported by a R00 grant HL121073 from the National Institutes of Health and an American Heart Association postdoctoral fellowship 12POST9260009 (to H.S.).	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Ahamed J, 2004, J IMMUNOL, V172, P6961, DOI 10.4049/jimmunol.172.11.6961; Ali H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-19; ALVING K, 1991, CELL TISSUE RES, V264, P529, DOI 10.1007/BF00319042; Amaral MM, 2007, J IMMUNOL, V179, P3425, DOI 10.4049/jimmunol.179.6.3425; Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Andrade MVM, 2004, J IMMUNOL, V172, P7254, DOI 10.4049/jimmunol.172.12.7254; ARIZONO N, 1990, LAB INVEST, V62, P626; Babolewska E, 2015, CELL IMMUNOL, V293, P67, DOI 10.1016/j.cellimm.2014.12.006; Ballas SK, 2012, BLOOD, V120, P3647, DOI 10.1182/blood-2012-04-383430; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; Befus AD, 1999, J IMMUNOL, V163, P947; BIENENSTOCK J, 1991, AM REV RESPIR DIS, V143, pS55, DOI 10.1164/ajrccm/143.3_Pt_2.S55; Bigliardi-Qi M, 2004, DERMATOLOGY, V209, P183, DOI 10.1159/000079887; Biro T, 2009, TRENDS PHARMACOL SCI, V30, P411, DOI 10.1016/j.tips.2009.05.004; Blanca-Lopez N, 2013, CLIN EXP ALLERGY, V43, P560, DOI 10.1111/cea.12099; Borici-Mazi R, 1999, ALLERGY, V54, P46, DOI 10.1034/j.1398-9995.1999.00726.x; Brightling CE, 2005, CURR ALLERGY ASTHM R, V5, P130, DOI 10.1007/s11882-005-0086-9; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Burstein ES, 2006, BRIT J PHARMACOL, V147, P73, DOI 10.1038/sj.bjp.0706448; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Busse WW, 1997, CIBA F SYMP, V206, P208; Cai YQ, 2003, AM J RESP CELL MOL, V29, P683, DOI 10.1165/rcmb.2002-0174OC; Carstens E, 2014, FRONT NEUROSCI, P1, DOI 10.1201/b16573; Cevikbas F, 2014, ITCH MECH TREATMENT; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chahdi A, 1998, EUR J PHARMACOL, V341, P329, DOI 10.1016/S0014-2999(97)01480-5; Chen XJ, 2007, EUR J IMMUNOL, V37, P434, DOI 10.1002/eji.200636379; DeHaven WI, 2008, J BIOL CHEM, V283, P19265, DOI 10.1074/jbc.M801535200; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Di Nardo A, 2008, J IMMUNOL, V180, P7565, DOI 10.4049/jimmunol.180.11.7565; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Douaiher J, 2014, ADV IMMUNOL, V122, P211, DOI 10.1016/B978-0-12-800267-4.00006-7; Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Erdei A, 2004, IMMUNOL LETT, V92, P39, DOI 10.1016/j.imlet.2003.11.019; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Ferry X, 2001, J IMMUNOL, V167, P4805, DOI 10.4049/jimmunol.167.9.4805; FOREMAN JC, 1982, BRIT J PHARMACOL, V77, P531, DOI 10.1111/j.1476-5381.1982.tb09328.x; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Fukuoka Y, 2008, J IMMUNOL, V180, P6307, DOI 10.4049/jimmunol.180.9.6307; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Gekara NO, 2008, CELL MICROBIOL, V10, P225, DOI 10.1111/j.1462-5822.2007.01033.x; Grimbaldeston MA, 2015, IMMUNOL CELL BIOL, V93, P221, DOI 10.1038/icb.2015.10; Guhl S, 2005, J NEUROIMMUNOL, V163, P92, DOI 10.1016/j.jneuroim.2005.02.015; Guo Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022559; Gupta K, 2016, INNATE IMMUN-LONDON, V22, P21, DOI 10.1177/1753425915610643; Gupta K, 2015, ONCOTARGET, V6, P28573, DOI 10.18632/oncotarget.5611; Gupta K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046369; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hazlett L, 2011, CELL TISSUE RES, V343, P175, DOI 10.1007/s00441-010-1022-4; HEANEY LG, 1995, CLIN EXP ALLERGY, V25, P179, DOI 10.1111/j.1365-2222.1995.tb01024.x; Hebbel RP, 2004, MICROCIRCULATION, V11, P129, DOI 10.1080/10739680490278402; Hilchie AL, 2013, NAT CHEM BIOL, V9, P761, DOI [10.1038/NCHEMBIO.1393, 10.1038/nchembio.1393]; Ikeya M, 2014, BIOCHEM BIOPH RES CO, V451, P62, DOI 10.1016/j.bbrc.2014.07.060; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Jawdat DM, 2006, J IMMUNOL, V177, P1755, DOI 10.4049/jimmunol.177.3.1755; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Kelesidis T, 2010, CLIN THER, V32, P515, DOI 10.1016/j.clinthera.2010.03.002; Koppert W, 2001, ANESTHESIOLOGY, V95, P659, DOI 10.1097/00000542-200109000-00019; Kuehn HS, 2007, IMMUNOL LETT, V113, P59, DOI 10.1016/j.imlet.2007.08.007; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Lee MG, 2008, J IMMUNOL, V180, P2251, DOI 10.4049/jimmunol.180.4.2251; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Lorenz D, 1998, J GEN PHYSIOL, V112, P577, DOI 10.1085/jgp.112.5.577; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40; MACQUEEN G, 1989, SCIENCE, V243, P83, DOI 10.1126/science.2911721; Malaviya R, 2002, CLIN REV ALLERG IMMU, V22, P189, DOI 10.1385/CRIAI:22:2:189; Malaviya R, 2001, IMMUNITY, V15, P313, DOI 10.1016/S1074-7613(01)00184-4; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; McGowen AL, 2009, VACCINE, V27, P3544, DOI 10.1016/j.vaccine.2009.03.069; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003; Michaels LA, 1998, BLOOD, V92, P3148, DOI 10.1182/blood.V92.9.3148.421k12_3148_3151; Mookherjee N, 2009, J IMMUNOL, V183, P2688, DOI 10.4049/jimmunol.0802586; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Mori K, 2000, J PHARM PHARMACOL, V52, P577, DOI 10.1211/0022357001774228; Mori K, 2000, EUR J PHARMACOL, V394, P51, DOI 10.1016/S0014-2999(00)00147-3; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MOUSLI M, 1990, IMMUNOL LETT, V25, P355, DOI 10.1016/0165-2478(90)90207-7; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; Nijnik A, 2010, J IMMUNOL, V184, P2539, DOI 10.4049/jimmunol.0901813; Niyonsaba F, 2002, INT IMMUNOL, V14, P421, DOI 10.1093/intimm/14.4.421; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Niyonsaba F, 2007, J INVEST DERMATOL, V127, P594, DOI 10.1038/sj.jid.5700599; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ogasawara T, 1997, J IMMUNOL, V158, P393; Okayama Yoshimichi, 2008, Allergol Int, V57, P197, DOI 10.2332/allergolint.R-08-163; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; PIOTROWSKI W, 1984, AGENTS ACTIONS, V14, P420, DOI 10.1007/BF01973842; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Proud D, 2006, CURR ALLERGY ASTHM R, V6, P81, DOI 10.1007/s11882-006-0015-6; Reber LL, 2015, MUCOSAL IMMUNOL, V8, P444, DOI 10.1038/mi.2014.131; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Rohrl J, 2010, J IMMUNOL, V184, P6688, DOI 10.4049/jimmunol.0903984; Roosterman D, 2006, PHYSIOL REV, V86, P1309, DOI 10.1152/physrev.00026.2005; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; Scheb-Wetzel M, 2014, INFECT IMMUN, V82, P4496, DOI 10.1128/IAI.02114-14; SCHWYZER R, 1987, EMBO J, V6, P2255, DOI 10.1002/j.1460-2075.1987.tb02498.x; Shelburne CP, 2009, CELL HOST MICROBE, V6, P331, DOI 10.1016/j.chom.2009.09.004; Siebenhaar F, 2008, J ALLERGY CLIN IMMUN, V121, P955, DOI 10.1016/j.jaci.2007.11.013; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X; Solinski HJ, 2014, PHARMACOL REV, V66, P570, DOI 10.1124/pr.113.008425; Solinski HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058756; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; Stefansson K, 2008, J INVEST DERMATOL, V128, P18, DOI 10.1038/sj.jid.5700965; Steinhoff M, 2003, ARCH DERMATOL, V139, P1479, DOI 10.1001/archderm.139.11.1479; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Steinhoff M, 2013, J AM ACAD DERMATOL, V69, pS15, DOI 10.1016/j.jaad.2013.04.045; Subramanian H, 2013, J IMMUNOL, V191, P345, DOI 10.4049/jimmunol.1300023; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; Subramanian H, 2011, MOL PHARMACOL, V79, P1005, DOI 10.1124/mol.111.071472; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040; Tanaka S, 2012, J IMMUNOL, V188, P6145, DOI 10.4049/jimmunol.1103660; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Taylor-Clark TE, 2008, BRIT J PHARMACOL, V154, P1359, DOI 10.1038/bjp.2008.196; Thakurdas SM, 2007, J BIOL CHEM, V282, P20809, DOI 10.1074/jbc.M611842200; Thangam EB, 2005, FASEB J, V19, P798, DOI 10.1096/fj.04-2797fje; Tjabringa GS, 2006, INT ARCH ALLERGY IMM, V140, P103, DOI 10.1159/000092305; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; van Diest SA, 2012, BBA-MOL BASIS DIS, V1822, P74, DOI 10.1016/j.bbadis.2011.03.019; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Venkatachalam TK, 2003, BIOORG MED CHEM LETT, V13, P485, DOI 10.1016/S0960-894X(02)00992-7; Vibhuti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019585; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Vincent L, 2013, BLOOD, V122, P1853, DOI 10.1182/blood-2013-04-498105; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005; Weller K, 2006, FASEB J, V20, P2366, DOI 10.1096/fj.06-5837fje; Wiehler S, 2007, AM J PHYSIOL-LUNG C, V293, pL505, DOI 10.1152/ajplung.00066.2007; Yamaura K, 2009, J TOXICOL SCI, V34, P427, DOI 10.2131/jts.34.427; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yoshioka M, 2008, BIOL PHARM BULL, V31, P212, DOI 10.1248/bpb.31.212; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; Yu HB, 2009, J BIOL CHEM, V284, P36007, DOI 10.1074/jbc.C109.073627; Zhang LJ, 2009, CURR OPIN INVEST DR, V10, P164; Zhang ZF, 2009, EUR J IMMUNOL, V39, P3181, DOI 10.1002/eji.200939496; Zhu J, 2014, CHEST, V145, P1219, DOI 10.1378/chest.13-1567; Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100	166	237	246	16	67	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					700	710		10.1016/j.jaci.2016.04.051	http://dx.doi.org/10.1016/j.jaci.2016.04.051			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27448446	Bronze, Green Accepted			2022-12-18	WOS:000385496000005
J	Thyssen, JP; Kezic, S				Thyssen, Jacob P.; Kezic, Sanja			Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; barrier function; filaggrin; histidine; ichthyosis vulgaris; lamellar body; pathogenesis; stratum corneum; T(H)2 cytokines; urocanic acid	THYMIC STROMAL LYMPHOPOIETIN; OF-FUNCTION MUTATIONS; DOWN-REGULATES FILAGGRIN; INNATE LYMPHOID-CELLS; SKIN BARRIER FUNCTION; STRATUM-CORNEUM; ICHTHYOSIS VULGARIS; FUNCTION VARIANTS; CORNIFIED ENVELOPE; PROTEASE ACTIVITY	The epidermis protects human subjects from exogenous stressors and helps to maintain internal fluid and electrolyte homeostasis. Filaggrin is a crucial epidermal protein that is important for the formation of the corneocyte, as well as the generation of its intracellular metabolites, which contribute to stratum corneum hydration and pH. The levels of filaggrin and its degradation products are influenced not only by the filaggrin genotype but also by inflammation and exogenous stressors. Pertinently, filaggrin deficiency is observed in patients with atopic dermatitis regardless of filaggrin mutation status, suggesting that the absence of filaggrin is a key factor in the pathogenesis of this skin condition. In this article we review the various causes of low filaggrin levels, centralizing the functional and morphologic role of a deficiency in filaggrin, its metabolites, or both in the etiopathogenesis of atopic dermatitis.	[Thyssen, Jacob P.] Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Dept Dermatoallergol, DK-2900 Hellerup, Denmark; [Kezic, Sanja] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands	University of Copenhagen; Herlev & Gentofte Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Thyssen, JP (corresponding author), Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Dept Dermatoallergol, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	jacob.p.thyssen@regionh.dk	Thyssen, Jacob/ABD-8517-2020	Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	COST Action TD1206 StanDerm; Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish	COST Action TD1206 StanDerm(European Cooperation in Science and Technology (COST)); Lundbeck Foundation(Lundbeckfonden)	Supported by the COST Action TD1206 StanDerm. J.P.T. is a Lundbeck Foundation Fellow and is supported by an unrestricted grant.	Akaza N, 2009, J DERMATOL, V36, P213, DOI 10.1111/j.1346-8138.2009.00626.x; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Angelova-Fischer I, 2014, ACTA DERM-VENEREOL, V94, P640, DOI 10.2340/00015555-1815; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Brauweiler AM, 2013, J ALLERGY CLIN IMMUN, V131, P421, DOI 10.1016/j.jaci.2012.10.030; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Cai SCS, 2012, BRIT J DERMATOL, V166, P200, DOI 10.1111/j.1365-2133.2011.10541.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Carson CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048678; Cascella R, 2011, J INVEST DERMATOL, V131, P982, DOI 10.1038/jid.2010.398; Choi EH, 2005, J INVEST DERMATOL, V124, P587, DOI 10.1111/j.0022-202X.2005.23589.x; Contassot E, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13590; Cooper MF, 1978, ICHTHYOSES, P19; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Danby SG, 2014, BRIT J DERMATOL, V170, P914, DOI 10.1111/bjd.12778; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Del Bino S, 2004, BRIT J DERMATOL, V150, P658, DOI 10.1111/j.0007-0963.2004.05886.x; Deleuran M, 2012, CHEM IMMUNOL ALLERGY, V96, P45, DOI 10.1159/000331871; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Droitcourt C, 2011, DERMATOLOGY, V222, P336, DOI 10.1159/000328408; Eichner R, 1996, BRIT J DERMATOL, V135, P687; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P323, DOI 10.1016/j.bbalip.2013.10.001; Elias PM, 2013, J HUM EVOL, V64, P687, DOI 10.1016/j.jhevol.2013.02.003; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gerritsen MJP, 1996, ACTA DERM-VENEREOL, V76, P6; Ginger RS, 2005, ARCH DERMATOL RES, V297, P235, DOI 10.1007/s00403-005-0590-8; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Harding CR, 2013, INT J COSMETIC SCI, V35, P412, DOI 10.1111/ics.12049; Hatano Y, 2013, EXP DERMATOL, V22, P30, DOI 10.1111/exd.12047; Hougaard MG, 2014, J EUR ACAD DERMATOL, V28, P238, DOI 10.1111/j.1468-3083.2012.04679.x; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Hvid M, 2011, EXP DERMATOL, V20, P633, DOI 10.1111/j.1600-0625.2011.01280.x; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Imokawa G, 2009, J DERMATOL SCI, V55, P1, DOI 10.1016/j.jdermsci.2009.04.006; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Jensen JM, 2007, J INVEST DERMATOL, V127, P1720, DOI 10.1038/sj.jid.5700788; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Jungersted JM, 2010, ALLERGY, V65, P911, DOI 10.1111/j.1398-9995.2010.02326.x; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Katagiri C, 2003, J DERMATOL SCI, V31, P29, DOI 10.1016/S0923-1811(02)00137-8; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kezic S, 2014, FRONT BIOSCI-LANDMRK, V19, P541, DOI 10.2741/4225; Khnykin D, 2012, J AM ACAD DERMATOL, V66, P606, DOI 10.1016/j.jaad.2011.04.014; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim BE, 2013, J INVEST DERMATOL, V133, P2678, DOI 10.1038/jid.2013.223; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Kypriotou M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067869; Landheer J, 2013, J ALLERGY CLIN IMMUN, V132, P1252, DOI 10.1016/j.jaci.2013.07.051; Lee KH, 2011, EXP DERMATOL, V20, P149, DOI 10.1111/j.1600-0625.2010.01203.x; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McPherson T, 2010, BRIT J DERMATOL, V163, P544, DOI 10.1111/j.1365-2133.2010.09866.x; MERRICK DT, 1992, AM J PATHOL, V140, P167; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Nakai K, 2012, AM J PATHOL, V181, P969, DOI 10.1016/j.ajpath.2012.06.005; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Noh M, 2010, EXP DERMATOL, V19, P355, DOI 10.1111/j.1600-0625.2009.00902.x; Nomura T, 2008, J INVEST DERMATOL, V128, P1436, DOI 10.1038/sj.jid.5701205; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; NylanderLundqvist E, 1996, J IMMUNOL, V157, P1699; NylanderLundqvist E, 1997, ACTA DERM-VENEREOL, V77, P203; Oji V, 2009, BRIT J DERMATOL, V160, P771, DOI 10.1111/j.1365-2133.2008.08999.x; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park YH, 2012, J INVEST DERMATOL, V132, P476, DOI 10.1038/jid.2011.333; Pearton DJ, 2001, EXP DERMATOL, V10, P193, DOI 10.1034/j.1600-0625.2001.010003193.x; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Perusquia-Ortiz AM, 2013, J EUR ACAD DERMATOL, V27, P1552, DOI 10.1111/jdv.12079; Presland RB, 2001, EXP CELL RES, V270, P199, DOI 10.1006/excr.2001.5348; RESING KA, 1993, BIOCHEMISTRY-US, V32, P10036, DOI 10.1021/bi00089a020; RESING KA, 1995, J BIOL CHEM, V270, P28193; Rinnerthaler M, 2013, EXP DERMATOL, V22, P329, DOI 10.1111/exd.12135; Ross-Hansen K, 2014, J INVEST DERMATOL, V134, P1164, DOI 10.1038/jid.2013.445; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sano Y, 2013, CLIN EXP IMMUNOL, V171, P330, DOI 10.1111/cei.12021; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Schuepbach-Mallepell S, 2013, J ALLERGY CLIN IMMUN, V132, P1348, DOI 10.1016/j.jaci.2013.06.033; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; SHEU H-M, 1991, Journal of Dermatology (Tokyo), V18, P454; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stout TE, 2014, J INVEST DERMATOL, V134, P423, DOI 10.1038/jid.2013.284; Swinkels OQJ, 2002, SKIN PHARMACOL APPL, V15, P262, DOI 10.1159/000065972; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Thyssen JP, 2013, BRIT J DERMATOL, V168, P1155, DOI 10.1111/bjd.12219; Thyssen JP, 2012, J ALLERGY CLIN IMMUN, V130, P1204, DOI 10.1016/j.jaci.2012.06.046; Torma H, 2008, J INVEST DERMATOL, V128, P1212, DOI 10.1038/sj.jid.5701170; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yuki T, 2011, J IMMUNOL, V187, P3230, DOI 10.4049/jimmunol.1100058; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852; Ziyab AH, 2013, J EUR ACAD DERMATOL, V27, pe420, DOI 10.1111/jdv.12000	115	237	254	0	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					792	799		10.1016/j.jaci.2014.06.014	http://dx.doi.org/10.1016/j.jaci.2014.06.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25065719				2022-12-18	WOS:000343155700003
J	Kleine-Tebbe, J; Wangorsch, A; Vogel, L; Crowell, DN; Haustein, UF; Vieths, S				Kleine-Tebbe, J; Wangorsch, A; Vogel, L; Crowell, DN; Haustein, UF; Vieths, S			Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1-related PR-10 protein in soybean, SAM22	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; soy protein; SAM22; pathogenesis-related protein; birch pollen allergy; Bet v 1; IgE	BIRCH POLLEN; SOY ALLERGY; MAJOR ALLERGEN; MESSENGER-RNAS; IDENTIFICATION; CHILDREN; ASTHMA; PEANUT; HYPERSENSITIVITY; CYTOKININ	Background: Anaphylactic reactions to soy products have been attributed to stable class I food allergens. Objective: IgE-mediated reactions to a soy-containing dietary food product in patients allergic to birch pollen were investigated. Methods: Detailed case histories were taken from 20 patients. Their sera were analyzed for IgE (UniCAP) specific for birch, grass, mugwort, the recombinant birch allergens rBet v 1 and rBet v2, and soy protein. Extracts from birch pollen, soy isolate, rBet v 1, and the recombinant PR-10 soy protein rSAM22 were coupled to paper disks or nitrocellulose for IgE measurements (enzyme allergosorbent test) or Western blot analysis. Enzyme allergosorbent testing, Western blot inhibition, and histamine release studies were performed with the same allergens. Results: Most patients (17/20) experienced facial, oropharyngeal, and/or systemic allergic symptoms within 20 minutes after ingesting the soy product for the first time. Birch pollen allergy (16/20) was common, along with oral allergy syndrome to apple (12/20) or hazelnut (11/20). IgE levels to birch and Bet v 1 but not to other inhalants were high in 18 of 20 patients. Significant IgE binding to rSAM22 occurred in 17 of 20 patients. Blot experiments with the soy isolate revealed IgE-binding bands at 17 kd (15/20), 22 kd (1/20), and 35 to 38 kd (2/20); the former was inhibited by preincubation of the sera with rBet v I or rSAM22. Birch extract and soy isolate, rBet v 1, and rSAM22 induced dose-dependent histamine release in the nanomolar range. Conclusion: Immediate-type allergic symptoms in patients with birch pollen allergy after ingestion of soy protein-containing food items can result from cross-reactivity of Bet v I-specific IgE to homologous pathogenesis-related proteins, particularly the PR-10 protein SAM22.	Univ Leipzig, Dept Dermatol, Leipzig, Germany; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Leipzig University; Paul Ehrlich Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Kleine-Tebbe, J (corresponding author), Allergy & Asthmas Ctr Berlin Westend, Spoandauer Damm 130,Haus 9, D-14050 Berlin, Germany.			Kleine-Tebbe, Joerg/0000-0002-2862-7353				Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BESLER M, 2000, INTERNET S FOOD A S3, V2, P1; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Bruno G, 1997, PEDIAT ALLERG IMM-UK, V8, P190, DOI 10.1111/j.1399-3038.1997.tb00159.x; Cantani A, 1997, PEDIAT ALLERG IMM-UK, V8, P59, DOI 10.1111/j.1399-3038.1997.tb00146.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Codina R, 1999, INT ARCH ALLERGY IMM, V119, P69, DOI 10.1159/000024178; CROWELL DN, 1990, P NATL ACAD SCI USA, V87, P8815, DOI 10.1073/pnas.87.22.8815; CROWELL DN, 1991, PLANT PHYSIOL, V95, P711, DOI 10.1104/pp.95.3.711; CROWELL DN, 1992, PLANT MOL BIOL, V18, P459, DOI 10.1007/BF00040662; Eigenmann PA, 1996, J ALLERGY CLIN IMMUN, V98, P969, DOI 10.1016/S0091-6749(96)80014-5; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Foucard T, 1999, ALLERGY, V54, P261, DOI 10.1034/j.1398-9995.1999.00924.x; Helm RM, 2000, INT ARCH ALLERGY IMM, V123, P205, DOI 10.1159/000024445; Jankiewicz A, 1996, INT ARCH ALLERGY IMM, V111, P268, DOI 10.1159/000237377; Jankiewicz A, 1997, J SCI FOOD AGR, V75, P359, DOI 10.1002/(SICI)1097-0010(199711)75:3&lt;359::AID-JSFA889&gt;3.0.CO;2-Y; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Kleine-Tebbe J, 2001, ALLERGO J, V10, P154; KleineTebbe J, 1996, J ALLERGY CLIN IMMUN, V98, P181, DOI 10.1016/S0091-6749(96)70241-5; KLEINETEBBE J, 1992, ALLERGY, V47, P618, DOI 10.1111/j.1398-9995.1992.tb02384.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer SB, 1999, INT ARCH ALLERGY IMM, V118, P298, DOI 10.1159/000024107; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VIETHS S, 1995, ANN ALLERG ASTHMA IM, V75, P48; White MC, 1997, AM J EPIDEMIOL, V145, P432, DOI 10.1093/oxfordjournals.aje.a009125; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; Zeiger RS, 1999, J PEDIATR-US, V134, P614, DOI 10.1016/S0022-3476(99)70249-0	35	237	253	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					797	804		10.1067/mai.2002.128946	http://dx.doi.org/10.1067/mai.2002.128946			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417891				2022-12-18	WOS:000179082500017
J	Giustizieri, ML; Mascia, F; Frezzolini, A; De Pita, O; Chinni, LM; Giannetti, A; Girolomoni, G; Pastore, S				Giustizieri, ML; Mascia, F; Frezzolini, A; De Pita, O; Chinni, LM; Giannetti, A; Girolomoni, G; Pastore, S			Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; psoriasis; keratinocytes; inflammation; cytokines; chemokines	MONOCYTE CHEMOATTRACTANT PROTEIN-1; GAMMA-INTERFERON; TNF-ALPHA; SKIN; EXPRESSION; RANTES; LYMPHOCYTES; ACTIVATION; INTERLEUKIN-8; EPIDERMIS	Background: Atopic dermatitis (AD) and psoriasis are genetically determined inflammatory skin disorders. Keratinocytes actively participate in cutaneous inflammatory responses by elaborating various chemokines. Objective: We investigated the capacity of IL-4, IFN-gamma, and TNF-a to modulate the expression of CCL and CXCL chemokines in cultured keratinocytes from patients and healthy individuals, as well as chemokine expression in situ. Methods: Keratinocyte cultures were established from normal-looking skin of adult patients with AD or psoriasis vulgaris and from healthy subjects. Monocyte chemoattractant protein 1 (MCP-1)/CCL2, RANTES/CCL5, IL-8/CXCL8, and IFN-gamma -induced protein of 10 kd (IP-10)/CXCL10 production was evaluated at the mRNA and protein levels by using RNase protection assay and ELISA, respectively. The expression of the same chemokines was studied in chronic Lesional skin by means of immunohistochemistry or in situ hybridization. Results: Only IL-8 mRNA was detected in unstimulated keratinocyte cultures. MCP-1 and IP-10 were potently induced by IFN-gamma, whereas IL-8 and RANTES were preferentially upregulated by TNF-a and, to a lesser extent, by IFN-gamma. IL-4 weakly induced IP-10, RANTES, and IL-8 but not MCP-I. Keratinocytes of patients with AD invariably responded with significantly earlier and higher RANTES expression. By contrast, keratinocytes of patients with psoriasis displayed much higher Levels of both constitutive and induced IL-8 and a stronger induction of MCP-1 and IP-10. RANTES and MCP-I mRNA(+) keratinocytes were detected in the basal layer of lesions of patients with AD and psoriasis. IP-10 and IL-8 were consistently upregulated in the epidermis of patients with psoriasis but not in lesions of patients with AD. Conclusions: Keratinocytes of patients with AD and psoriasis show an intrinsically abnormal and different chemokine production profile and may thus favor the recruitment of distinct leukocyte subsets into the skin.	IRCCS, Ist Dermopat Immacolata, Immunol Lab, I-00167 Rome, Italy; Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Universita di Modena e Reggio Emilia	Pastore, S (corresponding author), IRCCS, Ist Dermopat Immacolata, Immunol Lab, Via Monti Creta 104, I-00167 Rome, Italy.		GIROLOMONI, Giampiero/AAC-3405-2022					Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; Albanesi C, 1999, J IMMUNOL, V162, P494; BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4; Chen SH, 2000, FASEB J, V14, P565, DOI 10.1096/fasebj.14.3.565; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; GILLITZER R, 1993, J INVEST DERMATOL, V101, P127, DOI 10.1111/1523-1747.ep12363613; GILLITZER R, 1991, J INVEST DERMATOL, V97, P73, DOI 10.1111/1523-1747.ep12478128; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Jackson M, 1999, FASEB J, V13, P495, DOI 10.1096/fasebj.13.3.495; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Li J, 1996, J INVEST DERMATOL, V106, P661, DOI 10.1111/1523-1747.ep12345482; MULLER C, 1988, J EXP MED, V167, P1124; NAKAMURA K, 1995, J INVEST DERMATOL, V105, P635, DOI 10.1111/1523-1747.ep12324061; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; Niwa Y, 2000, ARCH DERMATOL, V136, P125, DOI 10.1001/archderm.136.1.125; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Pastore S, 2000, J INVEST DERMATOL, V115, P1134, DOI 10.1046/j.1523-1747.2000.00149.x; Raychaudhuri SP, 1999, ACTA DERM-VENEREOL, V79, P9; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Yamada H, 1997, INT ARCH ALLERGY IMM, V114, P28, DOI 10.1159/000237713; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	34	237	243	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					871	877		10.1067/mai.2001.114707	http://dx.doi.org/10.1067/mai.2001.114707			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344355	Bronze			2022-12-18	WOS:000168812300016
J	YASUEDA, H; YUI, Y; SHIMIZU, T; SHIDA, T				YASUEDA, H; YUI, Y; SHIMIZU, T; SHIDA, T			ISOLATION AND PARTIAL CHARACTERIZATION OF THE MAJOR ALLERGEN FROM JAPANESE CEDAR (CRYPTOMERIA-JAPONICA) POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											YASUEDA, H (corresponding author), NATL SAGAMIHARA HOSP, CLIN RES CTR ALLERGY & RHEUMATOL, Sagamihara, KANAGAWA 228, JAPAN.							AAS K, 1978, ALLERGY, V33, P3, DOI 10.1111/j.1398-9995.1978.tb01501.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; BABA M, 1978, ALLERGY WORLD, P100; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BERGGARD I, 1961, ARK KEMI, V18, P281; BERRENS L, 1974, ANN NY ACAD SCI, V221, P183, DOI 10.1111/j.1749-6632.1974.tb28216.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DIEZEL W, 1969, ANAL BIOCHEM, V48, P4406; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GOODFRIEND L, 1981, J ALLERGY CLIN IMMUN, V67, P299, DOI 10.1016/0091-6749(81)90025-7; GROSS GN, 1978, SCAND J IMMUNOL, V8, P437, DOI 10.1111/j.1365-3083.1978.tb00539.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; KING TP, 1972, BIOCHEMISTRY-US, V11, P367, DOI 10.1021/bi00753a010; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLEY A, 1967, J IMMUNOL, V99, P825; MARSH DG, 1975, ANTIGENS, V3, P271; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PAULL BR, 1979, J ALLERGY CLIN IMMUN, V64, P539, DOI 10.1016/0091-6749(79)90065-4; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SUVUNRUNGSI R, 1982, Journal of Allergy and Clinical Immunology, V69, P126; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMSON AR, 1973, ANN NY ACAD SCI, V209, P210, DOI 10.1111/j.1749-6632.1973.tb47530.x; YASUEDA H, 1980, Japanese Journal of Allergology, V29, P763; YOO TJ, 1975, ANN ALLERGY, V34, P87	30	237	250	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					77	86		10.1016/0091-6749(83)90550-X	http://dx.doi.org/10.1016/0091-6749(83)90550-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6822692	Bronze			2022-12-18	WOS:A1983PZ46100012
J	Van Zele, T; Gevaert, P; Holtappels, G; Beule, A; Wormald, PJ; Mayr, S; Hens, G; Hellings, P; Ebbens, FA; Fokkens, W; Van Cauwenberge, P; Bachert, C				Van Zele, Thibaut; Gevaert, Philippe; Holtappels, Gabriele; Beule, Achim; Wormald, Peter John; Mayr, Susanne; Hens, Greet; Hellings, Peter; Ebbens, Fenna A.; Fokkens, Wytske; Van Cauwenberge, Paul; Bachert, Claus			Oral steroids and doxycycline: Two different approaches to treat nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Randomized controlled trial; placebo-controlled; double blind; methylprednisolone; doxycycline; Staphylococcus aureus; nasal polyposis; chronic rhinosinusitis; double-blind placebo-controlled; corticosteroids; antibiotics	QUALITY-OF-LIFE; CHRONIC SINUSITIS; MATRIX METALLOPROTEINASES; BUDESONIDE; EFFICACY; CORTICOSTEROIDS; TETRACYCLINES; INFLAMMATION; FORMULATION; CYTOKINES	Background: There is little scientific evidence to support the current practice of using oral glucocorticosteroids and antibiotics to treat patients with chronic rhinosinusitis and nasal polyps. Objective: We evaluated the effects of oral glucocorticoids and doxycycline on symptoms and objective clinical and biological parameters in patients with chronic rhinosinusitis and nasal polyps. Methods: In a double-blind, placebo-controlled, multicenter trial, we randomly assigned 47 participants with bilateral nasal polyps to receive either methylprednisolone in decreasing doses (32-8 mg once daily), doxycycline (200 mg on the first day, followed by 100 mg once daily), or placebo for 20 days. Participants were followed for 12 weeks. Patients were assessed for nasal peak inspiratory flow and symptoms and by nasal endoscopy. Markers of inflammation such as eosinophilic cationic protein (ECP), IL-5, myeloperoxidase, matrix metalloproteinase 9, and IgE were measured in nasal secretions. Concentrations of eosinophils, ECP, and soluble IL-5 receptor a were measured in peripheral blood samples. Results: Methylprednisolone and doxycycline each significantly decreased nasal polyp size compared with placebo. The effect of methylprednisolone was maximal at week 3 and lasted until week 8, whereas the effect of doxycycline was moderate but present for 12 weeks. Methylprednisolone significantly reduced levels of ECP, IL-5, and IgE in nasal secretions, whereas doxycycline significantly reduced levels of myeloperoxidase, ECP, and matrix metalloproteinase 9 in nasal secretions. Conclusion: This is the first double-blind, placebo-controlled study to show a significant effect of oral methylprednisolone and doxycycline on size of nasal polyps, nasal symptoms, and mucosal and systemic markers of inflammation. (J Allergy Clin Immunol 2010;125:1069-76.)	[Van Zele, Thibaut] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium; [Hens, Greet; Hellings, Peter] Univ Hosp St Rafael, Dept Otorhinolaryngol, Louvain, Belgium; [Mayr, Susanne] Univ Erlangen Nurnberg, Dept Otorhinolaryngol Head & Neck Surg, Erlangen, Germany; [Beule, Achim; Wormald, Peter John] Univ Adelaide, Dept Surg Otorhinolaryngol, Adelaide, SA 5005, Australia; [Ebbens, Fenna A.; Fokkens, Wytske] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands	Ghent University; Ghent University Hospital; University of Erlangen Nuremberg; University of Adelaide; University of Amsterdam; Academic Medical Center Amsterdam	Van Zele, T (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, De Pintelaan 85, B-9000 Ghent, Belgium.	thibaut.vanzele@ugent.be	Hellings, Peter W/I-4068-2018; Fokkens, Wytske WJ/ABF-2185-2020; Beule, Achim/J-3525-2019; Gevaert, Philippe/AAP-1892-2020; Bachert, Claus/J-8825-2012; Gevaert, Philippe/ABA-4588-2021	Hellings, Peter W/0000-0001-6898-688X; Beule, Achim/0000-0002-1622-6077; Gevaert, Philippe/0000-0002-1629-8468; Van Zele, Thibaut/0000-0002-6031-4293; Hens, Greet/0000-0001-9690-7376	Flemish Scientific Research Board, FWO [A12/5-HB-KH 3]; Research Foundation Flanders (FWO)	Flemish Scientific Research Board, FWO(FWO); Research Foundation Flanders (FWO)(FWO)	Supported by a grant from the Flemish Scientific Research Board, FWO Nr. A12/5-HB-KH 3 (holder of a Fundamenteel Klinisch Mandaat), by a postdoctoral grant from the Research Foundation Flanders (FWO), and by postdoctoral mandate from the Research Foundation Flanders (FWO).	Alobid I, 2006, RHINOLOGY, V44, P8; Alobid I, 2005, ALLERGY, V60, P452, DOI 10.1111/j.1398-9995.2005.00725.x; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Benitez P, 2006, LARYNGOSCOPE, V116, P770, DOI 10.1097/01.mlg.0000205218.37514.0f; DEUSCHL H, 1977, Rhinology (Utrecht), V15, P17; DINGSOR G, 1985, Rhinology (Utrecht), V23, P49; Fokkens W, 2007, RHINOLOGY, V45, P97; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gueders MM, 2008, BIOCHEM PHARMACOL, V75, P514, DOI 10.1016/j.bcp.2007.09.012; Hashiba M, 1996, ACTA OTO-LARYNGOL, P73; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; HOLOPAINEN E, 1982, EUR J RESPIR DIS, V63, P221; JOHANSEN LV, 1993, CLIN OTOLARYNGOL, V18, P524, DOI 10.1111/j.1365-2273.1993.tb00628.x; Kuzin II, 2001, INT IMMUNOL, V13, P921, DOI 10.1093/intimm/13.7.921; LEGENT F, 1994, CHEMOTHERAPY, V40, P1, DOI 10.1159/000239308; Lildholdt T, 1997, ARCH OTOLARYNGOL, V123, P595; Lildholdt T, 1989, Rhinol Suppl, V8, P31; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; Patiar S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005232.pub2; Rempe S., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P232, DOI 10.2174/187153007782794344; Richards RN, 2008, J CUTAN MED SURG, V12, P77, DOI 10.2310/7750.2008.07029; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Subramanian HN, 2002, AM J RHINOL, V16, P303, DOI 10.1177/194589240201600605; SUNDBERG L, 1983, ACTA OTO-LARYNGOL, V96, P501, DOI 10.3109/00016488309132737; Tos M, 1998, AM J RHINOL, V12, P183, DOI 10.2500/105065898781390217; Van Camp C., 1994, Rhinology (Utrecht), V32, P5; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; VIROLAINEN E, 1980, Rhinology (Utrecht), V18, P9; Watelet JB, 2004, EUR ARCH OTO-RHINO-L, V261, P242, DOI 10.1007/s00405-003-0691-y; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x	33	236	243	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1069	1076		10.1016/j.jaci.2010.02.020	http://dx.doi.org/10.1016/j.jaci.2010.02.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451040				2022-12-18	WOS:000277686700016
J	Turvey, SE; Broide, DH				Turvey, Stuart E.; Broide, David H.			Innate immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Host defense; innate immunity; Toll-like receptors; nucleotide oligomerization domain-like receptors	PYOGENIC BACTERIAL-INFECTIONS; TOLL-LIKE RECEPTORS; NOD-LIKE RECEPTORS; INFLAMMATORY DISEASE; CROHNS-DISEASE; ALLERGIC RHINITIS; SUSCEPTIBILITY; ADJUVANT; ENDOTOXIN; RESPONSES	Recent years have witnessed an explosion of interest in the innate immune system. Questions about how the innate immune system senses infection and empowers a protective immune response are being answered at the molecular level. These basic science discoveries are being translated into a more complete understanding of the central role innate immunity plays in the pathogenesis of many human infectious and inflammatory diseases. It is particularly exciting that we are already seeing a return on these scientific investments with the emergence of novel therapies to harness the power of the innate immune system. In this review we explore the defining characteristics of the innate immune system, and through more detailed examples, we highlight recent breakthroughs that have advanced our understanding of the role of innate immunity in human health and disease. (J Allergy Clin Immunol 2010;125:S24-32.)	[Turvey, Stuart E.] Univ British Columbia, Div Infect & Immunol Dis, BC Childrens Hosp, Dept Paediat, Vancouver, BC V5Z 4H4, Canada; [Turvey, Stuart E.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	BC Childrens Hospital; University of British Columbia; Child & Family Research Institute; University of British Columbia; University of California System; University of California San Diego	Turvey, SE (corresponding author), Univ British Columbia, Div Infect & Immunol Dis, BC Childrens Hosp, Dept Paediat, 950 W 28 Ave, Vancouver, BC V5Z 4H4, Canada.	sturvey@cw.bc.ca	Turvey, Stuart/HGV-1191-2022	Turvey, Stuart/0000-0003-1599-1065; Broide, David/0000-0001-8405-9090	Canadian Immunodeficiency Society; Canadian Cystic Fibrosis Foundation; CIHR Team in Mutagenesis and Infectious Diseases; NIH [AI 038425, AI072115, AI070535]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI038425, R37AI038425, R01AI072115] Funding Source: NIH RePORTER	Canadian Immunodeficiency Society; Canadian Cystic Fibrosis Foundation; CIHR Team in Mutagenesis and Infectious Diseases(Canadian Institutes of Health Research (CIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. E. T. is supported by a Chaim Roifman Scholar Award from the Canadian Immunodeficiency Society and a Career Development Award from the Canadian Child Health Clinician Scientist Program (CCHCSP)-a CIHR Strategic Training Program and operating grants from the Canadian Cystic Fibrosis Foundation and the CIHR Team in Mutagenesis and Infectious Diseases. D. H. B. is supported by NIH grants AI 038425, AI072115 and AI070535.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Benko S, 2008, CYTOKINE, V43, P368, DOI 10.1016/j.cyto.2008.07.013; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Broide D, 1998, J IMMUNOL, V161, P7054; Casale TB, 2006, ANN ALLERG ASTHMA IM, V97, P454, DOI 10.1016/S1081-1206(10)60934-9; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Fanucchi MV, 2004, AM J RESP CRIT CARE, V170, P1153, DOI 10.1164/rccm.200404-533OC; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Frank MM, 2010, J ALLERGY CLIN IMMUN, V125, pS262, DOI 10.1016/j.jaci.2009.10.063; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Goldstein DB, 2005, NATURE, V437, P1241, DOI 10.1038/4371241a; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; HO J, 2004, J RESP DIS THORAC SU, V3, P7; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Horner AA, 2004, CURR OPIN ALLERGY CL, V4, P555, DOI 10.1097/00130832-200412000-00014; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Joncker NT, 2008, IMMUNOL REV, V224, P85, DOI 10.1111/j.1600-065X.2008.00658.x; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976; Kong NCT, 2008, KIDNEY INT, V73, P856, DOI 10.1038/sj.ki.5002725; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627; Miao EA, 2007, SEMIN IMMUNOPATHOL, V29, P275, DOI 10.1007/s00281-007-0078-z; Nejentsev S, 2008, NAT GENET, V40, P261, DOI 10.1038/ng0308-261; Noguchi E, 2009, NAT IMMUNOL, V10, P471, DOI 10.1038/ni.1722; Notarangelo L, 2004, J ALLERGY CLIN IMMUN, V114, P677, DOI 10.1016/j.jaci.2004.06.044; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Schwarz TF, 2008, EXPERT REV VACCINES, V7, P1465, DOI 10.1586/14760584.7.10.1465; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Strober W, 2008, MUCOSAL IMMUNOL, V1, pS5, DOI 10.1038/mi.2008.42; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turvey SE, 2006, CLIN IMMUNOL, V120, P1, DOI 10.1016/j.clim.2006.02.003; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016	53	236	246	4	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S24	S32		10.1016/j.jaci.2009.07.016	http://dx.doi.org/10.1016/j.jaci.2009.07.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	19932920	Green Accepted			2022-12-18	WOS:000280170600003
J	Henderson, J; Northstone, K; Lee, SP; Liao, HH; Zhao, YW; Pembrey, M; Mukhopadhyay, S; Smith, GD; Palmer, CNA; McLean, WHI; Irvine, AD				Henderson, John; Northstone, Kate; Lee, Simon P.; Liao, Haihui; Zhao, Yiwei; Pembrey, Marcus; Mukhopadhyay, Somnath; Smith, George Davey; Palmer, Colin N. A.; McLean, W. H. Irwin; Irvine, Alan D.			The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopic dermatitis; asthma; skin barrier; filaggrin; birth cohort; atopy	ATOPIC-DERMATITIS; BRONCHIAL RESPONSIVENESS; BARRIER; METHODOLOGY; PHENOTYPES; CHILDREN; ALSPAC; ASTHMA; ECZEMA; GENE	Background: Atopic disease is a major health problem. Mutations in the filaggrin gene (FLG) confer major susceptibility to eczema and related asthma. Objective: We sought to determine the natural history and burden of atopic disease conferred by the 2 most common FLG mutations in a large, population-based birth cohort study. Methods: We analyzed the effect of the most common null alleles (R501X and 2282del4) on several atopic phenotypes in a cohort of approximately 7000 English children born in 1990-1991. Results: FLG null alleles associated strongly with eczema; eczema associated with these mutations presents in early life and is more persistent (hazard ratio for eczema resolution for those with FLG mutations to FLG wild type, 0.67; 95% CI, 0.58-0.77; P = 5 x 10(-8)). FLG mutations conferred a population asthma risk of 1.80 (95% CI, 1.34-2.41; P = .00019); asthma risk was especially high in the context of eczema (odds ratio, 3.16; 95% CI, 2.25-4.43; P = 1.4 x 10(-11)). Strong associations were identified with sensitization to grass, house dust mite, and cat dander and sensitization to multiple allergens (odds ratio, 2.12; 95% CI, 1.03-4.37; P = 5.42 x 10(-27)). Conclusion: FLG mutations are strong genetic determinants of eczema, early wheeze, asthma in the context of eczema, and atopic sensitization. They confer risk of a particular trajectory for eczema, with increased duration of disease and greater risk of asthma and multiple allergic sensitizations. FLG alleles help define the risk profile of children with eczema and help define the "eczema plus early wheeze" and "eczema plus asthma" phenotypes.	[Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Dept Paediat Dermatol, Dublin 12, Ireland; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Northstone, Kate] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; [Smith, George Davey] Univ Bristol, MRC, Ctr Causal Anal Translat Epidemiol, Bristol BS8 1TH, Avon, England; [Lee, Simon P.; Palmer, Colin N. A.] Univ Dundee, Populat Pharmacogenet Grp, Biomed Res Ctr, Dundee DD1 4HN, Scotland; [Mukhopadhyay, Somnath] Univ Dundee, Childrens Asthma & Allergy Res Unit, Dundee DD1 4HN, Scotland; [Liao, Haihui; Zhao, Yiwei; McLean, W. H. Irwin] Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci, Dundee DD1 4HN, Scotland; [Pembrey, Marcus] UCL, Inst Child Hlth, London WC1E 6BT, England	National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; University of Bristol; University of Bristol; University of Bristol; University of Dundee; University of Dundee; University of Dundee; University of London; University College London	Irvine, AD (corresponding author), Our Ladys Childrens Hosp Crumlin, Dept Paediat Dermatol, Dublin 12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008; McLean, William HI/C-6352-2009; Northstone, Kate/A-8165-2011; Palmer, Colin NA/C-7053-2008; Davey Smith, George/A-7407-2013	Irvine, Alan D/0000-0002-9048-2044; Northstone, Kate/0000-0002-0602-1983; Palmer, Colin NA/0000-0002-6415-6560; Davey Smith, George/0000-0002-1407-8314; McLean, William Henry Irwin/0000-0001-5539-5757; s, hema/0000-0002-3440-9475; Venkatasubramanian, Siddharth/0000-0002-5860-0768	Medical Research Council [G0600705, G0700314, G9815508] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0600705, G0700314] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chinn S, 1998, THORAX, V53, P984, DOI 10.1136/thx.53.11.984; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jones RW, 2000, EUR J HUM GENET, V8, P653, DOI 10.1038/sj.ejhg.5200502; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Virtanen H, 2007, J ALLERGY CLIN IMMUN, V120, P1464, DOI 10.1016/j.jaci.2007.08.021; Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	20	236	248	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					872	877		10.1016/j.jaci.2008.01.026	http://dx.doi.org/10.1016/j.jaci.2008.01.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18325573	Bronze			2022-12-18	WOS:000254884000010
J	Lee, J; Seto, D; Bielory, L				Lee, Joohee; Seto, David; Bielory, Leonard			Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						meta-analysis; pediatric atopic dermatitis; atopic dermatitis; probiotics; Lactobacillus; SCORAD; quality scales	PLACEBO-CONTROLLED TRIAL; ALLERGIC DISEASES; DOUBLE-BLIND; MANAGEMENT; QUALITY; CHILDREN	Background: Prenatal and postnatal probiotic supplementation for prevention and treatment of pediatric atopic dermatitis (PAD) has been studied in clinical trials, but results have been mixed and hindered by heterogeneity of study design. Objectives: To summarize and interpret quantitatively clinical trial findings on the efficacy of probiotics for PAD and to define key trial features correlating with high methodologic quality. Methods: PubMed and Cochrane database searches yielded 21 trials (n = 1898; age 0-13 y) published between February 1997 and May 2007 for review and quality assessment. Ten double-blind randomized controlled clinical trials were meta-analyzed by using RevMan. Data from the 6 prevention studies (n = 1581) and 4 treatment trials (n = 299) were pooled by using fixed-effects and random-effects models of relative risk ratios and of weighted mean difference, respectively. Results: Prevention corresponded with summary effect sizes of 0.69 (0.57, 0.83) and 0.66 (0.49, 0.89), respectively, supporting probiotics' PAD prevention potential, which decreased further to 0.61 after exclusion of the 1 trial of postnatal-only probiotics. The clinical significance of the treatment trial findings of intergroup Scoring Atopic Dermatitis (quantification of PAD severity) score reduction by -6.64 points (-9.78, -3.49) and -8.56 (-18.39, 1.28), and intragroup change of -1.06 (-3.86, 1.73) and -1.37 (-4.81, 2.07), is questionable. Conclusion: Current evidence is more convincing for probiotics' efficacy in prevention than treatment of PAD.	[Lee, Joohee; Seto, David; Bielory, Leonard] Univ Med & Dent New Jersey, Sch Med, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bielory, L (corresponding author), Univ Med & Dent New Jersey, Sch Med, Dept Med, 90 Bergen St,DOC Suite 4700, Newark, NJ 07103 USA.	bielory@umdnj.edu						Boyle RJ, 2006, CLIN EXP ALLERGY, V36, P568, DOI 10.1111/j.1365-2222.2006.02472.x; Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Cucchiara S, 2002, DIGEST LIVER DIS, V34, pS44, DOI 10.1016/S1590-8658(02)80163-3; Helfenstein U, 2002, POSTGRAD MED J, V78, P131, DOI 10.1136/pmj.78.917.131; Isolauri E, 2004, CURR ALLERGY ASTHM R, V4, P270, DOI 10.1007/s11882-004-0070-9; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; O'Sullivan GC, 2005, CURR PHARM DESIGN, V11, P3, DOI 10.2174/1381612053382368; Ogden NS, 2005, CURR OPIN ALLERGY CL, V5, P179, DOI 10.1097/01.all.0000162312.64308.fc; Pelto L, 1998, CLIN EXP ALLERGY, V28, P1474, DOI 10.1046/j.1365-2222.1998.00449.x; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Rautava S, 2005, J ALLERGY CLIN IMMUN, V116, P31, DOI 10.1016/j.jaci.2005.02.010; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sistek D, 2006, CLIN EXP ALLERGY, V36, P629, DOI 10.1111/j.1365-2222.2006.02485.x; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Yusuf S, 1997, CONTROL CLIN TRIALS, V18, P594, DOI 10.1016/S0197-2456(97)00052-4	22	236	256	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					116	121		10.1016/j.jaci.2007.10.043	http://dx.doi.org/10.1016/j.jaci.2007.10.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206506	Bronze			2022-12-18	WOS:000252372000017
J	Ou, LS; Goleva, E; Hall, C; Leung, DYM				Ou, LS; Goleva, E; Hall, C; Leung, DYM			T regulatory cells in atopic dermatitis and subversion of their activity by superantigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T regulatory cell; atopic dermatitis; superantigen	LYMPHOCYTE-ASSOCIATED ANTIGEN; IMMUNOLOGICAL SELF-TOLERANCE; STAPHYLOCOCCUS-AUREUS; IN-VITRO; BACTERIAL SUPERANTIGENS; HOMING RECEPTOR; EXPRESSION; INFLAMMATION; STIMULATION; DISEASE	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease involving colonization by superantigen (SAg)-secreting Staphylococcus aureus. CD4(+)CD25(+) T regulatory (Treg) cells are thought to play an important role in controlling inflammatory responses. Objective: In this study we examined whether Treg cells might he deficient in patients with AD. Methods: CD4(+)CD25(+) and CD4(+)CD25(-) T cells were isolated from PBMCs by using immunomagnetic beads. Cells were cultured with anti-CD3 or SAg, staphylococcal enterotoxin B (SEB), for 72 hours. Proliferation was measured by means of tritiated thymidine incorporation. CD4, CD8, CD25, and cutaneous lymphocyte-associated antigen expression on PBMCs was assessed by means of flow cytometry. RNA was extracted from isolated subsets of T cells, and the results of real-time PCR for FoxP3 mRNA were determined. Results: Surprisingly, CD4(+)CD25(+) T cells were significantly (P < .01) increased in patients with AD (6.68% +/- 0.99%, n = 15) compared with in asthmatic patients (3.42% +/- 0.58%, n = 12) or nonatopic healthy control subjects (3.34% +/- 0.43%, n = 14). Patients with AD also had a higher expression of CD25(+) in skin-homing, CD4(+), cutaneous lymphocyte-associated antigen-positive T cells than asthmatic and nonatopic subjects, with values of 35.95% versus 22.44% versus 23.03%, respectively (P < .006). Only CD4(+)CD25(+) cells expressed FoxP3, whereas CD4(+)CD25(-) T cells and CD4(-) cells did not. Consistent with known properties of Treg cells, CD4(+)CD25(+) cells were anergic to anti-CD3 stimulation. When CD4(+)CD25(+) cells from each study group were mixed with CD4(+)CD25(-) cells, proliferative responses were equally suppressed after anti-CD3 stimulation. In contrast, after SEB stimulation, CD4(+)CD25(+) cells were no longer anergic. Furthermore, when CD4(+)CD25(+) cells were mixed with CD4(+)CD25(-) cells and stimulated with SEB, the suppressive function of Treg cells was reversed. Conclusion: Patients with AD have significantly increased numbers of peripheral blood Treg cells with normal immunosuppressive activity. However, after SAg stimulation, Treg cells lose their immunosuppressive activity. These data suggest a novel mechanism by which SAgs could augment T-cell activation in patients with AD.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Chang Gung Childrens Hosp, Div Allergy Asthma & Rheumatol, Dept Pediat, Taoyuan, Taiwan; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; Chang Gung Memorial Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, P01HL036577, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00051] Funding Source: Medline; NHLBI NIH HHS [HL 36577, HL 37260] Funding Source: Medline; NIAMS NIH HHS [AR 41256] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akdis M, 1997, J IMMUNOL, V159, P4611; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Bieber T, 2002, ATOPIC DERMATITIS; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gavin M, 2003, CURR OPIN IMMUNOL, V15, P690, DOI 10.1016/j.coi.2003.09.011; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Mittrucker HW, 1996, J EXP MED, V183, P2481, DOI 10.1084/jem.183.6.2481; MURAILLE E, 1995, INT IMMUNOL, V7, P295, DOI 10.1093/intimm/7.2.295; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; Saha B, 1996, J EXP MED, V183, P2675, DOI 10.1084/jem.183.6.2675; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Suri-Payer E, 2001, J AUTOIMMUN, V16, P115, DOI 10.1006/jaut.2000.0473; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Suto A, 2001, AM J RESP CRIT CARE, V164, P680, DOI 10.1164/ajrccm.164.4.2010170; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Zelenika D, 2002, J IMMUNOL, V168, P1069, DOI 10.4049/jimmunol.168.3.1069	53	236	265	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					756	763		10.1016/j.jaci.2004.01.772	http://dx.doi.org/10.1016/j.jaci.2004.01.772			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100684				2022-12-18	WOS:000220956600026
J	Watanabe, S; Narisawa, Y; Arase, S; Okamatsu, H; Ikenaga, T; Tajiri, Y; Kumemura, M				Watanabe, S; Narisawa, Y; Arase, S; Okamatsu, H; Ikenaga, T; Tajiri, Y; Kumemura, M			Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopic dermatitis; microflora; bifidobacterium; bacteroides; staphylococcus; fecal IgA; skin IgA; minority; case control study	INTESTINAL MICROFLORA; STAPHYLOCOCCUS-AUREUS; ALLERGY; FLORA; DISEASE	The prevalence of allergic diseases, such as atopic dermatitis (AD), has been increasing. However, few investigations have been made of the intestinal microflora in Japanese patients with AD. Objective: The purpose of this study was to determine the differences in microflora, fecal serum IgA concentrations, and skin IgA contents between patients with AD and healthy control subjects. Methods: This trial was conducted as a case-control study using 30 minor patients with AD and age- and sex-matched healthy control subjects (n = 68). One week after a questionnaire was administered, fecal specimens and 24-hour skin secretion specimens were collected from all subjects. Fecal microflora, fecal IgA concentrations, and IgA contents on the skin surface were analyzed. Results: The counts of Bifidobacterium (in log(10) colony-forming units per gram) were significantly lower in patients with AD than in healthy control subjects (9.75 +/- 0.68 vs 10.10 +/- 0.50 log(10) colony-forming units/g, P <.05). In particular, percentages of Bifidobacterium were significantly lower in patients with severe skin symptoms than in those with mild skin symptoms (40% +/- 6 % vs 19 % +/- 6 %, P <.05). In addition, the frequency of occurrence of Staphylococcus was significantly higher in patients with AD than in healthy control subjects (83% vs 59%, P <.05). There were no significant differences in fecal IgA content or IgA content on the skin between the 2 groups. Conclusion: Patients with AD had lower counts of Bifidobacterium than healthy control subjects, and the frequency of Staphylococcus was higher in patients with AD than in control subjects. Disorder of the intestinal microflora might play a role in the onset of AD and the aggravation of skin symptoms.	Otsuka Pharmaceut Co Ltd, Nutraceut Res Inst, Otsu, Shiga 5200002, Japan; Teikyo Univ, Sch Med, Dept Dermatol, Tokyo 173, Japan; Saga Med Sch, Dept Internal Med, Div Dermatol, Saga, Japan; Univ Tokushima, Sch Med, Dept Dermatol, Tokushima 770, Japan	Otsuka Pharmaceutical; Teikyo University; Saga University; Tokushima University	Kumemura, M (corresponding author), Otsuka Pharmaceut Co Ltd, Nutraceut Res Inst, 31-13-3 Saigawa, Otsu, Shiga 5200002, Japan.							Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Benno Y., 1986, Bifidobacteria and Microflora, V5, P13; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; HOLDEMAN LV, 1976, APPL ENVIRON MICROB, V31, P359, DOI 10.1128/AEM.31.3.359-375.1976; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; IIKURA Y, 1989, PROG MED, V9, P1803; IMAYAMA S, 1995, ACTA DERM-VENEREOL, V75, P212; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kanazawa K, 1996, CANCER-AM CANCER SOC, V77, P1701, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1701::AID-CNCR18>3.3.CO;2-6; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LASEN FS, 1996, J AM ACAD DERMATOL, V34, P760; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Levitan M C, 1976, Am J Proctol, V27, P49; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; MITSUOKA T, 1992, NUTR REV, V50, P438, DOI 10.1111/j.1753-4887.1992.tb02499.x; MITSUOKA T, 1980, COLOR ATLAS ANAEROBI, P341; Sudo N, 1997, J IMMUNOL, V159, P1739; Tagami H, 1995, J DERMATOL, V22, P966; Takeuchi M, 2000, ENV DERMATOL, V7, P133; TSUYUKI S, 1988, BIFIDUS, V2, P9; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x	29	236	255	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					587	591		10.1067/mai.2003.105	http://dx.doi.org/10.1067/mai.2003.105			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642841				2022-12-18	WOS:000181639500022
J	Pastorello, EA; Farioli, L; Pravettoni, V; Ortolani, C; Ispano, M; Monza, M; Baroglio, C; Scibola, E; Ansaloni, R; Incorvaia, C; Conti, A				Pastorello, EA; Farioli, L; Pravettoni, V; Ortolani, C; Ispano, M; Monza, M; Baroglio, C; Scibola, E; Ansaloni, R; Incorvaia, C; Conti, A			The major allergen of peach (Prunus persica) is a lipid transfer protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral allergy syndrome; peach; birch pollinosis; immunoblotting; major allergen; lipid transfer protein	FOOD HYPERSENSITIVITY; POLLEN ALLERGY; BIRCH POLLEN; APPLE	Background: Allergy to fresh fruits and vegetables is mostly observed in subjects with pollinosis, especially from birch, because of cross-reacting allergens in vegetable foods and pollens. However, allergic reactions to fruits, specifically Rosaceae fruits, have been reported in subjects without pollinosis. Objective: This study evaluated the pattern of IgE reactivity, identifying the allergen responsible in 2 groups of patients with oral allergy syndrome to peach with or without birch pollinosis. Methods: The allergenic components of peach were detected by SDS-PAGE and immunoblotting. The major peach allergen was purified by HPLC with a cation-exchange column followed by gel filtration chromatography. Its IgE-binding capacity and its homology with the protein of the crude extract were demonstrated by immunoblotting inhibition techniques, To better characterize this allergen, periodic acid-Schiff stain and isoelectrofocusing were used. The amino acid sequencing was done with a gas-phase sequencer. Results: SDS-PAGE and immunoblotting of the 15 patients allergic to peach, 8 without and 7 with birch pollinosis, showed that they all recognized a protein with a molecular weight of 9 kd. This was the only allergen recognized by patients not sensitized to pollen, whereas the birch pollen-sensitive patients had IgE binding to other allergenic proteins at higher molecular weights. The purified 9-kd protein retained its IgE-binding capacity, was negative to periodic acid-Schiff stain, and had an isoelectric point value of greater than 9. A search in the Swiss Prot Bank showed this was a lipid transfer protein, belonging to It group of molecules involved in the defensive system of plants. Conclusions: The major allergen of peach is a 9-kd protein belonging to the group of Lipid transfer proteins. This is the only allergen recognized by patients allergic to peach but not sensitized to birch pollen.	Osped Maggiore, IRCCS, Dept Gen Med 3, Allergy Ctr, I-20122 Milan, Italy; Unita Operat Osped Med Lavoro, Milan, Italy; Niguarda Ca Granda Hosp, Bizzozzero Div, Milan, Italy; Natl Res Council, Turin, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico	Pastorello, EA (corresponding author), Osped Maggiore, IRCCS, Dept Gen Med 3, Allergy Ctr, Via F Sforza 35, I-20122 Milan, Italy.		PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CLARK AM, 1993, PLANT PHYSIOL, V103, P677, DOI 10.1104/pp.103.2.677; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; KADER JC, 1984, EUR J BIOCHEM, V139, P411, DOI 10.1111/j.1432-1033.1984.tb08020.x; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1997, PROGR ALLERGY CLIN I, P65; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1997, CLIN REV ALLERG IMMU, V15, P415, DOI 10.1007/BF02737737; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; Warburg O., 1942, BIOCHEM Z, V310, P384	20	236	243	3	21	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				520	526		10.1016/S0091-6749(99)70480-X	http://dx.doi.org/10.1016/S0091-6749(99)70480-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069889				2022-12-18	WOS:000079175700024
J	JUJO, K; RENZ, H; ABE, J; GELFAND, EW; LEUNG, DYM				JUJO, K; RENZ, H; ABE, J; GELFAND, EW; LEUNG, DYM			DECREASED INTERFERON-GAMMA AND INCREASED INTERLEUKIN-4 PRODUCTION IN ATOPIC-DERMATITIS PROMOTES IGE SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; IMMUNOGLOBULIN-E; SKIN; INTERLEUKIN-4; INTERFERON GAMMA	HUMAN B-CELLS; T-CELL; IFN-GAMMA; SUPERNATANTS; INDUCTION; INVITRO; SERUM; IL-4; DIFFERENTIATION; ABNORMALITIES	The mechanism(s) responsible for increased IgE synthesis in atopic dermatitis (AD) are unknown, but they may be related to either decreased interferon gamma (IFN-gamma) and/or increased interleukin (IL)-4 production. In this study we examined peripheral blood mononuclear cells (PBMCs) from 21 patients with AD, six patients with psoriasis, and 22 nonatopic healthy controls for IFN-gamma and IL-4 production after stimulation with concanavalin A (Con A). The Con A-induced proliferative response of AD PBMCs was similar to the response of healthy controls (p = 0.9). After mitogen stimulation, however, AD culture supernatants contained significantly less IFN-gamma (p = 0.001) but increased IL-4 (p = 0.001) compared with supernatants from nonatopic controls. In contrast, PBMCs from patients with psoriasis produced normal levels of IFN-gamma and IL-4 in vitro. Since IL-4 is known to decrease IFN-gamma synthesis, we examined the effect of neutralizing anti-IL-4 on IFN-gamma production. Anti-IL-4 significantly increased IFN-gamma production in patients with AD (p = 0.008) and nonatopic controls (p = 0.02) but did not normalize IFN-gamma production by AD PBMCs. Supernatants from AD PBMCs, but not supernatants from nonatopic PBMCs, induced IgE synthesis in PBMCs from nonatopic donors (p = 0.02). When an anti-IFN-gamma receptor antibody, which blocks cellular binding of IFN-gamma, was added to supernatants from nonatopic controls their capacity to induce IgE synthesis was significantly greater (p = 0.03). These results demonstrate an imbalance of IL-4 and IFN-gamma production, which may contribute to increased IgE synthesis in AD.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAID NIH HHS [AI-26490] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOGUNIEWICZ M, 1990, AM J MED, V88, P376; COFFMAN RL, 1986, J IMMUNOL, V136, P949; CUSTER MC, 1990, J IMMUNOL METHODS, V128, P109, DOI 10.1016/0022-1759(90)90469-C; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; LEUNG DYM, 1986, CLIN REV ALLERG, V4, P67; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; RENZ H, 1990, J IMMUNOL, V145, P3641; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SCHNEIDER LC, 1991, J ALLERGY CLIN IMMUN, V87, pA38; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; TURNER KJ, 1983, CLIN EXP IMMUNOL, V51, P387; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; ZHANG K, 1991, J IMMUNOL, V146, P1836	30	236	242	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				323	331		10.1016/S0091-6749(05)80010-7	http://dx.doi.org/10.1016/S0091-6749(05)80010-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527316				2022-12-18	WOS:A1992JP52000008
J	SAGER, N; FELDMANN, A; SCHILLING, G; KREITSCH, P; NEUMANN, C				SAGER, N; FELDMANN, A; SCHILLING, G; KREITSCH, P; NEUMANN, C			HOUSE DUST MITE SPECIFIC T-CELLS IN THE SKIN OF SUBJECTS WITH ATOPIC-DERMATITIS - FREQUENCY AND LYMPHOKINE PROFILE IN THE ALLERGEN PATCH TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INHALANT ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; INTERLEUKIN-4; INTERFERON-GAMMA; T-CELL CLONES; IGE	INTERCELLULAR-ADHESION MOLECULE-1; DELAYED-TYPE HYPERSENSITIVITY; INHALANT ALLERGENS; CONTACT-DERMATITIS; STIMULATORY FACTOR; HUMAN-LYMPHOCYTES; TH1 CLONES; SUBSETS; EXPRESSION; GAMMA	The mechanism underlying positive patch tests with house dust mite-allergen, Dermatophagoides pteronyssinus (Der p), in patients with atopic dermatitis was investigated by isolating T cells from the test sites of two patients. Eighty-five T cell clones (TCC) were established from the epidermis and dermis of lesional skin by the limiting-dilution method with Der p and interleukin (IL)-2. With restimulation assays, 29 of 60 TCCs tested demonstrated specific proliferation; 85% were of the CD3+, CD2+, and CD4+ phenotype. Der p-specific T cells constituted 0.4% to 2.7% of lesional T cells, and they were more frequent in the skin than in the blood of the patients by one order of magnitude. The mitogen-stimulated lymphokine profile of 55 TCCs was assessed; 42% (11/26) of the allergen-specific TCCs secreted IL-4 but almost no interferon-gamma, as described for the Th2 subset of the mouse. Also, six selected TCCs supported IgE secretion by autologous lymphocytes. Only three of 26 allergen-specific, skin-derived TCCs demonstrated a Thl-like lymphokine profile. These results support the specific nature of Der p-induced patch test lesions in patients with atopic dermatitis, and the results demonstrate also that a considerable proportion of lesional T cells are allergen-specific, IL-4-producing T cells that are capable of enhancing IgE production.	MED SCH HANNOVER,DEPT DERMATOL,RICKLINGER STR 5,W-3000 HANNOVER 91,GERMANY; UNIV GOTTINGEN,DEPT IMMUNOL,W-3400 GOTTINGEN,GERMANY	Hannover Medical School; University of Gottingen								ATHERTON DJ, 1991, EUR J PEDIATR DERMAT, V1, P41; BRUYNZEELKOOMEN CAFM, 1988, BRIT J DERMATOL, V118, P229, DOI 10.1111/j.1365-2133.1988.tb01779.x; CHER DJ, 1987, J IMMUNOL, V138, P3688; CLARK RA, 1989, CLIN IMMUNOPATHOL, V53, P132; FISHER AA, 1986, CONTACT DERMATITIS, P26; FONG TAT, 1989, J IMMUNOL, V143, P2887; FURUE M, 1991, J INVEST DERMATOL, V96, P468, DOI 10.1111/1523-1747.ep12470153; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; GRIFFITHS CEM, 1989, AM J PATHOL, V135, P1045; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; KALISH R, 1989, J IMMUNOL, V145, P3706; KAPSENBERG ML, 1987, EUR J IMMUNOL, V17, P861, DOI 10.1002/eji.1830170620; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P261; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MCCLUSKEY RT, 1963, J IMMUNOL, V90, P466; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; NOMA T, 1989, J EXP MED, V169, P1853, DOI 10.1084/jem.169.5.1853; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PFEIFER JD, 1987, J EXP MED, V166, P1464, DOI 10.1084/jem.166.5.1464; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; REINHOLD U, 1991, J INVEST DERMATOL, V96, P370, DOI 10.1111/1523-1747.ep12466152; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, P13; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; SMITT JHS, 1986, CLIN EXP DERMATOL, V11, P159, DOI 10.1111/j.1365-2230.1986.tb00441.x; STEINMAN L, 1978, EUR J IMMUNOL, V8, P29, DOI 10.1002/eji.1830080107; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; SWAIN SL, 1988, J IMMUNOL, V141, P3445; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; WIDMER MB, 1987, NATURE, V326, P795, DOI 10.1038/326795a0; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x; [No title captured]	44	236	241	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					801	810		10.1016/0091-6749(92)90434-4	http://dx.doi.org/10.1016/0091-6749(92)90434-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1373161				2022-12-18	WOS:A1992HN86000004
J	Kim, HY; Chang, YJ; Subramanian, S; Lee, HH; Albacker, LA; Matangkasombut, P; Savage, PB; McKenzie, ANJ; Smith, DE; Rottman, JB; DeKruyff, RH; Umetsu, DT				Kim, Hye Young; Chang, Ya-Jen; Subramanian, Srividya; Lee, Hyun-Hee; Albacker, Lee A.; Matangkasombut, Ponpan; Savage, Paul B.; McKenzie, Andrew N. J.; Smith, Dirk E.; Rottman, James B.; DeKruyff, Rosemarie H.; Umetsu, Dale T.			Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate; natural killer T; natural helper cells; T(H)2; IL-33; IL-13; glycolipid; asthma	KILLER T-CELLS; INVARIANT NKT CELLS; ASTHMA; RECEPTOR; EXPRESSION; CYTOKINE; INFLAMMATION; RECOGNITION; RESPONSES; T1/ST2	Background: Asthma has been considered an immunologic disease mediated by T(H)2 cells and adaptive immunity. However, clinical and experimental observations suggest that additional pathways might regulate asthma, particularly in its nonallergic forms, such as asthma associated with air pollution, stress, obesity, and infection. Objectives: Our goal was to understand T(H)2 cell-independent conditions that might lead to airway hyperreactivity (AHR), a cardinal feature of asthma. Methods: We examined a murine model of experimental asthma in which AHR was induced with glycolipid antigens, which activate natural killer T (NKT) cells. Results: In this model AHR developed rapidly when mice were treated with NKT cell-activating glycolipid antigens, even in the absence of conventional CD4(+) T cells. The activated NKT cells directly induced alveolar macrophages to produce IL-33, which in turn activated NKT cells, as well as natural helper cells, a newly described non-T, non-B, innate lymphoid cell type, to increase production of IL-13. Surprisingly, this glycolipid-induced AHR pathway required not only IL-13 but also IL-33 and its receptor, ST2, because it was blocked by an anti-ST2 mAb and was greatly reduced in ST2(-/-) mice. When adoptively transferred into IL-13(-/-) mice, both wild-type natural helper cells and NKT cells were sufficient for the development of glycolipid-induced AHR. Conclusion: Because plant pollens, house dust, and some bacteria contain glycolipids that can directly activate NKT cells, these studies suggest that AHR and asthma can fully develop or be greatly enhanced through innate immune mechanisms involving IL-33, natural helper cells, and NKT cells. (J Allergy Clin Immunol 2012;129:216-27.)	[Kim, Hye Young; Chang, Ya-Jen; Subramanian, Srividya; Lee, Hyun-Hee; Albacker, Lee A.; Matangkasombut, Ponpan; DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol & Allergy, Boston, MA 02115 USA; [Savage, Paul B.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [McKenzie, Andrew N. J.] MRC Lab Mol Biol, Cambridge, England; [Smith, Dirk E.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA; [Rottman, James B.] Amgen Inc, Dept Pathol, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Brigham Young University; MRC Laboratory Molecular Biology; Amgen; Amgen	Umetsu, DT (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Karp Labs,Div Immunol, Rm 10127,1 Blackfan Circle, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu	Savage, Paul B/E-1448-2011; Savage, Paul B/HGB-3414-2022; Kim, Hye Young/AAF-7609-2020; Chang, Ya-Jen/O-1584-2018	Savage, Paul B/0000-0002-4642-6109; Savage, Paul B/0000-0002-4642-6109; Kim, Hye Young/0000-0001-5978-512X; Chang, Ya-Jen/0000-0003-1377-6142; Albacker, Lee/0000-0002-5070-1783	National Institutes of Health; Amgen, Inc.; MRC [MC_U105178805] Funding Source: UKRI; Medical Research Council [MC_U105178805] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322, R01AI068085] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen, Inc.(Amgen); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	P. B. Savage has received research support from the National Institutes of Health. J. B. Rottman is employed by and has received research support from Amgen, Inc. The rest of the authors declare that they have no relevant conflicts of interest.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kim S, 2008, J CLIN INVEST, V118, P2301, DOI [10.1172/JC133071, 10.1172/JCI33071]; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Mangan NE, 2007, EUR J IMMUNOL, V37, P1302, DOI 10.1002/eji.200636520; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI 10.1038/mi.2009.96; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mu R, 2010, J RHEUMATOL, V37, P2006, DOI 10.3899/jrheum.100184; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Pastorelli L, 2010, P NATL ACAD SCI USA, V107, P8017, DOI 10.1073/pnas.0912678107; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Verri WA, 2010, ANN RHEUM DIS, V69, P1697, DOI 10.1136/ard.2009.122655; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	55	235	249	2	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					216	U319		10.1016/j.jaci.2011.10.036	http://dx.doi.org/10.1016/j.jaci.2011.10.036			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22119406	Green Accepted			2022-12-18	WOS:000298634000028
J	Chanez, P; Wenzel, SE; Anderson, GP; Anto, JM; Bel, EH; Boulet, LP; Brightling, CE; Busse, WW; Castro, M; Dahlen, B; Dahlen, SE; Fabbri, LM; Holgate, ST; Humbert, M; Gaga, M; Joos, GF; Levy, B; Rabe, KF; Sterk, PJ; Wilson, SJ; Vachier, I				Chanez, Pascal; Wenzel, Sally E.; Anderson, Gary P.; Anto, Josep M.; Bel, Elisabeth H.; Boulet, Louis-Philippe; Brightling, Christopher E.; Busse, William W.; Castro, Mario; Dahlen, Babro; Dahlen, Sven Erik; Fabbri, Leo M.; Holgate, Stephen T.; Humbert, Marc; Gaga, Mina; Joos, Guy F.; Levy, Bruce; Rabe, Klaus F.; Sterk, Peter J.; Wilson, Susan J.; Vachier, Isabelle			Severe asthma in adults: What are the important questions?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						epidemiology; pathophysiology; management; research perspectives; severe asthma	AIRWAY SMOOTH-MUSCLE; GROWTH-FACTOR RECEPTOR; EXHALED NITRIC-OXIDE; ANTI-IGE ANTIBODY; PERSISTENT ASTHMA; RISK-FACTORS; GLUCOCORTICOID-RECEPTOR; BRONCHIAL THERMOPLASTY; CHLAMYDIA-PNEUMONIAE; CLINICAL PHENOTYPES	The term severe refractory asthma (SRA) in adults applies to patients who remain difficult to control despite extensive reevaluation of diagnosis and management following an observational period of at least 6 months by a specialist. Factors that influence asthma control should be recognized and adequately addressed prior to confirming the diagnosis of SRA.	Clin Malad Resp, F-34295 Montpellier 05, France		Chanez, P (corresponding author), Clin Malad Resp, 371 Av Doyen Gaston Giraud, F-34295 Montpellier 05, France.	chanez@montp.inserm.fr	Fabbri, Leonardo M/I-4055-2012; Anto, J M/H-2676-2014; Humbert, Marc/ABD-5112-2021; Sterk, P.J./AAK-8175-2020; Gaga, Mina/AAP-8348-2020; Vachier, Isabelle/AAV-5731-2020; Rabe, Klaus F./AAW-6296-2021	Fabbri, Leonardo M/0000-0001-8894-1689; Anto, J M/0000-0002-4736-8529; Vachier, Isabelle/0000-0003-2730-5165; Rabe, Klaus F./0000-0002-7020-1401; Anderson, Gary/0000-0001-6580-3398; Gaga, Mina/0000-0002-9949-6012; chanez, pascal/0000-0003-4059-0917; brightling, chris/0000-0002-9345-4903; Humbert, Marc/0000-0003-0703-2892	MRC [G0800766] Funding Source: UKRI; Medical Research Council [G0800766] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Barnes Peter J, 2004, Proc Am Thorac Soc, V1, P264, DOI 10.1513/pats.200402-014MS; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Bel EH, 2006, AM J RESP CRIT CARE, V173, P941, DOI 10.1164/rccm.2602002; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bonnans C, 2003, EUR RESPIR J, V21, P985, DOI 10.1183/09031936.03.00059802; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; *BRIT THOR SOC, 2005, BRIT GUID MAN ASTH N; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Carlsen KCL, 2006, PEDIAT ALLERG IMM-UK, V17, P304, DOI 10.1111/j.1399-3038.2006.00412.x; Carroll NG, 2002, THORAX, V57, P677, DOI 10.1136/thorax.57.8.677; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chung KF, 1999, EUR RESPIR J, V13, P1198; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Cote J, 2001, AM J RESP CRIT CARE, V163, P1415, DOI 10.1164/ajrccm.163.6.2006069; Cox G, 2006, AM J RESP CRIT CARE, V173, P965, DOI 10.1164/rccm.200507-1162OC; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Everard ML, 2006, CURR OPIN ALLERGY CL, V6, P56, DOI 10.1097/01.all.0000200506.62048.06; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Fredberg JJ, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-2; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 2003, COCHRANE DATABASE SY, pCD001496, DOI DOI 10.1002/14651858.CD001496; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Gyllfors P, 2006, J ALLERGY CLIN IMMUN, V118, P78, DOI 10.1016/j.jaci.2006.03.040; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; Henricks PAJ, 2001, PULM PHARMACOL THER, V14, P409, DOI 10.1006/pupt.2001.0319; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Hunter CJ, 2002, CHEST, V121, P1051, DOI 10.1378/chest.121.4.1051; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Johnston SL, 2006, J ALLERGY CLIN IMMUN, V117, P1233, DOI 10.1016/j.jaci.2006.03.035; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.015; Kostadima E, 2004, EUR RESPIR J, V23, P714, DOI 10.1183/09031936.04.00118404; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Kraft M, 2000, CLIN CHEST MED, V21, P301, DOI 10.1016/S0272-5231(05)70268-9; Lacasse Yves, 2005, Can Respir J, V12, P211; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976, DOI 10.1164/ajrccm.162.3.9910031; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Liu JQ, 2006, AM J PHYSIOL-LUNG C, V291, pL281, DOI 10.1152/ajplung.00320.2005; Maksym GN, 2005, CAN J PHYSIOL PHARM, V83, P913, DOI 10.1139/Y05-091; Malo JL, 2005, AM J RESP CRIT CARE, V172, P406, DOI 10.1164/rccm.2506006; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Misso NLA, 2005, EUR RESPIR J, V26, P257, DOI 10.1183/09031936.05.00006705; Moser Marvin, 2006, J Clin Hypertens (Greenwich), V8, P434, DOI 10.1111/j.1524-6175.2006.05328.x; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; *NIH, 1997, EXP PAN REP 2 GUID D; *NIH, 1995, GLOB STRAT ASTHM MAN; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Petasis NA, 2005, PROSTAG LEUKOTR ESS, V73, P301, DOI 10.1016/j.plefa.2005.05.020; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Ricciardolo FLM, 2003, THORAX, V58, P175, DOI 10.1136/thorax.58.2.175; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Szczeklik W, 2004, J ALLERGY CLIN IMMUN, V114, P248, DOI 10.1016/j.jaci.2004.05.030; Tan KS, 2001, DRUGS, V61, P2079, DOI 10.2165/00003495-200161140-00005; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, J PSYCHOSOM RES, V50, P7, DOI 10.1016/S0022-3999(00)00203-8; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Vachier I, 2003, RESP MED, V97, P1225, DOI 10.1016/S0954-6111(03)00253-1; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Wark P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001108.pub2, DOI 10.1002/14651858.CD001108.PUB2]; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weiss Scott T, 2004, Proc Am Thorac Soc, V1, P364, DOI 10.1513/pats.200409-043MS; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Wenzel S, 2003, MT SINAI J MED, V70, P185; Westby M, 2004, Cochrane Database Syst Rev, pCD003269	117	235	242	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1337	1348		10.1016/j.jaci.2006.11.702	http://dx.doi.org/10.1016/j.jaci.2006.11.702			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17416409				2022-12-18	WOS:000247232800008
J	Szczeklik, A; Stevenson, DD				Szczeklik, A; Stevenson, DD			Aspirin-induced asthma: Advances in pathogenesis and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; aspirin-induced asthma; cyclooxygenase enzymes; 5-lipoxygenase enzymes; leukotrienes; leukotriene C-4 synthase; aspirin desensitization	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LEUKOTRIENE C-4 SYNTHASE; MAST-CELL ACTIVATION; SENSITIVE ASTHMA; NASAL SECRETIONS; BRONCHIAL-ASTHMA; INDUCED BRONCHOCONSTRICTION; MECHANICAL VENTILATION; INTOLERANT ASTHMATICS; RHINOSINUSITIS-ASTHMA	In some patients with asthma, aspirin (ASA) and all nonsteroidal anti-inflammatory drugs that inhibit cyclooxygenase enzymes (cyclooxygenase-1 and -2) precipitate asthmatic attacks and naso-ocular reactions. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterized by a typical sequence of symptoms, intense eosinophilic inflammation of nasal and bronchial tissues, combined with overproduction of cysteinyl-leukotrienes (Cys-LTs), At baseline, cys-LT urinary excretion is augmented, and ASA administration leads to its further temporary increase. After ASA challenge, cys-LTs are released into nasal and bronchial secretions and can be collected in the urine, LTC4 synthase, the terminal enzyme for cys-LT production, is markedly overexpressed in eosinophils and mast cells from bronchial biopsy specimens of most patients with AIA, An allelic variant of LTC4 synthase that enhances enzyme transcription is associated with AIA, Avoiding ASA and nonsteroidal anti-inflammatory drugs does not prevent progression of the inflammatory disease, Corticosteroids continue to he the mainstay of therapy, and anti-LT drugs are abo indicated for treatment of the underlying disease. After ASA desensitization, daily ingestion of high doses of ASA reduces inflammatory mucosal disease symptoms, particularly in the nasal passages, in most patients with AIA.	Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland	Scripps Research Institute; Jagiellonian University	Stevenson, DD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ANDRI L, 1994, ANN ALLERGY, V72, P29; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; Bianco S, 1993, Drugs, V46 Suppl 1, P115; Bochenek G, 1996, ALLERGY, V51, P16, DOI 10.1111/j.1398-9995.1996.tb00004.x; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CHRISTMAN BW, 1993, J IMMUNOL, V151, P2096; Churg A, 1998, LANCET, V352, P32, DOI 10.1016/S0140-6736(05)79511-8; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DAHLEN B, 1994, ALLERGY, V49, P43, DOI 10.1111/j.1398-9995.1994.tb00772.x; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670, DOI 10.1164/ajrccm.155.2.9032211; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; FEIGENBAUM BA, 1995, J ALLERGY CLIN IMMUN, V96, P545, DOI 10.1016/S0091-6749(95)70299-7; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; GERBER JG, 1979, J ALLERGY CLIN IMMUN, V63, P289, DOI 10.1016/0091-6749(79)90115-5; GOETZL EJA, 1998, ALLERGY PRINCIPLES P, P168; Green RL, 1999, LANCET, V353, P725, DOI 10.1016/S0140-6736(99)00565-6; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; Kahn RM, 1996, J CLIN INVEST, V98, P299, DOI 10.1172/JCI118793; Kosnik M, 1998, ALLERGY, V53, P1231, DOI 10.1111/j.1398-9995.1998.tb03854.x; KOWALSKI ML, 1993, J ALLERGY CLIN IMMUN, V91, P580, DOI 10.1016/0091-6749(93)90264-G; KOWALSKI ML, 1992, ALLERGY PROC, V13, P175, DOI 10.2500/108854192778817202; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; KUNA P, 1997, AM J RESP CRIT CARE, V155, pA975; LASSALLE P, 1993, EUR J IMMUNOL, V23, P796, DOI 10.1002/eji.1830230404; LEE TH, 1992, AM REV RESPIR DIS, V145, pS34, DOI 10.1164/ajrccm/145.2_Pt_2.S34; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; Mastalerz L, 1997, ALLERGY, V52, P895, DOI 10.1111/j.1398-9995.1997.tb01248.x; Mewes T, 1996, ALLERGY, V51, P506; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581, DOI 10.1016/S0091-6749(98)70163-0; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nasser SMS, 1998, LUNG BIOL HEALTH DIS, V114, P317; NASSER SMS, 1994, THORAX, V49, P749, DOI 10.1136/thx.49.8.743; Nizankowska E, 1998, LUNG BIOL HEALTH DIS, V114, P451; NIZANKOWSKA E, 1995, EUR RESPIR J, V8, P1091, DOI 10.1183/09031936.95.08071091; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Pauls JD, 1999, J ALLERGY CLIN IMMUN, V103, pS229; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; PICADO C, 1989, EUR RESPIR J, V2, P127; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M., 1998, European Respiratory Journal, V12, p373S; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SCHLUMBERGER HD, 1980, PSEUDOALLERGIC REACT, P125; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SETTIPANE RA, 1995, J ALLERGY CLIN IMMUN, V96, P480, DOI 10.1016/S0091-6749(95)70290-3; SLADEK K, 1993, EUR RESPIR J, V6, P391; SMITH CM, 1992, EUR RESPIR J, V5, P693; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; STEVENSON DD, 1987, J ALLERGY CLIN IMMUN, V80, P788, DOI 10.1016/S0091-6749(87)80266-X; STEVENSON DD, 1986, J ALLERGY CLIN IMMUN, V78, P182, DOI 10.1016/0091-6749(86)90011-4; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1985, J ALLERGY CLIN IMMUN, V76, P530, DOI 10.1016/0091-6749(85)90771-7; Szczeklik A, 1998, AM J RESP CRIT CARE, V158, P1168, DOI 10.1164/ajrccm.158.4.9710043; SZCZEKLIK A, 1992, CLIN EXP ALLERGY, V22, P283, DOI 10.1111/j.1365-2222.1992.tb03084.x; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1990, EUR RESPIR J, V3, P588; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 1997, ALLERGY, V52, P352, DOI 10.1111/j.1398-9995.1997.tb01006.x; Szczeklik A, 1998, LUNG BIOL HEALTH DIS, V114, P299; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; Szczeklik A., 1998, Allergy (Copenhagen), V53, P61; SZCZEKLIK A, IN PRESS AM J RESP C; Szmidt M, 1996, J INVEST ALLERG CLIN, V6, P121; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VIRCHOW C, 1988, RESPIRATION, V53, P20, DOI 10.1159/000195391; WARREN MS, 1995, J ALLERGY CLIN IMMUN, V95, P170; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Widal M, 1922, PRESSE MED, V30, P189; YAMAMOTO H, 1994, AM J RESP CRIT CARE, V150, P254, DOI 10.1164/ajrccm.150.1.8025759	90	235	242	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					5	13		10.1016/S0091-6749(99)70106-5	http://dx.doi.org/10.1016/S0091-6749(99)70106-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400832				2022-12-18	WOS:000081738900001
J	RENZ, H; SMITH, HR; HENSON, JE; RAY, BS; IRVIN, CG; GELFAND, EW				RENZ, H; SMITH, HR; HENSON, JE; RAY, BS; IRVIN, CG; GELFAND, EW			AEROSOLIZED ANTIGEN EXPOSURE WITHOUT ADJUVANT CAUSES INCREASED IGE PRODUCTION AND INCREASED AIRWAY RESPONSIVENESS IN THE MOUSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALTERED AIRWAY RESPONSIVENESS; IGE; MOUSE; INVIVO LUNG FUNCTION; OVALBUMIN	NEUTROPHIL CHEMOTACTIC ACTIVITY; LATE ASTHMATIC REACTIONS; CELL-MEDIATED-IMMUNITY; SENSITIZED GUINEA-PIGS; BRONCHIAL HYPERREACTIVITY; MAST-CELLS; COMPARATIVE SELECTIVITY; CORYNEBACTERIUM-PARVUM; BORDETELLA-PERTUSSIS; ANTIBODY-RESPONSES	Inhalation of an antigen, ovalbumin (OVA), in the absence of adjuvant has been demonstrated to induce an immune response that is associated with increase airway responsiveness. Determination of OVA-specific serum IgE and IgG antibody responses revealed an early increase in antibody titers that were initially restricted to the IgE class. Subsequently, IgG antibody titers increased and IgE antibody plateaued. Furthermore, we observed a tenfold increase in the number of lymphocytes caused by a predominant expansion of CD3+ T cells in the peribronchial-associated lymph modes (PBLNs) of sensitized animals compared with the numbers of cells in control animals or in the gut-associated lymphoid tissue. The sensitized animals demonstrated an increase in airway responsiveness to intravenous methacholine challenge. Analysis of in vitro immunoglobulin production by spleen mononuclear cells revealed increased spontaneous IgE production that was more than fourfold enhanced in the presence of OVA, but IgG production was not increased. Spleen and PBLN lymphocytes, but not lymphocytes from gut-draining lymp nodes, demonstrated a proliferative response to OVA. Control animals exhibited no proliferative response to OVA. Histopathologic examination of the sensitized lung revealed an absence of acute inflammatory cells (e.g., neutrophils and macrophages), lymphocytes, or monocytes at the time of the increased airway hyperresponsiveness. These data indicate that, after sensitization of mice by inhalation of antigen, the animals develop a specific IgE antibody response, expansion of PBLN lymphocyte numbers, and increased airway hyperresponsiveness in the absence of signs of airway inflammation.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206; RAYMOND & BEVERLY SACKLER FDN,DENVER,CO; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV BASIC SCI,DENVER,CO 80206	National Jewish Health; National Jewish Health					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704, R01AI026490] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL36577] Funding Source: Medline; NIAID NIH HHS [AI-26490, AI-29704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLSTEDT S, 1983, INT ARCH ALLER A IMM, V71, P293, DOI 10.1159/000233410; AHLSTEDT S, 1983, INT ARCH ALLER A IMM, P295; AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; ANDERSSON P, 1980, ALLERGY, V35, P65, DOI 10.1111/j.1398-9995.1980.tb01718.x; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; AZUMA M, 1987, J IMMUNOL, V139, P2538; BECK L, 1989, CELL IMMUNOL, V123, P1, DOI 10.1016/0008-8749(89)90263-3; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; BLYTHE S, 1986, AM REV RESPIR DIS, V134, P1246; BOMFORD R, 1980, CLIN EXP IMMUNOL, V39, P435; BOMFORD R, 1980, CLIN EXP IMMUNOL, V39, P426; CHEN SS, 1989, J IMMUNOL, V142, P4225; CLAY MM, 1983, THORAX, V38, P755, DOI 10.1136/thx.38.10.755; DESQUAND S, 1989, INT ARCH ALLER A IMM, V89, P71, DOI 10.1159/000234926; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; EVANS TW, 1988, AM REV RESPIR DIS, V138, P140, DOI 10.1164/ajrccm/138.1.140; GLEICH GJ, 1989, J ALLERGY CLIN IMMUN, V89, P422; HABIB MP, 1988, J APPL PHYSIOL, V69, P1009; HALL E, 1982, INT ARCH ALLER A IMM, V67, P96, DOI 10.1159/000232995; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42, DOI 10.1159/000232736; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; HULBERT WM, 1985, AM REV RESPIR DIS, V132, P7; HUTSON PA, 1990, AM REV RESPIR DIS, V141, P535, DOI 10.1164/ajrccm/141.3.535; ISHIZAKA T, 1981, J ALLERGY CLIN IMMUN, V67, P90, DOI 10.1016/0091-6749(81)90002-6; ITO K, 1979, INT ARCH ALLER A IMM, V58, P474, DOI 10.1159/000232229; KRISTOFFERSON A, 1979, INT ARCH ALLER A IMM, V60, P295, DOI 10.1159/000232354; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MANNING JK, 1989, P SOC EXP BIOL MED, V170, P367; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MURLAS C, 1985, J APPL PHYSIOL, V58, P1630, DOI 10.1152/jappl.1985.58.5.1630; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; SAVELKOUL HFJ, 1989, INT ARCH ALLER A IMM, V89, P113, DOI 10.1159/000234933; SCHLEIMER RP, 1982, FED PROC, V41, P487; SPIEGELBERG HL, 1983, FED PROC, V42, P124; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; TAYLOR WA, 1980, IMMUNOLOGY, V39, P583; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TONNEL JM, 1983, J CLIN INVEST, V71, P221; VAZ EM, 1971, IMMUNOLOGY, V21, P11; YU CP, 1978, POWDER TECHNOL, V21, P55, DOI 10.1016/0032-5910(78)80107-7	48	235	240	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1127	1138		10.1016/0091-6749(92)90296-E	http://dx.doi.org/10.1016/0091-6749(92)90296-E			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607548	Bronze			2022-12-18	WOS:A1992HZ74800007
J	Jerschow, E; Lin, RY; Scaperotti, MM; McGinn, AP				Jerschow, Elina; Lin, Robert Y.; Scaperotti, Moira M.; McGinn, Aileen P.			Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fatal anaphylaxis; drug; food; venom; death certificate; epidemiology	FOOD ALLERGY; DEATHS; RISK; HOSPITALIZATIONS; PRESCRIPTIONS; DISPARITIES; PREVALENCE; AUSTRALIA; SUDDEN; HEALTH	Background: Anaphylaxis-related deaths in the United States have not been well characterized in recent years. Objectives: We sought to define epidemiologic features and time trends of fatal anaphylaxis in the United States from 1999 to 2010. Methods: Anaphylaxis-related deaths were identified by using the 10th clinical modification of the International Classification of Diseases system diagnostic codes on death certificates from the US National Mortality Database. Rates were calculated by using census population estimates. Results: There were a total of 2458 anaphylaxis-related deaths in the United States from 1999 to 2010. Medications were the most common cause (58.8%), followed by "unspecified" (19.3%), venom (15.2%), and food (6.7%). There was a significant increase in fatal drug-induced anaphylaxis over 12 years: from 0.27 (95% CI, 0.23-0.30) per million in 1999 to 2001 to 0.51 (95% CI, 0.47-0.56) per million in 2008 to 2010 (P < .001). Fatal anaphylaxis caused by medications, food, and unspecified allergens was significantly associated with African American race and older age (P <. 001). Fatal anaphylaxis to venom was significantly associated with white race, older age, and male sex (P < .001). The rates of fatal anaphylaxis to foods in male African American subjects increased from 0.06 (95% CI, 0.01-0.17) per million in 1999 to 2001 to 0.21 (95% CI, 0.11-0.37) per million in 2008 to 2010 (P < .001). The rates of unspecified fatal anaphylaxis decreased over time from 0.30 (95% CI, 0.26-0.34) per million in 1999 to 2001 to 0.09 (95% CI, 0.07-0.11) per million in 2008 to 2010 (P < .001). Conclusion: There are strong and disparate associations between race and specific classes of anaphylaxis-related mortality in the United States. The increase in medication-related deaths caused by anaphylaxis likely relates to increased medication and radiocontrast use, enhanced diagnosis, and coding changes.	[Jerschow, Elina] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Allergy Immunol, Bronx, NY 10467 USA; [Lin, Robert Y.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Scaperotti, Moira M.] Albert Einstein Coll Med, Sch Med, Bronx, NY 10467 USA; [McGinn, Aileen P.] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Jerschow, E (corresponding author), Div Allergy Immunol, 1635a Poplar St, Bronx, NY 10461 USA.	Elina.Jerschow@einstein.yu.edu			CTSA grant National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [5KL2TR001071]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001071] Funding Source: NIH RePORTER	CTSA grant National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This publication was supported by CTSA grant number 5KL2TR001071 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Akinbami Lara J, 2012, NCHS Data Brief, P1; Alvarez-Twose I, 2014, J ALLERGY CLIN IMMUN, V133, P520, DOI 10.1016/j.jaci.2013.06.020; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Anderson R N, 2001, Natl Vital Stat Rep, V49, P1; [Anonymous], 2010, MORTALITY MED DATA S; [Anonymous], 2014, INSTRUCTIONS CLASSIF; [Anonymous], 1999, MULT CAUS DEATH; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Centers for Disease Control and Prevention National Center for Health Statistics, 1999, VIT STAT US MORT 199; Demain JG, 2010, CURR OPIN ALLERGY CL, V10, P318, DOI 10.1097/ACI.0b013e32833a6c72; Fay MP, 1997, STAT MED, V16, P791; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Graft DF, 2006, MED CLIN N AM, V90, P211, DOI 10.1016/j.mcna.2005.08.006; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P378, DOI 10.1016/j.jaip.2013.04.009; Harduar-Morano L, 2010, J ALLERGY CLIN IMMUN, V126, P98, DOI 10.1016/j.jaci.2010.04.017; Hoyos-Bachiloglu R, 2014, PEDIAT ALLERG IMM-UK, V25, P338, DOI 10.1111/pai.12211; Kochanek Kenneth D, 2011, Natl Vital Stat Rep, V60, P1; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Liu Andrew H, 2010, J Allergy Clin Immunol, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Low I, 2006, PATHOLOGY, V38, P328, DOI 10.1080/00313020600820831; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Meyer PA, 2013, MMWR-MORBID MORTAL W, V62, P3; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SCHWARTZ HJ, 1995, CLIN EXP ALLERGY, V25, P866, DOI 10.1111/j.1365-2222.1995.tb00029.x; SCHWARTZ HJ, 1988, CLIN ALLERGY, V18, P461, DOI 10.1111/j.1365-2222.1988.tb02896.x; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Squires David A, 2011, Issue Brief (Commonw Fund), V16, P1; Umasunthar T, 2013, CLIN EXP ALLERGY, V43, P1333, DOI 10.1111/cea.12211; Warner JO, 2007, PEDIAT ALLERG IMM-UK, V18, P1, DOI 10.1111/j.1399-3038.2007.00532.x; Wilson R, 2000, BRIT MED J, V321, P1021	51	234	241	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1318	+		10.1016/j.jaci.2014.08.018	http://dx.doi.org/10.1016/j.jaci.2014.08.018			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25280385	Green Accepted			2022-12-18	WOS:000346075400014
J	LYNCH, NR; HAGEL, I; PEREZ, M; DIPRISCO, MC; LOPEZ, R; ALVAREZ, N				LYNCH, NR; HAGEL, I; PEREZ, M; DIPRISCO, MC; LOPEZ, R; ALVAREZ, N			EFFECT OF ANTHELMINTIC TREATMENT ON THE ALLERGIC REACTIVITY OF CHILDREN IN A TROPICAL SLUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; PARASITES; HELMINTHIC INFECTION; IGE; SOCIOECONOMIC LEVEL; ANTHELMINTIC TREATMENT	IGE LEVELS; SERUM IGE; INFECTION; ENVIRONMENT; RATS; PARASITES	It is well known that helminthic infection can cause a polyclonal stimulation of the synthesis of IgE, which is dependent on interleukin-4 (IL-4) production, and it has been suggested that this can modulate the expression of allergic reactivity in tropical populations. We evaluated the effect of regular anthelmintic treatment, for a period of 22 months, on certain aspects of the allergic reactivity of children in a slum area of Caracas, Venezuela, where helminths are endemic. The treatment (Oxantel-Pyrantel,; Quantrel) effectively eliminated intestinal helminthic infection and resulted in a significant decrease in the initially elevated total serum IgE levels. IL-4 was detectable in the serum, and a significant reduction in IL-4 was also observed after treatment. In contrast, both the immediate-hypersensitivity skin-test reactivity and serum levels of specific IgE antibody against environmental allergens were markedly increased in the treated children. In a group of children who were also evaluated in the same slum, but who declined treatment, a substantial increase in helminthic infection occurred, which was related to an acute deterioration of the socioeconomic conditions of Venezuela over the course of our study period. This was paralleled by a considerable increase in total IgE levels in these children and a decrease in the skin-test reactivities and specific IgE levels. The application of Prausnitz-Kustner passive transfer tests and analysis of specific IgE antibody levels indicated that the polyclonal stimulation of IgE synthesis by helminthic parasites results in mast cell Fcepsilon receptor saturation and suppression of specific IgE antibody synthesis. This inhibition of allergic reactivity is reversible by anthelmintic treatment.	JOSE MANUEL RIOS CHILDRENS HOSP, CARACAS, VENEZUELA; CENT UNIV VENEZUELA, SCH BIOANAL, CARACAS 1010A, VENEZUELA	University of Central Venezuela	LYNCH, NR (corresponding author), CENT UNIV VENEZUELA, INST BIOMED, APTDO 4043, CARACAS 1010A, VENEZUELA.		Lynch, Natalie/GSI-7336-2022	Hagel, Isabel/0000-0003-4464-1830				BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; BIROUMNO, 1973, CLIN EXP IMMUNOL, V13, P545; BUTCHKO GM, 1984, INT ARCH ALLER A IMM, V75, P27, DOI 10.1159/000233585; DIPRISCOFUENMAY.MC, 1987, THESIS CENTRAL U VEN; EVENGARD B, 1988, CLIN EXP IMMUNOL, V73, P383; FINKELMAN FD, 1991, IMMUNOPARASITOL TOD, pA62, DOI 10.1016/S0167-5699(05)80018-0; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GROVE DI, 1974, CLIN EXP IMMUNOL, V18, P565; GROVE DI, 1982, ALLERGY, V37, P139, DOI 10.1111/j.1398-9995.1982.tb01889.x; HUNTLEY CC, 1976, NEW ENGL J MED, V294, P1295; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JOHANSSON SG, 1968, LANCET, V1, P1118; JOUBERT JR, 1980, S AFR MED J, V57, P409; KAPLAN JE, 1980, AM J TROP MED HYG, V29, P1012, DOI 10.4269/ajtmh.1980.29.1012; KING CL, 1990, J CLIN INVEST, V85, P1810, DOI 10.1172/JCI114639; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; Lynch N. R., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P51; LYNCH NR, 1988, T ROY SOC TROP MED H, V82, P275, DOI 10.1016/0035-9203(88)90446-4; LYNCH NR, 1983, ANN ALLERGY, V51, P547; LYNCH NR, 1984, J ALLERGY CLIN IMMUN, V73, P229, DOI 10.1016/S0091-6749(84)80012-3; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1983, INT ARCH ALLER A IMM, V72, P369, DOI 10.1159/000234899; LYNCH NR, 1984, CLIN ALLERGY, V14, P233, DOI 10.1111/j.1365-2222.1984.tb02202.x; LYNCH NR, 1992, PARASITOL TODAY, V8, P166, DOI 10.1016/0169-4758(92)90011-P; LYNCH NR, 1987, ALLERGOL IMMUNOPATH, V15, P19; LYNCH NR, 1987, BAILLIERE CLIN TROP, V2, P573; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; MOQBEL R, 1990, CLIN EXP ALLERGY, V20, P611, DOI 10.1111/j.1365-2222.1990.tb02699.x; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; TURNER KJ, 1982, CLIN IMMUNOL IMMUNOP, V24, P440, DOI 10.1016/0090-1229(82)90014-9; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; TURNER KJ, 1980, ADV ALLERGOL IMMUNOL, P279; WATANABE N, 1988, INT ARCH ALLER A IMM, V86, P436, DOI 10.1159/000234631; 1986, DIASPER INFORME SOCI, V3	35	234	247	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					404	411		10.1016/0091-6749(93)90119-Z	http://dx.doi.org/10.1016/0091-6749(93)90119-Z			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360391				2022-12-18	WOS:A1993LX30900006
J	ROBINSON, DS; YING, S; BENTLEY, AM; MENG, Q; NORTH, J; DURHAM, SR; KAY, AB; HAMID, Q				ROBINSON, DS; YING, S; BENTLEY, AM; MENG, Q; NORTH, J; DURHAM, SR; KAY, AB; HAMID, Q			RELATIONSHIPS AMONG NUMBERS OF BRONCHOALVEOLAR LAVAGE CELLS EXPRESSING MESSENGER-RIBONUCLEIC-ACID FOR CYTOKINES, ASTHMA SYMPTOMS, AND AIRWAY METHACHOLINE RESPONSIVENESS IN ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; T-LYMPHOCYTES; INTERLEUKINS	COLONY-STIMULATING FACTOR; HUMAN EOSINOPHILS; BRONCHIAL-ASTHMA; ANTIGEN CHALLENGE; ALLERGIC RHINITIS; PERIPHERAL-BLOOD; IDENTIFICATION; INTERLEUKIN-3; LYMPHOCYTES; NEUTROPHILS	Background: We recently demonstrated that T lymphocytes in bronchoalveolar lavage (BAL) fluid from atopic asthmatic patients were activated and expressed increased cytokine messenger ribonucleic acid (mRNA) for ''T(H2)-type'' cytokines, particularly IL-4 and IL-5, when compared with those in normal control subjects. This pattern of cytokines may determine the nature of the cellular infiltrate in the bronchial mucosa in asthma and hence the bronchial hyperresponsiveness (BHR) and symptoms that characterize this condition. Methods: To examine the association between these cytokines and clinical measures of asthma seventy we have extended our studies of BAL cells from subjects with atopic asthma. Numbers of BAL cells with positive in situ hybridization signals for IL-2, IL-3, IL-4, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF), and interferon-gamma were counted on cytocentrifuge preparations. Results were compared between patients with symptomatic (n = 19) and asymptomatic asthma (n = 10), and associations were sought with airway methacholine responsiveness, resting airway caliber, and asthma symptom scores. Results: There were increased proportions of cells positive for IL-3 (p < 0.05), IL-4 (p < 0.005), IL-5 (p < 0.005), and GM-CSF (p < 0.005) mRNA in BAL fluid from patients with symptomatic asthma when compared with that from subjects free of symptoms, but no difference between the groups in numbers of cells expressing IL-2 and interferon-gamma mRNA. There were significant associations among numbers of cells expressing mRNA for IL-4, IL-5, and GM-CSF, and airflow restriction, BHR, and Aas asthma score. Conclusions: These findings support the hypothesis that cytokines contribute to airway events that determine asthma symptoms and BHR.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; NATL HEART & LUNG INST,DEPT THORAC PATHOL,LONDON SW3 6LY,ENGLAND	Imperial College London; Imperial College London				Bentley, Andrew/0000-0002-6883-9246				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DELPRETE G, 1988, J IMMUNOL, V140, P4651; DENBURG JA, 1992, BLOOD, V79, P846; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; FANSLOW WC, 1991, J IMMUNOL, V147, P535; FILLEY WV, 1982, LANCET, V2, P11; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LI JTC, 1990, J ALLERGY CLIN IMMUN, V85, P934, DOI 10.1016/0091-6749(90)90080-N; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MAHANTY S, 1992, J IMMUNOL, V148, P3567; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, IN PRESS J ALLERGY C; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109	33	234	239	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					397	403		10.1016/0091-6749(93)90118-Y	http://dx.doi.org/10.1016/0091-6749(93)90118-Y			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360390				2022-12-18	WOS:A1993LX30900005
J	Kumar, M; Ahmad, T; Sharma, A; Mabalirajan, U; Kulshreshtha, A; Agrawal, A; Ghosh, B				Kumar, Manish; Ahmad, Tanveer; Sharma, Amit; Mabalirajan, Ulaganathan; Kulshreshtha, Ankur; Agrawal, Anurag; Ghosh, Balaram			Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Let-7 microRNA; IL-13; allergic airway inflammation; posttranscriptional regulation; primary T cells; airway hyperresponsiveness	POSTTRANSCRIPTIONAL REGULATION; EXPERIMENTAL ASTHMA; RT-PCR; PROINFLAMMATORY ROLE; EXPRESSION; RNA; QUANTIFICATION; TARGET; CELLS; IDENTIFICATION	Background: IL-13, a cytokine secreted by T(H)2 lymphocytes and other cells, critically modulates allergic inflammation and tissue remodeling in allergic asthma. Although much is known about transcriptional regulation of IL-13, posttranscriptional regulation is poorly understood. Objective: Because many inflammatory pathways are known to be regulated by microRNAs, permitting a rapid and fine-tuned response, the role of microRNA-mediated regulation of IL-13 was investigated using both in vitro and in vivo studies. Methods: A combination of in silico approaches and in vitro transfections in A549 cells and primary cultured T cells was used to demonstrate the involvement of let-7 in IL-13 regulation. Furthermore, intranasal delivery of let-7 microRNA mimic in mice was performed to study its effects in allergic airway inflammatory conditions. Results: Using a combination of bioinformatics and molecular approaches, we demonstrate that the let-7 family of microRNAs regulates IL-13 expression. Induced levels of IL-13 in cultured T cells were inversely related to let-7 levels. In an IL-13-dependent murine model of allergic airway inflammation, we observed that inflammation was associated with a reduction in most of the members of the let-7 family. Exogenous administration of let-7 mimic to lungs of mice with allergic inflammation resulted in a decrease in IL-13 levels, resolution of airway inflammation, reduction in airway hyperresponsiveness, and attenuation of mucus metaplasia and subepithelial fibrosis. Conclusion: Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. (J Allergy Clin Immunol 2011;128:1077-85.)	[Ghosh, Balaram] Inst Genom & Integrat Biol, Immunogenet Mol Lab, Unit CSIR, Delhi 110007, India; Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Unit CSIR, Delhi 110007, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)	Ghosh, B (corresponding author), Inst Genom & Integrat Biol, Immunogenet Mol Lab, Unit CSIR, Mall Rd, Delhi 110007, India.	bghosh@igib.res.in	Agrawal, Anurag/GZL-5821-2022; Kumar, Manish/AAC-2278-2019; KULSHRESHTHA, ANKUR/AFP-2527-2022	Kumar, Manish/0000-0002-0855-3406; KULSHRESHTHA, ANKUR/0000-0001-5139-6744; Ahmad, Tanveer/0000-0002-8384-5273; Agrawal, Anurag/0000-0002-0340-5252	CSIR	CSIR(Council of Scientific & Industrial Research (CSIR) - India)	M.K. and A.S. acknowledge the help of CSIR for their fellowships. We also thank Kamiya Mehla, Jyotirmoi Aich, Sudipta Das, Lokesh Makhija, Neha Singhal, and Himpriya Chopra for their help.	Agrawal A, 2007, J APPL PHYSIOL, V102, P399, DOI 10.1152/japplphysiol.00630.2006; Agrawal A, 2011, AM J RESP CELL MOL, V44, P270, DOI 10.1165/rcmb.2010-0141TR; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Arvey A, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.24; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Casolaro V, 2008, J ALLERGY CLIN IMMUN, V121, P853, DOI 10.1016/j.jaci.2007.12.1166; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen XM, 2007, J BIOL CHEM, V282, P28929, DOI 10.1074/jbc.M702633200; Cho SJ, 2006, J BIOL CHEM, V281, P8161, DOI 10.1074/jbc.M506770200; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; Fukuyama S, 2009, AM J RESP CRIT CARE, V179, P992, DOI 10.1164/rccm.200806-992OC; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang HY, 2009, CURR OPIN MOL THER, V11, P652; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kariyawasam H, 2009, AM J RESP CRIT CARE, V179, DOI [10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A3642, DOI 10.1164/AJRCCM-CONFERENCE.2009.179.1_MEETINGABSTRACTS.A3642]; Kasaian MT, 2008, BIOCHEM PHARMACOL, V76, P147, DOI 10.1016/j.bcp.2008.04.002; Kitamura N, 2005, IMMUNOL CELL BIOL, V83, P536, DOI 10.1111/j.1440-1711.2005.01364.x; Knibbs RN, 1998, J IMMUNOL, V161, P6305; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Kumar M, 2010, J BIOL CHEM, V285, pLE19, DOI 10.1074/jbc.L110.145698; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lively TN, 2008, J ALLERGY CLIN IMMUN, V121, P88, DOI 10.1016/j.jaci.2007.08.029; Lu H, 2010, CARDIOVASC RES, V86, P410, DOI 10.1093/cvr/cvq010; Mabalirajan U, 2008, J IMMUNOL, V181, P3540, DOI 10.4049/jimmunol.181.5.3540; Mabalirajan U, 2010, J ALLERGY CLIN IMMUN, V125, P626, DOI 10.1016/j.jaci.2009.10.065; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Monticelli S, 2004, J BIOL CHEM, V279, P36210, DOI 10.1074/jbc.M406354200; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Neilson JR, 2007, GENE DEV, V21, P578, DOI 10.1101/gad.1522907; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piper E, STUDY EVALUATE SAFET; Polikepahad S, 2010, J BIOL CHEM, V285, pLE20, DOI 10.1074/jbc.N110.145698; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Schroeder JT, 2010, CLIN EXP ALLERGY, V40, P745, DOI 10.1111/j.1365-2222.2010.03456.x; Sharma A, 2009, P NATL ACAD SCI USA, V106, P5761, DOI 10.1073/pnas.0808743106; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Torrisani J, 2007, CURR GENOMICS, V8, P229; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	47	233	258	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1077	U545		10.1016/j.jaci.2011.04.034	http://dx.doi.org/10.1016/j.jaci.2011.04.034			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21616524				2022-12-18	WOS:000296578200022
J	Liu, AH				Liu, AH			Endotoxin exposure in allergy and asthma: Reconciling a paradox	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; therapy; prevention; endotoxin; LPS; infection; hygiene; IFN-gamma; IL-12; T(H)1	CD4(+) T-CELLS; GROWTH-FACTOR-BETA; INDUCED AIRWAY HYPERRESPONSIVENESS; STIMULATORY FACTOR INTERLEUKIN-12; INTERFERON-GAMMA PRODUCTION; GRASS-POLLEN IMMUNOTHERAPY; HAY-FEVER; MESSENGER-RNA; COLLAGEN-SYNTHESIS; INHALED ENDOTOXIN	Well-established evidence links endotoxin exposure, especially in the workplace, to airways disease. Endotoxin can increase disease severity by acting as a natural adjuvant to augment asthma and atopic inflammation. Recent studies suggest that it can even act on its own, causing a distinct endotoxic form of asthma. Other studies, however, contradict the paradigm that endotoxin's influence is solely a negative one. Epidemiologic associations of environmental endotoxin exposure with allergy and asthma prevention are consistent with hygiene hypothesis associations of other microbial exposures or infections with a lower incidence of atopic disease. Currently, microbe-derived products are being developed as potential therapies for allergy and asthma. Thus it is an ideal time to consider endotoxin as a prototype of a natural intervention with microbial components. Nature's ongoing experiment with endotoxin can provide clues for the development of effective and safe microbe-based products for disease treatment and prevention. This article will discuss (1) conventional paradigms in which endotoxin-induced immune modulation by T(H)1-type induction leads to mitigation of T(H)2-type immune development, allergen sensitization, and atopic inflammation; (2) newer concepts of T(H)1-type immune responses that may provide additional asthma-protective effects by preventing airways remodeling; (3) home and environmental features that significantly contribute to endotoxin exposure; (4) different aspects of asthma mediated by endotoxin exposure; and (5) how to understand endotoxin's paradoxical nature of serving as both friend and foe.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy & Immunol, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004272] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23-HL-04272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; BRIGHAM KL, 1994, ENDOTOXIN LUNGS, V77; Broide D, 1998, J IMMUNOL, V161, P7054; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHILLER JM, 1973, J EXP MED, V137, P740, DOI 10.1084/jem.137.3.740; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1999, J IMMUNOL, V162, P6178; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282, DOI 10.1164/ajrccm/144.6.1282; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 2000, AM J IND MED, V38, P426, DOI 10.1002/1097-0274(200010)38:4&lt;426::AID-AJIM8&gt;3.0.CO;2-R; Dow SW, 1999, HUM GENE THER, V10, P2961, DOI 10.1089/10430349950016375; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DRESSER DW, 1961, NATURE, V191, P1169, DOI 10.1038/1911169a0; DUNCAN MR, 1985, J EXP MED, V162, P516, DOI 10.1084/jem.162.2.516; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Dutton S, 2002, J ALLERGY CLIN IMMUN, V109, pS48, DOI 10.1016/S0091-6749(02)81233-7; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Fanucchi MV, 1998, TOXICOL APPL PHARM, V152, P1, DOI 10.1006/taap.1998.8484; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; Gao JJ, 1999, J IMMUNOL, V163, P4095; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; George CLS, 2001, AM J PHYSIOL-LUNG C, V280, pL203, DOI 10.1152/ajplung.2001.280.2.L203; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GILLERY P, 1992, FEBS LETT, V302, P231, DOI 10.1016/0014-5793(92)80448-P; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; HAGMAR L, 1990, INT ARCH OCC ENV HEA, V62, P159, DOI 10.1007/BF00383592; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HAYES MP, 1995, BLOOD, V86, P646, DOI 10.1182/blood.V86.2.646.bloodjournal862646; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hilkens CMU, 1997, BLOOD, V90, P1920, DOI 10.1182/blood.V90.5.1920; Hofstra CL, 1998, AM J RESP CELL MOL, V19, P826, DOI 10.1165/ajrcmb.19.5.3027; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jeffery P, 2001, PEDIATR PULM, P3; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Kim TS, 1997, J IMMUNOL, V158, P4137; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kirshenbaum AS, 1998, EXP HEMATOL, V26, P245; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; LACK G, 1994, J IMMUNOL, V152, P2546; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LE JM, 1986, J IMMUNOL, V136, P4525; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 2000, ANN ALLERG ASTHMA IM, V85, P305, DOI 10.1016/S1081-1206(10)62534-3; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MICHEL O, 1991, ANN ALLERGY, V66, P39; Michel O, 2000, TOXICOLOGY, V152, P25, DOI 10.1016/S0300-483X(00)00288-2; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; Mungan D, 2001, ALLERGY ASTHMA PROC, V22, P87, DOI 10.2500/108854101778250643; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ng'ang'a LW, 1998, THORAX, V53, P919, DOI 10.1136/thx.53.11.919; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; PABST MJ, 1982, J IMMUNOL, V128, P123; PABST MJ, 1980, J EXP MED, V151, P101, DOI 10.1084/jem.151.1.101; Pape KA, 1997, J IMMUNOL, V159, P591; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Roy SR, 2002, J ALLERGY CLIN IMMUN, V109, pS41, DOI 10.1016/S0091-6749(02)81209-X; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Salkowski CA, 1997, INFECT IMMUN, V65, P3239, DOI 10.1128/IAI.65.8.3239-3247.1997; Saraf A, 1997, APPL ENVIRON MICROB, V63, P2554, DOI 10.1128/AEM.63.7.2554-2559.1997; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; SCHILLING RSF, 1956, LANCET, V271, P319; SCHILLING RSF, 1956, LANCET, V271, P260; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SEMPOWSKI GD, 1994, J IMMUNOL, V152, P3606; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shnyra A, 1998, J IMMUNOL, V160, P3729; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705, DOI 10.1164/ajrccm.160.2.9810002; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; SOUSA CR, 1997, J EXP MED, V186, P1799; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Su HJ, 2001, ENVIRON RES, V85, P135, DOI 10.1006/enrs.2000.4113; Sur S, 1996, J IMMUNOL, V157, P4173; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Wagner JG, 2001, TOXICOL SCI, V60, P338, DOI 10.1093/toxsci/60.2.338; Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261, DOI 10.1164/ajrccm.154.5.8912733; Wickens K, 1999, J ALLERGY CLIN IMMUN, V104, P554, DOI 10.1016/S0091-6749(99)70323-4; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	161	233	243	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					379	392		10.1067/mai.2002.122157	http://dx.doi.org/10.1067/mai.2002.122157			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897980				2022-12-18	WOS:000174586400001
J	Kaplan, AP; Joseph, K; Silverberg, M				Kaplan, AP; Joseph, K; Silverberg, M			Pathways for bradykinin formation and inflammatory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						bradykinin; factor XII; prekallikrein; kininogen; kininase; angioedema	HIGH-MOLECULAR-WEIGHT; HUMAN HAGEMAN-FACTOR; HEREDITARY ANGIONEUROTIC-EDEMA; BLOOD-COAGULATION FACTOR; AMINO-ACID-SEQUENCE; HUMAN-PLASMA PREKALLIKREIN; VEIN ENDOTHELIAL-CELLS; NASAL AIRWAY CHALLENGE; HUMAN FACTOR-XI; CONTACT ACTIVATION	Bradykinin is formed by the interaction of factor XII, prekallikrein, and high-molecular-weight kininogen on negatively charged inorganic surfaces (silicates, urate, and pyrophosphate) or macromolecular organic surfaces (heparin, other mucopolysaccharides, and sulfatides) or on assembly along the surface of cells. Catalysis along the cell surface requires zinc-dependent binding of factor XII and high-molecular-weight kininogen to proteins, such as the receptor for the globular heads of the C1q subcomponent of complement, cytokeratin 1, and urokinase plasminogen activator receptor. These 3 proteins complex together within the cell membrane, and initiation depends on autoactivation of factor XII on binding to gC1qR (the receptor for the globular heads of the C1q subcomponent of complement). There is also a factor XII-independent bypass mechanism requiring a cell-derived cofactor or protease that activates prekallikrein. Bradykinin is degraded by carboxypeptidase N and angiotensin-converting enzyme. Angioedema that is bradykinin dependent results from hereditary or acquired Cl inhibitor deficiencies or use of angiotensin-converting enzyme inhibitors to treat hypertension, heart failure, diabetes, or scleroderma. The role for bradykinin in allergic rhinitis, asthma, and anaphylaxis is to contribute to tissue hyperresponsiveness, local inflammation, and hypotension. Activation of the plasma cascade occurs as a result of heparin release and endothelial-cell activation and as a secondary event caused by other pathways of inflammation.	Med Univ S Carolina, Dept Med, Konishi MUSC Inst Inflammat Res, Div Pulm & Crit Care Med & Allergy & Clin Immunol, Charleston, SC 29425 USA; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Medical University of South Carolina; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Allergy, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.							Akbary AM, 1996, IMMUNOPHARMACOLOGY, V33, P238, DOI 10.1016/0162-3109(96)00065-3; ALABASTER VA, 1992, CIRC RES, V31, P72; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Brunnee T, 1997, CLIN EXP ALLERGY, V27, P653; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; CITARELLA F, 1988, HUM GENET, V80, P397, DOI 10.1007/BF00273661; CLARKE BJ, 1989, J BIOL CHEM, V264, P11497; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COCHRANE CG, 1980, J EXP MED, V152, P608, DOI 10.1084/jem.152.3.608; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; COOL DE, 1985, J BIOL CHEM, V260, P3666; Cugno M, 1996, IMMUNOPHARMACOLOGY, V33, P361, DOI 10.1016/0162-3109(96)00086-0; CURD JG, 1982, MOL IMMUNOL, V19, P1365, DOI 10.1016/0161-5890(82)90035-9; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DAVIS AJ, 1994, BRIT J PHARMACOL, V113, P63, DOI 10.1111/j.1476-5381.1994.tb16174.x; Dedio J, 1998, J IMMUNOL, V160, P3534; DERKX FHM, 1979, NATURE, V280, P315, DOI 10.1038/280315a0; DISCIPIO RG, 1982, IMMUNOLOGY, V45, P587; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1977, ANN INTERN MED, V86, P312, DOI 10.7326/0003-4819-86-3-312; DONALDSON VH, 1976, J LAB CLIN MED, V87, P327; DUNN JT, 1982, J CLIN INVEST, V70, P627, DOI 10.1172/JCI110656; DUNN JT, 1982, J BIOL CHEM, V257, P1779; ERDOS EG, 1962, BIOCHEM PHARMACOL, V11, P585, DOI 10.1016/0006-2952(62)90119-3; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GALLIN JI, 1974, J IMMUNOL, V113, P1928; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GEPPETTI P, 1993, REGUL PEPTIDES, V47, P1, DOI 10.1016/0167-0115(93)90268-D; GHEBREHIWET B, 1983, J CLIN INVEST, V71, P1450, DOI 10.1172/JCI110898; GRIFFIN JH, 1978, P NATL ACAD SCI USA, V75, P1998, DOI 10.1073/pnas.75.4.1998; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HAUPTMANN G, 1976, BLUT, V32, P195, DOI 10.1007/BF00995913; He SP, 1998, MOL MED, V4, P119, DOI 10.1007/BF03401735; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HIGASHIYAMA S, 1986, BIOCHEMISTRY-US, V25, P1669, DOI 10.1021/bi00355a034; HOJIMA Y, 1984, BLOOD, V63, P1453; Huang TJ, 1999, AM J RESP CRIT CARE, V160, P1717, DOI 10.1164/ajrccm.160.5.9901029; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; JACOBSEN S, 1967, BRIT J PHARM CHEMOTH, V29, P25, DOI 10.1111/j.1476-5381.1967.tb01935.x; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2001, BIOL CHEM, V382, P71, DOI 10.1515/BC.2001.012; Joseph K, 2001, THROMB HAEMOSTASIS, V85, P119; Joseph K, 1999, CLIN IMMUNOL, V92, P246, DOI 10.1006/clim.1999.4753; JOSEPH K, 2001, THROMB HAEMOST S, P2093; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P20; Kaplan AP, 1998, CLIN REV ALLERG IMMU, V16, P403, DOI 10.1007/BF02737659; KAPLAN AP, 1987, BLOOD, V70, P1; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; KAPLAN AP, 1970, J IMMUNOL, V105, P802; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; KELLERMANN J, 1986, EUR J BIOCHEM, V154, P471, DOI 10.1111/j.1432-1033.1986.tb09421.x; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KRAMER J, 1991, J CLIN INVEST, V87, P1614, DOI 10.1172/JCI115175; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LIN YL, 1977, BLOOD, V90, P690; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOTTSPEICH F, 1995, EUR J BIOCHEM, V152, P307; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Margolius HS, 1998, CLIN REV ALLERG IMMU, V16, P337, DOI 10.1007/BF02737655; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; MULLERESTERL W, 1985, FEBS LETT, V182, P310, DOI 10.1016/0014-5793(85)80322-7; MULLERESTERL W, 1985, EUR J BIOCHEM, V149, P15, DOI 10.1111/j.1432-1033.1985.tb08886.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAITO K, 1991, J BIOL CHEM, V266, P7353; NAKAYASU T, 1979, J BIOCHEM, V85, P249, DOI 10.1093/oxfordjournals.jbchem.a132318; NISHIKAWA K, 1992, BLOOD, V80, P1980; Noga O, 1999, INT ARCH ALLERGY IMM, V120, P310, DOI 10.1159/000024284; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Peerschke EIB, 1996, J IMMUNOL, V157, P4154; PIXLEY RA, 1987, J BIOL CHEM, V262, P10140; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; QUE BG, 1986, BIOCHEMISTRY-US, V25, P1525, DOI 10.1021/bi00355a009; REDDIGARI S, 1988, BLOOD, V71, P1334; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; REDDIGARI SR, 1993, BLOOD, V81, P1306; REGOLI D, 1980, PHARMACOL REV, V32, P1; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; REVAK SD, 1976, J CLIN INVEST, V57, P852, DOI 10.1172/JCI108361; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; SCHEIBER RD, 1976, BLOOD, V48, P567; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SEALEY JE, 1979, P NATL ACAD SCI USA, V76, P5914, DOI 10.1073/pnas.76.11.5914; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; SHEIKH IA, 1986, BIOCHEM PHARMACOL, V35, P1951, DOI 10.1016/0006-2952(86)90726-4; SHEIKH IA, 1986, BIOCHEM PHARMACOL, V35, P1957, DOI 10.1016/0006-2952(86)90727-6; SHEIKH IA, 1989, BIOCHEM PHARMACOL, V38, P993, DOI 10.1016/0006-2952(89)90290-6; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SILVERBERG M, 1980, THROMB RES, V20, P173, DOI 10.1016/0049-3848(80)90383-7; SILVERBERG M, 1982, BLOOD, V60, P64; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; WEISS AS, 1974, J CLIN INVEST, V53, P622, DOI 10.1172/JCI107597; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636; WUEPPER KD, 1975, J CLIN INVEST, V56, P1663, DOI 10.1172/JCI108248; WUEPPER KD, 1973, J EXP MED, V138, P1345, DOI 10.1084/jem.138.6.1345; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; ZAHEDI R, 1995, J CLIN INVEST, V95, P1299, DOI 10.1172/JCI117780; Zahedi R, 1997, J IMMUNOL, V159, P983; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	155	233	245	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					195	209		10.1067/mai.2002.121316	http://dx.doi.org/10.1067/mai.2002.121316			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842287	Bronze			2022-12-18	WOS:000174232600002
J	O'Regan, GM; Sandilands, A; McLean, WHI; Irvine, AD				O'Regan, Grainne M.; Sandilands, Aileen; McLean, W. H. Irwin; Irvine, Alan D.			Filaggrin in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; barrier function; cornified cell envelope; eczema; epidermal differentiation complex; filaggrin; ichthyosis vulgaris; natural moisturizing factor; pH; proteases; Staphylococcus aureus	OF-FUNCTION MUTATIONS; GENE; BARRIER; ECZEMA; PREDISPOSE; POPULATION; VARIANTS; ASTHMA; RISK	The recent identification of loss-of-function mutations in the structural protein filaggrin as a widely replicated major risk factor for eczema sheds new light on disease mechanisms in eczema, a disease that had heretofore largely been considered to have a primarily immunologic etiopathogenesis. The filaggrin gene (FLG) mutation findings are consistent with a recently proposed unifying hypothesis that offers a mechanistic understanding of eczema pathogenesis synthesizing a heritable epithelial barrier defect and resultant diminished epidermal defense mechanisms to allergens and microbes, followed by polarized T(H)2 lymphocyte responses with resultant chronic inflammation, including autoimmune mechanisms. Although compelling evidence from genetic studies on FLG implicates perturbed barrier function as a key player in the pathogenesis of eczema in many patients, much is still unknown about the sequence of biologic, physicochemical, and aberrant regulatory events that constitute the transition from an inherited barrier defect to clinical manifestations of inflammatory eczematous lesions and susceptibility to related atopic disorders. The exact contribution of FLG to the wider atopic story, factors modifying FLG expression, and the role of other barrier proteins remain to be delineated. In this review we highlight recent advances in our understanding of the FLG genetics in the cause of eczema and related complex diseases.	[O'Regan, Grainne M.; Irvine, Alan D.] Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland; [Sandilands, Aileen; McLean, W. H. Irwin] Div Mol Med, Epithelial Genet Grp, Dundee, Scotland; [Irvine, Alan D.] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland	Our Ladys Children Hospital Crumlin; University of Dundee; Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008; McLean, William HI/C-6352-2009	Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Sevilla LM, 2007, J CELL BIOL, V179, P1599, DOI 10.1083/jcb.200706187; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014	25	232	248	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					689	693		10.1016/j.jaci.2008.08.002	http://dx.doi.org/10.1016/j.jaci.2008.08.002			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18774165				2022-12-18	WOS:000259989000008
J	Nadeem, A; Chhabra, SK; Masood, A; Raj, HG				Nadeem, A; Chhabra, SK; Masood, A; Raj, HG			Increased oxidative stress and altered levels of antioxidants in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; oxidative stress; superoxide anion; reactive oxygen species; antioxidants; glutathione peroxidase; catalase; superoxide dismutase; glutathione	NITRIC-OXIDE; GLUTATHIONE-PEROXIDASE; LIPID-PEROXIDATION; FREE-RADICALS; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA; OXYGEN RADICALS; MILD ASTHMA; SUPEROXIDE; HYPERRESPONSIVENESS	Background: Reactive oxygen species might play an important role in the modulation of airway inflammation. There is evidence of an oxidant-antioxidant imbalance in asthma. Although several oxidants and antioxidants are likely to be involved, alterations in only limited parameters have been studied in isolation. Objective: We investigated changes in a wide range of oxidants and antioxidants to create a comprehensive picture of oxidant-antioxidant imbalance. Methods: In the peripheral blood of 38 patients with bronchial asthma and 23 control subjects, oxidative stress was measured in terms of superoxide anion generation by leukocytes, lipid peroxidation products, total nitrates and nitrites, total protein carbonyls, and total protein sulfhydrils in plasma. Antioxidant status was evaluated by measuring red blood cell superoxide dismutase and catalase activity, total blood glutathione, and glutathione peroxidase activity in red blood cells and leukocytes and total antioxidant capacity in plasma. Results: Asthmatic patients showed increased superoxide generation from leukocytes, increased total nitrites and nitrates, increased protein carbonyls, and increased lipid peroxidation products and decreased protein sulfhydrils in plasma, indicating increased oxidative stress. They also showed increased superoxide dismutase activity in red blood cells and increased total blood glutathione and decreased glutathione peroxidase activity in red blood cells and leukocytes. Red blood cell catalase activity and the total antioxidant capacity of plasma were not altered. Conclusion: There are alterations in a wide array of oxidants and antioxidants, with balance shifting toward increased oxidative stress in asthma. Therapeutic augmentation of the antioxidant defenses might be beneficial.	Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Cardiorespiratory Physiol, Delhi 110007, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Biochem, Delhi 110007, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Pharmacol, Delhi 110007, India	University of Delhi; University of Delhi; University of Delhi	Chhabra, SK (corresponding author), Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Cardiorespiratory Physiol, Delhi 110007, India.		NADEEM, AHMED/AFO-7618-2022; Nadeem, Ahmed/ABA-1974-2020	NADEEM, AHMED/0000-0003-2038-8367; Nadeem, Ahmed/0000-0003-2038-8367				ABBE MR, 1986, CLIN CHEM, V197, P175; Aebi H., 1974, METHODS ENZYMATIC AN, V2, P673, DOI 10.1016/B978-0-12-091302-2.50032-3; AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CALHOUN W J, 1987, American Review of Respiratory Disease, V135, pA224; CHANEZ P, 1990, EUR RESPIR J, V3, P1002; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DOUSSET JC, 1983, CLIN CHIM ACTA, V129, P319, DOI 10.1016/0009-8981(83)90035-9; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Grisham MB, 1996, METHOD ENZYMOL, V268, P237; HASSELMARK L, 1990, ALLERGY, V45, P523, DOI 10.1111/j.1398-9995.1990.tb00528.x; HEFFNER JE, 1991, LUNG SCI F, P1811; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HU ML, 1988, AGENTS ACTIONS, V25, P132, DOI 10.1007/BF01969104; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; KATSUMATA U, 1990, AM REV RESPIR DIS, V141, P1158, DOI 10.1164/ajrccm/141.5_Pt_1.1158; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; LEHMEYER JE, 1979, BLOOD, V54, P35; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LITTLE C, 1970, J BIOL CHEM, V245, P3632; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; *NIH, 1997, EXP PAN REP GUID DIA; PEARSON DJ, 1991, CLIN EXP ALLERGY, V21, P203, DOI 10.1111/j.1365-2222.1991.tb00831.x; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; RADI R, 1991, J BIOL CHEM, V266, P4244; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; RAHMAN IU, 1991, AM J PHYSIOL, V260, pL412, DOI 10.1152/ajplung.1991.260.6.L412; ROBINSON C, 1985, CLIN SCI, V68, P103, DOI 10.1042/cs0680103; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SEARLE AJ, 1980, INT J RADIAT BIOL, V37, P213, DOI 10.1080/09553008014550261; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; TOTH KM, 1984, J CLIN INVEST, V74, P292, DOI 10.1172/JCI111414; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x; 1981, NUTR REV, V29, P21	48	232	248	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					72	78		10.1067/mai.2003.17	http://dx.doi.org/10.1067/mai.2003.17			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532099				2022-12-18	WOS:000180465500011
J	Bunikowski, R; Mielke, MEA; Skarabis, H; Worm, M; Anagnostopoulos, I; Kolde, G; Wahn, U; Renz, H				Bunikowski, R; Mielke, MEA; Skarabis, H; Worm, M; Anagnostopoulos, I; Kolde, G; Wahn, U; Renz, H			Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Staphylococcus aureus; staphylococcus enterotoxins (SEA, SEB, SEC, SED, TSST-1)	T-CELLS; BACTERIAL SUPERANTIGENS; SKIN COLONIZATION; ENTEROTOXIN-B; BETA-CHAIN; EXPRESSION; PATHOGENESIS; ANTIGEN; INFLAMMATION; ANTIBODIES	Background: The skin of patients with atopic dermatitis (AD) exhibits a striking susceptibility to colonization with Staphylococcus aureus. Some strains of S aureus secrete exotoxins with T-cell superantigen activity (toxigenic strains), and abnormal T-cell functions are known to play a critical role in AD. Objective: Our purpose was to examine the impact of superantigen production hy skin-colonizing S aureus on disease severity. Methods: In a cross-sectional study of 74 children with AD, the presence and density of toxigenic and nontoxigenic strains of S aureus was correlated with disease severity. In a subgroup of patients the T-cell receptor V beta repertoire of peripheral blood and lesional T cells was investigated and correlated with individual superantigen activity of skin-colonizing S aureus. Results: Fifty-three percent of children with AD were colonized with toxigenic strains of S aureus producing staphylococcal enterotoxin C, staphylococcal enterotoxin A, toxic shock syndrome toxin-1, staphylococcal enterotoxin B, and staphylococcal enterotoxin D in decreasing frequency. Children colonized with toxigenic S aureus strains had higher disease severity compared,vith the nontoxigenic and S aureus-negative groups. Patients colonized with toxigenic S aureus exhibited shifts in the intradermal T-cell receptor V beta repertoire that correspond to the respective superantigen-responsive T-cell subsets. Conclusion: The data demonstrate that S aureus-released exotoxins can modulate disease severity and dermal T-cell infiltration.	Humboldt Univ, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Infect Dis, D-12200 Berlin, Germany; Free Univ Berlin, Inst Sociol, Dept Stat, D-1000 Berlin, Germany; Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany; Humboldt Univ, Inst Lab Med & Pathobiochem, Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Bunikowski, R (corresponding author), Humboldt Univ, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1,Charite Campus Virchow Klinik, D-13353 Berlin, Germany.			Worm, Margitta/0000-0002-3449-1245				ALOUF JE, 1991, SOURCEBOOK BACTERIAL, P367; Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAVID TJ, 1986, ARCH DIS CHILD, V61, P20, DOI 10.1136/adc.61.1.20; deVries IJM, 1997, J ALLERGY CLIN IMMUN, V100, P694, DOI 10.1016/S0091-6749(97)70175-1; Ha SJ, 1998, ACTA DERM-VENEREOL, V78, P424; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; HOEGER PH, 1992, J INFECT DIS, V165, P1064, DOI 10.1093/infdis/165.6.1064; Isenberg HD., 2007, CLIN MICROBIOLOGY PR; Jappe U, 1998, J INVEST DERMATOL, V110, P844, DOI 10.1046/j.1523-1747.1998.00177.x; Kapsenberg ML, 1998, CURR OPIN IMMUNOL, V10, P607, DOI 10.1016/S0952-7915(98)80077-0; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LEROUX M, 1985, J IMMUNOL METHODS, V79, P251, DOI 10.1016/0022-1759(85)90105-X; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; MOLLICK JA, 1993, J EXP MED, V177, P283, DOI 10.1084/jem.177.2.283; Monti G, 1996, DERMATOLOGY, V193, P83, DOI 10.1159/000246218; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STICKLAND I, 1999, J INVEST DERMATOL, V112, P249; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Torres MJ, 1998, CLIN EXP ALLERGY, V28, P1264; Werfel T, 1997, J IMMUNOL, V158, P2500; Yudate T, 1996, J DERMATOL SCI, V13, P63, DOI 10.1016/0923-1811(95)00502-1; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P49	31	232	244	0	13	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					814	819		10.1067/mai.2000.105528	http://dx.doi.org/10.1067/mai.2000.105528			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756234				2022-12-18	WOS:000086604100022
J	Rajan, JP; Wineinger, NE; Stevenson, DD; White, AA				Rajan, Jessica P.; Wineinger, Nathan E.; Stevenson, Donald D.; White, Andrew A.			Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; Samter triad; aspirin-induced asthma; prevalence	NEAR-FATAL ASTHMA; NASAL POLYPS; INTOLERANT ASTHMA; NATURAL-HISTORY; POPULATION; INFLAMMATION; ASSOCIATION; SENSITIVITY; HYPERSENSITIVITY	Background: Aspirin-exacerbated respiratory disease (AERD) is manifested by adult-onset asthma, nasal polyposis, chronic rhinosinusitis, and aspirin sensitivity. Previously reported prevalence rates have been widely variable based on the population studied, method of diagnosis, and definition of aspirin sensitivity. Objective: We sought to determine the prevalence of AERD among asthmatic adults. Methods: A systematic review of databases was performed to identify all clinical trials published on or before June 16, 2013, that evaluated the prevalence of AERD. The studies were clustered into 7 different groups based on underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as well as on the methodology of prevalence determination. Results: A total of 1770 articles were identified, with 27 considered appropriate for inclusion. Prevalence rates of AERD ranged from 5.5% to 12.4% based on study type. Among all studies in asthmatic patients, regardless of method, the prevalence of AERD was 7.15% (95% CI, 5.26% to 9.03%). The prevalence of AERD was highest among patients with severe asthma (14.89% [95% CI, 6.48% to 23.29%]). Among patients with nasal polyps and chronic rhinosinusitis, the prevalence was 9.69% (95% CI, 2.16% to 17.22%) and 8.7%(95% CI, 21.02% to 18.34%), respectively. Conclusion: AERD is a distinct and important subtype of asthma and polypoid sinus disease. The prevalence of AERD is 7% in typical adult asthmatic patients and twice that number in patients with severe asthma, which underscores the importance of recognizing this disorder. Early identification of this syndrome is critical in view of the increased morbidity and costs associated with asthma exacerbations and the option to treat patients with AERD with long-term aspirin treatment after desensitization.	[Rajan, Jessica P.; Stevenson, Donald D.; White, Andrew A.] Scripps Clin, Dept Allergy Asthma & Immunol, San Diego, CA 92130 USA; [Wineinger, Nathan E.] Scripps Translat Sci Inst, San Diego, CA USA	Scripps Research Institute	Rajan, JP (corresponding author), Scripps Clin, 3811 Valley Ctr Dr,S99, San Diego, CA 92130 USA.	jessicarajan@gmail.com			Scripps Clinic; Rease Steahly Clinic; SCMG Education and Research [8194]; NIH [UL1TR001114]	Scripps Clinic; Rease Steahly Clinic; SCMG Education and Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Scripps Clinic. J. P. Rajan is employed by Scripps Clinic, which funded this study. D. D. Stevenson has received consultancy fees from the Rease Steahly Clinic, support for travel or other study- related purposes from the Scripps Clinic, and payment for editing the Immunology and Allergy Clinics of North American issue on aspirin and nonsteroidal anti-inflammatory drugs. A. A. White is employed by Scripps Clinic and has received or has funding pending through an SCMG Education and Research Grant #8194. N. E. Wineinger was supported, in part, by NIH grant UL1TR001114.	Bavbek S, 2012, ALLERGOL IMMUNOPATH, V40, P225, DOI 10.1016/j.aller.2011.05.015; Bavbek S, 2011, AM J RHINOL ALLERGY, V25, P411, DOI 10.2500/ajra.2011.25.3660; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; CASTILLO JA, 1986, RESPIRATION, V50, P153, DOI 10.1159/000194922; Celejewska-Wojcik N, 2012, POL ARCH MED WEWN, V122, P422, DOI 10.20452/pamw.1379; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; Charpin D, 2003, J ASTHMA, V40, P87, DOI 10.1081/JAS-120017211; Cho SH, 2013, PHARMACOGENET GENOM, V23, P341, DOI 10.1097/FPC.0b013e328361d4bb; Dufour X, 2004, LARYNGOSCOPE, V114, P1982, DOI 10.1097/01.mlg.0000147933.14014.12; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; Fan YP, 2012, AM J RHINOL ALLERGY, V26, pE20, DOI 10.2500/ajra.2012.26.3738; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Johansson L, 2004, ACTA OTO-LARYNGOL, V124, P77, DOI 10.1080/00016480310016037; Kasper L, 2003, ALLERGY, V58, P1064, DOI 10.1034/j.1398-9995.2003.00267.x; Kasper Lukasz, 2009, Pneumonol Alergol Pol, V77, P431; Kim JE, 2007, ENT-EAR NOSE THROAT, V86, P396, DOI 10.1177/014556130708600715; Lee ML, 1968, B GEISINGER MED CTR, V20, P125; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; Mita H, 2004, CLIN EXP ALLERGY, V34, P1262, DOI 10.1111/j.1365-2222.2004.02034.x; MOLONEY JR, 1977, J LARYNGOL OTOL, V91, P837, DOI 10.1017/S0022215100084450; Moon JY, 2013, RESP MED, V107, P202, DOI 10.1016/j.rmed.2012.10.020; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; PATRIARCA G, 1986, ARCH OTO-RHINO-LARYN, V243, P16, DOI 10.1007/BF00457900; PICADO C, 1989, EUR RESPIR J, V2, P127; Sabry EY, 2010, ALLERGOL IMMUNOPATH, V38, P181, DOI 10.1016/j.aller.2009.09.010; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Staikuniene J, 2008, MEDICINA-LITHUANIA, V44, P257, DOI 10.3390/medicina44040033; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Team RC, 2012, LANGUAGE ENV STAT CO; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; White AA, 2013, ALLERGY ASTHMA PROC, V34, P378, DOI 10.2500/aap.2013.34.3670; Yoshimine F, 2005, RESPIROLOGY, V10, P477, DOI 10.1111/j.1440-1843.2005.00740.x; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang N, 2006, AM J RHINOL, V20, P445, DOI 10.2500/ajr.2006.20.2887	45	231	238	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					676	U140		10.1016/j.jaci.2014.08.020	http://dx.doi.org/10.1016/j.jaci.2014.08.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25282015				2022-12-18	WOS:000351065000011
J	Schauber, J; Gallo, RL				Schauber, Juergen; Gallo, Richard L.			Antimicrobial peptides and the skin immune defense system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						antimicrobial peptides; alarmins; skin; cathelicidin; rosacea; atopic dermatitis; psoriasis; 1,25 dihydroxy vitamin D3	INVASIVE BACTERIAL-INFECTION; VITAMIN-D-RECEPTOR; HUMAN KERATINOCYTES; 1,25-DIHYDROXYVITAMIN D-3; CATHELICIDIN LL-37; ATOPIC-DERMATITIS; ALPHA-DEFENSINS; POTENTIAL ROLE; CUTTING EDGE; HOST-DEFENSE	Our skin is constantly challenged by microbes but is rarely infected. Cutaneous production of antimicrobial peptides (AMPS) is a primary system for protection, and expression of some AMPS further increases in response to microbial invasion. Cathelicidins are unique AMPS that protect the skin through 2 distinct pathways: (1) direct antimicrobial activity and (2) initiation of a host response resulting in cytokine release, inflammation, angiogenesis, and reepithelialization. Cathelicidin dysfunction emerges as a central factor in the pathogenesis of several cutaneous diseases, including atopic dermatitis, in which cathelicidin is suppressed; rosacea, in which cathelicidin peptides are abnormally processed to forms that induce inflammation; and psoriasis, in which cathelicidin peptide converts self-DNA to a potent stimulus in an autoinflammatory cascade. Recent work identified vitamin D3 as a major factor involved in the regulation of cathelicidin. Therapies targeting control of cathelicidin and other AMPS might provide new approaches in the management of infectious and inflammatory skin diseases.	[Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; [Schauber, Juergen] Univ Munich, Dept Dermatol & Allergol, Munich, Germany; [Gallo, Richard L.] VASDHS, San Diego, CA USA	University of California System; University of California San Diego; University of Munich	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, 3350 La Jolla Village Dr,Mail Code 151, San Diego, CA 92161 USA.	rgallo@ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NIAID NIH HHS [R01 AI052453, R37 AI052453, R01 AI052453-07] Funding Source: Medline; NIAMS NIH HHS [R01 AR052728-04, R01 AR052728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Allain TJ, 2003, GERONTOLOGY, V49, P273, DOI 10.1159/000071707; Allaker RP, 1999, FEMS IMMUNOL MED MIC, V23, P289, DOI 10.1016/S0928-8244(98)00148-5; Bikle DD, 2007, CURR OPIN RHEUMATOL, V19, P383, DOI 10.1097/BOR.0b013e32818e9d58; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P347, DOI 10.1016/j.jsbmb.2004.03.113; Bikle DD, 2004, J CELL BIOCHEM, V92, P436, DOI 10.1002/jcb.20095; BIKLE DD, 1989, ENDOCRINOLOGY, V124, P655, DOI 10.1210/endo-124-2-655; Blankenvoorde MFJ, 1998, BIOL CHEM, V379, P1371; Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; Braff MH, 2005, J INVEST DERMATOL, V125, P9, DOI 10.1111/j.0022-202X.2004.23587.x; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Braff MH, 2005, INFECT IMMUN, V73, P6771, DOI 10.1128/IAI.73.10.6771-6781.2005; Buechau AS, 2007, J INVEST DERMATOL, V127, P2596, DOI 10.1038/sj.jid.5700946; Caccavo D, 2002, J ENDOTOXIN RES, V8, P403, DOI 10.1179/096805102125001000; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Cumberbatch M, 2000, IMMUNOLOGY, V100, P21, DOI 10.1046/j.1365-2567.2000.00014.x; Cutuli M, 2000, J LEUKOCYTE BIOL, V67, P233, DOI 10.1002/jlb.67.2.233; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Di Nardo A, 2007, J IMMUNOL, V178, P1829, DOI 10.4049/jimmunol.178.3.1829; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Jansen T, 2004, J DERMATOL, V31, P244, DOI 10.1111/j.1346-8138.2004.tb00665.x; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kowalska K, 2002, LIFE SCI, V71, P747, DOI 10.1016/S0024-3205(02)01740-X; Lambert RW, 2002, NEUROPEPTIDES, V36, P246, DOI 10.1016/S0143-4179(02)00020-3; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P416, DOI 10.1016/j.jaad.2002.12.002; LEE DY, 2008, J INVEST DERMATOL, V17, P17; Lehmann B, 2001, J INVEST DERMATOL, V117, P1179, DOI 10.1046/j.0022-202x.2001.01538.x; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lopez-Garcia B, 2005, J INVEST DERMATOL, V125, P108, DOI 10.1111/j.0022-202X.2005.23713.x; Marchini G, 2002, BRIT J DERMATOL, V147, P1127, DOI 10.1046/j.1365-2133.2002.05014.x; Meyer-Hoffert U, 2003, EXP DERMATOL, V12, P418, DOI 10.1034/j.1600-0625.2002.120409.x; Moan J, 2008, P NATL ACAD SCI USA, V105, P668, DOI 10.1073/pnas.0710615105; Murakami M, 2005, PEDIATR RES, V57, P10, DOI 10.1203/01.PDR.0000148068.32201.50; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Niyonsaba F, 2005, J IMMUNOL, V175, P1776, DOI 10.4049/jimmunol.175.3.1776; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2007, J INVEST DERMATOL, V127, P594, DOI 10.1038/sj.jid.5700599; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Oda Y, 2004, J STEROID BIOCHEM, V89-90, P273, DOI 10.1016/j.jsbmb.2004.03.106; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; RADEK KA, 2008, J INVEST DERMAT 0110; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; Schauber J, 2008, J INVEST DERMATOL, V128, P816, DOI 10.1038/sj.jid.5701102; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schauber J, 2007, J INVEST DERMATOL, V127, P510, DOI 10.1038/sj.jid.5700761; Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Takahashi M, 2004, EXP DERMATOL, V13, P55, DOI 10.1111/j.0906-6705.2004.00116.x; Tang YQ, 2002, INFECT IMMUN, V70, P6524, DOI 10.1128/IAI.70.12.6524-6533.2002; Tasiemski A, 2002, BLOOD, V100, P553, DOI 10.1182/blood.V100.2.553; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Yamasaki K, 2007, NAT MED, V13, P975, DOI 10.1038/nm1616; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com; Yang D, 2001, J LEUKOCYTE BIOL, V69, P691; Yim S, 2007, J CYST FIBROS, V6, P403, DOI 10.1016/j.jcf.2007.03.003; Yu J, 2007, J IMMUNOL, V179, P7684, DOI 10.4049/jimmunol.179.11.7684; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zheng Y, 2007, BRIT J DERMATOL, V157, P1124, DOI 10.1111/j.1365-2133.2007.08196.x	87	231	254	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					261	266		10.1016/j.jaci.2008.03.027	http://dx.doi.org/10.1016/j.jaci.2008.03.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18439663	Green Accepted			2022-12-18	WOS:000258426300007
J	Burney, P; Malmberg, E; Chinn, S; Jarvis, D; Luczynska, C; Lai, E				Burney, P; Malmberg, E; Chinn, S; Jarvis, D; Luczynska, C; Lai, E			The distribution of total and specific serum IgE in the European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						serum IgE; prevalence; Dermatophagoides pteronyssinus; grass; cat; Cladosporium herbarum; birch; ragweed; Parietaria judaica	ASTHMA; ASSOCIATION; REACTIVITY; POPULATION; ALLERGENS; SMOKING; AGE	Background: Variations in the prevalence of atopy could provide important clues to the etiology of atopy and asthma, Although estimates of prevalence are available from different studies, a lack of standardization makes comparisons difficult. Objective: This study was conducted to estimate the variation of geometric mean levels of serum IgE and the prevalence of specific IgE to common allergens between populations as part of the European Community Respiratory Health Survey (ECRHS), a multicenter survey of asthma and risk factors for asthma. Methods: Random samples of subjects living in 37 centers in 16 countries who had answered a questionnaire about their respiratory symptoms were invited for further assessment including total serum IgE and the presence of specific IgE against house dust mite (Dermatophagoides pteronyssinus), timothy grass, cat, Cladosporium herbarum, and a local allergen. Sera were tested from 13,883 persons. Results: The estimated prevalence of atopy, defined as the presence of at least one positive specific IgE, ranged from 16% in Albacete (Spain) to 45% in Christchurch (New Zealand). The geometric mean total serum IgE varied from 13 kU/L in Reykjavik (Iceland) to 62 kU/L in Bordeaux (France). There was no relation between the geometric mean total serum IgE in a center and the prevalence of atopy. Conclusions: There are substantial variations in the prevalence of atopy and the level of serum IgE. These variations are independent of each other and likely to he largely environmental in origin.			Burney, P (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND.		Jarvis, Deborah/E-6494-2011; SESM, SESM/C-1440-2008	Burney, Peter/0000-0001-8635-5678; Jarvis, Deborah/0000-0002-1753-3896	NCRR NIH HHS [2S07 RR05521-28] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P377; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COOKSON WOCM, 1988, LANCET, V1, P86; *EUR COMM RESP HLT, 1996, EUR RESPIR J, V9, P687; *EUR COMM RESP HLT, 1993, EUR COMM RESP HLTH S, V13, pL2920; FREIDHOFF LR, 1986, INT ARCH ALLER A IMM, V79, P188, DOI 10.1159/000233969; Gassner M, 1992, Schweiz Rundsch Med Prax, V81, P426; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; HAAHTELA T, 1982, ALLERGY, V37, P597, DOI 10.1111/j.1398-9995.1982.tb02346.x; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; SCHULTZLARSEN F, 1993, EPIDEMIOLOGY CLIN AL, P9; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; SNEDECOR GW, 1982, STAT METHODS, P30; SPECTOR SL, 1976, CLIN ALLERGY, V6, P83, DOI 10.1111/j.1365-2222.1976.tb01416.x; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; 1986, VITAL HLTH STAT, V11	25	231	233	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					314	322		10.1016/S0091-6749(97)70048-4	http://dx.doi.org/10.1016/S0091-6749(97)70048-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058686	Bronze			2022-12-18	WOS:A1997WM42200007
J	WHITE, MV				WHITE, MV			THE ROLE OF HISTAMINE IN ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM							WHITE, MV (corresponding author), NIAID,RM 11C207,BLDG 10,BETHESDA,MD 20892, USA.							Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; DRUCE HM, 1988, JAMA-J AM MED ASSOC, V259, P260, DOI 10.1001/jama.259.2.260; KALINER M, 1985, CHEST, V87, pS2, DOI 10.1378/chest.87.1_Supplement.2S; KALINER MA, 1987, FUNDAMENTALS IMMUNOL, P203; KAPLAN AP, 1988, ALLERGY PRINCIPLES P, P1377; MULLOL J, 1990, Journal of Allergy and Clinical Immunology, V85, P224; ORANGE RP, 1972, BIOL ROLE IMMUNOGLOB; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; WHITE MV, 1987, AM REV RESPIR DIS, V135, P1165; WHITE MV, 1989, BIOCH ACUTE ALLERGIC, P83; WHITE MV, IN PRESS LUNG SCI F	13	231	237	0	21	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			599	605		10.1016/S0091-6749(05)80223-4	http://dx.doi.org/10.1016/S0091-6749(05)80223-4			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	1699987				2022-12-18	WOS:A1990EH09300004
J	RAK, S; LOWHAGEN, O; VENGE, P				RAK, S; LOWHAGEN, O; VENGE, P			THE EFFECT OF IMMUNOTHERAPY ON BRONCHIAL HYPERRESPONSIVENESS AND EOSINOPHIL CATIONIC PROTEIN IN POLLEN-ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CENT HOSP VASTERAS, DEPT LUNG MED, VASTERAS, SWEDEN; GOTHENBURG UNIV, CTR ASTHMA & ALLERGY, S-41124 GOTHENBURG, SWEDEN; UNIV HOSP UPPSALA, DEPT CLIN CHEM, UPPSALA, SWEDEN	Vasteras Central Hospital; University of Gothenburg; Uppsala University; Uppsala University Hospital								AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DREBORG S, 1985, ALLERGY S4, V40, P55; DREBORG S, 1986, IMMUNOCHEMISTRY, V1, P1; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; FINK JN, 1985, J ALLERGY CLIN IMMUN, V76, P402, DOI 10.1016/0091-6749(85)90662-1; FORMGREN H, 1985, ANN ALLERGY, V55, P312; FRANKLAND AW, 1954, LANCET, V1, P1055; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GRANT IWB, 1986, CLIN ALLERGY, V16, P7, DOI 10.1111/j.1365-2222.1986.tb01947.x; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; HOLGATE ST, 1985, CLIN ALLERGY, V15, P221, DOI 10.1111/j.1365-2222.1985.tb02279.x; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; LICHTENSTEIN LM, 1984, AM REV RESPIR DIS, V129, P657, DOI 10.1164/arrd.1984.129.5.657; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P343, DOI 10.1016/0091-6749(85)90070-3; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; LOWHAGEN O, UNPUB NONSPECIFIC BR; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MOLLER C, 1986, THESIS U UMEA UMEA; MURRAY AB, 1985, ANN ALLERGY, V54, P541; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V75, P531, DOI 10.1016/0091-6749(85)90024-7; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1985, THESIS COPENHAGEN U; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENGE P, 1988, IN PRESS P TRANSATLA; WARNER JD, 1984, LANCET, V2, P912	46	231	234	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				470	480		10.1016/0091-6749(88)90021-8	http://dx.doi.org/10.1016/0091-6749(88)90021-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170995				2022-12-18	WOS:A1988Q322900022
J	ANDERSON, SD				ANDERSON, SD			IS THERE A UNIFYING HYPOTHESIS FOR EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ANDERSON, SD (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,CAMPERDOWN,NSW 2050,AUSTRALIA.			Anderson, Sandra/0000-0002-6308-8770				ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1983, ALLERGY, V38, P289, DOI 10.1111/j.1398-9995.1983.tb04122.x; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P472; ANDERSON SD, 1983, AM REV RESPIR DIS, V127, P228; ANDERSON SD, AM REV RESPIR DIS; ANDERSON SD, 1983, ASTHMATIC CHILD PLAY, P145; BENDOV I, 1982, AM REV RESPIR DIS, V125, P530, DOI 10.1164/arrd.1982.125.5.530; BLACK JL, AM REV RESPIR DIS; BORLAND C, 1983, THORAX, V38, P221; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; CADE JF, 1972, CLIN SCI, V43, P759, DOI 10.1042/cs0430759; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; EDMONDS AT, 1978, AM REV RESPIR DIS, V117, P247; ELWOOD RK, 1982, AM REV RESPIR DIS, V125, P61; FERRUS L, 1980, RESP PHYSIOL, V39, P367, DOI 10.1016/0034-5687(80)90067-5; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; HAHN AG, THORAX; INGELSTEDT S, 1956, Acta Otolaryngol Suppl, V131, P1; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MALIK SK, 1972, CHEST, V62, P660, DOI 10.1378/chest.62.6.660; MCFADDEN ER, 1982, J CLIN INVEST, V69, P700, DOI 10.1172/JCI110498; MENZIES IS, 1974, BIOCHEM SOC T, V2, P1042, DOI 10.1042/bst0021042; MITCHELL JW, 1972, J APPL PHYSIOL, V32, P474, DOI 10.1152/jappl.1972.32.4.474; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; RESNICK AD, 1979, J CLIN INVEST, V64, P541, DOI 10.1172/JCI109492; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SHAW R, 1983, AUST NZ J MED, V13, P541; SHAW R, UNPUB MEDIATORS HYPE; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; Weibel ER, 1964, HDB PHYSIOLOGY RES 3, V1, P285; WEINSTEIN RE, 1976, J ALLERGY CLIN IMMUN, V57, P250	43	231	233	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					660	665		10.1016/0091-6749(84)90301-4	http://dx.doi.org/10.1016/0091-6749(84)90301-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715730	Bronze			2022-12-18	WOS:A1984SS04600008
J	Mosen, DM; Schatz, M; Magid, DJ; Carnargo, CA				Mosen, David M.; Schatz, Michael; Magid, David J.; Carnargo, Carlos A., Jr.			The relationship between obesity and asthma severity and control in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; quality of life; obesity; hospitalization; inhaled; corticosleroids	BODY-MASS INDEX; HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; WEIGHT-REDUCTION; ASSOCIATION; PREVALENCE; OVERWEIGHT; TRENDS	Background: The association of obesity with asthma outcomes is not well understood. Objective: The objective of this study was to examine the association of obesity, as represented by a body mass index (BMI) of greater than 30 kg/m(2), with quality-of-life scores, asthma control problems, and asthma-related hospitalizations. Methods: The study followed a cross-sectional design. Questionnaires were completed at home by a random sample of 1113 members of a large integrated health care organization who were 35 years of age or older with health care use suggestive of active asthma. Outcomes included the mini-Asthma Quality of Life Questionnaire, the Asthma Therapy Assessment Questionnaire, and self-reported asthma-related hospitalization. Several other factors known to influence asthma outcomes also were collected: demographics, smoking status, oral corticosteroid use in the past month, evidence of gastroesophageal reflux disease, and inhaled corticosteroid use in the past month. Multiple logistic regression models were used to measure the association of BMI status with outcomes. Results: Even after adjusting for demographics, smoking status, oral corticosteroid use, evidence of gastroesophageal reflux disease, and inhaled corticosteroid use, obese adults were more likely than those with normal BMIs (<25 k g/m(2)) to report poor asthma-specific quality of life (odds ratio [OR], 2.8; 95% Cl, 1.6-4.9), poor asthma control (OR, 2.7; 95% Cl, 1.7-4.3), and a history of asthma-related hospitalizations (OR, 4.6; 95% Cl, 1.4-14.4). Conclusions: Our findings suggest that obesity is associated with worse asthma outcomes, especially an increased risk of asthma related hospitalizations.	[Schatz, Michael] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Magid, David J.] Kaiser Permanente, Clin Res Unit, Denver, CO USA; [Carnargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Mosen, David M.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA	Kaiser Permanente; Kaiser Permanente; Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaiser Permanente	Mosen, DM (corresponding author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR USA.	david.m.mosen@kpchr.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health; Research Foundations; AstraZeneca; Critical Therapeutics; GlaxoSmithKline; Merck; Novartis; Respironics	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Foundations; AstraZeneca(AstraZeneca); Critical Therapeutics; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Novartis(Novartis); Respironics	M. Schatz has consulting arrangements with GlaxoSmithKline and has received research support from GlaxoSmithKline and Merck. C. A. Camargo has consulting arrangements with AstraZeneca, Novartis, and Critical Therapeutics; is on the advisory board for Dey, Genentech. GlaxoSmithKline. Merck, Novartis, and Schering-Plough: is on the speakers bureau for AstraZeneca, GlaxoSmithKline, and Merck: and has received research support from the National Institutes of Health, Research Foundations. AstraZeneca. Critical Therapeutics. GlaxoSmithKline. Merck. Novartis. and Respironics. The rest of the authors have declared that they have no conflict of interest.	Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; MACGREGOR AMC, 1993, OBES SURG, V3, P15, DOI 10.1381/096089293765559700; Mosen DM, 2007, J AMBUL CARE MANAG, V30, P21, DOI 10.1097/00004479-200701000-00005; Nyholm M, 2007, OBESITY, V15, P197, DOI 10.1038/oby.2007.536; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Peters SP, 2003, AM J MED, V115, p49S, DOI 10.1016/S0002-9343(03)00193-1; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Schatz M, 2007, J ASTHMA, V44, P341, DOI 10.1080/02770900701344421; Schatz M, 2007, QUAL LIFE RES, V16, P345, DOI 10.1007/s11136-006-9103-2; SCHILLER JS, 2004, VITAL HLTH STAT 10, V220, P1; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835	27	230	239	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					507	511		10.1016/j.jaci.2008.06.024	http://dx.doi.org/10.1016/j.jaci.2008.06.024			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774387	Bronze			2022-12-18	WOS:000259234000010
J	Stevenson, DD; Szczeklik, A				Stevenson, Donald D.; Szczeklik, Andrew			Clinical and pathologic perspectives on aspirin sensitivity and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						aspirin; nonsteroidal anti-inflammatory drugs; asthma; nasal polyps; chronic hyperplastic eosinophilic sinusitis; aspirin-exacerbated respiratory disease; aspirin desensitization	LEUKOTRIENE C-4 SYNTHASE; DIESEL EXHAUST PARTICLES; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NASAL PROVOCATION TEST; ASA-INTOLERANT ASTHMA; ADVERSE-REACTIONS; BRONCHIAL-ASTHMA; INDUCED BRONCHOCONSTRICTION; CYCLOOXYGENASE-2 INHIBITOR; URINARY LEUKOTRIENE-E4	Aspirin and other nonsteroidal anti-inflammatory drugs that inhibit COX-1 induce unique nonallergic reactions, consisting of attacks of rhinitis and asthma. These hypersensitivity reactions occur in a subset of asthmatic subjects, thus identifying them as having this exclusive clinical presentation. We refer to these patients as having aspirin-exacerbated respiratory disease, a disease process that produces devastating eosinophilic inflammation of both the upper and lower respiratory tracts. This review focuses on a description of patients with aspirin-exacerbated respiratory disease, methods available to diagnose their condition, the unique ability of all nonsteroidal anti-inflammatory drugs that inhibit COX-1 to cross-react with aspirin, an update on pathogenesis, and current thoughts about treatment.	Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; Scripps Clin, Dept Med, La Jolla, CA USA; Scripps Res Inst, La Jolla, CA USA; Jagiellonian Univ, Sch Med, Dept Med, PL-31007 Krakow, Poland	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Jagiellonian University	Stevenson, DD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dstevemd@AOL.com; donald@scrippshealth.org						Alonso-Llamazares A, 2002, ALLERGY, V57, P632, DOI 10.1034/j.1398-9995.2002.t01-1-13447.x; Amar YG, 2000, J OTOLARYNGOL, V29, P7; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Asero R, 2000, ALLERGY, V55, P893, DOI 10.1034/j.1398-9995.2000.00698.x; Bachert C, 1998, ALLERGY, V53, P2, DOI 10.1111/j.1398-9995.1998.tb03767.x; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 1999, ACI INT, V11, P130; Baldassarre S, 2006, J ALLERGY CLIN IMMUN, V117, P215, DOI 10.1016/j.jaci.2005.10.021; Bavbek S, 1999, J ASTHMA, V36, P657, DOI 10.3109/02770909909055417; Bavbek S, 2004, J ASTHMA, V41, P67, DOI 10.1081/JAS-120026063; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; BERGESGIMENO M, 2003, ANN ALLERG ASTHMA IM, V90, P1; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Brune K, 2004, ARTHRITIS RHEUM-US, V50, P2391, DOI 10.1002/art.20424; Choi JH, 2004, J ALLERGY CLIN IMMUN, V113, P562, DOI 10.1016/j.jaci.2003.12.012; Choi JH, 2004, HUM GENET, V114, P337, DOI 10.1007/s00439-004-1082-1; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; DAHLEN B, 1990, EUR RESPIR J, V3, P527; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; DAHLEN SE, 1995, AM J RESP CRIT CARE, V151, P376; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; Finkelman FD, 2004, J IMMUNOL, V172, P3808, DOI 10.4049/jimmunol.172.6.3808; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gamboa P, 2004, CLIN EXP ALLERGY, V34, P1448, DOI 10.1111/j.1365-2222.2004.02050.x; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hawley C., 1999, LANCET, V353, P307; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Jinnai N, 2004, HUM MOL GENET, V13, P3203, DOI 10.1093/hmg/ddh332; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; JOHNSTONE RAW, 1959, CHEM REV, V59, P885, DOI 10.1021/cr50029a004; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kasper L, 2003, ALLERGY, V58, P1064, DOI 10.1034/j.1398-9995.2003.00267.x; Kaur C, 2001, DERMATOLOGY, V203, P351, DOI 10.1159/000051790; Kedda MA, 2005, CLIN EXP ALLERGY, V35, P332, DOI 10.1111/j.1365-2222.2005.02188.x; Kennedy D W, 1992, Laryngoscope, V102, P1; Kim SH, 2005, ALLERGY, V60, P760, DOI 10.1111/j.1398-9995.2005.00780.x; Kowalski ML, 1996, CLIN EXP ALLERGY, V26, P807, DOI 10.1046/j.1365-2222.1996.d01-371.x; KOWALSKI ML, 1993, J ALLERGY CLIN IMMUN, V91, P580, DOI 10.1016/0091-6749(93)90264-G; Kowalski ML, 2003, J ALLERGY CLIN IMMUN, V112, P505, DOI 10.1067/mai.2003.1678; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy MB, 2001, ANN ALLERG ASTHMA IM, V87, P72, DOI 10.1016/S1081-1206(10)62327-7; Martin-Garcia C, 2002, CHEST, V121, P1812, DOI 10.1378/chest.121.6.1812; Mastalerz L, 2002, EUR J CLIN INVEST, V32, P949, DOI 10.1046/j.1365-2362.2002.01088.x; Mastalerz L, 2002, CLIN EXP ALLERGY, V32, P1360, DOI 10.1046/j.1365-2745.2002.01484.x; Mastalerz L, 1997, ALLERGY, V52, P895, DOI 10.1111/j.1398-9995.1997.tb01248.x; Mastalerz L, 2006, J ALLERGY CLIN IMMUN, V118, P957, DOI 10.1016/j.jaci.2006.06.028; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MATHISON DA, 1983, IMMUNOL ALLERGY PRAC, V5, P340; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; McFadden EA, 1997, AM J RHINOL, V11, P263, DOI 10.2500/105065897781446702; MELILLO G, 1993, ANN ALLERGY, V71, P61; Melillo G, 2001, ALLERGY, V56, P899, DOI 10.1034/j.1398-9995.2001.00025.x; MICHELETTO C, 2006, RESP MED; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581, DOI 10.1016/S0091-6749(98)70163-0; Mita H, 2001, ALLERGY, V56, P1061; Monneret G, 2003, J PHARMACOL EXP THER, V304, P349, DOI 10.1124/jpet.102.042937; Morais-Almeida M, 2006, ALLERGY, V61, P144, DOI 10.1111/j.1398-9995.2005.00878.x; NASSER MS, 2002, CLIN EXP ALLERGY, V32, P1540; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; Park HS, 2004, J ALLERGY CLIN IMMUN, V114, P688, DOI 10.1016/j.jaci.2004.05.051; Passero M, 2003, CHEST, V123, P2155, DOI 10.1378/chest.123.6.2155; PAWLOWICZ A, 1991, ALLERGY, V46, P405, DOI 10.1111/j.1398-9995.1991.tb04218.x; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; Powell WS, 2003, PROSTAG LEUKOTR ESS, V69, P179, DOI 10.1016/S0952-3278(03)00079-6; Pujols L, 2004, J ALLERGY CLIN IMMUN, V114, P814, DOI 10.1016/j.jaci.2004.07.050; Quaratino D, 2000, ANN ALLERG ASTHMA IM, V84, P613, DOI 10.1016/S1081-1206(10)62412-X; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; Rordorf CM, 2005, CLIN PHARMACOKINET, V44, P1247, DOI 10.2165/00003088-200544120-00004; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Sanak M, 2001, J ALLERGY CLIN IMMUN, V107, P561, DOI 10.1067/mai.2001.112853; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Schafer D, 1999, EUR RESPIR J, V13, P638, DOI 10.1183/09031936.99.13363899; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; SMITH CM, 1992, EUR RESPIR J, V5, P693; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; STEVENSON DD, 1990, J ALLERGY CLIN IMMUN, V86, P749, DOI 10.1016/S0091-6749(05)80179-4; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2001, IMMUNOL ALLERGY CLIN, V21, P745; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; STEVENSON DD, 2003, ALLERGY PRINCIPLES P, P1695; Stevenson DD, 1984, N ENGL REG ALLERGY P, V5, P111; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; SZCZEKLIK A, 1987, ANN ALLERGY, V59, P113; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1995, LANCET, V345, P1056, DOI 10.1016/S0140-6736(95)90799-8; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; VAGHI A, 1998, J RESP CRIT CARE MED, V157, P715; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; Viola M, 2006, J ALLERGY CLIN IMMUN, V117, P1189, DOI 10.1016/j.jaci.2006.02.011; Warner TD, 1999, P NATL ACAD SCI USA, V96, P9966; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; WHITE AA, 2006, IN PRESS ANN ALLERGY; Widal M, 1922, PRESSE MED, V30, P189; WJST M, 1994, ALLERGY, V49, P766, DOI 10.1111/j.1398-9995.1994.tb02100.x; Woessner KM, 2003, CLIN REV ALLERG IMMU, V24, P149, DOI 10.1385/CRIAI:24:2:149; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426; WOESSNER KW, 2004, ANN ALLERG ASTHMA IM, V93, P1; Yamashita T, 1989, Rhinol Suppl, V8, P15; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201, DOI 10.1067/mai.2000.110926; Ziroli NE, 2002, OTOLARYNG HEAD NECK, V126, P141, DOI 10.1067/mhn.2002.121913	146	230	247	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					773	786		10.1016/j.jaci.2006.07.024	http://dx.doi.org/10.1016/j.jaci.2006.07.024			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030227	Green Submitted			2022-12-18	WOS:000241434200001
J	Mittag, D; Akkerdaas, J; Ballmer-Weber, BK; Vogel, L; Wenising, M; Becker, WM; Koppelman, SJ; Knulst, AC; Helbling, A; Hefle, SL; van Ree, R; Vieths, S				Mittag, D; Akkerdaas, J; Ballmer-Weber, BK; Vogel, L; Wenising, M; Becker, WM; Koppelman, SJ; Knulst, AC; Helbling, A; Hefle, SL; van Ree, R; Vieths, S			Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; double-blind; placebo-controlled food challenge; Ara h 8; oral allergy syndrome; birch pollen-related food allergy; legumes; Gly m 4; recombinant allergen; diagnosis	TREE NUT ALLERGY; CONTROLLED FOOD CHALLENGE; DIAL TELEPHONE SURVEY; ARA-H-I; CROSS-REACTIVITY; HISTAMINE-RELEASE; ATOPIC-DERMATITIS; HUMAN BASOPHILS; CELERY ALLERGY; PHAGE DISPLAY	Background: We recently described patients with soybean allergy mainly mediated by cross-reactivity to birch pollen allergens. A majority of those patients were reported to have peanut allergy. Objective: We sought to study the occurrence of peanut allergy in patients allergic to birch pollen and characterized the Bet v 1-homologous peanut allergen Ara h 8. Methods: Recombinant Ara h 8 was cloned with degenerated primers and expressed in Escherichia coli. Nine Swiss and 11 Dutch patients with peanut and birch pollen allergy and a positive double-blind, placebo-controlled food challenge result to peanut were investigated for IgE reactivity to birch pollen and purified peanut allergens and cross-reactivity between birch and peanut. Ara h 8 stability against digestion and roasting was assessed by means of RAST inhibition. The IgE cross-linking potency of Ara h 8 was tested on the basis of basophil histamine release. Results: During double-blind, placebo-controlled food challenge, all patients experienced symptoms in the oral cavity, progressing to more severe symptoms in 40% of patients. CAP-FEIA detected recombinant (r) Ara h 8-specific IgE in 85%. IgE binding to Ara h 8 was inhibited by Bet v I in peanut extract immunoblotting and in RAST inhibition. In EAST inhibition recombinant rAra h 8 inhibited IgE binding to peanut in 4 of 7 tested patient sera. Antipeanut response was dominated by Ara It 8 in 12 of 17 tested patients. Furthermore, our results demonstrate a low stability of Ara h 8 to roasting and no stability to gastric digestion. Basophil histamine release with rAra It 8 was more than 20% in 5 of 7 tested sera. Conclusions: Peanut allergy might be mediated in a subgroup of our patients by means of cross-reaction of Bet v I with the homologous peanut allergen Ara h 8.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Dept Immunopathol, Amsterdam, Netherlands; Univ Med Ctr, Dept Dermatol Allerogol, Utrecht, Netherlands; Res Ctr, Borstel, Germany; TNO, Nutr & Food Res, NL-3700 AJ Zeist, Netherlands; Inselspital Bern, Div Allergol, Dept Rheumatol, Bern, Switzerland; Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital; Utrecht University; Utrecht University Medical Center; Forschungszentrum Borstel; Netherlands Organization Applied Science Research; University of Bern; University Hospital of Bern; University of Nebraska System; University of Nebraska Lincoln	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany.	viest@pei.de						AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Budde IK, 2000, ALLERGY, V55, P653; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Kleber-Janke T, 2001, J CHROMATOGR B, V756, P295, DOI 10.1016/S0378-4347(01)00088-3; KLEINE BI, 2001, INT ARCH ALLERGY IMM, V126, P277; KNOL EF, 1993, J IMMUNOL, V151, P4926; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Koppelman SJ, 2003, ALLERGY, V58, P1144, DOI 10.1034/j.1398-9995.2003.00259.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; PASMANS SGMA, 1994, INT ARCH ALLERGY IMM, V103, P44, DOI 10.1159/000236604; Pons L, 2002, ALLERGY, V57, P88, DOI 10.1034/j.1398-9995.57.s72.16.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350, DOI 10.1016/S1081-1206(10)62363-0; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	49	230	245	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1410	1417		10.1016/j.jaci.2004.09.014	http://dx.doi.org/10.1016/j.jaci.2004.09.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577846				2022-12-18	WOS:000225577400025
J	Strait, RT; Morris, SC; Yang, MY; Qu, XW; Finkelman, FD				Strait, RT; Morris, SC; Yang, MY; Qu, XW; Finkelman, FD			Pathways of anaphylaxis in the mouse	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; mast cell; macrophage; allergy; histamine; platelet-activating factor; Fc receptors	MAST-CELL-DEFICIENT; MURINE IMMUNE-SYSTEM; FC-EPSILON-RI; IN-VIVO; INDUCED THROMBOCYTOPENIA; CARDIOPULMONARY CHANGES; POLYCLONAL ACTIVATION; GOAT ANTIBODY; UP-REGULATION; GAMMA-RIII	Background: Although anaphylaxis is classically mediated by IgE, FcepsilonRI, mast cells, and histamine, several rodent studies suggest that an alternative pathway involving IgG, FcgammaRIII, macrophages and platelets, and platelet-activating factor (PAF) may be more important in the anaphylactic response to antigen challenge. Objectives: We sought to determine the relative roles of the classical and alternative pathways of anaphylaxis in a mouse model characterized by mastocytosis and a high level of antigen-specific IgE antibody. Methods: Wild-type, IgE-deficient, FeepsilonRI-deficient, and mast cell-deficient mice were immunized with goat anti-mouse IgD antibody, which induces mastocytosis and a large IgE and IgG anti-goat IgG response, and then challenged 14 days later with antigen (goat IgG) or rat anti-mouse IgE mAb. Specific vasoactive mediators, cell types, Ig isotypes. or Ig receptors were blocked or eliminated before challenge in some experiments. The severity of anaphylaxis was gauged by changes in body, temperature. physical activity, and mortality. Results: Equal doses of antigen or anti-IgE mAb induced similar anaphylactic responses. Anti-IgE mAb-induced anaphylaxis was FcepsilonRI and mast cell dependent and mediated predominantly by histamine, In contrast, neither mast cells nor platelets appeared important for antigen-induced anaphylaxis which was FcgammaRIII and macrophage dependent and mediated predominantly by PAF. Conclusions: Antigen-induced anaphylaxis in the mouse proceeds primarily through the IgG, FcgammaRIII. macrophage, and RAF pathway, even in an experimental model that is characterized by strong mast cell and IgE responses. The presence of FcgammaRIII on human macrophages makes it possible that the IgG, FcgammaRIII, macrophage, and PAF pathway also contributes to human anaphylaxis.	Vet Adm Med Ctr, Res Serv 151, Cincinnati, OH 45220 USA; Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Div Immunol, Dept Internal Med, Cincinnati, OH USA; Northwestern Univ, Sch Med, Dept Pathol, Childrens Mem Med Ctr, Chicago, IL 60611 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Northwestern University	Finkelman, FD (corresponding author), Vet Adm Med Ctr, Res Serv 151, 3200 Vine St, Cincinnati, OH 45220 USA.		Li, Yapeng/N-1042-2017	Li, Yapeng/0000-0002-5042-6881	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050006, R01AI045766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR044059] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45766, KO8 AI50006] Funding Source: Medline; NIAMS NIH HHS [P60-AR-44059] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIMURA A, 1990, EXPERIENTIA, V46, P739, DOI 10.1007/BF01939952; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Bruschi F, 1999, INT ARCH ALLERGY IMM, V119, P291, DOI 10.1159/000024206; BURKS AW, 1997, CLIN REV ALLERG IMMU, V17, P339; Choi IH, 1998, J EXP MED, V188, P1587, DOI 10.1084/jem.188.9.1587; CSABA B, 1971, ACTA PHYSIOL HUNG, V39, P369; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1995, J EXP MED, V181, P515, DOI 10.1084/jem.181.2.515; FINKELMAN FD, 1982, J IMMUNOL, V129, P638; FINKELMAN FD, 1981, J IMMUNOL, V126, P680; Gueant J.-L., 1998, Clinical and Experimental Allergy, V28, P65; HA TY, 1987, EXP CELL BIOL, V55, P63; HALPERN BN, 1963, BRIT J PHARM CHEMOTH, V20, P389, DOI 10.1111/j.1476-5381.1963.tb01477.x; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Kato Y, 1998, BIOCHEM BIOPH RES CO, V242, P250, DOI 10.1006/bbrc.1997.7917; Kimura S, 1997, CELL MOL LIFE SCI, V53, P663, DOI 10.1007/s000180050085; KITAMURA Y, 1978, BLOOD, V52, P447; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; LAZAR JG, 1994, PCR METH APPL, V4, P1; Lei HY, 1996, INT ARCH ALLERGY IMM, V109, P407, DOI 10.1159/000237270; LEIR SH, 1995, CLIN EXP ALLERGY, V25, P273, DOI 10.1111/j.1365-2222.1995.tb01040.x; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Miller HRP, 1999, BLOOD, V93, P3473, DOI 10.1182/blood.V93.10.3473.410k01_3473_3486; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mizgerd JP, 1996, J LEUKOCYTE BIOL, V59, P189, DOI 10.1002/jlb.59.2.189; MORRIS SC, 1994, J IMMUNOL, V152, P3777; MOURAD FH, 1995, GUT, V36, P553, DOI 10.1136/gut.36.4.553; OETTIGEN HC, 1994, NATURE, V340, P367; PINCKARD RN, 1977, J IMMUNOL, V119, P2185; QU X, 1996, PROSTAGLANDINS, V51, P246; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; STENBERG PE, 1991, J CELL PHYSIOL, V147, P7, DOI 10.1002/jcp.1041470103; SVETIC A, 1991, J IMMUNOL, V147, P2391; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VAZ NM, 1977, INT ARCH ALLER A IMM, V53, P545, DOI 10.1159/000231796; Wedi B, 1996, ARCH DERMATOL RES, V289, P21, DOI 10.1007/s004030050147; WIEDMEIER S, 1987, PEDIATR RES, V22, P22	48	230	236	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					658	668		10.1067/mai.2002.123302	http://dx.doi.org/10.1067/mai.2002.123302			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941316				2022-12-18	WOS:000175132600015
J	Roehr, CC; Reibel, S; Ziegert, M; Sommerfeld, C; Wahn, U; Niggemann, B				Roehr, CC; Reibel, S; Ziegert, M; Sommerfeld, C; Wahn, U; Niggemann, B			Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy patch test; children; food challenge; double-blind; placebo-controlled; food challenge; skin prick test; specific IgE; positive predictive value; cow's milk; hen's egg	COWS MILK ALLERGY; 1ST 3 YEARS; DOUBLE-BLIND; SKIN-PRICK; DIAGNOSTIC-ACCURACY; HYPERSENSITIVITY; INFANTS; PATHOGENESIS; REACTIVITY; TOLERANCE	Background: Atopic dermatitis is commonly associated with food allergy. In addition to skin prick tests (SPTs) and measurements of specific IgE levels, the atopy patch test (APT) has recently been introduced into the diagnostic procedure for food allergy. Objective: Our aim was to evaluate whether a combination of allergologic tests could improve the prognostic value of the individual tests for positive food challenge results. We hypothesized that the combination of a positive APT result plus proof of specific IgE, a positive SPT result, or both would render double-blind, placebo-controlled, food challenges unnecessary. Methods: One hundred seventy-three double-blind, placebo-controlled, food challenges were performed in 98 children (median age, 13 months) with atopic dermatitis. All children were subjected to SPTs, APTs, and determination of specific IgE. Sensitivity, specificity, and positive and negative predictive values were calculated. Results: Ninety-five (55%) of 173 oral provocations were assessed as positive. For evaluating suspected cow's milk (CM) allergy, the APT was the best single predictive test (positive predictive value [PPV], 95%), and the combination of a positive APT result with evidence of specific IgE or an APT result together with a positive skin prick test response optimized the PPV to 100%. For hen's egg (HE) allergy, the APT was also the best single predictive test (PPV, 94%). The combination of 2 or more tests did not exceed the APT's predictive value. In both CM and HE challenges, the predictability of oral challenges depended on the level of specific IgE. For wheat allergy, the APT proved to be the most reliable test, and the PPV of 94% could not be improved by a combination with other allergologic tests. Conclusion: The combination of positive APT results and measurement of levels of specific IgE (CRI, greater than or equal to0.35 kU/L; HE, greater than or equal to 17.5 kU/L) makes double-blind, placebo-controlled, food challenges superfluous for suspected CM and HE allergy.	Humboldt Univ, Univ Childrens Hosp Charite, Dept Pneumol & Immunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Niggemann, B (corresponding author), Humboldt Univ, Childrens Hosp Charite, Dept Paediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.			Roehr, Charles Christoph/0000-0001-7965-4637				AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; CRESPO JF, 1994, ALLERGY PROC, V15, P73, DOI 10.2500/108854194778703099; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Gordon BR, 1998, OTOLARYNG CLIN N AM, V31, P35, DOI 10.1016/S0030-6665(05)70028-1; HANIFIN JM, 1987, MONOGR ALLERGY, V21, P116; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Kekki OM, 1997, ALLERGY, V52, P755, DOI 10.1111/j.1398-9995.1997.tb01234.x; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; NORGAARD A, 1995, ALLERGY, V50, P636, DOI 10.1111/j.1398-9995.1995.tb02580.x; Reibel S, 2000, ALLERGY, V55, P940, DOI 10.1034/j.1398-9995.2000.00689.x; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Vanto T, 1999, ALLERGY, V54, P837, DOI 10.1034/j.1398-9995.1999.00134.x; Wistokat-Wulfing A, 1999, CLIN EXP ALLERGY, V29, P513; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	37	230	235	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					548	553		10.1067/mai.2001.112849	http://dx.doi.org/10.1067/mai.2001.112849			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240959	Bronze			2022-12-18	WOS:000167793300020
J	TAKENAKA, H; ZHANG, K; DIAZSANCHEZ, D; TSIEN, A; SAXON, A				TAKENAKA, H; ZHANG, K; DIAZSANCHEZ, D; TSIEN, A; SAXON, A			ENHANCED HUMAN IGE PRODUCTION RESULTS FROM EXPOSURE TO THE AROMATIC-HYDROCARBONS FROM DIESEL EXHAUST - DIRECT EFFECTS ON B-CELL IGE PRODUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HUMAN IGE; ALLERGIC AIRWAY DISEASE; DIESEL EXHAUST; AIR POLLUTION; HUMAN HUMORAL IMMUNE RESPONSE	NUCLEAR TRANSLOCATOR PROTEIN; ANTIBODY-PRODUCTION; AH RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN TCDD; ADJUVANT ACTIVITY; HUMORAL IMMUNITY; MICE; IMMUNOGLOBULIN; SUPPRESSION; STIMULATION	Epidemiologic and experimental studies suggest that air pollution, and particularly diesel exhaust particles (DEPs) may play a role in the increasing prevalence and severity of airway allergic disease. We show that the extract of polyaromatic hydrocarbons (PAHs) from DEPs (PAH-DEP) enhances human IgE production from purified B cells. Interleukin-4 plus CD40 monoclonal antibody-stimulated IgE production was enhanced 20% to 360% by the addition of PAH-DEP over a period of 10 to 14 days. This effect was ina eased when PAH-DEP was added 2 to 5 days after cultures were initiated. PAH-DEP itself did not induce IgE production or synergize with interleukin-4 alone to induce IgE from purified B cells, suggesting that it was enhancing ongoing IgE production rather than inducing germline transcription of isotype switching. The prototype nonmetabolized aromatic hydrocarbon 2,3,7,8 tetracholorodibenzo-p-dioxin, which functions solely through activation of the cytosolic aromatic hydrocarbon receptor complex, also increased IgE production. Additionally the pattern of mRNAs coding for distinct isoforms of the E chain was altered by PAH-DEP, and B-cell expression of the low-affinity IgE receptor was upregulated by PAH-DEP. Enhanced IgE production in the human airway, resulting from exposure to PAH-DEP, may be an important factor in the increase in airway allergic disease.	UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV CLIN IMMUNOL ALLERGY, HART & LOUISE LYON LAB, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIAID NIH HHS [AI-15251, AI-34567] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, R01AI015251, U19AI034567, U01AI034567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS GE, 1989, J AEROSOL SCI, V20, P1373, DOI 10.1016/0021-8502(89)90840-9; CLARK GC, 1991, MOL PHARMACOL, V39, P495; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; FINN R, 1992, LANCET, V340, P1453; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GORDON J, 1992, CLIN EXP ALLERGY, V22, P199, DOI 10.1111/j.1365-2222.1992.tb03073.x; HANKINSON O, 1991, BIOCHIMIE, V73, P61, DOI 10.1016/0300-9084(91)90075-C; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; HOLSAPPLE MP, 1984, J PHARMACOL EXP THER, V231, P518; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JABARA HH, 1990, J IMMUNOL, V145, P3468; JENSEN EJ, 1992, J ALLERGY CLIN IMMUN, V90, P224, DOI 10.1016/0091-6749(92)90075-D; KANEKO S, 1980, OTORHINOLARYNGOLO S4, V23, P270; KARENLAMPI SO, 1983, J BIOL CHEM, V258, P378; KITTELSON DB, 1984, AEROSOLS, P783; KRAMER CM, 1987, BIOCHEM BIOPH RES CO, V145, P25, DOI 10.1016/0006-291X(87)91282-4; LORENZEN A, 1991, TOXICOL APPL PHARM, V107, P203, DOI 10.1016/0041-008X(91)90203-Q; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MILLS GA, 1983, J I ENERGY, V56, P131; MORRIS DL, 1993, IMMUNOPHARMACOLOGY, V26, P105, DOI 10.1016/0162-3109(93)90002-8; MORRIS DL, 1991, IMMUNOPHARMACOLOGY, V21, P171, DOI 10.1016/0162-3109(91)90022-Q; MORRIS DL, 1991, IMMUNOPHARMACOLOGY, V21, P159, DOI 10.1016/0162-3109(91)90021-P; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NAGARKATTI PS, 1984, TOXICOL APPL PHARM, V72, P169, DOI 10.1016/0041-008X(84)90261-8; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RYKOWSKI RA, 1986, AEROSOLS, P443; SAXON A, 1993, IMMUNOLOGY, V80, P477; SHERR EH, 1987, J IMMUNOL, V138, P3836; STOREK J, 1992, J IMMUNOL METHODS, V22, P1759; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1, DOI 10.1159/000234990; TURNER KJ, 1989, CIBA F SYMP, V147, P205; VOSTAL JJ, 1980, B NEW YORK ACAD MED, V56, P914; WAITHE WI, 1991, BIOCHEM PHARMACOL, V41, P85, DOI 10.1016/0006-2952(91)90014-V; Ward E.C., 1985, IMMUNOTOXICOLOGY IMM, P291; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILLIAMS PT, 1986, FUEL, V65, P1150, DOI 10.1016/0016-2361(86)90184-5; YAMANE K, 1988, 880343 SOC AUT ENG T, P1; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZHANG K, 1994, IN PRESS J BIOL CHEM	48	230	236	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				103	115		10.1016/S0091-6749(95)70158-3	http://dx.doi.org/10.1016/S0091-6749(95)70158-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7529782				2022-12-18	WOS:A1995QC31200014
J	Shamji, MH; Durham, SR				Shamji, Mohamed H.; Durham, Stephen R.			Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; mechanisms; allergic rhinitis; allergic asthma; long-term tolerance; T cells; B cells; type 2 innate lymphoid cells; IgE-FAB; biomarkers	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; INNATE LYMPHOID-CELLS; HOUSE-DUST-MITE; MESSENGER-RNA EXPRESSION; SUBLINGUAL IMMUNOTHERAPY; CLINICAL-EFFICACY; IMMUNOGLOBULIN-E; B-CELLS; IMMUNOLOGICAL CHANGES	Allergen immunotherapy is effective in patients with IgE-dependent allergic rhinitis and asthma. When immunotherapy is given continuously for 3 years, there is persistent clinical benefit for several years after its discontinuation. This disease-modifying effect is both antigen-specific and antigen-driven. Clinical improvement is accompanied by decreases in numbers of effector cells in target organs, including mast cells, basophils, eosinophils, and type 2 innate lymphoid cells. Immunotherapy results in the production of blocking IgG/IgG(4) antibodies that can inhibit IgE-dependent activation mediated through both high-affinity IgE receptors (Fc epsilon RI) on mast cells and basophils and low-affinity IgE receptors (Fc epsilon RII) on B cells. Suppression of T(H)2 immunity can occur as a consequence of either deletion or anergy of antigen-specific T cells; induction of antigenspecific regulatory T cells; or immune deviation in favor of T(H)1 responses. It is not clear whether the altered long-term memory resides within the T-cell or the B-cell compartment. Recent data highlight the role of IL-10-producing regulatory B cells and "protective'' antibodies that likely contribute to long-term tolerance. Understanding mechanisms underlying induction and persistence of tolerance should identify predictive biomarkers of clinical response and discover novel and more effective strategies for immunotherapy.	[Shamji, Mohamed H.; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, Immunomodulat & Tolerance Grp,Allergy & Clin Immu, London, England	Imperial College London	Durham, SR (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk	Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; 	ALK; Regeneron; Merck; ASIT Biotech; Immune Tolerance Network; Allergopharma; Biotech Tools; Food Standards Agency; National Institute of Health Research; Immune Tolerance Network/National Institute of Allergy and Infectious Diseases; Anergis; Circassia; Biomay; Allergy Therapeutics; Med Update GmbH; MRC [G0601303] Funding Source: UKRI	ALK; Regeneron(Regeneron); Merck(Merck & Company); ASIT Biotech; Immune Tolerance Network; Allergopharma; Biotech Tools; Food Standards Agency; National Institute of Health Research(National Institute for Health Research (NIHR)); Immune Tolerance Network/National Institute of Allergy and Infectious Diseases; Anergis; Circassia; Biomay; Allergy Therapeutics; Med Update GmbH; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	M. H. Shamji has received grants from ALK, Regeneron, Merck, ASIT Biotech, and the Immune Tolerance Network, and has received personal fees from ASIT Biotech, ALK, and Allergopharma. S. R. Durham has received grants from Regeneron, Biotech Tools, ALK, Food Standards Agency, the National Institute of Health Research, and the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases, and has received personal fees from Anergis, Circassia, Biomay, Merck, Allergy Therapeutics, ALK, and Med Update GmbH.	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Agache I, 2015, ALLERGY, V70, P355, DOI 10.1111/all.12586; Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Amano T, 2001, J BIOCHEM-TOKYO, V129, P739, DOI 10.1093/oxfordjournals.jbchem.a002914; Angelini F, 2011, WORLD J PEDIATR, V7, P24, DOI 10.1007/s12519-011-0242-3; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Buhring HJ, 1999, BLOOD, V94, P2343; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Burton OT, 2017, J ALLERGY CLIN IMMUN; Calderon MA, 2013, ALLERGY, V68, P825, DOI 10.1111/all.12180; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; Chaker AM, 2016, J ALLERGY CLIN IMMUN, V137, P452, DOI 10.1016/j.jaci.2015.08.046; Ciepiela O, 2014, PEDIAT ALLER IMM PUL, V27, P17, DOI 10.1089/ped.2014.0328; Committee for Medicinal Products for Human Use, 2008, GREEN PAP TERR COH T, P1; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dawicki W, 2017, J ALLERGY CLIN IMMUN, V139, P1608, DOI 10.1016/j.jaci.2016.07.042; Demoly P, 2017, ALLERGY, V72, P1576, DOI 10.1111/all.13155; Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ebo DG, 2012, J IMMUNOL METHODS, V375, P30, DOI 10.1016/j.jim.2011.09.003; Eifan AO, 2016, CLIN EXP ALLERGY, V46, P1139, DOI 10.1111/cea.12780; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Eifan AO, 2015, AM J RESP CRIT CARE, V192, P1431, DOI 10.1164/rccm.201502-0339OC; Ellis AK, 2017, J ALLERGY CLIN IMMUN, V140, P486, DOI 10.1016/j.jaci.2016.11.043; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Fujimura T, 2011, CLIN IMMUNOL, V139, P65, DOI 10.1016/j.clim.2010.12.022; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Furuno T, 1996, BIOCHEM BIOPH RES CO, V219, P740, DOI 10.1006/bbrc.1996.0304; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; Gould HJ, 2015, TRENDS IMMUNOL, V36, P40, DOI 10.1016/j.it.2014.11.002; Gueguen C, 2016, J ALLERGY CLIN IMMUN, V137, P545, DOI 10.1016/j.jaci.2015.09.015; Guerra F, 2001, J ALLERGY CLIN IMMUN, V107, P647, DOI 10.1067/mai.2001.112263; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hams E, 2013, J IMMUNOL, V191, P5349, DOI 10.4049/jimmunol.1301176; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Hoffmann HJ, 2017, ALLERGY, V72, P1022, DOI 10.1111/all.13135; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Kouser Lubna, 2017, Curr Treat Options Allergy, V4, P43, DOI 10.1007/s40521-017-0117-5; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Nullens S, 2013, CYTOM PART B-CLIN CY, V84B, P173, DOI 10.1002/cyto.b.21084; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; O'Mahony L, 2016, J ALLERGY CLIN IMMUN, V137, P559, DOI 10.1016/j.jaci.2015.10.047; Oefner CM, 2012, J ALLERGY CLIN IMMUN, V129, P1647, DOI 10.1016/j.jaci.2012.02.037; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129; Palomares O, 2017, IMMUNOL REV, V278, P219, DOI 10.1111/imr.12555; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Palomares O, 2011, J ALLERGY CLIN IMMUN, V127, P1541, DOI 10.1016/j.jaci.2011.04.002; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pilette C, 2013, ALLERGY, V68, P312, DOI 10.1111/all.12090; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Renand A, 2015, J ALLERGY CLIN IMMUN, V136, P1627, DOI 10.1016/j.jaci.2015.07.031; Rispens T, 2011, J AM CHEM SOC, V133, P10302, DOI 10.1021/ja203638y; Roberts G, 2017, ALLERGY; Rolland JM, 2010, CURR OPIN ALLERGY CL, V10, P559, DOI 10.1097/ACI.0b013e32833ff2b2; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Sakaguchi S, 2005, INT REV IMMUNOL, V24, P211, DOI 10.1080/08830180590934976; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Scadding GW, 2015, ALLERGY, V70, P689, DOI 10.1111/all.12608; Scadding GW, 2015, CLIN EXP ALLERGY, V45, P613, DOI 10.1111/cea.12434; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Scadding Glenis, 2011, Clin Transl Allergy, V1, P2, DOI 10.1186/2045-7022-1-2; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Scadding GW, 2012, J IMMUNOL METHODS, V384, P25, DOI 10.1016/j.jim.2012.06.013; Schulten V, 2017, J ALLERGY CLIN IMMUN; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Semitekolou M, 2017, J ALLERGY CLIN IMMUN; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2012, CLIN EXP ALLERGY, V42, P1816; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Shamji M, 2013, J ALLERGY CLIN IMMUN, V131, pAB146, DOI 10.1016/j.jaci.2012.12.1182; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Shamji MH, 2013, J ALLERGY CLIN IMMUN, V132, P1003, DOI 10.1016/j.jaci.2013.05.025; Shamji MH, 2013, IMMUNOTHERAPY-UK, V5, P203, DOI [10.2217/IMT.13.6, 10.2217/imt.13.6]; Slovick A, 2017, J ALLERGY CLIN IMMUN, V139, P1830, DOI 10.1016/j.jaci.2016.09.024; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van der Aar AMG, 2011, J ALLERGY CLIN IMMUN, V127, P1532, DOI 10.1016/j.jaci.2011.01.068; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Van Overtvelt L, 2011, ALLERGY, V66, P1530, DOI 10.1111/j.1398-9995.2011.02696.x; Varricchi G, 2016, ALLERGY, V71, P1086, DOI 10.1111/all.12878; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wambre E, 2015, CURR OPIN ALLERGY CL, V15, P581, DOI 10.1097/ACI.0000000000000216; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wechsler ME, 2012, J ALLERGY CLIN IMMUN, V130, P563, DOI 10.1016/j.jaci.2012.07.027; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Wu YCB, 2014, J ALLERGY CLIN IMMUN, V134, P604, DOI 10.1016/j.jaci.2014.07.010; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Zieglmayer P, 2016, EBIOMEDICINE, V11, P43, DOI 10.1016/j.ebiom.2016.08.022; Zimmer A, 2012, J ALLERGY CLIN IMMUN, V129, P1020, DOI 10.1016/j.jaci.2012.02.014	154	229	239	15	48	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1485	1498		10.1016/j.jaci.2017.10.010	http://dx.doi.org/10.1016/j.jaci.2017.10.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	29221580	Green Published, hybrid			2022-12-18	WOS:000417206000002
J	Boguniewicz, M; Leung, DYM				Boguniewicz, Mark; Leung, Donald Y. M.			Recent insights into atopic dermatitis and implications for management of infectious complications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; filaggrin; epidermal barrier; Staphylococcus aureus; herpes simplex virus; superantigens; T regulatory cells; eczema herpeticum; antimicrobial peptides; probiotics	STAPHYLOCOCCUS-AUREUS COLONIZATION; SILVER-COATED TEXTILES; T-CELLS; METHICILLIN-RESISTANT; ECZEMA HERPETICUM; ENTEROTOXIN-B; DOUBLE-BLIND; VITAMIN-D; ANTIMICROBIAL PEPTIDES; MAINTENANCE TREATMENT	Atopic dermatitis (AD) is a common complex disease that frequently follows a chronic relapsing course and affects the quality of life of patients and families in a significant manner. New insights into the pathophysiology of AD point to an important role of structural abnormalities in the epidermis combined with immune dysregulation. Patients with AD have a unique predisposition to colonization or infection by a number of microbial organisms, most notably Staphylococcus aureus and herpes simplex virus. A multipronged approach directed at healing or protecting the skin barrier and addressing the immune dysregulation is necessary to improve the likelihood of successful outcomes. (J Allergy Clin Immunol 2010;125:4-13.)	[Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Boguniewicz, M (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy Immunol, 1400 Jackson St,Rm J310, Denver, CO 80206 USA.	boguniewiczm@njhealth.org			National Institutes of Health/National Institute of Allergy and Infectious Diseases [N01 AI 40029, 40030, AR41256]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases contracts N01 AI 40029 and 40030, as well as AR41256.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beattie PE, 2006, BRIT J DERMATOL, V155, P145, DOI 10.1111/j.1365-2133.2006.07185.x; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Birnie AJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003871.pub2; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Boguniewicz Mark, 2007, J Drugs Dermatol, V6, P416; Boguniewicz M, 2008, SEMIN CUTAN MED SURG, V27, P115, DOI 10.1016/j.sder.2008.05.001; Bonness S, 2008, J CLIN MICROBIOL, V46, P456, DOI 10.1128/JCM.01734-07; BORK K, 1988, J AM ACAD DERMATOL, V19, P1024, DOI 10.1016/S0190-9622(88)70267-4; Boyle RJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006135.pub2; Breneman D, 2008, J AM ACAD DERMATOL, V58, P990, DOI 10.1016/j.jaad.2008.02.008; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Buonpane RA, 2007, NAT MED, V13, P725, DOI 10.1038/nm1584; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Chung HJ, 2008, J CLIN MICROBIOL, V46, P991, DOI 10.1128/JCM.00698-07; Clarke SR, 2006, J INFECT DIS, V193, P1098, DOI 10.1086/501471; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Ding BW, 2004, ORG LETT, V6, P3433, DOI 10.1021/ol048845t; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elston DM, 2007, J AM ACAD DERMATOL, V56, P1, DOI 10.1016/j.jaad.2006.04.018; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Gao P, 2009, J ALLERGY CLIN IMMUN, V123, pS70, DOI 10.1016/j.jaci.2008.12.239; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gauger A, 2006, J EUR ACAD DERMATOL, V20, P534, DOI 10.1111/j.1468-3083.2006.01526.x; Gauger A, 2003, DERMATOLOGY, V207, P15, DOI 10.1159/000070935; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Gutzmer R, 2009, J ALLERGY CLIN IMMUN, V123, P619, DOI 10.1016/j.jaci.2008.12.1110; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; HIJEN DJ, 2009, J ALLERGY CLIN IMMUN, V124, P856; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, P1022, DOI 10.1016/j.jaci.2007.01.044; Howell MD, 2009, J INVEST DERMATOL, V129, P2668, DOI 10.1038/jid.2009.120; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Hung SH, 2007, ANN ALLERG ASTHMA IM, V98, P51, DOI 10.1016/S1081-1206(10)60859-9; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Jolles S, 2002, CLIN EXP DERMATOL, V27, P3, DOI 10.1046/j.0307-6938.2001.00955.x; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Leung AD, 2008, CLIN EXP ALLERGY, V38, P789, DOI 10.1111/j.1365-2222.2008.02964.x; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Mancini AJ, 2008, PEDIATR DERMATOL, V25, P1, DOI 10.1111/j.1525-1470.2007.00572.x; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Michail SK, 2008, ANN ALLERG ASTHMA IM, V101, P508, DOI 10.1016/S1081-1206(10)60290-6; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oren E, 2008, J ALLERGY CLIN IMMUN, V121, P533, DOI 10.1016/j.jaci.2007.11.005; Otto M, 2008, BIODRUGS, V22, P27, DOI 10.2165/00063030-200822010-00003; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Paller AS, 2008, PEDIATRICS, V122, pE1210, DOI 10.1542/peds.2008-1343; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park J, 2007, CHEM BIOL, V14, P1119, DOI 10.1016/j.chembiol.2007.08.013; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; Peserico A, 2008, BRIT J DERMATOL, V158, P801, DOI 10.1111/j.1365-2133.2008.08436.x; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Salfeld P, 2009, J ALLERGY CLIN IMMUN, V124, P170, DOI 10.1016/j.jaci.2009.02.038; Salt BH, 2007, J ALLERGY CLIN IMMUN, V119, P508, DOI 10.1016/j.jaci.2006.11.006; Savage PB, 2002, FEMS MICROBIOL LETT, V217, P1; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schlievert PM, 2008, CLIN INFECT DIS, V46, P1562, DOI 10.1086/586746; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Sun YG, 2009, SCIENCE, V325, P1531, DOI 10.1126/science.1174868; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Travers JB, 2010, J ALLERGY CLIN IMMUN, V125, P146, DOI 10.1016/j.jaci.2009.09.052; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Weidenmaier C, 2004, NAT MED, V10, P243, DOI 10.1038/nm991; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Wollenberg A, 2008, ALLERGY, V63, P742, DOI 10.1111/j.1398-9995.2008.01683.x; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wollenberg A, 2009, ALLERGY, V64, P276, DOI 10.1111/j.1398-9995.2008.01803.x; Yang X, 2008, J INFECT DIS, V198, P344, DOI 10.1086/589776; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	118	229	244	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					4	13		10.1016/j.jaci.2009.11.027	http://dx.doi.org/10.1016/j.jaci.2009.11.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109729	Green Accepted			2022-12-18	WOS:000273660500001
J	McCarl, CA; Picard, C; Khalil, S; Kawasaki, T; Rother, J; Papolos, A; Kutok, J; Hivroz, C; LeDeist, F; Plogmann, K; Ehl, S; Notheis, G; Albert, MH; Belohradsky, BH; Kirschner, J; Rao, A; Fischer, A; Feske, S				McCarl, Christie-Ann; Picard, Capucine; Khalil, Sara; Kawasaki, Takumi; Roether, Jens; Papolos, Alexander; Kutok, Jeffery; Hivroz, Claire; LeDeist, Francoise; Plogmann, Katrin; Ehl, Stephan; Notheis, Gundula; Albert, Michael H.; Belohradsky, Bernd H.; Kirschner, Janbernd; Rao, Anjana; Fischer, Alain; Feske, Stefan			ORAI1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ORAI1; STIM1; CRAC; calcium channel; Ca2+; store-operated Ca2+ entry; T cells; immunodeficiency; signal transduction; congenital myopathy; anhydrotic ectodermal dysplasia; dental enamel; amelogenesis imperfecta	ACTIVATED CALCIUM-CHANNELS; T-CELL IMMUNODEFICIENCY; SKELETAL-MUSCLE; CRAC CHANNEL; IMMUNE-DEFICIENCY; PORE SUBUNIT; MICE LACKING; STIM1; MUTATION; INFLUX	Background: Defects in the development or activation of T cells result in immunodeficiency associated with severe infections early in life. T-cell activation requires Ca2+ influx through Ca2+-release activated Ca2+ (CRAC) channels encoded by the gene ORAI1. Objective: Investigation of the genetic causes and the clinical phenotype of immunodeficiency in patients with impaired Ca2+ influx and CRAC channel function. Methods: DNA sequence analysis for mutations in the genes ORAI1, ORAI2, ORAI3, and stromal interaction molecule (STIM) 1 and 2, as well as mRNA and protein expression analysis of ORAI1 in immunodeficient patients. Immunohistochemical analysis of ORAI1 tissue distribution in healthy human donors. Results: We identified mutations in ORAI1 in patients from 2 unrelated families. One patient is homozygous for a frameshift nonsense mutation in ORAI1 (ORAI1-A88SfsX25), and a second patient is compound heterozygous for 2 missense mutations in ORAI1 (ORAI1-A103E/L194P). All 3 mutations abolish ORAI1 expression and impair Ca2+ influx and CRAC channel function. The clinical syndrome associated with ORAI1 deficiency is characterized by immunodeficiency with a defect in the function but not in the development of lymphocytes, congenital myopathy, and anhydrotic ectodermal dysplasia with a defect in dental enamel calcification. In contrast with the limited clinical phenotype, we found ORAI1 protein expression in a wide variety of cell types and organs. Conclusion: Ca2+ influx through ORAI1 is crucial for lymphocyte function in vivo. Despite almost ubiquitous ORAI1 expression, the channel has a nonredundant role in only a few cell types judging from the limited clinical phenotype in ORAI1-deficient patients. (J Allergy Clin Immunol 2009;124:1311-8.)	[McCarl, Christie-Ann; Khalil, Sara; Kawasaki, Takumi; Papolos, Alexander; Feske, Stefan] NYU, Dept Pathol, Langone Med Ctr, New York, NY 10016 USA; [McCarl, Christie-Ann; Roether, Jens; Rao, Anjana; Feske, Stefan] Harvard Univ, Sch Med, Dept Pathol, Program Cellular & Mol Med,Childrens Hosp Boston, Boston, MA 02115 USA; [McCarl, Christie-Ann; Roether, Jens; Rao, Anjana; Feske, Stefan] Immune Dis Inst, Boston, MA USA; [Picard, Capucine; LeDeist, Francoise] AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Hivroz, Claire; LeDeist, Francoise; Fischer, Alain] INSERM, U768, Paris, France; [Fischer, Alain] Necker Enfants Malades Hosp, Pediat Hematol Immunol Unit, Paris, France; [Picard, Capucine] Fac Med Necker Enfants Malad, Human Genet Infect Dis INSERM, U550, Paris, France; [Picard, Capucine; Fischer, Alain] Paris Descartes Univ, Paris, France; [Kutok, Jeffery] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Hivroz, Claire] Inst Curie, INSERM, U653, Paris, France; [LeDeist, Francoise] Univ Montreal, Dept Microbiol & Immunol, Ctr Hosp Univ St Justine, Montreal, PQ H3C 3J7, Canada; [LeDeist, Francoise] Univ Montreal, Ctr Rech, Ctr Hosp Univ St Justine, Montreal, PQ, Canada; [Plogmann, Katrin] Univ Freiburg, Dept Operat Dent & Periodontol, Freiburg, Germany; [Ehl, Stephan] Univ Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Kirschner, Janbernd] Univ Freiburg, Dept Neuropediat & Muscle Disorders, Freiburg, Germany; [Notheis, Gundula; Belohradsky, Bernd H.] Univ Munich, Dr von Haunersches Kinderspital, Dept Infect & Immun, Munich, Germany; [Albert, Michael H.] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany	New York University; NYU Langone Medical Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Brigham & Women's Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; University of Freiburg; University of Freiburg; University of Freiburg; University of Munich; University of Munich	Feske, S (corresponding author), NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.	feskes01@nyumc.org	Hivroz, Claire/H-2711-2014; Feske, stefan/ABB-3554-2021; Picard, Capucine/H-3914-2017; Kirschner, Janbernd/H-7418-2016; Kirschner, Janbernd/Q-1493-2019; Ehl, Stephan/AAM-6006-2020	Hivroz, Claire/0000-0002-6794-2890; Feske, stefan/0000-0001-5431-8178; Picard, Capucine/0000-0001-8788-5056; Kirschner, Janbernd/0000-0003-1618-7386; Kirschner, Janbernd/0000-0003-1618-7386; Ehl, Stephan/0000-0002-9265-2721	National Institutes of Health; March of Dimes Foundation; INSERM; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066128] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes Foundation(March of Dimes); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants (S.F., A.R.), a March of Dimes Foundation grant (S.F.), and an INSERM grant (A.F.).	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Bergmeier W, 2009, BLOOD, V113, P675, DOI 10.1182/blood-2008-08-174516; Beyersdorf N, 2009, J IMMUNOL, V182, P3390, DOI 10.4049/jimmunol.0802888; Braun A, 2009, BLOOD, V113, P2056, DOI 10.1182/blood-2008-07-171611; Caraux A, 2006, BLOOD, V107, P994, DOI 10.1182/blood-2005-06-2428; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Darbellay B, 2009, J BIOL CHEM, V284, P5370, DOI 10.1074/jbc.M806726200; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Feske S, 1996, EUR J IMMUNOL, V26, P2119, DOI 10.1002/eji.1830260924; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Feske S, 2009, IMMUNOL REV, V231, P189, DOI 10.1111/j.1600-065X.2009.00818.x; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Gwack Y, 2008, MOL CELL BIOL, V28, P5209, DOI 10.1128/MCB.00360-08; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang YH, 2008, EXPERT OPIN THER TAR, V12, P391, DOI 10.1517/14728222.12.4.391 ; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; King LB, 2009, IMMUNOL REV, V231, P265, DOI 10.1111/j.1600-065X.2009.00822.x; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Launikonis BS, 2007, J PHYSIOL-LONDON, V583, P81, DOI 10.1113/jphysiol.2007.135046; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065; Lyfenko AD, 2008, J PHYSIOL-LONDON, V586, P4815, DOI 10.1113/jphysiol.2008.160481; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Orzaez M, 2004, J MOL BIOL, V335, P631, DOI 10.1016/j.jmb.2003.10.062; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Rodig SJ, 2005, AM J SURG PATHOL, V29, P196, DOI 10.1097/01.pas.0000149689.75462.ff; Scharenberg AM, 2007, NAT REV IMMUNOL, V7, P778, DOI 10.1038/nri2172; Schlesier M, 1993, Immunodeficiency, V4, P133; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Stiber J, 2008, NAT CELL BIOL, V10, P688, DOI 10.1038/ncb1731; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yohannan S, 2004, J MOL BIOL, V341, P1, DOI 10.1016/j.jmb.2004.06.025; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	50	229	235	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1311	1318		10.1016/j.jaci.2009.10.007	http://dx.doi.org/10.1016/j.jaci.2009.10.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004786	Green Accepted			2022-12-18	WOS:000273071500024
J	Bates, CA; Ellison, MC; Lynch, DA; Cool, CD; Brown, KK; Routes, JM				Bates, CA; Ellison, MC; Lynch, DA; Cool, CD; Brown, KK; Routes, JM			Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunodeficiency; common variable immunodeficiency; sarcoidosis; interstitial lung disease; pulmonary fibrosis	HYPOGAMMAGLOBULINEMIA; PNEUMONITIS; SARCOIDOSIS; FEATURES	Background: Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low levels of serum immunoglobulins and an inability to make specific antibodies. Objective: We sought to determine the prevalence, clinical characteristics, and effect on survival of noninfectious pulmonary disease in patients with CVID. Methods: A retrospective analysis of 69 patients with CVID was performed. Patients were divided into 3 groups on the basis of the type of pulmonary disease present: group 1 (n = 29), no pulmonary disease; group 2 (n = 23), chronic respiratory symptoms without diffuse radiographic abnormalities; and group 3 (n = 18), chronic respiratory symptoms and diffuse radiographic abnormalities. Group 3 patients were divided into 2 subgroups on the basis of the histopathologic pattern seen on biopsy. Group 3A (n = 13) included patients with granulomatous lung disease, lymphocytic interstitial pneumonia, follicular bronchiolitis, and lymphoid hyperplasia, a group of syndromes referred to as granulomatous-lymphocytic interstitial lung disease (GLILD). Group 3B (n = 5) consisted of patients with all other types of interstitial lung disease (ILD). Results: Fifty-eight percent of patients with CVID had noninfectious pulmonary complications. Group 3A (GLILD) patients had worse prognosis than the other groups, with a median survival of 13.7 versus 28.8 years (P < .001). Lymphoproliferative disease occurred in 31% of patients with GLILD. GLILD was associated with the presence of dyspnea (P < .05); splenomegaly (P < .05); restrictive pulmonary physiology; consolidation, ground-glass, and reticular radiographic abnormalities; and low CD3(+) (P < .05) and CD8(+) cell populations (P < .01). Conclusion: ILD is common in patients with CVID. The presence of GLILD was associated with a worse prognosis and increased prevalence of lymphoproliferative disorders.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Biometr, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Radiol, Boulder, CO 80309 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Routes, JM (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	routesj@njc.org	Brown, Kevin/ABF-2544-2020; Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067671, P01HL067671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67671] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Collins J, 1998, RADIOLOGY, V208, P749, DOI 10.1148/radiology.208.3.9722856; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; CUNNINGHAMRUNDLES S, 1981, J CLIN IMMUNOL, V1, P65, DOI 10.1007/BF00915478; CURTIN JJ, 1991, CLIN RADIOL, V44, P82, DOI 10.1016/S0009-9260(05)80501-X; Davies CWH, 2000, THORAX, V55, P88, DOI 10.1136/thorax.55.1.88; Duddridge M, 2000, LANCET, V355, P804, DOI 10.1016/S0140-6736(99)11450-8; FANBURG BL, 2000, SARCOIDOSIS, P1717; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; JAMES DG, 1993, SARCOIDOSIS, V10, P1; KATZENSTEIN AL, 1997, KATZENSTEINS ASKINS; LIEBOW AA, 1973, MED CLIN N AM, V57, P809, DOI 10.1016/S0025-7125(16)32278-7; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; *NIH, 1995, GLOB INASTHM GLOB ST; Park JS, 2002, J COMPUT ASSIST TOMO, V26, P13, DOI 10.1097/00004728-200201000-00003; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; ROIFMAN CM, 1987, LANCET, V1, P1075; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; Schkade PA, 1996, J ALLERGY CLIN IMMUN, V98, P710, DOI 10.1016/S0091-6749(96)70108-2; SONES M, 1960, AM J MED, V29, P84, DOI 10.1016/0002-9343(60)90009-7; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; Sutor GC, 2000, RESPIRATION, V67, P204, DOI 10.1159/000029488; Winfield JB, 1997, CLIN EXP IMMUNOL, V109, P1, DOI 10.1046/j.1365-2249.1997.00439.x; Wislez M, 2000, RESPIRATION, V67, P467, DOI 10.1159/000029552	24	229	237	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					415	421		10.1016/j.jaci.2004.05.057	http://dx.doi.org/10.1016/j.jaci.2004.05.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316526	Bronze			2022-12-18	WOS:000223405600033
J	Pope, SM; Brandt, EB; Mishra, A; Hogan, SP; Zimmermann, N; Matthaei, KI; Foster, PS; Rothenberg, ME				Pope, SM; Brandt, EB; Mishra, A; Hogan, SP; Zimmermann, N; Matthaei, KI; Foster, PS; Rothenberg, ME			IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; interleukin; chemokine; eotaxin	ADHESION MOLECULE-1 EXPRESSION; PERENNIAL ALLERGIC RHINITICS; AIRWAY EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; TISSUE EOSINOPHILIA; ENDOTHELIAL-CELLS; MESSENGER-RNA; T-CELLS; DIFFERENTIAL REGULATION; CHEMOKINE EXPRESSION	Background: IL-13 induces several characteristic features of asthma, including airway eosinophilia, airway hyperresponsiveness, and mucus overproduction; however, the mechanisms involved are largely unknown. Objective: We hypothesized that IL-13-induced inflammatory changes in the lung were dependent in part on IL-5 and eotaxin, two eosinophil-selective cytokines. Methods: Recombinant murine IL-13 was repeatedly administered to the lung by intranasal delivery until the characteristic features of asthma developed. To analyze the role of IL-5 and eotaxin, we subjected eotaxin gene-targeted, IL-5 gene-targeted, eotaxin/IL-5-double-deficient, IL-5 transgenic, and wild-type mice, of the Balb/C background to the experimental regime. Results: The induction of IL-13-mediated airway eosinophilia was found to occur independently of eosinophilia in the blood or bone marrow, indicating that IL-13-induced airway inflammation is primarily mediated by local effects of IL-13 in the lung. Eosinophil recruitment into both the lung tissue and bronchoalveolar lavage fluid was markedly attenuated in IL-5-deficient mice in comparison with wild-type controls. Accordingly, IL-13 delivery to IL-5 transgenic mice resulted in a large increase in airway eosinophils in comparison with wild-type mice. Interestingly, IL-13-induced eosinophilia in the bronchoalveolar lavage fluid of eotaxin-deficient mice was not impaired; however, these same mice failed to mount a significant tissue eosinophilia in response to IL-13. Finally, IL-13-induced mucus production was not affected by the presence of IL-5 or eotaxin, suggesting that IL-13-induced mucus secretion is mechanistically dissociated from airway eosinophilia. Conclusion: Selective components of the IL-13-induced asthma phenotype-airway eosinophilia but not mucus secretion-are differentially regulated by IL-5 and eotaxin. IL-5 is required for IL-13 to induce eosinophilia throughout the lung, whereas eotaxin regulates the distribution of airway eosinophils.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Australian National University; John Curtin School of Medical Research	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA.		Foster, Paul/G-5057-2013; Klaus, Matthaei/D-8691-2011; MISHRA, ANIL/S-7983-2017	MISHRA, ANIL/0000-0003-4266-4684; Brandt, Eric/0000-0003-0617-4100; , Paul/0000-0002-0827-8299; Pope, Sam/0000-0002-7724-9141	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI045898] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI42242-03, R01 AI45898-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis M, 1997, J IMMUNOL, V159, P4611; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Campbell EM, 1998, J IMMUNOL, V161, P7047; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Cohn L, 1999, J IMMUNOL, V162, P6178; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DISCOMBE G, 1946, LANCET, V250, P195; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Hohki G, 1997, BIOCHEM BIOPH RES CO, V241, P136, DOI 10.1006/bbrc.1997.7785; Horie S, 1997, INTERNAL MED, V36, P179, DOI 10.2169/internalmedicine.36.179; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Li L, 1999, J IMMUNOL, V162, P2477; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Luttmann W, 1996, J IMMUNOL, V157, P1678; Luttmann W, 1999, AM J RESP CELL MOL, V20, P474, DOI 10.1165/ajrcmb.20.3.3326; Matsukura S, 1999, J IMMUNOL, V163, P6876; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mochizuki M, 1999, INT ARCH ALLERGY IMM, V120, P19, DOI 10.1159/000053587; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Stellato C, 1999, J IMMUNOL, V163, P5624; Tachimoto H, 2000, J IMMUNOL, V165, P2748, DOI 10.4049/jimmunol.165.5.2748; Terada N, 2000, CLIN EXP ALLERGY, V30, P348; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1997, J IMMUNOL, V158, P5050; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313; Zaitsu M, 2000, BLOOD, V96, P601; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	55	229	246	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					594	601		10.1067/mai.2001.118600	http://dx.doi.org/10.1067/mai.2001.118600			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590387	Bronze			2022-12-18	WOS:000171760300020
J	Boguniewicz, M; Fiedler, VC; Raimer, S; Lawrence, ID; Leung, DYM; Hanifin, JM				Boguniewicz, M; Fiedler, VC; Raimer, S; Lawrence, ID; Leung, DYM; Hanifin, JM		Pediat Tacrolimus Study Grp	A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; tacrolimus; ointment; children/pediatric; eczema	CYCLOSPORINE-A; GENE-EXPRESSION; T-LYMPHOCYTES; FK506; SKIN; FK-506; CELLS; EFFICACY; GAMMA	Background: A topical formulation of tacrolimus, an immune; suppressant currently marketed for the prevention of rejection after solid organ transplant, is a potential therapeutic agent for atopic dermatitis. Objective: We sought to determine the safety and efficacy of tacrolimus ointment in pediatric patients with moderate-to-severe atopic dermatitis. Methods: In this double-blind, vehicle-controlled multicenter trial, children ages 7 to 16 years were treated with twice daily application of tacrolimus ointment at 1 of 3 concentrations (0.03% [n = 43], 0.1% [n = 49], or 0.3% [n = 44]) or vehicle (n = 44) for up to 22 days, with a 2-week follow-up period. Results: The Physician's Global Evaluation of clinical response showed that 69% (95% confidence interval: 53-82) of patients in the 0.03% tacrolimus ointment group, 67% (95% confidence interval: 52-81) in the 0.1% tacrolimus ointment group, and 70% (95% confidence interval: 54-83) in the 0.3% tacrolimus ointment group, compared with 38% (95% confidence interval: 24-54) in the vehicle group, had a marked to excellent (greater than or equal to 75%) improvement or clearing of their atopic dermatitis (P =.005, .007, and .004, respectively for the 3 tacrolimus groups compared with the vehicle group), The mean percent improvement for a modified Eczema Area and Severity Index at end of treat ment for each of the 3 tacrolimus groups (0.03%, 72%; 0.1%, 77%; and 0.3%, 81%) was significantly better than that of the vehicle group (26%; P<.001), The median percent reduction in pruritus was significantly greater for tacrolimus-treated patients (74% to 89%) than for vehicle-treated patients (51%, P=.027),No serious systemic adverse events were noted, and systemic absorption was minimal. Conclusion: Tacrolimus ointment appears to be safe and effective in children with atopic dermatitis.	Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Illinois, Dept Dermatol, Chicago, IL 60680 USA; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77550 USA; Fujisawa USA Inc, Dept Res & Dev, Deerfield, IL 60015 USA	Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; University of Texas Medical Branch Galveston	Hanifin, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, 3181 SW Sam Jackson Pk Rd L468, Portland, OR 97201 USA.							Alak AM, 1997, THER DRUG MONIT, V19, P88, DOI 10.1097/00007691-199702000-00016; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KAPLAN A, 1995, J DERMATOL SCI, V10, P130, DOI 10.1016/0923-1811(95)00395-9; Kawashima M, 1996, LANCET, V348, P1240, DOI 10.1016/S0140-6736(05)65512-2; Kershner RP, 1996, TRANSPLANTATION, V62, P920, DOI 10.1097/00007890-199610150-00009; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; OHMEN JD, 1995, J IMMUNOL, V154, P1956; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; RASMUSSEN JE, 1989, ALLERGY, V44, P108; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; THOMSON AW, 1991, TRANSPLANT P, V23, P3330; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; YOSHIMURA N, 1989, TRANSPLANTATION, V47, P356, DOI 10.1097/00007890-198902000-00035	27	229	244	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				637	644		10.1016/S0091-6749(98)70281-7	http://dx.doi.org/10.1016/S0091-6749(98)70281-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802373				2022-12-18	WOS:000076600400015
J	Rondon, C; Romero, JJ; Lopez, S; Artunez, C; Martin-Casanez, E; Torres, MJ; Mayorga, C; R-Pena, R; Blanca, M				Rondon, Carmen; Romero, Jose J.; Lopez, Soledad; Artunez, Cristina; Martin-Casanez, Enrique; Torres, Maria J.; Mayorga, Cristobalina; R-Pena, Rebeca; Blanca, Miguel			Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						flow cytometry; lymphocyte subtypes; nasal allergen provocation test; nasal lavage; nasal specific IgE; persistent allergic rhinitis; persistent nonallergic rhinitis	ALLERGIC-RHINITIS; IDIOPATHIC RHINITIS; PREVALENCE; ANTIBODIES; HISTAMINE; SECRETION; ABSENCE; DISEASE; MUCOSA	Background: Allergic rhinitis is an IgE-mediated inflammatory disease of the nasal mucosa, which is usually diagnosed by typical symptoms, positive skin tests, and/or serum specific IgE antibodies to allergens. Despite suggestive symptoms of allergic rhinitis, some patients have a negative diagnostic test for atopy. Objective: To evaluate in the nose the inflammatory response, specific IgE to Dermatophagoides pteronyssinus (DP), and the response to a nasal allergen provocation test with DP (NAPT-DP), in patients with persistent nonallergic rhinitis (PNAR) compared with patients with persistent allergic rhinitis (PAR) and healthy controls. Methods: Fifty patients with PNAR, 30 with PAR to DP, and 30 healthy controls were studied by determining the nasal leukocyte-lymphocyte phenotype by flow cytometry (CD16, CD8, CD4, CD33, CD3, and CD45), nasal eosinophil cationic protein (ECP), albumin, total and specific IgE to DP, and NAPT-DP. Results: The PNAR patients showed a similar leukocyte-lymphocyte phenotype in nasal lavage to the PAR patients and. p was different to the healthy controls. Within the PNAR group, 54% showed a positive NAPT-DP, with 22% of these having nasal specific IgE to DP. Conclusion: These data support the hypothesis that in persistent nonallergic rhinitis some patients may have local inflammation, nasal IgE production, and a positive response to a nasal allergen provocation test despite no evidence of systemic atopy. Further research is needed to evaluate the influence of other perennial allergens and/or immunologic mechanisms. Clinical implications: The local production of IgE antibodies without systemic detection is a condition that should be considered in patients with PNAR.			Torres, MJ (corresponding author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	mariaj.torres.sspa@juntadeandalucia.es	Torres, María José/T-3518-2017; Mayorga, Cristobalina/D-7167-2018; Lopez, Soledad/O-5873-2015; Mayorga, Lina/FBO-7730-2022; Torres, Maria/GVU-3391-2022	Torres, María José/0000-0001-5228-471X; Mayorga, Cristobalina/0000-0001-8852-8077; Lopez, Soledad/0000-0003-3727-1843; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402				ALI M, 1979, ARCH PATHOL LAB MED, V103, P274; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Carney AS, 1996, CLIN OTOLARYNGOL, V21, P198, DOI 10.1111/j.1365-2273.1996.tb01724.x; Garay R, 2004, ALLERGY, V59, P4, DOI 10.1111/j.0108-1675.2004.00388.x; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Hilberg O, 2000, RHINOLOGY, P3; HOWARTH PH, 2003, ALLERGY PRINCIPLES P, V2, P1391; HUGGINS KG, 1975, LANCET, V2, P148; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Lacroix JS, 1995, EUR ARCH OTO-RHINO-L, V252, P465, DOI 10.1007/BF02114752; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; MALCOMSON K G, 1959, J Laryngol Otol, V73, P73, DOI 10.1017/S0022215100054980; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; MIDDLETON E, 1988, J ALLERGY CLIN IMMUN, V81, P971, DOI 10.1016/0091-6749(88)90163-7; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; SIBBALD B, 1993, EPIDEMIOLOGY CLIN AL, P61; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; van Rijswijk JB, 2005, ALLERGY, V60, P1471, DOI 10.1111/j.1398-9995.2005.00975.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Wedback A, 2005, RHINOLOGY, V43, P86; WOLF G, 1988, LARYNGO RHINO OTOL, V67, P438, DOI 10.1055/s-2007-998536; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	30	228	243	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					899	905		10.1016/j.jaci.2007.01.006	http://dx.doi.org/10.1016/j.jaci.2007.01.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17337294				2022-12-18	WOS:000245729500018
J	Saarinen, KM; Pelkonen, AS; Makela, M; Savilahti, E				Saarinen, KM; Pelkonen, AS; Makela, M; Savilahti, E			Clinical course and prognosis of cow's milk allergy are dependent on milk-specific IgE status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; IgE; sensitization; skin test; tolerance; atopy	FOLLOW-UP; ATOPIC-DERMATITIS; EGG ALLERGY; 4 REGIONS; CHILDREN; AGE; INFANTS; SENSITIZATION; TOLERANCE; FOOD	Background: Large, prospective population-based studies on clinical course, development of tolerance, and risk for other atopy in children with cow's milk allergy (CMA) are lacking. Objective: We investigated the development of tolerance and the risk for asthma, rhinoconjunctivitis, atopic dermatitis, and sensitization in children with CMA followed to school age. Methods: We followed 118 children with CMA until recovery and repeatedly measured their sensitization to cow's milk (CM). At age 8.6 years, 94 allergic subjects and 80 control subjects from the same cohort were studied for atopic diseases and sensitization. In addition, the parents of 12 allergic subjects and 26 control children returned a questionnaire on atopy, respectively. Results: IgE-mediated CMA was detected in 86 (73%) children; at age 8.6 years, 13 (15%) had persistent CMA. All children with IgE-negative CMA were tolerant by age 5.0 years (P < .0001). Risk factors for persistent CMA at age 2.0 years were sensitization to CM at age 1.6 years (odds ratio, 6.3; 95% CI, 2.6-15.2), urticaria at diagnostic challenge (odds ratio, 3.3; 95% CI, 1.4-7.8), CM exposure at the maternity hospital (odds ratio, 3.2; 95% CI, 1.4-7.8), and early sensitization to egg (odds ratio, 2.8; 95% CI, 1.2-6.6). By age 8.6 years, children with IgE-positive CMA more frequently had asthma (31% vs 13%, P <= .01), rhinoconjunctivitis (66% vs 21%, P <= .001), atopic eczema (81% vs 26%, P <= .001), and sensitization to any allergen (88% vs 39%, P <= .001) than control subjects. CMA and family history of atopy were independent risk factors for atopic diseases, and CMA was also a risk factor for sensitization to inhalant allergens. Conclusion: IgE-mediated CMA often persists to school age and is a risk factor for other atopy; non-IgE-mediated CMA, by contrast, is a benign infantile condition.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Allergol Skin & Allergy Hosp, Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Savilahti, E (corresponding author), Univ Helsinki, Hosp Children & Adolescents, POB 281, FIN-00029 Helsinki, Finland.	erkki.savilahti@hus.fi	Pelkonen, Anna/D-3153-2018	Pelkonen, Anna/0000-0002-1482-8947; Makela, Mika/0000-0002-2933-3111				Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; DANNAEUS A, 1979, ACTA PAEDIATR SCAND, V68, P377, DOI 10.1111/j.1651-2227.1979.tb05023.x; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Gustafsson D, 2003, PEDIAT ALLERG IMM-UK, V14, P448, DOI 10.1046/j.0905-6157.2003.00093.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; SCHRANDER JJP, 1992, EUR J PEDIATR, V151, P783, DOI 10.1007/BF01959091; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0	28	228	244	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					869	875		10.1016/j.jaci.2005.06.018	http://dx.doi.org/10.1016/j.jaci.2005.06.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210063				2022-12-18	WOS:000235686600023
J	Tosi, MF				Tosi, MF			Innate immune responses to infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						innate immunity; antimicrobial peptides; Toll-like receptors; chemokines; natural killer cells; complement; phagocytes	NECROSIS-FACTOR-ALPHA; NATURAL-KILLER-CELLS; TOLL-LIKE RECEPTORS; HUMAN-NEUTROPHILS; ANTIMICROBIAL PEPTIDES; POLYMORPHONUCLEAR LEUKOCYTES; SUBCELLULAR-LOCALIZATION; ADAPTIVE IMMUNITY; EPITHELIAL-CELLS; DENDRITIC CELLS	The human host survives many infectious challenges in the absence of preexisting specific (adaptive) immunity because of the existence of a separate set of protective mechanisms that do not depend on specific antigenic recognition. These antigen-independent mechanisms constitute innate immunity. Antimicrobial peptides are released at epithelial surfaces and disrupt the membranes of many microbial pathogens. Toll-like receptors on epithelial cells and leukocytes recognize a range of microbial molecular patterns and generate intracellular signals for activation of a range of host responses. Cytokines released from leukocytes and other cells exhibit a vast array of regulatory functions in both adaptive and innate immunity. Chemokines released from infected tissues recruit diverse populations of leukocytes that express distinct chemokine receptors. Natural killer cells recognize and bind virus-infected host cells and tumor cells and induce their apoptosis. Complement, through the alternative and mannose-binding lectin pathways, mediates antibody-independent opsonization, phagocyte recruitment, and microbial lysis. Phagocytes migrate from the microcirculation into infected tissue and ingest and kill invading microbes. These innate immune mechanisms and their interactions in defense against infection provide the host with the time needed to mobilize the more slowly developing mechanisms of adaptive immunity, which might protect against subsequent challenges.	Maimonides Hosp, Div Pediat Infect Dis, Brooklyn, NY 11219 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Maimonides Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tosi, MF (corresponding author), Maimonides Hosp, Div Pediat Infect Dis, 977 48th St, Brooklyn, NY 11219 USA.	mtosi@maimonidesmed.org						ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ANDERSON DC, 1981, J CLIN INVEST, V68, P863, DOI 10.1172/JCI110341; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; Bacon K, 2003, CYTOKINE, V21, P48, DOI 10.1016/S1043-4666(02)00493-3; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; BAINTON DF, 1992, INFLAMMATION BASIC P, P303; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BERGER M, 2004, IMMUNOLOGIC DISORDER, P157; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bisset LR, 2005, CURR OPIN PULM MED, V11, P35, DOI 10.1097/01.mcp.0000144502.50149.e0; BORISH LC, 2003, J ALLERGY CLIN IMMUN, V111, P5460; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOTTGER EC, 1987, IMMUNOL TODAY, V8, P261, DOI 10.1016/0167-5699(87)90184-8; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campos MA, 2004, INFECT IMMUN, V72, P7107, DOI 10.1128/IAI.72.12.7107-7114.2004; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; CLARK RA, 1987, J BIOL CHEM, V262, P4065; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Comerford L, 2005, IMMUNOL LETT, V96, P163, DOI 10.1016/j.imlet.2004.08.018; Cooper N.R., 1986, IMMUNOBIOLOGY COMPLE, P139; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; ERDEI A, 1991, IMMUNOL TODAY, V12, P332, DOI 10.1016/0167-5699(91)90011-H; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Glass WG, 2003, CURR OPIN ALLERGY CL, V3, P467, DOI [10.1097/00130832-200312000-00008, 10.1097/01.all.0000104448.09202.91]; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; HOSTETTER MK, 1986, J INFECT DIS, V153, P682, DOI 10.1093/infdis/153.4.682; HOSTOFFER RW, 1994, J INFECT DIS, V170, P82, DOI 10.1093/infdis/170.1.82; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; Kim Chang H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P343, DOI 10.2174/1568008043339712; Kishore SP, 2005, FEBS LETT, V579, P699, DOI 10.1016/j.febslet.2004.12.047; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kurt-Jones EA, 2005, J INFECT DIS, V191, P746, DOI 10.1086/427339; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LEVY O, 1993, J BIOL CHEM, V268, P6058; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Metchnikoff E., 1905, IMMUNITY INFECT DIS; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Niyonsaba F, 2002, INT IMMUNOL, V14, P421, DOI 10.1093/intimm/14.4.421; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; OCHS HD, 1993, CLIN IMMUNOL IMMUNOP, V67, pS33, DOI 10.1006/clin.1993.1081; Oppenheim JJ, 2003, ANN RHEUM DIS, V62, P17, DOI 10.1136/ard.62.suppl_2.ii17; OPPENHEIM JJ, 2001, CYTOKINE REFERENCE, P3; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Perregaux DG, 2002, J IMMUNOL, V168, P3024, DOI 10.4049/jimmunol.168.6.3024; Petersen SV, 2001, MOL IMMUNOL, V38, P133; Regunathan J, 2005, BLOOD, V105, P233, DOI 10.1182/blood-2004-03-1075; Rice TW, 2005, ANNU REV MED, V56, P225, DOI 10.1146/annurev.med.56.082103.104356; ROOT RK, 1981, REV INFECT DIS, V3, P565; Rosenkilde MM, 2005, NEUROPHARMACOLOGY, V48, P1, DOI 10.1016/j.neuropharm.2004.09.017; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rubinstein M, 1998, CYTOKINE GROWTH F R, V9, P175; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Seo SM, 2001, AM J PHYSIOL-CELL PH, V281, pC1568, DOI 10.1152/ajpcell.2001.281.5.C1568; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; Smyth MJ, 2005, MOL IMMUNOL, V42, P501, DOI 10.1016/j.molimm.2004.07.034; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; Steinstraesser L, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-2; Stossel T P, 1977, Prog Clin Biol Res, V13, P87; STOSSEL TP, 1992, BASIC PRINCIPLES CLI, P459; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TOSI MF, 2004, TXB PEDIAT INFECT DI, P20; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; van der Pol WL, 1998, IMMUNOGENETICS, V48, P222, DOI 10.1007/s002510050426; Vanichkin A, 1996, J INFECT DIS, V173, P927, DOI 10.1093/infdis/173.4.927; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; WALKER RI, 1980, REV INFECT DIS, V2, P282; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WEISS J, 1983, J CLIN INVEST, V71, P540, DOI 10.1172/JCI110798; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	94	228	250	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					241	249		10.1016/j.jaci.2005.05.036	http://dx.doi.org/10.1016/j.jaci.2005.05.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083775	Bronze			2022-12-18	WOS:000235686400001
J	PEAT, JK; SALOME, CM; WOOLCOCK, AJ				PEAT, JK; SALOME, CM; WOOLCOCK, AJ			LONGITUDINAL CHANGES IN ATOPY DURING A 4-YEAR PERIOD - RELATION TO BRONCHIAL HYPERRESPONSIVENESS AND RESPIRATORY SYMPTOMS IN A POPULATION-SAMPLE OF AUSTRALIAN SCHOOLCHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney								BARBATO A, 1987, ANN ALLERGY, V58, P121; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; CORBO GM, 1987, ALLERGY, V42, P230, DOI 10.1111/j.1398-9995.1987.tb02204.x; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; DREBORG S, 1987, ALLERGY, V42, P117, DOI 10.1111/j.1398-9995.1987.tb02369.x; FLEISS JL, 1973, STATISTICAL METHODS; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GILLIES DRN, 1987, CLIN ALLERGY, V17, P105, DOI 10.1111/j.1365-2222.1987.tb02327.x; GODFREY RC, 1976, CLIN ALLERGY, V6, P79, DOI 10.1111/j.1365-2222.1976.tb01415.x; GREEN WF, 1986, AUST NZ J MED, V16, P639, DOI 10.1111/j.1445-5994.1986.tb00002.x; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; HERBERT FA, 1982, ANN ALLERGY, V49, P311; KRILIS S, 1985, AUST NZ J MED, V15, P421, DOI 10.1111/j.1445-5994.1985.tb02764.x; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; PAGGIARO PL, 1986, CLIN ALLERGY, V16, P49, DOI 10.1111/j.1365-2222.1986.tb01953.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SPEIGHT ANP, 1983, BRIT MED J, P286; STENIUS B, 1973, ALLERGY, V31, P137; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	37	228	230	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				65	74		10.1016/0091-6749(90)90223-Q	http://dx.doi.org/10.1016/0091-6749(90)90223-Q			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299108	Bronze			2022-12-18	WOS:A1990CM37800011
J	Canonica, GW; Passalacqua, G				Canonica, GW; Passalacqua, G			Noninjection routes for immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen immunotherapy; sublingual immunotherapy; local nasal immunotherapy; noninjection routes	LOCAL NASAL IMMUNOTHERAPY; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; HOUSE-DUST-MITE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; SHORT RAGWEED EXTRACT; CD4(+) T-CELLS; PRESEASONAL INTRANASAL IMMUNOTHERAPY	Allergen specific immunotherapy, together with drugs and allergen avoidance, is a cornerstone in the management of respiratory allergy. The traditional subcutaneous route is burdened with the risk of severe adverse events; therefore, safer routes of administration (noninjection or local routes) have been investigated and developed. Controlled trials failed to demonstrate the clinical efficacy and the safety of oral and bronchial administration, and these routes have been abandoned. Local nasal immunotherapy proved effective and safe in 17 of 18 controlled trials; thus it is considered a viable route of immunotherapy. Nevertheless, nasal immunotherapy is effective in rhinitis only and requires a particular administration technique; therefore its use is slowly declining. The sublingual route is supported by numerous controlled trials showing its efficacy in asthma and rhinitis in adults and children. The safety profile, assessed in clinical trials and postmarketing surveillance studies, is satisfactory; the most frequent side effects are gastrointestinal complaints, which can be easily managed by proper dose adjusting. Sublingual immunotherapy is now accepted by the World Health Organization as a valid alternative to the subcutaneous route also in children. Although the long-lasting efficacy has been recently documented for the sublingual route, several points still need to be elucidated, including mechanisms of action, optimal dosage, cost-effectiveness, and adherence.	Univ Genoa, Dept Internal Med, Div Allergy & Resp Dis, I-16126 Genoa, Italy	University of Genoa	Canonica, GW (corresponding author), DIMI, Allergy & Resp Dis, Lgo R Benzi 10, I-16132 Genoa, Italy.		canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557				Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; Andri L, 1996, J ALLERGY CLIN IMMUN, V97, P34, DOI 10.1016/S0091-6749(96)70280-4; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; BARDARE M, 1996, J INVESTIG ALLERGOL, V97, P34; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bertoni M, 1999, ANN ALLERG ASTHMA IM, V82, P47, DOI 10.1016/S1081-1206(10)62659-2; BJORKSTEN B, 1994, ALLERGY, V49, P299, DOI 10.1111/j.1398-9995.1994.tb02271.x; Black JH, 1927, J LAB CLIN MED, V12, P1156; BLACK JH, 1928, J LAB CLIN MED, V13, P709; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 1998, ALLERGY S, V53; Brown JL, 2001, CLIN EXP ALLERGY, V31, P8, DOI 10.1046/j.1365-2222.2001.01009.x; BUCKLE FG, 1975, J ALLERGY CLIN IMMUN, V55, P213, DOI 10.1016/0091-6749(75)90139-6; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Cirla AM, 1996, ALLERGY, V51, P299, DOI 10.1111/j.1398-9995.1996.tb00089.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; Curtis H. H, 1900, MEDICAL NEWSLETTER, V77, P16; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P141, DOI 10.1111/j.1365-2222.1995.tb01019.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Douglass J, 2002, CLIN EXP ALLERGY, V32, P1, DOI 10.1046/j.0022-0477.2001.01278.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EINARSSON R, 1988, ALLERGY, V43, P469, DOI 10.1111/j.1398-9995.1988.tb00921.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Falagiani P, 1997, ALLERGY, V52, P17, DOI 10.1111/j.1398-9995.1997.tb04799.x; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; Giannarini L, 1998, CLIN EXP ALLERGY, V28, P404; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HASSEUS B, 1995, J ORAL PATHOL MED, V24, P56, DOI 10.1111/j.1600-0714.1995.tb01139.x; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P189, DOI 10.1159/000227963; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P40, DOI 10.1159/000227899; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; HOLT PG, 1987, CELL IMMUNOL, V104, P434, DOI 10.1016/0008-8749(87)90045-1; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; Holt PG, 1989, CLIN EXP ALLERGY, V19, P55; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P447, DOI 10.1159/000232376; Kagi MK, 2002, ALLERGY, V57, P379, DOI 10.1034/j.1398-9995.2002.01153.x; KHINCHI S, 2000, ALLERGY S, V55, P24; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LAISSUE JA, 1993, DIGEST DIS, V11, P298, DOI 10.1159/000171421; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Litwin A, 1997, J ALLERGY CLIN IMMUN, V100, P30, DOI 10.1016/S0091-6749(97)70191-X; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47, DOI 10.1016/S1081-1206(10)62195-3; Lombardi C, 2000, ALLERGY, V55, P677, DOI 10.1034/j.1398-9995.2000.00687.x; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; LOWER T, 1993, ANN ALLERGY, V70, P480; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Malling HJ, 1998, ALLERGY, V53, P461; MALLING HJ, 1993, ALLERGY S44, V53, P6; Marcucci F, 2002, ALLERGY, V57, P23, DOI 10.1034/j.1398-9995.2002.13149.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; MEHTA S B, 1975, Clinical Allergy, V5, P279; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MISTRELLO G, 1991, ALLERGY, V46, P52, DOI 10.1111/j.1398-9995.1991.tb00543.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; Motta G, 2000, LARYNGOSCOPE, V110, P132, DOI 10.1097/00005537-200001000-00024; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; Noon L, 1911, LANCET, V1, P1572; ONGARI S, 1995, ALLERGY, V50, P358; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; OSTERGAARD PA, 1986, ALLERGY, V41, P588; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; Passalacqua G, 2002, ALLERGY, V57, P275, DOI 10.1034/j.1398-9995.2002.03264.x; Passalacqua G, 2001, ALLERGY, V56, P578, DOI 10.1034/j.1398-9995.2001.056006578.x; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Pocobelli D, 2001, J INVEST ALLERG CLIN, V11, P79; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; REBIEN W, 1980, Allergologie, V3, P101; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SCHUMACHER MJ, 1982, ALLERGY, V37, P241, DOI 10.1111/j.1398-9995.1982.tb01906.x; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAUDORF E, 1983, ALLERGY, V38, P561, DOI 10.1111/j.1398-9995.1983.tb04140.x; TAYLOR DRF, 1997, P 18 INT CART C STOC, V1, P1; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; URBANEK R, 1982, MONATSSCHR KINDERH, V130, P150; VanDeusen MA, 1997, ANN ALLERG ASTHMA IM, V78, P573, DOI 10.1016/S1081-1206(10)63218-8; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vervloet D, 2002, ALLERGY, V57, P70; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1	137	227	243	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					437	448		10.1067/mai.2003.129	http://dx.doi.org/10.1067/mai.2003.129			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642818				2022-12-18	WOS:000181639500001
J	BARNES, PJ; CHUNG, KF; PAGE, CP				BARNES, PJ; CHUNG, KF; PAGE, CP			PLATELET-ACTIVATING FACTOR AS A MEDIATOR OF ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV LONDON KINGS COLL,DEPT PHARMACOL,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	BARNES, PJ (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT THORAC MED,FULHAM RD,LONDON SW3 6HP,ENGLAND.		Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ALBERT DH, 1983, J BIOL CHEM, V258, P97; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; ARNOUX B, 1981, AGENTS ACTIONS, V11, P555, DOI 10.1007/BF01978737; ARNOUX B, 1982, AM REV RESPIR DIS, V125, P70; ARNOUX B, 1985, American Review of Respiratory Disease, V131, pA2; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; AURSUDKIJ B, 1987, American Review of Respiratory Disease, V135, pA160; BARBARO JF, 1966, P SOC EXP BIOL MED, V122, P1245; BARNES PJ, 1987, BRIT J PHARMACOL, V90, P709, DOI 10.1111/j.1476-5381.1987.tb11224.x; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; BARNES PJ, 1987, TRENDS PHARMACOL SCI, V8, P285, DOI 10.1016/0165-6147(87)90115-5; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, IN PRESS PHARM RES; BEER HJ, 1984, THESIS U ZURICH ZURI; BEIJER L, 1987, British Journal of Pharmacology, V90, p118P; BENVENISTE J, 1982, THROMB RES, V25, P375, DOI 10.1016/0049-3848(82)90128-1; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BESSIN P, 1983, EUR J PHARMACOL, V86, P403, DOI 10.1016/0014-2999(83)90190-5; BETZ SJ, 1980, J IMMUNOL, V125, P2749; BJORK J, 1983, EUR J PHARMACOL, V96, P87, DOI 10.1016/0014-2999(83)90532-0; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P523; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRAQUET P, 1985, PROSTAGLANDINS, V30, P721, DOI 10.1016/0090-6980(85)90065-6; BRAQUET P, 1986, TRENDS PHARMACOL SCI, V7, P397, DOI 10.1016/0165-6147(86)90401-3; BRAQUET P, 1985, BLOOD VESSELS, V16, P559; BURHOP KE, 1986, J APPL PHYSIOL, V61, P2210, DOI 10.1152/jappl.1986.61.6.2210; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CAMUSSI G, 1981, LAB INVEST, V44, P241; CAPRON M, 1984, J IMMUNOL, V132, P462; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CASALSSTENZEL J, 1987, IMMUNOPHARMACOLOGY, V3, P7; CAVERO I, 1987, British Journal of Pharmacology, V90, p116P; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; CHAN TB, 1986, BRIT J DIS CHEST, V80, P375, DOI 10.1016/0007-0971(86)90091-4; CHAP H, 1981, NATURE, V289, P312, DOI 10.1038/289312a0; CHIGNARD M, 1980, BRIT J HAEMATOL, V46, P455, DOI 10.1111/j.1365-2141.1980.tb05993.x; CHUNG K F, 1987, American Review of Respiratory Disease, V135, pA181; CHUNG K F, 1987, American Review of Respiratory Disease, V135, pA159; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1987, LANCET, V1, P248; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CHUNG KF, IN PRESS J ALLERGY C; CLAY KL, 1984, BIOCHEM BIOPH RES CO, V121, P815, DOI 10.1016/0006-291X(84)90751-4; COCKCROFT DW, 1983, LANCET, V2, P253; COYLE AJ, IN PRESS EUR J PHARM; CUNNINGHAM F M, 1987, British Journal of Pharmacology, V90, p117P; CUSS FM, 1986, LANCET, V2, P189; DARIUS H, 1986, SCIENCE, V232, P58, DOI 10.1126/science.3082008; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENJEAN A, 1983, J APPL PHYSIOL, V55, P799, DOI 10.1152/jappl.1983.55.3.799; DEWAR A, 1984, J PATHOL, V44, P25; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; EVANS TW, IN PRESS BR J PHARM; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FITZGERALD MF, 1986, BRIT J PHARMACOL, V88, P149, DOI 10.1111/j.1476-5381.1986.tb09481.x; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; GATEAU O, 1984, AM REV RESPIR DIS, V133, pA129; GODFROID JJ, 1980, FEBS LETT, V116, P161, DOI 10.1016/0014-5793(80)80633-8; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; HALONEN M, 1980, AM REV RESPIR DIS, V122, P915; HAMASAKI Y, 1984, AM REV RESPIR DIS, V129, P742, DOI 10.1164/arrd.1984.129.5.742; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HANDLEY DA, 1986, IMMUNOPHARMACOLOGY, V12, P11, DOI 10.1016/0162-3109(86)90046-9; HARTUNG HP, 1983, INT J IMMUNOPHARMACO, V5, P115, DOI 10.1016/0192-0561(83)90002-4; HEFFNER JE, 1983, J CLIN INVEST, V71, P351, DOI 10.1172/JCI110776; HELLEWELL PG, 1986, J IMMUNOL, V137, P302; HELLEWELL PG, IN PRESS BR J PHARM; HENOCQ E, 1986, LANCET, V1, P1378; HSUEH W, 1986, J CLIN INVEST, V78, P108, DOI 10.1172/JCI112538; HUMPHREY DM, 1982, LAB INVEST, V46, P422; HUMPHREY JH, 1954, J PHYSIOL-LONDON, V124, P305, DOI 10.1113/jphysiol.1954.sp005109; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; HWANG SB, 1985, J BIOL CHEM, V260, P5639; HWANG SB, 1987, EUR J PHARMACOL, V141, P269, DOI 10.1016/0014-2999(87)90272-X; HWANG SB, 1985, BIOCHEM BIOPH RES CO, V128, P972, DOI 10.1016/0006-291X(85)90142-1; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; JOSEPH M, 1983, NATURE, V303, P310; JOUVINMARCHE E, 1983, EUR J PHARMACOL, V89, P19, DOI 10.1016/0014-2999(83)90603-9; KARLSSON G, 1984, EUR J CLIN PHARMACOL, V27, P1142; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; KORNECKI E, 1985, SCIENCE, V226, P1954; KRAVIS TC, 1977, J IMMUNOL, V118, P1569; LAGENTE V, 1987, PROSTAGLANDINS, V33, P265, DOI 10.1016/0090-6980(87)90011-6; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAMBRECHT G, 1986, BRIT J PHARMACOL, V87, P287, DOI 10.1111/j.1476-5381.1986.tb10816.x; LATRIGUEMATTEI C, 1984, AGENTS ACTIONS, V15, P643; LEE TC, 1981, ARCH BIOCHEM BIOPHYS, V208, P353, DOI 10.1016/0003-9861(81)90519-1; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEFORT J, 1984, BRIT J PHARMACOL, V82, P525; LELLOUCHTUBIANA A, 1987, INT ARCH ALLER A IMM, V83, P198, DOI 10.1159/000234356; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; LEVI R, 1984, CIRC RES, V54, P117, DOI 10.1161/01.RES.54.2.117; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LIN AH, 1982, J CLIN INVEST, V70, P1058, DOI 10.1172/JCI110693; LOTNER GZ, 1980, J IMMUNOL, V124, P676; LYNCH JM, 1986, J IMMUNOL, V137, P2653; MAZZONI L, 1985, J PHYSIOL-LONDON, V365, pP107; MCMANUS LM, 1980, J IMMUNOL, V124, P2919; MCMURTRY IF, 1986, AM REV RESPIR DIS, V134, P757; MENCIAHUERTA JM, 1981, CELL IMMUNOL, V57, P281, DOI 10.1016/0008-8749(81)90087-3; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MORLEY J, 1983, BRIT J PHARMACOL, V80, P503, DOI 10.1111/j.1476-5381.1983.tb10722.x; MORLEY J, 1985, PROG RESPIR RES, V19, P117; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1982, LAB INVEST, V47, P314; OKAMOTO M, 1986, CHEM PHARM BULL, V34, P345; PARENTE L, 1985, LIFE SCI, V36, P1225, DOI 10.1016/0024-3205(85)90266-8; PATTERSON R, 1984, J LAB CLIN MED, V104, P340; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PIPER P J, 1986, British Journal of Pharmacology, V88, p238P; PIPKORN U, 1984, ALLERGY, V39, P141, DOI 10.1111/j.1398-9995.1984.tb01946.x; PIROTZKY E, 1984, LAB INVEST, V51, P567; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; ROBINSON C, 1985, CLIN SCI, V68, P103, DOI 10.1042/cs0680103; ROBINSON C, 1985, J ALLERGY CLIN IMMUN, V76, P140, DOI 10.1016/0091-6749(85)90691-8; ROGERS D F, 1987, American Review of Respiratory Disease, V135, pA160; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUBIN R, 1982, EUR J IMMUNOL, V12, P141, DOI 10.1002/eji.1830120208; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; RYLANDER R, 1987, AM REV RESPIR DIS, V135, P83; SANCHEZCRESPO M, 1985, IMMUNOPHARMACOLOGY, V10, P69, DOI 10.1016/0162-3109(85)90031-1; SAUNDERS RN, 1983, THROMB HAEMOSTASIS, V50, pA1493; SCHELLENBERG RR, 1983, J ALLERGY CLIN IMMUN, V71, P145, DOI 10.1016/0091-6749(83)90351-2; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SEDIVY P, 1987, ADV INFLAMMATION RES, P171; SHAW JO, 1981, J IMMUNOL, V127, P1250; SHEN TY, 1985, P NATL ACAD SCI USA, V82, P672, DOI 10.1073/pnas.82.3.672; SHUKLA SD, 1982, BIOCHEM BIOPH RES CO, V106, P697, DOI 10.1016/0006-291X(82)91767-3; SIRAGANIAN RP, 1971, J IMMUNOL, V106, P1244; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SNYDER F, 1987, NEW HORIZONS PLATELE, P13; STIMLERGERARD NP, 1986, J PHARMACOL EXP THER, V237, P209; SZCZEKLIK A, 1986, THROMB HAEMOSTASIS, V56, P183; TAYTARD A, 1986, AM REV RESPIR DIS, V134, P983, DOI 10.1164/arrd.1986.134.5.983; TENCE M, 1980, BIOCHIMIE, V62, P251, DOI 10.1016/S0300-9084(80)80399-3; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; THOMPSON P J, 1984, American Review of Respiratory Disease, V129, pA3; TOUQUI L, 1983, BIOCHEM BIOPH RES CO, V110, P890, DOI 10.1016/0006-291X(83)91045-8; TOUVAY C, 1985, AGENTS ACTIONS, V17, P371; TUFFIN DP, 1985, PROSTAGLANDINS, V30, P702, DOI 10.1016/0090-6980(85)90046-2; UKENA D, IN PRESS FEBS LETT; VALONE FH, 1982, J IMMUNOL, V129, P1637; VALONE FH, 1983, IMMUNOLOGY, V48, P141; Vargaftig B B, 1981, Ann N Y Acad Sci, V370, P119, DOI 10.1111/j.1749-6632.1981.tb29727.x; VARGAFTIG BB, 1982, EUR J PHARMACOL, V82, P121; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1984, J ALLERGY CLIN IMMUN, V74, P275, DOI 10.1016/0091-6749(84)90258-6; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WIRTZ H, 1986, FED PROC, V45, P418; YASAKA T, 1982, J IMMUNOL, V128, P1939	166	227	228	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				919	934		10.1016/0091-6749(88)90952-9	http://dx.doi.org/10.1016/0091-6749(88)90952-9			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3286723				2022-12-18	WOS:A1988N703600025
J	Wechsler, ME; Laviolette, M; Rubin, AS; Fiterman, J; Silva, JRLE; Shah, PL; Fiss, E; Olivenstein, R; Thomson, NC; Niven, RM; Pavord, ID; Simoff, M; Hales, JB; McEvoy, C; Slebos, DJ; Holmes, M; Phillips, MJ; Erzurum, SC; Hanania, NA; Sumino, K; Kraft, M; Cox, G; Sterman, DH; Hogarth, K; Kline, JN; Mansur, AH; Louie, BE; Leeds, WM; Barbers, RG; Austin, JHM; Shargill, NS; Quiring, J; Armstrong, B; Castro, M				Wechsler, Michael E.; Laviolette, Michel; Rubin, Adalberto S.; Fiterman, Jussara; Silva, Jose R. Lapa e; Shah, Pallav L.; Fiss, Elie; Olivenstein, Ronald; Thomson, Neil C.; Niven, Robert M.; Pavord, Ian D.; Simoff, Michael; Hales, Jeff B.; McEvoy, Charlene; Slebos, Dirk-Jan; Holmes, Mark; Phillips, Martin J.; Erzurum, Serpil C.; Hanania, Nicola A.; Sumino, Kaharu; Kraft, Monica; Cox, Gerard; Sterman, Daniel H.; Hogarth, Kyle; Kline, Joel N.; Mansur, Adel H.; Louie, Brian E.; Leeds, William M.; Barbers, Richard G.; Austin, John H. M.; Shargill, Narinder S.; Quiring, John; Armstrong, Brian; Castro, Mario		Asthma Intervention Res 2	Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial thermoplasty; asthma; bronchoscopic procedure; Alair System; asthma exacerbation	PHENOTYPE; TRIAL; LUNG	Background: Bronchial thermoplasty (BT) has previously been shown to improve asthma control out to 2 years in patients with severe persistent asthma. Objective: We sought to assess the effectiveness and safety of BT in asthmatic patients 5 years after therapy. Methods: BT-treated subjects from the Asthma Intervention Research 2 trial (ClinicalTrials.gov NCT01350414) were evaluated annually for 5 years to assess the long-term safety of BT and the durability of its treatment effect. Outcomes assessed after BT included severe exacerbations, adverse events, health care use, spirometric data, and high-resolution computed tomographic scans. Results: One hundred sixty-two (85.3%) of 190 BT-treated subjects from the Asthma Intervention Research 2 trial completed 5 years of follow-up. The proportion of subjects experiencing severe exacerbations and emergency department (ED) visits and the rates of events in each of years 1 to 5 remained low and were less than those observed in the 12 months before BT treatment (average 5-year reduction in proportions: 44% for exacerbations and 78% for ED visits). Respiratory adverse events and respiratory-related hospitalizations remained unchanged in years 2 through 5 compared with the first year after BT. Prebronchodilator FEV1 values remained stable between years 1 and 5 after BT, despite a 18% reduction in average daily inhaled corticosteroid dose. High-resolution computed tomographic scans from baseline to 5 years after BT showed no structural abnormalities that could be attributed to BT. Conclusions: These data demonstrate the 5-year durability of the benefits of BT with regard to both asthma control (based on maintained reduction in severe exacerbations and ED visits for respiratory symptoms) and safety. BT has become an important addition to our treatment armamentarium and should be considered for patients with severe persistent asthma who remain symptomatic despite taking inhaled corticosteroids and long-acting beta(2)-agonists.	[Wechsler, Michael E.] Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, Denver, CO 80206 USA; [Laviolette, Michel] Univ Laval, IUCPQ Hop Laval, Dept Pneumol, Quebec City, PQ G1K 7P4, Canada; [Rubin, Adalberto S.] Irmandade Santa Casa Misericordia Porto Alegre, Serv Pneumol, Porto Alegre, RS, Brazil; [Fiterman, Jussara] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Porto Alegre, RS, Brazil; [Silva, Jose R. Lapa e] Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; [Shah, Pallav L.] Chelsea & Westminster Hosp NHS Fdn Trust, London, England; [Fiss, Elie] Fac Med ABC, Sao Paulo, Brazil; [Olivenstein, Ronald] Montreal Chest Inst, Montreal, PQ, Canada; [Thomson, Neil C.] Univ Glasgow, Gartnavel Gen Hosp, Dept Resp Med, Glasgow G12 8QQ, Lanark, Scotland; [Niven, Robert M.] Univ Manchester, MAHSC, Manchester, Lancs, England; [Niven, Robert M.] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; [Pavord, Ian D.] Univ Hosp Leicester NHS Trust, Glenfield Gen Hosp, Div Resp Med, Leicester, Leics, England; [Simoff, Michael] Henry Ford Med Ctr, Div Pulm & Crit Care Med, Detroit, MI USA; [Hales, Jeff B.] Pulm & Med Associate Northern Virginia, Arlington, TX USA; [McEvoy, Charlene] HealthPartners Specialty Ctr Lung & Sleep Hlth, St Paul, MN USA; [Slebos, Dirk-Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 AV Groningen, Netherlands; [Holmes, Mark] Royal Adelaide Hosp, Resp Clin Trials Unit, Adelaide, SA, Australia; [Phillips, Martin J.] Sir Charles Gairdner Hosp, Western Australia Lung Res, Perth, WA, Australia; [Erzurum, Serpil C.] Cleveland Clin, Dept Pulm & Crit Care Med, Cleveland, OH USA; [Hanania, Nicola A.] Baylor Coll Med, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA; [Sumino, Kaharu; Castro, Mario] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO 63130 USA; [Kraft, Monica] Duke Univ, Med Ctr, Dept Pulm Med, Durham, NC 27706 USA; [Cox, Gerard] McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Hamilton, ON L8S 4L8, Canada; [Sterman, Daniel H.] Univ Penn Hlth Syst, Pulm Allergy & Crit Care Div, Sect Intervent Pulmonol & Thorac Oncol, Philadelphia, PA USA; [Hogarth, Kyle] Univ Chicago, Dept Pulm & Crit Care Med, Chicago, IL 60637 USA; [Kline, Joel N.] Univ Iowa, Iowa City, IA USA; [Mansur, Adel H.] Univ Birmingham, Resp Unit, Birmingham Heartlands Hosp, Birmingham B15 2TT, W Midlands, England; [Louie, Brian E.] Swedish Med Ctr, Sect Thorac & Foregut Surg, Seattle, WA USA; [Leeds, William M.] Veritas Clin Specialties, Topeka, KS USA; [Barbers, Richard G.] Univ So Calif, Keck Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90033 USA; [Austin, John H. M.] Columbia Univ, Med Ctr, Div Radiol, New York, NY USA; [Shargill, Narinder S.] Boston Sci Corp, Sunnyvale, CA USA; [Quiring, John; Armstrong, Brian] QST Consultat Ltd, Allendale, MI USA	National Jewish Health; Laval University; Pontificia Universidade Catolica Do Rio Grande Do Sul; Imperial College London; Faculdade de Medicina do ABC; McGill University; University of Glasgow; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Henry Ford Health System; University of Groningen; Royal Adelaide Hospital; Cleveland Clinic Foundation; Baylor College of Medicine; Washington University (WUSTL); Duke University; McMaster University; University of Pennsylvania; University of Chicago; University of Iowa; Heart of England NHS Foundation Trust; University of Birmingham; Swedish Medical Center; University of Southern California; Columbia University; Boston Scientific	Wechsler, ME (corresponding author), Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, 1400 Jackson St, Denver, CO 80206 USA.	mikewechsler@gmail.com	Louie, Brian E./AAJ-1840-2020; Fiss, Elie/E-2677-2018; Shah, Pallav L/AAB-2758-2019; Hanania, Nicola A/C-5875-2016; Lapa e Silva, Jose R./AAS-4793-2020; Wechsler, Michael/AAC-5506-2019; Sumino, Kaharu/AAA-2028-2021	Louie, Brian E./0000-0002-7599-1000; Shah, Pallav L/0000-0002-9052-4638; Hanania, Nicola A/0000-0003-3087-9530; Lapa e Silva, Jose R./0000-0003-3116-0253; Sumino, Kaharu/0000-0002-6214-2966; Caneja, Cielito/0000-0002-6122-920X; Thomson, Neil/0000-0003-1632-6630; Niven, Robert/0000-0003-2249-960X; Sterman, Daniel/0000-0003-1249-0804; kline, joel/0000-0002-5523-8855; Pavord, Ian/0000-0002-4288-5973; Aye, Ralph/0000-0003-3726-6673	Boston Scientific Corporation, Sunnyvale, Calif.; National Institute for Health Research [NF-SI-0510-10157] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	Boston Scientific Corporation, Sunnyvale, Calif.; National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by Boston Scientific Corporation, Sunnyvale, Calif.	American Lung Association, 2012, TRENDS ASTHM MORB MO; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Castro M, 2011, ANN ALLERG ASTHMA IM, V107, P65, DOI 10.1016/j.anai.2011.03.005; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chipps BE, 2012, CURR PULMONOL REP, V1, P259, DOI 10.1007/s13665-012-0025-x; Cox G, 2009, AM J RESP CRIT CARE, V179; Cox G, 2008, AM J RESP CRIT CARE, V177, pA567; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Pavord ID, 2013, ANN ALLERG ASTHMA IM, V111, P402, DOI 10.1016/j.anai.2013.05.002; Schatz M, 2008, AM J MANAG CARE, V14, P206; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8; World Medical Association (WMA), 2008, DECL HELS ETH PRINC	18	226	243	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1295	+		10.1016/j.jaci.2013.08.009	http://dx.doi.org/10.1016/j.jaci.2013.08.009			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23998657	Green Accepted			2022-12-18	WOS:000327538200008
J	Sonkoly, E; Janson, P; Majuri, ML; Savinko, T; Fyhrquist, N; Eidsmo, L; Xu, N; Meisgen, F; Wei, TL; Bradley, M; Stenvang, J; Kauppinen, S; Alenius, H; Lauerma, A; Homey, B; Winqvist, O; Stahle, M; Pivarcsi, A				Sonkoly, Eniko; Janson, Peter; Majuri, Marja-Leena; Savinko, Terhi; Fyhrquist, Nanna; Eidsmo, Liv; Xu, Ning; Meisgen, Florian; Wei, Tianling; Bradley, Maria; Stenvang, Jan; Kauppinen, Sakari; Alenius, Harri; Lauerma, Antti; Homey, Bernhard; Winqvist, Ola; Stahle, Mona; Pivarcsi, Andor			MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema/dermatitis; microRNA; miR-155; cytotoxic T lymphocyte-associated antigen; CD4(+) T-H cells; inflammation	GENOME-WIDE SEARCH; SUSCEPTIBILITY LOCI; AIRWAY INFLAMMATION; CTLA-4; MICRORNAS; EXPRESSION; ABSENCE; ACTIVATION; DIFFERENTIATION; INHIBITION	Background: MicroRNAs (miRNAs) are short noncoding RNAs that suppress gene expression at the posttranscriptional level. Atopic dermatitis is a common chronic inflammatory skin disease characterized by the presence of activated T cells within the skin. Objective: We sought to explore the role of miRNAs in the pathogenesis of atopic dermatitis. Methods: Global miRNA expression in healthy and lesional skin of patients with atopic dermatitis was compared by using TaqMan MicroRNA Low Density Arrays. miR-155 expression in tissues and cells was quantified by means of quantitative real-time PCR. The cellular localization of miR-155 was analyzed by means of in situ hybridization. The regulation of cytotoxic T lymphocyte-associated antigen (CTLA-4) by miR-155 was investigated by using luciferase reporter assays and flow cytometry. CTLA-4 expression and functional assays were performed on T-H cells overexpressing miR-155. Results: miR-155 was one of the highest-ranked upregulated miRNAs in patients with atopic dermatitis. In the skin miR-155 was predominantly expressed in infiltrating immune cells. miR-155 was upregulated during T-cell differentiation/activation and was markedly induced by T-cell activators in PBMCs in vitro and by superantigens and allergens in the skin in vivo. CTLA-4, an important negative regulator of T-cell activation, was identified as a direct target of miR-155. Overexpression of miR-155 in T-H cells resulted in decreased CTLA-4 levels accompanied by an increased proliferative response. Conclusion: miR-155 is significantly overexpressed in patients with atopic dermatitis and might contribute to chronic skin inflammation by increasing the proliferative response of TH cells through the downregulation of CTLA-4. (J Allergy Clin Immunol 2010; 126: 581-9.)	[Sonkoly, Eniko] Karolinska Inst, Dept Med, CMM, Dermatol & Venereol Unit,Mol Dermatol Res Grp, Stockholm, Sweden; [Janson, Peter; Winqvist, Ola] Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; [Majuri, Marja-Leena; Savinko, Terhi; Fyhrquist, Nanna; Alenius, Harri] Finnish Inst Occupat Hlth, Unit Excellence Immunotoxicol, Helsinki, Finland; [Bradley, Maria] Karolinska Inst, Dept Mol Med & Surg, CMM, Stockholm, Sweden; [Stenvang, Jan; Kauppinen, Sakari] Santaris Pharma, Horsholm, Denmark; [Kauppinen, Sakari] Aalborg Univ, Copenhagen Inst Technol, Aalborg, Denmark; [Lauerma, Antti] Finnish Inst Occupat Hlth, Control Hypersensit Dis, Helsinki, Finland; [Lauerma, Antti] Univ Helsinki, Dept Dermatol, FIN-00014 Helsinki, Finland; [Homey, Bernhard] Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany; [Pivarcsi, Andor] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary	Karolinska Institutet; Karolinska Institutet; Finnish Institute of Occupational Health; Karolinska Institutet; Aalborg University; Finnish Institute of Occupational Health; University of Helsinki; Heinrich Heine University Dusseldorf; Szeged University	Sonkoly, E (corresponding author), Karolinska Inst, Dept Med, CMM, Dermatol & Venereol Unit,Mol Dermatol Res Grp, Stockholm, Sweden.	eniko.sonkoly@ki.se	Landén, Ning Xu/AFL-2883-2022; Pivarcsi, Andor/J-5801-2017; Lauerma, Antti/J-8180-2016	Landén, Ning Xu/0000-0003-4868-3798; Pivarcsi, Andor/0000-0003-2196-1102; Sonkoly, Eniko/0000-0002-4909-5413; Stenvang, Jan/0000-0001-5647-4828; Fyhrquist, Nanna Theresia/0000-0002-5408-0005; Eidsmo, Liv/0000-0001-9237-8374; Bradley, Maria/0000-0001-7192-5041; Alenius, Harri/0000-0003-0106-8923; Savinko, Terhi/0000-0003-4483-7235; winqvist, Ola/0000-0003-0842-4441	Swedish Research Council; Medical Research Council (Vetenskapsradet); Welander Finsens Foundation; Karolinska Institutet; Tore Nilsons, Hesselman, Konsul ThC Bergh, and Wallenberg Foundations;  [TAMOP-4.2.2/08/1]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Medical Research Council (Vetenskapsradet)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Swedish Research Council); Welander Finsens Foundation; Karolinska Institutet(Karolinska Institutet); Tore Nilsons, Hesselman, Konsul ThC Bergh, and Wallenberg Foundations; 	Supported by the Swedish Research Council; the Medical Research Council (Vetenskapsradet); the Welander Finsens Foundation; the Karolinska Institutet; the Tore Nilsons, Hesselman, Konsul ThC Bergh, and Wallenberg Foundations; and TAMOP-4.2.2/08/1.	Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blumenthal MN, 2006, J ALLERGY CLIN IMMUN, V117, P79, DOI 10.1016/j.jaci.2005.09.038; Bu LM, 2006, ALLERGY, V61, P617, DOI 10.1111/j.1398-9995.2006.01072.x; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Cobb BS, 2005, J EXP MED, V201, P1367, DOI 10.1084/jem.20050572; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Eidsmo L, 2009, J IMMUNOL, V182, P3165, DOI 10.4049/jimmunol.0802950; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fernandez N, 2002, J IMMUNOL, V169, P3321, DOI 10.4049/jimmunol.169.6.3321; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Hellings PW, 2002, EUR J IMMUNOL, V32, P585, DOI 10.1002/1521-4141(200202)32:2<585::AID-IMMU585>3.0.CO;2-U; Hwang S T, 2001, Adv Dermatol, V17, P211; Jago CB, 2004, CLIN EXP IMMUNOL, V136, P463, DOI 10.1111/j.1365-2249.2004.02478.x; Janson PCJ, 2008, J IMMUNOL, V181, P2878, DOI 10.4049/jimmunol.181.4.2878; Jen KY, 2007, J IMMUNOL, V179, P4212, DOI 10.4049/jimmunol.179.6.4212; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kouki T, 2002, J ENDOCRINOL INVEST, V25, P208, DOI 10.1007/BF03343992; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lachapelle JM, 2009, PATCH TESTING PRICK; Love TM, 2008, J ALLERGY CLIN IMMUN, V121, P309, DOI 10.1016/j.jaci.2007.12.1167; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Nakasa T, 2008, ARTHRITIS RHEUM-US, V58, P1284, DOI 10.1002/art.23429; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pauley KM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2493; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Sonkoly E, 2008, CLIN EXP DERMATOL, V33, P312, DOI 10.1111/j.1365-2230.2008.02804.x; Sonkoly E, 2009, J CELL MOL MED, V13, P24, DOI 10.1111/j.1582-4934.2008.00534.x; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Stahl HF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007158; Stenvang J, 2008, SEMIN CANCER BIOL, V18, P89, DOI 10.1016/j.semcancer.2008.01.004; Teft WA, 2006, ANNU REV IMMUNOL, V24, P65, DOI 10.1146/annurev.immunol.24.021605.090535; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; THULIN H, 1980, ACTA DERM-VENEREOL, V60, P235; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	51	226	248	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					581	U306		10.1016/j.jaci.2010.05.045	http://dx.doi.org/10.1016/j.jaci.2010.05.045			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673989				2022-12-18	WOS:000281512500026
J	Lemanske, RF; Busse, WW				Lemanske, Robert F., Jr.; Busse, William W.			Asthma: Clinical expression and molecular mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; respiratory syncytial virus; rhinovirus; allergen; prevention; exacerbation; inception; treatment	ACTING BETA-AGONISTS; EXHALED BREATH CONDENSATE; LUNG-FUNCTION DECLINE; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; PRESCHOOL-CHILDREN; AIRWAY INFLAMMATION; EARLY-LIFE; ASPIRIN DESENSITIZATION; RHINOVIRUS ILLNESSES	Asthma is a complex disorder that displays heterogeneity and variability in its clinical expression both acutely and chronically. This heterogeneity is influenced by multiple factors including age, sex, socioeconomic status, race and/or ethnicity, and gene by environment interactions. Presently, no precise physiologic, immunologic, or histologic characteristics can be used to definitively make a diagnosis of asthma, and therefore the diagnosis is often made on a clinical basis related to symptom patterns (airways obstruction and hyperresponsiveness) and responses to therapy (partial or complete reversibility) over time. Although current treatment modalities are capable of producing control of symptoms and improvements in pulmonary function in the majority of patients, acute and often severe exacerbations still occur and contribute significantly to both the morbidity and mortality of asthma in all age groups. This review will highlight some of the important clinical features of asthma and emphasize recent advances in both pathophysiology and treatment. (J Allergy Clin Immunol 2010;125:S95-102.)	[Lemanske, Robert F., Jr.; Busse, William W.] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, Dept Pediat, 600 Highland Ave K4-916, Madison, WI 53792 USA.	rfl@medicine.wisc.edu			National Institutes of Health [1P01HL70831-01, HL56396, AI50500]; Novartis; Centocor; GlaxoSmithKline; MedImmune; Ception; National Institutes of Health-National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, P50HL056396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050500] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Centocor; GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; National Institutes of Health-National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 1P01HL70831-01, HL56396, and AI50500.; Disclosure of potential conflict of interest: R. F. Lemanske is a Speaker for Merck, Doembecher Children's Hospital, Washington University, Medicus Group, Park Nicolet Institute, ACAAI, LA Allergy Society, Michigan Allergy/Asthma Society, Medical College of Wisconsin, Fund for Medical Research and Education (Detroit), Children's Hospital of Minnesota, Toronto Allergy Society, AAAAI, Beaumont Hospital, University of Illinois, Canadian Society of Allergy and Clinical Immunology, and New York Presbyterian; is a consultant and speaker for AstraZeneca; is a consultant for Map Pharmaceuticals, Gray Consulting, Smith Research, Inc., Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, Inc., International Meetings and Science, and Scienomics; is an author for Up-to-Date; and is an Editor for Elsevier, Inc. W. W. Busse is on the Advisory Board for Altair, Amgen, Abbott Laboratories, Asthmatx, Bristol-Meyer Squibb, Centocor, Genentech, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, and Wyeth; is a speaker for Merck, and a consultant for Alexion, AstraZeneca, Boehringer Ingelheim, Dainippon Sumitomo, Funxional Therapeutics Ltd, Novartis, and TEVA; and has received research support from Novartis, Centocor, GlaxoSmithKline, MedImmune, Ception, and the National Institutes of Health-National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute.	AMRANI Y, 2009, MIDDLETONS ALLERGY P, P399; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Borrego LM, 2009, THORAX, V64, P203, DOI 10.1136/thx.2008.099903; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Bush RK, 2009, J ALLERGY CLIN IMMUN, V123, P575, DOI 10.1016/j.jaci.2009.01.062; Busse WW, 2007, J ALLERGY CLIN IMMUN, V120, P1012, DOI 10.1016/j.jaci.2007.09.016; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; Coughlan JL, 2001, THORAX, V56, P198, DOI 10.1136/thorax.56.3.198; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Fitch KD, 2008, J ALLERGY CLIN IMMUN, V122, P254, DOI 10.1016/j.jaci.2008.07.003; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hasler G, 2005, AM J RESP CRIT CARE, V171, P1224, DOI 10.1164/rccm.200412-1669OC; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Holloway JW, 2008, J ALLERGY CLIN IMMUN, V121, P573, DOI 10.1016/j.jaci.2008.01.007; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Jartti T, 2007, PEDIATR PULM, V42, P1125, DOI 10.1002/ppul.20706; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Kelly JT, 2008, J ALLERGY CLIN IMMUN, V122, P671, DOI 10.1016/j.jaci.2008.08.013; Kiljander TO, 2006, AM J RESP CRIT CARE, V173, P1091, DOI 10.1164/rccm.200507-1167OC; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Krishnan V, 2006, AM J RESP CRIT CARE, V174, P633, DOI 10.1164/rccm.200601-007OC; Kusel MMH, 2008, CLIN EXP ALLERGY, V38, P1921, DOI 10.1111/j.1365-2222.2008.03138.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Lowe AJ, 2008, J ALLERGY CLIN IMMUN, V121, P1190, DOI 10.1016/j.jaci.2008.01.034; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOSS MH, 2003, MIDDLETONS ALLERGY P, P1225; Newcomb Dawn C, 2009, Proc Am Thorac Soc, V6, P266, DOI 10.1513/pats.200806-056RM; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Platts-Mills TAE, 2008, J ALLERGY CLIN IMMUN, V122, P694, DOI 10.1016/j.jaci.2008.07.045; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Spahn JD, 2008, J ALLERGY CLIN IMMUN, V121, P548, DOI 10.1016/j.jaci.2008.01.012; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; von Mutius E, 2008, J ALLERGY CLIN IMMUN, V122, P99, DOI 10.1016/j.jaci.2008.05.017; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Wang CW, 2008, PEDIATRICS, V122, pE107, DOI 10.1542/peds.2007-3370; Watson MA, 2009, RESP CARE, V54, P467; Wechsler ME, 2005, AM J RESP CRIT CARE, V172, P12, DOI 10.1164/rccm.200412-1635OE; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118; Yang IA, 2007, CLIN EXP ALLERGY, V37, P1264, DOI 10.1111/j.1365-2222.2007.02798.x; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	108	226	229	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S95	S102		10.1016/j.jaci.2009.10.047	http://dx.doi.org/10.1016/j.jaci.2009.10.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176271	Green Published, Green Accepted, Bronze			2022-12-18	WOS:000280170600009
J	Assa'ad, AH; Putnam, PE; Collins, MH; Akers, RM; Jameson, SC; Kirby, CL; Buckmeier, BK; Bullock, JZ; Collier, AR; Konikoff, MR; Noel, RJ; Guajardo, JR; Rothenberg, ME				Assa'ad, Amal H.; Putnam, Philip E.; Collins, Margaret H.; Akers, Rachel M.; Jameson, Sean C.; Kirby, Cassie L.; Buckmeier, Bridget K.; Bullock, Jennifer Z.; Collier, Ann R.; Konikoff, Michael R.; Noel, Richard J.; Guajardo, Jesus R.; Rothenberg, Marc E.			Pediatric patients with eosinophilic esophagitis: An 8-year follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophilic esophagitis; food allergy; atopy patch test; eosinophil; pediatric; eosinophilic gastroenteritis; environmental allergy; atopy; skin test	GASTROESOPHAGEAL-REFLUX; FLUTICASONE PROPIONATE; CHILDREN; GASTROENTERITIS; CORTICOSTEROIDS; SPECTRUM; DIET	Background: Eosinophilic esophagitis (EE) is a gastrointestinal disorder that is increasingly diagnosed in pediatric patients. Objective: We aimed to define, in pediatric patients with EE, their demographic and atopic characteristics, the histopathology of all segments of the gastrointestinal tract, and the effect of therapeutic interventions on the natural history. Methods: We conducted a retrospective analysis of a database of pediatric patients with EE followed over a period of 8 years. Results: In 89 pediatric patients with EE, male sex (78.6%), white race (94.4%), young age at diagnosis, mean +/- SD, 6.2 +/- 4.8 years, and atopy with sensitization to environmental and food allergens in 79% and 75%, respectively, were prevalent. Patients had EE of the proximal and distal esophagus, and 77% had in addition either mucosal eosinophilia or noneosinophilic histopathology in the stomach, duodenum, and colon. EE was chronic, with a duration of mean SD, 0.91 +/- 0.84 years, until first resolution, and was recurrent; of 66% of the patients who had resolution, 79% later relapsed. Conclusion: Eosinophilic esophagitis in the pediatric population is a chronic and relapsing condition, associated with atopy and sometimes with subsequent histopathology in segments of the gastrointestinal tract other than the esophagus.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Pathol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA; Univ Missouri, Columbia, MO 65211 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University of Missouri System; University of Missouri Columbia	Assa'ad, AH (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 2000, Cincinnati, OH 45229 USA.	amal.assa'ad@cchmc.org						De Agustin JC, 2002, J PEDIATR SURG, V37, P207, DOI 10.1053/jpsu.2002.30256; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; Fenoglio-Preiser CM, 1999, GASTROINTESTINAL PAT, P15; HOEFER RA, 1977, J PEDIATR SURG, V12, P955, DOI 10.1016/0022-3468(77)90606-6; Kaijser R., 1937, ARCH KLIN CHIR, V138, P36; KATZ AJ, 1984, J ALLERGY CLIN IMMUN, V74, P72, DOI 10.1016/0091-6749(84)90090-3; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; MELAMED I, 1991, AM J MED, V90, P310, DOI 10.1016/0002-9343(91)90570-N; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; STEFFEN RM, 1991, CLIN PEDIATR, V30, P404, DOI 10.1177/000992289103000701; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Sun HL, 2001, ASIAN PAC J ALLERGY, V19, P221; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Vanderhoof JA, 2003, J PEDIATR GASTR NUTR, V36, P293, DOI 10.1097/00005176-200302000-00027; WHITINGTON PF, 1988, J PEDIATR GASTR NUTR, V7, P379, DOI 10.1097/00005176-198805000-00011	22	226	241	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					731	738		10.1016/j.jaci.2006.10.044	http://dx.doi.org/10.1016/j.jaci.2006.10.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17258309				2022-12-18	WOS:000244925000029
J	Dunford, PJ; Williams, KN; Desai, PJ; Karlsson, L; McQueen, D; Thurmond, RL				Dunford, Paul J.; Williams, Kacy N.; Desai, Pragnya J.; Karlsson, Lars; McQueen, Daniel; Thurmond, Robin L.			Histamine H-4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; histamine H-1; receptor; histamine H-4 receptor; pruritus; must cells	BONE-MARROW-TRANSPLANTATION; ATOPIC-DERMATITIS; MAST-CELLS; HUMAN-SKIN; CHRONIC URTICARIA; 1ST POTENT; MICE; ITCH; ACTIVATION; COMPOUND-48/80	Background: Histamine is a potent mediator of itch in humans, yet histamine H-1 receptor antagonists have been shown to be of limited use in the treatment of certain chronic pruritic diseases. The histamine H-4 receptor is a recently described histamine receptor, expressed on hematopoietic cells, linked to the pathology of allergy and asthma. Objective: The contribution of the novel histamine H-4 receptor to histaminergic and allergic pruritus was investigated. Results: Histamine and a selective histamine H-4 receptor agonist caused scratching responses in mice, which were almost completely attenuated in histamine H-4 receptor knockout mice or by pretreatment with the selective histamine H-4 receptor antagonist, JNJ 7777120. Pruritus induced by allergic mechanisms was also potently inhibited with histamine H-4 receptor antagonist treatment or in histamine H-4 receptor knockout mice. In all cases, the inhibitory effect of histamine H-4 receptor antagonist was greater than those observed with histamine H-1 receptor antagonists. The histamine H-4 receptor-mediated pruritus was shown to be independent of mast cells or other hematopoietic cells and may result from actions on peripheral neurons. Conclusion: These results demonstrate that the histamine H-4 receptor is involved in pruritic responses in mice to a greater extent than the histamine H-1 receptor. Clinical implications: Histamine H-4 receptor antagonists may have therapeutic utility for treating chronic pruritic diseases in humans where histamine H, receptor antagonists are not effective.	Johnson & Johnson Res & Dev LLC, San Diego, CA 92121 USA; Univ Edinburgh, Coll Med, Div Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland	Johnson & Johnson; University of Edinburgh	Thurmond, RL (corresponding author), Johnson & Johnson Res & Dev LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.	rthurmon@prdus.jnj.com		Thurmond, Robin/0000-0001-6911-889X				ADVENIER C, 1989, DRUGS, V38, P634, DOI 10.2165/00003495-198938040-00009; Badertscher K, 2005, ARCH DERMATOL RES, V296, P503, DOI 10.1007/s00403-005-0542-3; Barbier AJ, 2004, BRIT J PHARMACOL, V143, P649, DOI 10.1038/sj.bjp.0705964; Bell JK, 2004, BRIT J PHARMACOL, V142, P374, DOI 10.1038/sj.bjp.0705754; Carlton SM, 1996, BRAIN RES, V734, P103, DOI 10.1016/S0006-8993(96)00619-1; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; Coge F, 2001, BIOCHEM BIOPH RES CO, V284, P301, DOI 10.1006/bbrc.2001.4976; DAVIES MG, 1980, BRIT J CLIN PHARMACO, V9, P461; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; EGLEZOS A, 1992, ARCH INT PHARMACOD T, V315, P96; Greaves MW, 1996, LANCET, V348, P938, DOI 10.1016/S0140-6736(96)04328-0; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Heyer G, 1997, PAIN, V73, P239, DOI 10.1016/S0304-3959(97)00098-5; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Ikoma A, 2005, PAIN, V113, P148, DOI 10.1016/j.pain.2004.10.003; Ikoma A, 2003, ARCH DERMATOL, V139, P1455, DOI 10.1001/archderm.139.11.1455; Inagaki N, 2002, EUR J PHARMACOL, V448, P175, DOI 10.1016/S0014-2999(02)01933-7; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; Jablonowski JA, 2003, J MED CHEM, V46, P3957, DOI 10.1021/jm0341047; Jarvikallio A, 1997, BRIT J DERMATOL, V136, P871, DOI 10.1046/j.1365-2133.1997.01831.x; Kamei J, 2005, J PHARMACOL SCI, V97, P266, DOI 10.1254/jphs.FP0040832; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; KITAMURA Y, 1978, BLOOD, V52, P447; KRAUSE L, 1983, BRIT MED J, V287, P1199, DOI 10.1136/bmj.287.6400.1199; Lim HD, 2005, J PHARMACOL EXP THER, V314, P1310, DOI 10.1124/jpet.105.087965; Lippert U, 2004, J INVEST DERMATOL, V123, P116, DOI 10.1111/j.0022-202X.2004.22721.x; Matute-Bello G, 2004, J IMMUNOL METHODS, V292, P25, DOI 10.1016/j.jim.2004.05.010; Musoh Keiichi, 1997, Allergology International, V46, P117, DOI 10.2332/allergolint.46.117; Nakaya M, 2004, ANN OTO RHINOL LARYN, V113, P552, DOI 10.1177/000348940411300707; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; RING J, 1983, CLIN ALLERGY, V13, P545, DOI 10.1111/j.1365-2222.1983.tb02636.x; Rukwied R, 2000, BRIT J DERMATOL, V142, P1114, DOI 10.1046/j.1365-2133.2000.03535.x; SCHMIDT R, 1995, J NEUROSCI, V15, P333; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Sugimoto Y, 2004, CLIN EXP ALLERGY, V34, P456, DOI 10.1111/j.1365-2222.2004.01876.x; Sugimoto Y, 2003, EUR J PHARMACOL, V470, P113, DOI 10.1016/S0014-2999(03)01786-2; Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754; Watson NT, 2000, CLIN EXP DERMATOL, V25, P186, DOI 10.1046/j.1365-2230.2000.00609.x; WILLIAMS RM, 1995, CHEM IMMUNOL, V61, P208	41	226	248	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					176	183		10.1016/j.jaci.2006.08.034	http://dx.doi.org/10.1016/j.jaci.2006.08.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208599				2022-12-18	WOS:000243622200025
J	Lai, CKW; de Guia, TS; Kim, YY; Kuo, SH; Mukhopadhyay, A; Soriano, JB; Trung, PL; Zhong, NS; Zainudin, N; Zainudin, BMZ				Lai, CKW; de Guia, TS; Kim, YY; Kuo, SH; Mukhopadhyay, A; Soriano, JB; Trung, PL; Zhong, NS; Zainudin, N; Zainudin, BMZ		Asthma Insights Reality Asia Pacif	Asthma control in the Asia-Pacific region: The asthma insights and reality in Asia-Pacific study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asia; asthma epidemiology; asthma control; asthma management; inhaled corticosteroids	MANAGEMENT; EPIDEMIOLOGY; POPULATION; PREVALENCE; GUIDELINES	Background: Few data on asthma management are available for the Asia-Pacific region. Objective: This study examined asthma symptoms, health care use, and management in the Asia-Pacific region. Methods: We performed a cross-sectional survey, followed by administration of a questionnaire in a face-to-face setting in the respondents' homes in their language of choice. Urban centers in 8 areas were surveyed: China, Hong Kong, Korea, Malaysia, The Philippines, Singapore, Taiwan, and Vietnam. Results: A population sample of 3207 respondents with physician-diagnosed asthma was identified by screening 108,360 households. Daytime asthma symptoms were reported by 51.4% of respondents, and 44.3% reported sleep disturbance caused by asthma in the preceding 4 weeks. At least 2 in every 5 respondents (43.6%) had been hospitalized, attended a hospital emergency department, or made unscheduled emergency visits to other health care facilities for treatment of asthma during the previous 12 months. Overall, 15.3% of respondents reported that they had required admission to the hospital for asthma treatment. Asthma severity correlated with the frequencies of hospitalizations and emergency visits for asthma in the past year. Even in those patients with severe persistent asthma, 34.3% regarded their disease as being well or completely controlled. Current use of an inhaled corticosteroid was reported by only 13.6% of respondents, and 56.3% used quick-relief bronchodilators. Absence from school and work in the past year was reported by 36.5 % of children and 26.5 % of adults. Conclusion: As reported for other regions, current levels of asthma control in the Asia-Pacific region fall markedly short of goals specified in international guidelines for asthma management. (J Allergy Clin Immunol 2003; 111:263-8.).	Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; Philippine Heart Ctr, Quezon City, Philippines; Seoul Natl Univ Hosp, Seoul 110744, South Korea; Natl Taiwan Univ Hosp, Taipei, Taiwan; Natl Univ Singapore Hosp, Singapore 117548, Singapore; GlaxoSmithKline Res & Dev Ltd, Worldwide Epidemiol, Greenford, Middx, England; Univ Med & Pharm, Ho Chi Minh City, Vietnam; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China; Paediat Inst Hosp, Kuala Lumpur, Malaysia; Damansara Specialist Hosp, Petaling Jaya, Malaysia	Chinese University of Hong Kong; Philippine Heart Center; Seoul National University (SNU); Seoul National University Hospital; National Taiwan University; National Taiwan University Hospital; National University of Singapore; GlaxoSmithKline; Hochiminh City University of Medicine & Pharmacy	Lai, CKW (corresponding author), Room 1403,Tak Shing House,20 Voeux Rd Ctr, Hong Kong, Hong Kong, Peoples R China.		Soriano, Joan B/O-1215-2017; Solebo, Colette N/B-6615-2008	Soriano, Joan B/0000-0001-9740-2994; Solebo, Colette N/0000-0001-9764-2541; Mukhopadhyay, Amartya/0000-0002-9747-5277				Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P514, DOI 10.1016/S0091-6749(96)70084-2; Bray GA, 1999, DIABETES CARE, V22, P623; Choy DKL, 1999, CLIN EXP ALLERGY, V29, P84; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HE WQ, 2001, CHIN J TUBERC RESP D, V24, P444; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Kim YY, 1997, CLIN EXP ALLERGY, V27, P761, DOI 10.1111/j.1365-2222.1997.tb01210.x; Kish L, 1965, SURVEY SAMPLING, VFirst; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Reid D, 2000, Respirology, V5, P281, DOI 10.1046/j.1440-1843.2000.00265.x; Taylor DM, 1999, CHEST, V116, P1638, DOI 10.1378/chest.116.6.1638; Woolcock A, 1998, Respirology, V3, P63, DOI 10.1111/j.1440-1843.1998.tb00098.x	20	226	264	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					263	268		10.1067/mai.2003.30	http://dx.doi.org/10.1067/mai.2003.30			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589343				2022-12-18	WOS:000180942700007
J	NORMAN, PS; LICHTENSTEIN, LM; SHIZAKA, K				NORMAN, PS; LICHTENSTEIN, LM; SHIZAKA, K			DIAGNOSTIC TESTS IN RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA	Johns Hopkins University								Alexander HL, 1931, ANN INTERN MED, V5, P52, DOI 10.7326/0003-4819-5-1-52; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; DORFMAN R. I., 1938, JOUR ALLERGY, V9, P464, DOI 10.1016/S0021-8707(38)90552-0; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1962, BIOCHEMISTRY-US, V1, P109; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P159; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1971, J ALLERGY, V47, P103; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; MAY CD, 1972, PEDIATRICS, V49, P536; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; STRENIUS B, 1971, CLIN ALLERGY, V1, P37; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2; WALZER M, 1936, J ALLERGY, V7, P597; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V49, P118; [No title captured]	29	226	227	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					210	224		10.1016/0091-6749(73)90059-6	http://dx.doi.org/10.1016/0091-6749(73)90059-6			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4126355				2022-12-18	WOS:A1973Q981700003
J	Marogna, M; Spadolini, I; Massolo, A; Canonica, GW; Passalacqua, G				Marogna, Maurizio; Spadolini, Igino; Massolo, Alessandro; Canonica, Giorgio Walter; Passalacqua, Giovanni			Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; allergic rhinitis; long-lasting effect; house dust mite	GRASS-POLLEN IMMUNOTHERAPY; TERM CLINICAL-EFFICACY; HOUSE-DUST MITE; RESPIRATORY ALLERGY; IMMUNOGLOBULIN-E; FOLLOW-UP; CHILDREN; ASTHMA; MECHANISMS; INCREASES	Background: Data on the long-term effects of sublingual immunotherapy (SLIT) are sparse, and the optimal duration of treatment is a matter of debate. Objective: We sought to prospectively evaluate the long-term effect of SLIT given for 3, 4, or 5 years and to compare the effect of those different durations. Methods: In this prospective open controlled study we followed up patients with respiratory allergy who were monosensitized to mites for 15 years. The subjects were divided in 4 groups receiving drug therapy alone or SLIT for 3, 4, or 5 years. Clinical scores, skin sensitizations, methacholine reactivity, and nasal eosinophil counts were evaluated every year during the winter months. The clinical effect was considered to persist until clinical scores remained at less than 50% of the baseline value, and then patients underwent another course of SLIT. Results: Seventy-eight patients were enrolled, and 59 completed the study. In the 12 control subjects no relevant change in clinical scores was seen throughout the study. In the patients receiving SLIT for 3 years, the clinical benefit persisted for 7 years. In those receiving immunotherapy for 4 or 5 years, the clinical benefit persisted for 8 years. New sensitizations occurred in all the control subjects over 15 years and in less than a quarter of the patients receiving SLIT (21%, 12%, and 11%, respectively). The second course of vaccination induced a benefit more rapidly than the first course. The behavior of bronchial hyperreactivity and nasal eosinophils paralleled the clinical score. Conclusion: Under the present conditions, it can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination. (J Allergy Clin Immunol 2010;126:969-75.)	[Marogna, Maurizio] Macchi Hosp Fdn, Pneumol Unit, Varese, Italy; [Spadolini, Igino] Anallergo, Dept Med, Florence, Italy; [Massolo, Alessandro] Univ Calgary, Fac Vet Med, Dept Ecosyst & Publ Hlth, Calgary, AB T2N 1N4, Canada; [Canonica, Giorgio Walter; Passalacqua, Giovanni] Univ Genoa, DIMI, I-16126 Genoa, Italy	Ospedale Circolo & Fondazione Macchi; University of Florence; University of Calgary; University of Genoa	Passalacqua, G (corresponding author), Padiglione Maragliano, Dept Internal Med, Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	Massolo, Alessandro/I-3437-2012; Massolo, Alessandro/AAO-5344-2021; canonica, giorgio walter/ABF-2037-2020	Massolo, Alessandro/0000-0002-6333-4281; canonica, giorgio walter/0000-0001-8467-2557	ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche)	ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche)	Supported in part by ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche).	Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2009, ANN ALLERG ASTHMA IM, V102, P69, DOI 10.1016/S1081-1206(10)60111-1; *NAT HEART LUNG BL, 1995, GLOB IN MAN ASTHM GI; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Tahamiler R, 2007, LARYNGOSCOPE, V117, P965, DOI 10.1097/MLG.0b013e31804f8141	27	225	242	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					969	975		10.1016/j.jaci.2010.08.030	http://dx.doi.org/10.1016/j.jaci.2010.08.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20934206				2022-12-18	WOS:000283727100012
J	Radulovic, S; Jacobson, MR; Durham, SR; Nouri-Aria, KT				Radulovic, Suzana; Jacobson, Mikila R.; Durham, Stephen R.; Nouri-Aria, Kayhan T.			Grass pollen immunotherapy induces Foxp3-expressing CD4(+)CD25(+) cells in the nasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Foxp3; CD4(+)CD25(+) Treg cells; IL-10; grass pollen immunotherapy; hay fever/allergic rhinitis	REGULATORY T-CELLS; TGF-BETA; INTESTINAL INFLAMMATION; MOLECULAR-MECHANISMS; MESSENGER-RNA; EXPRESSION; FOXP3; ALLERGY; EXPANSION; RHINITIS	Background: Regulatory T (Treg) cells play an important role in controlling allergic inflammation. The transcription factor Foxp3 regulates the development and function of natural and adaptive CD4(+)CD25(+) Treg cells. Objectives: We sought to examine the effect of grass pollen injection immunotherapy on the numbers of Foxp3(+)CD4(+) and Foxp3(+)CD25(+) T cells in and out of season and their expression of IL-10 in the nasal mucosa of patients with hay fever. Methods: Nasal biopsy specimens were obtained from untreated patients with hay fever, participants with grass pollen allergy who had received 2 years of immunotherapy, and healthy control subjects. Dual-immunofluorescence microscopy was used to enumerate and colocalize Foxp3 expression to CD4(+) and CD25(+) T cells in the nasal mucosa. Triple staining was performed to colocalize Foxp3(+) cells to CD3(+)CD25(+) and CD3(+) IL-10-expressing cells. Results: At peak season, numbers of Foxp3(+)CD25(+) (P=.02) and Foxp3(+)CD4(+) (P=.03) cells were significantly increased in the nasal mucosa of immunotherapy-treated patients compared with numbers before treatment. Foxp3(+)CD25(+) (P=.03) and Foxp3(+)CD4(+) (P=.04) cells were also greater in immunotherapy-treated patients out of season compared with those in untreated patients with hay fever. Within the immunotherapy-treated group, 20% of CD3(+)CD25(+) cells expressed Foxp3, and 18% of Foxp3(+)CD3(+) cells were IL-10 positive. Conclusion: The presence of local Foxp3(+)CD25(+)CD3(+) cells in the nasal mucosa, their increased numbers after immunotherapy, and their association with clinical efficacy and suppression of seasonal allergic inflammation support a putative role for Treg cells in the induction of allergen-specific tolerance in human subjects.	[Nouri-Aria, Kayhan T.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Dept Upper Resp Med, London SW7 2AZ, England; Royal Brompton Hosp London, London, England	Imperial College London; Royal Brompton Hospital	Nouri-Aria, KT (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Dept Upper Resp Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	k.nouri-aria@imperial.ac.uk		Jacobson, Mikila/0000-0002-2921-6169	Medical Research Council [G0400503B] Funding Source: researchfish; MRC [G0601303] Funding Source: UKRI; Medical Research Council [G0601303] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gerstmayr M, 2007, J IMMUNOL, V179, P7270, DOI 10.4049/jimmunol.179.11.7270; Hansen I, 2004, CURR OPIN ALLERGY CL, V4, P159, DOI 10.1097/01.all.0000129444.81350.23; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Lim HW, 2006, J IMMUNOL, V177, P840, DOI 10.4049/jimmunol.177.2.840; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu HY, 2003, J IMMUNOL, V171, P5012, DOI 10.4049/jimmunol.171.10.5012; Maggi L, 2007, J ALLERGY CLIN IMMUN, V120, P429, DOI 10.1016/j.jaci.2007.05.002; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; T Le N, 2007, BONE MARROW TRANSPL, V39, P1, DOI 10.1038/sj.bmt.1705529; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Uhlig HH, 2006, J IMMUNOL, V177, P5852, DOI 10.4049/jimmunol.177.9.5852; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018	33	225	246	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1467	1472		10.1016/j.jaci.2008.03.013	http://dx.doi.org/10.1016/j.jaci.2008.03.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18423565				2022-12-18	WOS:000256771700025
J	Ono, SJ; Abelson, MB				Ono, SJ; Abelson, MB			Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic; eye; conjunctivitis	VERNAL KERATOCONJUNCTIVITIS; EYE DISEASE; MAST-CELLS; EXPRESSION; PREVENTION; SYMPTOMS; RECEPTOR	Allergic conjunctivitis is in actuality a group of diseases affecting the ocular surface and is usually associated with type 1 hypersensitivity reactions. Two acute disorders, seasonal allergic conjunctivitis and perennial allergic conjunctivitis, exist, as do 3 chronic diseases, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis. The ocular surface inflammation (usually mast cell driven) results in itching, tearing, lid and conjunctival edema-redness, and photophobia during the acute phase and can lead to a classic late-phase response (with associated eosinophilia and neutrophilia) in a subset of individuals. As is the case in other allergic diseases, a chronic disease can also develop, accompanied by remodeling of the ocular surface tissues. In severe cases the patient experiences extreme discomfort and sustains damage to the ocular surface. For such cases, there is no highly effective and safe treatment regimen. Topical administration of corticosteroids is used in severe cases but is associated with an increased risk for the development of cataracts and glaucoma. Thus there is a worldwide search for new biotargets for the treatment of these diseases. Here we provide a brief update of the clinical symptoms associated with these diseases, the rationale for disease classification, recent advances in our understanding of the pathogenesis of the diseases, and an update on both preclinical and clinical advances toward refined therapies for these diseases.	UCL, Inst Ophthalmol, Dept Immunol, London EC1V 9EL, England; NHS Trust, Child Hlth & Moorfields Eye Hosp, London EC1V 9EL, England; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Schepens Eye Res Inst, Boston, MA 02115 USA	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Ono, SJ (corresponding author), UCL, Inst Ophthalmol, Dept Immunol, 11-43 Bath St, London EC1V 9EL, England.	santa.ono@ucl.ac.uk						Abelson MB, 1995, OPHTHALMOLOGY, V102, P1958, DOI 10.1016/S0161-6420(95)30768-3; Abelson MB, 2003, CLIN THER, V25, P931, DOI 10.1016/S0149-2918(03)80115-7; ABELSON MB, 1979, IMMUNOLOGY IMMUNOPAT, P362; Allam JP, 2004, J INVEST DERMATOL, V123, P676, DOI 10.1111/j.0022-202X.2004.23428.x; BERGER WE, 2004, ACAAAI NOV; BERGER WE, 2004, ACAAI           1112; Bundoc VG, 2003, CURR OPIN ALLERGY CL, V3, P375, DOI 10.1097/01.all.0000092609.76804.5c; Cook EB, 1998, INVEST OPHTH VIS SCI, V39, P336; Crampton HJ, 2002, CLIN THER, V24, P1800; GUPTA G, COMPAR OCULAR DRYING; Keane-Myers AM, 1999, INVEST OPHTH VIS SCI, V40, P3041; LANGLEY KE, 1987, OPHTHALMIC SURG LAS, V18, P594; LAVKER RM, 1988, J INVEST DERMATOL, V90, P325, DOI 10.1111/1523-1747.ep12456193; Leonardi A, 2003, OPHTHALMOLOGY, V110, P487, DOI 10.1016/S0161-6420(02)01767-0; Metz DP, 1997, J ALLERGY CLIN IMMUN, V100, P817, DOI 10.1016/S0091-6749(97)70279-3; Miyazaki D, 2000, INVEST OPHTH VIS SCI, V41, P3850; MIYAZAKI D, IN PRESS J CLIN INVE; Miyazaki Dai, 2004, Cornea, V23, pS48, DOI 10.1097/01.ico.0000136671.50777.fe; Nakamura T, 2004, IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY, P527; Nakamura T, 2003, CORNEA, V22, pS13, DOI 10.1097/00003226-200310001-00003; Nishimura A, 2001, INT ARCH ALLERGY IMM, V124, P197, DOI 10.1159/000053709; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V112, P1050, DOI 10.1016/j.jaci.2003.09.022; Ono SJ, 2003, CLIN EXP ALLERGY, V33, P279, DOI 10.1046/j.1365-2745.2003.01616.x; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; TODA M, 2004, MEDIMOND INT P, P517; Welch D, 2002, ADV EXP MED BIOL, V506, P1051	26	225	247	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					118	122		10.1016/j.jaci.2004.10.042	http://dx.doi.org/10.1016/j.jaci.2004.10.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637556				2022-12-18	WOS:000226267000016
J	Bossley, CJ; Fleming, L; Gupta, A; Regamey, N; Frith, J; Oates, T; Tsartsali, L; Lloyd, CM; Bush, A; Saglani, S				Bossley, Cara J.; Fleming, Louise; Gupta, Atul; Regamey, Nicolas; Frith, Jennifer; Oates, Timothy; Tsartsali, Lemonia; Lloyd, Clare M.; Bush, Andrew; Saglani, Sejal			Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; eosinophilia; remodeling; severe therapy-resistant asthma; mediators	NEUTROPHILIC AIRWAY INFLAMMATION; DIFFICULT ASTHMA; NONATOPIC CHILDREN; BASEMENT-MEMBRANE; FLOW LIMITATION; SMOOTH-MUSCLE; CHRONIC COUGH; CELL; MEPOLIZUMAB; RESPONSIVENESS	Background: The pathology of pediatric severe therapy-resistant asthma (STRA) is little understood. Objectives: We hypothesized that STRA in children is characterized by airway eosinophilia and mast cell inflammation and is driven by the T(H)2 cytokines IL-4, IL-5, and IL-13. Methods: Sixty-nine children (mean age, 11.8 years; interquartile range, 5.6-17.3 years; patients with STRA, n = 53; control subjects, n = 16) underwent fiberoptic bronchoscopy, bronchoalveolar lavage (BAL), and endobronchial biopsy. Airway inflammation, remodeling, and BAL fluid and biopsy specimen T(H)2 cytokines were quantified. Children with STRA also underwent symptom assessment (Asthma Control Test), spirometry, exhaled nitric oxide and induced sputum evaluation. Results: Children with STRA had significantly increased BAL fluid and biopsy specimen eosinophil counts compared with those found in control subjects (BAL fluid, P < .001; biopsy specimen, P < .01); within the STRA group, there was marked between-patient variability in eosinophilia. Submucosal mast cell, neutrophil, and lymphocyte counts were similar in both groups. Reticular basement membrane thickness and airway smooth muscle were increased in patients with STRA compared with those found in control subjects (P < .0001 and P < .001, respectively). There was no increase in BAL fluid IL-4, IL-5, or IL-13 levels in patients with STRA compared with control subjects, and these cytokines were rarely detected in induced sputum. Biopsy IL-5(+) and IL-13(+) cell counts were also not higher in patients with STRA compared with those seen in control subjects. The subgroup (n = 15) of children with STRA with detectable BAL fluid T(H)2 cytokines had significantly lower lung function than those with undetectable BAL fluid T(H)2 cytokines. Conclusions: STRA in children was characterized by remodeling and variable airway eosinophil counts. However, unlike in adults, there was no neutrophilia, and despite the wide range in eosinophil counts, the T(H)2 mediators that are thought to drive allergic asthma were mostly absent. (J Allergy Clin Immunol 2012;129:974-82.)	[Bossley, Cara J.; Fleming, Louise; Gupta, Atul; Oates, Timothy; Lloyd, Clare M.; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, London SW7 2AZ, England; [Bossley, Cara J.; Fleming, Louise; Gupta, Atul; Frith, Jennifer; Tsartsali, Lemonia; Bush, Andrew] Royal Brompton & Harefield NHS Trust, London, England; [Regamey, Nicolas] Univ Bern, CH-3012 Bern, Switzerland	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Bern	Saglani, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, 374 Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	s.saglani@imperial.ac.uk	Fleming, Louise/ABD-7452-2020; Saglani, Sejal/AAE-5072-2019	Saglani, Sejal/0000-0001-5192-6418; Lloyd, Clare/0000-0001-8977-6726; Fleming, Louise/0000-0002-7268-7433; Regamey, Nicolas/0000-0001-6849-6469	Asthma UK Foundation; Royal Brompton & Harefield Biomedical Research Unit; Wellcome Trust, UK [083586/Z/07/Z]; European Respiratory Society [64]; Swiss National Science Foundation [1172/05b]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London; British Medical Association; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192, NF-SI-0508-10212] Funding Source: researchfish; Asthma UK [10/058, 08/010] Funding Source: researchfish	Asthma UK Foundation; Royal Brompton & Harefield Biomedical Research Unit; Wellcome Trust, UK(Wellcome Trust); European Respiratory Society; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London(General Electric); British Medical Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	J.F. was funded by an Asthma UK Foundation Grant and a grant from the Royal Brompton & Harefield Biomedical Research Unit. S.S. is funded by the Wellcome Trust, UK, grant no. 083586/Z/07/Z. N.R. is the recipient of a European Respiratory Society Fellowship (no. 64) and a grant of the Swiss National Science Foundation (no. 1172/05b). The project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.; A. Gupta receives research support from the British Medical Association. N. Regamey is on advisory boards for Merck-Sharp and Dome and Novartis. C. M. Lloyd is a consultant for MedImmune. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Antoniu SA, 2009, EXPERT OPIN INV DRUG, V18, P869, DOI [10.1517/13543780902922678 , 10.1517/13543780902922678]; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnes PJ, 2001, RESPIR RES, V2, P64, DOI 10.1186/rr39; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Collins DP, 1998, CYTOMETRY, V33, P249, DOI 10.1002/(SICI)1097-0320(19981001)33:2<249::AID-CYTO21>3.0.CO;2-T; de Blic J, 2000, EUR RESPIR J, V15, P217; Ferreira FD, 2007, PEDIATR PULM, V42, P857, DOI 10.1002/ppul.20648; Fitch PS, 2000, EUR RESPIR J, V16, P1109, DOI 10.1034/j.1399-3003.2000.16f15.x; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hansbro PM, 2011, BRIT J PHARMACOL, V163, P81, DOI 10.1111/j.1476-5381.2011.01219.x; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Lex C, 2005, PEDIATR PULM, V39, P318, DOI 10.1002/ppul.20159; McAleer JP, 2011, J LEUKOCYTE BIOL, V90, P263, DOI 10.1189/jlb.0211099; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mosmann TR, 2005, J IMMUNOL, V175, P5; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; ORMANNS W, 1985, HISTOCHEMISTRY, V82, P421, DOI 10.1007/BF02450475; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC; Regamey N, 2009, PEDIATR PULM, V44, P76, DOI 10.1002/ppul.20949; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Shaw DE, 2007, CHEST, V132, P1871, DOI 10.1378/chest.07-1047; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Woolhouse IS, 2002, THORAX, V57, P667, DOI 10.1136/thorax.57.8.667	45	224	231	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					974	U469		10.1016/j.jaci.2012.01.059	http://dx.doi.org/10.1016/j.jaci.2012.01.059			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22385633	Green Published, Green Accepted			2022-12-18	WOS:000302144600011
J	Li, XN; Howard, TD; Zheng, SL; Haselkorn, T; Peters, SP; Meyers, DA; Bleecker, ER				Li, Xingnan; Howard, Timothy D.; Zheng, Siqun L.; Haselkorn, Tmirah; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.			Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; GWAS; RAD50; IL13; HLA-DQB1; TENOR	LOCUS-CONTROL REGION; SERUM IGE LEVELS; RANGE INTRACHROMOSOMAL INTERACTIONS; TH2 CYTOKINE LOCUS; TO-TREAT ASTHMA; SUSCEPTIBILITY GENE; POSITIONAL CLONING; ALLERGIC-ASTHMA; LARGE COHORT; EXPRESSION	Background: Asthma is a heterogeneous disease that is caused by the interaction of genetic susceptibility with environmental influences. Genome-wide association studies (GWASs) represent a powerful approach to investigate the association of DNA variants with disease susceptibility. To date, few GWASs for asthma have been reported. Objectives: A GWAS was performed on a population of patients with severe or difficult-to-treat asthma to identify genes that are involved in the pathogenesis of asthma. Methods: A total of 292,443 single nucleotide polymorphisms (SNPs) were tested for association with asthma in 473 The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) cases and 1892 Illumina general population controls. Asthma-related quantitative traits (total serum IgE, FEV(1), forced vital capacity, and FEV(1)/forced vital capacity) were also tested in identified candidate regions in 473 TENOR cases and 363 phenotyped controls without a history of asthma to analyze GWAS results further. Imputation was performed in identified candidate regions for analysis with denser SNP coverage. Results: Multiple SNPs in the RAD50-IL13 region on chromosome 5q31.1 were associated with asthma: rs2244012 in intron 2 of RAD50 (P = 3.04E-07). The HLA-DR/DQ region on chromosome 6p21.3 was also associated with asthma: rs1063355 in the 3' untranslated region of HLA-DQB1 (P = 9.55E-06). Imputation identified several significant SNPs in the T(H)2 locus control region 3' of RAD50. Imputation also identified a more significant SNP, rs3998159 (P = 1.45E-06), between HLA-DQB1 and HLA-DQA2. Conclusion: This GWAS confirmed the important role of T(H)2 cytokine and antigen presentation genes in asthma at a genome-wide level and the importance of additional investigation of these 2 regions to delineate their structural complexity and biologic function in the development of asthma. (J Allergy Clin Immunol 2010;125:328-35.)	[Li, Xingnan; Howard, Timothy D.; Zheng, Siqun L.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; [Haselkorn, Tmirah] EpiMetrix Inc, Sunnyvale, CA USA	Wake Forest University	Meyers, DA (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wfubmc.edu			Genentech, Inc,; Novartis Pharmaceuticals Corp.; NIH [HL76285, HL87665]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076285, R01HL087665] Funding Source: NIH RePORTER	Genentech, Inc,(Roche HoldingGenentech); Novartis Pharmaceuticals Corp.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The clinical TENOR study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corp. and this genetic study was funded by NIH HL76285 and HL87665.	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BEATY JS, 1995, MOL CELL BIOL, V15, P4771; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Cho SH, 2000, CLIN EXP ALLERGY, V30, P1568, DOI 10.1046/j.1365-2222.2000.00915.x; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; Denham S, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-38; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Ge DL, 2008, GENOME RES, V18, P640, DOI 10.1101/gr.071571.107; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hoffjan S, 2002, CURR OPIN IMMUNOL, V14, P709, DOI 10.1016/S0952-7915(02)00393-X; Horton R, 2008, IMMUNOGENETICS, V60, P1, DOI 10.1007/s00251-007-0262-2; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Li Y, 2006, AM J HUM GENET S, VS79, P2290; Lin YC, 2002, ALLERGY, V57, P831, DOI 10.1034/j.1398-9995.2002.23719.x; Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Noguchi E, 2005, AM J RESP CRIT CARE, V172, P183, DOI 10.1164/rccm.200409-1223OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; Torio A, 2003, HUM IMMUNOL, V64, P811, DOI 10.1016/S0198-8859(03)00109-5; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Willis-Owen SAG, 2009, CURR ALLERGY ASTHM R, V9, P3, DOI 10.1007/s11882-009-0001-x; Yabuki M, 2005, NAT IMMUNOL, V6, P730, DOI 10.1038/ni1215; Zhang J, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-4; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	47	224	229	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					328	335		10.1016/j.jaci.2009.11.018	http://dx.doi.org/10.1016/j.jaci.2009.11.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159242	Green Accepted			2022-12-18	WOS:000274764000007
J	Bohlke, K; Davis, RL; DeStefano, F; Marcy, SM; Braun, MM; Thompson, RS				Bohlke, K; Davis, RL; DeStefano, F; Marcy, SM; Braun, MM; Thompson, RS		Vaccine Safety Datalink Team	Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; children; adolescents; epidemiology	VACCINE SAFETY DATALINK; EMERGENCY; TREND	Background: There is little information about the incidence of anaphylaxis from all causes. Objective: The objects of this study were (1) to estimate the incidence of anaphylaxis; (2) to explore the range of diagnoses attributed to an anaphylactic episode; and (3) to describe the clinical features of anaphylaxis. Methods: The study population consisted of children and adolescents enrolled at a health maintenance organization. We identified potential episodes of anaphylaxis occurring between 1991 and 1997 from automated databases and reviewed the medical record to confirm the diagnosis. We reviewed all diagnoses specific for anaphylaxis (eg, ICD-9 995.0, anaphylactic shock) and sampled from among other related diagnoses (eg, ICD-9 995.3, allergy unspecified). Estimation of the incidence of provider-diagnosed anaphylaxis was based on cases confirmed from among the specific diagnosis codes. Description of the clinical features of anaphylaxis involved all confirmed cases regardless of diagnosis. Results: We identified 67 episodes of anaphylaxis among children with diagnosis codes specific for anaphylaxis (10.5 episodes per 100,000 person-years). There was no increase in incidence over time. Review of samples of diagnoses not specific for anaphylaxis yielded an additional 18 episodes. Among all identified episodes (n = 85), mucocutaneous and respiratory manifestations were the most common. Seventy-one percent of episodes were treated in the emergency department. Nine episodes (11%) resulted in hospitalization. Conclusions: The incidence of anaphylaxis did not increase during these years. A majority of episodes were treated in the emergency department. Anaphylaxis in this population was frequently diagnosed as another related condition, and the basis and implications of diagnostic practices in this disorder warrant further exploration.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Grp Hlth Cooperat Puget Sound, Dept Prevent Care, Seattle, WA 98101 USA; US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA; Kaiser Fdn Hosp, Panorama City, CA USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA; Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA	Group Health Cooperative; Group Health Cooperative; US Food & Drug Administration (FDA); Kaiser Permanente; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bohlke, K (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.				PHS HHS [200-0957] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Blumenthal MN, 1998, ALLERGY PRINCIPLES P, P28; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Boros CA, 2000, J PAEDIATR CHILD H, V36, P36, DOI 10.1046/j.1440-1754.2000.00444.x; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Chen RT, 2000, B WORLD HEALTH ORGAN, V78, P186; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; Ditto AM, 1996, ANN ALLERG ASTHMA IM, V77, P285, DOI 10.1016/S1081-1206(10)63322-4; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V103, P698, DOI 10.1016/S0091-6749(99)70245-9; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Kohl KS, 2003, PHARMACOEPIDEM DR S, V12, P335, DOI 10.1002/pds.851; Lieberman P., 1998, ALLERGY PRINCIPLES P, P1079; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; VANDERKLAUW MM, 1993, BRIT J CLIN PHARMACO, V35, P400; Wilson R, 2000, BRIT MED J, V321, P1021; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1	22	224	233	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					536	542		10.1016/j.jaci.2003.11.033	http://dx.doi.org/10.1016/j.jaci.2003.11.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007358	Bronze			2022-12-18	WOS:000220144200028
J	Cooper, PJ; Chico, ME; Rodrigues, LC; Ordonez, M; Strachan, D; Griffin, GE; Nutman, TB				Cooper, PJ; Chico, ME; Rodrigues, LC; Ordonez, M; Strachan, D; Griffin, GE; Nutman, TB			Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						geohelminths; intestinal helminths; atopy; total IgE; anti-Ascaris lumbricoides IgG4; tropics; Ecuador	ALLERGIC REACTIVITY; HELMINTH INFECTION; PREVALENCE; RESPONSES; ASTHMA; URBAN; SLUM; IGE	Background: Childhood infections might protect against the expression of atopy. Geohelminths are among the most prevalent infections of childhood and might contribute to the low prevalence of allergic disease reported from rural areas of the tropics. Objective: We sought to establish whether geohehninth infections protect against atopy and to explore whether this protection is dependent on infection chronicity. Methods: The risk of atopy (measured by means of allergen skin test reactivity) associated with active geohelminth infections (measured by means of the presence of eggs in stool samples) or with chronic geohelminth infections (measured by means of high levels [greater than or equal to3564 IU/mL] of total serum IgE or the presence of detectable anti-Ascaris lumbricoides IgG4 antibodies) was investigated in an analytic cross-sectional study conducted among school-age children attending rural schools in Pichincha Province in Ecuador. Results: A total of 2865 children aged 5 to 19 years from 55 schools was examined. Active infection with any geohelminth and infections with A lumbricoides or Ancylostoma duodenale were associated with significant protective effects against allergen skin test reactivity. Children with the highest levels of total IgE or with anti-A lumbricoides IgG4 antibodies were protected against skin test reactivity also, and the protective effects of high IgE or anti-A lumbricoides IgG4 and or active geohelminth infections were statistically independent. Conclusion: Active infections with geohelminth parasites and the presence of serologic markers of chronic infections (high levels of total serum IgE or anti-A lumbricoides IgG4) are independent protective factors against allergen skin test reactivity among school-age children living in an endemic region of the rural tropics.	NIAID, LPD, NIH, Bethesda, MD 20892 USA; Hosp Pedro Vicente Maldonado, Lab Invest, Pedro Vicente Maldonado, Ecuador; London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; London School of Hygiene & Tropical Medicine; St Georges University London; St Georges University London	Nutman, TB (corresponding author), NIAID, LPD, NIH, 4 Ctr Dr,Room 4-126, Bethesda, MD 20892 USA.		RODRIGUES, LAURA CUNHA/AAO-4130-2021	Rodrigues, Laura Cunha/0000-0001-9008-660X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000805, ZIAAI000805] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; Johnston SL, 2001, BRIT MED J, V322, P376, DOI 10.1136/bmj.322.7283.376; KLION AD, 1991, J INFECT DIS, V163, P1318, DOI 10.1093/infdis/163.6.1318; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Naus CWA, 1999, INFECT IMMUN, V67, P3444, DOI 10.1128/IAI.67.7.3444-3451.1999; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Palmer DR, 1996, B WORLD HEALTH ORGAN, V74, P381; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; *WHO, 1985, WHOPDP852; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	19	224	233	0	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					995	1000		10.1067/mai.2003.1348	http://dx.doi.org/10.1067/mai.2003.1348			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743563	Bronze			2022-12-18	WOS:000182904500013
J	Binkley, KE; Davis, A				Binkley, KE; Davis, A			Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; estrogen; Cl inhibitor	HEREDITARY ANGIONEUROTIC-EDEMA; FACTOR-XII; C1 INHIBITOR; ORAL-CONTRACEPTIVES; WOMEN	Background: Two genetic forms of hereditary angioedema (HAE) are currently recognized. Both are transmitted in an autosomal dominant manner and are characterized by recurrent episodes of localized angioedema. Involvement of the gut leads to episodes of severe abdominal pain, and laryngeal involvement can lead to airway obstruction and even death. One type results from heterozygosity for a nonexpressed C1 inhibitor allele, and the other results from heterozygosity for a nonfunctional C1 inhibitor allele. Objective: This report identifies a third type of HAE, with a unique estrogen-dependent phenotype. Methods: Detailed medical histories were obtained from family members, and a pedigree was constructed to ascertain the mode of inheritance. Determination of serum complement factors, C1 inhibitor protein, C1 inhibitor function, coagulation factor XII, plasma prekallikrein, high molecular weight kininogen, and selected DNA sequences were performed in affected members by using standard assays. Results: Episodes of angioedema were clinically indistinguishable from those associated with previously described forms of HAE; however, these occurred only during pregnancy or the use of exogenous estrogens. Patients were otherwise asymptomatic, except for one patient who had acetyl salicylic acid/nonsteroidal anti-inflammatory drug-related angioedema later in life. History was available for members spanning 4 generations, and affected individuals were identified in 3 generations. Of 46 family members, phenotype could be determined in 13 members. Seven were affected, and 6 were not. One male of undetermined phenotype was an obligate carrier. The unique estrogen-dependent nature of the phenotype means that the status of several members in the third and fourth generation remains unknown. The disorder appears to be transmitted in an autosomal dominant fashion, although other modes of inheritance cannot be excluded entirely. C1 inhibitor protein, C1 inhibitor function, C2, C4, C1q, coagulation factor XII, prekallikrein, and high molecular kininogen were normal in 3 affected family members during asymptomatic periods. DNA sequencing revealed no abnormality in 3 patients in the coding region of the gene encoding C1 inhibitor or in the 5' flanking regions of the genes encoding C1 inhibitor and factor XII, Conclusions: This family appears to have a novel form of inherited angioedema that does not result from CI inhibitor deficiency or dysfunction, The phenotype is uniquely estrogen dependent. Implications for diagnosis and treatment are discussed. Further studies are required to define the exact nature of the genetic abnormality involved.	Univ Toronto, St Michaels Hosp, Div Clin Immunol & Allergy, Toronto, ON M5B 1W8, Canada; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Binkley, KE (corresponding author), 30 St Clair Ave W,Suite 201, Toronto, ON M4V 3A1, Canada.				NICHD NIH HHS [HD337327, HD22082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022082, R37HD022082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AL-ABDULLAH I H, 1984, Complement, V1, P27; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; BRECKENRIDGE RT, 1962, BLOOD, V20, P137, DOI 10.1182/blood.V20.2.137.137; COHEN AJ, 1992, J ALLERGY CLIN IMMUN, V90, P412, DOI 10.1016/S0091-6749(05)80025-9; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; FALUS A, 1990, MOL IMMUNOL, V27, P101; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GORDON EM, 1988, J LAB CLIN MED, V111, P52; GORDON EM, 1980, J LAB CLIN MED, V96, P762; GROSS BM, 1973, EUR J BIOCHEM, V35, P32; HALBMAYER WM, 1991, THROMB HAEMOSTASIS, V2, P134; JESPERSEN J, 1985, THROMB HAEMOSTASIS, V54, P454; LAPPIN DF, 1989, EUR J CLIN INVEST, V19, P45, DOI 10.1111/j.1365-2362.1989.tb00194.x; OGSTON D, 1981, THROMB RES, V23, P454; PEARSON KD, 1972, AM J ROENTGENOL, V116, P256, DOI 10.2214/ajr.116.2.256; Prada AE, 1998, IMMUNOBIOLOGY, V199, P377, DOI 10.1016/S0171-2985(98)80042-9; RATNOFF OD, 1962, BIOCHEMISTRY-US, V1, P967, DOI 10.1021/bi00912a005; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; WARIN RP, 1986, BRIT J DERMATOL, V115, P731, DOI 10.1111/j.1365-2133.1986.tb06656.x; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503	23	224	228	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					546	550						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984376				2022-12-18	WOS:000089471900019
J	Sicherer, SH; Sampson, HA				Sicherer, SH; Sampson, HA			Food hypersensitivity and atopic dermatitis: Pathophysiology, epidemiology, diagnosis, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NEW YORK			atopic dermatitis; food allergy; oral food challenges	EPIDERMAL LANGERHANS CELLS; HISTAMINE-RELEASING FACTOR; SKIN-PRICK TESTS; DOUBLE-BLIND; NATURAL-HISTORY; IGE ANTIBODIES; PEANUT ALLERGY; COWS MILK; HIGH-RISK; FISH HYPERSENSITIVITY	Laboratory and clinical investigations over the past two decades have demonstrated that food allergy plays a pathogenic role in a subset of patients, primarily infants and children, with atopic dermatitis (AD), Approximately 40% of infants and young children with moderate to severe AD have food allergy, but identifying this subset of patients and isolating the relevant food allergens requires a high index of suspicion, the use of appropriate laboratory tests, and, in some cases, physician-supervised oral food challenges, Removal of the causal food protein(s) leads to clinical improvement but requires a great deal of education because most of the common causal foods (egg, milk, wheat, soy, peanut, and so forth) are ubiquitous in the food supply, and food elimination diets risk causing nutritional deficits. Fortunately, most food allergies resolve in early childhood, and food allergy is not a common cause for AD in older children and adults.	Mt Sinai Sch Med, Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Sch Med, Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.							ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; ATHERTON DJ, 1978, LANCET, V1, P401; BEMHISELBROADBE.J, 1989, J ALLERGY CLIN IMMUN, V83, P435; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Blackfan KD, 1920, AM J MED SCI, V160, P341; BOCK S, 1978, J ALLERGY CLIN IMMUN, V62, P3327; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; DAVID TJ, 1989, ALLERGY, V44, P101, DOI 10.1111/j.1398-9995.1989.tb02464.x; DAVID TJ, 1984, ARCH DIS CHILD, V59, P323, DOI 10.1136/adc.59.4.323; deMaatBleeker F, 1996, MONOGR ALLERGY, V32, P157; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FUGLSANG G, 1994, ALLERGY, V49, P31, DOI 10.1111/j.1398-9995.1994.tb00770.x; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin Jon M., 1997, Journal of Dermatology (Tokyo), V24, P495; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HILL DJ, 1982, CLIN ALLERGY, V12, P313, DOI 10.1111/j.1365-2222.1982.tb02533.x; HOFFMAN DR, 1975, ADV DIAGNOSIS ALLERG, P165; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; JUTO P, 1978, CLIN ALLERGY, V8, P493, DOI 10.1111/j.1365-2222.1978.tb01502.x; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P12; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Lever R, 1998, PEDIATR ALLERGY IMMU, V9, P13, DOI 10.1111/j.1399-3038.1998.tb00294.x; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; Lyczak JB, 1996, J BIOL CHEM, V271, P3428; MAGNARIN M, 1995, J ALLERGY CLIN IMMUN, V96, P200, DOI 10.1016/S0091-6749(95)70009-9; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; MUNKVAD M, 1984, ACTA DERM-VENEREOL, V64, P524; NEILD VS, 1986, BRIT J DERMATOL, V114, P117, DOI 10.1111/j.1365-2133.1986.tb02786.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SAMPSON HA, 1992, JAMA-J AM MED ASSOC, V268, P2840, DOI 10.1001/jama.268.20.2840; SAMPSON HA, 1997, J ROY SOC MED, V30, P2; SCHLOSS OM, 1915, T AM PEDIATR SOC, V27, P62; SCHWARTZ HJ, 1997, FOOD ALLERGY ADVERSE, P411; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; SIGURS N, 1992, PEDIATRICS, V89, P735; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Suomalainen H, 1994, Pediatr Allergy Immunol, V5, P27, DOI 10.1111/j.1399-3038.1994.tb00215.x; TALBOT FB, 1918, MED CLIN N AM, V1, P985; TERR AI, 1996, ALLERGY ASTHMA IMMUN, P749; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Walzer M, 1927, J IMMUNOL, V14, P143; Wilson SJ, 1935, AM J DIS CHILD, V50, P49, DOI 10.1001/archpedi.1935.01970070058005; YOUNG E, 1987, J ROY COLL PHYS LOND, V21, P241; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	92	224	231	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S114	S122		10.1016/S0091-6749(99)70053-9	http://dx.doi.org/10.1016/S0091-6749(99)70053-9			9	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242FP	10482862				2022-12-18	WOS:000082928500005
J	Nickel, R; Kulig, M; Forster, J; Bergmann, R; Bauer, CP; Lau, S; GuggenmoosHolzmann, I; Wahn, U				Nickel, R; Kulig, M; Forster, J; Bergmann, R; Bauer, CP; Lau, S; GuggenmoosHolzmann, I; Wahn, U			Sensitization to hen's egg at the age of twelve months is predictive for allergic sensitization to common indoor and outdoor allergens at the age of three years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prediction; risk factors; infancy; atopy; food allergens; inhalant allergens	ATOPIC DISEASE; EARLY-CHILDHOOD; ENVIRONMENTAL-FACTORS; NATURAL-HISTORY; GENETIC RISK; CHILDREN; ASTHMA; INFANTS; EXPOSURE; AVOIDANCE	Background: Specific predictors for atopic sensitization in early infancy are prerequisites for preventive intervention studies, Objective: To identify predictors of allergic sensitization to common aeroallergens in infancy, 1314 children in five German cities were followed up from birth (1990) to the age of 3 years, Methods: Blood samples mere taken from cord blood and at follow-up visits at the ages of 1, 2, and 3 years. Total serum IgE and specific IgE antibodies to common food and inhalant allergens were determined, Results: Among our study population, risk factors for sensitization to indoor and/or outdoor allergens at the age of 3 years were a positive family history, the presence of hen's egg-specific IgE antibodies (greater than or equal to 0.35 kU/L), and increased log[total IgE] levels at the age of 12 months, Elevated cord blood IgE was not associated with sensitization to inhalant allergens at the age of 3 years, Egg-specific IgE greater than 2 kU/L in combination with a positive family history of atopy was a highly specific (specificity, 99%) and predictive (positive predictive value, 78%) marker for sensitization to inhalant allergens at 3 Sears of age, Conclusions: Hen's egg-specific IgE at the age of 12 months is a valuable marker for subsequent allergic sensitization to allergens that cause asthma, allergic rhinitis, and atopic dermatitis.	HUMBOLDT UNIV BERLIN, DEPT PEDIAT, BERLIN, GERMANY; FREE UNIV BERLIN, INST MED STAT & DOCUMENTAT, D-1000 BERLIN, GERMANY; UNIV FREIBURG, CHILDRENS HOSP, FREIBURG, GERMANY; UNIV MUNICH, CHILDRENS HOSP, D-8000 MUNICH, GERMANY	Humboldt University of Berlin; Free University of Berlin; University of Freiburg; University of Munich								ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BERGMANN KE, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02466.x; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; BERGMANN RL, 1997, IN PRESS CLIN EXP AL, V27; BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; BORRES MP, 1995, CLIN EXP ALLERGY, V25, P543, DOI 10.1111/j.1365-2222.1995.tb01092.x; BORRES MP, 1995, J ALLERGY CLIN IMMUN, V95, P694, DOI 10.1016/S0091-6749(95)70174-5; BOUSQUET J, 1983, ANN ALLERGY, V51, P291; BOUSQUET J, 1995, NESTLE NUTR WORKS SE, V34, P93; BURROWS B, 1989, NEW ENGL J MED, V325, P1067; COOKSON WOCM, 1989, LANCET, V1, P1292; CRONER S, 1992, J PEDIATR-US, V121, pS58, DOI 10.1016/S0022-3476(05)81408-8; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; DUCHATEAU J, 1983, LANCET, V1, P413; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P80, DOI 10.1111/j.1399-3038.1995.tb00263.x; Host A, 1995, Pediatr Allergy Immunol, V6 Suppl 8, P20; Kjellman N I, 1994, Pediatr Allergy Immunol, V5, P13, DOI 10.1111/j.1399-3038.1994.tb00342.x; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644, DOI 10.1164/ajrccm.151.5.7735627; MERRETT T, 1992, CLIN EXP ALLERGY, V22, P506, DOI 10.1111/j.1365-2222.1992.tb00155.x; NORRUSIS MJ, 1990, SPSS ADV STAT USERS; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PRICE GW, 1995, J ALLERGY CLIN IMMUN, V96, P266, DOI 10.1016/S0091-6749(95)70020-X; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7; ZEIGER RS, 1995, NESTLE NUTR WORKS SE, V34, P203	39	224	226	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					613	617		10.1016/S0091-6749(97)70021-6	http://dx.doi.org/10.1016/S0091-6749(97)70021-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155826	hybrid			2022-12-18	WOS:A1997WY60000007
J	Cockcroft, DW; Swystun, VA				Cockcroft, DW; Swystun, VA			Asthma control versus asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											Cockcroft, DW (corresponding author), UNIV SASKATCHEWAN,ROYAL UNIV HOSP,DEPT MED,DIV RESP MED,103 HOSP DR,ELLIS HALL,SASKATOON,SK S7N 0W8,CANADA.							Ernst P, 1996, CAN RESPIR J, V3, P89; KALINER M, 1995, ANN ALLERG ASTHMA IM, V75, P169; KERIGAN AT, 1977, CAN MED ASSOC J, V116, P876; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; *US DEP HHS, 1992, INT CONS REP DIAGN T	5	224	229	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1016	1018		10.1016/S0091-6749(96)80185-0	http://dx.doi.org/10.1016/S0091-6749(96)80185-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977499				2022-12-18	WOS:A1996WB37800003
J	HOPP, RJ; BEWTRA, AK; WATT, GD; NAIR, NM; TOWNLEY, RG				HOPP, RJ; BEWTRA, AK; WATT, GD; NAIR, NM; TOWNLEY, RG			GENETIC-ANALYSIS OF ALLERGIC DISEASE IN TWINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT MED,CTR ALLERG DIS,OMAHA,NE 68179	Creighton University			Hopp, Russell/K-4578-2019					ALLEN G, 1967, ACTA GENET STAT MED, V17, P475; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BIAS W B, 1973, P39; BLUMENTHAL MN, 1980, J ALLERGY CLIN IMMUN, V65, P403, DOI 10.1016/0091-6749(80)90231-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BUCKLEY CE, 1979, COMPREHENSIVE IMMUNO, P229; CAVALLISTORZA LL, 1965, GENETICS HUMAN POPUL, P579; CHRISTIAN JC, 1974, AM J HUM GENET, V26, P154; COMSTOCK G, 1962, AM REV RESPIR DIS, V86, P165; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367; KEMPTHORNE O, 1961, AM J HUM GENET, V13, P320; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; KLEINBAUM DG, 1978, APPL REGRESSION ANAL, P106; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; MARSH D, 1980, J ALLERGY CLIN IMMUN, V66, P322; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; ORGEL HA, 1975, PEDIATR CLIN N AM, V22, P17; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; SISTONEN P, 1980, HUM HERED, V30, P155, DOI 10.1159/000153120; SMITH C, 1972, HUM HERED, V22, P97, DOI 10.1159/000152476; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x; ZERBE GO, 1980, COMMUN STATIST THE A, P1641; [No title captured]	29	224	229	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					265	270		10.1016/S0091-6749(84)80018-4	http://dx.doi.org/10.1016/S0091-6749(84)80018-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6538209				2022-12-18	WOS:A1984SF02000008
J	Coulter, TI; Chandra, A; Bacon, CM; Babar, J; Curtis, J; Screaton, N; Goodlad, JR; Farmer, G; Steele, CL; Leahy, TR; Doffinger, R; Baxendale, H; Bernatoniene, J; Edgar, JDM; Longhurst, HJ; Ehl, S; Speckmann, C; Grimbacher, B; Sediva, A; Milota, T; Faust, SN; Williams, AP; Hayman, G; Kucuk, ZY; Hague, R; French, P; Brooker, R; Forsyth, P; Herriot, R; Cancrini, C; Palma, P; Ariganello, P; Conlon, N; Feighery, C; Gavin, PJ; Jones, A; Imai, K; Ibrahim, MAA; Markelj, G; Abinun, M; Rieux-Laucat, F; Latour, S; Pellier, I; Fischer, A; Touzot, F; Casanova, JL; Durandy, A; Burns, SO; Savic, S; Kumararatne, DS; Moshous, D; Kracker, S; Vanhaesebroeck, B; Okkenhaug, K; Picard, C; Nejentsev, S; Condliffe, AM; Cant, AJ				Coulter, Tanya I.; Chandra, Anita; Bacon, Chris M.; Babar, Judith; Curtis, James; Screaton, Nick; Goodlad, John R.; Farmer, George; Steele, Cathal Laurence; Leahy, Timothy Ronan; Doffinger, Rainer; Baxendale, Helen; Bernatoniene, Jolanta; Edgar, J. David M.; Longhurst, Hilary J.; Ehl, Stephan; Speckmann, Carsten; Grimbacher, Bodo; Sediva, Anna; Milota, Tomas; Faust, Saul N.; Williams, Anthony P.; Hayman, Grant; Kucuk, Zeynep Yesim; Hague, Rosie; French, Paul; Brooker, Richard D; Forsyth, Peter; Herriot, Richard; Cancrini, Caterina; Palma, Paolo; Ariganello, Paola; Conlon, Niall; Feighery, Conleth; Gavin, Patrick J.; Jones, Alison; Imai, Kohsuke; Ibrahim, Mohammad A; Markelj, Gasper; Abinun, Mario; Rieux-Laucat, Frederic; Latour, Sylvain; Pellier, Isabelle; Fischer, Alain; Touzot, Fabien; Casanova, Jean-Laurent; Durandy, Anne; Burns, Siobhan O; Savic, Sinisa; Kumararatne, D. S.; Moshous, Despina; Kracker, Sven; Vanhaesebroeck, Bart; Okkenhaug, Klaus; Picard, Capucine; Nejentsev, Sergey; Condliffe, Alison M.; Cant, Andrew James			Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activated phosphoinositide 3-kinase delta syndrome; p110 delta-activating mutation causing senescent T cells; lymphadenopathy; immunodeficiency; phosphoinositide 3-kinase delta; PIK3CD gene; bronchiectasis; immunodeficiency; hematopoietic stem cell; transplantation; phosphoinositide 3-kinase inhibitor	COMMON VARIABLE IMMUNODEFICIENCY; HYPER-IGM SYNDROME; B-CELL; REFERENCE VALUES; IMMUNOLOGICAL FEATURES; P110 DELTA; P110-DELTA; MUTATIONS; PIK3CD; CT	Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase delta (PI3K delta). Objective: We sought to review the clinical, immunologic, histopathologic, and radiologic features of APDS in a large genetically defined international cohort. Methods: We applied a clinical questionnaire and performed review of medical notes, radiology, histopathology, and laboratory investigations of 53 patients with APDS. Results: Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood. Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%). Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3K delta in the central nervous system; consistent with this, PI3K delta is broadly expressed in the developing murine central nervous system. Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%). Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunologic features. No immunologic marker reliably predicted clinical severity, which ranged from asymptomatic to death in early childhood. The majority of patients received immunoglobulin replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation. Five patients died from complications of APDS. Conclusion: APDS is a combined immunodeficiency with multiple clinical manifestations, many with incomplete penetrance and others with variable expressivity. The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease. Clinical trials of selective PI3K delta inhibitors offer new prospects for APDS treatment.	[Coulter, Tanya I.; Conlon, Niall; Feighery, Conleth] Trinity Coll Dublin, Sch Med, Dept Immunol, Dublin, Ireland; [Coulter, Tanya I.; Leahy, Timothy Ronan; Gavin, Patrick J.] Our Ladys Childrens Hosp Crumlin, Dept Paediat Immunol & Infect Dis, Dublin, Ireland; [Chandra, Anita; Doffinger, Rainer; Kumararatne, D. S.] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; [Chandra, Anita; Okkenhaug, Klaus] Babraham Inst, Lymphocyte Signalling & Dev, Cambridge, England; [Chandra, Anita; Curtis, James; Nejentsev, Sergey; Condliffe, Alison M.] Univ Cambridge, Dept Med, Cambridge, England; [Bacon, Chris M.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Babar, Judith] Cambridge Univ Hosp NHS Fdn Trust, Dept Radiol, Cambridge, England; [Farmer, George; Forsyth, Peter] Raigmore Hosp, Inverness, Scotland; [Steele, Cathal Laurence; Edgar, J. David M.; Cancrini, Caterina] Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland; [Doffinger, Rainer] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England; [Bernatoniene, Jolanta] Bristol Royal Hosp Children, Univ Hosp Bristol NHS Fdn Trust, Dept Infect Dis & Immunol, London, England; [Longhurst, Hilary J.] Barts Hlth NHS Trust, London, England; [Ehl, Stephan; Speckmann, Carsten; Grimbacher, Bodo; Savic, Sinisa] Univ Hosp Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Speckmann, Carsten] Univ Med Ctr, Dept Pediat & Adolescent Med, Freiburg, Germany; [Sediva, Anna; Milota, Tomas] Univ Hosp Motol, Inst Immunol, Prague, Czech Republic; [Faust, Saul N.; Williams, Anthony P.] Univ Southampton, Fac Med, Southampton, Hants, England; [Faust, Saul N.; Williams, Anthony P.] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Faust, Saul N.] Univ Hosp Southampton NHS Fdn Trust, NIHR Wellcome Trust Clin Res Facil, Southampton, Hants, England; [Hayman, Grant] Epsom, Dept Immunol, Surrey, England; [Hayman, Grant] St Helier Univ Hosp NHS Trust, Surrey, England; [Kucuk, Zeynep Yesim] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Brooker, Richard D; Herriot, Richard] Royal Aberdeen Childrens Hosp, Aberdeen, Scotland; [Palma, Paolo; Ariganello, Paola] Osped Pediat Bambino Gesu, Dept Pediat, Rome, Italy; [Palma, Paolo; Ariganello, Paola] Univ Roma Tor Vergata, Rome, Italy; [Jones, Alison] Great Ormond St Hosp NHS Fdn Trust, Dept Immunol, London, England; [Ibrahim, Mohammad A] Kings Coll Hosp NHS Fdn Trust, Kings Hlth Partners, Kings Coll London, Sch Med,Div Asthma Allergy & Lung Biol,Dept Immun, London, England; [Markelj, Gasper] Univ Childrens Hosp, Univ Med Ctr, Dept Allergol Rheumatol & Clin Immunol, Ljubljana, Slovenia; [Abinun, Mario; Cant, Andrew James] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Touzot, Fabien] Necker Childrens Hosp, AP HP, Ctr Invest Clin Integre Biotherapies, Dept Biotherapie, Paris, France; [Rieux-Laucat, Frederic; Latour, Sylvain; Fischer, Alain; Touzot, Fabien; Casanova, Jean-Laurent; Durandy, Anne; Moshous, Despina; Kracker, Sven; Picard, Capucine] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Rieux-Laucat, Frederic; Latour, Sylvain; Fischer, Alain; Touzot, Fabien; Durandy, Anne; Kracker, Sven; Picard, Capucine] INSERM UMR1163, Paris, France; [Fischer, Alain; Casanova, Jean-Laurent; Moshous, Despina; Picard, Capucine] Necker Childrens Hosp, AP HP, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Pellier, Isabelle] CHU Angers, Unite Oncohematoimmunol Pediat, Angers, France; [Pellier, Isabelle; Picard, Capucine] AP HP, Ctr Reference Deficits Immunitaires Hereditaires, Paris, France; [Pellier, Isabelle] Inserm UMR 892, Angers, France; [Pellier, Isabelle] CNRS UMR 6299, Angers, France; [Fischer, Alain] Coll France, Paris, France; [Casanova, Jean-Laurent; Picard, Capucine] Necker Childrens Hosp, Imagine Inst, INSERM UMR1163, Lab Human Genet Infect Dis,Necker Branch, Paris, France; [Casanova, Jean-Laurent; Picard, Capucine] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, Chevy Chase, MD USA; [Burns, Siobhan O] UCL, Inst Immun & Transplantat, London, England; [Savic, Sinisa] St James Univ Hosp, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England; [Vanhaesebroeck, Bart] UCL, UCL Canc Inst, London, England; [Condliffe, Alison M.] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield S10 2RX, S Yorkshire, England; [Abinun, Mario; Cant, Andrew James] Newcastle Univ, Newcastle Upon Tyne Hosp NHS Trust, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Bacon, Chris M.] Newcastle Upon Tyne NHS Fdn Trust, Northern England Haematooncol Diagnost Serv, Newcastle Upon Tyne, Tyne & Wear, England; [Baxendale, Helen] Papworth Everard, Papworth Hosp NHS Trust, Cambridge, England; [Screaton, Nick] Papworth Everard Hosp, Papworth Hosp NHS Fdn Trust, Dept Radiol, Cambridge, England; [Goodlad, John R.] Western Gen Hosp, Dept Pathol, Edinburgh, Midlothian, Scotland; [Hague, Rosie] Dept Royal Hosp Children, Glasgow, Lanark, Scotland; [French, Paul] Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow, Lanark, Scotland; [Imai, Kohsuke] Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan	Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; Newcastle University - UK; University of Cambridge; University of Cambridge; Bristol Royal Hospital For Children; Barts Health NHS Trust; University of Freiburg; University of Freiburg; Motol University Hospital; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Cincinnati Children's Hospital Medical Center; University of Aberdeen; IRCCS Bambino Gesu; University of Rome Tor Vergata; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; King's College Hospital NHS Foundation Trust; University of London; King's College London; University Medical Centre Ljubljana; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute; University of London; University College London; Saint James's University Hospital; University of London; University College London; University of Sheffield; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Papworth Hospital; Papworth Hospital; University of Edinburgh; Queen Elizabeth University Hospital (QEUH); Tokyo Medical & Dental University (TMDU)	Condliffe, AM (corresponding author), Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield S10 2RX, S Yorkshire, England.	a.m.condliffe@sheffield.ac.uk	Kracker, Sven/H-3681-2017; Touzot, Fabien/T-7797-2018; Ehl, Stephan/AAM-6006-2020; Leahy, Ronan/AAL-5008-2021; Casanova, Jean-Laurent/I-3418-2017; Okkenhaug, Klaus/H-3154-2019; Sediva, Anna/AAE-2774-2019; Imai, Kohsuke/Q-2602-2015; Ibrahim, Mohammad A. A./G-1387-2011; Moshous, Despina/B-7507-2017; Sediva, Anna/J-5904-2017; Rieux-Laucat, Frédéric/A-7916-2017; Durandy, Anne/H-7475-2017; Palma, Paolo/K-3379-2016; Milota, Tomas/N-5853-2017; Savic, Sinisa/Q-6217-2019; Palma, Paolo/AAK-9275-2020; Latour, Sylvain/H-3652-2017; Faust, Saul/J-9779-2014	Kracker, Sven/0000-0003-4543-8236; Touzot, Fabien/0000-0002-0889-4905; Leahy, Ronan/0000-0001-6419-9328; Okkenhaug, Klaus/0000-0002-9432-4051; Sediva, Anna/0000-0001-7730-2304; Imai, Kohsuke/0000-0003-2132-8403; Ibrahim, Mohammad A. A./0000-0002-0116-597X; Moshous, Despina/0000-0001-6719-3693; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Durandy, Anne/0000-0001-7706-8466; Savic, Sinisa/0000-0001-7910-0554; Palma, Paolo/0000-0002-3066-4719; Latour, Sylvain/0000-0001-8238-4391; Bacon, Chris/0000-0002-8268-2812; Faust, Saul/0000-0003-3410-7642; Goodlad, John Robert/0000-0002-8385-8517; Edgar, John David Moore/0000-0003-2969-4475; Burns, Siobhan/0000-0002-3356-9506; Speckmann, Carsten/0000-0002-6217-1556; Ehl, Stephan/0000-0002-9265-2721; Doffinger, R/0000-0002-9841-3617; Milota, Tomas/0000-0003-2105-3462; Casanova, Jean-Laurent/0000-0002-7782-4169	National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Wellcome Trust [103413/Z/13/Z]; BBSRC; MRC; GlaxoSmithKline; National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, United Kingdom; German Federal Ministry of Education and Research [BMBF 01 EO 0803, 01GM1111B]; Southampton UK NIHR Wellcome Trust Clinical Research Facility; NIHR Respiratory Biomedical Research Unit; NHS Innovation London and King's College Hospital Charitable Trust; European Union [249816]; French Agence Nationale de la Recherche as part of the "Investments for the Future'' program [ANR-10-IAHU-01]; Agence Nationale de la Recherche (ANR) [ANR-14-CE14-0028-01]; Foundation ARC pour la Recherche sur le Cancer (France); Rare Diseases Foundation (France); Francaois Aupetit Association (France); Institut National de la Sante et de la Recherche Medicale; Fondation pour la Recherche Medicale [ING20130526624]; la Ligue Contre le Cancer (Comite de Paris); Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH); Higher Education Funding Council for England; UK Biotechnology and Biological Sciences Research Council [BB/I007806/1]; Cancer Research UK [C23338/A15965]; NIHR University College London Hospitals Biomedical Research Centre; European Research Council Starting grant [260477]; EU [261441]; NIHR Cambridge Biomedical Research Centre, UK; Medical Research Council [MR/M012328/1]; British Lung Foundation; Cambridge NIHR-BRC; Novartis; MedImmune; University of Sheffield; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0407, BBS/E/B/000C0409, BB/I007806/1] Funding Source: researchfish; Cancer Research UK [15965] Funding Source: researchfish; Medical Research Council [MR/M012328/2] Funding Source: researchfish; BBSRC [BBS/E/B/000C0407, BBS/E/B/000C0427, BBS/E/B/000C0409, BB/I007806/1] Funding Source: UKRI; MRC [MR/M012328/1, MR/M012328/2] Funding Source: UKRI	National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Wellcome Trust(Wellcome Trust); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); GlaxoSmithKline(GlaxoSmithKline); National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, United Kingdom; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Southampton UK NIHR Wellcome Trust Clinical Research Facility; NIHR Respiratory Biomedical Research Unit; NHS Innovation London and King's College Hospital Charitable Trust; European Union(European Commission); French Agence Nationale de la Recherche as part of the "Investments for the Future'' program(French National Research Agency (ANR)); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Foundation ARC pour la Recherche sur le Cancer (France); Rare Diseases Foundation (France); Francaois Aupetit Association (France); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); la Ligue Contre le Cancer (Comite de Paris); Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH); Higher Education Funding Council for England(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); NIHR University College London Hospitals Biomedical Research Centre(General Electric); European Research Council Starting grant(European Research Council (ERC)); EU(European Commission); NIHR Cambridge Biomedical Research Centre, UK(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation; Cambridge NIHR-BRC(National Institute for Health Research (NIHR)); Novartis(Novartis); MedImmune(AstraZenecaMedimmune); University of Sheffield; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	T.C. is supported by the National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland. A.C. has a Wellcome Trust Postdoctoral Training Fellowship for Clinicians (103413/Z/13/Z). K.O. is supported by funding from BBSRC, MRC, the Wellcome Trust, and GlaxoSmithKline. R.D. and D.S.K. are funded by National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, United Kingdom. C.S. and S.E. are supported by the German Federal Ministry of Education and Research (BMBF 01 EO 0803 grant to the Center of Chronic immunodeficiency and BMBF 01GM1111B grant to the PID-NET initiative). S.N.F is supported in part by the Southampton UK NIHR Wellcome Trust Clinical Research Facility and NIHR Respiratory Biomedical Research Unit. M.A.A.I. is funded by NHS Innovation London and King's College Hospital Charitable Trust. A.F., S.L., A.D., F.R.-L. and S.K. are supported by the European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE contract 249816) and a government grant managed by the French Agence Nationale de la Recherche as part of the "Investments for the Future'' program (ANR-10-IAHU-01). S.L. is supported by the Agence Nationale de la Recherche (ANR) (ANR-14-CE14-0028-01), the Foundation ARC pour la Recherche sur le Cancer (France), the Rare Diseases Foundation (France), and the Francaois Aupetit Association (France). S.L. is a senior scientist and S.K. is a researcher at the Centre National de la Recherche Scientifique-CNRS (France). A.D. and S. K. are supported by the "Institut National de la Sante et de la Recherche Medicale.'' S. K. is supported by the Fondation pour la Recherche Medicale (grant no. ING20130526624), la Ligue Contre le Cancer (Comite de Paris), and Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH). S.O.B. is supported by the Higher Education Funding Council for England. B.V. is supported by the UK Biotechnology and Biological Sciences Research Council [BB/I007806/1], Cancer Research UK [C23338/A15965), and the NIHR University College London Hospitals Biomedical Research Centre. B.V. is consultant to Karus Therapeutics (Oxford, United Kingdom). S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477, the EU FP7 collaborative grant 261441 (PEVNET project), and the NIHR Cambridge Biomedical Research Centre, UK. A.M.C. is funded by the Medical Research Council (MR/M012328/1), British Lung Foundation, University of Sheffield, and Cambridge NIHR-BRC. Research in A.M.C.'s laboratory has received noncommercial grant support from GlaxoSmithKline, Novartis, and MedImmune.	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Conte E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024663; Copley SJ, 2002, RADIOLOGY, V223, P812, DOI 10.1148/radiol.2233010760; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712; Hartman HN, 2015, J CLIN IMMUNOL, V35, P11, DOI 10.1007/s10875-014-0109-1; Imai K, 2014, J CLIN IMMUNOL, V34, pS286; Jou ST, 2006, INT J IMMUNOGENET, V33, P361, DOI 10.1111/j.1744-313X.2006.00627.x; Kok K, 2009, TRENDS BIOCHEM SCI, V34, P115, DOI 10.1016/j.tibs.2009.01.003; Kracker S, 2014, J ALLERGY CLIN IMMUN, V134, P233, DOI 10.1016/j.jaci.2014.02.020; Law AJ, 2012, P NATL ACAD SCI USA, V109, P12165, DOI 10.1073/pnas.1206118109; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Maarschalk-Ellerbroek LJ, 2014, J CLIN IMMUNOL, V34, P642, DOI 10.1007/s10875-014-0068-6; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Okkenhaug K, 2002, SCIENCE, V297, P1031; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Patton DT, 2006, J IMMUNOL, V177, P6598, DOI 10.4049/jimmunol.177.10.6598; Peng J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6937; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Sawyer C, 2003, CANCER RES, V63, P1667; Spinelli L, 2015, J MED GENET, V52, P128, DOI 10.1136/jmedgenet-2014-102803; Suarez-Fueyo A, 2011, J IMMUNOL, V187, P2376, DOI 10.4049/jimmunol.1101602; Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Whitehead MA, 2012, BIOCHEM J, V443, P857, DOI 10.1042/BJ20112214; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	41	223	234	2	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					597	+		10.1016/j.jaci.2016.06.021	http://dx.doi.org/10.1016/j.jaci.2016.06.021			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27555459	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000397002400025
J	Voort, AMMSVD; Arends, LR; Jongste, JC; Annesi-Maesano, I; Arshad, SH; Barros, H; Basterrechea, M; Bisgaard, H; Chatzi, L; Corpeleijn, E; Correia, S; Craig, LC; Devereux, G; Dogaru, C; Dostal, M; Duchen, K; Eggesbo, M; van der Ent, CK; Fantini, MP; Forastiere, F; Frey, U; Gehring, U; Gori, D; van der Gugten, AC; Hanke, W; Henderson, AJ; Heude, B; Iniguez, C; Inskip, HM; Keil, T; Kelleher, CC; Kogevinas, M; Kreiner-Moller, E; Kuehni, CE; Kupers, LK; Lancz, K; Larsen, PS; Lau, S; Ludvigsson, J; Mommers, M; Andersen, AMN; Palkovicova, L; Pike, KC; Pizzi, C; Polanska, K; Porta, D; Richiardi, L; Roberts, G; Schmidt, A; Sram, RJ; Sunyer, J; Thijs, C; Torrent, M; Viljoen, K; Wijga, AH; Vrijheid, M; Jaddoe, VWV; Duijts, L				Voort, Agnes M. M. Sonnenschein-van der; Arends, Lidia R.; de Jongste, Johan C.; Annesi-Maesano, Isabella; Arshad, S. Hasan; Barros, Henrique; Basterrechea, Mikel; Bisgaard, Hans; Chatzi, Leda; Corpeleijn, Eva; Correia, Sofia; Craig, Leone C.; Devereux, Graham; Dogaru, Cristian; Dostal, Miroslav; Duchen, Karel; Eggesbo, Merete; van der Ent, C. Kors; Fantini, Maria P.; Forastiere, Francesco; Frey, Urs; Gehring, Ulrike; Gori, Davide; van der Gugten, Anne C.; Hanke, Wojciech; Henderson, A. John; Heude, Barbara; Iniguez, Carmen; Inskip, Hazel M.; Keil, Thomas; Kelleher, Cecily C.; Kogevinas, Manolis; Kreiner-Moller, Eskil; Kuehni, Claudia E.; Kuepers, Leanne K.; Lancz, Kinga; Larsen, Pernille S.; Lau, Susanne; Ludvigsson, Johnny; Mommers, Monique; Andersen, Anne-Marie Nybo; Palkovicova, Lubica; Pike, Katharine C.; Pizzi, Costanza; Polanska, Kinga; Porta, Daniela; Richiardi, Lorenzo; Roberts, Graham; Schmidt, Anne; Sram, Radim J.; Sunyer, Jordi; Thijs, Carel; Torrent, Maties; Viljoen, Karien; Wijga, Alet H.; Vrijheid, Martine; Jaddoe, Vincent W. V.; Duijts, Liesbeth			Preterm birth, infant weight gain, and childhood asthma risk: A meta-analysis of 147,000 European children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gestational age; low birth weight; infant growth; wheezing; asthma; children; cohort studies; epidemiology	OBSTRUCTIVE AIRWAYS DISEASE; HE-3 MAGNETIC-RESONANCE; ADULT LUNG-FUNCTION; BODY-MASS INDEX; GESTATIONAL-AGE; RESPIRATORY SYMPTOMS; PRESCHOOL-CHILDREN; GENERATION R; COHORT; GROWTH	Background: Preterm birth, low birth weight, and infant catch-up growth seem associated with an increased risk of respiratory diseases in later life, but individual studies showed conflicting results. Objectives: We performed an individual participant data meta-analysis for 147,252 children of 31 birth cohort studies to determine the associations of birth and infant growth characteristics with the risks of preschool wheezing (1-4 years) and school-age asthma (5-10 years). Methods: First, we performed an adjusted 1-stage random-effect meta-analysis to assess the combined associations of gestational age, birth weight, and infant weight gain with childhood asthma. Second, we performed an adjusted 2-stage random-effect meta-analysis to assess the associations of preterm birth (gestational age < 37 weeks) and low birth weight (< 2500 g) with childhood asthma outcomes. Results: Younger gestational age at birth and higher infant weight gain were independently associated with higher risks of preschool wheezing and school-age asthma (P <. 05). The inverse associations of birth weight with childhood asthma were explained by gestational age at birth. Compared with term-born children with normal infant weight gain, we observed the highest risks of school-age asthma in children born preterm with high infant weight gain (odds ratio [OR], 4.47; 95% CI, 2.58-7.76). Preterm birth was positively associated with an increased risk of preschool wheezing (pooled odds ratio [pOR], 1.34; 95% CI, 1.25-1.43) and school-age asthma (pOR, 1.40; 95% CI, 1.18-1.67) independent of birth weight. Weaker effect estimates were observed for the associations of low birth weight adjusted for gestational age at birth with preschool wheezing (pOR, 1.10; 95% CI, 1.00-1.21) and school-age asthma (pOR, 1.13; 95% CI, 1.01-1.27). Conclusion: Younger gestational age at birth and higher infant weight gain were associated with childhood asthma outcomes. The associations of lower birth weight with childhood asthma were largely explained by gestational age at birth.	[Voort, Agnes M. M. Sonnenschein-van der; Jaddoe, Vincent W. V.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands; [Voort, Agnes M. M. Sonnenschein-van der; Jaddoe, Vincent W. V.; Duijts, Liesbeth] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Voort, Agnes M. M. Sonnenschein-van der; Annesi-Maesano, Isabella; Duijts, Liesbeth] Erasmus MC, Dept Paediat, Div Resp Med, Rotterdam, Netherlands; [Arends, Lidia R.] Erasmus MC, Dept Biostat, Rotterdam, Netherlands; [Jaddoe, Vincent W. V.] Erasmus MC, Dept Paediat, Rotterdam, Netherlands; [Duijts, Liesbeth] Erasmus MC, Dept Paediat, Div Neonatol, Rotterdam, Netherlands; [Arends, Lidia R.] Erasmus Univ, Inst Pedag Sci, Rotterdam, Netherlands; [Arends, Lidia R.] Erasmus Univ, Inst Psychol, Rotterdam, Netherlands; [Annesi-Maesano, Isabella] INSERM, EPAR, UMR S 707, Paris, France; [Annesi-Maesano, Isabella] Univ Paris 06, EPAR, UMR S 707, Paris, France; [Arshad, S. Hasan; Roberts, Graham; Sunyer, Jordi; Vrijheid, Martine] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Barros, Henrique; Correia, Sofia] Univ Porto, Sch Med, Dept Clin Epidemiol Predict Med & Publ Hlth, P-4100 Oporto, Portugal; [Basterrechea, Mikel] Publ Hlth Div Gipuzkoa, Gipuzkoa, Spain; [Basterrechea, Mikel; Iniguez, Carmen; Sunyer, Jordi; Vrijheid, Martine] Spanish Consortium Res Epidemiol & Publ Hlth CIBE, Barcelona, Spain; [Bisgaard, Hans; Kreiner-Moller, Eskil] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood COPS, Fac Hlth Sci, DK-1168 Copenhagen, Denmark; [Larsen, Pernille S.; Andersen, Anne-Marie Nybo] Univ Copenhagen, Dept Publ Hlth, Sect Social Med, DK-1168 Copenhagen, Denmark; [Bisgaard, Hans; Kreiner-Moller, Eskil] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark; [Chatzi, Leda] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece; [Corpeleijn, Eva; Kuepers, Leanne K.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Craig, Leone C.; Devereux, Graham] Univ Aberdeen, Aberdeen AB9 1FX, Scotland; [Dogaru, Cristian; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Dostal, Miroslav; Sram, Radim J.] Acad Sci Czech Republ, Inst Expt Med, Prague, Czech Republic; [Duchen, Karel; Ludvigsson, Johnny] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, Linkoping, Sweden; [Duchen, Karel; Ludvigsson, Johnny] Cty Council Ostergotland Cty Council, Pediat Clin, Linkoping, Sweden; [Eggesbo, Merete] Norwegian Inst Publ Hlth, Dept Genes & Environm, Div Epidemiol, Oslo, Norway; [van der Ent, C. Kors; van der Gugten, Anne C.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Pulmonol, Utrecht, Netherlands; [Torrent, Maties] Univ Bologna, Dept Biomed & Neuromotor Sci, I-40126 Bologna, Italy; [Forastiere, Francesco; Porta, Daniela] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy; [Frey, Urs] Univ Basel, Univ Childrens Hosp Basel UKBB, CH-4003 Basel, Switzerland; [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Hanke, Wojciech; Polanska, Kinga] Nofer Inst Occupat Med, Dept Environm Epidemiol, Lodz, Poland; [Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Heude, Barbara] INSERM, Ctr Res Epidemiol & Populat Hlth, Lifelong Epidemiol Obes Diabet & Renal Dis Team, U1018, Villejuif, France; [Heude, Barbara] Univ Paris 11, Villejuif, France; [Iniguez, Carmen] Univ Valencia, Ctr Publ Hlth Res CSISP, E-46003 Valencia, Spain; [Iniguez, Carmen] Univ Valencia, Fac Nursery & Chiropody, E-46003 Valencia, Spain; [Inskip, Hazel M.] Univ Southampton, Southampton Gen Hosp, Lifecourse Epidemiol Unit, MRC, Southampton, Hants, England; [Keil, Thomas] Charite, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Kelleher, Cecily C.; Viljoen, Karien] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin, Ireland; [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece; [Lancz, Kinga; Palkovicova, Lubica] Slovak Med Univ, Fac Publ Hlth, Dept Environm Med, Bratislava, Slovakia; [Lau, Susanne] Charite, Ctr Med, Dept Paediat Pneumol & Immunol, Berlin, Germany; [Mommers, Monique; Thijs, Carel] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [Pike, Katharine C.] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton SO9 5NH, Hants, England; [Pizzi, Costanza; Richiardi, Lorenzo] Univ Turin, Dept Med Sci, Canc Epidemiol Unit, I-10124 Turin, Italy; [Schmidt, Anne] Univ Bern, Inselspital, Dept Pediat, Div Resp Med, CH-3010 Bern, Switzerland; [Sunyer, Jordi; Vrijheid, Martine] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Sunyer, Jordi; Vrijheid, Martine] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, Spain; [Sunyer, Jordi] Hosp del Mar, Inst Municipal Invest Med, Barcelona, Spain; [Wijga, Alet H.] Natl Inst Publ Hlth & Environm RIVM, Ctr Prevent & Hlth Serv Res, Bilthoven, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus University Rotterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universidade do Porto; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Crete; University of Groningen; University of Aberdeen; University of Bern; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; Linkoping University; City Council Ostergotland; Norwegian Institute of Public Health (NIPH); Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; University of Bologna; University of Basel; Utrecht University; Nofer Institute of Occupational Medicine; University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Valencia; University of Valencia; University of Southampton; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University College Dublin; National & Kapodistrian University of Athens; Slovak Medical University Bratislava; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Maastricht University; University of Southampton; University of Turin; University of Bern; University Hospital of Bern; Pompeu Fabra University; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Netherlands National Institute for Public Health & the Environment	Duijts, L (corresponding author), Sophia Childrens Univ Hosp, Erasmus Med Ctr, Sp-3435,POB 2060, NL-3000 CB Rotterdam, Netherlands.	l.duijts@erasmusmc.nl	Sram, Radim J/H-2455-2014; Iñiguez, Carmen/AAA-5866-2019; Gori, Davide/AAC-3486-2022; Bisgaard, Hans/N-4761-2016; Barros, Henrique/A-5488-2008; Dogaru, Cristian/I-1861-2019; Nybo Andersen, Anne-Marie/AAA-1997-2022; Thijs, Carel/H-8340-2019; Correia, Sofia/AAD-6210-2020; Sunyer, Jordi/G-6909-2014; Porta, Daniela/J-9042-2016; Ludvigsson, Johnny/AAI-2051-2020; Vrijheid, Martine/H-2702-2014; Dogaru, Cristian/N-6290-2015; Sram, Radim/S-9574-2019; Barros, Henrique/Q-8609-2019; Andersen, Anne-Marie Nybo/E-4993-2013; Hanke, Wojciech E/F-7604-2010; Kogevinas, Manolis/C-3918-2017; Annesi-Maesano, Isabella/D-9173-2016; Heude, Barbara/GLU-9626-2022; kelleher, cecily c/A-4233-2013; Heude, Barbara/G-3095-2016; Forastiere, Francesco/J-9067-2016; Dostal, Miroslav/H-2832-2014; Inskip, Hazel/L-5467-2018; richiardi, lorenzo/J-3480-2018	Sram, Radim J/0000-0003-4256-3816; Iñiguez, Carmen/0000-0003-3471-4928; Gori, Davide/0000-0003-4954-9419; Bisgaard, Hans/0000-0003-4131-7592; Dogaru, Cristian/0000-0002-0722-6147; Nybo Andersen, Anne-Marie/0000-0002-4296-8488; Thijs, Carel/0000-0001-6646-5458; Correia, Sofia/0000-0002-9361-1999; Sunyer, Jordi/0000-0002-2602-4110; Porta, Daniela/0000-0002-3431-2729; Ludvigsson, Johnny/0000-0003-1695-5234; Vrijheid, Martine/0000-0002-7090-1758; Dogaru, Cristian/0000-0002-0722-6147; Sram, Radim/0000-0002-2500-4572; Barros, Henrique/0000-0003-4699-6571; Andersen, Anne-Marie Nybo/0000-0002-4296-8488; Kogevinas, Manolis/0000-0002-9605-0461; Annesi-Maesano, Isabella/0000-0002-6340-9300; Heude, Barbara/0000-0002-1565-1629; kelleher, cecily c/0000-0001-9548-4914; Heude, Barbara/0000-0002-1565-1629; Forastiere, Francesco/0000-0002-9162-5684; Hanke, Wojciech/0000-0001-7162-2569; Van der Ent, Cornelis/0000-0002-2501-4121; Larsen, Pernille Stemann/0000-0002-4541-1167; Kupers, Leanne/0000-0001-9850-5215; Inskip, Hazel/0000-0001-8897-1749; richiardi, lorenzo/0000-0003-0316-9402; Gehring, Ulrike/0000-0003-3612-5780; Kuehni, Claudia E./0000-0001-8957-2002; Iniguez, Carmen/0000-0002-5156-0732; Frey, Urs/0000-0003-3773-2822; Corpeleijn, Eva/0000-0002-2974-3305; Larsen, Pernille Stemann/0000-0003-2472-5359; Duchen, Karel/0000-0002-0570-8898; Eggesbo, Merete/0000-0002-0006-5336; BASTERRECHEA, MIKEL/0000-0002-8735-8691; Polanska, Kinga/0000-0002-3212-2307; Kreiner, Eskil/0000-0003-1204-2438	European Community's; European Respiratory Society; European Community's Seventh Framework Programme Marie Curie Actions (RESPIRE) [PCOFUND-GA-2008-229571]; NATIONAL CANCER INSTITUTE [R01CA096525] Funding Source: NIH RePORTER; Medical Research Council [G0400473, MC_PC_15018, G0900453, MC_UP_A620_1017] Funding Source: researchfish; MRC [G0900453, G0400473, MC_UP_A620_1017] Funding Source: UKRI	European Community's; European Respiratory Society; European Community's Seventh Framework Programme Marie Curie Actions (RESPIRE); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the European Community's Seventh Framework Programme FP7/20072013, project CHICOS. The research leading to these results has received funding from the European Respiratory Society and the European Community's Seventh Framework Programme FP7/2007-2013-Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571.	[Anonymous], 2013, COMPOSITION MACRO GE; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baek HS, 2011, ANN ALLERG ASTHMA IM, V107, P14, DOI 10.1016/j.anai.2011.03.013; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Cadman RV, 2013, J ALLERGY CLIN IMMUN, V131, P369, DOI 10.1016/j.jaci.2012.10.032; Canoy D, 2007, THORAX, V62, P396, DOI 10.1136/thx.2006.066241; Caudri D, 2007, AM J RESP CRIT CARE, V175, P1078, DOI 10.1164/rccm.200610-1441OC; Caudri D, 2009, AM J RESP CRIT CARE, V180, P491, DOI 10.1164/rccm.200903-0327OC; Colin AA, 2010, PEDIATRICS, V126, P115, DOI 10.1542/peds.2009-1381; Debray TPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060650; Duijts L, 2012, CHEST, V141, P876, DOI 10.1378/chest.11-0112; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Friedrich L, 2006, AM J RESP CRIT CARE, V173, P442, DOI 10.1164/rccm.200503-444OC; Getahun D, 2010, ARCH PEDIAT ADOL MED, V164, P187, DOI 10.1001/archpediatrics.2009.238; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Hancox RJ, 2009, THORAX, V64, P228, DOI 10.1136/thx.2008.103978; Hoo AF, 2002, J PEDIATR-US, V141, P652, DOI 10.1067/mpd.2002.128114; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jartti T, 2009, ALLERGY, V64, P770, DOI 10.1111/j.1398-9995.2008.01872.x; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Jobe AH, 2002, AM J RESP CRIT CARE, V166, P1529, DOI 10.1164/rccm.2209012; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kindlund K, 2010, THORAX, V65, P146, DOI 10.1136/thx.2009.117101; Koopman L, 2008, AM J EPIDEMIOL, V167, P540, DOI 10.1093/aje/kwm341; Kotecha S, 2000, Paediatr Respir Rev, V1, P308, DOI 10.1053/prrv.2000.0069; Kotecha SJ, 2012, THORAX, V67, P54, DOI 10.1136/thoraxjnl-2011-200329; Kumar R, 2008, J ALLERGY CLIN IMMUN, V121, P878, DOI 10.1016/j.jaci.2008.01.030; Kumar R, 2008, CURR OPIN PEDIATR, V20, P682, DOI 10.1097/MOP.0b013e3283154f26; Latzin P, 2007, PEDIATR PULM, V42, P41, DOI 10.1002/ppul.20542; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Lopuhaa CE, 2000, THORAX, V55, P555, DOI 10.1136/thorax.55.7.555; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matias V, 2012, PEDIAT ALLERG IMM-UK, V23, P441, DOI 10.1111/j.1399-3038.2012.01269.x; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Narayanan M, 2012, AM J RESP CRIT CARE, V185, P186, DOI 10.1164/rccm.201107-1348OC; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Pike KC, 2010, THORAX, V65, P1099, DOI 10.1136/thx.2010.134742; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sevelsted A, 2012, ALLERGY, V67, P670, DOI 10.1111/j.1398-9995.2012.02805.x; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Sonnenschein-van der Voort AMM, 2012, EUR RESPIR J, V39, P81, DOI 10.1183/09031936.00178110; Sonnenschein-van der Voort AMM, 2012, AM J RESP CRIT CARE, V185, P731, DOI 10.1164/rccm.201107-1266OC; Taal HR, 2013, OBESITY, V21, P1261, DOI 10.1002/oby.20116; Tai A, 2009, J ASTHMA, V46, P362, DOI 10.1080/02770900902759260; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; Tunon K, 2000, ULTRASOUND OBST GYN, V15, P41, DOI 10.1046/j.1469-0705.2000.00004.x; Tunon K, 1996, ULTRASOUND OBST GYN, V8, P178, DOI 10.1046/j.1469-0705.1996.08030178.x; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Vogt H, 2011, PEDIATRICS, V127, P1052, DOI 10.1542/peds.2010-3083; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	59	223	227	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1317	1329		10.1016/j.jaci.2013.12.1082	http://dx.doi.org/10.1016/j.jaci.2013.12.1082			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24529685	Green Submitted, Green Published, hybrid			2022-12-18	WOS:000335450700012
J	Peters, MC; Mekonnen, ZK; Yuan, SP; Bhakta, NR; Woodruff, PG; Fahy, JV				Peters, Michael C.; Mekonnen, Zesemayat K.; Yuan, Shaopeng; Bhakta, Nirav R.; Woodruff, Prescott G.; Fahy, John V.			Measures of gene expression in sputum cells can identify T(H)2-high and T(H)2-low subtypes of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; phenotypes; T(H)2 cell; mast cells; eotaxin; inflammation; sputum; cytokines; eosinophils; IL-4; IL-5; IL-13; IL-17	AIRWAY INFLAMMATION; RNA INTEGRITY; MODERATE	Background: The 3-gene signature of periostin, chloride channel accessory 1 (CLCA1), and Serpin beta 2 (SERPINB2) in airway epithelial brushings is used to classify asthma into T(H)2-high and T(H)2-low endotypes. Little is known about the utility of gene profiling in sputum as a molecular phenotyping method. Objective: We sought to determine whether gene profiling in sputum cells can identify T(H)2-high and T(H)2-low subtypes of asthma. Methods: In induced sputum cell pellets from 37 asthmatic patients and 15 healthy control subjects, PCR was used to profile gene expression of the epithelial cell signature of IL-13 activation (periostin, CLCA1, and SERPINB2), T(H)2 genes (IL4, IL5, and IL13), and other genes associated with airway T(H)2 inflammation. Results: Gene expression levels of CLCA1 and periostin, but not SerpinB2, were significantly higher than normal in sputum cells from asthmatic subjects. Expression levels of IL-4, IL-5, and IL-13 were also significantly increased in asthmatic patients and highly correlated within individual subjects. By combining the expression levels of IL-4, IL-5, and IL-13 in a single quantitative metric ("T(H)2 gene mean"), 26 (70%) of the 37 asthmatic patients had T(H)2-high asthma, which was characterized by more severe measures of asthma and increased blood and sputum eosinophilia. T(H)2 gene mean values tended to be stable when initial values were very high or very low but fluctuated above or below the T(H)2-high cutoff when initial values were intermediate. Conclusion: IL-4, IL-5, and IL-13 transcripts are easily detected in sputum cells from asthmatic patients, and their expression levels can be used to classify asthma into T(H)2-high and T(H)2-low endotypes.	[Peters, Michael C.; Bhakta, Nirav R.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Peters, Michael C.; Mekonnen, Zesemayat K.; Yuan, Shaopeng; Bhakta, Nirav R.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fahy, JV (corresponding author), 513 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.	john.fahy@ucsf.edu	Peters, Michael/AAO-6544-2020; Yuan, Shaopeng/Z-4410-2019; Yuan, Shaopeng/B-4343-2015	Yuan, Shaopeng/0000-0001-9554-1325; Mekonnen, Zesemayat/0000-0001-6139-3328; Peters, Michael/0000-0003-1854-4447	Genentech; National Institutes of Health [P01HL107202, T32HL007185]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080414, R01HL095372, P01HL107202, R01HL097591, U10HL109146, T32HL007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by a research grant from Genentech, and National Institutes of Health grants P01HL107202 and T32HL007185.	Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Fleige S, 2006, BIOTECHNOL LETT, V28, P1601, DOI 10.1007/s10529-006-9127-2; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	20	223	230	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					388	U181		10.1016/j.jaci.2013.07.036	http://dx.doi.org/10.1016/j.jaci.2013.07.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24075231	Green Accepted			2022-12-18	WOS:000332397100011
J	Wood, RA; Sicherer, SH; Vickery, BP; Jones, SM; Liu, AH; Fleischer, DM; Henning, AK; Mayer, L; Burks, AW; Grishin, A; Stablein, D; Sampson, HA				Wood, Robert A.; Sicherer, Scott H.; Vickery, Brian P.; Jones, Stacie M.; Liu, Andrew H.; Fleischer, David M.; Henning, Alice K.; Mayer, Lloyd; Burks, A. Wesley; Grishin, Alexander; Stablein, Donald; Sampson, Hugh A.			The natural history of milk allergy in an observational cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Milk allergy; natural history; food allergy; IgE	COWS MILK; SURVIVAL ANALYSIS; CLINICAL-COURSE; CHILDREN; INFANTS; IGE; TOLERANCE; HYPERSENSITIVITY; PROTEIN	Objective: There are few studies on the natural history of milk allergy. Most are single-site and not longitudinal, and these have not identified a means for early prediction of outcomes. Methods: Children aged 3 to 15 months were enrolled in an observational study with either (1) a convincing history of egg allergy, milk allergy, or both with a positive skin prick test (SPT) response to the trigger food and/or (2) moderate-to-severe atopic dermatitis (AD) and a positive SPT response to milk or egg. Children enrolled with a clinical history of milk allergy were followed longitudinally, and resolution was established by means of successful ingestion. Results: The cohort consists of 293 children, of whom 244 were given a diagnosis of milk allergy at baseline. Milk allergy has resolved in 154 (52.6%) subjects at a median age of 63 months and a median age at last follow-up of 66 months. Baseline characteristics that were most predictive of resolution included milk-specific IgE level, milk SPT wheal size, and AD severity (all P < .001). Baseline milk-specific IgG(4) level and milk IgE/IgG(4) ratio were not predictive of resolution and neither was expression of cytokine-inducible SH2-containing protein, forkhead box protein 3, GATA3, IL-10, IL-4, IFN-gamma, or T-bet by using real-time PCR in CD25-selected, casein-stimulated mononuclear cells. A calculator to estimate resolution probabilities using baseline milk IgE level, SPT response, and AD severity was devised for use in the clinical setting. Conclusions: In this cohort of infants with milk allergy, approximately one half had resolved over 66 months of follow-up. Baseline milk-specific IgE level, SPT wheal size, and AD severity were all important predictors of the likelihood of resolution. (J Allergy Clin Immunol 2013;131:805-12.)	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Sicherer, Scott H.; Mayer, Lloyd; Grishin, Alexander; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Vickery, Brian P.; Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Jones, Stacie M.; Stablein, Donald] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.; Stablein, Donald] Arkansas Childrens Hosp, Little Rock, AR USA; [Liu, Andrew H.; Fleischer, David M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Henning, Alice K.] EMMES Corp, Rockville, MD USA	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; National Jewish Health; Emmes Corporation	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 North Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR) [UL1 RR025780, UL1 1TR000067, UL 1 TR000039, UL 1 RR024128, UL1 RR 025005]; National Institutes of Health (NIH); NIH/National Institute of Allergy and Infectious Diseases (NIAID); NIH/NIAID; Thrasher Research Fund; American Lung Association, and Cephalon; NIH; FAAN; National Peanut Board; Department of Defense; Wallace Research Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000039, UL1TR000067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128, UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, U01AI066560] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Thrasher Research Fund; American Lung Association, and Cephalon; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAAN; National Peanut Board; Department of Defense(United States Department of Defense); Wallace Research Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases grants U19AI066738 and U01AI066560. The project was also supported by grant nos. UL1 RR025780 (National Jewish), UL1 1TR000067 (Mount Sinai), UL 1 TR000039 (Arkansas), UL 1 RR024128 (North Carolina) and UL1 RR 025005 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or the NIH.; Disclosure of potential conflict of interest: R. A. Wood has consultant arrangements with the Asthma and Allergy Foundation of America, is employed by Johns Hopkins University, has received research support from the National Institutes of Health (NIH), and receives royalties from UpToDate. S. H. Sicherer has received grants from the NIH/National Institute of Allergy and Infectious Diseases (NIAID) and has consultant arrangements with the Food Allergy Initiative. B. P. Vickery has received grants and travel support from the NIH/NIAID; has consultant arrangements with Mead Johnson; has received grants from the NIH/NIAID, the Thrasher Research Fund, the American Lung Association, and Cephalon. S. M. Jones is a member of the medical advisory board for the Food Allergy & Anaphylaxis Network (FAAN); has received grants from the NIH, the FAAN, and the National Peanut Board; has received payment for lectures, including service on speakers' bureaus, from Abbott Nutrition International, the Kentucky Society for Allergy, Asthma & Immunology, the New England Allergy Society, the American College of Allergy, Asthma & Immunology, Indiana University Medical School and Riley Children's Hospital, the Spanish Society of Allergy & Clinic Immunology, and the Oregon Allergy Asthma & Immunology Society; has served on the NIAID Safety Monitoring Committee, the Arkansas Medicaid Drug Review Committee, and the NIAID Study Section. D. M. Fleischer has received grants from the NIH/NIAID, has consultant arrangements with Sanofi-Aventis, and receives royalties from UpToDate. A. K. Henning has received grants from the NIH. A. W. Burks has received grants or has grants pending from the NIH, the Department of Defense, and theWallace Research Foundation; is a board member for the American Academy of Allergy, Asthma & Immunology, the NIH Hypersensitivity, Autoimmune, and Immune-mediated Disease Study Section, the Journal of Allergy and Clinical Immunology, and the US Food and Drug Administration; is on advisory boards for ExploraMed Development, LLC, the FAAN, and ActoGeniX; has consultant arrangements with Merck & Co, Novartis Pharma AG, the Dannon Company, McNeill Nutritionals, and Schering-Plough; is employed by UNC Children's Hospital and Duke University; has received payment for lectures from Mylan Specialty; has received royalties from UpToDate; has received payment for development of educational presentations from Current Views; has stock/stock options in Allertein, Mastcell Pharmaceuticals, and Dow AgroSciences; and has received travel expenses from the European Academy of Allergy & Clinical Immunology. A. Grishin has received grants from the NIH/NIAID and has consultant arrangements with Allertein Therapeutics. D. Stablein has received grants from the NIH. H. A. Sampson has received grants from the NIH and the NIAID, has received travel support from the NIAID, is on the Danone Scientific Advisory Board, has consultant arrangements with Allertein Therapeutics and the Food Allergy Initiative, is employed by Mount Sinai Medical School, and has received royalties from Elsevier-Wiley and UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Baker SS, 2000, PEDIATRICS, V106, P346; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; BUSINCO L, 1985, ANN ALLERGY, V55, P844; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; Clark TG, 2003, BRIT J CANCER, V89, P232, DOI 10.1038/sj.bjc.6601118; DANNAEUS A, 1979, ACTA PAEDIATR SCAND, V68, P377, DOI 10.1111/j.1651-2227.1979.tb05023.x; Elizur A, 2012, J PEDIAT, V161, P482; Fiocchi A, 2008, ANN ALLERG ASTHMA IM, V101, P166, DOI 10.1016/S1081-1206(10)60205-0; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HOST A, 1995, EUR J CLIN NUTR, V49, pS13; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Schmitt J, 2012, ALLERGY, V67, P1111, DOI 10.1111/j.1398-9995.2012.02874.x; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063	30	223	233	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					805	+		10.1016/j.jaci.2012.10.060	http://dx.doi.org/10.1016/j.jaci.2012.10.060			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23273958	Green Accepted, Green Published			2022-12-18	WOS:000315587800023
J	Hofmann, AM; Scurlock, AM; Jones, SM; Palmer, KP; Lokhnygina, Y; Steele, PH; Kamilaris, J; Burks, AW				Hofmann, Alison M.; Scurlock, Amy M.; Jones, Stacie M.; Palmer, Kricia P.; Lokhnygina, Yuliya; Steele, Pamela H.; Kamilaris, Janet; Burks, A. Wesley			Safety of a peanut oral immunotherapy protocol in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; food allergy; oral immunotherapy	TOLERANCE INDUCTION; FOOD; DESENSITIZATION	Background: Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern. Objective: The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study. Methods: Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed. Results: Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory tract (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a buildup phase dose was 46%, with a risk of 29% for upper respiratory tract symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory tract (1.2%) and skin (1.1%) symptoms were the most likely after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after I home dose each. Conclusions: Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare. (J Allergy Clin Immunol 2009;124:286-91.)	[Hofmann, Alison M.; Steele, Pamela H.; Kamilaris, Janet; Burks, A. Wesley] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Scurlock, Amy M.; Jones, Stacie M.; Palmer, Kricia P.] Univ Arkansas, Dept Pediat, Div Allergy & Immunol, Little Rock, AR 72204 USA; [Lokhnygina, Yuliya] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA	Duke University; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Duke University	Burks, AW (corresponding author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Box 2644, Durham, NC 27710 USA.	wesley.burks@duke.edu			Food Allergy and Anaphylaxis Network; Gerber Foundation; Food Allergy Project; Dorothy and Frank Robins Family Foundation; National Center for Research Resources (NCRR) [1 UL 1 RR024128-01]; National Institutes of Health (NIH); NIH Roadmap for Medical Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068074] Funding Source: NIH RePORTER	Food Allergy and Anaphylaxis Network; Gerber Foundation; Food Allergy Project; Dorothy and Frank Robins Family Foundation; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Food Allergy and Anaphylaxis Network, the Gerber Foundation, the Food Allergy Project, and the Dorothy and Frank Robins Family Foundation. The project described was supported by grant no. 1 UL 1 RR024128-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.	Allen CW, 2007, J PAEDIATR CHILD H, V43, P214, DOI 10.1111/j.1440-1754.2007.00996.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; *INT TREE NUT COUN, NUTR 1 OUNC TREE NUT; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mansfield L, 2006, ANN ALLERG ASTHMA IM, V97, P266, DOI 10.1016/S1081-1206(10)60026-9; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	21	223	232	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					286	291		10.1016/j.jaci.2009.03.045	http://dx.doi.org/10.1016/j.jaci.2009.03.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19477496	Green Accepted			2022-12-18	WOS:000268860400015
J	HALPERN, SR; SELLARS, WA; JOHNSON, RB; ANDERSON, DW; SAPERSTEIN, S; REISCH, JS				HALPERN, SR; SELLARS, WA; JOHNSON, RB; ANDERSON, DW; SAPERSTEIN, S; REISCH, JS			DEVELOPMENT OF CHILDHOOD ALLERGY IN INFANTS FED BREAST, SOY, OR COW MILK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS, SW MED SCH, DEPT PEDIAT, DALLAS, TX 75219 USA; UNIV TEXAS, SW MED SCH, DEPT BIOPHYS, DIV BIOMATH & BIOSTATISTICS, DALLAS, TX 75219 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								APPEL SJ, 1961, PENN MED J, V64, P621; ARBEITER HI, 1967, CLIN PEDIATR, V6, P140, DOI 10.1177/000992286700600307; BACHMAN DK, 1957, PEDIATRICS, V20, P393; BACHMAN DK, 1957, PEDIATRICS, V20, P400; BROWN EB, 1969, AM J DIS CHILD, V117, P693, DOI 10.1001/archpedi.1969.02100030695013; CROOK WG, 1958, J PEDIATR-US, V52, P20, DOI 10.1016/S0022-3476(58)80005-0; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; GLASER J, 1953, JAMA-J AM MED ASSOC, V153, P620, DOI 10.1001/jama.1953.02940240012003; GLASER J, 1970, BRENNEMANNS PRACTICE; GLASER J, PERSONAL COMMUNICATI; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; GOLDMAN AS, 1963, PEDIATRICS, V32, P572; HAGGERTY RJ, 1967, PEDIATRICS, V40, P157; HALPERN SR, 1972, SOUTH MED J, V65, P100, DOI 10.1097/00007611-197201000-00023; HANSON LA, 1961, ACTA PAEDIATR, V50, P484, DOI 10.1111/j.1651-2227.1961.tb08203.x; Hill Lewis Webb, 1942, JOUR ALLERGY, V13, P366, DOI 10.1016/S0021-8707(42)90293-4; HILL LW, 1955, J PEDIATR-US, V47, P648, DOI 10.1016/S0022-3476(55)80088-1; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; London AH, 1937, J PEDIATR-US, V10, P762, DOI 10.1016/S0022-3476(37)80105-5; LOWELL FC, 1954, JAMA-J AM MED ASSOC, V154, P262, DOI 10.1001/jama.1954.02940370074024; LOWELL FC, 1954, J ALLERGY, V25, P57; MUELLER HL, 1963, NEW ENGL J MED, V268, P1220, DOI 10.1056/NEJM196305302682204; RATNER BRET, 1955, ANN ALLERGY, V13, P289; SAPERSTEIN S, 1962, J PEDIATR-US, V61, P196, DOI 10.1016/S0022-3476(62)80253-4; SAPERSTEIN SIDNEY, 1960, ANN ALLERGY, V18, P765; SELLARS WA, 1971, ANN ALLERGY, V29, P126; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; 1963, ILLNESS AMONG CHILDR	28	223	227	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	3					139	151		10.1016/0091-6749(73)90019-5	http://dx.doi.org/10.1016/0091-6749(73)90019-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0896	4739434				2022-12-18	WOS:A1973P089600002
J	Rivas, MN; Chatila, TA				Rivas, Magali Noval; Chatila, Talal A.			Regulatory T cells in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; food allergy; regulatory T cells; forkhead box P3; IL-4; T(H)2 cells	INNATE LYMPHOID-CELLS; TRANSCRIPTION FACTOR FOXP3; DENDRITIC CELLS; FOOD ALLERGY; IN-VITRO; IMMUNE DYSREGULATION; AIRWAY INFLAMMATION; ORAL TOLERANCE; CUTTING EDGE; CIS-ELEMENT	The pathogenesis of allergic diseases entails an ineffective tolerogenic immune response to allergens. Regulatory T (Treg) cells play a key role in sustaining immune tolerance to allergens, yet mechanisms by which Treg cells fail to maintain tolerance in patients with allergic diseases are not well understood. We review current concepts and established mechanisms regarding how Treg cells regulate different components of allergen-triggered immune responses to promote and maintain tolerance. We will also discuss more recent advances that emphasize the "dual'' functionality of Treg cells in patients with allergic diseases: how Treg cells are essential in promoting tolerance to allergens but also how a proallergic inflammatory environment can skew Treg cells toward a pathogenic phenotype that aggravates and perpetuates disease. These advances highlight opportunities for novel therapeutic strategies that aim to re-establish tolerance in patients with chronic allergic diseases by promoting Treg cell stability and function.	[Rivas, Magali Noval] Cedars Sinai Med Ctr, Infect & Immunol Dis Res Ctr, Dept Pediat, Div Pediat Infect Dis & Immunol, Los Angeles, CA 90048 USA; [Chatila, Talal A.] Boston Childrens Hosp, Div Immunol, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA; [Chatila, Talal A.] Harvard Med Sch, Dept Pediat, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA	Cedars Sinai Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA.; Chatila, TA (corresponding author), Harvard Med Sch, Dept Pediat, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Noval Rivas, Magali/R-4987-2016	Noval Rivas, Magali/0000-0001-5570-8928; Chatila, Talal/0000-0001-7439-2762	National Institutes of Health [5R01AI065617, 1R56AI117983]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085090, R01AI065617, R56AI117983] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (5R01AI065617 and 1R56AI117983; to T.A.C.).	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alroqi FJ, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0606-9; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Benoist C, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007021; Berin MC, 2016, IMMUNOL ALLERGY CLIN, V36, P87, DOI 10.1016/j.iac.2015.08.002; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Charbonnier LM, 2015, NAT IMMUNOL, V16, P1162, DOI 10.1038/ni.3288; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chatila TA, 2009, ENDOCRIN METAB CLIN, V38, P265, DOI 10.1016/j.ecl.2009.01.002; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Feehley T, 2012, SEMIN IMMUNOPATHOL, V34, P671, DOI 10.1007/s00281-012-0337-5; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; Feuerer M, 2010, P NATL ACAD SCI USA, V107, P5919, DOI 10.1073/pnas.1002006107; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Girtsman T, 2010, J LEUKOCYTE BIOL, V88, P537, DOI 10.1189/jlb.0110044; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Gregori S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00030; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Haribhai D, 2011, IMMUNITY, V35, P109, DOI 10.1016/j.immuni.2011.03.029; Haribhai D, 2009, J IMMUNOL, V182, P3461, DOI 10.4049/jimmunol.0802535; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Heederik D, 2012, J ALLERGY CLIN IMMUN, V130, P44, DOI 10.1016/j.jaci.2012.01.067; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Hong XM, 2012, SEMIN IMMUNOPATHOL, V34, P655, DOI 10.1007/s00281-012-0323-y; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kim YC, 2012, BLOOD, V119, P2810, DOI 10.1182/blood-2011-09-377895; Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917; Koch MA, 2012, IMMUNITY, V37, P501, DOI 10.1016/j.immuni.2012.05.031; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030; Liang BT, 2008, J IMMUNOL, V180, P5916, DOI 10.4049/jimmunol.180.9.5916; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lio CWJ, 2011, CURR OPIN IMMUNOL, V23, P213, DOI 10.1016/j.coi.2010.11.010; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Loftus PA, 2016, CURR OPIN OTOLARYNGO, V24, P245, DOI 10.1097/MOO.0000000000000262; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Mamessier E, 2008, ALLERGY, V63, P1202, DOI 10.1111/j.1398-9995.2008.01687.x; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Massoud AH, 2016, NAT MED, V22, P1013, DOI 10.1038/nm.4147; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; SAKAGUCHI S, 1982, J EXP MED, V156, P1577, DOI 10.1084/jem.156.6.1577; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Siddiqui KRR, 2008, MUCOSAL IMMUNOL, V1, pS34, DOI 10.1038/mi.2008.43; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Sudo N, 1997, J IMMUNOL, V159, P1739; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; van Wijk F, 2007, CLIN EXP ALLERGY, V37, P572, DOI 10.1111/j.1365-2222.2007.02681.x; Verbsky JW, 2013, CURR OPIN PEDIATR, V25, P708, DOI 10.1097/MOP.0000000000000029; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wang S, 2015, IMMUNITY, V43, P289, DOI 10.1016/j.immuni.2015.06.014; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Xia MC, 2015, J ALLERGY CLIN IMMUN, V136, P441, DOI 10.1016/j.jaci.2015.02.014; Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	150	222	229	2	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					639	652		10.1016/j.jaci.2016.06.003	http://dx.doi.org/10.1016/j.jaci.2016.06.003			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27596705	Green Accepted, Bronze			2022-12-18	WOS:000385496000001
J	Mattoo, H; Mahajan, VS; Della-Torre, E; Sekigami, Y; Carruthers, M; Wallace, ZS; Deshpande, V; Stone, JH; Pillai, S				Mattoo, Hamid; Mahajan, Vinay S.; Della-Torre, Emanuel; Sekigami, Yurie; Carruthers, Mollie; Wallace, Zachary S.; Deshpande, Vikram; Stone, John H.; Pillai, Shiv			De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG(4)-related disease; autoreactivity; rituximab; next-generation sequencing; somatic hypermutation; plasmablasts; immunoglobulin heavy chain variable region repertoire; CDR3	B-CELLS; AUTOIMMUNE PANCREATITIS; RITUXIMAB; REPERTOIRE; ANTIBODY; EXPRESSION; GENERATION; ISSUES; MEMORY; CS1	Background: IgG(4)-related disease (IgG(4)-RD) is a poorly understood, multiorgan, chronic inflammatory disease characterized by tumefactive lesions, storiform fibrosis, obliterative phlebitis, and accumulation of IgG(4)-expressing plasma cells at disease sites. Objective: The role of B cells and IgG(4) antibodies in IgG(4)-RD pathogenesis is not well defined. We evaluated patients with IgG(4)-RD for activated B cells in both disease lesions and peripheral blood and investigated their role in disease pathogenesis. Methods: B-cell populations from the peripheral blood of 84 patients with active IgG(4)-RD were analyzed by using flow cytometry. The repertoire of B-cell populations was analyzed in a subset of patients by using next-generation sequencing. Fourteen of these patients were longitudinally followed for 9 to 15 months after rituximab therapy. Results: Numbers of CD19(+)CD27(+)CD20(-)CD38(hi) plasmablasts, which are largely IgG(4)(+), are increased in patients with active IgG(4)-RD. These expanded plasmablasts are oligoclonal and exhibit extensive somatic hypermutation, and their numbers decrease after rituximab-mediated B-cell depletion therapy; this loss correlates with disease remission. A subset of patients relapse after rituximab therapy, and circulating plasmablasts that re-emerge in these subjects are clonally distinct and exhibit enhanced somatic hypermutation. Cloning and expression of immunoglobulin heavy and light chain genes from expanded plasmablasts at the peak of disease reveals that disease-associated IgG(4) antibodies are self-reactive. Conclusions: Clonally expanded CD19(+)CD27(+)CD20(-)CD38(hi) plasmablasts are a hallmark of active IgG(4)-RD. Enhanced somatic mutation in activated B cells and plasmablasts and emergence of distinct plasmablast clones on relapse indicate that the disease pathogenesis is linked to de novo recruitment of naive B cells into T cell-dependent responses by CD4(+) T cells, likely driving a self-reactive disease process.	Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Pillai, S (corresponding author), Ctr Canc Res, 149 13th St Boston, Boston, MA 02129 USA.	jhstone@partners.org; pillai@helix.mgh.harvard.edu	Mahajan, Vinay S/AAF-3303-2019; Della Torre, Emanuel/AAB-5024-2022	Della Torre, Emanuel/0000-0002-9192-4270; Mahajan, Vinay/0000-0003-0814-2989	National Institutes of Health [AI 064930, AI 076505]; Helmsley Charitable Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI110495, R01AI064930, K08AI113163, R01AI076505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helmsley Charitable Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants AI 064930 and AI 076505 from the National Institutes of Health and a pilot grant from the Harvard Institute of Translational Immunology supported by the Helmsley Charitable Trust (to S.P.).	Aoki S, 2005, HISTOPATHOLOGY, V47, P147, DOI 10.1111/j.1365-2559.2005.02204.x; Asada M, 2006, PANCREAS, V33, P20, DOI 10.1097/01.mpa.0000226881.48204.fd; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Carruthers MN, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/259408; Della-Torre E, 2013, J RHEUMATOL, V40, P1927, DOI 10.3899/jrheum.130678; Deshpande V, 2012, SEMIN DIAGN PATHOL, V29, P191, DOI 10.1053/j.semdp.2012.08.001; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hsi ED, 2008, CLIN CANCER RES, V14, P2775, DOI 10.1158/1078-0432.CCR-07-4246; Kamburova EG, 2013, AM J TRANSPLANT, V13, P1503, DOI 10.1111/ajt.12220; Kamisawa T, 2003, AM J GASTROENTEROL, V98, P2811, DOI 10.1111/j.1572-0241.2003.08758.x; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Khosroshahi A, 2010, ARTHRITIS RHEUM-US, V62, P1755, DOI 10.1002/art.27435; Kusuda T, 2011, PANCREAS, V40, P1120, DOI 10.1097/MPA.0b013e31821fc796; Larimore K, 2012, J IMMUNOL, V189, P3221, DOI 10.4049/jimmunol.1201303; Leandro MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3908; Lee JK, 2007, J IMMUNOL, V179, P4672, DOI 10.4049/jimmunol.179.7.4672; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Maurer MA, 2012, J CLIN INVEST, V122, P1393, DOI 10.1172/JCI58743; Nicholas MIW, 2008, CLIN IMMUNOL, V126, P189, DOI 10.1016/j.clim.2007.10.004; Nishimori I, 2005, GUT, V54, P274, DOI 10.1136/gut.2004.049064; Ohm-Laursen L, 2006, IMMUNOLOGY, V119, P265, DOI 10.1111/j.1365-2567.2006.02431.x; Owczarczyk K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002432; Ryan MC, 2007, MOL CANCER THER, V6, P3009, DOI 10.1158/1535-7163.MCT-07-0464; Sah RP, 2011, CURR OPIN RHEUMATOL, V23, P108, DOI 10.1097/BOR.0b013e3283413469; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Takeuchi M, 2014, MOD PATHOL; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiller T, 2010, J EXP MED, V207, P2767, DOI 10.1084/jem.20100171; Tsubaki T, 2005, CLIN EXP IMMUNOL, V141, P363, DOI 10.1111/j.1365-2249.2005.02850.x; Wenniger LJMD, 2013, HEPATOLOGY, V57, P2390, DOI 10.1002/hep.26232; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697	34	222	249	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					679	687		10.1016/j.jaci.2014.03.034	http://dx.doi.org/10.1016/j.jaci.2014.03.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24815737	Green Accepted			2022-12-18	WOS:000341372400022
J	Staevska, M; Popov, TA; Kralimarkova, T; Lazarova, C; Kraeva, S; Popova, D; Church, DS; Dimitrov, V; Church, MK				Staevska, Maria; Popov, Todor A.; Kralimarkova, Tanya; Lazarova, Cvetelina; Kraeva, Steliana; Popova, Dora; Church, Diana S.; Dimitrov, Vasil; Church, Martin K.			The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria; levocetirizine; antihistamines; desloratadine; somnolence; quality of life	CHRONIC IDIOPATHIC URTICARIA; QUALITY-OF-LIFE; HISTAMINE-INDUCED WHEAL; SKIN IN-VIVO; EAACI/GA(2)LEN/EDF GUIDELINE; DOUBLE-BLIND; FLARE; ANTIHISTAMINES; FEXOFENADINE; CETIRIZINE	Background: HI-antihistamines are first line treatment of chronic urticaria, but many patients do not get satisfactory relief with recommended doses. European guidelines recommend increased antihistamine doses of up to 4-fold. Objective: To provide supportive evidence for the European guidelines. Methods: Eighty tertiary referral patients with chronic urticaria (age range, 19-67 years) were randomized for double-blind treatment with levocetirizine or desloratadine (40/40). Treatment started at the conventional daily dose of 5 mg and then increased weekly to 10 mg, 20 mg, or 20 mg of the opposite drug if relief of symptoms was incomplete. Wheal and pruritus scores, quality of life, patient discomfort, somnolence, and safety were assessed. Results: Thirteen patients became symptom-free at 5 mg (9 levocetirizine vs 4 desloratadine), compared with 28 subjects on the higher doses of 10 mg (8/7) and 20 mg (5/1). Of the 28 patients nonresponsive to 20 mg desloratadine, 7 became symptom-free with 20 mg levocetirizine. None of the 18 levocetirizine nonresponders benefited with 20 mg desloratadine. Increasing antihistamine doses improved quality of life but did not increase somnolence. Analysis of the effect of treatment on discomfort caused by urticaria showed great individual heterogeneity of antihistamine responsiveness: similar to 15% of patients were good responders, similar to 10% were nonresponders, and similar to 75% were responders to higher than conventional antihistamine doses. No serious or severe adverse effects warranting discontinuation of treatment occurred with either drug. Conclusion: Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria. (J Allergy Clin Immunol 2010;125:676-82.)	[Staevska, Maria; Popov, Todor A.; Kralimarkova, Tanya; Lazarova, Cvetelina; Kraeva, Steliana; Popova, Dora; Dimitrov, Vasil] Med Univ, Clin Ctr Allergol, Sofia 1431, Bulgaria; [Church, Diana S.; Church, Martin K.] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England; [Church, Martin K.] Charite Univ Med Berlin, Allergie Ctr Charite, Berlin, Germany	Medical University Sofia; University of Southampton; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Popov, TA (corresponding author), Med Univ, Clin Ctr Allergol, 1 Sv Georgi Sofiyski St, Sofia 1431, Bulgaria.	tedpop@rtb-mu.com	Staevska, Maria/AAG-4569-2020; Popov, Todor/Q-9928-2016; Beldar, Sagar V/C-8542-2011	Staevska, Maria/0000-0002-9154-303X; Popov, Todor/0000-0001-5052-5866; Dimitrov, Vasil/0000-0001-7704-4202	UCB Pharma; Chiesi Pharma; Novartis	UCB Pharma(UCB Pharma SA); Chiesi Pharma(Chiesi Pharmaceuticals Inc); Novartis(Novartis)	Supported by an unrestricted educational grant by UCB Pharma. UCB Pharma had no involvement in the study or the preparation of this article either practically or editorially.; Disclosure of potential conflict of interest: M. K. Church has consulted for FAES Pharma. T. A. Popov has received honoraria from Merck & Co, Schering-Plough, and UCB Pharma and has received research support from Chiesi Pharma, c. and UCB Pharma. V. Dimitrov has received honoraria front AstraZeneca, Chiesi Pharma, UCB Pharma and Shering Plough and has received research support from Novartis. The rest of the authors have declared that they have no conflict of interest.	Asero R, 2007, CLIN EXP DERMATOL, V32, P34, DOI 10.1111/j.1365-2230.2006.02278.x; Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; Asero R, 2009, J ALLERGY CLIN IMMUN, V123, P1417, DOI 10.1016/j.jaci.2009.02.039; Baiardini I, 2003, ALLERGY, V58, P621, DOI 10.1034/j.1398-9995.2003.00091.x; Baiardini I, 2005, ALLERGY, V60, P1073, DOI 10.1111/j.1398-9995.2005.00833.x; Denham KJ, 2003, INFLAMM RES, V52, P424, DOI 10.1007/s00011-003-1193-5; Devillier P, 2008, CLIN PHARMACOKINET, V47, P217, DOI 10.2165/00003088-200847040-00001; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; Frossard N, 2008, BRIT J CLIN PHARMACO, V65, P172, DOI 10.1111/j.1365-2125.2007.03009.x; Garcia-Gea C, 2008, J CLIN PSYCHOPHARM, V28, P675, DOI 10.1097/JCP.0b013e31818b2091; Gimenez-Arnau A, 2009, J EUR ACAD DERMATOL, V23, P1088, DOI 10.1111/j.1468-3083.2009.03289.x; Grattan CEH, 2004, IMMUNOL ALLERGY CLIN, V24, P163, DOI 10.1016/j.iac.2004.01.003; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Humphreys F, 1998, BRIT J DERMATOL, V138, P635; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Metz M, 2009, J ALLERGY CLIN IMMUN, V123, P705, DOI 10.1016/j.jaci.2008.11.040; Nelson HS, 2000, ANN ALLERG ASTHMA IM, V84, P517, DOI 10.1016/S1081-1206(10)62515-X; Nordness M, 2003, CUTIS, V71, P396; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Petersen LJ, 1997, CLIN EXP ALLERGY, V27, P284; Popov TA, 2006, INFLAMM RES, V55, P241, DOI 10.1007/s00011-006-0075-z; Potter PC, 2009, ALLERGY, V64, P596, DOI 10.1111/j.1398-9995.2008.01893.x; Powell RJ, 2007, CLIN EXP ALLERGY, V37, P631, DOI 10.1111/j.1365-2222.2007.02678.x; Purohit A, 2003, BRIT J CLIN PHARMACO, V56, P388, DOI 10.1046/j.1365-2125.2003.01897.x; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Siebenhaar F, 2009, J ALLERGY CLIN IMMUN, V123, P672, DOI 10.1016/j.jaci.2008.12.008; Verster JC, 2004, ANN ALLERG ASTHMA IM, V92, P294, DOI 10.1016/S1081-1206(10)61566-9; Zuberbier T, 2006, ALLERGY, V61, P321, DOI 10.1111/j.1398-9995.2006.00962.x; Zuberbier T, 1996, DERMATOLOGY, V193, P324, DOI 10.1159/000246281; Zuberbier T, 2006, ALLERGY, V61, P316, DOI 10.1111/j.1398-9995.2005.00964.x	30	222	230	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					676	682		10.1016/j.jaci.2009.11.047	http://dx.doi.org/10.1016/j.jaci.2009.11.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226302				2022-12-18	WOS:000275883200025
J	Malone, DC; Lawson, KA; Smith, DH; Arrighi, HM; Battista, C				Malone, DC; Lawson, KA; Smith, DH; Arrighi, HM; Battista, C			A cost of illness study of allergic rhinitis in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; hay fever; cost of illness; cost and cost analysis; National Medical Expenditure Survey	HAY-FEVER	Background: Allergic rhinitis is a common condition, but the burden of this condition on the national economy is not well understood. Objective: The purpose of this study was to estimate the national direct and indirect costs of allergic rhinitis. Methods: Data from the National Medical Expenditure Survey were used to provide estimates of resource utilization, medical expenditures, and lost productivity. With the complex survey design, variance estimates were used to construct confidence intervals for cost estimates of resource utilization and lost productivity. Results: it is estimated that approximately 39 million persons in the United Slates experienced allergic rhinitis in 1987. However only 12.3% (4.8 million) sought medical treatment for allergic rhinitis. The total estimated cost of the condition, in 1994 dollars, was $1.23 billion (95% confidence interval, $846 million to $1.62 billion). Direct medical expenses accounted for 94% of total costs. Allergic rhinitis resulted in approximately 811,000 missed workdays, 824,000 missed school days, and 4,230,000 reduced activity clays. Conclusion: Allergic rhinitis clearly creates a burden in terms of the number of persons affected, total expenditures, and lost productivity. It also appears that a relatively large proportion of persons with allergic rhinitis were not seeking medical treatment.	UNIV TEXAS,AUSTIN,TX 78712; UNIV WASHINGTON,SEATTLE,WA 98195; AMGEN INC,THOUSAND OAKS,CA 91320	University of Texas System; University of Texas Austin; University of Washington; University of Washington Seattle; Amgen	Malone, DC (corresponding author), UNIV COLORADO,HLTH SCI CTR,4200 E 9TH AVE,DENVER,CO 80262, USA.							*AG HLTH POL RES, 1994, 1987 MED EXP SURV PU; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BERK ML, 1990, HEALTH AFFAIR, V9, P146, DOI 10.1377/hlthaff.9.3.146; EDWARDS WS, 1989, 893450 PHS DHHS NAT; HODGKINSON DP, 1983, RADIOACT WASTE MANAG, V4, P129; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; *INT RHIN MAN WORK, 1994, ALLERGY, V49, P5; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Miller TR, 1994, MMWR-MORBID MORTAL W, V43, P581; Shah BV, 1997, SOFTWARE STAT ANAL C; *US BUR CENS, 1994, 1994 STAT ABSTR US, P8; *US BUR CENS, 1995, 1995 STAT ABSTR US, P431; WALDROP J, 1993, AM DEMOGR, V15, P4; Weeke E R, 1992, Rhinol Suppl, V13, P5	14	222	230	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				22	27		10.1016/S0091-6749(97)81040-8	http://dx.doi.org/10.1016/S0091-6749(97)81040-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003207				2022-12-18	WOS:A1997WD06100004
J	LOGSDON, PJ; MIDDLETON, E; COFFEY, RG				LOGSDON, PJ; MIDDLETON, E; COFFEY, RG			STIMULATION OF LEUKOCYTE ADENYL-CYCLASE BY HYDROCORTISONE AND ISOPROTERENOL IN ASTHMATIC AND NONASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AMES BN, 1960, J BIOL CHEM, V235, P769; BOURNE HR, 1971, J PHARMACOL EXP THER, V178, P1; BOURNE HR, 1971, J CLIN INVEST, V50, P920, DOI 10.1172/JCI106564; BRAUN T, 1970, P NATL ACAD SCI USA, V66, P995, DOI 10.1073/pnas.66.3.995; BRODIE BB, 1966, PHARMACOL REV, V18, P273; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; FALLIERS CJ, 1970, CLINICAL PHYSIOLOGIC; HUMES JL, 1969, ANAL BIOCHEM, V32, P210, DOI 10.1016/0003-2697(69)90077-3; KRISHNA G, 1968, J PHARMACOL EXP THER, V163, P379; KRISHNA G, 1970, ROLE CYCLIC AMP CELL, P155; KUO JF, 1969, J BIOL CHEM, V244, P2252; LICHTENSTEIN LL, 1972, BIOCHEMISTRY ACUTE A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON E, IN PRESS; MILLER TB, 1971, J BIOL CHEM, V246, P3672; MOSKOWITZ J, 1970, J BIOL CHEM, V245, P1101; MUNCK A, 1971, PERSPECT BIOL MED, V14, P265; REED CE, 1968, 6 P INT C ALL AMST; ROBISON GA, 1967, ANN NY ACAD SCI, V139, P703, DOI 10.1111/j.1749-6632.1967.tb41239.x; SCOTT RE, 1970, BLOOD-J HEMATOL, V35, P514, DOI 10.1182/blood.V35.4.514.514; Senft G, 1968, Diabetologia, V4, P330, DOI 10.1007/BF01211767; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; SMITH JW, 1970, J LAB CLIN MED, V76, P993; SMITH JW, 1970, P CENT SOC CLIN RES, V43, P76; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1970, J ALLERGY, V45, P71; YOUNG DA, 1969, J BIOL CHEM, V244, P2210	27	222	222	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	1					45	+		10.1016/0091-6749(72)90078-4	http://dx.doi.org/10.1016/0091-6749(72)90078-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M9284	4338225				2022-12-18	WOS:A1972M928400005
J	Kerstjens, HAM; Disse, B; Schroder-Babo, W; Bantje, TA; Gahlemann, M; Sigmund, R; Engel, M; van Noord, JA				Kerstjens, Huib A. M.; Disse, Bernd; Schroeder-Babo, Winfried; Bantje, Theo A.; Gahlemann, Martina; Sigmund, Ralf; Engel, Michael; van Noord, Jan A.			Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; severe uncontrolled asthma; randomized controlled trial; anticholinergics; tiotropium	ANTICHOLINERGIC AGENTS; BROMIDE; ADULTS; SALMETEROL; EFFICACY	Background: Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients. Objective: We sought to compare the efficacy and safety of 2 doses of tiotropium (5 and 10 mu g daily) administered through the Respimat inhaler with placebo as add-on therapy in patients with uncontrolled severe asthma (Asthma Control Questionnaire score, >= 1.5; postbronchodilator FEV1, <= 80% of predicted value) despite maintenance treatment with at least a high-dose inhaled corticosteroid plus a long-acting beta(2)-agonist. Methods: This was a randomized, double-blind, crossover study with three 8-week treatment periods. The primary end point was peak FEV1 at the end of each treatment period. Results: Of 107 randomized patients (54% female patients; mean, 55 years of age; postbronchodilator FEV1, 65% of predicted value), 100 completed all periods. Peak FEV1 was significantly higher with 5 mu g (difference, 139 mL; 95% CI, 96181 mL) and 10 mu g (difference, 170 mL; 95% CI, 128-213 mL) of tiotropium than with placebo (both P < .0001). There was no significant difference between the active doses. Trough FEV1 at the end of the dosing interval was higher with tiotropium (5 mg: 86 mL [95% CI, 41-132 mL]; 10 mg: 113 mL [95% CI, 67-159 mL]; both P < .0004). Daily home peak expiratory flow measurements were higher with both tiotropium doses. There were no significant differences in asthma-related health status or symptoms. Adverse events were balanced across groups except for dry mouth, which was more common on 10 mu g of tiotropium. Conclusion: The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting beta(2)-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma. (J Allergy Clin Immunol 2011;128:308-14.)	[Kerstjens, Huib A. M.] Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Disse, Bernd; Gahlemann, Martina; Sigmund, Ralf; Engel, Michael] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Schroeder-Babo, Winfried] Krankenhaus Gelnhausen, Gelnhausen, Germany; [Bantje, Theo A.] Amphia Ziekenhuis, Dept Pulmonol, Breda, Netherlands; [van Noord, Jan A.] Atrium Med Ctr, Dept Pulmonol, Heerlen, Netherlands	University of Groningen; Boehringer Ingelheim; Amphia Hospital; Atrium Medical Center	Kerstjens, HAM (corresponding author), Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, Postbox 30-001, NL-9700 RB Groningen, Netherlands.	h.a.m.kerstjens@long.umcg.nl	Kerstjens, Huib/N-4754-2017	Kerstjens, Huib/0000-0001-7705-7927	Boehringer Ingelheim; Pfizer; Chiesi; Novartis; GlaxoSmithKline	Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Chiesi(Chiesi Pharmaceuticals Inc); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline)	H. A. M. Kerstjens receives research support from Boehringer Ingelheim and Pfizer and has consulted with Boehringer Ingelheim. J. A. van Noord receives research support from Boehringer Ingelheim, Chiesi, Novartis, and GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	Bateman ED, 2010, RESP MED, V104, P1460, DOI 10.1016/j.rmed.2010.06.004; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Disse B, 1999, LIFE SCI, V64, P457, DOI 10.1016/S0024-3205(98)00588-8; Fardon T, 2007, RESP MED, V101, P1218, DOI 10.1016/j.rmed.2006.11.001; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Gross NJ, 2006, EUR J PHARMACOL, V533, P36, DOI 10.1016/j.ejphar.2005.12.072; Iwamoto H, 2008, EUR RESPIR J, V31, P1379, DOI 10.1183/09031936.00014108; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Kapoor AS, 2009, CAN RESPIR J, V16, P99, DOI 10.1155/2009/206506; Littner MR, 2000, AM J RESP CRIT CARE, V161, P1136, DOI 10.1164/ajrccm.161.4.9903044; Magnussen H, 2008, RESP MED, V102, P50, DOI 10.1016/j.rmed.2007.08.003; Park HW, 2009, ALLERGY, V64, P778, DOI 10.1111/j.1398-9995.2008.01876.x; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rodrigo G, 1999, AM J MED, V107, P363, DOI 10.1016/S0002-9343(99)00243-0; ROISIN RR, GLOB IN CHRON OBSTR; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; van Noord JA, 2009, RESP MED, V103, P22, DOI 10.1016/j.rmed.2008.10.002; van Noord JA, 2005, EUR RESPIR J, V26, P214, DOI 10.1183/09031936.05.00140404; Westby M, 2004, Cochrane Database Syst Rev, pCD003269	26	221	233	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					308	314		10.1016/j.jaci.2011.04.039	http://dx.doi.org/10.1016/j.jaci.2011.04.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21636120				2022-12-18	WOS:000293280800009
J	Renner, ED; Rylaarsdam, S; Anover-Sombke, S; Rack, AL; Reichenbach, J; Carey, JC; Zhu, Q; Jansson, AF; Barboza, J; Schimke, LF; Leppert, MF; Getz, MM; Seger, RA; Hill, HR; Belohradsky, BH; Torgerson, TR; Ochs, HD				Renner, Ellen D.; Rylaarsdam, Stacey; Anover-Sombke, Stephanie; Rack, Anita L.; Reichenbach, Janine; Carey, John C.; Zhu, Qili; Jansson, Annette F.; Barboza, Julia; Schimke, Lena F.; Leppert, Mark F.; Getz, Melissa M.; Seger, Reinhard A.; Hill, Harry R.; Belohradsky, Bernd H.; Torgerson, Troy R.; Ochs, Hans D.			Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hyper-IgE syndrome; HIES; autosomal-dominant hyper-IgE syndrome; Job syndrome; IgE; STAT3 mutations; STAT3 phosphorylation; T(H)17 cells	COLD STAPHYLOCOCCAL ABSCESSES; ACUTE LUNG INJURY; HYPERIMMUNOGLOBULINEMIA-E; JOBS-SYNDROME; NEUTROPHIL CHEMOTAXIS; RECURRENT INFECTIONS; T-CELLS; CYTOKINE; GENERATION; PATHWAY	Background: Hyper-IgE syndrome (HIES) is a rare, autosomal-dominant immunodeficiency characterized by eczema, Staphylococcus aureus skin abscesses, pneumonia with pneumatocele formation, Candida infections, and skeletal/connective tissue abnormalities. Recently it was shown that heterozygous signal transducer and activator of transcription 3 (STAT3) mutations cause autosomal-dominant HIES. Objective: To determine the spectrum and functional consequences of heterozygous STAT3 mutations in a cohort of patients with HIE S. Methods: We sequenced the STAT3 gene in 38 patients with HIES (National Institutes of Health score > 40 points) from 35 families, quantified T(H)17 cells in peripheral blood, and evaluated tyrosine phosphorylation of STAT3. Results: Most STAT3 mutations in our cohort were in the DNA-binding domain (DBD; 22/35 families) or Src homology 2 (SH2) domain (10/35) and were missense mutations. We identified 2 intronic mutations resulting in exon skipping and in-frame deletions within the DBD. In addition, we identified 2 mutations located in the transactivation domain downstream of the SH2 domain: a 10-amino acid deletion and an amino acid. substitution. In 1 patient, we were unable to identify a STAT3 mutation. T(H)17 cells were absent or low in the peripheral blood of all patients who were evaluated (n = 17). IL-6-induced STAT3-phosphorylation was consistently reduced in patients with SH2 domain mutations but comparable to normal controls in patients with mutations in the DBD. Conclusion: Heterozygous STAT3 mutations were identified in 34 of 35 unrelated HIES families. Patients had impaired TH17 cell development, and those with SH2 domain mutations had reduced STAT3 phosphorylation.	[Ochs, Hans D.] Univ Washington, Sch Med, Jeffrey Modell Chair Pediat Immunol Res, Dept Pediat, Seattle, WA 98101 USA; [Renner, Ellen D.; Rack, Anita L.; Jansson, Annette F.; Schimke, Lena F.; Belohradsky, Bernd H.] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Reichenbach, Janine; Seger, Reinhard A.] Univ Childrens Hosp, Div Immunol Hematol Bone Marrow Transplantat, Zurich, Switzerland; [Carey, John C.; Hill, Harry R.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Leppert, Mark F.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT USA; [Hill, Harry R.] Univ Utah, Sch Med, Dept Pathol & Med, Salt Lake City, UT USA; [Hill, Harry R.] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA	University of Washington; University of Washington Seattle; University of Munich; University Children's Hospital Zurich; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories	Ochs, HD (corresponding author), Univ Washington, Sch Med, Jeffrey Modell Chair Pediat Immunol Res, Dept Pediat, 1900 9th Ave, Seattle, WA 98101 USA.	Troy.Torgerson@seattlechildrens.org; allgau@u.washington.edu	Reichenbach, Janine/U-2171-2018; Renner, Ellen/R-7168-2016	Reichenbach, Janine/0000-0002-9008-1312; Renner, Ellen/0000-0001-9816-8538	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017427, R01HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI063267] Funding Source: NIH RePORTER; NIAID NIH HHS [AI063267-01, K08 AI063267] Funding Source: Medline; NICHD NIH HHS [HD017427-41, R37 HD017427] Funding Source: Medline; PHS HHS [N01A130070] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Barboza JA, 2004, MOL BIOL REP, V31, P13, DOI 10.1023/B:MOLE.0000013503.16301.82; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BLUM R, 1977, J PEDIATR-US, V90, P607, DOI 10.1016/S0022-3476(77)80380-6; Borges WG, 1998, J PEDIATR-US, V133, P303, DOI 10.1016/S0022-3476(98)70243-4; Borges WG, 2000, J PEDIATR-US, V136, P176, DOI 10.1016/S0022-3476(00)70098-9; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Chehimi J, 2001, CLIN IMMUNOL, V100, P49, DOI 10.1006/clim.2001.5039; DAVIS SD, 1966, LANCET, V1, P1013; den Dunnen JT, 2000, HUM MUTAT, V15, P7; DONABEDIAN H, 1983, INFECT IMMUN, V40, P1030, DOI 10.1128/IAI.40.3.1030-1037.1983; Gao HW, 2004, J IMMUNOL, V172, P7703, DOI 10.4049/jimmunol.172.12.7703; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; HILL HR, 1974, LANCET, V2, P617; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Nester TA, 1998, AM J MED, V105, P162, DOI 10.1016/S0002-9343(98)00200-9; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Nishihara M, 2007, INT IMMUNOL, V19, P695, DOI 10.1093/intimm/dxm045; Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood-2006-02-003012; Renner ED, 2005, J CLIN IMMUNOL, V25, P321, DOI 10.1007/s10875-005-4183-2; Renner ED, 2007, NEW ENGL J MED, V357, P1667, DOI 10.1056/NEJMc076367; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019	35	221	229	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					181	187		10.1016/j.jaci.2008.04.037	http://dx.doi.org/10.1016/j.jaci.2008.04.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602572	Green Accepted			2022-12-18	WOS:000257605100029
J	Williams, H; Flohr, C				Williams, Hywel; Flohr, Carsten			How epidemiology has challenged 3 prevailing concepts about atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; atopic march; eczema; hygiene	ECZEMA; SENSITIZATION; CHILDREN; ALLERGY; ASTHMA; ASSOCIATION; PREVALENCE; DISEASES; SCHOOLCHILDREN; RHINITIS	We challenge 3 prevailing concepts in understanding atopic dermatitis using data from epidemiologic studies. First, we show that although atopy is associated with atopic dermatitis to some degree, its importance is not likely to be a simple cause-and-effect relationship, especially at a population level. Our epidemiologic data do not exclude a contributory role for IgE-mediated immunologic processes, especially in those with existing and severe disease. Second, evidence is presented that does not support a straightforward inverse relationship between infections and atopic dermatitis risk. A link, if present, is likely to be more complex, depending critically on the timing and type of infectious exposure. Third, recent evidence suggests that the risk of subsequent childhood asthma is not increased in children with early atopic dermatitis who are not also early wheezers, suggesting a comanifestation of phenotypes rather than a progressive atopic march. Collectively, these observations underline the importance of epidemiologic studies conducted at a population level to gain a more balanced understanding of the enigma of atopic dermatitis.	Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2NR, England	University of Nottingham	Williams, H (corresponding author), Univ Nottingham, Ctr Evidence Based Dermatol, Kings Meadow Campus,Room A103,Lenton Lane, Nottingham NG7 2NR, England.	hywel.williams@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093				Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BIEBER T, 2005, J ALLERGY CLIN IMMUN, V117, P378; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; FLOHR C, 2005, J ALLERGY CLIN IMMUN, V117, P378; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; Mohrenschlager M, 2006, BRIT J DERMATOL, V154, P505, DOI 10.1111/j.1365-2133.2005.07042.x; Mortz CG, 2003, ACTA DERM-VENEREOL, V83, P194, DOI 10.1080/00015550310007201; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perkin MR, 2004, PEDIATR ALLERGY IMMU, V15, P221, DOI 10.1111/j.1399-3038.2004.00160.x; Ring J, 2001, J AM ACAD DERMATOL, V45, pS49, DOI 10.1067/mjd.2001.117015.24; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 2000, ATOPIC DERMATITIS EP, P221; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Williams HC, 2005, J ALLERGY CLIN IMMUN, V116, P1064, DOI 10.1016/j.jaci.2005.08.026; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005; Williams HC., 2000, ATOPIC DERMATITIS EP, P3; WILLIAMS HC, 2006, IN PRESS ARCH DERMAT; Yemaneberhan H, 2004, CLIN EXP ALLERGY, V34, P779, DOI 10.1111/j.1365-2222.2004.1946.x	38	221	235	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					209	213		10.1016/j.jaci.2006.04.043	http://dx.doi.org/10.1016/j.jaci.2006.04.043			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815157	Green Accepted, Green Submitted			2022-12-18	WOS:000239184800025
J	Kabesch, M; Schedel, M; Carr, D; Woitsch, B; Fritzsch, C; Weiland, SK; von Mutius, E				Kabesch, M; Schedel, M; Carr, D; Woitsch, B; Fritzsch, C; Weiland, SK; von Mutius, E			IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; IL-4; IL-13; pathway; polymorphism	RECEPTOR ALPHA-CHAIN; POLYMORPHISMS; ASSOCIATION; HAPLOTYPE; ATOPY; INTERLEUKIN-4; POPULATION; CHILDREN	Background: IgE production, a hallmark of asthma and atopic disease, may be under genetic control. Genes of the IL-4 and IL-13 pathway, central for IgE regulation, have so far only been assessed in studies of single gene effects. Objective: Here we analyzed combined extended haplotypes involving IL-4, IL-13, their shared receptor chain IL-4R alpha, and the intracellular signal transducer and activator of transcription, STAT6, to assess the combined effect of single nucleotide polymorphisms in this important immunological signaling pathway. Methods: We genotyped a large cross-sectional population of 1120 children age 9 to 11 years for 18 polymorphisms in the respective genes of the IL-4/IL-13 pathway. One polymorphism per gene was selected because of its putative functional role, and extended haplotypes were built in a stepwise procedure where gene-by-gene interactions were assessed by using a Cordell model. Results: Combining polymorphisms in all 4 major pathway genes in a stepwise procedure, the risk for high serum IgE levels increased 10.8-fold (P = .02) and the risk for the development of asthma increased by a factor of 16.8-fold (P = .005) compared with the maximum effect of any single polymorphism. Significant interactions in a model with additive and dominant effects, for both pair and triplet combinations for asthma (lowest P = .005), and for pairs of polymorphisms in IgE regulation were observed (lowest P = .054). Conclusion: These data indicate that only the combined analyses of genetic alterations in the IL-4/IL-13 pathway reveal its actual significance to the development of atopy and childhood asthma.	Univ Munich, Childrens Univ Hosp, D-80337 Munich, Germany; Univ Childrens Hosp, Leipzig, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Kabesch, M (corresponding author), Univ Munich, Childrens Univ Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Michael.Kabesch@med.uni-muenchen.de	Schedel, Michaela/B-3065-2019; Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022	Schedel, Michaela/0000-0001-8465-2986; von Mutius, Erika/0000-0002-8893-4515				Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463; Corry DB, 1999, NATURE, V402, pB18; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hackstein H, 2001, IMMUNOGENETICS, V53, P264, DOI 10.1007/s002510100324; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Rosenwasser LJ, 1998, CLIN EXP ALLERGY, V28, P13; SAS Institute Inc, 2004, SAS GEN 9 1 US GUID; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Woitsch B, 2004, INT ARCH ALLERGY IMM, V135, P319, DOI 10.1159/000082326; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986	22	221	237	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					269	274		10.1016/j.jaci.2005.10.024	http://dx.doi.org/10.1016/j.jaci.2005.10.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461126				2022-12-18	WOS:000235687300007
J	Matricardi, PM; Rosmini, F; Panetta, V; Ferrigno, L; Bonini, S				Matricardi, PM; Rosmini, F; Panetta, V; Ferrigno, L; Bonini, S			Hay fever and asthma in relation to markers of infection in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hay fever; hepatitis A virus; hygiene; infection; epidemiology; National Health and Nutrition Examination Survey III	ATOPY; PREVALENCE; HYGIENE; ALLERGY; LIFE; IMMUNOLOGY; INCREASE; EXPOSURE; CHILDREN; INDOOR	Background: The hygiene hypothesis proposes that declining exposure to infections is implicated in the rising trend of allergy, and asthma. Objective: We sought to test this hypothesis by examining the relationship of hay fever, asthma, and atopic sensitization with markers of infection in a large general population sample of the United States. Methods: We analyzed the data of 33,994 US residents recorded in a public database of a nationally representative cross-sectional survey (Third National Health and Nutrition Examination Survey, 1988-1994). The variables examined were sociodemographic information, lifetime diagnosis and age at first diagnosis of hay fever or asthma, current skin sensitization to 9 airborne allergens and peanut, and current serology for Toxoplasma gondii, herpes simplex viruses type 1 and 2, and hepatitis A, B, and C viruses. Results: Hay fever (adjusted odds ratio, 0.27; 95% CI, 0.18-0.41; P<.001) and asthma (adjusted odds ratio, 0.45; 95% CI, 0.31-0.66; P<.001) were less frequent in subjects seropositive for hepatitis A virus (HAV), T gondii, and herpes simplex virus 1 versus seronegative subjects after adjusting for age, sex, race, urban residence, census region, family size, income, an education. Skin sensitization to peanut and to all the airborne allergens examined, except for cockroach, was less frequent among HAV-seropositive versus HAV-seronegative subjects younger than 40 years of age. The prevalence of hay fever and asthma diagnosed at or before 18 years of age in HAV-seronegative subjects increased progressively from 2.7% (95% CI, 0.71%-4.7%) and 0.4% (95% CI, 0.1%-1.6%), respectively, in cohorts born before 1920 to 8.5% (95% CI, 7.3%-9.7%) and 5.8% (95% CI, 4.8%-6.8%), respectively, in cohorts born in the 1960s, whereas they remained constant at around 2% in all cohorts of HAV-seropositive subjects. Conclusion: In the United States serologic evidence of acquisition of certain infections, mainly food-borne and orofecal infection, is associated with a lower probability of having hay, fever and asthma. Third National Health and Nutrition Examination Survey data support the hypothesis that hygiene is a major factor contributing to the increase in hay fever, asthma, and atopic sensitization in westernized countries.	CNR, Inst Neurobiol & Mol Med, Rome, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS)	Matricardi, PM (corresponding author), WHO, Chron Resp Dis & Arthrit Unit, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.		Bonini, Sergio/T-6594-2019	Bonini, Sergio/0000-0003-0079-3031				Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; GUNTER EW, 1996, NCHS CDC PUBLICATION; Holgate ST, 2000, BMJ-BRIT MED J, V320, P231, DOI 10.1136/bmj.320.7229.231; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; *PLAN OP 3 NAT HLT, 1994, VITAL HLTH STAT, V32, P1; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107, DOI 10.1164/ajrccm.164.7.2107130b; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SNEDECOR GW, 1967, STATISTICAL METHODS, P246; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; Weiss ST, 1997, CIBA F SYMP, V206, P244; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	29	221	232	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					381	387		10.1067/mai.2002.126658	http://dx.doi.org/10.1067/mai.2002.126658			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209083				2022-12-18	WOS:000177936900006
J	RICHERSON, HB; BERNSTEIN, IL; FINK, JN; HUNNINGHAKE, GW; NOVEY, HS; REED, CE; SALVAGGIO, JE; SCHUYLER, MR; SCHWARTZ, HJ; STECHSCHULTE, DJ				RICHERSON, HB; BERNSTEIN, IL; FINK, JN; HUNNINGHAKE, GW; NOVEY, HS; REED, CE; SALVAGGIO, JE; SCHUYLER, MR; SCHWARTZ, HJ; STECHSCHULTE, DJ			GUIDELINES FOR THE CLINICAL-EVALUATION OF HYPERSENSITIVITY PNEUMONITIS - REPORT OF THE SUBCOMMITTEE-ON-HYPERSENSITIVITY-PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RICHERSON, HB (corresponding author), UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.							BRAUN SR, 1979, AM REV RESPIR DIS, V119, P185; BURRELL R, 1981, EUR J RESPIR DIS, V62, P332; DANIELE RP, 1985, ANN INTERN MED, V102, P93, DOI 10.7326/0003-4819-102-1-93; EMANUEL DA, 1983, CLIN REV ALLERG, V1, P509; FINK JN, 1983, ALLERGY PRINCIPLES P, P1085; HENDRICK DJ, 1980, THORAX, V35, P415, DOI 10.1136/thx.35.6.415; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; HUNNINGHAKE GW, 1984, SEMIN RESPIR MED, V6, P31, DOI 10.1055/s-2007-1011479; HUNNINGHAKE GW, 1987, HARRISONS PRINCIPLES, P1065; KAWANAMI O, 1983, AM J PATHOL, V110, P275; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; Pepys J., 1969, MONOGR ALLERGY, V4, P147; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1982, CLIN CHEST MED, V3, P503; RICHERSON HB, 1983, CLIN REV ALLERG, V1, P469; RICHERSONHB, 1988, PULMONARY DISEASES D, P667; SALVAGGIO JE, 1987, J ALLERGY CLIN IMMUN, V79, P558, DOI 10.1016/S0091-6749(87)80149-5; SCHATZ M, 1983, CLIN REV ALLERG, V1, P451; SCHLUETER DP, 1976, ANN INTERN MED, V70, P457; STANKUS RP, 1983, CLIN CHEST MED, V4, P55; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V78, P411, DOI 10.1016/0091-6749(86)90026-6; UNGER GF, 1973, RADIOL CLIN N AM, V11, P339	22	221	230	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	2	S			839	844		10.1016/0091-6749(89)90349-7	http://dx.doi.org/10.1016/0091-6749(89)90349-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CC527	2809034				2022-12-18	WOS:A1989CC52700009
J	LEUNG, DYM; BHAN, AK; SCHNEEBERGER, EE; GEHA, RS				LEUNG, DYM; BHAN, AK; SCHNEEBERGER, EE; GEHA, RS			CHARACTERIZATION OF THE MONONUCLEAR CELL INFILTRATE IN ATOPIC-DERMATITIS USING MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DIV HYDROBIOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NCI NIH HHS [CA-29061] Funding Source: Medline; NIADDK NIH HHS [AM-16392] Funding Source: Medline; NIAID NIH HHS [AI-05877] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAN AK, 1980, J EXP MED, V152, P771, DOI 10.1084/jem.152.4.771; BHAN AK, 1981, BRIT J DERMATOL, V105, P617, DOI 10.1111/j.1365-2133.1981.tb00970.x; BHAN AK, 1981, J EXP MED, V154, P737, DOI 10.1084/jem.154.3.737; BRAATHEN LR, 1979, BRIT J DERMATOL, V100, P511, DOI 10.1111/j.1365-2133.1979.tb05576.x; BYROM NA, 1979, BRIT J DERMATOL, V100, P491, DOI 10.1111/j.1365-2133.1979.tb05574.x; Cohen S., 1979, BIOL LYMPHOKINES; DELESPESSE G, 1982, Journal of Allergy and Clinical Immunology, V69, P135; ENGLEMAN EG, 1981, P NATL ACAD SCI-BIOL, V78, P1791, DOI 10.1073/pnas.78.3.1791; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; EVANS EI, 1952, ANN SURG, V135, P804, DOI 10.1097/00000658-195206000-00006; FULTON R, 1981, ANN DERMATOL VENER, V108, P243; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KARNOVSKY MJ, 1965, J CELL BIOL, V27, P137; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MCGREADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MITCHELL EB, 1982, LANCET, V1, P127; MURPHY GF, 1981, LAB INVEST, V45, P465; MURPHY GF, 1982, LAB INVEST, V46, P60; MUSGROVE K, 1976, BRIT J DERMATOL, V95, P365, DOI 10.1111/j.1365-2133.1976.tb00837.x; POPPEMA S, 1981, J EXP MED, V153, P30, DOI 10.1084/jem.153.1.30; RAJKA G, 1975, MAJOR PROBLEMS DERMA, V3, P4; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; RODRIGUEZ EM, 1978, J ULTRA MOL STRUCT R, V65, P279, DOI 10.1016/S0022-5320(78)80065-3; ROTH HL, 1964, ARCH DERMATOL, V89, P209, DOI 10.1001/archderm.1964.01590260047008; SHU SM, 1981, AM J CLIN PATHOL, V75, P734; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; THUESON DO, 1979, J IMMUNOL, V123, P626; UNO H, 1980, J INVEST DERMATOL, V75, P52, DOI 10.1111/1523-1747.ep12521130	35	221	222	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					47	56		10.1016/0091-6749(83)90546-8	http://dx.doi.org/10.1016/0091-6749(83)90546-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6337197				2022-12-18	WOS:A1983PZ46100008
J	Czarnowicki, T; He, H; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; He, Helen; Krueger, James G.; Guttman-Yassky, Emma			Atopic dermatitis endotypes and implications for targeted therapeutics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; phenotype; endotype; precision medicine; targeted therapies; European American; Asian; African American; filaggrin; intrinsic and extrinsic	AFRICAN-AMERICAN CHILDREN; DOWN-REGULATES FILAGGRIN; OF-FUNCTION VARIANTS; SKIN BARRIER; ECZEMA PREVALENCE; UNITED-STATES; IFN-GAMMA; ALLERGIC DISEASES; CLINICAL-FEATURES; EUROPEAN-ACADEMY	Recent research advancements indicate that atopic dermatitis (AD) is a complex disease characterized by different subtypes/phenotypes based on age, disease chronicity, ethnicity, filaggrin and IgE status, and underlying molecular mechanisms/endotypes. This heterogeneity advocates against the traditional "one-size-fits-all" therapeutic approaches still used to manage AD. Precision medicine approaches, striving for targeted, tailored, endotype-driven disease prevention and treatment, rely on detailed definitions of the disease's variability across different phenotypes. Studies have shown that AD harbors different endotypes across different age groups and ethnicities and according to IgE levels and filaggrin mutation status. These include European American versus Asian patients, children versus adults, intrinsic versus extrinsic (IgE status) disease, and patients with and without filaggrin mutations. Therapies targeting different cytokine axes and other mechanisms involved in disease pathogenesis, which are currently being tested for patients with AD across the disease spectrum, will expand our ability to dissect the relative contribution of each of these pathways to disease perpetuation.	[Czarnowicki, Tali; He, Helen; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Czarnowicki, Tali; He, Helen; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org						Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; Agache I, 2016, ALLERGOL INT, V65, P243, DOI 10.1016/j.alit.2016.04.011; Agner T, 2010, BRIT J DERMATOL, V163, P1147, DOI 10.1111/j.1365-2133.2010.10114.x; Akdis CA, 2003, CLIN EXP ALLERGY, V33, P1618, DOI 10.1111/j.1365-2222.2003.01803.x; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Alhamwe BA, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0259-4; Allen HB, 2008, J AM ACAD DERMATOL, V58, P503, DOI 10.1016/j.jaad.2007.03.033; Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; [Anonymous], 2015, DERMATOL ONLINE J; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brunner PM, 2017, ALLERGY, V72, P2017, DOI 10.1111/all.13223; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Buster KJ, 2012, DERMATOL CLIN, V30, P53, DOI 10.1016/j.det.2011.08.002; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chan TC, 2018, J INVEST DERMATOL, V138, pS10, DOI 10.1016/j.jid.2018.03.062; Czarnowicki T, 2018, ANN ALLERG ASTHMA IM, V120, P631, DOI 10.1016/j.anai.2018.03.013; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V140, P134, DOI 10.1016/j.jaci.2016.09.060; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x; De Jongh CM, 2008, CONTACT DERMATITIS, V58, P269, DOI 10.1111/j.1600-0536.2008.01317.x; De Marchi F, 2015, ALLERGY ASTHMA PROC, V36, pE127, DOI 10.2500/aap.2015.36.3872; Elias PM, 2018, EXP DERMATOL, V27, P847, DOI 10.1111/exd.13693; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Eshtiaghi P, 2018, CORE EVID, V13, P13, DOI 10.2147/CE.S133661; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Fu T, 2014, PEDIATR DERMATOL, V31, P21, DOI 10.1111/pde.12237; Fujita H, 2013, J DERMATOL SCI, V72, P3, DOI 10.1016/j.jdermsci.2013.04.028; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gong JQ, 2006, BRIT J DERMATOL, V155, P680, DOI 10.1111/j.1365-2133.2006.07410.x; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Guttman-Yassky E, 2017, J INVEST DERMATOL, V137, pS53, DOI 10.1016/j.jid.2017.02.329; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2017, SEMIN CUTAN MED SURG, V36, P100, DOI 10.12788/j.sder.2017.036; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Harb H, 2017, BIOSCIENCE REP, V37, DOI [10.1042/bsr20160485, 10.1042/BSR20160485]; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Kawamoto N, 2006, PEDIAT ALLERG IMM-UK, V17, P125, DOI 10.1111/j.1399-3038.2005.00363.x; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Kim BE, 2018, ALLERGY ASTHMA IMMUN, V10, P207, DOI 10.4168/aair.2018.10.3.207; Kim H, 2012, BRIT J NUTR, V108, P1726, DOI 10.1017/S0007114511007306; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kolls JK, 2008, NAT REV IMMUNOL, V8, P829, DOI 10.1038/nri2433; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Krueger JG, 2018, EXP DERMATOL, V27, P115, DOI 10.1111/exd.13467; Kulthanan K, 2011, ASIA PAC ALLERGY, V1, P80, DOI 10.5415/apallergy.2011.1.2.80; La Grutta S, 2005, ALLERGY, V60, P391, DOI 10.1111/j.1398-9995.2005.00733.x; Liu P, 2016, CHINESE MED J-PEKING, V129, P757, DOI 10.4103/0366-6999.178960; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Margolis D, 2018, J INVEST DERMATOL, V138, pS44, DOI 10.1016/j.jid.2018.03.265; Margolis DJ, 2018, J INVEST DERMATOL, V138, P1501, DOI 10.1016/j.jid.2018.01.029; Margolis DJ, 2014, J INVEST DERMATOL, V134, P2272, DOI 10.1038/jid.2014.126; Margolis DJ, 2014, JAMA DERMATOL, V150, P254, DOI 10.1001/jamadermatol.2013.7954; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Martel BC, 2016, EXP DERMATOL, V25, P453, DOI 10.1111/exd.12967; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Merriman JA, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00295-16; Mills KHG, 2008, EUR J IMMUNOL, V38, P2636, DOI 10.1002/eji.200838535; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nagaraja, 1996, PEDIATR DERMATOL, V13, P10, DOI 10.1111/j.1442-200X.1996.tb02838.x; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; Novak N, 2011, CURR PROBL DERMATOL, V41, P47, DOI 10.1159/000323295; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park JH, 2006, BRIT J DERMATOL, V155, P778, DOI 10.1111/j.1365-2133.2006.07394.x; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Pavel A, 2018, J INVEST DERMATOL, V138, pS74, DOI 10.1016/j.jid.2018.03.441; Pierron D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03342-5; Potaczek DP, 2017, EPIGENOMICS-UK, V9, P539, DOI 10.2217/epi-2016-0162; Purath U, 2016, J ALLERGY CLIN IMMUN, V137, P644, DOI 10.1016/j.jaci.2015.09.022; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Saeki H, 2017, BRIT J DERMATOL, V177, P419, DOI 10.1111/bjd.15493; Saeki H, 2006, J DERMATOL, V33, P817, DOI 10.1111/j.1346-8138.2006.00187.x; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Sanyal RD, 2018, J INVEST DERMATOL, V138, pS218, DOI 10.1016/j.jid.2018.03.1301; Sanyal RD, 2018, ANN ALLERGY ASTHMA I; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Silverberg NB, 2016, CUTIS, V97, P408; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2018, J INVEST DERMATOL, V138, P2224, DOI 10.1016/j.jid.2018.03.1517; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Stout TE, 2014, J INVEST DERMATOL, V134, P423, DOI 10.1038/jid.2013.284; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Szegedi A, 2015, BRIT J DERMATOL, V172, P320, DOI 10.1111/bjd.13534; Tanei R, 2016, GERIATR GERONTOL INT, V16, P75, DOI 10.1111/ggi.12771; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Thijs JL, 2017, J ALLERGY CLIN IMMUN, V140, P730, DOI 10.1016/j.jaci.2017.03.023; Thijs JL, 2017, J ALLERGY CLIN IMMUN, V139, P1065, DOI 10.1016/j.jaci.2016.08.023; Thijs JL, 2015, J CLIN MED, V4, P479, DOI 10.3390/jcm4030479; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Torrelo A, 2014, J EUR ACAD DERMATOL, V28, P2, DOI 10.1111/jdv.12480; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Vachiramon V, 2012, PEDIATR DERMATOL, V29, P395, DOI 10.1111/j.1525-1470.2012.01740.x; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; van Laarhoven AIM, 2015, J INVEST DERMATOL, V135, P1234, DOI 10.1038/jid.2014.522; Wang HH, 2016, J ALLERGY CLIN IMMUN, V138, P1719, DOI 10.1016/j.jaci.2016.05.038; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wen HC, 2018, J ALLERGY CLIN IMMUN, V142, P324, DOI 10.1016/j.jaci.2018.02.047; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Zhou L, 2018, J INVEST DERMATOL, V138, pS182, DOI 10.1016/j.jid.2018.03.1084	143	220	227	10	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					1	11		10.1016/j.jaci.2018.10.032	http://dx.doi.org/10.1016/j.jaci.2018.10.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30612663	Bronze			2022-12-18	WOS:000454918300001
J	Raap, U; Wichmann, K; Bruder, M; Stander, S; Wedi, B; Kapp, A; Werfel, T				Raap, Ulrike; Wichmann, Katja; Bruder, Manuela; Staender, Sonja; Wedi, Bettina; Kapp, Alexander; Werfel, Thomas			Correlation of IL-31 serum levels with severity of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; NC/NGA MICE; EXPRESSION; PRURITUS		[Raap, Ulrike; Wichmann, Katja; Bruder, Manuela; Wedi, Bettina; Kapp, Alexander; Werfel, Thomas] Hannover Med Sch, Dept Dermatol & Allergol, D-3000 Hannover, Germany; [Wichmann, Katja; Werfel, Thomas] Univ Munster, Dept Immunodermatol & Allergy Res, Munster, Germany; [Staender, Sonja] Univ Munster, Dept Dermatol, Munster, Germany	Hannover Medical School; University of Munster; University of Munster	Raap, U (corresponding author), Hannover Med Sch, Dept Dermatol & Allergol, D-3000 Hannover, Germany.	Raap.Ulrike@mh-hannover.de	Wedi, Bettina/ABE-3636-2021; Werfel, Thomas/B-6921-2012	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276; Stander, Sonja/0000-0003-3612-7786				Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Schulz F, 2007, J ALLERGY CLIN IMMUN, V120, P1097, DOI 10.1016/j.jaci.2007.07.065; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2002, EXP DERMATOL, V11, P12, DOI 10.1034/j.1600-0625.2002.110102.x; Takaoka A, 2006, EXP DERMATOL, V15, P161, DOI 10.1111/j.1600-0625.2006.00405.x; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040	9	220	237	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					421	423		10.1016/j.jaci.2008.05.047	http://dx.doi.org/10.1016/j.jaci.2008.05.047			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18678344				2022-12-18	WOS:000258426300036
J	Flohr, C; Johansson, SGO; Wahlgren, CF; Williams, H				Flohr, C; Johansson, SGO; Wahlgren, CF; Williams, H			How atopic is atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eczema; atopy; epidemiology	HIGH-RISK CHILDREN; NATURAL-HISTORY; CLINICAL-FEATURES; FOLLOW-UP; REVISED NOMENCLATURE; RESPIRATORY SYMPTOMS; INHALANT ALLERGENS; IMMUNOGLOBULIN-E; FOOD ALLERGENS; HENS EGG	Background: The extent to which the phenotype of atopic dermatitis (AD) is truly atopic has been the subject of much debate. Objective: We sought to systematically evaluate the evidence for the value of measurement of IgE antibodies in diagnosing AD and whether knowledge of IgE sensitization increases clinical diagnostic and predictive ability. Methods: We searched Medline from its inception until September 2003. Only studies that measured atopy as either skin prick test positivity or IgE-antibody sensitization to environmental allergens were included within a descriptive analysis. Because the small number of studies of adequate quality did not allow a formal meta-analysis, we assigned strength of evidence according to predefined quality criteria and ranked studies accordingly. Results: Inclusion of atopy as part of the diagnostic criteria for AD did not enhance the criteria's sensitivity and specificity in relation to the clinical phenotype of AD. The strength of association between atopy and AD varied significantly between hospital studies (47% to 75%; n = 14 studies) and was stronger in hospital than in community populations (7.4% to 78%; n = 13 studies). Whereas study quality did not have an effect on atopy prevalence in hospital populations, low atopy prevalences in community surveys were seen in less rigidly conducted studies. AD severity was positively associated with the number of positive skin prick test responses or IgE-antibody levels in 7 of 8 studies that measured both. Only one study suggested that IgE-specific sensitization to hen's egg is associated with subsequent development of AD, and 2 studies found that allergen-specific IgE sensitization in patients with AD is a prognostic marker for allergic airway disease in later life. Atopy-associated AD might also have a worse long-term prognosis than AD that is not associated with atopy. Conclusion: Although atopy is clearly associated with AD, the role of IgE sensitization in AD needs further study. Current evidence suggests that up to two thirds of persons with AD are not atopic, which implies that continued use of the term atopic dermatitis is problematic. Longitudinal studies are needed to compare the treatment response and prognosis of IgE-associated and non-IgE-associated AD.	Univ Nottingham, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England; Karolinska Univ Hosp, Dept Clin Immunol, Solna, Sweden; Karolinska Inst, Stockholm, Sweden; Karolinska Univ Hosp, Dept Med Dermatol & Venereol, Solna, Sweden	University of Nottingham; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Flohr, C (corresponding author), Univ Nottingham, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England.	carsten.flohr@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; BENNICH HH, 1968, B WORLD HEALTH ORGAN, V38, P151; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bohme M, 2001, ACTA DERM-VENEREOL, V81, P193, DOI 10.1080/000155501750376294; Bos JD, 2002, BRIT J DERMATOL, V147, P426, DOI 10.1046/j.1365-2133.2002.05010.x; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; BYROM NA, 1979, BRIT J DERMATOL, V100, P491, DOI 10.1111/j.1365-2133.1979.tb05574.x; de Longueville M, 1997, PEDIATR ALLERGY IMMU, V8, P177; DIEPGEN TL, 1989, ACTA DERM-VENEREOL, P50; Diepgen TL, 1996, J CLIN EPIDEMIOL, V49, P1031, DOI 10.1016/0895-4356(96)00119-9; DIEPGEN TL, 1990, Z HAUTKRANKHEITEN, V66, P38; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Emerson RM, 1998, BRIT J DERMATOL, V139, P73; Fabrizi G, 1999, EUR J DERMATOL, V9, P380; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; Hanifin JM, 2002, BRIT J DERMATOL, V147, P430, DOI 10.1046/j.1365-2133.2002.05011.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; HOARE C, 2000, HTA MONOGRAPHS, V4; HOCHREUTENER H, 1991, MONATSSCHR KINDERH, V139, P618; JOHANSSON SG, 1969, P ROY SOC MED, V62, P975, DOI 10.1177/003591576906200947; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P229, DOI 10.1111/j.1651-2227.1994.tb13057.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Laan MP, 2000, CLIN EXP ALLERGY, V30, P944, DOI 10.1046/j.1365-2222.2000.00856.x; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; Lilja G, 1996, CLIN EXP ALLERGY, V26, P1073; LINNA O, 1992, ACTA PAEDIATR, V81, P1013, DOI 10.1111/j.1651-2227.1992.tb12165.x; Mortz CG, 2003, ACTA DERM-VENEREOL, V83, P194, DOI 10.1080/00015550310007201; MURPHY R, 1999, BR J DERMATOL S55, V141, P25; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; Patrizi A, 2000, PEDIATR DERMATOL, V17, P261, DOI 10.1046/j.1525-1470.2000.01771.x; Pepys J., 1975, , Clinical aspects of immunology., P877; PERKIN M, 2003, IN PRESS PEDIAT ALLE; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; SALOB SP, 1993, PEDIATRICS, V91, P8; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Wolkerstorfer A, 2002, CLIN EXP ALLERGY, V32, P70, DOI 10.1046/j.0022-0477.2001.01265.x; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; YEMANEBERHAN H, 2004, IN PRESS CLIN EXP AL; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	56	220	229	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					150	158		10.1016/j.jaci.2004.04.027	http://dx.doi.org/10.1016/j.jaci.2004.04.027			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241359	Bronze			2022-12-18	WOS:000222534300023
J	Apter, AJ; Boston, RC; George, M; Norfleet, AL; Tenhave, T; Coyne, JC; Birck, K; Reisine, ST; Cucchiara, AJ; Feldman, HI				Apter, AJ; Boston, RC; George, M; Norfleet, AL; Tenhave, T; Coyne, JC; Birck, K; Reisine, ST; Cucchiara, AJ; Feldman, HI			Modifiable barriers to adherence to inhaled steroids among adults with asthma: It's not just black and white	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adherence; health beliefs; health disparities; inhaled corticosteroids; minority groups; African American; socioeconomic status	HEALTH	Background: Sociobehavioral factors influence adherence to inhaled corticosteroid (ICS) in adults with asthma and warrant exploration as explanations of apparent racial disparities in adherence. Objective: The purposes of this study were to identify barriers to adherence, potentially modifiable by healthcare providers, in a group of African Americans and non-African Americans and to test modifiable barriers as explanations of racial-ethnic differences in adherence. Methods: We conducted a cohort study of 85 adults (mean age, 47 +/- 15 years; 61 [72%] female; 55 [65%] African American) with moderate or severe persistent asthma to determine modifiable sociobehavioral predictors of adherence. These were knowledge of the function of ICS, patient-perceived adequacy of communication with the provider, social support, attitude (perception of risks/benefits of ICS), depression, and self-efficacy. Adherence was calculated from electronic monitoring data as the mean of the number of doses recorded per 12 hours divided by the number prescribed, truncated at 100%. Past adherence, baseline severity of symptoms, and sociodemographics were treated as fixed confounders in ordinal logistic modeling. Results: Adherence was 60% +/- 30%. In bivariate analyses, favorable attitude to ICS (P = .01) was associated with better adherence. Of immutable predictors, African American race-ethnicity (P = .001), lower educational achievement (P = .01), lower household income (P = .002), and more baseline symptoms (P = .003) were associated with poorer adherence. In multivariable analysis, controlling for immutable predictors, favorable attitude was associated with adherence. Favorable attitude was associated with greater adherence in African Americans and non-African Americans. Controlling for immutable factors, the race-adherence relationship was not mediated by the mutable factors, but economic factors (income and insurance) were mediators. Conclusion: Attitude is strongly related to adherence but does not mediate the effect of race-ethnicity.	Univ Penn, Dept Med, Div Pulm Allergy Crit Care Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Sci, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Gen Clin Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychiat, Dept Family Practice & Community Med, Philadelphia, PA 19104 USA; Univ Connecticut, Sch Dent Med, Dept Behav Sci & Community Hlth, Storrs, CT 06269 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Connecticut	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.			George, Maureen/0000-0001-9234-7842	NCRR NIH HHS [M01 RR 00040] Funding Source: Medline; NHLBI NIH HHS [HL 04337-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajzen H., 1980, UNDERSTANDING ATTITU; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 1996, J ALLERGY CLIN IMMUN, V98, P295, DOI 10.1016/S0091-6749(96)70153-7; Apter AJ, 2001, ANN ALLERG ASTHMA IM, V86, P421, DOI 10.1016/S1081-1206(10)62488-X; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A, 1995, SELF EFFICACY CHANGI, DOI DOI 10.1017/CBO9780511527692; Becker M. H., 1974, HLTH ED MONOGRAPHS; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; BOSLEY CM, 1995, EUR RESPIR J, V8, P899; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; DOLCE JJ, 1991, CHEST, V99, P837, DOI 10.1378/chest.99.4.837; *I MED, 2002, UNEQ TREATM CONFR RA; MANN M, 1992, CHEST, V101, P496, DOI 10.1378/chest.101.2.496; McDowell I., 1996, MEASURING HLTH GUIDE; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; *NIH NAT HEART LUN, 1997, EXP PAN REP 2 GUID D; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PICADO C, 1989, J ASTHMA, V26, P231, DOI 10.3109/02770908909073254; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Rothman K., 1998, MODERN EPIDEMIOLOGY; SHERBOURNE CD, 1992, J BEHAV MED, V15, P447, DOI 10.1007/BF00844941; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B	27	220	219	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1219	1226		10.1067/mai.2003.1479	http://dx.doi.org/10.1067/mai.2003.1479			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	688FZ	12789220				2022-12-18	WOS:000183424700008
J	TARGONSKI, PV; PERSKY, VW; RAMEKRISHNAN, V				TARGONSKI, PV; PERSKY, VW; RAMEKRISHNAN, V			EFFECT OF ENVIRONMENTAL MOLDS ON RISK OF DEATH FROM ASTHMA DURING THE POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA MORTALITY; MOLD; POLLENS	RESPIRATORY MORBIDITY; NORTHERN CALIFORNIA; CHILDHOOD ASTHMA; HOME DAMPNESS; TIME TRENDS; INDOOR AIR; CHILDREN; MORTALITY; HEALTH; IMMUNOTHERAPY	Objective: Many studies have noted an association of ambient aeroallergen levels with exacerbation of asthma. This study was undertaken to examine the relationship of aeroallergen levels with asthma-related mortality in Chicago. Methods: The association of environmental aeroallergen levels with death caused by asthma among 5- to 34-year-olds in Chicago was examined for the period of 1985 through 1989. Logistic regression analysis was used to compare the probability of a death caused by asthma occurring on the basis of environmental tree, grass, or ragweed pollen and mold spore levels. Results: Mean mold spore levels but not tree, grass, or ragweed pollen levels were significantly highs for days on which asthma-related death occurred than for days on which no deaths occurred (z = 2.80, p < 0.005). The odds of a death caused by asthma occurring on days with mold spore counts of 1000 spores per cubic meter or greater was 2.16 times higher (95% confidence interval = 1.31, 3.56, p = 0.003) than on days on which mold spore counts were less than 1000 spores per cubic meter The association with mold spore levels remained significant on multivariate logistic regression with mold spore counts measured as a continuous variable and controlling for pollens, with the odds of an asthma-related death occurring being 1.2 times higher (95% confidence interval = 1.07-1.34) for every increase of 1000 spores per cubic meter in daily mold spore levels. Conclusion: Although death caused by asthma also involves personal, social, and medical access factors, these data suggest that exposure to environmental molds may play a role in asthma-related mortality and should be considered in prevention strategies.	UNIV ILLINOIS,SCH PUBL HLTH,DIV EPIDEMIOL BIOSTAT,EPIDEMIOL BIOSTAT PROGRAM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIOSH CDC HHS [T15 OH07104-14] Funding Source: Medline	NIOSH CDC HHS		BRITTON J, 1988, J ALLERGY CLIN IMMUN, V82, P134, DOI 10.1016/0091-6749(88)90063-2; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; DHILLON M, 1991, ANN ALLERGY, V66, P385; GERBLICH AA, 1986, J ALLERGY CLIN IMMUN, V77, P676, DOI 10.1016/0091-6749(86)90408-2; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; JENKINS PF, 1980, CLIN ALLERGY, V11, P611; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; KHOT A, 1984, BRIT MED J, V289, P233, DOI 10.1136/bmj.289.6439.233; LEBOWITZ MD, 1987, ENVIRON RES, V43, P332, DOI 10.1016/S0013-9351(87)80033-6; MACKAY TW, 1992, SCOT MED J, V37, P5, DOI 10.1177/003693309203700102; MALLING HJ, 1986, ALLERGY, V41, P1673; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MARTIN CJ, 1987, BRIT MED J, V294, P1125, DOI 10.1136/bmj.294.6580.1125; MORROW MB, 1964, ANN ALLERGY, V22, P575; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; RICHARDS W, 1981, ANN ALLERGY, V47, P348; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; VERHOEFF AP, 1992, ALLERGY, V47, P83, DOI 10.1111/j.1398-9995.1992.tb05093.x; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; 1982, STATISTICAL REPORT P	28	220	224	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				955	961		10.1016/S0091-6749(95)70095-1	http://dx.doi.org/10.1016/S0091-6749(95)70095-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751516				2022-12-18	WOS:A1995QY91700006
J	CORREN, J; ADINOFF, AD; IRVIN, CG				CORREN, J; ADINOFF, AD; IRVIN, CG			CHANGES IN BRONCHIAL RESPONSIVENESS FOLLOWING NASAL PROVOCATION WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; RHINITIS; AIRWAY HYPERRESPONSIVENESS; ANTIGEN CHALLENGE; DIURNAL VARIATIONS	INHALATION CHALLENGE; ASTHMA; BRONCHOCONSTRICTION; IRRITATION; ASPIRATION; SINUSITIS; RHINITIS; DISEASE; POLLEN	The relationship between upper airway inflammation and asthma is controversial. In the current study, we sought to investigate the relationship between allergic rhinitis and lower airway dysfunction by performing double-blind, randomized nasal challenges with allergen or placebo. Subjects were selected for a prior history of asthma exacerbations after the onset of seasonal allergic rhinitis symptoms. After the induction of a marked nasal-allergic reaction (with a technique of nasal provocation that limited allergen delivery to the nose), there were no changes in FEV1, specific conductance, or lung volumes either 30 minutes or 41/2 hours after nasal allergen challenge, nor any changes in peak flow rates followed hourly until the next day. However, nasal provocation with allergen resulted in a relative increase in bronchial responsiveness to methacholine compared with that to placebo (p = 0.011 at 30 minutes and p = 0.0009 at 41/2 hours after challenge). Our study suggests that, although a nasal-allergic response does not induce airflow limitation of the lower airways, it can alter bronchial responsiveness.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DEPT MED & PEDIAT,DIV ALLERGY & CLIN IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DIV PULM SCI,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					PHS HHS [37765] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BONNET R, 1990, AM REV RESPIR DIS, V141, P358; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRUGMAN SM, 1989, AM REV RESPIR DIS, V139, P107; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Coffman D A, 1974, J R Coll Gen Pract, V24, P171; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; DAREMBERG C, 1854, OEVRES ANATOMIQUE PH, V1; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HATCH TF, 1961, BACTERIOL REV, V237, P25; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; INCORVAIA C, 1990, Journal of Allergy and Clinical Immunology, V85, P167; JONES B, 1989, DESIGN ANAL CROSSOVE; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MOYER DB, 1985, ANN ALLERGY, V55, P680; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; PLOTKOWSKI LM, 1990, AM REV RESPIR DIS, V141, P652; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; Small P., 1989, AM J RHINOL, V3, P17, DOI [10.2500/105065889782024384, DOI 10.2500/105065889782024384]; SMITH JM, 1984, RHINITIS; SOLOMON WR, 1989, PROVOCATIVE CHALLENG, P569; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; VANAALDEREN WMC, 1987, RES DIS, V135, P460; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WYLLIE JW, 1976, SURG FORUM, V27, P535; YAN K, 1983, EUR J RESPIR DIS, V64, P105; 1980, AM THORACIC SOC  SPR, P11	43	220	225	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					611	618		10.1016/0091-6749(92)90329-Z	http://dx.doi.org/10.1016/0091-6749(92)90329-Z			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740589				2022-12-18	WOS:A1992HD75300014
J	Nadeau, K; McDonald-Hyman, C; Noth, EM; Pratt, B; Hammond, SK; Balmes, J; Tager, I				Nadeau, Kari; McDonald-Hyman, Cameron; Noth, Elizabeth M.; Pratt, Boriana; Hammond, S. Katharine; Balmes, John; Tager, Ira			Ambient air pollution impairs regulatory T-cell function in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ambient air pollution; asthma; immune system; regulatory T cell; Treg; epigenetics	DIESEL EXHAUST PARTICLES; CYTOKINE PRODUCTION; FOXP3 EXPRESSION; DNA METHYLATION; LUNG-FUNCTION; EXPOSURE; CHALLENGE; CHILDREN; HYDROCARBONS; HEALTH	Background: Asthma is the most frequent chronic disease in children, and children are at high risk for adverse health consequences associated with ambient air pollution (AAP) exposure. Regulatory T (Treg) cells are suppressors of immune responses involved in asthma pathogenesis. Treg-cell impairment is associated with increased DNA methylation of Forkhead box transcription factor 3 (Foxp3), a key transcription factor in Treg-cell activity. Because AAP exposure can induce epigenetic changes, we hypothesized that Treg-cell function would be impaired by AAP, allowing amplification of an inflammatory response. Objectives: To assess whether exposure to AAP led to hypermethylation of the Foxp3 gene, causing impaired Treg-cell suppression and worsened asthma symptom scores. Methods: Children with and without asthma from Fresno, Calif (high pollution, Fresno Asthma Group [FA], n = 71, and Fresno Non Asthmatic Group, n = 30, respectively), and from Stanford, Calif (low pollution, Stanford Asthma Group, n = 40, and Stanford Non Asthmatic Group, n 5 40), were enrolled in a cross-sectional study. Peripheral blood Treg cells were used in functional and epigenetic studies. Asthma outcomes were assessed by Global Initiative in Asthma score. Results: Fresno Asthma Group Treg-cell suppression was impaired and FA Treg-cell chemotaxis were reduced compared with other groups (P <= .05). Treg-cell dysfunction was associated with more pronounced decreases in asthma Global Initiative in Asthma score in FA versus the Stanford Asthma Group. Foxp3 was decreased in FA compared with the Fresno Non Asthmatic Group (P <= .05). FA also contained significantly higher levels of methylation at the Foxp3 locus (P <= .05). Conclusion: Increased exposure to AAP is associated with hypermethylation of the Foxp3 locus, impairing Treg-cell function and increasing asthma morbidity. AAP could play a role in mediating epigenetic changes in Treg cells, which may worsen asthma by an immune mechanism. (J Allergy Clin Immunol 2010;126:845-52.)	[Nadeau, Kari] Stanford Univ, Div Immunol & Allergy, Sch Med, Stanford, CA 94305 USA; [Noth, Elizabeth M.; Pratt, Boriana; Hammond, S. Katharine; Balmes, John; Tager, Ira] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Stanford University; University of California System; University of California Berkeley	Nadeau, K (corresponding author), Stanford Univ, Div Immunol & Allergy, Sch Med, 269 Campus Dr,CCSR Bldg,Room 2115, Stanford, CA 94305 USA.	knadeau@stanford.edu	Balmes, John/L-6281-2019		McCormick Fund at Stanford; American Academy of Allergy, Asthma, and Immunology Junior Faculty Fund; Westly Foundation; Global Health Research Foundation; NIEHS [R01 HL081521]; CDC [5U19EH000097-04]; California Air Resources Board [99-322, 99-323, 01-346]; US EPA [2A-0540-NASX]; Austin Memorial Fund; Mickey Leland National Urban Air Toxics Research Center [RFA 2005-01]; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH [U19EH000097] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081521] Funding Source: NIH RePORTER	McCormick Fund at Stanford; American Academy of Allergy, Asthma, and Immunology Junior Faculty Fund; Westly Foundation; Global Health Research Foundation; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); California Air Resources Board; US EPA(United States Environmental Protection Agency); Austin Memorial Fund; Mickey Leland National Urban Air Toxics Research Center; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the McCormick Fund at Stanford, the American Academy of Allergy, Asthma, and Immunology Junior Faculty Fund, the Westly Foundation, the Global Health Research Foundation, NIEHS (R01 HL081521), CDC cooperative agreement 5U19EH000097-04, the California Air Resources Board (contract nos. 99-322, 99-323, and 01-346), the US EPA (PO no. 2A-0540-NASX), the Austin Memorial Fund, and the Mickey Leland National Urban Air Toxics Research Center (RFA 2005-01).; Disclosure of potential conflict of interest: S. K. Hammond has received research support from the National Institutes of Health-National Heart, Lung, and Blood Institute and National Institute of Environmental Health Sciences, the National Institute for Occupational Safety and Health, the Flight Attendant Medical Research Institute, and the Environmental Protection Agency and has provided legal consultation or expert witness testimony on the topic of exposure to chemicals in semiconductor manufacturing. J. Balmes is a member of the California Air Resources Board and has received research support from the National Institutes of Health, Centers for Disease Control and Prevention, and the California Air Resource Board. The rest of the authors have declared that they have no conflict of interest.	Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Balmes JR, 2009, J ALLERGY CLIN IMMUN, V123, P626, DOI 10.1016/j.jaci.2008.10.062; Bergstrom SE, 2008, RESP MED, V102, P1335, DOI 10.1016/j.rmed.2008.03.020; Bluestone JA, 2008, AM J TRANSPLANT, V8, P2086, DOI 10.1111/j.1600-6143.2008.02377.x; Bour-Jordan H, 2009, J IMMUNOL, V183, P4147, DOI 10.4049/jimmunol.0990078; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2005, AM J PHYSIOL-LUNG C, V289, pL722, DOI 10.1152/ajplung.00217.2005; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Islam T, 2007, THORAX, V62, P957, DOI 10.1136/thx.2007.078964; Janson PCJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001612; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kohlmeier JE, 2006, CURR OPIN IMMUNOL, V18, P357, DOI 10.1016/j.coi.2006.03.012; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Lal G, 2009, J IMMUNOL, V182, P259, DOI 10.4049/jimmunol.182.1.259; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Margolis HG, 2009, INT J ENVIRON HEAL R, V19, P139, DOI 10.1080/09603120802415792; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mastrangelo G, 2003, INT J IMMUNOPATH PH, V16, P145, DOI 10.1177/039463200301600208; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Nguyen KD, 2008, J IMMUNOL, V181, P5386, DOI 10.4049/jimmunol.181.8.5386; Nguyen KD, 2008, EUR J IMMUNOL, V38, P2034, DOI 10.1002/eji.200738082; Nguyen KD, 2009, J ALLERGY CLIN IMMUN, V123, P933, DOI 10.1016/j.jaci.2008.11.037; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peters JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002233; Sakaguchi S, 2009, EUR J IMMUNOL, V39, P2331, DOI 10.1002/eji.200939688; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.1s3256.x; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; TAGER I, 2006, FINAL REPORT FACES, P1; Taylor A, 2005, MICROBES INFECT, V7, P1049, DOI 10.1016/j.micinf.2005.03.029; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Umetsu Dale T, 2006, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P211; UMETSU DT, 2006, ARB P EHRLICH I BUND, V95, P215; Yu GP, 2009, CLIN IMMUNOL, V131, P240, DOI 10.1016/j.clim.2008.12.006	40	219	230	0	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					845	U280		10.1016/j.jaci.2010.08.008	http://dx.doi.org/10.1016/j.jaci.2010.08.008			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920773				2022-12-18	WOS:000282510000024
J	Holzhauser, T; Wackermann, O; Ballmer-Weber, BK; Bindslev-Jensen, C; Scibilia, J; Perono-Garoffo, L; Utsumi, S; Poulsen, LK; Vieths, S				Holzhauser, Thomas; Wackermann, Olga; Ballmer-Weber, Barbara K.; Bindslev-Jensen, Carsten; Scibilia, Joseph; Perono-Garoffo, Lorenza; Utsumi, Shigeru; Poulsen, Lars K.; Vieths, Stefan			Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Soybean allergy; soybean allergens; beta-conglycinin; glycinin; DBPCFC; anaphylaxis; cDNA expression library	CONTROLLED FOOD CHALLENGE; IGE-BINDING PROTEINS; ATOPIC-DERMATITIS; DOUBLE-BLIND; MOLECULAR CHARACTERIZATION; ANAPHYLACTIC REACTIONS; SENSITIVE PATIENTS; TRYPSIN-INHIBITOR; PEANUT ALLERGY; IDENTIFICATION	Background: Soybean is considered an important allergenic food, but published data on soybean allergens are controversial. Objective: We sought to identify relevant soybean allergens and correlate the IgE-binding pattern to clinical characteristics in European patients with confirmed soy allergy. Methods: IgE-reactive proteins were identified from a soybean cDNA expression library, purified from natural soybean source, or expressed in Escherichia coli. The IgE reactivity in 30 sera from subjects with a positive double-blind, placebo-controlled soybean challenge (n = 25) or a convincing history of anaphylaxis to soy (n = 5) was analyzed by ELISA or CAP-FEIA. Results: All subunits of Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) were IgE-reactive: 53% (16/30) of the study subjects had specific IgE to at least 1 major storage protein, 43% (13/30) to Gly m 5, and 36% (11/30) to Gly m 6. Gly m 5 was IgE-reactive in 5 of 5 and Gly m 6 in 3 of 5 children. IgE-binding to Gly m 5 or Gly m 6 was found in 86% (6/7) subjects with anaphylaxis to soy and in 55% (6/11) of subjects with moderate but only 33% (4/12) of subjects with mild soy-related symptoms. The odds ratio (P < .05) for severe versus mild allergic reactions in subjects with specific IgE to Gly m 5 or Gly m 6 was 12/1. Conclusion: Sensitization to the soybean allergens Gly m 5 or Gly m 6 is potentially indicative for severe allergic reactions to soy. (J Allergy Clin Immunol 2009;123:452-8.)	[Holzhauser, Thomas; Wackermann, Olga; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-63225 Langen, Germany; [Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Bindslev-Jensen, Carsten] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Scibilia, Joseph] Osped Niguarda Ca Granda, Allergol & Clin Immunol Unit, Dept Med, Milan, Italy; [Utsumi, Shigeru] Kyoto Univ, Food Sci Res Inst, Kyoto 6068501, Japan; [Poulsen, Lars K.] Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital; University of Southern Denmark; Odense University Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Kyoto University	Holzhauser, T (corresponding author), Paul Ehrlich Inst, Div Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	holth@pei.de	SCIBILIA, GIUSEPPE/AAC-9673-2022; Holzhauser, Thomas/ABD-5038-2020; Bindslev-Jensen, Carsten/H-1877-2011; Poulsen, Lars K/J-3065-2019	SCIBILIA, GIUSEPPE/0000-0002-5452-4024; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Poulsen, Lars K/0000-0002-1730-847X; Holzhauser, Thomas/0000-0002-7818-7261	European Commission [QLK4-CT-2001-00301]; Swiss Federal Office for Education and Science [BBW01.0159-1]	European Commission(European CommissionEuropean Commission Joint Research Centre); Swiss Federal Office for Education and Science	Supported by the 5th Framework Programme: Quality of Life and Management of Living Resources of the European Commission, QLK4-CT-2001-00301, and by the Swiss Federal Office for Education and Science. BBW01.0159-1.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; BESLER M, 2000, INTERNET S FOOD A S3, V2, P1; BURKS AW, 1994, INT ARCH ALLERGY IMM, V105, P143; Conti A, 2007, Eur Ann Allergy Clin Immunol, V39, P116; Gu XL, 2001, INT ARCH ALLERGY IMM, V126, P218, DOI 10.1159/000049517; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Helm RM, 2000, INT ARCH ALLERGY IMM, V123, P205, DOI 10.1159/000024445; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; Helm RM, 2000, J ALLERGY CLIN IMMUN, V105, P378, DOI 10.1016/S0091-6749(00)90091-5; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Hoff M, 2003, MOL IMMUNOL, V39, P965, DOI 10.1016/S0161-5890(03)00026-9; Holzhauser T, 1999, J AGR FOOD CHEM, V47, P603, DOI 10.1021/jf980775f; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Lin J, 2006, INT ARCH ALLERGY IMM, V141, P91, DOI 10.1159/000094535; Liu X, 2008, CLIN EXP ALLERGY, V38, P350, DOI 10.1111/j.1365-2222.2007.02893.x; Maruyama N, 1998, EUR J BIOCHEM, V258, P854, DOI 10.1046/j.1432-1327.1998.2580854.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; Prak K, 2005, J AGR FOOD CHEM, V53, P3650, DOI 10.1021/jf047811x; Reese G, 2005, J IMMUNOL, V175, P8354, DOI 10.4049/jimmunol.175.12.8354; Rozenfeld P, 2002, CLIN EXP IMMUNOL, V130, P49, DOI 10.1046/j.1365-2249.2002.t01-1-01935.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	32	219	240	0	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					452	458		10.1016/j.jaci.2008.09.034	http://dx.doi.org/10.1016/j.jaci.2008.09.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	18996574	Green Accepted			2022-12-18	WOS:000263495000025
J	Cazzoletti, L; Marcon, A; Janson, C; Corsico, A; Jarvis, D; Pin, I; Accordini, S; Almar, E; Bugiani, M; Carolei, A; Cerveri, I; Duran-Tauleria, E; Gislason, D; Gulsvik, A; Jogi, R; Marinoni, A; Martinez-Moratalla, J; Vermeire, P; de Marco, R				Cazzoletti, Lucia; Marcon, Alessandro; Janson, Christer; Corsico, Angelo; Jarvis, Deborah; Pin, Isabelle; Accordini, Simone; Almar, Enrique; Bugiani, Massimiliano; Carolei, Adriana; Cerveri, Isa; Duran-Tauleria, Enric; Gislason, David; Gulsvik, Amund; Jogi, Rain; Marinoni, Alessandra; Martinez-Moratalla, Jesus; Vermeire, Paul; de Marco, Roberto		Therapy & Hlth Economics Grp Europ	Asthma control in Europe: A real-world evaluation based on an international population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma control; inhaled corticosteroids; Global Initiative for Asthma; predictors of uncontrolled asthma; Cladosporium species; total IgE; body mass index; European Community Respiratory Health Survey; population-based study; cross-sectional study	LUNG-FUNCTION; COMMUNITY; SEVERITY; ADULTS	Background: Epidemiologic evidence related to asthma control in patients from the general population is scanty. Objectives: We sought to assess asthma control in several European centers according to the Global Initiative for Asthma (GINA) guidelines and to investigate its determinants. Methods: In the European Community Respiratory Health Survey 11 (1999-2002), 1241 adults with asthma were identified and classified into inhaled corticosteroid (ICS) users and non-ICS users in the last year. Control was assessed in both groups by using the GINA proposal (controlled, partly controlled, and uncontrolled asthma), and it was related to potential determinants. Results: Only 15% (95% CI, 12% to 19%) of subjects who had used ICSs in the last year and 45% (95% CI, 41% to 50%) of non-ICS users had their asthma under control; individuals with uncontrolled asthma accounted for 49% (95% CI, 44% to 53%) and 18% (95% CI, 15% to 21%), respectively. Among ICS users, the prevalence of uncontrolled asthma showed great variability across Europe, ranging from 20% (95% CI, 7% to 41%; Iceland) to 67% (95% CI, 35% to 90%; Italy). Overweight status, chronic cough and phlegm, and sensitization to Cladosporium species were associated with poor control in ICS users. About 65% and 87% of ICS users with uncontrolled and partly controlled asthma, respectively, were on a medication regimen that was less than recommended by the GINA guidelines. Conclusion: Six of 7 European asthmatic adults using ICSs in the last year did not achieve good disease control. The large majority of subjects with poorly controlled asthma were using antiasthma drugs in a suboptimal way. A wide variability in asthma control emerged across Europe. Clinical implications: Greater attention should be paid to asthma management and to the implementation of the GINA guidelines.	[Cazzoletti, Lucia; Marcon, Alessandro; Accordini, Simone; de Marco, Roberto] Univ Verona, Ist Biol 2, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37134 Verona, Italy; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Corsico, Angelo; Cerveri, Isa] Univ Pavia, Carrattere Sci San Matteo Hosp, Ist Ricovero & Cura, Div Resp Dis, I-27100 Pavia, Italy; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London, England; [Pin, Isabelle] CHU Grenoble, Dept Pediat, F-38043 Grenoble, France; [Pin, Isabelle] Inst Albert Bonniot, INSERM, U823, Grenoble, France; [Almar, Enrique; Martinez-Moratalla, Jesus] Hosp Gen Univ Albacete, Serv Neumol, Albacete, Spain; [Bugiani, Massimiliano] Azienda Sanit Locale 4 Piemonte, Consorzio Prov Antitubercolare, Unit Pneumol, Turin, Italy; [Carolei, Adriana; Marinoni, Alessandra] Univ Pavia, Fac Med, Dept Appl Hlth Sci, I-27100 Pavia, Italy; [Duran-Tauleria, Enric] Univ Pompeu Fabra, IMIM, Barcelona, Spain; [Gislason, David] Landspitali Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; [Gulsvik, Amund] Univ Bergen, Haukeland Univ Hosp, Dept Thorac Med, N-5020 Bergen, Norway; [Jogi, Rain] Fdn Tartu Univ Clin, Lung Clin, Tartu, Estonia; [Vermeire, Paul] Univ Antwerp, B-2020 Antwerp, Belgium	University of Verona; Uppsala University; University of Pavia; Imperial College London; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Pavia; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; Landspitali National University Hospital; University of Bergen; Haukeland University Hospital; University of Antwerp	Cazzoletti, L (corresponding author), Univ Verona, Ist Biol 2, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Str Le Grazie 8, I-37134 Verona, Italy.	lucia.cazzoletti@univr.it	de Marco, Roberto/A-5470-2008; Corsico, Angelo Guido/AAC-8138-2019; Marcon, Alessandro/C-3349-2012; Jarvis, Deborah/E-6494-2011; SESM, SESM/C-1440-2008; Carolei, Adriana/AAQ-7656-2021; PIN, Isabelle/N-3020-2013	Corsico, Angelo Guido/0000-0002-8716-4694; Marcon, Alessandro/0000-0002-2778-658X; Carolei, Adriana/0000-0002-5254-8532; Jarvis, Deborah/0000-0002-1753-3896; Cerveri, Isa/0000-0003-0337-043X				Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; Chinn S, 2005, LANCET, V365, P1629, DOI 10.1016/S0140-6736(05)66511-7; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; de Marco R, 2003, ALLERGY, V58, P221, DOI 10.1034/j.1398-9995.2003.00059.x; de Marco R, 2007, J ALLERGY CLIN IMMUN, V119, P611, DOI 10.1016/j.jaci.2006.11.696; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Janson C, 2005, EUR RESPIR J, V26, P1047, DOI 10.1183/09031936.05.00031905; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; Laforest L, 2006, J ALLERGY CLIN IMMUN, V117, P1404, DOI 10.1016/j.jaci.2006.03.007; Lundback B, 2007, ALLERGY, V62, P611, DOI 10.1111/j.1398-9995.2007.01399.x; *NAT HEART LUNG BL, 2006, NAT HEART LUNG BLOOD; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Revicki D, 2006, J ASTHMA, V43, P481, DOI 10.1080/02770900600619618; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	25	219	226	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1360	1367		10.1016/j.jaci.2007.09.019	http://dx.doi.org/10.1016/j.jaci.2007.09.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17981317	Bronze			2022-12-18	WOS:000251653800017
J	MICHEL, FB; BOUSQUET, J; GREILLIER, P; ROBINETLEVY, M; COULOMB, Y				MICHEL, FB; BOUSQUET, J; GREILLIER, P; ROBINETLEVY, M; COULOMB, Y			COMPARISON OF CORD BLOOD IMMUNOGLOBULIN-E CONCENTRATIONS AND MATERNAL ALLERGY FOR THE PREDICTION OF ATOPIC DISEASES IN INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MICHEL, FB (corresponding author), HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.							ARBESMAN CE, 1977, ALLERGY CLIN IMMUNOL, P392; BAZARAL M, 1971, J IMMUNOL, V107, P794; BESEDOVSKY H, 1977, CLIN EXP IMMUNOL, V27, P1; BOUSQUET J, 1978, ANN ALLERGY, V41, P170; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHANDRA RK, 1974, LANCET, V2, P1393; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V59, P377, DOI 10.1016/0091-6749(77)90022-7; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HAMBURGER RN, 1973, J ALLERGY CLIN IMMUN, V51, P129; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P495; KUROUME T, 1976, ANN ALLERGY, V37, P41; LEVIN S, 1971, PEDIATR RES, V5, P87, DOI 10.1203/00006450-197102000-00028; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MATHUR S, 1977, CLIN EXP IMMUNOL, V30, P403; MATTHEW DJ, 1977, LANCET, V1, P321; MCINTOSH K, 1976, J ALLERGY CLIN IMMUN, V57, P595, DOI 10.1016/0091-6749(76)90011-7; MICHEL FB, 1978, IMMUNOL ALLERGOL, V6, P169; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; MORI T, 1975, IMMUNOL COMMUN, V46, P519; NYE L, 1975, Clinical Allergy, V5, P13, DOI 10.1111/j.1365-2222.1975.tb01832.x; POLMAR SH, 1972, PEDIATRICS, V50, P279; RAPAPORT HOWARD G., 1960, ANN ALLERGY, V18, P45; REISMAN RE, 1975, PEDIATR CLIN N AM, V22, P251; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; WEINBERGER M, 1977, LANCET, V1, P795; WEINSTEIN Y, 1977, NATURE, V266, P632, DOI 10.1038/266632a0; WYLE FA, 1977, CLIN EXP IMMUNOL, V27, P407	33	219	220	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					422	430		10.1016/0091-6749(80)90234-1	http://dx.doi.org/10.1016/0091-6749(80)90234-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	7372964				2022-12-18	WOS:A1980JV76400004
J	LICHTENSTEIN, LM; VALENTINE, MD; SOBOTKA, AK				LICHTENSTEIN, LM; VALENTINE, MD; SOBOTKA, AK			INSECT ALLERGY - STATE OF THE ART	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218	Johns Hopkins University								ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; AUSTEN KF, 1978, IMMUNOLOGICAL DISEAS, V2, P885; BENSON RL, 1930, J ALLERGY, V1, P105; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BERNTON HS, 1966, J ALLERGY, V36, P315; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; COLEMAN M, 1975, J ALLERGY CLIN IMMUN, V56, P222, DOI 10.1016/0091-6749(75)90093-7; CONROY MC, 1977, FED PROC, V36, P1216; FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAPLAN AP, 1977, CLIN RES, V25, pA261; KARPAS AB, 1977, J ALLERGY CLIN IMMUN, V60, P155, DOI 10.1016/0091-6749(77)90118-X; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LOVELESS MH, 1962, J IMMUNOL, V89, P204; MARKLEY L, 1978, J ALLERGY CLIN IMMUN, V61, P134, DOI 10.1016/0091-6749(78)90259-2; MUELLER HL, 1977, PEDIATRICS, V59, P773; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OWEN MD, 1971, EXPERIENTIA, V27, P544, DOI 10.1007/BF02147590; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SHELDON JM, 1967, MANUAL CLIN ALLERGY, P130; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SOBOTKA AK, UNPUBLISHED; 1965, JAMA, V193, P109	34	219	220	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					5	12		10.1016/0091-6749(79)90075-7	http://dx.doi.org/10.1016/0091-6749(79)90075-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447951	Bronze			2022-12-18	WOS:A1979HC42400003
J	GLEICH, GJ; LARSON, JB; JONES, RT; BAER, H				GLEICH, GJ; LARSON, JB; JONES, RT; BAER, H			MEASUREMENT OF POTENCY OF ALLERGY EXTRACTS BY THEIR INHIBITORY CAPACITIES IN RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT MICROBIOL,ROCHESTER,MN 55901; FDA,BUR BIOL,ROCKVILLE,MD	Mayo Clinic; Mayo Clinic; Mayo Clinic; US Food & Drug Administration (FDA)								BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BAER H, 1973, J ALLERGY CLIN IMMUN, V51, P116, DOI 10.1016/S0091-6749(73)80081-8; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, INT ARCH ALLER A IMM, V42, P430, DOI 10.1159/000230623; DIXON WJ, 1957, INTRO STATISTICAL AN; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; JOHNSON P, 1965, EUR POLYM J, V1, P63; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; REISMAN ROBERT E., 1964, J ALLERGY, V35, P227, DOI 10.1016/0021-8707(64)90005-X; SHELDON JM, 1967, MANUAL CLINICAL ALLE; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	20	219	220	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	3					158	169		10.1016/0091-6749(74)90004-9	http://dx.doi.org/10.1016/0091-6749(74)90004-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S3550	4205187	Bronze			2022-12-18	WOS:A1974S355000004
J	Jartti, T; Gern, JE				Jartti, Tuomas; Gern, James E.			Role of viral infections in the development and exacerbation of asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; bronchiolitis; child; exacerbation; respiratory syncytial virus; rhinovirus; virus; wheeze; wheezing	RESPIRATORY-SYNCYTIAL-VIRUS; HUMAN RHINOVIRUS C; AIRWAY EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSES; 1-YEAR FOLLOW-UP; VITAMIN-D LEVELS; EARLY-LIFE; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; RSV BRONCHIOLITIS	Viral infections are closely linked to wheezing illnesses in children of all ages. Respiratory syncytial virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly detected in wheezing children thereafter. Severe respiratory illness induced by either of these viruses is associated with subsequent development of asthma, and the risk is greatest for young children who wheeze with RV infections. Whether viral illnesses actually cause asthma is the subject of intense debate. RSV-induced wheezing illnesses during infancy influence respiratory health for years. There is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway obstruction and recurrent wheezing. RV likely causes less structural damage and yet is a significant contributor to wheezing illnesses in young children and in the context of asthma. For both viruses, interactions between viral virulence factors, personal risk factors (eg, genetics), and environmental exposures (eg, airway microbiome) promote more severe wheezing illnesses and the risk for progression to asthma. In addition, allergy and asthma are major risk factors for more frequent and severe RV-related illnesses. Treatments that inhibit inflammation have efficacy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze. Developing a greater understanding of personal and environmental factors that promote more severe viral illnesses might lead to new strategies for the prevention of viral wheezing illnesses and perhaps reduce the subsequent risk for asthma.	[Jartti, Tuomas] Turku Univ Hosp, Dept Paediat, POB 52, FIN-20520 Turku, Finland; [Jartti, Tuomas] Univ Turku, Turku, Finland; [Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Gern, James E.] Univ Wisconsin, Dept Med, Madison, WI USA	University of Turku; University of Turku; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jartti, T (corresponding author), Turku Univ Hosp, Dept Paediat, POB 52, FIN-20520 Turku, Finland.	tuomas.jartti@utu.fi			Sigrid Juselius Foundation, Helsinki, Finland; National Institutes of Health [UG3 OD023282, P01 HL070831, U19 AI104317, UM1 AI114271]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104317, UM1AI114271] Funding Source: NIH RePORTER	Sigrid Juselius Foundation, Helsinki, Finland(Sigrid Juselius Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Sigrid Juselius Foundation, Helsinki, Finland, and National Institutes of Health grants UG3 OD023282, P01 HL070831, U19 AI104317, and UM1 AI114271.	Aab A, 2017, ALLERGY, V72, P232, DOI 10.1111/all.12931; Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263, DOI 10.1164/ajrccm.160.4.9812025; Andreoletti L, 2000, J MED VIROL, V61, P341, DOI 10.1002/1096-9071(200007)61:3&lt;341::AID-JMV10&gt;3.0.CO;2-0; Annamalay AA, 2017, J MED VIROL, V89, P582, DOI 10.1002/jmv.24684; Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689; Basta HA, 2014, VIROLOGY, V448, P82, DOI 10.1016/j.virol.2013.10.004; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bergroth E, 2016, PEDIATR INFECT DIS J, V35, P363, DOI 10.1097/INF.0000000000001017; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Blaser MJ, 2016, SCIENCE, V352, P544, DOI 10.1126/science.aad9358; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bosco A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2405-z; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Caballero MT, 2015, J CLIN INVEST, V125, P571, DOI 10.1172/JCI75183; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carroll KN, 2017, J ALLERGY CLIN IMMUN, V139, P66, DOI 10.1016/j.jaci.2016.01.055; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Denlinger LC, 2016, AM J RESP CRIT CARE, V193, P634, DOI 10.1164/rccm.201506-1169OC; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Dumas O, 2016, THORAX, V71, P712, DOI 10.1136/thoraxjnl-2016-208535; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Edwards M. R., 2017, ALLERGY; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Esquivel A, 2017, AM J RESP CRIT CARE; Fuchs O, 2012, J ALLERGY CLIN IMMUN, V130, P382, DOI 10.1016/j.jaci.2012.04.049; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Glanville N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003669; Graham BS, 2017, CURR OPIN VIROL, V23, P107, DOI 10.1016/j.coviro.2017.03.012; Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16; Guo-Parke H, 2013, AM J RESP CRIT CARE, V188, P842, DOI 10.1164/rccm.201304-0750OC; Haahtela T, 2015, CLIN EXP ALLERGY, V45, P891, DOI 10.1111/cea.12527; Han MY, 2016, J ALLERGY CLIN IMMUN, V138, P1619, DOI 10.1016/j.jaci.2016.01.037; Hao WD, 2012, J VIROL, V86, P13524, DOI 10.1128/JVI.02094-12; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003; Heinonen S, 2016, AM J RESP CRIT CARE, V193, P772, DOI 10.1164/rccm.201504-0749OC; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Hotard AL, 2015, J VIROL, V89, P8258, DOI 10.1128/JVI.01045-15; Hu CP, 2002, AM J PHYSIOL-LUNG C, V283, pL494, DOI 10.1152/ajplung.00414.2001; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2015, J ALLERGY CLIN IMMUN, V135, P691, DOI 10.1016/j.jaci.2014.07.001; Jartti T, 2011, CURR RESPIR MED REV, V7, P160, DOI 10.2174/157339811795589423; Jartti T, 2013, PAEDIATR RESPIR REV, V14, P38, DOI 10.1016/j.prrv.2012.04.002; Jartti T, 2009, PEDIATR INFECT DIS J, V28, P311, DOI 10.1097/INF.0b013e31818ee0c1; Johnson SM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005318; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kantor DB, 2016, AM J RESP CRIT CARE, V194, P1552; Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Kloepfer KM, 2017, J ALLERGY CLIN IMMUN, V140, P312, DOI 10.1016/j.jaci.2017.01.038; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Koistinen A, 2017, PEDIAT ALLERGY IMMUN; Koponen P, 2012, EUR RESPIR J, V39, P76, DOI 10.1183/09031936.00040211; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Korppi M, 2012, EUR RESPIR J, V39, P787, DOI 10.1183/09031936.00170511; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609; LEE S, 2016, NAT COMMUN, V7; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; LIU L, 2017, BMJ OPEN, V7; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Ludka-Gaulke T, 2017, J ALLERGY CLIN IMMUN; Lukkarinen M, 2017, J ALLERGY CLIN IMMUN; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Mansbach JM, 2008, ACAD EMERG MED, V15, P111, DOI 10.1111/j.1553-2712.2007.00034.x; Mansbach JM, 2016, J PEDIATR-US, V172, P202, DOI 10.1016/j.jpeds.2016.01.041; Marguet C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004596; Mazur N, 2015, LANCET RESP MED, V3, P888, DOI 10.1016/S2213-2600(15)00255-6; McIntyre CL, 2013, J GEN VIROL, V94, P1791, DOI 10.1099/vir.0.053686-0; Meissner HC, 2016, NEW ENGL J MED, V374, P1793, DOI 10.1056/NEJMc1601509; Mejias A, 2014, CURR OPIN INFECT DIS, V27, P228, DOI [10.1097/QCO.0000000000000065, 10.1097/QCO.0000000000000063]; Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549; Midulla F, 2012, EUR RESPIR J, V39, P396, DOI 10.1183/09031936.00188210; Midulla F, 2010, ARCH DIS CHILD, V95, P35, DOI 10.1136/adc.2008.153361; Midulla F, 2014, ACTA PAEDIATR, V103, P1094, DOI 10.1111/apa.12720; Miller EK, 2013, PEDIATR INFECT DIS J, V32, P950, DOI 10.1097/INF.0b013e31829b7e43; Mochizuki H, 2017, AM J RESP CRIT CARE, V196, P29, DOI [10.1164/rccm.201609-1812OC, 10.1164/rccm.201609-1812oc]; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nakagome K, 2014, J ALLERGY CLIN IMMUN, V134, P332, DOI 10.1016/j.jaci.2014.01.029; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Asthma Education and Prevention Program. National Heart Lung and Blood Institute National Institutes of Health, 2007, 3 US DEP HLTH HUM SE; Nicolai A, 2017, PEDIATR INFECT DIS J, V36, P179, DOI 10.1097/INF.0000000000001385; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Park HW, 2017, ALLERGY ASTHMA IMMUN, V9, P191, DOI 10.4168/aair.2017.9.3.191; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Ramratnam SK, 2017, AM J RESP CRIT CARE, V195, P674, DOI 10.1164/rccm.201602-0272OC; Ren LL, 2008, J CLIN VIROL, V43, P330, DOI 10.1016/j.jcv.2008.08.003; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Rossi GA, 2015, EUR RESPIR J, V45, P774, DOI 10.1183/09031936.00062714; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Ruotsalainen M, 2013, PEDIATR PULM, V48, P633, DOI 10.1002/ppul.22692; Saglani S, 2013, THER ADV INFECT DIS, V1, P139, DOI 10.1177/2049936113497202; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Scottish Intercollegiate Guidelines Network SIGN, BRONCH CHILDR NAT CL; Shariff S, 2017, AM J RESP CELL MOL, V56, P796, DOI 10.1165/rcmb.2016-0252OC; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simpson J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02564-9; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Singh AM, 2010, J ALLERGY CLIN IMMUN, V125, P491, DOI 10.1016/j.jaci.2009.11.026; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P131, DOI 10.1016/j.jaci.2008.10.042; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Toivonen L, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1309; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; Turner RB, 2017, CLIN VIROLOGY, P1143; Turunen R, 2017, PEDIATR INFECT DIS J, V36, P539, DOI 10.1097/INF.0000000000001495; Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318; Vandini S, 2017, PAEDIAT RESP REV; Williams JV, 2017, CLIN VIROLOGY, P873; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zheng SY, 2017, J MED VIROL; Zhivaki D, 2017, IMMUNITY, V46, P301, DOI 10.1016/j.immuni.2017.01.010; Zhu J, 2014, CHEST, V145, P1219, DOI 10.1378/chest.13-1567	152	218	238	5	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					895	906		10.1016/j.jaci.2017.08.003	http://dx.doi.org/10.1016/j.jaci.2017.08.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28987219	Green Published, Bronze			2022-12-18	WOS:000412172900001
J	Cosmi, L; Maggi, L; Santarlasci, V; Capone, M; Cardilicchia, E; Frosali, F; Querci, V; Angeli, R; Matucci, A; Fambrini, M; Liotta, F; Parronchi, P; Maggi, E; Romagnani, S; Annunziato, F				Cosmi, Lorenzo; Maggi, Laura; Santarlasci, Veronica; Capone, Manuela; Cardilicchia, Elisa; Frosali, Francesca; Querci, Valentina; Angeli, Roberta; Matucci, Andrea; Fambrini, Massimiliano; Liotta, Francesco; Parronchi, Paola; Maggi, Enrico; Romagnani, Sergio; Annunziato, Francesco			Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2; T(H)17; RORC; GATA-3; CD161	HUMAN TH17 CELLS; AUTOIMMUNE INFLAMMATION; TGF-BETA; CYTOKINE; T(H)17; DIFFERENTIATION; PHENOTYPE; ARTHRITIS; DISTINCT; LINEAGE	Background: IL-17A has been suggested to play a pathogenic role in bronchial asthma and other allergic disorders. Objective: Study of the relationship between human IL-17A-producing CD4(+) T-H cells (T(H)17) and IL-4-producing CD4(+) T-H (T(H)2) cells. Methods: T-cell clones generated from the CCR6(+)CD161(+) fraction of human circulating CD4(+) T cells, which contains virtually all T(H)17 cells, as well as circulating CD4(+) T cells from both healthy subjects and patients with asthma, were assessed by flow cytometry for their cytokine production profile. Results: A small proportion of CCR6(+)CD161(+)CD4(+) T-cell clones showed the ability to produce both IL-17A and IL-4 (T(H)17/T(H)12). T(H)17/T(H)2 clones also produced IL-5, IL-8, IL-9, IL-13, IL-21, and IL-22 and displayed the ability to induce the in vitro secretion of IgE. A very few T(H)17/T(H)12 cells were found among circulating CD4(+) T cells from normal subjects, but their proportions were significantly increased in the circulation of patients with chronic asthma. TT(H)17/T(H)2 cells could not be derived from naive umbilical cord blood CD4(+) T cells under any experimental condition. However, when circulating memory CCR6(+)CD161(+)CD4(+) T cells were cloned under appropriate polarizing conditions, T(H)17/T(H)2 clones originated in the presence of IL-4, suggesting that an IL-4-rich microenvironment may induce the shifting of memory T(H)17 cells into T(H)17/T(H)2 cells. Conclusion: Because of its peculiar functional properties and the increased numbers in the circulation of patients with bronchial asthma, this previously unknown population of T(H)17/T(H)2 cells may play some role in the pathogenesis of this disease. (J Allergy Clin Immunol 2010;125:222-230.)	[Cosmi, Lorenzo; Maggi, Laura; Santarlasci, Veronica; Capone, Manuela; Cardilicchia, Elisa; Frosali, Francesca; Querci, Valentina; Angeli, Roberta; Matucci, Andrea; Liotta, Francesco; Parronchi, Paola; Maggi, Enrico; Romagnani, Sergio; Annunziato, Francesco] Univ Florence, Ctr Excellence DENOthe, Florence, Italy; [Fambrini, Massimiliano] Univ Florence, Dept Gynecol Perinatol & Human Reprod, Florence, Italy	University of Florence; University of Florence	Romagnani, S (corresponding author), Univ Florence, Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it	Annunziato, Francesco/C-1155-2013; Maggi, Enrico/AAA-8045-2019; Maggi, Laura/B-6693-2013; Parronchi, Paola/AAE-5422-2022; Fambrini, Massimiliano/K-5835-2016	Maggi, Enrico/0000-0002-1824-3583; Maggi, Laura/0000-0003-2862-9591; Parronchi, Paola/0000-0002-9184-5089; Annunziato, Francesco/0000-0001-8798-7589; Fambrini, Massimiliano/0000-0003-0461-6390	Italian Ministry of Education; Italian Ministry of Health; Ente Cassa di Risparmio, Florence, Italy; EU [FP6-LSBH-CT-2006-018861]; INNOCHEM [FP6-LSHB-CT-2005-518167]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Italian Ministry of Education; Italian Ministry of Health(Ministry of Health, Italy); Ente Cassa di Risparmio, Florence, Italy; EU(European Commission); INNOCHEM(European Commission); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	The experiments reported in this article have been supported by funds of the Italian Ministry of Education, the Italian Ministry of Health (AIDS Project), the Ente Cassa di Risparmio, Florence, Italy, EU Projects SENS-IT-IV (FP6-LSBH-CT-2006-018861) and INNOCHEM (FP6-LSHB-CT-2005-518167),	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Annunziato F, 2008, INT IMMUNOL, V20, P1361, DOI 10.1093/intimm/dxn106; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Doodes PD, 2008, J IMMUNOL, V181, P329, DOI 10.4049/jimmunol.181.1.329; Dubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.x; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Kiene A, 2001, ARTHRITIS RHEUM-US, V44, P469, DOI 10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0; Kleinschek MA, 2009, J EXP MED, V206, P525, DOI 10.1084/jem.20081712; Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159; LANIER LL, 1994, J IMMUNOL, V153, P2417; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Martin-Orozco N, 2009, EUR J IMMUNOL, V39, P216, DOI 10.1002/eji.200838475; Mavilia C, 1997, AM J PATHOL, V151, P1751; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Santarlasci V, 2009, EUR J IMMUNOL, V39, P207, DOI 10.1002/eji.200838748; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; WIE G, 2009, IMMUNITY, V30, P155; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497	28	218	223	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					222	230		10.1016/j.jaci.2009.10.012	http://dx.doi.org/10.1016/j.jaci.2009.10.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109749	Bronze			2022-12-18	WOS:000273660500028
J	Huss, K; Adkinson, NF; Eggleston, PA; Dawson, C; Van Natta, ML; Hamilton, RG				Huss, K; Adkinson, NF; Eggleston, PA; Dawson, C; Van Natta, ML; Hamilton, RG			House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; childhood asthma; cockroach allergy; Childhood Asthma Management Program; allergy sensitization; indoor allergens; atopy; risk factors for asthma; allergen exposure	INNER-CITY CHILDREN; CAT ALLERGEN; SENSITIZATION; ANTIGEN; SCHOOL; HOMES; DOG	Background: Children with asthma have a high prevalence of environmental allergies, especially to indoor allergens. The relationships of exposure to indoor allergens (dust mites, cat, dog, cockroach, and molds) and other host factors to allergy sensitization have not been evaluated simultaneously in a large cohort. Objectives: We studied 1041 children aged 5 to 12 years with mild-to-moderate asthma to determine risk factors associated with having positive allergy skin test responses to indoor allergens. Also, we described, compared, and contrasted 6 allergens in the home environments of these children from 8 North American cities. Methods: Data were used from baseline visits of the Childhood Asthma Management Program. Patients' sensitivities to house dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), cats, dogs, cockroaches, and molds were examined for relationships to demographic variables, home dust allergen exposures, number of other positive allergy skin test responses, total serum IgE levels, and smoking in the home. Results: San Diego (78.5%) and Toronto (59.3%) had the topmost percentages of homes with moderate-to-high house dust mite levels. Boston (21.5%), St Louis (16.3%), and Baltimore (13.4%) had the highest percentages of homes with detectable levels of cockroach allergen. For house dust mites, the higher the level of allergen exposure, the more likely patients were to have positive allergy skin test responses, with relative odds of 9.0 (95% confidence interval, 5.4-15.1) for those exposed to high mite levels: (>10.0 mug/g dust) relative to those unexposed. Even exposure to low levels of mite allergen (0.020-2.0 mug/g) was found to be a significant risk factor for sensitization. For cockroach allergen, those with detectable home exposure were more likely to have positive skin test responses (relative odds, 2.2; 95% confidence interval, 1.3-3.8) than those with undetectable exposure. In contrast, levels of exposure to cat, dog, and mold allergens were not related to sensitization rates. For cat allergen, this may reflect lower rates of cat ownership among highly sensitized subjects. Furthermore, the number of allergy skin test responses that were positive, excluding the test for the outcome of interest for each model, and total serum IgE levels were strong independent predictors of sensitization. Conclusions: Levels of exposure determined by house dust analysis are important determinants of sensitization for dust mite and cockroach allergen. This relationship was not demonstrable for cat, dog, or mold allergens, possibly because of confounding factors. For all allergens studied, the degree of atopy; determined by the total number of positive skin test responses or by total serum IgE levels, is an important contributing risk factor for sensitization.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Asthma & Allergy Ctr, DACI Reference Lab, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Huss, K (corresponding author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St,Room 416, Baltimore, MD 21205 USA.							ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BACKER V, 1992, ALLERGY, V47, P484, DOI 10.1111/j.1398-9995.1992.tb00669.x; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; CHAPMAN MD, 1995, PEDIAT ALLERG IMM-UK, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Hamilton R. G., 1997, MANUAL CLIN LAB IMMU, P881; HAMILTON S, 1992, NEW ENGL REV-MIDDLEB, V14, P96; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OWNBY DR, 1984, J ALLERGY CLIN IMMUN, V73, P466, DOI 10.1016/0091-6749(84)90356-7; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; *SAS I INC, 1989, SAS STAT US GUID VER, V1; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	32	218	232	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					48	54		10.1067/mai.2001.111146	http://dx.doi.org/10.1067/mai.2001.111146			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149990				2022-12-18	WOS:000166533300009
J	Kharitonov, SA; Rajakulasingam, K; OConnor, B; Durham, SR; Barnes, PJ				Kharitonov, SA; Rajakulasingam, K; OConnor, B; Durham, SR; Barnes, PJ			Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; allergic rhinitis; inducible nitric oxide synthase; glucocorticoids	LUNG EPITHELIAL-CELLS; EXHALED AIR; SYNTHASE; EXPRESSION; AIRWAYS; HUMANS	Nitric oxide (NO) is produced in large amounts in the noses of normal individuals. We have measured NO by chemiluminescence in the noses and exhaled air of subjects with symptomatic allergic rhinitis, some of whom had concomitant asthma, during the pollen season and compared this with values measured in normal subjects and in patients treated with nasal and/or inhaled glucocorticoids. We found that nasal levels of NO were significantly (p < 0.001) elevated in patients with untreated rhinitis (1527 +/- 87 ppb, n = 12) compared with normal individuals (996 +/- 39 ppb, n = 46) or subjects treated with nasal steroids (681 +/- 34 ppb, n = 10), whereas exhaled NO in patients with untreated rhinitis was similar. to that in normal subjects (10 +/- 2 ppb vs 7 +/- 0.6 ppb, respectively). In five subjects who were nasally challenged with allergen, there was a significant decrease in nasal NO I hour after challenge, and this was significantly correlated with increased rhinitis symptoms. In patients with rhinitis and concomitant asthma, nasal NO was also significantly elevated (1441 +/- 76 ppb, n = 16) but not when they were treated with nasal or inhaled steroids; whereas exhaled NO was elevated in untreated patients and in patients treated with nasal but not inhaled steroids. Our data suggest that the increase in exhaled NO in patients with allergic rhinitis is likely to be due to increased local production, caused by long-term exposure to allergen, which is suppressed by locally administered steroids. Measurement of nasal NO may be useful to study the inflammatory response in rhinitis and its response to antiinflammatory treatments.	NATL HEART & LUNG INST,DEPT THORAC MED,LONDON,ENGLAND; NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON,ENGLAND	Imperial College London; Imperial College London				Barnes, Peter/0000-0002-5122-4018				ALVING K, 1993, EUR RESPIR J, V6, P1268; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BERNAREGGI M, 1996, IN PRESS AM J RESP C; BORLAND C, 1993, THORAX, V48, P1160, DOI 10.1136/thx.48.11.1160; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; DEAR JW, 1995, BRIT J PHARMACOL, V116, P1720, DOI 10.1111/j.1476-5381.1995.tb16653.x; DUBOIS AB, 1994, AM J RESP CRIT CARE, V149, pA197; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FURUKAWA K, 1995, AM J RESP CRIT CARE, V181, pA128; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889, DOI 10.1164/ajrccm.151.6.7767536; KHARITONOV SA, 1995, IN PRESS EUR J RESP, V9; KHARITONOV SA, 1995, IN PRESS AM J RESP C; KULKARNI AP, 1994, J COMP NEUROL, V345, P125, DOI 10.1002/cne.903450110; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; MARTIN U, 1995, AM J RESP CRIT CARE, V151, pA128; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P1027; SPRINGALL DR, 1995, AM J RESP CRIT CARE, V151, pA833; VOSSWINKEL R, 1991, ARCH MICROBIOL, V156, P62, DOI 10.1007/BF00418189; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801	31	218	230	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				58	64						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003212				2022-12-18	WOS:A1997WD06100009
J	MULLER, U; HELBLING, A; BERCHTOLD, E				MULLER, U; HELBLING, A; BERCHTOLD, E			IMMUNOTHERAPY WITH HONEYBEE VENOM AND YELLOW JACKET VENOM IS DIFFERENT REGARDING EFFICACY AND SAFETY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYMENOPTERA-STING ALLERGY; HONEYBEE VENOM; YELLOW JACKET VENOM; VENOM IMMUNOTHERAPY	HYMENOPTERA STING ALLERGY; INSECT; RUSH; BEE; HYPOSENSITIZATION; HYPERSENSITIVITY; EXTRACTS; PROGRAM	Venom immunotherapy (VIT) for Hymenoptera allergy is accepted as safe and effective. However, widely varying success rates and frequencies of side effects are reported. Differences between various Hymenoptera species could account for these diverging results. We therefore analyzed 205 patients with a history of systemic allergic reactions to either honeybee (148 patients) or yellow jacket stings (57 patients) during VIT. All patients had a positive skin test to the respective venom before VIT, were monitored for side effects of VIT, and submitted to a sting challenge while they were receiving VIT. Patients with honeybee-venom allergy had a higher sensitivity in both skin tests (p < 0.05) and RAST (p < 0.001) than patients with yellow jacket-venom allergy. They developed systemic side effects to VIT injections significantly more often (41% versus 25%; p < 0.01) and also reacted more frequently to the sting challenge (23% versus 9%; p < 0.01) than patients with yellow jacket-venom allergy. We conclude that results obtained from studies on the allergy to one Hymenoptera venom cannot be extrapolated to allergies to other Hymenoptera venoms.	TULANE UNIV, SCH MED, DIV CLIN IMMUNOL & ALLERGY, NEW ORLEANS, LA 70112 USA	Tulane University	MULLER, U (corresponding author), ZIEGLERSPITAL BERN, DIV MED, CH-3007 BERN, SWITZERLAND.							Adolph J, 1986, Z Erkr Atmungsorgane, V166, P119; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; GILLMAN SA, 1980, ANN ALLERGY, V45, P351; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P367, DOI 10.1016/0091-6749(77)90020-3; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KIND LS, 1981, ALLERGY, V36, P155, DOI 10.1111/j.1398-9995.1981.tb01830.x; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MOSBECH H, 1986, ALLERGY, V41, P95, DOI 10.1111/j.1398-9995.1986.tb00284.x; Mueller H L, 1966, J Asthma Res, V3, P331; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Muller UR., 1990, INSECT STING ALLERGY; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; REISMAN RE, 1983, ALLERGY PRINCIPLES P, P1361; ROCKLIN R E, 1982, Journal of Allergy and Clinical Immunology, V69, P125; RZANY B, 1991, ALLERGY, V46, P251, DOI 10.1111/j.1398-9995.1991.tb00582.x; SCHUBERTH KC, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90332-9; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; WUTHRICH B, 1981, PRAXIS, V70, P934; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	31	218	222	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					529	535		10.1016/0091-6749(92)90319-W	http://dx.doi.org/10.1016/0091-6749(92)90319-W			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740583				2022-12-18	WOS:A1992HD75300004
J	SALVAGGIO, J; AUKRUST, L				SALVAGGIO, J; AUKRUST, L			MOLD-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SALVAGGIO, J (corresponding author), TULANE UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,NEW ORLEANS,LA 70112, USA.				PHS HHS [13401-07] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; AAS K, 1968, INT ARCH ALLERGY APP, V36, P152; ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; ARNER B, 1958, Sven Lakartidn, V55, P3761; AUKRUST L, 1977, SCAND J IMMUNOL, V6, P1093; AUKRUST L, 1980, ALLERGY, V35, P206, DOI 10.1111/j.1398-9995.1980.tb01747.x; AUKRUST L, 1978, ALLERGY, V33, P24, DOI 10.1111/j.1398-9995.1978.tb01503.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P371; AUKRUST L, 1980, ADV ALLERGOLOGY IMMU; AUKRUST L, 1981, 14TH P NORD C ALL GO; AUKRUST L, 1980, DIAGNOSIS TREATMENT; AUKRUST L, 1980, ALLERGOL IMMUNOPATH, V8, P306; BJELDANES L, 1978, APPL ENV MICROBIOL, V35, P115; Blackley CH., 1873, EXPT RES CAUSES NATU; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BONILLAS.O, 1969, J ALLERGY, V43, P125, DOI 10.1016/S0021-8707(69)80003-1; BORCH SM, 1980, ALLERGY, V35, P194, DOI 10.1111/j.1398-9995.1980.tb01741.x; BURRELL RG, 1966, PHYTOPATHOLOGY, V56, P422; BURROUGHS R, 1976, APPL ENVIRON MICROB, V31, P685, DOI 10.1128/AEM.31.5.685-690.1976; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V59, P289; Chemists AOOA., 1975, OFFICIAL METHODS ANA; CLAYTON C, 1936, W VA ACAD SCI P, V36, P30; de Vries GA., 1952, CONTRIBUTION KNOWLED; DESSAINT JP, 1976, CLIN IMMUNOL IMMUNOP, V5, P314, DOI 10.1016/0090-1229(76)90039-8; DOBREY AN, 1962, CAN MED ASSOC J, V87, P1310; DURHAM OC, 1946, J ALLERGY, V17, P79, DOI 10.1016/0021-8707(46)90025-1; ELSAYED S, 1971, INT ARCH ALLER A IMM, V40, P428, DOI 10.1159/000230425; FEINBERG SM, 1935, WISC MED J, V34, P254; FLAHERTY D K, 1970, Mycopathologia et Mycologia Applicata, V42, P165, DOI 10.1007/BF02051838; FROSTAD A, CLIN ALLERGY; FUST B, 1964, 5TH P C INT AL MADR; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; GRIMMER O, 1980, ALLERGY, V35, P220, DOI 10.1111/j.1398-9995.1980.tb01753.x; HALPERN SR, 1961, ANN ALLERGY, V19, P1407; HILSBY J, 1949, ACTA ALLERGOL, V11, P57; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; ITKIN IH, 1966, J ALLERGY, V37, P187, DOI 10.1016/0021-8707(66)90113-4; JOFFE AZ, 1969, APPL MICROBIOL, V18, P517, DOI 10.1128/AEM.18.3.517-518.1969; JUHLIN-DANNFELT C, 1950, Acta Med Scand Suppl, V239, P320; KARR RM, 1979, J ALLERGY CLIN IMMUN, V63, P213; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1297; KIMURA P, 1975, Clinical Allergy, V5, P331, DOI 10.1111/j.1365-2222.1975.tb01871.x; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; KOBAYASHI G, 1978, J ALLERGY CLIN IMMUN, V61, P230, DOI 10.1016/0091-6749(78)90191-4; LEBEAU L, 1952, THESIS U ILLINOIS CH; LIACOPOULOS P, 1975, PROG ALLERGY, V18, P97; LICHTENSTEIN LM, 1978, AM REV RESPIR DIS, V117, P191; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOWELL F, 1963, J ALLERGY, V34, P105; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P1, DOI 10.1159/000231900; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; LOWENSTEIN H, 1980, ALLERGY, V35, P180; MEMON N A, 1977, American Review of Respiratory Disease, V115, P65; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; ORDMAN D, 1964, 5TH P C INT AL MADR; PADY S, 1966, J ALLERGY CLIN IMMUN, V39, P302; PENNINGTON ES, 1940, SOUTH MED J, V33, P931; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; POPA V, 1968, J ALLERGY, V42, P130, DOI 10.1016/0021-8707(68)90086-5; Pratt Henry N., 1942, JOUR ALLERGY, V13, P227, DOI 10.1016/S0021-8707(42)90161-8; PRINCE HE, 1934, TEXAS J MED, V30, P340; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P227, DOI 10.1016/0091-6749(78)90189-6; RIPE E, 1966, ACTA ALLERGOL, V21, P370, DOI 10.1111/j.1398-9995.1966.tb03146.x; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SALVAGGIO JE, 1967, J ALLERGY, V39, P227, DOI 10.1016/0021-8707(67)90015-9; SAYER WJ, 1972, AM J CLIN PATHOL, V58, P558; SCHUMACHER MJ, 1976, J ALLERGY CLIN IMMUN, V58, P263, DOI 10.1016/0091-6749(76)90131-7; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SEPULVEDA R, 1980, ADV ALLERGOLOGY IMMU; Solomon W.R., 1978, ALLERGY PRINCIPLES P, P312; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; SOLOMON WR, 1974, J ALLERGY CLIN IMMUN, V54, P222, DOI 10.1016/0091-6749(74)90064-5; STERNBERGER LA, 1956, J ALLERGY, V27, P16, DOI 10.1016/0021-8707(56)90034-X; STEYN PS, 1980, BIOSYNTHESIS MYCOTOX; THURSTON JR, 1973, MYCOPATH MYCOL APPL, V51, P327, DOI 10.1007/BF02057803; VIJAY HM, 1979, INT ARCH ALLER A IMM, V60, P229, DOI 10.1159/000232347; VONDERWERFF P, 1958, MOLD FUNGI BRONCHIAL; WALLENBACK I, UNPUBLISHED; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WEEKE B, SCAND J IMMUNOL; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3; 1976, AM TYPE CULTURE COLL, P12	99	218	220	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					327	346		10.1016/0091-6749(81)90131-7	http://dx.doi.org/10.1016/0091-6749(81)90131-7			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7028841				2022-12-18	WOS:A1981MQ45400001
J	Salo, PM; Arbes, SJ; Jaramillo, R; Calatroni, A; Weir, CH; Sever, ML; Hoppin, JA; Rose, KM; Liu, AH; Gergen, PJ; Mitchell, HE; Zeldin, DC				Salo, Paeivi M.; Arbes, Samuel J., Jr.; Jaramillo, Renee; Calatroni, Agustin; Weir, Charles H.; Sever, Michelle L.; Hoppin, Jane A.; Rose, Kathryn M.; Liu, Andrew H.; Gergen, Peter J.; Mitchell, Herman E.; Zeldin, Darryl C.			Prevalence of allergic sensitization in the United States: Results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergy; allergic sensitization; serum IgE	IMMEDIATE-TYPE HYPERSENSITIVITY; POPULATION-BASED COHORT; URBAN AIR-POLLUTION; CLIMATE-CHANGE; CROSS-REACTIVITY; RESPIRATORY ALLERGY; RISK-FACTORS; SURVEY I; ASTHMA; IGE	Background: Allergic sensitization is an important risk factor for the development of atopic disease. The National Health and Nutrition Examination Survey (NHANES) 2005-2006 provides the most comprehensive information on IgE-mediated sensitization in the general US population. Objective: We investigated clustering, sociodemographic, and regional patterns of allergic sensitization and examined risk factors associated with IgE-mediated sensitization. Methods: Data for this cross-sectional analysis were obtained from NHANES 2005-2006. Participants aged 1 year or older (n = 9440) were tested for serum specific IgEs (sIgEs) to inhalant and food allergens; participants 6 years or older were tested for 19 sIgEs, and children aged 1 to 5 years were tested for 9 sIgEs. Serum samples were analyzed by using the ImmunoCAP System. Information on demographics and participants' characteristics was collected by means of questionnaire. Results: Of the study population aged 6 years and older, 44.6% had detectable sIgEs, whereas 36.2% of children aged 1 to 5 years were sensitized to 1 or more allergens. Allergen-specific IgEs clustered into 7 groups that might have largely reflected biological cross-reactivity. Although sensitization to individual allergens and allergen types showed regional variation, the overall prevalence of sensitization did not differ across census regions, except in early childhood. In multivariate modeling young age, male sex, non-Hispanic black race/ethnicity, geographic location (census region), and reported pet avoidance measures were most consistently associated with IgE-mediated sensitization. Conclusions: The overall prevalence of allergic sensitization does not vary across US census regions, except in early life, although allergen-specific sensitization differs based on sociodemographic and regional factors. Biological cross-reactivity might be an important but not the sole contributor to the clustering of allergen-specific IgEs.	[Salo, Paeivi M.; Hoppin, Jane A.; Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; [Arbes, Samuel J., Jr.; Calatroni, Agustin; Sever, Michelle L.; Mitchell, Herman E.] Rho Fed Syst Div, Chapel Hill, NC USA; [Jaramillo, Renee; Rose, Kathryn M.] Social & Sci Syst, Durham, England; [Weir, Charles H.] Univ N Carolina, Dept Environm Sci & Engn, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Gergen, Peter J.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Zeldin, DC (corresponding author), NIEHS, NIH, 111 TW Alexander Dr,Rm A214, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Hoppin, Jane/0000-0001-8456-0969	National Institutes of Health, National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	Accordini S, 2012, CURR ALLERGY ASTHM R, V12, P185, DOI 10.1007/s11882-012-0260-9; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asarnoj A, 2010, ALLERGY, V65, P213, DOI 10.1111/j.1398-9995.2009.02138.x; Bertelsen RJ, 2010, INDOOR AIR, V20, P187, DOI 10.1111/j.1600-0668.2009.00640.x; Bottema RW, 2005, IMMUNOL ALLERGY CLIN, V25, P621, DOI 10.1016/j.iac.2005.07.002; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Bousquet PJ, 2010, ANN EPIDEMIOL, V20, P797, DOI 10.1016/j.annepidem.2010.05.012; Bufford JD, 2005, IMMUNOL ALLERGY CLIN, V25, P247, DOI 10.1016/j.iac.2005.03.005; Cabanos C, 2010, PROTEIN EXPRES PURIF, V73, P36, DOI 10.1016/j.pep.2010.03.005; Calabria CW, 2009, ALLERGY ASTHMA PROC, V30, P386, DOI 10.2500/aap.2009.30.3258; Calatroni A, 2009, J ALLERGY CLIN IMMUN, V123, pS193, DOI 10.1016/j.jaci.2008.12.732; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Chan-Yeung M, 2010, ALLERGY, V65, P1404, DOI 10.1111/j.1398-9995.2010.02399.x; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Cox L, 2008, ANN ALLERG ASTHMA IM, V101, P580, DOI 10.2500/aap.2008.29.3162; Cox L, 2011, CURR ALLERGY ASTHM R, V11, P447, DOI 10.1007/s11882-011-0226-3; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; D'Amato G, 2011, MULTIDISCIP RESP MED, V6, P28, DOI 10.1186/2049-6958-6-1-28; Ebert CS, 2011, OTOLARYNG CLIN N AM, V44, P537, DOI 10.1016/j.otc.2011.03.001; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gordon BR, 2011, OTOLARYNG CLIN N AM, V44, P765, DOI 10.1016/j.otc.2011.03.006; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V125, pS284, DOI 10.1016/j.jaci.2009.09.055; Hancox RJ, 2008, J ALLERGY CLIN IMMUN, V121, P38, DOI 10.1016/j.jaci.2007.09.052; Havstad SL, 2012, RESPIROLOGY, V17, P1068, DOI 10.1111/j.1440-1843.2012.02201.x; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Linden CC, 2011, ANN ALLERG ASTHMA IM, V106, P153, DOI 10.1016/j.anai.2010.11.004; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Mediaty Anja, 2005, Immun Ageing, V2, P9, DOI 10.1186/1742-4933-2-9; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Meyer KC, 2005, AGING P AM THORAC SO, V2, P433; National Center for Health Statistics, 2009, ALL SPEC IGES TOT IG; National Center for Health Statistics, 2005, PUBL DAT GEN REL FIL; Niggemann B, 2011, ALLERGY, V66, P980, DOI 10.1111/j.1398-9995.2011.02561.x; Parker JD, 2009, ENVIRON HEALTH PERSP, V117, P140, DOI 10.1289/ehp.11497; Poole JA, 2012, ANN ALLERG ASTHMA IM, V109, P93, DOI 10.1016/j.anai.2011.12.014; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Reid CE, 2009, ECOHEALTH, V6, P458, DOI 10.1007/s10393-009-0261-x; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Soderstrom L, 2003, ALLERGY, V58, P921, DOI 10.1034/j.1398-9995.2003.00227.x; Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021; Svanes C, 2006, J ALLERGY CLIN IMMUN, V118, P691, DOI 10.1016/j.jaci.2006.06.017; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; Wang JL, 2011, J ALLERGY CLIN IMMUN, V128, P834, DOI 10.1016/j.jaci.2011.07.045; WAO, 2011, WHIT BOOK ALL; Wegienka G, 2013, CURR ALLERGY ASTHM R, V13, P255, DOI 10.1007/s11882-013-0343-2; Wegienka G, 2010, J ALLERGY CLIN IMMUN, V126, P274, DOI 10.1016/j.jaci.2010.05.001; Weir CH, 2013, RESP MED, V107, P1763, DOI 10.1016/j.rmed.2013.08.010; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044; Ziska LH, 2012, J ALLERGY CLIN IMMUN, V129, P27, DOI 10.1016/j.jaci.2011.10.032	58	217	226	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					350	359		10.1016/j.jaci.2013.12.1071	http://dx.doi.org/10.1016/j.jaci.2013.12.1071			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24522093	Green Accepted			2022-12-18	WOS:000341370800014
J	Forno, E; Lescher, R; Strunk, R; Weiss, S; Fuhlbrigge, A; Celedon, JC				Forno, Erick; Lescher, Rachel; Strunk, Robert; Weiss, Scott; Fuhlbrigge, Anne; Celedon, Juan C.		Childhood Asthma Management	Decreased response to inhaled steroids in overweight and obese asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; pediatric asthma; childhood obesity; budesonide	BODY-MASS INDEX; MANAGEMENT PROGRAM CAMP; GLUCOCORTICOID-RECEPTOR; CHILDHOOD ASTHMA; RISK-FACTOR; PROINFLAMMATORY CYTOKINES; AIRWAY INFLAMMATION; METABOLIC SYNDROME; PULMONARY-FUNCTION; UNITED-STATES	Background: The mechanisms and consequences of the observed association between obesity and childhood asthma are unclear. Objectives: We sought to determine the effect of obesity on treatment responses to inhaled corticosteroids in asthmatic children. Methods: We performed a post hoc analysis to evaluate the interaction between body mass index (BMI) and treatment with inhaled budesonide on lung function in the Childhood Asthma Management Program trial. Participants were then stratified into overweight/obese and nonoverweight groups, and their response to inhaled budesonide was analyzed longitudinally over the 4 years of the trial. Results: There was a significant interaction between BMI and budesonide for prebronchodilator FEV(1)/forced vital capacity (FVC) ratio (P = .0007) and bronchodilator response (BDR; P = .049) and a nonsignificant trend for an interaction between BMI and budesonide on prebronchodilator FEV(1) (P = .15). Nonoverweight children showed significant improvement with inhaled budesonide in lung function (FEV(1), FEV(1)/FVC ratio, and BDR) during the early (years 1-2) and late (years 3-4) stages of the trial. Overweight/obese children had improved FEV(1) and BDR during the early but not the late stage of the trial and showed no improvement in FEV(1)/FVC ratio. When comparing time points at which both groups showed a significant response, the degree of improvement among nonoverweight children was significantly greater than in overweight/obese children at most visits. Nonoverweight children had a 44% reduction in the risk of emergency department visits or hospitalizations throughout the trial P = .001); there was no reduction in risk among overweight/obese children (P = .97). Conclusions: Compared with children of normal weight, overweight/obese children in the Childhood Asthma Management Program showed a decreased response to inhaled budesonide on measures of lung function and emergency department visits/hospitalizations for asthma. (J Allergy Clin Immunol 2011;127:741-9.)	[Forno, Erick; Weiss, Scott; Fuhlbrigge, Anne; Celedon, Juan C.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Fuhlbrigge, Anne; Celedon, Juan C.] Brigham & Womens Hosp, Dept Med, Div Pulm Crit Care Med, Boston, MA 02115 USA; [Forno, Erick] Childrens Hosp, Dept Pediat, Div Pediat Pulmonol, Boston, MA 02115 USA; [Forno, Erick; Weiss, Scott; Fuhlbrigge, Anne; Celedon, Juan C.] Harvard Univ, Sch Med, Boston, MA USA; [Lescher, Rachel] Washington Univ, Dept Pediat, Div Endocrinol, St Louis, MO 63130 USA; [Strunk, Robert] Washington Univ, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63130 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL)	Forno, E (corresponding author), Univ Miami, Batchelor Childrens Res Inst, 1580 NW 10th Ave 125, Miami, FL 33136 USA.	eforno@med.miami.edu	Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885	National Heart, Lung, and Blood Institute [NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, 16052]; General Clinical Research Center [M01RR00051, M01RR0099718-24, M01RR02719-14]; National Center for Research Resources [RR00036 from the]; DIVISION OF LUNG DISEASES [N01HR016050, N01HR016049, N01HR016048, N01HR016044, N01HR016052, N01HR016046, N01HR016045, N01HR016047, N01HR016051] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000036, M01RR000051] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Study were supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources.	Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Buemann B, 2005, OBES RES, V13, P862, DOI 10.1038/oby.2005.99; Castro-Giner F, 2009, EUR RESPIR J, V33, P1003, DOI 10.1183/09031936.00140608; *CDC, 2009, DEF CHILDH OV OB; CHEN Y, 1993, THORAX, V48, P375, DOI 10.1136/thx.48.4.375; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Choi IW, 2005, J ALLERGY CLIN IMMUN, V116, P537, DOI 10.1016/j.jaci.2005.05.034; Chu YT, 2009, PEDIATR PULM, V44, P472, DOI 10.1002/ppul.21023; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Garcia-Marcos L, 2008, MATERN CHILD NUTR, V4, P304, DOI 10.1111/j.1740-8709.2008.00144.x; Hawkins GA, 2004, DNA SEQUENCE, V15, P167, DOI 10.1080/10425170410001704517; HOLLIS BW, 1993, CLIN CHEM, V39, P529; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Khaodhiar L, 2004, JPEN-PARENTER ENTER, V28, P410, DOI 10.1177/0148607104028006410; Kotseva K, 2009, LANCET, V373, P929, DOI 10.1016/S0140-6736(09)60330-5; Lagakos SW, 2006, NEW ENGL J MED, V354, P1667, DOI 10.1056/NEJMp068070; Ma J, 2010, ALLERGY, V65, P1455, DOI 10.1111/j.1398-9995.2010.02402.x; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; Matricardi PM, 2007, CLIN EXP ALLERGY, V37, P476, DOI 10.1111/j.1365-2222.2007.02664.x; Michelson PH, 2009, ANN ALLERG ASTHMA IM, V103, P381, DOI 10.1016/S1081-1206(10)60356-0; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Patel SP, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-57; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; SIROISGAGNON D, 2010, OBESITY SILVER SPRIN; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Strine TW, 2008, PSYCHIAT SERV, V59, P1383, DOI 10.1176/appi.ps.59.12.1383; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Thyagarajan B, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-31; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; van Gent R, 2007, J ALLERGY CLIN IMMUN, V119, P591, DOI 10.1016/j.jaci.2006.11.007; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; Warnberg J, 2008, CURR OPIN LIPIDOL, V19, P11, DOI 10.1097/MOL.0b013e3282f4096b; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020	50	217	228	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					741	749		10.1016/j.jaci.2010.12.010	http://dx.doi.org/10.1016/j.jaci.2010.12.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377042	Green Accepted			2022-12-18	WOS:000288018400029
J	Busse, WW; Katial, R; Gossage, D; Sari, S; Wang, B; Kolbeck, R; Coyle, AJ; Koike, M; Spitalny, GL; Kiener, PA; Geba, GP; Molfino, NA				Busse, William W.; Katial, Rohit; Gossage, David; Sari, Suha; Wang, Bing; Kolbeck, Roland; Coyle, Anthony J.; Koike, Masamichi; Spitalny, George L.; Kiener, Peter A.; Geba, Gregory P.; Molfino, Nestor A.			Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; eosinophils; IL-5; IL-5 receptor; monoclonal antibody; antibody-dependent cell-mediated cytotoxicity	DEPENDENT CELLULAR CYTOTOXICITY; FC-GAMMA-RIIIA; CREATINE-KINASE ACTIVITY; GM-CSF; MYOCARDIAL-INFARCTION; EOSINOPHIL SURVIVAL; SPUTUM EOSINOPHILIA; HUMAN BLOOD; IL-5; INTERLEUKIN-5	Background: Increased eosinophil levels have been linked to airway inflammation and asthma exacerbations. IL-5 is responsible for eosinophil differentiation, proliferation, and activation; IL-5 receptors are expressed on eosinophils and their progenitors, and targeting such receptors induces eosinophil apoptosis. Objective: To evaluate the safety profile, pharmacokinetics, and pharmacodynamics of MEDI-563, a humanized mAb targeting the IL-5 receptor alpha chain. Methods: Single, escalating, intravenous doses (0.0003-3 mg/kg) of MEDI-563 were administered to subjects with mild atopic asthma (n = 44) over similar to 3 to 30 minutes in this open-label study. Pulmonary function, symptom scores, adverse events, MEDI-563 pharmacokinetics, and levels of C-reactive protein (CRP), IL-6, eosinophil cationic protein (ECP), and eosinophils were evaluated. Results: Mean peripheral blood (PB) eosinophil levels decreased in a dose-dependent fashion (baseline +/- SD, 0.27 +/- 0.2 x 10(3)/mu L; 24 hours postdose, 0.01 +/- 0.0 x 10(3)/mu L); 94.0% of subjects receiving >= 0.03 mg/kg exhibited levels between 0.00 x 10(3)/mu L and 0.01 x 10(3)/mu L. Eosinopenia lasted at least 8 or 12 weeks with doses of 0.03 to 0.1 and 0.3 to 3 mg/kg, respectively. ECP levels were reduced from 21.4 +/- 17.2 mu g/L (baseline) to 10.3 +/- 7.0 mu g/L (24 hours postdose). The most frequently reported adverse events were reduced white blood cell counts (34.1%), nasopharyngitis (27.3%), and increased blood creatine phosphokinase (25.0%). Mean C-reactive protein levels increased similar to 5.5-fold at 24 hours postdose but returned to baseline by study end; mean IL-6 levels increased, similar to 3.9-fold to 4.7-fold at 6 to 12 hours postdose, respectively. Pharmacokinetic activity was dose proportional at doses of 0.03 to 3 mg/kg. Conclusion: Single escalating doses of MEDI-563 had an acceptable safety profile and resulted in marked reduction of PB eosinophil counts within 24 hours after dosing. (J Allergy Clin Immunol 2010;125:1237-44.)	[Gossage, David; Sari, Suha; Wang, Bing; Kolbeck, Roland; Coyle, Anthony J.; Kiener, Peter A.; Geba, Gregory P.; Molfino, Nestor A.] MedImmune LLC, Gaithersburg, MD 20878 USA; [Koike, Masamichi; Spitalny, George L.] Biowa Inc, Princeton, NJ USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Katial, Rohit] Natl Jewish Hlth, Denver, CO USA	AstraZeneca; Medimmune; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health	Molfino, NA (corresponding author), MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878 USA.	Molfinon@MedImmune.com			MedImmune, LLC, Gaithersburg, Md; Biowa, Inc, Princeton, NJ; NIH-NIAID; Novartis; Centocor; GlaxoSmithKline; Ception; NIH-NHLBI	MedImmune, LLC, Gaithersburg, Md; Biowa, Inc, Princeton, NJ; NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis(Novartis); Centocor; GlaxoSmithKline(GlaxoSmithKline); Ception; NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by MedImmune, LLC, Gaithersburg, Md, and Biowa, Inc, Princeton, NJ.; Disclosure of potential conflict of interest: W. W. Busse is a consultant for and is on the advisory board of Altair. GlaxoSmithKline, Merck, Wyeth, Pfizer, Centocor, Amgen, UCB, Johnson & Johnson, Novartis, AstraZeneca, Eisai, TEVA, CompleWare, KaloBios, Boehringer Ingelheim, and Sandoz and has received research support from NIH-NIAID, NIH-NHLBI, Novartis, Centocor, GlaxoSmithKline, MedImmune, and Ception. D. Gossage, S. Sari, B. Wang, R. Kolbeck, A. J. Coyle, G. P. Geba, and N. A. Molfino are employed by MedImmune. P. A. Kiener was employed by MedImmune at the time of the study conduct. M. Koike and G. L. Spitalny are employed by Biowa, Inc. R. Katial declares no conflict of interest.	Bhowmick Binita, 2008, Expert Rev Respir Med, V2, P617, DOI 10.1586/17476348.2.5.617; BURKI NK, 1977, AM REV RESPIR DIS, V116, P327; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Chazan R, 1994, Pneumonol Alergol Pol, V62, P70; Dahl C, 2004, ALLERGY, V59, P1087, DOI 10.1111/j.1398-9995.2004.00606.x; Dente FL, 2008, ANN ALLERG ASTHMA IM, V100, P457, DOI 10.1016/S1081-1206(10)60471-1; Ducrest S, 2005, ALLERGY, V60, P1446, DOI 10.1111/j.1398-9995.2005.00910.x; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Gregory B, 2003, J IMMUNOL, V170, P5359, DOI 10.4049/jimmunol.170.11.5359; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Iida S, 2006, CLIN CANCER RES, V12, P2879, DOI 10.1158/1078-0432.CCR-05-2619; JUHLIN L, 1977, LANCET, V1, P1233; KARETZKY MS, 1975, AM REV RESPIR DIS, V112, P607; Kashani A, 2006, CIRCULATION, V114, P2788, DOI 10.1161/CIRCULATIONAHA.106.624890; Koike Masamichi, 2009, Human Antibodies, V18, P17, DOI 10.3233/HAB-2009-0198; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; LAPORTA MA, 1978, JAMA-J AM MED ASSOC, V239, P2685, DOI 10.1001/jama.239.25.2685; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; MITCHELL EB, 1983, CLIN LAB HAEMATOL, V5, P253; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Niwa R, 2004, CLIN CANCER RES, V10, P6248, DOI 10.1158/1078-0432.CCR-04-0850; Ogata N, 1998, BLOOD, V91, P2264, DOI 10.1182/blood.V91.7.2264.2264_2264_2271; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Scott KA, 2006, SEMIN RESP CRIT CARE, V27, P128, DOI 10.1055/s-2006-939515; Shinagawa K, 2003, INT ARCH ALLERGY IMM, V130, P150, DOI 10.1159/000069005; Solarewicz-Madejek K, 2009, CLIN EXP ALLERGY, V39, P845, DOI 10.1111/j.1365-2222.2009.03244.x; SYKES AP, 1991, THORAX, V46, P580, DOI 10.1136/thx.46.8.580; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAKATSU K, 1994, ADV IMMUNOL, V57, P145, DOI 10.1016/S0065-2776(08)60673-2; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOMPSON WG, 1988, CLIN CHEM, V34, P2208; Toba K, 1999, CYTOMETRY, V35, P249, DOI 10.1002/(SICI)1097-0320(19990301)35:3<249::AID-CYTO8>3.0.CO;2-O; van Meerten T, 2006, CLIN CANCER RES, V12, P4027, DOI 10.1158/1078-0432.CCR-06-0066; Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037; Zhang JY, 2007, IMMUNOL ALLERGY CLIN, V27, P623, DOI 10.1016/j.iac.2007.09.003	41	217	249	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1237	1244		10.1016/j.jaci.2010.04.005	http://dx.doi.org/10.1016/j.jaci.2010.04.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513521				2022-12-18	WOS:000278831000009
J	Cox, L; Li, JT; Nelson, H; Lockey, R				Cox, Linda; Li, James T.; Nelson, Harold; Lockey, Richard			Allergen immunotherapy: A practice parameter second update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							HOUSE-DUST-MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; IMPORTED FIRE ANT; PLACEBO-CONTROLLED EVALUATION; LOCAL NASAL IMMUNOTHERAPY; INSECT STING ALLERGY; CLADOSPORIUM-HERBARUM PREPARATION; AMERICAN PERIPLANETA-AMERICANA	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the "Allergen immunotherapy: a practice parameter second update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.	Joint Council Allergy Asthma & Immunol, Palatine, IL 60067 USA; Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA; Mayo Clin, Div Allerg Dis, Rochester, MN USA; Univ S Florida, Coll Med, Dept Med, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pediat, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Publ Hlth, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	Nova Southeastern University; Mayo Clinic; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; National Jewish Health	Cox, L (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 3-3, Palatine, IL 60067 USA.		Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, pS483; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; Asero R, 2004, INT ARCH ALLERGY IMM, V135, P332, DOI 10.1159/000082328; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P375, DOI 10.1159/000232217; AYUSO R, 1984, ANN ALLERGY, V53, P426; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bahima AC, 2004, J INVEST ALLERG CLIN, V14, P17; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; Bernardini R, 2006, CURR MED RES OPIN, V22, P1515, DOI 10.1185/030079906X115711; Bernardo FP, 2004, COMP AID CH, V18, P151; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; Black J, 1929, J ALLERGY, V1, P71; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; CANTANI A, 2004, EUR REV MED PHARMACO, P139; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Chanez P, 1996, ALLERGY, V51, P850; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2006, ANN ALLERG ASTHMA IM, V97, P126, DOI 10.1016/S1081-1206(10)60003-8; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; *CURR STAT ALL IMM, 1989, LANCET, V333, P259; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Drugs Anaphylaxis Comm, 1998, ANN ALLERG ASTHMA IM, V81, P101; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; ESCH RE, 1992, ARB PEI GSH, V85, P171; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254, DOI 10.1016/S1081-1206(10)61222-7; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANKLIN W, 1967, JAMA-J AM MED ASSOC, V201, P951; Freeman J, 1911, LANCET, V2, P814; Freeman J, 1930, LANCET, V1, P744; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Goldberg A, 2003, ANN ALLERG ASTHMA IM, V91, P405, DOI 10.1016/S1081-1206(10)61689-4; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOMEZ J, 1989, J ASTHMA, V26, P243, DOI 10.3109/02770908909073256; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENERT S, 1971, LANCET, V2, P1121; Grier TJ, 2007, ANN ALLERG ASTHMA IM, V99, P151, DOI 10.1016/S1081-1206(10)60639-4; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414, DOI 10.1016/S1081-1206(10)61776-0; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43, DOI 10.1016/S1081-1206(10)62194-1; Jain VV, 2003, CLIN EXP ALLERGY, V33, P1330, DOI 10.1046/j.1365-2222.2003.01763.x; Javeed N, 1996, CATHETER CARDIO DIAG, V39, P383, DOI 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.3.CO;2-G; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; *JOINT TASK FORC P, 1995, J ALLERGY CLIN IMMUN, V96, pS707; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 1995, CLIN EXP ALLERGY, V25, P1205, DOI 10.1111/j.1365-2222.1995.tb03044.x; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; Kanter L, 2006, ANN ALLERG ASTHMA IM, V97, P7, DOI 10.1016/S1081-1206(10)61363-4; Kanter LJ, 2003, ANN ALLERG ASTHMA IM, V90, P389, DOI 10.1016/S1081-1206(10)61821-2; Kao N, 2000, ANN ALLERG ASTHMA IM, V84, P273, DOI 10.1016/S1081-1206(10)62769-X; Karl S, 1988, Z Hautkr, V63 Suppl 4, P55; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; Katial RK, 1997, ANN ALLERG ASTHMA IM, V79, P340, DOI 10.1016/S1081-1206(10)63025-6; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kelso JM, 2004, ANN ALLERG ASTHMA IM, V92, P225, DOI 10.1016/S1081-1206(10)61551-7; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; KIVITY S, 1990, J ALLERGY CLIN IMMUN, V85, P669, DOI 10.1016/0091-6749(90)90111-G; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Kohno Y, 1998, J ALLERGY CLIN IMMUN, V102, P927, DOI 10.1016/S0091-6749(98)70330-6; KORDASH TR, 1993, ANN ALLERGY, V71, P240; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; LEAVENGOOD DC, 1985, J ALLERGY CLIN IMMUN, V76, P789, DOI 10.1016/0091-6749(85)90749-3; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; Lewis WH VP, 1983, AIRBORNE ALLERGENIC; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Li JT, 1998, ANN ALLERG ASTHMA IM, V81, P415, DOI 10.1016/S1081-1206(10)63138-9; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LIN MS, 1993, ANN ALLERGY, V71, P557; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; Litwin A, 1997, J ALLERGY CLIN IMMUN, V100, P30, DOI 10.1016/S0091-6749(97)70191-X; Lockey R, 2003, MIDDLETONS ALLERGY P, P573; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47, DOI 10.1016/S1081-1206(10)62195-3; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; LOWENSTEIN H, 1980, ALLERGY, V35, P188, DOI 10.1111/j.1398-9995.1980.tb01739.x; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1983, 11 P INT C ALL CLIN, P545; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Malling HJ, 2000, DRUG SAFETY, V23, P323, DOI 10.2165/00002018-200023040-00005; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274, DOI 10.1016/S1081-1206(10)60718-1; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; MILLER DL, 1971, ANN ALLERGY, V29, P178; Modrzynski Marek, 2003, Przegl Lek, V60, P130; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; Nguyen SA, 2005, ANN ALLERG ASTHMA IM, V94, P387, DOI 10.1016/S1081-1206(10)60992-1; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Niemeijer NR, 1996, ANN ALLERG ASTHMA IM, V76, P535, DOI 10.1016/S1081-1206(10)63274-7; NIGGEMANN B, 2006, FIVE YEAR FOLLOW UP, V855, P9; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Ohashi Y, 1998, ARCH OTOLARYNGOL, V124, P1337, DOI 10.1001/archotol.124.12.1337; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1987, CLIN REV ALLERG, V5, P37; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; PALACIOS AS, 2001, ALLERGOL IMMUNOPATH, V29, P60; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2005, CLIN EXP ALLERGY, V35, P880, DOI 10.1111/j.1365-2222.2005.2226.x; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; PORTNOY J, 1992, ANN ALLERGY, V68, P493; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Portnoy JM, 2001, ANN ALLERG ASTHMA IM, V87, P28, DOI 10.1016/S1081-1206(10)62191-6; Portnoy JM, 2001, CLIN REV ALLERG IMMU, V21, P241, DOI 10.1385/CRIAI:21:2-3:241; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Radcliffe MJ, 2003, BMJ-BRIT MED J, V327, P251, DOI 10.1136/bmj.327.7409.251; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; RAGUSA VF, 2004, ALLERGY IMMUNOL PARI, V36, P52; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Rance F, 2000, Allerg Immunol (Paris), V32, P366; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; Roll A, 2006, J INVEST ALLERG CLIN, V16, P79; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Rossi RE, 2005, INT J IMMUNOPATH PH, V18, P277, DOI 10.1177/039463200501800210; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82, DOI 10.1016/S1081-1206(10)60626-6; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Russelo M, 2006, ALLERG IMMUNOL, V38, P31; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; Schiavino D, 2004, ANN ALLERG ASTHMA IM, V92, P409, DOI 10.1016/S1081-1206(10)61775-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; Schramm G, 1999, J IMMUNOL, V162, P2406; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; Sharkey P, 1996, ANN ALLERG ASTHMA IM, V76, P175, DOI 10.1016/S1081-1206(10)63419-9; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; SHERMAN MS, 1988, J ALLERGY CLIN IMMUN, V81, P908, DOI 10.1016/0091-6749(88)90949-9; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423, DOI 10.1016/S0091-6749(98)70259-3; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; SRIDHARA S, 1992, ASIAN PAC J ALLERGY, V10, P33; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 1999, J INVEST ALLERG CLIN, V9, P155; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; Theodoropoulos DS, 2000, ALLERGY ASTHMA PROC, V21, P159, DOI 10.2500/108854100778149007; Thomas M, 2005, EMERG MED J, V22, P272, DOI 10.1136/emj.2005.023507; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Till Stephen J, 2004, Clin Allergy Immunol, V18, P85; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; Tripodi S, 2006, INT ARCH ALLERGY IMM, V139, P149, DOI 10.1159/000090391; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turkeltaub PC, 1988, ALLERGY PRINCIPLES P, V3rd, P388; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VanMetre TE, 1996, J ALLERGY CLIN IMMUN, V97, P1033, DOI 10.1016/S0091-6749(96)70254-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325, DOI 10.1159/000234316; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Walker Ross F., 2000, Limnology, V1, P107, DOI 10.1007/s102010070016; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Weber RW, 2004, CURR ALLERGY ASTHM R, V4, P401, DOI 10.1007/s11882-004-0091-4; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WEBER RW, 1984, ANN ALLERGY, V52, P226; WEBER RW, 1987, ANN ALLERGY, V58, P287; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Williams PB, 2003, ANN ALLERG ASTHMA IM, V91, P26; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wolf BL, 2006, ANN ALLERG ASTHMA IM, V97, P52, DOI 10.1016/S1081-1206(10)61369-5; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; YOO TJ, 1975, ANN ALLERGY, V34, P87; Yoshihiro O, 2006, ANN ALLERG ASTHMA IM, V96, P600, DOI 10.1016/S1081-1206(10)63556-9; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x	349	217	220	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3		S			S25	S85		10.1016/j.jaci.2007.06.019	http://dx.doi.org/10.1016/j.jaci.2007.06.019			61	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	216OP	17765078				2022-12-18	WOS:000249888200001
J	Gallo, RL; Murakami, M; Ohtake, T; Zaiou, M				Gallo, RL; Murakami, M; Ohtake, T; Zaiou, M			Biology and clinical relevance of naturally occurring antimicrobial peptides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						innate immunity; psoriasis; cathelicidins; defensins; wound repair	HUMAN BETA-DEFENSINS; INNATE HOST-DEFENSE; HUMAN BETA-DEFENSIN-1; EPITHELIAL-CELLS; ANTIBACTERIAL PEPTIDE; CYSTIC-FIBROSIS; AIRWAY SURFACE; PANETH CELLS; HUMAN SKIN; NEUTROPHIL DEFENSINS	Within the last decade, several peptides have been discovered on the basis of their ability to inhibit the growth of potential microbial pathogens. These so-called antimicrobial peptides participate in the innate immune response by providing a rapid first-line defense against infection. Recent advances in this field have shown that peptides belonging to the cathelicidin and defensin gene families are of particular importance to the mammalian immune defense system. This review discusses the biology of these molecules, with emphasis on their structure, processing, expression and function. Current evidence has shown that both cathelicidins and defensins are multifunctional and that they act both as natural antibiotics and as signaling molecules that activate host cell processes involved in immune defense and repair. The abnormal expression of these peptides has also been associated with human disease. Current and future studies are likely to implicate the presence of antimicrobial peptides in several unexplained human inflammatory disorders and to provide novel therapeutic approaches to the treatment of disease.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92161 USA; VA San Diego Hlthcare Ctr, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Gallo, RL (corresponding author), 111B,3350 LaJolla Village Dr, San Diego, CA 92161 USA.		Zaiou, Mohamed/AAG-8923-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; ZAIOU, Mohamed/0000-0002-4113-4350				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Ashcroft GS, 2000, NAT MED, V6, P1147, DOI 10.1038/80489; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Barnathan ES, 1997, AM J PATHOL, V150, P1009; Befus AD, 1999, J IMMUNOL, V163, P947; Chaly YV, 2000, EUR CYTOKINE NETW, V11, P257; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Cole AM, 2001, BLOOD, V97, P297, DOI 10.1182/blood.V97.1.297; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Cunliffe RN, 2001, GUT, V48, P176, DOI 10.1136/gut.48.2.176; Cunliffe RN, 2002, J CLIN PATHOL, V55, P298, DOI 10.1136/jcp.55.4.298; Dale BA, 2001, J PERIODONTAL RES, V36, P285, DOI 10.1034/j.1600-0765.2001.360503.x; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Dunsche A, 2002, EUR J ORAL SCI, V110, P121, DOI 10.1034/j.1600-0722.2002.11186.x; Dunsche A, 2001, J ORAL PATHOL MED, V30, P154, DOI 10.1034/j.1600-0714.2001.300305.x; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; EVERSOLE LR, 1992, ARCH ORAL BIOL, V37, P963, DOI 10.1016/0003-9969(92)90068-J; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hao HN, 2001, J NEUROCHEM, V77, P1027, DOI 10.1046/j.1471-4159.2001.00305.x; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; Hoffmeyer MR, 2000, AM J PHYSIOL-HEART C, V279, pH2824, DOI 10.1152/ajpheart.2000.279.6.H2824; Huang HJ, 1997, J LEUKOCYTE BIOL, V61, P624, DOI 10.1002/jlb.61.5.624; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; LEHRER RI, 1985, J VIROL, V54, P467, DOI 10.1128/JVI.54.2.467-472.1985; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Martinez A, 1997, ENDOCRINOLOGY, V138, P5597, DOI 10.1210/en.138.12.5597; McNamara NA, 1999, EXP EYE RES, V69, P483, DOI 10.1006/exer.1999.0722; Milner SM, 1999, BURNS, V25, P411, DOI 10.1016/S0305-4179(98)00192-2; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; MURAKAMI M, 2002, IN PRESS J INVEST DE; MURAKAMI M, 2002, IN PRESS J DENT RES; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; O'Neil DA, 2000, INFECT IMMUN, V68, P5412, DOI 10.1128/IAI.68.9.5412-5415.2000; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ohtake T, 1999, BRIT J CANCER, V81, P393, DOI 10.1038/sj.bjc.6690707; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Quayle AJ, 1998, AM J PATHOL, V152, P1247; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sahasrabudhe KS, 2000, J DENT RES, V79, P1669, DOI 10.1177/00220345000790090601; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schnapp D, 1998, J PATHOL, V186, P99, DOI 10.1002/(SICI)1096-9896(199809)186:1<99::AID-PATH133>3.0.CO;2-#; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Steinstraesser L, 2001, CRIT CARE MED, V29, P1431, DOI 10.1097/00003246-200107000-00022; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; Tani K, 2000, INT IMMUNOL, V12, P691, DOI 10.1093/intimm/12.5.691; Tunzi CR, 2000, PEDIATR RES, V48, P30, DOI 10.1203/00006450-200007000-00008; van Wetering S, 1999, J ALLERGY CLIN IMMUN, V104, P1131, DOI 10.1016/S0091-6749(99)70004-7; VANDERSPEK JC, 1989, AM J HUM GENET, V45, P381; Wehkamp J, 2002, DIGEST DIS SCI, V47, P1349, DOI 10.1023/A:1015334917273; Weinberg A, 1998, CRIT REV ORAL BIOL M, V9, P399, DOI 10.1177/10454411980090040201; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x; ZHAO CQ, 1995, FEBS LETT, V368, P197, DOI 10.1016/0014-5793(95)00633-K; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	99	217	232	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					823	831		10.1067/mai.2002.129801	http://dx.doi.org/10.1067/mai.2002.129801			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464945	Bronze			2022-12-18	WOS:000179777400001
J	Illi, S; von Mutius, E; Lau, S; Nickel, R; Niggermann, B; Sommerfeld, C; Wahn, U				Illi, S; von Mutius, E; Lau, S; Nickel, R; Niggermann, B; Sommerfeld, C; Wahn, U		Multicenter Allergy Study Grp	The pattern of atopic sensitization is associated with the development of asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						early and persistent sensitization; asthma; childhood; atopic family history	FOOD-ALLERGEN AVOIDANCE; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; NATURAL COURSE; CHILDREN; INFANCY; DISEASE; AGE; EGG; SCHOOLCHILDREN	Background: Even though atopic sensitization has been shown to be strongly associated with childhood asthma, asthma eventually develops in only one third of atopic children. Objective: The aim of this study was to prospectively investigate the pattern of atopic sensitization typically associated with the development of asthma in childhood. Methods: The German Multicenter Allergy Study followed 1314 children from birth to the age of 7 years. Parental questionnaires on asthma and asthmatic symptoms were completed 6 times up to the age of 2 years and from then on yearly. Determination of specific IgE to 9 food and inhalant allergens was performed yearly, and at the age of 7 years, a bronchial histamine challenge was conducted. Results: Onset of atopic sensitization in atopic children with current asthma at the age of 7 years was significantly earlier than in atopic children without current asthma (39.4% before age 1 year vs 21.0%, P =.015). Early atopic sensitization without any sensitization to inhalant allergens at the age of 7 years conferred no increased risk for asthma at this age. Only those children sensitized to any allergen early in life and sensitized to inhalant allergens by the age of 7 years were at a significantly increased risk of being asthmatic at this age (odds ratio, 10.12; 95% CI, 3.81-26.88). However, even in this group of persistently sensitized children, the risk of being asthmatic at the age of 7 years was only increased if a positive parental history of asthma or atopy was present (odds ratio, 15.56; 95% CI, 5.78-41.83), with the effect being strongest for maternal asthma. Conclusion: Our results indicate that an underlying factor pertaining to asthma and maternal transmission may determine both a certain pattern of sensitization and the expression of asthma.	Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; Univ Childrens Hosp, Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Illi, S (corresponding author), Dr von Haunersches Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.							Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; Furuhashi M, 1997, BIOL NEONATE, V72, P210, DOI 10.1159/000244486; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Holt PG, 1999, NATURE, V402, pB12; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Wahn U, 1997, PEDIAT ALLERG IMM-UK, V8, P16; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	21	217	229	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					709	714		10.1067/mai.2001.118786	http://dx.doi.org/10.1067/mai.2001.118786			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692093				2022-12-18	WOS:000172523800008
J	Hoshino, M; Nakamura, Y; Hamid, QA				Hoshino, M; Nakamura, Y; Hamid, QA			Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angiogenesis; airway vascularity; vascular endothelial growth factor; flt-1; flk-1; airway remodeling	COLONY-STIMULATING FACTOR; MESSENGER-RNA; FACTOR VPF/VEGF; AIRWAYS; INTERLEUKIN-5; ACCUMULATION; FLK-1; CELLS	Background: Angiogenesis is a feature of airway remodeling in bronchial asthma, The mechanism responsible for this angiogenesis is unknown. Vascular endothelial growth factor (VEGF) is a potent inducer of endothelial cells, which may contribute to chronic inflammation and angiogenesis, Objective: We sought to investigate the molecular mechanisms underlying increased vascularity, and we examined the mRNA expression of VEGF and its receptors (flt-1 and flk-1) within bronchial biopsy specimens from asthmatic patients and normal control subjects. Methods: Endobronchial biopsy specimens were examined immunocytochemically by staining with anti-type IV collagen mAb to evaluate vessel density by using computer-assisted image analysis. Specimens were also analyzed for the presence of the mRNAs of VEGF and its receptors with in situ hybridization, Results: The extent of airway vascularity was increased in asthmatic subjects compared with that in control subjects (P < .01). Asthmatic subjects exhibited a greater expression of VEGF, flt-1, and flk-1 mRNA(+) cells in the airway mucosa compared with that in control subjects (P < .001 for each comparison). The degree of vascularity was associated with the number of VEGF, flt-1, and flk-1 mRNA(+) cells. Numbers of cells expressing VEGF mRNA inversely correlated with airway caliber (r = -0.83, P < .01) and airway hyperresponsiveness (r = -0.97, P < .001). Colocalization studies showed that macrophages, eosinophils, and CD34(+) cells were the major sources or VEGF; CD34(+) cells, macrophages, and T cells expressed both flt-1 and flk-1, Conclusion: These findings provide evidence that VEGF may play an important role in angiogenesis and subsequent airway remodeling in bronchial asthma.	Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, Tokyo, Japan; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	McGill University	Hoshino, M (corresponding author), Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, 6-11-1 Omori Nishi, Tokyo, Japan.		Nakamura, Yutaka/AAE-1546-2019	Nakamura, Yutaka/0000-0001-8717-1475				*AM THOR SOC, 1998, AM REV RESPIR DIS, V136, P225; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1988, AM J PATHOL, V130, P455; Christou H, 1998, AM J RESP CELL MOL, V18, P768, DOI 10.1165/ajrcmb.18.6.2980; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Demoly P, 1999, CLIN EXP ALLERGY, V29, P1390; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hidaka M, 1999, P NATL ACAD SCI USA, V96, P7370, DOI 10.1073/pnas.96.13.7370; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; ITO A, 1995, PATHOL INT, V45, P715, DOI 10.1111/j.1440-1827.1995.tb03387.x; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	28	217	231	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1034	1038		10.1067/mai.2001.115626	http://dx.doi.org/10.1067/mai.2001.115626			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398081				2022-12-18	WOS:000169454800015
J	WEINBERGER, M; HUDGEL, D; SPECTOR, S; CHIDSEY, C				WEINBERGER, M; HUDGEL, D; SPECTOR, S; CHIDSEY, C			INHIBITION OF THEOPHYLLINE CLEARANCE BY TROLEANDOMYCIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA HOSP & CLIN,DEPT PEDIAT,IOWA CITY,IA 52242	University of Iowa								BRODIE BB, 1952, J BIOL CHEM, V194, P215; CHRISTENSEN LK, 1969, LANCET, V2, P1397; CORNISH HH, 1957, J BIOL CHEM, V228, P315; GILBERT FI, 1962, JAMA-J AM MED ASSOC, V182, P1048; HAYTON SC, 1969, NEW ZEALAND MEDICAL, V69, P42; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE JW, 1974, J ALLERGY CLIN IMMUN, V53, P80; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JENNE JW, 1976, CLIN PHARMACOL THER, V19, P375; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; PIAFSKY KM, 1975, CLIN PHARMACOL THER, V17, P241; PIAFSKY KM, 1974, CLIN RES, V22, pA726; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN CHEM, V21, P834; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	19	217	218	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					228	231		10.1016/0091-6749(77)90154-3	http://dx.doi.org/10.1016/0091-6749(77)90154-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	300083				2022-12-18	WOS:A1977CZ24900007
J	Debarry, J; Garn, H; Hanuszkiewicz, A; Dickgreber, N; Blumer, N; von Mutius, E; Bufe, A; Gatermann, S; Renz, H; Holst, O; Heine, H				Debarry, Jennifer; Garn, Holger; Hanuszkiewicz, Anna; Dickgreber, Nina; Bluemer, Nicole; von Mutius, Erika; Bufe, Albrecht; Gatermann, Soeren; Renz, Harald; Holst, Otto; Heine, Holger			Acinetobacter lwoffli and Lactococcus lactis strains isolated from farm cowsheds possess strong allergy-protective properties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene hypothesis; Acinetobacter lwoffii; Lactococcus lactis; cowshed; allergy protection; ovalbumin mouse model	INNATE IMMUNE-SYSTEM; TOLL-LIKE RECEPTORS; CD4(+) T-CELLS; DENDRITIC CELLS; MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE; AIRWAY INFLAMMATION; NOTCH LIGANDS; MOUSE MODEL; ASTHMA	Background: Children who grow up in a farming environment show lower levels of atopic sensitization, hay fever, and asthma than children of the same age not living in such an environment. A number of investigations provided good evidence that this is due to an early-life contact with cowsheds, farm animals, and/or consumption of products like raw milk. Also, it had been indicated that microorganisms might have an important effect on the development of allergies, and thus the question arose of which farm microbial organisms, their products, or both might induce or influence allergy-protective mechanisms. Objective: We sought to gain further insight into the potential allergy-protective properties of microbes isolated from the farming environment. Methods: Of a number of bacterial species identified in cowsheds of farms, 2 were selected, isolated, and characterized, namely Acinetobacter lwoffii F78 and Lactococcus lactis G121. The isolates were investigated with regard to their activation of pattern-recognition receptors, the maturation of human monocyte-derived dendritic cells, the upregulation of inflammatory cytokines, the T(H)1-polarizing Notch ligand expression, and their influence on the allergic phenotype. Results: It is shown that both bacterial isolates were able to reduce allergic reactions in mice, to activate mammalian cells in vitro, and to induce a TH1-polarizing program in dendritic cells. Conclusion: Our data strongly support the hygiene hypothesis, which states that an environment rich in microbiologic structures, such as a farming environment, might protect against the development of allergies. Clinical implications: This work provides the first data on a potential application of cowshed bacteria in allergy protection.	Leibniz Ctr Med & Biosci, Div Struct Biochem, Res Ctr Borstel, D-23845 Borstel, Germany; Leibniz Ctr Med & Biosci, Div Innate Immun, Res Ctr Borstel, D-23845 Borstel, Germany; Leibniz Ctr Med & Biosci, Div Struct Biochem, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, Fac Med, Marburg, Germany; Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; Ruhr Univ Bochum, BGFA XU18, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Med Microbiol, Inst Hyg & Microbiol, D-4630 Bochum, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; Philipps University Marburg; University of Munich; Ruhr University Bochum; Ruhr University Bochum	Holst, O (corresponding author), Leibniz Ctr Med & Biosci, Div Struct Biochem, Res Ctr Borstel, Parkallee 4A, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Heine, Holger/H-4552-2012	Heine, Holger/0000-0001-8128-5068; Bufe, Albrecht/0000-0001-7335-9362; von Mutius, Erika/0000-0002-8893-4515; Debarry, Jennifer/0000-0002-3818-3768; Garn, Holger/0000-0002-5178-4023				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; Chu HW, 2003, INFECT IMMUN, V71, P1520, DOI 10.1128/IAI.71.3.1520-1526.2003; Delayre-Orthez C, 2005, INT ARCH ALLERGY IMM, V138, P298, DOI 10.1159/000088867; Delayre-Orthez C, 2004, CLIN EXP ALLERGY, V34, P1789, DOI 10.1111/j.1365-2222.2004.02082.x; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Kabesch M, 2004, J LEUKOCYTE BIOL, V75, P383, DOI 10.1189/jlb.1003468; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Kon OM, 1999, INT ARCH ALLERGY IMM, V118, P133, DOI 10.1159/000024049; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Marks GB, 2006, CLIN EXP PHARMACOL P, V33, P285, DOI 10.1111/j.1440-1681.2006.04360.x; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Noverr MC, 2004, INFECT IMMUN, V72, P6206, DOI 10.1128/IAI.72.11.6206-6210.2004; Park SJ, 2005, J KOREAN MED SCI, V20, P225, DOI 10.3346/jkms.2005.20.2.225; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; RASTLL RA, 2004, J NUTR S, V134; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Rutz S, 2005, EUR J IMMUNOL, V35, P2443, DOI 10.1002/eji.200526294; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SOMOZA C, 1995, RES IMMUNOL, V146, P171, DOI 10.1016/0923-2494(96)80253-7; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Turpin J, 1986, J Clin Apher, V3, P111, DOI 10.1002/jca.2920030207; Vandenbulcke L, 2006, INT ARCH ALLERGY IMM, V139, P159, DOI 10.1159/000090393; von Mutius E, 2001, THORAX, V56, P153, DOI 10.1136/thorax.56.2.153; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yasuda H, 2005, TOHOKU J EXP MED, V207, P109, DOI 10.1620/tjem.207.109; Zahringer U, 2004, J BIOL CHEM, V279, P21046, DOI 10.1074/jbc.M313370200	43	216	220	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1514	1521		10.1016/j.jaci.2007.03.023	http://dx.doi.org/10.1016/j.jaci.2007.03.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481709				2022-12-18	WOS:000247232800030
J	Khetsuriani, N; Kazerouni, NN; Erdman, DD; Lu, XY; Redd, SC; Anderson, LJ; Teague, WG				Khetsuriani, Nino; Kazerouni, N. Neely; Erdman, Dean D.; Lu, Xiaoyan; Redd, Stephen C.; Anderson, Larry J.; Teague, W. Gerald			Prevalence of viral respiratory tract infections in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	100th International Conference of the American-Thoracic-Society	MAY 21-26, 2004	Orlando, FL	Amer Thorac Soc		respiratory viruses; asthma; asthma exacerbation; case-control study; PCR; rhinovirus	SEPTEMBER EPIDEMIC; HUMAN BOCAVIRUS; YOUNG-CHILDREN; EXACERBATIONS; RHINOVIRUS; VIRUSES; ILLNESS; PCR; HOSPITALIZATION; SURVEILLANCE	Background: Previous studies support a strong association between viral respiratory tract infections and asthma exacerbations. The effect of newly discovered viruses on asthma control is less well defined. Objective: We sought to determine the contribution of respiratory viruses to asthma exacerbations in children with a panel of PCR assays for common and newly discovered respiratory viruses. Methods: Respiratory specimens from children aged 2 to 17 years with asthma exacerbations (case patients, n = 65) and with well-controlled asthma (control subjects, n = 77), frequency matched by age and season of enrollment, were tested for rhinoviruses, enteroviruses, respiratory syncytial virus, human metapneumovirus, coronaviruses 229E and OC43, parainfluenza viruses 1 to 3, influenza viruses, adenoviruses, and human bocavirus. Results: Infection with respiratory viruses was associated with asthma exacerbations (63.1% in case patients vs 23.4% in control subjects; odds ratio, 5.6; 95% CI, 2.7- 11.6). Rhinovirus was by far the most prevalent virus (60% among case patients vs 18.2% among control subjects) and the only virus significantly associated with exacerbations (odds ratio, 6.8; 95% CI, 3.2-14.5). However, in children without clinically manifested viral respiratory tract illness, the prevalence of rhinovirus infection was similar in case patients (29.2%) versus control subjects (23.4%, P > .05). Other viruses detected included human metapneumovirus (4.6% in patients with acute asthma vs 2.6% in control subjects), enteroviruses (4.6% vs 0%), coronavirus 229E (0% vs 1.3%), and respiratory syncytial virus (1.5% vs 0%). Conclusion: Symptomatic rhinovirus infections are an important contributor to asthma exacerbations in children. Clinical implications: These results support the need for therapies effective against rhinovirus as a means to decrease asthma exacerbations.	Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazard & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA; Emory Univ, Div Pulm Allergy Cyst Fibrosis & Sleep Med, Dept Pediat, Sch Med, Atlanta, GA 30322 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	Teague, WG (corresponding author), Emory Pediat, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	wteague@emory.edu			PHS HHS [200-1998-00103] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; Carrat F, 2006, INTENS CARE MED, V32, P156, DOI 10.1007/s00134-005-2861-4; CLARKE CW, 1979, THORAX, V34, P344, DOI 10.1136/thx.34.3.344; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003; Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64; GWALTNEY JM, 2000, MANDELL DOUGLAS BENN, P1940; Hall CB, 2000, PRINCIPLES PRACTICE, P1782; HAMELIN ME, 2005, PEDIAT INFECT DIS S, V24, P203; Hankinson JL, 2003, CHEST, V124, P1805, DOI 10.1378/chest.124.5.1805; Harji TH., 2006, THORAX; Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069; Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HOSMER DW, 2000, WILEY PS TX, P1; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC; LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323; Lu XY, 2006, J CLIN MICROBIOL, V44, P3231, DOI 10.1128/JCM.00889-06; Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006; MANTEL N, 1959, J NATL CANCER I, V22, P719; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oberste MS, 2004, J GEN VIROL, V85, P2577, DOI 10.1099/vir.0.79925-0; Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Pelaia G, 2006, RESP MED, V100, P775, DOI 10.1016/j.rmed.2005.08.025; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Schrag SJ, 2004, EMERG INFECT DIS, V10, P185, DOI 10.3201/eid1002.030752; Turner RB, 2005, PEDIATR ANN, V34, P53, DOI 10.3928/0090-4481-20050101-12; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weinberger M, 2004, DRUG DISCOV TODAY, V9, P831, DOI 10.1016/S1359-6446(04)03239-8; Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392; Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	50	216	222	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					314	321		10.1016/j.jaci.2006.08.041	http://dx.doi.org/10.1016/j.jaci.2006.08.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	137YB	17140648	Green Published, Bronze			2022-12-18	WOS:000244327900007
J	Stevenson, DD; Hankammer, MA; Mathison, DA; Christiansen, SC; Simon, RA				Stevenson, DD; Hankammer, MA; Mathison, DA; Christiansen, SC; Simon, RA			Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: Long-term outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; asthma; desensitization; histamine; leukotriene; nonsteroidal antiinflammatory drugs	URINARY LEUKOTRIENE-E4; REFRACTORY PERIOD; HISTAMINE; CHALLENGES; RELEASE	Background: Aspirin-sensitive patients with asthma experience continuous inflammation of their nasal and sinus tissues, complicated by recurrent sinusitis, which frequently leads to asthma attacks. Systemic corticosteroid therapy and sinus or polyp surgery are currently required to central underlying rhinosinusitis, and bursts of corticosteroids are used for asthma control. Objective: After aspirin desensitization therapy, objective measures of respiratory disease activity, linked to the need for systemic corticosteroids and sinus surgery, were studied to determine whether any changes occurred. Methods: Sixty-five aspirin-sensitive patients with asthma underwent aspirin challenge, followed by aspirin desensitization and daily treatment with aspirin over 1 to 6 years (mean, 3.1 years). Clinical outcome measurements before aspirin desensitization treatment and during follow-up were analyzed for the larger group of 65 patients and subgroups (29 patients receiving therapy for 1 to 3 years and 36 patients receiving therapy for 3 to 6 years). Results: In the larger group of 65 patients, there were significant reductions in numbers of sinus infections per year (median, 6 to 2), hospitalizations for treatment of asthma per year (median, 0.2 to 0), improvement in olfaction (median, 0 to 2), and reduction in use of systemic corticosteroids (mean, 10.2 to 2.5 mg) with p values less than 0.0001. Numbers of sinus and polyp operations per year were significantly reduced (median, 0.2 to 0; p = 0.004), and doses of nasal corticosteroids (in micrograms) were significantly reduced (mean dose, 139 to 106 mu g, p = 0.01). Emergency department visits and use of inhaled corticosteroids were unchanged. Conclusions: The results support a role for aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma.	Scripps Res Inst, RES INST, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, GREEN HOSP, GEN CLIN RES CTR, LA JOLLA, CA USA	Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clinic, DIV ALLERGY ASTHMA & IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [M01-RR00833] Funding Source: Medline; NIAID NIH HHS [AI32834] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; DAFFERN P, UNPUB URINARY LTE4 C; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LOCKEY RF, 1978, HOSP PRACT, V13, P129, DOI 10.1080/21548331.1978.11707389; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; NAEIJE N, 1984, ANN ALLERGY, V53, P262; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; *NAT HEART LUNG BL, 1992, US DEP HHS PUBL; NELSON RP, 1986, NEW ENGL REG ALLERGY, V7, P117; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1987, J ALLERGY CLIN IMMUN, V80, P788, DOI 10.1016/S0091-6749(87)80266-X; STEVENSON DD, 1986, NEW ENGL REG ALLERGY, V7, P101; Stevenson DD, 1993, ALLERGY PRINCIPLES P, V4th, P1747; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SZCZEKLIK A, 1978, THORAX, V33, P664, DOI 10.1136/thx.33.5.664; Widal M, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	27	216	219	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					751	758		10.1016/S0091-6749(96)70123-9	http://dx.doi.org/10.1016/S0091-6749(96)70123-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876550				2022-12-18	WOS:A1996VM66500007
J	PLESKOW, WW; STEVENSON, DD; MATHISON, DA; SIMON, RA; SCHATZ, M; ZEIGER, RS				PLESKOW, WW; STEVENSON, DD; MATHISON, DA; SIMON, RA; SCHATZ, M; ZEIGER, RS			ASPIRIN DESENSITIZATION IN ASPIRIN-SENSITIVE ASTHMATIC-PATIENTS - CLINICAL MANIFESTATIONS AND CHARACTERIZATION OF THE REFRACTORY PERIOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DEPT CLIN RES,LA JOLLA,CA 92037; KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,SAN DIEGO,CA	Scripps Research Institute; Kaiser Permanente				Zeiger, Robert/0000-0001-5788-5063	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 0083] Funding Source: Medline; NIAID NIH HHS [AI-10386-09] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; CHAMPION GD, 1977, BRIT J PHARMACOL, V59, P29, DOI 10.1111/j.1476-5381.1977.tb06973.x; DAY RO, 1978, BIOCHEM PHARMACOL, V27, P1385, DOI 10.1016/0006-2952(78)90126-0; Dysart BR, 1933, J AMER MED ASSOC, V101, P446, DOI 10.1001/jama.1933.27430310002009a; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; GOETZL EJ, 1980, NEW ENGL J MED, V303, P822, DOI 10.1056/NEJM198010023031421; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; KALINER M, 1974, J IMMUNOL, V112, P664; Lamson RW, 1932, J AMER MED ASSOC, V99, P107, DOI 10.1001/jama.1932.02740540015005; LECOMTE J, 1956, INT ARCH ALLER A IMM, V9, P250, DOI 10.1159/000228341; LEWIS GP, 1977, BRIT J PHARMACOL, V61, P229, DOI 10.1111/j.1476-5381.1977.tb08409.x; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; LOEFFLER LJ, 1971, BIOCHEM PHARMACOL, V20, P2287, DOI 10.1016/0006-2952(71)90228-0; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MARTELLI NA, 1979, AM REV RESPIR DIS, V120, P1073; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; OKAZAKI T, 1977, J ALLERGY CLIN IMMUN, V60, P360, DOI 10.1016/0091-6749(77)90067-7; OTT L, 1919, JAMA-J AM MED ASSOC, V73, P760; PARKER CW, 1979, J ALLERGY CLIN IMMUN, V63, P1, DOI 10.1016/0091-6749(79)90155-6; Prickman LE, 1937, J AMER MED ASSOC, V108, P445, DOI 10.1001/jama.1937.02780060011004; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P85; SCHLUMBERGER HD, 1974, ACTA MED SCAND, V196, P451; SELYE H, 1965, MAST CELLS, P80; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; THOMAS RU, 1976, BRIT J PHARMACOL, V57, P474; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; WALTON CHA, 1951, CAN MED ASSOC J, V64, P95; Widal M, 1922, PRESSE MED, V30, P189; WUTHRICH B, 1979, RESPIRATION, V37, P224; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	40	216	217	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					11	19		10.1016/0091-6749(82)90081-1	http://dx.doi.org/10.1016/0091-6749(82)90081-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	7054250				2022-12-18	WOS:A1982MZ37700003
J	Esaki, H; Brunner, PM; Renert-Yuval, Y; Czarnowicki, T; Huynh, T; Tran, G; Lyon, S; Rodriguez, G; Immaneni, S; Johnson, DB; Bauer, B; Fuentes-Duculan, J; Zheng, XZ; Peng, XY; Estrada, YD; Xu, H; Strong, CD; Suarez-Farinas, M; Krueger, JG; Paller, AS; Guttman-Yassky, E				Esaki, Hitokazu; Brunner, Patrick M.; Renert-Yuval, Yael; Czarnowicki, Tali; Thy Huynh; Tran, Gary; Lyon, Sarah; Rodriguez, Giselle; Immaneni, Supriya; Johnson, Donald B.; Bauer, Bruce; Fuentes-Duculan, Judilyn; Zheng, Xiuzhong; Peng, Xiangyu; Estrada, Yeriel D.; Xu, Hui; Strong, Christina de Guzman; Suarez-Farinas, Mayte; Krueger, James G.; Paller, Amy S.; Guttman-Yassky, Emma			Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; pediatric; adult; skin; T(H)2; T(H)9; T(H)17; IL-17; IL-19; antimicrobials	THYMIC STROMAL LYMPHOPOIETIN; AGE-RELATED-CHANGES; MEDIATED ALLERGIC INFLAMMATION; IFN-GAMMA; T-CELLS; ANTIMICROBIAL PEPTIDES; DENDRITIC CELLS; CYTOKINE PRODUCTION; NATURAL-HISTORY; LESIONAL SKIN	Background: Atopic dermatitis (AD) affects 15% to 25% of children and 4% to 7% of adults. Paradigm-shifting discoveries about AD have been based on adult biomarkers, reflecting decades of disease activity, although 85% of cases begin by 5 years. Blood phenotyping shows only T(H)2 skewing in patients with early-onset pediatric AD, but alterations in early pediatric skin lesions are unknown, limiting advancement of targeted therapies. Objective: We sought to characterize the early pediatric AD skin phenotype and its differences from pediatric control subjects and adults with AD. Methods: Using immunohistochemistry and quantitative real-time PCR, we assessed biopsy specimens from 19 children with AD younger than 5 years within 6 months of disease onset in comparison with adults with AD or psoriasis and pediatric and adult control subjects. Results: In lesional skin children showed comparable or greater epidermal hyperplasia (thickness and keratin 16) and cellular infiltration (CD3(+), CD11c(+), and Fc epsilon RI+) than adults with AD. Similar to adults, strong activation of the T(H)2 (IL-13, IL-31, and CCL17) and T(H)22 (IL-22 and S100As) axes and some T(H)1 skewing (IFN-gamma and CXCL10) were present. Children showed significantly higher induction of T(H)17-related cytokines and antimicrobials (IL-17A, IL-19, CCL20, LL37, and peptidase inhibitor 3/elafin), T(H)9/IL-9, IL-33, and innate markers (IL-8) than adults (P < .02). Despite the characteristic downregulation in adult patients with AD, filaggrin expression was similar in children with AD and healthy children. Nonlesional skin in pediatric patients with AD showed higher levels of inflammation (particularly IL-17A and the related molecules IL-19 and LL37) and epidermal proliferation (keratin 16 and S100As) markers (P <.001). Conclusion: The skin phenotype of new-onset pediatric AD is substantially different from that of adult AD. Although excess T(H)2 activation characterizes both, T(H)9 and T(H)17 are highly activated at disease initiation. Increases in IL-19 levels might link T(H)2 and T(H)17 activation.	[Esaki, Hitokazu; Renert-Yuval, Yael; Peng, Xiangyu; Estrada, Yeriel D.; Xu, Hui; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Esaki, Hitokazu; Renert-Yuval, Yael; Peng, Xiangyu; Estrada, Yeriel D.; Xu, Hui; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Esaki, Hitokazu; Brunner, Patrick M.; Czarnowicki, Tali; Fuentes-Duculan, Judilyn; Zheng, Xiuzhong; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Thy Huynh; Tran, Gary; Lyon, Sarah; Rodriguez, Giselle; Immaneni, Supriya; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Johnson, Donald B.; Bauer, Bruce] Univ Chicago, Pritzker Sch Med, NorthShore Univ HealthSyst, Northbrook, IL USA; [Strong, Christina de Guzman] Washington Univ, Div Biol & Biomed Sci, St Louis, MO 63130 USA; [Suarez-Farinas, Mayte] Icahn Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; Northwestern University; Feinberg School of Medicine; NorthShore University Health System; Washington University (WUSTL)	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Renert-Yuval, Yael/AAP-5414-2020	Brunner, Patrick/0000-0002-3488-3345; Esaki, Hitokazu/0000-0002-3716-520X; Paller, Amy/0000-0001-6187-6549	LEO Foundation; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1 TR00043]	LEO Foundation(LEO Pharma); National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by a research grant from the LEO Foundation. P.M.B. and M.S.-F. were supported in part by grant no. UL1 TR00043 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.	Antunez C, 2004, Allergol Immunopathol (Madr), V32, P252, DOI 10.1157/13066301; Antunez C, 2006, PEDIAT ALLERG IMM-UK, V17, P166, DOI 10.1111/j.1399-3038.2006.00390.x; Arkwright PD, 2013, J ALLER CL IMM-PRACT, V1, P142, DOI 10.1016/j.jaip.2012.09.002; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Black A, 2012, EUR J IMMUNOL, V42, P311, DOI 10.1002/eji.201141847; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Burr ML, 2013, BRIT J DERMATOL, V168, P1339, DOI 10.1111/bjd.12216; Campbell DE, 1999, CLIN EXP IMMUNOL, V115, P377; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Chernyshov PV, 2009, J EUR ACAD DERMATOL, V23, P462, DOI 10.1111/j.1468-3083.2008.02909.x; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Dorschner RA, 2003, PEDIATR RES, V53, P566, DOI 10.1203/01.PDR.0000057205.64451.B7; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Ezzat MHM, 2011, J EUR ACAD DERMATOL, V25, P334, DOI 10.1111/j.1468-3083.2010.03794.x; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Ganguly D, 2009, J EXP MED, V206, P1983, DOI 10.1084/jem.20090480; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; Gelmetti C, 2014, BRIT J DERMATOL, V170, P19, DOI 10.1111/bjd.12957; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Goyette J, 2011, AMINO ACIDS, V41, P821, DOI 10.1007/s00726-010-0528-0; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harden JL, 2015, J AUTOIMMUN, V64, P66, DOI 10.1016/j.jaut.2015.07.008; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Hon KLE, 2004, CLIN EXP DERMATOL, V29, P293, DOI 10.1111/j.1365-2230.2004.01501.x; Horimukai K, 2016, ALLERGOL INT, V65, P103, DOI 10.1016/j.alit.2015.09.004; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Iram N, 2012, DEVELOPMENT, V139, P4210, DOI 10.1242/dev.083477; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Katsunuma T, 2004, INT ARCH ALLERGY IMM, V134, P240, DOI 10.1159/000078772; Kawamoto N, 2006, PEDIAT ALLERG IMM-UK, V17, P125, DOI 10.1111/j.1399-3038.2005.00363.x; Keijsers RRMC, 2014, EXP DERMATOL, V23, P799, DOI 10.1111/exd.12487; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim J, 2016, J ALLERGY CLIN IMMUN, V137, pe1; Kim J, 2016, J ALLERGY CLIN IMMUN, V137, P1282, DOI 10.1016/j.jaci.2015.12.1306; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; La Grutta S, 2005, ALLERGY, V60, P391, DOI 10.1111/j.1398-9995.2005.00733.x; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Leonardi S, 2007, ALLERGY ASTHMA PROC, V28, P529, DOI 10.2500/aap2007.28.3038; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P296, DOI 10.1034/j.1399-3038.2003.00052.x; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Macheleidt O, 2002, J INVEST DERMATOL, V119, P166, DOI 10.1046/j.1523-1747.2002.01833.x; Machura E, 2007, EUR J PEDIATR, V166, P789, DOI 10.1007/s00431-006-0319-5; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Nakazato J, 2008, PEDIAT ALLERG IMM-UK, V19, P605, DOI 10.1111/j.1399-3038.2007.00692.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Nukui T, 2008, J CELL BIOCHEM, V104, P453, DOI 10.1002/jcb.21639; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; Rozenblit M, 2014, J ALLERGY CLIN IMMUN, V134, P955, DOI 10.1016/j.jaci.2014.05.024; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Simon D, 2014, ALLERGY, V69, P46, DOI 10.1111/all.12339; Simpson EL, 2012, SEMIN CUTAN MED SURG, V31, pS6, DOI 10.1016/j.sder.2012.08.001; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wu KG, 2011, INT J IMMUNOPATH PH, V24, P15, DOI 10.1177/039463201102400103; Xie JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045377	102	215	227	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1639	1651		10.1016/j.jaci.2016.07.013	http://dx.doi.org/10.1016/j.jaci.2016.07.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27671162	Bronze			2022-12-18	WOS:000390019300020
J	Steinke, JW; Platts-Mills, TAE; Commins, SP				Steinke, John W.; Platts-Mills, Thomas A. E.; Commins, Scott P.			The alpha-gal story: Lessons learned from connecting the dots	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; delayed reaction to red meat; galactose-alpha-1,3-galactose	RED MEAT ALLERGY; REACTIVE CARBOHYDRATE DETERMINANTS; IGE ANTIBODIES; INFUSION REACTIONS; MASS-SPECTROMETRY; MAMMALIAN MEAT; SOLID-PHASE; GALACTOSE-ALPHA-1,3-GALACTOSE; CETUXIMAB; ASSOCIATION	Anaphylaxis is a severe allergic reaction that can be rapidly progressing and fatal, and therefore establishing its cause is pivotal to long-term risk management. Our recent work has identified a novel IgE antibody response to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). IgE to alpha-gal has been associated with 2 distinct forms of anaphylaxis: (1) immediate-onset anaphylaxis during first exposure to intravenous cetuximab and (2) delayed-onset anaphylaxis 3 to 6 hours after ingestion of mammalian food products (eg, beef and pork). Results of our studies and those of others strongly suggest that tick bites are a cause, if not the only significant cause, of IgE antibody responses to alpha-gal in the southern, eastern, and central United States; Europe; Australia; and parts of Asia. Typical immune responses to carbohydrates are considered to be T-cell independent, whereas IgE antibody production is thought to involve sequential class-switching that requires input from T cells. Therefore, establishing the mechanism of the specific IgE antibody response to alpha-gal will be an important aspect to address as this area of research continues.	[Steinke, John W.; Platts-Mills, Thomas A. E.; Commins, Scott P.] Univ Virginia Hlth Syst, Dept Med, Asthma & Allerg Dis Ctr, Carter Immunol Ctr, Charlottesville, VA USA	University of Virginia	Platts-Mills, TAE (corresponding author), Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22903 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	Genentech [HSR17123]; National Institutes of Health (NIH) [AI-20565]; National Institute of Allergy and Infectious Diseases (NIAID) [AI-085190]; Phadia/Thermo Fisher; IBT/Viracor; NIH/NIAID [AI-20565, AI-085190, K08]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, P01AI050989, R56AI113095, K08AI085190, T32AI007496, R21AI087985] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Phadia/Thermo Fisher; IBT/Viracor; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J. W. Steinke has received research support from Genentech (HSR17123), has received a lecture honorarium from North-western, and receives royalties for human mast cell line developed. T. A. E. Platts-Mills has received research support from the National Institutes of Health (NIH; AI-20565)/National Institute of Allergy and Infectious Diseases (NIAID; AI-085190), has received travel support from Phadia/Thermo Fisher, and receives royalties from IBT/Viracor. S. P. Commins has received research support from the NIH/NIAID (AI-20565; AI-085190; grant K08), has received consultancy fees from Sanofi, and receives royalties from UpToDate.	Aalberse RC, 1996, MONOGR ALLERGY, V32, P78; Apostolovic D, 2014, ALLERGY, V69, P1308, DOI 10.1111/all.12462; Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; Ayoub D, 2013, MABS-AUSTIN, V5, P699, DOI 10.4161/mabs.25423; Burke GS, 2005, EMERG INFECT DIS, V11, P36; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cornmins SP, 2012, AM J RESP CRIT CARE, V185, P723, DOI 10.1164/rccm.201111-2017OC; Cote SD, 2004, ANNU REV ECOL EVOL S, V35, P113, DOI 10.1146/annurev.ecolsys.35.021103.105725; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Fagerstone KA, 1997, WILDLIFE SOC B, V25, P413; Fischer J, 2014, J ALLERGY CLIN IMMUN, V134, P755, DOI 10.1016/j.jaci.2014.05.051; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GONEN B, 1987, BIOCHIM BIOPHYS ACTA, V917, P418, DOI 10.1016/0005-2760(87)90121-4; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Hurtado-Guerrero R, 2012, CURR OPIN CHEM BIOL, V16, P479, DOI 10.1016/j.cbpa.2012.10.013; Kennedy JL, 2013, PEDIATRICS, V131, pE1545, DOI 10.1542/peds.2012-2585; Kleine-Tebbe J, 2006, J ALLERGY CLIN IMMUN, V117, P190, DOI 10.1016/j.jaci.2005.08.056; Koike C, 2007, P NATL ACAD SCI USA, V104, P559, DOI 10.1073/pnas.0610012104; Landsteiner K, 1936, SPECIFICITY SEROLOGI; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Maier S, 2015, CANCER MED-US, V4, P36, DOI 10.1002/cam4.333; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Milland J, 2006, TISSUE ANTIGENS, V68, P459, DOI 10.1111/j.1399-0039.2006.00721.x; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Moody DB, 2007, NATURE, V448, P36, DOI 10.1038/nature05890; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Pratt E, 2010, AM J RHINOL ALLERGY, V24, P416, DOI 10.2500/ajra.2010.24.3538; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; SCHULMAN ES, 1987, BIOCHEM BIOPH RES CO, V148, P553, DOI 10.1016/0006-291X(87)90912-0; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Wang Y, 2011, SCAND J IMMUNOL, V73, P496, DOI 10.1111/j.1365-3083.2011.02525.x	46	215	216	0	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					589	596		10.1016/j.jaci.2014.12.1947	http://dx.doi.org/10.1016/j.jaci.2014.12.1947			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25747720	Green Accepted			2022-12-18	WOS:000351065000001
J	Confino-Cohen, R; Chodick, G; Shalev, V; Leshno, M; Kimhi, O; Goldberg, A				Confino-Cohen, Ronit; Chodick, Gabriel; Shalev, Varda; Leshno, Moshe; Kimhi, Oded; Goldberg, Arnon			Chronic urticaria and autoimmunity: Associations found in a large population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic urticaria; autoimmunity; hypothyroidism; hyperthyroidism; rheumatoid arthritis; Sjogren syndrome; celiac disease; type I diabetes mellitus; systemic lupus erythematosus; mean platelet volume	CHRONIC IDIOPATHIC URTICARIA; MEAN PLATELET VOLUME; AUTOANTIBODIES; GEOEPIDEMIOLOGY; ANTIBODIES; DISEASE; TSH; IGE	Background: Chronic urticaria (CU) is a common disease in which most cases were considered to be idiopathic. Recent evidence indicates that at least a subset of cases of chronic idiopathic urticaria are autoimmune in origin. Objective: We aimed to characterize the association between CU, autoimmune diseases, and autoimmune/inflammatory serologic markers in a large unselected population. Methods: Data on 12,778 patients given a diagnosis of CU by either allergy or dermatology specialists during 17 years in a large health maintenance organization in Israel were collected. For each patient, we collected information on diagnosis of major, well-defined autoimmune diseases and autoimmunity- and inflammatory-related serologic markers. Similar data were collected for a control group comprised of 10,714 patients who visited dermatologists, family physicians, or allergy specialists and had no indication of CU. Results: Having CU was associated with an increased odds ratio for hypothyroidism, hyperthyroidism, and antithyroid antibodies. Female patients with CU had a significantly higher incidence of rheumatoid arthritis, Sjogren syndrome, celiac disease, type I diabetes mellitus, and systemic lupus erythematosus, mostly diagnosed during the 10 years after the diagnosis of CU. High mean platelet volume, positive rheumatoid factor, and antinuclear antibodies were all significantly more prevalent in patients with CU. Conclusions: A strong association was found between CU and major autoimmune diseases. A common pathogenic mechanism is implied by the high prevalence of autoantibodies and the existence of a chronic inflammatory process expressed by the high mean platelet volume. These findings have implications for the diagnosis, management, and prognosis of patients with CU. (J Allergy Clin Immunol 2012;129:1307-13.)	[Confino-Cohen, Ronit; Goldberg, Arnon] Meir Med Ctr, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel; [Kimhi, Oded] Meir Med Ctr, Dept Med, IL-44281 Kefar Sava, Israel; [Confino-Cohen, Ronit; Chodick, Gabriel; Shalev, Varda; Leshno, Moshe; Goldberg, Arnon] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Chodick, Gabriel; Shalev, Varda] Maccabi Healthcare Serv, Div Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Confino-Cohen, R (corresponding author), Meir Med Ctr, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel.	ronitco@clalit.org.il		/0000-0002-5189-8995				Aamir IS, 2010, JCPSP-J COLL PHYSICI, V20, P158, DOI 03.2010/JCPSP.158161; Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Asero R, 2003, J ALLERGY CLIN IMMUN, V111, P1129, DOI 10.1067/mai.2003.1389; Atta AM, 2004, BRAZ J MED BIOL RES, V37, P13, DOI 10.1590/S0100-879X2004000100002; Aversano M, 2005, ALLERGY, V60, P489, DOI 10.1111/j.1398-9995.2005.00723.x; Bagnasco M, 2011, THYROID, V21, P401, DOI 10.1089/thy.2010.0103; Borchers AT, 2010, AUTOIMMUN REV, V9, pA277, DOI 10.1016/j.autrev.2009.12.008; Canpolat F, 2010, CLIN RHEUMATOL, V29, P325, DOI 10.1007/s10067-009-1323-8; COLLET E, 1995, ANN DERMATOL VENER, V122, P413; Coppinger JA, 2004, BLOOD, V103, P2096, DOI 10.1182/blood-2003-08-2804; Eyre S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3139; Gaig P, 2000, J INVEST ALLERG CLIN, V10, P342; Gaig P, 2004, J INVESTIG ALLERGOL, V14, P14; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Kessel A, 2010, INT ARCH ALLERGY IMM, V153, P288, DOI 10.1159/000314370; Kikuchi Y, 2003, J ALLERGY CLIN IMMUN, V112, P218, DOI 10.1067/mai.2003.1605; Kulthanan K, 2007, J DERMATOL, V34, P294, DOI 10.1111/j.1346-8138.2007.00276.x; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; Magen E, 2010, AM J MED SCI, V339, P504, DOI 10.1097/MAJ.0b013e3181db6ed5; Mavragani CP, 2010, AUTOIMMUN REV, V9, pA305, DOI 10.1016/j.autrev.2009.11.004; Meneghetti R, 2004, ARCH DIS CHILD, V89, P293, DOI 10.1136/adc.2003.037259; Milovanovic A, 2004, CLIN CHIM ACTA, V343, P237, DOI 10.1016/j.cccn.2003.12.030; Purnak T, 2011, UPSALA J MED SCI, V116, P208, DOI 10.3109/03009734.2011.581399; Rodriguez-Reyna TS, 2006, AUTOIMMUN REV, V5, P86, DOI 10.1016/j.autrev.2005.09.005; Ryhal B, 2001, J INVEST ALLERG CLIN, V11, P16; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Tobon GJ, 2010, J AUTOIMMUN, V35, P10, DOI 10.1016/j.jaut.2009.12.009; Yazici S, 2010, PLATELETS, V21, P122, DOI 10.3109/09537100903474373	31	215	220	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1307	1313		10.1016/j.jaci.2012.01.043	http://dx.doi.org/10.1016/j.jaci.2012.01.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22336078				2022-12-18	WOS:000303418000019
J	Guttman-Yassky, E; Nograles, KE; Krueger, JG				Guttman-Yassky, Emma; Nograles, Kristine E.; Krueger, James G.			Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; pathogenesis; therapy	PLASMACYTOID DENDRITIC CELLS; THYMIC STROMAL LYMPHOPOIETIN; ANTIGEN-PRESENTING CELLS; MEMORY T-CELLS; CUTANEOUS LYMPHOCYTE ANTIGEN; ALLERGIC SKIN INFLAMMATION; FC-EPSILON-RI; MAST-CELLS; LANGERHANS CELLS; IN-VIVO	Atopic dermatitis (AD) and psoriasis are among the most common inflammatory skin diseases. In the first part of this 2-part review, we discussed the similarities and differences between AD and psoriasis with respect to clinical features and pathology. The diseases are characterized by infiltration of skin lesions by large numbers of inflammatory cells; the second part of this review focuses on immune cell subsets that distinguish each disease and the therapeutic strategies that might be used or developed based on this information. We discuss the interactions among different populations of immune cells that ultimately create the complex inflammatory phenotype of AD and compare these with psoriasis. Therapeutic strategies have been developed for psoriasis based on the cytokine network that promotes inflammation in this disease. Antibodies against IL-12 and IL-23p40 antibody and antagonists of TNF are used to treat patients with psoriasis, and studies are underway to test specific antagonists of IL-23, IL-17, IL-17 receptor, IL-20, and IL-22. We discuss how these therapeutic approaches might be applied to AD. (J Allergy Clin Immunol 2011;127:1420-32.)	[Guttman-Yassky, Emma; Nograles, Kristine E.; Krueger, James G.] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Guttman-Yassky, Emma] Weill Cornell Med Coll, Dept Dermatol, New York, NY USA	Rockefeller University; Cornell University	Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10065 USA.	eguttman@rockefeller.edu	Nograles, Kristine/V-3648-2019		Amgen; Centocor; Merck; Eli Lilly	Amgen(Amgen); Centocor; Merck(Merck & Company); Eli Lilly(Eli Lilly)	Disclosure of potential conflict of interest: E. Guttman-Yassky and K. E. Nograles have declared that they have no conflict of interest. J. G. Krueger has consulted for Amgen, Anacor Pharmaceuticals, Centocor, Gateway Pharmaceuticals, Idera Pharmaceuticals, and Pfizer; has performed investigations for Boehringer Ingelheim, Eli Lilly, and Merck; has served on an advisory board for Janssen; and has received research support (through Rockefeller University) from Amgen, Centocor, Merck, and Eli Lilly.	Ackermann L, 1999, BRIT J DERMATOL, V140, P624; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P1022, DOI 10.1016/j.jaci.2009.03.034; Akhavan A, 2008, SEMIN CUTAN MED SURG, V27, P151, DOI 10.1016/j.sder.2008.04.004; Albanesi C, 2010, AUTOIMMUNITY, V43, P215, DOI 10.3109/08916930903510906; Alenius H, 2002, J ALLERGY CLIN IMMUN, V109, P106, DOI 10.1067/mai.2002.120553; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Angel CE, 2006, J IMMUNOL, V176, P5730, DOI 10.4049/jimmunol.176.10.5730; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Assmann T, 2002, CLIN DERMATOL, V20, P505, DOI 10.1016/S0738-081X(02)00271-7; Bath-Hextall FJ, 2010, BRIT J DERMATOL, V163, P12, DOI 10.1111/j.1365-2133.2010.09743.x; Belloni B, 2008, CURR OPIN ALLERGY CL, V8, P423, DOI 10.1097/ACI.0b013e32830fb8fd; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bieber T, 2007, IMMUNOBIOLOGY, V212, P499, DOI 10.1016/j.imbio.2007.03.001; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; Bussmann C, 2009, J DTSCH DERMATOL GES, V7, P205, DOI 10.1111/j.1610-0387.2008.06834.x; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Caproni M, 2000, INT ARCH ALLERGY IMM, V121, P324, DOI 10.1159/000024346; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; Chang Timothy T, 2002, Am J Clin Dermatol, V3, P175, DOI 10.2165/00128071-200203030-00004; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Chien YH, 2007, CLIN REV ALLERG IMMU, V33, P178, DOI 10.1007/s12016-007-0041-8; CHIRICOZZI A, 2010, J INVEST DERMATOL; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Darsow U, 2010, J EUR ACAD DERMATOL, V24, P317, DOI 10.1111/j.1468-3083.2009.03415.x; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; DEBOER OJ, 1994, IMMUNOLOGY, V81, P359; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Ferran M, 2008, EUR J DERMATOL, V18, P647, DOI 10.1684/ejd.2008.0513; Finkelman FD, 2010, J ALLERGY CLIN IMMUN, V125, P312, DOI 10.1016/j.jaci.2009.12.936; Fleischer AB, 2010, J DRUGS DERMATOL, V9, P488; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Gaga M, 2007, CURR MED CHEM, V14, P1049, DOI 10.2174/092986707780362961; Ganguly D, 2009, J EXP MED, V206, P1983, DOI 10.1084/jem.20090480; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P680, DOI 10.1111/1523-1747.ep12499901; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grimalt R, 2007, DERMATOLOGY, V214, P61, DOI 10.1159/000096915; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Guilloteau K, 2010, J IMMUNOL; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Guttman-Yassky E, 2007, BRIT J DERMATOL, V157, P1103, DOI 10.1111/j.1365-2133.2007.08135.x; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Haider AS, 2008, J IMMUNOL, V180, P1913, DOI 10.4049/jimmunol.180.3.1913; Haider AS, 2007, J IMMUNOL, V178, P7442, DOI 10.4049/jimmunol.178.11.7442; Hanifin JM, 2004, J AM ACAD DERMATOL, V51, pS23, DOI 10.1016/j.jaad.2004.01.010; Harper EG, 2008, J INVEST DERMATOL, V128, P1173, DOI 10.1038/sj.jid.5701169; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Hashimoto S, 2006, J DERMATOL SCI, V44, P93, DOI 10.1016/j.jdermsci.2006.08.004; Hassan AS, 2007, J AM ACAD DERMATOL, V56, P217, DOI 10.1016/j.jaad.2006.08.025; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Haw S, 2010, ANN DERMATOL, V22, P9, DOI 10.5021/ad.2010.22.1.9; Hayek B, 2004, 23 EAACI C JUN 12 16, V224, P744; He R, 2010, ANN NY ACAD SCI, V1183, P13, DOI 10.1111/j.1749-6632.2009.05128.x; Heidenreich R, 2009, INT J EXP PATHOL, V90, P232, DOI 10.1111/j.1365-2613.2009.00669.x; Hijnen DJ, 2007, DERMATITIS, V18, P163, DOI 10.2310/6620.2007.06025; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Ishii N, 2010, ADV IMMUNOL, V105, P63, DOI 10.1016/S0065-2776(10)05003-0; Ito Y, 2009, ANN ALLERG ASTHMA IM, V103, P160, DOI 10.1016/S1081-1206(10)60170-6; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Johnson-Huang LM, 2009, J CLIN IMMUNOL, V29, P247, DOI 10.1007/s10875-009-9278-8; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kagen MH, 2006, E SCHERING RES FDN W, V56, P193; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kawakami T, 2009, CURR OPIN IMMUNOL, V21, P666, DOI 10.1016/j.coi.2009.09.006; KHANDKE L, 1991, ARCH DERMATOL, V127, P1172, DOI 10.1001/archderm.127.8.1172; Kiehl P, 2001, BRIT J DERMATOL, V145, P720, DOI 10.1046/j.1365-2133.2001.04456.x; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Kneilling M, 2009, EXP DERMATOL, V18, P488, DOI 10.1111/j.1600-0625.2009.00860.x; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Komine M, 2009, J PHARMACOL SCI, V110, P260, DOI 10.1254/jphs.09R06FM; Kondo S, 2001, J DERMATOL, V28, P237, DOI 10.1111/j.1346-8138.2001.tb00124.x; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krakowski AC, 2008, PEDIATRICS, V122, P812, DOI 10.1542/peds.2007-2232; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; Krutmann J, 2000, CLIN EXP DERMATOL, V25, P552, DOI 10.1046/j.1365-2230.2000.00700.x; Kunz Manfred, 2009, Curr Drug Discov Technol, V6, P231; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lee SY, 2004, ALLERGY, V59, P1129, DOI 10.1111/j.1398-9995.2004.00639.x; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Menter A, 2009, CUTIS, V84, P14; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Moul DK, 2008, J AM ACAD DERMATOL, V58, P984, DOI 10.1016/j.jaad.2008.02.007; Murphy LA, 2002, BRIT J DERMATOL, V147, P308, DOI 10.1046/j.1365-2133.2002.04922.x; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2010, SEMIN CUTAN MED SURG, V29, P3, DOI 10.1016/j.sder.2010.03.001; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nograles KE, 2009, NAT CLIN PRACT RHEUM, V5, P83, DOI 10.1038/ncprheum0987; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2007, ADV EXP MED BIOL, V601, P97; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; Oldhoff JM, 2006, INT ARCH ALLERGY IMM, V141, P290, DOI 10.1159/000095299; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ong PY, 2010, IMMUNOL ALLERGY CLIN, V30, P425, DOI 10.1016/j.iac.2010.05.002; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Ozdemir C, 2009, CLIN EXP ALLERGY, V39, P626, DOI 10.1111/j.1365-2222.2009.03242.x; Plotz SG, 2010, EXPERT OPIN EMERG DR, V15, P249, DOI 10.1517/14728211003792518; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Prodanovich S, 2010, AM J CLIN DERMATOL, V11, P3, DOI 10.2165/1153413-S0-000000000-00000; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Mortel MR, 2010, J DRUGS DERMATOL, V9, P947; Rozenblit M, 2009, DERMATOL THER, V22, P56, DOI 10.1111/j.1529-8019.2008.01216.x; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sabat R, 2007, CLIN DERMATOL, V25, P504, DOI 10.1016/j.clindermatol.2007.08.002; Schmitt J, 2007, J EUR ACAD DERMATOL, V21, P606, DOI 10.1111/j.1468-3083.2006.02023.x; Schnopp C, 2010, EXPERT OPIN PHARMACO, V11, P929, DOI 10.1517/14656561003659992; Schwarz T, 2009, J INVEST DERM SYMP P, V14, P63, DOI 10.1038/jidsymp.2009.3; Sediva A, 2008, J ALLERGY CLIN IMMUN, V121, P1515, DOI 10.1016/j.jaci.2008.03.007; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P85, DOI 10.1016/j.jaci.2009.11.031; Sidbury R, 2000, CLIN EXP DERMATOL, V25, P559, DOI 10.1046/j.1365-2230.2000.00697.x; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Singh TP, 2010, J IMMUNOL, V184, P7257, DOI 10.4049/jimmunol.0903719; Strid J, 2006, IMMUNOLOGY, V119, P27, DOI 10.1111/j.1365-2567.2006.02401.x; Sugarman JL, 2010, PEDIATR DERMATOL, V27, P337, DOI 10.1111/j.1525-1470.2010.01162.x; Takaoka A, 2006, EXP DERMATOL, V15, P161, DOI 10.1111/j.1600-0625.2006.00405.x; Takiguchi R, 2007, J AM ACAD DERMATOL, V56, P222, DOI 10.1016/j.jaad.2006.08.031; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Traidl-Hoffmann C, 2010, CURR DRUG METAB, V11, P234, DOI 10.2174/138920010791196319; Trifari S, 2010, EUR J IMMUNOL, V40, P2369, DOI 10.1002/eji.201040848; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; UEHARA M, 1990, CLIN EXP DERMATOL, V15, P264, DOI 10.1111/j.1365-2230.1990.tb02086.x; van Beelen AJ, 2007, CURR OPIN ALLERGY CL, V7, P374, DOI 10.1097/ACI.0b013e3282ef869e; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Weger W, 2010, BRIT J PHARMACOL, V160, P810, DOI 10.1111/j.1476-5381.2010.00702.x; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wilsmann-Theis D, 2008, EUR J DERMATOL, V18, P172, DOI 10.1684/ejd.2008.0357; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	176	215	227	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1420	1432		10.1016/j.jaci.2011.01.054	http://dx.doi.org/10.1016/j.jaci.2011.01.054			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21419481				2022-12-18	WOS:000291048500017
J	Akin, C; Valent, P; Metcalfe, DD				Akin, Cem; Valent, Peter; Metcalfe, Dean D.			Mast cell activation syndrome: Proposed diagnostic criteria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; tryptase; histamine; mastocytosis; allergy; anaphylaxis; urticaria	TRYPTASE LEVELS; MASTOCYTOSIS; ANAPHYLAXIS; KIT	The term mast cell activation syndrome (MCAS) is finding increasing use as a diagnosis for subjects who present with signs and symptoms involving the dermis, gastrointestinal track, and cardiovascular system frequently accompanied by neurologic complaints. Such patients often have undergone multiple extensive medical evaluations by different physicians in varied disciplines without a definitive medical diagnosis until the diagnosis of MCAS is applied. However, MCAS as a distinct clinical entity has not been generally accepted, nor do there exist definitive criteria for diagnosis. Based on current understanding of this disease "syndrome" and on what we do know about mast cell activation and resulting pathology, we will explore and propose criteria for its diagnosis. The proposed criteria will be discussed in the context of other disorders involving mast cells or with similar presentations and as a basis for further scientific study and validation. (J Allergy Clin Immunol 2010;126:1099-104.)	[Metcalfe, Dean D.] NIAID, NIH, LAD, Bethesda, MD 20892 USA; [Akin, Cem] Univ Michigan, Dept Internal Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA; [Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan; Medical University of Vienna	Metcalfe, DD (corresponding author), NIAID, NIH, LAD, Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	dmetcalfe@niaid.nih.gov	Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Akin, Cem/0000-0001-6301-4520	Division of Intramural Research, National Institute of Allergy and Infectious Diseases; Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) [P21173-B13, SFB-F01820]; Food Allergy Initiative; Novartis; Bristol-Myers Squibb; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000249, ZIAAI000249] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF)(Austrian Science Fund (FWF)); Food Allergy Initiative; Novartis(Novartis); Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, and grants #P21173-B13 and #SFB-F01820 of the Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF).; Disclosure of potential conflict of interest: C. Akin receives research support from the Food Allergy Initiative, has provided legal consultation/expert witness testimony in cases related to anaphylaxis, and is on the Medical Advisory Board for the Mastocytosis Society. P. Valent receives research support from Novartis and Bristol-Myers Squibb. D. D. Metcalfe receives research support from the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, and is a member of the Editorial Board for the World Allergy Organization.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, pS242, DOI 10.1016/j.jaci.2008.12.935; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P135; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Iwaki S, 2008, CELL SIGNAL, V20, P195, DOI 10.1016/j.cellsig.2007.10.013; Kassab D, 2008, J ALLERGY CLIN IMMUN, V121, pS67, DOI 10.1016/j.jaci.2007.12.268; KEFFER JM, 1989, J ALLERGY CLIN IMMUN, V83, P595, DOI 10.1016/0091-6749(89)90071-7; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; *MAST SOC, WHAT AR SYMPT MAST C; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS1, DOI 10.1111/1523-1747.ep12468869; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Molderings GJ, 2007, SCAND J GASTROENTERO, V42, P1045, DOI 10.1080/00365520701245744; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; ROBERTS LJ, 1988, ENDOCRIN METAB CLIN, V17, P415, DOI 10.1016/S0889-8529(18)30427-4; ROBERTS LJ, 1991, J INVEST DERMATOL, V96, pS19, DOI 10.1111/1523-1747.ep12468945; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; Sonneck K, 2007, INT ARCH ALLERGY IMM, V142, P158, DOI 10.1159/000096442; Sperr WR, 2009, EUR J CLIN INVEST, V39, P914, DOI 10.1111/j.1365-2362.2009.02184.x; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007	28	215	223	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1099	U60		10.1016/j.jaci.2010.08.035	http://dx.doi.org/10.1016/j.jaci.2010.08.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21035176	Green Accepted			2022-12-18	WOS:000284947800003
J	ten Brinke, A; Grootendorst, DC; Schmidt, JT; de Bruine, FT; van Buchem, MA; Sterk, PJ; Rabe, KF; Bel, EH				ten Brinke, A; Grootendorst, DC; Schmidt, JT; de Bruine, FT; van Buchem, MA; Sterk, PJ; Rabe, KF; Bel, EH			Chronic sinusitis in severe asthma is related to sputum eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity-of-illness index; age of onset; inflammation; nasal mucosa; eosinophils; sputum; computed tomography; human	NASAL; INFLAMMATION; EXPRESSION; AIRWAYS	Background: Chronic rhinosinusitis and asthma are conditions that frequently coexist, particularly in severe asthma. The precise mechanism of the relationship between upper and lower airway, inflammation is still a matter of debate. We hypothesized that the extent of inflammation in the nasal mucosa is related to lung function and inflammation in the bronchial mucosa in patients with severe asthma. Objective: We sought to investigate the relationship between sinonasal inflammation as assessed on computed tomography (CT) scanning, lung function, sputum eosinophilia, and nitric oxide (NO) in exhaled air in patients with severe asthma. Methods: Eighty-nine nonsmoking outpatients with severe asthma (29 men and 60 women; mean age 45 years; age range, 18-74 years) were included in this study. CT scans were scored (0-30) by a blinded investigator using a validated method. Lung function, NO in exhaled air, and sputum eosinophils were measured by using standard procedures. Results: CT scans showed abnormalities in 84% of patients. Extensive sinus disease (score 12-30) was found in 24% of patients. There was a significant positive correlation between CT scores and eosinophils in peripheral blood (R-s = 0.46) and induced sputum (R-s = 0.40) and level of exhaled NO (R-s = 0.45, P < .01). CT scores were also positively related to functional residual capacity and inversely, related to diffusion capacity, particularly in patients with adult-onset asthma (R-s = 0.47 and R-s = -0.53, respectively). Conclusions: The results of this study show a direct relationship between sinonasal mucosa thickness and bronchial inflammation in severe asthma, particularly in patients with adult-onset disease. Whether sinus disease directly affects the intensity of bronchial inflammation is still an unanswered question.	Leiden Univ, Med Ctr, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otorhinolaryngol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands; Med Ctr Leeuwarden, Dept Pulm Dis, Leeuwarden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Medical Center Leeuwarden	Bel, EH (corresponding author), Leiden Univ, Med Ctr, Dept Pulm Dis, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Rabe, Klaus F./AAW-6296-2021; van Buchem, Mark/AAC-9843-2022; Sterk, P.J./AAK-8175-2020	Rabe, Klaus F./0000-0002-7020-1401; van Buchem, Mark/0000-0003-1881-1998; 				[Anonymous], 1999, AM J RESP CRIT CARE, V160, P1778; Armitage P., 1987, STAT METHODS MED RES; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chung KF, 1999, EUR RESPIR J, V13, P1198; COTES JE, 1995, EUR RESPIR J, V16, P41; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Nakamura H, 1999, ACTA OTO-LARYNGOL, V119, P592; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Senior BA, 1996, ANN ALLERG ASTHMA IM, V77, P6, DOI 10.1016/S1081-1206(10)63473-4; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P749, DOI 10.1164/ajrccm.164.5.2009035; TENBRINKE A, 2001, EUR RESPIR J, V18, pS66; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863, DOI 10.1177/01945998901030S505	33	215	224	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					621	626		10.1067/mai.2002.122458	http://dx.doi.org/10.1067/mai.2002.122458			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941310	Bronze			2022-12-18	WOS:000175132600008
J	Suissa, S; Ernst, P				Suissa, S; Ernst, P			Inhaled corticosteroids: Impact on asthma morbidity and mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; case-control studies; cohort studies; ecologic studies; epidemiologic studies; hospitalization; inhaled glucocorticoids; mortality; registries	NEW-ZEALAND; PRESCRIBED FENOTEROL; HOSPITAL ADMISSION; CHILDHOOD ASTHMA; BETA-AGONISTS; UNITED-STATES; YOUNG-ADULTS; RISK-FACTORS; MILD ASTHMA; DEATH	Inhaled corticosteroids are now recommended as first-line therapy for asthma, Although these drugs clearly improve the symptoms of the disease and the associated physiologic abnormalities, epidemiologic studies provide important information on their effectiveness in preventing asthma morbidity and mortality. We review the evidence regarding the role of inhaled corticosteroids in the prevention of asthma fatality and hospitalization. In the process, we discuss the methodologic complexities of the nonexperimental studies and the implications of the methodologic issues on the evaluation of the impart of these drugs. Eight of the cohort and ecologic studies conducted to date strongly suggest that inhaled corticosteroids. when taken regularly, decrease the number of hospitalizations for asthma by up to 80%. For asthma death, the results of 11 investigations appear less consistent, especially those of several cohort and case-control studies whose principal objective was to examine not the benefit of inhaled corticosteroids but the adverse effects of other drug classes, Much of the inconsistency in the results, however, can be explained by weaknesses in study design and analysis-in particular, the failure to consider exposure in terms of regular use of inhaled corticosteroids. When the most recent study involving the use of the Saskatchewan databases is considered, it is evident that regular treatment with conventional or low-dose inhaled corticosteroids results in a significant reduction in fatalities due to asthma, In all, the evidence to date strongly indicates that regular use of inhaled corticosteroids, even at low doses, would prevent the major portion of asthma hospitalizations and deaths.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Resp Med, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University	Suissa, S (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, 687 Pine Ave W,Ross 4-29, Montreal, PQ H3A 1A1, Canada.							ADELROTH E, 1988, LANCET, V1, P476; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P1535; Cochrane GM, 1996, DRUGS, V52, P12, DOI 10.2165/00003495-199600526-00004; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; DEVOY MAB, 1995, CHEST, V108, P1768, DOI 10.1378/chest.108.6.1768-a; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; ERNST P, 1992, EUR RESPIR J, V5, P773; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERSTMAN BB, 1993, J ALLERGY CLIN IMMUN, V91, P838, DOI 10.1016/0091-6749(93)90340-L; GODFREY S, 1977, BRIT J CLIN PHARMACO, V4, pS273, DOI 10.1111/j.1365-2125.1977.tb04519.x; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; Haahtela T, 1998, THORAX, V53, P1005, DOI 10.1136/thx.53.12.1005; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; Hessel PA, 1999, ANN ALLERG ASTHMA IM, V83, P362, DOI 10.1016/S1081-1206(10)62832-3; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; HORWOOD LJ, 1991, NEW ZEAL MED J, V104, P277; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; JANSONBJERKLIE S, 1992, HEART LUNG, V21, P265; Konig P, 1996, J ALLERGY CLIN IMMUN, V98, P1103, DOI 10.1016/S0091-6749(96)80198-9; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; LI D, 1995, AM J RESP CRIT CARE, V151, P647; MAHR TA, 1993, ANN ALLERGY, V71, P115; MIETTINEN OS, 1989, J CLIN EPIDEMIOL, V42, P325, DOI 10.1016/0895-4356(89)90037-1; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; National Asthma and Prevention Program, 1997, NIH PUBL, V97-4051; *NATL HEART LONG B, 1991, NAT ASTHM ED PROGR G; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1996, CAN RESPIR J, V3, P261; SEARS MR, 2001, EVIDENCE BASED ASTHM, P112; SENTHILSELVAN A, 1995, J CLIN EPIDEMIOL, V48, P1277, DOI 10.1016/0895-4356(95)00019-Z; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; STROM BL, 1984, AM J MED, V77, P703, DOI 10.1016/0002-9343(84)90369-3; Suissa S, 1997, J CLIN EPIDEMIOL, V50, P1079, DOI 10.1016/S0895-4356(97)00158-3; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Tasche MJA, 2000, THORAX, V55, P913, DOI 10.1136/thorax.55.11.913; Tough SC, 1996, J ASTHMA, V33, P179, DOI 10.3109/02770909609054550; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; WILKINS K, 1993, CAN MED ASSOC J, V148, P185	71	215	226	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					937	944		10.1067/mai.2001.115653	http://dx.doi.org/10.1067/mai.2001.115653			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398069	Bronze			2022-12-18	WOS:000169454800001
J	GLEICH, GJ; ZIMMERMANN, EM; HENDERSON, LL; YUNGINGER, JW				GLEICH, GJ; ZIMMERMANN, EM; HENDERSON, LL; YUNGINGER, JW			EFFECT OF IMMUNOTHERAPY ON IMMUNOGLOBULIN-E AND IMMUNOGLOBULIN-G ANTIBODIES TO RAGWEED ANTIGENS - A 6-YEAR PROSPECTIVE-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	GLEICH, GJ (corresponding author), MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT MED,ALLERG DIS RES LAB,ROCHESTER,MN 55905, USA.				NIAID NIH HHS [AI 11483, AI 00107] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1980, 4TH P INT C IMM PAR, P31; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; IIO A, 1977, J CLIN INVEST, V59, P743, DOI 10.1172/JCI108695; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Loveless MH, 1943, J IMMUNOL, V47, P165; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1978, IMMUNOLOGICAL DISEAS, P832; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; TJIO AH, 1979, J IMMUNOL, V122, P2131; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	30	215	216	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					261	271		10.1016/0091-6749(82)90062-8	http://dx.doi.org/10.1016/0091-6749(82)90062-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6811645				2022-12-18	WOS:A1982PL15100006
J	Roekevisch, E; Spuls, PI; Kuester, D; Limpens, J; Schmitt, J				Roekevisch, Evelien; Spuls, Phyllis Ira; Kuester, Denise; Limpens, Jacqueline; Schmitt, Jochen			Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; evidence-based medicine/systematic review; immunosuppressive therapy; immunomodulator; systemic treatment; recommendations; GRADE	RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; CYCLOSPORINE-A; INTRAVENOUS IMMUNOGLOBULIN; ORAL CYCLOSPORINE; CONSENSUS REPORT; HERBAL REMEDIES; ADULT PATIENTS	Background: Many patients with moderate-to-severe atopic dermatitis (AD) require systemic immunomodulating treatment to achieve adequate disease control. Objective: We sought to systematically evaluate the efficacy and safety of systemic treatments for moderate-to-severe AD. Methods: A systematic literature search was performed in MEDLINE, EMBASE, and CENTRAL (until June 2012). Randomized controlled trials (RCTs) evaluating systemic immunomodulating treatments for moderate-to-severe AD were included. Selection, data extraction, quality assessment, and generation of treatment recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach were performed independently by 2 reviewers. Efficacy outcomes were clinical signs, symptoms, quality of life, and the course of AD. Safety data were compared by calculating the weekly incidence rates (as percentages) for adverse events. Results: Thirty-four RCTs with 12 different systemic treatments and totaling 1653 patients were included. Fourteen trials consistently indicate that cyclosporin A efficaciously improves clinical signs of AD. Cyclosporin A is recommended as first-line treatment for short-term use. A second-line treatment option is azathioprine, but efficacy is lower, and evidence is weaker. Methotrexate can be considered a third-line treatment option. Recommendations are impossible for mycophenolate, montelukast, intravenous immunoglobulins, and systemic glucocorticosteroids because of limited evidence. A meta-analysis was not performed because of a lack of standardization in outcome measures. Conclusion: Although 12 different interventions for moderate-to-severe AD have been studied in 34 RCTs, strong recommendations are only possible for the short-term use of cyclosporin A. Methodological limitations in the majority of trials prevent evidence-based conclusions. Large head-to-head trials evaluating long-term treatments are required.	[Roekevisch, Evelien; Spuls, Phyllis Ira; Limpens, Jacqueline] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands; [Kuester, Denise; Schmitt, Jochen] Univ Hosp Dresden, Ctr Evidence Based Healthcare, D-01307 Dresden, Germany; [Kuester, Denise; Schmitt, Jochen] Tech Univ Dresden, Inst Occupat & Social Med, Dresden, Germany	University of Amsterdam; Academic Medical Center Amsterdam; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden	Schmitt, J (corresponding author), Univ Hosp Dresden, Ctr Evidence Based Healthcare, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de	Limpens, Jacqueline/AGO-4697-2022	Limpens, Jacqueline/0000-0002-7362-8574; Spuls, Phyllis/0000-0002-6035-2863	Novartis; Abbott; MSD; Wyeth	Novartis(Novartis); Abbott(Abbott Laboratories); MSD; Wyeth(Wyeth)	P. I. Spuls is the coauthor of the MACAD trial included in this review, has consultant arrangements for Novartis, and is the principal investigator of the Department for Clinical Trials with Pharma. J. Schmitt has consultant arrangements with Novartis and has grants/grants pending with Novartis, Abbott, MSD, and Wyeth. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Bemanian Mohammad Hassan, 2005, Iran J Allergy Asthma Immunol, V4, P139; Berth-Jones J, 2006, CLIN EXP ALLERGY, V36, P1115, DOI 10.1111/j.1365-2222.2006.02558.x; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; Capella GL, 2001, EUR J DERMATOL, V11, P209; Cheng HM, 2011, INT ARCH ALLERGY IMM, V155, P141, DOI 10.1159/000318861; Czech W, 2000, J AM ACAD DERMATOL, V42, P653, DOI 10.1016/S0190-9622(00)90180-4; GRAHAMBROWN R, 1992, LANCET, V340, P673, DOI 10.1016/0140-6736(92)92208-W; Granlund H, 2001, ACTA DERM-VENEREOL, V81, P22, DOI 10.1080/000155501750208137; Haeck IM, 2011, J AM ACAD DERMATOL, V64, P1074, DOI 10.1016/j.jaad.2010.04.027; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x; HEDDLE RJ, 1984, BRIT MED J, V289, P651, DOI 10.1136/bmj.289.6446.651; Higgins JPT, COCHRANE HDB SYSTEMA, P4; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hon KLE, 2007, BRIT J DERMATOL, V157, P357, DOI 10.1111/j.1365-2133.2007.07941.x; Hon KL, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-17; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; Jee SJ, 2011, ALLERGY ASTHMA IMMUN, V3, P89, DOI 10.4168/aair.2011.3.2.89; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LAROSA E, 1995, CURR THER RES CLIN E, V56, P720; Lee SS, 2004, ANN ACAD MED SINGAP, V33, P311; Leung TF, 2008, BRIT J DERMATOL, V158, P1216, DOI 10.1111/j.1365-2133.2008.08502.x; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; MOSTEFAKARA N, 1992, LANCET, V340, P674, DOI 10.1016/0140-6736(92)92209-X; MUNRO CS, 1994, BRIT J DERMATOL, V130, P376, DOI 10.1111/j.1365-2133.1994.tb02936.x; Pacor ML, 2004, CLIN EXP ALLERGY, V34, P639, DOI 10.1111/j.1365-2222.2004.1907.x; Paul C, 2002, BRIT J DERMATOL, V147, P518, DOI 10.1046/j.1365-2133.2002.04833.x; Pei AYS, 2001, PEDIAT ALLERG IMM-UK, V12, P154, DOI 10.1034/j.1399-3038.2001.012003154.x; Rahman M L, 2006, Mymensingh Med J, V15, P85; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Saeki H, 2009, J DERMATOL, V36, P563, DOI 10.1111/j.1346-8138.2009.00706.x; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; Schmitt J, 2010, BRIT J DERMATOL, V162, P661, DOI 10.1111/j.1365-2133.2009.09561.x; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schmitt J, 2012, ALLERGY, V67, P1111, DOI 10.1111/j.1398-9995.2012.02874.x; Schmitt J, 2009, J DTSCH DERMATOL GES, V7, P345, DOI 10.1111/j.1610-0387.2008.06967.x; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Schram ME, 2011, J ALLERGY CLIN IMMUN, V128, P353, DOI 10.1016/j.jaci.2011.03.024; Schunemann HJ, 2008, ANN INTERN MED, V149, DOI 10.7326/0003-4819-149-12-200812160-02002; Sharek Z, 2012, J LAW MED ETHICS, V40, P368, DOI 10.1111/j.1748-720X.2012.00670.x; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; STILLER MJ, 1994, J AM ACAD DERMATOL, V30, P597, DOI 10.1016/S0190-9622(94)70068-0; VANJOOST T, 1994, BRIT J DERMATOL, V130, P634; Veien NK, 2005, J AM ACAD DERMATOL, V53, P147, DOI 10.1016/j.jaad.2004.12.011; WAHLGREN CF, 1990, ACTA DERM-VENEREOL, V70, P323; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Wolff K, 2005, BRIT J DERMATOL, V152, P1296, DOI 10.1111/j.1365-2133.2005.06674.x; Zonneveld IM, 1996, BRIT J DERMATOL, V135, P15, DOI 10.1111/j.1365-2133.1996.tb00704.x; Zurbriggen B, 1999, DERMATOLOGY, V198, P56, DOI 10.1159/000018065	56	214	219	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					429	438		10.1016/j.jaci.2013.07.049	http://dx.doi.org/10.1016/j.jaci.2013.07.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24269258				2022-12-18	WOS:000332397100018
J	Levanen, B; Bhakta, NR; Paredes, PT; Barbeau, R; Hiltbrunner, S; Pollack, JL; Skold, CM; Svartengren, M; Grunewald, J; Gabrielsson, S; Eklund, A; Larsson, BM; Woodruff, PG; Erle, DJ; Wheelock, AM				Levanen, Bettina; Bhakta, Nirav R.; Paredes, Patricia Torregrosa; Barbeau, Rebecca; Hiltbrunner, Stefanie; Pollack, Joshua L.; Skold, C. Magnus; Svartengren, Magnus; Grunewald, Johan; Gabrielsson, Susanne; Eklund, Anders; Larsson, Britt-Marie; Woodruff, Prescott G.; Erle, David J.; Wheelock, Asa M.			Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						microRNA; allergic asthma; IL-13; exosome; lung function	MESSENGER-RNA; MESENCHYMAL TRANSITION; SUBWAY ENVIRONMENT; GABA(A) RECEPTORS; POSSIBLE ROLES; HUMAN SALIVA; URBAN AIR; CELLS; EXPRESSION; BIOINFORMATICS	Background: Asthma is characterized by increased airway narrowing in response to nonspecific stimuli. The disorder is influenced by both environmental and genetic factors. Exosomes are nanosized vesicles of endosomal origin released from inflammatory and epithelial cells that have been implicated in asthma. In this study we characterized the microRNA (miRNA) content of exosomes in healthy control subjects and patients with mild intermittent asthma both at unprovoked baseline and in response to environmental challenge. Objective: To investigate alterations in bronchoalveolar lavage fluid (BALF) exosomal miRNA profiles due to asthma, and following subway air exposure. Methods: Exosomes were isolated from BALF from healthy control subjects (n = 10) and patients with mild intermittent asthma (n = 10) after subway and control exposures. Exosomal RNA was analyzed by using microarrays containing probes for 894 human miRNAs, and selected findings were validated with quantitative RT-PCR. Results were analyzed by using multivariate modeling. Results: The presence of miRNAs was confirmed in exosomes from BALF of both asthmatic patients and healthy control subjects. Significant differences in BALF exosomal miRNA was detected for 24 miRNAs with a subset of 16 miRNAs, including members of the let-7 and miRNA-200 families, providing robust classification of patients with mild nonsymptomatic asthma from healthy subjects with 72% cross-validated predictive power (Q(2) = 0.72). In contrast, subway exposure did not cause any significant alterations in miRNA profiles. Conclusion: These studies demonstrate substantial differences in exosomal miRNA profiles between healthy subjects and patients with unprovoked, mild, stable asthma. These changes might be important in the inflammatory response leading to bronchial hyperresponsiveness and asthma. (J Allergy Clin Immunol 2013;131:894-903.)	[Levanen, Bettina; Skold, C. Magnus; Grunewald, Johan; Eklund, Anders; Wheelock, Asa M.] Karolinska Inst, Dept Med, Resp Med Unit, SE-17176 Stockholm, Sweden; [Levanen, Bettina; Skold, C. Magnus; Grunewald, Johan; Eklund, Anders; Wheelock, Asa M.] Karolinska Inst, Ctr Mol Med, SE-17176 Stockholm, Sweden; [Bhakta, Nirav R.; Woodruff, Prescott G.; Erle, David J.] Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, San Francisco, CA 94143 USA; [Bhakta, Nirav R.; Woodruff, Prescott G.; Erle, David J.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Paredes, Patricia Torregrosa; Hiltbrunner, Stefanie; Gabrielsson, Susanne] Karolinska Inst, Translat Immunol Unit, Dept Med, SE-17176 Stockholm, Sweden; [Barbeau, Rebecca; Pollack, Joshua L.; Erle, David J.] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; [Svartengren, Magnus; Larsson, Britt-Marie] Karolinska Inst, Div Occupat & Environm Med, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet; University of California System; University of California San Francisco; Karolinska Institutet	Wheelock, AM (corresponding author), Karolinska Inst, Dept Med, Resp Med Unit, Lung Res Lab L4 01, SE-17176 Stockholm, Sweden.	bettina.levanen@ki.se; asa.wheelock@ki.se	Wheelock, Åsa/B-7904-2017; Grunewald, Johan/GQZ-8122-2022; Gabrielsson, S./E-4145-2014; Svartengren, Magnus/AAM-7777-2021	Wheelock, Åsa/0000-0002-8013-2745; Gabrielsson, S./0000-0003-1771-1346; Svartengren, Magnus/0000-0002-8165-7236; Grunewald, Johan/0000-0003-0473-3984; Erle, David/0000-0002-2171-0648; Hiltbrunner, Stefanie/0000-0002-3415-7992	Swedish Heart-Lung Foundation; King Oscar II Jubilee Foundation; Swedish Foundation for Strategic Research (SSF), VINNOVA; Karolinska Institutet; Center for Allergy Research; Hesselman Foundation; Swedish Transport Administration; University of California-San Francisco Sandler Asthma Basic Research (SABRE) Center; National Institutes of Health [HL007185, HL095372]; Regulus; VINNOVA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095372, P01HL107202, R01HL097591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); King Oscar II Jubilee Foundation; Swedish Foundation for Strategic Research (SSF), VINNOVA; Karolinska Institutet(Karolinska Institutet); Center for Allergy Research; Hesselman Foundation; Swedish Transport Administration; University of California-San Francisco Sandler Asthma Basic Research (SABRE) Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Regulus; VINNOVA(Vinnova); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Swedish Heart-Lung Foundation, the King Oscar II Jubilee Foundation, the Swedish Foundation for Strategic Research (SSF), VINNOVA, the Karolinska Institutet, the Center for Allergy Research, the Hesselman Foundation and the Swedish Transport Administration, the University of California-San Francisco Sandler Asthma Basic Research (SABRE) Center, and National Institutes of Health grants HL007185 (to N.R.B.) and HL095372 (to P.G.W.) and through the regional agreement on medical training and clinical research (ALF) between the Stockholm County Council and the Karolinska Institutet.; S. Gabrielsson has a patent pending on using B-cell exosomes for cancer therapy paid for by Immune Therapy Holdings. B.-M. Larsson has received grants from the Swedish Transport Administration. P. G. Woodruff has received grants from Regulus and has a provisional patent on epithelial miRNAs in asthma with the University of California-San Francisco. D. J. Erle has pending grant applications from the National Institutes of Health and has a pending patent application with the University of California-San Francisco. A. M. Wheelock has received grants from VINNOVA and the Swedish Heart-Lung Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Admyre C, 2008, ALLERGY, V63, P404, DOI 10.1111/j.1398-9995.2007.01600.x; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Almqvist N, 2008, IMMUNOLOGY, V125, P21, DOI 10.1111/j.1365-2567.2008.02812.x; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Ariel D, 2012, CURR OPIN ALLERGY CL, V12, P49, DOI 10.1097/ACI.0b013e32834ecb7f; Bigert C, 2011, SCAND J WORK ENV HEA, V37, P129, DOI 10.5271/sjweh.3074; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Chiba Y, 2010, J PHARMACOL SCI, V114, P264, DOI 10.1254/jphs.10R10FM; Cho JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-8; EKLUND A, 1986, THORAX, V41, P629, DOI 10.1136/thx.41.8.629; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Farraj AK, 2011, AM J RESP CELL MOL, V44, P185, DOI 10.1165/rcmb.2009-0456OC; Gallos G, 2012, AM J PHYSIOL-LUNG C, V302, pL248, DOI 10.1152/ajplung.00131.2011; Garbacki N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016509; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.0000181308.51440.75; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hackett TL, 2012, CURR OPIN ALLERGY CL, V12, P53, DOI 10.1097/ACI.0b013e32834ec6eb; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Johansson SM, 2008, IMMUNOLOGY, V123, P491, DOI 10.1111/j.1365-2567.2007.02714.x; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Klepczynska-Nystrom A, 2012, RESP MED, V106, P25, DOI 10.1016/j.rmed.2011.09.008; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390; Lundstrom SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023864; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x; Mizuta K, 2008, AM J PHYSIOL-LUNG C, V294, pL1206, DOI 10.1152/ajplung.00287.2007; Moltzahn F, 2011, CANCER RES, V71, P550, DOI 10.1158/0008-5472.CAN-10-1229; Nystrom AK, 2010, EUR RESPIR J, V36, P240, DOI 10.1183/09031936.00099909; Oglesby IK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-148; Paredes PT, 2012, ALLERGY, V67, P911, DOI 10.1111/j.1398-9995.2012.02835.x; Penttinen P, 2006, INHAL TOXICOL, V18, P191, DOI 10.1080/08958370500434230; Qazi KR, 2010, THORAX, V65, P1016, DOI 10.1136/thx.2009.132027; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Renz H, 2011, J ALLERGY CLIN IMMUN, V128, pS27, DOI 10.1016/j.jaci.2011.09.039; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Sonkoly E, 2011, MUTAT RES-FUND MOL M, V717, P46, DOI 10.1016/j.mrfmmm.2011.02.002; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Van Pottelberge GR, 2011, AM J RESP CRIT CARE, V183, P898, DOI 10.1164/rccm.201002-0304OC; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wiklund S, 2008, ANAL CHEM, V80, P115, DOI 10.1021/ac0713510; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722; Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91; Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339	73	214	227	3	63	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					894	+		10.1016/j.jaci.2012.11.039	http://dx.doi.org/10.1016/j.jaci.2012.11.039			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23333113	Green Accepted			2022-12-18	WOS:000315587800034
J	Fleischer, DM; Burks, AW; Vickery, BP; Scurlock, AM; Wood, RA; Jones, SM; Sicherer, SH; Liu, AH; Stablein, D; Henning, AK; Mayer, L; Lindblad, R; Plaut, M; Sampson, HA				Fleischer, David M.; Burks, A. Wesley; Vickery, Brian P.; Scurlock, Amy M.; Wood, Robert A.; Jones, Stacie M.; Sicherer, Scott H.; Liu, Andrew H.; Stablein, Donald; Henning, Alice K.; Mayer, Lloyd; Lindblad, Robert; Plaut, Marshall; Sampson, Hugh A.		Consortium Food Allergy Res CoFAR	Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; sublingual immunotherapy; desensitization; food allergy	ORAL TOLERANCE INDUCTION; HAZELNUT FOOD ALLERGY; COW MILK ALLERGY; QUALITY-OF-LIFE; NATURAL-HISTORY; ANAPHYLACTIC REACTIONS; RESOURCE IMPLICATIONS; BUDGET IMPACT; KIWI FRUIT; CHILDREN	Background: There are presently no available therapeutic options for patients with peanut allergy. Objective: We sought to investigate the safety, efficacy, and immunologic effects of peanut sublingual immunotherapy (SLIT). Methods: After a baseline oral food challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15 years), were randomized 1:1 across 5 sites to daily peanut or placebo SLIT. A 5-g OFC was performed after 44 weeks, followed by unblinding; placebo-treated subjects then crossed over to higher dose peanut SLIT, followed by a subsequent crossover Week 44 5-g OFC. Week 44 OFCs from both groups were compared with baseline OFCs; subjects successfully consuming 5 g or at least 10-fold more peanut powder than the baseline OFC threshold were considered responders. Results: After 44 weeks of SLIT, 14 (70%) of 20 subjects receiving peanut SLIT were responders compared with 3 (15%) of 20 subjects receiving placebo (P < .001). In peanut SLIT responders, median SCD increased from 3.5 to 496 mg. After 68 weeks of SLIT, median SCD significantly increased to 996 mg (compared with Week 44, P = .05). The median SCD at the Week 44 Crossover OFC was significantly higher than baseline (603 vs 71 mg, P = .02). Seven (44%) of 16 crossover subjects were responders; median SCD increased from 21 to 496 mg among responders. Of 10,855 peanut doses through the Week 44 OFCs, 63.1% were symptom free; excluding oral-pharyngeal symptoms, 95.2% were symptom free. Conclusions: Peanut SLIT safely induced a modest level of desensitization in a majority of subjects compared with placebo. Longer duration of therapy showed statistically significant increases in the SCD. (J Allergy Clin Immunol 2013;131:119-27.)	[Fleischer, David M.; Liu, Andrew H.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Burks, A. Wesley; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Scurlock, Amy M.; Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Scurlock, Amy M.; Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Sicherer, Scott H.; Mayer, Lloyd; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Stablein, Donald; Henning, Alice K.; Lindblad, Robert] EMMES Corp, Rockville, MD USA; [Plaut, Marshall] NIAID, NIH, Bethesda, MD 20892 USA	National Jewish Health; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fleischer, DM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,J321, Denver, CO 80206 USA.	Fleischerd@njhealth.org		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR)/National Institutes of Health (NIH) [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences (National Jewish) [UL1 TR000154]; NCRR [UL1 TR000067, UL1 TR000039, UL1 RR024128, UL1 RR 025005]; NIH; Department of Defense; Wallace Research Foundation; NIH/NIAID; American Lung Association, Cephalon; Foundation of the American College of Allergy, Asthma Immunology; Thrasher Research Fund; Food Allergy & Anaphylaxis Network; National Peanut Board; NIAID; UpToDate; Elsevier-Wiley; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Center for Advancing Translational Sciences (National Jewish); NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Wallace Research Foundation; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Lung Association, Cephalon; Foundation of the American College of Allergy, Asthma Immunology; Thrasher Research Fund; Food Allergy & Anaphylaxis Network; National Peanut Board; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); UpToDate; Elsevier-Wiley; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant U19AI066738 and U01AI066560. The project was also supported by grant no. UL1 RR025780 from the National Center for Research Resources (NCRR)/National Institutes of Health (NIH) and grant nos. UL1 TR000154 from the NIH/National Center for Advancing Translational Sciences (National Jewish) and grant nos. UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL1 RR024128 (North Carolina), and UL1 RR 025005 (Johns Hopkins) from the NCRR. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH.; D. M. Fleischer has received grants from the National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases (NIAID), has consultant arrangements with Sanofi-Aventis, is employed by National Jewish Health, and receives royalties from UpToDate. A. W. Burks has board memberships with the American Academy of Allergy, Asthma & Immunology, the NIH Hypersensitivity, Autoimmune, and Immune-mediated Diseases study section, the US Food and Drug Administration, and the Journal of Allergy and Clinical Immunology; is on advisory boards for the Food Allergy & Anaphylaxis Network, ActoGeniX, and Exploramed Development; has consultant arrangements with Merck, Novartis Pharma AG, the Dannon Company, McNeill Nutritionals, and Schering-Plough; is employed by UNC Children's Hospital and Duke University; has received grants from the NIH; has grants pending from the Department of Defense and the Wallace Research Foundation; receives payment for lectures from Myland Specialty; receives royalties from UpToDate; receives payment for development of educational presentations from Current Views; has stock/stock options with Allertein, Mastcell Pharmaceuticals, and Dow AgroSciences; and has received travel expenses from the European Academy of Allergy and Clinical Immunology. B. P. Vickery has received grants and travel support from the NIH/NIAID and has received grants from the American Lung Association, Cephalon, the Foundation of the American College of Allergy, Asthma & Immunology, and the Thrasher Research Fund. A. M. Scurlock has received grants from the NIH. R. A. Wood has consultant arrangements with the Asthma and Allergy Foundation of America, is employed by Johns Hopkins University, has provided expert testimony for the NIH, and received royalties from UpToDate. S. M. Jones has received grants from the NIH, the Food Allergy & Anaphylaxis Network, and the National Peanut Board; is on the Medical Advisory Board for the Food Allergy & Anaphylaxis Network; has received payment for lectures from Abbot Nutrition International, the Kentucky Society for Allergy, Asthma, and Immunology, the New England Allergy Society, the American College of Allergy, Asthma & Immunology, Indiana University Medical School and Riley Children's Hospital, the Spanish Society of Allergy and Clinic Immunology, and Oregon Allergy, Asthma & Immunology; and serves on the National Institute of Allergy and Infectious Disease Safety Monitoring Committee, the Arkansas Medicaid Drug Review Committee, and the NIAID Study Section. S. H. Sicherer has received grants from the NIH/NIAID and has consultant arrangements with the Food Allergy Initiative. D. Stablein has received grants from the NIH. A. K. Henning has received grants from the NIH. R. Lindblad has received grants from the NIH/NIAID. H. A. Sampson has received grants and travel support from the NIAID, has received grants from the NIH, is on the Danone Scientific Advisory Board, has consultant arrangements with Allertein Therapeutics and the Food Allergy Initiative, is employed by Mount Sinai Medical School, and has received royalties from Elsevier-Wiley and UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; Bafeta A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e813; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Dechartres A, 2011, ANN INTERN MED, V155, P39, DOI 10.7326/0003-4819-155-1-201107050-00006; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Enrique E, 2008, ANN ALLERG ASTHMA IM, V100, P283, DOI 10.1016/S1081-1206(10)60456-5; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Guest JF, 2009, CURR MED RES OPIN, V25, P339, DOI 10.1185/03007990802594685 ; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Kulis M, 2012, J ALLERGY CLIN IMMUN, V129, P1159, DOI 10.1016/j.jaci.2011.11.045; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Patel DA, 2011, J ALLERGY CLIN IMMUN, V128, P110, DOI 10.1016/j.jaci.2011.03.013; Rodriguez-Perez N, 2008, ANN ALLERG ASTHMA IM, V101, P304, DOI 10.1016/S1081-1206(10)60496-6; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Sheikh A, 2012, PRIM CARE RESP J, V21, P41, DOI 10.4104/pcrj.2011.00071; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Sladkevicius E, 2010, J Med Econ, V13, P119, DOI 10.3111/13696990903543242; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	52	214	216	0	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					119	U184		10.1016/j.jaci.2012.11.011	http://dx.doi.org/10.1016/j.jaci.2012.11.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23265698	Green Accepted, Green Published			2022-12-18	WOS:000312961200015
J	Katz, Y; Goldberg, MR; Rajuan, N; Cohen, A; Leshno, M				Katz, Yitzhak; Goldberg, Michael R.; Rajuan, Nelly; Cohen, Adi; Leshno, Moshe			The prevalence and natural course of food protein-induced enterocolitis syndrome to cow's milk: A large-scale, prospective population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; oral challenge; soy allergy; skin prick test	CLINICAL-FEATURES; ALLERGY; CHALLENGE; SOY	Background: The prevalence and natural history for food protein-induced enterocolitis syndrome (FPIES) have not been determined. Objective: We sought to determine the prevalence, clinical manifestations, and rate of recovery for FPIES in a large-scale, population-based prospective study. Methods: In a prospective study the feeding history of 13,019 infants was obtained. Infants with probable adverse reactions to cow's milk protein (CMP) were clinically examined, skin prick tested, and challenged orally. Diagnostic criteria for CMP-induced FPIES included age less than 9 months, delayed recurrent vomiting (usually with nausea), and lethargy after exposure to CMP in the absence of other IgE-mediated symptoms, such as rash, urticaria, and respiratory symptoms. In addition, a positive challenge response to milk resulted in the above-mentioned gastrointestinal symptoms, removal of milk from the diet resulted in the resolution of those symptoms, or both. Results: Ninety-eight percent of the cohort participated in the study. The cumulative incidence for FPIES was 0.34% (44/13,019 patients). The most common symptoms were recurrent vomiting (100%), lethargy (77%) diarrhea (25%), pallor (14%), and bloody diarrhea (4.5%). All patients had FPIES within the first 6 months of life. By the age of 3 years, 90% of the patients had recovered. We did not detect any concomitant reaction to soy. Eight patients with FPIES had IgE-mediated cow's milk allergy (IgE-CMA). Conclusions: The prevalence of FPIES is significant, and its clinical presentation is distinct from that of IgE-CMA. Most patients with FPIES recover, although a proportion might convert to IgE-CMA. The likelihood for a cross-reactivity to soy in this population was less than previously estimated. (J Allergy Clin Immunol 2011;127:647-53.)	[Katz, Yitzhak; Goldberg, Michael R.; Cohen, Adi] Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel; [Katz, Yitzhak; Rajuan, Nelly] Tel Aviv Univ, Dept Pediat, IL-69978 Tel Aviv, Israel; [Leshno, Moshe] Tel Aviv Univ, Sackler Fac Med, Fac Management, IL-69978 Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Katz, Y (corresponding author), Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel.	ykatz49@gmail.com			Israel Dairy Foundation; Israel dairy board	Israel Dairy Foundation; Israel dairy board	Supported by the Israel Dairy Foundation.; Y. Katz receives research support from the Israel dairy board. The rest of the authors have declared that they have no conflict of interest.	Bruni F, 2008, ALLERGY, V63, DOI 10.1111/j.1398-9995.2008.01911.x; Elizur A, 2007, ANN ALLERG ASTHMA IM, V98, P540, DOI 10.1016/S1081-1206(10)60732-6; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Levy Y, 2003, PEDIAT ALLERG IMM-UK, V14, P325, DOI 10.1034/j.1399-3038.2003.00039.x; Maloney J, 2007, PEDIAT ALLERG IMM-UK, V18, P360, DOI 10.1111/j.1399-3038.2007.00561.x; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P371, DOI 10.1097/ACI.0b013e32832d6315; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7	14	214	236	5	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					647	U163		10.1016/j.jaci.2010.12.1105	http://dx.doi.org/10.1016/j.jaci.2010.12.1105			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377033				2022-12-18	WOS:000288018400014
J	Passalacqua, G; Durham, SR				Passalacqua, Giovanni; Durham, Stephen R.		Global Allergy Asthma	Allergic rhinitis and its impact on asthma update: Allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						injection immunotherapy; sublingual immunotherapy; efficacy; safety; mechanisms	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; MONOPHOSPHORYL-LIPID-A; PRESEASONAL-SPECIFIC IMMUNOTHERAPY; SYSTEMIC IMMUNOLOGICAL CHANGES; MESSENGER-RNA EXPRESSION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND	The Allergic Rhinitis and its Impact on Asthma document was first published in 2001. Since then, new data on specific immunotherapy have appeared. This review is intended as an update to the original document. MedLine (2001 to June 2006) was searched with appropriate key words, and panelists were asked to identify further relevant articles. Randomized controlled trials were considered for the evaluation of efficacy. For the evaluation of safety, and additional effects, studies with lower grades of evidence were included. The clinical efficacy of injection immunotherapy in rhinitis and asthma was confirmed, as well as the safety, provided that recommendations are followed. Studies have demonstrated the long-term efficacy and the preventive effect of immunotherapy in reducing the onset of new sensitizations. One randomized open trial demonstrated that in children with allergic rhinitis, injection immunotherapy may reduce the risk of developing asthma. There is strong evidence that sublingual immunotherapy is effective in allergic rhinitis in adults. Recent meta-analyses demonstrated its efficacy in allergic rhinitis in children and in asthma, although more definitive trials are required. Current data indicate that sublingual immunotherapy is safe and the rate of adverse reactions is not greater below 5 years of age. One randomized open trial showed that in children with allergic rhinitis, sublingual immunotherapy reduced the onset of asthma. Further studies are needed to identify the optimal maintenance dose and to elucidate the mechanism of action. Novel approaches for immunotherapy are currently under evaluation, including the use of adjuvants, peptides. and DNA-conjugated and recombinant allergens.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	University of Genoa; Imperial College London	Passalacqua, G (corresponding author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it			Medical Research Council [G9805965] Funding Source: Medline; MRC [G9805965] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Arifhodzic N, 2003, INT ARCH ALLERGY IMM, V132, P258, DOI 10.1159/000074307; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bonini S, 2006, ALLERGY, V61, P681, DOI 10.1111/j.1398-9995.2006.01080.x; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38, DOI 10.1016/S1081-1206(10)61186-6; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254, DOI 10.1016/S1081-1206(10)61222-7; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048, DOI 10.1164/ajrccm.162.6.9909087; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414, DOI 10.1016/S1081-1206(10)61776-0; Horner AA, 2002, ALLERGY, V57, P24, DOI 10.1034/j.1398-9995.57.s72.12.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Limb SL, 2006, INT ARCH ALLERGY IMM, V140, P245, DOI 10.1159/000093250; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Marcucci F, 2005, PEDIAT ALLERG IMM-UK, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nettis E, 2002, CLIN EXP ALLERGY, V32, P1745, DOI 10.1046/j.1365-2222.2002.01544.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; NIGGEMANN B, 2006, ALLERGY, V61, P865; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3, DOI 10.1016/S1081-1206(10)61440-8; Passalacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P1054, DOI 10.1016/j.jaci.2005.12.1308; Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Polosa R, 2003, CLIN EXP ALLERGY, V33, P873, DOI 10.1046/j.1365-2222.2003.01676.x; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Rak S, 2005, ALLERGY, V60, P643, DOI 10.1111/j.1398-9995.2005.00763.x; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Walker Ross F., 2000, Limnology, V1, P107, DOI 10.1007/s102010070016; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Watanabe Hiroshi, 2004, Allergology International, V53, P255, DOI 10.1111/j.1440-1592.2004.00342.x; *WHO, 1998, ALLERGY S54, V53, pS3; Wilcock LK, 2004, CLIN EXP ALLERGY, V34, P1373, DOI 10.1111/j.1365-2222.2004.02052.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Zan H, 1998, J IMMUNOL, V161, P5217; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	144	214	234	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					881	891		10.1016/j.jaci.2007.01.045	http://dx.doi.org/10.1016/j.jaci.2007.01.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17418661				2022-12-18	WOS:000245729500016
J	Sabroe, RA; Fiebiger, E; Francis, DM; Maurer, D; Seed, PT; Grattan, CEH; Black, AK; Stingl, G; Greaves, MW; Barr, RM				Sabroe, RA; Fiebiger, E; Francis, DM; Maurer, D; Seed, PT; Grattan, CEH; Black, AK; Stingl, G; Greaves, MW; Barr, RM			Classification of anti-Fc epsilon RI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; Fc epsilon RI; autoantibodies; histamine; basophils; human dermal mast cells	HISTAMINE-RELEASE; HUMAN BASOPHILS; ALPHA-SUBUNIT; RECEPTOR; ACTIVATION	Background: Circulating autoantibodies against FcepsilonRI, IgE, or both occur in approximately one third of patients with chronic idiopathic urticaria (CIU), but not all autoantibodies initiate histamine release. Objective: We sought to classify patients with CIU into subsets on the basis of serum bioactivity and immunoreactivity and to examine the relationship between newly defined subtype and disease severity. Methods: Sera from patients with CIU (n = 78), dermographism (n = 15), and cholinergic urticaria (n = 10) and sera from healthy subjects (n = 39) were analyzed by means of Western blot analysis for anti-FcepsilonRI autoantibodies and for histamine release from basophils and dermal mast cells. In vivo reactivity of autologous serum was tested by means of intradermal injection, and CIU severity was determined on the basis of clinical interview. Results: We classified sera from patients with CIU into 5 subsets: immunoreactive histamine-releasing anti-FcepsilonRI autoantibodies (n = 20 [26%]); immunoreactive anti-FcepsilonRI autoantibodies without histamine-releasing activity (n = 12 [15%]); anti-IgE-like autoantibodles (n = 7 [9%]); serum containing a mast cell-specific histamine-releasing factor (n = 7 [9%]); and sera with no identifiable factor (n = 32 [41%]). Patients with serum histamine-releasing activity, had more severe urticaria than patients without such activity. Positive skin test responses to autologous sera were associated with histamine-releasing anti-FcepsilonRI autoantibodies but not with non-histamine-releasing anti-FcepsilonRI autoantibodies. Neither healthy subjects nor patients with dermographism or cholinergic urticaria had histamine-releasing anti-FcepsilonRI autoantibodies. Conclusion: These data support the specificity of functional anti-FcepsilonRI autoantibodies to CIU. The identification of distinctive subsets of patients suggests that other pathogenic mechanisms occur in CIU in addition to direct ligation of FcepsilonRI by autoantibodies causing dermal mast cell degranulation. Elucidating these mechanisms might lead to new treatments for CIU.	Univ London Kings Coll, St Thomas Hosp, Guys Kings & St Thomas Sch Med, St Johns Inst Dermatol, London WC2R 2LS, England; Univ London Kings Coll, St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Obstet & Gynaecol, London WC2R 2LS, England; Univ Vienna, Sch Med, Dept Dermatol, Div Immunol Allergy & Infect Dis, Vienna, Austria; W Norwich Hosp, Dept Dermatol, Norwich, Norfolk, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Vienna	Sabroe, RA (corresponding author), Barnsley Dist Gen Hosp NHS Trust, Dept Dermatol, Gawber Rd, Barnsley S75 2EP, S Yorkshire, England.		Seed, Paul T/C-4435-2008; Maurer, Dieter/W-1079-2019	Seed, Paul T/0000-0001-7904-7933; 				CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; FUREDER W, 1995, J IMMUNOL, V155, P3152; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; KOBZABLACK A, 1996, CLIN EXP DERMATOL, V21, P424; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RISKE F, 1991, J BIOL CHEM, V266, P11245; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Zuberbier T, 2000, ALLERGY, V55, P951, DOI 10.1034/j.1398-9995.2000.00445.x	19	214	228	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					492	499		10.1067/mai.2002.126782	http://dx.doi.org/10.1067/mai.2002.126782			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209101	Bronze			2022-12-18	WOS:000177936900024
J	Hoffman, HM; Wanderer, AA; Broide, DH				Hoffman, HM; Wanderer, AA; Broide, DH			Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						familial cold urticaria; autoinflammatory syndromes; hereditary fevers; amyloidosis; diagnostic criteria	MUCKLE-WELLS-SYNDROME; URTICARIA; AMYLOIDOSIS; MUTATIONS; DIAGNOSIS; SPECTRUM; ALLERGY	Background: Familial cold autoinflammatory syndrome (FCAS), commonly known as familial cold urticaria, is a rare autosomal dominant inflammatory disorder with episodic symptoms precipitated by exposure to cold. Objective: The goal of this study was to formulate clinical diagnostic criteria for FCAS in a large cohort in whom the diagnosis of FCAS was supported by genetic linkage to chromosome 1q44. Methods: We assessed 45 affected and 68 unaffected members from 6 American families. DNA analysis was performed to confirm linkage to chromosome 1q44. Clinical characteristics were determined by means of analysis of detailed questionnaires and medical histories. Results: Pedigree and genetic analyses confirmed autosomal dominant transmission and linkage to chromosome 1q44 in all families. The most consistent symptom during attacks were rash (100%), fever (93%), arthralgia (96%), and conjunctivitis (84%). Age of onset was within the first 6 months of life in 95% of affected subjects. The average delay between cold exposure and onset of symptoms was 2.5 hours, and the average duration of an episode was 12 hours. Renal disease with amyloidosis occurs infrequently in FCAS (2%). Conclusion: The most consistent clinical characteristics of FCAS that discriminate it from other periodic fevers are association with cold exposure, conjunctivitis, age of onset, duration of episodes, and an autosomal dominant inheritance pattern. On the basis of the analysis of genotype and phenotype of FCAS, we formulated clinical diagnostic criteria that can be used to distinguish FCAS from other hereditary periodic fever syndromes.	Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Dept Med, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat & Allergy, Denver, CO USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hoffman, HM (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Dept Med, Mail Code 0635,9500 Gilman Dr, La Jolla, CA 92093 USA.			Broide, David/0000-0001-8405-9090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001508] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI001508, 5-K08 AI01508] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertelloni S, 2000, HORM RES, V53, P72, DOI 10.1159/000023517; BLACK JT, 1969, ANN INTERN MED, V70, P989, DOI 10.7326/0003-4819-70-5-989; CASTELAIN MPY, 1971, B SOC FR DERMATOL SY, V78, P525; COMMERFORD PJ, 1977, S AFR MED J, V51, P105; Cuisset L, 1999, AM J HUM GENET, V65, P1054, DOI 10.1086/302589; DERBES VJ, 1972, ANN ALLERGY, V30, P335; DOEGLAS HMG, 1974, ARCH DERMATOL, V110, P382, DOI 10.1001/archderm.110.3.382; DOEGLAS HMG, 1973, ARCH DERMATOL, V107, P136, DOI 10.1001/archderm.107.1.136; Drenth JPH, 2000, BRIT MED J, V320, P1091, DOI 10.1136/bmj.320.7242.1091; FORDYCE AM, 1993, BRIT DENT J, V175, P417, DOI 10.1038/sj.bdj.4808345; Galon J, 2000, CURR OPIN IMMUNOL, V12, P479, DOI 10.1016/S0952-7915(00)00124-2; Gerbig AW, 1998, QJM-INT J MED, V91, P489, DOI 10.1093/qjmed/91.7.489; Hoffman HM, 2000, AM J HUM GENET, V66, P1693, DOI 10.1086/302874; Jung M., 1996, American Journal of Human Genetics, V59, pA223; KALOGEROMITROS D, 1995, ANN ALLERG ASTHMA IM, V74, P295; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; Kastner DL, 1998, HOSP PRACT, V33, P131, DOI 10.3810/hp.1998.04.90; Kile RL., 1940, J AM MED ASS, V114, P1067, DOI [10.1001/jama.1940.62810120003010b, DOI 10.1001/JAMA.1940.62810120003010B]; Kizaki T, 1997, J APPL PHYSIOL, V83, P1116, DOI 10.1152/jappl.1997.83.4.1116; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; MARTIN S, 1981, CUTIS, V27, P173; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; McDermott MF, 2000, ARTHRITIS RHEUM-US, V43, P2034, DOI 10.1002/1529-0131(200009)43:9<2034::AID-ANR14>3.0.CO;2-J; Mitobe J, 1999, MOL GEN GENET, V262, P73; MUCKLE TJ, 1979, BRIT J DERMATOL, V100, P87, DOI 10.1111/j.1365-2133.1979.tb03572.x; ORMEROD AD, 1993, ARCH DERMATOL, V129, P343, DOI 10.1001/archderm.129.3.343; PAGE EH, 1988, J AM ACAD DERMATOL, V18, P1003, DOI 10.1016/S0190-9622(88)70098-5; RODIN HH, 1951, AMA ARCH DERM SYPH, V63, P152; ROUX H, 1982, REV RHUM, V49, P131; SHEPARD MK, 1971, 3 C CLIN DEL BIRT 12; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TONNESEN MG, 1985, CLIN RES, V33, pA690; Tumer N, 1997, NEUROPHARMACOLOGY, V36, P1065, DOI 10.1016/S0028-3908(97)00093-2; Urano Y, 1998, BRIT J DERMATOL, V139, P504; Urback E, 1941, ARCH DERMATOL SYPH, V43, P366, DOI 10.1001/archderm.1941.01490200148014; VLAGOPOULOS T, 1975, ANN ALLERGY, V34, P366; WANDERER AA, 1979, HOSP PRACT, V14, P136, DOI 10.1080/21548331.1979.11707566; WANDERER AA, 1995, IMMUNOL ALLERGY CLIN, V15, P701; WITHERSPOON FG, 1948, ARCH DERMATOL SYPH, V58, P52, DOI 10.1001/archderm.1948.01520200055007; ZIP CM, 1993, CLIN EXP DERMATOL, V18, P338, DOI 10.1111/j.1365-2230.1993.tb02212.x	40	214	226	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					615	620		10.1067/mai.2001.118790	http://dx.doi.org/10.1067/mai.2001.118790			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590390	Green Accepted, Bronze			2022-12-18	WOS:000171760300023
J	Sanchez-Monge, R; Lombardero, M; Garcia-Selles, FJ; Barber, D; Salcedo, G				Sanchez-Monge, R; Lombardero, M; Garcia-Selles, FJ; Barber, D; Salcedo, G			Lipid-transfer proteins are relevant allergens in fruit allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apple; peach; allergen; lipid-transfer proteins; IgE binding	BIRCH-POLLEN ALLERGEN; MAJOR ALLERGEN; APPLE; IDENTIFICATION; CHERRY; PEACH; IGE; ISOFORMS; PROFILIN; BINDING	Background: Allergy to apple and Prunus fruits is frequently associated with birch pollinosis, with the principal cross-reacting allergens involved being members of the Bet v 1 family. However, a major 13-kd component, nonimmunologically related to Bet v 1, has been implicated as allergen in patients allergic to Prunoideae fruit but not to birch pollen. Objective: We sought to isolate and characterize the 13-kd allergen present in apple and peach. Methods: Sera from patients allergic to both fruits were selected on the basis of clinical symptoms, skin prick tests responses, and specific IgE levels. Allergens were purified by reverse-phase HPLC and characterized by N-terminal amino acid sequencing,MALDI analysis, specific IgE inmunodetection, and immunoblot inhibition assays. Results: A 13-kd protein band was recognized in crude apple and peach extracts by 9 of 10 and 10 of 10 sera from patients allergic to fruit, respectively, The isolation and characterization of the corresponding allergens allowed their identification as lipid-transfer proteins, with a molecular mass of 9058 d for the apple protein and 9138 d for the peach protein. Both purified allergens were recognized by sera from patients allergic to fruit and fully inhibited the IgE binding by the 13-kd component present in the 2 crude fruit extracts. Conclusion: Lipid-transfer proteins are relevant apple and peach allergens and, considering their ubiquitous distribution in tissues of many plant species, could be a novel type of panallergen of fruits and vegetables.	ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; ALK Abello, Madrid, Spain; Hosp Virgen Arrixaca, Dept Alergol, Murcia, Spain	ALK-Abello AS; Hospital Clinico Universitario Virgen de la Arrixaca	Salcedo, G (corresponding author), ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.		Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; COUTOSTHEVENOT P, 1993, EUR J BIOCHEM, V217, P885, DOI 10.1111/j.1432-1033.1993.tb18317.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLEONART R, 1992, ANN ALLERGY, V69, P128; Navarro AM, 1997, ALLERGY, V52, P1144, DOI 10.1111/j.1398-9995.1997.tb00192.x; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; Schoning B, 1996, J SCI FOOD AGR, V71, P475, DOI [10.1002/(SICI)1097-0010(199608)71:4<475::AID-JSFA603>3.3.CO;2-3, 10.1002/(SICI)1097-0010(199608)71:4&lt;475::AID-JSFA603&gt;3.0.CO;2-C]; Toriyama K, 1998, FEBS LETT, V424, P234, DOI 10.1016/S0014-5793(98)00174-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; Vieths S, 1998, SCAND J IMMUNOL, V47, P263; Vieths S, 1996, MONOGR ALLERGY, V32, P63	27	214	218	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				514	519		10.1016/S0091-6749(99)70479-3	http://dx.doi.org/10.1016/S0091-6749(99)70479-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069888				2022-12-18	WOS:000079175700023
J	NIEBER, K; BAUMGARTEN, CR; RATHSACK, R; FURKERT, J; OEHME, P; KUNKEL, G				NIEBER, K; BAUMGARTEN, CR; RATHSACK, R; FURKERT, J; OEHME, P; KUNKEL, G			SUBSTANCE-P AND BETA-ENDORPHIN-LIKE IMMUNOREACTIVITY IN LAVAGE FLUIDS OF SUBJECTS WITH AND WITHOUT ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEUROPEPTIDES; CONCENTRATIONS; BAL; NAL; ALLERGY; RHINITIS; ASTHMA	GUINEA-PIG; AIRWAY EPITHELIUM; SMOOTH-MUSCLE; PEPTIDES; RELEASE; CONTRACTION; NEURONS; LUNG	Six atopic subjects with grass pollen allergy and six nonallergic healthy volunteers were enrolled into this study. Substance P-like immunoreactivity (SP-LIR) and beta-endorphin-like immunoreactivity (betaE-LIR) were determined in bronchoalveolar lavage (BAL) and nasal lavage (NAL) fluids before and after allergen (grass pollen) provocation. A significant increase in the baseline concentration of SP-LIR and betaE-LIR was seen in BAL of allergic subjects. In NAL of allergic subjects an increased baseline concentration of SP-LIR was found (betaE-LIR not detectable). After allergen provocation there was a rise of SP-LIR and betaE-LIR in BAL fluids of allergic subjects immediately after provocation. In NAL fluids of allergic subjects allergen challenge resulted in a rise of SP-LIR within 10 minutes. Allergen provocation did not influence SP-LIR and betaE-LIR concentration in BAL and NAL in nonallergic controls. The demonstrated higher baseline levels of SP-LIR and betaE-LIR as well as the increase after provocation in the BAL and NAL of allergic subjects but not in nonallergic controls support the hypothesis that these neuropeptides contribute to allergic reactions in airways of humans.	FREE UNIV BERLIN,DEPT CLIN IMMUNOL & ASTHMA OPD,UKRV W,AUGUSTENBURGER PL 1,W-1000 BERLIN 65,GERMANY	Free University of Berlin								ABBOTT A, 1988, TIPS, V9, P145; BARNES PJ, 1987, J ALLERGY CLIN IMMUN, V79, P285, DOI 10.1016/0091-6749(87)90143-6; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P113; BARTHO L, 1987, N-S ARCH PHARMACOL, V336, P316; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P97; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; DAY R, 1983, LIFE SCI, V33, P1869, DOI 10.1016/0024-3205(83)90671-9; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FREDERICKSON RCA, 1982, PROG NEUROBIOL, V19, P19, DOI 10.1016/0301-0082(82)90020-X; FULLER RW, 1987, J APPL PHYSIOL, V62, P1473, DOI 10.1152/jappl.1987.62.4.1473; GOLDIE RG, 1990, TRENDS PHARMACOL SCI, V11, P67, DOI 10.1016/0165-6147(90)90320-8; HENNIG R, 1991, IN PRESS J ASTHMA; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; JACOBY DB, 1990, TRENDS PHARMACOL SCI, V11, P393, DOI 10.1016/0165-6147(90)90141-T; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAI YL, 1987, J APPL PHYSIOL, V62, P746, DOI 10.1152/jappl.1987.62.2.746; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LUNDBERG JM, 1984, ACTA PHYSIOL SCAND, V120, P217, DOI 10.1111/j.1748-1716.1984.tb00127.x; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; LUNDBERG JM, 1985, TACHYKININ ANTAGONIS, P159; LUNDBLAD L, 1983, ACTA OTO-LARYNGOL, V96, P485, DOI 10.3109/00016488309132735; MULLER S, 1989, ALLERGOLOGIE S, V12, P70; NIEBER K, 1991, INT ARCH ALLER A IMM, V94, P334, DOI 10.1159/000235397; PETERSSON G, 1989, ANN ALLERGY, V62, P410; POLAK JM, 1986, ARCH INT PHARMACOD T, V280, P16; PUJOL JL, 1989, CLIN EXP ALLERGY, V19, P625, DOI 10.1111/j.1365-2222.1989.tb02757.x; RATHSACK R, 1983, BIOMED BIOCHIM ACTA, V42, P955; SARIA A, 1987, ACTA PHYSIOL HUNG, V69, P421; SODERBERG M, 1988, ALLERGY, V43, P98	31	214	218	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				646	652		10.1016/0091-6749(92)90138-R	http://dx.doi.org/10.1016/0091-6749(92)90138-R			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1383307				2022-12-18	WOS:A1992JT99500011
J	Chen, E; Hanson, MD; Paterson, LQ; Griffin, MJ; Walker, HA; Miller, GE				Chen, Edith; Hanson, Margaret D.; Paterson, Laurel Q.; Griffin, Melissa J.; Walker, Hope A.; Miller, Gregory E.			Socioeconomic status and inflammatory processes in childhood asthma: The role of psychological stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Socioeconomic status; stress; immune; asthma	SOCIAL-CLASS GRADIENTS; ALLERGEN SENSITIZATION; HOSPITALIZATION RATES; AIRWAY INFLAMMATION; ECONOMIC HARDSHIP; CYTOKINE PROFILES; HEALTH; CHILDREN; ADOLESCENTS; EXPRESSION	Background: Although social environment variables such as socioeconomic status (SES) have been linked to childhood asthma, little is known about the psychobiological mechanisms underlying this relationship. Objectives: The goal of this study was to investigate relationships among SES, psychological stress, and immune processes implicated in asthma. Methods: Thirty-seven children ages 9 to 18 years, physician-diagnosed with asthma, and 39 healthy children participated. Families were interviewed about chronic life stress, perceptions of threat, and SES. Blood samples were drawn from children to assess stimulated production of cytokines implicated in asthma (IL-4, IL-5, IL-13) and eosinophil counts. Results: In children with asthma, lower SES was associated with heightened production of IL-5 and IL-13 and higher eosinophil counts (P values <.05). Lower SES also was associated with higher chronic stress and perceived threat (both groups: P values <.05). Higher levels of stress and threat perception were associated with heightened production of IL-5 and IT-13, and higher eosinophil counts in children with asthma (P values <.05). Statistical mediation tests revealed that chronic stress and threat perception represented statistically significant pathways between SES and immune processes in children with asthma (P values <.05). In healthy children, associations were in the opposite direction from the asthma group, though generally not significant. Conclusion: This is one or the first studies to document empirically a psychobiological explanation for the epidemiologic relationship between low SES and poor asthma outcomes. Clinical implications: Associations among SES, psychological stress, and immune pathways suggest that the experience of stress, particularly among lower SES children, has implications for childhood asthma morbidity.	Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Chen, E (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	echen@psych.ubc.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073975] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073975] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Brydon L, 2004, BRAIN BEHAV IMMUN, V18, P281, DOI 10.1016/j.bbi.2003.09.011; Chen E, 2004, CHILD DEV, V75, P1039, DOI 10.1111/j.1467-8624.2004.00724.x; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen E, 2003, HEALTH PSYCHOL, V22, P106, DOI 10.1037/0278-6133.22.1.106; Chen E, 2002, PSYCHOL BULL, V128, P295, DOI 10.1037/0033-2909.128.2.295; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; Cohen S, 2001, LUNG BIOL HEALTH DIS, V154, P193; Cohen S., 1995, MEASURING STRESS GUI, P3; CONGER RD, 1992, CHILD DEV, V63, P526, DOI 10.2307/1131344; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; FINKELHOR D, 1994, PEDIATRICS, V94, P413; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Fries E, 2005, PSYCHONEUROENDOCRINO, V30, P1010, DOI 10.1016/j.psyneuen.2005.04.006; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; HAMMEN C, 1991, J ABNORM PSYCHOL, V100, P555, DOI 10.1037/0021-843X.100.4.555; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139, DOI 10.1016/S0091-6749(99)70005-9; Joachim RA, 2003, PSYCHOSOM MED, V65, P811, DOI 10.1097/01.PSY.0000088582.50468.A3; JUSTER FT, 1999, LABOUR ECON, V0006; Kamfar HZ, 1999, J ASTHMA, V36, P153, DOI 10.3109/02770909909056311; Kang DH, 1997, J INTERF CYTOK RES, V17, P481, DOI 10.1089/jir.1997.17.481; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; LANPHEAR BP, 2001, PEDIATRICS, V107, P1; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; Marshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917; MCLOYD VC, 1990, CHILD DEV, V61, P311, DOI 10.1111/j.1467-8624.1990.tb02781.x; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; Starfield B, 2002, AMBUL PEDIATR, V2, P238, DOI 10.1367/1539-4409(2002)002<0238:SCGAHI>2.0.CO;2; Starfield B, 2002, J EPIDEMIOL COMMUN H, V56, P354, DOI 10.1136/jech.56.5.354; Steptoe A, 2002, BRAIN BEHAV IMMUN, V16, P774, DOI 10.1016/S0889-1591(02)00030-2; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Weiss ST, 1999, CLIN EXP ALLERGY, V29, P96, DOI 10.1046/j.1365-2222.1999.00017.x; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Ying S, 1997, J IMMUNOL, V158, P3539	54	213	216	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1014	1020		10.1016/j.jaci.2006.01.036	http://dx.doi.org/10.1016/j.jaci.2006.01.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	041EM	16675327				2022-12-18	WOS:000237436300007
J	Roberts, G; Lack, G				Roberts, G; Lack, G		Avon Longitudinal Study Parents	Diagnosing peanut allergy with skin prick and specific IgE testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; children; skin prick testing; specific IgE; positive predictive value	FOOD CHALLENGES; CHILDREN	Background: Food allergy is common in childhood. It has been suggested that the magnitude of a skin prick test or specific IgE result can improve diagnostic usefulness, but this has been addressed in only a few tertiary challenge-based studies. Objective: To determine the predictive value of a wheal >= 8 mm or serum specific IgE >= 15 kU(A)/L for clinical allergy and investigate whether results are generalizable. Methods: All subjects, up to 16 years of age, who had been investigated with a peanut or tree nut food challenge were eligible for the study. Subjects were referred from either a tertiary allergy clinic or a community birth cohort. All subjects with a history suggestive of food allergy were offered a challenge unless there were features of anaphylaxis. Details of challenges were prospectively recorded. Results were modeled by using logistic regression. Results: There was a total of 161 peanut challenges. Recent skin prick (longest wheal diameter) and specific IgE data were available for 135 and 136 challenges, respectively. The results suggest that a skin prick result >= 8 mm and a specific IgE >= 15 kU(A)/L have predictive values of 95% (95% CI, 76.2% to 99.9%) and 92.0% (74.0% to 99.0%), respectively, for a positive challenge. Age, the type of nut, and referral pattern of the subject did not appear to alter this relationship. Conclusion: These data suggest that a skin prick result >= 8 mm or a specific IgE >= 15 kU(A)/L have a high predictive value for clinical allergy to peanut and that these cutoff figures appear generalizable to different populations of children undergoing an assessment for peanut allergy.	Imperial Coll St Marys, London, England	Imperial College London	Lack, G (corresponding author), St Marys Hosp, Ground Floor,Praed St, London W2 1NY, England.	gideon.lack@st-marys.nhs.uk		Roberts, Graham/0000-0003-2252-1248; Lack, Gideon/0000-0001-7350-4021	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Hamilton Robert G., 2003, Journal of Allergy and Clinical Immunology, V111, pS687; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P837, DOI 10.1016/S0091-6749(95)70127-3; HELEN S, 2001, J ALLERGY CLIN IMMUN, V107, P367; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219	16	213	219	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1291	1296		10.1016/j.jaci.2005.02.038	http://dx.doi.org/10.1016/j.jaci.2005.02.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940149				2022-12-18	WOS:000229815400029
J	Gervais, FG; Cruz, RPG; Chateauneuf, A; Gale, S; Sawyer, N; Nantel, F; Metters, KM; O'Neill, GP				Gervais, FG; Cruz, RPG; Chateauneuf, A; Gale, S; Sawyer, N; Nantel, F; Metters, KM; O'Neill, GP			Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD(2) receptors CRTH2 and DP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; G-protein-coupled receptor; receptors; CRTH2; DP; PGD(2); chemokinesis; degranulation; apoptosis	PLATELET-ACTIVATING FACTOR; PROSTAGLANDIN D-2; PROSTANOID RECEPTORS; DE-GRANULATION; SURVIVAL; CELLS; IL-5; INTERLEUKIN-5; EXPRESSION; RAT	Background: PGD(2) is the major prostanoid released by mast cells during an allergic response. Its role in the allergic response, however, remains unclear. Objective: Because the accumulation of eosinophils is a feature of allergic reactions, we investigated the role of PGD(2) in the modulation of eosinophil function. Methods: Circulating human eosinophils were isolated and challenged with PGD(2). The effects of PGD(2) on various eosinophil functions were then analyzed. Results: PGD(2) binds with high affinity preferentially to 2 receptors, DP and chemoattractant receptor-homologous molecule expressed on T(H)2 cells (CRTH2). We show that both DP and CRTH2 are detectable on circulating eosinophils. We demonstrate that PGD(2) (1-10 nmol/L) induces a rapid change in human eosinophil morphology and an increase in chemokinesis and promotes eosinophil degranulation. These effects are induced by the CRTH2-selective agonist 13-14-dihydro-15-keto-PGD(2) (DK-PGD(2)) but not by the DP-selective agonist BW245C. These results suggest a role for CRTH2 in the modulation of eosinophil movement and in triggering the release of cytotoxic proteins. Finally, we demonstrate that BW245C, but not DK-PGD(2), can delay the onset of apoptosis in cultured eosinophils, presumably through interaction with DP. Conclusion: These data support the hypothesis that PGD(2) controls eosinophil functions through 2 pharmacologically distinct receptors with independent functions. Blockade of PGD(2)-mediated effects on human eosinophils may reduce the damage caused by these cells during an allergic response, but inhibition of both receptors may be required.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9R 4P8, Canada	Merck & Company	Gervais, FG (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Kirkland, PQ H9R 4P8, Canada.							Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN PM, 1995, PROTEIN EXPRES PURIF, V6, P63, DOI 10.1006/prep.1995.1009; CARLSON M, 1993, ALLERGY, V48, P437; Chang HS, 2000, CELL IMMUNOL, V203, P29, DOI 10.1006/cimm.2000.1668; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; EMERY DL, 1989, J APPL PHYSIOL, V67, P959, DOI 10.1152/jappl.1989.67.3.959; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GOETZL EJ, 1979, ADV INFLAMMAT RES, V14, P157; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MANTOVANI A, 1994, LANCET, V343, P1499, DOI 10.1016/S0140-6736(94)92607-7; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; Schweizer RC, 1996, J LEUKOCYTE BIOL, V59, P347, DOI 10.1002/jlb.59.3.347; STERN M, 1992, J IMMUNOL, V148, P3543; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wright DH, 1999, EUR J PHARMACOL, V377, P101, DOI 10.1016/S0014-2999(99)00358-1; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	33	213	234	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					982	988		10.1067/mai.2001.119919	http://dx.doi.org/10.1067/mai.2001.119919			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742277				2022-12-18	WOS:000172938400015
J	Zimmermann, KC; Green, DR				Zimmermann, KC; Green, DR			How cells die: Apoptosis pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CALIFORNIA	Bayer Biol		apoptosis; caspases; death receptor; mitochondria	CYTOCHROME-C RELEASE; NF-KAPPA-B; CD95-INDUCED APOPTOSIS; CASPASE ACTIVATION; DEATH RECEPTORS; PROTEIN; MITOCHONDRIA; INHIBITION; CLEAVAGE; BCL-2	Generally speaking, there are 2 types of cell death: apoptosis and necrosis. Necrotic cell death is considered an accidental type or death, caused by gross cell injury, and results in the death of groups of cells within a tissue. In contrast, apoptotic cell death may be induced or Is preprogrammed into the cell (eg, during development) and results in the death of the individual cells. Apoptotic cells may be characterized by specific morphologic and biochemical changes orchestrated by a family of cysteine proteases known as caspases. At the molecular level, apoptosis is tightly regulated. There are 2 main pathways to apoptotic cell death. One involves the interaction of a death receptor, such as the TNF receptor-1 or the Fas receptor with its ligand, and the second pathway depends on the participation of mitochondria. Proapoptotic and antipoptotic members or the Bcl-2 family regulate the mitochondrial pathway. The end result of either pathway is caspase activation and the cleavage of specific cellular substrates, resulting in the morphologic and biochemical changes associated with the apoptotic phenotype.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Zimmermann, KC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; COHEN GM, 1994, J IMMUNOL, V153, P507; COTTER TG, 1992, CANCER RES, V52, P997; De Laurenzi V, 2000, NATURE, V406, P135, DOI 10.1038/35018190; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	61	213	224	0	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S99	S103		10.1067/mai.2001.117819	http://dx.doi.org/10.1067/mai.2001.117819			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	487KL	11586274				2022-12-18	WOS:000171874200004
J	Sousa, AR; Lane, SJ; Cidlowski, JA; Staynov, DZ; Lee, TH				Sousa, AR; Lane, SJ; Cidlowski, JA; Staynov, DZ; Lee, TH			Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid receptor alpha and beta; glucocorticoid-resistant asthma	BRONCHIAL-ASTHMA; HORMONE; TRANSCRIPTION; PREDNISOLONE; MODULATION	Background: Glucocorticoid-resistant bronchial asthma is characterized by failure of corticosteroids to suppress key asthma-relevant, cell-mediated inflammatory responses in the airways. Objective: The mechanism of this phenomenon is not clear but may involve aberrant expression of the beta-isoform of the glucocorticoid receptor. Methods: We have measured expression of the alpha- and beta-glucocorticoid receptor isoforms in tuberculin-driven cutaneous cell-mediated inflammatory lesions in people with asthma who are glucocorticoid sensitive and resistant after 9 days of therapy with oral prednisolone (40 mg/day) or matching placebo in a random order, crossover design, Results: After placebo therapy, the mean numbers of cells expressing glucocorticoid receptor alpha immunoreactivity in the lesions evoked in glucocorticoid-sensitive and -resistant patients with asthma were statistically equivalent. The numbers of cells expressing glucocorticoid receptor beta were significantly elevated in the patients who were glucocorticoid resistant, resulting in an 8-fold higher ratio of expression of glucocorticoid receptor alpha/glucocorticoid receptor beta in the patients who were glucocorticoid sensitive. Glucocorticoid receptor alpha/glucocorticoid receptors beta were colocalized to the same cells. Oral prednisolone therapy was associated with a significant decrease in the numbers of cells expressing glucocorticoid receptor alpha but not glucocorticoid receptor beta in the subjects who were glucocorticoid sensitive. No significant change was found in the numbers of cells expressing glucocorticoid receptor alpha and glucocorticoid receptor beta in the patients who were glucocorticoid resistant. Prednisolone therapy reduced the ratio of glucocorticoid receptor alpha/glucocorticoid receptor beta expression for the patients who were glucocorticoid sensitive to a level seen in the patients who were glucocorticoid resistant before therapy. Conclusion: Because glucocorticoid receptor beta inhibits alpha-glucocorticoid receptor-mediated transactivation of target genes, the increased expression of glucocorticoid receptor beta in inflammatory cells might be a critical mechanism for conferring glucocorticoid resistance.	Guys Hosp, Univ London Kings Coll, Dept Resp Med & Allergy, London SE1 9RT, England; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Lee, TH (corresponding author), Guys Hosp, Univ London Kings Coll, Dept Resp Med & Allergy, 5th Floor Thomas Guy House, London SE1 9RT, England.		Cidlowski, John A/G-2548-2019; Lee, Tak/AAA-9526-2020	Cidlowski, John A/0000-0003-1420-0516; Lee, Tak/0000-0002-7554-4059				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, J IMMUNOL, V154, P3500; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Korn SH, 1997, AM J RESP CRIT CARE, V155, P1117, DOI 10.1164/ajrccm.155.3.9116996; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lane SJ, 1996, AM J RESP CRIT CARE, V154, pS49, DOI 10.1164/ajrccm/154.2_Pt_2.S49; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Sousa AR, 1996, J ALLERGY CLIN IMMUN, V97, P698, DOI 10.1016/S0091-6749(96)70317-2; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	20	213	227	6	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					943	950		10.1067/mai.2000.106486	http://dx.doi.org/10.1067/mai.2000.106486			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808175				2022-12-18	WOS:000087185000013
J	ALLEN, DB; MULLEN, ML; MULLEN, B				ALLEN, DB; MULLEN, ML; MULLEN, B			A METAANALYSIS OF THE EFFECT OF ORAL AND INHALED CORTICOSTEROIDS ON GROWTH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; INHALED CORTICOSTEROIDS; GROWTH; STEROID-DEPENDENT ASTHMA	BECLOMETHASONE DIPROPIONATE AEROSOL; LONG-TERM TREATMENT; ASTHMATIC-CHILDREN; CHILDHOOD ASTHMA; THERAPY; BUDESONIDE	This analysis summarizes studies comparing attained heights with expected heights of children with asthma treated with inhaled or oral corticosteroids. The possible moderating effects of treatment duration, and dosage and asthma severity are also examined. A preliminary database of 95 articles rendered 21 includable studies representing 810 patients with asthma, which yielded 29 tests of the corticosteroid-growth effect. Statistical integration of the results of these studies revealed a significant but small tendency for corticosteroid-growth effect. Statistical integration of the results of these studies revealed a significant but small tendency for corticosteroid therapy in general to be associated with diminished final height (Z = 2.328, p = 0.01, mean r = -0.023). However, this effect varied for the specific drugs under consideration. As expected significant weak growth impairment was observed for prednisone (Z = 2.137, p = 0.0164, mean r = -0.295) and ''other oral corticosteriods'' (Z = 9.107, p = 2.44E-18, mean r = -0.260). On the other hand, a significant moderate tendency was observed for inhaled beclomethasone dipropionate therapy to be associated with attaining normal stature (Z = 7.395, p = 2.17E-13, mean r = +0.43). There was no statistical evidence for beclomethasone diproprionate therapy to be associated with growth impairment at higher doese, for longer therapy durations, or among patients with more severe asthma. This meta-analytic integration indicated that available studies of inhaled beclomethasone dipropionate therapy do not show an association between its use and the adverse effect of diminshed stature.	UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI USA; SCI SOLUT INC, FAYETTEVILLE, AR USA	University of Wisconsin System; University of Wisconsin Madison								ALLEN DB, 1993, ALLERGY PRINCIPLES P, P6; BAGER B, 1977, SCANDINAVIAN J RES S, V101, P189; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BARAN D, 1987, BRIT J DIS CHEST, V81, P170, DOI 10.1016/0007-0971(87)90135-5; BHAN GL, 1980, LANCET, V1, P96; BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402; BROWN HM, 1980, PRACTITIONER, V224, P847; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; DELACOURT C, 1991, EUR RESPIR J S14, V4, pS593; DOUGLASS JA, 1990, MED J AUSTRALIA, V152, P475, DOI 10.5694/j.1326-5377.1990.tb125307.x; Dutau G, 1978, Poumon Coeur, V34, P247; EAGLY AH, 1981, PSYCHOL BULL, V90, P1, DOI 10.1037/0033-2909.90.1.1; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; FISHER RA, 1932, STATISTICAL METHODS; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; FRIEDMAN M, 1974, POSTGRAD MED J, V50, P33; Glass G.V., 1976, ED RES, V5, P3, DOI [10.3102/0013189X005010003, DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; GWYNN C M, 1974, Clinical Allergy, V4, P325, DOI 10.1111/j.1365-2222.1974.tb01393.x; HOLLMAN GA, 1988, PEDIATRICS, V81, P452; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; KUZEMKO JA, 1974, POSTGRAD MED J, V50, P38; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAW CM, 1986, LANCET, V1, P942; Maccoby E.E., 1978, PSYCHOL SEX DIFFEREN, V2; MAXWELL DL, 1990, BIOMED PHARMACOTHER, V44, P421, DOI 10.1016/0753-3322(90)90047-D; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; MELTZER EO, 1982, PEDIATRICS, V69, P340; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; MULLEN B, 1988, BRIT J SOC PSYCHOL, V27, P333, DOI 10.1111/j.2044-8309.1988.tb00836.x; MULLEN B, 1989, ADV BASIC META ANAL; MULLEN B, 1991, RES METHODS SOCIAL R, P425; MULLEN B, 1985, BASIC METAANALYSIS P; Pearson K, 1933, BIOMETRIKA, V25, P379, DOI 10.1093/biomet/25.3-4.379; PRIFTIS K, 1990, ARCH DIS CHILD, V65, P838, DOI 10.1136/adc.65.8.838; REED CE, 1991, J ALLERGY CLIN IMMUN, V87, P202; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; Rosenthal R., 1991, METAANALYTIC PROCEDU, DOI [10.2307/1175262, DOI 10.2307/1175262]; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SIEGEL S, 1956, NONPARAMETRIC STAT, P42; SMITH JM, 1965, ANN ALLERGY, V23, P492; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403; TARADA J, 1981, JPN PHARMACOL THER, V9, P1607; TARLO SM, 1988, CHEST, V93, P998, DOI 10.1378/chest.93.5.998; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; Thorndike RL, 1933, J EDUC PSYCHOL, V24, P543, DOI 10.1037/h0070255; VALENTINE MD, 1976, J PEDIATR-US, V89, P827, DOI 10.1016/S0022-3476(76)80817-7; VANMETRE TE, 1960, J ALLERGY, V31, P531, DOI 10.1016/0021-8707(60)90088-5; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; WESTPHAL O, 1968, ACTA PAEDIATR SCAND, V182, P56; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; 1991, GUIDELINES DIAGNOSIS	55	213	218	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					967	976		10.1016/S0091-6749(94)70043-5	http://dx.doi.org/10.1016/S0091-6749(94)70043-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006318				2022-12-18	WOS:A1994NT17200003
J	Palmer, DJ; Metcalfe, J; Makrides, M; Gold, MS; Quinn, P; West, CE; Loh, R; Prescott, SL				Palmer, Debra J.; Metcalfe, Jessica; Makrides, Maria; Gold, Michael S.; Quinn, Patrick; West, Christina E.; Loh, Richard; Prescott, Susan L.			Early regular egg exposure in infants with eczema: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; complementary feeding; eczema; egg; food allergy; oral tolerance; randomized controlled trial	ORAL IMMUNOTHERAPY; ALLERGIC DISEASES; FISH; CHILDREN; SENSITIZATION; CHALLENGE; ASTHMA; RISK; LIFE	Background: Observational studies suggest that early regular ingestion of allergenic foods might reduce the risk of food allergy. Objective: We sought to determine whether early regular oral egg exposure will reduce subsequent IgE-mediated egg allergy in infants with moderate-to-severe eczema. Methods: In a double-blind, randomized controlled trial infants were allocated to 1 teaspoon of pasteurized raw whole egg powder (n = 49) or rice powder (n = 37) daily from 4 to 8 months of age. Cooked egg was introduced to both groups after an observed feed at 8 months. The primary outcome was IgE-mediated egg allergy at 12 months, as defined based on the results of an observed pasteurized raw egg challenge and skin prick tests. Results: A high proportion (31% [15/49]) of infants randomized to receive egg had an allergic reaction to the egg powder and did not continue powder ingestion. At 4 months of age, before any known egg ingestion, 36% (24/67) of infants already had eggspecific IgE levels of greater than 0.35 kilounits of antibody (kUA)/L. At 12 months, a lower (but not significant) proportion of infants in the egg group (33%) were given a diagnosis of IgE-mediated egg allergy compared with the control group (51%; relative risk, 0.65; 95% CI, 0.38-1.11; P 5.11). Egg-specific IgG4 levels were significantly (P <.001) greater in the egg group at both 8 and 12 months. Conclusion: Induction of immune tolerance pathways and reduction in egg allergy incidence can be achieved by early regular oral egg exposure in infants with eczema. Caution needs to be taken when these high-risk infants are first exposed to egg because many have sensitization already by 4 months of age.	[Palmer, Debra J.; Metcalfe, Jessica; West, Christina E.; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Palmer, Debra J.; Makrides, Maria] Womens & Childrens Hlth Res Inst, Adelaide, SA, Australia; [Makrides, Maria; Gold, Michael S.] Univ Adelaide, Sch Paediat & Reprod Hlth, Children Youth & Womens Hlth Serv, Adelaide, SA, Australia; [Quinn, Patrick] Children Youth & Womens Hlth Serv, Adelaide, SA, Australia; [West, Christina E.] Umea Univ, Dept Clin Sci, S-90187 Umea, Sweden; [Loh, Richard; Prescott, Susan L.] Princess Margaret Hosp, Dept Immunol, Perth, WA, Australia	University of Western Australia; Womens & Childrens Hospital Australia; University of Adelaide; Umea University	Palmer, DJ (corresponding author), Univ Western Australia M561, Sch Paediat & Child Hlth, 35 Stirling Highway, Crawley, WA 6009, Australia.	debbie.palmer@uwa.edu.au	Palmer, Debra/AAH-6160-2019; Palmer, Debra J/L-8554-2013; Makrides, Maria/B-6392-2014; Prescott, Susan/H-5665-2014	Palmer, Debra J/0000-0003-2498-8343; Makrides, Maria/0000-0003-3832-541X; West, Christina/0000-0001-9599-2580	Women's and Children's Hospital Foundation; Ilhan Food Allergy Foundation	Women's and Children's Hospital Foundation; Ilhan Food Allergy Foundation	Supported by a grant from the Women's and Children's Hospital Foundation and a grant from the Ilhan Food Allergy Foundation.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; Baker SS, 2000, PEDIATRICS, V106, P346; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Hesselmar B, 2010, ACTA PAEDIATR, V99, P1861, DOI 10.1111/j.1651-2227.2010.01939.x; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Jurado-Palomo J, 2010, INT ARCH ALLERGY IMM, V151, P331, DOI 10.1159/000250441; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Martino DJ, 2012, ALLERGY, V67, P191, DOI 10.1111/j.1398-9995.2011.02737.x; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618, DOI 10.5694/j.1326-5377.2007.tb01077.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Smith KM, 2000, AM J RESP CRIT CARE, V162, pS175, DOI 10.1164/ajrccm.162.supplement_3.15tac7; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Virtanen SM, 2010, BRIT J NUTR, V103, P266, DOI 10.1017/S0007114509991541; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	25	212	216	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					387	+		10.1016/j.jaci.2013.05.002	http://dx.doi.org/10.1016/j.jaci.2013.05.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23810152	Green Published			2022-12-18	WOS:000322631700016
J	Marks, GB; Mihrshahi, S; Kemp, AS; Tovey, ER; Webb, K; Almqvist, C; Ampon, RD; Crisafulli, D; Belousova, EG; Mellis, CM; Peat, JK; Leeder, SR				Marks, Guy B.; Mihrshahi, Seema; Kemp, Andrew S.; Tovey, Euan R.; Webb, Karen; Almqvist, Catarina; Ampon, Rosario D.; Crisafulli, Daniel; Belousova, Elena G.; Mellis, Craig M.; Peat, Jennifer K.; Leeder, Stephen R.		Childhood Asthma Prevention Study	Prevention of asthma during the first 5 years of life: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; omega-3 fatty acids; prevention; birth cohort; house dust mite	DUST-MITE ALLERGEN; FATTY-ACID MODIFICATION; CHILDHOOD ASTHMA; MATTRESS ENCASINGS; ATOPIC ECZEMA; PREVALENCE; CHILDREN; SYMPTOMS; EXPOSURE; OUTCOMES	Background: Early life exposures may be important in the development of asthma and allergic disease. Objective: To test house dust mite (HDM) avoidance and dietary fatty acid modification, implemented throughout the first 5 years of life, as interventions to prevent asthma and allergic disease. Methods: We recruited newborns with a family history of asthma antenatally and randomized them, separately, to HDM avoidance or control and to dietary modification or control. At age 5 years, they were assessed for asthma and eczema and had skin prick tests for atopy. Results: Of 616 children randomized, 516 (84%) were evaluated at age 5 years. The HDM avoidance intervention resulted in a 61% reduction in HDM allergen concentrations (mu g/g dust) in the child's bed but no difference in the prevalence of asthma, wheeze, or atopy (P > .1). The prevalence of eczema was higher in the active HDM avoidance group (26% vs 19%; P = .06). The ratio of omega-6 to omega-3 fatty acids in plasma was lower in the active diet group (5.8 vs 7.4; P < .0001). However, the prevalence of asthma, wheezing, eczema, or atopy did not differ between the diet groups (P > .1). Conclusion: Further research is required to establish whether other interventions can be recommended for the prevention of asthma and allergic disease. Clinical implications: House dust mite avoidance measures and dietary fatty acid modification, as implemented in this trial during infancy and early childhood, did not prevent the onset of asthma, eczema, or atopy in high-risk children.	Woolcock Inst Med Res, Camperdown, NSW 2050, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Childrens Hosp, Westmead, NSW, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; University of Sydney	Marks, GB (corresponding author), Woolcock Inst Med Res, POB M77,Missenden Rd PO, Camperdown, NSW 2050, Australia.	g.marks@unsw.edu.au	Tovey, Euan R/G-8604-2017; Mihrshahi, Seema/A-9877-2009; Marks, Guy B./F-5058-2013; Mihrshahi, Seema/AAW-1854-2020	Tovey, Euan R/0000-0002-1802-7266; Mihrshahi, Seema/0000-0001-6567-9884; Marks, Guy B./0000-0002-8976-8053; Mihrshahi, Seema/0000-0002-2394-5432				Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; MENEGHINI CL, 1982, CONTACT DERMATITIS, V8, P285, DOI 10.1111/j.1600-0536.1982.tb04231.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2003, ALLERGY, V58, P784, DOI 10.1034/j.1398-9995.2003.00194.x; Mihrshahi S, 2002, RESPIROLOGY, V7, P147, DOI 10.1046/j.1440-1843.2002.00384.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; Tovey ER, 2003, NEW ENGL J MED, V349, P1669; Tovey ER, 2003, ALLERGY, V58, P790, DOI 10.1034/j.1398-9995.2003.00228.x; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Warner JO, 1998, PEDIATR PULM, V25, P1; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	35	212	217	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					53	61		10.1016/j.jaci.2006.04.004	http://dx.doi.org/10.1016/j.jaci.2006.04.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815138				2022-12-18	WOS:000239184800006
J	Friedman, NJ; Zeiger, RS				Friedman, NJ; Zeiger, RS			The role of breast-feeding in the development of allergies and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breast-feeding; asthma; atopic dermatitis; food allergy; allergy prevention	COWS MILK PROTEIN; ATOPIC DISEASE; FED INFANTS; HIGH-RISK; BETA-LACTOGLOBULIN; MATERNAL AVOIDANCE; IMMUNOGLOBULIN-E; EARLY-CHILDHOOD; ANTIBIOTIC USE; BIRTH COHORT	Breast-feeding is the preferred method of infant nutrition for numerous reasons. However, its role in the prevention of allergic disease remains controversial. Reasons for this controversy include methodological differences and flaws in the studies performed to date, the immunologic complexity of breast milk itself and, possibly, genetic differences among patients that would affect whether breast-feeding is protective against the development of allergies or is in fact sensitizing. The preponderance of evidence does suggest, however, that there would be much to lose by not recommending breast-feeding. In general, studies reveal that infants fed formulas of intact cow's milk or soy protein compared with breast milk have a higher incidence of atopic dermatitis and wheezing illnesses in early childhood. Consistent with these findings, exclusive breast-feeding should be encouraged for at least 4 to 6 months in infants at both high and low risk of atopy and irrespective of a history of maternal asthma.	So Calif Permanente Med Grp, San Diego, CA 92120 USA; Univ Calif San Diego, San Diego, CA 92103 USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of California System; University of California San Diego	Friedman, NJ (corresponding author), 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	noah.j.friedman@kp.org		Zeiger, Robert/0000-0001-5788-5063				Baker SS, 2000, PEDIATRICS, V106, P346; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes KC, 2000, ALLERGY, V55, P803, DOI 10.1034/j.1398-9995.2000.00123.x; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; Bottcher MF, 2000, PEDIATR RES, V47, P157, DOI 10.1203/00006450-200001000-00026; BUSINCO L, 1989, ANN ALLERGY, V62, P333; CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; Casas R, 2000, J ALLERGY CLIN IMMUN, V105, P1236, DOI 10.1067/mai.2000.105805; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; Dandrifosse G, 2000, P NUTR SOC, V59, P81, DOI 10.1017/S0029665100000100; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Duchen K, 2000, PEDIAT ALLERG IMM-UK, V11, P29, DOI 10.1034/j.1399-3038.2000.00052.x; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; FRIEDMAN NJ, 2003, PEDIAT ALLERGY PRINC, P496; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; GORDON RR, 1982, LANCET, V1, P72; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Hattevig G, 1999, ACTA PAEDIATR, V88, P7, DOI 10.1080/080352599750029268; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; HIDE DW, 1985, PEDIATRICS, V76, P973; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; KRAMER MS, 2000, COCHRANE DB SYST REV; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Labeta MO, 2000, J EXP MED, V191, P1807, DOI 10.1084/jem.191.10.1807; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; LIFSCHITZ CH, 1988, J PEDIATR GASTR NUTR, V7, P141, DOI 10.1097/00005176-198801000-00026; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oddy WH, 2003, ARCH DIS CHILD, V88, P224, DOI 10.1136/adc.88.3.224; OLDAEUS G, 1992, J ALLERGY CLIN IMMUN, V90, P133; Openshaw PJM, 2000, AM J RESP CRIT CARE, V162, pS40, DOI 10.1164/ajrccm.162.supplement_1.maic-11; Osborn DA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Osterlund P, 2004, PEDIATR RES, V55, P296, DOI 10.1203/01.PDR.0000106315.00474.6F; Peat JK, 2003, PEDIATR PULM, V35, P331, DOI 10.1002/ppul.10276; PLEHANI A, 1997, CLIN EXP ALLERGY, V27, P949; Pollard C., 1996, Journal of Allergy and Clinical Immunology, V97, P240, DOI 10.1016/S0091-6749(96)80449-0; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Saarinen KM, 2000, ADV EXP MED BIOL, V478, P121; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1979, LANCET, V2, P163; SAMPSON HA, 1992, PEDIATRICS, V90, P463; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; Sears MR, 2003, PEDIATR PULM, V36, P366, DOI 10.1002/ppul.10374; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Shek LPC, 2001, ALLERGY, V56, P749, DOI 10.1034/j.1398-9995.2001.056008749.x; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TRONCONE R, 1987, ACTA PAEDIATR SCAND, V76, P453, DOI 10.1111/j.1651-2227.1987.tb10498.x; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Wetzig H, 2000, INT J HYG ENVIR HEAL, V203, P17, DOI 10.1078/S1438-4639(04)70003-6; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	84	212	230	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1238	1248		10.1016/j.jaci.2005.01.069	http://dx.doi.org/10.1016/j.jaci.2005.01.069			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940141				2022-12-18	WOS:000229815400021
J	Menzies-Gow, A; Flood-Page, P; Sehmi, R; Burman, J; Hamid, Q; Robinson, DS; Kay, AB; Denburg, J				Menzies-Gow, A; Flood-Page, P; Sehmi, R; Burman, J; Hamid, Q; Robinson, DS; Kay, AB; Denburg, J			Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil progenitors; bone marrow; asthma; anti-IL-5	INTERLEUKIN-5; DIFFERENTIATION; EXPRESSION; PROLIFERATION; ANTIBODY; BLOOD; CELLS	Background: Eosinophils develop from CD34(+) progenitors under the influence of IL-5. Atopic asthmatic individuals have increased numbers of mature eosinophils and eosinophil progenitors within their bone marrow and bronchial mucosa. We have previously reported that anti-IL-5 monoclonal antibody treatment decreases total bone marrow and bronchial mucosal eosinophil numbers in asthma. Objective: Using an anti-IL-5 monoclonal antibody, we examined the role of IL-5 in eosinophil development within the bone marrow and bronchial mucosa in asthma. Methods: Blood, bone marrow, and airway mucosal biopsy specimens were examined before and after anti-IL-5 (mepolizumab) treatment of asthmatic individuals in a double-blind, placebo-controlled trial. Numbers of mature and immature eosinophils were measured by histologic stain (bone marrow myelocytes, metamyelocytes, and mature eosinophils), flow cytometry (bone marrow and blood CD34(+)/IL-5Ralpha(+) cells), enumeration of bone marrow-derived eosinophil/basophil colony-forming units in methylcellulose culture, and sequential immunohistochemistry and in situ hybridization (bronchial mucosal CD34(+)/IL-5Ralpha mRNA(+) cells). Results: Mepolizumab decreased mature eosinophil numbers in the bone marrow by 70% (P = .017) in comparison with placebo and decreased numbers of eosinophil myelocytes and metamyelocytes by 37% (P = .006) and 44% (P = .003), respectively. However, mepolizumab had no effect on numbers of blood or bone marrow CD34(+), CD34(+)/IL-5Ra(+) cells, or eosinophil/basophil colony-forming units. There was a significant decrease in bronchial mucosal CD34(+)/IL-5Ralpha mRNA(+) c ell numbers in the anti-IL-5 treated group (P = .04). Conclusion: These data suggest that anti-IL-5 therapy might induce partial maturational arrest of the eosinophil lineage in the bone marrow. The reduction in airway CD34(+)/IL-5 mRNA(+) cell numbers suggests that IL-5 might also be required for local tissue eosinophilopoiesis.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London, England; St Josephs Hosp, Firestone Inst Resp Hlth, Hamilton, ON, Canada; Royal Brompton & Harefield NHS Trust, Dept Haematol, London, England; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	McMaster University; Imperial College London; McGill University; McMaster University; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; McGill University	Denburg, J (corresponding author), McMaster Univ, Dept Med, HSC 3V46,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 2002, TRENDS MOL MED, V8, P162, DOI 10.1016/S1471-4914(02)02302-X; Hashida R, 2001, INT ARCH ALLERGY IMM, V125, P2, DOI 10.1159/000053843; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; OGAWA M, 1993, BLOOD, V81, P2844; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; Saito H, 2002, J IMMUNOL, V168, P3017, DOI 10.4049/jimmunol.168.6.3017; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; SEHMI R, 1992, BLOOD, V79, P2952; Sehmi R, 2001, J ALLERGY CLIN IMMUN, V107, pS324; STEINBACH KH, 1979, BLUT, V39, P27, DOI 10.1007/BF01008072; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Zeibecoglou K, 1999, J ALLERGY CLIN IMMUN, V103, P99, DOI 10.1016/S0091-6749(99)70532-4	26	212	218	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					714	719		10.1067/mai.2003.1382	http://dx.doi.org/10.1067/mai.2003.1382			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704348				2022-12-18	WOS:000182258500007
J	CLUZEL, M; DAMON, M; CHANEZ, P; BOUSQUET, J; DEPAULET, AC; MICHEL, FB; GODARD, P				CLUZEL, M; DAMON, M; CHANEZ, P; BOUSQUET, J; DEPAULET, AC; MICHEL, FB; GODARD, P			ENHANCED ALVEOLAR CELL LUMINOL-DEPENDENT CHEMILUMINESCENCE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ARNOUX B, 1982, AM REV RESPIR DIS, V125, pA70; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BANNISTER WH, 1980, BIOL CLIN ASPECTS B, V11; BIGGAR WD, 1976, INFECT IMMUN, V14, P6, DOI 10.1128/IAI.14.1.6-10.1976; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOYER LA, 1979, BLOOD, V53, P486; BROWN K, 1980, ACTA PHYSL SCAND S, V492, P9; BURMAN WJ, 1986, CHEST, V89, P410, DOI 10.1378/chest.89.3.410; CADENAS E, 1981, FEBS LETT, V123, P225, DOI 10.1016/0014-5793(81)80293-1; DALHEN SE, 1980, NATURE, V288, P484; DAMON M, 1983, BIOCHEM BIOPH RES CO, V111, P518, DOI 10.1016/0006-291X(83)90337-6; DECHATELET LR, 1975, J INFECT DIS, V131, P443, DOI 10.1093/infdis/131.4.443; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUROUX P, 1982, AM REV RESPIR DIS, V125, pA70; DYER RM, 1983, INFLAMMATION, V7, P169, DOI 10.1007/BF00917821; FELDS ADS, 1982, P NATL ACAD SCI USA, V79, P7866; FORMAN HJ, 1980, J BIOL CHEM, V255, P9879; FOX RB, 1981, AM REV RESPIR DIS, V123, P521; FRANK L, 1980, AM J MED, V69, P177; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GODARD P, 1981, NOUV PRESSE MED, V10, P3141; GODARD P, 1985, American Review of Respiratory Disease, V131, pA38; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GREENING AP, 1983, CLIN SCI, V65, P661, DOI 10.1042/cs0650661; HOIDAL JR, 1978, J LAB CLIN MED, V92, P787; HOLROYDE MC, 1981, LANCET, V2, P17; HSUEH W, 1979, AM J PATHOL, V97, P137; JOHNSTON RB, 1978, J EXP MED, V148, P115; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; KIJLSTRA A, 1980, IMMUNOLOGY, V41, P237; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KONG S, 1981, BIOCHIM BIOPHYS ACTA, V640, P313, DOI 10.1016/0005-2736(81)90555-1; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MCCORD JM, 1982, PATHOLOGY OXYGEN, P75; NATHAN CF, 1982, FED PROC, V41, P2206; PAPERMASTERBENDER G, 1980, J RETICULOENDOTH SOC, V28, P129; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHRAUFSTATTER I, 1984, FED PROC, V43, P2807; SELVARAJ RJ, 1982, J RETICULOENDOTH SOC, V31, P3; SHULT PA, 1986, J ALLERGY CLIN IMMUN, V77, P702, DOI 10.1016/0091-6749(86)90414-8; TONNEL AB, 1986, AM REV RESPIR DIS, V133, pA213; TONNEL AB, 1983, J CLIN INVEST, V71, P221; TONNEL AB, 1985, TRAITEMENT ASTHME, P21; WILLIAMS AJ, 1981, J CLIN PATHOL, V34, P167, DOI 10.1136/jcp.34.2.167; WILLIAMS AJ, 1981, THORAX, V36, P866, DOI 10.1136/thx.36.11.866; YAMAGUCHI T, 1980, J BIOCHEM-TOKYO, V87, P1449, DOI 10.1093/oxfordjournals.jbchem.a132886; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405; 1975, CHEST, V63, P383	54	212	212	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					195	201		10.1016/0091-6749(87)90129-1	http://dx.doi.org/10.1016/0091-6749(87)90129-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611540				2022-12-18	WOS:A1987J657500011
J	Quinti, I; Lougaris, V; Milito, C; Cinetto, F; Pecoraro, A; Mezzaroma, I; Mastroianni, CM; Turriziani, O; Bondioni, MP; Filippini, M; Soresina, A; Spadaro, G; Agostini, C; Carsetti, R; Plebani, A				Quinti, Isabella; Lougaris, Vassilios; Milito, Cinzia; Cinetto, Francesco; Pecoraro, Antonio; Mezzaroma, Ivano; Mastroianni, Claudio Maria; Turriziani, Ombretta; Bondioni, Maria Pia; Filippini, Matteo; Soresina, Annarosa; Spadaro, Giuseppe; Agostini, Carlo; Carsetti, Rita; Plebani, Alessandro			A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Quinti, Isabella; Milito, Cinzia; Turriziani, Ombretta] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Mezzaroma, Ivano] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy; [Mastroianni, Claudio Maria] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Bondioni, Maria Pia] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy; [Filippini, Matteo] 2nd Div Anesthesia & ICU, Brescia, Italy; [Soresina, Annarosa] Paediat Unit, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] ASST Spedali Civili Brescia, Brescia, Italy; [Cinetto, Francesco; Agostini, Carlo] Univ Padua, Dept Med, Padua, Italy; [Cinetto, Francesco; Agostini, Carlo] Ca Foncello Hosp, Internal Med 1, Treviso, Italy; [Pecoraro, Antonio; Spadaro, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Carsetti, Rita] Bambino Gesu Pediat Hosp, Diagnost Immunol Unit, Dept Labs, Cell Pathophysiol Unit B,Immunol Res Area, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; University of Brescia; University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Padua; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso; University of Naples Federico II; IRCCS Bambino Gesu	Quinti, I (corresponding author), Sapienza Univ Rome, Dept Mol Med, Rome, Italy.	isabella.quinti@uniroma1.it	Carrabba, Maria/AAM-5651-2020; Cinetto, Francesco/AAE-5328-2019; Cinetto, Francesco/J-7386-2018	Carrabba, Maria/0000-0002-0717-9096; Cinetto, Francesco/0000-0001-8486-5850; Cinetto, Francesco/0000-0001-8486-5850; Filippini, Matteo/0000-0003-0023-6710; Ziyadullaev, Shukhrat/0000-0002-9309-3933				Arkatkar T, 2017, J EXP MED, V214, P3207, DOI 10.1084/jem.20170580; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Cron RQ, 2020, J RHEUMATOL, V47, P639, DOI 10.3899/jrheum.200334; Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387; Grimsholm O, 2020, CELL REP, V30, P2963, DOI 10.1016/j.celrep.2020.02.022; Jones TPW, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2049; Lougaris V, 2020, J ALLERGY CLIN IMMUN, V6749, P30330; Pecoraro Antonio, 2019, Clin Mol Allergy, V17, P9, DOI 10.1186/s12948-019-0113-3; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004	9	211	220	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					211	+		10.1016/j.jaci.2020.04.013	http://dx.doi.org/10.1016/j.jaci.2020.04.013			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32333914	Green Published, hybrid			2022-12-18	WOS:000579170500032
J	Ege, MJ; Frei, R; Bieli, C; Schram-Bijkerk, D; Waser, M; Benz, MR; Weiss, G; Nyberg, F; van Hage, M; Pershagen, G; Brunekreef, B; Riedler, J; Lauener, R; Braun-Fahrlander, C; von Mutius, E				Ege, Markus Johannes; Frei, Remo; Bieli, Christian; Schram-Bijkerk, Dieneke; Waser, Marco; Benz, Marcus R.; Weiss, Gertraud; Nyberg, Fredrik; van Hage, Marianne; Pershagen, Goeran; Brunekreef, Bert; Riedler, Josef; Lauener, Roger; Braun-Fahrlaender, Charlotte; von Mutius, Erika		PARSIFAL Study team	Not all farming environments protect against the development of asthma and wheeze in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheeze; atopic sensitization; farming; microbial components	SCHOOL-AGE-CHILDREN; ALLERGIC DISEASES; FARMERS CHILDREN; HAY-FEVER; ATOPIC SENSITIZATION; LIFE-STYLE; HOUSE DUST; PREVALENCE; EXPOSURE; DEOXYNIVALENOL	Background: In recent years, studies have shown a protective effect of being raised in a farm environment on the development of hay fever and atopic sensitization. Inconsistent data on the relation of farming to asthma and wheeze have raised some doubt about a true protective effect. Objective: We sought to study the differential effects of farm-associated exposures on specific asthma-related health outcomes. Methods: The cross-sectional Prevention of Allergy Risk Factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle study included 8263 school-age children from rural areas in 5 European countries. Information on farm-related exposures and health outcomes was obtained by using questionnaires. In subsamples allergen-specific IgE and RNA expression of CD14 and Toll-like receptor genes were measured, and dust from children's mattresses was evaluated for microbial components. Results: Inverse relations with a diagnosis of asthma were found for pig keeping (odds ratio [OR], 0.57; 95% CI, 0.38-0.86), farm milk consumption (OR, 0.77; 95% CI, 0.60-0.99), frequent stay in animal sheds (OR, 0.71; 95% CI, 0.54-0.95), child's involvement in haying (OR, 0.56; 95% CI, 0.38-0.81), and use of silage (OR, 0.55; 95% CI, 0.31-0.98; for nonatopic asthma) and in Germany for agriculture (OR, 0.34; 95% CI, 0.22-0.53). Protective factors were related with higher expression levels of genes of the innate immunity. Potential risk factors for asthma and wheeze were also identified in the farm milieu. Levels of endotoxin and extracellular polysaccharides were related to the health outcomes independently of the farm exposures. Conclusions: The protective effect of being raised in a farm environment was ascribed to distinct exposures. Clinical implications: The development of atopic sensitization and atopic and nonatopic asthma is most likely determined by different environmental factors, possibly reflecting distinct pathomechanisms.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Utrecht, Med Ctr, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands; Childrens Hosp, Salzburg, Austria; AstraZeneca R&D, Molndal, Sweden; Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Childrens Hosp, Stockholm, Sweden	University of Munich; University of Basel; Utrecht University; Utrecht University; AstraZeneca; Karolinska Institutet; Karolinska Institutet	Ege, MJ (corresponding author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-803371 Munich, Germany.	markus.ege@med.uni-muenchen.de	riedler, josef/AAQ-4666-2020; van Hage, Marianne/A-9678-2017; Lauener, Roger P/O-8612-2016; Ege, Markus/C-1962-2012; Frei, Remo/AAI-9180-2020; Bieli, Christian/F-7209-2014	van Hage, Marianne/0000-0003-3091-1596; Lauener, Roger P/0000-0002-8412-606X; Ege, Markus/0000-0001-6643-3923; brunekreef, bert/0000-0001-9908-0060; Bieli, Christian/0000-0002-2128-6082; Pershagen, Goran/0000-0002-9701-1130; von Mutius, Erika/0000-0002-8893-4515; Nyberg, Fredrik/0000-0003-0892-5668				Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Pestka J, 2006, TOXICOL SCI, V92, P445, DOI 10.1093/toxsci/kfl012; Pestka JJ, 2005, J TOXICOL ENV HEAL B, V8, P39, DOI 10.1080/10937400590889458; Pestka JJ, 2004, TOXICOL LETT, V153, P61, DOI 10.1016/j.toxlet.2004.04.023; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2003, OCCUP ENVIRON MED, V60, P770, DOI 10.1136/oem.60.10.770; Remes ST, 2005, CLIN EXP ALLERGY, V35, P160, DOI 10.1111/j.1365-2222.2005.02172.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Roussel S, 2005, ANN AGR ENV MED, V12, P217; Roussel S, 2004, OCCUP ENVIRON MED, V61; Schneweis I, 2000, APPL ENVIRON MICROB, V66, P3639, DOI 10.1128/AEM.66.8.3639-3641.2000; Schollenberger M, 2006, MYCOPATHOLOGIA, V161, P43, DOI 10.1007/s11046-005-0199-7; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wagner M, 2005, J VET MED B, V52, P278, DOI 10.1111/j.1439-0450.2005.00866.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; WASER M, 2007, IN PRESS ALLERGY; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Yeung VP, 1998, J IMMUNOL, V161, P4146	41	211	214	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1140	1147		10.1016/j.jaci.2007.01.037	http://dx.doi.org/10.1016/j.jaci.2007.01.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17349684				2022-12-18	WOS:000246427200014
J	Cohen, BL; Noone, S; Munoz-Furlong, A; Sicherer, SH				Cohen, BL; Noone, S; Munoz-Furlong, A; Sicherer, SH			Development of a questionnaire to measure quality of life in families with a child with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TREE NUT ALLERGY; CLINICAL-TRIALS; PEANUT; RHINOCONJUNCTIVITIS; PARENTS; ADULTS	Background: Food allergy is potentially severe, affects approximately 5% of children, and requires numerous measures for food avoidance to maintain health. The effect of this disease on health-related quality of life (HRQL) has been documented by using generic instruments, but no disease-specific instrument is available. Objective: To create a validated, food allergy-specific HRQL instrument to measure parental burden associated with having a child with food allergy: the Food Allergy Quality of Life-Parental Burden questionnaire. Methods: After identification of 74 items affecting families with children with food allergy, 88 families were approached for effect scoring. Final items were generated by score results, elimination of redundancies, and content review. Resulting high-effect areas were queried for validation with a 7-point Likert scale. A final instrument including 17 items and 2 expectation of outcome questions was distributed to 352 families for validation. Results: Areas of effect included family/social activities (restaurant meals, social activities, child care, vacation), school, time for meal preparation, health concerns, and emotional issues. Validation steps showed strong internal validity (Cronbach alpha, 0.95) and good correlation with expectation of outcome questions (r = 0.412; P < .01) and scores on a generic HRQL instrument, the Children's Health Questionnaire-PF50. (r = -0.36 to -0.4; P < .01). The instrument showed the ability to discriminate by disease burden: parents whose children had multiple (>2) food allergies were more affected than parents whose children had fewer allergies (scores, 3.1 vs 2.6; P < .001). Conclusions: The Food Allergy Quality of Life-Parental Burden demonstrates strong internal and cross-sectional validity. Its discriminative ability suggests that it will be a useful tool to measure outcomes in treatment studies of food allergy for children.	Food Allergy & Anaphylaxis Network, Fairfax, VA USA; Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy Immunol, Dept Pediat, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Jaffe Food Allergy Inst, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI 01709] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; Blaiss MS, 1999, ANN ALLERG ASTHMA IM, V83, P449, DOI 10.1016/S1081-1206(10)62850-5; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; LANDGRAF J, 1996, CHILD HLTH QUESTIONA; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Roberts G, 2003, J ALLERGY CLIN IMMUN, V111, P491, DOI 10.1067/mai.2003.138; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schuck P, 2004, QUAL LIFE RES, V13, P571, DOI 10.1023/B:QURE.0000021318.92272.2a; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306	19	211	214	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1159	1163		10.1016/j.jaci.2004.08.007	http://dx.doi.org/10.1016/j.jaci.2004.08.007			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536425				2022-12-18	WOS:000225047800025
J	Remes, ST; Castro-Rodriguez, JA; Holberg, CJ; Martinez, FD; Wright, AL				Remes, ST; Castro-Rodriguez, JA; Holberg, CJ; Martinez, FD; Wright, AL			Dog exposure in infancy decreases the subsequent risk of frequent wheeze but not of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheezing; atopy; allergy; epidemiology; risk; children; cat; dog; pets; IgE	HAY-FEVER; ASTHMA; CHILDREN; ENVIRONMENT; PREVALENCE; CHILDHOOD; ALLERGEN; SENSITIZATION; PETS; FARM	Background: Influence of household pets in the development of childhood asthma or atopy has been controversial. Objective: The purpose of this study was to investigate whether pet exposure in early life decreases the subsequent risk of frequent wheezing and/or allergic sensitization. Methods: This was a prospective observational birth cohort study. The setting was a large health maintenance organization in Tucson, Ariz; the subjects were a population sample of 1246 newborns enrolled at birth and followed prospectively to age 13 years. The main outcome measures were as follows: time to first report of frequent wheezing (>3 episodes in the past year), skin prick test reactivity at 6 years and 11 years of age, an total serum IgE at 9 months, 6 years, and 11 years of age. Results: Children living in households with greater than or equal to1 indoor dogs at birth were less likely to develop frequent wheeze than those not having indoor dogs (P = .004). This inverse association was confined to children without parental asthma (hazard ratio = 0.47; P < .001 [Cox regression]) and was not evident for children with parental asthma (hazard ratio = 0.96; P = .87). Adjustment by potential confounders did not change the results. Indoor cat exposure was not significantly associated with the risk of frequent wheezing. Neither cat exposure in early life nor dog exposure in early life was associated with skin prick test reactivity or total serum IgE at any age. Conclusion: Dog exposure in early life might prevent the development of asthmalike symptoms, at least in low-risk children with no family history of asthma. Nevertheless, early pet exposure does not seem to significantly influence the development of allergic sensitization.	Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA; Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland	University of Arizona; University of Arizona Health Sciences; Finland National Institute for Health & Welfare	Wright, AL (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA.		Castro-Rodriguez, Jose A./ABA-6591-2021; Castro-Rodriguez, Jose A./ABA-2760-2021	Castro-Rodriguez, Jose A./0000-0002-0708-4281; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177, P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56177, HL 14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Peat J, 1998, Eur Respir J Suppl, V27, p28s; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rothman K., 1998, MODERN EPIDEMIOLOGY; SIGURS N, 1995, PEDIATRICS, V95, P500; *STATACORP, 1999, STAT STAT SOFTW REL; Strachan D, 1998, Eur Respir J Suppl, V27, p23s; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; vonMutius E, 1997, LANCET, V350, P14; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	30	211	215	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					509	515		10.1067/mai.2001.117797	http://dx.doi.org/10.1067/mai.2001.117797			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590373				2022-12-18	WOS:000171760300006
J	Chatchatee, P; Jarvinen, KM; Bardina, L; Beyer, K; Sampson, HA				Chatchatee, P; Jarvinen, KM; Bardina, L; Beyer, K; Sampson, HA			Identification of IgE- and IgG-binding epitopes on alpha(s1)-casein: Differences in patients with persistent and transient cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; tolerance; epitope; conformational; linear; alpha(s1)-casein; spot membrane	1ST 3 YEARS; PEPTIDE-SYNTHESIS; BOVINE ALPHA(S1)-CASEIN; ALPHA-S1-CASEIN; PROTEIN; CASEIN; INFANTS; DETERMINANTS; INTOLERANCE; ANTIBODIES	Background: Cow's milk allergy (CMA) affects 2.5% of children less than 2 years of age, but about 80% become clinically tolerant within the first 3 years of life. Casein is one of the major allergens responsible for CMA and seems to play an important role in persistent allergy. Previous studies on egg allergy suggested that linear epitopes are associated with longlasting food allergy. Objective: The aim of the study was to identify IgE- and IgG-binding epitopes on alpha (s1)-casein and to determine whether the patterns of epitope recognition are associated with the natural history of CMA. Methods: According to the known amino acid (AA) sequence, 96 overlapping decapeptides representing the entire length of alpha (s1)-casein were synthesized on a cellulose-derived membrane. Sera from 24 children with milk allergy were used to identify IgE- and IgG-binding epitopes. Results: Six major and 3 minor IgE-binding, as well as 5 major and 1 minor IgG-binding, regions on alpha (s1)-casein were identified. Two IgE-binding regions (AA 69-78 and AA 173-194) were recognized by the majority of patients over a years of age with persistent allergy (67% and 100%, respectively) but by none of the children less than 3 years of age who are likely to outgrow CMA. No differences in IgG binding between the groups were observed. Conclusion: There appears to be a difference in epitope recognition between patients with different natural histories of CMA. Screening for IgE antibodies to these epitopes may be useful in identifying children who will have persistent milk hypersensitivity.	Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00052] Funding Source: Medline; NIAID NIH HHS [AI44236, AI24439] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMETANI A, 1987, J BIOCHEM, V102, P421, DOI 10.1093/oxfordjournals.jbchem.a122069; BOCK SA, 1987, PEDIATRICS, V79, P683; Cooke SK, 1997, J IMMUNOL, V159, P2026; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; ENOMOTO A, 1990, MOL IMMUNOL, V27, P581, DOI 10.1016/0161-5890(90)90077-D; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; KIM SM, 1993, INT ARCH ALLERGY IMM, V101, P260, DOI 10.1159/000236455; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; Nakajima-Adachi H, 1998, J ALLERGY CLIN IMMUN, V101, P660, DOI 10.1016/S0091-6749(98)70175-7; OTANI H, 1987, AGR BIOL CHEM TOKYO, V51, P2049; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Spuergin P, 1996, ALLERGY, V51, P306, DOI 10.1111/j.1398-9995.1996.tb00090.x; Swaisgood H., 1985, FOOD CHEM, V2, P796; Tabar AI, 1996, ALLERGY, V51, P343, DOI 10.1111/j.1398-9995.1996.tb00097.x; VANDERSTOEP N, 1994, EUR J IMMUNOL, V24, P1307, DOI 10.1002/eji.1830240610; Wal JM, 1998, ALLERGY, V53, P1013, DOI 10.1111/j.1398-9995.1998.tb03811.x	22	211	231	2	26	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					379	383		10.1067/mai.2001.112372	http://dx.doi.org/10.1067/mai.2001.112372			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174208				2022-12-18	WOS:000167071400028
J	Urisu, A; Ando, H; Morita, Y; Wada, E; Yasaki, T; Yamada, K; Komada, K; Torii, S; Goto, M; Wakamatsu, T				Urisu, A; Ando, H; Morita, Y; Wada, E; Yasaki, T; Yamada, K; Komada, K; Torii, S; Goto, M; Wakamatsu, T			Allergenic activity of heated and ovomucoid-depleted egg white	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg hypersensitivity; ovomucoid; double-blind; placebo-controlled food challenges; specific IgE antibodies; heated and ovomucoid-depleted egg white	FOOD HYPERSENSITIVITY; DOUBLE-BLIND	Background: No egg white products have been clearly proven to be hypoallergenic. The role of egg white proteins in allergic reactions to eggs is still debatable. Objective: This study was designed to determine the importance of ovomucoid, an egg,white protein, in the development of allergies to egg white. Methods: We performed a double-blind, placebo-controlled food challenge in subjects with high levels of IgE antibodies for egg white to compare the allergenicities of heated and ovomucoid-depleted egg white, freeze-dried egg white, and heated egg white, Levels of IgE antibodies for egg white, ovomucoid, ovalbumin, ovotransferrin, and lysozyme were measured in serum by RAST. Results: Twenty-one of 38 subjects with positive challenge responses to freeze-dried egg white had negative challenge responses to heated egg white, whereas 16 of 17 subjects (94.1%) with positive responses to heated egg white did not respond to the heated and ovomucoid-depleted egg white challenge. The subjects with positive challenge responses to freeze-dried egg white tended to have higher IgE antibody values to ovomucoid than those with negative responses. IgE antibody levels to ovomucoid were significantly higher in subjects with positive responses to a challenge with heated egg white than in those with no response. There were no significant differences in the levels of IgE antibodies to the other proteins, except ovomucoid, in the negative-response and positive-response groups in challenge tests with freeze-dried and heated egg white. Conclusion: The heated and ovomucoid-depleted egg white preparation was less allergenic than heated or freeze-dried preparations. Ovomucoid has a more important role in the pathogenesis of allergic reactions to egg white than other proteins in egg white.	YAMADA CLIN,TOYOAKE,AICHI,JAPAN; EKISAIKAI HOSP,TOYOAKE,AICHI,JAPAN; NAGOYA UNIV,SCH MED,DEPT PEDIAT,COLL MED TECHNOL,TOYOAKE,AICHI,JAPAN; QP CORP,R&D DIV,TOYOAKE,AICHI,JAPAN	Nagoya University	Urisu, A (corresponding author), FUJITA HLTH UNIV,SCH MED,DEPT PEDIAT,TOYOAKE,AICHI 47011,JAPAN.							BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BLEUMINK E, 1971, INT ARCH ALLER A IMM, V40, P72, DOI 10.1159/000230396; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; ELSAYED S, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P287; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOLEN E, 1990, INT ARCH ALLER A IMM, V91, P136, DOI 10.1159/000235104; LANGELAND T, 1983, ALLERGY, V38, P493, DOI 10.1111/j.1398-9995.1983.tb02358.x; MILLER H, 1959, J ALLERGY, V21, P522; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, ACTA DERM-VENEREOL S, V176, P34; WAHEED A, 1975, BIOCHEM J, V147, P139, DOI 10.1042/bj1470139	12	211	225	1	30	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					171	176		10.1016/S0091-6749(97)70220-3	http://dx.doi.org/10.1016/S0091-6749(97)70220-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275136				2022-12-18	WOS:A1997XR35100005
J	BENTLEY, AM; JACOBSON, MR; CUMBERWORTH, V; BARKANS, JR; MOQBEL, R; SCHWARTZ, LB; IRANI, AMA; KAY, AB; DURHAM, SR				BENTLEY, AM; JACOBSON, MR; CUMBERWORTH, V; BARKANS, JR; MOQBEL, R; SCHWARTZ, LB; IRANI, AMA; KAY, AB; DURHAM, SR			IMMUNOHISTOLOGY OF THE NASAL-MUCOSA IN SEASONAL ALLERGIC RHINITIS - INCREASES IN ACTIVATED EOSINOPHILS AND EPITHELIAL MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; MACROPHAGES; MAST CELLS; NASAL BIOPSIES; NEUTROPHILS; RHINITIS; SEASONAL; LYMPHOCYTES-T	HAY-FEVER; CATIONIC PROTEIN; INTRAEPITHELIAL MIGRATION; GLUCOCORTICOID TREATMENT; ANTIGEN CHALLENGE; ANTIBODIES; EXPOSURE	The immunohistology of the nasal mucosa was examined in 13 grass pollen-sensitive patients and in seven normal nonatopic control subjects before and during the pollen season. Cryostat sections (6-mu-m) of biopsy specimens from the inferior turbinate were immunostained with the alkaline-phosphatase antialkaline-phosphatase method and a panel of monoclonal antibodies. Mast cell subtypes were measured with a double sequential immunostaining method. Within the submucosa, seasonal increases in total (MBP+, p < 0.01) and "activated" (EG2+, p < 0.01) eosinophils were observed for the patients, which were significant when these counts were compared with counts for those of control subjects (MBP+ p < 0.01; EG2+ p < 0.001). Within the nasal epithelium, seasonal increases in total (p < 0.05) and "activated" (p < 0.02) eosinophils were also observed. Mast cell counts revealed seasonal increases in tryptase-only positive mast cell (MC(T)) (p < 0.02) but not chymase plus tryptase-positive mast cells (MC(TC)) within the epithelium that were significant when counts were compared with those of control subjects (p < 0.03). No significant changes were observed within the submucosa or epithelium for total leukocytes (CD45+ cells) or T-lymphocytes (CD3+, CD4+, CD8+, and CD 25+ cells) for either group. Similarly, no significant changes were observed for neutrophils (antielastase), macrophages (CD68+), nor HLA-DR+ cells. In the subjects with rhinitis, seasonal submucosal CD3+ counts correlated with MBP+ eosinophils (r = 0.56; p < 0.05) and MC(T)s (r = 0.65; p < 0.02). Similarly, seasonal epithelial EG2+ eosinophil counts correlated with MC(T)s (r = 0.56; p < 0.05). The results indicate that seasonal allergic rhinitis is associated with local accumulation of "activated" eosinophils and the epithelial migration of MC(T)s but not MC(TC)s during natural grass-pollen exposure.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON & NATL HEART & LUNG HOSP,NOSE CLIN,LONDON,ENGLAND	Imperial College London; Imperial College London				Jacobson, Mikila/0000-0002-2921-6169; Bentley, Andrew/0000-0002-6883-9246				BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; CLUTTERBUCK EJ, 1988, BLOOD, V73, P1304; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1990, J ALLERGY CLIN IMMUN, V84, P39; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOQBEL R, IN PRESS CLIN EXP AL; OKUDA M, 1983, EUR J RESPIR DIS, V64, P7; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123, DOI 10.1159/000234410; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; VARNEY VA, IN PRESS AM REV RESP; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968; WODNARFILIPOWIC.A, 1989, NATURE, V389, P150	30	211	212	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					877	883		10.1016/0091-6749(92)90444-7	http://dx.doi.org/10.1016/0091-6749(92)90444-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1532808				2022-12-18	WOS:A1992HN86000014
J	GREENBERGER, PA; PATTERSON, R				GREENBERGER, PA; PATTERSON, R			THE PREVENTION OF IMMEDIATE GENERALIZED REACTIONS TO RADIOCONTRAST MEDIA IN HIGH-RISK PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							OSMOLAR CONTRAST AGENTS; EXCRETORY UROGRAPHY; ADVERSE REACTIONS; ANTAGONISTS; EXPERIENCE; HISTAMINE; IOHEXOL; HISTORY; SAFETY; LEGAL	The use of lower osmolality radiocontrast media (RCM) has been associated with satisfactory radiographic opacification and a reduced incidence of severe reactions. The higher cost without clearly established benefit of these media have limited their use. This investigation assessed the incidence of immediate generalized reactions (IGRs) to repeated RCM IGRs in pretreated high-risk patients who received iopamidol or iohexol during 200 procedures (181 intravascular). All patients had experienced a previous IGR to a conventional RCM. Pretreatment consisted of prednisone, 50 mg, 13, 7, and 1 hour before the procedure and diphenhydramine, 50 mg, 1 hour before the procedure in 140 intravascular infusions. Ephedrine, 25 mg, 1 hour before the infusion was added to prednisone-diphenhydramine in 41 cases. Only one (0.7%) urticarial reaction occurred in 141 procedures with prednisone-diphenhydramine. No repeated IGR occurred with the three-drug regimen. The reaction rate after pretreatment with prednisone-diphenhydramine or prednisone-diphenhydramine-ephedrine and use of conventional contrast media during 800 intravascular procedures was 9.1%, and with pretreatment and lower osmolality contrast media in 181 intravascular infusions, it was 0.5% X2 = 14.35; p < 0.001). Lower osmolality contrast media should be the contrast media of choice for patients with a prior IGR to conventional contrast media. In addition, patients should receive prednisone-diphenhydramine-ephedrine or prednisone-diphenhydramine prophylaxis.			GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; BRETTMAN MA, 1987, NEW ENGL J MED, V317, P891; BRETTMAN MA, 1985, INVEST RADIOL, V20, pS70; FISCHER HW, 1988, JAMA-J AM MED ASSOC, V260, P1614; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; FISCHER HW, 1988, INVEST RADIOL, V23, pS186, DOI 10.1097/00004424-198809001-00033; GRAINGER RG, 1984, BRIT MED J, V289, P144, DOI 10.1136/bmj.289.6438.144; GRAINGER RG, 1988, INVEST RADIOL S, V233, pS95; GREENBERGER PA, 1987, ARCH INTERN MED, V147, P2208, DOI 10.1001/archinte.147.12.2208; GREENBERGER PA, 1988, PROG CARDIOVASC DIS, V31, P239, DOI 10.1016/0033-0620(88)90017-5; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; HARTMAN GW, 1982, AM J ROENTGENOL, V139, P919, DOI 10.2214/ajr.139.5.919; HOLTAS S, 1984, INVEST RADIOL, V19, P563, DOI 10.1097/00004424-198411000-00016; JACOBSON PD, 1988, JAMA-J AM MED ASSOC, V260, P1586, DOI 10.1001/jama.260.11.1586; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KATAYAMA H, 1988, INVEST RADIOL, V23, pS88, DOI 10.1097/00004424-198809001-00005; KATAYAMA H, 1988, NOV ANN M RAD SOC N; KING BF, 1989, MAYO CLIN PROC, V64, P976, DOI 10.1016/S0025-6196(12)61226-9; KING J, 1985, INT ARCH ALLERGY APO, V78, P9; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; PALMER F J, 1988, Australasian Radiology, V32, P426, DOI 10.1111/j.1440-1673.1988.tb02770.x; PENDERGRASS HP, 1958, RADIOLOGY, V71, P1; PHILBIN DM, 1981, ANESTHESIOLOGY, V55, P292, DOI 10.1097/00000542-198109000-00019; REUTER SR, 1988, AM J ROENTGENOL, V151, P529; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SCHROTT KM, 1986, FORTSCHR MED, V104, P153; SHEHADI WH, 1982, RADIOLOGY, V143, P11, DOI 10.1148/radiology.143.1.7063711; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SLOVAK M, 1988, INVEST RADIOL S, V23, pS79; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	32	211	218	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					867	872		10.1016/0091-6749(91)90135-B	http://dx.doi.org/10.1016/0091-6749(91)90135-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013681				2022-12-18	WOS:A1991FG05900017
J	STEVENSON, DD; SIMON, RA				STEVENSON, DD; SIMON, RA			SENSITIVITY TO INGESTED METABISULFITES IN ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DEPT CLIN RES,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHICHESTER DF, 1972, HDB FOOD ADDITIVES; CLAYTON DE, 1980, CLIN ALLERGY, V10, P341, DOI 10.1111/j.1365-2222.1980.tb02116.x; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GOLD WM, 1973, ASTHMA PHYSL IMMUNOP; HOTZEL D, 1969, INT Z VITAMINFORSCH, V39, P372; JOSLYN MA, 1954, ADV FOOD RES, V5, P97, DOI 10.1016/S0065-2628(08)60222-0; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; WILMES G, 1967, 7TH P INT C NUTR, P540; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2	12	211	211	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					26	32		10.1016/0091-6749(81)90119-6	http://dx.doi.org/10.1016/0091-6749(81)90119-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240597				2022-12-18	WOS:A1981LY10100005
J	Brough, HA; Liu, AH; Sicherer, S; Makinson, K; Douiri, A; Brown, SJ; Stephens, AC; McLean, WHI; Turcanu, V; Wood, RA; Jones, SM; Burks, W; Dawson, P; Stablein, D; Sampson, H; Lack, G				Brough, Helen A.; Liu, Andrew H.; Sicherer, Scott; Makinson, Kerry; Douiri, Abdel; Brown, Sara J.; Stephens, Alick C.; McLean, W. H. Irwin; Turcanu, Victor; Wood, Robert A.; Jones, Stacie M.; Burks, Wesley; Dawson, Peter; Stablein, Donald; Sampson, Hugh; Lack, Gideon			Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; peanut sensitization; peanut allergy; environmental peanut exposure; dust	OF-FUNCTION VARIANTS; FOOD ALLERGY; RISK-FACTOR; FILAGGRIN; PROTEIN; CONSUMPTION; GENE; MUTATIONS; TOLERANCE; INFANTS	Background: History and severity of atopic dermatitis (AD) are risk factors for peanut allergy. Recent evidence suggests that children can become sensitized to food allergens through an impaired skin barrier. Household peanut consumption, which correlates strongly with peanut protein levels in household dust, is a risk factor for peanut allergy. Objective: We sought to assess whether environmental peanut exposure (EPE) is a risk for peanut sensitization and allergy and whether markers of an impaired skin barrier modify this risk. Methods: Peanut protein in household dust (in micrograms per gram) was assessed in highly atopic children (age, 3-15 months) recruited to the Consortium of Food Allergy Research Observational Study. History and severity of AD, peanut sensitization, and likely allergy (peanut-specific IgE, >= 5 kU(A)/mL) were assessed at recruitment into the Consortium of Food Allergy Research study. Results: There was an exposure-response relationship between peanut protein levels in household dust and peanut skin prick test (SPT) sensitization and likely allergy. In the final multivariate model an increase in 4 log(2) EPE units increased the odds of peanut SPT sensitization (1.71-fold; 95% CI, 1.13-to 2.59-fold; P = .01) and likely peanut allergy (PA; 2.10-fold; 95% CI, 1.20-to 3.67-fold; P < .01). The effect of EPE on peanut SPT sensitization was augmented in children with a history of AD (OR, 1.97; 95% CI, 1.26-3.09; P < .01) and augmented even further in children with a history of severe AD (OR, 2.41; 95% CI, 1.30-4.47; P < .01); the effect of EPE on PA was also augmented in children with a history of AD (OR, 2.34; 95% CI, 1.31-4.18; P < .01). Conclusion: Exposure to peanut antigen in dust through an impaired skin barrier in atopically inflamed skin is a plausible route for peanut SPT sensitization and PA.	[Brough, Helen A.; Makinson, Kerry; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Kings Coll London, Guys Hosp, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Sicherer, Scott; Sampson, Hugh] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Dept Pediat, New York, NY 10029 USA; [Brown, Sara J.; McLean, W. H. Irwin] Univ Dundee, Coll Life Sci, Ctr Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Brown, Sara J.; McLean, W. H. Irwin] Univ Dundee, Coll Med Dent & Nursing, Dundee DD1 4HN, Scotland; [Douiri, Abdel] Kings Coll London, Sch Med, Dept Publ Hlth Sci, London WC2R 2LS, England; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Burks, Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Dawson, Peter; Stablein, Donald] EMMES Corp, Rockville, MD USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; National Jewish Health; Icahn School of Medicine at Mount Sinai; University of Dundee; University of Dundee; University of London; King's College London; Johns Hopkins University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill; Emmes Corporation	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Serv, 2nd Floor,Stairwell B,South Wing, London SE1 7EH, England.	Gideon.lack@kcl.ac.uk	Brown, Sara J/AAF-7095-2019	Brown, Sara J/0000-0002-3232-5251; Lack, Gideon/0000-0001-7350-4021; Douiri, Abdel/0000-0002-4354-4433	MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: Medline; NCATS NIH HHS [UL1 TR-000039, UL1 TR-000154, UL1 TR-000067, UL1 TR000083, UL1 TR000067, UL1 TR000154, UL1 TR-000083, UL1 TR000424, UL1 TR-000424, UL1 TR000039] Funding Source: Medline; NIAID NIH HHS [U01 AI066560, U19 AI066738, U19AI066738, U01AI066560] Funding Source: Medline; NIDDK NIH HHS [P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [P30 ES023515] Funding Source: Medline; Wellcome Trust [098439, WT086398MA, 098439/Z/12/Z] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000424, UL1TR000039, UL1TR000083, UL1TR000154, UL1TR000067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, U19AI066738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023515] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Wellcome Trust(Wellcome Trust); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Bertelsen RJ, 2014, CLIN EXP ALLERGY, V44, P142, DOI 10.1111/cea.12231; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Brown S, 2008, TLS-TIMES LIT SUPPL, P27; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 1996, BRIT MED J, V313, P300, DOI 10.1136/bmj.313.7052.300; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Londin ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013443; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park DL, 2005, J AOAC INT, V88, P156; Poms RE, 2005, FOOD ADDIT CONTAM A, V22, P104, DOI 10.1080/02652030400027953; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Trendelenburg V, 2013, ALLERGY, V68, P1460, DOI 10.1111/all.12226; Yamashita H, 2012, ALLERGY, V67, P201, DOI 10.1111/j.1398-9995.2011.02742.x; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67	35	210	214	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					164	U249		10.1016/j.jaci.2014.10.007	http://dx.doi.org/10.1016/j.jaci.2014.10.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25457149	Green Published, hybrid			2022-12-18	WOS:000347298200020
J	Kaplan, AP; Joseph, K; Maykut, RJ; Geba, GP; Zeldin, RK				Kaplan, Allen P.; Joseph, Kusumam; Maykut, Robert J.; Geba, Gregory P.; Zeldin, Robert K.			Treatment of chronic autoimmune urticaria with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; angioedema; autoantibody; omalizumab; IgE receptor; antihistamines	CHRONIC IDIOPATHIC URTICARIA; AFFINITY IGE RECEPTOR; SERUM SKIN-TEST; FC-EPSILON-RI; HISTAMINE-RELEASE; AUTOANTIBODIES; CYCLOSPORINE; ACTIVATION; ANGIOEDEMA; INFILTRATE	Background: Approximately 45% of patients with chronic urticaria have an IgG autoantibody directed to the a-subunit of the high-affinity IgE receptor (chronic autoimmune urticaria, CAU) leading to cutaneous mast cell and basophil activation. Treatment of allergic asthma with omalizumab produces rapid reduction in free IgE levels and subsequent decrease in Fc is an element of RI expression on mast cells and basophils. If this occurs in CAU, cross-linking of IgE receptors by autoantibody would be less likely, reducing cell activation and urticaria/angioedema. Objective: To investigate the efficacy of omalizumab in patients with CAU symptomatic despite antihistamine therapy. Methods: Twelve patients with CAU, identified by basophil histamine release assay and autologous skin test, with persistent symptoms for at least 6 weeks despite antihistamines, were treated with placebo for 4 weeks followed by omalizumab ( >= 0.016mg/kg/IU mL(-1) IgE per month) every 2 or 4 weeks for 16 weeks. Primary efficacy variable was change from baseline to the final 4 weeks of omalizumab treatment in mean Urticaria Activity Score (UAS, 0-9 scale). Changes in rescue medication use and quality of life were assessed. Results: Mean UAS declined significantly from baseline to the final 4 weeks of omalizumab treatment (7.50 +/- 1.78 to 2.66 +/- 3.31, -4.84 +/- 2.86, P =.0002). Seven patients achieved complete symptom resolution. In 4 patients, mean UAS decreased, but urticaria persisted. One patient did not respond. Rescue medication use was reduced significantly, and quality of life improved. No adverse effects were reported or observed. Conclusion: This exploratory proof of concept study suggests omalizumab is an effective therapy for CAU resistant to antihistamines.	[Kaplan, Allen P.] Med Univ S Carolina, Dept Med, Div Pulm Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA; [Kaplan, Allen P.] Natl Allergy Asthma & Urticaria Ctr Charleston, Charleston, SC USA; [Maykut, Robert J.; Geba, Gregory P.; Zeldin, Robert K.] Novartis Pharmaceut, E Hanover, NJ USA	Medical University of South Carolina; Novartis	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA.	kaplana@musc.edu			US Medical, Novartis Pharmaceuticals Corp. East Hanover, NJ.; Lev Pharmaceuticals; Novartis Pharmaceuticals	US Medical, Novartis Pharmaceuticals Corp. East Hanover, NJ.; Lev Pharmaceuticals; Novartis Pharmaceuticals(Novartis)	Supported by US Medical, Novartis Pharmaceuticals Corp. East Hanover, NJ.; Disclosure of potential conflict of interest: A. P. Kaplan is a consultant for Novartis Pharmaceuticals Corp. and Lev Pharmaceuticals; receives honoraria from GlaxoSmithKline and Sanofi-Aventis receives grant support from Lev Pharmaceuticals and Novartis Pharmaceuticals: and serves as the historian for the World Allergy Organization. K. Joseph receives grant support from Lev Pharmaceuticals and Novartis Pharmaceuticals. R. J. Maykut. G. P. Geba, and R. K. Zeldin are employed by Novartis Pharmaceuticals Corp.	Baiardini I, 2003, ALLERGY, V58, P621, DOI 10.1034/j.1398-9995.2003.00091.x; BECK LA, 2005, J ALLERGY CLIN IMMUN, V1050, P73; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Gomez G, 2007, J IMMUNOL, V179, P1353, DOI 10.4049/jimmunol.179.2.1353; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; Kaplan AP, 2007, J ALLERGY CLIN IMMUN, V120, P729, DOI 10.1016/j.jaci.2007.05.008; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Kaplan AP, 2007, FITZPATRICKS DERMATO, P330; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2003, J ALLERGY CLIN IMMUN, V112, P218, DOI 10.1067/mai.2003.1605; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Poon E, 1999, BRIT J DERMATOL, V140, P667; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8; Toubi E, 1997, ALLERGY, V52, P312, DOI 10.1111/j.1398-9995.1997.tb00996.x	28	210	219	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					569	573		10.1016/j.jaci.2008.07.006	http://dx.doi.org/10.1016/j.jaci.2008.07.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774392				2022-12-18	WOS:000259234000019
J	Simons, FER; Frew, AJ; Ansotegui, IJ; Bochner, BS; Golden, DBK; Finkelman, FD; Leung, DYM; Lotvall, J; Marone, G; Metcalfe, DD; Muller, U; Rosenwasser, LJ; Sampson, HA; Schwartz, LB; van Hage, M; Walls, AF				Simons, F. Estelle R.; Frew, Anthony J.; Ansotegui, Ignacio J.; Bochner, Bruce S.; Golden, David B. K.; Finkelman, Fred D.; Leung, Donald Y. M.; Lotvall, Jan; Marone, Gianni; Metcalfe, Dean D.; Mueller, Ulrich; Rosenwasser, Lanny J.; Sampson, Hugh A.; Schwartz, Lawrence B.; van Hage, Marianne; Walls, Andrew F.			Risk assessment in anaphylaxis: Current and future approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						anaphylaxis; mast cell; basophil; IgE; Fc epsilon RI; histamine; tryptase; most cell carboxypeptidase; allergens; insect venom allergy; food allergy	HYMENOPTERA VENOM ALLERGY; INSECT-STING CHALLENGE; HUMAN MAST-CELLS; FC-EPSILON-RI; BASOPHIL ACTIVATION TEST; PEANUT ALLERGY; FOOD ALLERGY; IN-VITRO; SKIN PRICK; FATAL REACTIONS	Risk assessment of individuals with anaphylaxis is currently hampered by lack of (1) an optimal and readily available laboratory test to confirm the clinical diagnosis of an anaphylaxis episode and (2) an optimal method of distinguishing allergen-sensitized individuals who are clinically tolerant from those at risk for anaphylaxis episodes after exposure to the relevant allergen. Our objectives were to review the effector mechanisms involved in the pathophysiology of anaphylaxis; to explore the possibility of developing an optimal laboratory test to confirm the diagnosis of an anaphylaxis episode, and the possibility of improving methods to distinguish allergen sensitization from clinical reactivity; and to develop a research agenda for risk assessment in anaphylaxis. Researchers from the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergology and Clinical Immunology held a PRACTALL (Practical Allergy) meeting to discuss these objectives. New approaches being investigated to support the clinical diagnosis of anaphylaxis include serial measurements of total tryptase in serum during an anaphylaxis episode, and measurement of baseline total tryptase levels after the episode. Greater availability of the test for mature beta-tryptase, a more specific mast cell activation marker for anaphylaxis than total tryptase, is needed. Measurement of chymase, mast cell carboxypeptidase A3, platelet-activating factor, and other mast cell products may prove to be useful. Consideration should be given to measuring a panel of mediators from mast cells and basophils. New approaches being investigated to help distinguish sensitized individuals at minimum or no risk from those at increased risk of developing anaphylaxis include measurement of the ratio of allergen-specific IgE to total IgE, determination of IgE directed at specific allergenic epitopes, measurement of basophil activation markers by using flow cytometry, and assessment of allergen-specific cytokine responses. Algorithms have been developed for risk assessment of individuals with anaphylaxis, along with a research agenda for studies that could lead to an improved ability to confirm the clinical diagnosis of anaphylaxis and to identify allergen-sensitized individuals who are at increased risk of anaphylaxis.	Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; Brighton Gen Hosp, Dept Resp Med, Brighton, E Sussex, England; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Royal Hosp, Belfast, Antrim, North Ireland; Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45221 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Dept Resp Med & Allergol, Gothenburg, Sweden; Univ Naples Federico II, Div Clin Immunol & Allergy, Naples, Italy; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Bern, Inselspital, Med Klin, CH-3010 Bern, Switzerland; Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO 64108 USA; Mt Sinai Sch Med, Dept Pediat & Biomed Sci, New York, NY 10029 USA; Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA 23284 USA; Karolinska Inst & Univ Hosp, Dept Med Clin Immunol & Allergy, Stockholm, Sweden; Southampton Gen Hosp, Immunopharmacol Grp, Southampton, Hants, England	University of Manitoba; Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital; Johns Hopkins University; University System of Ohio; University of Cincinnati; National Jewish Health; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Bern; University Hospital of Bern; Children's Mercy Hospital; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; Karolinska Institutet; Karolinska University Hospital; University of Southampton	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	Imcniven@hsc.mb.ca	Kelly, Frank J/C-6125-2009; van Hage, Marianne/A-9678-2017	Kelly, Frank J/0000-0003-2558-8392; van Hage, Marianne/0000-0003-3091-1596; Walls, Andrew/0000-0003-4803-4595	Intramural NIH HHS Funding Source: Medline; Medical Research Council [G0500729] Funding Source: Medline; Department of Health [H039] Funding Source: Medline; National Institute for Health Research [H039] Funding Source: researchfish; Asthma UK [06/026] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, Z01AI000249] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aalto-Korte K, 2001, ALLERGY, V56, P461, DOI 10.1034/j.1398-9995.2001.056005461.x; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown RH, 2005, ANESTHESIOLOGY, V102, P496, DOI 10.1097/00000542-200503000-00004; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Buckley MG, 2006, J ALLERGY CLIN IMMUN, V117, pS69, DOI 10.1016/j.jaci.2005.12.278; Carr WW, 2005, J ALLERGY CLIN IMMUN, V116, P341, DOI 10.1016/j.jaci.2005.03.035; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Crameri R, 2006, IMMUNOL ALLERGY CLIN, V26, P179, DOI 10.1016/j.iac.2006.02.003; de Weck AL, 2004, J INVEST ALLERG CLIN, V14, P253; Dominguez-Ortega J, 2001, INT ARCH ALLERGY IMM, V125, P86, DOI 10.1159/000053801; Eberlein-Konig B, 2006, ALLERGY, V61, P1084, DOI 10.1111/j.1398-9995.2006.01122.x; Ebo DG, 2006, ALLERGY, V61, P1028, DOI 10.1111/j.1398-9995.2006.01039.x; Ebo DG, 2006, ALLERGY, V61, P211, DOI 10.1111/j.1398-9995.2006.00982.x; Ebo DG, 2005, CYTOM PART B-CLIN CY, V64B, P28, DOI 10.1002/cyto.b.20042; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Edston E, 1998, FORENSIC SCI INT, V93, P135, DOI 10.1016/S0379-0738(98)00040-1; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Gamboa P, 2004, CLIN EXP ALLERGY, V34, P1448, DOI 10.1111/j.1365-2222.2004.02050.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Grammer LC, 2000, ANN ALLERG ASTHMA IM, V85, P368, DOI 10.1016/S1081-1206(10)62547-1; Gruchalla RS, 2006, NEW ENGL J MED, V354, P601, DOI 10.1056/NEJMcp043986; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Hand S, 2004, CLIN EXP ALLERGY, V34, P720, DOI 10.1111/j.1365-2222.2004.1932.x; Harboe T, 2006, ACTA ANAESTH SCAND, V50, P324, DOI 10.1111/j.1399-6576.2006.00962.x; Harboe T, 2005, ANESTHESIOLOGY, V102, P897, DOI 10.1097/00000542-200505000-00006; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Hershko AY, 2001, SCAND J CLIN LAB INV, V61, P449, DOI 10.1080/00365510152567086; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2005, ALLERGY, V60, P1312, DOI 10.1111/j.1398-9995.2005.00896.x; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; JUTEL M, 1995, J IMMUNOL, V154, P4187; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Ko J, 2006, ANN ALLERG ASTHMA IM, V97, P365, DOI 10.1016/S1081-1206(10)60802-2; Kounis NG, 2006, INT J CARDIOL, V110, P7, DOI 10.1016/j.ijcard.2005.08.007; Kulka M, 2005, BLOOD, V105, P592, DOI 10.1182/blood-2004-07-2838; Le TH, 2006, J CLIN INVEST, V116, P866, DOI 10.1172/JCI28312; Lebel B, 2001, ALLERGY, V56, P688, DOI 10.1034/j.1398-9995.2001.00103.x; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Marone G, 2000, MAST CELLS BASOPHILS, P454; Marone Gianni, 2004, Novartis Found Symp, V257, P133; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; McEuen AR, 2001, FOOD ALLERGY INTOLER, V2, P105; Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Min HK, 2004, J ALLERGY CLIN IMMUN, V114, P48, DOI 10.1016/j.jaci.2004.04.008; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; MULLER U, 2006, ALLERGOL, V26, P45; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nishio H, 2005, INT J LEGAL MED, V119, P331, DOI 10.1007/s00414-005-0524-1; Nopp A, 2006, ALLERGY, V61, P1366, DOI 10.1111/j.1398-9995.2006.01211.x; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; PATELLA V, 1995, J IMMUNOL, V154, P2855; Peng DJ, 2004, J HAZARD MATER, V114, P1, DOI 10.1016/j.jhazmat.2004.08.029; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Radcliffe M, 2005, LANCET, V365, P1360, DOI 10.1016/S0140-6736(05)61036-7; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166, DOI 10.1046/j.1365-2222.2000.00863.x; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Saxon A, 2004, CURR OPIN ALLERGY CL, V4, P563, DOI 10.1097/00130832-200412000-00015; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; Shanmugam G, 2006, J ALLERGY CLIN IMMUN, V117, P950, DOI 10.1016/j.jaci.2005.12.1356; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2006, ANN ALLERG ASTHMA IM, V96, P865, DOI 10.1016/S1081-1206(10)61351-8; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STELLATO C, 1991, BRIT J ANAESTH, V67, P751, DOI 10.1093/bja/67.6.751; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x; Taylor ML, 2004, J MOL DIAGN, V6, P335, DOI 10.1016/S1525-1578(10)60529-6; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619, DOI 10.1016/S1081-1206(10)61427-5; Thottingal TB, 2006, J ALLERGY CLIN IMMUN, V118, P905, DOI 10.1016/j.jaci.2006.06.016; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vadas P., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80712-1; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERLINDEN PWG, 1993, BLOOD, V82, P1740; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732, DOI 10.1182/blood.V82.6.1732.bloodjournal8261732; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; Vigorito C, 1997, INT J CLIN LAB RES, V27, P178, DOI 10.1007/BF02912454; Walls AF, 2000, ASTHMA RHINITIS, P968; Wang J, 2006, J ALLERGY CLIN IMMUN, V117, pS39, DOI 10.1016/j.jaci.2005.12.161; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2004.00764.x; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694; Zhou X, 2006, J ALLERGY CLIN IMMUN, V117, pS85, DOI 10.1016/j.jaci.2005.12.342	150	210	220	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1		S			S2	S24		10.1016/j.jaci.2007.05.001	http://dx.doi.org/10.1016/j.jaci.2007.05.001			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	193KY	17602945				2022-12-18	WOS:000248274100002
J	Sampson, MA; Munoz-Furlong, A; Sicherer, SH				Sampson, Margaret A.; Munoz-Furlong, Anne; Sicherer, Scott H.			Risk-taking and coping strategies of adolescents and young adults with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; adolescent; risk taking	DIAL TELEPHONE SURVEY; TREE NUT ALLERGY; ANAPHYLACTIC REACTIONS; PREVALENCE; CHILDREN; PEANUT	Background: Fatal food-allergic reactions are most common among adolescents and young adults. Objective: To gain insight toward devising interventions, we queried risk-taking behaviors and coping strategies of persons age 13 to 21 years with food allergy. Methods: We used an Internet-based anonymous questionnaire devised on the basis of data from focus groups. Results: Participants (174 subjects; 49% male; mean age, 16 years) reported the following: 75% had peanut allergy, 75% had 2 or more food allergies, and 87% had been prescribed self-injectable epinephrine. Regarding risk taking, 61% reported that they "always" carry self-injectable epinephrine, but frequencies varied according to activities: traveling (94%), restaurants (81%), friends' homes (67%), school dance (61%), wearing tight clothes (53%), and sports (43%). Fifty-four percent indicated purposefully ingesting a potentially unsafe food. Willingness to eat a food labeled "may contain" an allergen was reported by 42%. Twenty-nine participants were designated at high risk because they did not always carry epinephrine and ate foods that "may contain" allergens. The high-risk group, compared with the rest of the participants (P < .05), felt less "concern" about and "different" because of their allergy and had more recent reactions. The high-risk group was not distinguishable (P = not significant) by age, sex, or number or severity of reactions. Participants variably (60%) tell their friends about their allergy, but 68% believe education of their friends would make living with food allergy easier. Conclusions: A significant number of teens with food allergy admit to risk taking that varies by social circumstances and perceived risks. The results imply that education of teenagers and, importantly, those around them during social activities might reduce risk taking and its consequences. Clinical implications: Our survey of adolescents and young adults with food allergy revealed risk-taking behaviors that vary by social circumstances and perceived risks, indicating that education of teenagers and their peers might reduce risk taking and its consequences.	Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immuonl, Dept Pediat, New York, NY USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Jaffe Food Allergy Inst, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Kim JS, 2005, J ALLERGY CLIN IMMUN, V116, P164, DOI 10.1016/j.jaci.2005.03.039; Noone S. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS133, DOI 10.1016/S0091-6749(03)80417-7; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Rolison MR, 2002, ADOLESCENCE, V37, P585; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	13	210	212	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1440	1445		10.1016/j.jaci.2006.03.009	http://dx.doi.org/10.1016/j.jaci.2006.03.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751011				2022-12-18	WOS:000238332300037
J	Shek, LPC; Soderstrom, L; Ahlstedt, S; Beyer, K; Sampson, HA				Shek, LPC; Soderstrom, L; Ahlstedt, S; Beyer, K; Sampson, HA			Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; egg allergy; milk allergy; CAP system FEIA; quantitative IgE; diagnostic test; natural history	NATURAL-HISTORY; BINDING EPITOPES; CLINICAL-COURSE; CHILDREN; IDENTIFICATION; PERSISTENT	Background: The majority of children with cow's milk and hen's egg allergy develop clinical tolerance with time. However, there are no good indices to predict when and in whom this occurs. Objective: The aim of this study was to determine if monitoring food specific IgE levels over time could be used as a predictor for determining when patients develop clinical tolerance. Methods: Eighty-eight patients with hen's egg and 49 patients with cow's milk allergy who underwent repeated double-blind, placebo-controlled food challenges were included in the study. Using the Pharmacia CAP-System FEIA, specific IgE (sIgE) levels to cow's milk and hen's egg were retrospectively determined from stored serum samples obtained at the time of the food challenges. Logistic regression was used to evaluate the relationship between tolerance development and the decrease in sIgE levels over a specific time period between the two challenges. Results: Twenty-eight of the 66 egg-allergic and 16 of the 33 milk-allergic patients lost their allergy over time. For egg, the decrease in sIgE levels (P = .0014) was significantly related to the probability of developing clinical tolerance, with the duration between challenges having an influence (P = .06). For milk there also was a significant relationship between the decrease in sIgE levels (P = .0175) and the probability of developing tolerance to milk but no significant contribution with regard to time. Stratification into 2 age groups, those below 4 years of age and those above 4 years of age at time of first challenge, had an effect, with the younger age group being more likely to develop clinical tolerance in relation to the rate of decrease in sIgE. The median food sIgE level at diagnosis was significantly less for the group developing "tolerance" to egg (P < .001), and a similar trend was seen for milk allergy (P = .06). Using these results, we developed a model for predicting the likelihood of developing tolerance in milk and egg allergy based on the decrease in food sIgE over time. Conclusion: We found that the rate of decrease in food sIgE levels over time was predictive for the likelihood of developing tolerance in milk and egg allergy. Using the likelihood estimates from this study could aid clinicians in providing prognostic information and in timing subsequent food challenges, thereby decreasing the number of premature and unnecessary double-blind, placebo-controlled food challenges.	Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; Karolinska Inst, Pharmacia AB Diagnost, S-10401 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Inst, Ctr Allergy, S-10401 Stockholm, Sweden	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Bo 1198,1 Gustave Levy Pl, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Shek, Lynette/D-8016-2015	Shek, Lynette/0000-0001-9064-8983; Soderstrom, Lars/0000-0002-6474-6501	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00071] Funding Source: Medline; NIAID NIH HHS [AI44236] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; EGGLESTON PA, 1987, ANN ALLERGY, V59, P179; Henderson CE, 1998, J IMMUNOL METHODS, V213, P99, DOI 10.1016/S0022-1759(98)00014-3; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SAMPSON HA, 1995, PROVOCATION TESTING, P623; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x	19	210	223	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					387	391		10.1016/j.jaci.2004.04.032	http://dx.doi.org/10.1016/j.jaci.2004.04.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316521	Bronze			2022-12-18	WOS:000223405600028
J	Walker, SM; Pajno, GB; Lima, MT; Wilson, DR; Durham, SR				Walker, SM; Pajno, GB; Lima, MT; Wilson, DR; Durham, SR			Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; hay fever; asthma; quality of life; airway hyperresponsiveness	PARTIALLY PURIFIED EXTRACT; DERMATOPHAGOIDES-PTERONYSSINUS; DOUBLE-BLIND; HAY-FEVER; CHILDREN; SYMPTOMS; ALLERGEN; EFFICACY; NASAL	Background: Grass pollen Immunotherapy significantly reduces hay fever symptoms and medication requirements, Effects on seasonal asthma are less clear, and concerns over safety persist. Objective: The goal of this study was to assess the effects of grass pollen immunotherapy on symptoms, bronchial hyperresponsiveness, and quality of life in seasonal rhinitis and asthma, Methods: Forty-four patients with severe summer hay fever (of whom 36 reported seasonal chest symptoms and 28 had seasonal bronchial hyperresponsiveness) participated in a randomized, double-blind, placebo-controlled, parallel group study. After symptom monitoring for one summer, participants received injections of a depot grass pollen vaccine (n = 22) or matched placebo Injections (n = 22) in a rapid updosing fluster regimen fur 4 weeks, followed by monthly injections for 2 years. Outcome measures included hay fever symptoms and medication use, health-related quality of life, and measurements of nonspecific bronchial responsiveness. Results: Significant reductions were observed in the immunotherapy group compared with the placebo group in hay fryer symptoms (49%, 15%; P =.01), medication scores (80%, 18%; P =,007), and seasonal chest symptoms (90%, 11%; P <.05). Impairment of overall quality of life (mean score of 7 domains) during the pollen season was less in the immunotherapy group than In the placebo group (median difference [95% CI], 0.8 [0.18-1.5]; P =.02). During the pollen season there was no change in airway methacholine PC20 (provocation concentration producing a 20% fall in FEV1) in the immunotherapy-treated group (P =.5), compared with an almost 3 doubling-dose decrease in the placebo-treated group (P =.01, between-group difference), There were no significant local or systemic side effects during the study. Conclusion: Grass pollen immunotherapy improves quality of life in seasonal allergic rhinitis and reduces seasonal asthma symptoms and bronchial hyperresponsiveness.	Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; Univ Messina, Inst Pediat Clin, I-98100 Messina, Italy	Imperial College London; University of Messina	Durham, SR (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258				Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; ARMITAGE P, 1987, ANONYMOUS STAT METHO, P408; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Chanez P, 1996, ALLERGY, V51, P850; *COMM SAF MED, 1994, CURR PROB PHARMACOVI, V20, P5; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; MALLING HJ, 1993, ALLERGY, V48, P9; McKean J. W., 1977, ACM Transactions on Mathematical Software, V3, P183, DOI 10.1145/355732.355740; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; ROBINSON DS, 1993, CLIN EXP ALLERGY, V23, P1, DOI 10.1111/j.1365-2222.1993.tb02475.x; Rusznak C, 1996, THORAX, V51, P1105, DOI 10.1136/thx.51.11.1105; VALOVIRTA E, 1999, J INVESTIG ALLERGOL, V7, P369; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WARNER JO, 1978, LANCET, V2, P912	27	210	218	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					87	93		10.1067/mai.2001.112027	http://dx.doi.org/10.1067/mai.2001.112027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149996				2022-12-18	WOS:000166533300016
J	BERNHISELBROADBENT, J; SAMPSON, HA				BERNHISELBROADBENT, J; SAMPSON, HA			CROSS-ALLERGENICITY IN THE LEGUME BOTANICAL FAMILY IN CHILDREN WITH FOOD HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K07AI000830, R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-30] Funding Source: Medline; NIAID NIH HHS [AI24439, AI00830] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1983, ALLERGY PRINCIPLES P, P1415; GALANT SP, 1980, ALLERGIC DISEASE INF, V211, P8; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; KEMP AS, 1985, CLIN ALLERGY, V15, P73, DOI 10.1111/j.1365-2222.1985.tb02258.x; LEINHAS JL, 1987, J AM DIET ASSOC, V87, P604; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; SAMPSON HA, 1986, ANN ALLERGY, V57, P209; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SPEER F, 1975, ANN ALLERGY, V34, P71; VAUGHAN WT, 1948, PRACTICE ALLERGY, P290; VAUGHAN WT, 1948, PRACTICE ALLERGY, P278; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x; 1984, NIH842442 NIAID TASK, P7; 1984, NIH842442 NIAID TASK, P10	21	210	212	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				435	440		10.1016/0091-6749(89)90130-9	http://dx.doi.org/10.1016/0091-6749(89)90130-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2918186				2022-12-18	WOS:A1989T448900011
J	MULLARKEY, MF; HILL, JS; WEBB, DR				MULLARKEY, MF; HILL, JS; WEBB, DR			ALLERGIC AND NON-ALLERGIC RHINITIS - THEIR CHARACTERIZATION WITH ATTENTION TO THE MEANING OF NASAL EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MULLARKEY, MF (corresponding author), MASON CLIN,DEPT MED,SECT IMMUNOL ALLERGY & RHEUMAT DIS,1100 9TH AVE,SEATTLE,WA 98101, USA.							BAZARAL M, 1971, J IMMUNOL, V107, P794; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; LICHTENSTEIN LM, 1978, IMMUNOLOGICAL DISEAS, P804; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; OTTESON EA, 1978, ALLERGY PRINCIPLES P, P600; SAMPTER M, 1968, ANN INTERN MED, V68, P975; SCHATZ M, 1978, J ALLERGY CLIN IMMUN, V61, P150, DOI 10.1016/0091-6749(78)90312-3; SEEBOHM PM, 1978, ALLERGY PRINCIPLES P, P868; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SMITH JM, 1971, J ALLERGY, V47, P23, DOI 10.1016/S0091-6749(71)80314-7; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; TENNENBAUM JI, 1972, ALLERGIC DISEASES DI, P183; UNDERDOWN BJ, 1976, J IMMUNOL, V116, P1435; WEBB DR, 1978, J ALLERGY CLIN IMMUN, V61, P185, DOI 10.1016/0091-6749(78)90427-X; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; 1978, PHADEBAS IGE PRIST R	16	210	211	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					122	126		10.1016/0091-6749(80)90196-7	http://dx.doi.org/10.1016/0091-6749(80)90196-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6101336				2022-12-18	WOS:A1980JF19900007
J	Wood, RA; Kim, JS; Lindblad, R; Nadeau, K; Henning, AK; Dawson, P; Plaut, M; Sampson, HA				Wood, Robert A.; Kim, Jennifer S.; Lindblad, Robert; Nadeau, Kari; Henning, Alice K.; Dawson, Peter; Plaut, Marshall; Sampson, Hugh A.			A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Milk allergy; oral immunotherapy; omalizumab; desensitization; sustained unresponsiveness; double-blind; placebo-controlled trial; dose-related adverse reactions	FC-EPSILON-RI; TOLERANCE INDUCTION; NATURAL-HISTORY; FOOD ALLERGY; FOLLOW-UP; IGE; PEANUT; CHILDREN; CELL; DESENSITIZATION	Background: Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued. Objective: We sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both. Methods: This was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU). Results: Fifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g "desensitization" OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008). Conclusions: In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU).	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Kim, Jennifer S.] NorthShore Univ HealthSyst, Evanston, IL USA; [Lindblad, Robert; Henning, Alice K.; Dawson, Peter] EMMES Corp, Rockville, MD USA; [Nadeau, Kari] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, 1425 Madison Ave,Box 1089, New York, NY 10029 USA	Johns Hopkins University; NorthShore University Health System; Emmes Corporation; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Box 1089, New York, NY 10029 USA.	hugh.sampson@mssm.edu			National Institute of Allergy and Infectious Diseases [AI-44236]; National Center for Advancing Translational Sciences, National Institutes of Health [RR-026134, UL1 TR 001079]; Food Allergy Research and Education; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236, U19AI044236] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Food Allergy Research and Education; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Omalizumab (Xolair) and omalizumab placebo for this trial were kindly provided by Genentech. The study was supported by grant AI-44236 from the National Institute of Allergy and Infectious Diseases and RR-026134 (Mount Sinai) and UL1 TR 001079 (Johns Hopkins) from the National Center for Advancing Translational Sciences, National Institutes of Health; and a supplemental grant from Food Allergy Research and Education.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Berin MC, 2012, SEMIN IMMUNOPATHOL, V34, P633, DOI 10.1007/s00281-012-0325-9; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; MAURER D, 1995, J IMMUNOL, V154, P6285; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; Wilcock LK, 2006, IMMUNOL ALLERGY CLIN, V26, P333, DOI 10.1016/j.iac.2006.02.004; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	34	209	216	1	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1103	+		10.1016/j.jaci.2015.10.005	http://dx.doi.org/10.1016/j.jaci.2015.10.005			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26581915	Green Accepted, Bronze			2022-12-18	WOS:000373351200016
J	Kim, EH; Bird, JA; Kulis, M; Laubach, S; Pons, L; Shreffler, W; Steele, P; Kamilaris, J; Vickery, B; Burks, AW				Kim, Edwin H.; Bird, J. Andrew; Kulis, Michael; Laubach, Susan; Pons, Laurent; Shreffler, Wayne; Steele, Pamela; Kamilaris, Janet; Vickery, Brian; Burks, A. Wesley			Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; sublingual immunotherapy; desensitization; food allergy	ANAPHYLACTIC REACTIONS; FOOD ALLERGY; DOUBLE-BLIND; KIWI FRUIT; FATALITIES	Background: There are no treatments currently available for peanut allergy. Sublingual immunotherapy (SLIT) is a novel approach to the treatment of peanut allergy. Objective: We sought to investigate the safety, clinical effectiveness, and immunologic changes with SLIT in children with peanut allergy. Methods: In this double-blind, placebo-controlled study subjects underwent 6 months of dose escalation and 6 months of maintenance dosing followed by a double-blind, placebo-controlled food challenge. Results: Eighteen children aged 1 to 11 years completed 12 months of dosing and the food challenge. Dosing side effects were primarily oropharyngeal and uncommonly required treatment. During the double-blind, placebo-controlled food challenge, the treatment group safely ingested 20 times more peanut protein than the placebo group (median, 1,710 vs 85 mg; P = .011). Mechanistic studies demonstrated a decrease in skin prick test wheal size (P = .020) and decreased basophil responsiveness after stimulation with 10(-2) mu g/mL (P = .009) and 10(-3) mu g/mL (P = .009) of peanut. Peanut-specific IgE levels increased over the initial 4 months (P = .002) and then steadily decreased over the remaining 8 months (P = .003), whereas peanut-specific IgG4 levels increased during the 12 months (P = .014). Lastly, IL-5 levels decreased after 12 months (P = .015). No statistically significant changes were found in IL-13 levels, the percentage of regulatory T cells, or IL-10 and IFN-gamma production. Conclusion: Peanut SLIT is able to safely induce clinical desensitization in children with peanut allergy, with evidence of immunologic changes suggesting a significant change in the allergic response. Further study is required to determine whether continued peanut SLIT is able to induce long-term immune tolerance. (J Allergy Clin Immunol 2011;127:640-6.)	[Kim, Edwin H.; Bird, J. Andrew; Kulis, Michael; Laubach, Susan; Pons, Laurent; Steele, Pamela; Kamilaris, Janet; Vickery, Brian; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Shreffler, Wayne] Massachusetts Gen Hosp, Food Allergy Ctr MGH, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA	Duke University; Harvard University; Massachusetts General Hospital	Burks, AW (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Box 2644, Durham, NC 27710 USA.	wesley.burks@duke.edu			National Institutes of Health [NCCAM R01-AT004435-03, 5T32-AI007062-32]; American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative; Wallace Research Foundation [WRF2010.01]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1RR024128]; NIH Roadmap for Medical Research; NIAID; NIH/NIAID; Thrasher Research Fund; American Lung Association; Cephalon; Anaphylaxis Network (FAAN); Wallace Research Foundation; National Center for Complementary & Integrative Health [R01AT004435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative; Wallace Research Foundation; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Thrasher Research Fund; American Lung Association; Cephalon; Anaphylaxis Network (FAAN); Wallace Research Foundation; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health: NCCAM R01-AT004435-03, 5T32-AI007062-32; the American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative Howard Gittis Memorial 3rd Year/4th Year Fellowship/Instructor Award (J. A. B.); and the Wallace Research Foundation (WRF2010.01). Additional support for the project was provided by grant UL1RR024128 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and the NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.; J. A. Bird has received research support from the American Academy of Allergy, Asthma & Immunology and the Food Allergy Initiative. M. Kulis has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). W. Shreffler has received research support from the NIAID. B. Vickery has received research support from the NIH/NIAID, Thrasher Research Fund, American Lung Association, and Cephalon. A. W. Burks has consulted for ActoGeniX NV, Intelliject, McNeil Nutritionals, Novartis, and Schering-Plough; is a minority stockholder in Allertein and MastCell, Inc; is on an advisory board for Dannon Co Probiotics; is on an expert panel for Nutricia; has received research support from the NIH, Food Allergy and Anaphylaxis Network (FAAN), and Wallace Research Foundation; and is on the medical board of directors of FAAN. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Branum Amy M, 2008, NCHS Data Brief, P1; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024	26	209	220	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					640	U153		10.1016/j.jaci.2010.12.1083	http://dx.doi.org/10.1016/j.jaci.2010.12.1083			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG		Green Accepted			2022-12-18	WOS:000288018400013
J	Brennan, PJ; Bouza, TR; Hsu, FI; Sloane, DE; Castells, MC				Brennan, Patrick J.; Bouza, Tito Rodriguez; Hsu, F. Ida; Sloane, David E.; Castells, Mariana C.			Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; rapid desensitization; adverse drug reaction; drug allergy; monoclonal antibody; anaphylaxis; hypersensitivity reaction; rituximab; infliximab; trastuzumab	MONOCLONAL-ANTIBODY; RAPID DESENSITIZATION; CROHNS-DISEASE; INFUSION REACTIONS; THERAPEUTIC-USE; ANAPHYLACTIC REACTION; RHEUMATOID-ARTHRITIS; HUMAN BASOPHILS; MOUSE ALLERGEN; MAST-CELLS	Background: Rapid desensitization, a procedure for graded drug administration, allows for the safe readministration of a medication after certain types of hypersensitivity reactions (HSRs) and is indicated in cases in which there are no reasonable therapeutic alternatives. The use of rapid desensitization for HSRs to mAbs has not been validated. Objective: We sought to describe our experience with rapid desensitization to mAbs, including rituximab, infliximab, and trastuzumab. Methods: One hundred five rapid desensitizations were performed in 23 patients with a standardized 12-step, 6-hour protocol. Our approach to patient evaluation before desensitization is described. The severity, characteristics, and timing of both initial HSRs and HSRs during desensitization were determined by means of retrospective review of medical records. After a reaction during desensitization, patient-specific protocol modifications were made before each subsequent desensitization. Results: 104 of 105 desensitizations undertaken were successfully completed. We observed HSRs during 29% of desensitizations, including 27 mild reactions, 1 moderate reaction, and 2 severe reactions. Overall, reactions during desensitization were markedly less severe than initial HSRs, but reactions did recur in a minority of successive desensitizations. Conclusions: Rapid desensitization is a promising method for the delivery of monoclonal therapeutics after an HSR, but the possibility of a reaction remains with each desensitization. (J Allergy Clin Immunol 2009;124:1259-66.)	[Brennan, Patrick J.; Bouza, Tito Rodriguez; Hsu, F. Ida; Sloane, David E.; Castells, Mariana C.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Castells, MC (corresponding author), 1 Jimmy Fund Way,Smith Bldg,Room 626D, Boston, MA 02115 USA.	mcastells@partners.org		Hsu, F. Ida/0000-0003-2201-9442	Ovations for the Cure	Ovations for the Cure	The desensitizadon program at Dana Farber Cancer Institute and Brigham and Women's hospital is supported in part by Ovations for the Cure.	Albrecht H, 2009, DRUG TODAY, V45, P199, DOI 10.1358/dot.2009.45.3.1341343; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Bartelds GM, 2007, ANN RHEUM DIS, V66, P921, DOI 10.1136/ard.2006.065615; Baudouin V, 2003, TRANSPLANTATION, V76, P459, DOI 10.1097/01.TP.0000073809.65502.8F; Breslow RG, 2009, ANN ALLERG ASTHMA IM, V102, P155, DOI 10.1016/S1081-1206(10)60247-5; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; Byrd JC, 1999, J CLIN ONCOL, V17, P791, DOI 10.1200/JCO.1999.17.3.791; Calogiuri G, 2008, CURR PHARM DESIGN, V14, P2883, DOI 10.2174/138161208786369786; Castells M, 2006, CURR OPIN ALLERGY CL, V6, P476, DOI 10.1097/ACI.0b013e3280108716; Castells M, 2006, IMMUNOL ALLERGY CLIN, V26, P465, DOI 10.1016/j.iac.2006.05.005; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; CHATENOUD L, 1986, J IMMUNOL, V137, P830; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cook-Bruns N, 2001, ONCOLOGY-BASEL, V61, P58, DOI 10.1159/000055403; Curtis BR, 2002, BLOOD, V99, P2054, DOI 10.1182/blood.V99.6.2054; Dillman RO, 1999, CANCER METAST REV, V18, P465, DOI 10.1023/A:1006341717398; Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V96, P624, DOI 10.1016/S1081-1206(10)63560-0; Duburque C, 2006, ALIMENT PHARM THER, V24, P851, DOI 10.1111/j.1365-2036.2006.03026.x; Ehrlich P., 1900, P R SOC            B, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; Feldweg AM, 2005, GYNECOL ONCOL, V96, P824, DOI 10.1016/j.ygyno.2004.11.043; FRODIN JE, 1992, CELL BIOPHYS, V21, P153; Gell PGH, 1968, CLIN ASPECTS IMMUNOL, VSecond, P580; *GEN, HERC PRESCR INF; GEORGITIS JW, 1991, ANN ALLERGY, V66, P343; Grillo-Lopez AJ, 1999, SEMIN ONCOL, V26, P66; Hawkins C, 2003, ALLERGY, V58, P688, DOI 10.1034/j.1398-9995.2003.00190.x; Jerath MR, 2009, J ALLERGY CLIN IMMUN, V123, P260, DOI 10.1016/j.jaci.2008.09.046; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lee CW, 2005, GYNECOL ONCOL, V99, P393, DOI 10.1016/j.ygyno.2005.06.028; LEGOUFFE E, 1994, CLIN EXP IMMUNOL, V98, P323; Lelong J, 2005, REV MAL RESPIR, V22, P239, DOI 10.1019/200539983; Leonard PA, 2002, TRANSPLANTATION, V74, P1697, DOI 10.1097/01.TP.0000038316.61592.28; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Melamed J, 2002, J ALLERGY CLIN IMMUN, V110, P813, DOI 10.1067/mai.2002.128689; Morales AR, 2005, ANN ALLERG ASTHMA IM, V94, P575, DOI 10.1016/S1081-1206(10)61136-2; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; Park A, 2003, BRIT MED J, V326, P541, DOI 10.1136/bmj.326.7388.541; Pharand C, 2002, PHARMACOTHERAPY, V22, P380, DOI 10.1592/phco.22.5.380.33196; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; PRUZANSKY JJ, 1988, IMMUNOLOGY, V65, P443; Puchner TC, 2001, INFLAMM BOWEL DIS, V7, P34, DOI 10.1097/00054725-200102000-00005; Rubinchik E, 1998, ALLERGY, V53, P14, DOI 10.1111/j.1398-9995.1998.tb03768.x; Soykan I, 2000, AM J GASTROENTEROL, V95, P2395; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126, DOI 10.1200/JCO.2001.19.12.3126	51	209	211	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1259	1266		10.1016/j.jaci.2009.09.009	http://dx.doi.org/10.1016/j.jaci.2009.09.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910036	Bronze			2022-12-18	WOS:000273071500018
J	Clark, S; Bock, SA; Gaeta, TJ; Brenner, BE; Cydulka, RK; Camargo, CA				Clark, S; Bock, SA; Gaeta, TJ; Brenner, BE; Cydulka, RK; Camargo, CA			Multicenter study of emergency department visits for food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; emergency department; epinephrine	ANAPHYLACTIC REACTIONS; EPIDEMIOLOGY; ROOM	Background: Relatively little is known about the characteristics of patients who visit the emergency department (ED) for an acute allergic reaction. Although anaphylaxis guidelines suggest treatment with epinephrine, teaching about self-injectable epinephrine, and referral to an allergist, current ED management remains uncertain. Objective: The objective of this study was to describe the management of food-related acute allergic reactions. Methods: The Multicenter Airway Research Collaboration performed a chart review study in 21 North American EDs. Investigators reviewed a random sample of 678 charts of patients who presented with food allergy (International Classification of Diseases-ninth revision codes 693.1, 995.0, 995.3, and 995.60-995.69). Results: Patients had an average age of 29 years; the cohort was 57% female and 40% white. A variety of foods provoked the allergic reaction, including nuts (21%), crustaceans (19%), fruit (12%), and fish (10%). Although exposure to these foods can be life threatening, only 18% of patients came to the ED by ambulance. In the ED, 72% of patients received antihistamines, 48% received systemic corticosteroids, and 16% received epinephrine; 33% received respiratory treatments such as inhaled albuterol. Among patients with severe reactions (55% of total), 24% received epinephrine. Overall, 97% of patients were discharged to home. At ED discharge, 16% of patients were prescribed self-injectable epinephrine, and 12% were referred to an allergist. Conclusions: Although guidelines suggest specific approaches for the management of acute allergic reactions, ED concordance for food allergy appears low. These findings support a new collaboration between professional organizations in allergy and emergency medicine and the development of educational programs and materials for ED patients and staff.	Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; New York Methodist Hosp, Dept Emergency Med, Brooklyn, NY USA; Univ Arkansas Med Sci, Dept Emergency Med, Little Rock, AR 72204 USA; Metrohlth Med Ctr, Dept Emergency Med, Cleveland, OH USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; National Jewish Health; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; University of Arkansas System; University of Arkansas Medical Sciences; MetroHealth System; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Clark, S (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St,Clin Bldg 397, Boston, MA 02114 USA.		Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007069] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07069] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Burks AW, 1999, CLIN REV ALLERG IMMU, V17, P339, DOI 10.1007/BF02737615; GAETA TJ, 2001, ACAD EMERG MED, V8, P449; Hosmer DW, 1989, APPL LOGISTIC REGRES; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; KRAUSE RS, 1999, ANAPHYLAXIS; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHWARTZ HJ, 1995, ALLERGY PROC, V16, P247, DOI 10.2500/108854195778702639; Shimamoto SR, 2002, CURR OPIN ALLERGY CL, V2, P211, DOI 10.1097/00130832-200206000-00010; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; *STAT, 1985, STAT REF MAN; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859, DOI 10.1093/qjmed/89.11.859; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 2000, FOOD ALLERGY ANAPHYL; 2000, SOURCEBOOK ZIP CODE; 1996, FEDERAL CENSUS DATA	18	209	211	0	16	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					347	352		10.1016/j.jaci.2003.10.053	http://dx.doi.org/10.1016/j.jaci.2003.10.053			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767453				2022-12-18	WOS:000188885700026
J	Chilvers, MA; Rutman, A; O'Callaghan, C				Chilvers, MA; Rutman, A; O'Callaghan, C			Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cilia; ultrastructure; dyskinesia; beat frequency; beat pattern	IMMOTILE CILIA; FREQUENCY; MOTILITY; EPITHELIUM; CHILDREN; INNER	Background: The main symptoms of primary ciliary dyskinesia (PCD) are nasal rhinorrhea or blockage and moist-sounding cough. Diagnosis can be difficult and is based on an abnormal ciliary beat frequency, accompanied by specific abnormalities of the ciliary axoneme. It is unknown whether determining ciliary beat pattern related to specific ultrastructural ciliary defects might help in the diagnosis of PCD. Objective: We sought to determine ciliary beat pattern and beat frequency (CBF) associated with the 5 common ultrastructural defects responsible for PCD. Methods: Nasal brushings were performed on 56 children with PCD. Ciliary movement was recorded using digital high-speed video imaging to assess beat frequency and pattern. Electron microscopy was performed. Results: In patients with an isolated outer dynein arm or with an outer and inner dynein arm defect, 55% and 80% of cilia were immotile, respectively. Cilia that moved were only flickering. Mean CBF (+/- 95% CI) was 2.3 Hz (+/- 1.2) and 0.8 Hz ( 0.8), respectively. Cilia with an isolated inner dynein arm or a radial spoke defect had similar beat patterns. Cilia appeared stiff, had a reduced amplitude, and failed to bend along their length. Immotile cilia were present in 10% of cilia with an inner dynein arm defect and in 30% of radial spoke defects. Mean CBF was 9.3 Hz (+/- 2.6) and 6.0 Hz (+/- 3.1), respectively. The ciliary transposition defect produced a large circular beat pattern (mean CBF, 10.7 Hz [+/- 1.1]). No cilia were immotile. Conclusions: Different ultrastructural defects responsible for PCD result in predictable beat patterns. Recognition of these might help in the diagnostic evaluation of patients suspected of having PCD.	Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Univ Leicester, Sch Med, Dept Child Hlth, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester	O'Callaghan, C (corresponding author), Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England.			Chilvers, Mark/0000-0003-2020-9429				AFZELIUS B A, 1976, Science (Washington D C), V193, P317; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Bush A, 1998, EUR RESPIR J, V12, P982, DOI 10.1183/09031936.98.12040982; Chilvers MA, 2000, THORAX, V55, P314, DOI 10.1136/thorax.55.4.314; Chilvers MA, 2001, EUR RESPIR J, V18, P965, DOI 10.1183/09031936.01.00093001; Chilvers MA, 2003, THORAX, V58, P333, DOI 10.1136/thorax.58.4.333; CORKEY CWB, 1981, AM REV RESPIR DIS, V124, P544; DALHAMN T, 1962, NATURE, V196, P592, DOI 10.1038/196592a0; DEIONGH RU, 1995, AM J RESP CRIT CARE, V151, P1559, DOI 10.1164/ajrccm.151.5.7735615; Ellerman A, 1997, EUR RESPIR J, V10, P2376, DOI 10.1183/09031936.97.10102376; GREENSTONE M, 1985, J LARYNGOL OTOL, V99, P985, DOI 10.1017/S0022215100098042; GREENSTONE M, 1988, Q J MED, V67, P405; Hadfield PJ, 1997, CLIN OTOLARYNGOL, V22, P302, DOI 10.1046/j.1365-2273.1997.00020.x; Jorissen M, 2000, Acta Otorhinolaryngol Belg, V54, P325; Jorissen M, 2000, Acta Otorhinolaryngol Belg, V54, P343; Meeks M, 2000, PEDIATR PULM, V29, P307, DOI 10.1002/(SICI)1099-0496(200004)29:4<307::AID-PPUL11>3.0.CO;2-2; Min Yang-Gi, 1995, Rhinology (Utrecht), V33, P189; OMOTO CK, 1979, NATURE, V279, P532, DOI 10.1038/279532a0; PEDERSEN M, 1983, EUR J RESPIR DIS, V64, P78; Rayner CFJ, 1996, AM J RESP CRIT CARE, V153, P1123, DOI 10.1164/ajrccm.153.3.8630555; ROSSMAN CM, 1984, AM REV RESPIR DIS, V129, P161; ROSSMAN CM, 1988, PEDIATR PULM, V5, P36, DOI 10.1002/ppul.1950050109; ROSSMAN CM, 1981, CHEST, V80, P860; SANDERSON MJ, 1981, J CELL SCI, V47, P331; Santamaria F, 1999, ACTA PAEDIATR, V88, P853; SCHIDLOW DV, 1994, ANN ALLERGY, V73, P457; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726; STURGESS JM, 1986, AM J MED GENET, V25, P149, DOI 10.1002/ajmg.1320250117; STURGESS JM, 1984, PERSPECT PEDIAT PATH, V8, P133; Taylor HC, 1999, CELL MOTIL CYTOSKEL, V43, P167, DOI 10.1002/(SICI)1097-0169(1999)43:2<167::AID-CM8>3.3.CO;2-H; TEICHTAHL H, 1986, MED BIOL ENG COMPUT, V24, P193, DOI 10.1007/BF02443935; TURNER JAP, 1981, PEDIATRICS, V67, P805; VANDERBAAN S, 1987, ANN OTO RHINOL LARYN, V96, P264, DOI 10.1177/000348948709600306; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383	34	209	215	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					518	524		10.1067/mai.2003.1701	http://dx.doi.org/10.1067/mai.2003.1701			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679810				2022-12-18	WOS:000185231200010
J	Knight, DA; Lim, S; Scaffidi, AK; Roche, N; Chung, KF; Stewart, GA; Thompson, PJ				Knight, DA; Lim, S; Scaffidi, AK; Roche, N; Chung, KF; Stewart, GA; Thompson, PJ			Protease-activated receptors in human airways: Upregulation of PAR-2 in respiratory epithelium from patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						protease-activated receptors; asthma; epithelium; inflammation; airway smooth muscle	INFLAMMATION; CELLS; HYPERRESPONSIVENESS; THROMBIN; ADHESION; RELEASE; PGE(2); AND-4	Background: Protease-activated receptors (PARs), which are G protein-coupled receptors that are activated after proteolytic cleavage of the amino terminus of the receptor, are likely to play a major role in airway inflammation. PARs are activated by endogenous proteases, including thrombin (PAR-1, -3, and -4) and tryptase (PAR-2 and -4), both of which are present in inflamed airways. Objective: The purpose of this study was to compare the expression and distribution of PARs in biopsy specimens obtained from asthmatic and normal subjects and to examine the effect of inhaled corticosteroids on PAR expression. Methods: Biopsy specimens were obtained from 10 normal and 20 asthmatic patients, and sections were stained for PAR-1, -2, -3, and -4 through use of specific antibodies. Staining was scored semiquantitatively for both intensity and distribution. Results: Staining for all PARs was seen on the epithelium and smooth muscle in biopsy specimens from both normal and asthmatic subjects. In the epithelium, PAR-1 and -3 staining appeared to be apically concentrated, whereas PAR-2 and -4 staining was more diffuse. In normal subjects, epithelial staining intensity of PAR-1 and -3 was significantly greater than for PAR-4 (P < .05). Staining for PAR-1, -3, and -4 in biopsy specimens from asthmatic subjects was similar to that in specimens from normal subjects, irrespective of whether the former were using inhaled corticosteroids. However, PAR-2 staining in asthmatic epithelium was significantly increased in comparison with normal epithelium. Expression of PARs in airway smooth muscle did not differ between groups. Conclusion: Asthma per se is associated with increased PAR-2 expression in bronchial epithelium. Importantly, staining was not influenced by inhaled corticosteroids. These results suggest that PAR-2 might be involved in airway inflammation.	Asthma & Allergy Res Inst Inc, Nedlands, WA, Australia; Univ Western Australia, Dept Med, Crawley, Australia; Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England; Univ Western Australia, Dept Microbiol, Div Inflammat & Infect Dis, Nedlands, WA 6009, Australia	University of Western Australia; Imperial College London; University of Western Australia	Thompson, PJ (corresponding author), Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst Inc, Ground Floor,E Block, Nedlands, WA 6009, Australia.		Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426				Bohm SK, 1996, J BIOL CHEM, V271, P22003; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Cairns JA, 1996, J IMMUNOL, V156, P275; Cicala C, 1999, CIRCULATION, V99, P2590, DOI 10.1161/01.CIR.99.19.2590; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2000, J BIOL CHEM, V275, P39207, DOI 10.1074/jbc.M007215200; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Damiano BP, 1999, THROMB HAEMOSTASIS, V81, P808; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; King C, 1998, J IMMUNOL, V161, P3645; KNIGHT DA, 1994, CLIN EXP ALLERGY, V24, P698, DOI 10.1111/j.1365-2222.1994.tb00980.x; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lan RS, 2000, BRIT J PHARMACOL, V129, P63, DOI 10.1038/sj.bjp.0703007; LINDMARK B, 1990, ALLERGY, V45, P197, DOI 10.1111/j.1398-9995.1990.tb00483.x; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Robinson C, 1998, CLIN EXP ALLERGY, V28, P530, DOI 10.1046/j.1365-2222.1998.00303.x; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Thompson PJ, 1999, AM J RESP CRIT CARE, V159, pA98; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Yoshinaga Sumiko, 1998, Journal of Medical Investigation, V45, P77	30	209	220	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					797	803		10.1067/mai.2001.119025	http://dx.doi.org/10.1067/mai.2001.119025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692107				2022-12-18	WOS:000172523800022
J	Bonfield, TL; Konstan, MW; Berger, M				Bonfield, TL; Konstan, MW; Berger, M			Altered respiratory epithelial cell cytokine production in cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epithelial cells; cystic fibrosis; cytokines; inflammation; lung disease	INTERLEUKIN-8 GENE-EXPRESSION; INDUCED LUNG INJURY; IN-VIVO; IL-10; INFLAMMATION; INFECTION; RELEASE; BIOLOGY; MODEL; LINE	Background: Reports that lung inflammation in patients with cystic fibrosis (CF) might precede infection raise the possibility that the excessive inflammatory response in lungs of patients with CF might be directly related to defects in epithelial cell cystic fibrosis transmembrane regulator, Objective: We sought to determine the relationship of epithelial cell cytokine production to CF lung disease, Methods: Immunofluorescence and cultures of freshly obtained bronchial epithelial cells and ELISA for IL-10, IL-8. and IL-6 were used to study alterations in epithelial cell cytokine production, Results: Fresh bronchial epithelial cells from healthy control subjects (HCs) secreted 98 +/- 20 pg/mL of the anti-inflammatory cytokine IL-10 when placed in primary culture in vitro but little or no IL-8 or IL-6, In contrast, fresh epithelial cells from patients with CF did not secrete detectable IL-10 but produced 38 +/- 17 pg/mL IL-8 and 40 +/- 17 pg/mL IL-6. These data correlated very well with the immunofluorescence data. The correlation between the immunofluorescent staining of fresh bronchial epithelial cells from both the HCs and patients with CF and the concentrations of cytokines in epithelial lining fluid suggests a reciprocal relationship between anti-inflammatory (IL-10) and proinflammatory (IL-6 and IL-8) cytokine production by the epithelial cells in HCs versus patients with CF, Conclusions: Alterations in epithelial cell cytokine production in the lungs of patients with CF may contribute to the excessive local inflammation.	Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA	Case Western Reserve University	Berger, M (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.			Konstan, Michael/0000-0002-0557-7277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07415, HL 37117] Funding Source: Medline; NIDDK NIH HHS [DK 27651] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEDARD M, 1993, AM J RESP CELL MOL, V9, P455, DOI 10.1165/ajrcmb/9.4.455; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Bonfield TL, 1995, AM J RESP CRIT CARE, V84, P1045; CRESTANI B, 1994, J CLIN INVEST, V94, P731, DOI 10.1172/JCI117392; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HOFFEMAN SP, 1995, AM J RESP CRIT CARE, V151, pA774; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; MULLIGAN MS, 1993, J IMMUNOL, V151, P5666; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; ROLFE MW, 1991, AM J RESP CELL MOL, V5, P493, DOI 10.1165/ajrcmb/5.5.493; SHANLEY TP, 1995, J IMMUNOL, V154, P3454; Shibata Y, 1996, J IMMUNOL, V156, P772; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785	26	209	210	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					72	78		10.1016/S0091-6749(99)70116-8	http://dx.doi.org/10.1016/S0091-6749(99)70116-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400842				2022-12-18	WOS:000081738900011
J	DiazSanchez, D; Tsien, A; Casillas, A; Dotson, AR; Saxon, A				DiazSanchez, D; Tsien, A; Casillas, A; Dotson, AR; Saxon, A			Enhanced nasal cytokine production in human beings after in vivo challenge with diesel exhaust particles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human IgE; pollution; cytokines; mucosal immunity; allergy	IGE PRODUCTION; MESSENGER-RNA; B-CELLS; RESPIRATORY DISORDERS; ADJUVANT ACTIVITY; EPITHELIAL-CELLS; IMMUNOGLOBULIN-E; IFN-GAMMA; INTERLEUKIN-4; EXPRESSION	Background: Diesel exhaust particles (DEPs) have been implicated in the worldwide increased incidence of allergic airway disorders over the past century. They can enhance in vivo IgE production in the human upper respiratory mucosa. Objective: The study was carried out to determine whether DEPs can alter the production of cytokines by cells residing in the nasal mucosa. Methods: Eighteen hours after intranasal challenge with saline solution or DEPs, we studied the levels of messenger RNA for cytokines in nasal lavage cells and the number of subjects in whom cytokine mRNA could be detected. Results: Before challenge, most subjects' nasal lavage cells had detectable levels of only interferon-gamma, IL-2, and IL-13 mRNA. After challenge, the cells produced readily detectable mRNA for IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, and interferon-gamma. In addition, the levels of all cytokine mRNA increased. Enhanced IL-4 protein was also present in the postchallenge lavage fluid. Although the cells in nasal lavage before and after challenge do not necessarily represent the same cells either in number or type, the broad increase in cytokine production was not simply the result of an increase in T cells recovered in the lavage fluid. Conclusion: An increase in nasal cytokine expression after exposure to EDPs can be predicted to contribute to enhanced local IgE production and thus play a role in the increased incidence of respiratory allergic disease.	HART & LOUISE LYON LAB, LOS ANGELES, CA USA		DiazSanchez, D (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CTR HLTH SCI 52175, DEPT MED, DIV CLIN IMMUNOL & ALLERGY, LOS ANGELES, CA 90024 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, R01AI015251, R21AI015251, U19AI034567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07126, AI-15251, AI-34567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; BONFIELD T, 1995, FASEB J, V9, pA772; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DUBAR V, 1993, EXP LUNG RES, V19, P345, DOI 10.3109/01902149309064351; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HELLMAN L, 1993, EUR J IMMUNOL, V23, P159, DOI 10.1002/eji.1830230126; KANEKO S, 1980, OTORHINOLARYNGOLO S4, V23, P270; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; KING CL, 1993, J IMMUNOL, V150, P1873; KRAMER CM, 1987, BIOCHEM BIOPH RES CO, V145, P25, DOI 10.1016/0006-291X(87)91282-4; LINDEN M, 1995, CLIN EXP ALLERGY, V25, P166, DOI 10.1111/j.1365-2222.1995.tb01022.x; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NAGARKATTI PS, 1984, TOXICOL APPL PHARM, V72, P169, DOI 10.1016/0041-008X(84)90261-8; PENG C, 1992, J IMMUNOL, V148, P129; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; YAMAMURA M, 1992, J IMMUNOL, V149, P1470; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1994, J BIOL CHEM, V269, P456; ZHANG K, 1991, J IMMUNOL, V146, P1836; 1994, DRAFT TECHNICAL REPO	38	209	210	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					114	123		10.1016/S0091-6749(96)70233-6	http://dx.doi.org/10.1016/S0091-6749(96)70233-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765825				2022-12-18	WOS:A1996VA69200014
J	Ciprandi, G; Buscaglia, S; Pesce, G; Pronzato, C; Ricca, V; Parmiani, S; Bagnasco, M; Canonica, GW				Ciprandi, G; Buscaglia, S; Pesce, G; Pronzato, C; Ricca, V; Parmiani, S; Bagnasco, M; Canonica, GW			Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dermatophagoides pteronyssinus; D-farinae; house dust mites; exposure level; minimal persistent inflammation; hyperreactivity; inflammatory infiltrate; ICAM-1/CD54	CONJUNCTIVAL PROVOCATION TEST; DERMATOPHAGOIDES-PTERONYSSINUS; ADHESION MOLECULES; EPITHELIAL-CELLS; DUST MITES; P-I; F-I; ASTHMA; ICAM-1; EOSINOPHILS	The natural exposure to house dust mites causes sensitization in genetically susceptible patients. Persistent exposure of sensitized patients causes chronic inflammation, and consequently, hyperreactivity, thus promoting the development of clinical features. Recently, intercellular adhesion molecule-1 (ICAM-1)/CD54 expression on epithelial cells triggered by allergen has been demonstrated and related to the inflammation caused by the allergic reaction. Therefore we evaluated the possible presence of inflammation (i.e., inflammatory cell infiltrate and ICAM-1/CD54 expression on epithelium) at conjunctival and nasal levels in patients with asymptomatic allergic rhinitis caused by mites, in their relatives living in the same environment, and in healthy volunteers. In addition the possible relationship between inflammation and house dust mite allergen exposure was evaluated Conjunctival and nasal scrapings of allergic subjects enrolled in the study showed many inflammatory cells. A mild ICAM-1/CD54 expression on conjunctival and nasal epithelium was detectable in allergic subjects, whereas relatives and healthy volunteers showed few inflammatory cells and no ICAM-1/CD54 expression on epithelial cells. A detectable level of house dust mite, sufficient to cause sensitization, was found in all houses. This study demonstrates a minimal persistent inflammation at conjunctival and nasal levels constantly detectable in patients without symptoms who are sensitized to mires and continuously exposed to the natural allergens.	NEO ABELLO, DEPT SCI, MILAN, ITALY	Italfarmaco	Ciprandi, G (corresponding author), UNIV GENOA, DEPT INTERNAL MED, ALLERGY & CLIN IMMUNOL SERV, VIALE BENEDETTO XV 6, I-16132 GENOA, ITALY.		Ciprandi, Giorgio/G-7462-2012; canonica, giorgio walter/ABF-2037-2020	Ciprandi, Giorgio/0000-0001-7016-8421; canonica, giorgio walter/0000-0001-8467-2557; Pesce, Giampaola/0000-0002-6294-9110				Barber D, 1990, REV ESP ALERGOL IMMU, V5, P125; Barnes P J, 1991, Clin Exp Allergy, V21 Suppl 1, P80, DOI 10.1111/j.1365-2222.1991.tb01710.x; BONINI S, 1988, J ALLERGY CLIN IMMUN, V81, P173, DOI 10.1016/0091-6749(88)90254-0; CALDERON E, 1992, J ALLERGY CLIN IMMUN, V90, P852, DOI 10.1016/0091-6749(92)90112-F; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CIPRANDI G, 1993, ALLERGY, V48, P421, DOI 10.1111/j.1398-9995.1993.tb00740.x; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; CIPRANDI G, 1992, INT ARCH ALLER A IMM, V907, P1; COCKCROFT DW, 1991, J ALLERGY CLIN IMMUN, V87, P914, DOI 10.1016/0091-6749(91)90412-H; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; HANSEL TT, 1992, CLIN EXP ALLERGY, V22, P345, DOI 10.1111/j.1365-2222.1992.tb03096.x; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KLEMENTSSON H, 1992, CLIN EXP ALLERGY, V22, P1058, DOI 10.1111/j.1365-2222.1992.tb00130.x; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; OLIVE D, 1986, HUMAN T CELL CLONES, P173; PAGE C, 1992, ANN ALLERGY, V69, P251; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; WARNER JA, 1992, CLIN EXP ALLERGY, V22, P1044, DOI 10.1111/j.1365-2222.1992.tb00127.x; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724	39	209	218	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				971	979		10.1016/S0091-6749(95)70235-0	http://dx.doi.org/10.1016/S0091-6749(95)70235-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543756				2022-12-18	WOS:A1995TN12400015
J	MUNIR, AKM; EINARSSON, R; SCHOU, C; DREBORG, SKG				MUNIR, AKM; EINARSSON, R; SCHOU, C; DREBORG, SKG			ALLERGENS IN SCHOOL DUST .1. THE AMOUNT OF THE MAJOR CAT (FEL D I) AND DOG (CAN F I) ALLERGENS IN DUST FROM SWEDISH SCHOOLS IS HIGH ENOUGH TO PROBABLY CAUSE PERENNIAL SYMPTOMS IN MOST CHILDREN WITH ASTHMA WHO ARE SENSITIZED TO CAT AND DOG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CAN-F-I; ELISA; FEL-D-I; SCHOOL DUST	DOMESTICUS; EXPOSURE; DISEASE	Background: We investigated the levels of Fel d I and Can f I in dust from tables, chairs, and floors in 29 classrooms in four Swedish schools. Methods: School authorities were questioned about building characteristics, students were interviewed about their health and exposure to animals, and cleaning personnel were asked about methods and frequency of cleaning. Dust samples were taken from floors and horizontal surfaces of chairs and tables in all classrooms during a 6-week period. Results: Higher amounts of Fel d I were found on chairs (geometric mean, 953 ng per gram of dust) than on tables (525 ng/gm) and floors (134 ng/gm). The concentration of Can f I (5.3 ng/gm) on chairs was 2 to 20 times higher than Fel d I. The concentration of Can f I (200 ng/gm) in dust from floors was twice as high as that of Fel d I. The concentration of Can f I on chairs was within the range previously found by other investigators in houses with dogs. Conclusions: Since the levels of both Fel d I and Can f I were much higher on chairs than on floors, we hypothesize that allergen is brought to schools on the clothes of students and teachers. We conclude that the levels of the two major allergens from furred pets (i.e., Fel d I and Can f I) in Swedish schools are probably high enough to sensitize children and to induce asthma in most children who are allergic to cats or dogs.	ALK RES,HORSHOLM,DENMARK		MUNIR, AKM (corresponding author), LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN.							CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COCKCROFT DW, 1983, LANCET, V2, P253; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; DREBORG S, 1987, THESIS LINKOPING U, P1; DREBORG S, 1990, RESPIRATORY ALLERGY, V2, P185; DREBORG S, 1992, ALLERGIC NONALLERGIC, P82; DREBORG SKG, 1989, J ALLERGY CLIN IMMUN, V83, P265; GELBER L, 1990, Journal of Allergy and Clinical Immunology, V85, P193; GUSTAFSSON PM, 1991, OESOPHAGEAL FUNCTION, P71; IHRE E, 1991, ALLERGY CLIN IMMU S1, V3, P227; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MILLER J D, 1990, Journal of Allergy and Clinical Immunology, V85, P226; MUNIR AKM, IN PRESS ALLERGY; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SHAMIE S, 1990, Journal of Allergy and Clinical Immunology, V85, P226; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P595, DOI 10.1016/0091-6749(91)90020-O; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x	24	209	213	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1067	1074		10.1016/0091-6749(93)90221-Z	http://dx.doi.org/10.1016/0091-6749(93)90221-Z			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491939				2022-12-18	WOS:A1993LC97800015
J	PAUWELS, R; VANRENTERGHEM, D; VANDERSTRAETEN, M; JOHANNESSON, N; PERSSON, CGA				PAUWELS, R; VANRENTERGHEM, D; VANDERSTRAETEN, M; JOHANNESSON, N; PERSSON, CGA			THE EFFECT OF THEOPHYLLINE AND ENPROFYLLINE ON ALLERGEN-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GHENT,DEPT RESP DIS,B-9000 GHENT,BELGIUM; UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN	Ghent University; Lund University; Skane University Hospital								ANDERSSON KE, 1984, EUR J CLIN PHARMACOL, V26, P33, DOI 10.1007/BF00546705; ANDERSSON P, 1982, THESIS U LUND; AVIADO DM, 1976, BRONCHIAL ASTHMA MEC, P715; BLEECKER E R, 1981, American Review of Respiratory Disease, V123, P53; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CUSHLEY, 1983, BR J CLIN PHARM, V15, P161; FINNEY M J B, 1983, British Journal of Pharmacology, V80, p709P; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; FREDHOLM BB, 1981, ACTA PHYSIOL SCAND, V111, P507, DOI 10.1111/j.1748-1716.1981.tb06772.x; FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129; HAMBLETON G, 1977, LANCET, V1, P381; HOLGATE ST, 1984, J ALLERGY CLIN IMMUN, V74, P302, DOI 10.1016/0091-6749(84)90262-8; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JOHANNESSON N, 1983, AM REV RESPIR DIS, V127, P111; JOHANNESSON N, 1983, 2 P WORLD C CLIN PHA; KROLL F, 1984, P IUPHAR INT C LONDO; LAURSEN LC, 1983, ALLERGY, V38, P75, DOI 10.1111/j.1398-9995.1983.tb00859.x; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LUNELL E, 1983, ACTA PHARMACOL TOX, V53, P205; LUNELL E, 1983, EUR J RESPIR DIS, V64, P333; LUNELL E, 1984, EUR J RESPIR DIS, V65, P28; MARONE G, 1979, J IMMUNOL, V123, P1473; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; NISSIM JE, 1980, J ALLERGY CLIN IMMUN, V65, P180; PERSSON CGA, 1982, ARCH INT PHARMACOD T, V258, P267; PERSSON CGA, 1983, J CARDIOVASC PHARM, V5, P778, DOI 10.1097/00005344-198309000-00012; PERSSON CGA, 1982, LIFE SCI, V30, P2181, DOI 10.1016/0024-3205(82)90292-2; PERSSON CGA, 1982, LIFE SCI, V31, P2673, DOI 10.1016/0024-3205(82)90711-1; PERSSON CGA, 1981, ACTA PHARMACOL TOX, V49, P313; PERSSON CGA, 1985, ASTHMA REV; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; RALL TW, 1980, PHARM BASIS THERAPEU, P502; SCHULTZEWERNINGHAUS G, 1979, PRAX KLIN PNEUMOL, V33, P312; SCHWABE U, 1981, TRENDS PHARMACOL SCI, V2, P299, DOI 10.1016/0165-6147(81)90347-3; Snedecor G.W., 1980, STAT METHODS, V7; SNYDER SH, 1981, TRENDS NEUROSCI, V4, P242, DOI 10.1016/0166-2236(81)90076-X; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; VINGE E, 1984, ACTA PHYSIOL SCAND, V120, P117, DOI 10.1111/j.1748-1716.1984.tb07380.x	42	209	210	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					583	590		10.1016/0091-6749(85)90779-1	http://dx.doi.org/10.1016/0091-6749(85)90779-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056246				2022-12-18	WOS:A1985ATH6600010
J	KAPLAN, AP; GRAY, L; SHAFF, RE; HORAKOVA, Z; BEAVEN, MA				KAPLAN, AP; GRAY, L; SHAFF, RE; HORAKOVA, Z; BEAVEN, MA			INVIVO STUDIES OF MEDIATOR RELEASE IN COLD URTICARIA AND CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NHLI, PULM BRANCH, BETHESDA, MD USA; NIAID, LAB CLIN INVEST, BLDG 10, ROOM 11N-246, BETHESDA, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAER RL, 1971, IMMUNOLOGICAL DISEAS, V2, P973; BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BEAVEN MA, 1975, HDB PSYCHOPHARMACOLO, V1; BENVENIS.J, 1972, FED PROC, V31, pA748; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; DELAUS FV, 1968, ARCH DERMATOL, V98, P67, DOI 10.1001/archderm.98.1.67; DUNER HANS, 1960, ACTA ALLERGOL, V15, P417, DOI 10.1111/j.1398-9995.1960.tb02869.x; Grant RT, 1936, CLIN SCI, V2, P253; HENDERSON LL, 1958, J ALLERGY, V29, P122, DOI 10.1016/0021-8707(58)90097-2; HERXHEIMER A, 1956, CLIN SCI, V15, P195; HOPKINS JG, 1936, ARCH DERMATOL, V38, P679; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; JUHLIN L, 1963, ARCH DERMATOL, V88, P771, DOI 10.1001/archderm.1963.01590240095017; KRAVIS TC, 1974, FED PROC, V33, P797; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; ORANGE RP, 1972, BIOLOGICAL ROLE IMMU, P151; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; PETERS GA, 1946, ARCH INTERN MED, V77, P526, DOI 10.1001/archinte.1946.00210400051005; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; SAAVEDRA JM, 1973, J PHARMACOL EXP THER, V186, P508; SPUZIC I, 1961, ACTA ALLERGOL, V16, P228, DOI 10.1111/j.1398-9995.1961.tb02896.x; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9	25	209	210	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					394	402		10.1016/0091-6749(75)90078-0	http://dx.doi.org/10.1016/0091-6749(75)90078-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	48522				2022-12-18	WOS:A1975AE59300006
J	Kawasaki, H; Nagao, K; Kubo, A; Hata, T; Shimizu, A; Mizuno, H; Yamada, T; Amagai, M				Kawasaki, Hiroshi; Nagao, Keisuke; Kubo, Akiharu; Hata, Tsuyoshi; Shimizu, Atsushi; Mizuno, Hideaki; Yamada, Taketo; Amagai, Masayuki			Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Filaggrin; filaggrin-null mice; atopic dermatitis; ichthyosis vulgaris; barrier function; flaky tail mice; stratum corneum; percutaneous immune response	OF-FUNCTION MUTATIONS; SKIN-BARRIER; FLAKY TAIL; ICHTHYOSIS VULGARIS; CLINICAL SEVERITY; KERATIN FILAMENTS; LANGERHANS CELLS; HOUSE-MOUSE; DIFFERENTIATION; DISEASE	Background: Loss-of-function mutations in filaggrin are major predisposing factors for atopic dermatitis. Although various reports suggest a critical role for filaggrin in stratum corneum (SC) barrier formation, the lack of filaggrin-null (Flg(-/-)) mice has hampered detailed in vivo analysis of filaggrin's functions. Objective: We sought to generate Flg(-/-) mice and to assess the effect of filaggrin loss on SC barrier function and percutaneous immune responses. Methods: We generated Flg(-/-) mice using gene targeting and assessed the morphology, hydration, mechanical strength, and antigen permeability of their SC. Percutaneous immune responses were evaluated through irritant-and hapten-induced contact hypersensitivity studies and by measuring humoral responses to epicutaneous sensitization with protein antigen. Results: Newborn Flg(-/-) mice exhibited dry scaly skin. Despite marked decreases in natural moisturizing factor levels, which are filaggrin degradation products, SC hydration and transepidermal water loss were normal. Microscopic analyses suggested premature shedding of SC layers, and indeed, increased desquamation under mechanical stress was demonstrated. Loss of keratin patterns, which are critical for corneocyte stabilization, is likely attributable to fragility in the Flg(-/-) SC. Antigens penetrated the Flg(-/-) SC more efficiently, leading to enhanced responses in hapten-induced contact hypersensitivity and higher serum levels of anti-ovalbumin IgG(1) and IgE. Conclusion: Complete filaggrin deficiency led to altered barrier integrity and enhanced sensitization, which are important factors in early-phase atopic dermatitis. Flg(-/-) mice should provide a valuable tool to further explore additional factors the dysfunction of which leads to uncontrolled inflammation in patients with atopic diseases. (J Allergy Clin Immunol 2012;129:1538-46.)	[Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Shinjyuku Ku, Tokyo, Japan; [Kubo, Akiharu] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Yamada, Taketo] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan; [Hata, Tsuyoshi] KOSE Corp, Fundamental Res Labs, Tokyo, Japan; [Mizuno, Hideaki] RIKEN, Brain Sci Inst, Wako, Saitama, Japan	Keio University; Keio University; Keio University; RIKEN	Amagai, M (corresponding author), Keio Univ, Sch Med, Dept Dermatol, Shinjyuku Ku, 35 Shinanomachi, Tokyo, Japan.	amagai@a7.keio.jp	Kubo, Akiharu/I-2711-2014; Nagao, Keisuke/P-3837-2018; Amagai, Masayuki/K-5325-2013; Nagao, Keisuke/J-5116-2013; Mizuno, Hideaki/AAH-5737-2021	Kubo, Akiharu/0000-0003-0902-3586; Nagao, Keisuke/0000-0002-7005-3138; Amagai, Masayuki/0000-0003-3314-7052; Nagao, Keisuke/0000-0002-7005-3138; Mizuno, Hideaki/0000-0002-6983-5255	Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; Keio University; Grants-in-Aid for Scientific Research [23390086] Funding Source: KAKEN	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Keio University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by a Health Labour Sciences Research Grant for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research; the "Promotion of Environmental Improvement for Independence of Young Researchers" program and a Matching Fund Subsidy for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Research Grants for Life Sciences and Medicine from Keio University Medical Science Fund; and a Keio University Grant-in-Aid for Encouragement of Young Medical Scientists.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; BRODY I, 1959, J ULTRA MOL STRUCT R, V2, P482, DOI 10.1016/S0022-5320(59)90007-3; BRODY I, 1960, J ULTRA MOL STRUCT R, V4, P264, DOI 10.1016/S0022-5320(60)80023-8; Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; Maghraby GM, 2008, EUR J PHARM SCI, V34, P203, DOI 10.1016/j.ejps.2008.05.002; ElGammal C, 1996, CLIN EXP DERMATOL, V21, P338; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fluhr JW, 2010, J INVEST DERMATOL, V130, P2141, DOI 10.1038/jid.2010.74; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; JARRETT A, 1957, J EMBRYOL EXP MORPH, V5, P103; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Norlen L, 2004, J INVEST DERMATOL, V123, P715, DOI 10.1111/j.0022-202X.2004.23213.x; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; SEARLE AG, 1957, J EMBRYOL EXP MORPH, V5, P93; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soma Y, 2005, INT J DERMATOL, V44, P197, DOI 10.1111/j.1365-4632.2004.02375.x; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; Tomita Y, 2005, EXP DERMATOL, V14, P619, DOI 10.1111/j.0906-6705.2005.00341.x; Weerheim A, 2001, ARCH DERMATOL RES, V293, P191, DOI 10.1007/s004030100212; YAMAMOTO Y, 1994, ACTA DERM-VENEREOL, P34; Zhen YX, 1999, ARCH DERMATOL RES, V291, P555, DOI 10.1007/s004030050453	46	208	213	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1538	+		10.1016/j.jaci.2012.01.068	http://dx.doi.org/10.1016/j.jaci.2012.01.068			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22409988				2022-12-18	WOS:000304764600014
J	Shikotra, A; Choy, DF; Ohri, CM; Doran, E; Butler, C; Hargadon, B; Shelley, M; Abbas, AR; Austin, CD; Jackman, J; Wu, LC; Heaney, LG; Arron, JR; Bradding, P				Shikotra, Aarti; Choy, David F.; Ohri, Chandra M.; Doran, Emma; Butler, Claire; Hargadon, Beverley; Shelley, Maria; Abbas, Alexander R.; Austin, Cary D.; Jackman, Janet; Wu, Lawren C.; Heaney, Liam G.; Arron, Joseph R.; Bradding, Peter			Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; asthma; mast cell; OX40; IL-13; T(H)2; airway remodeling; nuocyte	HUMAN EPITHELIAL-CELLS; AIRWAY INFLAMMATION; IL-13 EXPRESSION; MAST-CELL; INTERLEUKIN-4; CHEMOKINES; SPUTUM	Background: Thymic stromal lymphopoietin (TSLP) is a cytokine implicated in the pathophysiology of asthma through 2 distinct pathways: a TSLP-OX40 ligand (OX40L)-T cell axis and a TSLP-mast cell axis. Whether these pathways are active in human asthma is unknown. Objective: We sought to investigate whether mucosal TSLP protein expression relates to asthma severity and distinct immunologic pathways. Methods: In healthy subjects and patients with mild-to-severe asthma, we immunostained bronchial biopsy specimens for TSLP, OX40, OX40L, T(H)2 cytokines, and inflammatory cell markers. We examined gene expression using RNA microarrays and quantitative RT-PCR. Results: There was considerable heterogeneity in the levels of TSLP, IL-13, and IL-4 immunostaining across the cohort of asthmatic patients examined. Overall, TSLP protein expression was significantly increased in airway epithelium and lamina propria of asthmatic patients, particularly in patients with severe asthma. TSLP immunostaining in both compartments correlated with the severity of airflow obstruction. The majority of leukocytes expressing IL-13 were possibly nuocytes. Accounting for intersubject variability, the 55% of asthmatic patients with increased IL-13 immunostaining in the lamina propria also had increased IL-4 and TSLP expression. This was further substantiated by significant correlations between TSLP gene expression, a T(H)2 gene expression signature, and eosinophilic inflammation in bronchial biopsy specimens. Immunostaining for OX40, OX40L, and CD83 was sparse, with no difference between asthmatic patients and healthy subjects. Conclusion: TSLP expression is increased in a subset of patients with severe asthma in spite of high-dose inhaled or oral corticosteroid therapy. Targeting TSLP might only be efficacious in the subset of asthma characterized by increased TSLP expression and T(H)2 inflammation. (J Allergy Clin Immunol 2012; 129: 104-11.)	[Shikotra, Aarti; Ohri, Chandra M.; Hargadon, Beverley; Shelley, Maria; Bradding, Peter] Univ Leicester, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester, Leics, England; [Choy, David F.; Arron, Joseph R.] Genentech Inc, ITGR Biomarker Discovery Grp, San Francisco, CA 94080 USA; [Abbas, Alexander R.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; [Austin, Cary D.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Jackman, Janet; Wu, Lawren C.] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; [Doran, Emma; Butler, Claire; Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland	University of Leicester; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Queens University Belfast	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com		Choy, David/0000-0003-1351-6113; Bradding, Peter/0000-0001-8403-0319; Arron, Joseph/0000-0001-7677-9979	Genentech, Inc, South San Francisco, Calif; ERDF [05567]; GlaxoSmithKline; Genentech, Inc; MedImmune; Novartis UK	Genentech, Inc, South San Francisco, Calif(Roche HoldingGenentech); ERDF(European Commission); GlaxoSmithKline(GlaxoSmithKline); Genentech, Inc(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Novartis UK(Novartis)	The Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, and the Centre for Infection and Immunity, Health Sciences Building, Queens University Belfast, were supported by grants from Genentech, Inc, South San Francisco, Calif. Research at the Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, was conducted in laboratories partially funded by ERDF no. 05567.; D. F. Choy, A. R. Abbas, C. D. Austin, J. Jackman, L. C. Wu, and J. R. Arron are employees of Genentech, Inc. L. G. Heaney has received travel and accommodation support to attend meetings from AstraZeneca, Chiesi, Novartis, GlaxoSmithKline, and Teva UK; has received research support from GlaxoSmithKline, Genentech, Inc, MedImmune, and Novartis UK; and has served on advisory boards for or received speakers' honoraria from GlaxoSmithKline, Merck Sharpe & Dohme, Nycomed, Novartis, and AstraZeneca. P. Bradding has received research support from Genentech, Inc. The rest of the authors declare that they have no relevant conflicts of interest.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Falaschetti E, 2004, EUR RESPIR J, V23, P456, DOI 10.1183/09031936.04.00055204; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Heaney LG, 2003, THORAX, V58, P561, DOI 10.1136/thorax.58.7.561; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Okayama Y, 2009, EUR RESPIR J, V34, P425, DOI 10.1183/09031936.00121008; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Rochman Y, 2008, CURR OPIN PHARMACOL, V8, P249, DOI 10.1016/j.coph.2008.03.002; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Siddiqui S, 2010, CHEST, V137, P797, DOI 10.1378/chest.09-1839; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	35	208	222	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					104	U147		10.1016/j.jaci.2011.08.031	http://dx.doi.org/10.1016/j.jaci.2011.08.031			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21975173				2022-12-18	WOS:000298634000013
J	[Anonymous]				[Anonymous]			National asthma education and prevention program - Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma - Summary report 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								Highlights of the National Asthma Education and Prevention Program's Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Full Report 2007 are presented in this EPR-3 summary report. The updated guidelines emphasize the importance of asthma control. Asthma control is the degree to which the manifestations of asthma are minimized by therapeutic intervention and the goals of therapy are met. Because asthma is highly variable, the level of control must be monitored on a periodic basis to determine whether therapy should be maintained or adjusted (stepped up if necessary, stepped down if possible). On the other hand, asthma severity is the intrinsic intensity of the disease process, most easily and directly measured in a patient not receiving long-term control therapy. For managing asthma, the recommendation is to assess severity to initiate therapy and assess control to adjust therapy. Recommendations for managing asthma include an expanded section on childhood asthma with addition of an age group 5 to 11 years old (earlier guidelines combined this group with adults). The guidelines provide new recommendations on patient education in settings beyond the physician's office, and new advice for controlling environmental factors that can cause asthma symptoms. The concepts of current impairment (frequency and intensity of symptoms, low lung function, and limitations of daily activities) and future risk (likelihood of exacerbations, progressive loss of lung function, or adverse side effects from medications) support a new approach to assessing and monitoring the patient's level of asthma control through use of multiple measures. The guidelines stress that some patients can still be at high risk for frequent exacerbations even if they have few day-to-day effects of asthma. Moreover, EPR-3 confirms the importance of teaching patients skills to self-monitor and manage asthma and to use a written asthma action plan, which should include instructions for daily treatment and ways to recognize and handle worsening asthma. New recommendations encourage expanding educational opportunities to reach patients in a variety of settings, such as pharmacies, schools, community centers, and patients' homes. A new section addresses the need for clinician education programs to improve communication with patients and to use system-wide approaches to integrate the guidelines into health care practice. The guidelines describe new evidence for using multiple approaches to limit exposure to allergens and other substances that can worsen asthma; research shows that single steps are rarely sufficient. EPR-3 also expands the section on common conditions that can affect asthma and notes that management of these conditions may help to improve asthma control. Expert Panel Report 3 continues the use of a stepwise approach to control asthma. When assessing the level of asthma control to determine the need for adjusting therapy, EPR-3 reconfirms the importance of assessing patient adherence to medication, inhaler technique, and environmental control measures before making a step up in therapy. The stepwise approach expands from 4 steps to 6 steps of care. Medications have been repositioned within these 6 steps. Recommendations on medications are updated to reflect the latest evidence on effectiveness and safety. EPR-3 reaffirms that patients with persistent asthma need both long-term control medications to control asthma and prevent exacerbations and quick-relief medication for symptoms, as needed. EPR-3 also reaffirms that inhaled corticosteroids are the most effective long-term control medication across all age groups. New recommendations on treatment options such as leukotriene receptor antagonists and cromolyn for long-term control; long-acting beta-agonists as adjunct therapy with inhaled corticosteroids; omalizumab for severe asthma; and albuterol, levalbuterol, and corticosteroids for acute exacerbations are included.											0	208	212	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5		S			S94	S138		10.1016/j.jaci.2007.09.029	http://dx.doi.org/10.1016/j.jaci.2007.09.029			45	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	235PU		Bronze			2022-12-18	WOS:000251247600002
J	Sorkness, CA; Lemanske, RF; Mauger, DT; Boehmer, SJ; Chinchilli, VM; Martinez, FD; Strunk, RC; Szefler, SJ; Zeiger, RS; Bacharier, LB; Bloomberg, GR; Covar, RA; Guilbert, TW; Heldt, G; Larsen, G; Mellon, MH; Morgan, WJ; Moss, MH; Spahn, JD; Taussig, LM				Sorkness, Christine A.; Lemanske, Robert F., Jr.; Mauger, David T.; Boehmer, Susan J.; Chinchilli, Vernon M.; Martinez, Fernando D.; Strunk, Robert C.; Szefler, Stanley J.; Zeiger, Robert S.; Bacharier, Leonard B.; Bloomberg, Gordon R.; Covar, Ronina A.; Guilbert, Theresa W.; Heldt, Gregory; Larsen, Gary; Mellon, Michael H.; Morgan, Wayne J.; Moss, Mark H.; Spahn, Joseph D.; Taussig, Lynn M.		Childhood Asthma Res Edu Network	Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; fluticasone propionate; salmeterol; montelukast; asthma control days; FEV1; forced vital capacity; maximum bronchodilator response; exhaled nitric oxide; methacholine PC20; Asthma Control Questionnaire	EXHALED NITRIC-OXIDE; FLUTICASONE PROPIONATE; AIRWAY HYPERRESPONSIVENESS; MONTELUKAST; SALMETEROL; CHILDREN; BUDESONIDE; TWICE; EXACERBATIONS; FORMOTEROL	Background: More evidence is needed on which to base recommendations for treatment of mild-moderate persistent asthma in school-aged children. Objective: The Pediatric Asthma Controller Trial (PACT) compared the effectiveness of 3 regimens in achieving asthma control. Methods: A total of 285 children (ages 6-14 years) with mild-moderate persistent asthma on the basis of symptoms, and with FEV1 >= 80% predicted and methacholine FEV1 PC20 <= 12.5 mg/mL, were randomized to 1 of 3 double-blind 48-week treatments: fluticasone 100 mu g twice daily (fluticasone monotherapy), fluticasone 100 mu g/salmeterol 50 mu g in the morning and salmeterol 50 mu g in the evening (PACT combination), and montelukast 5 mg in the evening. Outcomes included asthma control days (primary outcome), exacerbations, humanistic measurements, and pulmonary function measurements. Results: Fluticasone monotherapy and PACT combination were comparable in many patient-measured outcomes, including percent of asthma control days, but fluticasone monotherapy was superior for clinic-measured FEV1/forced vital capacity (P = .015), maximum bronchodilator response (P = .009), exhaled nitric oxide (P < .001), and PC20 (P < .001). Fluticasone monotherapy was superior to montelukast for asthma control days (64.2% vs 52.5%; P = .004) and for all other control outcomes. Growth over 48 weeks was not statistically different (fluticasone, 5.3 cm; PACT combination, 5.3 cm; montelukast, 5.7 cm). Conclusion: Both fluticasone monotherapy and PACT combination achieved greater improvements in asthma control days than montelukast. However, fluticasone monotherapy was superior to PACT combination in achieving other dimensions of asthma control. Growth was similar in all groups. Clinical implications: Therefore, of the regimens tested, the PACT study findings favor fluticasone monotherapy in treating children with mild-moderate persistent asthma with FEV1 >= 80% predicted, confirming current guideline recommendations.	Univ Wisconsin, Ctr Clin Sci, Madison, WI 53792 USA; Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Natl Jewish & Res Ctr, Dept Pediat, Denver, CO USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Kaiser Permanente, Dept Allergy, San Diego, CA 92103 USA; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA	University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of California System; University of California San Diego; Kaiser Permanente; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sorkness, CA (corresponding author), Univ Wisconsin, Ctr Clin Sci, K4-950,600 Highland Ave, Madison, WI 53792 USA.	Sorkness@facstaff.wisc.edu		Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [M01 RR03186, M01 RR00051, M01 RR00036] Funding Source: Medline; NHLBI NIH HHS [HL064307, HL064305, HL64287, HL064295, HL64288] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186, M01RR000051, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064307, U10HL064287, U10HL064305, U10HL064288, U10HL064295] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HOLT S, 2001, BRIT MED J, V323, P1, DOI DOI 10.1136/BMJ.323.7307.253; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; LaForce CF, 2000, ANN ALLERG ASTHMA IM, V85, P407, DOI 10.1016/S1081-1206(10)62556-2; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P68, DOI 10.1046/j.1365-2125.2003.01955.x; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Li AM, 2006, J ASTHMA, V43, P107, DOI 10.1080/02770900500497990; Masoli M, 2004, RESPIROLOGY, V9, P528, DOI 10.1111/j.1440-1843.2004.00635.x; Masoli M, 2005, RESPIROLOGY, V10, P183, DOI 10.1111/j.1440-1843.2005.00688.x; *NAT ASTHM ED PREV, 2003, J ALLERGY CLIN IMM S, V11, P466; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ostrom NK, 2005, J PEDIATR-US, V147, P213, DOI 10.1016/j.jpeds.2005.03.052; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; RUSSELL G, 1995, ANN ALLERG ASTHMA IM, V75, P423; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Shigyo M, 2005, RESPIRATION, V72, P480, DOI 10.1159/000087671; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tal A, 2002, PEDIATR PULM, V34, P342, DOI 10.1002/ppul.10173; *US PHARM CONV INC, 2005, US PHARM NAT FORM, P2412; Verberne AAPH, 1998, AM J RESP CRIT CARE, V158, P213, DOI 10.1164/ajrccm.158.1.9706048; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Wolfe J, 2000, J ALLERGY CLIN IMMUN, V105, P1153, DOI 10.1067/mai.2000.107037; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003	34	208	217	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					64	72		10.1016/j.jaci.2006.09.042	http://dx.doi.org/10.1016/j.jaci.2006.09.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17140647				2022-12-18	WOS:000243622200011
J	Murosaki, S; Yamamoto, Y; Ito, K; Inokuchi, T; Kusaka, H; Ikeda, H; Yoshikai, Y				Murosaki, S; Yamamoto, Y; Ito, K; Inokuchi, T; Kusaka, H; Ikeda, H; Yoshikai, Y			Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; IL-12; food allergy; Lactobacillus plantarum	CD4+ T-CELLS; LYMPHOCYTE MATURATION FACTOR; IFN-GAMMA PRODUCTION; INTERFERON-GAMMA; FUNCTIONAL SUBSETS; IN-VIVO; INTERLEUKIN-12; PURIFICATION; MACROPHAGES; CYTOKINE	Background: Food allergy is caused by production of IDE against dietary antigen induced by T-H2 response. IL-12 inhibits T-H2 responses and strongly suppresses IgE production. We have recently established a murine model for IgE production with a predominant T-H2 response induced by feeding antigen. Objective: We here show a suppressive effect of heat-killed Lactobacillus plantarum L-137, a potent inducer of IL-12, on IgE production against naturally fed antigen in a murine model. Methods: The ability of L. plantarum L-137 to induce IL-12 production was examined in vitro and in vivo. DBA/2 mice were fed a casein diet and injected intraperitoneally with L. plantarum L-137 from the beginning of feeding or 2 weeks later. Recombinant mouse IL-12 was also injected 2 weeks after the start of feeding, Casein-specific IgE and IgG1 in plasma were determined by ELISA. Results: L. plantarum L-137 directly induced IL-12 production by the peritoneal macrophages and also stimulated spleen cells to produce both IL-12 and interferon-gamma in vitro. In vivo treatment of L. plantarum L-137 also increased the plasma level of IL-12 in mice, Plasma anti-casein IgG1 and IgE levels were gradually elevated in DBA/2 mice fed a casein diet. Administration of L, plantarum L-137 from the beginning of feeding suppressed the elevation of anti-casein IgE levels, whereas the levels of anti-casein IgG1 were rather augmented by L. plantarum L-137. IL-12 production of the peritoneal macrophages was enhanced, but IL-4 production of concanavalin A (Con A)-stimulated spleen cells was suppressed in the L. plantarum L-137-treated mice compared with control mice fed a casein diet, When L. plantarum L-137 was given from 2 weeks after the start of feeding, anti-casein IgE levels mere also significantly suppressed, which was similar to the result found in mice treated with IL-12. Conclusion: Our results suggest that L. plantarum L-137, a potent IL-12 inducer, is useful for prevention and treatment of food allergy.	Takeda Chem Ind Ltd, Pharmaceut Res Labs 1, Yodogawa Ku, Osaka 532, Japan; Takeda Food Prod Ltd, Res & Dev Sect, Itami, Hyogo, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Nagoya, Aichi 466, Japan	Takeda Chemical Industries; Nagoya University	Murosaki, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Res Labs 1, Yodogawa Ku, 2-17-85 Juso Honmachi, Osaka 532, Japan.							Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DESIMONE C, 1986, NUTR REP INT, V33, P419; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; Fulton SA, 1996, INFECT IMMUN, V64, P2523, DOI 10.1128/IAI.64.7.2523-2531.1996; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GERMANN T, 1995, INT IMMUNOL, V7, P1649, DOI 10.1093/intimm/7.10.1649; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ito K, 1997, EUR J IMMUNOL, V27, P3427, DOI 10.1002/eji.1830271243; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KING CL, 1995, J IMMUNOL, V155, P454; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MARSHALL JD, 1995, J IMMUNOL, V155, P111; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172; MOON A, 1995, ANN ALLERG ASTHMA IM, V74, P5; MORRIS SC, 1994, J IMMUNOL, V152, P1047; MUSCETTOLA M, 1994, ANN NY ACAD SCI, V717, P226, DOI 10.1111/j.1749-6632.1994.tb12092.x; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; VIERA LQ, 1994, IMMUNOL LETT, V40, P157; Wang LF, 1996, J IMMUNOL, V156, P4079; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	29	208	220	2	19	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					57	64		10.1016/S0091-6749(98)70055-7	http://dx.doi.org/10.1016/S0091-6749(98)70055-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679848				2022-12-18	WOS:000074909500010
J	CORREN, J; ADINOFF, AD; BUCHMEIER, AD; IRVIN, CG				CORREN, J; ADINOFF, AD; BUCHMEIER, AD; IRVIN, CG			NASAL BECLOMETHASONE PREVENTS THE SEASONAL INCREASE IN BRONCHIAL RESPONSIVENESS IN PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; RHINITIS; BRONCHIAL RESPONSIVENESS; CORTICOSTEROIDS; RAGWEED ALLERGY	INHALATION CHALLENGE; FLOW-RATE; POLLEN; PHYSIOLOGY; AIRWAYS	Experimental studies have demonstrated that induction of a nasal allergic reaction can lead to an increase in bronchial responsiveness (BR). To assess the clinical relevance of these experimental changes to chronic asthma, we sought to determine the effect of nasal beclomethasone dipropionate (Bdp) on BR in patients with seasonal allergic rhinitis and asthma. Eighteen subjects with histories of seasonal allergic rhinitis and asthma during the fall pollen season with positive skin tests to short ragweed and bronchial hyperresponsiveness to inhaled methacholine were assigned to receive either nasal Bdp (336-mu-g / day) or placebo for the entire ragweed season. Patients recorded daily nasal and chest symptoms, nasal blockage index, oral peak expiratory flow rates, and supplemental medication use. BR to methacholine was measured during the baseline period and 6 weeks into the ragweed season. Although the Bdp group did have a significant improvement in nasal blockage index, there was no improvement in daily asthma symptom scores, oral peak expiratory flow, or asthma medication use. However, subjects treated with Bdp were protected from the increase in BR seen in the placebo group (geometric mean PC20 placebo group: baseline = 0.70, week 6 = 0.29; Bdp group: baseline = 0.80, week 6 = 0.93; intergroup difference, p = 0.022). We conclude that nasal corticosteroid therapy can prevent the increase in BR associated with seasonal pollen exposure in patients with allergic rhinitis and asthma.	UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT INTERNAL MED,DIV ALLERGY & CLIN IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PULM SCI,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					PHS HHS [37765] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRUGMAN S M, 1989, American Review of Respiratory Disease, V139, pA107; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Coffman D A, 1974, J R Coll Gen Pract, V24, P171; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HATCH TF, 1961, BACTERIOL REV, V237, P25; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; KALINER M, 1989, J ALLERGY CLIN IMMUN, V83, P510, DOI 10.1016/0091-6749(89)90031-6; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; PLOTKOWSKI L M, 1990, American Review of Respiratory Disease, V141, pA652; PROCTOR DF, 1977, AM REV RESPIR DIS, V115, P97; Raphael GD, 1988, AM J RHINOL, V2, P109; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Small P., 1989, AM J RHINOL, V3, P17, DOI [10.2500/105065889782024384, DOI 10.2500/105065889782024384]; SMITH JM, 1984, RHINITIS; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WIHL JA, 1988, ANN ALLERGY, V61, P50; YAN K, 1983, EUR J RESPIR DIS, V64, P105; 1980, ATS NEWS         SPR, P11	34	208	214	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					250	256		10.1016/0091-6749(92)90079-H	http://dx.doi.org/10.1016/0091-6749(92)90079-H			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500629				2022-12-18	WOS:A1992JJ42300016
J	TOOGOOD, JH; LEFCOE, NM; HAINES, DSM; JENNINGS, B; ERRINGTON, N; BAKSH, L; CHUANG, L				TOOGOOD, JH; LEFCOE, NM; HAINES, DSM; JENNINGS, B; ERRINGTON, N; BAKSH, L; CHUANG, L			GRADED DOSE ASSESSMENT OF EFFICACY OF BECLOMETHASONE DIPROPIONATE AEROSOL FOR SEVERE CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VICTORIA HOSP, ALLERGY CLIN, LONDON N6A 4G5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, SCH MED, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, SCH MED, DEPT PATHOL CHEM, LONDON N6A 3K7, ONTARIO, CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)								ASRILANT M, 1975, POSTGRAD MED J, V51, P79; BLOOM SW, 1963, DOCTOR HIS PATIENT S, P98; BOE J, 1975, CURR THER RES CLIN E, V17, P460; BROGDEN RN, 1975, DRUGS, V10, P166, DOI 10.2165/00003495-197510030-00002; BRUUN E, 1973, ACTA ALLERGOL, V28, P425, DOI 10.1111/j.1398-9995.1973.tb01456.x; BULOW KB, 1974, CURR THER RES CLIN E, V16, P1110; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CAYTON RM, 1973, BRIT MED J, V2, P547, DOI 10.1136/bmj.2.5865.547-b; CAYTON RM, 1974, LANCET, V2, P303; CHAMPION P, 1975, CAN MED ASSOC J, V113, P213; CHOO-KANG Y F J, 1972, British Journal of Diseases of the Chest, V66, P101, DOI 10.1016/S0007-0971(72)80031-7; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; DOLLERY CT, 1971, ANN NY ACAD SCI, V179, P108, DOI 10.1111/j.1749-6632.1971.tb46893.x; Eriksson N E, 1975, Allergol Immunopathol (Madr), V3, P77; GADDIE J, 1973, LANCET, V2, P280; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; GODFREY S, 1974, ANN ALLERGY, V33, P150; GODFREY S, 1975, PEDIATR CLIN N AM, V22, P147; GODFREY S, 1974, BMJ-BRIT MED J, V2, P387, DOI 10.1136/bmj.2.5915.387-b; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GRAFFLONNEVIG V, 1975, POSTGRAD MED J, V51, P93; GWYNN C M, 1974, Clinical Allergy, V4, P325, DOI 10.1111/j.1365-2222.1974.tb01393.x; HARRIS D M, 1973, Clinical Allergy, V3, P243, DOI 10.1111/j.1365-2222.1973.tb01329.x; HARRIS DM, 1975, J STEROID BIOCHEM, V6, P711, DOI 10.1016/0022-4731(75)90057-6; HODSON ME, 1974, AM REV RESPIR DIS, V110, P403; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; KREUS KE, 1975, SCAND J RESPIR DIS, V56, P47; LAHDENSUO A, 1974, SCAND J RESPIR DIS, V55, P309; LAL S, 1972, BMJ-BRIT MED J, V3, P314, DOI 10.1136/bmj.3.5822.314; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MARTIN LE, 1974, CLIN PHARMACOL THER, V15, P267; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MCALISTER NH, 1974, COMPUT BIOMED RES, V7, P496, DOI 10.1016/0010-4809(74)90028-7; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; MESSERLI C, 1975, PNEUMONOLOGIE, V153, P29, DOI 10.1007/BF02096333; MILNE LJR, 1974, BRIT MED J, V3, P797, DOI 10.1136/bmj.3.5934.797; MORRIS HG, 1974, J PEDIATR-US, V85, P248, DOI 10.1016/S0022-3476(74)80406-3; MORROWBROWN H, 1973, BRIT MED J, V3, P161; MORROWBROWN H, 1972, BRIT MED J, V8, P110; MORROWBROWN H, 1975, POSTGRAD MED J    S4, V51, P59; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; REES HA, 1962, BMJ-BRIT MED J, P1575, DOI 10.1136/bmj.1.5292.1575; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; THOMAS P, 1976, ANN R COLL PHYS SURG, V9, P12; TOOGOOD J, 1974, ACTA ALLERGOL, P50; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; VANDENBERG R, 1975, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1975.tb111324.x; 1976, BRIT J DIS CHEST, V70, P95; 1969, STANDARDS EPIDEMOLOG; 1975, LANCET, V1, P469	54	208	208	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					298	308		10.1016/0091-6749(77)90051-3	http://dx.doi.org/10.1016/0091-6749(77)90051-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	321503	Bronze			2022-12-18	WOS:A1977DB88600005
J	Schwab, C; Gabrysch, A; Olbrich, P; Patino, V; Warnatz, K; Wolff, D; Hoshino, A; Kobayashi, M; Imai, K; Takagi, M; Dybedal, I; Haddock, JA; Sansom, DM; Lucena, JM; Seidl, M; Schmitt-Graeff, A; Reiser, V; Emmerich, F; Frede, N; Bulashevska, A; Salzer, U; Schubert, D; Hayakawa, S; Okada, S; Kanariou, M; Kucuk, ZY; Chapdelaine, H; Petruzelkova, L; Sumnik, Z; Sediva, A; Slatter, M; Arkwright, PD; Cant, A; Lorenz, HM; Giese, T; Lougaris, V; Plebani, A; Price, C; Sullivan, KE; Moutschen, M; Litzman, J; Freiberger, T; van de Veerdonk, FL; Recher, M; Albert, MH; Hauck, F; Seneviratne, S; Schmid, JP; Kolios, A; Unglik, G; Klemann, C; Speckmann, C; Ehl, S; Leichtner, A; Blumberg, R; Franke, A; Snapper, S; Zeissig, S; Cunningham-Rundles, C; Giulino-Roth, L; Elemento, O; Duckers, G; Niehues, T; Fronkova, E; Kanderova, V; Platt, CD; Chou, J; Chatila, TA; Geha, R; McDermott, E; Bunn, S; Kurzai, M; Schulz, A; Alsina, L; Casals, F; Deya-Martinez, A; Hambleton, S; Kanegane, H; Tasken, K; Neth, O; Grimbacher, B				Schwab, Charlotte; Gabrysch, Annemarie; Olbrich, Peter; Patino, Virginia; Warnatz, Klaus; Wolff, Daniel; Hoshino, Akihiro; Kobayashi, Masao; Imai, Kohsuke; Takagi, Masatoshi; Dybedal, Ingunn; Haddock, Jamanda A.; Sansom, David M.; Lucena, Jose M.; Seidl, Maximilian; Schmitt-Graeff, Annette; Reiser, Veronika; Emmerich, Florian; Frede, Natalie; Bulashevska, Alla; Salzer, Ulrich; Schubert, Desiree; Hayakawa, Seiichi; Okada, Satoshi; Kanariou, Maria; Kucuk, Zeynep Yesim; Chapdelaine, Hugo; Petruzelkova, Lenka; Sumnik, Zdenek; Sediva, Anna; Slatter, Mary; Arkwright, Peter D.; Cant, Andrew; Lorenz, Hanns-Martin; Giese, Thomas; Lougaris, Vassilios; Plebani, Alessandro; Price, Christina; Sullivan, Kathleen E.; Moutschen, Michel; Litzman, Jiri; Freiberger, Tomas; van de Veerdonk, Frank L.; Recher, Mike; Albert, Michael H.; Hauck, Fabian; Seneviratne, Suranjith; Schmid, Jana Pachlopnik; Kolios, Antonios; Unglik, Gary; Klemann, Christian; Speckmann, Carsten; Ehl, Stephan; Leichtner, Alan; Blumberg, Richard; Franke, Andre; Snapper, Scott; Zeissig, Sebastian; Cunningham-Rundles, Charlotte; Giulino-Roth, Lisa; Elemento, Olivier; Dueckers, Gregor; Niehues, Tim; Fronkova, Eva; Kanderova, Veronika; Platt, Craig D.; Chou, Janet; Chatila, Talal A.; Geha, Raif; McDermott, Elizabeth; Bunn, Su; Kurzai, Monika; Schulz, Ansgar; Alsina, Laia; Casals, Ferran; Deya-Martinez, Angela; Hambleton, Sophie; Kanegane, Hirokazu; Tasken, Kjetil; Neth, Olaf; Grimbacher, Bodo			Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytotoxic T-lymphocyte antigen 4; primary immunodeficiency; autoimmunity; hypogammaglobulinemia; hematopoietic stem cell transplantation; abatacept; sirolimus; immune dysregulation; common variable immunodeficiency	STEM-CELL TRANSPLANTATION; IMMUNE DYSREGULATION; LRBA DEFICIENCY; CTLA-4 HAPLOINSUFFICIENCY; GERMLINE MUTATIONS; PATIENT; DISEASE; CLASSIFICATION; AUTOIMMUNITY; FAMILY	Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative immune regulator. Heterozygous CTLA4 germline mutations can cause a complex immune dysregulation syndrome in human subjects. Objective: We sought to characterize the penetrance, clinical features, and best treatment options in 133 CTLA4 mutation carriers. Methods: Genetics, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers. Results: We identified 133 subjects from 54 unrelated families carrying 45 different heterozygous CTLA4 mutations, including 28 previously undescribed mutations. Ninety mutation carriers were considered affected, suggesting a clinical penetrance of at least 67%; median age of onset was 11 years, and the mortality rate within affected mutation carriers was 16%(n = 15). Main clinical manifestations included hypogammaglobulinemia (84%), lymphoproliferation (73%), autoimmune cytopenia (62%), and respiratory (68%), gastrointestinal (59%), or neurological features (29%). Eight affectedmutation carriers had lymphoma, and 3 had gastric cancer. An EBV association was found in 6 patients with malignancies. CTLA4 mutations were associated with lymphopenia and decreased T-, B-, and natural killer (NK) cell counts. Successful targeted therapies included application of CTLA-4 fusion proteins, mechanistic target of rapamycin inhibitors, and hematopoietic stem cell transplantation. EBV reactivation occurred in 2 affected mutation carriers after immunosuppression. Conclusions: Affected mutation carriers with CTLA-4 insufficiency can present in any medical specialty. Family members should be counseled because disease manifestation can occur as late as 50 years of age. EBV- and cytomegalovirus-associated complications must be closely monitored. Treatment interventions should be coordinated in clinical trials.	[Schwab, Charlotte; Gabrysch, Annemarie; Warnatz, Klaus; Reiser, Veronika; Frede, Natalie; Bulashevska, Alla; Salzer, Ulrich; Schubert, Desiree; Klemann, Christian; Speckmann, Carsten; Ehl, Stephan; Grimbacher, Bodo] Univ Freiburg, Fac Med, Med Ctr, CCI, Freiburg, Germany; [Olbrich, Peter; Neth, Olaf] Hosp Virgen del Rocio, Inst Biomed Sevilla IBiS, Unidad Pediat, Secc Infectol & Inmunopatol, Seville, Spain; [Patino, Virginia] Amer Insurance, Immunol Team, Montevideo, Uruguay; [Wolff, Daniel] Univ Hosp Regensburg, Dept Internal Med 3, Regensburg, Germany; [Hoshino, Akihiro; Kanegane, Hirokazu] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan; [Imai, Kohsuke; Takagi, Masatoshi] Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Kobayashi, Masao; Hayakawa, Seiichi; Okada, Satoshi] Hiroshima Univ, Grad Sch Biomedical& Hlth Sci, Dept Pediat, Hiroshima, Japan; [Dybedal, Ingunn] Oslo Univ Hosp, Dept Hematol, Oslo, Norway; [Haddock, Jamanda A.] UCL, Royal Free Hosp, Dept Radiol, London, England; [Sansom, David M.] Royal Free Hosp, UCL Inst Immun & Transplantat, London, England; [Lucena, Jose M.] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Unidad Inmunol, Seville, Spain; [Seidl, Maximilian] Univ Freiburg, Dept Pathol, Ctr Chron Immunodeficiency & Mol Pathol, Freiburg, Germany; [Schmitt-Graeff, Annette] Univ Freiburg, Dept Pathol, Univ Med Ctr, Freiburg, Germany; [Reiser, Veronika] Univ Freiburg, Fac Med, Inst Med Biometry & Stat, Freiburg, Germany; [Reiser, Veronika] Univ Freiburg, Med Ctr, Freiburg, Germany; [Emmerich, Florian] Univ Med Ctr Freiburg, Inst Transfus Med & Gene Therapy, Freiburg, Germany; [Schubert, Desiree] Freiburg Univ, Spemann Grad Sch Biol & Med, Freiburg, Germany; [Kanariou, Maria] Aghia Sophia Childrens Hosp, Ctr Primary Immunodeficiencies, Dept Immunol & Histocompatibil, Athens, Greece; [Kucuk, Zeynep Yesim] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Chapdelaine, Hugo] Univ Montreal, CHUM, Dept Med, Clin Immunol & Allergy Div, Montreal, PQ, Canada; [Petruzelkova, Lenka; Sumnik, Zdenek] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Sediva, Anna] Univ Hosp Motol, Dept Immunol, Prague, Czech Republic; Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Slatter, Mary; Cant, Andrew; Hambleton, Sophie] Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Slatter, Mary; Cant, Andrew; Hambleton, Sophie] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England; [Lorenz, Hanns-Martin] Heidelberg Univ, Dept Internal Med 5, Div Rheumatol, Heidelberg, Germany; [Giese, Thomas] Univ Hosp Heidelberg, Inst Immunol, Heidelberg, Germany; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, ASST Spedali Civili Brescia, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, ASST Spedali Civili Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Price, Christina] Yale Univ, Sch Med, Sect Allergy & Clin Immunol, New Haven, CT USA; [Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA; [Moutschen, Michel] Univ Hosp Liege, Dept Infect Dis & Gen Internal Med, Liege, Belgium; [Litzman, Jiri] Masaryk Univ, Fac Med, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Freiberger, Tomas] Masaryk Univ, Cent European Inst Technol, Med Genom RG, Brno, Czech Republic; [Litzman, Jiri] St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Freiberger, Tomas] Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Brno, Czech Republic; [van de Veerdonk, Frank L.] Radboudumc Ctr Infect Dis RCI, Dept Internal Med, Nijmegen, Netherlands; [Recher, Mike] Univ Hosp, Med Outpatient Unit, Immunodeficiency Clin, Basel, Switzerland; [Recher, Mike] Univ Hosp, Dept Biomed, Immunodeficiency Lab, Basel, Switzerland; [Albert, Michael H.; Hauck, Fabian] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat Immunol & Stem Cell Transplantat, Munich, Germany; [Seneviratne, Suranjith; Grimbacher, Bodo] UCL, Royal Free Hosp, Inst Immunol & Transplantat, London, England; [Schmid, Jana Pachlopnik] Univ Zurich, Univ Childrens Hosp Zurich, Div Immunol, Zurich, Switzerland; [Kolios, Antonios] Univ Zurich, Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland; [Unglik, Gary] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia; [Speckmann, Carsten] Univ Freiburg, Fac Med, Univ Med Ctr, Ctr Pediat, Freiburg, Germany; [Leichtner, Alan] Harvard Med Sch, Div Gastroenterol, Boston, MA USA; [Leichtner, Alan] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Blumberg, Richard; Zeissig, Sebastian] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA; [Franke, Andre] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Snapper, Scott] Childrens Hosp, Dept Med, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA 02115 USA; [Zeissig, Sebastian] Tech Univ Dresden, Univ Med Ctr Dresden, Dept Med 1, Dresden, Germany; [Zeissig, Sebastian] Univ Med Ctr Schleswig Holstein, Dept Internal Med 1, Kiel, Germany; [Cunningham-Rundles, Charlotte] Mt Sinai Hosp, Mt Sinai St Lukes & Mt Sinai West, Dept Med Allergy & Immunol, New York, NY 10029 USA; [Giulino-Roth, Lisa] Weill Cornell Med, Div Pediat Hematol Oncol, Dept Pediat, New York, NY USA; [Elemento, Olivier] Weill Cornell Med Coll, Dept Physiol & Biophys, Inst Computat Biomed, New York, NY USA; [Dueckers, Gregor; Niehues, Tim] HELIOS Childrens Hosp, Krefeld, Germany; [Fronkova, Eva; Kanderova, Veronika] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, CLIP, Prague, Czech Republic; [Fronkova, Eva; Kanderova, Veronika] Univ Hosp Motol, Prague, Czech Republic; [Platt, Craig D.; Chou, Janet; Chatila, Talal A.; Geha, Raif] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Platt, Craig D.; Chou, Janet; Chatila, Talal A.; Geha, Raif] Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [McDermott, Elizabeth] Nottingham Univ Hosp, Clin Immunol & Allergy Unit, Nottingham, England; [Bunn, Su] Great North Childrens Hosp, Dept Paediat Gastroenterol, Newcastle Upon Tyne, Tyne & Wear, England; [Kurzai, Monika] Univ Hosp Jena, Dept Pediat, Jena, Germany; [Schulz, Ansgar] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Alsina, Laia; Deya-Martinez, Angela] Hosp St Joan de Deu, Inst Recerca Pediat, Allergy & Clin Immunol Dept, Funct Unit,Immunol SJD Clin, Esplugas de Llobregat, Spain; [Casals, Ferran] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Serv Genom, Parc Recerca Biomed Barcelona, Barcelona, Spain; [Tasken, Kjetil] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway, Oslo, Norway; [Tasken, Kjetil] Univ Hosp Oslo, Inst Canc Res, Oslo, Norway; [Klemann, Christian] Hannover Med Sch, Dept Pediat Pneumol Allergy & Neonatol, Hannover, Germany; [Klemann, Christian] Hannover Med Sch, Ctr Pediat Surg, Hannover, Germany	University of Freiburg; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; University of Regensburg; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Hiroshima University; University of Oslo; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; The Aghia Sophia Children's Hospital; Cincinnati Children's Hospital Medical Center; Universite de Montreal; Motol University Hospital; Motol University Hospital; Charles University Prague; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Royal Manchester Children's Hospital; University of Manchester; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Yale University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Liege; Masaryk University Brno; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); University of Munich; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University Children's Hospital Zurich; University of Zurich; University of Zurich; University Zurich Hospital; Royal Melbourne Hospital; University of Freiburg; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Kiel; Harvard University; Boston Children's Hospital; Technische Universitat Dresden; University of Kiel; Schleswig Holstein University Hospital; Icahn School of Medicine at Mount Sinai; Mount Sinai St. Luke's; Mount Sinai West; Cornell University; Cornell University; Charles University Prague; Motol University Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Nottingham University Hospital NHS Trust; University of Nottingham; Friedrich Schiller University of Jena; Ulm University; Pompeu Fabra University; University of Oslo; University of Oslo; Hannover Medical School; Hannover Medical School	Grimbacher, B (corresponding author), Univ Klinikum Freiburg, CCI, Breisacher Str 115, D-79106 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Okada, Satoshi/B-8901-2011; van de Veerdonk, Frank L/C-7256-2008; Freiberger, Tomas/D-8421-2011; Olbrich, Peter/AAV-3601-2021; Ehl, Stephan/AAM-6006-2020; Warnatz, Klaus/AAD-3464-2022; Alsina, Laia/AID-4372-2022; Klemann, Christian/AAQ-9301-2020; Neth, Olaf/F-1167-2015; Hauck, Fabian/H-5556-2016; Seidl, Maxmilian/ABF-3322-2021; Zeissig, Sebastian/B-6297-2012; Casals, Ferran/H-4347-2015; Bulashevska, Alla/C-4910-2019; Imai, Kohsuke/Q-2602-2015; Franke, Andre/B-2151-2010; Sediva, Anna/AAE-2774-2019; Alsina, Laia/GQI-3516-2022; Pachlopnik Schmid, Jana/N-8018-2018	Okada, Satoshi/0000-0002-4622-5657; van de Veerdonk, Frank L/0000-0002-1121-4894; Freiberger, Tomas/0000-0001-6532-7053; Olbrich, Peter/0000-0001-9853-7903; Klemann, Christian/0000-0002-5639-8690; Neth, Olaf/0000-0001-5018-0466; Seidl, Maxmilian/0000-0002-5559-4980; Zeissig, Sebastian/0000-0001-5124-0897; Casals, Ferran/0000-0002-8941-0369; Imai, Kohsuke/0000-0003-2132-8403; Franke, Andre/0000-0003-1530-5811; Sediva, Anna/0000-0001-7730-2304; Sumnik, Zdenek/0000-0002-6462-6462; Hauck, Fabian/0000-0001-9644-2003; Speckmann, Carsten/0000-0002-6217-1556; Kanderova, Veronika/0000-0001-8513-1066; Deya-Martinez, Angela/0000-0002-8026-7674; Chatila, Talal/0000-0001-7439-2762; Tasken, Kjetil/0000-0003-2841-4697; Hambleton, Sophie/0000-0001-7954-3267; Alsina, Laia/0000-0002-3559-0018; Salzer, Ulrich/0000-0002-1769-1157; Sansom, David/0000-0001-6506-3115; Chapdelaine, Hugo/0000-0001-6256-0271; Recher, Mike/0000-0002-9121-6936; Litzman, Jiri/0000-0002-1926-5426; Kolios, Antonios/0000-0002-3897-4578; Ehl, Stephan/0000-0002-9265-2721; Pachlopnik Schmid, Jana/0000-0002-6653-9047	German Ministry of Education and Research (BMBF) [01E01303, 01ZX1306 F]; German Center for Infection Research [DZIF 8039807801]; Deutsche Forschungsgemeinschaft (DFG) [SFB1160]; Bristol-Myers Squibb [BMS_OT125-252]; National Institute of Health;  [NV15-30626A]; BBSRC [BB/H013598/1, BB/H013598/2] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [K08CA219473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085090, R34AI106570, P01AI061093] Funding Source: NIH RePORTER	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Center for Infection Research; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Bristol-Myers Squibb(Bristol-Myers Squibb); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the German Ministry of Education and Research (BMBF, grant no. 01E01303 and sysINFLAME (grant no 01ZX1306 F) by the German Center for Infection Research (DZIF 8039807801), the Deutsche Forschungsgemeinschaft (DFG; grant SFB1160, IMPATH, P07), and Bristol-Myers Squibb (BMS_OT125-252). E.F. and V.K. were supported by NV15-30626A. T.C. was funded by the National Institute of Health. The funding organizations had no role in the study design; collection, analysis and interpretation of data; writing of the report; or decision to submit the paper for publication. The authors are responsible for the content of this research.	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Bour-Jordan H, 2009, IMMUNOL REV, V229, P41, DOI 10.1111/j.1600-065X.2009.00775.x; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; European Society for Immunodeficiencies, NEW CLIN DIAGN CRIT; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Friedline RH, 2009, J EXP MED, V206, P421, DOI 10.1084/jem.20081811; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Hayakawa S, 2016, J CLIN IMMUNOL, V36, P28, DOI 10.1007/s10875-015-0221-x; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hou TZ, 2018, CLIN IMMUNOL, V188, P94, DOI 10.1016/j.clim.2018.01.001; Hou TZ, 2017, BLOOD, V129, P1458, DOI 10.1182/blood-2016-10-745174; Kucuk ZY, 2017, J ALLERGY CLIN IMMUN, V140, P862, DOI 10.1016/j.jaci.2017.02.032; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Levy E, 2016, CLIN IMMUNOL, V168, P88, DOI 10.1016/j.clim.2016.03.006; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Navarini AA, 2017, J ALLERGY CLIN IMMUN, V139, P1043, DOI 10.1016/j.jaci.2016.08.042; Ochs HD, 2007, IMMUNOL RES, V38, P112, DOI 10.1007/s12026-007-0022-2; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Sari S, 2016, J CLIN IMMUNOL, V36, P8, DOI 10.1007/s10875-015-0220-y; Schreiner F, 2016, J CLIN ENDOCR METAB, V101, P898, DOI 10.1210/jc.2015-3382; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Serwas NK, 2015, INFLAMM BOWEL DIS, V21, P40, DOI 10.1097/MIB.0000000000000266; Slatter MA, 2016, J ALLERGY CLIN IMMUN, V138, P615, DOI 10.1016/j.jaci.2016.01.045; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tesi B, 2016, J CLIN IMMUNOL, V36, P480, DOI 10.1007/s10875-016-0289-y; Walker LSK, 2013, J AUTOIMMUN, V45, P49, DOI 10.1016/j.jaut.2013.06.006; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Zeissig S, 2015, GUT, V64, P1889, DOI 10.1136/gutjnl-2014-308541	42	207	213	6	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1932	1946		10.1016/j.jaci.2018.02.055	http://dx.doi.org/10.1016/j.jaci.2018.02.055			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29729943	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000452315800026
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			Allergens and the airway epithelium response: Gateway to allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; epithelium; dendritic cells; T(H)2	HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; INNATE LYMPHOID-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR GATA3; LUNG DENDRITIC CELLS; INHALED ANTIGEN; IMMUNE-RESPONSES; BARRIER FUNCTION; TYPE-2 IMMUNITY	Allergic sensitization to inhaled antigens is common but poorly understood. Although lung epithelial cells were initially merely regarded as a passive barrier impeding allergen penetrance, we now realize that they recognize allergens through expression of pattern recognition receptors and mount an innate immune response driven by activation of nuclear factor kappa B. On allergen recognition, epithelial cells release cytokines, such as IL-1, IL-25, IL-33, thymic stromal lymphopoietin, and GM-CSF, and endogenous danger signals, such as high-mobility group box 1, uric acid, and ATP, that activate the dendritic cell network and other innate immune cells, such as basophils and type 2 innate lymphoid cells. Different allergens stimulate different aspects of this general scheme, and common environmental risk factors for sensitization, such as cigarette smoke and diesel particle exposure, do so as well. All of this is influenced by genetic polymorphisms affecting epithelial pattern recognition, barrier function, and cytokine production. Therefore, epithelial cells are crucial in determining the outcome of allergen inhalation.	[Lambrecht, Bart N.; Hammad, Hamida] VIB, Inflammat Res Ctr, Immunoregulat Lab, Ghent, Belgium; [Lambrecht, Bart N.; Hammad, Hamida] Univ Hosp Ghent, Dept Resp Med, Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC	Lambrecht, BN (corresponding author), Univ Ghent, VIB, Inflammat Res Ctr, Technol Pk 927, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart N/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart N/0000-0003-4376-6834	European Union ERC Consolidator grant; FWO grants; European Union FP7 grant EUBiopred; MedALL; University of Ghent Multidisciplinary Research Platform grant (GROUP-ID)	European Union ERC Consolidator grant; FWO grants(FWO); European Union FP7 grant EUBiopred; MedALL; University of Ghent Multidisciplinary Research Platform grant (GROUP-ID)	Supported by a European Union ERC Consolidator grant to B.N.L., several FWO grants to B.N.L. and H.H., and by European Union FP7 grants EUBiopred and MedALL to B.N.L. and H.H. Work in the authors' lab is supported by a University of Ghent Multidisciplinary Research Platform grant (GROUP-ID).	Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Allen IC, 2012, J IMMUNOL, V188, P2884, DOI 10.4049/jimmunol.1102488; Arizmendi NG, 2011, J IMMUNOL, V186, P3164, DOI 10.4049/jimmunol.0903812; Arora M, 2010, MUCOSAL IMMUNOL, V3, P578, DOI 10.1038/mi.2010.41; Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barry J, 2013, AM J RESP CELL MOL, V49, P481, DOI 10.1165/rcmb.2012-0425OC; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Blume C, 2013, EUR RESPIR J, V42, P87, DOI 10.1183/09031936.00075612; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Botelho FM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-81; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; Finkelman MA, 2006, J ENDOTOXIN RES, V12, P241, DOI 10.1179/096805106X102237; Gangl K, 2009, ALLERGY, V64, P398, DOI 10.1111/j.1398-9995.2008.01861.x; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kerksiek KM, 2005, BLOOD, V105, P742, DOI 10.1182/blood-2004-05-1891; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Koning H, 2012, FASEB J, V26, P439, DOI 10.1096/fj.11-185207; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Kuipers H, 2003, J IMMUNOL, V171, P3645, DOI 10.4049/jimmunol.171.7.3645; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2000, CLIN EXP ALLERGY, V30, P214; Lanckacker EA, 2013, EUR RESPIR J, V41, P1189, DOI 10.1183/09031936.00096612; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Lee HC, 2012, J ALLERGY CLIN IMMUN, V130, P1187, DOI 10.1016/j.jaci.2012.07.031; Leino MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071278; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Magalhaes JG, 2011, P NATL ACAD SCI USA, V108, P14896, DOI 10.1073/pnas.1015063108; Martin RA, 2013, AM J RESP CELL MOL, V48, P655, DOI 10.1165/rcmb.2012-0423OC; Melkamu T, 2009, J MEMBRANE BIOL, V229, P101, DOI 10.1007/s00232-009-9175-3; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; Mueller GA, 2013, J ALLERGY CLIN IMMUN, V132, P1420, DOI 10.1016/j.jaci.2013.06.014; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nawijn MC, 2011, TRENDS IMMUNOL, V32, P248, DOI 10.1016/j.it.2011.03.004; Norimoto A, 2014, AM J RESP CELL MOL B; Osterlund C, 2009, CLIN EXP ALLERGY, V39, P1199, DOI 10.1111/j.1365-2222.2009.03284.x; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Pacheco K, 2008, J ALLERGY CLIN IMMUN, V122, P896, DOI 10.1016/j.jaci.2008.08.025; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Post S, 2012, THORAX, V67, P488, DOI 10.1136/thoraxjnl-2011-200606; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Rezaee F, 2013, J VIROL, V87, P11088, DOI 10.1128/JVI.01573-13; Ryu JH, 2013, J ALLERGY CLIN IMMUN, V131, P549, DOI 10.1016/j.jaci.2012.07.050; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Semmrich M, 2012, MUCOSAL IMMUNOL, V5, P150, DOI 10.1038/mi.2011.61; Shim EJ, 2012, CLIN EXP ALLERGY, V42, P958, DOI 10.1111/j.1365-2222.2012.03998.x; Sidhaye VK, 2011, AM J RESP CELL MOL, V45, P120, DOI 10.1165/rcmb.2010-0235OC; Suzukawa M, 2012, J IMMUNOL, V189, P3641, DOI 10.4049/jimmunol.1200461; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tully JE, 2013, J IMMUNOL, V191, P5811, DOI 10.4049/jimmunol.1301329; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Williams MA, 2008, J IMMUNOL, V181, P4545, DOI 10.4049/jimmunol.181.7.4545; Wills-Karp M, 2012, J EXP MED, V209, P607, DOI 10.1084/jem.20110079; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zhou Y, 2012, HUM IMMUNOL, V73, P1171, DOI 10.1016/j.humimm.2012.08.016	113	207	212	1	68	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					499	507		10.1016/j.jaci.2014.06.036	http://dx.doi.org/10.1016/j.jaci.2014.06.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25171864				2022-12-18	WOS:000341372400001
J	Saha, SK; Berry, MA; Parker, D; Siddiqui, S; Morgan, A; May, R; Monk, P; Bradding, P; Wardlaw, AJ; Pavord, ID; Brightling, CE				Saha, Shironjit K.; Berry, Mike A.; Parker, Deborah; Siddiqui, Salman; Morgan, Angela; May, Richard; Monk, Phillip; Bradding, Peter; Wardlaw, Andrew J.; Pavord, Ian D.; Brightling, Christopher E.			Increased sputum and bronchial biopsy IL-13 expression in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						severe asthma; IL-13; sputum; bronchus; airway smooth muscle; eosinophilia	AIRWAY SMOOTH-MUSCLE; MAST-CELLS; EOSINOPHILIC BRONCHITIS; SIGNALING PATHWAYS; MESSENGER-RNA; INTERLEUKIN-13; IMMUNOHISTOCHEMISTRY; IDENTIFICATION; INFLAMMATION; CHALLENGE	Background: The importance of IL-13 in the asthma paradigm is supported by increased expression in human subjects, particularly in patients with mild-to-moderate asthma. However, the role of IL-13 in severe asthma needs to be further defined. Objective: We sought to assess IL-13 expression in sputum and bronchial biopsy specimens from subjects with mild-to-severe asthma. Methods: Sputum IL-13 concentrations were measured in 32 control subjects, 34 subjects with mild asthma, 21 subjects with moderate asthma, and 26 subjects with severe asthma. Enumeration of mast cells, eosinophils, and IL-13(+) cells in the bronchial submucosa and airway smooth muscle (ASM) bundle was performed in 7 control subjects, 14 subjects with mild asthma, 7 subjects with moderate asthma, and 7 subjects with severe asthma. Results: The proportion of subjects with measurable IL-13 in the sputum was increased in the mild asthma group (15/34) and severe asthma group (10/26) compared with that seen in the control group (4/32; P =.004). IL-13(+) cells were increased within the submucosa in all asthma severity groups compared with control subjects (P =.006). The number of IL-13+ cells were increased within the ASM bundle in the severe asthma group compared with that seen in the other groups (P <.05). Asthma control questionnaire scores positively correlated with sputum IL-13 concentrations (R-s = 0.35, P =.04) and mast cells in the ASM bundle (R-s = 0.7, P =.007). IL-13(+) cells within the submucosa and ASM correlated with sputum eosinophilia (R-s = 0.4, P <=.05). Conclusions: IL-13 overexpression in sputum and bronchial biopsy specimens is a feature of severe asthma.	[Saha, Shironjit K.; Berry, Mike A.; Parker, Deborah; Siddiqui, Salman; Morgan, Angela; Bradding, Peter; Wardlaw, Andrew J.; Pavord, Ian D.; Brightling, Christopher E.] Univ Hosp Leicester, Clin Sci Wing, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; [May, Richard] Cambridge Antibody Technol, Cambridge, England; [Monk, Phillip] Synairgen Res Ltd, Southampton, Hants, England	University Hospitals of Leicester NHS Trust; University of Leicester; AstraZeneca	Brightling, CE (corresponding author), Univ Hosp Leicester, Clin Sci Wing, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	cebl7@le.ac.uk		Pavord, Ian/0000-0002-4288-5973; Wardlaw, Andrew/0000-0001-6583-0791; brightling, chris/0000-0002-9345-4903; May, Richard/0000-0001-7825-2716; Bradding, Peter/0000-0001-8403-0319	Asthma UK [05/058] Funding Source: researchfish; Wellcome Trust [082265] Funding Source: Medline	Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission)		Amin K, 2005, ALLERGY, V60, P1241, DOI 10.1111/j.1398-9995.2005.00823.x; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520, DOI 10.1152/ajplung.00343.2001; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Honeybourne D, 2001, THORAX, V56, pI1; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kaur D, 2006, ALLERGY, V61, P1047, DOI 10.1111/j.1398-9995.2006.01139.x; Komai-Koma M, 2001, CLIN EXP ALLERGY, V31, P1441, DOI 10.1046/j.1365-2222.2001.01174.x; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Peng Q, 2004, AM J RESP CRIT CARE, V169, P596, DOI 10.1164/rccm.200307-888OC; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Sutcliffe A, 2006, THORAX, V61, P657, DOI 10.1136/thx.2005.056770; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Wardlaw AJ, 2002, CLIN SCI, V103, P201; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	34	207	223	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					685	691		10.1016/j.jaci.2008.01.005	http://dx.doi.org/10.1016/j.jaci.2008.01.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328894	Green Accepted			2022-12-18	WOS:000253918900022
J	RYAN, G; DOLOVICH, MB; OBMINSKI, G; COCKCROFT, DW; JUNIPER, E; HARGREAVE, FE; NEWHOUSE, MT				RYAN, G; DOLOVICH, MB; OBMINSKI, G; COCKCROFT, DW; JUNIPER, E; HARGREAVE, FE; NEWHOUSE, MT			STANDARDIZATION OF INHALATION PROVOCATION TESTS - INFLUENCE OF NEBULIZER OUTPUT, PARTICLE-SIZE, AND METHOD OF INHALATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University								BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P92; ELLETT WH, 1965, BRIT J RADIOL, V38, P541, DOI 10.1259/0007-1285-38-451-541; JUNIPER E, 1978, THORAX, V33, P700; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MERCER TT, 1965, ANN ALLERGY, V23, P314; MERCER TT, 1969, ANN ALLERGY, V27, P211; MERCER TT, 1970, AEROSOL SCI, V1, P9; NEWHOUSE MT, 1968, RESP PHYSIOL, V4, P141, DOI 10.1016/0034-5687(68)90048-0; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; RYAN G, AM REV RESPIR DIS; SANCHIS J, 1972, J APPL PHYSIOL, V33, P757, DOI 10.1152/jappl.1972.33.6.757; SOKAL RR, 1969, BIOMETRY, P239	18	207	207	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					156	161		10.1016/0091-6749(81)90012-9	http://dx.doi.org/10.1016/0091-6749(81)90012-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451782				2022-12-18	WOS:A1981LB94700012
J	Glassner, KL; Abraham, BP; Quigley, EMM				Glassner, Kerri L.; Abraham, Bincy P.; Quigley, Eamonn M. M.			The microbiome and inflammatory bowel disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammatory bowel disease; ulcerative colitis; Crohn disease; microbiome; microbiota; inflammation; genetics; environmental factors; antibiotics; probiotics; prebiotics; fecal microbiota transplantation	ACTIVE CROHNS-DISEASE; PROBIOTIC THERAPY VSLNUMBER-3; ULCERATIVE-COLITIS; DOUBLE-BLIND; ESCHERICHIA-COLI; MAINTAINING REMISSION; ENTERAL NUTRITION; CONTROLLED-TRIAL; FECAL STREAM; T-CELLS	Inflammatory bowel disease (IBD) is a chronic immune-mediated disease affecting the gastrointestinal tract. IBD consists of 2 subtypes: ulcerative colitis and Crohn disease. IBD is thought to develop as a result of interactions between environmental, microbial, and immune-mediated factors in a genetically susceptible host. Of late, the potential role of the microbiome in the development, progression, and treatment of IBD has been a subject of considerable interest and enquiry. Indeed, studies in human subjects have shown that the gut microbiome is different in patients with IBD compared with that in healthy control subjects. Other evidence in support of a fundamental role for the microbiome in patients with IBD includes identification of mutations in genes involved in microbiome-immune interactions among patients with IBD and epidemiologic observations implicating such microbiota-modulating risk factors as antibiotic use, cigarette smoking, levels of sanitation, and diet in the pathogenesis of IBD. Consequently, there has been much interest in the possible benefits of microbiome-modulating interventions, such as probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation in the treatment of IBD. In this review we will discuss the role of the gut microbiome in patients with IBD; our focus will be on human studies.	Houston Methodist Hosp, Div Gastroenterol & Hepatol, Lynda K & David M Underwood Ctr Digest Disorders, Fondren IBD Program, Houston, TX 77030 USA; Weill Cornell Med Coll, Houston, TX USA	The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University	Glassner, KL (corresponding author), 6550 Fannin St,SM 1201, Houston, TX 77030 USA.	klglassner@houstonmethodist.org			Fondren Foundation; Underwood Center for Digestive Disorders	Fondren Foundation; Underwood Center for Digestive Disorders	Supported by the Fondren Foundation, Underwood Center for Digestive Disorders, William and Marie Wise, and Claudia and Jan Rask.	Abraham BP, 2017, GASTROENTEROL CLIN N, V46, P769, DOI 10.1016/j.gtc.2017.08.003; Abreu MT, 2002, GASTROENTEROLOGY, V123, P679, DOI 10.1053/gast.2002.35393; Al Nabhani Z, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006177; Al Nabhani Z, 2016, J CROHNS COLITIS, V10, P1428, DOI 10.1093/ecco-jcc/jjw095; Albenberg L, 2019, GASTROENTEROLOGY, V157, P128, DOI 10.1053/j.gastro.2019.03.015; Alberto L, 2006, GASTROENTEROLOGY, V130, P1588, DOI 10.1053/j.gastro.2006.02.004; Alvarez-Lobos M, 2005, ANN SURG, V242, P693, DOI 10.1097/01.sla.0000186173.14696.ea; An DD, 2014, CELL, V156, P123, DOI 10.1016/j.cell.2013.11.042; Ananthakrishnan AN, 2017, CELL HOST MICROBE, V21, P603, DOI 10.1016/j.chom.2017.04.010; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Backhed F, 2011, ANN NUTR METAB, V58, P44, DOI 10.1159/000328042; Batista D, 2014, INFLAMM BOWEL DIS, V20, P1481, DOI 10.1097/MIB.0000000000000055; Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677; Bernstein CN, 2006, AM J GASTROENTEROL, V101, P993, DOI 10.1111/j.1572-0241.2006.00381.x; BERNSTEIN LH, 1980, GASTROENTEROLOGY, V79, P599; Biedermann L, 2014, INFLAMM BOWEL DIS, V20, P1496, DOI 10.1097/MIB.0000000000000129; Bourreille A, 2013, CLIN GASTROENTEROL H, V11, P982, DOI 10.1016/j.cgh.2013.02.021; Bousvaros A, 2005, INFLAMM BOWEL DIS, V11, P833, DOI 10.1097/01.MIB.0000175905.00212.2c; BRANDT LJ, 1982, GASTROENTEROLOGY, V83, P383; Britton GJ, 2019, IMMUNITY, V50, P212, DOI 10.1016/j.immuni.2018.12.015; Chu HT, 2016, SCIENCE, V352, P1116, DOI 10.1126/science.aad9948; Cohen LJ, 2019, GASTROENTEROLOGY, V156, P2174, DOI 10.1053/j.gastro.2019.03.017; Coppa GV, 2006, PEDIATR RES, V59, P377, DOI 10.1203/01.pdr.0000200805.45593.17; Costello SP, 2019, JAMA-J AM MED ASSOC, V321, P156, DOI 10.1001/jama.2018.20046; COUTURIERMAILLA.A, 2013, J CLIN INVESTIGATION, V0123; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Drummond RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01836; Duijts L, 2010, PEDIATRICS, V126, pE18, DOI 10.1542/peds.2008-3256; Dziechciarz P, 2007, ALIMENT PHARM THER, V26, P795, DOI 10.1111/j.1365-2036.2007.03431.x; Forbes Alastair, 2017, Clin Nutr, V36, P321, DOI 10.1016/j.clnu.2016.12.027; Frank DN, 2011, INFLAMM BOWEL DIS, V17, P179, DOI 10.1002/ibd.21339; Franzosa EA, 2019, NAT MICROBIOL, V4, P293, DOI 10.1038/s41564-018-0306-4; Gassull MA, 2002, GUT, V51, P164, DOI 10.1136/gut.51.2.164; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Gionchetti P, 2003, GASTROENTEROLOGY, V124, P1202, DOI 10.1016/S0016-5085(03)00171-9; Glick LR, 2019, J CROHNS COLITIS, V13, P1158, DOI 10.1093/ecco-jcc/jjz047; Goethel A, 2019, MUCOSAL IMMUNOL, V12, P720, DOI 10.1038/s41385-018-0128-y; Goverse G, 2017, J IMMUNOL, V198, P2172, DOI 10.4049/jimmunol.1600165; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Halfvarson J, 2003, GASTROENTEROLOGY, V124, P1767, DOI 10.1016/S0016-5085(03)00385-8; Halfvarson J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.4; HARPER PH, 1985, GUT, V26, P279, DOI 10.1136/gut.26.3.279; Hehlio T, 2003, GUT, V52, P558, DOI 10.1136/gut.52.4.558; Henke MT, 2019, P NATL ACAD SCI USA, V116, P12672, DOI 10.1073/pnas.1904099116; Heuston S, 2012, MICROBIOL-SGM, V158, P1389, DOI 10.1099/mic.0.051599-0; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hou JK, 2011, AM J GASTROENTEROL, V106, P563, DOI 10.1038/ajg.2011.44; Huynh HQ, 2009, INFLAMM BOWEL DIS, V15, P760, DOI 10.1002/ibd.20816; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; JAKOBOVITS J, 1984, AM J GASTROENTEROL, V79, P533; Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787; Janowitz HD, 1998, INFLAMM BOWEL DIS, V4, P29, DOI 10.1097/00054725-199802000-00006; Jhingran A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004589; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Knox NC, 2019, AM J GASTROENTEROL, V114, P1051, DOI 10.14309/ajg.0000000000000305; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009; Kruis W, 1997, ALIMENT PHARM THER, V11, P853, DOI 10.1046/j.1365-2036.1997.00225.x; Kruis W, 2004, GUT, V53, P1617, DOI 10.1136/gut.2003.037747; Kuhbacher T, 2006, GUT, V55, P833, DOI 10.1136/gut.2005.078303; Kuenzig ME, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0555-8; Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102; Lanternier F, 2015, J ALLERGY CLIN IMMUN, V135, P1558, DOI 10.1016/j.jaci.2014.12.1930; Lavoie S, 2019, ELIFE, V8, DOI 10.7554/eLife.39982; Lee JS, 2012, NAT IMMUNOL, V13, P144, DOI 10.1038/ni.2187; Lerouge I, 2002, FEMS MICROBIOL REV, V26, P17, DOI 10.1111/j.1574-6976.2002.tb00597.x; Levine A, 2019, GASTROENTEROLOGY, V157, P440, DOI 10.1053/j.gastro.2019.04.021; Levy AN, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819836893; Lewis JD, 2015, CELL HOST MICROBE, V18, P489, DOI 10.1016/j.chom.2015.09.008; Li E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026284; Li JJ, 2017, EMBO MOL MED, V9, P571, DOI 10.15252/emmm.201606987; Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27; Limon JJ, 2019, CELL HOST MICROBE, V25, P377, DOI 10.1016/j.chom.2019.01.007; Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Lopez-Siles M, 2017, ISME J, V11, P841, DOI 10.1038/ismej.2016.176; Malchow HA, 1997, J CLIN GASTROENTEROL, V25, P653, DOI 10.1097/00004836-199712000-00021; Marteau P, 2006, GUT, V55, P842, DOI 10.1136/gut.2005.076604; Martin R, 2014, INFLAMM BOWEL DIS, V20, P417, DOI 10.1097/01.MIB.0000440815.76627.64; Messori A, 1996, SCAND J GASTROENTERO, V31, P267, DOI 10.3109/00365529609004877; Miele E, 2009, AM J GASTROENTEROL, V104, P437, DOI 10.1038/ajg.2008.118; Mimura T, 2004, GUT, V53, P108, DOI 10.1136/gut.53.1.108; Miquel S, 2015, MBIO, V6, DOI 10.1128/mBio.00300-15; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Moossavi S, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00197; Naughton J, 2014, GUT MICROBES, V5, P48, DOI 10.4161/gmic.26680; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Nishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5; Norman JM, 2015, CELL, V160, P447, DOI 10.1016/j.cell.2015.01.002; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Ohkusa T, 2003, GUT, V52, P79, DOI 10.1136/gut.52.1.79; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Paramsothy S, 2019, GASTROENTEROLOGY, V156, P1440, DOI 10.1053/j.gastro.2018.12.001; Paramsothy S, 2017, J CROHNS COLITIS, V11, P1180, DOI 10.1093/ecco-jcc/jjx063; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Parigi SM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00415; Pascal V, 2017, GUT, V66, P813, DOI 10.1136/gutjnl-2016-313235; Petnicki-Ocwieja T, 2009, P NATL ACAD SCI USA, V106, P15813, DOI 10.1073/pnas.0907722106; Petrof EO, 2004, GASTROENTEROLOGY, V127, P1474, DOI 10.1053/j.gastro.2004.09.001; Porter CK, 2008, GASTROENTEROLOGY, V135, P781, DOI 10.1053/j.gastro.2008.05.081; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; Pronio A, 2008, INFLAMM BOWEL DIS, V14, P662, DOI 10.1002/ibd.20369; Quevrain E, 2016, GUT, V65, P415, DOI 10.1136/gutjnl-2014-307649; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Rahimi R, 2008, DIGEST DIS SCI, V53, P2524, DOI 10.1007/s10620-007-0171-0; Rajca S, 2014, INFLAMM BOWEL DIS, V20, P978, DOI 10.1097/MIB.0000000000000036; Ramanan D, 2014, IMMUNITY, V41, P311, DOI 10.1016/j.immuni.2014.06.015; Regueiro M, 2017, GASTROENTEROLOGY, V152, P277, DOI 10.1053/j.gastro.2016.10.039; Rehman A, 2011, GUT, V60, P1354, DOI 10.1136/gut.2010.216259; Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0; ROEDIGER WEW, 1993, GASTROENTEROLOGY, V104, P802, DOI 10.1016/0016-5085(93)91016-B; Rogier EW, 2014, GUT MICROBES, V5, P663, DOI 10.4161/19490976.2014.969984; Rolfe VE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004826; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Rutgeerts P, 2005, GASTROENTEROLOGY, V128, P856, DOI 10.1053/j.gastro.2005.01.010; RUTGEERTS P, 1995, GASTROENTEROLOGY, V108, P1617, DOI 10.1016/0016-5085(95)90121-3; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; Sakurai T, 2002, JPEN-PARENTER ENTER, V26, P98, DOI 10.1177/014860710202600298; SANTAVIRTA J, 1991, INT J COLORECTAL DIS, V6, P38, DOI 10.1007/BF00703959; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Sartor RB, 2017, GASTROENTEROLOGY, V152, P327, DOI 10.1053/j.gastro.2016.10.012; Sartor RB, 2004, GASTROENTEROLOGY, V126, P1620, DOI 10.1053/j.gastro.2004.03.024; Schaubeck M, 2016, GUT, V65, P225, DOI 10.1136/gutjnl-2015-309333; Schirmer M, 2018, NAT MICROBIOL, V3, P337, DOI 10.1038/s41564-017-0089-z; Schultz M, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-5; Shanahan ER, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0531-3; Shanahan F, 2010, GASTROENTEROL CLIN N, V39, P721, DOI 10.1016/j.gtc.2010.08.006; Shaw SY, 2013, J PEDIATR-US, V162, P510, DOI 10.1016/j.jpeds.2012.08.037; Shaw SY, 2011, AM J GASTROENTEROL, V106, P2133, DOI 10.1038/ajg.2011.304; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Shen B, 2001, INFLAMM BOWEL DIS, V7, P301, DOI 10.1097/00054725-200111000-00004; Shiba T, 2003, MICROBIOL IMMUNOL, V47, P371, DOI 10.1111/j.1348-0421.2003.tb03368.x; Shimada H, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090250; Small CL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005907; Smith FM, 2005, COLORECTAL DIS, V7, P563, DOI 10.1111/j.1463-1318.2005.00833.x; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Sokol H, 2020, GUT, V69, P462, DOI 10.1136/gutjnl-2019-318719; Sokol H, 2017, GUT, V66, P1039, DOI [10.1136/gutjnl-2015-310746, 10.1136/gutjnl-20]; Sokol H, 2013, GASTROENTEROLOGY, V145, P591, DOI 10.1053/j.gastro.2013.05.047; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Thia KT, 2009, INFLAMM BOWEL DIS, V15, P17, DOI 10.1002/ibd.20608; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; Ungaro R, 2014, AM J GASTROENTEROL, V109, P1728, DOI 10.1038/ajg.2014.246; Van Gossum A, 2007, INFLAMM BOWEL DIS, V13, P135, DOI 10.1002/ibd.20063; Veltkamp C, 2001, GASTROENTEROLOGY, V120, P900, DOI 10.1053/gast.2001.22547; Verma R, 2010, J CLIN MICROBIOL, V48, P4279, DOI 10.1128/JCM.01360-10; Verma S, 2000, AM J GASTROENTEROL, V95, P735, DOI 10.1111/j.1572-0241.2000.01527.x; Webb CR, 2018, INFLAMM BOWEL DIS, V24, P361, DOI 10.1093/ibd/izx014; Xu L, 2017, ALIMENT PHARM THER, V46, P780, DOI 10.1111/apt.14291; Yadav P, 2017, GASTROENTEROLOGY, V153, P550, DOI 10.1053/j.gastro.2017.05.010; Yamamoto H, 2014, INFECT IMMUN, V82, P1606, DOI 10.1128/IAI.01089-13; Yilmaz B, 2019, NAT MED, V25, P323, DOI 10.1038/s41591-018-0308-z; Zachos M, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000542.pub2; Zhang MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109146; Zuo T, 2019, GUT, V68, P1169, DOI 10.1136/gutjnl-2018-318131	158	206	214	40	114	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					16	27		10.1016/j.jaci.2019.11.003	http://dx.doi.org/10.1016/j.jaci.2019.11.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31910984	Bronze			2022-12-18	WOS:000505590800003
J	Muraro, A; Lemanske, RF; Hellings, PW; Akdis, CA; Bieber, T; Casale, TB; Jutel, M; Ong, PY; Poulsen, LK; Schmid-Grendelmeier, P; Simon, HU; Seys, SF; Agache, I				Muraro, Antonella; Lemanske, Robert F., Jr.; Hellings, Peter W.; Akdis, Cezmi A.; Bieber, Thomas; Casale, Thomas B.; Jutel, Marek; Ong, Peck Y.; Poulsen, Lars K.; Schmid-Grendelmeier, Peter; Simon, Hans-Uwe; Seys, Sven F.; Agache, Ioana			Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Precision medicine; personalized care; phenotype; endotype; biomarker; allergic rhinitis; allergic asthma; allergic skin disease	SEVERE EOSINOPHILIC ASTHMA; SURROGATE END-POINTS; DOUBLE-BLIND; CORTICOSTEROID RESPONSIVENESS; INTERNATIONAL CONSENSUS; CHRONIC RHINOSINUSITIS; IL-13 EXPRESSION; BARRIER FUNCTION; EVALUATE SAFETY; GENE-EXPRESSION	In this consensus document we summarize the current knowledge on major asthma, rhinitis, and atopic dermatitis endotypes under the auspices of the PRACTALL collaboration platform. PRACTALL is an initiative of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology aiming to harmonize the European and American approaches to best allergy practice and science. Precision medicine is of broad relevance for the management of asthma, rhinitis, and atopic dermatitis in the context of a better selection of treatment responders, risk prediction, and design of disease-modifying strategies. Progress has been made in profiling the type 2 immune response-driven asthma. The endotype driven approach for non-type 2 immune response asthma, rhinitis, and atopic dermatitis is lagging behind. Validation and qualification of biomarkers are needed to facilitate their translation into pathway-specific diagnostic tests. Wide consensus between academia, governmental regulators, and industry for further development and application of precision medicine in management of allergic diseases is of utmost importance. Improved knowledge of disease pathogenesis together with defining validated and qualified biomarkers are key approaches to precision medicine.	[Muraro, Antonella] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Hellings, Peter W.] Univ Hosp Leuven, Dept Otorhinolaryngol, Louvain, Belgium; [Akdis, Cezmi A.] Univ Zurich, Christine Kuhne Ctr Allergy Res & Educ, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Bieber, Thomas] Univ Bonn, Christine Kuhne Ctr Allergy Res & Educ, Dept Dermatol & Allergy, Bonn, Germany; [Casale, Thomas B.] Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; [Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Jutel, Marek] ALL MED Med Res Inst, Wroclaw, Poland; [Ong, Peck Y.] Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA 90027 USA; [Ong, Peck Y.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; [Poulsen, Lars K.] Copenhagen Univ Hosp Gentofte, Allergy Clin, Copenhagen, Denmark; [Schmid-Grendelmeier, Peter] Univ Zurich, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Schmid-Grendelmeier, Peter] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland; [Seys, Sven F.] Univ Leuven, Clin Immunol Lab, Louvain, Belgium; [Agache, Ioana] Transylvania Univ Brasov, Dept Allergy & Clin Immunol, Brasov, Romania	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Wisconsin System; University of Wisconsin Madison; KU Leuven; University Hospital Leuven; Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Bonn; State University System of Florida; University of South Florida; Wroclaw Medical University; Children's Hospital Los Angeles; University of Southern California; University of Copenhagen; Herlev & Gentofte Hospital; University of Zurich; University of Bern; KU Leuven; Transylvania University of Brasov	Muraro, A (corresponding author), Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Ctr, Padua, Italy.	muraro@centroallergiealimentari.eu	Hellings, Peter W/I-4068-2018; Ong, Peck Y/AAE-2944-2021; Poulsen, Lars K/J-3065-2019; Agache, Ioana/AAP-7403-2020; Akdis, Cezmi/AAV-4844-2020; Simon, Hans-Uwe/AAU-7410-2020	Hellings, Peter W/0000-0001-6898-688X; Ong, Peck Y/0000-0002-6664-463X; Poulsen, Lars K/0000-0002-1730-847X; Akdis, Cezmi/0000-0001-8020-019X; Simon, Hans-Uwe/0000-0002-9404-7736; JUTEL, MAREK/0000-0003-1555-9379; Seys, Sven/0000-0002-4399-9892	Novartis; European Commission; Swiss National Science Foundation; Christine Kuhne-Center for Allergy Research; Astra Zeneca; Novatis; Genentech; Sanofi-Regeneron; EU Commission; Fund for Scientific Research Flanders; Astellas; L'Oreal; Sanofi; Regeneron; Bioderma	Novartis(Novartis); European Commission(European CommissionEuropean Commission Joint Research Centre); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne-Center for Allergy Research; Astra Zeneca(AstraZeneca); Novatis; Genentech(Roche HoldingGenentech); Sanofi-Regeneron(Regeneron); EU Commission(European CommissionEuropean Commission Joint Research Centre); Fund for Scientific Research Flanders(FWO); Astellas(Astellas Pharmaceuticals); L'Oreal(L'Oreal Group); Sanofi; Regeneron(Regeneron); Bioderma	C. A. Akdis serves as a consultant from Actellion, Aventis, Stallergenes, Allergopharma, Circacia; and receives research support from Novartis, The European Commission, Swiss National Science Foundation, and Christine Kuhne-Center for Allergy Research. T. Bieber is a member of the board of Astellas, Novartis, L'Oreal, Sanofi, Regeneron, Bioderma, Pfizer, Galderma, and Chugai and serves as a consultant for Astellas, Novartis, L'Oreal, Sanofi, Regeneron, Bioderma, Pfizer, Galderma, and Chugai; receives payment for lectures from Astellas, Novartis, L'Oreal, Sanofi, Regeneron, and Bioderma. T. B. Casale serves as a consultant for Novartis, Genentech, Teva and AstraZeneca; receives grant funding from Astra Zeneca, Novatis, Genentech, and Sanofi-Regeneron; and is the Executive Vice President of the American Academy of Allergy, Asthma & Immunology. M. Jutel serves as a consultant from Anergis SA and Allergopharma/Merck. L. Poulsen serves as a consultant for Novozymes; receives research support from the EU Commission; and receives travel support from the EAACI. P. Schmid-Grendelmeier serves on a the board for Menarini and Novartis. H.-U. Simon receives travel support from the EAACI. S. F. Seys receives travel support from the EAACI and receives research support from Fund for Scientific Research Flanders. The rest of the authors declare that they have no relevant conflicts of interest.	Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Agache IO, 2013, CURR OPIN ALLERGY CL, V13, P249, DOI 10.1097/ACI.0b013e32836093dd; Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; [Anonymous], 2005, GUIDANCE IND PHARMAC; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Bieber T, 2012, ALLERGY, V67, P969, DOI 10.1111/j.1398-9995.2012.02845.x; Bieber T., 2013, STRATIFIED MED NEW C, P75; Bieber T, 2015, PERSONALIZED TREATME; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Boyman O, 2015, ALLERGY, V70, P727, DOI 10.1111/all.12616; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 2015, LANCET RESP MED, V3, P692, DOI 10.1016/S2213-2600(15)00197-6; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Busse W, 2013, J ALLERGY CLIN IMMUN, V132, P485, DOI 10.1016/j.jaci.2013.02.032; Castano R, 2010, OTOLARYNG HEAD NECK, V143, P301, DOI 10.1016/j.otohns.2010.04.272; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Clemmer GL, 2015, J ALLERGY CLIN IMMUN, V136, P274, DOI 10.1016/j.jaci.2015.03.029; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2015, J ALLERGY CLIN IMMUN, V135, P877, DOI 10.1016/j.jaci.2014.10.026; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Fens N, 2015, AM J RESP CRIT CARE, V191, P1086, DOI 10.1164/rccm.201411-2010LE; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Goodsaid FM, 2008, TOXICOLOGY, V245, P219, DOI 10.1016/j.tox.2007.12.023; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Han NR, 2014, J INVEST DERMATOL, V134, P2521, DOI 10.1038/jid.2014.198; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hellings PW, 2013, ALLERGY, V68, P1, DOI 10.1111/all.12040; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holguin F, 2013, AM J RESP CRIT CARE, V187, P153, DOI 10.1164/rccm.201207-1270OC; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hox V, 2014, ALLERGY, V69, P282, DOI 10.1111/all.12347; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141909; Linden A, 2014, EUR RESPIR J, V44, P1319, DOI 10.1183/09031936.00002314; Lipworth BJ, 2015, J ALLERGY CLIN IMMUN, V136, P515, DOI 10.1016/j.jaci.2015.04.037; Marijsse GS, 2014, AM J RESP CRIT CARE, V189, P1284, DOI 10.1164/rccm.201311-2011LE; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nemoto O, 2016, BRIT J DERMATOL, V174, P296, DOI 10.1111/bjd.14207; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Papadopoulos NG, 2015, ALLERGY, V70, P474, DOI 10.1111/all.12573; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Pettipher R, 2014, ALLERGY, V69, P1223, DOI 10.1111/all.12451; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Radonjic-Hoesli S, 2015, ANNU REV PHARMACOL, V55, P633, DOI 10.1146/annurev-pharmtox-010814-124407; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson JL, 2013, CLIN EXP ALLERGY, V43, P29, DOI 10.1111/j.1365-2222.2012.04075.x; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Staudacher A, 2015, ALLERGY, V70, P1432, DOI 10.1111/all.12699; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Steinke JW, 2013, J ALLERGY CLIN IMMUN, V132, P856, DOI 10.1016/j.jaci.2013.05.008; Steinke JW, 2013, J ALLERGY CLIN IMMUN, V134, pe1; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; van der Schee MP, 2013, CLIN EXP ALLERGY, V43, P1217, DOI 10.1111/cea.12147; Van Gerven L, 2014, J ALLERGY CLIN IMMUN, V133, P1332, DOI 10.1016/j.jaci.2013.08.026; Wagner JA, 2007, CLIN PHARMACOL THER, V81, P104, DOI 10.1038/sj.clpt.6100017; Wagner JA, 2002, DIS MARKERS, V18, P41, DOI 10.1155/2002/929274; Wang M, 2013, CLIN EXP ALLERGY, V43, P956, DOI 10.1111/cea.12123; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wenzel SE, 2013, NEW ENGL J MED, V369, P1276, DOI 10.1056/NEJMc1309809; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiao C, 2015, J ALLERGY CLIN IMMUN, V136, P923, DOI 10.1016/j.jaci.2015.01.045; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xie Y, 2012, J ALLERGY CLIN IMMUN, V130, P968, DOI 10.1016/j.jaci.2012.05.004	98	206	215	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1347	1358		10.1016/j.jaci.2016.03.010	http://dx.doi.org/10.1016/j.jaci.2016.03.010			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155030	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000376180200006
J	Chu, DK; Llop-Guevara, A; Walker, TD; Flader, K; Goncharova, S; Boudreau, JE; Moore, CL; In, TS; Waserman, S; Coyle, AJ; Kolbeck, R; Humbles, AA; Jordana, M				Chu, Derek K.; Llop-Guevara, Alba; Walker, Tina D.; Flader, Kristin; Goncharova, Susanna; Boudreau, Jeanette E.; Moore, Cheryl Lynn; In, Tracy Seunghyun; Waserman, Susan; Coyle, Anthony J.; Kolbeck, Roland; Humbles, Alison A.; Jordana, Manel			IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2; allergy; asthma; house dust mite; peanut; thymic stromal lymphopoietin; IL-25; IL-33; OX40 ligand; innate lymphoid cells	DENDRITIC CELLS; AIRWAY INFLAMMATION; IMMUNE-RESPONSES; TSLP; RECEPTOR; INNATE; CYTOKINE; BASOPHILS; ASTHMA; HYPERRESPONSIVENESS	Background: Allergen exposure at lung and gut mucosae can lead to aberrant T(H)2 immunity and allergic disease. The epithelium-associated cytokines thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 are suggested to be important for the initiation of these responses. Objective: We sought to investigate the contributions of TSLP, IL-25, and IL-33 in the development of allergic disease to the common allergens house dust mite (HDM) or peanut. Methods: Neutralizing antibodies or mice deficient in TSLP, IL-25, or IL-33 signaling were exposed to HDM intranasally or peanut intragastrically, and immune inflammatory and physiologic responses were evaluated. In vitro assays were performed to examine specific dendritic cell (DC) functions. Results: We showed that experimental HDM-induced allergic asthma and food allergy and anaphylaxis to peanut were associated with TSLP production but developed independently of TSLP, likely because these allergens functionally mimicked TSLP inhibition of IL-12 production and induction of OX40 ligand (OX40L) on DCs. Blockade of OX40L significantly lessened allergic responses to HDM or peanut. Although IL-25 and IL-33 induced OX40L on DCs in vitro, only IL-33 signaling was necessary for intact allergic immunity, likely because of its superior ability to induce DC OX40L and expand innate lymphoid cells in vivo. Conclusion: These data identify a nonredundant, IL-33-driven mechanism initiating T(H)2 responses to the clinically relevant allergens HDM and peanut. Our findings, along with those in infectious and transgenic/surrogate allergen systems, favor a paradigm whereby multiple molecular pathways can initiate T(H)2 immunity, which has implications for the conceptualization and manipulation of these responses in health and disease. (J Allergy Clin Immunol 2013;131:187-200.)	[Chu, Derek K.; Llop-Guevara, Alba; Walker, Tina D.; Flader, Kristin; Goncharova, Susanna; Boudreau, Jeanette E.; Moore, Cheryl Lynn; In, Tracy Seunghyun; Coyle, Anthony J.; Jordana, Manel] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Coyle, Anthony J.] Pfizer, Cambridge, MA USA; [Kolbeck, Roland; Humbles, Alison A.] MedImmune LLC, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD USA	McMaster University; McMaster University; Pfizer; AstraZeneca; Medimmune	Jordana, M (corresponding author), McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, MDCL 4013,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jordanam@mcmaster.ca		Chu, Derek/0000-0001-8269-4496; Boudreau, Jeanette/0000-0003-0203-2180; Llop-Guevara, Alba/0000-0002-7913-9472	CIHR; Anaphylaxis Canada; MedImmune LLC; Fundacion Caja Madrid doctoral scholarship (Spain); NSERC Doctoral Canada Graduate Scholarship; Canadian Institutes of Health Research	CIHR(Canadian Institutes of Health Research (CIHR)); Anaphylaxis Canada; MedImmune LLC(AstraZenecaMedimmune); Fundacion Caja Madrid doctoral scholarship (Spain); NSERC Doctoral Canada Graduate Scholarship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by CIHR, Anaphylaxis Canada, and grants from MedImmune LLC. D.K.C. is a CIHR Vanier Scholar. A.L.-G. is supported by a Fundacion Caja Madrid doctoral scholarship (Spain). J.E.B. holds an NSERC Doctoral Canada Graduate Scholarship. M.J. holds a Senior Canada Research Chair in Immunobiology of Respiratory Diseases and Allergy.; Disclosure of potential conflict of interest: S. Waserman has received research support from Anaphylaxis Canada and is employed by McMaster University. A. J. Coyle was an employee of MedImmune LLC and is now an employee of Pfizer. R. Kolbeck is employed by and has stock options in MedImmune LLC. A. A. Humbles is employed by MedImmune LLC and has stock options in MedImmune (AZ). M. Jordana has received research support from MedImmune LLC, Anaphylaxis Canada, and the Canadian Institutes of Health Research and is employed by McMaster University. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barlow JL, 2009, BIOFACTORS, V35, P178, DOI 10.1002/biof.24; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Boudreau Jeanette, 2008, J Vis Exp, DOI 10.3791/769; Boudreau JE, 2009, MOL THER, V17, P1465, DOI 10.1038/mt.2009.95; Bulek K, 2010, IMMUNOL CELL BIOL, V88, P257, DOI 10.1038/icb.2009.113; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; Cates Elizabeth C., 2007, V14, P42, DOI 10.1159/000107054; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Claudio E, 2009, J IMMUNOL, V182, P1617, DOI 10.4049/jimmunol.182.3.1617; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Damayanti T, 2010, AM J RESP CRIT CARE, V181, P688, DOI 10.1164/rccm.200910-1598OC; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gratchev A, 2004, SCAND J IMMUNOL, V60, P233, DOI 10.1111/j.0300-9475.2004.01443.x; Gregory LG, 2010, AM J RESP CRIT CARE, V182, P143, DOI 10.1164/rccm.200905-0725OC; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Jessup HK, 2008, J IMMUNOL, V181, P4311, DOI 10.4049/jimmunol.181.6.4311; Johnson JR, 2007, AM J PHYSIOL-LUNG C, V293, pL730, DOI 10.1152/ajplung.00056.2007; Kashyap M, 2011, J IMMUNOL, V187, P1207, DOI 10.4049/jimmunol.1100355; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Llop-Guevara A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002426; Massacand JC, 2009, P NATL ACAD SCI USA, V106, P13968, DOI 10.1073/pnas.0906367106; Nakanishi K, 2010, CURR OPIN IMMUNOL, V22, P814, DOI 10.1016/j.coi.2010.10.018; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Ramalingam TR, 2009, J IMMUNOL, V182, P6452, DOI 10.4049/jimmunol.0900181; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Senn KA, 2000, EUR J IMMUNOL, V30, P1929, DOI 10.1002/1521-4141(200007)30:7&lt;1929::AID-IMMU1929&gt;3.0.CO;2-1; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zhou BH, 2008, J IMMUNOL, V181, P6557, DOI 10.4049/jimmunol.181.9.6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	62	206	216	1	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					187	U283		10.1016/j.jaci.2012.08.002	http://dx.doi.org/10.1016/j.jaci.2012.08.002			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23006545				2022-12-18	WOS:000312961200024
J	Bousquet, J; Neukirch, F; Bousquet, PJ; Gehano, P; Klossek, JM; Le Gal, M; Allaf, B				Bousquet, J; Neukirch, F; Bousquet, PJ; Gehano, P; Klossek, JM; Le Gal, M; Allaf, B			Severity and impairment of allergic rhinitis in patients consulting in primary care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; classification; ARIA; intermittent; persistent	QUALITY-OF-LIFE; MEDICAL HISTORY; ASTHMA; POLLEN; IMPACT; POPULATION; MANAGEMENT; DIAGNOSIS; SLEEP; WORK	Background: Allergic rhinitis is a disease impairing quality of life, sleep, and work. A new classification for allergic rhinitis, Allergic Rhinitis and its Impact on Asthma (ARIA), has recently been proposed. Objective: To study the effect of allergic rhinitis using ARIA definitions to determine severity and duration. Methods: A total of 3052 patients consulting general practitioners for allergic rhinitis were studied. Patients were classified according to the 4 classes of ARIA. In all patients, quality of life (Rhinoconjunctivitis Quality-of-Life Questionnaire), sleep (Jenkins questionnaire), and work performance (Allergy-Specific Work Productivity and Activity Impairment questionnaire) were assessed. Results: Mild intermittent rhinitis was diagnosed in 11% of the patients, mild persistent rhinitis in 8%, moderate/severe intermittent rhinitis in 35%, and moderate/severe persistent rhinitis in 46%. The severity of rhinitis has more of an effect on quality of life, sleep, daily activities, and work performance than the duration of rhinitis. In moderate/severe rhinitis, more than 80% of patients report impaired activities, as opposed to only 40% with mild rhinitis. Conclusion: It seems that the term moderate/severe should be replaced by severe. A study in the general population is necessary, however, to assess the prevalence of the 4 ARIA classes of allergic rhinitis, especially in patients who are not consulting physicians for their symptoms.	Univ Hosp Montpellier, Montpellier, France; INSERM, U454, Montpellier, France; INSERM, U408, Paris, France; Assistance Publ Hosp Paris, Paris, France; Univ Poitiers, Hosp Miletrie, Poitiers, France; MAPI SA, CRO, Lyon, France; Almirall France, Paris, France	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); CHU Poitiers; Universite de Poitiers; Almirall	Bousquet, J (corresponding author), Ctr Hosp Univ, Clin Malad Resp, Hop Arnaud Villeneuve, F-34295 Montpellier 5, France.	jean.bousquet@wanadoo.fr	Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; 				Annesi-Maesano I, 2002, ALLERGY, V57, P107, DOI 10.1034/j.1398-9995.2002.1o3170.x; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet PJ, 2004, ALLERGY, V59, P1015, DOI 10.1111/j.1398-9995.2004.00579.x; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUCHOLTZ GA, 1991, ANN ALLERGY, V67, P534; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30; CROBACH MJJS, 1994, ALLERGY, V49, P170, DOI 10.1111/j.1398-9995.1994.tb00821.x; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; KRANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; Meltzer EO, 1999, ANN ALLERG ASTHMA IM, V83, P311, DOI 10.1016/S1081-1206(10)62671-3; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; OLSEN KD, 1981, OTOLARYNG HEAD NECK, V89, P804, DOI 10.1177/019459988108900522; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Rydzewski B, 2000, ACTA OTO-LARYNGOL, V120, P323; SIBBALD B, 1991, THORAX, V46, P378, DOI 10.1136/thx.46.5.378; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Simola M, 1998, ALLERGY, V53, P190, DOI 10.1111/j.1398-9995.1998.tb03869.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	34	206	220	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					158	162		10.1016/j.jaci.2005.09.047	http://dx.doi.org/10.1016/j.jaci.2005.09.047			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387600	Bronze			2022-12-18	WOS:000235687100025
J	Shin, SH; Ponikau, JU; Sherris, DA; Congdon, D; Frigas, E; Homburger, HA; Swanson, MC; Gleich, GJ; Kita, H				Shin, SH; Ponikau, JU; Sherris, DA; Congdon, D; Frigas, E; Homburger, HA; Swanson, MC; Gleich, GJ; Kita, H			Chronic rhinosinusitis: An enhanced immune response to ubiquitous airborne fungi	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; immune response; cytokines; inflammation; fungus; Alternaria	CHRONIC SINUSITIS; NASAL POLYPS; ANTIFUNGAL TREATMENT; TH1/TH2 PARADIGM; HEALTH SURVEY; ASTHMA; CELLS; EXPRESSION; EOSINOPHIL; RHINITIS	Background: Chronic rhinosinusitis (CRS) is one of the most common long-term illnesses in the United States. The etiology of CRS is unknown, and no effective treatment has been established. Objective: We investigated the hypothesis that abnormal immunologic responses to ubiquitous airborne fungi contribute to the pathogenesis of this disease. Methods: The proliferative and cytokine responses of PBMCs to extracts from 4 common airborne fungi-including Alternaria, Aspergillus, Cladosporium, and Penicillium-were examined by in vitro culture. Serum specimens were tested for specific IgE and IgG to these fungi. Results: PBMCs from approximately 90% of the patients with CRS, but not those from normal individuals, produced both IL-5 and IL-13 when exposed to Alternaria. Furthermore, PBMCs from patients with CRS produced significantly more IFN-gamma than PBMCs from normal individuals in response to Alternaria (median, 553 pg/mL vs 98 pg/mL; P <.01). Levels of serum IgG antibodies to Alternaria and Cladosporium were clearly increased in patients with CRS compared with normal individuals (P <.01). Less than 30% of the patients with CRS had specific IgE antibodies to Alternaria or Cladosporium. The increased Immoral (serum IgG) response strongly correlated with the increased cellular (IL-5 production) response to Alternaria (r = 0.619; P < .01). Conclusion: Patients with CRS show exaggerated Immoral and cellular responses, both T(H)1 and T(H)2 types, to common airborne fungi, particularly Alternaria. The anomalous immune and inflammatory responses to ubiquitous fungi may explain the chronicity of airway inflammation in CRS.	Mayo Clin & Mayo Fdn, Div Allerg Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Rochester, MN 55905 USA; SUNY Buffalo, Dept Otorhinolaryngol, Buffalo, NY USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Mayo Clinic; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kita, H (corresponding author), Mayo Clin & Mayo Fdn, Div Allerg Dis, Guggenheim Bldg 401A,200 1st St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49235] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KARLINER MA, 1997, OTOLARYNGOL HEAD NEC, V116, pS1; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; LANZA SC, 1997, OTOLARYNGOL HEAD NEC, V117, pS1; LETHBRIDGE-CEJKU M, 2004, VITAL HLTH STAT, V10, P222; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343, DOI 10.1164/ajrccm.164.8.2103080; Sanchez-Segura A, 1998, J ALLERGY CLIN IMMUN, V102, P953, DOI 10.1016/S0091-6749(98)70333-1; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; Spector S L, 1998, J Allergy Clin Immunol, V102, pS107; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; van Burik JAH, 2001, ANNU REV MICROBIOL, V55, P743, DOI 10.1146/annurev.micro.55.1.743; Vassallo R, 1999, CHEST, V116, P583, DOI 10.1378/chest.116.2.583; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	34	206	215	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1369	1375		10.1016/j.jaci.2004.08.012	http://dx.doi.org/10.1016/j.jaci.2004.08.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577837				2022-12-18	WOS:000225577400018
J	Mittag, D; Vieths, S; Vogel, L; Becker, WM; Rihs, HP; Helbling, A; Wuthrich, B; Ballmer-Weber, BK				Mittag, D; Vieths, S; Vogel, L; Becker, WM; Rihs, HP; Helbling, A; Wuthrich, B; Ballmer-Weber, BK			Soybean allergy in patients allergic to birch pollen: Clinical investigation and molecular characterization of allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						double-blind; placebo-controlled food challenge; soy allergy; birch pollen-related food allergy; starvation-associated message 22; Gly m 4; birch pollen allergy; soy food products	CONTROLLED FOOD CHALLENGE; BET V 1; CROSS-REACTIVITY; TRYPSIN-INHIBITOR; DOUBLE-BLIND; IGE-BINDING; IDENTIFICATION; SENSITIZATION; CELERY; HYPERSENSITIVITY	Background: Allergic reactions to legumes are generally thought to be acquired by means of primary sensitization through the gastrointestinal tract. Recently, Gly m 4 (starvation-associated message 22), a Bet v 1-related pathogenesis-related protein 10 from soy, was suggested to be an allergen in patients with allergic reactions to a dietary product containing a soy protein isolate. Objective: We sought to evaluate the clinical relevance of Gly m 4 in subjects allergic to birch pollen with soy allergy and to assess the risk for subjects allergic to birch pollen to acquire soy allergy. Methods: Twenty-two patients allergic to birch pollen with soy allergy confirmed by means of positive double-blind, placebo-controlled food challenge results (n=16) or. a convincing history (n=6) were investigated for IgE reactivity to birch pollen and soy allergens by using the Pharmacia CAP system and immunoblot analysis. Cross-reactivity was assessed by means of enzyme allergosorbent test inhibition. Ninety-four patients with birch pollen allergy were interviewed to assess soy tolerance and screened for IgE reactivity to Gly m 4 by means of immunoblotting. The Gly m 4 content in soy foods and soybean varieties was investigated by means of quantitative evaluation of immunoblots. Results: During double-blind, placebo-controlled food challenge, 10 patients experienced symptoms localized to the oral cavity, and 6 patients had a more severe reaction. CAP analysis revealed Gly m 4-specific IgE in 96 % (21/22) of the patients. All patients had Bet v 1-specific IgE antibodies, and 23% (5/22) had positive Bet v 2 results. In IgE immunoblotting 25 % (6/22) of the patients recognized soy profilin (Gly m 3), and 64% (14/22) recognized other soy proteins. IgE binding to soy was at least 80% inhibited by birch pollen and 60% inhibited by rGly m 4 in 9 of 11 sera tested. Seventy-one percent (67/94) of highly Bet v 1-sensitized patients with birch pollen allergy were sensitized to Gly m 4, and 9 (9.6%) of those patients reported soy allergy. The Gly m 4 content in soy products ranged between 0 and 70 ppm (milligrams per kilogram). Conclusions: Our results confirm that soybean is another birch pollen-related allergenic food. Gly m 4 is the major soy allergen for patients allergic to birch pollen with soy allergy. The content of Gly m 4 in soy food products strongly depends on the degree of food processing.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; Res Ctr, Borstel, Germany; Ruhr Univ Bochum, Berufsgenossenschaften BGFA, Inst Occupat Med, Dept Mol Genet, D-4630 Bochum, Germany; Univ Bern, Inselspital, Dept Rheumatol Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute; Forschungszentrum Borstel; Ruhr University Bochum; University of Bern; University Hospital of Bern	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.							ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Baur X, 1996, ALLERGY, V51, P326, DOI 10.1111/j.1398-9995.1996.tb00093.x; BURKS AW, 1994, INT ARCH ALLERGY IMM, V105, P143; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Codina R, 2002, CLIN EXP ALLERGY, V32, P1059, DOI 10.1046/j.1365-2222.2002.01411.x; CROWELL DN, 1991, PLANT PHYSIOL, V95, P711, DOI 10.1104/pp.95.3.711; CROWELL DN, 1992, PLANT MOL BIOL, V18, P459, DOI 10.1007/BF00040662; DJURTOFT R, 1991, ADV EXP MED BIOL, V289, P281; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; Friedman M, 2001, J AGR FOOD CHEM, V49, P1069, DOI 10.1021/jf0009246; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GONZALEZ R, 1992, CLIN EXP ALLERGY, V22, P748, DOI 10.1111/j.1365-2222.1992.tb02814.x; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Jeep S, 2001, J INVEST ALLERG CLIN, V11, P264; Keinan-Boker L, 2002, PUBLIC HEALTH NUTR, V5, P1217, DOI 10.1079/PHN2002400; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; MISTERECK A, 1992, ALLERGOLOGIE, V15, P304; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; Quirce S, 2000, CLIN EXP ALLERGY, V30, P839; Rihs HP, 1999, J ALLERGY CLIN IMMUN, V104, P1293, DOI 10.1016/S0091-6749(99)70027-8; ROODT L, 1995, S AFR MED J, V85, P522; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; San Ireneo MM, 2000, J INVEST ALLERG CLIN, V10, P187; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Smith TA, 1998, OCCUP MED-OXFORD, V48, P321, DOI 10.1093/occmed/48.5.321; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Taramarcaz P, 2001, ALLERGY, V56, P792, DOI 10.1034/j.1398-9995.2001.00211.x; Vidal C, 1997, ANN ALLERG ASTHMA IM, V79, P350, DOI 10.1016/S1081-1206(10)63027-X; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380	41	206	213	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					148	154		10.1016/j.jaci.2003.09.030	http://dx.doi.org/10.1016/j.jaci.2003.09.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713921				2022-12-18	WOS:000187837900020
J	Untersmayr, E; Scholl, I; Swoboda, I; Beil, WJ; Forster-Waldl, E; Walter, F; Riemer, A; Kraml, G; Kinaciyan, T; Spitzauer, S; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Untersmayr, E; Scholl, I; Swoboda, I; Beil, WJ; Forster-Waldl, E; Walter, F; Riemer, A; Kraml, G; Kinaciyan, T; Spitzauer, S; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Antacid medication inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in Balb/c mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; caviar; parvalbumin; IgE; nutrition; antacids; digestion; animal model	PEANUT; HYPERSENSITIVITY; DIGESTIBILITY; EPIDEMIOLOGY; INTOLERANCE; PREVALENCE; POPULATION; RESPONSES; EPITOPES; EXPOSURE	Background: Digestible proteins were supposed to be irrelevant for oral sensitization and induction of food allergy. Approximately 10% of the adult population uses antacids for the treatment of dyspeptic disorders, drugs that hinder peptic digestion. In these patients, proteins that are normally degradable might act as food allergens. Objective: We aimed to study the influence of antacid intake on the allergenicity of dietary proteins, taking sturgeon caviar and parvalbumin, the major fish allergen, as examples. Methods: Caviar proteins and recombinant parvalbumin from carp, rCyp c 1, were applied for intragastric feedings with or without the antacids sucralfate, ranitidine or omeprazole, using a Balb/c mouse model. Results: Both caviar proteins and parvalbumin were rapidly degraded in an in vitro digestion assay at pH 2.0, but not at pH 5.0, imitating the effect of antacids. The groups fed with caviar in combination with ranitidine hydrochloride intramuscularly or sucralfate orally had significant levels of caviar-specific IgE antibodies (P < .01), T-cell reactivity, and elevated counts of gastrointestinal eosinophils and mast cells. Food allergy in these groups was further evidenced by oral provocation tests and positive immediate-type skin reactivity. In contrast, feedings with caviar alone led to antigen-specific T-cell tolerance. None of the groups showed immune reactivity against the daily mouse diet. As a proof of the principle, feeding mice with parvalbumin in combination with ranitidine or omeprazole intramuscularly induced allergen-specific IgE antibodies (P < .05). Conclusions: When antacid medication impairs the gastric digestion, IgE synthesis toward novel dietary proteins is promoted, leading to food allergy.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Clin Chem & Lab Med, Vienna, Austria; Univ Vienna, Dept Pathol, Vienna, Austria; Univ Vienna, Dept Pediat & Juvenile Med, Vienna, Austria; Univ Vienna, Dept Dermatol, Vienna, Austria; Vienna Univ Technol, A-1060 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; Technische Universitat Wien	Jensen-Jarolim, E (corresponding author), Univ Vienna, Dept Pathophysiol, AKH-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018; Roth-Walter, Franziska/V-4651-2017; Untersmayr, Eva/GRY-4470-2022	Jensen-Jarolim, Erika/0000-0003-4019-5765; Roth-Walter, Franziska/0000-0001-5005-9228; Riemer, Angelika/0000-0002-5865-0714; Kinaciyan, Tamar/0000-0002-8238-2561; Untersmayr, Eva/0000-0002-1963-499X; Forster-Waldl, Elisabeth/0000-0002-8484-9890; Swoboda, Ines/0000-0002-9164-1721				AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Bell WJ, 1997, HISTOCHEM J, V29, P759, DOI 10.1023/A:1026421303260; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1111/j.1398-9995.2001.00922.x; Bischoff SC, 1997, GUT, V40, P745, DOI 10.1136/gut.40.6.745; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewer JM, 1999, J IMMUNOL, V163, P6448; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Dearman RJ, 2002, FOOD CHEM TOXICOL, V40, P625, DOI 10.1016/S0278-6915(01)00132-6; Dearman RJ, 2001, TOXICOLOGY, V167, P217, DOI 10.1016/S0300-483X(01)00462-0; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Furu K, 1999, J CLIN EPIDEMIOL, V52, P509, DOI 10.1016/S0895-4356(99)00020-7; GARNETT W R, 1982, Clinical Pharmacy, V1, P307; Hong SJ, 1999, J ALLERGY CLIN IMMUN, V104, P473, DOI 10.1016/S0091-6749(99)70396-9; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1999, CLIN EXP ALLERGY, V29, P1075, DOI 10.1046/j.1365-2222.1999.00592.x; JensenJarolim E, 1997, CLIN EXP ALLERGY, V27, P1299, DOI [10.1046/j.1365-2222.1997.1580956.x, 10.1111/j.1365-2222.1997.tb01175.x]; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; PEDEN NR, 1979, LANCET, V1, P690; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; Schafer T, 2001, ALLERGY, V56, P1172, DOI 10.1034/j.1398-9995.2001.00196.x; SCHOLL I, 2002, CLIN EXP ALLERGY, V323, P1583; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Svensson L, 2003, IMMUNOLOGY, V108, P98, DOI 10.1046/j.1365-2567.2003.01561.x; Swoboda I, 2002, J IMMUNOL, V168, P4576, DOI 10.4049/jimmunol.168.9.4576; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Untersmayr E, 2002, J ALLERGY CLIN IMMUN, V109, P1034, DOI 10.1067/mai.2002.124893; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; Zivny JH, 2001, CLIN IMMUNOL, V101, P158, DOI 10.1006/clim.2001.5103	38	206	213	3	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					616	623		10.1016/mai.2003.1681	http://dx.doi.org/10.1016/mai.2003.1681			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679824				2022-12-18	WOS:000185231200024
J	Craig, TJ; Teets, S; Lehman, EB; Chinchilli, VM; Zwillich, C				Craig, TJ; Teets, S; Lehman, EB; Chinchilli, VM; Zwillich, C			Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sleep; fatigue; rhinitis; corticosteroids; sleep disorders; sleep disturbances; nasal congestion; allergic disease	INTRANASAL FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; TERFENADINE TABLETS; SPRAY; FRAGMENTATION; AEROSOL; APNEA	Background: Allergic rhinitis (AR) is a frequent disease affecting up to 20% of the population. AR causes a hypersensitivity reaction, which results in inflamed nasal mucosa and nasal congestion. Negative pressure generated during inspiration in the nasal airway secondary to nasal congestion may lead to nasal collapse, airway obstruction, and an increased number of sleep microarousals. Sleep disturbances and microarousals can detrimentally affect daytime energy levels, mood, and daytime function. It is unknown whether treatment directed to reduce congestion may reduce these microarousals, sleep problems, and, consequently, associated daytime fatigue. Objective: We sought to determine whether reducing nasal congestion with nasal steroids will reduce sleep complaints and daytime sleepiness. Method: We enrolled 20 subjects in a double-blind, placebo-controlled study using Balaam's Design. Patients were treated with topical nasal corticosteroids or placebo. Subjective data were collected by use of a daily diary, which focused on nasal symptoms, sleep, and daytime sleepiness. Results: The results demonstrated that nasal congestion and subjective sleep improved significantly in the topical corticosteroid-treated subjects but not in the placebo group. Sleepiness improved, but not significantly (p = 0.08). Conclusion: Often, people with perennial allergies may attribute their daytime fatigue to causes such as the side effects of medications, when in fact, the fatigue may be a result of nasal congestion and associated sleep fragmentation. Decreasing nasal congestion with nasal steroids may improve sleep, daytime fatigue, and the quality of Life of patients with AR.	Penn State Univ, Div Med, Sect Pulm Allergy & Crit Care, Allergy Clin,Dept Med, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Hershey, PA 17033 USA; Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA 17033 USA; Denver Vet Affairs Med Ctr, Med Serv, Denver, CO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Craig, TJ (corresponding author), Penn State Univ, Div Med, Sect Pulm Allergy & Crit Care, Allergy Clin,Dept Med, 500 Univ Dr, Hershey, PA 17033 USA.							Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BONNET MH, 1987, SLEEP, V10, P364, DOI 10.1093/sleep/10.4.364; BONNET MH, 1989, PHYSIOL BEHAV, V45, P1049, DOI 10.1016/0031-9384(89)90236-9; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; Guarderas JC, 1996, MAYO CLIN PROC, V71, P882, DOI 10.4065/71.9.882; GUILLEMINAULT C, 1991, CHEST, V99, P40, DOI 10.1378/chest.99.1.40; Janson C, 1996, EUR RESPIR J, V9, P2132, DOI 10.1183/09031936.96.09102132; JEAL A, 1997, DRUGS, V53, P257; Jordana G, 1996, J ALLERGY CLIN IMMUN, V97, P588, DOI 10.1016/S0091-6749(96)70303-2; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; LANCER JM, 1987, J LARYNGOL OTOL, V101, P350; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; LEZNOFF A, 1986, AM REV RESPIR DIS, V133, P935; Martin SE, 1997, AM J RESP CRIT CARE, V155, P1596, DOI 10.1164/ajrccm.155.5.9154863; Martin SE, 1996, AM J RESP CRIT CARE, V153, P1328, DOI 10.1164/ajrccm.153.4.8616562; MCALLEN MK, 1980, BRIT J DIS CHEST, V74, P32, DOI 10.1016/0007-0971(80)90005-4; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V133, P935; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NATHAN RA, 1991, ANN ALLERGY, V67, P332; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P531; STEPANSKI E, 1984, SLEEP, V7, P18, DOI 10.1093/sleep/7.1.18; STORMS W, 1991, ANN ALLERGY, V66, P329; Tan Ricardo A., 1996, Comprehensive Therapy, V22, P363; TARLO SM, 1977, J ALLERGY CLIN IMMUN, V59, P232, DOI 10.1016/0091-6749(77)90155-5; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010; VONESH EF, 1997, LINEAR NONLINEAR MOD, P160; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WELCH MJ, 1993, WESTERN J MED, V158, P616; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6; ZWILLICH CW, 1981, AM REV RESPIR DIS, V124, P158	34	206	209	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					633	637		10.1016/S0091-6749(98)70171-X	http://dx.doi.org/10.1016/S0091-6749(98)70171-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600500				2022-12-18	WOS:000073697400011
J	TARLO, SM; WONG, L; ROOS, J; BOOTH, N				TARLO, SM; WONG, L; ROOS, J; BOOTH, N			OCCUPATIONAL ASTHMA CAUSED BY LATEX IN A SURGICAL GLOVE MANUFACTURING PLANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; ONTARIO MINIST LABOUR,TORONTO,ONTARIO,CANADA	University of Toronto	TARLO, SM (corresponding author), TORONTO GEN HOSP,EN 10-216,200 ELIZABETH ST,TORONTO M5G 2C4,ONTARIO,CANADA.			Tarlo, Susan/0000-0002-4746-5310				AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CHANYEUNG M, 1984, AM REV RESPIR SA152, V129, P909; FISHER AA, 1986, CUTIS, V38, P307; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; JANCELOWICZ Z, 1989, J ALLERGY CLIN IMMUN, V83, P267; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KLEINHANS D, 1984, CONTACT DERMATITIS, V10, P124, DOI 10.1111/j.1600-0536.1984.tb00363.x; Kopman A, 1983, Duodecim, V99, P221; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLOVAK AJM, 1981, THORAX, V36, P906, DOI 10.1136/thx.36.12.906; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; 1984, US DHEW NIOSH84100 P; 1978, US DHEW NIOSH78215 P	22	206	209	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					626	631		10.1016/0091-6749(90)90103-B	http://dx.doi.org/10.1016/0091-6749(90)90103-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2312994				2022-12-18	WOS:A1990CU66800014
J	Vickery, BP; Berglund, JP; Burk, CM; Fine, JP; Kim, EH; Kim, JI; Keet, CA; Kulis, M; Orgel, KG; Guo, RS; Steele, PH; Virkud, YV; Ye, P; Wright, BL; Wood, RA; Burks, AW				Vickery, Brian P.; Berglund, Jelena P.; Burk, Caitlin M.; Fine, Jason P.; Kim, Edwin H.; Kim, Jung In; Keet, Corinne A.; Kulis, Michael; Orgel, Kelly G.; Guo, Rishu; Steele, Pamela H.; Virkud, Yamini V.; Ye, Ping; Wright, Benjamin L.; Wood, Robert A.; Burks, A. Wesley			Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; desensitization; sustained unresponsiveness; early intervention; peanut allergy; randomized clinical trial	NATURAL-HISTORY; FOOD ALLERGY; DOUBLE-BLIND; EGG ALLERGY; IGE LEVELS; HIGH-RISK; INFANTS; DESENSITIZATION; PREDICTORS; RESOLUTION	Background: Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment. Objective: We sought to test the safety, effectiveness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy. Methods: We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block randomized 1: 1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-SU), was assessed by double blinded, placebo-controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut-specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard-care controls. Results: Of 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent-to-treat analysis achieved 4-SU (300-mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P =.43) over a median of 29 months. Per-protocol, the overall proportion achieving 4-SU was 29 of 32 (91%). Peanut-specific IgE levels significantly declined in E-OIT-treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard-care controls, in whom peanut-specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7-43.7; P < .001). Allergic side effects during E-OIT were common but all were mild to moderate. Conclusions: At both doses tested, E-OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction.	[Berglund, Jelena P.] Duke Univ, Sch Med, Durham, NC USA; [Keet, Corinne A.; Wood, Robert A.] Johns Hopkins Sch Med, Baltimore, MD USA; [Virkud, Yamini V.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wright, Benjamin L.] Mayo Clin, Scottsdale, AZ USA	Duke University; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital; Mayo Clinic; Mayo Clinic Phoenix	Burks, AW (corresponding author), Univ North Carolina Chapel Hill, 4032 Bondurant Hall,CB 7000, Chapel Hill, NC 27599 USA.	wesley.burks@unc.edu		Burk, Caitlin/0000-0001-7652-8248; Vickery, Brian/0000-0002-7243-5543	National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [UL1TR001111, UL1TR001117]; National Institutes of Allergy and Infectious Disease [5K23AI099083, 1K23AI103187, 1R21HD: 073557]; Thrasher Research Fund [NR-0101]; Departments of Pediatrics at Duke; Departments of Pediatrics at UNC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001111, KL2TR001109, UL1TR002489, UL1TR001117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062, K23AI099083, R01AI068074, K23AI103187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences, National Institutes of Health (NIH); National Institutes of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Thrasher Research Fund; Departments of Pediatrics at Duke; Departments of Pediatrics at UNC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant Awards (nos. UL1TR001111 and UL1TR001117); the National Institutes of Allergy and Infectious Disease (through grant no. 5K23AI099083 to B.P.V. and grant nos. 1K23AI103187 and 1R21HD: 073557 to C.K.); the Thrasher Research Fund (award no. NR-0101 to B.P.V.); and departmental funds from the Departments of Pediatrics at Duke and UNC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bird JA, 2015, ALLERGY, V70, P110; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Datta S, 2011, J ALLERGY CLIN IMMUN, V127, P351, DOI 10.1016/j.jaci.2010.11.033; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2014, J CLIN INVEST, V124, P1880, DOI 10.1172/JCI72061; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P397, DOI 10.1016/j.jaci.2011.04.044; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Savage JH, 2010, J ALLERGY CLIN IMMUN, V125, P683, DOI 10.1016/j.jaci.2009.12.994; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Venter C, 2007, J HUM NUTR DIET, V20, P565, DOI 10.1111/j.1365-277X.2007.00828.x; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Yan J, 2004, STAT MED, V23, P859, DOI 10.1002/sim.1650	39	205	208	1	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					173	+		10.1016/j.jaci.2016.05.027	http://dx.doi.org/10.1016/j.jaci.2016.05.027			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27522159	Green Accepted, Bronze			2022-12-18	WOS:000393996800019
J	Fuhlbrigge, A; Peden, D; Apter, AJ; Boushey, HA; Camargo, CA; Gern, J; Heymann, PW; Martinez, FD; Mauger, D; Teague, WG; Blaisdell, C				Fuhlbrigge, Anne; Peden, David; Apter, Andrea J.; Boushey, Homer A.; Camargo, Carlos A., Jr.; Gern, James; Heymann, Peter W.; Martinez, Fernando D.; Mauger, David; Teague, William G.; Blaisdell, Carol			Asthma outcomes: Exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbations; severity of acute asthma; systemic steroids in asthma; urgent asthma care	METERED-DOSE INHALER; BUDESONIDE/FORMOTEROL COMBINATION THERAPY; SEVERE PERSISTENT ASTHMA; BROMIDE PLUS FENOTEROL; AMBIENT AIR-POLLUTION; EXHALED NITRIC-OXIDE; DRY POWDER INHALER; LONG-TERM SAFETY; QUALITY-OF-CARE; STEP-UP THERAPY	Background: The goals of asthma treatment include preventing recurrent exacerbations. Yet there is no consensus about the terminology for describing or defining "exacerbation" or about how to characterize an episode's severity. Objective: National Institutes of Health institutes and other federal agencies convened an expert group to propose how asthma exacerbation should be assessed as a standardized asthma outcome in future asthma clinical research studies. Methods: We used comprehensive literature reviews and expert opinion to compile a list of asthma exacerbation outcomes and classified them as either core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at a National Institutes of Health-organized workshop in March 2010 and finalized in September 2011. Results: No dominant definition of "exacerbation" was found. The most widely used definitions included 3 components, all related to treatment, rather than symptoms: (1) systemic use of corticosteroids, (2) asthma-specific emergency department visits or hospitalizations, and (3) use of short-acting beta-agonists as quick-relief (sometimes referred to as "rescue" or "reliever") medications. Conclusions: The working group participants propose that the definition of "asthma exacerbation" be "a worsening of asthma requiring the use of systemic corticosteroids to prevent a serious outcome." As core outcomes, they propose inclusion and separate reporting of several essential variables of an exacerbation. Furthermore, they propose the development of a standardized, component-based definition of "exacerbation" with clear thresholds of severity for each component. (J Allergy Clin Immunol 2012; 129: S34-48.)	[Blaisdell, Carol] NHLBI, DLD, NIH, Bethesda, MD 20892 USA; [Fuhlbrigge, Anne] Brigham & Womens Hosp, Boston, MA 02115 USA; [Peden, David] Univ N Carolina, Chapel Hill, NC USA; [Apter, Andrea J.] Univ Penn, Philadelphia, PA 19104 USA; [Boushey, Homer A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Gern, James] Univ Wisconsin, Madison, WI 53706 USA; [Heymann, Peter W.; Teague, William G.] Univ Virginia, Charlottesville, VA USA; [Martinez, Fernando D.] Univ Arizona, Tucson, AZ USA; [Mauger, David] Penn State Univ, Hershey, PA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Virginia; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Blaisdell, C (corresponding author), NHLBI, DLD, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.	blaisdellcj@nhlbi.nih.gov	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Peden, David/0000-0003-4526-4627	National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; NIH/NIAID; MedImmune; Aquinox Pharmaceuticals; GlaxoSmithKline; Genentech; Sanofi-Aventis; Centocor; Boehringer Ingelheim; Biota; Theraclone; NIH; Novartis; NIH/NHLBI; American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); Aquinox Pharmaceuticals; GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Sanofi-Aventis(Sanofi-Aventis); Centocor; Boehringer Ingelheim(Boehringer Ingelheim); Biota; Theraclone; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: A. Fuhlbrigge is on the Merck Respiratory Advisory Board and is a consultant for the Lovelace Respiratory and Research Institute. D. Peden has received research support from the NIH/NIAID, MedImmune, the US Environmental Protection Agency, and Aquinox Pharmaceuticals. A. J. Apter has received research support from the NHLBI and is on the AAAAI Board of Directors. H. A. Boushey has provided ad-hoc consultation for Kalobics; is on the Pharmaxis advisory committee; is on the ad-hoc advisory committee for Merck and GlaxoSmithKline; has provided consultation for Genentech and Johnson & Johnson; and has received research support from GlaxoSmithKline and Genentech. C. A. Camargo, Jr, is a consultant for Dey, Genentech, Merck, Novartis, and Pfizer; and has received research support from GlaxoSmithKline and Sanofi-Aventis. J. Gern is on the Scientific Advisory Board and has stock options in 3V Biosciences, and has received consulting fees from Centocor, Boehringer Ingelheim, GlaxoSmithKline, Biota, MedImmune, and Theraclone. P. W. Heymann has received research support from the NIH and Novartis. F. D. Martinez has consulted for MedImmune and received lecture honorarium from Abbott. W. G. Teague is a speaker for Merck and Genentech, and has received research support from the NIH/NHLBI and the American Lung Association. C. Blaisdell is on the American Academy of Pediatrics Executive Board and is an abstract reviewer for the Pediatric Academic Society. The rest of the authors declare that they have no relevant conflicts of interest.	Allen SC, 2003, AGE AGEING, V32, P299, DOI 10.1093/ageing/32.3.299; ALTMAN DG, 1994, BRIT MED J, V309, P996, DOI 10.1136/bmj.309.6960.996; Ash M, 2006, AM J PUBLIC HEALTH, V96, P358, DOI 10.2105/AJPH.2004.050203; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, pe8; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; Bateman E, 2006, CHEST, V129, P1176, DOI 10.1378/chest.129.5.1176; Bateman ED, 2006, ANN ALLERG ASTHMA IM, V96, P679, DOI 10.1016/S1081-1206(10)61065-4; BECKER AB, 1984, AM J DIS CHILD, V138, P574, DOI 10.1001/archpedi.1984.02140440058015; Bhakta NR, 2011, IMMUNOL REV, V242, P220, DOI 10.1111/j.1600-065X.2011.01032.x; BISHOP J, 1992, J CLIN EPIDEMIOL, V45, P71, DOI 10.1016/0895-4356(92)90190-X; Bland JM, 1996, BRIT MED J, V312, P1079; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse W, 2001, J FAM PRACTICE, V50, P595; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1407, DOI 10.1016/j.jaci.2008.03.019; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Chalut DS, 2000, J PEDIATR-US, V137, P762, DOI 10.1067/mpd.2000.110121; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Dusser D, 2005, RESPIRATION, V72, P20, DOI 10.1159/000083689; Engelstatter R, 2009, RESP MED, V103, P1643, DOI 10.1016/j.rmed.2009.06.004; Escribano A, 2006, CURR MED RES OPIN, V22, P1085, DOI 10.1185/030079906X104812; Farber HJ, 1998, J ASTHMA, V35, P95, DOI 10.3109/02770909809055410; Fish JE, 1997, AM J RESP CRIT CARE, V156, P1165, DOI 10.1164/ajrccm.156.4.9703012; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge AL, 2006, PEDIATRICS, V118, P619, DOI 10.1542/peds.2005-2963; Gamble J, 2007, J CLIN NURS, V16, P59, DOI 10.1111/j.1365-2702.2006.01750.x; GINA, 2010, GLOB STRAT ASTHM MAN; Gonem S, 2011, CURR OPIN ALLERGY CL, V11, P381, DOI 10.1097/ACI.0b013e328348a8f9; Gorelick MH, 2004, ACAD EMERG MED, V11, P10, DOI 10.1197/S106-6563(03)00579-7; Greenberg RA, 2008, CLIN PEDIATR, V47, P817, DOI 10.1177/0009922808316988; Gries DM, 2000, J PEDIATR-US, V136, P298, DOI 10.1067/mpd.2000.103353; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Homer CJ, 1996, PEDIATRICS, V98, P18; Huchon G, 2009, RESP MED, V103, P41, DOI 10.1016/j.rmed.2008.09.002; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Irvin CG, 2007, AM J RESP CRIT CARE, V175, P235, DOI 10.1164/rccm.200603-416OC; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Janson S, 1998, J ASTHMA, V35, P427, DOI 10.3109/02770909809048951; Kattan M, 2006, PEDIATRICS, V117, pE1095, DOI 10.1542/peds.2005-2160; Kiley J, 2007, CURR OPIN PULM MED, V13, P19; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lee TA, 2007, J ASTHMA, V44, P189, DOI 10.1080/02770900701209723; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Leone FT, 2001, CHEST, V119, P1027, DOI 10.1378/chest.119.4.1027; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Louis R, 2009, INT J CLIN PRACT, V63, P1479, DOI 10.1111/j.1742-1241.2009.02185.x; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; McConnochie KM, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e75; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Montuschi P, 2007, CHEST, V132, P1876, DOI 10.1378/chest.07-1587; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Morice AH, 2007, INT J CLIN PRACT, V61, P1874, DOI 10.1111/j.1742-1241.2007.01574.x; Morice AH, 2008, PULM PHARMACOL THER, V21, P32, DOI 10.1016/j.pupt.2006.10.006; Morice AH, 2008, PULM PHARMACOL THER, V21, P152, DOI 10.1016/j.pupt.2007.01.006; Naimi DR, 2009, J ALLERGY CLIN IMMUN, V123, P1335, DOI 10.1016/j.jaci.2009.02.022; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; National Heart Lung and Blood Institute, 1996, NAEPP WORK GROUP REP; Niphadkar P, 2005, CLIN THER, V27, P1752, DOI 10.1016/j.clinthera.2005.11.005; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Olson LM, 2007, PEDIATRICS, V119, pE93, DOI 10.1542/peds.2005-3211; Papi A, 2007, ALLERGY, V62, P1182, DOI 10.1111/j.1398-9995.2007.01493.x; Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Parkin PC, 1996, J CLIN EPIDEMIOL, V49, P821, DOI 10.1016/0895-4356(96)00027-3; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearlman DS, 2005, J ALLERGY CLIN IMMUN, V116, P1206, DOI 10.1016/j.jaci.2005.08.037; Pedersen S, 2009, PULM PHARMACOL THER, V22, P214, DOI 10.1016/j.pupt.2008.12.013; Peters SP, 2008, ALLERGY ASTHMA PROC, V29, P499, DOI 10.2500/aap.2008.29.3147; Peters SP, 2007, NEW ENGL J MED, V356, P2027; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pezzoli L, 2003, AGE AGEING, V32, P43, DOI 10.1093/ageing/32.1.43; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Qureshi F, 2001, J PEDIATR-US, V139, P20, DOI 10.1067/mpd.2001.115021; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Roy SR, 2010, CURR ALLERGY ASTHM R, V10, P56, DOI 10.1007/s11882-009-0083-5; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Sears MR, 2008, EUR RESPIR J, V31, P982, DOI 10.1183/09031936.00104007; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Shields AE, 2004, PEDIATRICS, V113, P496, DOI 10.1542/peds.113.3.496; Smith SR, 2002, ACAD EMERG MED, V9, P99, DOI 10.1197/aemj.9.2.99; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Suissa S, 2006, AM J RESP CRIT CARE, V173, P842, DOI 10.1164/rccm.200508-1338PP; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Teach SJ, 2006, PEDIATRICS, V117, pS78, DOI 10.1542/peds.2005-2000E; Vincken W, 2004, CLIN DRUG INVEST, V24, P17, DOI 10.2165/00044011-200424010-00003; von Berg A, 2004, PEDIATR PULM, V37, P264, DOI 10.1002/ppul.10428; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wenzel S, 2007, J ASTHMA, V44, P305, DOI 10.1080/02770900701344199; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041; Wolfenden LL, 2002, J AM GERIATR SOC, V50, P877, DOI 10.1046/j.1532-5415.2002.50214.x; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003	134	205	206	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S34	S48		10.1016/j.jaci.2011.12.983	http://dx.doi.org/10.1016/j.jaci.2011.12.983			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	901OL	22386508	Green Submitted, Green Accepted			2022-12-18	WOS:000300976600004
J	Vereda, A; van Hage, M; Ahlstedt, S; Ibanez, MD; Cuesta-Herranz, J; van Odijk, J; Wickman, M; Sampson, HA				Vereda, Andrea; van Hage, Marianne; Ahlstedt, Staffan; Dolores Ibanez, Maria; Cuesta-Herranz, Javier; van Odijk, Jenny; Wickman, Magnus; Sampson, Hugh A.			Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; rAra h 1; rAra h 2; rAra h 3; rAra h 8; rAra h 9; clinical features; molecular diagnosis	LIPID TRANSFER PROTEIN; PEACH ALLERGY; FOOD ALLERGY; BIRCH POLLEN; CHILDREN; SPANISH	Background: Peanut allergy affects persons from various geographic regions where populations are exposed to different dietary habits and environmental pollens. Objective: We sought to describe the clinical and immunologic characteristics of patients with peanut allergy from 3 countries (Spain, the United States, and Sweden) using a molecular component diagnostic approach. Methods: Patients with peanut allergy from Madrid (Spain, n = 50), New York (United States, n = 30), Gothenburg, and Stockholm (both Sweden, n = 35) were enrolled. Clinical data were obtained either from a specific questionnaire or gathered from chart reviews. IgE antibodies to peanut extract and the peanut allergens rAra h 1, 2, 3, 8 and 9, as well as to cross-reactive birch (rBet v 1) and grass (rPhl p 1, 5, 7, and 12) pollen allergens, were analyzed. Results: American patients frequently had IgE antibodies to rAra h 1 to 3 (56.7% to 90.0%) and often presented with severe symptoms. Spanish patients recognized these 3 recombinant peanut allergens less frequently (16.0% to 42.0%), were more often sensitized to the lipid transfer protein rAra h 9 (60.0%), and typically had peanut allergy after becoming allergic to other plant-derived foods. Swedish patients detected rAra h 1 to 3 more frequently than Spanish patients (37.1% to 74.3%) and had the highest sensitization rate to the Bet v 1 homologue rAra h 8 (65.7%), as well as to rBet v 1 (82.9%). Spanish and Swedish patients became allergic to peanut at 2 years or later, whereas the American children became allergic around 1 year of age. Conclusions: Peanut allergy has different clinical and immunologic patterns in different areas of the world. Allergen component diagnostics might help us to better understand this complex entity. (J Allergy Clin Immunol 2011;127:603-7.)	[Vereda, Andrea; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat Allergy, New York, NY USA; [Vereda, Andrea; Cuesta-Herranz, Javier] Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; [Vereda, Andrea; Dolores Ibanez, Maria] Hosp Infantil Univ Nino Jesus, Allergy Serv, Madrid, Spain; [van Hage, Marianne] Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [van Hage, Marianne; Ahlstedt, Staffan; Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Ahlstedt, Staffan; Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [van Odijk, Jenny] Sahlgrens Univ Hosp, Dept Resp Med & Allergy, Gothenburg, Sweden; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Dept Paediat, Stockholm, Sweden	Icahn School of Medicine at Mount Sinai; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sahlgrenska University Hospital; Karolinska Institutet	van Hage, M (corresponding author), Karolinska Univ, Hosp Solna, Dept Med, Allergy & Clin Immunol Unit, L2 04, SE-17176 Stockholm, Sweden.	marianne.van.hage@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596	World Allergy Organization; Swedish Research Council; Stockholm County Council; Swedish Asthma and Allergy Association's Research Foundation; King Gustaf V 80th Birthday Foundation; Swedish Heart-Lung Foundation; Hesselman's Foundation; Centre for Allergy Research at Karolinska Institute; Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health	World Allergy Organization; Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Swedish Asthma and Allergy Association's Research Foundation; King Gustaf V 80th Birthday Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Hesselman's Foundation; Centre for Allergy Research at Karolinska Institute(Karolinska Institutet); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Long-term Fellowship from World Allergy Organization, the Swedish Research Council, the Stockholm County Council, the Swedish Asthma and Allergy Association's Research Foundation, the King Gustaf V 80th Birthday Foundation, the Swedish Heart-Lung Foundation, the Hesselman's Foundation and the Centre for Allergy Research at Karolinska Institute, and the Food Allergy Initiative.; A. Vereda receives a fellowship from the World Allergy Organization. M. van Hage receives research support from the Swedish Research Council, the Stockholm County Council, and the Swedish Asthma and Allergy Association's Research Foundation. M. Wickman serves as a lecturer for Phadia. H. A. Sampson is a consultant for and 4% shareholder of Allertein Pharmaceuticals, LLC; receives research support from the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases/National Institutes of Health; serves as a consultant/scientific advisor for the Food Allergy Initiative; has served as president of the American Academy of Allergy, Asthma & Immunology; and is 45% owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.	Asarnoj A, 2010, ALLERGY, V65, P213, DOI 10.1111/j.1398-9995.2009.02138.x; Asero R, 2009, CLIN EXP ALLERGY, V39, P547, DOI 10.1111/j.1365-2222.2008.03167.x; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Crespo JF, 2006, BRIT J NUTR, V96, pS95, DOI 10.1017/BJN20061869; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Gamboa PM, 2007, ALLERGY, V62, P408, DOI 10.1111/j.1398-9995.2006.01284.x; Gregori D, 2008, EUR ARCH OTO-RHINO-L, V265, P971, DOI 10.1007/s00405-007-0566-8; Hofmann A, 2008, CURR ALLERGY ASTHM R, V8, P413, DOI 10.1007/s11882-008-0080-0; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Pastorello EA, 2004, J ALLERGY CLIN IMMUN, V114, P908, DOI 10.1016/j.jaci.2004.06.020; Romano A, 2009, EUR ANN ALLERGY CLIN, V41, P106; SAAVEDRADELGADO AM, 1989, ALLERGY PROC, V10, P291, DOI 10.2500/108854189778959957; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350	22	205	209	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					603	607		10.1016/j.jaci.2010.09.010	http://dx.doi.org/10.1016/j.jaci.2010.09.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21093026				2022-12-18	WOS:000288018400007
J	Simon, HU; Rothenberg, ME; Bochner, BS; Weller, PF; Wardlaw, AJ; Wechsler, ME; Rosenwasser, LJ; Roufosse, F; Gleich, GJ; Klion, AD				Simon, Hans-Uwe; Rothenberg, Marc E.; Bochner, Bruce S.; Weller, Peter F.; Wardlaw, Andrew J.; Wechsler, Michael E.; Rosenwasser, Lanny J.; Roufosse, Florence; Gleich, Gerald J.; Klion, Amy D.			Refining the definition of hypereosinophilic syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Definition; eosinophilia; eosinophilic leukemia; hypereosinophilic syndromes	EOSINOPHILIC LEUKEMIA; IMATINIB; FUSION; CLONES	Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition. (J Allergy Clin Immunol 2010;126:45-9.)	[Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland; [Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA; [Weller, Peter F.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, Boston, MA USA; [Weller, Peter F.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA USA; [Wardlaw, Andrew J.] Univ Leicester, Inst Lung Hlth Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Wechsler, Michael E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Rosenwasser, Lanny J.] UMKC Sch Med, Childrens Mercy Hosp, Div Allergy Immunol, Kansas City, MO USA; [Roufosse, Florence] Univ Libre Bruxelles, Hop Erasme, Serv Med Interne, Brussels, Belgium; [Roufosse, Florence] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Klion, Amy D.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	University of Bern; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Leicester; Harvard University; Brigham & Women's Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Simon, HU (corresponding author), Univ Bern, Inst Pharmacol, Friedbuehlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019; Simon, Hans-Uwe/AAU-7410-2020	Wechsler, Michael/0000-0003-3505-2946; Simon, Hans-Uwe/0000-0002-9404-7736; Wardlaw, Andrew/0000-0001-6583-0791; Klion, Amy/0000-0002-4986-5326	GlaxoSmithKline; AstraZeneca; Roche; CSL Behring; Nycomed; National Institutes of Health; Novartis; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Roche(Roche Holding); CSL Behring; Nycomed; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H.-U. Simon has received research support from GlaxoSmithKline, AstraZeneca, Roche, CSL Behring, and Nycomed, and has provided legal consultation or expert witness testimony for Pfizer on the topic of general pharmacology. M. E. Rothenberg has consulted for and given talks for Merck; has consulted for Centocor, Ception Therapeutics, Nycomed, Array BioPharma, Biocrystal Pharmaceuticals, and Endo Pharmaceuticals; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation; is on the medical advisory board of the American Partnership for Eosinophilic Diseases; and is on the executive council of the International Eosinophil Society. B. S. Bochner has consulted for Sanofi-Aventis and GlaxoSmithKline and has received research support from Sanofi-Aventis. P. F. Weller has received research support from Merck and has provided legal consultation services or expert witness testimony on the topic of eosinophilic diseases. A. J. Wardlaw is on advisory boards for GlaxoSmithKline and has received research support from GlaxoSmithKline, Pfizer, and AstraZeneca. M. E. Wechsler has consulted for and given talks for Genentech, Merck, and Novartis; has consulted for Medlmmune, Medicinova, and GlaxoSmithKline; is on the data safety monitoring board for MAP Pharmaceuticals; and has received research support from the National Institutes of Health and GlaxoSmithKline. L. J. Rosenwasser has received research support from Novartis and Genentech and has consulted for Alcon, Sanofi-Aventis, GlaxoSmithKline, and AstraZeneca. F. Roufosse has consulted for GlaxoSmithKline. G. J. Gleich has provided legal consultation or expert witness testimony on the topic of heparin contamination and is on the board directors for the American Partnership for Eosinophilic Disorders. A. D. KI ion declares that she has no relevant conflicts of interest to disclose.	Bain BJ, 2001, WHO CLASSIFICATION T, P29; Banerji A, 2006, IMMUNOL ALLERGY CLIN, V26, P769, DOI 10.1016/j.iac.2006.09.001; Capovilla M, 2008, EUR J HAEMATOL, V80, P81, DOI 10.1111/j.1600-0609.2007.00973.x; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; de Lavareille A, 2002, J ALLERGY CLIN IMMUN, V110, P476, DOI 10.1067/mai.2002.127003; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Helbig G, 2009, HAEMATOL-HEMATOL J, V94, P1236, DOI 10.3324/haematol.2008.005447; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; Metzgeroth G, 2007, LEUKEMIA, V21, P1183, DOI 10.1038/sj.leu.2404662; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Plager DA, 2006, J IMMUNOL, V177, P7340, DOI 10.4049/jimmunol.177.10.7340; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Roufosse F, 2003, ANNU REV MED, V54, P169, DOI 10.1146/annurev.med.54.101601.152431; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P39, DOI 10.1016/j.jaci.2010.04.011; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P1054, DOI 10.1016/j.jaci.2007.11.027; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 2001, INT ARCH ALLERGY IMM, V124, P242, DOI 10.1159/000053723; Valent P, 2009, BLOOD REV, V23, P157, DOI 10.1016/j.blre.2009.01.001; Vassina EM, 2006, EUR J IMMUNOL, V36, P1975, DOI 10.1002/eji.200635943	24	205	224	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					45	49		10.1016/j.jaci.2010.03.042	http://dx.doi.org/10.1016/j.jaci.2010.03.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20639008	Green Accepted, Green Submitted			2022-12-18	WOS:000280061800009
J	Metcalfe, DD; Peavy, RD; Gilfillan, AM				Metcalfe, Dean D.; Peavy, Richard D.; Gilfillan, Alasdair M.			Mechanisms of mast cell signaling in anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; mast cells; Fc is an element of RI; signal transduction	FC-EPSILON-RI; AFFINITY IGE RECEPTOR; NEGATIVE REGULATION; ALLERGIC RESPONSES; TYROSINE KINASE; MICE LACKING; FYN KINASE; ACTIVATION; CA2+; LYN	The recent development of a consensus definition and proposed diagnostic criteria for anaphylaxis offers promise for research efforts and a better understanding of the epidemiology and pathogenesis of this enigmatic and life-threatening disease. This review examines basic principles and recent research advances in the mechanisms of mast cell signaling believed to underlie anaphylaxis. The unfolding complexity of mast cell signaling suggests that the system is sensitive to regulation by any of several individual signaling pathways and intermediates and that complementary pathways regulate mast cell activation by amplified signals. The signaling events underlying anaphylactic reactions have largely been identified through experiments in genetically modified mice and supported by biochemical studies of mast cells derived from these mice. These studies have revealed that signaling pathways exist to both upregulate and downregulate mast cell responses. In this review we will thus describe the key molecular players in these pathways in the context of anaphylaxis. (J Allergy Clin Immunol 2009;124:639-46.)	[Metcalfe, Dean D.; Peavy, Richard D.; Gilfillan, Alasdair M.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Metcalfe, DD (corresponding author), Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	dmetcalfe@niaid.nih.gov			Merck Co., Inc.; National Institute of Allergy anti Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000965, ZIAAI000967] Funding Source: NIH RePORTER	Merck Co., Inc.(Merck & Company); National Institute of Allergy anti Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This CME activity is supported by an educational grant from Merck & Co., Inc.; Supported by the Intramural Research Program of the National Institute of Allergy anti Infectious Diseases, National Institutes of Health.	Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Ali K, 2008, J IMMUNOL, V180, P2538, DOI 10.4049/jimmunol.180.4.2538; Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Bansal G, 2008, NAT IMMUNOL, V9, P73, DOI 10.1038/ni1533; Brockow K, 2006, J ALLERGY CLIN IMMUN, V117, pS307, DOI 10.1016/j.jaci.2005.12.1213; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Costello PS, 1996, ONCOGENE, V13, P2595; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Iwaki S, 2008, CELL SIGNAL, V20, P195, DOI 10.1016/j.cellsig.2007.10.013; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Kim WK, 2008, J ENVIRON BIOL, V29, P501; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kuehn HS, 2007, IMMUNOL LETT, V113, P59, DOI 10.1016/j.imlet.2007.08.007; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lenchner K, 2003, CURR OPIN ALLERGY CL, V3, P305, DOI 10.1097/01.all.0000083959.99396.1a; Lieberman P, 2008, CURR OPIN ALLERGY CL, V8, P316, DOI 10.1097/ACI.0b013e3283036a69; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu Y, 2007, J EXP MED, V204, P93, DOI 10.1084/jem.20061598; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Mertsching E, 2008, J ALLERGY CLIN IMMUN, V121, P441, DOI 10.1016/j.jaci.2007.08.051; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nieuwenhuizen N, 2007, J IMMUNOL, V179, P2758, DOI 10.4049/jimmunol.179.5.2758; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Ogawa Y, 2007, IMMUNOL ALLERGY CLIN, V27, P249, DOI 10.1016/j.iac.2007.03.013; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Repetto B, 1996, J IMMUNOL, V156, P4876; Ring Johannes, 2002, Curr Allergy Asthma Rep, V2, P40, DOI 10.1007/s11882-002-0036-8; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Saitoh S, 2003, J EXP MED, V198, P831, DOI 10.1084/jem.20030574; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silverman MA, 2006, MOL CELL BIOL, V26, P1826, DOI 10.1128/MCB.26.5.1826-1838.2006; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Tkaczyk C, 2005, CHEM IMMUNOL ALLERGY, V87, P43, DOI 10.1159/000087570; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; Vennekens R, 2007, NAT IMMUNOL, V8, P312, DOI 10.1038/ni1441; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; Yamasaki S, 2008, INT IMMUNOL, V20, P1289, DOI 10.1093/intimm/dxn085; Yamashita Y, 2007, J IMMUNOL, V179, P740, DOI 10.4049/jimmunol.179.2.740; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; Zhu MH, 2004, J EXP MED, V200, P991, DOI 10.1084/jem.20041223	71	205	210	6	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					639	646		10.1016/j.jaci.2009.08.035	http://dx.doi.org/10.1016/j.jaci.2009.08.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815110	Green Accepted, Bronze			2022-12-18	WOS:000270802800002
J	Cloutier, MM; Baptist, AP; Blake, KV; Brooks, EG; Bryant-Stephens, T; DiMango, E; Dixon, AE; Elward, KS; Hartert, T; Krishnan, JA; Lemanske Jr, RF; Ouellette, DR; Pace, WD; Schatz, M; Skolnik, NS; Stout, JW; Teach, SJ; Umscheid, CA; Walsh, CG				Cloutier, Michelle M.; Baptist, Alan P.; Blake, Kathryn V.; Brooks, Edward G.; Bryant-Stephens, Tyra; DiMango, Emily; Dixon, Anne E.; Elward, Kurtis S.; Hartert, Tina; Krishnan, Jerry A.; Lemanske, Robert F., Jr.; Ouellette, Daniel R.; Pace, Wilson D.; Schatz, Michael; Skolnik, Neil S.; Stout, James W.; Teach, Stephen J.; Umscheid, Craig A.; Walsh, Colin G.		NHLBI; NAEPPCC	2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NHLBI; Asthma Guideline; asthma; fractional exhaled nitric oxide; allergen mitigation; inhaled corticosteroids; long-acting muscarinic antagonist; bronchial thermoplasty; immunotherapy	EXHALED NITRIC-OXIDE; HOUSE-DUST-MITE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; GRASS-POLLEN IMMUNOTHERAPY; MILD PERSISTENT ASTHMA; STANDARDIZED SPECIFIC IMMUNOTHERAPY; PLACEBO-CONTROLLED IMMUNOTHERAPY; ALLERGEN-SPECIFIC IMMUNOTHERAPY; HEALTH WORKER INTERVENTION	The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group was coordinated and supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. It is designed to improve patient care and support informed decision making about asthma management in the clinical setting. This update addresses six priority topic areas as determined by the state of the science at the time of a needs assessment, and input from multiple stakeholders: Fractional Exhaled Nitric Oxide Testing Indoor Allergen Mitigation Intermittent Inhaled Corticosteroids Long-Acting Muscarinic Antagonists Immunotherapy in the Treatment of Allergic Asthma Bronchial Thermoplasty A rigorous process was undertaken to develop these evidence-based guidelines. The Agency for Healthcare Research and Quality's (AHRQ) Evidence-Based Practice Centers conducted systematic reviews on these topics, which were used by the Expert Panel Working Group as a basis for developing recommendations and guidance. The Expert Panel used GRADE (Grading of Recommendations, Assessment, Development and Evaluation), an internationally accepted framework, in consultation with an experienced methodology team for determining the certainty of evidence and the direction and strength of recommendations based on the evidence. Practical implementation guidance for each recommendation incorporates findings from NHLBI-led patient, caregiver, and clinician focus groups. To assist clincians in implementing these recommendations into patient care, the new recommendations have been integrated into the existing Expert Panel Report-3 (EPR-3) asthma management step diagram format.	NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Cloutier, Michelle M.] UCONN Hlth, Expert Panel Working Grp, Farmington, CT 06030 USA; [Baptist, Alan P.] Univ Michigan, Ann Arbor, MI 48109 USA; [Blake, Kathryn V.] Nemours Childrens Hlth Syst, Jacksonville, FL USA; [Brooks, Edward G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [DiMango, Emily] Columbia Univ, Irving Med Ctr, New York, NY USA; [Dixon, Anne E.] Univ Vermont, Burlington, VT USA; [Elward, Kurtis S.] Virginia Commonwealth Univ, Charlottesville, VA USA; [Hartert, Tina] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Madison, WI USA; [Ouellette, Daniel R.] Henry Ford Hlth Syst, Detroit, MI USA; [Pace, Wilson D.] Univ Colorado, Aurora, CO USA; [Schatz, Michael] Kaiser Permanente, San Diego, CA USA; [Skolnik, Neil S.] Abington Jefferson Hlth, Jenkintown, PA USA; [Stout, James W.] Univ Washington, Seattle, WA 98195 USA; [Teach, Stephen J.] George Washington Univ, Washington, DC USA; [Umscheid, Craig A.] Univ Chicago, Chicago, IL 60637 USA; [Walsh, Colin G.] Vanderbilt Univ, Med Ctr, Nashville, TN USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Columbia University; NewYork-Presbyterian Hospital; University of Vermont; Virginia Commonwealth University; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison; Henry Ford Health System; Henry Ford Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; Kaiser Permanente; Abington Memorial Hospital; University of Washington; University of Washington Seattle; George Washington University; University of Chicago; Vanderbilt University	Cloutier, MM (corresponding author), UCONN Hlth, Expert Panel Working Grp, Farmington, CT 06030 USA.				NHLBI NIH HHS [HHSN268201700020B] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2089; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Altintas D, 1999, Allergol Immunopathol (Madr), V27, P309; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; [Anonymous], 2018, J ALLERGY CLIN IMMUN; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Atienza T, 2013, RESPIROLOGY, V18, P354, DOI 10.1111/resp.12009; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bahir A, 1997, ANN ALLERG ASTHMA IM, V78, P506, DOI 10.1016/S1081-1206(10)63239-5; Balu A, 2015, J ASTHMA, V52, P740, DOI 10.3109/02770903.2015.1005844; Barnes CS, 2008, ALLERGY ASTHMA PROC, V29, P197, DOI 10.2500/aap.2008.29.3099; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Beerthuizen T, 2016, THORAX, V71, P607, DOI 10.1136/thoraxjnl-2015-207593; Berg J, 2008, RESP MED, V102, P219, DOI 10.1016/j.rmed.2007.09.008; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Bloemen K, 2011, CLIN EXP ALLERGY, V41, P346, DOI 10.1111/j.1365-2222.2010.03638.x; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Brozek J, GRADEPRO GUIDELINE D; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; Bryant-Stephens T, 2009, AM J PUBLIC HEALTH, V99, pS657, DOI [DOI 10.2105/AJPH.2009.165423, 10.2105/AJPH.2009.165423]; Bryant-Stephens T, 2008, J NATL MED ASSOC, V100, P306, DOI 10.1016/S0027-9684(15)31243-8; Burr ML, 2007, THORAX, V62, P767, DOI 10.1136/thx.2006.070847; Busse WW, 2018, NEW ENGL J MED, V378, P2497, DOI 10.1056/NEJMoa1716868; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Camargos P, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0192-0; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2010, THORAX, V65, P801, DOI 10.1136/thx.2009.126912; Chakraborty P, 2006, J INVEST ALLERG CLIN, V16, P377; Chang D, 2015, EUR RESPIR J, V45, P98, DOI 10.1183/09031936.00034614; Cho HJ, 2014, ALLERGY ASTHMA IMMUN, V6, P169, DOI 10.4168/aair.2014.6.2.169; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Cox G, 2006, AM J RESP CRIT CARE, V173, P965, DOI 10.1164/rccm.200507-1162OC; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Nguyen DV, 2016, CHEST, V149, pE95, DOI 10.1016/j.chest.2015.09.016; DAnci KE, AHRQ PUBLICATION, DOI [10.23970/AHRQEPCCER202., DOI 10.23970/AHRQEPCCER202, 10.23970/AHRQEPCCER202]; de Blay F, 2014, RESP MED, V108, P1430, DOI 10.1016/j.rmed.2014.07.017; de Bot CMA, 2013, PRIM CARE RESP J, V22, P44, DOI 10.4104/pcrj.2013.00009; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; de Vries MP, 2007, BRIT J GEN PRACT, V57, P184; Devillier P, 2016, ALLERGY, V71, P249, DOI 10.1111/all.12791; Dharmage S, 2006, INT ARCH ALLERGY IMM, V139, P132, DOI 10.1159/000090388; DiMango E, 2016, J ALLER CL IMM-PRACT, V4, P671, DOI 10.1016/j.jaip.2016.01.016; Doeing DC, 2013, J ASTHMA, V50, P799, DOI 10.3109/02770903.2013.796974; Doeing DC, 2013, J ASTHMA, V50, P215, DOI 10.3109/02770903.2012.751997; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; El-Ghitany Engy M., 2012, Environmental Health and Preventive Medicine, V17, P377, DOI 10.1007/s12199-011-0263-5; Elliott M, 2013, CLIN EXP ALLERGY, V43, P1351, DOI 10.1111/cea.12171; Balinotti JE, 2013, ARCH ARGENT PEDIATR, V111, P191, DOI [10.5546/aap.2013.191, 10.5546/aap.2013.eng.191]; Epstein TG, 2019, J ALLER CL IMM-PRACT, V7, P1996, DOI 10.1016/j.jaip.2019.01.058; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Facciolongo N, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0002-7; Francis H, 2003, CLIN EXP ALLERGY, V33, P101, DOI 10.1046/j.1365-2222.2003.01570.x; Franco C, 1995, Allergol Immunopathol (Madr), V23, P58; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Fritsch M, 2006, PEDIATR PULM, V41, P855, DOI 10.1002/ppul.20455; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Funatsu A, 2018, RESPIROL CASE REP, V6, DOI 10.1002/rcr2.286; Gallego MT, 2010, INT ARCH ALLERGY IMM, V153, P61, DOI 10.1159/000301580; Garcia-Robaina JC, 2006, J ALLERGY CLIN IMMUN, V118, P1026, DOI 10.1016/j.jaci.2006.07.043; Garg Y, 2018, ARMED FORCES MED J I, V76, P17; Geller-Bernstein C, 1995, Allerg Immunol (Paris), V27, P147; Gill M, 2005, ACAD EMERG MED, V12, P579, DOI 10.1197/j.acm.2005.01.018; Gomez Vera J, 2005, Rev Alerg Mex, V52, P231; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.03.017, 10.1016/j.jclinepi.2011.06.004]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Hamelmann E, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01100-2016; Hamelmann E, 2016, J ALLERGY CLIN IMMUN, V138, P441, DOI 10.1016/j.jaci.2016.01.011; Han XD, 2019, J ASTHMA, V56, P1004, DOI 10.1080/02770903.2018.1509992; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Hashimoto S, 2011, THORAX, V66, P514, DOI 10.1136/thx.2010.153411; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; Honkoop PJ, 2015, J ALLERGY CLIN IMMUN, V135, P682, DOI 10.1016/j.jaci.2014.07.016; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Hui Y, 2014, EXP THER MED, V7, P630, DOI 10.3892/etm.2014.1469; Hultcrantz M, 2017, J CLIN EPIDEMIOL, V87, P4, DOI 10.1016/j.jclinepi.2017.05.006; Institute of Medicine, 2009, CONFLICT INTEREST ME; Jackson DJ, 2018, NEW ENGL J MED, V378, P891, DOI 10.1056/NEJMoa1710988; Jenkins CR, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0401-y; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Juniper EF, 2010, EUR RESPIR J, V36, P1410, DOI 10.1183/09031936.00117509; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kilic M, 2011, TURKISH J PEDIATR, V53, P285; Klaassen EMM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/162571; Ko FWS, 2012, RESPIROLOGY, V17, P370, DOI 10.1111/j.1440-1843.2011.02105.x; Krieger J, 2009, ARCH PEDIAT ADOL MED, V163, P141, DOI 10.1001/archpediatrics.2008.532; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Krueger R. A., 2002, DESIGNING CONDUCTING; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; Kuna P, 2011, J ALLERGY CLIN IMMUN, V127; Kwok MY, 2009, ACAD EMERG MED, V16, P21, DOI 10.1111/j.1553-2712.2008.00304.x; LaForce C, 2014, ANN ALLERG ASTHMA IM, V113, P619, DOI 10.1016/j.anai.2014.06.013; Lahdensuo A, 1996, BRIT MED J, V312, P748; Leas BF, 2018, AHRQ PUBLICATION, V18-EHC002-EF; Lee IS, 2003, YONSEI MED J, V44, P313, DOI 10.3349/ymj.2003.44.2.313; Lee LA, 2015, RESP MED, V109, P54, DOI 10.1016/j.rmed.2014.09.012; Levy JI, 2006, SOC SCI MED, V63, P2191, DOI 10.1016/j.socscimed.2006.05.006; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Lieberman P, 2012, AM J RHINOL ALLERGY, V26, P469, DOI 10.2500/ajra.2012.26.3811; Lieu TA, 2011, AM J RESP CRIT CARE, V184, P848, DOI 10.1164/rccm.201104-0634WS; Lin SY, 2013, 290200710061I2013 J; Lin SY, 2018, AHRQ PUBLICATION, V17(18)- EHC029-EF; Louis R, 2009, INT J CLIN PRACT, V63, P1479, DOI 10.1111/j.1742-1241.2009.02185.x; Lozano J, 2014, INT ARCH ALLERGY IMM, V165, P140, DOI 10.1159/000368832; Luczynska C, 2003, CLIN EXP ALLERGY, V33, P1648, DOI 10.1111/j.1365-2222.2003.01729.x; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Mahajan AK, 2012, J ASTHMA, V49, P527, DOI 10.3109/02770903.2012.676124; Malerba M, 2015, CURR PHARM DESIGN, V21, P4752, DOI 10.2174/1871524915666150710123415; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; Maloney J, 2016, ANN ALLERG ASTHMA IM, V116, P59, DOI 10.1016/j.anai.2015.10.024; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Marogna M, 2013, ALLERGOL IMMUNOPATH, V41, P216, DOI 10.1016/j.aller.2012.07.004; Marogna M, 2010, J INVEST ALLERG CLIN, V20, P146; Marogna M, 2009, ANN ALLERG ASTHMA IM, V102, P69, DOI 10.1016/S1081-1206(10)60111-1; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; McCormack MC, 2013, CHEST, V144, P923, DOI 10.1378/chest.12-3098; McKeever T, 2018, NEW ENGL J MED, V378, P902, DOI 10.1056/NEJMoa1714257; Mensah GA, 2018, J ALLERGY CLIN IMMUN, V142, P744, DOI 10.1016/j.jaci.2018.07.004; Menzella F, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0252-y; Menzies D, 2008, ANN ALLERG ASTHMA IM, V101, P248, DOI 10.1016/S1081-1206(10)60489-9; Meyts I, 2003, PEDIATR PULM, V36, P283, DOI 10.1002/ppul.10317; Michils A, 2009, EUR RESPIR J, V33, P1295, DOI 10.1183/09031936.00154008; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Mosges R, 2010, PEDIAT ALLERG IMM-UK, V21, P1135, DOI 10.1111/j.1399-3038.2010.01078.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Murray CS, 2017, AM J RESP CRIT CARE, V196, P150, DOI 10.1164/rccm.201609-1966OC; Nambu Mitsuhiko, 2008, Pediatric Asthma Allergy & Immunology, V21, P137, DOI 10.1089/pai.2008.0002; National Asthma Education and Prevention Program, 1991, EXP PAN REP GUID DIA; National Asthma Education and Prevention Program, 2007, 3 US DEP HLTH HUM SE, P213; National Asthma Education and Prevention Program, 2007, 3 EXP PAN DIAGN MAN; National Asthma Education Prevention Program (National Heart Lung and Blood Institute), 1997, 2 NAT ASTHM ED PREV; National Heart Lung and Blood Advisory Council Asthma Expert Working Group, 2007, 3 NAT HEART LUNG BLO; Nelson HS, 2014, MIDDLETONS ALLERGY, V8th, P1416; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; OHehir RE, 2014, MIDDLETONS ALLERGY P, P1438; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Papi A, 2013, LANCET RESP MED, V1, P23, DOI 10.1016/S2213-2600(13)70012-2; Parker EA, 2008, HEALTH EDUC BEHAV, V35, P376, DOI 10.1177/1090198106290622; Patel M, 2013, LANCET RESP MED, V1, P32, DOI 10.1016/S2213-2600(13)70007-9; Patton MQ., 2015, QUALITATIVE RES EVAL, V4th edn.; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Pavord ID, 2013, ANN ALLERG ASTHMA IM, V111, P402, DOI 10.1016/j.anai.2013.05.002; Pedroletti C, 2009, RESP MED, V103, P1313, DOI 10.1016/j.rmed.2009.03.020; Peirsman EJ, 2014, PEDIATR PULM, V49, P624, DOI 10.1002/ppul.22873; Peters M, 2009, DRUGS, V69, P137, DOI 10.2165/00003495-200969020-00001; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Petsky HL, 2015, PEDIATR PULM, V50, P535, DOI 10.1002/ppul.23064; Pham-Thi N, 2007, PEDIAT ALLERG IMM-UK, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pike K, 2013, CLIN RESPIR J, V7, P204, DOI 10.1111/j.1752-699X.2012.00306.x; Powell H, 2011, LANCET, V378, P983, DOI 10.1016/S0140-6736(11)60971-9; Prado Carla M, 2011, ISRN Allergy, V2011, P832560, DOI 10.5402/2011/832560; Qaseem A, 2019, ANN INTERN MED, V171, P354, DOI 10.7326/M18-3279; Qiu MZ, 2018, J THORAC DIS, V10, pE721, DOI 10.21037/jtd.2018.09.116; Quaedvlieg V, 2009, CLIN EXP ALLERGY, V39, P1822, DOI 10.1111/j.1365-2222.2009.03332.x; Quirce S, 2011, J ASTHMA, V48, P839, DOI 10.3109/02770903.2011.611954; Rabe KF, 2006, CHEST, V129, P246, DOI 10.1378/chest.129.2.246; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rabito FA, 2017, J ALLERGY CLIN IMMUN, V140, P565, DOI [10.1016/j.jaci.2016.10.019, 10.1016/j.jaci.2016.12.221]; Raj D, 2014, INDIAN PEDIATR, V51, P105, DOI 10.1007/s13312-014-0351-x; Rajanandh MG, 2014, CLIN THER, V36, P526, DOI 10.1016/j.clinthera.2014.02.006; Rajanandh MG, 2015, CLIN THER, V37, P418, DOI 10.1016/j.clinthera.2014.12.008; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; Riemersma RA, 2012, PRIM CARE RESP J, V21, P50, DOI 10.4104/pcrj.2011.00090; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Sabatelli L, 2017, J INVEST ALLERG CLIN, V27, P89, DOI 10.18176/jiaci.0103; Salmeron S, 2001, LANCET, V358, P629, DOI 10.1016/S0140-6736(01)05779-8; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Schunemann H.B., 2013, HDB GRADING QUALITY; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; Sears MR, 2008, EUR RESPIR J, V31, P982, DOI 10.1183/09031936.00104007; Shao J, 2014, AM J RHINOL ALLERGY, V28, P131, DOI 10.2500/ajra.2014.28.4006; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Sheikh Aziz, 2002, BMC Fam Pract, V3, P12, DOI 10.1186/1471-2296-3-12; Shirai T, 2005, CHEST, V127, P1565, DOI 10.1378/chest.127.5.1565; Sin B, 1996, J INVEST ALLERG CLIN, V6, P341; Singer F, 2013, ALLERGY, V68, P531, DOI 10.1111/all.12127; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Sobieraj DM, 2018, AHRQ PUBLICATION, V17(18)-EHC027-EF; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; Syk J, 2013, J ALLERGY CLIN IMMUN, V1; Sykora T, 2004, CZE ALERGIE, V6, P170; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Takeuchi A, 2018, J THORAC DIS, V10, pE678, DOI 10.21037/jtd.2018.08.144; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tenero L, 2016, TRANSL PEDIATR, V5, P31, DOI 10.3978/j.issn.2224-4336.2015.12.01; Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8; Tsurikisawa N, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-44; Turpeinen M, 2008, ARCH DIS CHILD, V93, P654, DOI 10.1136/adc.2007.116632; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; van Vliet D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119434; van Wonderen Karina E, 2009, BMC Pulm Med, V9, P13, DOI 10.1186/1471-2466-9-13; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Verini M, 2010, J ALLERGY; Vijverberg SJH, 2012, PEDIAT ALLERG IMM-UK, V23, P529, DOI 10.1111/j.1399-3038.2012.01279.x; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Visitsunthorn N, 2017, RESPIROLOGY, V22, P71, DOI 10.1111/resp.12857; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; Vogelmeier C, 2012, CLIN DRUG INVEST, V32, P439, DOI 10.2165/11598840-000000000-00000; Voorend-van Bergen S, 2015, THORAX, V70, P543, DOI 10.1136/thoraxjnl-2014-206161; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Wang K, 2015, INT J CLIN EXP MED, V8, P19476; Wang L, 2014, ALLERGY, V69, P1181, DOI 10.1111/all.12188; Wang Z., 2017, AHRQ PUBLICATION; Warke TJ, 2004, J ASTHMA, V41, P751, DOI 10.1081/JAS-200027838; WARNER JA, 1993, THORAX, V48, P330, DOI 10.1136/thx.48.4.330; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Wechsler ME, 2015, JAMA-J AM MED ASSOC, V314, P1720, DOI 10.1001/jama.2015.13277; Wechsler ME, 2013, J ALLERGY CLIN IMMUN, V132, P1295, DOI 10.1016/j.jaci.2013.08.009; Williams SG, 2006, J NATL MED ASSOC, V98, P249; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright GR, 2009, ALLERGY, V64, P1671, DOI 10.1111/j.1398-9995.2009.02098.x; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647; Zeiger RS, 2011, J ASTHMA, V48, P8, DOI 10.3109/02770903.2010.539295; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	264	204	207	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1217	1270		10.1016/j.jaci.2020.10.003	http://dx.doi.org/10.1016/j.jaci.2020.10.003			54	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	PC3XH	33280709	Green Accepted			2022-12-18	WOS:000596937900002
J	Irvin, C; Zafar, I; Good, J; Rollins, D; Christianson, C; Gorska, MM; Martin, RJ; Alam, R				Irvin, Chaoyu; Zafar, Iram; Good, James; Rollins, Donald; Christianson, Christina; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul			Increased frequency of dual-positive T(H)2/T(H)17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dual-positive T(H)2/T(H)17 cells; asthma; bronchoalveolar lavage; glucocorticoid resistance; MEK	SEGMENTAL ALLERGEN CHALLENGE; STEROID-RESISTANT ASTHMA; CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; CYTOKINE EXPRESSION; EPITHELIAL-CELLS; MESSENGER-RNA; ATOPIC ASTHMA; INFLAMMATION; IL-4	Background: T(H)2 cells can further differentiate into dual-positive T(H)2/T(H)17 cells. The presence of dual-positive T(H)2/T(H)17 cells in the airways and their effect on asthma severity are unknown. Objective: We sought to study dual-positive T(H)2/T(H)17 cells in bronchoalveolar lavage (BAL) fluid from asthmatic patients, examine their response to glucocorticoids, and define their relevance for disease severity. Methods: Bronchoscopy and lavage were performed in 52 asthmatic patients and 25 disease control subjects. T(H)2 and T(H)2/T(H)17 cells were analyzed by using multicolor flow cytometry and confocal immunofluorescence microscopy. Cytokines were assayed by means of ELISA. Results: Dual-positive T(H)2/T(H)17 cells were present at a higher frequency in BAL fluid from asthmatic patients compared with numbers seen in disease control subjects. High-level IL-4 production was typically accompanied by high-level IL-17 production and coexpression of GATA3 and retinoic acid receptor-related orphan receptor gamma t. Increased presence of T(H)2/T(H)17 cells was associated with increased IL-17 production in lavage fluid. T(H)2/T(H)17 cell counts and IL-17 production correlated with PC20 for methacholine, eosinophil counts, and FEV1. T(H)2/T(H)17 cells, unlike T(H)2 cells, were resistant to dexamethasone-induced cell death. They expressed higher levels of mitogen-activated protein-extracellular signal-regulated kinase kinase 1, a molecule that induces glucocorticoid resistance. On the basis of the dominance of BAL fluid T(H)2 or T(H)2/T(H)17 cells, we identified 3 subgroups of asthma: T(H)2(predominant), T(H)2/T(H)17(predominant), and T(H)2/T(H)17(low). The T(H)2/T(H)17(predominant) subgroup manifested the most severe form of asthma, whereas the T(H)2/T(H)17(low) subgroup had the mildest asthma. Conclusion: Asthma is associated with a higher frequency of dual-positive T(H)2/T(H)17 cells in BAL fluid. The T(H)2/T(H)17(predominant) subgroup of asthmatic patients manifested glucocorticoid resistance in vitro. They also had the greatest airway obstruction and hyperreactivity compared with the T(H)2(predominant) and T(H)2/T(H)17(low) subgroups.	[Irvin, Chaoyu; Zafar, Iram; Good, James; Rollins, Donald; Christianson, Christina; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Irvin, Chaoyu; Zafar, Iram; Good, James; Rollins, Donald; Christianson, Christina; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Natl Jewish Hlth, Div Pulm & Crit Care Med, Denver, CO 80206 USA; [Good, James; Rollins, Donald; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Univ Colorado, Sch Med, Denver, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org			National Institutes of Health (NIH) [RO1 AI091614, N01 HHSN272200700048C]; CCTSI (NIH/NCATS) [TR000156]; National Institute of Environmental Health Sciences (NIEHS) [PO1 ES-018181/EPA GAD 834515010]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, KL2TR001080, KL2TR000156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091614, R01AI102943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCTSI (NIH/NCATS); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health (NIH) grants RO1 AI091614 and N01 HHSN272200700048C to R. A. M. M. G. is supported by career development grants from CCTSI (NIH/NCATS Colorado CTSI KL2 TR000156) and Children's Environmental Center grant from the National Institute of Environmental Health Sciences (NIEHS PO1 ES-018181/EPA GAD 834515010).	ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Coffman RL, 1995, CIBA F SYMP, V195, P20; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Fontanet P, 2013, J NEUROSCI, V33, P15940, DOI 10.1523/JNEUROSCI.0928-13.2013; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Guo L, 2013, J IMMUNOL, V190, P159, DOI 10.4049/jimmunol.1201657; Hartenstein B, 2002, EMBO J, V21, P6321, DOI 10.1093/emboj/cdf648; HUANG SK, 1995, J IMMUNOL, V155, P2688; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Kaplan MH, 1998, J LEUKOCYTE BIOL, V64, P2, DOI 10.1002/jlb.64.1.2; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Li XY, 2012, NEURON, V75, P1035, DOI 10.1016/j.neuron.2012.08.031; Liang QL, 2010, J IMMUNOL, V185, P5704, DOI 10.4049/jimmunol.1000690; Malmhall C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040012; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; MOCCI S, 1995, J IMMUNOL, V154, P3779; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Perez L, 2013, EUR RESPIR J, V42, P594, DOI 10.1183/09031936.00031112; Pham D, 2014, J ALLERGY CLIN IMMUN, V134, P204, DOI 10.1016/j.jaci.2013.12.021; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Striz I, 1999, AM J PHYSIOL-LUNG C, V277, pL58, DOI 10.1152/ajplung.1999.277.1.L58; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Tabarani CM, 2013, PEDIATR INFECT DIS J, V32, pE437, DOI 10.1097/INF.0b013e3182a14407; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Thompson AMS, 2010, ENVIRON HEALTH PERSP, V118, P120, DOI 10.1289/ehp.0900550; Thunberg S, 2010, ALLERGY, V65, P311, DOI 10.1111/j.1398-9995.2009.02218.x; To T, 2013, ENVIRON HEALTH PERSP, V121, P46, DOI 10.1289/ehp.1104816; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; Vazquez-Tello A, 2010, CLIN EXP ALLERGY, V40, P1312, DOI 10.1111/j.1365-2222.2010.03544.x; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	62	204	216	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1175	+	1186.e1	10.1016/j.jaci.2014.05.038	http://dx.doi.org/10.1016/j.jaci.2014.05.038			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25042748	Green Accepted			2022-12-18	WOS:000344938900023
J	CHARLESWORTH, EN; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM				CHARLESWORTH, EN; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM			EFFECT OF CETIRIZINE ON MAST CELL-MEDIATOR RELEASE AND CELLULAR TRAFFIC DURING THE CUTANEOUS LATE-PHASE REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHARLESWORTH, EN (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI8270, AI7290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1979, ALLERGY, V34, P121, DOI 10.1111/j.1398-9995.1979.tb01372.x; ADKINSON NF, 1977, J LAB CLIN MED, V90, P1043; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FISCHER N, 1982, J INVEST DERMATOL, V79, P222, DOI 10.1111/1523-1747.ep12500065; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229, DOI 10.1111/j.1476-5381.1976.tb07446.x; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GILBERT HS, 1975, BLOOD, V46, P279; GOETZL EJ, 1980, IMMUNOLOGY, V39, P491; GOETZL EJ, 1975, P NATL ACAD SCI USA, V81, P691; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; Halpern BN, 1942, ARCH INT PHARMACOD T, V68, P339; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HIRASHIMA M, 1983, IMMUNOLOGY, V50, P85; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; KAY AB, 1971, J IMMUNOL, V107, P899; LEMANSKE R, 1983, J ALLERGY CLIN IMMUN, V71, P136, DOI 10.1016/0091-6749(83)90313-5; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LOWE E, 1946, J PHARMACOL EXP THER, V86, P229; MADDIN S, 1985, DERMATOLOGY, P1966; MOTA I, 1960, BRIT J PHARM CHEMOTH, V15, P396, DOI 10.1111/j.1476-5381.1960.tb01262.x; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Staub AM, 1937, CR SOC BIOL, V125, P818; TALBOT S, 1984, Journal of Allergy and Clinical Immunology, V73, P147; TING S, 1985, J ALLERGY CLIN IMMUN, V75, P63, DOI 10.1016/0091-6749(85)90013-2; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; TRZECIAKOWSKI JP, 1983, ALLERGY PRINCIPLES P, P575; VALENTINE MD, 1974, PRINCIPLES TECHNIQUE, P227; WOLFE HI, 1964, J ALLERGY, V35, P271, DOI 10.1016/0021-8707(64)90016-4; WOOD SG, 1987, ANN ALLERGY, V59, P31; YONKMAN FF, 1946, J PHARMACOL EXP THER, V87, P256	38	204	208	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					905	912		10.1016/0091-6749(89)90104-8	http://dx.doi.org/10.1016/0091-6749(89)90104-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2469708				2022-12-18	WOS:A1989U716100010
J	CHAPMAN, MD; HEYMANN, PW; WILKINS, SR; BROWN, MJ; PLATTSMILLS, TAE				CHAPMAN, MD; HEYMANN, PW; WILKINS, SR; BROWN, MJ; PLATTSMILLS, TAE			MONOCLONAL IMMUNOASSAYS FOR MAJOR DUST MITE (DERMATOPHAGOIDES) ALLERGENS, DER-P-I AND DER-F-I, AND QUANTITATIVE-ANALYSIS OF THE ALLERGEN CONTENT OF MITE AND HOUSE DUST EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHAPMAN, MD (corresponding author), UNIV VIRGINIA,MED CTR,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,BOX 225,CHARLOTTESVILLE,VA 22908, USA.			Chapman, Martin/0000-0002-0845-3632	PHS HHS [A1-205665] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V71, P160, DOI 10.1016/0091-6749(83)90409-8; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BALDO BA, 1983, ALLERGY, V38, P535, DOI 10.1111/j.1398-9995.1983.tb04137.x; BRONSWIJK JE, 1971, J ALLERGY, V47, P31; BROWN M, 1987, J ALLERGY CLIN IMMUN, V79, P221; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHAPMAN MD, 1985, INT ARCH ALLER A IMM, V77, P168; CORBI AL, 1985, MOL IMMUNOL, V22, P1081, DOI 10.1016/0161-5890(85)90111-7; CORBI AL, 1985, J IMMUNOL METHODS, V83, P83, DOI 10.1016/0022-1759(85)90060-2; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GRIFFITHS DA, 1961, J STORED PROD RES, V7, P1; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; Hughes A. M., 1976, TECH B, V9; KAHN CR, 1986, MOL IMMUNOL, V23, P1281, DOI 10.1016/0161-5890(86)90013-1; KRILIS S, 1983, J ALLERGY CLIN IMMUN, V71, P261, DOI 10.1016/0091-6749(83)90079-9; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; LIND P, 1979, ALLERGY, V34, P319; LIND P, IN PRESS 15 P ANN M; OLSON JR, 1986, J IMMUNOL, V136, P2109; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Voorhorst R., 1969, HOUSE DUST ATOPY HOU; WU J, UNPUB ANAL EPITOPES	33	204	208	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					184	194		10.1016/0091-6749(87)90128-X	http://dx.doi.org/10.1016/0091-6749(87)90128-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611539				2022-12-18	WOS:A1987J657500010
J	SPECTOR, SL; WANGAARD, CH; FARR, RS				SPECTOR, SL; WANGAARD, CH; FARR, RS			ASPIRIN AND CONCOMITANT IDIOSYNCRASIES IN ADULT ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,DENVER,CO 80206	National Jewish Health								BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BERNSTEIN IL, 1978, J ALLERGY CLIN IMMUN, V61, P208; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; FALLIERS CJ, 1973, J ALLERGY CLIN IMMUN, V52, P141, DOI 10.1016/0091-6749(73)90030-4; FARR RS, 1978, HOSP PRACT, V13, P113, DOI 10.1080/21548331.1978.11707318; FARR RS, 1978, ANN INTERN MED, V89, P577, DOI 10.7326/0003-4819-89-4-577_2; GERBER JG, 1979, J ALLERGY CLIN IMMUN, V63, P289, DOI 10.1016/0091-6749(79)90115-5; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; HARNETT JC, 1978, ALLERGY PRINCIPLES P; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; KORDANSKY D, 1978, ANN INTERN MED, V88, P508, DOI 10.7326/0003-4819-88-4-508; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P85; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091-6749(76)90181-0; VANLEEUWEN WS, 1928, MUCH MED WOECHENSCHR, V75, P1588; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; VONMAUR K, 1974, J ALLERGY CLIN IMMUN, V54, P380; YUNGINGER JW, 1973, J PEDIATR-US, V82, P218, DOI 10.1016/S0022-3476(73)80157-X; 1962, AM REV RESPIR DIS, V85, P762	30	204	205	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					500	506		10.1016/0091-6749(79)90059-9	http://dx.doi.org/10.1016/0091-6749(79)90059-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	512268				2022-12-18	WOS:A1979HX84000005
J	JUHLIN, L; ZETTERSTROM, O; MICHAELSSON, G				JUHLIN, L; ZETTERSTROM, O; MICHAELSSON, G			URTICARIA AND ASTHMA INDUCED BY FOOD-AND-DRUG ADDITIVES IN PATIENTS WITH ASPIRIN HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CRIEP LH, 1971, J ALLERGY CLIN IMMUN, V48, P7, DOI 10.1016/0091-6749(71)90049-2; DEWECK AL, 1971, INT ARCH ALLER A IMM, V41, P393, DOI 10.1159/000230534; FARR RS, 1970, J ALLERGY, V45, P321, DOI 10.1016/0021-8707(70)90040-7; FEINGOLD BF, 1968, ANN ALLERGY, V26, P309; JONES R, 1964, Food Cosmet Toxicol, V2, P447, DOI 10.1016/S0015-6264(64)80287-X; LOCKEY SD, 1971, ANN ALLERGY, V29, P461; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6; 1968, LANCET, P618	14	204	204	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					92	+		10.1016/0091-6749(72)90004-8	http://dx.doi.org/10.1016/0091-6749(72)90004-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	5039915				2022-12-18	WOS:A1972N179500004
J	Cuello-Garcia, CA; Brozek, JL; Fiocchi, A; Pawankar, R; Yepes-Nunez, JJ; Terracciano, L; Gandhi, S; Agarwal, A; Zhang, Y; Schunemann, HJ				Cuello-Garcia, Carlos A.; Brozek, Jan L.; Fiocchi, Alessandro; Pawankar, Ruby; Jose Yepes-Nunez, Juan; Terracciano, Luigi; Gandhi, Shreyas; Agarwal, Arnav; Zhang, Yuan; Schuenemann, Holger J.			Recommendations on probiotics in allergy prevention should not be based on pooling data from different strains Reply	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Cuello-Garcia, Carlos A.; Brozek, Jan L.; Jose Yepes-Nunez, Juan; Zhang, Yuan; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Cuello-Garcia, Carlos A.] Tecnol Monterrey Sch Med, Monterrey, Mexico; [Brozek, Jan L.; Gandhi, Shreyas; Agarwal, Arnav; Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Fiocchi, Alessandro] Pediat Hosp Bambino Gesu, Vatican City, Vatican; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Tokyo 113, Japan; [Jose Yepes-Nunez, Juan] Univ Antioquia, Sch Med, Medellin, Colombia; [Terracciano, Luigi] Univ Milan, Sch Med, Melloni Hosp, Dept Child & Maternal Med, Milan, Italy; [Gandhi, Shreyas; Agarwal, Arnav] Univ Toronto, Fac Med, Toronto, ON, Canada	McMaster University; Tecnologico de Monterrey; McMaster University; IRCCS Bambino Gesu; Nippon Medical School; Universidad de Antioquia; University of Milan; University of Toronto	Cuello-Garcia, CA (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.	brozekj@mcmaster.ca	Terracciano, Luigi M./AAB-5335-2022; Agarwal, Arnav/J-1553-2014; Cuello-Garcia, Carlos/E-8620-2016; Yepes-Nuñez, Juan Jose/M-3796-2017; Fiocchi, Alessandro/K-9235-2016	Terracciano, Luigi M./0000-0002-9393-9660; Agarwal, Arnav/0000-0002-0931-7851; Cuello-Garcia, Carlos/0000-0002-1742-0242; Yepes-Nuñez, Juan Jose/0000-0002-9912-0031; Fiocchi, Alessandro/0000-0002-2549-0523; Zhang, Yuan/0000-0002-4174-0641				Fiocchi A, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0055-2; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Szajewska H, 2015, J ALLERGY CLIN IMMUN, V136, P1422, DOI 10.1016/j.jaci.2015.07.022; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011	4	203	223	1	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1423	1425		10.1016/j.jaci.2015.07.021	http://dx.doi.org/10.1016/j.jaci.2015.07.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26329512	Bronze			2022-12-18	WOS:000364787200041
J	Cuello-Garcia, CA; Brozek, JL; Fiocchi, A; Pawankar, R; Yepes-Nunez, JJ; Terracciano, L; Gandhi, S; Agarwal, A; Zhang, Y; Schunemann, HJ				Cuello-Garcia, Carlos A.; Brozek, Jan L.; Fiocchi, Alessandro; Pawankar, Ruby; Yepes-Nunez, Juan Jose; Terracciano, Luigi; Gandhi, Shreyas; Agarwal, Arnav; Zhang, Yuan; Schuenemann, Holger J.			Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; prevention; probiotics systematic reviews	1ST 6 MONTHS; DOUBLE-BLIND; ATOPIC DISEASE; FOLLOW-UP; ECZEMA; SUPPLEMENTATION; PREGNANCY; LIFE; CHILDREN; RISK	Background: Allergic diseases are considered a health burden because of their high and constantly increasing prevalence, high direct and indirect costs, and undesirable effects on quality of life. Probiotics have been suggested as an intervention to prevent allergic diseases. Objective: We sought to synthesize the evidence supporting use of probiotics for the prevention of allergies and inform World Allergy Organization guidelines on probiotic use. Methods: We performed a systematic review of randomized trials assessing the effects of any probiotic administered to pregnant women, breast-feeding mothers, and/or infants. Results: Of 2403 articles published until December 2014 identified in Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, 29 studies fulfilled a priori specified inclusion criteria for the analyses. Probiotics reduced the risk of eczema when used by women during the last trimester of pregnancy (relative risk [RR], 0.71; 95% CI, 0.60-0.84), when used by breast-feeding mothers (RR, 0.57; 95% CI, 0.47-0.69), or when given to infants (RR, 0.80; 95% CI, 0.68-0.94). Evidence did not support an effect on other allergies, nutrition status, or incidence of adverse effects. The certainty in the evidence according to the Grading of Recommendation Assessment Development and Evaluation approach is low or very low because of the risk of bias, inconsistency and imprecision of results, and indirectness of available research. Conclusion: Probiotics used by pregnant women or breast-feeding mothers and/or given to infants reduced the risk of eczema in infants; however, the certainty in the evidence is low. No effect was observed for the prevention of other allergic conditions.	[Cuello-Garcia, Carlos A.; Brozek, Jan L.; Yepes-Nunez, Juan Jose; Zhang, Yuan; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Brozek, Jan L.; Gandhi, Shreyas; Agarwal, Arnav; Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cuello-Garcia, Carlos A.] Tecnol Monterrey Sch Med, Monterrey, Mexico; [Fiocchi, Alessandro] Pediat Hosp Bambino Gesu, Vatican City, Japan; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Tokyo 113, Japan; [Yepes-Nunez, Juan Jose] Univ Antioquia, Sch Med, Medellin, Colombia; [Terracciano, Luigi] Univ Milan, Sch Med, Dept Child & Maternal Med, Melloni Hosp, Milan, Italy; [Gandhi, Shreyas; Agarwal, Arnav] Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada	McMaster University; McMaster University; Tecnologico de Monterrey; Nippon Medical School; Universidad de Antioquia; University of Milan; University of Toronto	Brozek, JL (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Rm 2C19,1200 Main St, West Hamilton, ON L8N 3Z5, Canada.	brozekj@mcmaster.ca	Terracciano, Luigi M./AAB-5335-2022; Agarwal, Arnav/J-1553-2014; Cuello-Garcia, Carlos/E-8620-2016; Yepes-Nuñez, Juan Jose/M-3796-2017; Fiocchi, Alessandro/K-9235-2016	Terracciano, Luigi M./0000-0002-9393-9660; Agarwal, Arnav/0000-0002-0931-7851; Cuello-Garcia, Carlos/0000-0002-1742-0242; Yepes-Nuñez, Juan Jose/0000-0002-9912-0031; Fiocchi, Alessandro/0000-0002-2549-0523; Zhang, Yuan/0000-0002-4174-0641				Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Allen SJ, 2012, ARCH DIS CHILD, V97, p[S1, A2, P05], DOI [10.1136/archdischild-2012-301885.5, DOI 10.1136/ARCHDISCHILD-2012-301885.5]; Allen SJ, 2010, J NUTR, V140, P483, DOI 10.3945/jn.109.117093; [Anonymous], 2006, PROB FOOD HLTH NUTR; Asher MI, 2012, ALLERGOL IMMUNOPATH, V40, P267, DOI 10.1016/j.aller.2011.11.004; Azad MB, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6471; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Doege K, 2012, BRIT J NUTR, V107, P1, DOI 10.1017/S0007114511003400; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Ebert CS, 2011, OTOLARYNG CLIN N AM, V44, P537, DOI 10.1016/j.otc.2011.03.001; Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246; Fiocchi A, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0055-2; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012; Hascoet JM, 2011, J PEDIATR GASTR NUTR, V52, P756, DOI 10.1097/MPG.0b013e3182105850; Hempel Susanne, 2011, Evid Rep Technol Assess (Full Rep), P1; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kim JY, 2010, PEDIAT ALLERG IMM-UK, V21, pE386, DOI 10.1111/j.1399-3038.2009.00958.x; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen AK, 2011, PEDIAT ALLERG IMM-UK, V22, P249, DOI 10.1111/j.1399-3038.2010.01079.x; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lodinova-Zadnikova R, 2010, INT ARCH ALLERGY IMM, V153, P201, DOI 10.1159/000312638; Marschan E, 2008, CLIN EXP ALLERGY, V38, P611, DOI 10.1111/j.1365-2222.2008.02942.x; Morisset M, 2011, EUR J CLIN NUTR, V65, P175, DOI 10.1038/ejcn.2010.250; Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x; Ortiz-Andrellucchi A, 2008, BRIT J NUTR, V100, P834, DOI 10.1017/S0007114508959183; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005090.pub2; Ou CY, 2012, CLIN EXP ALLERGY, V42, P1386, DOI 10.1111/j.1365-2222.2012.04037.x; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x; Prokesova L, 2006, PEDIAT ALLERG IMM-UK, V17, P175, DOI 10.1111/j.1399-3038.2006.00395.x; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Rautava S, 2012, J ALLERGY CLIN IMMUN, V130, P1355, DOI 10.1016/j.jaci.2012.09.003; Saengtawesin Varaporn, 2014, Journal of the Medical Association of Thailand, V97, pS20; Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x; Tang MLK, 2010, CURR OPIN PEDIATR, V22, P626, DOI 10.1097/MOP.0b013e32833d9728; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x; Wickens K, 2012, CLIN EXP ALLERGY, V42, P1071, DOI 10.1111/j.1365-2222.2012.03975.x; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011	47	203	223	1	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					952	961		10.1016/j.jaci.2015.04.031	http://dx.doi.org/10.1016/j.jaci.2015.04.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26329512				2022-12-18	WOS:000362976300014
J	Sofen, H; Smith, S; Matheson, RT; Leonardi, CL; Calderon, C; Brodmerkel, C; Li, K; Campbell, K; Jr, SJM; Wasfi, Y; Wang, YH; Szapary, P; Krueger, JG				Sofen, Howard; Smith, Stacy; Matheson, Robert T.; Leonardi, Craig L.; Calderon, Cesar; Brodmerkel, Carrie; Li, Katherine; Campbell, Kim; Marciniak, Stanley J., Jr.; Wasfi, Yasmine; Wang, Yuhua; Szapary, Philippe; Krueger, James G.			Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Histology; IL-23; gene expression; guselkumab; psoriasis; Psoriasis Area and Severity Index; serum; skin; T cell; T(H)17	EPIDERMAL HYPERPLASIA; INCREASED EXPRESSION; CELL; IL-23; SKIN; GAMMA; IDENTIFICATION; ASSOCIATION; ANTIBODY; THERAPY	Background: IL-23 expression is increased in psoriatic lesions and might regulate T(H)17 T-cell counts in patients with psoriasis. Objectives: We sought to test a novel IL-23-specific therapeutic agent for the treatment of psoriasis. Methods: In this randomized, double-blind, placebo-controlled study the safety, tolerability, and clinical response of guselkumab, an anti-IL-23-specific mAb, were evaluated in patients with moderate-to-severe plaque psoriasis. A total of 24 patients were randomized to receive a single dose of placebo or 10, 30, 100, or 300 mg of guselkumab. Clinical response was assessed by using the Psoriasis Area and Severity Index (PASI). Additionally, histologic analysis and gene expression in skin biopsy specimens from guselkumab-treated patients were compared with those from placebo-treated patients. Results: At week 12, 50% (10 mg), 60% (30 and 100 mg), and 100% (300 mg) of guselkumab-treated patients, respectively, achieved a 75% improvement in PASI scores from baseline compared with 0% of placebo-treated patients. Improvements in PASI scores were generally maintained through week 24 in all guselkumab-treated patients. The proportion of patients experiencing an adverse event was comparable between the combined guselkumab (13/20 [65.0%]) and placebo (2/4 [50.0%]) groups through week 24. Analysis of lesional and nonlesional skin biopsy specimens demonstrated decreases in epidermal thickness and T-cell and dendritic cell expression in guselkumab-treated patients compared with values seen in placebo-treated patients. At week 12, significant reductions in psoriasis gene expression and serum IL-17A levels were observed in guselkumab-treated patients. Conclusion: IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.	[Sofen, Howard] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA USA; [Matheson, Robert T.] Oregon Med Res Ctr, Portland, OR USA; [Leonardi, Craig L.] St Louis Univ, Dept Dermatol, St Louis, MO 63103 USA; [Calderon, Cesar; Brodmerkel, Carrie; Li, Katherine; Campbell, Kim; Marciniak, Stanley J., Jr.; Wasfi, Yasmine; Wang, Yuhua; Szapary, Philippe] Janssen Res & Dev LLC, Spring House, PA USA; [Krueger, James G.] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Saint Louis University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Rockefeller University	Krueger, JG (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA.	jgk@rockefeller.edu	Sofen, Howard/AAD-1321-2021	Sofen, Howard/0000-0001-7789-6915; Smith, Stacy/0000-0002-4384-6888	Janssen Research & Development, LLC; Janssen; Amgen; Abbvie; Novartis; Pfizer; Lilly; Abbvie/Abbott; Abbott; Anacor; Celgene; Centocor/Janssen; Eli Lilly; Galderma; GlaxoSmithKline; Incyte; Maruho; Merck; Schering Plough, Sirtris; Stiefel; Leo; Tolmar; Novo Nordisk; Vascular Biogenics; Warner Chilcott; Wyeth	Janssen Research & Development, LLC; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Amgen(Amgen); Abbvie(AbbVie); Novartis(Novartis); Pfizer(Pfizer); Lilly(Eli Lilly); Abbvie/Abbott(AbbVie); Abbott(Abbott Laboratories); Anacor; Celgene(Bristol-Myers SquibbCelgene Corporation); Centocor/Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Eli Lilly(Eli Lilly); Galderma; GlaxoSmithKline(GlaxoSmithKline); Incyte; Maruho; Merck(Merck & Company); Schering Plough, Sirtris; Stiefel; Leo(LEO Pharma); Tolmar; Novo Nordisk(Novo Nordisk); Vascular Biogenics; Warner Chilcott; Wyeth(Wyeth)	Supported by Janssen Research & Development, LLC.; H. Sofen has received consulting fees or honoraria from Janssen; was provided writing assistance, medicines, equipment, or administrative support from Janssen; and has received payment for lectures from Janssen, Amgen, Abbvie, Novartis, Pfizer, and Lilly. S. Smith has received research support from Janssen and has received payment for lectures from Janssen and Abbvie. R. T. Matheson has received research support from Janssen. C. L. Leonardi has consultant arrangements with Abbvie/Abbott, Amgen, Centocor/Janssen, Eli Lilly, Leo Pharmaceuticals, and Pfizer; has received payment for lectures from Amgen and Abbvie/Abbott; and has received fees for service for conducting clinical trials from Abbott, Amgen, Anacor, Celgene, Centocor/Janssen, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Maruho, Merck, Pfizer, Schering Plough, Sirtris, Stiefel, Leo, Novartis, Tolmar, Novo Nordisk, Vascular Biogenics, Warner Chilcott, and Wyeth. C. Calderon, C. Brodmerkel, K. Li, K. Campbell, Y. Wasfi, Y. Wang, and P. Szapary are employed by Janssen (Johnson & Johnson) and have stock/stock options from Johnson & Johnson. S. J. Marciniak is employed by Janssen. J. Krueger has consultant arrangements with Pfizer, Centocor/Janssen, and Lilly and has received research support from Pfizer, Amgen, Centocor/Janssen, Lilly, and Merck.	Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Di Meglio P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017160; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Gray EE, 2011, J IMMUNOL, V186, P6091, DOI 10.4049/jimmunol.1100427; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Krueger JG, 2005, ANN RHEUM DIS, V64, P30, DOI 10.1136/ard.2004.031120; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nograles KE, 2010, SEMIN CUTAN MED SURG, V29, P3, DOI 10.1016/j.sder.2010.03.001; Papp KA, 2013, BRIT J DERMATOL, V168, P844, DOI 10.1111/bjd.12214; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Piskin G, 2006, J IMMUNOL, V176, P1908, DOI 10.4049/jimmunol.176.3.1908; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Suarez-Farinas M, 2012, J INVEST DERMATOL, V132, P2552, DOI 10.1038/jid.2012.184; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yawalkar N, 2009, J DERMATOL SCI, V54, P99, DOI 10.1016/j.jdermsci.2009.01.003; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zhang L, 2010, CLIN IMMUNOL, V135, P108, DOI 10.1016/j.clim.2009.11.008	29	203	219	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1032	1040		10.1016/j.jaci.2014.01.025	http://dx.doi.org/10.1016/j.jaci.2014.01.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24679469	hybrid			2022-12-18	WOS:000333531700013
J	Schneider, LC; Rachid, R; LeBovidge, J; Blood, E; Mittal, M; Umetsu, DT				Schneider, Lynda C.; Rachid, Rima; LeBovidge, Jennifer; Blood, Emily; Mittal, Mudita; Umetsu, Dale T.			A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; desensitization; food allergy; peanut allergy; omalizumab	TOLERANCE INDUCTION; DOUBLE-BLIND; FOOD ALLERGY; IMMUNOTHERAPY; CHILDREN; SAFETY; EGG; EFFICACY; PROTOCOL; THERAPY	Background: Peanut allergy is a major public health problem that affects 1% of the population and has no effective therapy. Objective: To examine the safety and efficacy of oral desensitization in peanut-allergic children in combination with a brief course of anti-IgE mAb (omalizumab [Xolair]). Methods: We performed oral peanut desensitization in peanut-allergic children at high risk for developing significant peanut-induced allergic reactions. Omalizumab was administered before and during oral peanut desensitization. Results: We enrolled 13 children (median age, 10 years), with a median peanut-specific IgE level of 229 kU(A)/L and a median total serum IgE level of 621 kU/L, who failed an initial double-blind placebo-controlled food challenge at peanut flour doses of 100 mg or less. After pretreatment with omalizumab, all 13 subjects tolerated the initial 11 desensitization doses given on the first day, including the maximum dose of 500 mg peanut flour (cumulative dose, 992 mg, equivalent to >2 peanuts), requiring minimal or no rescue therapy. Twelve subjects then reached the maximum maintenance dose of 4000 mg peanut flour per day in a median time of 8 weeks, at which point omalizumab was discontinued. All 12 subjects continued on 4000 mg peanut flour per day and subsequently tolerated a challenge with 8000 mg peanut flour (equivalent to about 20 peanuts), or 160 to 400 times the dose tolerated before desensitization. During the study, 6 of the 13 subjects experienced mild or no allergic reactions, 5 subjects had grade 2 reactions, and 2 subjects had grade 3 reactions, all of which responded rapidly to treatment. Conclusions: Among children with high-risk peanut allergy, treatment with omalizumab may facilitate rapid oral desensitization and qualitatively improve the desensitization process.	Boston Childrens Hosp, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Umetsu, DT (corresponding author), Karp Labs, Rm 10127,1 Blackfan Circle, Boston, MA 02115 USA.	dale.umetsu@gmail.com			Thrasher Research Foundation; Clinical and Translational Science Center/Harvard Catalyst [NIH UL1 RR 025758]; Food Allergy Initiative; Dave and Denise Bunning Food Allergy Project; Jasmine and Paul Mashikian Fund; Genentech; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER	Thrasher Research Foundation; Clinical and Translational Science Center/Harvard Catalyst; Food Allergy Initiative; Dave and Denise Bunning Food Allergy Project; Jasmine and Paul Mashikian Fund; Genentech(Roche HoldingGenentech); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was funded by the Thrasher Research Foundation, the Clinical and Translational Science Center/Harvard Catalyst (NIH UL1 RR 025758), the Food Allergy Initiative, the Dave and Denise Bunning Food Allergy Project, the Jasmine and Paul Mashikian Fund, and Genentech.	Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Calvani M, 2010, EUR ANN ALLERGY CLIN, V42, P11; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Meglio P, 2013, PEDIAT ALLERG IMM-UK, V24, P75, DOI 10.1111/j.1399-3038.2012.01341.x; Nadeau KC, 2012, IMMUNOL ALLERGY CLIN, V32, P111, DOI 10.1016/j.iac.2011.11.004; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nash S., 2008, J ALLERGY CLIN IMMUN, V121, pS147; Nowak-Wegrzyn A, 2010, CURR OPIN ALLERGY CL, V10, P214, DOI 10.1097/ACI.0b013e3283399404; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2008, J ALLERGY CLIN IMMUN, V122, P418, DOI 10.1016/j.jaci.2008.06.002; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Yu GP, 2012, INT ARCH ALLERGY IMM, V159, P179, DOI 10.1159/000336391	37	203	220	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1368	1374		10.1016/j.jaci.2013.09.046	http://dx.doi.org/10.1016/j.jaci.2013.09.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24176117	Green Accepted			2022-12-18	WOS:000327538200016
J	Schmidt-Weber, CB; Akdis, M; Akdis, CA				Schmidt-Weber, Carsten B.; Akdis, Muebeccel; Akdis, Cezmi A.			T(H)17 cells in the big picture of immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						tolerance; differentiation; T(H)17; T(H)2; transcription factor; allergy	REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; GENE-EXPRESSION; EPITHELIAL-CELLS; TGF-BETA; RHEUMATOID-ARTHRITIS; INTERFERON-GAMMA; MESSENGER-RNA	The pathogenesis of chronic inflammatory diseases is assumed to depend on activated T cells interacting with resident tissue cells or migratory inflammatory cells. The discovery of new T-cell subsets such as the IL-17-producing T(H)17 and T-regulatory cells innovated our understanding of T-cell biology. Studies on new subsets confirm the important role of T cells in the instruction of tissue cells and also demonstrate the important role of feedback regulation for the polarization toward distinct T-cell subsets. The understanding of IL-17 and T(H)17 differentiation pathways has also changed the perspective of immunologists regarding the basis of chronic tissue inflammation, particularly where T(H)1 cells were considered as driving force of the pathology. This review summarizes the recent developments on T-H cell subsets and integrates these findings into existing concepts of immunopathologic mechanisms.	Swiss Inst Allergy & Asthma Res, SIAF, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.uzh.ch	Schmidt-Weber, Carsten B./AAU-1621-2021; Akdis, Cezmi/AAV-4844-2020	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Akdis, Cezmi/0000-0001-8020-019X	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; Andoh A, 2001, CLIN EXP IMMUNOL, V125, P56, DOI 10.1046/j.1365-2249.2001.01588.x; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Awane M, 1999, J IMMUNOL, V162, P5337; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barao I, 2006, P NATL ACAD SCI USA, V103, P5460, DOI 10.1073/pnas.0509249103; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Boutten A, 2004, THORAX, V59, P850, DOI 10.1136/thx.2004.025247; Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Bush KA, 2002, ARTHRITIS RHEUM-US, V46, P802, DOI 10.1002/art.10173; Cai XY, 1998, IMMUNOL LETT, V62, P51, DOI 10.1016/S0165-2478(98)00027-3; Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X; Chabaud M, 2000, CYTOKINE, V12, P1092, DOI 10.1006/cyto.2000.0681; Chattopadhyay S, 2007, J BIOL CHEM, V282, P3014, DOI 10.1074/jbc.M609655200; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Clark RA, 2007, BLOOD, V109, P194, DOI 10.1182/blood-2006-02-002873; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Fields ML, 2005, J IMMUNOL, V175, P4255, DOI 10.4049/jimmunol.175.7.4255; Gorelik L, 2000, J IMMUNOL, V165, P4773, DOI 10.4049/jimmunol.165.9.4773; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gudmundsson KO, 2002, CLIN EXP IMMUNOL, V128, P532, DOI 10.1046/j.1365-2249.2002.01870.x; Han SY, 2006, BIOCHEM J, V400, P439, DOI 10.1042/BJ20061085; Harada M, 2006, J EXP MED, V203, P2929, DOI 10.1084/jem.20062206; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hashimoto T, 2005, INT ARCH ALLERGY IMM, V137, P51, DOI 10.1159/000085432; Hauber HP, 2003, THORAX, V58, P519, DOI 10.1136/thorax.58.6.519; Heath VL, 2000, EUR J IMMUNOL, V30, P2639, DOI 10.1002/1521-4141(200009)30:9<2639::AID-IMMU2639>3.0.CO;2-7; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Honorati MC, 2004, OSTEOARTHR CARTILAGE, V12, P683, DOI 10.1016/j.joca.2004.05.009; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Inatomi O, 2007, PANCREAS, V34, P126, DOI 10.1097/01.mpa.0000246662.23128.57; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Jovanovic DV, 2000, ARTHRITIS RHEUM-US, V43, P1134, DOI 10.1002/1529-0131(200005)43:5<1134::AID-ANR24>3.0.CO;2-#; Kalomenidis I, 2005, CHEST, V128, P2978, DOI 10.1378/chest.128.4.2978; Kao CY, 2005, J IMMUNOL, V175, P6676, DOI 10.4049/jimmunol.175.10.6676; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Katz Y, 2000, CLIN EXP IMMUNOL, V120, P22, DOI 10.1046/j.1365-2249.2000.01199.x; Kehlen A, 2003, ARTHRITIS RES THER, V5, pR186, DOI 10.1186/ar762; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kiene A, 2001, ARTHRITIS RHEUM-US, V44, P469, DOI 10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0; Kim HR, 2007, RHEUMATOLOGY, V46, P57, DOI 10.1093/rheumatology/kel159; Koenders MI, 2005, ARTHRITIS RHEUM-US, V52, P3239, DOI 10.1002/art.21342; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Koshy PJ, 2002, ANN RHEUM DIS, V61, P704, DOI 10.1136/ard.61.8.704; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Krug N, 1998, AM J RESP CRIT CARE, V158, P754, DOI 10.1164/ajrccm.158.3.9507038; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Letimier FA, 2007, EMBO J, V26, P1292, DOI 10.1038/sj.emboj.7601586; Lewkowicz P, 2006, J IMMUNOL, V177, P7155, DOI 10.4049/jimmunol.177.10.7155; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Liu RL, 2005, J IMMUNOL, V175, P7898, DOI 10.4049/jimmunol.175.12.7898; Lubberts E, 2000, ARTHRITIS RHEUM-US, V43, P1300, DOI 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D; Macon-Lemaitre L, 2005, IMMUNOLOGY, V115, P170, DOI 10.1111/j.1365-2567.2005.02145.x; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mary C, 1999, INFECT IMMUN, V67, P5559, DOI 10.1128/IAI.67.11.5559-5566.1999; McNamara PS, 2004, LANCET, V363, P1031, DOI 10.1016/S0140-6736(04)15838-8; Mehta DS, 2003, J IMMUNOL, V170, P4111, DOI 10.4049/jimmunol.170.8.4111; Misra N, 2004, J IMMUNOL, V172, P4676, DOI 10.4049/jimmunol.172.8.4676; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Nakamura T, 1997, J IMMUNOL, V158, P1085; Oida T, 2006, J IMMUNOL, V177, P2331, DOI 10.4049/jimmunol.177.4.2331; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Panzner P, 2003, CHEST, V124, P1909, DOI 10.1378/chest.124.5.1909; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Perrigoue JG, 2007, J EXP MED, V204, P481, DOI 10.1084/jem.20061791; Prause O, 2004, THORAX, V59, P313, DOI 10.1136/thx.2003.008854; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Rahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clim.2005.01.014; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; Rangachari M, 2006, J EXP MED, V203, P2009, DOI 10.1084/jem.20052222; Schmidt-Weber CB, 2004, CURR OPIN IMMUNOL, V16, P709, DOI 10.1016/j.coi.2004.09.008; Schmidt-Weber CB, 1999, J IMMUNOL, V162, P238; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Scott JT, 2000, PARASITE IMMUNOL, V22, P341, DOI 10.1046/j.1365-3024.2000.00311.x; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Sigurdsson V, 2000, J CUTAN PATHOL, V27, P429, DOI 10.1034/j.1600-0560.2000.027009429.x; Simon D, 2002, ALLERGY, V57, P431, DOI 10.1034/j.1398-9995.2002.13506.x; SOMASSE T, 1996, J EXP MED, V184, P473; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; van den Berg A, 2005, AM J RESP CELL MOL, V33, P97, DOI 10.1165/rcmb.2005-0022OC; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	103	203	228	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					247	254		10.1016/j.jaci.2007.06.039	http://dx.doi.org/10.1016/j.jaci.2007.06.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17666214				2022-12-18	WOS:000248654900003
J	Peters, SP; Jones, CA; Haselkorn, T; Mink, DR; Valacer, DJ; Weiss, ST				Peters, Stephen P.; Jones, Craig A.; Haselkorn, Tmirah; Mink, David R.; Valacer, David J.; Weiss, Scott T.			Real-world Evaluation of Asthma Control and Treatment (REACT): Findings from a national Web-based survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma control; asthma action plan; health survey; epidemiology; comorbidity	RISK-FACTORS; SEVERITY; ADULT; BECLOMETHASONE; RESPONSIVENESS; VARIABILITY; MONTELUKAST	Background: Despite health initiatives for advancing the management of asthma, evidence suggests that many asthmatic subjects have uncontrolled disease. However, the prevalence of uncontrolled asthma in the United States is not known and has not been fully characterized. Objective: We sought to assess the prevalence, morbidity, and factors associated with uncontrolled asthma in a nationally representative sample of patients with moderate-to-severe asthma using standard asthma medications. Methods: A Web-based survey was administered to patients with diagnoses of asthma for at least 1 year who were receiving multiple controller medications. The Asthma Control Test score was used to stratify respondents into controlled and uncontrolled cohorts. Results: A total of 1812 patients were assessed; 809 (45%) had controlled asthma, and 1003 (55%) had uncontrolled asthma. Most patients had health care coverage and received care from a general practitioner; a large proportion of patients with controlled asthma (74%) and patients with uncontrolled asthma (65%) reported never receiving an asthma action plan. Inhaled corticosteroid plus long-acting P-agonist was the most common medication regimen in patients with controlled asthma (60%) and patients with uncontrolled asthma (48%) patients. Patients with uncontrolled asthma reported significantly higher rates of health care use. Several comorbidities were predictive of uncontrolled asthma. Conclusion: Uncontrolled asthma is highly prevalent (55%) in patients using standard asthma medications. There is need for improved asthma care in patients with moderate-to-severe asthma, including a global evaluation of asthma control, implementation of treatment plans and asthma control tests, and addressing comorbid conditions. Clinical implications: Improved asthma care requires broader assessments of asthma control, including asthma-related health care and medication use, comorbidities, and the implementation of treatment plans and formal asthma control tests.	Wake Forest Univ, Sch Med, Ctr Human Genome, Dept Internal Med,Sect Pulm Crit Care A&ID, Winston Salem, NC 27109 USA; Univ So Calif, Los Angeles Cty Med Ctr, Dept Pediat, Div Allergy & Immunol, Los Angeles, CA 90033 USA; Genentech Inc, San Francisco, CA 94080 USA; Ovat Res Grp, San Francisco, CA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Genet & Genome,Channing Lab, Boston, MA 02115 USA	Wake Forest University; University of Southern California; Roche Holding; Genentech; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Peters, SP (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genome, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sppeters@wfubmc.edu						Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; *AM LUNG ASS, RES PROGR SERV TREND; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P512, DOI 10.1016/j.jaci.2005.12.1353; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Ben-Noun L, 2001, Public Health Rev, V29, P49; Bunting BA, 2006, J AM PHARM ASSOC, V46, P133, DOI 10.1331/154434506776180658; Calhoun WJ, 2003, J ALLERGY CLIN IMMUN, V112, P1088, DOI 10.1016/j.jaci.2003.09.044; Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DeNavas-Walt C, 2005, INCOME POVERTY HLTH; Ehrs PO, 2006, CHEST, V129, P925, DOI 10.1378/chest.129.4.925; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; GIBSON PG, 2004, COCHRANE DB SYST REV, P1117; *GLOB IN ASTH, 2004, POCK GUID PHYS NURS; Houston JD, 1998, M D COMPUT, V15, P116; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; LeNoir M, 2006, CURR MED RES OPIN, V22, P17, DOI 10.1185/030079905X74925; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Lohr S.L., 2021, SAMPLING DESIGN ANAL; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; MASSEY JT, 1998, 1997 P SURV RES METH, P707; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; *NIELS NET RAT, 2004, EN STUD; Rainie, 2003, PEW INTERNET AM LIFE; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2003, AM J MANAG CARE, V9, P538; Singh K, 1998, J Assoc Physicians India, V46, P179; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szklo M., 2000, EPIDEMIOLOGY BASICS; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Wilson A., 2003, MIP, V21, P79, DOI [10.1108/02634500310465380, DOI 10.1108/02634500310465380]; 2005, J ALLERGY CLIN IMM S, V116, pS3; 2004, GREENFIELD ONLINE PA; ASTHMA AM LANDMARK S; [No title captured]	42	203	212	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1454	1461		10.1016/j.jaci.2007.03.022	http://dx.doi.org/10.1016/j.jaci.2007.03.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481716	Bronze			2022-12-18	WOS:000247232800022
J	Howell, MD; Wollenberg, A; Gallo, RL; Flaig, M; Streib, JE; Wong, C; Pavicic, T; Boguniewicz, M; Leung, DYM				Howell, MD; Wollenberg, A; Gallo, RL; Flaig, M; Streib, JE; Wong, C; Pavicic, T; Boguniewicz, M; Leung, DYM			Cathelicidin deficiency predisposes to eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antimicrobial peptides; herpes simplex virus; atopic dermatitis; eczema herpeticum	HERPES-SIMPLEX-VIRUS; ATOPIC-DERMATITIS; ANTIBACTERIAL; INFECTIONS; EXPRESSION; PEPTIDE; LL-37; IGE	Background: The cathelicidin family of antimicrobial peptides is an integral component of the innate immune response that exhibits activity against bacterial, fungal, and viral pathogens. Eczema herpeticum (ADEH) develops in a subset of patients with atopic dermatitis (AD) because of disseminated infection with herpes simplex virus (HSV). Objective: This study investigated the potential role of cathelicidins in host susceptibility to HSV infection. Methods: Glycoprotein D was measured by means of real-time RT-PCR as a marker of HSV replication in skin biopsy specimens and human keratinocyte cultures. Cathelicidin expression was evaluated in skin biopsy specimens from patients with AD (n = 10) without a history of HSV skin infection and from patients with ADEH (n = 10). Results: The cathelicidin peptide LL-37 (human cathelicidin) exhibited activity against HSV in an antiviral assay, with significant killing (P <.001) within the physiologic range. The importance of cathelicidins in antiviral skin host defense was confirmed by the observation of higher levels of HSV-2 replication in cathelicidin-deficient (Cnlp(-/-)) mouse skin (2.6 +/- 0.5 pg HSV/pg GAPDH, P <.05) compared with that seen in skin from their wild-type counterparts (0.9 +/- 0.3). Skin from patients with ADEH exhibited significantly (P <.05) lower levels of cathelicidin protein expression than skin from patients with AD. We also found a significant inverse correlation between cathelicidin expression and serum IgE levels (r(2) = 0.46, P <.05) in patients with AD and patients with ADEH. Conclusion: This study demonstrates that the cathelicidin peptide LL-37 possesses antiviral activity against HSV and demonstrates the importance of variable skin expression of cathelicidins in controlling susceptibility to ADEH. Additionally, serum IgE levels might be a surrogate marker for innate immune function and serve as a biomarker for which patients with AD are susceptible to ADEH. Clinical implications: A deficiency of LL-37 might render patients with AD susceptible to ADEH. Therefore increasing production of skin LL-37 might prevent herpes infection in patients with AD.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Munich, Dept Dermatol & Allergy, Munich, Germany; Univ Calif San Diego, Dept Med & Pediat, Div Dermatol, San Diego, CA 92103 USA; VA San Diego Hlth Care Syst, San Diego, CA USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munich; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njc.org	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NCRR NIH HHS [M01 RR000051, M01 RR000051-360942, M01 RR00051] Funding Source: Medline; NIAID NIH HHS [T32 AI007365, AI052453, U01 AI147462, R37 AI052453, R01 AI052453, T32 AI 07365, N01AI40030, N01 AI040029] Funding Source: Medline; NIAMS NIH HHS [5R21AR051634, R01 AR041256, R01 AR041256-17, AR41256, R01 AR045676, AR45676, R21 AR051634, R21 AR051634-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, T32AI007365, R37AI052453, N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256, R01AR045676, R21AR051634] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gordon YJ, 2005, CURR EYE RES, V30, P385, DOI 10.1080/02713680590934111; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; LAGACESIMARD J, 1986, J ALLERGY CLIN IMMUN, V77, P582, DOI 10.1016/0091-6749(86)90349-0; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; SANDERSON IR, 1987, BMJ-BRIT MED J, V294, P693, DOI 10.1136/bmj.294.6573.693; Tukey J. W., 1977, EXPLORATORY DATA ANA; Weidmann M, 2003, J CLIN MICROBIOL, V41, P1565, DOI 10.1128/JCM.41.4.1565-1568.2003; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Yasin B, 2000, EUR J CLIN MICROBIOL, V19, P187, DOI 10.1007/s100960050457	18	203	214	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					836	841		10.1016/j.jaci.2005.12.1345	http://dx.doi.org/10.1016/j.jaci.2005.12.1345			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630942	Green Accepted			2022-12-18	WOS:000236862800018
J	Wright, RJ; Finn, P; Contreras, JP; Cohen, S; Wright, RO; Staudenmayer, J; Wand, M; Perkins, D; Weiss, ST; Gold, DR				Wright, RJ; Finn, P; Contreras, JP; Cohen, S; Wright, RO; Staudenmayer, J; Wand, M; Perkins, D; Weiss, ST; Gold, DR			Chronic caregiver stress and IgE expression, allergen-induced proliferation, and cytokine profiles in a birth cohort predisposed to atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						caregiver stress; IgE; lymphocyte proliftration; cytokines; birth cohort	CD4(+) T-CELLS; TNF-ALPHA; PSYCHOLOGICAL STRESS; PERCEIVED STRESS; RESPONSES; GLUCOCORTICOIDS; ACTIVATION; TH1; SENSITIZATION; CHALLENGE	Background: Psychologic stress modifies immune function and cytokine production. Objective: We examined relationships between caregiver stress on the following markers of early childhood immune response: (1) IgE expression (n = 215); (2) mitogen-induced and allergen-specific (Dermatophagoides farinae [Der f 1] and cockroach [Bla g 2]) proliferative response (n = 114); and (3) subsequent cytokine expression (INF-gamma, TNF-alpha, IL-10, and IL-13) in a prospective birth cohort predisposed to atopy. Methods: Caregiver stress was measured at 2-month intervals for the first 2 years of life and yearly thereafter by using the Perceived Stress Scale. A subsequent blood sample obtained from the children (median age, 2.1 years; range, 18-32 months) was analyzed for total serum IgE level and allergen-induced proliferation quantified as the stimulation index (SI; mean thymidine incorporation of the stimulated sample divided by that of the unstimulated sample). The relationship between stress and the proliferative response (SI >3 vs SI less than or equal to3), and total IgE level (less than or equal to100 IU/mL vs >100 IU/mL) was examined by using logistic regression. The relationship between cytokine levels and stress was analyzed by using linear regression. Results: In adjusted analyses higher caregiver stress in the first 6 months after birth was associated with a Der f 1 SI of greater than 3 (odds ratio [OR], 1.5; 95% CI, 1.0-2.3) and nominally associated with a Bla g 2 SI of greater than 3 (OR, 1.13; 95% CI, 0.7-1.8). Higher stress between ages 6 and 18 months was associated with a high total IgE level (OR, 2.03; 95% CI, 1.1-3.6). Higher stress was significantly associated with increased production of TNF-alpha, with a suggested trend between higher stress and reduced INF-gamma production. Conclusion: Increased stress in early childhood was associated with an atopic immune profile in these children predisposed to atopy-asthma.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Emergency Med, Childrens Hosp, Boston, MA 02115 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Massachusetts, Dept Math & Stat, Amherst, MA 01003 USA; Univ New S Wales, Sch Math, Dept Stat, Sydney, NSW, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Carnegie Mellon University; University of Massachusetts System; University of Massachusetts Amherst; University of New South Wales Sydney	Wright, RJ (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu	Wand, Matt P/F-9413-2012	Wand, Matt P/0000-0003-2555-896X; Cohen, Sheldon/0000-0003-2248-4600	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL 04187] Funding Source: Medline; NIAID NIH HHS [R01 AI/EH 35786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI S, 1993, CANCER RES, V53, P4153; BACHEN EA, 1995, PSYCHOSOM MED, V57, P366, DOI 10.1097/00006842-199507000-00008; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chrousos George P., 2000, Journal of Allergy and Clinical Immunology, V106, pS275; Cohen S, 1999, PSYCHOSOM MED, V61, P175, DOI 10.1097/00006842-199903000-00009; COHEN S, 1990, HEALTH PSYCHOL, V9, P466, DOI 10.1037/0278-6133.9.4.466; COHEN S, 1988, CLAR SYMP, P31; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S., 1995, MEASURING STRESS GUI, P3; Contreras JP, 2003, J ALLERGY CLIN IMMUN, V112, P1072, DOI 10.1016/j.jaci.2003.08.036; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Donovan CE, 1999, THORAX, V54, P938, DOI 10.1136/thx.54.10.938; Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; FUKATA J, 1994, J ENDOCRINOL INVEST, V17, P141, DOI 10.1007/BF03347705; Glosli H, 2002, FASEB J, V16, P1450, DOI 10.1096/fj.01-0948fje; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Halasz A, 2002, RESP MED, V96, P262, DOI 10.1053/rmed.2001.1256; Holt PG, 1997, CIBA F SYMP, V206, P35; Irie M, 2000, NEUROSCI LETT, V288, P13, DOI 10.1016/S0304-3940(00)01194-0; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kim MH, 2002, J ASTHMA, V39, P441, DOI 10.1081/JAS-120004037; KOSUGI H, 1994, BIOL PHARM BULL, V17, P1645; KOYAMA H, 2000, THORAX S, V55, pS51; Lara-Marquez ML, 1998, J ALLERGY CLIN IMMUN, V101, P699, DOI 10.1016/S0091-6749(98)70180-0; Lazarus R.S., 1984, STRESS APPRAISAL; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MANUCK SB, 1991, PSYCHOL SCI, V2, P111, DOI 10.1111/j.1467-9280.1991.tb00110.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Ng DM, 2003, HEALTH PSYCHOL, V22, P638, DOI 10.1037/0278-6133.22.6.638; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; PATTERSON JM, 1995, REPORT 25 ROUNDTABLE, P11; Peebles RS, 2000, CLIN EXP ALLERGY, V30, P1257; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Prescott SL, 1998, J IMMUNOL, V160, P4730; Ramirez F, 1996, J IMMUNOL, V156, P2406; RAMSAY DS, 1994, CHILD DEV, V65, P1491, DOI 10.2307/1131513; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Ruppert D., 2003, SEMIPARAMETRIC REGRE; Vallee M, 1997, J NEUROSCI, V17, P2626; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	51	203	204	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1051	1057		10.1016/j.jaci.2004.03.032	http://dx.doi.org/10.1016/j.jaci.2004.03.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208584				2022-12-18	WOS:000222091000008
J	Fuhlbrigge, AL; Kitch, BT; Paltiel, AD; Kuntz, KM; Neumann, PJ; Dockery, DW; Weiss, ST				Fuhlbrigge, AL; Kitch, BT; Paltiel, AD; Kuntz, KM; Neumann, PJ; Dockery, DW; Weiss, ST			FEV1 is associated with risk of asthma attacks in a pediatric population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; FEV1; percent predicted FEV1; severity; attack; outcome	QUALITY-OF-LIFE; OBSTRUCTIVE AIRWAY DISEASE; PULMONARY-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; FOLLOW-UP; CHILDREN; DIAGNOSIS; MORTALITY; PREVALENCE	Background: FEV1 is endorsed by the National Asthma Education and Prevention Program as a means for grading asthma severity. However, few data exist on the relationship between FEV1 and asthma outcomes during long-term follow-up. Objective:We explored the relationship between the percent predicted FEV1 (FEV1%) and subsequent asthma attacks in a longitudinal study of pediatric lung health. Methods: A retrospective cohort of 13,842 children (100,292 observations) seen annually over a 15-year Interval was analyzed for measurement of pulmonary Function, and a respiratory questionnaire was completed. Up to grade 9, a standard questionnaire was completed by a pal ent or guardian; thereafter it was completed by the patient. For each observation, the report of an attack during the past year was paired with FEV1 recorded at the field survey 1 year earlier. Results: A progressive decrease in the proportion of individuals reporting an attack was associated with increasing decile of FEV1%. Two categorization schemes fur FEV1% were examined: a scheme based on the National Asthma Education and Prevention Program recommendations (<60%, 60%-80%, and >80%), and an alternative scheme (<80%, 80%-100%, and >100%). In multivariate models, FEV1% was an independent predictor of attacks: among the parental report group, the odds ratios were 2.1 (95% CI, 1.3-3.4) and 1.4 (95% CI, 1.2-1.6) fur FEV1% < 60% and FEV1% of 60% to 80% compared with FEV1% > 80%, respectively; and among the self-report group, odds ratios were 5.3 (95% CI, 2.2-12.9) and 1.4 (95% CI, 1.2-1.7) for FEV1% < 60% and FEV1% of 60% to 80% compared with FEV1% > 80%, respectively. With the alternative classification scheme, the relationship was similar, but the difference in risk between categories of FEV1% decreased. Conclusion: The strong association between FEV1% and risk of asthma attack over the subsequent year supports an emphasis on objective measures of lung function in assessment of risk for adverse asthma outcomes.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Yale Sch Med, New Haven, CT USA; Yale Sch Management, New Haven, CT USA; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yale University; Yale University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Fuhlbrigge, AL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		, dwdockery/AAO-7272-2021	Dockery, Douglas/0000-0002-6052-4880; Paltiel, A. David/0000-0002-4861-3290	NHLBI NIH HHS [HL07427, 1-K08 HL03919-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Braun-Fahrlander C, 1998, PEDIATR PULM, V25, P159, DOI 10.1002/(SICI)1099-0496(199803)25:3<159::AID-PPUL5>3.0.CO;2-H; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; DEMOKOSH AI, 1994, AM J RESP CRIT CARE, V149, pA917; DZYNGEL B, 1994, J ASTHMA, V31, P291; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; FERRIS BG, 1979, AM REV RESPIR DIS, V120, P767; FERRIS BG, 1978, B EUR PHYSIOPATH RES, V14, P145; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; JONES KP, 1993, CLIN EXP ALLERGY, V23, P627, DOI 10.1111/j.1365-2222.1993.tb01787.x; JONES KP, 1993, CLIN EXP ALLERGY, V23, P696; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; LUYT DK, 1994, ARCH DIS CHILD, V71, P24, DOI 10.1136/adc.71.1.24; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MELTZER AA, 1989, CHEST, V96, P329, DOI 10.1378/chest.96.2.329; National Asthma Education Prevention Program (National Heart Lung and Blood Institute), 1997, 2 NAT ASTHM ED PREV; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; OGIRALA RG, 1995, AM J RESP CRIT CARE, V152, P1461, DOI 10.1164/ajrccm.152.5.7582277; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; OTULANA BA, 1992, RESP MED, V86, P105, DOI 10.1016/S0954-6111(06)80224-6; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; Sippel JM, 1999, CHEST, V115, P691, DOI 10.1378/chest.115.3.691; SLY PD, 1994, BRIT MED J, V308, P572, DOI 10.1136/bmj.308.6928.572; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804, DOI 10.1164/ajrccm.157.6.9708092; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; VAUGHAN TR, 1989, CHEST, V95, P558, DOI 10.1378/chest.95.3.558; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; Wolf RL, 1999, CHEST, V116, p224S, DOI 10.1378/chest.116.suppl_2.224S; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	45	203	207	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					61	67		10.1067/mai.2001.111590	http://dx.doi.org/10.1067/mai.2001.111590			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149992				2022-12-18	WOS:000166533300011
J	Busse, WW; Brazinsky, S; Jacobson, K; Stricker, W; Schmitt, K; Vanden Burgt, J; Donnell, D; Hannon, S; Colice, GL				Busse, WW; Brazinsky, S; Jacobson, K; Stricker, W; Schmitt, K; Vanden Burgt, J; Donnell, D; Hannon, S; Colice, GL			Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beclomethasone dipropionate; chlorofluorocarbons; hydrofluoroalkane-134a; propellants; metered-dose inhalers; inhaled corticosteroids	FLUTICASONE PROPIONATE; DOUBLE-BLIND; BUDESONIDE; AEROSOL; INFLAMMATION; CORTICOSTEROIDS; TURBUHALER; MODERATE; SAFETY	Background: This study tested the hypothesis that there mould be improved asthma control with increasing doses of beclomethasone dipropionate (BDP) formulated in hydrofluoroalkane-134a (HFA-BDP) and the standard chlorofluorocarbon propellants (CFC-BDP), Because HFA-BDP has improved lung deposition compared with CFC-BDP, this study also tested the hypothesis that HFA-BDP would provide more effective control of asthma than CFC-BDP, Methods: In this multicenter, randomized, parallel-group blinded study, asthmatic subjects who had deterioration in asthma control after discontinuation of inhaled corticosteroids were randomized to receive one of 6 possible treatments: 100 mu g/d, 400 mu g/d, or 800 mu g/d of HFA-BDP or 100 mu g/d, 400 mu g/d, or 800 mu g/d of CFC-BDP for 6 weeks. Changes in spirometry, daytime asthma symptom and nighttime asthma-related sleep disturbance scores, morning and evening peak expiratory flows, and daily use of inhaled beta-agonist for symptom control on diary cards were assessed over 6 weeks of treatment. Results: Three hundred twenty-three patients mere randomized to the 6 treatment groups, which had similar demographics and baseline lung function, There were significantly larger changes from baseline at week 6 in FEV1 percent predicted with increasing doses of both HFA-BDP and CFC-BDP, The FEV1 percent predicted dose-response curve for HFA-BDP was shifted to the left compared with the dose-response curve for CFC-BDP, By using the Finney bioassay method, it was calculated that 2.6 times as much CFC-BDP would be required to achieve the same improvement in FEV1 percent predicted as HFA-BDP (95% confidence interval, 1.1-11.6), All treatment groups except the 100 mu g/d CFC-BDP group tolerated study drug well, Ten (17%) of 59 patients in this group reported an acute asthma episode, increased asthma symptoms (6 of the 8 reports of increased asthma symptoms were classified as severe), or both, and 8 patients withdrew from the study (3 for adverse events related to asthma), Conclusions: Increasing doses of inhaled corticosteroids lead to improved lung function and asthma control. Moreover, the reformulation of BDP in HFA enables effective asthma control at much lower doses than CFC-BDP.	Univ Wisconsin, Sch Med, Allergy Immunol Serv, Madison, WI USA; Inst Hlth Care Assessment Inc, San Diego, CA USA; Allergy & Asthma Res Grp, Eugene, OR USA; Ozarks Inc, Clin Res, Columbia, MO USA; 3M Pharmaceut, St Paul, MN USA	University of Wisconsin System; University of Wisconsin Madison; 3M	Colice, GL (corresponding author), Washington Hosp Ctr, Pulm & Resp Serv, 110 Irving St NW, Washington, DC 20010 USA.							Agertoft L, 1997, J ALLERGY CLIN IMMUN, V99, P773, DOI 10.1016/S0091-6749(97)80011-5; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAVIES PJ, 1998, RESP MED, V92, pS23; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FINNEY D. J., 1978, STAT METHOD BIOL ASS; GADDIE J, 1973, LANCET, V2, P280; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Harrison LI, 1999, J PHARM PHARMACOL, V51, P263, DOI 10.1211/0022357991772439; JOHANSSON SA, 1988, ALLERGY, V43, P173; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lawrence M, 1997, AM J RESP CRIT CARE, V156, P744, DOI 10.1164/ajrccm.156.3.9608058; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; MCCUBBIN MM, 1995, CLIN PHARMACOL THER, V57, P455, DOI 10.1016/0009-9236(95)90216-3; *NAT HEART LUNG BL, 1997, EXP PAN REP 2 GUID D; Nathan RA, 1997, CHEST, V112, P34, DOI 10.1378/chest.112.1.34; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Redelmeier DA, 1996, CHEST, V109, P1163, DOI 10.1378/chest.109.5.1163; Thompson PJ, 1998, RESP MED, V92, P33, DOI 10.1016/S0954-6111(98)90215-3; Toogood JH, 1997, J ALLERGY CLIN IMMUN, V99, P186, DOI 10.1016/S0091-6749(97)70094-0; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; Welch MJ, 1997, CHEST, V112, P597, DOI 10.1378/chest.112.3.597	30	203	207	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1215	1222		10.1016/S0091-6749(99)70016-3	http://dx.doi.org/10.1016/S0091-6749(99)70016-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589004	Bronze			2022-12-18	WOS:000084289200016
J	Roost, HP; Kunzli, N; Schindler, C; Jarvis, D; Chinn, S; Perruchoud, AP; Ackermann-Liebrich, U; Burney, P; Wuthrich, B				Roost, HP; Kunzli, N; Schindler, C; Jarvis, D; Chinn, S; Perruchoud, AP; Ackermann-Liebrich, U; Burney, P; Wuthrich, B		European Community Resp Hlth Surve	Role of current and childhood exposure to cat and atopic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; sensitization; cat allergen; allergy prevention; risk factors; childhood	RESPIRATORY-HEALTH-SURVEY; ALLERGIC SENSITIZATION; BARTONELLA-HENSELAE; RISK FACTOR; FOLLOW-UP; ASTHMA; INDOOR; SYMPTOMS; CHILDREN; INFANCY	Background: Clinical and population studies have shown that exposure and sensitization to allergens derived from furred pets, particularly cats, represent an important risk factor of allergic respiratory disease and also a significant risk factor for asthma, Objective: In the framework of the multicenter European Community Respiratory Health Survey an analysis of the association of current and childhood exposure to cat with atopic sensitization to cat was conducted. Methods: This study included cross-sectional data from 35 centers representing 16 countries. Altogether, 18,097 subjects were included, of whom 13,509 (75%) provided a blood sample for the measurement of specific IgE, Exposure data and data for potential confounders were extracted from an interviewer-led questionnaire. Results: The prevalence of sensitization to cat (serum specific IgE >0.35 kU/L) was 9%.Among those who did not report allergic symptoms in the presence of pets or house dust, those who owned cats were significantly more likely to be sensitized to eats than were those who did not (odds ratio [95% confidence interval] 1.57 [1.20-2.06], Childhood exposure to pets including cats was associated with lower sensitization to cats in adulthood, particularly among those with a positive family history of atopy (odds ratio [95% confidence interval] 0.68 [0.51-0.93], Positive correlations were found between the community prevalence of cat and the prevalences of sensitization to cat, respiratory symptoms, physician-diagnosed asthma, and current asthma medication. Conclusions: Current cat ownership represents a significant risk for sensitization to cat if cats are allowed indoors. Our results support the hypothesis that childhood exposure to pets, including cats, might modulate immunologic mechanisms and reduce sensitization to eat in adulthood. The significant correlation found between the community prevalence of cat ownership and community prevalence of specific sensitization to cat represents the first documentation of such a relationship.	Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; United Med & Dent Sch Guys & St Thomas, Dept Publ Hlth Med, London SE1 7EH, England; Univ Basel Hosp, Div Pneumol, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland	University of Basel; University of London; King's College London; University of Basel; University of Zurich; University Zurich Hospital	Kunzli, N (corresponding author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.		Kuenzli, Nino/F-7195-2014; Jarvis, Deborah/E-6494-2011; Schindler, Christian/D-3472-2015	Kuenzli, Nino/0000-0001-8360-080X; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678				AMMANN B, 1985, DEUT MED WOCHENSCHR, V110, P1239, DOI 10.1055/s-2008-1068989; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BORDELLO SP, 1983, J CLIN PATHOL, V36, P84; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Coren S, 1997, BRIT MED J, V314, P517, DOI 10.1136/bmj.314.7079.517; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESJARDINS A, 1993, J ALLERGY CLIN IMMUN, V91, P979, DOI 10.1016/0091-6749(93)90210-7; Dotterud LK, 1997, CLIN EXP ALLERGY, V27, P252, DOI 10.1111/j.1365-2222.1997.tb00703.x; Facchetti F, 1999, AM J PATHOL, V154, P145, DOI 10.1016/S0002-9440(10)65261-3; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Glaus T, 1997, J CLIN MICROBIOL, V35, P2883, DOI 10.1128/JCM.35.11.2883-2885.1997; Gordon S, 1997, CLIN EXP ALLERGY, V27, P479, DOI 10.1046/j.1365-2222.1997.d01-537.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Jacobs RF, 1998, CLIN INFECT DIS, V26, P80, DOI 10.1086/516256; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Power CA, 1998, INFECT IMMUN, V66, P5743, DOI 10.1128/IAI.66.12.5743-5750.1998; POYSA L, 1991, ALLERGY PROC, V12, P107, DOI 10.2500/108854191779011800; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; *STAT CORP, 1997, STAT VERS 5 0; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Tan JS, 1997, ARCH INTERN MED, V157, P1933, DOI 10.1001/archinte.157.17.1933; Tubiolo VC, 1997, CLIN EXP ALLERGY, V27, P354; vonMutius E, 1996, BRIT MED J, V312, P1448, DOI 10.1136/bmj.312.7044.1448; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	48	203	208	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					941	947		10.1016/S0091-6749(99)70072-2	http://dx.doi.org/10.1016/S0091-6749(99)70072-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550736				2022-12-18	WOS:000083778400014
J	Simons, FER				Simons, FER			Allergic rhinobronchitis: The asthma-allergic rhinitis link	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; bronchitis; chronic allergic inflammation; inhaled glucocorticoids; intranasal glucocorticoids; bronchial hyperresponsiveness	BRONCHIAL HYPERRESPONSIVENESS; MILD ASTHMA; NASAL; RESPONSIVENESS; CORTICOSTEROIDS; INFLAMMATION; MECHANISMS; SINUSITIS; SYMPTOMS; EFFICACY	Allergic rhinitis and asthma are linked by epidemiologic, histologic, physiologic, and immunopathologic characteristics and by a common therapeutic approach. Epidemiologically, the disorders often coexist. Histologically, the upper and lower airways are lined, and linked, by the respiratory epithelium. Physiologically, they may be linked by the nasobronchial reflex. Pathologically, they are linked by similar early- and late-phase allergic responses throughout the airways and by the systemic immunologic response to airborne allergens. Uncontrolled allergic rhinitis may be associated with worsening of coexisting asthma, and optimal treatment of allergic rhinitis may improve coexisting asthma, The key to managing both disorders is prevention and relief of chronic allergic inflammation in both the upper and lower airways. The similarities between allergic rhinitis and asthma outweigh the differences. To facilitate appropriate recognition and treatment of the common inflammatory process throughout the airways, consideration should be given to introducing the new term "allergic rhinobronchitis,".	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada	University of Manitoba	Simons, FER (corresponding author), Childrens Hosp, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; Bousquet J, 1998, EUR RESPIR J, V11, p42S; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Bufe A, 1998, AM J RESP CRIT CARE, V157, P1269, DOI 10.1164/ajrccm.157.4.9709040; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Denburg JA, 1998, INT ARCH ALLERGY IMM, V117, P155, DOI 10.1159/000024004; Derendorf H, 1997, RESP MED, V91, P22, DOI 10.1016/S0954-6111(97)90102-5; Devalia JL, 1997, ALLERGY, V52, P45, DOI 10.1111/j.1398-9995.1997.tb04870.x; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; GERRAND M, 1998, HARRISONS PRINCIPLES, P179; Greiff L, 1998, EUR RESPIR J, V11, P1268, DOI 10.1183/09031936.98.11061268; Hoffmann BB, 1996, GOODMAN GILMANS PHAR, P204; Huse D., 1996, AM J RESP CRIT CARE, V153, pA860; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; Kapsali T., 1997, Journal of Allergy and Clinical Immunology, V99, pS138; Kay AB, 1997, ALLERGY ALLERGIC DIS, P23; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580, DOI 10.1164/ajrccm/141.3.580; MOORE KL, 1993, ESSENTIALS EMBRYOLOG, P153; NACLERIO RM, 1985, AM J MED, V79, P43, DOI 10.1016/0002-9343(85)90087-7; NELSON HS, 1998, ALLERGY PRINCIPLES P, P1050; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; *NIH, 1997, NIH PUBL; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; PAULSEN DF, 1993, BASIC HISTOLOGY, P246; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Simons FER., 1994, ANCESTORS ALLERGY; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110	35	203	222	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				534	540		10.1016/S0091-6749(99)70320-9	http://dx.doi.org/10.1016/S0091-6749(99)70320-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482824				2022-12-18	WOS:000082870000012
J	Helenius, IJ; Tikkanen, HO; Sarna, S; Haahtela, T				Helenius, IJ; Tikkanen, HO; Sarna, S; Haahtela, T			Asthma and increased bronchial responsiveness in elite athletes: Atopy and sport event as risk factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic allergy; pollen allergy; lung function; speed and power sports; long-distance running; swimming	EXERCISE-INDUCED ASTHMA; CROSS-COUNTRY SKIERS; PREVALENCE; SWIMMERS; EXPOSURE; RUNNERS; ALLERGY; AIR	Background: High prevalence of bronchial hyperresponsiveness and asthma has been found in cross-country skiers. There is limited evidence that asthma and bronchial responsiveness would be common also in athletes with summer events. Objectives: The objective of this study was to investigate occurrence of and risk factors for increased bronchial responsiveness and asthma in elite athletes with summer events and to compare their results with those of control subjects. Methods: Forty-nine speed and power athletes (mean age 21.1 years, range 16 to 31), 71 long-distance runners (mean age 26.6 years, range 16 to 39), 42 swimmers (mean age 18.6 years, range 14 to 25), and 45 control subjects (mean age 26.7 years, range 21 to 37) were studied. The subjects answered questionnaires and were given a resting spirometric examination, a skin prick test, and a histamine challenge test. Results: Current asthma (current asthmatic symptoms and increased bronchial responsiveness) was observed in 14% (22 of 162) of the athletes and in 2% (1 of 45) of the control subjects (p = 0.041). Total asthma (current asthmatic symptoms and increased bronchial responsiveness or physician-diagnosed asthma) occurred in 23% (37 of 162) of the athletes and in 4% (2 of 45) of the control subjects (p = 0.0048), Atopy according to skin prick test results was found in 48% (77 of 162) of the athletes and in 36% (16 of 45) of the control subjects (not significant). Clinical pollen allergy (positive skin test reaction to pollen and symptoms of rhinoconjunctivitis) was significantly (p = 0.037) more common in athletes than in control subjects, Atopic athletes showed significantly more often increased bronchial responsiveness, current asthma, and total asthma than nonatopic athletes (p = 0.011, p = 0.0049, and p < 0.0001, respectively), and the odds ratios of increased bronchial responsiveness and asthma increased with the number of positive skin test reactions. After adjustment for confounding factors, the odds ratio for the occurrence of current asthma was 5.49 (95% confidence interval 0.56 to 53.7) in speed and power athletes, 2.88 (0.30 to 27.7) in long-distance runners, and 10.8 (1.10 to 106.0) in swimmers compared with control subjects, The adjusted odds ratios for the occurrence of total asthma were 3.56 (0.62 to 20.5) in speed and power athletes, 6.01 (1.19 to 30.2) in long-distance runners, and 5.89 (1.00 to 33.5) in swimmers. Conclusions: Asthma is more common in highly trained athletes than in control subjects. Asthma is especially common in elite swimmers, but the risk of asthma is increased also in long-distance runners. Increased bronchial responsiveness and asthma are strongly associated with atopic disposition and its severity in elite athletes.	Univ Helsinki, Cent Hosp, Dept Allergol, FIN-00250 Helsinki, Finland; Res Inst Olymp Sports, Jyvaskyla, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00250 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Helenius, IJ (corresponding author), Univ Helsinki, Cent Hosp, Dept Allergol, FIN-00250 Helsinki, Finland.		Helenius, Ilkka/AAM-5803-2020	Helenius, Ilkka/0000-0001-5200-3279; Sarna, Seppo/0000-0003-3458-1627				*AM THOR SOC, 1987, AM REV RESPIR DIS, V121, P1285; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Astrand PO., 1986, TXB WORK PHYSL, P391; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; Godfrey S, 1992, ASTHMA, P73; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1997, THORAX, V52, P157, DOI 10.1136/thx.52.2.157; Hennekens C.H., 1987, EPIDEMIOLOGY MED; KARJALAINEN J, 1989, CLIN EXP ALLERGY, V19, P273, DOI 10.1111/j.1365-2222.1989.tb02383.x; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; PIERSON WE, 1986, MED SCI SPORT EXER, V18, P322, DOI 10.1249/00005768-198606000-00012; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; TIKKANEN HO, 1994, BRIT MED J, V309, P1087, DOI 10.1136/bmj.309.6961.1087; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	21	203	205	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					646	652		10.1016/S0091-6749(98)70173-3	http://dx.doi.org/10.1016/S0091-6749(98)70173-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600502				2022-12-18	WOS:000073697400013
J	Custovic, A; Taggart, SCO; Francis, HC; Chapman, MD; Woodcock, A				Custovic, A; Taggart, SCO; Francis, HC; Chapman, MD; Woodcock, A			Exposure to house dust mite allergens and the clinical activity of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; house dust mite allergen; airborne; reservoir; bronchial hyperreactivity	DER-P-I; BRONCHIAL RESPONSIVENESS; SEASONAL-VARIATION; CHILDREN; METHACHOLINE; HYPERRESPONSIVENESS; ASSOCIATION; REACTIVITY; POPULATION; CHILDHOOD	Background: House dust mite allergens play an important role in inducing IgE-mediated sensitization and the development of bronchial hyperresponsiveness (BHR) and asthma. This study investigated the relationship between mite allergen exposure and the clinical activity and severity of asthma. Methods: Nonsmoking adult patients with asthma (n = 53) were randomly recruited from the asthma registry of two large family practitioner surgeries. Each participant underwent skin testing with common inhalant allergens, a methacholine bronchoprovocation test, and pulmonary function testing on up to 3 separate occasions over a 4-week period. BHR was expressed both as PD20 and dose-response ratio (DRR), and the patients with PD20 of less than 12.25 mu mol methacholine were classified as methacholine reactors. Patients were also asked to record peak expiratory flow rate (PEFR) values at 2-hour intervals during waking hours for 1 month. Daily PEFR variability was calculated as amplitude percent mean. Dust samples were collected by vacuuming bedding, bedroom carpets and mattresses. In addition, in the homes of 32 subjects with positive skin test responses to mites, airborne samples were taken overnight for 8 hours with a personal sampler attached to each subject's pillow. Der p 1 and Der p 2 levels were determined by a two-site monoclonal antibody-based ELISA. Results: No difference in mite allergen exposure was found between subjects who were sensitive to mites and those who were not. However, mite-sensitive methacholine reactors were exposed to significantly higher concentrations of Der p 1 in beds than mite-sensitive methacholine nonreactors (13.2 mu g/gm and 1.45 mu g/gm, respectively; p < 0.02). Der p 1 and Der p 2 were undetectable in 30 of 32 airborne samples. In mite-sensitive patients both Der p 1 and Der p 2 in beds significantly correlated with BHR (PD20: r = -0.49, DRR, r = 0.49; PD20: r = -0.46, DRR: r = 0.43) and amplitude percent mean PEFR (r = 0.38, r = 0.41) for Der p 1 and Der p 2, respectively. There was a significant negative correlation between exposure to Der p 1 and percent predicted FEV(1) (r = -0.43). The correlation between Der p 2 and percent predicted FEV(1) just failed to reach a significant level but showed a clear trend (r = -0.35, p = 0.068). Conclusions: Clinical activity and severity of asthma (measured by the level of BHR, PEFR variability, and percent predicted FEV(1)) in mite-sensitive patients is related to exposure to mite allergens in the dust reservoir, with levels in bed being an important indicator that correlated with disease activity.	UNIV VIRGINIA,HLTH SCI CTR,ASTHMA & ALLERG DIS CTR,CHARLOTTESVILLE,VA	University of Virginia	Custovic, A (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,SOUTHMOOR RD,MANCHESTER M23 9LT,LANCS,ENGLAND.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Chapman, Martin/0000-0002-0845-3632; Woodcock, Ashley/0000-0002-5428-8578	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607, R01AI032557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; ANDERSEN I, 1986, Environment International, V12, P121, DOI 10.1016/0160-4120(86)90022-X; BONER AL, 1985, ANN ALLERGY, V54, P42; Burge H, 1993, INDOOR ALLERGENS ASS; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHINN S, 1987, THORAX, V42, P45, DOI 10.1136/thx.42.1.45; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; KELLY CA, 1989, CLIN EXP ALLERGY, V19, P169, DOI 10.1111/j.1365-2222.1989.tb02360.x; KIVITY S, 1993, J ALLERGY CLIN IMMUN, V91, P844, DOI 10.1016/0091-6749(93)90341-C; MARKS G, 1993, AM REV RESPIR DIS, V147, pA458; MILLS TAE, 1993, J ALLERGY CLIN IMMUN, V89, P1046; MILLS TAE, 1990, ALLERGY PROC, V11, P269; MILLS TAE, 1982, LANCET, V2, P675; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OHALLAREN MT, 1991, NEW ENGL J MED, V324, P359; OVSIANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537; PLATTSMILLS TAE, 1995, PROGR ALLERGY CLIN I, P90; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SHOAF CR, 1991, ENVIRON HEALTH PERSP, V95, P111, DOI 10.2307/3431117; SMITH JM, 1969, BRIT MED J, V1, P723; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	39	203	213	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					64	72		10.1016/S0091-6749(96)70227-0	http://dx.doi.org/10.1016/S0091-6749(96)70227-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765819	Green Published			2022-12-18	WOS:A1996VA69200008
J	BURGE, H				BURGE, H			BIOAEROSOLS - PREVALENCE AND HEALTH-EFFECTS IN THE INDOOR ENVIRONMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BURGE, H (corresponding author), UNIV MICHIGAN,MED CTR,R6621 KRESGE 1,BOX 0529,ANN ARBOR,MI 48109, USA.							Administration UFaD, 1985, BACT ENDO TOXINS; AHMED T, 1982, AM REV RESPIR DIS, V125, P152; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; BANAZAK EF, 1974, AM REV RESPIR DIS, V110, P383; BLOCH AB, 1985, PEDIATRICS, V75, P676; BURG WR, 1981, AM IND HYG ASSOC J, V42, P1, DOI 10.1080/15298668191419271; BURGE H, 1984, ATMOS ENVIRON, V21, P451; BURGE HA, 1980, APPL ENVIRON MICROB, V39, P840, DOI 10.1128/AEM.39.4.840-844.1980; BURGE HA, 1990, TOXICOL IND HEALTH, V6, P263, DOI 10.1177/074823379000600205; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; BURGE HA, 1987, SHORT TERM BIOASSAYS; BURGE HA, 1988, P AM SOC HEARING REF; BURGE HP, 1977, J ALLERGY CLIN IMMUN, V60, P199, DOI 10.1016/0091-6749(77)90124-5; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; EDMONDS RL, 1972, PLANT DIS REP, V56, P704; EDWARDS JH, 1976, NATURE, V264, P438, DOI 10.1038/264438a0; EICKHOFF TC, 1979, ANN INTERN MED, V90, P499, DOI 10.7326/0003-4819-90-4-499; EMMONS CW, 1955, AM J HYG, V62, P227, DOI 10.1093/oxfordjournals.aje.a119775; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; FLIERMANS CB, 1981, APPL ENVIRON MICROB, V41, P9, DOI 10.1128/AEM.41.1.9-16.1981; Gregory P.H., 1973, MICROBIOLOGY ATMOSPH, V2nd; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; KAMINSKI E, 1974, APPL MICROBIOL, V27, P1001, DOI 10.1128/AEM.27.6.1001-1004.1974; KOZAK PP, 1978, J ALLERGY CLIN IMMUN, V61, P185, DOI 10.1016/0091-6749(78)90429-3; Kreiss K., 1984, INDOOR AIR QUALITY; KUNDSIN RB, 1980, ANN NY ACAD SCI, V353, P1; LAFORCE FM, 1969, ARCH ENVIRON HEALTH, V18, P798, DOI 10.1080/00039896.1969.10665490; MACHER JM, 1983, APPL ENVIRON MICROB, V45, P1960, DOI 10.1128/AEM.45.6.1960-1962.1983; MANNIS MJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P1313, DOI 10.1001/archopht.1986.01050210067027; Melius J., 1984, ANN AM C GOVT IND HY, V10, P3; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RYLANDER R, 1984, CLIN ALLERGY, V14, P109, DOI 10.1111/j.1365-2222.1984.tb02197.x; RYLANDER R, 1978, CLIN ALLERGY, V8, P511, DOI 10.1111/j.1365-2222.1978.tb01504.x; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SAMET JM, 1987, J ALLERGY CLIN IMMUN, V79, P685, DOI 10.1016/0091-6749(87)90197-7; SHANK RC, 1981, MYCOTOXINS N NITROSO; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1974, J ALLERGY CLIN IMMUN, V54, P222, DOI 10.1016/0091-6749(74)90064-5; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SORENSON WG, 1984, J TOXICOL ENV HEALTH, V14, P525, DOI 10.1080/15287398409530603; SPENDLOVE JC, 1983, PUBLIC HEALTH REP, V98, P229; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TERR AI, 1987, J ALLERGY CLIN IMMUN, V79, P423, DOI 10.1016/0091-6749(87)90357-5; 1989, GUIDELINES ASSESSMEN; 1981, INDOOR POLLUTANTS	47	203	209	2	65	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					687	701		10.1016/S0091-6749(05)80170-8	http://dx.doi.org/10.1016/S0091-6749(05)80170-8			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229836				2022-12-18	WOS:A1990EJ63100001
J	Christianson, CA; Goplen, NP; Zafar, I; Irvin, C; Good, JT; Rollins, DR; Gorentla, B; Liu, WM; Gorska, MM; Chu, HW; Martin, RJ; Alam, R				Christianson, Christina A.; Goplen, Nicholas P.; Zafar, Iram; Irvin, Chaoyu; Good, James T., Jr.; Rollins, Donald R.; Gorentla, Balachandra; Liu, Weimin; Gorska, Magdalena M.; Chu, HongWei; Martin, Richard J.; Alam, Rafeul			Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 2 innate lymphoid cells; IL-33; T cells; feedback circuit; chronic asthma	INDUCED AIRWAY HYPERREACTIVITY; SIGNAL-REGULATED KINASE; LUNG INFLAMMATION; MURINE MODEL; DUST-MITE; EXPRESSION; MICE; RESOLUTION; HYPERRESPONSIVENESS; SENSITIZATION	Background: Asthma in a mouse model spontaneously resolves after cessation of allergen exposure. We developed a mouse model in which asthma features persisted for 6 months after cessation of allergen exposure. Objective: We sought to elucidate factors contributing to the persistence of asthma. Methods: We used a combination of immunologic, genetic, microarray, and pharmacologic approaches to dissect the mechanism of asthma persistence. Results: Elimination of T cells though antibody-mediated depletion or lethal irradiation and transplantation of recombination-activating gene (Rag1) 2/2 bone marrow in mice with chronic asthma resulted in resolution of airway inflammation but not airway hyperreactivity or remodeling. Elimination of T cells and type 2 innate lymphoid cells (ILC2s) through lethal irradiation and transplantation of Rag2(-/-) gamma c(-/-) bone marrow or blockade of IL-33 resulted in resolution of airway inflammation and hyperreactivity. Persistence of asthma required multiple interconnected feedback and feed-forward circuits between ILC2s and epithelial cells. Epithelial IL-33 induced ILC2s, a rich source of IL-13. The latter directly induced epithelial IL-33, establishing a positive feedback circuit. IL-33 autoinduced, generating another feedback circuit. IL-13 upregulated IL-33 receptors and facilitated IL-33 autoinduction, thus establishing a feed-forward circuit. Elimination of any component of these circuits resulted in resolution of chronic asthma. In agreement with the foregoing, IL-33 and ILC2 levels were increased in the airways of asthmatic patients. IL-33 levels correlated with disease severity. Conclusions: We present a critical network of feedback and feed-forward interactions between epithelial cells and ILC2s involved in maintaining chronic asthma. Although T cells contributed to the severity of chronic asthma, they were redundant in maintaining airway hyperreactivity and remodeling.	[Christianson, Christina A.; Goplen, Nicholas P.; Zafar, Iram; Irvin, Chaoyu; Gorentla, Balachandra; Liu, Weimin; Gorska, Magdalena M.; Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Good, James T., Jr.; Rollins, Donald R.; Chu, HongWei; Martin, Richard J.] Natl Jewish Hlth, Dept Med, Div Pulm Med, Denver, CO 80206 USA; [Gorska, Magdalena M.; Chu, HongWei; Martin, Richard J.; Alam, Rafeul] Univ Colorado, Denver, CO 80202 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Denver	Alam, R (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	AlamR@njhealth.org			National Institutes of Health [RO1 AI68088, AI091614, RO1 AI102943, U19 AI100275, PPG HL36577]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122995, R01HL126895, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102943, R01AI091614, U19AI100275, R01AI068088] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI68088, AI091614, RO1 AI102943, U19 AI100275, and PPG HL36577.	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Chang DE, 2010, P NATL ACAD SCI USA, V107, P175, DOI 10.1073/pnas.0908314107; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Doherty TA, 2009, AM J PHYSIOL-LUNG C, V296, pL229, DOI 10.1152/ajplung.90543.2008; Duez C, 2001, J ALLERGY CLIN IMMUN, V108, P547; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Goplen N, 2012, FASEB J, V26, P1934, DOI 10.1096/fj.11-196477; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Haile S, 1999, AM J RESP CELL MOL, V20, P891, DOI 10.1165/ajrcmb.20.5.3446; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Haworth O, 2011, J IMMUNOL, V186, P6129, DOI 10.4049/jimmunol.1004007; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P1796, DOI 10.1111/j.1365-2222.2004.02097.x; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Leech MD, 2007, J IMMUNOL, V179, P7050, DOI 10.4049/jimmunol.179.10.7050; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Liu WM, 2010, MOL CELL BIOL, V30, P1783, DOI 10.1128/MCB.01003-09; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Masamune A, 2010, AM J PHYSIOL-GASTR L, V299, pG821, DOI 10.1152/ajpgi.00178.2010; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; MOLLER DR, 1986, AM REV RESPIR DIS, V134, P175; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Petersen BC, 2012, NAT MED, V18, P751, DOI 10.1038/nm.2735; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schramm CM, 2004, AM J PATHOL, V164, P295, DOI 10.1016/S0002-9440(10)63119-7; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin SY, 2010, CANCER RES, V70, P6715, DOI 10.1158/0008-5472.CAN-10-1377; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Srividhya J, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/4/046005; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; Zhang LL, 2011, INT J BIOCHEM CELL B, V43, P1383, DOI 10.1016/j.biocel.2011.06.003	53	202	210	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					59	U142		10.1016/j.jaci.2014.11.037	http://dx.doi.org/10.1016/j.jaci.2014.11.037			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25617223	Green Accepted			2022-12-18	WOS:000357542200007
J	Bochner, BS; Busse, WW				Bochner, BS; Busse, WW			Allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; mast cells; smooth muscle; cysteinyl leukotrienes; asthma	FC-EPSILON-RI; SMOOTH-MUSCLE-CELLS; HYPEREOSINOPHILIC SYNDROME; HUMAN BASOPHILS; NITRIC-OXIDE; AIRWAY; EXPRESSION; EOSINOPHILS; BETA; ANTIBODY	Initiation and regulation of allergic inflammation is influenced by many factors, including cell type, membrane receptors, and mediators generated. Furthermore, the altered response of targeted tissues (ie, airway smooth muscle) becomes important to the eventual expression of asthma. Finally, the genetic regulation and association of genetic polymorphisms has enhanced our understanding of host susceptibility. In this review key findings published in 2004 issues of the Journal of Allergy and Clinical Immunology are highlighted to demonstrate recent advances in these areas.	Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53792 USA; Johns Hopkins Univ, Baltimore, MD USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Busse, WW (corresponding author), Univ Wisconsin, Sch Med, Dept Med, K4-912 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P683, DOI 10.1016/j.jaci.2003.12.311; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P876, DOI 10.1016/j.jaci.2004.02.029; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Guyer B., 2004, Journal of Allergy and Clinical Immunology, V113, pS28, DOI 10.1016/j.jaci.2003.12.058; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Isogai S, 2004, J ALLERGY CLIN IMMUN, V114, P1345, DOI 10.1016/j.jaci.2004.09.021; Isogai S, 2004, J ALLERGY CLIN IMMUN, V113, P455, DOI 10.1016/j.jaci.2003.11.035; Jogie-Brahim S, 2004, J ALLERGY CLIN IMMUN, V113, P1086, DOI 10.1016/j.jaci.2004.02.032; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; Mochizuki A, 2003, J ALLERGY CLIN IMMUN, V112, P102, DOI 10.1067/mai.2003.1511; Munthe-Kaas MC, 2004, J ALLERGY CLIN IMMUN, V114, P280, DOI 10.1016/j.jaci.2004.03.050; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Raby BA, 2004, J ALLERGY CLIN IMMUN, V113, P1071, DOI 10.1016/j.jaci.2004.03.035; Radinger M, 2004, J ALLERGY CLIN IMMUN, V113, P1109, DOI 10.1016/j.jaci.2004.03.022; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sedgwick JB, 2004, J ALLERGY CLIN IMMUN, V114, P568, DOI 10.1016/j.jaci.2004.05.023; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Ying S, 2004, J ALLERGY CLIN IMMUN, V114, P1309, DOI 10.1016/j.jaci.2004.08.034; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zuyderduyn S, 2004, J ALLERGY CLIN IMMUN, V114, P791, DOI 10.1016/j.jaci.2004.06.037	37	202	215	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					953	959		10.1016/j.jaci.2005.02.032	http://dx.doi.org/10.1016/j.jaci.2005.02.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867851				2022-12-18	WOS:000229055100009
J	Lin, H; Boesel, KM; Prussin, C; Foster, B; Romero, FA; Townley, R; Casale, TB				Lin, H; Boesel, KM; Prussin, C; Foster, B; Romero, FA; Townley, R; Casale, TB			Omalizumab rapidly decreases nasal allergic response and Fc epsilon RI on basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; anti-IgE treatment; omalizumab; Fc epsilon RI receptor; basophils	ANTI-IGE ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; ASTHMATIC SUBJECTS; PERIPHERAL-BLOOD; RHINITIS; EXPRESSION; CELLS	Background: Omalizumab is a monoclonal anti-IgE antibody that is effective for the treatment of allergic respiratory disorders; however, its onset of action is unknown. Objective: This study was designed to determine the onset of action of omalizumab through the use of a challenge model to determine time-dependent inhibition of ragweed-induced changes in nasal volume as well as correlate the kinetics of omalizumab-induced decreases in serum free IgE and FcepsilonRI receptors on basophils. Methods: We conducted a 6-week, randomized, double-blind, placebo-controlled study of 24 rhinitic patients with ragweed allergy. After PD30 ragweed nasal allergen challenge, patients received either omalizumab, similar to0.016 mg/kg per IgE (IU/mL), or placebo at days 0 and 28 and were rechallenged with ragweed PD30 dose biweekly. FcepsilonRI expression on blood basophils was determined by flow cytometry at baseline and 7, 14, 28, and 42 days after treatment. IgE levels were measured at baseline and on days 3, 28, and 42. Results: Mean IgE levels decreased by 96% (P < .001) from baseline within 3 days in the omalizumab group. Baseline 30% ragweed-induced nasal volume response was decreased to 20.4% at 7 to 14 days (P < .001) and 12.2% at 35 to 42 days (P < .001) for the omalizumab group. There was a median decrease in basophil FcepsilonRI expression of 73% (P < .001) in the omalizumab group, with maximum inhibition occurring within 14 days of treatment. No significant changes in IgE levels, nasal allergen challenge responses, or basophil FcepsilonRI expression were observed throughout the study in the placebo group. Conclusions: Our study showed that the onset of action by omalizumab in blunting ragweed-induced nasal responses is within 2 weeks, and this response was associated with 2 putative mechanisms of action: decreased serum free IgE and decreased FcepsilonRI receptor expression on immune effector cells.	Creighton Univ, Dept Med, Div Allergy immunol, Omaha, NE 68131 USA; NIAID, NIH, Lab Allerg Dis, Bethesda, MD USA	Creighton University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Casale, TB (corresponding author), Creighton Univ, Dept Med, Div Allergy immunol, 601 N 30th St, Omaha, NE 68131 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Prussin, Calman/0000-0002-3917-3326				Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; BOULET LP, 1997, AM J RESP CRIT CARE, V100, P110; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 2001, J ALLERGY CLIN IMMUN, V108, pS84, DOI 10.1067/mai.2001.116433; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Foster B, 2002, J ALLERGY CLIN IMMUN, V109, P287, DOI 10.1067/mai.2002.121454; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Nayak A, 2003, ALLERGY ASTHMA PROC, V24, P323; PRUSSIN C, 2002, CURRENT PROTOCOLS IM; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101	15	202	211	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					297	302		10.1016/j.jaci.2003.11.044	http://dx.doi.org/10.1016/j.jaci.2003.11.044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767445				2022-12-18	WOS:000188885700018
J	Warner, JO				Warner, JO		ETAC Study Grp	A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; asthma; prevention; house dust mite; grass pollen; cetirizine; antihistamine; children	ALLERGIC AIRWAY DISEASE; YOUNG-CHILDREN; CAT ALLERGEN; RISK; RECRUITMENT; CHALLENGE; CHILDHOOD	Background: Because asthma is not a curable condition, the development of strategies for prevention of the disease has a high priority. Atopic dermatitis is a common precursor to the development of asthma, and 2 studies have suggested that the use of an H-1 receptor antagonist might reduce the development of asthma while the treatment is being administered, at least in subgroups with evidence of high IgE levels. However, no trial to date has conducted follow-up after the initial treatment has been stopped to establish whether the intervention has merely suppressed symptoms or truly prevented disease. Objective: We sought to establish whether the use of cetirizine compared with placebo for 18 months in infants with atopic dermatitis suppressed or truly delayed the onset of asthma, even after cessation of therapy. Methods: The Early Treatment of the Atopic Child study was a double-blinded, parallel-group, randomized trial of 0.25 mg/kg body weight cetirizine administered twice daily compared with placebo given to infants between I and 2 years of age with atopic dermatitis. After 18 months of treatment, follow-up continued for a further 18 months. This article reports the outcome over the full 3 years of follow-up and relates the outcomes to the allergic status on the basis of IgE antibody measurements at recruitment. Results: Although there was no difference in cumulative prevalence of asthma between active and placebo treatment in the intention-to-treat population (P = .7), those infants with evidence of sensitivity to house dust mite, grass pollen, or both who were treated with cetirizine were significantly less likely to have asthma compared with those treated with placebo over the 18 months of treatment (P = .005 and .002, respectively), and this effect was sustained for the grass pollen-sensitized infants over the full 36 months (P = .008). In the house dust mite-sensitized group there was a gradual narrowing of the difference between active and placebo treatment in terms of cumulative prevalence of asthma at the end of 36 months but no evidence of a rebound immediately after the treatment stopped (P = .04). In the placebo population there was a significantly higher risk of development of asthma in those sensitized at baseline to egg (relative risk, 1.4 [95% CI, 1.1-1.7]), house dust mite (relative risk, 1.6 [95% CI, 1.3-1.9%]), grass pollen (relative risk, 1.7 [95% CI, 1.4-2.1]), or cat (relative risk, 1.5 [95% CI, 1.2-1.9]). Early and persistent sensitization conferred a higher risk than transient or later sensitization. Conclusions: Cetirizine compared with placebo truly delays or, in some cases, prevents the development of asthma in a subgroup of infants with atopic dermatitis sensitized to grass pollen and, to a lesser extent, house dust mite. Further studies are required focusing specifically on sensitized groups to substantiate this finding. The study also highlights risk factors for asthma in infants with atopic dermatitis and indicates that early and persistent aeroallergen sensitization confers a higher risk than later development of sensitivity.	Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton S016 6YD, Hants, England	University of Southampton	Warner, JO (corresponding author), Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton S016 6YD, Hants, England.		Warner, John/AAF-9587-2020					Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arnold R, 1999, CLIN EXP ALLERGY, V29, P1681, DOI 10.1046/j.1365-2222.1999.00630.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; Eriksson Nils E., 1998, Allergology International, V47, P187, DOI 10.2332/allergolint.47.187; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; IIKURA Y, 1992, ANN ALLERGY, V68, P233; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Marguet C, 2001, PEDIATR ALLERGY IMMU, V12, P27, DOI 10.1034/j.1399-3038.2001.012001027.x; *NAT HEART LUNG BL, 1995, NIH PUBL; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; WARNER JO, 1998, CLIN EXP ALLERGY, V28, P179; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	20	202	218	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					929	937		10.1067/mai.2001.120015	http://dx.doi.org/10.1067/mai.2001.120015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742270				2022-12-18	WOS:000172938400008
J	Arlian, LG; Platts-Mills, TAE				Arlian, LG; Platts-Mills, TAE			The biology of dust mites and the remediation of mite allergens in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite abatement; allergen remediation; mite allergy; dust mite biology	DERMATOPHAGOIDES-PTERONYSSINUS ACARI; SOLIDIFIED BENZYL BENZOATE; HOUSE-DUST; FARINAE ACARI; BRONCHIAL HYPERREACTIVITY; RELATIVE HUMIDITIES; EUROGLYPHUS-MAYNEI; ASTHMATIC-CHILDREN; BEDDING ENCASEMENT; SEASONAL-VARIATION	In most temperate humid areas of the world, house dust mites are a major source of multiple allergens in house dust Mite allergens sensitize and induce perennial rhinitis, asthma, or atopic dermatitis in a large portion of patients with allergic disease. There is convincing evidence that avoidance of mite allergen can effectively reduce allergic symptoms, Patients can be moved to a mite allergen-free environment, or mite and mite allergen abatement can be performed to reduce exposure in existing residences. Some knowledge of the biology of house dust mites is essential to understand the basis of the recommendations for reducing mites and mite allergens in homes and to appreciate the difficulty of eliminating house dust mites and mite allergens from homes. This article reviews key aspects of the biology of dust mites, the properties of mite allergens, recommendations for reducing mite and mite allergen concentrations in homes, and practical recommendations for treatment.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	University System of Ohio; Wright State University Dayton; University of Virginia	Arlian, LG (corresponding author), Wright State Univ, Dept Biol Sci, 235 Biol Sci Bldg, Dayton, OH 45435 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Arlian L. G., 1996, The immunology of host-ectoparasitic arthropod relationships., P232; Arlian LG, 1999, ANN ALLERG ASTHMA IM, V83, P529, DOI 10.1016/S1081-1206(10)62864-5; Arlian LG, 2000, ANN ALLERG ASTHMA IM, V85, P161, DOI 10.1016/S1081-1206(10)62461-1; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852, DOI 10.1016/S0091-6749(99)70298-8; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1982, PHYSIOL ZOOL, V55, P344, DOI 10.1086/physzool.55.4.30155862; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Arlian LG, 1998, J MED ENTOMOL, V35, P46, DOI 10.1093/jmedent/35.1.46; ARLIAN LG, 1981, J MED ENTOMOL, V18, P351, DOI 10.1093/jmedent/18.4.351; ARLIAN LG, 1990, J MED ENTOMOL, V27, P1035, DOI 10.1093/jmedent/27.6.1035; ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437, DOI 10.1093/jmedent/12.4.437; ARLIAN LG, 1974, J INSECT PHYSIOL, V20, P1063, DOI 10.1016/0022-1910(74)90148-6; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; Arlian LG, 1999, J MED ENTOMOL, V36, P457, DOI 10.1093/jmedent/36.4.457; Arlian LG, 1998, J MED ENTOMOL, V35, P962, DOI 10.1093/jmedent/35.6.962; Arlian LG, 1996, J MED ENTOMOL, V33, P257, DOI 10.1093/jmedent/33.2.257; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, J ALLERGY CLIN IMMUN, V107, P699; Bischoff ERC, 1996, CLIN EXP ALLERGY, V26, P945, DOI 10.1111/j.1365-2222.1996.tb00631.x; Bischoff ERC, 1998, CLIN EXP ALLERGY, V28, P60, DOI 10.1046/j.1365-2222.1998.00192.x; BONER AL, 1985, ANN ALLERGY, V54, P42; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; Chang JCS, 1998, INDOOR AIR, V8, P34, DOI 10.1111/j.1600-0668.1998.t01-3-00005.x; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; Custovic A, 1998, J ALLERGY CLIN IMMUN, V101, pS81; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; DOBSON RM, 1980, ACAROLOGIA, V21, P482; DODIN A, 1993, J MED ENTOMOL, V30, P810, DOI 10.1093/jmedent/30.4.810; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; ELLINGSON AR, 1995, J ALLERGY CLIN IMMUN, V96, P473, DOI 10.1016/S0091-6749(95)70289-X; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Hallam C, 1999, ALLERGY, V54, P407, DOI 10.1034/j.1398-9995.1999.00066.x; Hart BJ, 1998, ALLERGY, V53, P13, DOI 10.1111/j.1398-9995.1998.tb04990.x; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HUSS R, 1992, J ALLERGY CLIN IMMUN, V94, P27; Juhas KM, 1998, J ALLERGY CLIN IMMUN, V101, pS28; KALRA S, 1993, THORAX, V48, P10, DOI 10.1136/thx.48.1.10; Kemp TJ, 1996, BMJ-BRIT MED J, V313, P916, DOI 10.1136/bmj.313.7062.916; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285, DOI 10.1016/S0091-6749(99)70026-6; KOEKKOEK HH, 1972, ENTOMOL EXP APPL, V15, P438, DOI 10.1007/BF00293608; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LARSON DG, 1969, THESIS OHIO STATE U; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1080/15428119891010776; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; MANJRA A, 1994, S AFR MED J, V84, P278; Matsumoto K., 1986, Japanese Journal of Sanitary Zoology, V37, P79; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; Miller JD, 1996, J ALLERGY CLIN IMMUN, V97, P962; Morgan MS, 1997, J ALLERGY CLIN IMMUN, V100, P222, DOI 10.1016/S0091-6749(97)70228-8; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; NORTON RA, 1992, EVOLUTION DIVERSITY, P8; O'Connor BM, 1982, SYNOPSIS CLASSIFICAT, P46; OCONNOR BM, 1982, ANNU REV ENTOMOL, V27, P385, DOI 10.1146/annurev.en.27.010182.002125; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Rains N, 1999, CLIN EXP ALLERGY, V29, P182, DOI 10.1046/j.1365-2222.1999.00470.x; Sakaki I., 1991, Japanese Journal of Sanitary Zoology, V42, P93; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Siebers RW, 1996, J ALLERGY CLIN IMMUN, V98, P853, DOI 10.1016/S0091-6749(96)70141-0; SPIEKSMA FTM, 1967, THESIS LEIDEN STATE; STEWART GA, 1995, CLIN REV ALLERG IMMU, V13, P135; Suto C., 1990, Japanese Journal of Sanitary Zoology, V41, P375; THOMAS B, 1991, INT ARCH ALLER A IMM, V94, P365, DOI 10.1159/000235405; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; TOVEY E, 1993, MED J AUSTRALIA, V158, P579, DOI 10.5694/j.1326-5377.1993.tb121900.x; TOVEY ER, 1990, J MED ENTOMOL, V27, P368, DOI 10.1093/jmedent/27.3.368; Tovey ER, 1997, J ALLERGY CLIN IMMUN, V100, P464, DOI 10.1016/S0091-6749(97)70136-2; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Tsay A, 2000, J ALLERGY CLIN IMMUN, V105, pS271, DOI 10.1016/S0091-6749(00)91229-6; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANDENHOVE T, 1993, ALLERGY, V48, P264, DOI 10.1111/j.1398-9995.1993.tb00726.x; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VYSZENSKIMOHER DL, 2000, ANN ALLERG ASTHMA IM, V84, P136; WALZL MG, 1992, EXP APPL ACAROL, V16, P85, DOI 10.1007/BF01201494; WHARTON G W, 1977, Acarologia (Paris), V19, P112; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; [No title captured]	96	202	226	2	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S406	S413		10.1067/mai.2001.113670	http://dx.doi.org/10.1067/mai.2001.113670			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	418KR	11242601	Bronze			2022-12-18	WOS:000167891800002
J	Svanes, C; Jarvis, D; Chinn, S; Burney, P				Svanes, C; Jarvis, D; Chinn, S; Burney, P		European Community Resp Hlth Survey	Childhood environment and adult atopy: Results from the European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; childhood; family size; European Community Respiratory Health Survey	HAY-FEVER; ALLERGIC SENSITIZATION; FETAL GROWTH; INFECTION; SIZE; ASSOCIATION; SIBLINGS; MEASLES; NUMBER; RISK	Background: Previous literature has indicated that environmental exposures in childhood influence development of atopic sensitization. Objective: We sought to study the association between childhood environment and adult atopy. Methods: Thirteen thousand nine hundred thirty-two subjects aged 20 to 44 years from 36 areas in Europe, New Zealand, the United States, and Australia took part in the European Community Respiratory Health Survey, answering interviewer-led questionnaires and providing blood tests for measurement of specific IgE to grass, house dust mite, cat, and Cladosporium allergens. Results: Atopy was negatively associated with family size (OR = 0.93; 95% Ct = 0.90-0.96 per 1 sib), partly attributable to an independent protective effect of a greater number of brothers (OR = 0.92; 95% Ct = 0.89-0.95 per 1 brother). Accounting for total number of siblings, no further influence was detected for number of older or younger siblings. Bedroom sharing was associated with a lower prevalence of atopy, particularly to cat allergen, A protective effect of family size and bedroom sharing could only be detected in subjects reporting no parental allergy (family size, test for interaction P =.012), The presence of a dog in the home in childhood was negatively associated with adult atopy (OR = 0.85, 95% Ct = 0.78-0.92), an effect that remained after adjustment for parental allergy, sibling allergy, and adult pet ownership. Conclusion: Subjects from large families with brothers, shared bedrooms, and dogs in childhood were less often atopic as adults, Our findings are consistent with the hypothesis that infectious agents could inhibit development of atopy during childhood. However, in subjects with a strong genetic predisposition, environmental factors in childhood are possibly of Less importance.	Univ Bergen, Dept Thorac Med, Bergen, Norway; UMDS, St Thomas Hosp, Dept Publ Hlth Med, London, England	University of Bergen; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Svanes, C (corresponding author), Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway.		Jarvis, Deborah/E-6494-2011; Svanes, Cecilie/N-7556-2017	Svanes, Cecilie/0000-0001-8512-5192; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678	NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; *EUR COMM RESP HLT, 1994, OFF OFF PUBL; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; HALL CB, 1981, TXB PEDIATRIC INFECT, P1247; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; MOSMAN TR, 1992, IMMUNOL TODAY, V13, P379; Office of Population Censuses and Surveys, 1980, CLASS OCC; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; PISON G, 1992, BRIT MED J, V304, P284, DOI 10.1136/bmj.304.6822.284; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1111/j.1365-2222.1997.tb00739.x; Shaheen S, 1997, BRIT MED J, V314, P987, DOI 10.1136/bmj.314.7086.987; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALD ER, 1988, J PEDIATR-US, V112, P540, DOI 10.1016/S0022-3476(88)80164-1; WJST M, 1994, ANN ALLERGY, V73, P450	25	202	203	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				415	420		10.1016/S0091-6749(99)70465-3	http://dx.doi.org/10.1016/S0091-6749(99)70465-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069874				2022-12-18	WOS:000079175700009
J	Bunikowski, R; Mielke, M; Skarabis, H; Herz, U; Bergmann, RL; Wahn, U; Renz, H				Bunikowski, R; Mielke, M; Skarabis, H; Herz, U; Bergmann, RL; Wahn, U; Renz, H			Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; S aureus colonization density; superficial S aureus skin infection; staphylococcal enterotoxins; total serum IgE; specific IgE SEA/SEB; severity of AD risk factors for sensitization to SEB/SEA	BLOOD MONONUCLEAR-CELLS; SHOCK SYNDROME TOXIN-1; HOUSE DUST MITE; T-CELLS; INTERFERON-GAMMA; ENTEROTOXIN-B; HYPERIMMUNOGLOBULIN-E; SKIN; ECZEMA; INFECTIONS	Background: The skin of patients with atopic dermatitis exhibits a striking susceptibility to colonization and infection with Staphylococcus aureus. In this contest it has been previously shown that S aureus-derived superantigens could function as classic allergens, inducing production of functionally relevant specific IgE antibodies. Objective: The aim of this study was to determine the prevalence and the role of circulating staphylococcal enterotoxin A (SEA)- and staphylococcal enterotoxin B (SEB)-specific IgE antibodies in children with atopic dermatitis. Methods: In a cross-sectional study of 58 children with atopic dermatitis, the presence of IgE antibodies to SEA and SEE was correlated with the severity of the disease and the total and other unrelated allergen-specific IgE titers and density of colonization with S aureus strains on atopic skin and episodes of superficial S aureus skin infections. Results: Twenty of 58 children (34%) were sensitized to superantigens (45% to SEB, 10% to SEA, 45% to SEA and SEE). In this group, severity of atopic dermatitis and levels of specific IgE to food and air allergens were significantly higher. The degree of disease severity correlated to a higher extent with the presence of SEA/SEB-specific antibodies than with total serum IgE levels. Density of colonization with superantigen-secreting S aureus strains was higher in the superantigen IgE-positive group, Sixty-three percent of these children experienced repeated episodes of superficial S aureus skin infections. Conclusions: Sensitization to S aureus-derived superantigens may be involved in disease exacerbation. The presence of SEA/SEB-specific antibodies had additional explanatory value for disease severity and therefore may be helpful in the characterization of children with severe atopic dermatitis.	Humboldt Univ, Charite Campus Virchow Klimikum, Dept Pediat, Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Infect Dis Med, D-12200 Berlin, Germany; Free Univ Berlin, Inst Sociol, Dept Stat, D-1000 Berlin, Germany; Humboldt Univ, Charite Campus Virchow Klinikum, Inst Lab Med & Pathobiochem, Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bunikowski, R (corresponding author), Humboldt Univ, Charite Campus Virchow Klinikum, Dept Pediat Pulmonol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.							Akiyama H, 1996, ARCH DERMATOL RES, V288, P418, DOI 10.1007/BF02507115; ALY R, 1977, ARCH DERMATOL, V113, P780, DOI 10.1001/archderm.113.6.780; BERGER M, 1980, J IMMUNOL, V125, P2437; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BIEBER T, 1989, CLIN EXP DERMATOL, V14, P35, DOI 10.1111/j.1365-2230.1989.tb00880.x; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; CASKEY L, 1992, CLIN MICROBIOLOGY PR, V1; DAVID TJ, 1986, ARCH DIS CHILD, V61, P20, DOI 10.1136/adc.61.1.20; DomiatiSaad R, 1996, J IMMUNOL, V156, P3608; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOEGER PH, 1992, J INFECT DIS, V165, P1064, DOI 10.1093/infdis/165.6.1064; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KONIG B, 1995, INT ARCH ALLERGY IMM, V106, P124, DOI 10.1159/000236832; KRISTIANSEN SV, 1994, J IMMUNOL, V153, P2974; LESTER MR, 1995, CLIN IMMUNOL IMMUNOP, V77, P332, DOI 10.1006/clin.1995.1160; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCSHARRY C, 1993, J CLIN IMMUNOASSAY, V16, P153; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; MOLLICK JA, 1993, J EXP MED, V177, P283, DOI 10.1084/jem.177.2.283; MOTALA C, 1986, J ALLERGY CLIN IMMUN, V78, P583, DOI 10.1016/0091-6749(86)90075-8; NEUBER K, 1995, INT ARCH ALLERGY IMM, V107, P179, DOI 10.1159/000236970; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRANGE P, 1994, J INVEST DERMATOL, V102, P150, DOI 10.1111/1523-1747.ep12371753; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Tada J, 1996, EUR J DERMATOL, V6, P552; TOKURA Y, 1994, J INVEST DERMATOL, V102, P131; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164	42	202	214	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				119	124		10.1016/S0091-6749(99)70535-X	http://dx.doi.org/10.1016/S0091-6749(99)70535-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893195	Bronze			2022-12-18	WOS:000078112300019
J	Tong, LJ; Balakrishnan, G; Kochan, JP; Kinet, JP; Kaplan, AP				Tong, LJ; Balakrishnan, G; Kochan, JP; Kinet, JP; Kaplan, AP			Assessment of autoimmunity in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria; histamine release; IgE receptor; autoimmunity	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; THYROID AUTOIMMUNITY; IGE RECEPTOR; MAST-CELLS; ANTI-IGE; AUTOANTIBODIES; ANGIOEDEMA; RELEASE	Background: The etiology of chronic urticaria is unknown, and an exogenous allergen cannot be identified as the cause in the vast majority of subjects. Thus the concept has evolved that it might be autoimmune. Objective: We have prospectively assessed sera obtained from 50 consecutive patients with chronic urticaria for the presence of autoantibodies that could be pathogenic. Methods: We tested sera for their ability to release histamine from human basophils and to activate rat basophil leukemia cells that were transfected with the alpha subunit of the IgE receptor. We also tested selected sera for anti-IgE antibodies and for IgG anti-Fc epsilon RI alpha by Western blot. Results: Sera from 38 of 50 patients with chronic urticaria released beta-hexosaminidase from transfected rat basophil leukemia cells, whereas only one of 20 control sera did so (p < 0.001); in 30 subjects this could be attributed to IgG anti-Fc epsilon RI alpha. When human basophils were used, sera from 20 of 50 patients with chronic urticaria released a significant quantity of histamine compared with one of 20 control subjects (p < 0.01). Six patients with chronic urticaria and one control subject had IgG anti-IgE. In selected sera we could demonstrate IgG anti-Fc epsilon RI alpha by Western blot; however, some sera are positive for histamine release but do not demonstrate such binding. Conclusion: A large fraction of patients with chronic urticaria have antibody directed to Fc epsilon RI alpha that is functional (60%). A smaller number have IgG anti-IgE (10%). A third group may also have circulating factors capable of activating basophils or mast cells of which the identity is unknown. Thus chronic urticaria may be autoimmune in origin.	SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV RHEUMATOL ALLERGY & CLIN IMMUNOL,STONY BROOK,NY 11794; WYOMING CHEST & ALLERGY PC,CASPER,WY; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT MOL GENET,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DEPT PATHOL,LAB ALLERGY & IMMUNOL,BOSTON,MA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Roche Holding; Harvard University; Harvard Medical School								ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KAPLAN AP, 1995, SAMTERS IMMUNOLOGIC, V2, P1329; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445	12	202	215	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					461	465		10.1016/S0091-6749(97)70071-X	http://dx.doi.org/10.1016/S0091-6749(97)70071-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111489				2022-12-18	WOS:A1997WU27400007
J	Shaker, MS; Wallace, DV; Golden, DBK; Oppenheimer, J; Bernstein, JA; Campbell, RL; Dinakar, C; Ellis, A; Greenhawt, M; Khan, DA; Lang, DM; Lang, ES; Lieberman, JA; Portnoy, J; Rank, MA; Stukus, DR; Wang, J; Riblet, N; Bobrownicki, AMP; Bontrager, T; Dusin, J; Foley, J; Frederick, B; Fregene, E; Hellerstedt, S; Hassan, F; Hess, K; Huntington, K; Kasireddy, P; Keeler, D; Kim, B; Lieberman, P; Lindhorst, E; McEnany, F; Milbank, J; Murphy, H; Pando, O; Patel, AK; Ratliff, N; Rhodes, R; Robertson, K; Scott, H; Snell, A; Sullivan, R; Trivedi, V; Wickham, A				Shaker, Marcus S.; Wallace, Dana V.; Golden, David B. K.; Oppenheimer, John; Bernstein, Jonathan A.; Campbell, Ronna L.; Dinakar, Chitra; Ellis, Anne; Greenhawt, Matthew; Khan, David A.; Lang, David M.; Lang, Eddy S.; Lieberman, Jay A.; Portnoy, Jay; Rank, Matthew A.; Stukus, David R.; Wang, Julie; Riblet, Natalie; Bobrownicki, Aiyana M. P.; Bontrager, Teresa; Dusin, Jarrod; Foley, Jennifer; Frederick, Becky; Fregene, Eyitemi; Hellerstedt, Sage; Hassan, Ferdaus; Hess, Kori; Huntington, Kelly; Kasireddy, Poojita; Keeler, David; Kim, Bertha; Lieberman, Phil; Lindhorst, Erin; McEnany, Fiona; Milbank, Jennifer; Murphy, Helen; Pando, Oriana; Patel, Ami K.; Ratliff, Nicole; Rhodes, Robert; Robertson, Kim; Scott, Hope; Snell, Audrey; Sullivan, Rhonda; Trivedi, Varahi; Wickham, Azadeh			Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; GRADE; epinephrine; risk factors; biphasic; severity; glucocorticoids; antihistamines; pretreatment-radiocontrast media; chemotherapy; mAb; infliximab; allergen immunotherapy; systematic meta-analysis; evidence to recommendations; guideline; practice parameter	PLATELET-ACTIVATING-FACTOR; EMERGENCY-DEPARTMENT PATIENTS; INDUCED HYPERSENSITIVITY REACTIONS; SELF-INJECTABLE EPINEPHRINE; INFLAMMATORY-BOWEL-DISEASE; TOXIC EPIDERMAL NECROLYSIS; INFUSION-RELATED REACTIONS; ACUTE ALLERGIC REACTIONS; QUALITY-OF-LIFE; BIPHASIC REACTIONS	Anaphylaxis is an acute, potential life-threatening systemic allergic reaction that may have a wide range of clinical manifestations. Severe anaphylaxis and/or the need for repeated doses of epinephrine to treat anaphylaxis are risk factors for biphasic anaphylaxis. Antihistamines and/or glucocorticoids are not reliable interventions to prevent biphasic anaphylaxis, although evidence supports a role for antihistamine and/or glucocorticoid premedication in specific chemotherapy protocols and rush aeroallergen immunotherapy. Evidence is lacking to support the role of antihistamines and/or glucocorticoid routine premedication in patients receiving low- or iso-osmolar contrast material to prevent recurrent radiocontrast media anaphylaxis. Epinephrine is the first-line pharmacotherapy for uniphasic and/or biphasic anaphylaxis. After diagnosis and treatment of anaphylaxis, all patients should be kept under observation until symptoms have fully resolved. All patients with anaphylaxis should receive education on anaphylaxis and risk of recurrence, trigger avoidance, self-injectable epinephrine education, referral to an allergist, and be educated about thresholds for further care.	[Shaker, Marcus S.] Geisel Sch Med Dartmouth, Dartmouth Hitchcock Med Ctr, Sect Allergy & Clin Immunol, Lebanon, NH USA; [Wallace, Dana V.] Nova Southeastern Allopath Med Sch, Ft Lauderdale, FL USA; [Golden, David B. K.] Johns Hopkins Univ, Div Allergy Clin Immunol, Baltimore, MD USA; [Oppenheimer, John] Univ Med & Dent New Jersey, Rutgers New Jersey Med Sch, Dept Internal Med Pulm & Allergy, Morristown, NJ USA; [Oppenheimer, John] Pulm & Allergy Associates, Morristown, NJ USA; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH 45221 USA; [Campbell, Ronna L.] Mayo Clin, Dept Emergency Med, Rochester, MN USA; [Dinakar, Chitra] Stanford Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Allergy Asthma & Immunodeficiency, Stanford, CA 94305 USA; [Ellis, Anne] Queens Univ, Dept Med, Div Allergy & Immunol, Kingston, ON, Canada; [Greenhawt, Matthew] Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Allergy & Immunol, Denver, CO USA; [Khan, David A.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, Dallas, TX USA; [Lang, David M.] Cleveland Clin, Dept Allergy & Clin Immunol, Resp Inst, Cleveland, OH 44106 USA; [Lang, Eddy S.] Univ Calgary, Cumming Sch Med, Dept Emergency Med, Calgary, AB, Canada; [Lieberman, Jay A.; Lieberman, Phil] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA; [Portnoy, Jay] Childrens Mercy Hosp, Kansas City Sch Med, Pediat Allergy & Immunol, Kansas City, MO 64108 USA; [Rank, Matthew A.] Mayo Clin, Div Allergy Asthma & Clin Immunol, Scottsdale, AZ USA; [Stukus, David R.] Nationwide Childrens Hosp, Div Allergy & Immunol, Columbus, OH USA; [Stukus, David R.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Wang, Julie] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA; [Riblet, Natalie; Bobrownicki, Aiyana M. P.; Fregene, Eyitemi; Hellerstedt, Sage; Kasireddy, Poojita; Kim, Bertha; McEnany, Fiona; Milbank, Jennifer; Pando, Oriana; Patel, Ami K.; Trivedi, Varahi] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Bontrager, Teresa; Dusin, Jarrod; Foley, Jennifer; Frederick, Becky; Hassan, Ferdaus; Hess, Kori; Huntington, Kelly; Keeler, David; Lindhorst, Erin; Murphy, Helen; Ratliff, Nicole; Rhodes, Robert; Robertson, Kim; Scott, Hope; Snell, Audrey; Sullivan, Rhonda; Wickham, Azadeh] Childrens Mercy Hosp, Off Evidence Based Practice, Kansas City, MO USA; Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA	Dartmouth College; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; University of Cincinnati; Mayo Clinic; Stanford University; Queens University - Canada; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; University of Calgary; University of Tennessee System; University of Tennessee Health Science Center; Children's Mercy Hospital; Mayo Clinic; Mayo Clinic Phoenix; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Icahn School of Medicine at Mount Sinai; Dartmouth College; Children's Mercy Hospital; Washington University (WUSTL)	Shaker, MS (corresponding author), Dartmouth Hitchcock Med Ctr, Sect Allergy & Clin Immunol, One Med Ctr Dr, Lebanon, NH 03756 USA.	Marcus.shaker@dartmouth.edu	Lang, Eddy/AAS-2080-2020	Murphy, Helen/0000-0002-5489-0614; Milbank, Jennifer/0000-0001-5091-8053; Bernstein, Jonathan/0000-0002-3476-1196				Abe S, 2016, EUR RADIOL, V26, P2148, DOI 10.1007/s00330-015-4028-1; ACR Committee on Drugs and Contrast Media, 2020, ACR MAN CONTR MED VE; Al-Ahmad M, 2017, ANN SAUDI MED, V37, P333, DOI 10.5144/0256-4947.2017.333; Allen KJ, 2012, IMMUNOL ALLERGY CLIN, V32, P35, DOI 10.1016/j.iac.2011.11.008; Alqurashi W, 2017, J ALLER CL IMM-PRACT, V5, P1194, DOI 10.1016/j.jaip.2017.05.022; Alqurashi W, 2015, ANN ALLERG ASTHMA IM, V115, P217, DOI 10.1016/j.anai.2015.05.013; Alvarez-Perea A, 2015, J INVEST ALLERG CLIN, V25, P288; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; Arroabarren E, 2011, PEDIAT ALLERG IMM-UK, V22, P708, DOI 10.1111/j.1399-3038.2011.01181.x; Augustsson J, 2007, ANN RHEUM DIS, V66, P1462, DOI 10.1136/ard.2007.070771; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012; BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; Blumenthal KG, 2018, J ALLER CL IMM-PRACT, V6, P1019, DOI 10.1016/j.jaip.2017.08.006; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Bower EA, 2003, AVIAT SPACE ENVIR MD, V74, P145; Braaten K, 2015, AM J HEMATOL, V90, pE207, DOI 10.1002/ajh.24132; Brady WJ, 1997, ACAD EMERG MED, V4, P193, DOI 10.1111/j.1553-2712.1997.tb03739.x; Brauer CEL, 2016, J ALLER CL IMM-PRACT, V4, P1220, DOI 10.1016/j.jaip.2016.06.003; Brazil E, 1998, J ACCID EMERG MED, V15, P252; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Brockow K, 2009, IMMUNOL ALLERGY CLIN, V29, P453, DOI 10.1016/j.iac.2009.04.001; Brown BB, 1968, DELPHI PROCESS METHO; Brown JC, 2016, ANN EMERG MED, V67, P307, DOI 10.1016/j.annemergmed.2015.07.011; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Buka RJ, 2017, J ALLER CL IMM-PRACT, V5, P1280, DOI 10.1016/j.jaip.2017.06.021; Calvani M, 2011, PEDIAT ALLERG IMM-UK, V22, P813, DOI 10.1111/j.1399-3038.2011.01200.x; Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P76, DOI 10.1016/j.jaip.2014.06.007; Campbell RL, 2014, ANN ALLERG ASTHMA IM, V113, P599, DOI 10.1016/j.anai.2014.10.007; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Caron EJ, 2009, TOXICON, V54, P779, DOI 10.1016/j.toxicon.2009.06.001; Carrard A, 2015, ALLERGY, V70, P1511, DOI 10.1111/all.12780; Castells M., 2011, EPIDEMIOLOGICAL APPR; Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012; Celikel S, 2006, Allergol Immunopathol (Madr), V34, P180, DOI 10.1157/13094024; Chang A, 2016, LEUKEMIA LYMPHOMA, V57, P1665, DOI 10.3109/10428194.2015.1105369; Choo Karen Jui Lin, 2013, Evid Based Child Health, V8, P1276, DOI 10.1002/ebch.1925; Church Martin K, 2013, Indian J Dermatol, V58, P219, DOI 10.4103/0019-5154.110832; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Clark S, 2014, J ALLERGY CLIN IMMUN, V134, P1125, DOI 10.1016/j.jaci.2014.05.018; Clark S, 2013, ALLERGY ASTHMA PROC, V34, P439, DOI 10.2500/aap.2013.34.3679; Confino-Cohen R, 2010, ANN ALLERG ASTHMA IM, V104, P73, DOI 10.1016/j.anai.2009.11.001; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Curtis C, 2014, ANN ALLERG ASTHMA IM, V112, P560, DOI 10.1016/j.anai.2014.04.009; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Davenport MS, 2017, RADIOL CLIN N AM, V55, P413, DOI 10.1016/j.rcl.2016.10.012; Davenport MS, 2016, RADIOLOGY, V279, P492, DOI 10.1148/radiol.2015151143; de Groot H, 2006, CURR OPIN ALLERGY CL, V6, P294, DOI 10.1097/01.all.0000235905.87676.09; De Schryver S, 2016, J ALLERGY CLIN IMMUN, V137, P1138, DOI 10.1016/j.jaci.2015.09.001; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Derakhshandeh K, 2009, RES PHARM SCI, V4, P113; DOUGLAS DM, 1994, J ALLERGY CLIN IMMUN, V93, P977, DOI 10.1016/S0091-6749(94)70044-3; Dreborg S, 2018, ANN ALLERG ASTHMA IM, V120, P648, DOI 10.1016/j.anai.2018.02.028; Dua S, 2018, J ALLER CL IMM-PRACT, V6, P1692, DOI 10.1016/j.jaip.2018.01.006; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Elberink JNGO, 2006, J ALLERGY CLIN IMMUN, V118, P699, DOI 10.1016/j.jaci.2006.03.049; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Evidence-Based Medicine Toolbox, ODDS RAT NNT CONV; Fan HW, 1999, BRIT MED J, V318, P1451, DOI 10.1136/bmj.318.7196.1451; Faria E, 2014, J INVEST ALLERG CLIN, V24, P40; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Francis A, 2017, CLIN EXP ALLERGY, V47, P361, DOI 10.1111/cea.12868; Francis A, 2018, EMERG MED AUSTRALAS, V30, P366, DOI 10.1111/1742-6723.12875; FRANCIS PA, 1994, J CLIN ONCOL, V12, P1232, DOI 10.1200/JCO.1994.12.6.1232; Fukuoka Y, 2008, J IMMUNOL, V180, P6307, DOI 10.4049/jimmunol.180.9.6307; Fumery M, 2019, DIGEST LIVER DIS, V51, P484, DOI 10.1016/j.dld.2018.12.002; Gabrielli S, 2019, J ALLER CL IMM-PRACT, V7, P2232, DOI 10.1016/j.jaip.2019.04.018; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Garvey LH, 2011, ANESTHESIOLOGY, V115, P111, DOI 10.1097/ALN.0b013e318218119d; Gelincik A, 2013, ANN ALLERG ASTHMA IM, V110, P96, DOI 10.1016/j.anai.2012.11.018; Gold SL, 2017, INFLAMM BOWEL DIS, V23, P1882, DOI 10.1097/MIB.0000000000001189; Golden DBK, 2017, ANN ALLERG ASTHMA IM, V118, P28, DOI 10.1016/j.anai.2016.10.031; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Gonzalez-Estrada A, 2017, ANN ALLERG ASTHMA IM, V118, P80, DOI 10.1016/j.anai.2016.10.025; GOODFELLOW T, 1986, BRIT J RADIOL, V59, P620, DOI 10.1259/0007-1285-59-702-620; Grabenhenrich LB, 2018, J ALLER CL IMM-PRACT, V6, P1898, DOI 10.1016/j.jaip.2018.02.026; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Graft DF, 2006, MED CLIN N AM, V90, P211, DOI 10.1016/j.mcna.2005.08.006; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; Grunau BE, 2015, ANN EMERG MED, V66, P381, DOI 10.1016/j.annemergmed.2015.03.003; Grunau BE, 2014, ANN EMERG MED, V63, P736, DOI 10.1016/j.annemergmed.2013.10.017; Guiot A, 2017, CLIN PEDIATR, V56, P1064, DOI 10.1177/0009922817701176; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Harduar-Morano L, 2011, J ALLERGY CLIN IMMUN, V128, P594, DOI 10.1016/j.jaci.2011.04.049; Harper NJN, 2018, BRIT J ANAESTH, V121, P172, DOI 10.1016/j.bja.2018.04.015; Hasdenteufel F, 2011, J ALLERGY CLIN IMMUN, V128, P1356, DOI 10.1016/j.jaci.2011.05.034; Hebert AA, 2004, J AM ACAD DERMATOL, V50, P286, DOI 10.1016/j.jaad.2003.07.017; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Hess EP, 2012, CARDIOL CLIN, V30, P501, DOI 10.1016/j.ccl.2012.07.013; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; INAGAKI N, 1988, JPN J PHARMACOL, V46, P189, DOI 10.1254/jjp.46.189; Inoue N, 2013, ASIA PAC ALLERGY, V3, P106, DOI 10.5415/apallergy.2013.3.2.106; Jackson KD, 1997, NCHS DATA BRIEF, V2013, P1; Jacobs TS, 2012, PEDIAT ALLERG IMM-UK, V23, P582, DOI 10.1111/j.1399-3038.2012.01315.x; Jacobstein DA, 2005, INFLAMM BOWEL DIS, V11, P442, DOI 10.1097/01.MIB.0000158166.88238.ea; Jagdis A, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-36; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Jerzak KJ, 2018, J ONCOL PHARM PRACT, V24, P83, DOI 10.1177/1078155216679028; Jirapongsananuruk O, 2007, ANN ALLERG ASTHMA IM, V98, P157, DOI 10.1016/S1081-1206(10)60689-8; Jung JW, 2014, ONCOLOGY-BASEL, V86, P127, DOI 10.1159/000357711; KALINER M, 1974, J IMMUNOL, V112, P664; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; Kawano T, 2017, ACAD EMERG MED, V24, P733, DOI 10.1111/acem.13147; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Kim TH, 2019, INT ARCH ALLERGY IMM, V179, P31, DOI 10.1159/000496092; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Ko BS, 2015, ANN ALLERG ASTHMA IM, V115, P312, DOI 10.1016/j.anai.2015.07.015; Kolbe AB, 2014, ABDOM IMAGING, V39, P432, DOI 10.1007/s00261-013-0058-9; Krause K, 2013, ALLERGY, V68, P256, DOI 10.1111/all.12083; Laffitte E, 2004, BRIT J DERMATOL, V150, P376, DOI 10.1111/j.1365-2133.2003.05763.x; LAI CKW, 1991, CLIN EXP ALLERGY, V21, P489, DOI 10.1111/j.1365-2222.1991.tb01690.x; Laroche D, 2014, ANESTHESIOLOGY, V121, P272, DOI 10.1097/ALN.0000000000000276; LASSER EC, 1994, AM J ROENTGENOL, V162, P523, DOI 10.2214/ajr.162.3.8109489; Lauritano EC, 2013, EUR REV MED PHARMACO, V17, P39; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Lee J, 2013, ALLERGY ASTHMA PROC, V34, P220, DOI 10.2500/aap.2013.34.3669; Lee S, 2017, ACAD EMERG MED, V24, pS24; Lee S, 2017, J ALLER CL IMM-PRACT, V5, P1295, DOI 10.1016/j.jaip.2017.07.020; Lee S, 2017, J ALLERGY CLIN IMMUN, V139, P182, DOI 10.1016/j.jaci.2016.04.029; Lee S, 2015, J ALLER CL IMM-PRACT, V3, P408, DOI 10.1016/j.jaip.2014.12.010; Lee SG, 2014, J ALLER CL IMM-PRACT, V2, P281, DOI 10.1016/j.jaip.2014.01.012; Lee SH, 2016, ASIA PAC ALLERGY, V6, P164, DOI 10.5415/apallergy.2016.6.3.164; Lertnawapan Ratchaya, 2011, Allergology International, V60, P283, DOI 10.2332/allergolint.10-OA-0256; Li X, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160729; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; Liew WK, 2013, ASIA PAC ALLERGY, V3, P29, DOI 10.5415/apallergy.2013.3.1.29; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Linstone HA, 1975, DELPHI METHOD TECHNI; Lippert WC, 2008, PEDIATRICS, V122, pE556, DOI 10.1542/peds.2008-0374; Liyanage CK, 2017, EUR ANN ALLERGY CLIN, V49, P196, DOI 10.23822/EurAnnACI.1764-1489.15; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Mach CM, 2016, PHARMACOTHERAPY, V36, P482, DOI 10.1002/phar.1739; Macy Eric M, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-072; Manivannan V, 2014, J ALLER CL IMM-PRACT, V2, P294, DOI 10.1016/j.jaip.2013.11.009; Mansfield L, 2003, ANN ALLERG ASTHMA IM, V90, P554, DOI 10.1016/S1081-1206(10)61850-9; Manuyakorn W, 2018, ASIAN PAC J ALLERGY, V36, P113, DOI 10.12932/AP-020317-0039; Manuyakorn W, 2017, ANN ALLERG ASTHMA IM, V118, P740, DOI 10.1016/j.anai.2017.04.005; Manuyakorn W, 2015, ASIAN PAC J ALLERGY, V33, P281, DOI 10.12932/AP0610.33.4.2015; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Mehr S, 2009, CLIN EXP ALLERGY, V39, P1390, DOI 10.1111/j.1365-2222.2009.03276.x; Mervak BM, 2015, AM J ROENTGENOL, V205, P77, DOI 10.2214/AJR.14.13810; Michelson KA, 2015, J PEDIATR-US, V167, P719, DOI 10.1016/j.jpeds.2015.05.033; Miranda-Romero A, 1999, DERMATOLOGY, V198, P295, DOI 10.1159/000018134; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Mostmans Y, 2017, ALLERGY, V72, P492, DOI 10.1111/all.13060; Motosue MS, 2018, PEDIAT ALLERG IMM-UK, V29, P538, DOI 10.1111/pai.12908; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Noone S, 2015, J ALLER CL IMM-PRACT, V3, P424, DOI 10.1016/j.jaip.2014.10.008; Nurmatov UB, 2014, ANN ALLERG ASTHMA IM, V112, P126, DOI 10.1016/j.anai.2013.11.010; O'Keefe A, 2017, J PEDIATR-US, V180, P217, DOI 10.1016/j.jpeds.2016.09.028; Onetto N, 1993, J Natl Cancer Inst Monogr, P131; Orhan F, 2011, CLIN EXP ALLERGY, V41, P1767, DOI 10.1111/j.1365-2222.2011.03859.x; Oude Elberink JNG, 2009, CLIN EXP ALLERGY, V39, P883, DOI 10.1111/j.1365-2222.2009.03230.x; Oya S, 2014, ACUTE MED SURG, V1, P228, DOI 10.1002/ams2.48; Park HJ, 2017, EUR RADIOL, V27, P2886, DOI 10.1007/s00330-016-4682-y; Park SJ, 2018, RADIOLOGY, V288, P710, DOI 10.1148/radiol.2018172524; Parlaman Joshua P, 2016, Hosp Pediatr, V6, P269, DOI 10.1542/hpeds.2015-0153; Patel DA, 2011, J ALLERGY CLIN IMMUN, V128, P110, DOI 10.1016/j.jaci.2011.03.013; Pfizer, 2002, PRESCRIBING INFORM; Pichichero ME, 2014, ANN ALLERG ASTHMA IM, V112, P404, DOI 10.1016/j.anai.2014.02.005; Poachanukoon O, 2006, ASIAN PAC J ALLERGY, V24, P111; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Pourang D, 2017, ANN ALLERG ASTHMA IM, V118, P186, DOI 10.1016/j.anai.2016.10.027; Pourmand A, 2018, AM J EMERG MED, V36, P1480, DOI 10.1016/j.ajem.2018.05.009; Prince BT, 2018, J ASTHMA ALLERGY, V11, P143, DOI 10.2147/JAA.S159400; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Rawas-Qalaji M, 2015, J PHARM PHARMACOL, V67, P20, DOI 10.1111/jphp.12312; Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; Robinson M, 2017, ANN ALLERG ASTHMA IM, V119, P164, DOI 10.1016/j.anai.2017.06.001; Rohacek M, 2014, ALLERGY, V69, P791, DOI 10.1111/all.12404; Romano A, 2002, RADIOLOGY, V225, P466, DOI 10.1148/radiol.2251011654; Rosado A, 2001, AM J ROENTGENOL, V176, P262, DOI 10.2214/ajr.176.1.1760262; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Rougier P, 1995, ANTI-CANCER DRUG, V6, P25, DOI 10.1097/00001813-199507004-00005; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Rueter K, 2018, J ALLER CL IMM-PRACT, V6, P1545, DOI 10.1016/j.jaip.2017.11.038; Russell WS, 2013, WORLD J EMERG MED, V4, P98, DOI [10.5847/wjem.j.issn.1920-8642.2013.02.003, 10.5847/wjem.j.1920-8642.2013.02.003]; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanders RP, 2005, BRIT J HAEMATOL, V130, P781, DOI 10.1111/j.1365-2141.2005.05670.x; SAVILL JS, 1988, POSTGRAD MED J, V64, P392, DOI 10.1136/pgmj.64.751.392; Schardt C, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-16; Schmidt BJ, 1998, AM J ROENTGENOL, V171, P1215, DOI 10.2214/ajr.171.5.9798850; SCHONING B, 1982, KLIN WOCHENSCHR, V60, P1048, DOI 10.1007/BF01716970; Schroeck JL, 2016, CLIN THER, V37, P2340, DOI 10.1016/j.clinthera.2016.09.010; Schunemann H, 2016, GRADE EVIDENCE COCHR; Scranton SE, 2009, J ALLERGY CLIN IMMUN, V123, P493, DOI 10.1016/j.jaci.2008.10.026; Seki K, 2011, INT J MED SCI, V8, P210, DOI 10.7150/ijms.8.210; Shaker M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.13951; Shaker M, 2019, ANN ALLERG ASTHMA IM, V122, P79, DOI 10.1016/j.anai.2018.06.035; Shaker M, 2018, J ALLER CL IMM-PRACT, V6, P2073, DOI 10.1016/j.jaip.2018.04.036; Shaker M, 2018, J ALLER CL IMM-PRACT, V6, P2143, DOI 10.1016/j.jaip.2018.04.006; Shaker MS, 2007, ANN ALLERG ASTHMA IM, V99, P424, DOI 10.1016/S1081-1206(10)60567-4; Shen YP, 2018, ONCOL RES, V26, P801, DOI 10.3727/096504017X15139039328978; Sicherer SH, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4006; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sidhu N, 2016, PEDIATR EMERG CARE, V32, P508, DOI 10.1097/PEC.0000000000000864; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1097/WOX.0b013e318211496c; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Simons FER, 2013, INT ARCH ALLERGY IMM, V162, P193, DOI 10.1159/000354543; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons KJ, 2010, CURR OPIN ALLERGY CL, V10, P354, DOI 10.1097/ACI.0b013e32833bc670; Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Sousa-Pinto B, 2017, ANN ALLERG ASTHMA IM, V119, P362, DOI 10.1016/j.anai.2017.07.009; Sricharoen P, 2015, ASIAN PAC J ALLERGY, V33, P8, DOI 10.12932/AP0477.33.1.2015; Srisawat C, 2016, ASIAN PAC J ALLERGY, V34, P38; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; Tanno LK, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0234-0; Thompson LM, 2014, ONCOLOGIST, V19, P228, DOI 10.1634/theoncologist.2013-0286; Trudeau ME, 1996, J CLIN ONCOL, V14, P422, DOI 10.1200/JCO.1996.14.2.422; Turner C, 2006, J PSYCHOPHARMACOL, V20, P506, DOI 10.1177/0269881106059804; Turner PJ, 2017, J ALLER CL IMM-PRACT, V5, P1169, DOI 10.1016/j.jaip.2017.06.031; Turner PJ, 2016, J ALLER CL IMM-PRACT, V4, P1143, DOI 10.1016/j.jaip.2016.05.005; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; VAILLANT L, 1990, CLIN EXP DERMATOL, V15, P232, DOI 10.1111/j.1365-2230.1990.tb02079.x; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; Vezir E, 2013, ALLERGY ASTHMA PROC, V34, P239, DOI 10.2500/aap.2013.34.3654; VIGORITO C, 1983, J CARDIOVASC PHARM, V5, P531, DOI 10.1097/00005344-198307000-00004; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; WITEK TJ, 1995, ANN ALLERG ASTHMA IM, V74, P419; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016; World Allergy Organization, 2013, WHITE BOOK ALLERGY U, P20; Worm M, 2014, ALLERGY, V69, P1397, DOI 10.1111/all.12475; Worm M, 2014, DTSCH ARZTEBL INT, V111, P367, DOI 10.3238/arztebl.2014.0367; Wright CD, 2017, ANN ALLERG ASTHMA IM, V118, P461, DOI 10.1016/j.anai.2017.02.002; Yang MS, 2008, ANN ALLERG ASTHMA IM, V100, P31, DOI 10.1016/S1081-1206(10)60401-2; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; Yoshihiro O, 2006, ANN ALLERG ASTHMA IM, V96, P600, DOI 10.1016/S1081-1206(10)63556-9; Yu Y, 2018, J FORENSIC SCI, V63, P980, DOI 10.1111/1556-4029.13611; Yu YYR, 2017, J PEDIATR SURG, V52, P1045, DOI 10.1016/j.jpedsurg.2017.03.032	263	201	211	7	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1082	1123		10.1016/j.jaci.2020.01.017	http://dx.doi.org/10.1016/j.jaci.2020.01.017			42	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32001253	Bronze			2022-12-18	WOS:000523633400005
J	Wollenberg, A; Howell, MD; Guttman-Yassky, E; Silverberg, JI; Kell, C; Ranade, K; Moate, R; van der Merwe, R				Wollenberg, Andreas; Howell, Michael D.; Guttman-Yassky, Emma; Silverberg, Jonathan I.; Kell, Christopher; Ranade, Koustubh; Moate, Rachel; van der Merwe, Rene			Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; tralokinumab; eczema; IL-13	PERSISTENT ASTHMA; DOUBLE-BLIND; DUPILUMAB; PLACEBO; SKIN; PHARMACOKINETICS; CYCLOSPORINE; BIOMARKERS; MANAGEMENT; PERIOSTIN	Background: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. Objective: We sought to evaluate the efficacy and safety of tralokinumab in adults with moderate-to-severe AD. Methods: In this phase 2b study (NCT02347176), 204 adults were randomized 1: 1: 1: 1 to receive 45, 150, or 300 mg of subcutaneous tralokinumab, or placebo, every 2 weeks for 12 weeks with concomitant topical glucocorticoids. Coprimary end points were change from baseline in Eczema Area Severity Index score and percentage of participants with an Investigator's Global Assessment response (0/1 score and reduction of >= 2 grades from baseline) at week 12. Results: At week 12, 300 mg of tralokinumab significantly improved change from baseline in Eczema Area Severity Index score versus placebo (adjusted mean difference, -4.94; 95% CI, -8.76 to -1.13; P =.01), and a greater percentage of participants achieved an Investigator's Global Assessment response (26.7% vs 11.8%). Greater responses were found in participants with greater concentrations of biomarkers of increased IL-13 activity. Participants treated with 300 mg of tralokinumab demonstrated improvements in SCORAD, Dermatology Life Quality Index, and pruritus numeric rating scale (7-day mean) scores versus placebo. Upper respiratory tract infection was the most frequent treatment-emergent adverse event reported as related to study drug in the placebo (3.9%) and pooled tralokinumab (3.9%) groups. Conclusions: Tralokinumab treatment was associated with early and sustained improvements in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with AD.	[Wollenberg, Andreas] Ludwig Maximillian Univ, Dept Dermatol & Allergy, Munich, Germany; [Howell, Michael D.; Ranade, Koustubh] MedImmune, Translat Med, Gaithersburg, MD USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Med Ctr Med, Dept Dermatol, New York, NY 10029 USA; [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol Prevent Med & Med Social Sci, Chicago, IL 60611 USA; [Kell, Christopher] MedImmune, Prod Dev, Cambridge, England; [Moate, Rachel] MedImmune, Clin Stat & Data, Cambridge, England; [van der Merwe, Rene] MedImmune, Clin Resp Management, Cambridge, England; [Howell, Michael D.] Incyte Corp, Wilmington, DE USA	University of Munich; AstraZeneca; Medimmune; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; AstraZeneca; Medimmune; AstraZeneca; Medimmune; AstraZeneca; Medimmune; Incyte	Wollenberg, A (corresponding author), Ludwig Maximillian Univ, Frauenlobstr 9-11, D-80337 Munich, Germany.	wollenberg@lrz.uni-muenchen.de	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805	MedImmune; Good Publication Practice (GPP3) guidelines	MedImmune(AstraZenecaMedimmune); Good Publication Practice (GPP3) guidelines	We thank Claire Birrell for her role in protocol development and Michelle Dawson for providing support with the statistical analysis. We thank Georgina Collett, PhD, CMPP, and Rebecca Plant, MSc, of QXV Comms, Macclesfield, an Ashfield Company, part of UDG Healthcare plc, for medical writing support that was funded by MedImmune in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).We also thank the participants and their families, as well as the staff members at all trial sites.	Baverel PG, 2015, BRIT J CLIN PHARMACO, V80, P1337, DOI 10.1111/bcp.12725; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Brightling CE, 2015, LANCET RESP MED, V3, P692, DOI 10.1016/S2213-2600(15)00197-6; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Ge MM, 2011, DRUG INF J, V45, P481, DOI 10.1177/009286151104500409; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanania NA, 2015, THORAX, V70, P748, DOI 10.1136/thoraxjnl-2014-206719; Hanifin JM, 1980, DIAGNOSTIC FEATURES; Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; May RD, 2012, BRIT J PHARMACOL, V166, P177, DOI 10.1111/j.1476-5381.2011.01659.x; Moreno AS, 2016, INT ARCH ALLERGY IMM, V171, P71, DOI 10.1159/000451083; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Oh CK, 2010, BRIT J CLIN PHARMACO, V69, P645, DOI 10.1111/j.1365-2125.2010.03647.x; Parulekar AD, 2014, CURR OPIN PULM MED, V20, P60, DOI 10.1097/MCP.0000000000000005; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Ranade K, 2016, AM J RESP CRIT CARE, V193; Rozenblit M, 2014, J ALLERGY CLIN IMMUN, V134, P955, DOI 10.1016/j.jaci.2014.05.024; Schram ME, 2012, ALLERGY, V67, P99, DOI 10.1111/j.1398-9995.2011.02719.x; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Singh D, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-3; Tazawa T, 2004, ARCH DERMATOL RES, V295, P459, DOI 10.1007/s00403-004-0455-6; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wollenberg A, 2016, J EUR ACAD DERMATOL, V30, P729, DOI 10.1111/jdv.13599; World Health Organization, 1997, WHO MOD PRESCR INF D	37	201	208	2	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					135	141		10.1016/j.jaci.2018.05.029	http://dx.doi.org/10.1016/j.jaci.2018.05.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29906525	hybrid			2022-12-18	WOS:000454918300020
J	Ahn, K				Ahn, Kangmo			The role of air pollutants in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; atopic dermatitis; environmental tobacco smoke; volatile organic compounds; formaldehyde; toluene; particulate matter	VOLATILE ORGANIC-COMPOUNDS; PRENATAL EXPOSURE; OXIDATIVE STRESS; BARRIER FUNCTION; DNA METHYLATION; STRATUM-CORNEUM; SMOKE EXPOSURE; TH2 CYTOKINES; TOBACCO-SMOKE; TERM EXPOSURE	Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease and a growing health concern, especially in children, because of its high prevalence and associated low quality of life. Genetic predisposition, environmental triggers, or interactions between them contribute to the pathophysiology of AD. Therefore, it is very important to identify and control risk factors from the environment in susceptible subjects for successful treatment and prevention. Both indoor and outdoor air pollution, which are of increasing concern with urbanization, are well-known environmental risk factors for asthma, whereas there is relatively little evidence in AD. This review highlights epidemiologic and experimental data on the role of air pollution in patients with AD. Recent evidence suggests that a variety of air pollutants, such as environmental tobacco smoke, volatile organic compounds, formaldehyde, toluene, nitrogen dioxide, and particulate matter, act as risk factors for the development or aggravation of AD. These air pollutants probably induce oxidative stress in the skin, leading to skin barrier dysfunction or immune dysregulation. However, these results are still controversial because of the low number of studies, limitations in study design, inaccurate assessment of exposure and absorption, and many other issues. Further research about the adverse effects of air pollution on AD will help to expand our understanding and to establish a better strategy for the prevention and management of AD.	[Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul 135710, South Korea; [Ahn, Kangmo] Samsung Med Ctr, Environm Hlth Ctr Atop Dis, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Ahn, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, 81 Irwon Ro, Seoul 135710, South Korea.	kmaped@skku.edu	Ahn, Kangmo/F-4609-2014					Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Auten RL, 2012, AM J RESP CELL MOL, V46, P454, DOI 10.1165/rcmb.2011-0256OC; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Carson CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048678; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Eberlein-Konig B, 1998, J ALLERGY CLIN IMMUN, V101, P141, DOI 10.1016/S0091-6749(98)70212-X; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Gunasekar PG, 2003, J BIOCHEM MOL TOXIC, V17, P92, DOI 10.1002/jbt.10065; Herbarth O, 2006, INT J HYG ENVIR HEAL, V209, P241, DOI 10.1016/j.ijheh.2006.01.003; Herberth G, 2014, J ALLERGY CLIN IMMUN, V133, P543, DOI 10.1016/j.jaci.2013.06.036; Herbstman JB, 2012, ENVIRON HEALTH PERSP, V120, P733, DOI 10.1289/ehp.1104056; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huss-Marp J, 2006, CLIN EXP ALLERGY, V36, P338, DOI 10.1111/j.1365-2222.2006.02448.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jedrychowski W, 2011, INT ARCH ALLERGY IMM, V155, P275, DOI 10.1159/000320376; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Just AC, 2012, ENVIRON HEALTH PERSP, V120, P1475, DOI 10.1289/ehp.1104544; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim J, 2013, J ALLERGY CLIN IMMUN, V132, P495, DOI 10.1016/j.jaci.2013.04.019; Lee JH, 2012, ASIA PAC ALLERGY, V2, P59, DOI 10.5415/apallergy.2012.2.1.59; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Lee YL, 2008, J INVEST DERMATOL, V128, P2412, DOI 10.1038/jid.2008.110; Lehmann I, 2002, ENVIRON TOXICOL, V17, P203, DOI 10.1002/tox.10055; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Liu T, 2012, NEUROSCI BULL, V28, P145, DOI 10.1007/s12264-012-1207-9; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; MORGAN DL, 1991, ENVIRON RES, V55, P51, DOI 10.1016/S0013-9351(05)80140-9; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nikolovski J, 2008, J INVEST DERMATOL, V128, P1728, DOI 10.1038/sj.jid.5701239; Niwa Y, 2003, BRIT J DERMATOL, V149, P248, DOI 10.1046/j.1365-2133.2003.05417.x; Pastore S, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/861949; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Penard-Morand C, 2010, EUR RESPIR J, V36, P33, DOI 10.1183/09031936.00116109; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Saito A, 2011, ENVIRON TOXICOL, V26, P224, DOI 10.1002/tox.20547; Seidenari S, 2003, ALLERGY, V58, P426, DOI 10.1034/j.1398-9995.2003.00142.x; Song S, 2011, ENVIRON RES, V111, P394, DOI 10.1016/j.envres.2010.10.010; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Sticozzi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033592; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Wang IJ, 2013, CLIN EXP ALLERGY, V43, P535, DOI 10.1111/cea.12108; Wang IJ, 2010, ANN ALLERG ASTHMA IM, V105, P124, DOI 10.1016/j.anai.2010.04.017; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Wu Z, 2004, CLIN EXP IMMUNOL, V135, P194, DOI 10.1111/j.1365-2249.2003.02372.x; Yang CT, 2011, MOL CELLS, V31, P531, DOI 10.1007/s10059-011-1025-3; Yi O, 2012, ENVIRON RES, V113, P40, DOI 10.1016/j.envres.2011.12.012	58	201	211	1	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					993	999		10.1016/j.jaci.2014.09.023	http://dx.doi.org/10.1016/j.jaci.2014.09.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25439225				2022-12-18	WOS:000344938900001
J	Baines, KJ; Simpson, JL; Wood, LG; Scott, RJ; Gibson, PG				Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Scott, Rodney J.; Gibson, Peter G.			Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma phenotypes; gene expression profiling; induced sputum; IL-1; TNF-alpha; neutrophils; eosinophils	NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY SUBTYPES; AIRWAY INFLAMMATION; CLUSTER-ANALYSIS; IDENTIFICATION; EXACERBATIONS; NEUTROPHILIA; MEPOLIZUMAB	Background: Previous studies have identified clinical or inflammatory phenotypes of asthma on the basis of clinical and demographic parameters or sputum cell counts; however, few studies have defined transcriptional phenotypes of asthma. Objective: To investigate asthma phenotypes at a transcriptional level by using gene expression profiling of induced sputum. Methods: Induced sputum samples were collected from 59 people with asthma with a mean age of 58 years and an FEV1% predicted of 76%, and 69% were taking inhaled corticosteroids. Thirteen healthy controls without asthma were also assessed. Inflammatory cell counts were performed, and RNA was extracted from selected sputum. Transcriptional profiles were generated (Illumina Humanref-8 V2) and analyzed by using GeneSpring GX11. Results: Unsupervised hierarchical clustering of gene expression profiles in asthma revealed 3 distinct groups. The first transcriptional phenotype (n = 21) had lower FEV1% predicted and higher asthma control questionnaire scores, exhaled nitric oxide, and sputum eosinophils. The second transcriptional phenotype (n = 14) had lower FEV1% predicted and forced vital capacity % predicted and higher sputum neutrophils compared with a third transcriptional phenotype (n = 24) that had higher sputum macrophages and resembled healthy controls. Differentially expressed genes between transcriptional asthma phenotypes were related to inflammatory and immune responses. Genes in the IL-1 and TNF-alpha/nuclear factor-kappa B pathways were overexpressed and correlated with clinical parameters and neutrophilic airway inflammation. Conclusion: Gene expression profiling provides a novel means to investigate the molecular mechanisms and classifications of asthma phenotypes. There are 3 distinct transcriptional phenotypes of asthma that relate to both clinical and inflammatory parameters. (J Allergy Clin Immunol 2011;127:153-60.)	[Scott, Rodney J.] Univ Newcastle, Hunter Med Res Inst, Prior Res Ctr Informat Based Med, Callaghan, NSW 2308, Australia; [Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Gibson, Peter G.] Univ Newcastle, Ctr Asthma & Resp Dis, Callaghan, NSW 2308, Australia; [Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Gibson, Peter G.] John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton, Australia	Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Baines, KJ (corresponding author), John Hunter Hosp, HMRI, Hunter Reg Mail Ctr, Level 3,Locked Bag 1, Newcastle, NSW 2310, Australia.	katherine.baines@newcastle.edu.au	SIMPSON, JODIE LOUISE/G-7639-2013; Scott, Rodney J/B-2827-2013; BAINES, KATHERINE JOANNE/G-7654-2013; Wood, Lisa G/G-7068-2013; gibson, peter/G-6194-2014	SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Scott, Rodney J/0000-0001-7724-3404; BAINES, KATHERINE JOANNE/0000-0002-4240-6581; Wood, Lisa/0000-0002-0941-9225; gibson, peter/0000-0001-5865-489X	John Hunter Hospital Charitable Trust; HMRI; XStrata Coal	John Hunter Hospital Charitable Trust; HMRI; XStrata Coal	Supported by the John Hunter Hospital Charitable Trust, HMRI, and XStrata Coal. Disclosure of potential conflict of interest: P. G. Gibson has received honoraria from GlaxoSmithKline, AstraZeneca, and Novartis. The rest of the authors have declared that they have no conflict of interest.	Alexis NE, 2008, ANN ALLERG ASTHMA IM, V100, P206, DOI 10.1016/S1081-1206(10)60444-9; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Baines KJ, 2009, OMICS, V13, P355, DOI 10.1089/omi.2009.0042; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry M, 2007, CURR OPIN PHARMACOL, V7, P279, DOI 10.1016/j.coph.2007.03.001; Bradding P, 2010, CURR OPIN ALLERGY CL, V10, P54, DOI 10.1097/ACI.0b013e32833489a9; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Green RH, 2007, CURR OPIN ALLERGY CL, V7, P43, DOI 10.1097/ACI.0b013e3280118a32; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nicholas B, 2009, BIOCHEM SOC T, V37, P868, DOI 10.1042/BST0370868; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Petsky HL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006340.pub3; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	36	201	209	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					153	U251		10.1016/j.jaci.2010.10.024	http://dx.doi.org/10.1016/j.jaci.2010.10.024			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211650	Bronze			2022-12-18	WOS:000285917300022
J	Alvarez-Twose, I; de Olano, DG; Sanchez-Munoz, L; Matito, A; Esteban-Lopez, MI; Vega, A; Mateo, MB; de Durana, MDAD; de la Hoz, B; Gil, MDD; Caballero, T; Rosado, A; Matas, IS; Teodosio, C; Jara-Acevedo, M; Mollejo, M; Garcia-Montero, A; Orfao, A; Escribano, L				Alvarez-Twose, Ivan; Gonzalez de Olano, David; Sanchez-Munoz, Laura; Matito, Almudena; Esteban-Lopez, Maria I.; Vega, Arantza; Belen Mateo, Maria; Alonso Diaz de Durana, Maria D.; de la Hoz, Belen; del Pozo Gil, Maria D.; Caballero, Teresa; Rosado, Ana; Sanchez Matas, Isabel; Teodosio, Cristina; Jara-Acevedo, Maria; Mollejo, Manuela; Garcia-Montero, Andres; Orfao, Alberto; Escribano, Luis			Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; mastocytosis; systemic mast cell activation disorders; anaphylaxis; clonal; CD25; KIT mutation; score	SPANISH NETWORK; SERUM TRYPTASE; MASTOCYTOSIS; ANAPHYLAXIS; OSTEOPOROSIS; EXPRESSION; DIAGNOSIS; CRITERIA; LESIONS; RISK	Background: Systemic mast cell activation disorders (MCADs) are characterized by severe and systemic mast cell (MC) mediators related symptoms frequently associated with increased serum baseline tryptase (sBt). Objective: To analyze the clinical, biological, and molecular characteristics of adult patients presenting with systemic MC activation symptoms/anaphylaxis in the absence of skin mastocytosis who showed clonal (c) versus nonclonal (nc) MCs and to provide indication criteria for bone marrow (BM) studies. Methods: Eighty-three patients were studied. Patients showing clonal BM MCs were grouped into indolent systemic mastocytosis without skin lesions (ISMs-; n = 48) and other c-MCADs (n = 3) both with CD25(++) BM MCs and either positive mast/stem cell growth factor receptor gene (KIT) mutation or clonal human androgen receptor assay (HUMARA) tests and nc-MCAD (CD25-negative BM MCs in the absence of KIT mutation; n = 32) and compared for their clinical, biological, and molecular characteristics. Results: Most clonal patients (48/51; 94%) met the World Health Organization criteria for systemic mastocytosis and were classified as ISMs-, whereas the other 3 c-MCAD and all nc-MCAD patients did not. In addition, although both patients with ISMs- and patients with nc-MCAD presented with idiopathic and allergen-induced anaphylaxis, the former showed a higher frequency of men, cardiovascular symptoms, and insect bite as a trigger, together with greater sBt. Based on a multivariate analysis, a highly efficient model to predict clonality before BM sampling was built that includes male sex (P = .01), presyncopal and/or syncopal episodes (P = .009) in the absence of urticaria and angioedema (P = .003), and sBt >25 mu g/L (P = .006) as independent predictive factors. Conclusions: Patients with c-MCAD and ISMs- display unique clinical and laboratory features different from nc-MCAD patients. A significant percentage of c-MCAD patients can be considered as true ISMs- diagnosed at early phases of the disease. (J Allergy Clin Immunol 2010;125:1269-78.)	[Alvarez-Twose, Ivan; Sanchez-Munoz, Laura; Matito, Almudena; Escribano, Luis] Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla La Mancha, Toledo 45071, Spain; [Gonzalez de Olano, David] Hosp Fuenlabrada, Allergy Unit, Madrid, Spain; [Esteban-Lopez, Maria I.] Hosp Gen Segovia, Dept Allergy, Segovia, Spain; [Vega, Arantza] Hosp Guadalajara, Dept Allergy, Guadalajara, Spain; [Alonso Diaz de Durana, Maria D.; Rosado, Ana] Fdn Hosp Alcorcon, Allergy Unit, Madrid, Spain; [de la Hoz, Belen] Hosp Ramon & Cajal, Dept Allergy, E-28034 Madrid, Spain; [Caballero, Teresa] Hosp La Paz, Dept Allergy, Madrid, Spain; [Sanchez Matas, Isabel] Hosp Principe Asturias Alcala de Henares, Dept Allergy, Madrid, Spain; [Teodosio, Cristina; Jara-Acevedo, Maria; Garcia-Montero, Andres; Orfao, Alberto] Univ Salamanca, Ctr Invest Canc, IBMCC, USAL,CSIC,Dept Med, E-37008 Salamanca, Spain; [Teodosio, Cristina; Jara-Acevedo, Maria; Garcia-Montero, Andres; Orfao, Alberto] Univ Salamanca, Serv Gen Citometria, E-37008 Salamanca, Spain; [Mollejo, Manuela] Hosp Virgen Salud, Dept Pathol, Toledo, Spain	Complejo Hospitalario de Toledo; Hospital Universitario Fuenlabrada; Alcorcon Foundation University Hospital; Hospital Universitario Ramon y Cajal; Hospital Universitario La Paz; Prince of Asturias University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Complejo Hospitalario de Toledo	Escribano, L (corresponding author), Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla La Mancha, Planta 3A,Carretera Cobisa S-N, Toledo 45071, Spain.	lescribanom@sescam.jccm.es	Garcia-Montero, Andres C/B-6558-2017; Montero, Andres/HGA-9093-2022; Shah, Mohd R/E-4826-2010; IBSAL, Secretaría/H-3719-2011; Caballero, Teresa/H-6454-2014; de la Hoz, Belen/AAA-8067-2019; Orfao, Alberto/B-5801-2017; Caballero, Teresa/AAU-3982-2020	Garcia-Montero, Andres C/0000-0003-4360-1386; Caballero, Teresa/0000-0003-3005-9858; de la Hoz, Belen/0000-0002-5127-8702; Caballero, Teresa/0000-0003-3005-9858; ALONSO-DIAZ DE DURANA, MARIA DOLORES/0000-0001-5869-6790; Rosado, Ana/0000-0002-4862-9006; Sanchez-Munoz, Laura/0000-0003-1757-7255; Matito, Almudena/0000-0002-9547-4844; Jara-Acevedo, Maria/0000-0001-7965-7512; Mollejo, Manuela/0000-0001-5658-0532; Teodosio, Cristina/0000-0002-2097-7199; Alvarez-Twose, Ivan/0000-0002-1190-4473	Ministerio de Sanidad y Consumo, Institut de Salud Carlos III [FIS060529, FIS061377, PS09/00032, FIS09/90871, RETICS RD06/0020/0035-FEDER]; Junta de Castilla y Leon [SAN196/SA10/07, SAN/1778/2009]; Junta de Comunidades de Castilla La Mancha [FISCAM 2007/36, FISCAM 2008/46]; Fundacion MMA; FIS/FEDER [CP03/00035]; FCT of Portugal [SFRH/BD/17545/2004]; RIRAAF	Ministerio de Sanidad y Consumo, Institut de Salud Carlos III; Junta de Castilla y Leon(Junta de Castilla y Leon); Junta de Comunidades de Castilla La Mancha(Junta de Comunidades de Castilla-La Mancha); Fundacion MMA; FIS/FEDER(Instituto de Salud Carlos IIIEuropean Commission); FCT of Portugal(Portuguese Foundation for Science and Technology); RIRAAF	Supported by grants from the Ministerio de Sanidad y Consumo, Institut de Salud Carlos III (FIS060529, FIS061377, PS09/00032, FIS09/90871, and RETICS RD06/0020/0035-FEDER); Junta de Castilla y Leon (Grant SAN196/SA10/07 and SAN/1778/2009); Junta de Comunidades de Castilla La Mancha (FISCAM 2007/36 and FISCAM 2008/46), and Fundacion MMA. A.G.-M. is supported by a grant from FIS/FEDER (CP03/00035) and C.T. from the FCT of Portugal (SFRH/BD/17545/2004).; Disclosure of potential conflict of interest: A. Rosado has received research support from the RIRAAF. The rest of the authors have declared that they have no conflict of interest.	Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Alvarez-Twose I, 2009, J ALLERGY CLIN IMMUN, V123, pS141, DOI 10.1016/j.jaci.2008.12.524; [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Butterfield JH, 2008, INT ARCH ALLERGY IMM, V147, P338, DOI 10.1159/000144042; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Florian S, 2005, INT ARCH ALLERGY IMM, V136, P273, DOI 10.1159/000083954; Fukuoka Y, 2008, J IMMUNOL, V180, P6307, DOI 10.4049/jimmunol.180.9.6307; Gaig P., 2004, ALERGOL INMUNOL CLIN, V19, P68; GALLI SJ, 1984, PROG ALLERGY, V34, P1; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Gommerman JL, 2000, J IMMUNOL, V165, P6915, DOI 10.4049/jimmunol.165.12.6915; Greenhawt M, 2007, CURR OPIN ALLERGY CL, V7, P387, DOI 10.1097/ACI.0b013e3282a6443e; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Hungness SI, 2007, J ALLERGY CLIN IMMUN, V119, pS29, DOI 10.1016/j.jaci.2006.11.132; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Kassab D, 2008, J ALLERGY CLIN IMMUN, V121, pS67, DOI 10.1016/j.jaci.2007.12.268; KATZ HR, 1992, J IMMUNOL, V148, P868; Koterba AP, 2008, J ALLERGY CLIN IMMUN, V121, pS68, DOI 10.1016/j.jaci.2007.12.273; LOBELL RB, 1994, J IMMUNOL, V152, P811; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS1, DOI 10.1111/1523-1747.ep12468869; Metcalfe DD, 1991, J INVEST DERMATOL, V96, p2S; Miller PD, 2006, REV ENDOCR METAB DIS, V7, P75, DOI 10.1007/s11154-006-9006-0; NUNEZ R, 2002, BRIT J HAEMATOL, V120, P257; ROBERTS LJ, 1988, ENDOCRIN METAB CLIN, V17, P415, DOI 10.1016/S0889-8529(18)30427-4; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sonneck K, 2007, INT ARCH ALLERGY IMM, V142, P158, DOI 10.1159/000096442; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; Wu Y, 2003, FERTIL STERIL, V79, P710, DOI 10.1016/S0015-0282(02)04821-5	46	201	201	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1269	1278		10.1016/j.jaci.2010.02.019	http://dx.doi.org/10.1016/j.jaci.2010.02.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20434205				2022-12-18	WOS:000278831000014
J	Dupont, C; Kalach, N; Soulaines, P; Legoue-Morillon, S; Piloquet, H; Benhamou, PH				Dupont, Christophe; Kalach, Nicolas; Soulaines, Pascale; Legoue-Morillon, Sandrine; Piloquet, Hughes; Benhamou, Pierre-Henri			Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Dupont, Christophe; Kalach, Nicolas; Soulaines, Pascale; Benhamou, Pierre-Henri] Paris Descartes Univ, Dept Pediat Gastroenterol, Cochin St Vincent Paul Hosp, Paris, France; [Benhamou, Pierre-Henri] DBV Technol, Paris, France; [Legoue-Morillon, Sandrine; Piloquet, Hughes] Hop Mere Enfant, Nantes, France; [Kalach, Nicolas] Catholic Univ, Dept Pediat, St Vincent de Paul Hosp, Lille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Nantes Universite; CHU de Nantes	Dupont, C (corresponding author), Paris Descartes Univ, Dept Pediat Gastroenterol, Cochin St Vincent Paul Hosp, Paris, France.	christophe.dupont@svp.aphp.fr						de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; MONDOULET L, CLIN EXP ALLERGY; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Soury D, 2005, PHARM RES, V22, P1530, DOI 10.1007/s11095-005-5881-4; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; Werfel T, 2009, J ALLERGY CLIN IMMUN, V124, P1003, DOI 10.1016/j.jaci.2009.09.049	10	201	208	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1165	1167		10.1016/j.jaci.2010.02.029	http://dx.doi.org/10.1016/j.jaci.2010.02.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451043				2022-12-18	WOS:000277686700032
J	Shea, KM; Truckner, RT; Weber, RW; Peden, DB				Shea, Katherine M.; Truckner, Robert T.; Weber, Richard W.; Peden, David B.			Climate change and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						climate change; global warming; pollen; air pollution; ozone; allergic rhinitis; asthma; mitigation; adaptation; prevention	RAGWEED AMBROSIA-ARTEMISIIFOLIA; PARTICULATE AIR-POLLUTION; DIESEL EXHAUST PARTICLES; ASTHMATIC-CHILDREN; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE; OZONE EXPOSURE; POLLEN SEASON; AMBIENT OZONE; RESPIRATORY SYMPTOMS	Climate change is potentially the largest global threat to human health ever encountered. The earth is warming, the warming is accelerating, and human actions are largely responsible. If current emissions and land use trends continue unchecked, the next generations will face more injury, disease, and death related to natural disasters and heat waves, higher rates of climate-related infections, and wide-spread malnutrition, as well as more allergic and air pollution-related morbidity and mortality. This review highlights links between global climate change and anticipated increases in prevalence and severity of asthma and related allergic disease mediated through worsening ambient air pollution and altered local and regional pollen production. The pattern of change will vary regionally depending on latitude, altitude, rainfall and storms, land-use patterns, urbanization, transportation, and energy production. The magnitude of climate change and related increases in allergic disease will be affected by how aggressively greenhouse gas mitigation strategies are pursued, but at best an average warming of I to 2 degrees C is certain this century. Thus, anticipation of a higher allergic disease burden will affect clinical practice as well as public health planning. A number of practical primary and secondary prevention strategies are suggested at the end of the review to assist in meeting this unprecedented public health challenge.	[Shea, Katherine M.] Univ N Carolina, Inst Environm, Sch Publ Hlth, Dept Mat & Child Health, Chapel Hill, NC 27599 USA; [Peden, David B.] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; [Truckner, Robert T.] US Environm Protect Agcy, Natl Hlth & Environm Effects Lab, NHEERL Human Res Protocol Off, Res Triangle Pk, NC USA; [Weber, Richard W.] Univ Colorado, Natl Jewish Med & Res Ctr, Dept Med, Hlth Sci Ctr, Boulder, CO 80309 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Shea, KM (corresponding author), Univ N Carolina, Inst Environm, Sch Publ Hlth, Dept Mat & Child Health, 111 Miller Hall,Campus Box 1105, Chapel Hill, NC 27599 USA.	kshea@email.unc.edu		Peden, David/0000-0003-4526-4627				*AQI, 2007, AQI ED TOOLK WEATH; Aw J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002688; Barck C, 2005, ENVIRON RES, V97, P58, DOI 10.1016/j.envres.2004.02.009; BARNES PJ, 1994, POSTGRAD MED J, V70, P319, DOI 10.1136/pgmj.70.823.319; Bates DV, 2005, EPIDEMIOLOGY, V16, P427, DOI 10.1097/01.ede.0000165793.71278.ec; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Bell ML, 2007, CLIMATIC CHANGE, V82, P61, DOI 10.1007/s10584-006-9166-7; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Breton MC, 2006, SCI TOTAL ENVIRON, V370, P39, DOI 10.1016/j.scitotenv.2006.05.022; BRUNEKREEF B, 2005, EURO RESP J, V6, P309; Charron A, 2007, ATMOS ENVIRON, V41, P1960, DOI 10.1016/j.atmosenv.2006.10.041; Chen KS, 2004, J AIR WASTE MANAGE, V54, P36, DOI 10.1080/10473289.2004.10470880; Cheng L, 1998, ATMOS ENVIRON, V32, P673, DOI 10.1016/S1352-2310(97)00319-1; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Dennis A, 2002, ATMOS ENVIRON, V36, P3779, DOI 10.1016/S1352-2310(02)00219-4; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Energy Information Administration, 2008, INT EN OUTL; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Fraser MP, 2003, ATMOS ENVIRON, V37, P2117, DOI 10.1016/S1352-2310(03)00075-X; Frei T, 1998, GRANA, V37, P172, DOI 10.1080/00173139809362662; Galan C, 2005, INT J BIOMETEOROL, V49, P184, DOI 10.1007/s00484-004-0223-5; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Ghio AJ, 2004, J AEROSOL MED, V17, P157, DOI 10.1089/0894268041457200; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Hansen J, 2007, ATMOS CHEM PHYS, V7, P2287, DOI 10.5194/acp-7-2287-2007; Hegerl GC, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P663; Holz O, 2002, CLIN EXP ALLERGY, V32, P681, DOI 10.1046/j.1365-2222.2002.01358.x; Jaffe D, 2003, ATMOS ENVIRON, V37, P391, DOI 10.1016/S1352-2310(02)00862-2; Jaffe D, 2007, ATMOS ENVIRON, V41, P5452, DOI 10.1016/j.atmosenv.2007.02.034; Jauregui E, 1997, ATMOS ENVIRON, V31, P3821, DOI 10.1016/S1352-2310(97)00136-2; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33, DOI 10.1164/ajrccm.160.1.9808119; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kan HD, 2005, BIOMED ENVIRON SCI, V18, P159; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; Kinney PL, 2002, ENVIRON HEALTH PERSP, V110, P539, DOI 10.1289/ehp.02110s4539; Kishikawa R, 2001, Arerugi, V50, P369; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717, DOI 10.1016/S0091-6749(99)70280-0; Kunii O, 2002, ARCH ENVIRON HEALTH, V57, P16, DOI 10.1080/00039890209602912; Lamarque JF, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023419; LEE BK, ENV MONITOR ASSESS, V136, P21; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; Lenton TM, 2008, P NATL ACAD SCI USA, V105, P1786, DOI 10.1073/pnas.0705414105; LEVIN L, URBANIZATION ENERGY; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Matthews HD, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032388; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Menetrez MY, 2007, ATMOS ENVIRON, V41, P8264, DOI 10.1016/j.atmosenv.2007.06.021; Mohan JE, 2006, P NATL ACAD SCI USA, V103, P9086, DOI 10.1073/pnas.0602392103; Moore D, 2006, CAN J PUBLIC HEALTH, V97, P105, DOI 10.1007/BF03405325; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mott JA, 2005, INT J HYG ENVIR HEAL, V208, P75, DOI 10.1016/j.ijheh.2005.01.018; Natural Resources Defense Council (NRDC), 1999, SCORCH EARTH IMP IMP; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Parry M. L., 2007, CLIMATE CHANGE 2007; Parry M. L., 2007, CLIMATE CHANGE 2007, P23; Peden DB, 1997, ALLERGY, V52, P37, DOI 10.1111/j.1398-9995.1997.tb04869.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; PEDEN DB, 2003, MIDDLETONS ALLERGY P, P515; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1996, AM J EPIDEMIOL, V144, P570, DOI 10.1093/oxfordjournals.aje.a008967; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Phuleria HC, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004626; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Purves DW, 2004, GLOBAL CHANGE BIOL, V10, P1737, DOI 10.1111/j.1365-2486.2004.00844.x; RADKE LF, 1995, ATMOS RES, V38, P315, DOI 10.1016/0169-8095(95)00003-A; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rodriguez-Rajo FJ, 2004, ANN AGR ENV MED, V11, P35; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368, DOI 10.1080/00039899709602213; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Salvador P, 2008, SCI TOTAL ENVIRON, V390, P495, DOI 10.1016/j.scitotenv.2007.10.052; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Shariat SF, 2008, CURR OPIN UROL, V18, P1, DOI 10.1097/MOU.0b013e3282f1c5c1; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SILLMAN S, 1995, J GEOPHYS RES-ATMOS, V100, P11497, DOI 10.1029/94JD02146; SOLOMON AM, 1971, BULL NJ ACAD SCI, V16, P30; Solomon S., 2007, PHYS SCI BASIS WORKI; SPIEKSMA FTM, 1995, GRANA, V34, P51, DOI 10.1080/00173139509429033; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Statheropoulos M, 2007, J ANAL APPL PYROL, V78, P430, DOI 10.1016/j.jaap.2006.10.011; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Swiston JR, 2008, EUR RESPIR J, V32, P129, DOI 10.1183/09031936.00097707; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Tzedakis PC, 2004, SCIENCE, V306, P2231, DOI 10.1126/science.1102398; *US EPA, SO2 WHAT IS IT DOES; *US EPA, NOX WHAT IS IT DOES; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; Watson JG, 2001, ATMOS ENVIRON, V35, P1567, DOI 10.1016/S1352-2310(00)00461-1; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1; Weber RW, 2003, IMMUNOL ALLERGY CLIN, V23, P357, DOI 10.1016/S0889-8561(03)00029-8; Weber RW, 2002, ANN ALLERG ASTHMA IM, V88, P251, DOI 10.1016/S1081-1206(10)62004-2; Weng CY, 2007, PHILOS T R SOC B, V362, P253, DOI 10.1098/rstb.2006.1985; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; *WHO, 2008, MESS WHO DIR GEN MAR; Wojas B, 2007, ATMOS ENVIRON, V41, P9064, DOI 10.1016/j.atmosenv.2007.08.010; Wu HWY, 2001, ENVIRON INT, V26, P213, DOI 10.1016/S0160-4120(00)00108-2; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	119	201	211	3	103	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					443	453		10.1016/j.jaci.2008.06.032	http://dx.doi.org/10.1016/j.jaci.2008.06.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774380				2022-12-18	WOS:000259234000001
J	Wark, PAB; Hensley, MJ; Saltos, N; Boyle, MJ; Toneguzzi, RC; Simpson, JL; McElduff, P; Gibson, PG				Wark, PAB; Hensley, MJ; Saltos, N; Boyle, MJ; Toneguzzi, RC; Simpson, JL; McElduff, P; Gibson, PG			Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						itraconazole; allergic bronchopulmonary aspergillosis; airway inflammation; induced sputum; asthma		Background: Allergic bronchopulmonary aspergillosis (ABPA) complicates chronic asthma and results from hypersensitivity to the fungus Aspergillus fumigatus, causing an intense systemic immune response and progressive lung damage. Objective: We sought to determine whether treatment with the antifungal agent itraconazole reduced eosinophilic airway inflammation in subjects with ABPA. Methods: A randomized, double-blind, placebo-controlled trial was performed in stable subjects with ABPA (n = 29). Subjects received 400 mg of itraconazole per day (n = 15) or placebo (n = 14) for 16 weeks. All subjects were reviewed monthly with history, spirometry, and sputum induction to measure airway inflammation, serum total IgE and IgG levels to A fumigatus, and blood eosinophil counts. Results: By using regression analysis in a random-effects model, subjects receiving itraconazole had a decrease in sputum eosinophils, of 35% per week, with no decrease seen in the placebo arm (P < .01). Sputum eosinophil cationic protein levels decreased with itraconazole treatment by 42% per week compared with 23% in the placebo group (P < .01). Itraconazole reduced systemic immune activation, leading to a decrease in serum IgE levels (310 IU/mL) compared with levels seen in the placebo group (increase of 18 IU/mL, P < .01) and a decrease in IgG levels to A fumigatus (15.4 IU/mL) compared with levels seen in the placebo group (increase of 3.7 IU/mL, P = .03). There were fewer exacerbations requiring oral corticosteroids in those treated with itraconazole compared with in the placebo group (P = .03). Conclusion: Itraconazole treatment of subjects with stable ABPA reduces eosinophilic airway inflammation, systemic immune activation, and exacerbations. These results imply that itraconazole is a potential adjunctive treatment for ABPA.	John Hunter Hosp, Dept Resp & Sleep Med, Hunter Region Mail Ctr, NSW 2310, Australia; John Hunter Hosp, Airways Infect & Immunol Res Grp, Hunter Region Mail Ctr, NSW 2310, Australia; Univ Newcastle, Fac Hlth, Newcastle, NSW 2308, Australia; John Hunter Hosp, Dept Immunol & Infect Dis, Newcastle, NSW, Australia; Univ Manchester, Sch Med, Manchester, Lancs, England	John Hunter Hospital; John Hunter Hospital; University of Newcastle; John Hunter Hospital; University of Manchester	Gibson, PG (corresponding author), John Hunter Hosp, Dept Resp & Sleep Med, Locked Bag 1, Hunter Region Mail Ctr, NSW 2310, Australia.		SIMPSON, JODIE LOUISE/G-7639-2013; Wark, Peter/G-7037-2013; gibson, peter/G-6194-2014	SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Wark, Peter/0000-0001-5676-6126; gibson, peter/0000-0001-5865-489X				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; DEBEULE K, 1988, MYCOSES, V31, P476, DOI 10.1111/j.1439-0507.1988.tb03653.x; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; GERMAUD P, 1992, American Review of Respiratory Disease, V145, pA736; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; KATZENSTEIN K, 1975, AM REV RESPIR DIS, V3, P232; LEBEAU B, 1994, MYCOSES, V37, P171, DOI 10.1111/j.1439-0507.1994.tb00296.x; LEBRUNVIGNES B, 1996, EXP CLIN PHARM S, V18, pB207; MANNES GPM, 1993, LANCET, V341, P492, DOI 10.1016/0140-6736(93)90244-B; Matsuzaki Y, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P352; NEOPMUCENO IB, 1999, CHEST, V115, P354; Nikaido Y, 1998, RESP MED, V92, P118, DOI 10.1016/S0954-6111(98)90042-7; PACHECO A, 1993, CHEST, V103, P980, DOI 10.1378/chest.103.3.980a; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; Skov M, 2002, EUR RESPIR J, V20, P127, DOI 10.1183/09031936.02.00248002; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; Varis T, 1998, CLIN PHARMACOL THER, V64, P363, DOI 10.1016/S0009-9236(98)90066-2; Varkey B, 1998, IMMUNOL ALLERGY CLIN, V18, P479, DOI 10.1016/S0889-8561(05)70018-7; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87; Wark PAB, 2000, EUR RESPIR J, V16, P1095, DOI 10.1034/j.1399-3003.2000.16f13.x; WARK PAB, 2001, COCHRANE DATABASE SY	25	201	220	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					952	957		10.1067/mai.2003.1388	http://dx.doi.org/10.1067/mai.2003.1388			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743557	Bronze			2022-12-18	WOS:000182904500007
J	Ouwehand, AC; Isolauri, E; He, F; Hashimoto, H; Benno, Y; Salminen, S				Ouwehand, AC; Isolauri, E; He, F; Hashimoto, H; Benno, Y; Salminen, S			Differences in Bifidobacterium flora composition in allergic and healthy infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		Univ Turku, Dept Biochem & Food Chem, Turku, Finland; Univ Turku, Cent Hosp, Dept Paediat, FIN-20520 Turku, Finland; Takanashi Milk Prod Co Ltd, Tech Res Lab, Yokohama, Kanagawa, Japan; RIKEN, Japan Collect Microorganisms, Wako, Saitama 35101, Japan	University of Turku; University of Turku; RIKEN	Ouwehand, AC (corresponding author), Univ Turku, Dept Biochem & Food Chem, Turku, Finland.			Ouwehand, Arthur/0000-0001-8348-0633				BALLONGUE L, 1998, LACTIC ACID BACTERIA, P519; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Gronlund MM, 2000, ARCH DIS CHILD-FETAL, V83, pF186, DOI 10.1136/fn.83.3.F186; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Mitsuoka T., 1984, Bifidobacteria and Microflora, V3, P11	7	201	218	0	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					144	145						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447399				2022-12-18	WOS:000170171200025
J	Leung, PSC; Chow, WK; Duffey, S; Kwan, HS; Gershwin, ME; Chu, KH				Leung, PSC; Chow, WK; Duffey, S; Kwan, HS; Gershwin, ME; Chu, KH			IgE reactivity against a cross-reactive allergen in crustacea and mollusca: Evidence fev tropomyosin as the common allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; cross-reactivity tropomyosin; crustaceans; mollusks; insects	PRIMARY BILIARY-CIRRHOSIS; SHRIMP ALLERGEN; IDENTIFICATION; HYPERSENSITIVITY; ANTIBODIES; LIMPET; ANAPHYLAXIS; EPITOPES; ANTIGENS; MUSCLE	Background: Although cross-reactivity between mollusks and other crustaceans in shrimp-sensitive subjects has been reported, the mechanism of this allergenic cross-reactivity has not been studied in detail. Objective: To investigate this cross-reactivity in vitro, we have taken advantage of a complementary DNA that expresses tropomyosin, the immunodominant shrimp allergen. Methods: Serum IgE from nine patients with known anaphylaxis to shrimp and five normal volunteers were analyzed by immunoblotting against 13 distinct crustaceans and mollusks. As additional antigens, muscle preparations were isolated from grasshopper, cockroach, fruit fly, chicken and mouse. Results: Sera from all patients, but not control subjects, reacted specifically with a 38 kd protein in all crustaceans and mollusks studied. In addition, 8 of 9 sera from patients, but from none of the normal control subjects, recognized proteins of various other molecular weights among the mollusk extracts studied. The 38 kd protein was identified as tropomyosin and was shown to share immunodominant epitopes among all species of crustaceans and mollusks tested by specific absorption studies. Moreover, sera from all nine subjects with shrimp allergy demonstrated IgE reactivities against grasshopper, cockroach, and fruit fly but not chicken or murine muscle. Conclusion: The allergic epitopes on tropomyosin are conserved among invertebrates including not only shellfish but also insects. This latter observation suggests that persons sensitive to shrimp should undergo further study for potential cross-reactive inhalant or ingested insect sensitivity.	CHINESE UNIV HONG KONG,DEPT BIOL,SHATIN,HONG KONG; UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616	Chinese University of Hong Kong; University of California System; University of California Davis	Leung, PSC (corresponding author), UNIV CALIF DAVIS,SCH MED,DIV RHEUMATOL ALLERGY & CLIN IMMUNOL,DAVIS,CA 95616, USA.		Kwan, Hoi Shan/F-3048-2010; Chu, Ka Hou/B-8010-2011	Chu, Ka Hou/0000-0001-8107-5415				CARRILLO T, 1994, ANN ALLERGY, V73, P504; CARRILLO T, 1992, ANN ALLERGY, V68, P483; CARRILLO T, 1991, ALLERGY, V46, P515, DOI 10.1111/j.1398-9995.1991.tb00614.x; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; CRESPO JF, 1995, J ALLERGY CLIN IMMUN, V95, P79; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DAUL CB, 1993, J ALLERGY CLIN IMMUN, V91, P341; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; GOETZ DW, 1990, J ALLERGY CLIN IMMUN, V85, P531; HALMEPURO L, 1987, INT ARCH ALLER A IMM, V84, P165, DOI 10.1159/000234418; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1985, INT ARCH ALLER A IMM, V77, P192, DOI 10.1159/000233783; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LEUNG PSC, 1992, HEPATOLOGY, V15, P367, DOI 10.1002/hep.1840150302; MORIKAWA A, 1990, ANN ALLERGY, V65, P415; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; ONEIL CE, 1985, ANN ALLERGY 2, V55, P174; PEMBERTON RW, 1994, PAN-PAC ENTOMOL, V70, P323; Remintton C. H., 1946, ENT NEWS, V57, P119; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHIBASAKI M, 1989, ANN ALLERGY, V64, P421; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR SL, 1988, ALLERGY INGESTION SE, V3; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V108, P165, DOI 10.1159/000237134	29	201	226	0	30	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				954	961		10.1016/S0091-6749(96)80012-1	http://dx.doi.org/10.1016/S0091-6749(96)80012-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939159				2022-12-18	WOS:A1996VU76400012
J	KELLY, KJ; KURUP, V; ZACHARISEN, M; RESNICK, A; FINK, JN				KELLY, KJ; KURUP, V; ZACHARISEN, M; RESNICK, A; FINK, JN			SKIN AND SEROLOGIC TESTING IN THE DIAGNOSIS OF LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX ALLERGY; ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA); SKIN TESTING; ANAPHYLAXIS; ADVERSE REACTIONS	BARIUM ENEMA; INTRAOPERATIVE ANAPHYLAXIS; CONTACT URTICARIA; RUBBER; GLOVES; IGE	Background: Later hypersensitivity is associated with occupational allergy, contact urticaria, rhinitis, asthma, and anaphylaxis. However, standardized sensitive and specific latex extract for skin prick or serologic testing is not available in the United States. Methods: We investigated the reliability of two latex extracts in 118 consecutive skin tests in patients with spina bifida, health care workers, and other patients with symptoms of latex allergy, and 10 control subjects. Results: Forty-two of 86 patients with spina bifida, 11 of 15 health care workers with symptoms of later allergy, 6 of 7 patients with symptoms of latex allergy, and 0 of 10 control subjects had demonstrable immediate wheal and flare responses to latex prick testing. In addition, 95 patients and 10 control subjects were tested concurrently for latex-specific IgE by ELISA. Of 55 patients with positive skin prick test results, 48 were reactive as determined by ELISA for IgE-specific latex antibody (sensitivity = 87%). Latex ELISA titers were significantly higher in patients with positive skin prick test results with a history of anaphylaxis to latex and in individuals without symptoms of latex allergy who had positive skin prick test results when compared with patients with negative skin prick test results. During the skin test procedure, nine patients had adverse reactions, including anaphylactic reactions in four. Conclusions: Skin prick and serum testing are reliable methods of diagnosing latex allergy. Serologic evaluation may be more desirable until allergen standardization is available.	MED COLL WISCONSIN, CHILDRENS HOSP WISCONSIN, MILWAUKEE CTY MED CTR, DEPT MED, MILWAUKEE, WI 53226 USA; VET AFFAIRS MED CTR, MILWAUKEE, WI USA; MED COLL WISCONSIN, CHILDRENS HOSP WISCONSIN, MILWAUKEE CTY MED CTR, DEPT PEDIAT, MILWAUKEE, WI 53226 USA	Children's Hospital of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Children's Hospital of Wisconsin; Medical College of Wisconsin				Kelly, Kevin/0000-0002-2954-6117				ALENIUS H, 1992, INT ARCH ALLER A IMM, V101, P683; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; FECZKO PJ, 1989, AM J ROENTGENOL, V153, P275, DOI 10.2214/ajr.153.2.275; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; KELLY KJ, 1992, J ALLERGY CLIN IMMUN, V89, P325; KURUP VP, 1986, ZBL BAKT-INT J MED M, V261, P509; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KWITTKEN PL, 1992, J ALLERGY CLIN IMMUN, V89, P324; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; NGUYEN DH, 1991, J UROLOGY, V146, P571, DOI 10.1016/S0022-5347(17)37858-8; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SCHWARTZ EE, 1984, AM J ROENTGENOL, V143, P103, DOI 10.2214/ajr.143.1.103; SLATER J E, 1991, Journal of Allergy and Clinical Immunology, V87, P268, DOI 10.1016/0091-6749(91)91799-Y; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; 1991, FDA MDA911 MED AL, P1	22	201	209	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1140	1145		10.1016/0091-6749(93)90316-8	http://dx.doi.org/10.1016/0091-6749(93)90316-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509577				2022-12-18	WOS:A1993LG74000005
J	GREWE, SR; CHAN, SC; HANIFIN, JM				GREWE, SR; CHAN, SC; HANIFIN, JM			ELEVATED LEUKOCYTE CYCLIC-AMP PHOSPHODIESTERASE IN ATOPIC DISEASE - A POSSIBLE MECHANISM FOR CYCLIC-AMP AGONIST HYPORESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201	Oregon Health & Science University					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015557] Funding Source: NIH RePORTER; NIADDK NIH HHS [5 T32 AMO 7153] Funding Source: Medline; NIAID NIH HHS [4-R01 AI 15557] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; CHAN SC, 1982, J CYCLIC NUCLEOTIDE; COOPER KD, 1982, J INVEST DERMATOL; COOPER KD, 1982, CLIN RES, V30, P27; Ferdinand W., 1976, ENZYME MOL; GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JUHLIN L, 1967, ACTA DERM-VENEREOL, V42, P218; KANG K, UNPUB IMMUNOREGULATI, V2; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MEIER PD, 1976, MOL BIOL SKIN, P469; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PICHARD AL, 1976, J BIOL CHEM, V251, P5726; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SANO Y, 1981, CLIN RES, V29, P172; SCHUSTER DL, 1980, J IMMUNOL, V124, P1662; STINGL G, 1981, J INVEST DERMATOL, V76, P468, DOI 10.1111/1523-1747.ep12521135; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Szentivanyi A, 1980, ACTA DERM-VENEREOL, VS92, P19; TERASAKI WL, 1975, METABOLISM, V24, P311, DOI 10.1016/0026-0495(75)90112-2; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; THOMPSON WJ, 1976, J BIOL CHEM, V251, P4922; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; WEDNER HJ, 1979, J IMMUNOL, V123, P725	29	201	207	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					452	457		10.1016/0091-6749(82)90008-2	http://dx.doi.org/10.1016/0091-6749(82)90008-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6128357				2022-12-18	WOS:A1982PT74400008
J	WITTIG, HJ; BELLOIT, J; DEFILLIPPI, I; ROYAL, G				WITTIG, HJ; BELLOIT, J; DEFILLIPPI, I; ROYAL, G			AGE-RELATED SERUM IMMUNOGLOBULIN-E LEVELS IN HEALTHY-SUBJECTS AND IN PATIENTS WITH ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL 32611 USA; APPALACHIAN STATE UNIV, DEPT ACCOUNTING & FINANCING, BOONE, NC 28607 USA	State University System of Florida; University of Florida; University of North Carolina; Appalachian State University	WITTIG, HJ (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN, 1514 JEFFERSON HWY, NEW ORLEANS, LA 70121 USA.							BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; CSORBA S, 1976, ACTA PAEDIATR HUNG, V17, P207; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; GAMO T, 1974, ACTA PAEDIATR JPN, V16, P32; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HUGGINS KG, 1975, LANCET, V2, P148; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Nye L, 1975, Clin Allergy, V5, P13; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; STIEHM ER, 1978, ALLERGY PRINCIPLES P, P44	15	201	209	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					305	313		10.1016/0091-6749(80)90026-3	http://dx.doi.org/10.1016/0091-6749(80)90026-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419833				2022-12-18	WOS:A1980KM25400008
J	Bunyavanich, S; Shen, N; Grishin, A; Wood, R; Burks, W; Dawson, P; Jones, SM; Leung, DYM; Sampson, H; Sicherer, S; Clemente, JC				Bunyavanich, Supinda; Shen, Nan; Grishin, Alexander; Wood, Robert; Burks, Wesley; Dawson, Peter; Jones, Stacie M.; Leung, Donald Y. M.; Sampson, Hugh; Sicherer, Scott; Clemente, Jose C.			Early-life gut microbiome composition and milk allergy resolution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; microbiome; microbiota; Clostridia; Firmicutes; Bacteroidetes; metagenome; fatty acid; food allergy; 16s rRNA sequencing	COWS MILK; FECAL MICROBIOTA; FOOD ALLERGY; NATURAL-HISTORY; INFANTS; SENSITIZATION; TOLERANCE; DIVERSITY; CHILDREN; ACQUISITION	Background: Gut microbiota may play a role in the natural history of cow's milk allergy. Objective: We sought to examine the association between early-life gut microbiota and the resolution of cow's milk allergy. Methods: We studied 226 children with milk allergy who were enrolled at infancy in the Consortium of Food Allergy observational study of food allergy. Fecal samples were collected at age 3 to 16 months, and the children were followed longitudinally with clinical evaluation, milk-specific IgE levels, and milk skin prick test performed at enrollment, 6 months, 12 months, and yearly thereafter up until age 8 years. Gut microbiome was profiled by 16s rRNA sequencing and microbiome analyses performed using Quantitative Insights into Microbial Ecology (QIIME), Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), and Statistical Analysis of Metagenomic Profiles (STAMP). Results: Milk allergy resolved by age 8 years in 128 (56.6%) of the 226 children. Gut microbiome composition at age 3 to 6 months was associated with milk allergy resolution by age 8 years (PERMANOVA P = .047), with enrichment of Clostridia and Firmicutes in the infant gut microbiome of subjects whose milk allergy resolved. Metagenome functional prediction supported decreased fatty acid metabolism in the gut microbiome of subjects whose milk allergy resolved (eta(2) = 0.43; ANOVA P = .034). Conclusions: Early infancy is a window during which gut microbiota may shape food allergy outcomes in childhood. Bacterial taxa within Clostridia and Firmicutes could be studied as probiotic candidates for milk allergy therapy.	[Bunyavanich, Supinda; Shen, Nan; Clemente, Jose C.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA; [Bunyavanich, Supinda; Shen, Nan; Clemente, Jose C.] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY USA; [Grishin, Alexander; Sampson, Hugh; Sicherer, Scott] Icahn Sch Med Mt Sinai, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY USA; [Wood, Robert] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Burks, Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Dawson, Peter] Emmes Corp, Rockville, MD USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR USA; [Jones, Stacie M.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Clemente, Jose C.] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY USA; [Clemente, Jose C.] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; Emmes Corporation; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; National Jewish Health; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,1498, New York, NY 10029 USA.	supinda@post.harvard.edu; jose.clemente@mssm.edu			National Institutes of Health [K08AI093538, R01AI118833, U19AI066738, U01AI066560]; SUCCESS; Crohn's and Colitis Foundation of America (CCFA) [362048]; Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai; National Center for Research Resources (NCRR), a component of the National Institutes of Health [UL1 TR-000154, UL1 TR-000067, UL1 TR-000039, UL1 TR-000083, UL1 TR-000424]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000039, UL1TR000154, UL1TR000067, UL1TR001082, UL1TR001433] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005, UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, R01AI118833, U19AI066738, K08AI093538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020541] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SUCCESS; Crohn's and Colitis Foundation of America (CCFA); Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai; National Center for Research Resources (NCRR), a component of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the National Institutes of Health (K08AI093538, R01AI118833, U19AI066738 and U01AI066560), SUCCESS, Crohn's and Colitis Foundation of America (CCFA #362048), and the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. The project was also supported by grant nos. UL1 TR-000154 (National Jewish), UL1 TR-000067 (Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (U North Carolina) and UL1 TR-000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health.	Abrahamsson TR, 2013, J ALLERGY CLIN IMMUN, V131, P248, DOI 10.1016/j.jaci.2012.10.045; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Benitez AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0085-6; Berin MC, 2013, CURR BIOL, V23, pR389, DOI 10.1016/j.cub.2013.02.043; Berin MC, 2012, IMMUNOL ALLERGY CLIN, V32, P1, DOI 10.1016/j.iac.2011.10.001; Berni Canani R, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Blaxter M, 2005, PHILOS T R SOC B, V360, P1935, DOI 10.1098/rstb.2005.1725; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Canani RB, 2013, NUTRIENTS, V5, P651, DOI 10.3390/nu5030651; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Faith DP, 2006, EVOL BIOINFORM, V2, P121; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kendler M, 2006, PEDIAT ALLERG IMM-UK, V17, P141, DOI 10.1111/j.1399-3038.2005.00371.x; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lim ES, 2015, NAT MED, V21, P1228, DOI 10.1038/nm.3950; Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Merrifield CA, 2016, ISME J, V10, P145, DOI 10.1038/ismej.2015.90; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Thompson-Chagoyan OC, 2011, INT ARCH ALLERGY IMM, V156, P325, DOI 10.1159/000323893; Thompson-Chagoyan OC, 2010, PEDIAT ALLERG IMM-UK, V21, pE394, DOI 10.1111/j.1399-3038.2009.00961.x; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	47	200	207	12	103	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1122	1130		10.1016/j.jaci.2016.03.041	http://dx.doi.org/10.1016/j.jaci.2016.03.041			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27292825	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000385499400018
J	Bachert, C; Zhang, L; Gevaert, P				Bachert, Claus; Zhang, Luo; Gevaert, Phillippe			Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; T(H)2; IL-5; IL-4; IL-13; GATA-3; IgE; humanized and fully human mAbs; gene silencing	ENDOSCOPIC SINUS SURGERY; ORAL CORTICOSTEROID-THERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; TISSUE EOSINOPHILIA; ANTI-IGE; ASTHMA; IL-5; INFLAMMATION; UPDATE	Chronic rhinosinusitis (CRS) affects more than 10% of the population in the United States and Europe. Recent findings point to a considerable variation of inflammatory subtypes in patients with CRS with nasal polyps and patients with CRS without nasal polyps. According to current guidelines, glucocorticosteroids and antibiotics are the principle pharmacotherapeutic approaches; however, they fail in a group of patients who share common clinical and laboratory markers. Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a T(H)2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment. As a consequence, several innovative approaches targeting the T(H)2 bias with humanized mAbs have been subjected to proof-of-concept studies in patients with CRS with nasal polyps with or without comorbid asthma: omalizumab, reslizumab, mepolizumab, and recently dupilumab. Future concepts using upstream targets, such as GATA-3, also focus on this endotype. This current development might result in advantages in the treatment of patients with the most severe CRS.	[Bachert, Claus; Gevaert, Phillippe] Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus; Gevaert, Phillippe] Ghent Univ Hosp, ENT Dept, Ghent, Belgium; [Bachert, Claus] Univ Stockholm, Karolinska Inst, CLINTEC, Div ENT Dis, S-10691 Stockholm, Sweden; [Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Karolinska Institutet; Stockholm University; Capital Medical University	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012; Gevaert, Philippe/ABA-4588-2021; Gevaert, Philippe/AAP-1892-2020	Gevaert, Philippe/0000-0002-1629-8468; Zhang, Luo/0000-0002-0910-9884				Aasbjerg K, 2013, RESP MED, V107, P1852, DOI 10.1016/j.rmed.2013.09.007; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Arm JP, 2014, CLIN EXP ALLERGY, V44, P1371, DOI 10.1111/cea.12400; Aukema AAC, 2005, J ALLERGY CLIN IMMUN, V115, P1017, DOI 10.1016/j.jaci.2004.12.1144; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2015, EAACI ONLINE LI 0606; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bermudez-Humaran LG, 2013, CURR OPIN MICROBIOL, V16, P278, DOI 10.1016/j.mib.2013.06.002; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Bonfils P, 2006, ACTA OTO-LARYNGOL, V126, P1195, DOI 10.1080/00016480600672667; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Dalziel K, 2006, AM J RHINOL, V20, P506, DOI 10.2500/ajr.2006.20.2923; Pilan RRD, 2012, RHINOLOGY, V50, P129, DOI [10.4193/Rhino11.256, 10.4193/Rhin11.256]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2003, ALLERGY, V58, P371, DOI 10.1034/j.1398-9995.2003.00110.x; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2015, J ALLERGY CLIN IMMUN, V135, pAB238, DOI 10.1016/j.jaci.2014.12.1713; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hopkins C, 2006, CLIN OTOLARYNGOL, V31, P390, DOI 10.1111/j.1749-4486.2006.01275.x; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Khalil HS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004458.pub2; Kim YS, 2011, AM J RHINOL ALLERGY, V25, pE117, DOI 10.2500/ajra.2011.25.3630; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lal D, 2011, INT FORUM ALLERGY RH, V1, P136, DOI 10.1002/alr.20024; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Lou HF, 2015, AM J RHINOL ALLERGY, V29, P350, DOI 10.2500/ajra.2015.29.4231; Martinez-Devesa P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005232.pub3; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; Nakayama T, 2012, AM J RHINOL ALLERGY, V26, P172, DOI 10.2500/ajra.2012.26.3749; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; Philpott C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006680; Pinto JM, 2010, RHINOLOGY, V48, P318, DOI [10.4193/Rhin09.144, 10.4193/Rhino09.144]; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; Schiller Jeannine S, 2012, Vital Health Stat 10, P1; Sel S, 2008, J ALLERGY CLIN IMMUN, V121, P910, DOI 10.1016/j.jaci.2007.12.1175; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577; Simon HU, 1997, J IMMUNOL, V158, P3902; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Tomassen P, 2011, ALLERGY, V66, P556, DOI 10.1111/j.1398-9995.2010.02503.x; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Videler WJM, 2012, RHINOLOGY, V50, P45, DOI 10.4193/Rhino11.123; Wallwork B, 2006, LARYNGOSCOPE, V116, P189, DOI 10.1097/01.mlg.0000191560.53555.08; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Zhang N, 2005, RHINOLOGY, V43, P162; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	56	200	223	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1431	1440		10.1016/j.jaci.2015.10.010	http://dx.doi.org/10.1016/j.jaci.2015.10.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26654192				2022-12-18	WOS:000366044300001
J	Fujisawa, D; Kashiwakura, J; Kita, H; Kikukawa, Y; Fujitani, Y; Sasaki-Sakamoto, T; Kuroda, K; Nunomura, S; Hayama, K; Terui, T; Ra, C; Okayama, Y				Fujisawa, Daisuke; Kashiwakura, Jun-ichi; Kita, Hirohito; Kikukawa, Yusuke; Fujitani, Yasushi; Sasaki-Sakamoto, Tomomi; Kuroda, Kazumichi; Nunomura, Satoshi; Hayama, Koremasa; Terui, Tadashi; Ra, Chisei; Okayama, Yoshimichi			Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic urticaria; eosinophils; eosinophil granule proteins; eosinophil peroxidase; histamine; human skin mast cells; major basic protein; Mas-related gene X2; substance P	CHRONIC IDIOPATHIC URTICARIA; MAJOR BASIC-PROTEIN; FC-EPSILON-RI; EOSINOPHIL CATIONIC PROTEIN; IN-VITRO; CUTANEOUS RESPONSES; HISTAMINE-RELEASE; MOLECULAR-CLONING; SUBSTANCE-P; ACTIVATION	Background: Wheal reactions to intradermally injected neuropeptides, such as substance P (SP) and vasoactive intestinal peptide, are significantly larger and longer lasting in patients with chronic urticaria (CU) than in nonatopic control (NC) subjects. Mas-related gene X2 (MrgX2) has been identified as a receptor for basic neuropeptides, such as SP and vasoactive intestinal peptide. Mast cell (MC) responsiveness to eosinophil mediators contributes to the late-phase reaction of allergy. Objective: We sought to compare the frequency of MrgX2 expression in skin MCs from patients with CU and NC subjects and to identify the receptor for basic eosinophil granule proteins on human skin MCs. Methods: MrgX2 expression was investigated by using immunofluorescence in skin tissues from NC subjects and patients with severe CU and on skin-derived cultured MCs. MrgX2 expression in human MCs was reduced by using a lentiviral small hairpin RNA silencing technique. Ca2+ influx was measured in CHO cells transfected with MrgX2 in response to eosinophil granule proteins. Histamine and prostaglandin D-2 levels were measured by using enzyme immunoassays. Results: The number of MrgX2(+) skin MCs and the percentage of MrgX2(+) MCs in all MCs in patients with CU were significantly greater than those in NC subjects. Eosinophil infiltration in urticarial lesions was observed in 7 of 9 patients with CU. SP, major basic protein, and eosinophil peroxidase, but not eosinophil-derived neurotoxin, induced histamine release from human skin MCs through MrgX2. Conclusion: MrgX2 might be a new target molecule for the treatment of wheal reactions in patients with severe CU.	[Fujisawa, Daisuke; Sasaki-Sakamoto, Tomomi; Nunomura, Satoshi; Hayama, Koremasa; Okayama, Yoshimichi] Nihon Univ, Sch Med, Res Inst Med Sci, Allergy & Immunol Grp, Tokyo 1738610, Japan; [Fujisawa, Daisuke; Nunomura, Satoshi; Hayama, Koremasa; Terui, Tadashi] Nihon Univ, Sch Med, Dept Dermatol, Tokyo 1738610, Japan; [Kashiwakura, Jun-ichi] Ctr Integrat Med Sci IMS RCAI, RIKEN, RCAI, Lab Allerg Dis, Yokohama, Kanagawa, Japan; [Kita, Hirohito] Mayo Clin Coll Med, Mayo Clin, Rochester, MI USA; [Kikukawa, Yusuke; Fujitani, Yasushi] Takeda Pharmaceut Co, Div Pharmaceut Res, Fujisawa, Kanagawa, Japan; [Kuroda, Kazumichi; Ra, Chisei] Nihon Univ, Sch Med, Dept Microbiol, Tokyo 1738610, Japan	Nihon University; Nihon University; RIKEN; Mayo Clinic; Takeda Pharmaceutical Company Ltd; Nihon University	Okayama, Y (corresponding author), Nihon Univ, Sch Med, Res Inst Med Sci, Allergy & Immunol Grp,Itabashi Ku, 30-1 Oyaguchikami Machi, Tokyo 1738610, Japan.	yoshimichi@nihon-u.ac.jp	Nunomura, Satoshi/Q-4249-2017; Okayama, Yoshimichi/AAG-4352-2021	Nunomura, Satoshi/0000-0002-9315-4185; Kikukawa, Yusuke/0000-0002-5603-3181; Terui, Tadashi/0000-0002-0275-4311; Hayama, Koremasa/0000-0001-8651-2493	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government [23591470]; Nihon University Multidisciplinary Research [Sou 13-014]; National Institutes of Health [AI34486]; Grants-in-Aid for Scientific Research [25253071] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034486, R01AI034486, R29AI034486] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nihon University Multidisciplinary Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government (Project no. [C] 23591470 to Y.O.), the Nihon University Multidisciplinary Research Grant for 2013 (Sou 13-014 to Y.O.), and the National Institutes of Health (AI34486 to H.K.).	Allia E, 2005, J PATHOL, V207, P336, DOI 10.1002/path.1839; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARKER RL, 1989, J IMMUNOL, V143, P952; Borici-Mazi R, 1999, ALLERGY, V54, P46, DOI 10.1034/j.1398-9995.1999.00726.x; Bossi F, 2011, ALLERGY, V66, P1538, DOI 10.1111/j.1398-9995.2011.02704.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cugno M, 2009, INT ARCH ALLERGY IMM, V148, P170, DOI 10.1159/000155748; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Elishmereni M, 2013, ALLERGY, V68, P171, DOI 10.1111/all.12059; Elishmereni M, 2011, ALLERGY, V66, P376, DOI 10.1111/j.1398-9995.2010.02494.x; Ferrer M, 2010, CLIN EXP ALLERGY, V40, P1760, DOI 10.1111/j.1365-2222.2010.03582.x; Forward NA, 2009, J IMMUNOL, V183, P3014, DOI 10.4049/jimmunol.0802509; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; IWASAKI A, 1995, CLIN EXP RHEUMATOL, V13, P173; JUHLIN L, 1991, ACTA DERM-VENEREOL, V71, P495; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Lee H, 2013, ARTHRITIS RHEUM-US, V65, P109, DOI 10.1002/art.37741; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; Marzano AV, 2011, CLIN EXP IMMUNOL, V165, P44, DOI 10.1111/j.1365-2249.2011.04391.x; Mathias SD, 2012, ANN ALLERG ASTHMA IM, V108, P20, DOI 10.1016/j.anai.2011.09.008; Mathias SD, 2010, ANN ALLERG ASTHMA IM, V105, P142, DOI 10.1016/j.anai.2010.06.011; Minai-Fleminger Y, 2010, CELL TISSUE RES, V341, P405, DOI 10.1007/s00441-010-1010-8; Nair P, 2013, ALLERGY, V68, P1177, DOI 10.1111/all.12206; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Ohsawa Y, 2012, ALLERGY, V67, P1014, DOI 10.1111/j.1398-9995.2012.02854.x; Okayama Y, 2012, ALLERGY, V67, P1241, DOI [10.1111/j.1398-9995.2012.02879.x, 10.1111/j.1398-9995.2012.02879.x.]; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; Okumura S, 2003, BLOOD, V102, P2547; Patella V, 1996, J IMMUNOL, V157, P1219; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SMITH CH, 1995, J ALLERGY CLIN IMMUN, V96, P360, DOI 10.1016/S0091-6749(95)70055-2; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; Subramanian H, 2011, MOL PHARMACOL, V79, P1005, DOI 10.1124/mol.111.071472; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Tedeschi A, 2005, CLIN EXP DERMATOL, V30, P171, DOI 10.1111/j.1365-2230.2005.01732.x; Tedeschi A, 2009, ALLERGY, V64, P1616, DOI 10.1111/j.1398-9995.2009.02069.x; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005; Wang XS, 2006, INT IMMUNOPHARMACOL, V6, P839, DOI 10.1016/j.intimp.2005.12.004; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236	61	200	205	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					622	+		10.1016/j.jaci.2014.05.004	http://dx.doi.org/10.1016/j.jaci.2014.05.004			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24954276				2022-12-18	WOS:000341372400015
J	Wei, CY; Chung, WH; Huang, HW; Chen, YT; Hung, SI				Wei, Chun-Yu; Chung, Wen-Hung; Huang, Hsiao-Wen; Chen, Yuan-Tsong; Hung, Shuen-Iu			Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Carbamazepine; drug hypersensitivity; HLA; Stevens-Johnson syndrome; toxic epidermal necrolysis	TOXIC EPIDERMAL NECROLYSIS; CUTANEOUS ADVERSE-REACTIONS; HYPERSENSITIVITY REACTIONS; HLA-B-ASTERISK-1502 ALLELE; DRUG HYPERSENSITIVITY; OXCARBAZEPINE; RISK; MARKER; ASSOCIATION; PEPTIDES	Background: Increasing studies have revealed that HLA alleles are the major genetic determinants of drug hypersensitivity; however, the underlying molecular mechanism remains unclear. Objective: We adopted the HLA-B*1502 genetic predisposition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the pathologic role of HLA in delayed-type drug hypersensitivity. Methods: We in vitro expanded CBZ-specific cytotoxic T lymphocytes (CTLs) from patients with CBZ-induced SJS/TEN and analyzed the interaction between HLA-B and CBZ analogs based on CTL response, surface plasmon resonance, peptide-binding assay, site-directed mutagenesis, and computer modeling. Results: The endogenous peptide-loaded HLA-B*1502 molecule presented CBZ to CTLs without the involvement of intracellular drug metabolism or antigen processing. The HLA-B*1502/peptide/beta(2)-microglobulin protein complex showed binding affinity toward chemicals sharing 5-carboxamide on the tricyclic ring, as with CBZ. However, modifications of the ring structure of CBZ altered HLA-B*1502 binding and CTL response. In addition to HLA-B*1502, other HLA-B75 family members could also present CBZ to activate CTLs, whereas members of the HLA-B62 and HLA-B72 families could not. Three residues (Asn63, Ile95, and Leu156) in the peptide-binding groove of HLA-B*1502 were involved in CBZ presentation and CTL activation. In particular, Asn63 shared by members of the B75 family was the key residue. Computer simulations revealed a preferred molecular conformation of the 5-carboxamide group of CBZ and the side chain of Arg62 on the B pocket of HLA-B*1502. Conclusions: This study demonstrates a direct interaction of HLA with drugs, provides a detailed molecular mechanism of HLA-associated drug hypersensitivity, and has clinical correlations for CBZ-related drug-induced SJS/TEN. (J Allergy Clin Immunol 2012;129:1562-9.)	[Hung, Shuen-Iu] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Genome Res Ctr, Taipei 11221, Taiwan; [Wei, Chun-Yu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 11221, Taiwan; [Wei, Chun-Yu; Huang, Hsiao-Wen; Chen, Yuan-Tsong; Hung, Shuen-Iu] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Wei, Chun-Yu] Taiwan Int Grad Program, Program Mol Med, Taipei, Taiwan; [Chung, Wen-Hung] Chang Gung Univ, Dept Dermatol, Chang Gung Mem Hosp, Coll Med, Keelung, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Chang Gung Memorial Hospital; Chang Gung University	Hung, SI (corresponding author), Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Genome Res Ctr, 155 Linong St,Sec 2, Taipei 11221, Taiwan.	chen0010@ibms.sinica.edu.tw; sihung@ym.edu.tw	Hung, Shuen-Iu/ABB-2139-2021	Hung, Shuen-Iu/0000-0001-6531-5538	National Science Council, Taiwan [96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3, NSC-98-3112-B-001-021, NSC-99-3112-B-001-023]; Taiwan Ministry of Education; Academia Sinica, Taiwan [AS-99-TP-B12]; Chang Gung Memorial Hospital	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Ministry of Education(Ministry of Education, Taiwan); Academia Sinica, Taiwan(Academia Sinica - Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	Supported by grants from the National Science Council, Taiwan (96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3, NSC-98-3112-B-001-021, NSC-99-3112-B-001-023, NSC-99-3112-B-001-023, and NSC-98-3112-B-001-021); the Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); Academia Sinica, Taiwan (AS-99-TP-B12); and Chang Gung Memorial Hospital.	Almeida L, 2007, NEUROTHERAPEUTICS, V4, P88, DOI 10.1016/j.nurt.2006.10.005; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Dogan EA, 2008, EPILEPSY BEHAV, V13, P156, DOI 10.1016/j.yebeh.2008.02.001; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224; Guglielmi L, 2006, CURR PHARM DESIGN, V12, P3309, DOI 10.2174/138161206778194088; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Aceves-Avila FJ, 2008, JCR-J CLIN RHEUMATOL, V14, P261, DOI 10.1097/RHU.0b013e31817a241a; Kaniwa N, 2010, EPILEPSIA, V51, P2461, DOI 10.1111/j.1528-1167.2010.02766.x; Kessler Jan H, 2004, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1812s61; Kim SH, 2011, EPILEPSY RES, V97, P190, DOI 10.1016/j.eplepsyres.2011.08.010; Ko TM, 2011, J ALLERGY CLIN IMMUN, V128, P1266, DOI 10.1016/j.jaci.2011.08.013; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; Lin LC, 2009, KAOHSIUNG J MED SCI, V25, P82, DOI 10.1016/S1607-551X(09)70045-2; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Tang YH, 2011, CLIN EXP ALLERGY; Tassaneeyakul W, 2010, EPILEPSIA, V51, P926, DOI 10.1111/j.1528-1167.2010.02533.x; Volosov A, 1999, CLIN PHARMACOL THER, V66, P547, DOI 10.1053/cp.1999.v66.103170001; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017; Yang L, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000441; Zanni MP, 1997, J IMMUNOL, V158, P1139	40	200	212	4	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1562	+		10.1016/j.jaci.2011.12.990	http://dx.doi.org/10.1016/j.jaci.2011.12.990			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22322005	Bronze			2022-12-18	WOS:000304764600017
J	Kim, S; Marigowda, G; Oren, E; Israel, E; Wechsler, ME				Kim, Sophia; Marigowda, Gautham; Oren, Eyal; Israel, Elliot; Wechsler, Michael E.			Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Churg-Strauss syndrome; eosinophilia; IL-5; asthma; mepolizumah; steroid sparing	HYPEREOSINOPHILIC SYNDROME; MONOCLONAL-ANTIBODY; HUMAN INTERLEUKIN-5; PERSISTENT ASTHMA; EOSINOPHILIA; THERAPY; ANTI-INTERLEUKIN-5; ACTIVATION; VASCULITIS; CYTOKINES	Background: Treatments for Churg-Strauss syndrome (CSS), a rare eosinophilic vasculitis characterized by asthma, sinusitis, peripheral eosinophilia, pulmonary infiltrates, and tissue infiltration, are limited by toxicity or poor efficacy. Levels of IL-5, a cytokine regulating eosinophils, can be increased in patients with CSS. Mepolizumab, a humanized monoclonal anti IL-5 antibody, decreases steroid requirements in patients with non-CSS hypereosinophilic syndromes. Objective: The purpose of this study was to assess whether mepolizumab would safely allow corticosteroid tapering in patients with steroid-dependent CSS while decreasing serum markers of disease activity. Methods: This open-label pilot study treated 7 patients with 4 monthly doses of mepolizumab to assess whether it safely decreased CSS disease activity and permitted tapering of systemic corticosteroids. Results: Mepolizumab was safe and well tolerated in patients with CSS. Mepolizumab reduced eosinophil counts and allowed for safe corticosteroid reduction in all 7 subjects. On cessation of mepolizumab, CSS manifestations recurred, necessitating corticosteroid bursts. Conclusion: Mepolizumab is a safe and well-tolerated therapy in patients with CSS, offering clinical benefit by enabling corticosteroid tapering while maintaining clinical stability. (J Allergy Clin Immunol 2010;125:1336-43.)	[Marigowda, Gautham; Israel, Elliot; Wechsler, Michael E.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02115 USA; [Kim, Sophia] Childrens Hosp Boston, Dept Pediat, Boston, MA USA; [Oren, Eyal] Asthma & Allergy Affiliates, Danvers, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	Wechsler, ME (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mwechsler@rics.bwh.harvard.edu	Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019; Oren, Eyal/AAD-5561-2019	Wechsler, Michael/0000-0003-3505-2946; 	GlaxoSmithKline; Aerovance; Ception Therapeutics; Genentech; Icagen; Johnson Johnson; MedImmune; National Institutes of Health; Novartis	GlaxoSmithKline(GlaxoSmithKline); Aerovance; Ception Therapeutics; Genentech(Roche HoldingGenentech); Icagen; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); MedImmune(AstraZenecaMedimmune); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis)	Supported by an investigator-initiated grant from GlaxoSmithKline. This study is registered at Clinicaltrials.gov as GRANT00375947.; Disclosure of potential conflict of interest: E. Oren is on the speaker's bureau for Meda Pharmaceuticals and GlaxoSmithKline. E. Israel has consultant arrangements with Abbott, Amgen, Astellas Pharma US, Cowen & Co, GlaxoSmithKline, Icagen. MedImmune, Merck, NewMentor. NKT Therapeutics, Novartis, PDL Biopharma, Pulmatrix, Schering-Plough, Sepracor. and Teva Specialty Pharmaceuticals and receives research support from Aerovance, Ception Therapeutics, Genentech, Icagen, Johnson & Johnson, MedImmune, the National Institutes of Health, and Novartis. M. E. Wechsler is a consultant for GlaxoSmithKline and MedImmune and receives research support front GlaxoSmithKline and Ception Therapeutics. The rest of the authors have declared that they have no conflict of interest.	DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harrold LR, 2007, PHARMACOEPIDEM DR S, V16, P620, DOI 10.1002/pds.1353; Hellmich B, 2005, ANN NY ACAD SCI, V1051, P121, DOI 10.1196/annals.1361.053; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kahn JE, 2010, J ALLERGY CLIN IMMUN, V125, P267, DOI 10.1016/j.jaci.2009.10.014; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Leckie Maggie J, 2003, Am J Respir Med, V2, P245; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LUQMANI RA, 1994, Q J MED, V87, P671; Martin RM, 1999, PHARMACOEPIDEM DR S, V8, P179, DOI 10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.3.CO;2-B; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Muschen M, 1999, AM J PATHOL, V155, P915, DOI 10.1016/S0002-9440(10)65191-7; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Peen E, 2000, ARTHRITIS RHEUM, V43, P1897, DOI 10.1002/1529-0131(200008)43:8<1897::AID-ANR29>3.0.CO;2-I; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schnabel A, 1999, THORAX, V54, P771, DOI 10.1136/thx.54.9.771; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Tsukadaira A, 1999, ALLERGY ASTHMA PROC, V20, P39, DOI 10.2500/108854199778681486; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; Zia-Amirhosseini P, 1999, J PHARMACOL EXP THER, V291, P1060	27	200	212	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1336	1343		10.1016/j.jaci.2010.03.028	http://dx.doi.org/10.1016/j.jaci.2010.03.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513524				2022-12-18	WOS:000278831000023
J	Escribano, L; Alvarez-Twose, I; Sanchez-Munoz, L; Garcia-Montero, A; Nunez, R; Almeida, J; Jara-Acevedo, M; Teodosio, C; Garcia-Cosio, M; Bellas, C; Orfao, A				Escribano, Luis; Alvarez-Twose, Ivan; Sanchez-Munoz, Laura; Garcia-Montero, Andres; Nunez, Rosa; Almeida, Julia; Jara-Acevedo, Maria; Teodosio, Cristina; Garcia-Cosio, Monica; Bellas, Carmen; Orfao, Alberto			Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; indolent systemic mastocytosis; long-term prognosis	MAST-CELL DISEASE; C-KIT; CATALYTIC DOMAIN; TRYPTASE LEVELS; MUTATION; OSTEOPOROSIS; DIAGNOSIS; CRITERIA	Background: Indolent systemic mastocytosis is a group of rare diseases for which reliable predictors of progression and outcome are still lacking. Objective: Here we investigate the prognostic impact of the clinical, biological, phenotypic, histopathological, and molecular disease characteristics in adults with indolent systemic mastocytosis, who were followed using conservative therapy. Methods: A total of 145 consecutive patients were prospectively followed between January 1983 and July 2008; in addition, from 1967 to 1983, 20 patients were retrospectively studied. Results: Multivariate analysis showed that serum beta 2-microglobulin (P = .003) together with the presence of mast/stem cell growth factor receptor gene (KIT) mutation in mast cells plus myeloid and lymphoid hematopoietic lineages (P = .02) was the best combination of independent parameters for predicting disease progression (cumulative probability of disease progression of 1.7% +/- 1.2% at 5-10 years and of 8.4% +/- 5.0% at 20-25 years). Regarding overall survival, the best predictive model included age >60 years (P = .005) and development of an associated clonal hematological non-mast cell disorder (P = .03) with a cumulative probability of death of 2.2% +/- 1.3% at 5 years and of 11% +/- 5.9% at 25 years. Conclusions: Indolent systemic mastocytosis in adults has a low disease progression rate, and the great majority of patients have a normal life expectancy, with the presence of KIT mutation in all hematopoietic lineages and increased serum beta 2-microglobulin the most powerful independent parameters for predicting transformation into a more aggressive form of the disease. (J Allergy Clin Immunol 2009;124:514-21.)	[Escribano, Luis; Alvarez-Twose, Ivan; Sanchez-Munoz, Laura] Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla La Mancha, E-45071 Toledo, Spain; [Garcia-Montero, Andres; Almeida, Julia; Jara-Acevedo, Maria; Teodosio, Cristina; Orfao, Alberto] Univ Salamanca, Dept Med & Cytometry & Hematol, Univ & Univ Hosp Salamanca, Ctr Invest Canc,IBMCC,CSIC, E-37008 Salamanca, Spain; [Garcia-Cosio, Monica] Hosp Ramon & Cajal, Serv Anat Patol, E-28034 Madrid, Spain; [Nunez, Rosa] Hosp Ramon & Cajal, Serv Hematol, E-28034 Madrid, Spain; [Bellas, Carmen] Clin Puerta de Hierro, Serv Anat Patol, Madrid, Spain	Complejo Hospitalario de Toledo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Escribano, L (corresponding author), Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla La Mancha, Carretera Cobisa S-N, E-45071 Toledo, Spain.	lescribanom@sescam.jccm.es	Garcia-Montero, Andres C/B-6558-2017; 2009, Secribsal/A-1266-2012; Orfao, Alberto/B-5801-2017; Montero, Andres/HGA-9093-2022	Garcia-Montero, Andres C/0000-0003-4360-1386; Teodosio, Cristina/0000-0002-2097-7199; Sanchez-Munoz, Laura/0000-0003-1757-7255; Jara-Acevedo, Maria/0000-0001-7965-7512; Alvarez-Twose, Ivan/0000-0002-1190-4473	Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III [REMA G03/007, FIS050769, FIS060529, FIS061377, RETICS RD06/0020/0035-FEDER]; Comunidad Autonoma de Madrid [GR/SAL/0133/2004]; Junta de Castilla y Leon [SAN196/SA10/07]; Junta de Comunidades de Castilla La Mancha [FISCAM 2007/36]; Fundacion MMA; FIS/FEDER [CP03/00035]; FCT of Portugal [SFRH/BD/17545/2004]	Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III(Instituto de Salud Carlos III); Comunidad Autonoma de Madrid(Comunidad de Madrid); Junta de Castilla y Leon(Junta de Castilla y Leon); Junta de Comunidades de Castilla La Mancha(Junta de Comunidades de Castilla-La Mancha); Fundacion MMA; FIS/FEDER(Instituto de Salud Carlos IIIEuropean Commission); FCT of Portugal(Portuguese Foundation for Science and Technology)	Supported by grants from the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (REMA G03/007, FIS050769, FIS060529, FIS061377, and RETICS RD06/0020/0035-FEDER); Comunidad Auto noma de Madrid (GR/SAL/0133/2004), Junta de Castilla y Leon (Grant SAN196/SA10/07); Junta de Comunidades de Castilla La Mancha (FISCAM 2007/36); and Fundacion MMA. A.G.-M. is supported by a grant from FIS/FEDER (CP03/00035) and C.T. from the FCT of Portugal (SFRH/BD/17545/2004).	Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2004, J ALLERGY CLIN IMMUN, V114, P28, DOI 10.1016/j.jaci.2004.02.042; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; HORNY HP, 1985, HUM PATHOL, V16, P808, DOI 10.1016/S0046-8177(85)80252-5; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Kocabas CN, 2005, J ALLERGY CLIN IMMUN, V115, P1155, DOI 10.1016/j.jaci.2005.02.030; Kushnir-Sukhov NM, 2006, INT ARCH ALLERGY IMM, V139, P265, DOI 10.1159/000091172; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS1, DOI 10.1111/1523-1747.ep12468869; Metcalfe DD, 1991, J INVEST DERMATOL, V96, p2S; Miller PD, 2006, REV ENDOCR METAB DIS, V7, P75, DOI 10.1007/s11154-006-9006-0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pardanani A, 2003, LEUKEMIA RES, V27, P883, DOI 10.1016/S0145-2126(03)00065-1; Pardanani A, 2002, MAYO CLIN PROC, V77, P1169, DOI 10.4065/77.11.1169; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P1097, DOI 10.1080/10428190290021470; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P2257, DOI 10.1080/1042819021000039965; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Sperr WR, 2000, LEUKEMIA LYMPHOMA, V37, P473, DOI 10.3109/10428190009058500; Tang X, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015156; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRAVIS WD, 1989, ARCH PATHOL LAB MED, V113, P365; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2001, WHO CLASSIFICATION T, P291; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Zhang LY, 2006, LEUKEMIA RES, V30, P373, DOI 10.1016/j.leukres.2005.08.015; 1994, WHO TECH REP SER, V243, P1	41	200	203	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					514	521		10.1016/j.jaci.2009.05.003	http://dx.doi.org/10.1016/j.jaci.2009.05.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19541349	Bronze			2022-12-18	WOS:000274315900017
J	Corren, J				Corren, J			Allergic rhinitis and asthma: How important is the link?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; bronchial hyperresponsiveness; intranasal corticosteroids; antihistamines; decongestants	BRONCHIAL HYPERRESPONSIVENESS; AIRWAY RESPONSIVENESS; SEASONAL INCREASE; NASAL OBSTRUCTION; CONTROLLED TRIAL; NATURAL-HISTORY; FOLLOW-UP; TERFENADINE; CETIRIZINE; RISK	Dysfunction of the upper and lower airways frequently coexist, and they appear to share key elements of pathogenesis. Data from epidemiologic studies indicate that nasal symptoms are experienced by as many as 78% of patients with asthma and that asthma is experienced by as many as 38% of patients with allergic rhinitis. Studies also have identified a temporal relation between the onset of rhinitis and asthma, with rhinitis frequently preceding the development of asthma. Patients with allergic rhinitis and no clinical evidence of asthma commonly exhibit nonspecific bronchial hyperresponsiveness. The observation that management of allergic rhinitis also relieves symptoms of asthma has heightened interest in the link between these diseases. Intranasal corticosteroids can prevent increases in nonspecific bronchial reactivity and asthma symptoms associated with seasonal pollen exposure. Similarly, among patients with perennial rhinitis, daily asthma symptoms, exercise-induced bronchospasm, and bronchial responsiveness to methacholine are reduced after administration of intranasal corticosteroids. Antihistamines, with or without decongestants, reduce seasonal rhinitis symptoms, asthma symptoms, and objective measurements of pulmonary function among patients with rhinitis and asthma. The mechanisms that connect upper and lower airway dysfunction are under investigation. They include a nasal-bronchial reflex, mouth breathing caused by nasal obstruction, and pulmonary aspiration of nasal contents. Nasal allergen challenge results in increases in lower airway reactivity with 30 minutes, suggesting a neural reflex. Improvements in asthma associated with increased nasal breathing may be the result of superior humidification, warming of inspired air, and decreased inhalation of airborne allergens. Postnasal drainage of inflammatory cells during sleep also may affect lower airway responsiveness. A link between allergic rhinitis and asthma is evident from epidemiologic, pathophysiologic, and clinical studies. Future research, however, is needed to determine whether nasal therapy can alter the natural history of asthma.			Corren, J (corresponding author), ALLERGY RES FDN INC, 11620 WILSHIRE BLVD, SUITE 200, LOS ANGELES, CA 90025 USA.							AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BOUSQUET J, 1992, EUR RESPIR J, V5, P1137; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CORREN J, 1990, American Review of Respiratory Disease, V141, pA177; CORREN J, IN PRESS ANN ALLERGY; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; KARLIN JM, 1972, ANN ALLERGY, V30, P342; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580, DOI 10.1164/ajrccm/141.3.580; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; MCLAURIN JG, 1932, ANN OTO RHINOL LARYN, V41, P780; MULLIN WV, 1920, AM REV TUBERC, V4, P683; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; PLOTKOWSKI L M, 1990, American Review of Respiratory Disease, V141, pA652; PRIETO L, 1994, ANN ALLERGY, V72, P534; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Sluder G, 1919, J AMER MED ASSOC, V73, P589, DOI 10.1001/jama.1919.02610340021006; Small P., 1989, AM J RHINOL, V3, P17, DOI [10.2500/105065889782024384, DOI 10.2500/105065889782024384]; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; VERDIANI P, 1990, J ALLERGY CLIN IMMUN, V86, P576, DOI 10.1016/S0091-6749(05)80215-5; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WHICKER JH, 1973, ANN OTO RHINOL LARYN, V82, P355, DOI 10.1177/000348947308200315; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WOODBAKER R, 1995, BRIT J CLIN PHARMACO, V39, P671, DOI 10.1111/j.1365-2125.1995.tb05727.x; WYLLIE JW, 1976, SURG FORUM, V27, P535; YAN K, 1983, EUR J RESPIR DIS, V64, P105	55	200	206	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S781	S786		10.1016/S0091-6749(97)70127-1	http://dx.doi.org/10.1016/S0091-6749(97)70127-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042071				2022-12-18	WOS:A1997WH83100039
J	Sarpong, SB; Hamilton, RG; Eggleston, PA; Adkinson, NF				Sarpong, SB; Hamilton, RG; Eggleston, PA; Adkinson, NF			Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergen; sensitization; socioeconomic status; race; urban; children; asthma	INNER-CITY; ANTIGENS	Background: The domestic cockroach has been identified as an important source of indoor aeroallergens worldwide in both temperate and tropical climates. Because cockroach populations are highest in crowded urban areas, some have suggested that the increased asthma morbidity and mortality rates in inner cities could be related in part to cockroach allergen exposure. We have examined cockroach allergen exposure in the homes of children with asthma in both urban and suburban locations and have related the rates of exposure and sensitization to socioeconomic, racial, and demographic factors. Objective: The study was designed to determine the independent contribution of race, socioeconomic status, and place of residence to the risk of cockroach allergen exposure and sensitization in children with asthma. Methods: Eighty-seven children with moderate to severe allergic asthma, aged 5 to 17 years, participating in a prospective trial of immunotherapy, were evaluated. Extracted dust samples from three home locations were analyzed by using two-site monoclonal immunoassays for major cockroach allergens (Bla g 1 and Bla g 2). A puncture skin test with a mixed cockroach allergen extract was performed in 81 of the 87 subjects. Results: In the 87 homes evaluated 26% of the bedroom dust samples had detectable levels of cockroach allergen. In homes with detectable bedroom cockroach allergen levels, mean Bla g 1 and Bla g 2 concentrations in urban and suburban homes were similar. Over 80% of children with bedroom Bla g 1 or Bla g 2 of 1 U/gm or greater demonstrated skin sensitivity to cockroach allergen. The rate of cockroach sensitization was directly related to the level of bedroom exposure. African-American race was the only factor that was independently associated with cockroach allergen exposure (p = 0.05). Lower socioeconomic status, age greater than 11 years, cockroach exposure, and African-American race were all independently associated with cockroach allergen sensitization on the basis of stepwise multiple linear regression analysis. Conclusions: African-American race and low socioeconomic status were both independent, significant risk factors for cockroach allergen sensitization in children with atopic asthma. Cockroach allergen is detectable throughout the house, including the critical bedroom environment.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT INTERNAL MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-21073, AI-30773] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073, U01AI030773] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHOOVIVATHANAVANICH P, 1970, LANCET, V2, P1362; FRASER BN, 1979, S AFR MED J, V55, P637; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Hollingshead A, 1965, SOCIAL CLASS MENTAL; KALINER MA, 1993, JAMA-J AM MED ASSOC, V269, P1994, DOI 10.1001/jama.269.15.1994; KANG B, 1978, ANN ALLERGY, V41, P333; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KOEHLER PG, 1987, J ECON ENTOMOL, V80, P446, DOI 10.1093/jee/80.2.446; LAN JL, 1988, J ALLERGY CLIN IMMUN, V81, P563; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; Norusis M J, 1993, SPSS WINDOWS ADV STA; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; PRATT HD, 1988, ANN ENTOMOL SOC AM, V81, P882, DOI 10.1093/aesa/81.6.882; SHULANER FA, 1970, PEDIATRICS, V45, P465; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; WEISS KB, 1992, CHEST, V101, P362; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	23	200	201	1	13	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1393	1401		10.1016/S0091-6749(96)70209-9	http://dx.doi.org/10.1016/S0091-6749(96)70209-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648037	hybrid			2022-12-18	WOS:A1996VD60700029
J	MOREL, AM; DELAAGE, MA				MOREL, AM; DELAAGE, MA			IMMUNOANALYSIS OF HISTAMINE THROUGH A NOVEL CHEMICAL DERIVATIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MOREL, AM (corresponding author), IMMUNOTECH,LUMINY CASE 915,F-13288 MARSEILLE 9,FRANCE.							AXELROD J, 1962, J PHARMACOL EXP THER, V138, P28; CAILLA HL, 1978, BIOCHEM BIOPH RES CO, V85, P1503, DOI 10.1016/0006-291X(78)91173-7; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CHEVRIER D, 1986, J IMMUNOL METHODS, V94, P119, DOI 10.1016/0022-1759(86)90223-1; CUPA A, 1981, EUR J BIOCH, V115, P169; DELAAGE MA, 1981, J PHYSIOL-PARIS, V77, P339; DESBUQUOIS B, 1971, J CLIN ENDOCR METAB, V33, P732, DOI 10.1210/jcem-33-5-732; DOUGLAS WW, 1975, PHARMACOL BASIS, P590; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GUESDON JL, 1986, J IMMUNOL METHODS, V87, P69, DOI 10.1016/0022-1759(86)90345-5; HAYDIK IB, 1983, J ALLERGY CLIN IMMUN, V71, P152, DOI 10.1016/0091-6749(83)90380-9; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LORENZ W, 1975, AGENTS ACTIONS, V5, P402, DOI 10.1007/BF01972656; Lorenz W, 1982, Ann Fr Anesth Reanim, V1, P271, DOI 10.1016/S0750-7658(82)80040-3; MITA H, 1980, J CHROMATOGR, V221, P1, DOI 10.1016/S0378-4347(00)81001-4; MITA H, 1984, AGENTS ACTIONS, V14, P574, DOI 10.1007/BF01978889; NILSSON K, 1959, CLIN SCI, V18, P313; POTTER M, 1972, J NATL CANCER I, V49, P305; PUIZILLOUT JJ, 1981, J PHARMACOL EXP THER, V217, P791; PUIZILLOUT JJ, 1982, HIGH PERFORMANCE RAD, P309; SCHULTZ WH, 1911, J PHARM EXP THER, V2, P221; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1983, TRENDS PHARMACOL SCI, V4, P432, DOI 10.1016/0165-6147(83)90478-9; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; VAITUKAITIS J, 1971, J CLIN ENDOCR, V33, P732; WARREN K, 1983, J ALLERGY CLIN IMMUN, V71, P206, DOI 10.1016/0091-6749(83)90101-X; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	28	200	206	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					646	654		10.1016/0091-6749(88)90978-5	http://dx.doi.org/10.1016/0091-6749(88)90978-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2459179				2022-12-18	WOS:A1988Q639900018
J	MAGNUSSON, CGM				MAGNUSSON, CGM			MATERNAL SMOKING INFLUENCES CORD SERUM IGE AND IGD LEVELS AND INCREASES THE RISK FOR SUBSEQUENT INFANT ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MAGNUSSON, CGM (corresponding author), KAROLINSKA HOSP,KAROLINSKA INST,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN.							BAHNA SL, 1983, CLIN EXP IMMUNOL, V51, P624; BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BONINI S, 1982, BRIT MED J, V284, P512, DOI 10.1136/bmj.284.6314.512-b; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CEDERQVIST LL, 1984, AM J OBSTET GYNECOL, V148, P1123, DOI 10.1016/0002-9378(84)90639-2; COLLEY JRT, 1974, LANCET, V2, P1031; COLLEY JRT, 1973, BRIT MED J, V3, P195, DOI 10.1136/bmj.3.5873.195; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; GULSVIK A, 1979, LANCET, V1, P449; HARLAP S, 1974, LANCET, V1, P529; HEINER DC, 1982, 11 P INT C ALL CLIN, P149; HOLT PG, 1977, BACTERIOL REV, V41, P205, DOI 10.1128/MMBR.41.1.205-216.1977; JONES JG, 1980, LANCET, V1, P66; KJELLMAN NIM, 1981, LANCET, V1, P993; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KOCHER HP, 1982, ANN NY ACAD SCI, V399, P69, DOI 10.1111/j.1749-6632.1982.tb25663.x; LANDESMANDWYER S, 1979, TERATOLOGY, V19, P119, DOI 10.1002/tera.1420190116; LEHRER SB, 1984, J ALLERGY CLIN IMMUN, V73, P240, DOI 10.1016/S0091-6749(84)80014-7; MAGNUSSON CGM, 1985, J ALLERGY CLIN IMMUN, V75, P513, DOI 10.1016/S0091-6749(85)80026-9; MAGNUSSON CGM, 1984, 1984 INT S PREV ALL, P35; MCSHARRY C, 1985, CLIN ALLERGY, V15, P487, DOI 10.1111/j.1365-2222.1985.tb02299.x; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MILLER LG, 1982, AM REV RESPIR DIS S, V60; NYMAND G, 1974, LANCET, V2, P1379; PAGANELLI R, 1979, CLIN EXP IMMUNOL, V36, P256; SAID G, 1984, BRIT MED J, V289, P660, DOI 10.1136/bmj.289.6446.660; VENABLES KM, 1985, BRIT MED J, V290, P210; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WELIKY N, 1980, CLIN ALLERGY, V10, P375, DOI 10.1111/j.1365-2222.1980.tb02121.x; WITTIG HJ, 1978, ANN ALLERGY, V41, P84; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; 1976, PEDIATRICS, V57, P411	38	200	201	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				898	904		10.1016/0091-6749(86)90237-X	http://dx.doi.org/10.1016/0091-6749(86)90237-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3782657				2022-12-18	WOS:A1986E971300012
J	MCDONALD, JR; MATHISON, DA; STEVENSON, DD				MCDONALD, JR; MATHISON, DA; STEVENSON, DD			ASPIRIN INTOLERANCE IN ASTHMA - DETECTION BY ORAL CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; DUKE W. W., 1933, JOUR ALLERGY, V4, P426, DOI 10.1016/S0021-8707(33)90035-0; Dysart BR, 1933, J AMER MED ASSOC, V101, P446, DOI 10.1001/jama.1933.27430310002009a; FARR RS, 1970, J ALLERGY, V45, P321, DOI 10.1016/0021-8707(70)90040-7; FARR RS, PERSONAL COMMUNICATI; Francis N, 1935, J ALLERGY, V6, P504; Gardner E, 1940, AM J MED SCI, V200, P390, DOI 10.1097/00000441-194009000-00015; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; HIRSCHBERG, 1902, DEUT MED WOCHENSCHR, V28, P416; Lamson RW, 1932, J AMER MED ASSOC, V99, P107, DOI 10.1001/jama.1932.02740540015005; MATHEWS KP, 1950, J LAB CLIN MED, V36, P416; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; Prickman LE, 1937, J AMER MED ASSOC, V108, P445, DOI 10.1001/jama.1937.02780060011004; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; VANDERVEER A, 1920, NY MED J, V112, P392; VANLEEUWEN WS, 1928, MUCH MED WOECHENSCHR, V75, P1588; WALTON CHA, 1937, CAN MED ASSOC J, V76, P1016; WIJNJA L, 1966, LANCET, V2, P768; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6	22	200	200	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	4					198	+		10.1016/0091-6749(72)90014-0	http://dx.doi.org/10.1016/0091-6749(72)90014-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N6855	5073322				2022-12-18	WOS:A1972N685500002
J	Uzel, G; Sampaio, EP; Lawrence, MG; Hsu, AP; Hackett, M; Dorsey, MJ; Noel, RJ; Verbsky, JW; Freeman, AF; Janssen, E; Bonilla, FA; Pechacek, J; Chandrasekaran, P; Browne, SK; Agharahimi, A; Gharib, AM; Mannurita, SC; Yim, JJ; Gambineri, E; Torgerson, T; Tran, DQ; Milner, JD; Holland, SM				Uzel, Gulbu; Sampaio, Elizabeth P.; Lawrence, Monica G.; Hsu, Amy P.; Hackett, Mary; Dorsey, Morna J.; Noel, Richard J.; Verbsky, James W.; Freeman, Alexandra F.; Janssen, Erin; Bonilla, Francisco A.; Pechacek, Joseph; Chandrasekaran, Prabha; Browne, Sarah K.; Agharahimi, Anahita; Gharib, Ahmed M.; Mannurita, Sara C.; Yim, Jae Joon; Gambineri, Eleonora; Torgerson, Troy; Tran, Dat Q.; Milner, Joshua D.; Holland, Steven M.			Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal transducer and activator of transcription 1; immune dysregulation-polyendocrinopathy-enteropathy-X-linked; forkhead box protein 3; regulatory T cell; chronic mucocutaneous candidiasis; aneurysms	REGULATORY T-CELLS; CHRONIC MUCOCUTANEOUS CANDIDIASIS; IPEX; DEFICIENCY; IMMUNODEFICIENCY; EXPRESSION; DISEASES	Background: Mutations in signal transducer and activator of transcription (STAT) 1 cause a broad spectrum of disease, ranging from severe viral and bacterial infections (amorphic alleles) to mild disseminated mycobacterial disease (hypomorphic alleles) to chronic mucocutaneous candidiasis (CMC; hypermorphic alleles). The hypermorphic mutations are also associated with arterial aneurysms, autoimmunity, and squamous cell cancers. Objective: We sought to investigate the role of STAT1 gain-of-function mutations in phenotypes other than CMC. Methods: We initially screened patients with CMC and autoimmunity for STAT1 mutations. We functionally characterized mutations in vitro and studied immune profiles and regulatory T (Treg) cells. After our initial case identifications, we explored 2 large cohorts of patients with wildtype forkhead box protein 3 and an immune dysregulation-polyendocrinopathy-enteropathy-X-linked (IPEX)-like phenotype for STAT1 mutations. Results: We identified 5 children with polyendocrinopathy, enteropathy, and dermatitis reminiscent of IPEX syndrome; all but 1 had a variety of mucosal and disseminated fungal infections. All patients lacked forkhead box protein 3 mutations but had uniallelic STAT1 mutations (c.629 G>T, p.R210I; c. 1073 T>G, p.L358W, c.796G>A; p.V266I; c.1154C>T, T385M [2 patients]). STAT1 phosphorylation in response to IFN-gamma, IL-6, and IL-21 was increased and prolonged. CD4(+) IL-17-producing T-cell numbers were diminished. All patients had normal Treg cell percentages in the CD4(+) T-cell compartment, and their function was intact in the 2 patients tested. Patients with cells available for study had normal levels of IL-2-induced STAT5 phosphorylation. Conclusions: Gain-of-function mutations in STAT1 can cause an IPEX-like phenotype with normal frequency and function of Treg cells.	[Uzel, Gulbu; Sampaio, Elizabeth P.; Hsu, Amy P.; Freeman, Alexandra F.; Pechacek, Joseph; Chandrasekaran, Prabha; Browne, Sarah K.; Agharahimi, Anahita; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Lawrence, Monica G.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Hackett, Mary; Torgerson, Troy] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Dorsey, Morna J.] Univ S Florida, Coll Med, Div Allergy Immunol & Rheumatol, St Petersburg, FL USA; [Noel, Richard J.; Verbsky, James W.] Med Coll Wisconsin, Dept Pediat, Div Gastroenterol, Milwaukee, WI 53226 USA; [Noel, Richard J.; Verbsky, James W.] Med Coll Wisconsin, Dept Pediat, Div Microbiol, Milwaukee, WI 53226 USA; [Noel, Richard J.; Verbsky, James W.] Med Coll Wisconsin, Dept Pediat, Div Mol Genet, Milwaukee, WI 53226 USA; [Janssen, Erin; Bonilla, Francisco A.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Janssen, Erin; Bonilla, Francisco A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Agharahimi, Anahita] Frederick Natl Lab Clin Res, SAIC Frederick, Clin Res Directorate CMRP, Lab Clin Infectious Dis, Frederick, MD USA; [Gharib, Ahmed M.] Natl Inst Diabet Digest & Kidney Dis, Biomed & Metab Imaging Branch, NIH, Bethesda, MD USA; [Mannurita, Sara C.; Gambineri, Eleonora] Univ Florence, Anna Meyer Childrens Hosp, Dept Sci Woman & Childs Hlth, I-50121 Florence, Italy; [Yim, Jae Joon] Seoul Natl Univ, Coll Med, Div Pulm & Crit Care Med, Seoul, South Korea; [Tran, Dat Q.] Univ Texas Med Sch, Dept Pediat, Div Pediat Res Ctr, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; State University System of Florida; University of South Florida; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Seoul National University (SNU); University of Texas System; University of Texas Health Science Center Houston	Holland, SM (corresponding author), NIAID, NIH, CRC B3-4141,MSC 1684, Bethesda, MD 20892 USA.	smh@nih.gov	Mannurita, Sara Ciullini/AAA-5395-2019; Gambineri, Eleonora/J-8747-2016; Gharib, Ahmed/O-2629-2016; Dorsey, Morna/V-7270-2018	Mannurita, Sara Ciullini/0000-0002-4498-6209; Gambineri, Eleonora/0000-0002-4676-6541; Gharib, Ahmed/0000-0002-2476-481X; Dorsey, Morna/0000-0002-9432-3542; Yim, Jae-Joon/0000-0002-9605-0074; Janssen, Erin/0000-0002-0687-2550	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health; National Cancer Institute, National Institutes of Health, Bethesda, Maryland [HHSN261200800001E]; National Institutes of Health; CSL Behring; Baxter; Immune Deficiency Foundation; American Research Group; Grifols; New England Regional Genetics Group; Baxter Biosciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001069, ZIAAI000647, ZIAAI001183, Z01AI000647, ZIAAI000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075083] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, National Institutes of Health, Bethesda, Maryland(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CSL Behring; Baxter; Immune Deficiency Foundation; American Research Group; Grifols; New England Regional Genetics Group; Baxter Biosciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health and in part by the National Cancer Institute, National Institutes of Health (contract no. HHSN261200800001E), Bethesda, Maryland. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.; Disclosure of potential conflict of interest: E. P. Sampaio has received grants from the National Institutes of Health and is employed by Medical Science and Computing. M. J. Dorsey has received grants from CSL Behring. J. W. Verbsky has received lecture fees from Baxter. F. A. Bonilla has received consultancy fees from CSL Behring, Immune Deficiency Foundation, American Research Group, and Grifols; is employed by the US Food and Drug Administration; has received lecture fees from New England Regional Genetics Group; and has received royalties from UpToDate. T. Torgerson has received grants from the National Institutes of Health, Baxter Biosciences, and CSL Behring; has consultant arrangements with and receives payment for lectures and development of educational presentations from Baxter Biosciences; and receives royalties from New England Biolabs. The rest of the authors declare that they have no relevant conflicts of interest.	Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bennett CL, 2001, CURR OPIN PEDIATR, V13, P533, DOI 10.1097/00008480-200112000-00007; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Ding L, 2012, J CLIN IMMUNOL, V32, P238, DOI 10.1007/s10875-011-9621-8; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Moraes-Vasconcelos D, 2008, J CLIN IMMUNOL, V28, pS11, DOI 10.1007/s10875-008-9176-5; Nadeau K, 2011, J PEDIATR-US, V158, P701, DOI 10.1016/j.jpeds.2010.12.042; Ochs HD, 2007, IMMUNOL RES, V38, P112, DOI 10.1007/s12026-007-0022-2; Piggott K, 2011, CIRCULATION, V123, P309, DOI 10.1161/CIRCULATIONAHA.110.936203; Sampaio EP, 2013, J ALLERGY C IN PRESS; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Torgerson TR, 2007, CURR OPIN ALLERGY CL, V7, P515, DOI 10.1097/ACI.0b013e3282f1a27a; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102	19	199	208	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1611	+		10.1016/j.jaci.2012.11.054	http://dx.doi.org/10.1016/j.jaci.2012.11.054			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23534974	Green Accepted, Green Submitted			2022-12-18	WOS:000320532800022
J	Liu, YJ				Liu, Yong-Jun			Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						TSLP; dendritic cells; T(H)2; allergy; asthma; atopic dermatitis; OX40	CD4(+) T-CELLS; HUMAN EPITHELIAL-CELLS; ATOPIC-DERMATITIS; MOUSE KERATINOCYTES; GROWTH-FACTOR; IN-VITRO; INDUCE; TSLP; CLONING; RECEPTOR	It was demonstrated 5 years ago that thymic stromal lymphopoietin (TSLP), a IL-7-like cytokine produced by epithelial cells, could strongly activate human myeloid dendritic cells to induce an inflammatory T(H)2 response characterized by high TNF-alpha and little IL-10 production, distinct from the regulatory T(H)2 responses characterized by low TNF-alpha and high IL-10 production. TSLP was found highly expressed by keratinocytes of skin lesions of atopic dermatitis and associated with dendritic cell activation in situ. This suggests for the first time that TSLP represents a master switch of allergic inflammation at the epithelial cell and dendritic cell interface. During the last several years, the evidence for the association of TSLP with human asthma was revealed. The direct link between TSLP expression with the pathogenesis of atopic dermatitis and asthma in vivo was demonstrated. In addition, OX40 ligand was found to be the TSLP-induced molecule on dendritic cells that triggers inflammatory T(H)2 differentiation in the absence of IL-12. TSLP was also demonstrated to direct the innate phase of allergic immune responses through activating mast cells. Therefore, TSLP and OX40 ligand may represent important targets for intervention of the initiation of allergic inflammatory responses.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, YJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 7455 Fannin,Unit 901, Houston, TX 77030 USA.	yjliu@mdanderson.org						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Croft M, 2003, CYTOKINE GROWTH F R, V14, P265, DOI 10.1016/S1359-6101(03)00025-X; de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Isaksen DE, 2002, J IMMUNOL, V168, P3288, DOI 10.4049/jimmunol.168.7.3288; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Sher A, 2003, CURR OPIN IMMUNOL, V15, P421, DOI 10.1016/S0952-7915(03)00072-4; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; So T, 2006, P NATL ACAD SCI USA, V103, P3740, DOI 10.1073/pnas.0600205103; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	40	199	214	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					238	244		10.1016/j.jaci.2007.06.004	http://dx.doi.org/10.1016/j.jaci.2007.06.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17666213	Bronze			2022-12-18	WOS:000248654900002
J	Adams, RJ; Fuhlbrigge, A; Guilbert, T; Lozano, P; Martinez, F				Adams, RJ; Fuhlbrigge, A; Guilbert, T; Lozano, P; Martinez, F			Inadequate use of asthma medication in the United States: Results of the Asthma in America national population survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma medication; population survey; race; socioeconomic status	DOSE INHALER ADHERENCE; SOCIOECONOMIC-STATUS; CLINICAL-TRIAL; CHILDREN; CARE; HEALTH; MORTALITY; CHILDHOOD; QUALITY; THERAPY	Background: Studies of the use of anti-inflammatory asthma therapy have been limited to selected populations or have been unable to assess the appropriateness of therapy for individuals. Objective: We sought to describe the current use of asthma medication in the United States population and to examine the influence of symptoms and sociodemographics on medication use. Methods: This study was based on a cross-sectional, national, random-digit-dial household telephone survey in 1998 designed to identify adult patients and parents of children with current asthma. Respondents were classified as having current asthma if they had a physician's diagnosis of asthma and were either taking medication for asthma or had asthma symptoms during the past year. Results: One or more persons met the study criteria for current asthma in 3273 (7.8%) households in which a screening questionnaire was completed. Of these, 2509 persons (721 children.,, 16 years) with current asthma were interviewed. Current use of anti-inflammatory medication was reported by 507 (20.1%). Of these, most were using inhaled corticosteroids (72.5%, with use of antileukotrienes reported by 11.4% and use of cromolyn-nedocromil reported by 18.6%. Of persons with persistent asthma symptoms in the past month, 26.2% reported current use of Some form of anti-inflammatory medication. In bivariate analysis persons reporting lower income, less education, and present unemployment, as well as smokers, were significantly (P <.001) less likely to report current anti-inflammatory use than were other populations. In a multiple regression model nonsmokers and those of white, non-Hispanic ethnicity, as well as persons reporting less asthma control, were more likely to report current anti-inflammatory medication use. Conclusion: In the United States use of appropriate asthma therapy remains inadequate. Strategies to increase use of anti-inflammatory therapy among patients with asthma are needed. These might include methods to increase access to asthma care for minorities and the socioeconomically disadvantaged.	Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98121 USA; Univ Arizona, Resp Sci Ctr, Tucson, AZ USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Adelaide, Dept Med, Woodville, SA, Australia; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; Group Health Cooperative; University of Arizona; Harvard University; Harvard Medical School; University of Adelaide; Harvard University; Brigham & Women's Hospital	Fuhlbrigge, A (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.		Lozano, Paula Maria/GPP-4090-2022	Guilbert, Theresa/0000-0002-6932-712X	NHLBI NIH HHS [1 K08 HL03919-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; BARNES PJ, 1993, AM REV RESPIR DIS, V148, P1; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; BURT C, 1996, AMBULATORY CARE VISI; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; COUPERPATRICK L, 1999, JAMA-J AM MED ASSOC, V282, P583; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; HAAS JS, 1994, J GEN INTERN MED, V9, P121, DOI 10.1007/BF02600024; Halterman JS, 2000, PEDIATRICS, V105, P272; ISLES AF, 1993, MED J AUSTRALIA, V158, P761, DOI 10.5694/j.1326-5377.1993.tb121958.x; LAL S, 1993, CHEST, V104, P438, DOI 10.1378/chest.104.2.438; Lang DM, 1997, ARCH INTERN MED, V157, P1193, DOI 10.1001/archinte.157.11.1193; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; MARTIN AJ, 1995, PEDIATR PULM, V20, P1, DOI 10.1002/ppul.1950200102; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P2, DOI 10.1016/S0091-6749(06)80005-9; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; *NAT ASTHM ED PREV, 1997, PUBL NATH ASTHM ED P; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Nestor A, 1998, ANN ALLERG ASTHMA IM, V81, P327, DOI 10.1016/S1081-1206(10)63124-9; Price JF, 1996, THORAX, V51, pS13, DOI 10.1136/thx.51.Suppl_1.S13; RAND CS, 1995, AM J RESP CRIT CARE, V152, P580, DOI 10.1164/ajrccm.152.2.7633711; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; Yeatts K, 2000, ANN ALLERG ASTHMA IM, V84, P94	33	199	207	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					58	64		10.1067/mai.2002.125489	http://dx.doi.org/10.1067/mai.2002.125489			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	574CF	12110821				2022-12-18	WOS:000176870300013
J	McKeever, TM; Lewis, SA; Smith, C; Collins, J; Heatlie, H; Frischer, M; Hubbard, R				McKeever, TM; Lewis, SA; Smith, C; Collins, J; Heatlie, H; Frischer, M; Hubbard, R			Early exposure to infections and antibiotics and the incidence of allergic disease: A birth cohort study with the West Midlands General Practice Research Database	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eczema; hay fever; infections; siblings; antibiotics; cohort	RESPIRATORY SYNCYTIAL VIRUS; HAY-FEVER; ATOPIC DISORDER; GUINEA-BISSAU; FAMILY-SIZE; ASTHMA; CHILDREN; MEASLES; RISK; PREVALENCE	Background: It has been suggested that the rise in prevalence of allergic disease in westernized countries is due in part to a decrease in exposure to infections and an increase in the use of antibiotics early in life. Objective: The purpose of this investigation was to quantify the relationships between (1) exposure to personal infections, infections in siblings, and use of antibiotics in early life and (2) the incidence of allergic disease. Methods: Using the West Midlands section of the UK General Practice Research Database, we established a historical birth cohort of children (N = 29,238). For each child, we identified all personal infections and infections in siblings and determined the use of antibiotics in early life; we also noted incident diagnoses of asthma, eczema, and hay fever. The data were analyzed through use of Cox regression. Results: There was no clear protective effect of exposure to either personal infections or infections in siblings with respect to the incidence of allergic disease. Antibiotic exposure was associated with an increased risk of developing allergic disease in a dose-related manner: having 4 or more courses of antibiotics in the first year of life was associated with an increased incidence of asthma (hazard ratio [HR), 3.13; 95% CI, 2.75-3.57), eczema (HR, 1.48; 95% CI, 1.31-1.68), and hay fever (HR, 2.12; 95% CI, 1.68-2.66). However, adjusting for consulting behavior reduced these effects (adjusted HR [95% CI]: asthma, 1.99 [1.72-2.31]; eczema, 1.01 [0.88-1.17]; hay fever, 1.14 [0.88-1.47]). Conclusions: We found no evidence that exposure to infections reduced the incidence of allergic disease, and infections did not explain the previous findings of a strong birth order effect in this cohort. The use of antibiotics might be associated with early diagnoses of allergic disease.	Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England; Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England	University of Nottingham; Keele University	McKeever, TM (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.			McKeever, Tricia/0000-0003-0914-0416				Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Lewis SA, 1998, CLIN EXP ALLERGY, V28, P1493; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; *OFF NAT STAT, 1996, GEN PRACT RES DAT IN; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shaheen SO, 1996, BRIT MED J, V313, P969, DOI 10.1136/bmj.313.7063.969; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; Sudo N, 1997, J IMMUNOL, V159, P1739; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211, DOI 10.1016/S0091-6749(99)70015-1; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009	25	199	209	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					43	50		10.1067/mai.2002.121016	http://dx.doi.org/10.1067/mai.2002.121016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799364				2022-12-18	WOS:000173739300007
J	SHEFFER, AL; AUSTEN, KF				SHEFFER, AL; AUSTEN, KF			EXERCISE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SHEFFER, AL (corresponding author), ROBERT B BRIGHAM HOSP,BOSTON,MA 02120, USA.							BAER RL, 1971, IMMUNOLOGICAL DISEAS, P973; HANSHIRO PK, 1967, ARCH INTERN MED, V119, P129; HARBER LC, 1963, J INVEST DERMATOL, V41, P439, DOI 10.1038/jid.1963.138; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ILLIG L, 1967, ARCH KLIN EXP DERM, V229, P360, DOI 10.1007/BF00509213; IVE H, 1965, BRIT J DERMATOL, V77, P229, DOI 10.1111/j.1365-2133.1965.tb14637.x; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; MATTHEWS CN, 1973, BRIT J DERMATOL, V88, P279; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; SAMTER M, 1978, IMMUNOLOGICAL DISEAS, P900; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; SOTER NA, 1977, FED PROC, V36, P1736; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	22	199	201	1	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					106	111		10.1016/0091-6749(80)90056-1	http://dx.doi.org/10.1016/0091-6749(80)90056-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7400473				2022-12-18	WOS:A1980KD11900003
J	Reber, LL; Hernandez, JD; Galli, SJ				Reber, Laurent L.; Hernandez, Joseph D.; Galli, Stephen J.			The pathophysiology of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophils; cysteinyl leukotrienes; epinephrine; food allergy; histamine; IgE; mast cells; platelet-activating factor; urticaria	PLATELET-ACTIVATING-FACTOR; MAST-CELL ACTIVATION; FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; PASSIVE CUTANEOUS ANAPHYLAXIS; PEANUT-INDUCED ANAPHYLAXIS; INSECT-STING ANAPHYLAXIS; GERMAN HEALTH INTERVIEW; HUMANIZED MOUSE MODEL; IMMUNOGLOBULIN-E	Anaphylaxis is a severe systemic hypersensitivity reaction that is rapid in onset; characterized by life-threatening airway, breathing, and/or circulatory problems; and usually associated with skin and mucosal changes. Because it can be triggered in some persons by minute amounts of antigen (eg, certain foods or single insect stings), anaphylaxis can be considered the most aberrant example of an imbalance between the cost and benefit of an immune response. This review will describe current understanding of the immunopathogenesis and pathophysiology of anaphylaxis, focusing on the roles of IgE and IgG antibodies, immune effector cells, and mediators thought to contribute to examples of the disorder. Evidence from studies of anaphylaxis in human subjects will be discussed, as well as insights gained from analyses of animal models, including mice genetically deficient in the antibodies, antibody receptors, effector cells, or mediators implicated in anaphylaxis and mice that have been 'humanized'' for some of these elements. We also review possible host factors that might influence the occurrence or severity of anaphylaxis. Finally, we will speculate about anaphylaxis from an evolutionary perspective and argue that, in the context of severe envenomation by arthropods or reptiles, anaphylaxis might even provide a survival advantage.	[Reber, Laurent L.] Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, Paris, France; [Reber, Laurent L.] Inst Natl Sante & Rech Med, Paris, France; [Reber, Laurent L.; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Hernandez, Joseph D.] Stanford Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Stanford, CA 94305 USA; [Reber, Laurent L.; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Stanford University; Stanford University; Stanford University; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Dept Pathol, Ctr Clin Sci Res, Sch Med, 269 Campus Dr,Rm 3255b, Stanford, CA 94305 USA.	sgalli@stanford.edu	Reber, Laurent L/K-4148-2014	Reber, Laurent L/0000-0003-3384-6769	European Commission (Marie Sklodowska-Curie Individual Fellowship) [H2020-MSCA-IF-2014 656086]; Institut National de la Sante et de la Recherche Medicale (INSERM); National Institutes of Health [U19 AI104209, NS 080062, R01 AR067145]; Department of Pathology, Stanford University School of Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067145] Funding Source: NIH RePORTER	European Commission (Marie Sklodowska-Curie Individual Fellowship); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pathology, Stanford University School of Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	L.L.R. is supported by the European Commission (Marie Sklodowska-Curie Individual Fellowship H2020-MSCA-IF-2014 656086) and the Institut National de la Sante et de la Recherche Medicale (INSERM). S.J.G. is supported by National Institutes of Health grants U19 AI104209, NS 080062, and R01 AR067145 and the Department of Pathology, Stanford University School of Medicine.	Abramson J, 2007, IMMUNOL REV, V217, P231, DOI 10.1111/j.1600-065X.2007.00518.x; Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2017, J ALLERGY CLIN IMMUN, V140, P349, DOI 10.1016/j.jaci.2017.06.007; Alcaniz L, 2013, FASEB J, V27, P2902, DOI 10.1096/fj.12-223867; Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; [Anonymous], 2017, CLIN EXP ALLERGY; [Anonymous], 2016, AAPS J; [Anonymous], 2016, IMMUNOL LETT; [Anonymous], 2017, CANC RES; [Anonymous], 2016, ALLERGY ASTHMA IMMUN; Apter AJ, 2008, J ALLERGY CLIN IMMUN, V122, P152, DOI 10.1016/j.jaci.2008.03.037; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Austen KF, 2008, NAT IMMUNOL, V9, P113, DOI 10.1038/ni0208-113; AWAI LE, 1984, ANN ALLERGY, V53, P48; Balbino B, 2017, J ALLERGY CLIN IMMUN, V139, P584, DOI 10.1016/j.jaci.2016.05.047; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bock G, 2004, ANAPHYLAXIS, V257; Bohlson SS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00402; Boni Elisa, 2016, Clin Mol Allergy, V14, P14; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; BRODER I, 1972, IMMUNOLOGY, V22, P651; Brown RH, 2005, ANESTHESIOLOGY, V102, P496, DOI 10.1097/00000542-200503000-00004; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Bryce PJ, 2016, J ALLERGY CLIN IMMUN, V138, P769, DOI 10.1016/j.jaci.2016.01.049; Buka RJ, 2015, ALLERGY, V70, P1580, DOI 10.1111/all.12702; Burton OT, 2017, J ALLERGY CLIN IMMUN, V139, P314, DOI 10.1016/j.jaci.2016.04.034; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; CAPRON A, 1987, INT ARCH ALLER A IMM, V82, P307, DOI 10.1159/000234214; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Commins SP, 2016, ALLERGOL INT, V65, P16, DOI 10.1016/j.alit.2015.10.001; De Schryver S, 2016, J ALLERGY CLIN IMMUN, V137, P1138, DOI 10.1016/j.jaci.2015.09.001; DENZLINGER C, 1995, INT ARCH ALLERGY IMM, V108, P158, DOI 10.1159/000237133; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Francuzik W, 2015, J ALLERGY CLIN IMMUN, V136, P1425, DOI 10.1016/j.jaci.2015.06.052; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Gillis CM, 2017, J ALLERGY CLIN IMMUN, V139, P1253, DOI 10.1016/j.jaci.2016.06.058; Golden David B K, 2004, Novartis Found Symp, V257, P101; Golden DB, 2004, NOVART FDN SYMP, V257, P276; Golden DB, 2004, NOVART FDN SYMP, V257, P157; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GORSKI JP, 1979, P NATL ACAD SCI USA, V76, P5299, DOI 10.1073/pnas.76.10.5299; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; GREY HM, 1971, J EXP MED, V133, P289, DOI 10.1084/jem.133.2.289; Guglielmi L, 2006, ALLERGY, V61, P921, DOI 10.1111/j.1398-9995.2006.01067.x; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Gulen T, 2017, J ALLERGY CLIN IMMUN; Haftenberger M, 2013, BUNDESGESUNDHEITSBLA, V56, P687, DOI 10.1007/s00103-012-1658-1; Hamilton RG, 2014, J ALLERGY CLIN IMMUN, V134, P360, DOI 10.1016/j.jaci.2014.02.022; Hamilton RG, 2010, IMMUNOL RES, V47, P273, DOI 10.1007/s12026-009-8160-3; HARADA M, 1991, IMMUNOL INVEST, V20, P515, DOI 10.3109/08820139109082632; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; HIRAYAMA N, 1982, P NATL ACAD SCI-BIOL, V79, P613, DOI 10.1073/pnas.79.2.613; Hox V, 2016, J ALLERGY CLIN IMMUN, V138, P187, DOI 10.1016/j.jaci.2015.11.024; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; ISHIZAKA K, 1966, J ALLERGY, V37, P135, DOI 10.1016/0021-8707(66)90088-8; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; Jiao DL, 2014, CELL IMMUNOL, V289, P97, DOI 10.1016/j.cellimm.2014.03.018; Jonsson F, 2013, J LEUKOCYTE BIOL, V94, P643, DOI 10.1189/jlb.1212623; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P197; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kalesnikoff J, 2010, CHEM IMMUNOL ALLERGY, V95, P45, DOI 10.1159/000315937; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Karasawa K, 2003, PROG LIPID RES, V42, P93, DOI 10.1016/S0163-7827(02)00049-8; Karasuyama H, 2011, ANNU REV IMMUNOL, V29, P45, DOI 10.1146/annurev-immunol-031210-101257; Kasperska-Zajac A, 2006, J INVEST ALLERG CLIN, V16, P1; KELEFIOTIS D, 1993, AGENTS ACTIONS, V40, P150, DOI 10.1007/BF01984054; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Kodama T, 2013, IMMUNOBIOLOGY, V218, P844, DOI 10.1016/j.imbio.2012.10.003; Korosec P, 2017, J ALLERGY CLIN IMMUN; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Krause K, 2013, ALLERGY, V68, P256, DOI 10.1111/all.12083; LAI CKW, 1991, CLIN EXP ALLERGY, V21, P489, DOI 10.1111/j.1365-2222.1991.tb01690.x; LANG DM, 1995, DRUG SAFETY, V12, P299, DOI 10.2165/00002018-199512050-00002; Langen U, 2013, BUNDESGESUNDHEITSBLA, V56, P698, DOI 10.1007/s00103-012-1652-7; Lee S, 2016, CURR OPIN ALLERGY CL, V16, P346, DOI 10.1097/ACI.0000000000000279; Lee S, 2013, J ALLERGY CLIN IMMUN, V131, P1103, DOI 10.1016/j.jaci.2013.01.011; LEPOW IH, 1970, AM J PATHOL, V61, P13; LESSOF MH, 1989, CLIN EXP ALLERGY, V19, P231, DOI 10.1111/j.1365-2222.1989.tb02370.x; Li M, 2004, J CLIN INVEST, V114, P112, DOI 10.1172/JCI200420805; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; MacGlashan Donald Jr., 2003, Journal of Allergy and Clinical Immunology, V112, pS53, DOI 10.1016/S0091-6749(03)01877-3; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mahdavinia M, 2017, J ALLER CL IMM-PRACT, V5, P352, DOI 10.1016/j.jaip.2016.10.006; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Nadeau KC, 2012, IMMUNOL ALLERGY CLIN, V32, P111, DOI 10.1016/j.iac.2011.11.004; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakamura T, 2017, J ALLERGY CLIN IMMUN; Nassiri M, 2015, J ALLERGY CLIN IMMUN, V135, P491, DOI 10.1016/j.jaci.2014.09.004; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Niedoszytko M, 2010, INT ARCH ALLERGY IMM, V153, P166, DOI 10.1159/000312634; Oettgen HC, 2016, J ALLERGY CLIN IMMUN, V137, P1631, DOI 10.1016/j.jaci.2016.04.009; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Pagovich OE, 2016, J ALLERGY CLIN IMMUN, V138, P1652, DOI 10.1016/j.jaci.2016.03.053; Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006; Peachell P, 2006, CLIN REV ALLERG IMMU, V31, P131, DOI 10.1385/CRIAI:31:2:131; Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x; PIPER PJ, 1967, NATURE, V213, P838, DOI 10.1038/213838a0; Platts-Mills TAE, 2016, J ALLERGY CLIN IMMUN, V137, P1662, DOI 10.1016/j.jaci.2016.04.010; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Pumphrey RS, 2004, NOVART FDN SYMP, V257, P28; Pumphrey RS, 2004, NOVART FDN SYMP, V257, P276; Pumphrey RS, 2004, NOVART FDN SYMP, V257, P57; Reber LL, 2014, PHARMACOL THERAPEUT, V142, P416, DOI 10.1016/j.pharmthera.2014.01.004; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Ricciardi L, 2016, INT J IMMUNOPATH PH, V29, P726, DOI 10.1177/0394632016670920; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Sala-Cunill A, 2015, J ALLERGY CLIN IMMUN, V135, P1031, DOI 10.1016/j.jaci.2014.07.057; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; Schafer T, 1996, ALLERGY, V51, P372; Schneider LA, 2007, J EXP MED, V204, P2629, DOI 10.1084/jem.20071262; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schuch A, 2017, IMMUNOL ALLERGY CLIN, V37, P153, DOI 10.1016/j.iac.2016.08.017; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STANWORTH DR, 1967, LANCET, V2, P330; Starkl P, 2016, J ALLERGY CLIN IMMUN, V137, P246, DOI 10.1016/j.jaci.2015.08.005; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x; Sturm GJ, 2014, J ALLERGY CLIN IMMUN, V133, P1635, DOI 10.1016/j.jaci.2013.10.046; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; Tordesillas L, 2016, J ALLERGY CLIN IMMUN; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732, DOI 10.1182/blood.V82.6.1732.bloodjournal8261732; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; VIGORITO C, 1983, J CARDIOVASC PHARM, V5, P531, DOI 10.1097/00005344-198307000-00004; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; Warrington Rj, 2006, Allergy Asthma Clin Immunol, V2, P62, DOI 10.1186/1710-1492-2-2-62; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Wechsler JB, 2013, ALLERGY, V68, P1338, DOI 10.1111/all.12227; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; Windbichler M, 2006, INT ARCH ALLERGY IMM, V141, P11, DOI 10.1159/000094177; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, pe1; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Worm M, 2012, ALLERGY, V67, P691, DOI 10.1111/j.1398-9995.2012.02795.x; WUEPPER KD, 1972, CLIN EXP IMMUNOL, V11, P13; Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232; Yamashita Y, 2007, J IMMUNOL, V179, P740, DOI 10.4049/jimmunol.179.2.740; YANCEY KB, 1985, J CLIN INVEST, V75, P486, DOI 10.1172/JCI111724; Zhang W, 2011, EUR J PHARMACOL, V650, P303, DOI 10.1016/j.ejphar.2010.10.015	216	198	205	10	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					335	348		10.1016/j.jaci.2017.06.003	http://dx.doi.org/10.1016/j.jaci.2017.06.003			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28780941	Bronze, Green Submitted, Green Accepted			2022-12-18	WOS:000406855500002
J	Leonard, SA; Sampson, HA; Sicherer, SH; Noone, S; Moshier, EL; Godbold, J; Nowak-Wegrzyn, A				Leonard, Stephanie A.; Sampson, Hugh A.; Sicherer, Scott H.; Noone, Sally; Moshier, Erin L.; Godbold, James; Nowak-Wegrzyn, Anna			Dietary baked egg accelerates resolution of egg allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; baked egg; heated egg; food allergy; egg tolerance; oral food challenge; egg oral immunotherapy	PEANUT ORAL IMMUNOTHERAPY; SKIN PRICK TEST; NATURAL-HISTORY; FOOD ALLERGY; MILK; TOLERANCE; CHALLENGES; ANTIBODIES; MANAGEMENT; UTILITY	Background: Baked egg is tolerated by a majority of eggallergic children. Objective: To characterize immunologic changes associated with ingestion of baked egg and evaluate the role that baked egg diets play in the development of tolerance to regular egg. Methods: Egg-allergic subjects who tolerated baked egg challenge incorporated baked egg into their diet. Immunologic parameters were measured at follow-up visits. A comparison group strictly avoiding egg was used to evaluate the natural history of the development of tolerance. Results: Of the 79 subjects in the intent-to-treat group followed for a median of 37.8 months, 89% now tolerate baked egg and 53% now tolerate regular egg. Of 23 initially baked egg-reactive subjects, 14 (61%) subsequently tolerated baked egg and 6 (26%) now tolerate regular egg. Within the initially baked egg-reactive group, subjects with persistent reactivity to baked egg had higher median baseline egg white (EW)-specific IgE levels (13.5 kU(A)/L) than those who subsequently tolerated baked egg (4.4 kU(A)/L; P 5.04) and regular egg (3.1 kU(A)/L; P = .05). In subjects ingesting baked egg, EW-induced skin prick test wheal diameter and EW-,ovalbumin-, and ovomucoid-specific IgE levels decreased significantly, while ovalbumin- and ovomucoid-specific IgG(4) levels increased significantly. Subjects in the per-protocol group were 14.6 times more likely than subjects in the comparison group (P < .0001) to develop regular egg tolerance, and they developed tolerance earlier (median 50.0 vs 78.7 months; P < .0001). Conclusion: Initiation of a baked egg diet accelerates the development of regular egg tolerance compared with strict avoidance. Higher serum EW-specific IgE level is associated with persistent baked and regular egg reactivity, while initial baked egg reactivity is not. (J Allergy Clin Immunol 2012; 130:473-80.)	[Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, Div Pediat Allergy, New York, NY 10029 USA; [Moshier, Erin L.; Godbold, James] Mt Sinai Sch Med, Dept Preventat Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, Div Pediat Allergy, 1 G Levy Pl,Box 1198, New York, NY 10029 USA.	anna.novak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institutes of Health-National Institute of Allergy and Infectious Diseases [AI 059318]; National Center for Research Resources, National Institutes of Health [UL1-RR029887]; Food Allergy Initiative; National Institute of Allergy and Infectious Diseases; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI059318] Funding Source: NIH RePORTER	National Institutes of Health-National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been supported by National Institutes of Health-National Institute of Allergy and Infectious Diseases grant AI 059318 to A. N.-W. and grant no. UL1-RR029887 from the National Center for Research Resources, a component of the National Institutes of Health.; H. A. Sampson has consultant arrangements with Allertein Therapeutics, LLC; serves on advisory boards for ImmusanT and Novartis; received research support from the Food Allergy Initiative and the National Institutes of Health-National Institute of Allergy and Infectious Diseases; is a consultant/scientific advisor for the Food Allergy Initiative; is a medical advisor for the Food Allergy & Anaphylaxis Network; is a scientific advisor for the University of Nebraska Food Allergy Research and Resource Program and for the Asthma & Allergy Foundation of America; and is 45% owner of Herb Springs, LLC. S. H. Sicherer has consultant arrangements with the Food Allergy Initiative; has received research support from the National Institute of Allergy and Infectious Diseases; and is a medical advisor for the Food Allergy & Anaphylaxis Network. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Clark A, 2011, CLIN EXP ALLERGY, V41, P706, DOI 10.1111/j.1365-2222.2011.03697.x; Clark AT, 2010, CLIN EXP ALLERGY, V40, P1116, DOI 10.1111/j.1365-2222.2010.03557.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; LARRAMENDI CH, 1992, ALLERGY, V47, P490, DOI 10.1111/j.1398-9995.1992.tb00670.x; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2011, CLIN EXP ALLERGY, V41, P609, DOI 10.1111/j.1365-2222.2011.03732.x; Lieberman JA, 2012, J ALLERGY CLIN IMMUN, V129, P1682, DOI 10.1016/j.jaci.2012.04.007; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Roches AD, 2006, ALLERGY, V61, P900, DOI 10.1111/j.1398-9995.2006.01134.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Tomicic S, 2009, PEDIAT ALLERG IMM-UK, V20, P35, DOI 10.1111/j.1399-3038.2008.00738.x; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wood RA, 2003, PEDIATRICS, V111, P1631	42	198	200	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					473	+		10.1016/j.jaci.2012.06.006	http://dx.doi.org/10.1016/j.jaci.2012.06.006			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846751	Green Accepted			2022-12-18	WOS:000307002200030
J	Haldar, P; Pavord, ID				Haldar, Pranab; Pavord, Ian D.			Noneosinophilic asthma: A distinct clinical and pathologic phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							SPUTUM EOSINOPHILS PREDICT; NECROSIS-FACTOR-ALPHA; C VIRUS-INFECTION; AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; NEUTROPHILIC INFLAMMATION; LYMPHOCYTE SUBSETS; PERSISTENT ASTHMA	The use of induced sputum to assess airway inflammation in large and diverse populations with asthma has led to the recognition that significant numbers of patients do not have evidence of eosinophilic airway inflammation. The absence of a sputum eosinophilia has been noted in patients across the range of asthma severity; it has also been reported in patients presenting with an asthma exacerbation. However, whether noneosinophilic asthma represents a pathologically distinct and clinically important asthma phenotype remains unclear. In this review, we present recent evidence suggesting that noneosinophilic asthma represents a stable phenotype associated with a distinct lower airway pathology and structure. We suggest that this lower airway inflammation develops in response to etiologic factors acting through the innate immune pathway and that elements of this immune response contribute to airway dysfunction. Finally, we argue that noneosinophilic asthma is associated with clinically important differences in natural history and treatment response. We particularly highlight evidence that noneosinophilic asthma is associated with a reduced short-term and long-term response to corticosteroid therapy.	Glenfield Gen Hosp, Inst Lung Hlth, Dept Resp Med, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Pavord, ID (corresponding author), Glenfield Gen Hosp, Inst Lung Hlth, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	ian.pavord@uhl-tr.nhs.uk		Haldar, Pranabashis/0000-0002-1572-5421; Pavord, Ian/0000-0002-4288-5973				Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; BERRY MA, 2007, THORAX          0313; Birring SS, 2005, THORAX, V60, P249, DOI 10.1136/thx.2004.034900; Birring SS, 2003, THORAX, V58, P1066, DOI 10.1136/thorax.58.12.1066; Birring SS, 2003, THORAX, V58, P533, DOI 10.1136/thorax.58.6.533; Birring SS, 2002, AM J RESP CRIT CARE, V166, P1078, DOI 10.1164/rccm.200203-245OC; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brightling CE, 2000, ANN MED, V32, P446, DOI 10.3109/07853890009002019; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROWN HM, 1958, LANCET, V2, P1245; Camus P, 2000, EUR RESPIR J, V15, P5, DOI 10.1183/09031936.00.15100500; Caselli M, 1999, SCAND J GASTROENTERO, V34, P828, DOI 10.1080/003655299750025787; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; CLEMENTSEN P, 1990, ALLERGY, V45, P10, DOI 10.1111/j.1398-9995.1990.tb01078.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; GEDDES DM, 1977, Q J MED, V46, P427; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 2002, THORAX, V57, P178, DOI 10.1136/thorax.57.2.178; *GINA, 2002, 023659 NHLBI WHO; Godon P, 2002, EUR RESPIR J, V20, P1364, DOI 10.1183/09031936.02.00017502; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Haldar P, 2006, THORAX, V61, pII31; HASSAN WU, 1994, ANN RHEUM DIS, V53, P511, DOI 10.1136/ard.53.8.511; Helenius I, 2005, SPORTS MED, V35, P565, DOI 10.2165/00007256-200535070-00002; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kanazawa H, 2003, CHEST, V123, P596, DOI 10.1378/chest.123.2.596; Kanazawa H, 2003, CHEST, V123, P600, DOI 10.1378/chest.123.2.600; Keatings VM, 1997, THORAX, V52, P372, DOI 10.1136/thx.52.4.372; Koyama H, 1997, THORAX, V52, P915, DOI 10.1136/thx.52.10.915; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Lumme A, 2003, EUR RESPIR J, V22, P113, DOI 10.1183/09031936.03.00112403; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Mund E, 2005, CHEST, V127, P1714, DOI 10.1378/chest.127.5.1714; Mund E, 2001, THORAX, V56, P450, DOI 10.1136/thorax.56.6.450; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pavord ID, 2006, EUR RESPIR J, V27, P884, DOI 10.1183/09031936.06.00128105; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Siddiqui SH, 2006, THORAX, V61, pII30; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; SIVA R, 2007, EUR RESP J      0214; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wardlaw AJ, 2002, CLIN SCI, V103, P201; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wark PAB, 2002, CLIN EXP ALLERGY, V32, P1750, DOI 10.1046/j.1365-2222.2002.01556.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411	87	198	211	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1043	1052		10.1016/j.jaci.2007.02.042	http://dx.doi.org/10.1016/j.jaci.2007.02.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17472810				2022-12-18	WOS:000246427200001
J	Kawaguchi, M; Takahashi, D; Hizawa, N; Suzuki, S; Matsukura, S; Kokubu, F; Maeda, Y; Fukui, Y; Konno, S; Huang, SK; Nishimura, M; Adachi, M				Kawaguchi, M; Takahashi, D; Hizawa, N; Suzuki, S; Matsukura, S; Kokubu, F; Maeda, Y; Fukui, Y; Konno, S; Huang, SK; Nishimura, M; Adachi, M			IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; candidate gene; case-control association analysis; IL-17F; single nucleotide polymorphism	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CYTOKINE; EXPRESSION; CELLS; ATOPY; ML-1; INTERLEUKIN-17F; IDENTIFICATION; POLYMORPHISMS; INDUCTION	Background: IL-17F is a recently discovered cytokine that plays a role in tissue inflammation by inducing release of proinflammatory and neutrophil-mobilizing cytokines. Upregulated IL17F gene expression has been observed at sites of allergen challenge in the airways of patients with asthma, suggesting that IL-17F is involved in the pathophysiology of asthma. Objective: To investigate the role of IL-17F in asthma pathogenesis, we conducted genetic analyses of association of asthma with the common variants of IL17F, using 867 unrelated Japanese subjects. Methods: Five polymorphisms were studied, including the coding-region sequence variant single nucleotide polymorphism rs763780 (7488T/C), which causes a His-to-Arg substitution at amino acid 161 (H 161 R). Functional consequences of the H161R substitution were examined by using recombinant wild-type and mutant IL-17F proteins. Results: Homozygosity of the H 161 R variant was inversely associated with asthma; the odds ratio (95% CI) for asthma was 0.06 (0.01-0.43) for the H 161 R homozygote compared with the wild-type homozygote (P =.0039). This result remains significant (P =.0079) after adjustment for the presence of atopy using the Mantel-Haenszel chi(2) test. In addition, in vitro functional experiments demonstrated that the H161R variant of IL-17F lacks the ability to activate the mitogen-activated protein kinase pathway, cytokine production, and chemokine production in bronchial epithelial cells, unlike wild-type IL-17F. Furthermore, the H161R variant blocked induction of IL-8 expression by wild-type IL-17F. Conclusion: The current findings indicate that the IL-17F H161R variant influences the risk of asthma and is a natural IL-17F antagonist, suggesting a potential role for IL-17F in the etiology of asthma.	Hokkaido Univ, Grad Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Showa Univ, Sch Med, Dept Internal Med 1, Tokyo 142, Japan; Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Hokkaido University; Showa University; Johns Hopkins University	Hizawa, N (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Med 1, Kita Ku, N-15 W-7, Sapporo, Hokkaido 0608638, Japan.	nhizawa@med.hokudai.ac.jp	Konno, Satoshi/G-1669-2012; Nishimura, Masaharu/A-4062-2012; Huang, Shau-Ku/F-5509-2010	Nishimura, Masaharu/0000-0002-6456-4361; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-52468] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Fearnhead NS, 2004, P NATL ACAD SCI USA, V101, P15992, DOI 10.1073/pnas.0407187101; Hizawa N, 2004, AM J RESP CRIT CARE, V169, P1014, DOI 10.1164/rccm.200307-933OC; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047; Kawaguchi M, 2003, J PHARMACOL EXP THER, V307, P1213, DOI 10.1124/jpet.103.056341; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kusunoki T, 1999, ANN ALLERG ASTHMA IM, V83, P343, DOI 10.1016/S1081-1206(10)62676-2; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Oda N, 2005, AM J RESP CRIT CARE, V171, P12, DOI 10.1164/rccm.200406-778OC; Ramsey CD, 2005, GENES IMMUN, V6, P236, DOI 10.1038/sj.gene.6364170; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Riva A, 2002, BIOINFORMATICS, V18, P1681, DOI 10.1093/bioinformatics/18.12.1681; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; SHEEHE PR, 1966, AM J PUBLIC HEALTH N, V56, P1745, DOI 10.2105/AJPH.56.10.1745; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137	20	198	209	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					795	801		10.1016/j.jaci.2005.12.1346	http://dx.doi.org/10.1016/j.jaci.2005.12.1346			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630936				2022-12-18	WOS:000236862800012
J	Meltzer, EO				Meltzer, Eli O.			Introduction: Stuffy is also related to Sleepy and Grumpy-The link between rhinitis and sleep-disordered breathing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									[Meltzer, Eli O.] Univ Calif San Diego, Dept Pediat, Allergy & Asthma Med Grp, San Diego, CA 92103 USA; [Meltzer, Eli O.] Univ Calif San Diego, Dept Pediat, Res Ctr, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Meltzer, EO (corresponding author), Care of Sweetman L, Amer Acad Allergy Asthma & Immunol, 611E Wells St, Milwaukee, WI 53202 USA.							Foresman B H, 2000, J Am Osteopath Assoc, V100, pS1; Guleria R, 2000, Natl Med J India, V13, P22; Horstmann S, 2000, SLEEP, V23, P383; Ing Alvin J., 2000, American Journal of Medicine, V108, p120S; Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479; PROCTOR DF, 1977, AM REV RESPIR DIS, V115, P97; Roux F, 2000, AM J MED, V108, P396, DOI 10.1016/S0002-9343(00)00302-8; Spiegel K, 2000, AM J PHYSIOL-REG I, V279, pR874, DOI 10.1152/ajpregu.2000.279.3.R874; Thase ME, 2000, J CLIN PSYCHIAT, V61, P46	9	198	200	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	5		S			S133	S134		10.1016/j.jaci.2004.09.011	http://dx.doi.org/10.1016/j.jaci.2004.09.011			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V17HV	15536443				2022-12-18	WOS:000207929200001
J	Herz, U; Gerhold, K; Gruber, C; Braun, A; Wahn, U; Renz, H; Paul, K				Herz, U; Gerhold, K; Gruber, C; Braun, A; Wahn, U; Renz, H; Paul, K			BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-H1-type immune response; Bacillus Calmette-Guerin; allergic sensitization; airway hyperresponsiveness; airway eosinophilia	MYCOBACTERIUM-BOVIS BCG; T-CELL RESPONSES; INTERFERON-GAMMA; IGE SYNTHESIS; CYTOKINE PRODUCTION; CALMETTE-GUERIN; TH1 CLONES; MICE; EOSINOPHIL; ASTHMA	Background: Epidemiologic studies suggest an inverse correlation between infections and development of atopy. The purpose of this study was to test the hypothesis whether a preexisting T-H1-type immune response elicited by BCG immunization could suppress allergic sensitization and airway hyperreactivity in an animal model. Methods: BALB/c mice were immunized with BCG and/or sensitized to ovalbumin. Results: BCG immunization alone resulted in cutaneous type-IV hypersensitivity reactions to tuberculin and granulomatous lesions in the liver. Splenic mononuclear cells (MNCs) produced increased levels of IFN-gamma after activation by Concanavalin A (ConA). Ovalbumin sensitization alone resulted in increased production of IL-4 after activation by ConA. Ovalbumin-sensitized animals also demonstrated markedly elevated anti-ovalbumin IgE/IgG1 serum antibody titers and increased airway reactivity after allergen challenges by means of the airways. BCG immunization 14 days before the start of ovalbumin sensitization markedly hindered the development of allergic responses as indicated by (1) increased IFN-gamma and normalized IL-4 and IL-10 production by splenic MNCs after activation with ConA, (2) a reduced proliferation rate of splenic MNCs after ovalbumin restimulation, (3) partial prevention of ovalbumin-specific IgE/IgG1 serum antibody titers but elevated (nonallergic) anti-ovalbumin IgG2a serum antibody titers, (4) prevention of airway responsiveness, (5) reduced eosinophilic influx into the airway lumen, and (6) reduced levels of IL-4 and IL-5 in broncho alveolar lavage fluids. Conclusion: In this model BCG immunization established a T-H1-type immune response that hinders allergic sensitization and the development of increased airway reactivity.	Campus Virchow Clin, Lab Med & Pathobiochem, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Paul, K (corresponding author), Campus Virchow Clin, Lab Med & Pathobiochem, Augustenburger Pl 1, D-13353 Berlin, Germany.		Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; DAUGELAT S, 1995, INFECT IMMUN, V63, P2033, DOI 10.1128/IAI.63.5.2033-2040.1995; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; Emoto M, 1997, EUR J IMMUNOL, V27, P183, DOI 10.1002/eji.1830270127; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FLESCH IEA, 1994, INT IMMUNOL, V6, P463, DOI 10.1093/intimm/6.3.463; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GROS P, 1981, J IMMUNOL, V127, P2417; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; HILL JA, 1995, JAMA-J AM MED ASSOC, V273, P1933, DOI 10.1001/jama.273.24.1933; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42, DOI 10.1159/000232736; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HUYGEN K, 1992, INFECT IMMUN, V60, P2880, DOI 10.1128/IAI.60.7.2880-2886.1992; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KUPPER T, 1987, J IMMUNOL, V138, P4280; LACK G, 1994, J IMMUNOL, V152, P2546; LAGRANDERIE M, 1993, TUBERCLE LUNG DIS, V74, P38, DOI 10.1016/0962-8479(93)90067-8; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; MOND JJ, 1986, J IMMUNOL, V137, P3534; NAGAI H, 1993, LIFE SCI, V53, pPL243, DOI 10.1016/0024-3205(93)90545-E; Orme Ian M., 1994, P113; ORME IM, 1993, J IMMUNOL, V151, P518; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Pope M, 1996, J IMMUNOL, V156, P3342; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; TEIXEIRA HC, 1995, IMMUNOL LETT, V46, P15, DOI 10.1016/0165-2478(95)00009-T; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	41	198	217	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					867	874		10.1016/S0091-6749(98)70030-2	http://dx.doi.org/10.1016/S0091-6749(98)70030-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819307				2022-12-18	WOS:000077033400024
J	WOOD, RA; CHAPMAN, MD; ADKINSON, NF; EGGLESTON, PA				WOOD, RA; CHAPMAN, MD; ADKINSON, NF; EGGLESTON, PA			THE EFFECT OF CAT REMOVAL ON ALLERGEN CONTENT IN HOUSEHOLD-DUST SAMPLES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT INTERNAL MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; UNIV VIRGINIA,DEPT MED,DEPT ALLERGY & CLIN IMMUNOL,CHARLOTTESVILLE,VA 22903	Johns Hopkins University; Johns Hopkins University; University of Virginia				Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21073] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; JELKS ML, 1985, ALLERGY, P255; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OHMAN JL, 1985, CURRENT THERAPY ALLE, P5; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P242; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	14	198	201	2	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					730	734		10.1016/0091-6749(89)90006-7	http://dx.doi.org/10.1016/0091-6749(89)90006-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708734	Bronze			2022-12-18	WOS:A1989U342000003
J	BARBEE, RA; KALTENBORN, W; LEBOWITZ, MD; BURROWS, B				BARBEE, RA; KALTENBORN, W; LEBOWITZ, MD; BURROWS, B			LONGITUDINAL CHANGES IN ALLERGEN SKIN-TEST REACTIVITY IN A COMMUNITY POPULATION-SAMPLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARBEE, RA (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,COLL MED,DIV RESP SCI,WESTEND RES LABS,TUCSON,AZ 85724, USA.				NHLBI NIH HHS [HL 14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GODFREY RC, 1976, CLIN ALLERGY, V6, P79, DOI 10.1111/j.1365-2222.1976.tb01415.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; Pepys J, 1968, CLIN ASPECTS IMMUNOL, P192; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x	15	198	198	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					16	24		10.1016/S0091-6749(87)80010-6	http://dx.doi.org/10.1016/S0091-6749(87)80010-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3492524				2022-12-18	WOS:A1987F881000006
J	ISHIZAKA, T				ISHIZAKA, T			ANALYSIS OF TRIGGERING EVENTS IN MAST-CELLS FOR IMMUNOGLOBULIN-E-MEDIATED HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21218 USA	Johns Hopkins University					NIAID NIH HHS [AI-10060] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTEN KF, 1961, J EXP MED, V113, P521, DOI 10.1084/jem.113.3.521; AUSTEN KF, 1966, J EXP MED, V124, P397, DOI 10.1084/jem.124.3.397; BECKER EL, 1966, J EXP MED, V124, P379, DOI 10.1084/jem.124.3.379; BOURNE HR, 1972, J IMMUNOL, V108, P695; CONRAD DH, 1977, J IMMUNOL, V120, P507; CONRAD DH, 1975, J IMMUNOL, V114, P1688; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P193, DOI 10.1113/jphysiol.1977.sp011996; HIRATA F, 1978, P NATL ACAD SCI USA, V75, P2348, DOI 10.1073/pnas.75.5.2348; HIRATA F, 1978, NATURE, V275, P219, DOI 10.1038/275219a0; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P4813, DOI 10.1073/pnas.76.10.4813; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P368, DOI 10.1073/pnas.76.1.368; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; ISHIZAKA K, 1968, J IMMUNOL, V101, P68; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1978, J IMMUNOL, V120, P800; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; ISHIZAKA T, 1979, P NATL ACAD SCI USA, V76, P5858, DOI 10.1073/pnas.76.11.5858; ISHIZAKA T, 1977, J IMMUNOL, V119, P1589; JOHNSON AR, 1970, J PHARMACOL EXP THER, V175, P632; KALINER M, 1974, J IMMUNOL, V112, P664; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LEWIS RA, 1979, J IMMUNOL, V123, P1663; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; PERERA BAV, 1963, IMMUNOLOGY, V6, P472; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; STRITTMATTER WJ, 1979, SCIENCE, V204, P1205, DOI 10.1126/science.221977; SULLIVAN TJ, 1976, J IMMUNOL, V117, P713; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1480	30	198	199	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					90	96		10.1016/0091-6749(81)90002-6	http://dx.doi.org/10.1016/0091-6749(81)90002-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	6161147	Bronze			2022-12-18	WOS:A1981LB94700002
J	McNeil, MM; Weintraub, ES; Duffy, J; Sukumaran, L; Jacobsen, SJ; Klein, NP; Hambidge, SJ; Lee, GM; Jackson, LA; Irving, SA; King, JP; Kharbanda, EO; Bednarczyk, RA; DeStefano, F				McNeil, Michael M.; Weintraub, Eric S.; Duffy, Jonathan; Sukumaran, Lakshmi; Jacobsen, Steven J.; Klein, Nicola P.; Hambidge, Simon J.; Lee, Grace M.; Jackson, Lisa A.; Irving, Stephanie A.; King, Jennifer P.; Kharbanda, Elyse O.; Bednarczyk, Robert A.; DeStefano, Frank			Risk of anaphylaxis after vaccination in children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; vaccine safety; immunization	UNITED-STATES; SEX-HORMONES; FOLLOW-UP; IMMUNIZATION; SAFETY; INFLUENZA; VACCINES; EPINEPHRINE; DEFINITION; DATALINK	Background: Anaphylaxis is a potentially life-threatening allergic reaction. The risk of anaphylaxis after vaccination has not been well described in adults or with newer vaccines in children. Objective: We sought to estimate the incidence of anaphylaxis after vaccines and describe the demographic and clinical characteristics of confirmed cases of anaphylaxis. Methods: Using health care data from the Vaccine Safety Datalink, we determined rates of anaphylaxis after vaccination in children and adults. We first identified all patients with a vaccination record from January 2009 through December 2011 and used diagnostic and procedure codes to identify potential anaphylaxis cases. Medical records of potential cases were reviewed. Confirmed cases met the Brighton Collaboration definition for anaphylaxis and had to be determined to be vaccine triggered. We calculated the incidence of anaphylaxis after all vaccines combined and for selected individual vaccines. Results: We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95% CI, 0.90-1.84) per million vaccine doses. The incidence did not vary significantly by age, and there was a nonsignificant female predominance. Vaccine-specific rates included 1.35 (95% CI, 0.65-2.47) per million doses for inactivated trivalent influenza vaccine (10 cases, 7,434,628 doses given alone) and 1.83 (95% CI, 0.22-6.63) per million doses for inactivated monovalent influenza vaccine (2 cases, 1,090,279 doses given alone). The onset of symptoms among cases was within 30 minutes (8 cases), 30 to less than 120 minutes (8 cases), 2 to less than 4 hours (10 cases), 4 to 8 hours (2 cases), the next day (1 case), and not documented (4 cases). Conclusion: Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat.	[McNeil, Michael M.; Weintraub, Eric S.; Duffy, Jonathan; Sukumaran, Lakshmi; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA; [Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA 91101 USA; [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA; [Hambidge, Simon J.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA; [Lee, Grace M.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA; [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA; [Irving, Stephanie A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA; [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA; [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA; [Bednarczyk, Robert A.] Kaiser Permanente Ctr Hlth Res, Atlanta, GA USA; [Bednarczyk, Robert A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Centers for Disease Control & Prevention - USA; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Kaiser Permanente; Kaiser Permanente; Emory University; Rollins School Public Health	McNeil, MM (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA.	mmm2@cdc.gov	Bednarczyk, Robert/L-9403-2017	Bednarczyk, Robert/0000-0002-6812-0928; King, Jennifer/0000-0003-4627-1378; McNeil, Michael/0000-0003-0713-8312; Jacobsen, Steven/0000-0002-8174-8533; Irving, Stephanie/0000-0001-7437-6797; Hambidge, Simon/0000-0002-7535-0668	CDC; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI074492] Funding Source: NIH RePORTER	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The findings and conclusions of this report are those of the authors and do not necessarily represent the official policy or position of the Centers for Disease Control and Prevention (CDC). Use of trade names and commercial sources is for identification only and does not imply endorsement by the CDC. The Vaccine Safety Datalink Project is funded by the CDC. This study was supported by the CDC, and no external funding was secured.	Austen KF., 1994, HARRISONS PRINCIPLES, P1630; Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H; BENJAMIN CM, 1992, BMJ-BRIT MED J, V304, P1075, DOI 10.1136/bmj.304.6834.1075; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Brotherton JML, 2008, CAN MED ASSOC J, V179, P525, DOI 10.1503/cmaj.080916; Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P88, DOI 10.1016/j.jaip.2014.07.011; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Clark S, 2014, J ALLERGY CLIN IMMUN, V134, P1125, DOI 10.1016/j.jaci.2014.05.018; Cook IF, 2009, HUM VACCINES, V5, P441, DOI 10.4161/hv.8476; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Dudley LS, 2015, WEST J EMERG MED, V16, P385, DOI 10.5811/westjem.2015.3.25337; Engler RJ., 2008, ARCH INTERN MED, V156, P1546; Erlewyn-Lajeunesse M, 2012, ARCH DIS CHILD, V97, P487, DOI 10.1136/archdischild-2011-301163; Erlewyn-Lajeunesse M, 2010, DRUG SAFETY, V33, P57, DOI 10.2165/11318970-000000000-00000; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Grabenstein JD, 1997, HOSP PHARM, V32, P77; Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Iribarren C, 2010, ANN ALLERG ASTHMA IM, V104, P371, DOI 10.1016/j.anai.2010.03.004; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Kelso JM, 2009, ANN ALLERG ASTHMA IM, V103, pS1, DOI 10.1016/S1081-1206(10)60350-X; Khalil M K, 2003, East Mediterr Health J, V9, P152; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; LEAR JT, 1995, LANCET, V345, P1249, DOI 10.1016/S0140-6736(95)92039-0; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Lieberman PL, 2008, MIDDLETONS ALLERGY P, P1027; McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; Rouleau I, 2013, VACCINE, V31, P5989, DOI 10.1016/j.vaccine.2013.10.033; Rudders SA, 2013, ANN ALLERG ASTHMA IM, V111, P199, DOI 10.1016/j.anai.2013.06.020; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sargant N, 2015, EMERG MED J, V32, P83, DOI 10.1136/emermed-2014-203603; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Simons FER, 2010, CURR OPIN ALLERGY CL, V10, P384, DOI 10.1097/ACI.0b013e32833c2038; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Stratton K., 2011, Adverse effects of vaccines: evidence and causality; Tavares F, 2011, VACCINE, V29, P6402, DOI 10.1016/j.vaccine.2011.04.026; Vellozzi C, 2010, VACCINE, V28, P7248, DOI 10.1016/j.vaccine.2010.09.021; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3	49	197	203	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					868	878		10.1016/j.jaci.2015.07.048	http://dx.doi.org/10.1016/j.jaci.2015.07.048			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26452420	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000371897500031
J	Shimbara, A; Christodoulopoulos, P; Soussi-Gounni, A; Olivenstein, R; Nakamura, Y; Levitt, RC; Nicolaides, NC; Holroyd, KJ; Tsicopoulos, A; Lafitte, JJ; Wallaert, B; Hamid, QA				Shimbara, A; Christodoulopoulos, P; Soussi-Gounni, A; Olivenstein, R; Nakamura, Y; Levitt, RC; Nicolaides, NC; Holroyd, KJ; Tsicopoulos, A; Lafitte, JJ; Wallaert, B; Hamid, QA			IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-9; IL-9 receptor; atopy	CD4+ T-CELLS; BRONCHIAL HYPERRESPONSIVENESS; MESSENGER-RNA; INHALATION CHALLENGE; AIRWAY INFLAMMATION; ATOPIC ASTHMA; INTERLEUKIN-9; GENE; MICE; HYPERREACTIVITY	Background: Bronchial asthma is a chronic inflammatory disease associated with genetic components. Recently IL-9 has been reported as a candidate gene for asthma and to be associated with bronchial hyperresponsiveness and elevated levels of total serum IgE. Objective: To investigate the contribution of IL-9 to the pathogenesis of asthma, we examined the expression of IL-9 and its receptor (IL-9R) in bronchial tissue from subjects with atopic asthma (n = 10), chronic bronchitis (n = 11), and sarcoidosis (n = 9) and from atopic (n = 7) and nonatopic (n = 10) healthy control subjects. Methods: Bronchial biopsy specimens were examined for the presence of IL-9 and IL-9R protein and messenger RNA (mRNA) by immunocytochemistry and in situ hybridization, respectively. To phenotype the cells expressing IL-9 in asthmatic tissue, combined in situ hybridization and immunocytochemistry was also performed. Results: There was a highly significant difference (P < 1.001) in the expression of IL-9 mRNA in asthmatic airways (20.6 +/- 4.0 cells/mm of basement membrane) compared with chronic bronchitis (5.6 +/- 4.4), sarcoidosis (2.5 +/- 1.8), atopic control subjects (7.7 +/- 2.2), and healthy control subjects (2.7 +/- 2.3). The number of IL-9 immunoreactive cells was also greater in asthmatic patients compared with the other groups (P < .05). Although the level of IL-9R mRNA expression did not differ in any of the groups (P > .05), IL-9R immunoreactivity was significantly higher in asthmatic compared with control subjects. Furthermore, IL-9 mRNA expression levels were also significantly correlated with FEV1 ( P < .05) and the airway responsiveness to methacholine producing a 20% fall in PEV1 (P < .01). The cells expressing IL-9 mRNA in asthmatic tissue were CD3(+) lymphocytes (68%), major basic protein(+) eosinophils (16%), and elastase(+) neutrophils (8%). Conclusion: The results of this study demonstrate the potential of IL-9 to be a marker for atopic asthma and furthermore suggest an important role for this cytokine in the pathophysiologic mechanisms of this disease.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Magainin Pharmaceut, Plymouth Meeting, PA 19462 USA; Inst Pasteur, Inst Natl Sante & Rech Med, U416, F-59019 Lille, France	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Gounni, Abdelilah Soussi/AAH-3456-2020; Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763; Holroyd, Kenneth/0000-0001-6050-3935; Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Grasso L, 1998, J BIOL CHEM, V273, P24016, DOI 10.1074/jbc.273.37.24016; GRENCIS RK, 1991, IMMUNOLOGY, V74, P329; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HOLGATE ST, 1995, INT ARCH ALLERGY IMM, V107, P29, DOI 10.1159/000236921; Holroyd KJ, 1998, GENOMICS, V52, P233, DOI 10.1006/geno.1998.5445; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; LOUAHED J, 1995, J IMMUNOL, V154, P5061; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Monteyne P, 1997, J IMMUNOL, V159, P2616; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; *NIH C, 1991, ANN INTERN MED, V94, P73; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RENAULD JC, 1990, J IMMUNOL, V144, P4235; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; SVETIC A, 1993, J IMMUNOL, V150, P3434; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; THOMAS PD, 1987, AM REV RESPIR DIS, V135, P747; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; 1987, AM REV RESP DIS, V136, P225	35	197	210	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				108	115		10.1016/S0091-6749(00)90185-4	http://dx.doi.org/10.1016/S0091-6749(00)90185-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629460	Bronze			2022-12-18	WOS:000084992100015
J	Nathan, RA; Meltzer, EO; Selner, JC; Storms, W				Nathan, RA; Meltzer, EO; Selner, JC; Storms, W			Prevalence of allergic rhinitis in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; self-administered questionnaire; prevalence; hay fever; immunoglobulin E (IgE)	SKIN-TEST REACTIVITY; POPULATION-SAMPLE; HAY-FEVER; ASTHMA; EPIDEMIOLOGY; COMMUNITY; CHILDREN; RUBBER	The study objective was to examine the current national prevalence of allergic rhinitis by gender, age, geographic region, population density (urban/rural), and household income. A self-administered questionnaire was sent to 15,000 households representative of the U.S. population in respect to these factors. The household member who knew the most about the family's health status and health history in the previous 12 months was asked to estimate the number of days during which household members had experienced sneezing, runny nose, stuffy nose or head, itchy eyes, or watery eyes. They were also asked about physician diagnosis of hay fever, rhinitis, persistent stuffy nose or head, or allergies involving the eyes, nose, or throat. The 9946 households responding (66.3%) represented 22,285 persons, 8394 of whom had experienced the symptoms described. In a follow-up questionnaire sent to a balanced sample of 1450 responders (>90% white, slightly more females than males), subjects were asked to indicate which of the following best described their symptoms: a common cold; a seasonal allergy (i.e., hay fever); an allergy I have all the time; an allergy only when exposed to triggers (i.e., dust, pollution); or sinus problems. Of the 1065 subjects (73.4%) responding, 31.5% reported greater than or equal to 7 days of nasal/ocular symptoms, and 17.7% reported greater than or equal to 31 days of symptoms. Physician-diagnosed hay fever was reported by 8.2% and allergic rhinitis (seasonal plus perennial) by 14.2%. Prevalence was highest among those age 18 to 34 years and 35 to 49 years, decreasing after age 50 years. No major trends were evident,vith regard to other variables studied. Extrapolation based on 1993 census data suggests that at least 35.9 million persons have symptoms associated with allergic rhinitis and up to 79.5 million persons experience greater than or equal to 7 days of nasal/ocular symptoms yearly.	ASTHMA & ALLERGY ASSOCIATES,COLORADO SPRINGS,CO; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; ALLERGY RESP INST COLORADO,DENVER,CO									ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ARRIGHI HM, 1995, J ALLERGY CLIN IMMUN, V95, P192; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; *BUR CENS, 1992, STAT ABSTR US 1992, P21; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; FINN R, 1992, LANCET, V340, P1453; FLANNERY LG, 1970, J HUNTONS DIARY WYOM, V6, P50; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; GERGEN PJ, 1991, ARCH INTERN MED, V151, P487, DOI 10.1001/archinte.151.3.487; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAGY GW, 1966, J ALLERGY, V37, P107; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KALINER M, 1987, JAMA-J AM MED ASSOC, V258, P2851, DOI 10.1001/jama.258.20.2851; MAGERA BE, 1995, J ALLERGY CLIN IMMUN, V95, P213; MCKEE WD, 1966, J ALLERGY, V38, P226, DOI 10.1016/0021-8707(66)90056-6; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; *ROY COLL GEN PRAC, 1986, MB5 ROYAL COLL GEN P; SIBBALD B, 1993, EPIDEMIOLOGY CLIN AL, P61; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1965, AM REV RESPIR DIS, V92, P31; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; *US DEP COMM, 1993, 933 CPS US DEP COMM; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7; WRIGHT AL, 1994, PEDIATRICS, V94, P895	30	197	200	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	2	S			S808	S814		10.1016/S0091-6749(97)80040-1	http://dx.doi.org/10.1016/S0091-6749(97)80040-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ363					2022-12-18	WOS:A1997XJ36300002
J	GERGEN, PJ; TURKELTAUB, PC				GERGEN, PJ; TURKELTAUB, PC			THE ASSOCIATION OF INDIVIDUAL ALLERGEN REACTIVITY WITH RESPIRATORY-DISEASE IN A NATIONAL SAMPLE - DATA FROM THE 2ND NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1976-80 (NHANES-II)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ALLERGIC RHINITIS; CHRONIC RHINITIS; SINUSITIS; ALLERGY; NHANES-II	SKIN-TEST REACTIVITY; HOUSE-DUST MITE; UNITED-STATES POPULATION; ASTHMATIC-CHILDREN; CHANGING PATTERNS; CHILDHOOD ASTHMA; POLLEN ALLERGENS; IGE ANTIBODIES; RAGWEED POLLEN; GRASS-POLLEN	The independent association of individual allergen reactivity with respiratory disease was evaluated with use of the second National Health and Nutrition Examination Survey, a sample of the U.S. white civilian population, ages 6 to 24 years (n = 4295). Eight, 1:20 wt/vol, 50% glycerol, unstandardized extracts were administered by prick puncture. Allergen reactivity was reported as the percent with a mean erythema diameter 10.5 mm or greater at 20 minutes. Only the prevalence of asthma and allergic rhinitis increased with the increasing number of positive allergen skin tests. The independent association of individual allergen reactivity with respiratory disease was quantified with logistic models that included other allergen reactivity, age, sex, smoking, and region. Asthma was associated with reactivity to house dust (odds ratio, 2.9; 95% confidence interval [CI] 1.7 to 5) and Alternaria (odds ratio, 5.1; 95% CI: 2.9 to 8.9). Allergic rhinitis was associated with reactivity to ragweed (odds ratio, 2.3; 95% CI: 1.5 to 3.3); ryegrass (odds ratio, 2.8; 95% CI: 1.8 to 4.3); house dust (odds ratio, 2.5; 95% CI: 1.6 to 3.9); Alternaria (odds ratio, 2.3; 95% CI: 1.5 to 3.4). Asthma only (without allergic rhinitis) was associated with dust and Alternaria. Allergic rhinitis only (without asthma) was associated with ryegrass, ragweed, and house dust. When both asthma and allergic rhinitis were present, only house dust and Alternaria remained associated. These findings highlight the association of specific allergens with upper and lower respiratory diseases and the interactions among coexisting respiratory diseases.	US FDA,CTR BIOL EVALUAT & RES,ALLERGY & IMMUNOCHEM LAB,BETHESDA,MD 20014	US Food & Drug Administration (FDA)	GERGEN, PJ (corresponding author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,SOLAR ROOM 4A29,BETHESDA,MD 20892, USA.		turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				ARLIAN L, 1992, J ALLERGY CLIN IMMUN, V89, P317; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; ESCOBEDO LG, 1990, JAMA-J AM MED ASSOC, V264, P1550, DOI 10.1001/jama.264.12.1550; FRIEDHOFF LR, 1981, AM J MED GENET, V9, P323; GERGEN PJ, 1991, ARCH INTERN MED, V151, P487, DOI 10.1001/archinte.151.3.487; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GERGEN PJ, 1986, DHHS PHS861685 NAT C; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAMMARLUND A, 1991, CLIN EXP ALLERGY, V21, P333, DOI 10.1111/j.1365-2222.1991.tb01665.x; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; KANG B, 1985, CLIN REV ALLERG, V3, P363, DOI 10.1007/BF02993001; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LUCAS SK, 1989, J ALLERGY CLIN IMMUN, V84, P465, DOI 10.1016/0091-6749(89)90359-X; MCDOWELL A, 1981, DHHS PHS811317 NAT C; MOORE CL, 1992, J ALLERGY CLIN IMMUN, V89, P314; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RESHEF A, 1989, J ALLERGY CLIN IMMUN, V84, P678, DOI 10.1016/0091-6749(89)90296-0; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHAH BV, 1984, RTP74 BATT COL LAB W; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V88, P425; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TURKELTAUB PC, 1989, ALLERGOL IMMUNOPATH, V17, P53; TURKELTAUB PC, 1991, ALLERGEN IMMUNOTHERA, P177; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; Voorhorst R., 1964, Allergie Asthma, V10, P329; WEEKE ER, 1987, MONOGR ALLERGY, V21, P1; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7; STATISTICAL REPORT P	42	197	202	1	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				579	588		10.1016/0091-6749(92)90130-T	http://dx.doi.org/10.1016/0091-6749(92)90130-T			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401641	Bronze			2022-12-18	WOS:A1992JT99500003
J	LEE, TH; BROWN, MJ; NAGY, L; CAUSON, R; WALPORT, MJ; KAY, AB				LEE, TH; BROWN, MJ; NAGY, L; CAUSON, R; WALPORT, MJ; KAY, AB			EXERCISE-INDUCED RELEASE OF HISTAMINE AND NEUTROPHIL CHEMOTACTIC FACTOR IN ATOPIC ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, LONDON SW3 6HP, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, LONDON W12 0HS, ENGLAND	Royal Brompton Hospital; Imperial College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Walport, Mark/0000-0001-7220-5273				ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BROWN MJ, 1981, CLIN SCI, V61, P591, DOI 10.1042/cs0610591; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BROWN MJ, 1980, NEW ENGL J MED, V303, P756; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DUNER H, 1958, SCAND J CLIN LAB INV, V10, P394, DOI 10.3109/00365515809051243; FERRIS L, 1978, BRIT MED J, V1, P1697, DOI 10.1136/bmj.1.6128.1697; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GRANERUS G, 1971, SCAND J RESPIR DIS, V52, P131; HARRIES MG, 1980, BRIT J IND MED, V37, P248; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; KARR RM, 1979, J ALLERGY CLIN IMMUN, V63, P153; LEE TH, 1981, THORAX, V36, P713; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MCFADDEN ER, 1980, J ALLERGY CLIN IMMUN, V66, P472, DOI 10.1016/0091-6749(80)90008-1; MCFADDEN ER, 1977, ASTHMA IMMUNOLOGY IM, P337; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; SHERMAN NA, 1979, J ALLERGY CLIN IMMUN, V63, P154; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P153; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	32	197	199	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					73	81		10.1016/0091-6749(82)90232-9	http://dx.doi.org/10.1016/0091-6749(82)90232-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	6178768				2022-12-18	WOS:A1982PB59100001
J	Gevaert, P; Omachi, TA; Corren, J; Mullol, J; Han, J; Lee, SE; Kaufman, D; Ligueros-Saylan, M; Howard, M; Zhu, R; Owen, R; Wong, K; Islam, L; Bachert, C				Gevaert, Philippe; Omachi, Theodore A.; Corren, Jonathan; Mullol, Joaquim; Han, Joseph; Lee, Stella E.; Kaufman, Derrick; Ligueros-Saylan, Monica; Howard, Monet; Zhu, Rui; Owen, Ryan; Wong, Kit; Islam, Lutaf; Bachert, Claus			Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyps; rhinosinusitis; omalizumab; quality of life; nasal obstruction; IgE; allergy; asthma	ADULT CHRONIC RHINOSINUSITIS; IGE; SURGERY; THERAPY; LIFE	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. Objective: Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2). Methods: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score. Secondary end points included change from baseline to week 24 in Sino-Nasal Outcome Test-22 (SNOT-22) score, University of Pennsylvania Smell Identification Test, sense of smell, postnasal drip, runny nose, and adverse events. Results: Patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) exhibited severe CRSwNP and substantial quality of life impairment evidenced by a mean NPS higher than 6 and SNOT-22 score of approximately 60. Both studies met both the coprimary end points. SNOT-22 score, University of Pennsylvania Smell Identification Test score, sense of smell, postnasal drip, and runny nose were also significantly improved for omalizumab versus placebo. In POLYP 1 and POLYP 2, the mean changes from baseline at week 24 for omalizumab versus placebo were as follows: NPS, -1.08 versus 0.06 (P < .0001) and - 0.90 versus -0.31 (P = .0140); Nasal Congestion Score, -0.89 versus -0.35 (P = .0004) and -0.70 versus -0.20 (P = .0017); and SNOT-22 score, -24.7 versus -8.6 (P < .0001) and -21.6 versus - 6.6 (P < .0001). Adverse events were similar between groups. Conclusion: Omalizumab significantly improved endoscopic, clinical, and patient-reported outcomes in severe CRSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.	[Gevaert, Philippe; Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, Ghent, Belgium; [Omachi, Theodore A.; Kaufman, Derrick; Howard, Monet; Zhu, Rui; Owen, Ryan; Wong, Kit] Genentech Inc, 1 DNAWay, San Francisco, CA 94080 USA; [Corren, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Corren, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Mullol, Joaquim] Univ Barcelona, Hosp Clin, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain; [Han, Joseph] Eastern Virginia Med Sch, Norfolk, VA 23501 USA; [Lee, Stella E.] Univ Pittsburgh, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA; [Ligueros-Saylan, Monica] Novartis Pharmaceut, E Hanover, NJ USA; [Islam, Lutaf] Roche, Welwyn Garden City, Herts, England; [Bachert, Claus] Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden	Ghent University; Ghent University Hospital; Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Eastern Virginia Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Novartis; Roche Holding; Karolinska Institutet	Omachi, TA (corresponding author), Genentech Inc, 1 DNAWay, San Francisco, CA 94080 USA.	omachi.theodore@gene.com	Bachert, Claus/J-8825-2012; Gevaert, Philippe/ABA-4588-2021; Gevaert, Philippe/AAP-1892-2020	Gevaert, Philippe/0000-0002-1629-8468; Omachi, Theodore/0000-0001-9167-768X	Genentech, Inc, a member of the Roche Group; Novartis Pharma AG; Novartis Pharmaceuticals Corporation	Genentech, Inc, a member of the Roche Group; Novartis Pharma AG; Novartis Pharmaceuticals Corporation(Novartis)	This study was funded by Genentech, Inc, a member of the Roche Group, and Novartis Pharma AG. Third-party writing assistance was provided by Mark Snape, MBBS, CMPP, and Nicole Tom, PhD, of Envision Pharma Inc, and funded by Genentech, Inc, a member of the Roche Group, and Novartis Pharmaceuticals Corporation.	[Anonymous], 2019, XOL; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Benjamin MR, 2019, J ALLER CL IMM-PRACT, V7, P1010, DOI 10.1016/j.jaip.2018.10.014; Bhutani M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183869; Bidder T, 2018, RHINOLOGY, V56, P42, DOI [10.4193/Rhin17.139, 10.4193/Rhino17.139]; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Chowdhury NI, 2017, INT FORUM ALLERGY RH, V7, P1149, DOI 10.1002/alr.22028; de Loos DD, 2019, J ALLERGY CLIN IMMUN, V143, P1207, DOI 10.1016/j.jaci.2018.12.986; De Schryver E, 2015, ALLERGY ASTHMA IMMUN, V7, P321, DOI 10.4168/aair.2015.7.4.321; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Vennera MD, 2011, THORAX, V66, P824, DOI 10.1136/thx.2010.152835; Deschildre A, 2015, EUR RESPIR J, V46, P856, DOI 10.1183/09031936.00008115; Erskine S, 2016, RHINOLOGY, V54, P311, DOI [10.4193/Rhin15.361, 10.4193/Rhino15.361]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hoehle LP, 2016, RHINOLOGY, V54, P316, DOI [10.4193/Rhin16.211, 10.4193/Rhino16.211]; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; International Council for Harmonisation, GUID GOOD CLIN PRACT; Khan A, 2019, RHINOLOGY, V57, P343, DOI 10.4193/Rhin19.158; Koennecke M, 2018, ALLERGO J, V27, P34; Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599; Lai TW, 2015, SCI REP-UK, V5, DOI 10.1038/srep08191; Le PT, 2018, OTOLARYNG HEAD NECK, V159, P414, DOI 10.1177/0194599818773065; Lieberman PL, 2017, J ALLERGY CLIN IMMUN, V140, P1734, DOI 10.1016/j.jaci.2017.07.013; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P1138, DOI 10.1016/j.jaci.2017.10.018; Naclerio R, 2020, J ALLER CL IMM-PRACT, V8, P1532, DOI 10.1016/j.jaip.2020.02.023; Rudmik L, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0690-5; Scheerens H, 2019, J ALLERGY CLIN IMMUN, V143, P805, DOI 10.1016/j.jaci.2018.10.011; Siergiejko Z, 2011, CURR MED RES OPIN, V27, P2223, DOI 10.1185/03007995.2011.620950; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; Staniorski CJ, 2018, INT FORUM ALLERGY RH, V8, P495, DOI 10.1002/alr.22064; Stevens WW, 2016, J ALLER CL IMM-PRACT, V4, P565, DOI 10.1016/j.jaip.2016.04.012; Takeda K, 2019, J ALLERGY CLIN IMMUN, V143, P1163, DOI 10.1016/j.jaci.2018.07.006; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Vickery TW, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0853-7; World Medical Association, WORLD MED ASS DECL H; Ye ZP, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1137-6; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x	42	196	205	9	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					595	605		10.1016/j.jaci.2020.05.032	http://dx.doi.org/10.1016/j.jaci.2020.05.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32524991	hybrid, Green Published			2022-12-18	WOS:000569168900012
J	O'Mahony, L; Akdis, M; Akdis, CA				O'Mahony, Liam; Akdis, Muebeccel; Akdis, Cezmi A.			Regulation of the immune response and inflammation by histamine and histamine receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Histamine receptor; innate immunity; adaptive immunity; immune regulation; G protein-coupled receptor; review	REACTIVE OXYGEN METABOLITES; IFN-GAMMA PRODUCTION; PIG BRAIN-SLICES; JURKAT T-CELLS; H-4 RECEPTOR; DENDRITIC CELLS; CYCLIC-AMP; MAST-CELLS; KNOCKOUT MICE; UP-REGULATION	Histamine is a biogenic amine with extensive effects on many cell types, including important immunologic cells, such as antigen-presenting cells, natural killer cells, epithelial cells, and T and B lymphocytes. Histamine and its 4 receptors represent a complex system of immunoregulation with distinct effects dependent on receptor subtypes and their differential expression. These are influenced by the stage of cell differentiation, as well as microenvironmental influences, leading to the selective recruitment of effector cells into tissue sites accompanied by effects on cellular maturation, activation, polarization, and effector functions, which lead to tolerogenic or proinflammatory responses. In this review we discuss the regulation of histamine secretion, receptor expression, and differential activation of cells within both the innate and adaptive immune responses. It is clear that the effects of histamine on immune homeostasis are dependent on the expression and activity of the 4 currently known histamine receptors, and we also recognize that 100 years after the original identification of this biogenic amine, we still do not fully understand the complex regulatory interactions between histamine and the host immune response to everyday microbial and environmental challenges. (J Allergy Clin Immunol 2011;128:1153-62.)	[O'Mahony, Liam; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; O'Mahony, Liam/AAG-5838-2019	Akdis, Cezmi/0000-0001-8020-019X; O'Mahony, Liam/0000-0003-4705-3583	Swiss National Science Foundation [32-125249, 32030-132899, 310030-127356]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); EU; COST Action [BM0806]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); EU(European Commission); COST Action(European Cooperation in Science and Technology (COST))	Supported by grants from the Swiss National Science Foundation (project nos. 32-125249, 32030-132899 and 310030-127356), the Christine Kuhne Center for Allergy Research and Education (CK-CARE), EU Marie Curie, and COST Action BM0806 "Recent advances in histamine receptor H4R research.''	Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Barger G, 1910, J PHYSIOL-LONDON, V41, P19; BAUDRY M, 1975, NATURE, V253, P362, DOI 10.1038/253362a0; Beghdadi W, 2008, J EXP MED, V205, P395, DOI 10.1084/jem.20071548; Boissel JP, 2004, BIOCHEMISTRY-US, V43, P7197, DOI 10.1021/bi0302191; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Botturi K, 2010, CLIN EXP ALLERGY, V40, P755, DOI 10.1111/j.1365-2222.2010.03457.x; Brune M, 1996, EUR J HAEMATOL, V57, P312; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Buhner S, 2009, GASTROENTEROLOGY, V137, P1425, DOI 10.1053/j.gastro.2009.07.005; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Cianchi F, 2005, CLIN CANCER RES, V11, P6807, DOI 10.1158/1078-0432.CCR-05-0675; Ciprandi Giorgio, 2003, Journal of Allergy and Clinical Immunology, V112, pS78, DOI 10.1016/S0091-6749(03)01880-3; CLARK RAF, 1977, J IMMUNOL, V118, P137; Coton M, 2010, FOOD MICROBIOL, V27, P1078, DOI 10.1016/j.fm.2010.07.012; Dai HM, 2007, NEUROSCI RES, V57, P306, DOI 10.1016/j.neures.2006.10.020; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; Damaj BB, 2007, J IMMUNOL, V179, P7907, DOI 10.4049/jimmunol.179.11.7907; Daugherty BL, 2004, BRIT J PHARMACOL, V142, P5, DOI 10.1038/sj.bjp.0705730; Dawicki W, 2010, J IMMUNOL, V184, P2116, DOI 10.4049/jimmunol.0803894; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106; Dijkstra D, 2008, J INVEST DERMATOL, V128, P1696, DOI 10.1038/sj.jid.5701250; DIMITRIADOU V, 1994, CLIN SCI, V87, P151, DOI 10.1042/cs0870151; Duan LG, 2010, J GASTROINTEST SURG, V14, P1180, DOI 10.1007/s11605-010-1208-9; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; Feng BS, 2007, AM J PATHOL, V171, P537, DOI 10.2353/ajpath.2007.061274; Fit KE, 2007, ANN PHARMACOTHER, V41, P1222, DOI 10.1345/aph.1H616; Fitzsimons CP, 2001, FEBS LETT, V508, P245, DOI 10.1016/S0014-5793(01)03070-8; Forward NA, 2009, J IMMUNOL, V183, P3014, DOI 10.4049/jimmunol.0802509; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fujimoto S, 2011, CYTOKINE, V54, P191, DOI 10.1016/j.cyto.2010.12.012; Fuld S, 2005, EXP CELL RES, V309, P161, DOI 10.1016/j.yexcr.2005.05.016; Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939; GARBARG M, 1988, MOL PHARMACOL, V33, P38; Gbahou F, 2003, P NATL ACAD SCI USA, V100, P11086, DOI 10.1073/pnas.1932276100; Gschwandtner M, 2010, ALLERGY, V65, P840, DOI 10.1111/j.1398-9995.2009.02279.x; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Haas HL, 2008, PHYSIOL REV, V88, P1183, DOI 10.1152/physrev.00043.2007; Hancock AA, 2003, LIFE SCI, V73, P3043, DOI 10.1016/j.lfs.2003.06.003; He SH, 2004, WORLD J GASTROENTERO, V10, P309; HELLSTRAND K, 1994, J IMMUNOL, V153, P4940; Hirai T, 2004, EPILEPSIA, V45, P309, DOI 10.1111/j.0013-9580.2004.19303.x; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Horio S, 2010, N-S ARCH PHARMACOL, V381, P305, DOI 10.1007/s00210-010-0491-z; Hou YF, 2006, MOL IMMUNOL, V43, P1982, DOI 10.1016/j.molimm.2005.11.013; Huang ZL, 2006, P NATL ACAD SCI USA, V103, P4687, DOI 10.1073/pnas.0600451103; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2009, CLIN EXP ALLERGY, V39, P1786, DOI 10.1111/j.1365-2222.2009.03374.x; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kobayashi T, 1996, GENOMICS, V37, P390, DOI 10.1006/geno.1996.0575; Kubo Y, 1999, INFLAMM RES, V48, P149, DOI 10.1007/s000110050438; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Leite-de-Moraes MC, 2009, J IMMUNOL, V182, P1233, DOI 10.4049/jimmunol.182.3.1233; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; LEURS R, 1995, BIOCHEM BIOPH RES CO, V214, P110, DOI 10.1006/bbrc.1995.2263; Leurs R, 2000, TRENDS PHARMACOL SCI, V21, P11, DOI 10.1016/S0165-6147(99)01411-X; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; Lim HD, 2005, J PHARMACOL EXP THER, V314, P1310, DOI 10.1124/jpet.105.087965; Ling P, 2004, BRIT J PHARMACOL, V142, P161, DOI 10.1038/sj.bjp.0705729; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Ma RLZ, 2002, SCIENCE, V297, P620, DOI 10.1126/science.1072810; MacGlashan Donald Jr., 2003, Journal of Allergy and Clinical Immunology, V112, pS53, DOI 10.1016/S0091-6749(03)01877-3; Masaki T, 2006, TRENDS PHARMACOL SCI, V27, P279, DOI 10.1016/j.tips.2006.03.008; Maslinska D, 2006, INFLAMM RES, V55, pS77, DOI 10.1007/s00011-005-0051-z; Mazzoni A, 2003, J IMMUNOL, V170, P2269, DOI 10.4049/jimmunol.170.5.2269; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mettler SE, 2007, AM J PHYSIOL-GASTR L, V293, pG532, DOI 10.1152/ajpgi.00138.2007; Metz M, 2011, INT ARCH ALLERGY IMM, V155, P355, DOI 10.1159/000321614; Minami T, 2007, J DENT RES, V86, P1083, DOI 10.1177/154405910708601112; Mobarakeh JI, 2006, NEUROPHARMACOLOGY, V51, P612, DOI 10.1016/j.neuropharm.2006.05.003; Moreno-Delgado D, 2006, NEUROPHARMACOLOGY, V51, P517, DOI 10.1016/j.neuropharm.2006.04.010; Moretta L, 2006, SEMIN IMMUNOL, V18, P151, DOI 10.1016/j.smim.2006.03.002; Morgan RK, 2007, J IMMUNOL, V178, P8081, DOI 10.4049/jimmunol.178.12.8081; Morichika T, 2003, J PHARMACOL EXP THER, V304, P624, DOI 10.1124/jpet.102.042515; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Murray F, 2003, BRIT J PHARMACOL, V138, P1313, DOI 10.1038/sj.bjp.0705190; Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008; Notcovich C, 2010, EXP CELL RES, V316, P401, DOI 10.1016/j.yexcr.2009.11.002; Noubade R, 2007, J CLIN INVEST, V117, P3507, DOI 10.1172/JCI32792; O'Mahony L, 2006, AM J PHYSIOL-GASTR L, V290, pG839, DOI 10.1152/ajpgi.00112.2005; O'Mahony L, 2010, AUTOIMMUNITY, V43, P493, DOI 10.3109/08916931003674725; O'Reilly M, 2002, J RECEPT SIGNAL TR R, V22, P431, DOI 10.1081/RRS-120014612; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Ohtani T, 2003, J INVEST DERMATOL, V121, P1073, DOI 10.1046/j.1523-1747.2003.12570.x; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Radvany Z, 2000, SEMIN CANCER BIOL, V10, P41, DOI 10.1006/scbi.2000.0306; San Tang K, 2007, BIOPHYS J, V92, P2735, DOI 10.1529/biophysj.106.088997; Sander LE, 2006, GUT, V55, P498, DOI 10.1136/gut.2004.061762; Sands WA, 2006, MOL CELL BIOL, V26, P6333, DOI 10.1128/MCB.00207-06; SAXENA SP, 1989, BIOCHEM BIOPH RES CO, V164, P164, DOI 10.1016/0006-291X(89)91697-5; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Shilling DA, 2007, CLIN EXP IMMUNOL, V149, P109, DOI 10.1111/j.1365-2249.2007.03393.x; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; Smit MJ, 1999, CLIN EXP ALLERGY, V29, P19, DOI 10.1046/j.1365-2222.1999.00008.x; Takahashi HK, 2004, CLIN IMMUNOL, V112, P30, DOI 10.1016/j.clim.2004.03.006; Teuscher C, 2004, AM J PATHOL, V164, P883, DOI 10.1016/S0002-9440(10)63176-8; Teuscher C, 2007, P NATL ACAD SCI USA, V104, P10146, DOI 10.1073/pnas.0702291104; Thoren FB, 2009, EXPERT OPIN BIOL TH, V9, P1217, DOI 10.1517/14712590903130566; Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; Tokita S, 2006, J PHARMACOL SCI, V101, P12, DOI 10.1254/jphs.FMJ06001X4; Toyota H, 2002, MOL PHARMACOL, V62, P389, DOI 10.1124/mol.62.2.389; TRAIFFORT E, 1995, BIOCHEM BIOPH RES CO, V211, P570, DOI 10.1006/bbrc.1995.1851; Triggiani M, 2007, J ALLERGY CLIN IMMUN, V119, P472, DOI 10.1016/j.jaci.2006.09.027; Umenishi F, 2006, BBA-BIOMEMBRANES, V1758, P1100, DOI 10.1016/j.bbamem.2006.06.001; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; Vanbervliet B, 2011, J ALLERGY CLIN IMMUN, V127, P943, DOI 10.1016/j.jaci.2010.12.002; Vancheri C, 2005, ALLERGY ASTHMA PROC, V26, P292; Varga C, 2005, EUR J PHARMACOL, V522, P130, DOI 10.1016/j.ejphar.2005.08.045; Wang RB, 2008, ORG BIOMOL CHEM, V6, P1955, DOI 10.1039/b801591k; Westly E, 2010, NAT MED, V16, P16, DOI 10.1038/nm0110-16; Wiedemann P, 2002, J NEURAL TRANSM, V109, P443, DOI 10.1007/s007020200036; Woolson HD, 2009, CELL SIGNAL, V21, P1706, DOI 10.1016/j.cellsig.2009.07.009; Wu L, 2007, IMMUNOL CELL BIOL, V85, P538, DOI 10.1038/sj.icb.7100079; Yanai K, 1998, LIFE SCI, V62, P1607, DOI 10.1016/S0024-3205(98)00115-5; Yarwood SJ, 2008, J BIOL CHEM, V283, P6843, DOI 10.1074/jbc.M710342200; Yoshimoto R, 2006, P NATL ACAD SCI USA, V103, P13866, DOI 10.1073/pnas.0506104103; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Zhang J, 2010, BRIT J PHARMACOL, V160, P1378, DOI 10.1111/j.1476-5381.2010.00800.x; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	135	196	203	3	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1153	1164		10.1016/j.jaci.2011.06.051	http://dx.doi.org/10.1016/j.jaci.2011.06.051			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21824648				2022-12-18	WOS:000298342700002
J	Loss, G; Apprich, S; Waser, M; Kneifel, W; Genuneit, J; Buchele, G; Weber, J; Sozanska, B; Danielewicz, H; Horak, E; van Neerven, RJJ; Heederik, D; Lorenzen, PC; von Mutius, E; Braun-Fahrlander, C				Loss, Georg; Apprich, Silvia; Waser, Marco; Kneifel, Wolfgang; Genuneit, Jon; Buechele, Gisela; Weber, Juliane; Sozanska, Barbara; Danielewicz, Hanna; Horak, Elisabeth; van Neerven, R. J. Joost; Heederik, Dick; Lorenzen, Peter C.; von Mutius, Erika; Braun-Fahrlaender, Charlotte		GABRIELA Study Grp	The protective effect of farm milk consumption on childhood asthma and atopy: The GABRIELA study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic diseases; asthma; atopy; children; farming; hay fever; microorganism; farm milk; risk; whey protein	INVERSE ASSOCIATION; INNATE IMMUNITY; EXPOSURE; HEALTH; BETA; LIFE; PREVALENCE; EXPLAIN; ALLERGY; FAT	Background: Farm milk consumption has been identified as an exposure that might contribute to the protective effect of farm life on childhood asthma and allergies. The mechanism of action and the role of particular constituents of farm milk, however, are not yet clear. Objective: We sought to investigate the farm milk effect and determine responsible milk constituents. Methods: In rural regions of Germany, Austria, and Switzerland, a comprehensive questionnaire about farm milk consumption and other farm-related exposures was completed by parents of 8334 school-aged children, and 7606 of them provided serum samples to assess specific IgE levels. In 800 cow's milk samples collected at the participants' homes, viable bacterial counts, whey protein levels, and total fat content were analyzed. Asthma, atopy, and hay fever were associated to reported milk consumption and for the first time to objectively measured milk constituents by using multiple regression analyses. Results: Reported raw milk consumption was inversely associated to asthma (adjusted odds ratio [aOR], 0.59; 95% CI, 0.46-0.74), atopy (aOR, 0.74; 95% CI, 0.61-0.90), and hay fever (aOR, 0.51; 95% CI, 0.37-0.69) independent of other farm exposures. Boiled farm milk did not show a protective effect. Total viable bacterial counts and total fat content of milk were not significantly related to asthma or atopy. Increased levels of the whey proteins BSA (aOR for highest vs lowest levels and asthma, 0.53; 95% CI, 0.30-0.97), alpha-lactalbumin (aOR for interquartile range and asthma, 0.71; 95% CI, 0.52-0.97), and beta-lactoglobulin (aOR for interquartile range and asthma, 0.62; 95% CI, 0.39-0.97), however, were inversely associated with asthma but not with atopy. Conclusions: The findings suggest that the protective effect of raw milk consumption on asthma might be associated with the whey protein fraction of milk. (J Allergy Clin Immunol 2011;128:766-73.)	[Loss, Georg; Waser, Marco; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Loss, Georg; Waser, Marco; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Apprich, Silvia; Kneifel, Wolfgang] Univ Nat Resources & Life Sci, BOKU Vienna, Dept Food Sci & Technol, Vienna, Austria; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Weber, Juliane; von Mutius, Erika] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, Munich, Germany; [Sozanska, Barbara; Danielewicz, Hanna] Wroclaw Med Univ, Dept Paediat Allergol & Cardiol 1, Wroclaw, Poland; [Horak, Elisabeth] Innsbruck Med Univ, Dept Pediat & Adolescents, Div Cardiol & Pulmonol, Innsbruck, Austria; [van Neerven, R. J. Joost] Friesland Campina Res, Deventer, Netherlands; [Heederik, Dick] Univ Utrecht, IRAS, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands; [Lorenzen, Peter C.] Max Rubner Inst, Fed Res Inst Nutr & Food, Dept Safety & Qual Milk & Fish Prod, Kiel, Germany	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Natural Resources & Life Sciences, Vienna; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Wroclaw Medical University; Medical University of Innsbruck; Utrecht University	Loss, G (corresponding author), Swiss Trop & Publ Hlth Inst, Socinstr 57,POB, CH-4002 Basel, Switzerland.	georg.loss@unibas.ch	Ege, Markus/C-1962-2012; Loss, Georg/AAE-7296-2019; Loss, Georg/F-1557-2013; Normand, Anne-Cécile/V-4271-2018; Lauener, Roger P/O-8612-2016; van Neerven, Joost/GWZ-3214-2022; Danielewicz, Hanna/AAY-6014-2020; Genuneit, Jon/I-9323-2012; Latzin, Philipp/F-2206-2017	Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Normand, Anne-Cécile/0000-0002-9589-4603; Lauener, Roger P/0000-0002-8412-606X; Danielewicz, Hanna/0000-0001-7999-8923; Genuneit, Jon/0000-0001-5764-1528; Frey, Urs/0000-0003-3773-2822; von Mutius, Erika/0000-0002-8893-4515; piarroux, renaud/0000-0002-4151-4134; Latzin, Philipp/0000-0002-5239-1571; Wouters, Inge M./0000-0001-7834-9390; Debinska, Anna/0000-0002-1136-1974; van Neerven, R.J.Joost/0000-0002-3991-5297; Heederik, Dick/0000-0002-4550-1437; Hyvarinen, Anne/0000-0002-2823-0866	European Union [LSH-2004-1.2.5-1, 018996]; European Commission; InfectoPharm; Airsonett AB; Deutsche Forschungsgemeinschaft (DFG); BMBF	European Union(European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); InfectoPharm; Airsonett AB; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	Supported by a European Union Research grant under the FP6-LifeSCIHEALTH Integrated Program LSH-2004-1.2.5-1 (contract no. 018996).; J. Weber, B. Sozanska, H. Danielewicz, A Boznanski, A. Debinska, M. Depner, A. Kosmeda, and C. Strunz-Lehner have received research support from the European Commission. D. Heederik and I. M. Wouters have received research support from the European Union. E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmun; has received a speaker's fee from InfectoPharm; has received research support from Airsonett AB; is a member of the Expert Panel for UK Research Excellence Framework; and is an Associate Editor for the Journal of Allergy and Clinical Immunology. M. Ege has received research support from the European Commission and the Deutsche Forschungsgemeinschaft (DFG). M. Kabesch has financial interests in Roxall, GlaxoSmithKline, Novartis, Sanofi-Aventis, Allergopharma, and AstraZeneca GmbH and has received research support from DFG, BMBF, and the European Union. The rest of the authors have declared that they have no conflict of interest.	Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Conroy ME, 2009, CURR OPIN ALLERGY CL, V9, P197, DOI 10.1097/ACI.0b013e32832b3f1d; Desmasures N, 1997, J APPL MICROBIOL, V83, P53, DOI 10.1046/j.1365-2672.1997.00166.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; International Dairy Federation, 1991, 100B IDF; Krissansen GW, 2007, J AM COLL NUTR, V26, p713S, DOI 10.1080/07315724.2007.10719652; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lorenzen PC, 2011, INT J DAIRY TECHNOL, V64, P166, DOI 10.1111/j.1471-0307.2010.00656.x; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Oddy WH, 2010, PEDIAT ALLERG IMM-UK, V21, P47, DOI 10.1111/j.1399-3038.2009.00913.x; Perkin MR, 2007, CLIN EXP ALLERGY, V37, P627, DOI 10.1111/j.1365-2222.2007.02715.x; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peroni DG, 2010, PEDIAT ALLERG IMM-UK, V21, P977, DOI 10.1111/j.1399-3038.2010.00995.x; Peroni DG, 2009, PEDIAT ALLERG IMM-UK, V20, P42, DOI 10.1111/j.1399-3038.2008.00737.x; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Puddu P, 2009, BIOCHIMIE, V91, P11, DOI 10.1016/j.biochi.2008.05.005; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rusu D, 2009, J NUTR, V139, P386, DOI 10.3945/jn.108.098459; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Thijs C, 2011, ALLERGY, V66, P58, DOI 10.1111/j.1398-9995.2010.02445.x; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Yoshida T, 2005, J AGR FOOD CHEM, V53, P6851, DOI 10.1021/jf050772k	31	196	200	0	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					766	U432		10.1016/j.jaci.2011.07.048	http://dx.doi.org/10.1016/j.jaci.2011.07.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21875744	Green Submitted			2022-12-18	WOS:000296538100010
J	Gruber, C; van Stuijvenberg, M; Mosca, F; Moro, G; Chirico, G; Braegger, CP; Riedler, J; Boehm, G; Wahn, U				Grueber, Christoph; van Stuijvenberg, Margriet; Mosca, Fabio; Moro, Guido; Chirico, Gaetano; Braegger, Christian P.; Riedler, Josef; Boehm, Guenther; Wahn, Ulrich		MIPS 1 Working Grp	Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oligosaccharides; atopic dermatitis; infant; primary prevention; prebiotics	ACTIVATION-REGULATED CHEMOKINE; 1ST 6 MONTHS; DOUBLE-BLIND; ACIDIC OLIGOSACCHARIDES; PRIMARY PREVENTION; SERUM THYMUS; PROBIOTICS; CHILDREN; DISEASE; ECZEMA	Background: Most infants developing atopic dermatitis have a low risk for atopy. Primary prevention of atopic dermatitis is difficult. Objective: To assess the effect of supplementation of an infant and follow-on formula with prebiotic and immunoactive oligosaccharides on the occurrence of atopic dermatitis in the first year of life. Methods: Healthy term infants from 5 European countries with low atopy risk were recruited before the age of 8 weeks, either having started with formula feeding or being on full breast-eeding (breast-feeding group). Formula-fed infants were randomized to feeding with a regular formula containing a specific mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group). Results: A total of 414 infants were randomized to the prebiotic group and 416 infants to the control group. A total of 300 infants were followed in the breast-feeding group. Up to the first birthday, atopic dermatitis occurred in significantly fewer infants from the prebiotic group (5.7%) than from the control group (9.7%; P = .04). The cumulative incidence of atopic dermatitis in the prebiotic group was in the low range of the breast-feeding group (7.3%). In a Cox regression model, the rate of atopic dermatitis was significantly lower by 44% in the prebiotic group versus the control group (P = .04). The number needed to prevent 1 case of atopic dermatitis by supplementation of prebiotics was 25 infants. Conclusion: Formula supplementation with a specific mixture of oligosaccharides was effective as primary prevention of atopic dermatitis in low atopy risk infants. (J Allergy Clin Immunol 2010;126:791-7.)	[Grueber, Christoph; Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Grueber, Christoph] Klinikum Frankfurt Oder GmbH, Dept Pediat, D-15202 Frankfurt, Oder, Germany; [van Stuijvenberg, Margriet] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Div Neonatol, Groningen, Netherlands; [Mosca, Fabio] Osped Maggiore, Fdn IRCCS Ca Granda, Milan, Italy; [Mosca, Fabio] Univ Milan, Univ Dept Mother & Infant Sci, Milan, Italy; [Moro, Guido] Macedonio Melloni Hosp, Milan, Italy; [Chirico, Gaetano] Spedali Civil Brescia, Dept Neonatol, I-25125 Brescia, Italy; [Braegger, Christian P.] Univ Childrens Hosp, Div Paediat Gastroenterol & Nutr, Zurich, Switzerland; [Riedler, Josef] Schwarzach Hosp, Childrens Hosp, Schwarzach, Austria; [Wahn, Ulrich] Danone Res Ctr Specialized Nutr, Friedrichshafen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Groningen; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Hospital Spedali Civili Brescia; University Children's Hospital Zurich; Danone Nutricia	Gruber, C (corresponding author), Klinikum Frankfurt Oder GmbH, Dept Pediat, POB 1281, D-15202 Frankfurt, Oder, Germany.	christoph.grueber@charite.de	Mosca, Fabio/C-5826-2017; garssen, johan/I-7159-2016; riedler, josef/AAQ-4666-2020; Braegger, Christian Peter/ABC-9884-2021	Mosca, Fabio/0000-0001-6477-0299; Braegger, Christian/0000-0001-8069-9875	Danone Research, Friedrichsdorf, Germany; Danone/Numico	Danone Research, Friedrichsdorf, Germany(Danone Nutricia); Danone/Numico	Supported by Danone Research, Friedrichsdorf, Germany. The role of the funder has been to supply the study formulas and facilitate the data collection and data analysis.; Disclosure of potential conflict of interest: C. Gruber receives honoraria from Danone. F. Mosca receives research support from Danone/Numico. C. P. Braegger has consultant arrangements and receives research support from Danone. J. Riedler is on the advisory board for Numico and receives research support from MIPS. U. Wahn receives research support from Danone. The rest of the authors have declared that they have no conflict of interest.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P905; Fanaro S, 2005, J PEDIATR GASTR NUTR, V41, P186, DOI 10.1097/01.mpg.0000172747.64103.d7; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandoval-Lopez G, 2001, CLIN EXP ALLERGY, V31, P1809, DOI 10.1046/j.1365-2222.2001.01268.x; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Song TW, 2006, CLIN EXP ALLERGY, V36, P346, DOI 10.1111/j.1365-2222.2006.02430.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Vos AP, 2007, CRIT REV IMMUNOL, V27, P97, DOI 10.1615/CritRevImmunol.v27.i2.10; Vos AP, 2007, PEDIAT ALLERG IMM-UK, V18, P304, DOI 10.1111/j.1399-3038.2007.00515.x; Vos AP, 2010, INT IMMUNOPHARMACOL, V10, P619, DOI 10.1016/j.intimp.2010.02.014; Westerbeek EAM, 2010, AM J CLIN NUTR, V91, P679, DOI 10.3945/ajcn.2009.28625; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	30	196	212	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					791	797		10.1016/j.jaci.2010.07.022	http://dx.doi.org/10.1016/j.jaci.2010.07.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20832848				2022-12-18	WOS:000282510000017
J	Woellner, C; Gertz, EM; Schaffer, AA; Lagos, M; Perro, M; Glocker, EO; Pietrogrande, MC; Cossu, F; Franco, JL; Matamoros, N; Pietrucha, B; Heropolitanska-Pliszka, E; Yeganeh, M; Moin, M; Espanol, T; Ehl, S; Gennery, AR; Abinun, M; Breborowicz, A; Niehues, T; Kilic, SS; Junker, A; Turvey, SE; Plebani, A; Sanchez, B; Garty, BZ; Pignata, C; Cancrini, C; Litzman, J; Sanal, O; Baumann, U; Bacchetta, R; Hsu, AP; Davis, JN; Hammarstrom, L; Davies, EG; Eren, E; Arkwright, PD; Moilanen, JS; Viemann, D; Khan, S; Laszlo, M; Cant, AJ; Freeman, AF; Puck, JM; Holland, SM; Grimbacher, B				Woellner, Cristina; Gertz, E. Michael; Schaeffer, Alejandro A.; Lagos, Macarena; Perro, Mario; Glocker, Erik-Oliver; Pietrogrande, Maria C.; Cossu, Fausto; Franco, Josee L.; Matamoros, Nuria; Pietrucha, Barbara; Heropolitanska-Pliszka, Edyta; Yeganeh, Mehdi; Moin, Mostafa; Espanol, Teresa; Ehl, Stephan; Gennery, Andrew R.; Abinun, Mario; Breborowicz, Anna; Niehues, Tim; Kilic, Sara Sebnem; Junker, Anne; Turvey, Stuart E.; Plebani, Alessandro; Sanchez, Berta; Garty, Ben-Zion; Pignata, Claudio; Cancrini, Caterina; Litzman, Jiri; Sanal, Oezden; Baumann, Ulrich; Bacchetta, Rosa; Hsu, Amy P.; Davis, Joie N.; Hammarstroem, Lennart; Davies, E. Graham; Eren, Efrem; Arkwright, Peter D.; Moilanen, Jukka S.; Viemann, Dorothee; Khan, Sujoy; Laszlo Marodi; Cant, Andrew J.; Freeman, Alexandra F.; Puck, Jennifer M.; Holland, Steven M.; Grimbacher, Bodo			Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hyper-IgE syndrome; HIES; Job syndrome; T(H)17 cells; STAT3 mutations; diagnostic guidelines	HOST-DEFENSE; CELLS	Background: The hyper-IgE syndrome (HIES) is a primary immunodeficiency characterized by infections of the lung and skin, elevated serum IgE, and involvement of the soft and bony tissues. Recently, HIES has been associated with heterozygous dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT-3) and severe reductions of T(H)17 cells. Objective: To determine whether there is a correlation between the genotype and the phenotype of patients with HIES and to establish diagnostic criteria to distinguish between STAT3 mutated and STAT3 wild-type patients. Methods: We collected clinical data, determined T(H)17 cell numbers, and sequenced STAT3 in 100 patients with a strong clinical suspicion of HIES and serum IgE > 1000 IU/mL. We explored diagnostic criteria by using a machine-learning approach to identify which features best predict a STAT3 mutation. Results: In 64 patients, we identified 31 different STAT3 mutations, 18 of which were novel. These included mutations at splice sites and outside the previously implicated DNA-binding and Src homology 2 domains. A combination of 5 clinical features predicted STAT3 mutations with 85% accuracy. T(H)17 cells were profoundly reduced in patients harboring STAT-3 mutations, whereas 10 of 13 patients without mutations had low (<1%) T(H)17 cells but were distinct by markedly reduced IFN-gamma-producing CD4(+)T cells. Conclusion: We propose the folio-wing diagnostic guidelines for STAT3-deficient HIES. Possible: IgE >1000IU/mL plus a weighted score of clinical features >30 based on recurrent pneumonia, newborn rash, pathologic bone fractures, characteristic face, and high palate. Probable: These characteristics plus lack of T(H)17 cells or a family history for definitive HIES. Definitive: These characteristics plus a dominant-negative heterozygous mutation in STAT3. (J Allergy Clin Immunol 2010;125:424-32.)	[Woellner, Cristina; Perro, Mario; Glocker, Erik-Oliver; Grimbacher, Bodo] UCL, Royal Free Hosp, Dept Immunol & Mol Pathol, London NW3 2QG, England; [Gertz, E. Michael; Schaeffer, Alejandro A.] NIAID, Natl Ctr Biotechnol Informat, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Hsu, Amy P.; Davis, Joie N.; Freeman, Alexandra F.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Lagos, Macarena] Univ Valparaiso, Catedra Inmunol, Escuela Med, Valparaiso, Chile; [Pietrogrande, Maria C.] Univ Milan, Fdn Policlin IRCCS, Dept Pediat, Milan, Italy; [Cossu, Fausto] Osped Microcitem, Bone Marrow Transplant Unit, Cagliari, Italy; [Franco, Josee L.] Univ Antioquia, Grp Primary Immunodeficiencies, Medellin, Colombia; [Matamoros, Nuria] Son Dureta Hosp, Serv Immunol, Palma de Mallorca, Spain; [Pietrucha, Barbara; Heropolitanska-Pliszka, Edyta] Childrens Mem Hlth Inst, Gastroenterol Hepatol & Immunol Clin, Warsaw, Poland; [Yeganeh, Mehdi; Moin, Mostafa] Univ Tehran Med Sci, Immunol Asthma & Allergy Res Inst, Children Med Ctr, Tehran, Iran; [Espanol, Teresa] Hosp Gen Valle Hebron, Sch Med, Immunol Unit, Barcelona, Spain; [Ehl, Stephan] Univ Hosp Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Gennery, Andrew R.; Abinun, Mario] Newcastle Univ, Childrens Bone Marrow Transplant Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Breborowicz, Anna] Poznan Univ Med Sci, Dept Pediat Pulmonol Allergy & Clin Immunol, Dept Pediat 3, Poznan, Poland; [Niehues, Tim] Univ Dusseldorf, Immunodeficiency & Pediat Rheumatol Ctr, HELIOS Klinikum Krefeld, Dusseldorf, Germany; [Kilic, Sara Sebnem] Uludag Univ, Dept Pediat Immunol, Fac Med, Bursa, Turkey; [Junker, Anne; Turvey, Stuart E.] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada; [Junker, Anne; Turvey, Stuart E.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Plebani, Alessandro] Univ Brescia, Dept Pediat, Brescia, Italy; [Plebani, Alessandro] Univ Brescia, Inst Mol Med A, Brescia, Italy; [Sanchez, Berta] Univ Hosp, Serv Immunol, Seville, Spain; [Garty, Ben-Zion] Schneider Childrens Med Ctr, Dept Pediat, Petah Tiqwa, Israel; [Pignata, Claudio] Univ Naples Federico II, Dept Pediat, Naples, Italy; [Cancrini, Caterina] Univ Roma Tor Vergata, Div Infect Dis & Immunol, Bambino Gesu Childrens Hosp, Rome, Italy; [Litzman, Jiri] Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Fac Med, Brno, Czech Republic; [Sanal, Oezden] Hacettepe Univ, Childrens Hosp, Div Immunol, Ankara, Turkey; [Baumann, Ulrich] Hannover Med Sch, Dept Pediat Pulmonol & Neonatol, D-3000 Hannover, Germany; [Bacchetta, Rosa] San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy; [Hammarstroem, Lennart] Karolinska Univ Hosp, Div Clin Immunol, Dept Lab Med, Karolinska Inst, Stockholm, Sweden; [Davies, E. Graham] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Eren, Efrem] Southampton Gen Hosp, Dept Immunol, Southampton, Hants, England; [Arkwright, Peter D.] Univ Manchester, Manchester, Lancs, England; [Moilanen, Jukka S.] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Moilanen, Jukka S.] Univ Oulu, Dept Clin Genet, Tampere, Finland; [Viemann, Dorothee] Univ Munster, Inst Immunol, Munster, Germany; [Viemann, Dorothee] Univ Munster, Dept Pediat, Munster, Germany; [Khan, Sujoy] Scunthorpe Gen Hosp, Scunthorpe, S Humberside, England; [Laszlo Marodi] Univ Debrecen, Dept Infect & Pediat Immunol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidad de Valparaiso; University of Milan; Universidad de Antioquia; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Children's Memorial Health Institute; Immunology Asthma & Allergy Research Institute - Iran; Tehran University of Medical Sciences; Hospital Universitari Vall d'Hebron; University of Freiburg; Newcastle University - UK; Poznan University of Medical Sciences; Heinrich Heine University Dusseldorf; Helios Kliniken; Uludag University; BC Childrens Hospital; University of British Columbia; University of British Columbia; University of Brescia; University of Brescia; University of Naples Federico II; IRCCS Bambino Gesu; University of Rome Tor Vergata; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Hacettepe University; Hannover Medical School; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Karolinska Institutet; Karolinska University Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Southampton; University of Manchester; Tampere University; University of Oulu; University of Munster; University of Munster; University of Debrecen; University of California System; University of California San Francisco	Grimbacher, B (corresponding author), UCL, Royal Free Hosp, Dept Immunol & Mol Pathol, Pond St, London NW3 2QG, England.	b.grimbacher@ucl.ac.uk	Ehl, Stephan/AAM-6006-2020; Perro, Mario/AAB-5554-2021; Khan, Sujoy/I-1651-2019; Schaffer, Alejandro/N-1222-2019; Moilanen, Jukka S/G-2604-2012; Arkwright, Peter/C-5149-2012; Rezaei, Nima/B-4245-2008; Turvey, Stuart/HGV-1191-2022; Schaffer, Alejandro A/F-2902-2012; Plebani, Alessandro/C-8593-2011; Kilic, Sara Sebnem/AAH-1658-2021; Pignata, Claudio/O-2466-2013	Perro, Mario/0000-0003-1375-8155; Khan, Sujoy/0000-0001-5654-2835; Moilanen, Jukka S/0000-0002-8041-3205; Rezaei, Nima/0000-0002-3836-1827; Pignata, Claudio/0000-0003-1568-9843; Pietrucha, Barbara/0000-0002-9723-8351; kilic, sara sebnem/0000-0001-8571-2581; Litzman, Jiri/0000-0002-1926-5426; Turvey, Stuart/0000-0003-1599-1065; Cossu, Fausto/0000-0001-5485-2098; Gertz, E. Michael/0000-0001-8390-4387; cancrini, caterina/0000-0001-8410-9617; FRANCO, JOSE/0000-0001-5664-6415; Arkwright, Peter/0000-0002-7411-5375; Heropolitanska-Pliszka, Edyta/0000-0001-5519-2730; Ehl, Stephan/0000-0002-9265-2721	GSK; European consortium [EURO-PADnet HEALRH-F2-2008-201549]; Brescia; National Institutes of Health, NLM; National Institute of Allergy and Infectious Diseases; National Cancer Institute, National Institutes of Health [N01-CO-1240];  [MEXT-CT-2006-042316];  [OTKA49017]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM000097] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom	GSK(GlaxoSmithKline); European consortium; Brescia; National Institutes of Health, NLM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Fondazione Telethon(Fondazione Telethon)	Supported by in part by the European grant MEXT-CT-2006-042316 to B.G., a grant of the Primary Immunodeficiency Association provided by GSK. the European consortium grant EURO-PADnet HEALRH-F2-2008-201549, the grant OTKA49017 to L.M., the foundation C. Golgi from Brescia to A.P.. the Intramural Research Program of the National Institutes of Health, NLM (E.M.G. A.A.S.). the National Institute of Allergy and Infectious Diseases (A.P.H., A.F.F., J.N.D., SACK). and federal funds from the National Cancer Institute, National Institutes of Health. under contract N01-CO-1240. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products. or organizations imply endorsement by the US Government.	BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Buettner M, 2005, J IMMUNOL, V174, P4203, DOI 10.4049/jimmunol.174.7.4203; DAVIS SD, 1966, LANCET, V1, P1013; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Gertz EM, 2003, ACM T MATH SOFTWARE, V29, P58, DOI 10.1145/641876.641880; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Jiao H, 2008, MOL IMMUNOL, V46, P202, DOI 10.1016/j.molimm.2008.07.001; Joachims T., 1999, MAKING LARGE SCALE S, P41, DOI 10.17877/DE290R-5098; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Moin M, 2006, SCAND J INFECT DIS, V38, P898, DOI 10.1080/00365540600740470; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Netea MG, 2005, EUR J CLIN INVEST, V35, P718, DOI 10.1111/j.1365-2362.2005.01564.x; R Development Core Team, 2006, R LANG ENV STAT COMP; Reich NC, 2006, NAT REV IMMUNOL, V6, P602, DOI 10.1038/nri1885; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; RENNER ED, 2008, ALLERGY CLIN IMMUNOL, V121, P181; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vapnik VN., 1996, COMPUTATIONAL LEARNI	28	196	214	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					424	432		10.1016/j.jaci.2009.10.059	http://dx.doi.org/10.1016/j.jaci.2009.10.059			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159255	Green Accepted			2022-12-18	WOS:000274764000022
J	Louten, J; Boniface, K; Malefyt, RD				Louten, Jennifer; Boniface, Katia; Malefyt, Rene de Waal			Development and function of T(H)17 cells in health and disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)17 cell; T-H cell; allergy; cytokines; IL-23; IL-17; IL-22	GROWTH-FACTOR-BETA; HUMAN TH17 CELLS; T-HELPER-CELLS; ROR-GAMMA-T; INFLAMMATORY-BOWEL-DISEASE; COLLAGEN-INDUCED ARTHRITIS; HYPER-IGE SYNDROME; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TGF-BETA; HOST-DEFENSE	T(H)17 cells are the newest member of the T-H cell family and are characterized by their ability to produce specific cytokines such as IL-17, IL-22, IL-17F, and CCL20. In this review, conditions for the differentiation of T(H)17 cells are defined in both murine and human systems, with discussion of T(H)17-specific cytokines and transcription factors. Functionally, T(H)17 cells contribute to host defense as a new effector T-H cell subset with a role in protection against extracellular bacteria through activities on immune and nonimmune cells. Their activities, however, are also pivotal in the development of autoimmune diseases under pathologic conditions. T(H)17 cells are also beginning to be associated with the development and pathophysiology of allergic diseases, such as allergic contact dermatitis, atopic dermatitis, and asthma. Lymphoid tissue inducer-like cells and natural killer-like cells, termed ROR gamma t(+)NKp46(+) or NK-22 cells, might also play a role in allergic diseases because of their propensity to produce IL-17 and IL-22. (J Allergy Clin Immunol 2009;123:1004-11.)			Malefyt, RD (corresponding author), 901 S Calif Ave, Palo Alto, CA 94304 USA.	Rene.de.Waal.Malefyt@spcorp.com	Boniface, Katia/N-5577-2016	Boniface, Katia/0000-0003-4428-1222; Louten, Jennifer/0000-0002-4568-187X; de Waal Malefyt, Rene/0000-0002-2663-383X				Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boniface K, 2008, IMMUNOL REV, V226, P132, DOI 10.1111/j.1600-065X.2008.00714.x; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen Z, 2007, ARTHRITIS RHEUM-US, V56, P2936, DOI 10.1002/art.22866; Cheung PFY, 2008, J IMMUNOL, V180, P5625, DOI 10.4049/jimmunol.180.8.5625; Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood-2008-05-155408; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Coquet JM, 2008, J IMMUNOL, V180, P7097, DOI 10.4049/jimmunol.180.11.7097; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Di Cesare A, 2008, J INVEST DERMATOL, V128, P2569, DOI 10.1038/jid.2008.283; DICESARE A, 2009, J INVEST DERMATOL; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; Goto M, 2009, CELL IMMUNOL, V254, P81, DOI 10.1016/j.cellimm.2008.10.002; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Ilvanov II, 2006, CURR TOP MICROBIOL, V308, P59; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kleinschek MA, 2009, J EXP MED, V206, P525, DOI 10.1084/jem.20081712; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Laan M, 1999, J IMMUNOL, V162, P2347; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Luci C, 2009, NAT IMMUNOL, V10, P75, DOI 10.1038/ni.1681; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Paulson ML, 2008, CURR OPIN ALLERGY CL, V8, P527, DOI 10.1097/ACI.0b013e3283184210; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; Romagnani S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2392; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Santarlasci V, 2009, EUR J IMMUNOL, V39, P207, DOI 10.1002/eji.200838748; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Sheibanie AF, 2004, FASEB J, V18, P1318, DOI 10.1096/fj.03-1367fje; Sheibanie AF, 2007, ARTHRITIS RHEUM-US, V56, P2608, DOI 10.1002/art.22794; Sheibanie AF, 2007, J IMMUNOL, V178, P8138, DOI 10.4049/jimmunol.178.12.8138; Sonderegger I, 2008, EUR J IMMUNOL, V38, P1833, DOI 10.1002/eji.200838511; Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Tanaka J, 2009, CLIN EXP ALLERGY, V39, P89, DOI 10.1111/j.1365-2222.2008.03151.x; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yoshiga Y, 2008, INT J MOL MED, V22, P369, DOI 10.3892/ijmm_00000032; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	94	196	231	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1004	1011		10.1016/j.jaci.2009.04.003	http://dx.doi.org/10.1016/j.jaci.2009.04.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19410689				2022-12-18	WOS:000266309400004
J	Pulimood, TB; Corden, JM; Bryden, C; Sharpies, L; Nasser, SM				Pulimood, Thomas B.; Corden, Julie M.; Bryden, Clare; Sharpies, Linda; Nasser, Shuaib M.			Epidemic asthma and the role of the fungal mold Alternaria alternata	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; thunderstorm; fungal spores; fungal molds; altemafia alternata; broken alternaria; didymella; cladosporium; grass pollen; epidemic; seasonal asthma	THUNDERSTORM-ASSOCIATED ASTHMA; GRASS-POLLEN; SPORES; SENSITIZATION; AEROALLERGEN; ADMISSIONS; MORTALITY; HEALTH; RISK; AGE	Background: After July 29, 2002, an epidemic of asthma admissions was associated with a thunderstorm in the United Kingdom. Objective: We sought to study the cause of epidemics of asthma associated with thunderstorms. Methods: We performed a case-control study of 26 patients presenting to Cambridge University Hospital with asthma after the thunderstorm. Control subjects were 31 patients with summer seasonal asthma. Subjects underwent skin tests and specific IgE serology to inhaled aeroallergens. Meteorologic and aerobiologic data correlated with asthma admissions were analyzed. Results: Twenty-three of 26 cases had IgE sensitization to Alternaria species. Eleven of 31 control subjects gave a history of asthma exacerbation during thunderstorms. Ten of these 11 control subjects were sensitive to Alternaria species on skin testing, but Alternaria species sensitivity was only identified in 4 of the 20 remaining control subjects who did not report thunderstorm-related asthma symptoms. The odds ratio of having epidemic thunderstorm-related asthma if sensitive to Alternaria species was 9.31 (95% CI, 2.305-37.601; P =.0008) and 63.966 (95% CI, 3.577-1143.9; P <.0001) if sensitive to Alternaria species, Cladosporium species, or both. Poisson regression analysis showed that counts of broken Alternatia species and Didymella and Cladosporium species were significantly correlated with each other and with asthma admissions. The thunderstorm was associated with increased levels of Alternaria, Cladosporium, and Didymella species. Conclusions: Alternaria alternata sensitivity is a compelling predictor of epidemic asthma in patients with seasonal asthma and grass pollen allergy and is likely to be the important factor in thunderstorm-related asthma. Clinical implications: Alternaria species sensitization in asthmatic subjects with grass pollen sensitivity predicts susceptibility to thunderstorm-associated asthma.	Cambridge Univ Hosp, NHS Fdn Trust, Cambridge CB2 2QQ, England; Midlands Asthma & Allergy Res Assoc, Derby, England; Met Off, Exeter, Devon, England; Papworth NHS Fdn Trust, MRC Biostat Unit, Cambridge, England; Papworth NHS Fdn Trust, R&D Unit, Cambridge, England	Oxford University Hospitals NHS Foundation Trust; University of Cambridge; Met Office - UK; MRC Biostatistics Unit; Papworth Hospital; Papworth Hospital	Nasser, SM (corresponding author), Cambridge Univ Hosp, NHS Fdn Trust, Cambridge CB2 2QQ, England.	shuaib.nassei@addenbrookes.nhs.uk		Sharples, Linda/0000-0003-0894-966X	Medical Research Council [MC_U105232027] Funding Source: Medline; MRC [MC_U105232027] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alderman P M, 1986, Arch Emerg Med, V3, P260; Anderson W, 2001, QJM-MON J ASSOC PHYS, V94, P429, DOI 10.1093/qjmed/94.8.429; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; BROWN HM, 1978, CLIN ALLERGY, V8, P589, DOI 10.1111/j.1365-2222.1978.tb01513.x; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Cantani A, 2004, Eur Rev Med Pharmacol Sci, V8, P289; Celenza A, 1996, BMJ-BRIT MED J, V312, P604; Corden J.M., 2001, AEROBIOLOGIA, V17, P127, DOI [10.1023/A, DOI 10.1023/A:1010876917512, 10.1023/A:1010876917512]; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; Friesen T.L., 2001, AEROBIOLOGIA, V17, P293, DOI [10.1023/A:1013045517513, DOI 10.1023/A:1013045517513]; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; Harrison Brian, 2005, Prim Care Respir J, V14, P303, DOI 10.1016/j.pcrj.2005.08.004; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Hyde H. A., 1946, TRANS BRIT MYCOL SOC, V29, P78; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MACKAY TW, 1992, SCOT MED J, V37, P5, DOI 10.1177/003693309203700102; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Newson R, 2000, OCCUP ENVIRON MED, V57, P786, DOI 10.1136/oem.57.11.786; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PACKE GE, 1986, LANCET, V1, P850; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794, DOI 10.1111/j.1365-2222.1996.tb00610.x; Taylor PE, 2004, CURR ALLERGY ASTHM R, V4, P409, DOI 10.1007/s11882-004-0092-3; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411; 1995, AIRBROME POLLENS SPO	33	196	201	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					610	617		10.1016/j.jaci.2007.04.045	http://dx.doi.org/10.1016/j.jaci.2007.04.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17624415	Bronze			2022-12-18	WOS:000249505400020
J	Zuberbier, T; Orlow, SJ; Paller, AS; Taieb, A; Allen, R; Hernanz-Hermosa, JM; Ocampo-Candiani, J; Cox, M; Langeraar, J; Simon, JC				Zuberbier, Torsten; Orlow, Seth J.; Paller, Amy S.; Taieb, Alain; Allen, Roger; Hernanz-Hermosa, Jose M.; Ocampo-Candiani, Jorge; Cox, Margaret; Langeraar, Joanne; Simon, Jan C.			Patient perspectives on the management of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						flare; patient management; atopic dermatitis; atopic eczema; international study of life with atopic eczema	QUALITY-OF-LIFE; INTERNATIONAL DEVELOPMENT; INDEX; PREVALENCE; ECZEMA; ASTHMA; IMPACT	Background: Atopic dermatitis (AD) is increasingly common, with a point prevalence of more than 30% in some countries, and is characterized by visible skin lesions and intense itching. Objective: The International Study of Life with Atopic Eczema (ISOLATE) is the first large-scale study to assess the effect of AD on the lives of patients and society, how patients and caregivers manage the condition, and how well patients and caregivers currently believe that AD is controlled. Methods: Two thousand two patients (> 13 years) and caregivers of children (2-13 years) with moderate-to-severe - AD randomly selected from 8 countries underwent standardized telephone interviews using questions developed in collaboration with national eczema patient groups and physicians. Results: During each year, patients spend, on average, 1 of 3 days in flare. The majority of patients receive prescription topical corticosteroids to treat flares; however, 49% of respondents are concerned about using these agents. On average, patients and caregivers delay initiating treatment for 7 days after onset of a flare. Only 24% of patients and caregivers feel confident they can manage AD flares adequately. Seventy-five percent of caregivers and patients feel that being able to effectively control AD would be the single most important improvement to their or their child's quality of life. The avoidable secondary economic cost of AD is estimated at 462 billion per year across the European Union. Conclusion: ISOLATE highlights the need to improve patients' control of AD to reduce the significant effect this condition has on the patient and society. Clinical implications: ISOLATE shows that patients with AD are untreated for half the time they are in flare, and thus there is an urgent need for physicians to ensure that the patients are educated and confident in using medication as prescribed to gain disease control.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, D-10117 Berlin, Germany; NYU, Sch Med, New York, NY USA; Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; CHU Bordeaux, Bordeaux, France; Queens Med Ctr, Nottingham NG7 2UH, England; CHU Gen Univ Gregorio Maranon, Madrid, Spain; Univ Autonoma Nuevo Leon, Univ Hosp, Monterrey, Mexico; Natl Eczema Soc, London, England; Natl Eczema Assoc Sci & Educ, San Rafael, CA USA; Univ Klinikum Leipzig, Dept Dermatol Venerol & Allergol, Leipzig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; New York University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; CHU Bordeaux; University of Nottingham; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Leipzig University	Zuberbier, T (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	torsten.zuberbier@charite.de	TAIEB, ALAIN/AAB-1085-2021; Ocampo-Candiani, Jorge/B-6853-2015	Ocampo-Candiani, Jorge/0000-0002-0213-0031; Orlow, Seth/0000-0003-2548-7380; Paller, Amy/0000-0001-6187-6549				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; Ellis C, 2003, BRIT J DERMATOL, V148, P3, DOI 10.1046/j.1365-2133.148.s63.1.x; Ellison JA, 2000, PEDIATRICS, V105, P794, DOI 10.1542/peds.105.4.794; Finlay AY, 1998, SEMIN CUTAN MED SURG, V17, P291, DOI 10.1016/S1085-5629(98)80026-6; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Herd RM, 1996, BRIT J DERMATOL, V135, P18; Kiebert G, 2002, INT J DERMATOL, V41, P151, DOI 10.1046/j.1365-4362.2002.01436.x; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Lapidus C S, 2001, Med Health R I, V84, P294; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 1997, CLIN EXP IMMUNOL, V107, P25; McKenna S, 2005, QUAL LIFE RES, V14, P231, DOI 10.1007/s11136-004-4231-z; Paller AS, 2002, CLIN PEDIATR, V41, P323, DOI 10.1177/000992280204100505; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Reilly MC, 2003, J AM ACAD DERMATOL, V48, P128, DOI 10.1067/mjd.2003.128; RICE DP, 1967, AM J PUBLIC HEALTH N, V57, P424, DOI 10.2105/AJPH.57.3.424; Schiffner R, 2003, PHARMACOECONOMICS, V21, P159, DOI 10.2165/00019053-200321030-00002; Whalley D, 2004, BRIT J DERMATOL, V150, P274, DOI 10.1111/j.1365-2133.2004.05783.x; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	21	196	207	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					226	232		10.1016/j.jaci.2006.02.031	http://dx.doi.org/10.1016/j.jaci.2006.02.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815160				2022-12-18	WOS:000239184800028
J	Kull, I; Almqvist, C; Lilja, G; Pershagen, G; Wickman, M				Kull, I; Almqvist, C; Lilja, G; Pershagen, G; Wickman, M			Breast-feeding reduces the risk of asthma during the first 4 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; sensitization; breast-fieeding; children; primary prevention; prospective studies; BAMSE	ATOPIC DISEASE; FOLLOW-UP; CHILDREN; PREVALENCE; CHILDHOOD; ASSOCIATION; PROTECT; INFANTS; WHEEZE; HEALTH	Background: The evidence for a preventive effect of breast-feeding on asthma and other allergic diseases in childhood is inconclusive. Objective: The aim of this study was to investigate the effect of breast-feeding on asthma and sensitization to airborne allergens among children up to 4 years of age. Methods: A birth cohort of 4089 children was followed. Exposure data were collected at 2 months and 1 year of age. The total dose of breast milk was estimated by combining periods of exclusive and partial breast-feeding. Outcomes data were collected at 1, 2, and 4 years of age. The response rate at 4 years was 90%, and 73% participated in a clinical investigation, including blood sampling for analysis of specific IgE and lung function testing. Children with onset of wheeze during lactation (n = 217) were excluded in some of the analyses to avoid disease-related modification of exposure. Results: Exclusive breast-feeding for 4 months or more reduced the risk of asthma at the age of 4 years (odds ratio [OR], 0.72; 95% CI, 0.53-0.97), irrespective of sensitization to common airborne allergens (P = .72). Excluding children with wheeze during lactation tended to strengthen the risk estimate (OR, 0.64; 95% CI, 0.46-0.88). A duration of 3 months or more of partial breast-feeding seemed to offer additional protection; exclusive breast-feeding for 3 to 4 months combined with partial breast-feeding for 3 months or more resulted in an OR of 0.44 (95% CI, 0.21-0.87). The effects tended to be stronger in children without heredity for allergy (P interaction = .36). Conclusion: Breast-feeding reduces the risk of asthma during the first 4 years of life.	Stockholm Cty Council, Dept Environm & Occupat Hlth, S-10726 Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Women & Child Hlth, Stockholm, Sweden; Sachs Childrens Hosp, Inst Sodersjukhuset, Karolinska Inst, Stockholm, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Stockholm County Council; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Kull, I (corresponding author), Karolinska Hosp, Dept Environm & Occupat Hlth, SE-17176 Stockholm, Sweden.	inger.kull@smd.sll.se		Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771				Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; Bottcher MF, 2000, PEDIATR RES, V47, P157, DOI 10.1203/00006450-200001000-00026; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; Fidler N, 2000, EUR J NUTR, V39, P31, DOI 10.1007/s003940050073; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Hanson LA, 2003, ANN ALLERG ASTHMA IM, V90, P59, DOI 10.1016/S1081-1206(10)61662-6; Hoppu U, 2001, ALLERGY, V56, P23, DOI 10.1034/j.1398-9995.2001.00908.x; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Peat JK, 2003, PEDIATR PULM, V35, P331, DOI 10.1002/ppul.10276; Quanjer PH, 1997, EUR RESPIR J, V10, pS2; Rothman K., 1998, MODERN EPIDEMIOLOGY; Rust GS, 2001, J NATL MED ASSOC, V93, P139; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Siltanen M, 2003, ALLERGY, V58, P524, DOI 10.1034/j.1398-9995.2003.00150.x; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wijga A, 2003, PEDIAT ALLERG IMM-UK, V14, P156, DOI 10.1034/j.1399-3038.2003.00022.x; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wright AL, 2001, ADV EXP MED BIOL, V501, P249; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	31	196	201	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					755	760		10.1016/j.jaci.2004.07.036	http://dx.doi.org/10.1016/j.jaci.2004.07.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480312				2022-12-18	WOS:000224439100006
J	Jarvinen, KM; Beyer, K; Vila, L; Chatchatee, P; Busse, PJ; Sampson, HA				Jarvinen, KM; Beyer, K; Vila, L; Chatchatee, P; Busse, PJ; Sampson, HA			B-cell epitopes as a screening instrument for persistent cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; cow's milk proteins; cow's milk-specific IgE; B-cell epitope; oral tolerance; natural history; children; caseins; alpha-lactalbumin; beta-lactoglobulin	IGG-BINDING EPITOPES; NATURAL-HISTORY; CLINICAL COURSE; INFANTS; PROTEIN; IDENTIFICATION; CHILDREN; INTOLERANT; TOLERANCE; CASEIN	Background: Cow's milk is one of the most common causes of food allergy in the first years of life. We recently defined IgE-binding epitopes of all 6 major cow's milk proteins (alpha(s1)-,alpha(s2)-, beta-, and kappa-casein; alpha-lactalbumin; and beta-lactoglobulin) and had some evidence suggesting that IgE antibodies from patients with persistent cow's milk allergy (CMA) recognize different epitopes on cow's milk proteins than do those from patients who were likely to outgrow their allergy. Objective: In this study we sought to assess whether recognition of IgE antibodies of certain epitopes of cow's milk proteins would clearly separate the patients with life-long CMA from those who will become clinically tolerant to cow's milk. Methods: According to the known IgE-binding regions of cow's milk proteins, 25 decapeptides of alpha(s1)-casein, alpha(s2)-casein, kappa-casein, alpha-lactalbumin, and beta-lactoglobulin, comprising the core epitopes, were synthesized on a cellulose-derivatized membrane. Sera from 10 patients with persistent CMA and 10 patients who subsequently outgrew their milk allergy were used to investigate the differences in epitope recognition. Results: Five IgE-binding epitopes; (2 on alpha(s1)-casein, 1 on alpha(s2)-casein, and 2 on kappa-casein) were not recognized by any of the patients with transient CMA but showed binding by the majority of the patients with persistent allergy. The presence of IgE antibodies against at least 1 of 3 epitopes (amino acid [AA] 123132 on alpha(s1)-casein, AA 171-180 on alpha(s2)-casein, and AA 155-164 on K-casein) identified all patients with persistent CMA. Conclusions: The presence of IgE antibodies to distinct allergenic epitopes of cow's milk proteins can be used as a marker of persistent CMA. Prospective studies are needed to investigate the usefulness of these informative epitopes in predicting life-long CMA in young children.	CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.			vila, leticia/0000-0002-2815-4285				BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; BUSSE PJ, 2002, IN PRESS INT ARCH AL; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; HOST A, 1992, ALLERGY, V47, P218, DOI 10.1111/j.1398-9995.1992.tb00654.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; KUITUNEN M, 1994, ALLERGY, V49, P354, DOI 10.1111/j.1398-9995.1994.tb02281.x; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Little CH, 1998, CLIN IMMUNOL IMMUNOP, V89, P160, DOI 10.1006/clin.1998.4594; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SCHRANDER JJP, 1992, EUR J PEDIATR, V151, P783, DOI 10.1007/BF01959091; SEXTO LV, 2001, CLIN EXP ALLERGY, V31, P1599; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Wal JM, 1998, ALLERGY, V53, P1013, DOI 10.1111/j.1398-9995.1998.tb03811.x	21	196	211	3	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					293	297	UNSP 1/87/126080	10.1067/mai.2002.126080	http://dx.doi.org/10.1067/mai.2002.126080			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170271				2022-12-18	WOS:000177509800015
J	Saarinen, KM; Juntunen-Backman, K; Jarvenpaa, AL; Kuitunen, P; Lope, L; Renlund, M; Siivola, M; Savilahti, E				Saarinen, KM; Juntunen-Backman, K; Jarvenpaa, AL; Kuitunen, P; Lope, L; Renlund, M; Siivola, M; Savilahti, E			Supplementary feeding in maternity hospitals and the risk of cow's milk allergy: A prospective study of 6209 infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk; formula; breast milk; food allergy; infant; maternity hospital	MACROMOLECULAR ABSORPTION; IMMUNE-SYSTEM; FOOD ALLERGY; FOLLOW-UP; FORMULA; LACTATION; PROTEIN; PREVENTION; AVOIDANCE; EXPOSURE	Background: Early; feeding with cow's milk (CM) may increase the risk of cow's milk allergy (CMA). Objective: We sought to examine prospectively whether supplementary feeding of CM at the maternity hospital would increase the risk when compared with feeding with pasteurized human milk or hydrolyzed formula, Methods: We studied 6209 unselected healthy, full-term infants, of whom 5385 (87%) required supplementary milk while in the hospital. The infants were randomly assigned to receive CM formula (1789 infants), pasteurized human milk (1859 infants), or whey hydrolysate formula (1737 infants). The comparison group (824 infants) was composed of infants who were exclusively breast-fed. The infants were followed for 18 to 34 months for symptoms suggestive of CMA. The primary endpoint was a challenge-proven adverse reaction to CM after a successful CM elimination diet. Results: The cumulative incidence of CMA in the infants fed CM was 2.4% Compared with 1.7% in the pasteurized human milli group (odds ratio [OR], 0.70; 95% confidence interval [CI], 0.44-1.12) and 1.5% in the whey hydrolysate group (OR, 0.61; 95% CI, 0.38-1.00), In the comparison group, CMA developed in 2.1% of the infants. Among the infants who required supplementary feeding at hospital, both exposure to CM while in the hospital (OR, 1.54; 95% CI, 1.04-2.30; P = .03) and obvious parental atopy (OR, 2.32; 95% CI, 1.53-3.52; P < .001) increased the risk of CMA, zConclusions: Our data indicate that feeding of CM at maternity hospitals increases the risk of CMA when compared with feeding of other supplements, but exclusive breast-feeding does not eliminate the risk.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland; Helsinki City Matern Hosp, Helsinki, Finland; Jorvi Hosp, SF-02740 Espoo, Finland; Univ Helsinki, Cent Hosp, Dept Obstet, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Saarinen, KM (corresponding author), Univ Helsinki, Hosp Children & Adolescents, POB 280, FIN-00029 Helsinki, Finland.							[Anonymous], 1989, ALLERGY S10, V10, P1; ARVOLA T, 1993, J PEDIATR GASTR NUTR, V16, P294, DOI 10.1097/00005176-199304000-00013; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; de Jong MH, 1998, ARCH DIS CHILD, V79, P126, DOI 10.1136/adc.79.2.126; FEINSTEIN JM, 1986, PEDIATRICS, V78, P210; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Hanson L A, 1995, Pediatr Allergy Immunol, V6 Suppl 8, P7; Hanson LA, 1996, MONOGR ALLERGY, V32, P10; HANSON LA, 1985, PEDIATRICS, V75, P172; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; HERNELL O, 1994, J PEDIATR-US, V125, pS56, DOI 10.1016/S0022-3476(06)80737-7; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; JARRETT EEE, 1984, LANCET, V2, P797; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; JUVONEN P, 1991, ARCH DIS CHILD, V66, P300, DOI 10.1136/adc.66.3.300; KUITUNEN M, 1994, ALLERGY, V49, P354, DOI 10.1111/j.1398-9995.1994.tb02281.x; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; MAKINENKILJUNEN S, 1993, CLIN EXP ALLERGY, V23, P287, DOI 10.1111/j.1365-2222.1993.tb00324.x; SAVILAHTI E, 1991, ACTA PAEDIATR SCAND, V80, P1207, DOI 10.1111/j.1651-2227.1991.tb11810.x; Strachan D, 1996, TOXICOL LETT, V86, P199, DOI 10.1016/0378-4274(96)03691-0; UDALL JN, 1990, J PEDIATR-US, V117, pS33, DOI 10.1016/S0022-3476(05)81128-X; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; ZEIGER RS, 1990, ANN ALLERGY, V65, P430; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	27	196	203	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				457	461		10.1016/S0091-6749(99)70393-3	http://dx.doi.org/10.1016/S0091-6749(99)70393-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452771				2022-12-18	WOS:000082364800042
J	BERNHISELBROADBENT, J; DINTZIS, HM; DINTZIS, RZ; SAMPSON, HA				BERNHISELBROADBENT, J; DINTZIS, HM; DINTZIS, RZ; SAMPSON, HA			ALLERGENICITY AND ANTIGENICITY OF CHICKEN EGG OVOMUCOID (GAL-D-III) COMPARED WITH OVALBUMIN (GAL-D-I) IN CHILDREN WITH EGG ALLERGY AND IN MICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EGG ALLERGY; FOOD HYPERSENSITIVITY OVOMUCOID; OVALBUMIN; DOUBLE-BLIND PLACEBO-CONTROLLED FOOD CHALLENGES; ELISA	COMMON FOOD PROTEINS; AMINO-ACID-SEQUENCE; HENS EGG; ATOPIC-DERMATITIS; CLINICAL SYMPTOMS; IGE RESPONSES; DOUBLE-BLIND; WHITE; HYPERSENSITIVITY; ANTIBODIES	When attempting to generate mouse monoclonal antibodies to hen's egg ovalbumin, injection of commercially purified ovalbumin resulted in monoclonal antibodies, which when assayed against commercially purified ovalbumin (Gal d I) or ovomucoid (Gal d III), apppeared to be specific to both. With the use of high-performance liquid chromatography (HPLC)-repurified ovalbumin and ovomucoid in assay procedures, monoclonal antibodies generated by commercially purified ovalbumin were found to be specific for ovomucoid only. To clarify, this phenomenon, mice were serially injected with commercially purified ovalbumin or HPLC-repurified ovalbumin. It was found that most of the antibody response to commercially purified ovalbumin was directed against the minor (<1%) ovomucoid contaminant and that HPLC-repurified ovalbumin failed to produce antibodies to ovomucoid. Commercially purified ovomucoid resulted in only minimal amounts of antibodies to ovalbumin. Thus when commercially purified ovalbumin is used both for immunization and immunoassay most of the antibodies produced are actually against the small amount of ovomucoid contaminant, and nor ovalbumin. To determine whether ovomucoid is the major antigenic and allergenic egg white protein in human beings, one group of 18 children with egg allergy were skin prick tested with half-log dilutions of egg white extract and diethylaminoethyl cellulose (DEAE)-repurified ovomucoid, ovalbumin, and lysozyme. Ovomucoid mean wheal diameters were significantly greater than wheal diameters in response to ovalbumin, lysozyme, and egg white extract at the three most concentrated of five dilutions tested: 0.01, 0.03, and 0.1 mg/ml (p < 0.01). Serum ovomucoid-specific IgE and IgG antibody concentrations to DEAE-repurified ovomucoid were significantly greater than that to DEAE-repurified ovalbumin (p < 0.05). In a second study 10 patients with egg allergy and persistent egg hypersensitivity were compared with 11 patients with egg allergy in whom clinical tolerance to egg developed IgE antibodies to repurified ovomucoid were significantly greater in patients with persistent egg hypersensitivity compared with patients in whom clinical tolerance developed at the time of both initial and follow-up food challenges. In contrast, there were no significant differences in IgE antibody concentrations to repurified ovalbumin in either group at any time. These results suggest chat ovomucoid is the immunodominant protein fraction in egg white and chat the use of commercially purified ovalbumin has led to an overestimation of the dominance of ovalbumin as a major egg allergen and antigen in human beings.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV ALLERGY & IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16754] Funding Source: Medline; NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANET J, 1985, INT ARCH ALLER A IMM, V77, P364, DOI 10.1159/000233846; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BLEUMINK E, 1971, INT ARCH ALLER A IMM, V40, P72, DOI 10.1159/000230396; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BRUCE MG, 1986, IMMUNOLOGY, V57, P627; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; DEUTSCH HF, 1956, ARCH BIOCHEM BIOPHYS, V64, P19, DOI 10.1016/0003-9861(56)90237-5; DINTZIS HM, 1992, P NATL ACAD SCI USA, V89, P1113, DOI 10.1073/pnas.89.3.1113; ELSAYED S, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P287; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GREENE G, 1990, J IMMUNOL METHODS, V129, P187, DOI 10.1016/0022-1759(90)90438-2; HAMILTON RG, 1990, ANN BIOL CLIN-PARIS, V48, P473; HAMILTON RG, 1991, ANN BIOL CLIN-PARIS, V49, P242; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOLEN E, 1990, INT ARCH ALLER A IMM, V91, P136, DOI 10.1159/000235104; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; KATO I, 1987, BIOCHEMISTRY-US, V26, P193, DOI 10.1021/bi00375a027; KEMENY DM, 1991, J ALLERGY CLIN IMMUN, V87, P920, DOI 10.1016/0091-6749(91)90413-I; LANGELAND T, 1983, ALLERGY, V38, P131, DOI 10.1111/j.1398-9995.1983.tb01597.x; LANGELAND T, 1983, ALLERGY, V38, P493, DOI 10.1111/j.1398-9995.1983.tb02358.x; LANGELAND T, 1982, ALLERGY, V37, P323, DOI 10.1111/j.1398-9995.1982.tb01918.x; LI-CHAN E, 1989, Critical Reviews in Poultry Biology, V2, P21; MATSUDA T, 1983, J BIOCHEM-TOKYO, V94, P43, DOI 10.1093/oxfordjournals.jbchem.a134352; MILLER H, 1950, J ALLERGY, V21, P522, DOI 10.1016/0021-8707(50)90103-1; MILLER HT, 1977, IMMUNOLOGICAL ASPECT, P152; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; OVARY Z, 1986, HDB EXPT IMMUNOLOGY, V1; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SCEARCE RM, 1983, METHOD ENZYMOL, V103, P459; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3	38	196	206	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1047	1059		10.1016/S0091-6749(94)70054-0	http://dx.doi.org/10.1016/S0091-6749(94)70054-0			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006309				2022-12-18	WOS:A1994NT17200014
J	Bateman, ED; Reddel, HK; Eriksson, G; Peterson, S; Ostlund, O; Sears, MR; Jenkins, C; Humbert, M; Buhl, R; Harrison, TW; Quirce, S; O'Byrne, PM				Bateman, Eric D.; Reddel, Helen K.; Eriksson, Goran; Peterson, Stefan; Ostlund, Ollie; Sears, Malcolm R.; Jenkins, Christine; Humbert, Marc; Buhl, Roland; Harrison, Tim W.; Quirce, Santiago; O'Byrne, Paul M.			Overall asthma control: The relationship between current control and future risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; ACQ; exacerbations; GINA	HEALTH-CARE UTILIZATION; RANDOMIZED CONTROLLED TRIAL; CONTROL QUESTIONNAIRE; ADULT ASTHMATICS; RELIEVER THERAPY; EXACERBATIONS; MAINTENANCE; BUDESONIDE/FORMOTEROL; BUDESONIDE; ASSOCIATION	Background: Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective: This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler*) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods: The percentage of patients with Global Initiative for Asthma defined controlled asthma over time was assessed for budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies; higher dose inhaled corticosteroid (ICS), same dose ICS/long-acting beta(2)-agonist (LABA), and higher dose ICS/LABA plus short-acting beta(2)-agonist. The relationship between baseline ACQ-5 and exacerbations was investigated. A Markov analysis examined the transitional probability of change in control status throughout the studies. Results: The percentage of patients achieving asthma control increased with time, irrespective of treatment; the percentage Controlled/Partly Controlled at study end was at least similar to budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies: higher dose ICS (56% vs 45%), same dose ICS/LABA (56% vs 53%), and higher dose ICS/LABA (54% vs 54%). Baseline ACQ-5 score correlated positively with exacerbation rates. A Controlled or Partly Controlled week predicted at least Partly Controlled asthma the following week (>= 80% probability). The better the control, the lower the risk of an Uncontrolled week. The probability of an exacerbation was related to current state and was lower with budesonide/formoterol maintenance and reliever therapy. Conclusions: Current control predicts future risk of instability and exacerbations. Budesonide/formoterol maintenance and reliever therapy reduces exacerbations versus comparators and achieves at least similar control. (J Allergy Clin Immunol 2010;125:600-8.)	[Bateman, Eric D.] Univ Cape Town, Dept Med, Div Pulmonol, ZA-7700 Cape Town, South Africa; [Reddel, Helen K.; Jenkins, Christine] Woolcock Inst Med Res, Clin Management Grp, Sydney, NSW, Australia; [Eriksson, Goran; Peterson, Stefan; Ostlund, Ollie] AstraZeneca Res & Dev, Lund, Sweden; [Eriksson, Goran] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden; [Sears, Malcolm R.] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8S 4L8, Canada; [O'Byrne, Paul M.] McMaster Univ, Fac Hlth Sci, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada; [Humbert, Marc] Univ Paris 11, Hop Antoine Beclere, APHP, Serv Pneumol & Reanimat Resp, Clamart, France; [Buhl, Roland] Mainz Univ Hosp, Dept Pulm, Mainz, Germany; [Harrison, Tim W.] Univ Nottingham, Resp Biomed Res Unit, Nottingham NG7 2RD, England; [Quirce, Santiago] Hosp La Paz Comunidad Autonoma Madrid, Dept Allergy, Madrid, Spain	University of Cape Town; University of Sydney; Woolcock Institute of Medical Research; AstraZeneca; Lund University; Skane University Hospital; McMaster University; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Universite Paris Saclay; University Hospital Mainz; University of Nottingham	Bateman, ED (corresponding author), Univ Cape Town, Dept Med, Div Pulmonol, George St, ZA-7700 Cape Town, South Africa.	Eric.Bateman@uct.ac.za	Humbert, Marc/AAC-8459-2019; s, q/AAD-7171-2020; Reddel, Helen/ABD-6338-2021; Reddel, Helen/AAC-3394-2020; Humbert, Marc/ABD-5112-2021	Humbert, Marc/0000-0003-0703-2892; Reddel, Helen/0000-0002-6695-6350; O'Byrne, Paul/0000-0003-0979-281X; Ostlund, Ollie/0000-0001-8028-2308	AstraZeneca AB, Lund, Sweden; GlaxoSmithKline; Merck; Morris Pharmaceuticals; Pfizer; Replidyne Inc; Almirall; Aeras; Eumedic Inc; Wyeth; Boehringer Ingelheim; Deutsche Forschungsgemeinschaft; Chiesi; Novartis; Ciber de Enfermedades Respiratorias (CIBERES)	AstraZeneca AB, Lund, Sweden(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Morris Pharmaceuticals; Pfizer(Pfizer); Replidyne Inc; Almirall(Almirall); Aeras; Eumedic Inc; Wyeth(Wyeth); Boehringer Ingelheim(Boehringer Ingelheim); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Chiesi(Chiesi Pharmaceuticals Inc); Novartis(Novartis); Ciber de Enfermedades Respiratorias (CIBERES)	Supported by AstraZeneca AB, Lund, Sweden.; Disclosure of potential conflict of interest: E. D. Bateman is on advisory boards for and has received speakers' honoraria from AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim; is on advisory boards for Nycomed, Merck, ALK-Abello, Hoffmann la Roche (Data Safety Board), and Almirall/Forest Pharmaceuticals; and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Morris Pharmaceuticals, Pfizer, Replidyne Inc. Almirall, Aeras, and Eumedic Inc. P. M. O'Byrne is on advisory boards for and has received speakers' honoraria from AstraZeneca and GlaxoSmithKline; is on advisory boards for Topigen. Wyeth, and Schering; and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth. Schering, and Alexion. M. R. Sears holds a chair endowed by AstraZeneca; has received consultation fees from AstraZeneca, Merck Frosst, and Schering-Plough; and has received research support from GlaxoSmithKline. T. W. Harrison has received honoraria from AstraZeneca and has received research support from GlaxoSmithKline and Boehringer Ingelheim. R. Buhl has received speakers' fees and consultants' fees, as well as reimbursement for attending scientific conferences from AstraZeneca, and his department has received research support from the Deutsche Forschungsgemeinschaft, Almirall, AstraZeneca, Boehringer Ingelheim. Chiesi, GlaxoSmithKline, and Novartis. S. Quirce is on advisory boards for and has received speakers' honoraria from AstraZeneca and has received research support from Ciber de Enfermedades Respiratorias (CIBERES), Madrid. G. Eriksson, S. Peterson, and O. Ostlund are employed by AstraZeneca. M. Humbert has consulted for Actelion, AstraZeneca, Amgen, Chiesi, GlaxoSmithKline, MSD, Novartis, and Pfizer. C. Jenkins has received speakers' honoraria from GlaxoSmithKline. Novartis, and AstraZeneca and has received research support from GlaxoSmithKline and AstraZeneca. H. K. Reddel is on advisory boards for and has received research support front AstraZeneca and GlaxoSmithKline and has received speakers' honoraria from AstraZeneca, Getz Pharma, and MerckSharp & Dohme.	[Anonymous], 2007, 3 NAEPP; Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2007, J ASTHMA, V44, P667, DOI 10.1080/02770900701554821; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Combescure C, 2003, EUR RESPIR J, V22, P298, DOI 10.1183/09031936.03.00081102; Dorinsky PM, 2001, CLIN THER, V23, P701, DOI 10.1016/S0149-2918(01)80020-5; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jenkins CR, 2005, EUR RESPIR J, V26, P36, DOI 10.1183/09031936.05.00144704; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; LI D, 1995, AM J RESP CRIT CARE, V151, P647; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084; Peters D, 2006, CHEST, V129, P918, DOI 10.1378/chest.129.4.918; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; SVENSSON K, 2003, QUAL LIFE RES, V12, P771; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wakefield M, 1997, CHEST, V112, P1527, DOI 10.1378/chest.112.6.1527	34	195	208	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					600	608		10.1016/j.jaci.2009.11.033	http://dx.doi.org/10.1016/j.jaci.2009.11.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153029				2022-12-18	WOS:000275883200014
J	Chatila, TA				Chatila, TA			Role of regulatory T cells in human diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						regulatory T cells; Foxp3; dysregulation polyendocrinopathy enteropathy-X linked; X-linked autoimmunity-allergic dysregulation; allergy; autoimmunity; lymphoproliferation; immunotherapy; IgE	IMMUNOLOGICAL SELF-TOLERANCE; KILLED MYCOBACTERIUM-VACCAE; TOLL-LIKE RECEPTORS; LINKED SYNDROME IPEX; TGF-BETA; IMMUNE DYSREGULATION; AUTOIMMUNE-DISEASE; ALPHA-CHAIN; SUPPRESSOR FUNCTION; ATOPIC-DERMATITIS	The discovery of regulatory T lymphocytes (Treg) that are actively involved in maintaining immune tolerance has led to new insights into mechanisms of tolerance breakdown in human diseases, including those resulting from allergic, autoimmune, or infectious causes. Congenital deficiency of CD4(+)CD25(+) Treg cells caused by loss-of-function mutations in the gene encoding Foxp3 triggers a syndrome of lymphoproliferation and myeloproliferation, autoimmunity, and allergic dysregulation, whereas deficient allergen-specific Treg cell responses have been associated with a number of allergic and autoimmune disorders. Tolerization to allergens and autoantigens is associated with augmentation of Treg cell numbers and suppressive function, suggesting the manipulation of Treg cell activity as a potential strategy for future therapeutic interventions in allergic and autoimmune diseases.	Univ Calif Los Angeles, Div Rheumatol Allergy & Immunol, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chatila, TA (corresponding author), Univ Calif Los Angeles, Div Rheumatol Allergy & Immunol, Dept Pediat, David Geffen Sch Med, MDCC 12-430,10833 Conte Ave, Los Angeles, CA 90095 USA.	tchatila@mednet.ucla.edu		Chatila, Talal/0000-0001-7439-2762	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060235] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21DK060235] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Baecher-Allan C, 2004, J EXP MED, V200, P273, DOI 10.1084/jem.20040812; Balandina A, 2005, BLOOD, V105, P735, DOI 10.1182/blood-2003-11-3900; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; BLAIR PJ, 1994, J IMMUNOL, V153, P3764; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024; Cao DJ, 2004, ARTHRITIS RES THER, V6, pR335, DOI 10.1186/ar1192; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Clark LB, 1999, J IMMUNOL, V162, P2546; Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x; Cosmi L, 2003, BLOOD, V102, P4107, DOI 10.1182/blood-2003-04-1320; Cottrez F, 2004, TRANSPLANTATION, V77, pS12, DOI 10.1097/01.TP.0000106471.23410.32; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Foussat A, 2003, J IMMUNOL, V171, P5018, DOI 10.4049/jimmunol.171.10.5018; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Gorham JD, 2001, J IMMUNOL, V166, P6413, DOI 10.4049/jimmunol.166.10.6413; Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jordan MS, 2000, EUR J IMMUNOL, V30, P136, DOI 10.1002/1521-4141(200001)30:1<136::AID-IMMU136>3.3.CO;2-S; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kawahata K, 2002, J IMMUNOL, V168, P4399, DOI 10.4049/jimmunol.168.9.4399; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530; Li SR, 2004, MOL CELL BIOL, V24, P809, DOI 10.1128/MCB.24.2.809-822.2004; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Liu JW, 2004, TRANSPL IMMUNOL, V13, P239, DOI 10.1016/j.trim.2004.10.006; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Manavalan JS, 2004, INT IMMUNOL, V16, P1055, DOI 10.1093/intimm/dxh107; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Menasche G, 2005, IMMUNOL REV, V203, P165, DOI 10.1111/j.0105-2896.2005.00224.x; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nguyen XD, 2004, J ALLERGY CLIN IMMUN, V114, P296, DOI 10.1016/j.jaci.2004.04.048; Nieves DS, 2004, ARCH DERMATOL, V140, P466, DOI 10.1001/archderm.140.4.466; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Owen CJ, 2003, J CLIN ENDOCR METAB, V88, P6034, DOI 10.1210/jc.2003-031080; Ozdemir C, 2003, CLIN EXP ALLERGY, V33, P266, DOI 10.1046/j.1365-2222.2003.01595.x; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Roifman CM, 2000, PEDIATR RES, V48, P6, DOI 10.1203/00006450-200007000-00004; Rouse BT, 2004, J IMMUNOL, V173, P2211, DOI 10.4049/jimmunol.173.4.2211; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shenoy S, 2005, BONE MARROW TRANSPL, V35, P345, DOI 10.1038/sj.bmt.1704795; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shirtcliffe PM, 2003, RESPIROLOGY, V8, P497, DOI 10.1046/j.1440-1843.2003.00510.x; Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x; Snow JW, 2003, J IMMUNOL, V171, P5042, DOI 10.4049/jimmunol.171.10.5042; Stassen M, 2004, J IMMUNOL, V173, P267, DOI 10.4049/jimmunol.173.1.267; Suvas S, 2003, J EXP MED, V198, P889, DOI 10.1084/jem.20030171; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Vaidya B, 2004, EUR J ENDOCRINOL, V150, P619, DOI 10.1530/eje.0.1500619; van Santen HM, 2004, J EXP MED, V200, P1221, DOI 10.1084/jem.20041022; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wang B, 2003, J BIOL CHEM, V278, P24259, DOI 10.1074/jbc.M207174200; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wolf M, 2001, EUR J IMMUNOL, V31, P1637, DOI 10.1002/1521-4141(200106)31:6<1637::AID-IMMU1637>3.0.CO;2-T; Xu DM, 2003, J IMMUNOL, V170, P394, DOI 10.4049/jimmunol.170.1.394; Xystrakis E, 2004, BLOOD, V104, P3294, DOI 10.1182/blood-2004-03-1214; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yamano Y, 2005, J CLIN INVEST, V115, P1361, DOI [10.1172/JCI200523913, 10.1172/JCI23913]; Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	121	195	231	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					949	959		10.1016/j.jaci.2005.08.047	http://dx.doi.org/10.1016/j.jaci.2005.08.047			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275360				2022-12-18	WOS:000235686700001
J	Kanda, N; Tamaki, K				Kanda, N; Tamaki, K			Estrogen enhances immunoglobulin production by human PBMCs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						estrogen; immunoglobulin; IL-10; B cell; monocyte	SYSTEMIC LUPUS-ERYTHEMATOSUS; HUMAN PERIPHERAL-BLOOD; IMMUNE-RESPONSE; LYMPHOCYTES-B; STROMAL CELLS; AUTO-IMMUNITY; LPR/LPR MICE; SEX-HORMONES; ANTIBODIES; INVITRO	Background: It has been suggested that estrogen may enhance humoral immune responses and may be involved in the pathogenesis of autoimmune diseases, Objective: We studied the in vitro effects of 17 beta-estradiol (E-2) on spontaneous immunoglobulin production by human PBMCs. Methods: PBMCs from healthy human volunteers were cultured with E-2. Levels of IgG and IgM and cytokine activity were measured by ELISA, proliferation was determined by [H-3]-thymidine uptake. The cell viability was assessed by a trypan blue exclusion test. Results: E-2 enhanced IgG and IgM production of PBMCs both from men and women without altering cell viability and proliferation, The stimulatory effect of E-2 was revealed at 10(-10) mol/L, increased in a dose-dependent fashion, and was maximized at 10(-8) mol/L, IgG production of PBMCs in the presence of E-2 (10(-8) mol/L) was 220% of control cells, and that of IgM was 211%. Immunoglobutin production of E-2-treated B cells was slightly higher than that of control cells; IgG production was 161% of control cells, and that of IgM was 157%. Anti-IL-10 antibody partially blocked the E-2 effect on immunoglobulin production of PBMCs; anti-IL-10 reduced IgG production in the presence of E-2 from 206% to 151% of control cells, and that of IgM from 206% to 152%. E-2 increased IL-10 production of monocytes up to 250% of control level, but it did not affect that of T cells or B cells. Exogenous IL-10 (1 U/mL) further enhanced E-2-induced increase of immunoglobulin production by B cells, although this level of IL-10 alone was ineffective for B cells. Conclusion: These results suggest that E2 may increase immunoglobulin production of human PBMCs mainly by increasing IL-10 production of monocytes, The results also support that E-2 may act as an important stimulator for human humoral immunity.	Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kanda, N (corresponding author), Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Kanda, Naoko/AAD-1808-2020					ABRAHAM GE, 1969, J CLIN ENDOCR METAB, V29, P866, DOI 10.1210/jcem-29-6-866; Ahmed S. Ansar, 1993, P148; AHMED SA, 1989, J IMMUNOL, V142, P2647; AHMED SA, 1988, FASEB J, V2, pA894; ARIGA H, 1989, CLIN IMMUNOL IMMUNOP, V53, P499, DOI 10.1016/0090-1229(89)90011-1; BATRA S, 1978, J CLIN ENDOCR METAB, V46, P622, DOI 10.1210/jcem-46-4-622; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLANK M, 1990, J RHEUMATOL, V17, P311; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; BURDIN N, 1993, J EXP MED, V177, P295, DOI 10.1084/jem.177.2.295; CARLSTEN H, 1990, CLIN EXP IMMUNOL, V80, P467; DE M, 1992, DEV BIOL, V151, P297, DOI 10.1016/0012-1606(92)90234-8; FARRANT J, 1985, CLIN EXP IMMUNOL, V61, P189; FERRE F, 1980, AM J OBSTET GYNECOL, V138, P500, DOI 10.1016/0002-9378(80)90276-8; FORMBY B, 1995, ENDOCRIN METAB CLIN, V24, P187, DOI 10.1016/S0889-8529(18)30059-8; FOX HS, 1991, J IMMUNOL, V146, P4362; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GEE AP, 1987, BONE MARROW TRANSPL, V2, P155; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; Kanda N, 1996, CLIN EXP IMMUNOL, V106, P410, DOI 10.1046/j.1365-2249.1996.d01-842.x; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; LIN H, 1993, J IMMUNOL, V151, P4562; LINKERISRAELI M, 1990, ARTHRITIS RHEUM, V33, P1216; MILLER MH, 1983, MEDICINE, V62, P327, DOI 10.1097/00005792-198309000-00005; MISHELL DR, 1971, AM J OBSTET GYNECOL, V111, P60, DOI 10.1016/0002-9378(71)90927-6; MORI H, 1991, J IN VITRO FERTIL EM, V8, P329, DOI 10.1007/BF01133023; PAAVONEN T, 1981, J EXP MED, V154, P1935, DOI 10.1084/jem.154.6.1935; POLAN ML, 1988, FERTIL STERIL, V49, P964; RAVECHE ES, 1976, NATURE, V263, P415, DOI 10.1038/263415a0; ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; STEINBERG AD, 1980, CLIN IMMUNOL IMMUNOP, V17, P562, DOI 10.1016/0090-1229(80)90152-X; STEINBERG AD, 1979, ARTHRITIS RHEUM, V22, P1170, DOI 10.1002/art.1780221103; STHOEGER ZM, 1988, J IMMUNOL, V141, P91; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611	37	195	203	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				282	288		10.1016/S0091-6749(99)70503-8	http://dx.doi.org/10.1016/S0091-6749(99)70503-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949320				2022-12-18	WOS:000078630100016
J	Torgerson, TR; Ochs, HD				Torgerson, Troy R.; Ochs, Hans D.			Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Forkhead box protein 3 mutations and lack of regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immune dysregulation; polyendocrinopathy; enteropathy; X-linked (IPEX); IPEX-like; autoimmunity; FOXP3; transcription factor; regulatory T cells; scurfy mice; immunosuppressive therapy; stem cell transplantation	NEONATAL DIABETES-MELLITUS; ALPHA-CHAIN; TRANSCRIPTION FACTORS; FOXP3 EXPRESSION; SYNDROME IPEX; TARGET GENES; ACTIVATION; SCURFIN; TRANSPLANTATION; AUTOIMMUNITY	The rare X-linked disorder immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and its murine counterpart scurfy have provided important new insights into the essential role of regulatory T cells (Treg) in maintaining tolerance to self-antigens. Mutations of the FOXP3 gene, identified in patients with IPEX, have helped pinpoint key structural domains of the protein that are essential for its function as a transcriptional regulator. Ongoing work using these and associated models has begun to elucidate factors important for the development, function, and competitive fitness of Treg. This improved understanding is beginning to lead to the identification of other defects that may be present in patients who have the clinical phenotype of IPEX but only wildtype FOXP3. It has also led to improved treatment options for IPEX including immunosuppressive drugs and bone marrow transplantation. We are hopeful that the knowledge gained about mechanisms that regulate FOXP3 expression and Treg function will have a major effect on how other autoimmune and allergic disorders are approached.	Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Torgerson, TR (corresponding author), 307 Westlake Ave N,Suite 300, Seattle, WA 98109 USA.	Troy.Torgerson@seattlechildrens.org						Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bennett CL, 2001, CURR OPIN PEDIATR, V13, P533, DOI 10.1097/00008480-200112000-00007; Bennett CL, 2001, IMMUNOGENETICS, V53, P435, DOI 10.1007/s002510100358; Berger CL, 2005, BLOOD, V105, P1640, DOI 10.1182/blood-2004-06-2181; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Beyer M, 2005, BLOOD, V106, P2018, DOI 10.1182/blood-2005-02-0642; Bindl L, 2005, J PEDIATR-US, V147, P256, DOI 10.1016/j.jpeds.2005.04.017; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Coenen JJA, 2007, BONE MARROW TRANSPL, V39, P537, DOI 10.1038/sj.bmt.1705628; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Ferguson PJ, 2000, AM J MED GENET, V90, P390, DOI 10.1002/(SICI)1096-8628(20000228)90:5<390::AID-AJMG9>3.0.CO;2-M; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Halonen M, 2002, J CLIN ENDOCR METAB, V87, P2568, DOI 10.1210/jc.87.6.2568; Hauet-Broere F, 2003, EUR J IMMUNOL, V33, P2801, DOI 10.1002/eji.200324115; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Jonsson H, 2005, CELL MOL LIFE SCI, V62, P397, DOI 10.1007/s00018-004-4365-8; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kobayashi I, 2001, J MED GENET, V38, P874, DOI 10.1136/jmg.38.12.874; Kobayashi I, 1998, CLIN EXP IMMUNOL, V111, P527; Levy-Labad E, 2001, J PEDIATR-US, V138, P577, DOI 10.1067/mpd.2001.111502; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133; Loser K, 2005, GENE THER, V12, P1294, DOI 10.1038/sj.gt.3302567; Lucas KG, 2007, BONE MARROW TRANSPL, V39, P55, DOI 10.1038/sj.bmt.1705542; Marinaki S, 2005, CLIN EXP IMMUNOL, V140, P181, DOI 10.1111/j.1365-2249.2005.02731.x; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mazzolari E, 2005, BONE MARROW TRANSPL, V35, P1033, DOI 10.1038/sj.bmt.1704954; McGinness JL, 2006, J AM ACAD DERMATOL, V55, P143, DOI 10.1016/j.jaad.2005.08.047; Myers AK, 2006, ARCH DIS CHILD, V91, P63, DOI 10.1136/adc.2005.078287; Nieves DS, 2004, ARCH DERMATOL, V140, P466, DOI 10.1001/archderm.140.4.466; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Ormandy LA, 2005, CANCER RES, V65, P2457, DOI 10.1158/0008-5472.CAN-04-3232; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; Randolph DA, 2006, ANNU REV MED, V57, P381, DOI 10.1146/annurev.med.57.121304.131337; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Roifman CM, 2000, PEDIATR RES, V48, P6, DOI 10.1203/00006450-200007000-00004; Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Sneller MC, 2003, CURR OPIN RHEUMATOL, V15, P417, DOI 10.1097/00002281-200307000-00008; So T, 2007, J IMMUNOL, V179, P1427, DOI 10.4049/jimmunol.179.3.1427; Stock P, 2006, CURR OPIN ALLERGY CL, V6, P12, DOI 10.1097/01.all.0000200502.69672.44; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Unitt E, 2005, HEPATOLOGY, V41, P722, DOI 10.1002/hep.20644; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444; VU MD, 2007, BLOOD; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wei WZ, 2004, CANCER IMMUNOL IMMUN, V53, P73, DOI 10.1007/s00262-003-0444-1; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Yu P, 2005, J IMMUNOL, V174, P6772, DOI 10.4049/jimmunol.174.11.6772; Zhang LJ, 2006, AUTOIMMUNITY, V39, P269, DOI 10.1080/08916930600753903; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zorn E, 2005, BLOOD, V106, P2903, DOI 10.1182/blood-2005-03-1257; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	81	194	204	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					744	750		10.1016/j.jaci.2007.08.044	http://dx.doi.org/10.1016/j.jaci.2007.08.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931557				2022-12-18	WOS:000250157700004
J	Allam, JP; Novak, N; Fuchs, C; Asen, S; Berge, S; Appel, T; Geiger, E; Kochan, JP; Bieber, T				Allam, JP; Novak, N; Fuchs, C; Asen, S; Berge, S; Appel, T; Geiger, E; Kochan, JP; Bieber, T			Characterization of dendritic cells from human oral mucosa: A new Langerhans' cell type with high constitutive Fc epsilon_RI expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans' cells; mucosa; high affinity receptor for IgE; Fc receptors; human	RECEPTOR; IGE; SUBUNIT; DIFFERENTIATION; TOLERANCE; RESPONSES; IMMUNITY; ANTIBODY; IL-10	Background: The oral mucosa represents a unique immunologic unit with a high frequency of native allergen contact within the gastrointestinal tract in which immune tolerance is the natural outcome of allergen contact. Although Langerhans' cells (LC), known to play a crucial role in initiating allergen-dependent immune responses in the skin, have also been detected in the oral mucosa, little is known about their phenotype and exact physiologic role. Objective: To elucidate whether LC from oral mucosa (oLC) differ from skin LC (sLC), these cells were subjected to detailed comparative analysis. Methods: Crude epidermal and oral mucosa cell suspensions were prepared by trypsinization. oLC and sLC were compared phenotypically by flow cytometry techniques and functionally in T-cell proliferation assays. Results: In contrast to sLC, freshly isolated oLC expressed significantly higher amounts of MHC class I and II, as well as costimulatory molecules CD40, CD80/B7.1, and CD86/B7.2. oLC displayed FcgammaRIII/CD16 and FcgammaRI/CD64. Most surprisingly, oLC constitutively expressed the high affinity receptor for IgE (FcepsilonRI) even in nonatopic donors. FcepsilonRI expression on oLC was further increased and correlated with the serum IgE levels in atopic individuals. oLC showed a higher allogeneic stimulatory activity than sLC, whereas the activation of autologous T cells correlated to the FcepsilonRI expression. Conclusion: Taken together, our results strongly indicate that oLC profoundly differ from their skin counterparts. The constitutive high expression of FcepsilonRI on oLC could point to particular skills of these cells within the regional immune system of the oral mucosa.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Munich, Dept Dermatol, D-8000 Munich, Germany; Univ Bonn, Dept Oral & Maxillofacial Surg, D-5300 Bonn, Germany; Hoffman LaRoche Inc, Dept Metab Dis, Nutley, NJ USA	University of Bonn; University of Munich; University of Bonn	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		Berge, Stefaan/AAP-3708-2020					Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; DELASALLE C, 1992, J INVEST DERMATOL, V99, pS15, DOI 10.1111/1523-1747.ep12668250; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Hasseus B, 1999, J DENT RES, V78, P751, DOI 10.1177/00220345990780030701; KASHIHARA M, 1986, J INVEST DERMATOL, V87, P602, DOI 10.1111/1523-1747.ep12455849; Kraft S, 1998, J IMMUNOL, V161, P1000; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Novak N, 2002, J INVEST DERMATOL, V119, P842, DOI 10.1046/j.1523-1747.2002.00102.x; Novak N, 2001, J ALLERGY CLIN IMMUN, V108, P588, DOI 10.1067/mai.2001.118597; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RISKE F, 1991, J BIOL CHEM, V266, P11245; Salgado CG, 1999, J INVEST DERMATOL, V113, P1021, DOI 10.1046/j.1523-1747.1999.00785.x; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9	25	194	206	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					141	148		10.1067/mai.2003.1607	http://dx.doi.org/10.1067/mai.2003.1607			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847491	Bronze			2022-12-18	WOS:000184010600022
J	Taylor, PE; Flagan, RC; Valenta, R; Glovsky, MM				Taylor, PE; Flagan, RC; Valenta, R; Glovsky, MM			Release of allergens as respirable aerosols: A link between grass pollen and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass; pollen; allergen; aerosol; asthma; air pollution	RYE-GRASS; ENVIRONMENTAL-FACTORS; DIESEL EXHAUST; AIR-POLLUTION; CITY; PARTICLES; MELBOURNE; WEATHER; RISK	Background: Asthma incidence has long been linked to pollen, even though pollen grains are too large to penetrate into the airways where asthmatic responses originate. Pollen allergens found in small, respirable particles have been implicated in a number of asthma epidemics, particularly ones following rainfall or thunderstorms. Objective: The aim of this study was to determine how pollen allergens form the respirable aerosols necessary for triggering asthma. Methods: Flowering grasses were humidified and then dried in a controlled-environment chamber connected to a cascade impactor and an aerosol particle counter. Particles shed from the flowers were analyzed with high-resolution microscopy and immunolabeled with rabbit anti-Phl p 1 antibody, which is specific for group 1 pollen allergens. Results: Contrary to what has been reported in other published accounts, most of the pollen in this investigation remained on the open anthers of wind pollinated plants unless disturbed-eg, by wind. Increasing humidity caused anthers to close. After a cycle of wetting and drying followed by wind disturbance, grasses flowering within a chamber produced an aerosol of particles that were collected in a cascade impactor. These particles consisted of fragmented pollen cytoplasm in the size range 0.12 to 4.67 mum; they were loaded with group I allergens. Conclusion: Here we provide the first direct observations of the release of grass pollen allergens as respirable aerosols. They can emanate directly from the flower after a moisture-drying cycle. This could explain asthmatic responses associated with grass pollination, particularly after moist weather conditions.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Huntington Mem Hosp, Huntington Med Res Inst, Ctr Asthma & Allergy, Pasadena, CA USA; Univ Vienna, Dept Pathophysiol, A-1010 Vienna, Austria	California Institute of Technology; Huntington Medical Research Institutes; University of Southern California; Huntington Memorial Hospital; University of Vienna	Flagan, RC (corresponding author), CALTECH, Div Chem & Chem Engn, 210-41, Pasadena, CA 91125 USA.			Valenta, Rudolf/0000-0001-5944-3365				ARBER A, 1934, GRAMINEAE; Bates D V, 1966, Health Phys, V12, P173; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; Blackley CH., 1873, EXPT RES CAUSES NATU; Crane P. R., 1986, POLLEN SPORES FORM F, P179; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; EDWARDS J, 1992, AM J BOT, V79, P144, DOI 10.2307/2445101; Foster A.S., 1974, COMP MORPHOLOGY VASC, V2nd ed, P588; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; Haberlandt G., 1914, PHYSL PLANT ANATOMY; HILL DJ, 1979, MED J AUSTRALIA, V1, P426, DOI 10.5694/j.1326-5377.1979.tb127014.x; Knox R. B., 1979, STUDIES BIOL, V107; KNOX RB, 1981, P 6 AUSTR WEEDS C 19, V2, P125; Lindon JC, 1996, PROG NUCL MAG RES SP, V29, P1, DOI 10.1016/0079-6565(95)01027-0; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; ONG EK, 1994, THESIS U MELBOURNE; PACINI E, 1992, ANN BOT-LONDON, V70, P179, DOI 10.1093/oxfordjournals.aob.a088455; PACINI E, 1982, CARYOLOGIA, V35, P205, DOI 10.1080/00087114.1982.10796925; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schauer JJ, 1996, ATMOS ENVIRON, V30, P3837, DOI 10.1016/1352-2310(96)00085-4; SMART IJ, 1979, AUST J BOT, V27, P333, DOI 10.1071/BT9790333; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TAYLOR PE, 1994, HISTOCHEM J, V26, P392, DOI 10.1007/BF00160051; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; Wuthrich B, 1991, ALLERGY CLIN IMMUNOL, V3, P41	38	194	198	1	62	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					51	56		10.1067/mai.2002.120759	http://dx.doi.org/10.1067/mai.2002.120759			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799365	Bronze			2022-12-18	WOS:000173739300008
J	Kero, J; Gissler, M; Hemminki, E; Isolauri, E				Kero, J; Gissler, M; Hemminki, E; Isolauri, E			Could T(H)1 and T(H)2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: A register study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; T(H)1; T(H)2; asthma; autoimmune disease; rheumatoid arthritis; coeliac disease; diabetes	INFLAMMATORY ARTHRITIS; CELIAC-DISEASE; PREVALENCE; TH1; LYMPHOCYTES; FINLAND; HEALTH; ATOPY; CELLS	Background: Asthma is generally regarded as a disease with strong T(H)2-type cytokine expression, whereas in autoimmune disorders, such as coeliac disease (CD), insulin-dependent diabetes mellitus (IDDM), and rheumatoid arthritis (RA), T(H)1-type expression is seen. According to the cross-regulatory properties of T(H)1 and T(H)2 cells, one would assume that these diseases exist in different patient populations. Objective: We sought to test the hypothesis that asthma could exist in children with T(H)1-type diseases, such as CD, IDDM, and RA. Methods: Comparison was made of the cumulative incidence of asthma in children with CD, IDDM, or RA by linking Finnish Medical Birth Register data on the whole 1987 birth cohort (n = 60,254 births) with the data of several national health registers to obtain information on the incidences of these diseases during the first 7 years of life. Results: The cumulative incidence of asthma in children with CD (24.6%) or RA (10.0%) was significantly higher than in children without CD (3.4%) or RA (3.4%; P < .001 and P = .016, respectively). Asthma tended to be more common in children with IDDM than in children without IDDM. Conclusion: These data indicate that the T(H)1 and T(H)2 diseases can coexist, indicating a common environmental denominator behind the disease processes.	Univ Turku, Dept Pediat, Turku, Finland; Natl Res & Dev Ctr Welf & Hlth, Helsinki, Finland	University of Turku	Kero, J (corresponding author), Heidelberg Univ, Inst Pharmakol, Neuenheimerfeld 366,Room 309, D-69120 Heidelberg, Germany.		kero, jukka/G-3448-2014	kero, jukka/0000-0001-8767-7222; Gissler, Mika/0000-0001-8254-7525				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Aho K, 1998, SEMIN ARTHRITIS RHEU, V27, P325, DOI 10.1016/S0049-0172(98)80053-X; Allanore Y, 1998, LANCET, V351, P497, DOI 10.1016/S0140-6736(05)78684-0; Aro S, 1990, Duodecim, V106, P1443; Assenmacher M, 1998, J IMMUNOL, V161, P2825; Auricchio S, 1999, ITAL J GASTROENTEROL, V31, P773; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Balasa B, 2000, IMMUNOL TODAY, V21, P19, DOI 10.1016/S0167-5699(99)01553-4; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Collin P, 1997, SCAND J GASTROENTERO, V32, P1129, DOI 10.3109/00365529709002992; DELPRETE G, 1992, ALLERGY, V47, P450; GALLI J, 1999, FUNDAMENTAL IMMUNOLO; Gissler M, 1998, PAEDIATR PERINAT EP, V12, P437; GISSLER M, 1995, SCAND J SOC MED, V23, P75, DOI 10.1177/140349489502300113; Hesse M, 1996, EUR J IMMUNOL, V26, P3234, DOI 10.1002/eji.1830261259; Karlsson MGE, 2000, DIABETOLOGIA, V43, P742, DOI 10.1007/s001250051372; KUNNAMO I, 1986, ARTHRITIS RHEUM, V29, P1232, DOI 10.1002/art.1780291008; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Muller B, 1998, SPRINGER SEMIN IMMUN, V20, P181, DOI 10.1007/s002810050029; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Remes ST, 1996, ACTA PAEDIATR, V85, P59, DOI 10.1111/j.1651-2227.1996.tb13891.x; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; Romagnani S, 1997, INT ARCH ALLERGY IMM, V113, P153, DOI 10.1159/000237532; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STROMBERG LGE, 1995, J ALLERGY CLIN IMMUN, V96, P188, DOI 10.1016/S0091-6749(95)70007-2; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wakelkamp IMMJ, 2000, CLIN EXP IMMUNOL, V121, P453, DOI 10.1046/j.1365-2249.2000.01335.x	29	194	203	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					781	783		10.1067/mai.2001.119557	http://dx.doi.org/10.1067/mai.2001.119557			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692104				2022-12-18	WOS:000172523800019
J	Hamid, QA; Schotman, E; Jacobson, MR; Walker, SM; Durham, SR				Hamid, QA; Schotman, E; Jacobson, MR; Walker, SM; Durham, SR			Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; cytokines; late responses IL-12	CD4+ T-CELLS; HAY-FEVER; ANTIBODY-RESPONSE; IMMUNE-RESPONSES; GAMMA PRODUCTION; INTERLEUKIN-12; CYTOKINE; ANTIGEN; INDIVIDUALS; PEPTIDE	IL-12, a novel cytokine produced by tissue macrophages and B lymphocytes, stimulates proliferation of T-H1-type T lymphocytes. We recently showed that in patients with summer hay fever, immunotherapy was effective and was associated with inhibition of allergen-induced late skin responses and increases in local interferon-gamma messenger RNA-positive cells. In this study 10 patients were reassessed after 4 years of immunotherapy and compared with 10 untreated patients with hay fever. Intradermal grass pollen challenge was performed, the late response was measured, and biopsies were performed at 24 hours. In situ hybridization of biopsy sections was performed by using a riboprobe coding for IL-12 mRNA. When immunotherapy and control subjects were compared, there as a marked reduction in the size of the late skin response (p = 0.0001). Significant increases in allergen-induce IL-12 mRNA+ cells in cutaneous biopsy specimens occurred only in the immunotherapy-treated group (all 10 patients, p = 0.002). At allergen-challenged sites, IL-12+ cells correlated positively with interferon-gamma+ cells (r = 0.64, p < 0.05) and inversely with IL-4+ cells (r = -0.67, p < 0.05). The principal cell source (55% to 80%) of IL-12 message was the tissue macrophage (CD68+ cells). We suggest that IL-12 may promote T-H1 responses and inhibit late-phase responses after successful immunotherapy.	NATL HEART & LUNG INST, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW3 6LY, ENGLAND; MCGILL UNIV, MEAKINS CHRISTIE LAB, DEPT PATHOL & MED, MONTREAL, PQ, CANADA	Imperial College London; McGill University			Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258; Jacobson, Mikila/0000-0002-2921-6169				BETTE M, 1994, J IMMUNOL, V10, P2435; CHANPALAY V, 1988, P NATL ACAD SCI USA, V85, P3213, DOI 10.1073/pnas.85.9.3213; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; Durham S R, 1991, Clin Exp Allergy, V21 Suppl 1, P206, DOI 10.1111/j.1365-2222.1991.tb01729.x; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IMADA M, 1995, IMMUNOLOGY, V85, P373; JUTEL M, 1995, J IMMUNOL, V154, P4187; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; LACK G, 1994, J IMMUNOL, V152, P2546; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MALLING HJ, 1993, ALLERGY, V48, P9; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; ROBINSON DS, 1993, CLIN EXP ALLERGY, V23, P1, DOI 10.1111/j.1365-2222.1993.tb02475.x; SALLUSTO F, 1993, ALLERGY, V48, P37, DOI 10.1111/j.1398-9995.1993.tb02172.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0	31	194	200	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					254	260		10.1016/S0091-6749(97)70106-4	http://dx.doi.org/10.1016/S0091-6749(97)70106-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042055				2022-12-18	WOS:A1997WH83100018
J	BRODER, I; HIGGINS, MW; MATHEWS, KP; KELLER, JB				BRODER, I; HIGGINS, MW; MATHEWS, KP; KELLER, JB			EPIDEMIOLOGY OF ASTHMA AND ALLERGIC RHINITIS IN A TOTAL COMMUNITY, TECUMSEH, MICHIGAN .4. NATURAL-HISTORY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,DEPT INTERN MED,ANN ARBOR,MI; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BRODER I, 1962, J ALLERGY, V33, P524, DOI 10.1016/0021-8707(62)90020-5; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; FREEMAN GL, 1969, AM J DIS CHILD, V118, P886, DOI 10.1001/archpedi.1969.02100040888012; FRY J, 1961, BRIT MED J, V1, P227, DOI 10.1136/bmj.1.5221.227; HIGGINS MW, 1970, ARCH ENVIRON HEALTH, V21, P418, DOI 10.1080/00039896.1970.10667260; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; PEARSON R S B, 1958, Acta Allergol, V12, P277; PEDVIS S, 1962, ANN ALLERGY, V20, P569; RACKEMAN FM, 1952, N ENGL J MED, V246, P816; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P858, DOI 10.1056/NEJM195205292462204; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SMITH JM, 1971, J ALLERGY, V47, P23, DOI 10.1016/S0091-6749(71)80314-7; WILLIAMS EO, 1949, BMJ-BRIT MED J, V2, P897, DOI 10.1136/bmj.2.4633.897	15	194	194	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	2					100	110		10.1016/0091-6749(74)90038-4	http://dx.doi.org/10.1016/0091-6749(74)90038-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	T7816	4851886				2022-12-18	WOS:A1974T781600005
J	Stevens, WW; Lee, RJ; Schleimer, RP; Cohen, NA				Stevens, Whitney W.; Lee, Robert J.; Schleimer, Robert P.; Cohen, Noam A.			Chronic rhinosinusitis pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; mucociliary clearance; epithelial cells; inflammation; microbiome	INNATE LYMPHOID-CELLS; TASTE RECEPTOR T2R38; MUCOID PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL PEPTIDE LL-37; SURFACTANT PROTEIN-A; NASAL POLYPS; STAPHYLOCOCCUS-AUREUS; NITRIC-OXIDE; HUMAN BETA-DEFENSIN-2; ALLERGIC RHINITIS	There are a variety of medical conditions associated with chronic sinonasal inflammation, including chronic rhinosinusitis (CRS) and cystic fibrosis. In particular, CRS can be divided into 2 major subgroups based on whether nasal polyps are present or absent. Unfortunately, clinical treatment strategies for patients with chronic sinonasal inflammation are limited, in part because the underlying mechanisms contributing to disease pathology are heterogeneous and not entirely known. It is hypothesized that alterations in mucociliary clearance, abnormalities in the sinonasal epithelial cell barrier, and tissue remodeling all contribute to the chronic inflammatory and tissue-deforming processes characteristic of CRS. Additionally, the host innate and adaptive immune responses are also significantly activated and might be involved in pathogenesis. Recent advancements in the understanding of CRS pathogenesis are highlighted in this review, with special focus placed on the roles of epithelial cells and the host immune response in patients with cystic fibrosis, CRS without nasal polyps, or CRS with nasal polyps.	[Stevens, Whitney W.; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA; [Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Perelman Sch Med, Philadelphia, PA USA; [Lee, Robert J.] Univ Penn, Dept Physiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Cohen, Noam A.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Monell Chemical Senses Center	Schleimer, RP (corresponding author), Div Allergy Immunol, 240 E Huron St,McGaw Rm M-318, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Lee, Robert J./L-4397-2017	Lee, Robert J./0000-0001-5826-6686; Cohen, Noam/0000-0002-9462-3932	USPHS grants [R01DC013588, R21DC013886, R03DC013862]; National Institutes of Health [T32 AI083216, R01 AI104733]; Ernest S. Bazley Foundation; Chronic Rhinosinusitis Integrative Studies Program [U19-AI106683]; RLG Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI104733, U19AI106683, T32AI083216, P01AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC013862, R01DC013588, R21DC013886] Funding Source: NIH RePORTER	USPHS grants; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; Chronic Rhinosinusitis Integrative Studies Program; RLG Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Some of the research described in this review and effort directed towards writing the review was supported by USPHS grants R01DC013588, R21DC013886 (to N.A.C.), and R03DC013862 (to R.J.L.); National Institutes of Health grants T32 AI083216 and R01 AI104733 (to R.P.S.); the Ernest S. Bazley Foundation (to R.P.S.); the Chronic Rhinosinusitis Integrative Studies Program U19-AI106683 (to R.P.S.), and a philanthropic contribution from the RLG Foundation (to N.A.C.).	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Adams KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103263; Adappa ND, 2014, INT FORUM ALLERGY RH, V4, P3, DOI 10.1002/alr.21253; Adappa ND, 2013, INT FORUM ALLERGY RH, V3, P184, DOI 10.1002/alr.21140; Akbar NA, 2011, CURR OPIN OTOLARYNGO, V19, P224, DOI 10.1097/MOO.0b013e3283465687; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; AMITANI R, 1995, INFECT IMMUN, V63, P3266, DOI 10.1128/IAI.63.9.3266-3271.1995; Aurora R, 2013, JAMA OTOLARYNGOL, V139, P1328, DOI 10.1001/jamaoto.2013.5465; Baba S, 2014, LARYNGOSCOPE, V124, pE115, DOI 10.1002/lary.24462; Balsalobre L, 2013, J OTOLARYNGOL-HEAD N, V42, DOI 10.1186/1916-0216-42-29; Biswas K, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00134; Blount A, 2011, LARYNGOSCOPE, V121, P1929, DOI 10.1002/lary.21921; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; Button B, 2012, SCIENCE, V337, P937, DOI 10.1126/science.1223012; Chen PH, 2004, AM J RHINOL, V18, P381, DOI 10.1177/194589240401800608; Chen PH, 2004, EUR ARCH OTO-RHINO-L, V261, P238, DOI 10.1007/s00405-003-0682-z; Chennupati SK, 2009, AM J RHINOL ALLERGY, V23, P46, DOI 10.2500/ajra.2009.23.3261; CLAMP JR, 1984, CIBA F SYMP, V109, P121, DOI 10.1002/9780470720905.ch9; Conner GE, 2007, FEBS LETT, V581, P271, DOI 10.1016/j.febslet.2006.12.025; DAVIES J, 1995, INFECT IMMUN, V63, P2485, DOI 10.1128/IAI.63.7.2485-2492.1995; Degano B, 2011, HUM PATHOL, V42, P1855, DOI 10.1016/j.humpath.2011.01.027; Deja M, 2003, AM J RESP CRIT CARE, V168, P281, DOI 10.1164/rccm.200207-640OC; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Do TQ, 2008, J IMMUNOL, V181, P4177, DOI 10.4049/jimmunol.181.6.4177; Farquhar DR, 2015, INT FORUM ALLERGY RH, V5, P111, DOI 10.1002/alr.21437; Feazel LM, 2012, LARYNGOSCOPE, V122, P467, DOI 10.1002/lary.22398; FEIZI T, 1984, BIOCHEM SOC T, V12, P591, DOI 10.1042/bst0120591; Fischer H, 2009, ANTIOXID REDOX SIGN, V11, P2453, DOI [10.1089/ars.2009.2558, 10.1089/ARS.2009.2558]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fragoso MA, 2004, J PHYSIOL-LONDON, V561, P183, DOI 10.1113/jphysiol.2004.071548; Golec M, 2007, ANN AGR ENV MED, V14, P1; Groneberg DA, 2003, LARYNGOSCOPE, V113, P520, DOI 10.1097/00005537-200303000-00023; Gudis D, 2012, AM J RHINOL ALLERGY, V26, P1, DOI 10.2500/ajra.2012.26.3716; Gudis DA, 2010, OTOLARYNG CLIN N AM, V43, P461, DOI 10.1016/j.otc.2010.02.007; Hamilos DL, 2014, J ALLERGY CLIN IMMUN, V133, P640, DOI 10.1016/j.jaci.2013.06.049; Hansdottir S, 2011, VITAM HORM, V86, P217, DOI 10.1016/B978-0-12-386960-9.00009-5; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Hatten KM, 2015, OTOLARYNG HEAD NECK, V152, P1140, DOI 10.1177/0194599815577567; Hayes SM, 2015, J ALLERGY CLIN IMMUN, V135, P1648, DOI 10.1016/j.jaci.2014.12.1929; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Illing EA, 2014, CURR OPIN PULM MED, V20, P623, DOI 10.1097/MCP.0000000000000107; Ishida A, 2012, ALLERGOL INT, V61, P589, DOI 10.2332/allergolint.11-OA-0370; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Kalfa VC, 2004, ANN ALLERG ASTHMA IM, V93, P288, DOI 10.1016/S1081-1206(10)61503-7; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2013, J ALLERGY CLIN IMMUN, V131, P933, DOI 10.1016/j.jaci.2013.02.023; Kim ST, 2003, ACTA OTO-LARYNGOL, V123, P81, DOI 10.1080/0036554021000028089; Kim U, 2005, HUM MUTAT, V26, P199, DOI 10.1002/humu.20203; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; Knight JA, 2000, ANN CLIN LAB SCI, V30, P145; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Lam M, 2015, AM J RHINOL ALLERGY, V29, P175, DOI 10.2500/ajra.2015.29.4176; Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; Lan F, 2013, J ALLERGY CLIN IMMUN, V132, P1314, DOI 10.1016/j.jaci.2013.06.010; Lane AP, 2006, AM J RHINOL, V20, P138, DOI 10.1177/194589240602000203; Lee JT, 2010, AM J RHINOL ALLERGY, V24, P99, DOI 10.2500/ajra.2010.24.3444; Lee RJ, 2015, CELL MOL LIFE SCI, V72, P217, DOI 10.1007/s00018-014-1736-7; Lee RJ, 2014, J MOL MED, V92, P1235, DOI 10.1007/s00109-014-1222-6; Lee RJ, 2014, AM J RHINOL ALLERGY, V28, P366, DOI 10.2500/ajra.2014.28.4077; Lee RJ, 2014, CELL CALCIUM, V55, P325, DOI 10.1016/j.ceca.2014.02.001; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Lee RJ, 2013, AM J RHINOL ALLERGY, V27, P283, DOI 10.2500/ajra.2013.27.3911; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Lee SH, 2002, ANN OTO RHINOL LARYN, V111, P135, DOI 10.1177/000348940211100205; Legrand D, 2012, BIOCHEM CELL BIOL, V90, P252, DOI [10.1139/O11-056, 10.1139/o11-056]; Lillehoj EP, 2013, INT REV CEL MOL BIO, V303, P139, DOI 10.1016/B978-0-12-407697-6.00004-0; Mahdavinia M, 2015, J ALLERGY CLIN IMMUN, V135, P576, DOI 10.1016/j.jaci.2014.08.031; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Major TA, 2010, ANTIMICROB AGENTS CH, V54, P4671, DOI 10.1128/AAC.00379-10; Malik Z, 2015, INT FORUM ALLERGY RH, V5, P551, DOI 10.1002/alr.21517; Mall MA, 2015, J CYST FIBROS, V14, P561, DOI 10.1016/j.jcf.2015.06.002; Maniscalco M, 2007, INFLAMM RES, V56, P58, DOI 10.1007/s00011-006-6111-1; Meng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082373; Mfuna Endam L, 2014, INT FORUM ALLERGY RH, V4, P200, DOI 10.1002/alr.21275; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Min JY, 2014, J ALLERGY CLIN IMMUN, V133, pAB236, DOI 10.1016/j.jaci.2013.12.840; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moskwa P, 2007, AM J RESP CRIT CARE, V175, P174, DOI 10.1164/rccm.200607-1029OC; Mulligan JK, 2011, CLIN EXP IMMUNOL, V164, P312, DOI 10.1111/j.1365-2249.2011.04325.x; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nash JA, 2006, J IMMUNOL, V177, P519, DOI 10.4049/jimmunol.177.1.519; Nofziger C, 2011, CLIN PHARMACOL THER, V90, P399, DOI 10.1038/clpt.2011.128; Nofziger C, 2011, CELL PHYSIOL BIOCHEM, V28, P571, DOI 10.1159/000335115; Nomura K, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-21; Olze H, 2006, RHINOLOGY, V44, P145; Ooi EH, 2008, AM J RHINOL, V22, P13, DOI 10.2500/ajr.2008.22.3127; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Pant H, 2014, AM J RHINOL ALLERGY, V28, pE83, DOI 10.2500/ajra.2013.28.4014; Parker D, 2011, AM J RESP CELL MOL, V45, P189, DOI 10.1165/rcmb.2011-0011RT; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; PERSSON CGA, 1991, EUR RESPIR J, V4, P1268; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Pezzulo AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016166; Phillips PS, 2011, OTOLARYNG HEAD NECK, V144, P159, DOI 10.1177/0194599810392667; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; PRINCE A, 1992, MICROB PATHOGENESIS, V13, P251, DOI 10.1016/0882-4010(92)90035-M; Prokhorenko IR, 2009, INT J GEN MED, V2, P33; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Psaltis AJ, 2008, LARYNGOSCOPE, V118, P895, DOI 10.1097/MLG.0b013e31816381d4; Ramakrishnan VR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085507; Ramanathan M, 2007, OTOLARYNG HEAD NECK, V136, P348, DOI 10.1016/j.otohns.2006.11.011; Reddy MS, 1997, OTOLARYNG HEAD NECK, V116, P175, DOI 10.1016/S0194-5998(97)70321-8; Rudack C, 2007, CLIN EXP ALLERGY, V37, P1009, DOI 10.1111/j.1365-2222.2007.02686.x; SAJJAN SU, 1992, INFECT IMMUN, V60, P1434, DOI 10.1128/IAI.60.4.1434-1440.1992; SANDERSON MJ, 1981, J CELL SCI, V47, P331; Sano H, 2003, EUR J IMMUNOL, V33, P2894, DOI 10.1002/eji.200324218; Schutte BC, 2002, ANNU REV PHYSIOL, V64, P709, DOI 10.1146/annurev.physiol.64.081501.134340; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Seshadri S, 2015, J ALLERGY CLIN IMMUN, V136, P1548, DOI 10.1016/j.jaci.2015.05.024; Seshadri S, 2013, J ALLERGY CLIN IMMUN, V132, P1227, DOI 10.1016/j.jaci.2013.05.042; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shen JC, 2012, INT FORUM ALLERGY RH, V2, P104, DOI 10.1002/alr.21002; Shin HW, 2012, AM J RESP CRIT CARE, V185, P944, DOI 10.1164/rccm.201109-1706OC; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; Sobol SE, 2002, ARCH OTOLARYNGOL, V128, P1295, DOI 10.1001/archotol.128.11.1295; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steinke JW, 2012, ANN OTO RHINOL LARYN, V121, P579, DOI 10.1177/000348941212100904; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Sultan B, 2013, INT FORUM ALLERGY RH, V3, P26, DOI 10.1002/alr.21087; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Tarran R, 2014, INT J BIOCHEM CELL B, V52, P130, DOI 10.1016/j.biocel.2014.03.002; Tewfik MA, 2007, AM J RHINOL, V21, P680, DOI 10.2500/ajr.2007.21.3103; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Bruaene N, 2012, CLIN EXP ALLERGY, V42, P883, DOI 10.1111/j.1365-2222.2011.03898.x; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wei CC, 2013, LARYNGOSCOPE, V123, P2347, DOI 10.1002/lary.24066; Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC; WILSON R, 1987, J CLIN INVEST, V79, P221, DOI 10.1172/JCI112787; Woods CM, 2012, RHINOLOGY, V50, P147, DOI [10.4193/Rhin11.229, 10.4193/Rhino11.229]; Woods CM, 2011, AM J RHINOL ALLERGY, V25, P236, DOI 10.2500/ajra.2011.25.3631; Woodworth BA, 2006, AM J RHINOL, V20, P461, DOI 10.2500/ajr.2006.20.2892; Workman AD, 2014, AM J RHINOL ALLERGY, V28, P454, DOI 10.2500/ajra.2014.28.4092; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com; Yamin M, 2015, INT FORUM ALLERGY RH, V5, P573, DOI 10.1002/alr.21516; Yang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128564; Yao T, 2009, LARYNGOSCOPE, V119, P1053, DOI 10.1002/lary.20191; Yim S, 2007, J CYST FIBROS, V6, P403, DOI 10.1016/j.jcf.2007.03.003; Yoon SS, 2006, J CLIN INVEST, V116, P436, DOI 10.1172/JCI24684; Zaravinos A, 2008, ONCOL REP, V19, P385; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang Z, 2014, INT FORUM ALLERGY RH, V4, P315, DOI 10.1002/alr.21269; Zhao KQ, 2012, FASEB J, V26, P3178, DOI 10.1096/fj.11-202184; Zhao KQ, 2011, AM J RHINOL ALLERGY, V25, P209, DOI 10.2500/ajra.2011.25.3614	157	193	206	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1442	1453		10.1016/j.jaci.2015.10.009	http://dx.doi.org/10.1016/j.jaci.2015.10.009			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26654193	Green Accepted, hybrid			2022-12-18	WOS:000366044300002
J	Caubet, JC; Ford, LS; Sickles, L; Jarvinen, KM; Sicherer, SH; Sampson, HA; Nowak-Wegrzyn, A				Caubet, Jean Christoph; Ford, Lara Simone; Sickles, Laura; Jaervinen, Kirsi M.; Sicherer, Scott H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna			Clinical features and resolution of food protein-induced enterocolitis syndrome: 10-year experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; allergic enterocolitis; food protein-induced enterocolitis; food allergy; milk allergy; soy allergy; rice allergy; oat allergy; natural history	ATOPY PATCH TEST; MANAGEMENT; UTILITY	Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy. FPIES diagnosis is frequently delayed because of the absence of classic allergic symptoms and lack of biomarkers. Objective: We sought to characterize the clinical features and resolution of FPIES in patients evaluated in our practice. Methods: Subjects 6 months to 45 years of age with FPIES were prospectively recruited for oral food challenges (OFCs). Medical records were searched to identify the subjects who did not participate in OFCs. Results: Among 160 subjects, 54% were male; median age at diagnosis was 15 months. We performed 180 OFCs to 15 foods in 82 subjects; 30% of the study population had FPIES confirmed based on OFC results. The most common foods were cow's milk (44%), soy (41%), rice (22.5%), and oat (16%). The majority (65%) reacted to 1 food, 26% reacted to 2 foods, and 9% reacted to 3 or more foods. The majority were atopic, and 39% had IgE sensitization to another food. Thirty-nine (24%) subjects had positive specific IgE levels to the food inducing FPIES. Among children with specific IgE to cow's milk, 41% changed from a milk FPIES to an IgE-mediated phenotype over time. The median age when tolerance was established was 4.7 years for rice, 4 years for oat, and 6.7 years for soy. Median age when milk tolerance was established for subjects with undetectable milk-specific IgE levels was 5.1 years, whereas none of the subjects with detectable milk-specific IgE became tolerant to milk during the study (P = .003). Conclusion: FPIES typically resolves by age 5 years. Milk FPIES, especially with detectable food-specific IgE, can have a protracted course and eventually transition to acute reactions.	[Caubet, Jean Christoph; Ford, Lara Simone; Sickles, Laura; Jaervinen, Kirsi M.; Sicherer, Scott H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna] Kravis Childrens Hosp, Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Div Allergy & Immunol,Dept Pediat, New York, NY USA; [Caubet, Jean Christoph] Univ Hosp Geneva, Div Pediat Allergy, Geneva, Switzerland; [Ford, Lara Simone] Childrens Hosp, Westmead, NSW, Australia; [Sickles, Laura] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Jaervinen, Kirsi M.] Albany Med Coll, Div Allergy & Immunol, Albany, NY 12208 USA; [Jaervinen, Kirsi M.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Icahn School of Medicine at Mount Sinai; University of Geneva; University of Sydney; Jefferson University; Albany Medical College; Albany Medical College	Nowak-Wegrzyn, A (corresponding author), Pediat Mt Sinai Sch Med, Div Allergy & Immunol, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health [UL1 TR-000067]; Jaffe Foundation Fellowship Award; Leff Family Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000067] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health; Jaffe Foundation Fellowship Award; Leff Family Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported in part by UL1 TR-000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health. L. S. F. was supported by the Jaffe Foundation Fellowship Award, and K. M. J. was supported in part by the Leff Family Grant.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bruni F, 2008, ALLERGY, V63, DOI 10.1111/j.1398-9995.2008.01911.x; Caubet JC, 2011, J ALLERGY CLIN IMMUN, V128, P1386, DOI 10.1016/j.jaci.2011.07.011; Caubet JC, 2011, EXPERT REV CLIN IMMU, V7, P317, DOI [10.1586/eci.11.13, 10.1586/ECI.11.13]; Fernandes BN, 2012, J ALLERGY CLIN IMMUN, V130, P1199, DOI 10.1016/j.jaci.2012.06.017; Fleischer DMSJ, 2012, J ALLERGY CLIN IMMUN, V1, P29; Fogg MI, 2006, PEDIAT ALLERG IMM-UK, V17, P351, DOI 10.1111/j.1399-3038.2006.00418.x; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Jarvinen KM, 2012, ANN ALLERG ASTHMA IM, V109, P221, DOI 10.1016/j.anai.2012.06.020; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; Leonard SA, 2011, ANN ALLERG ASTHMA IM, V107, P95, DOI 10.1016/j.anai.2011.06.004; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Monti G, 2011, ACTA PAEDIATR, V100, pE236, DOI 10.1111/j.1651-2227.2011.02325.x; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Mori F, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/679381; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, P685, DOI 10.1016/j.jaci.2011.01.019; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P371, DOI 10.1097/ACI.0b013e32832d6315; Onesimo R, 2011, EUR ANN ALLERGY CLIN, V43, P61; Powell GK, 1986, COMPR THER, V12, P28; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sopo SM, 2012, CLIN EXP ALLERGY, V42, P1257, DOI 10.1111/j.1365-2222.2012.04027.x	30	193	202	3	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					382	+		10.1016/j.jaci.2014.04.008	http://dx.doi.org/10.1016/j.jaci.2014.04.008			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24880634				2022-12-18	WOS:000341370800018
J	Shearer, WT; Dunn, E; Notarangelo, LD; Dvorak, CC; Puck, JM; Logan, BR; Griffith, LM; Kohn, DB; O'Reilly, RJ; Fleisher, TA; Pai, SY; Martinez, CA; Buckley, RH; Cowan, MJ				Shearer, William T.; Dunn, Elizabeth; Notarangelo, Luigi D.; Dvorak, Christopher C.; Puck, Jennifer M.; Logan, Brent R.; Griffith, Linda M.; Kohn, Donald B.; O'Reilly, Richard J.; Fleisher, Thomas A.; Pai, Sung-Yun; Martinez, Caridad A.; Buckley, Rebecca H.; Cowan, Morton J.			Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allogeneic hematopoietic cell transplantation; gene therapy; primary immunodeficiency; clinical trial	STEM-CELL TRANSPLANTATION; GENE-THERAPY; BONE-MARROW; MUTATIONS; RECONSTITUTION; OUTCOMES; ANTIGEN	Background: The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and related disorders varies among institutions and countries. Objectives: The Primary Immune Deficiency Treatment Consortium attempted to develop a uniform set of criteria for diagnosing SCID and related disorders and has evaluated the results as part of a retrospective study of SCID in North America. Methods: Clinical records from 2000 through 2009 at 27 centers in North America were collected on 332 children treated with hematopoietic stem cell transplantation (HCT), enzyme replacement therapy, or gene therapy for SCID and related disorders. Eligibility for inclusion in the study and classification into disease groups were established by using set criteria and applied by an expert review group. Results: Two hundred eighty-five (86%) of the patients were determined to be eligible, and 47 (14%) were not eligible. Of the 285 eligible patients, 84% were classified as having typical SCID; 13% were classified as having leaky SCID, Omenn syndrome, or reticular dysgenesis; and 3% had a history of enzyme replacement or gene therapy. Detection of a genotype predicting an SCID phenotype was accepted for eligibility. Reasons for noneligibility were failure to demonstrate either impaired lymphocyte proliferation or maternal T-cell engraftment. Overall (n = 332) rates of testing were as follows: proliferation to PHA, 77%; maternal engraftment, 35%; and genotype, 79% (mutation identified in 62%). Conclusion: Lack of complete laboratory evaluation of patients before HCT presents a significant barrier to definitive diagnosis of SCID and related disorders and prevented inclusion of subjects in our observational HCT study. This lesson is critical for patient care, as well as the design of future prospective treatment studies for such children because a well-defined and consistent study population is important for precision in outcomes analysis.	[Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Dunn, Elizabeth; Dvorak, Christopher C.; Puck, Jennifer M.; Cowan, Morton J.] Univ Calif San Francisco, Div Pediat Allergy Immunol & Blood & Marrow Trans, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Notarangelo, Luigi D.] Med Coll Wisconsin, Div Biostat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; [Logan, Brent R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Logan, Brent R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA; [Logan, Brent R.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA; [Griffith, Linda M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA USA; [O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [Fleisher, Thomas A.] NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Div Hematol & Oncol, Boston Childrens Hosp, Boston, MA 02115 USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Martinez, Caridad A.] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Ctr Canc, Houston, TX 77030 USA; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat & Immunol, Durham, NC 27706 USA	Baylor College of Medicine; University of California System; University of California San Francisco; Center for International Blood & Marrow Transplant Research; Medical College of Wisconsin; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Baylor College of Medicine; Duke University	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Immunol Allergy & Rheumatol Serv, 1102 Bates St,Suite FC330, Houston, TX 77030 USA.	wtshearer@texaschildrens.org	Notarangelo, Luigi D/F-9718-2016; Pai, Sung-Yun/AAH-7762-2019; Kohn, Donald/N-5085-2016; Dvorak, Christopher C/AAX-1630-2020	Notarangelo, Luigi D/0000-0002-8335-0262; Pai, Sung-Yun/0000-0002-0158-8147; Kohn, Donald/0000-0003-1840-6087; Dvorak, Christopher C/0000-0002-6146-3952; Shearer, William/0000-0002-2483-2130	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT-NIAID); Intramural Research Programs of the National Human Genome Research Institute (NHGRI); National Institute of Allergy and Infectious Diseases; Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (ORDR-NACTS-NIH), Bethesda, Maryland [U54-AI082973, U54-NS064808, R13-AI094943]; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; Robert A. Good Immunology Society, St Petersburg, Fla; John P. McGovern Foundation, Houston, Tex; David Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; DAIT-NIAID; NHGRI NIAID; ORDR-NCATS-NIH; National Institutes of Health (NIH); NIH; March of Dimes; Jeffrey Modell Foundation; NIAID; NIH-Gene Therapy Resource Program;  [NCI23766]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943, R01AI105776, R01AI078248, U54AI082973, N01AI030070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS064808] Funding Source: NIH RePORTER	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT-NIAID); Intramural Research Programs of the National Human Genome Research Institute (NHGRI); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (ORDR-NACTS-NIH), Bethesda, Maryland; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; Robert A. Good Immunology Society, St Petersburg, Fla; John P. McGovern Foundation, Houston, Tex; David Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; DAIT-NIAID; NHGRI NIAID; ORDR-NCATS-NIH; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Jeffrey Modell Foundation; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-Gene Therapy Resource Program; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The Primary Immune Deficiency Treatment Consortium (PIDTC) is supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT-NIAID); the Intramural Research Programs of the National Human Genome Research Institute (NHGRI) and the National Institute of Allergy and Infectious Diseases; and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (ORDR-NACTS-NIH), Bethesda, Maryland: U54-AI082973 (PI: M. J. Cowan), U54-NS064808 (PI: J. P. Krischer), and R13-AI094943 (PIs: M. J. Cowan and L. D. Notarangelo). This manuscript was presented at the PIDTC Third Annual Scientific Workshop, Houston, Tex, May 2-4, 2013, supported in part by the Immune Deficiency Foundation, Towson, Md; the Jeffrey Modell Foundation, New York, NY; the Robert A. Good Immunology Society, St Petersburg, Fla; the John P. McGovern Foundation, Houston, Tex; the David Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; and Sigma-Tau Pharmaceuticals, Gaithersburg, Md. The opinions expressed are those of the authors and do not represent the position of the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences, the National Institutes of Health, or the US Government.; W. T. Shearer has received research support from DAIT-NIAID, NHGRI NIAID, and ORDR-NCATS-NIH; has received travel support from the PIDTC Workshop; is employed by Baylor College of Medicine; and has grants/grants pending with the National Institutes of Health (NIH). E. Dunn has received research support from DAIT-NIAID, NHGRI NIAID, and ORDR-NCATS-NIH; has received travel support from the PIDTC Scientific Workshop; is employed by the University of California-San Francisco (UCSF); and has grants/grants pending from the NIH. L. D. Notarangelo has received research support from the NIH, March of Dimes, and the Jeffrey Modell Foundation; is a board member on the Immune Disease Institute, the Meyer Pediatric Hospital, DMC, Watermark and DMC, NovImmune, Board of Scientific Counselors for the NIAID and NIH, is an Associate Editor for the Journal of Allergy and Clinical Immunology, is an Associate Editor for Clinical Immunology; is employed by Children's Hospital Boston; and receives royalties from UpToDate. C. C. Dvorak has received research support from DAIT-NIAID, NHGRI NIAID, and ORDR-NCATS-NIH and has received travel support from DAIT-NIAID, NHGR NIAID, and ORDR-NCATS-NIH. J. M. Puck has received research support from DAIT-NIAID, NHGRI NIAID, and ORDR-NCATS-NIH; has received travel support from the PIDTC Workshop; is employed by UCSF; has grants/grants pending from the NIH; and receives royalties from a published textbook. B. R. Logan has received research support from the NIAID. L. M. Griffith is a medical officer for the NIAID and is employed by the NIH. D. B. Kohn has received travel support from the PIDTC. R. J. O'Reilly has received research support from the NIAID for the PIDTC and NCI23766, is employed by MSKCC, has provided expert testimony for Miltenyi Biotech, and has patents pending for WT1 peptides. S.-Y. Pai has received grants from DAIT-NIAID, has received support for travel to meetings for study or other purposes from the PIDTC Workshop, is employed by the Boston Children's Hospital, and has grants/grants pending from NIH-Gene Therapy Resource Program. R. H. Buckley has received grants from the NIAID, has received support for travel to meetings from the PIDTC, is employed by the Duke University Medical Center, receives royalties from UpToDate, has stock/stock option in TIAA/CREF, and receives travel expenses from the Foundation for Primary immunodeficiency disease. M. J. Cowan has received research support from DAIT-NIAID, NHGRI NIAID, ORDR-NCATS-NIH, and the NIH; has received travel support to PIDTC workshops; and is employed by the University of California. These authors declare that they have no relevant conflicts of interest.	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Aiuti Alessandro, 2009, Hematology Am Soc Hematol Educ Program, P682, DOI 10.1182/asheducation-2009.1.682; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Chinen J, 2007, BLOOD, V110, P67, DOI 10.1182/blood-2006-11-058933; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; DROR Y, 1993, BLOOD, V81, P2021; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Griffith LM, 2008, J ALLERGY CLIN IMMUN, V122, P1087, DOI 10.1016/j.jaci.2008.09.045; Griffith LM, 2013, J ALLERGY CLIN IMMUN, V2013; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Hirschhom R, 2007, PRIMARY IMMUNODEFICI, P169; Kung C, 2000, NAT MED, V6, P343; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Lagresle-Peyrou C, 2009, NAT GENET, V41, P106, DOI 10.1038/ng.278; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Notarangelo LD, 2006, CURR OPIN ALLERGY CL, V6, P443, DOI 10.1097/01.all.0000246616.47708.2f; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; Patel NC, 2009, J ALLERGY CLIN IMMUN, V124, P1062, DOI 10.1016/j.jaci.2009.08.041; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Read JS, 2007, PEDIATRICS, V120, pE1547, DOI 10.1542/peds.2007-2951; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Roberts JL, 2007, BLOOD, V109, P3198, DOI 10.1182/blood-2006-08-043166; Sarzotti M, 2003, J IMMUNOL, V170, P2711, DOI 10.4049/jimmunol.170.5.2711; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Small TN, 2009, THOMAS HEMATOPOIETIC, V75, P1105; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141	43	193	206	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1092	1098		10.1016/j.jaci.2013.09.044	http://dx.doi.org/10.1016/j.jaci.2013.09.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24290292	Green Accepted			2022-12-18	WOS:000333531700020
J	Ivanova, JI; Bergman, R; Birnbaum, HG; Colice, GL; Silverman, RA; McLaurin, K				Ivanova, Jasmina I.; Bergman, Rachel; Birnbaum, Howard G.; Colice, Gene L.; Silverman, Robert A.; McLaurin, Kimmie			Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Moderate persistent asthma; severe persistent asthma; asthma-related costs; asthma-related resource use; asthma exacerbations	TO-TREAT ASTHMA; PLAN EMPLOYER DATA; ADMINISTRATIVE DATA; INFORMATION SET; UNITED-STATES; HEDIS ASTHMA; RISK-FACTORS; BURDEN; COMORBIDITY; DIFFICULT	Background: Health care costs increase in patients with more severe asthma, but the effect of asthma exacerbations on costs among patients with more severe asthma has not been quantified. Objective: This study compared direct health care costs between patients with moderate/severe persistent asthma with and without exacerbations. Methods: Patients who had an asthma diagnosis (International Classification of Diseases-ninth revision-Clinical Modification code 493.x), were 12 to 64 years old, and were receiving controller therapy were identified from a large administrative claims database. Patients were categorized as having moderate/severe persistent asthma and were further evaluated for exacerbations during a 12-month exacerbation identification period. Patients with 1 or more exacerbations (asthma-related inpatient or emergency department visit or corticosteroid prescription) were matched to patients without exacerbations on demographic characteristics and asthma severity. Total and asthma-related health care costs during the 1-year study period after the exacerbation index date were calculated. Results: Patients with exacerbations had significantly higher total health care costs ($9223 vs $5011, P < .0001) and asthma-related costs ($1740 vs $847, P < .0001). The cost differences remained significant after controlling for patient differences by using multivariate models. Patients with exacerbations (n = 3830) had higher rates of sinusitis, allergy-related diagnoses or medications, pneumonia, and mental disorders and higher average Charlson Comorbidity Index scores at baseline. Patients with exacerbations filled their prescriptions for controllers more often and had higher asthma-related drug costs. Conclusions: Patients with moderate/severe persistent asthma who had exacerbations had higher total and asthma-related health care costs than those without exacerbations. Moreover, controller medication use was higher in patients with exacerbations. (J Allergy Clin Immunol 2012;129:1229-35.)	[Ivanova, Jasmina I.; Bergman, Rachel] Anal Grp Inc, New York, NY 10020 USA; [Birnbaum, Howard G.] Anal Grp Inc, Boston, MA USA; [Colice, Gene L.] Washington Hosp Ctr, Washington, DC 20010 USA; [Silverman, Robert A.] N Shore LIJ Hlth Syst, New York, NY USA; [McLaurin, Kimmie] MedImmune, Gaithersburg, MD USA	Analysis Group Inc.; Analysis Group Inc.; MedStar Washington Hospital Center; Northwell Health; AstraZeneca; Medimmune	Ivanova, JI (corresponding author), Anal Grp Inc, 10 Rockefeller Plaza,15th Floor, New York, NY 10020 USA.	jivanova@analysisgroup.com			MedImmune	MedImmune(AstraZenecaMedimmune)	Supported by MedImmune.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adams RJ, 2006, CHEST, V129, P285, DOI 10.1378/chest.129.2.285; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; American Lung Association Epidemiology and Statistics Unit, TRENDS ASTHM MORB MO; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Berger WE, 2004, ANN ALLERG ASTHMA IM, V93, P538, DOI 10.1016/S1081-1206(10)61260-4; Birnbaum HG, 2009, J ASTHMA, V46, P67, DOI 10.1080/02770900802503099; Birnbaum HG, 2002, J ALLERGY CLIN IMMUN, V109, P264, DOI 10.1067/mai.2002.121310; Cabana MD, 2004, PEDIATRICS, V114, P1049, DOI 10.1542/peds.2003-1162-L; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Colice GL, 2008, J ASTHMA, V45, P293, DOI 10.1080/02770900801911178; Collice G, 2006, J OCCUP ENVIRON MED, V48, P794, DOI 10.1097/01.jom.0000229819.26852.0e; Gaga M, 2005, CLIN EXP ALLERGY, V35, P954, DOI 10.1111/j.1365-2222.2005.02281.x; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Gelfand EW, 2006, ANN ALLERG ASTHMA IM, V97, P298, DOI 10.1016/S1081-1206(10)60793-4; Gershon AS, 2010, THORAX, V65, P612, DOI 10.1136/thx.2009.131078; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; Kandane-Rathnayake RK, 2009, THORAX, V64, P1025, DOI 10.1136/thx.2009.118430; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Leidy NK, 1999, VALUE HEALTH, V2, P394, DOI DOI 10.1016/S1098-3015(10)75867-8; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P1181, DOI 10.1164/rccm.201003-0321UP; Mosen DM, 2005, AM J MANAG CARE, V11, P650; National Committee for Quality Assurance, 2004, HEDIS 2005 TECHN SPE, V2, P127; [National Heart Lung and Blood Institute Chartbook on Cardiovascular Lung and Blood Diseases U.S. Department of Health and Human Services National Institute of Health], 2009, NAT HEART LUNG BLOOD; Prosser R, 2010, CHRONIC DIS CAN, V30, P46; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Soriano JB, 2005, CHEST, V128, P2099, DOI 10.1378/chest.128.4.2099; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Szefler SJ, 2011, ANN ALLERG ASTHMA IM, V107, P110, DOI 10.1016/j.anai.2011.04.008; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Thomas M, 2003, EXPERT OPIN PHARMACO, V4, P351, DOI 10.1517/14656566.4.3.351; van Manen JG, 2001, J CLIN EPIDEMIOL, V54, P287, DOI 10.1016/S0895-4356(01)00346-8; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Yong PL, 2009, J ALLERGY CLIN IMMUN, V124, P961, DOI 10.1016/j.jaci.2009.07.027	43	193	195	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1229	1235		10.1016/j.jaci.2012.01.039	http://dx.doi.org/10.1016/j.jaci.2012.01.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22326484				2022-12-18	WOS:000303418000008
J	Schatz, M; Dombrowski, MP; Wise, R; Thom, EA; Landon, M; Mabie, W; Newman, RB; Hauth, JC; Lindheimer, M; Caritis, SN; Leveno, KJ; Meis, P; Miodovnik, M; Wapner, RJ; Paul, RH; Varner, MW; O'Sullivan, MJ; Thurnau, GR; Conway, D; McNellis, D				Schatz, M; Dombrowski, MP; Wise, R; Thom, EA; Landon, M; Mabie, W; Newman, RB; Hauth, JC; Lindheimer, M; Caritis, SN; Leveno, KJ; Meis, P; Miodovnik, M; Wapner, RJ; Paul, RH; Varner, MW; O'Sullivan, MJ; Thurnau, GR; Conway, D; McNellis, D		Nat I Child Hlth Dev Maternal Feta; Nat Heart Lung Blood I	Asthma morbidity during pregnancy can be predicted by severity classification	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pregnancy; morbidity; severity		Background: The 1993 National Asthma Education Program Working Group on Asthma and Pregnancy defined asthma severity as mild, moderate, or severe on the basis of symptoms and spirometry, but no studies have evaluated the relationship between this classification system and subsequent asthma morbidity during pregnancy. Objective: The objective of this study was to evaluate the relationship between asthma severity classification during pregnancy and gestational asthma exacerbations. Methods: Asthma severity was defined according to the 1993 classification, adjusted to include medication requirements, in a volunteer sample of 1739 pregnant asthmatic patients who were less than 26 weeks' gestation. Results: Initial asthma classification (mild, moderate, or severe) was significantly related to subsequent asthma morbidity during pregnancy (hospitalizations, unscheduled visits, corticosteroid requirements, and asthma symptoms during labor and delivery). Exacerbations during pregnancy occurred in 12.6% of patients initially classified as mild, 25.7% of patients classified as moderate, and 51.9% of patients classified as severe (P < .001). Asthma morbidity was similar, whether patients were classified as moderate or severe by symptoms and spirometry or by medication requirement. Thirty percent of initially mild patients were reclassified as moderate-severe during pregnancy, and 23% of the initially moderate-severe patients were reclassified as mild later in pregnancy; asthma morbidity in these patients changed accordingly. Conclusion: The National Asthma Education Program Working Group on Asthma and Pregnancy classification of asthma severity, adapted to include medication use, predicts subsequent asthma morbidity during pregnancy.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48202 USA; Johns Hopkins Univ, Dept Pulm Med, Baltimore, MD 21218 USA; George Washington Univ, Ctr Biostat, Washington, DC 20052 USA; Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA; Univ Tennessee, Dept Obstet & Gynecol, Knoxville, TN 37996 USA; Med Coll S Carolina, Dept Obstet & Gynecol, Columbia, SC 29208 USA; Univ Alabama, Dept Obstet & Gynecol, Tuscaloosa, AL 35487 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Obstet & Gynecol, Pittsburgh, PA 15260 USA; Wake Forest Univ, Dept Obstet & Gynecol, Winston Salem, NC 27109 USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH 45221 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Obstet & Gynecol, Philadelphia, PA 19107 USA; Univ So Calif, Dept Obstet & Gynecol, Los Angeles, CA 90089 USA; Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT 84112 USA; Miami Univ, Dept Obstet & Gynecol, Oxford, OH 45056 USA; Univ Oklahoma, Dept Obstet & Gynecol, Norman, OK 73019 USA; Univ Texas, Dept Obstet & Gynecol, San Antonio, TX USA; NICHHD, Bethesda, MD 20892 USA	Kaiser Permanente; Wayne State University; Johns Hopkins University; George Washington University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center; Medical University of South Carolina; University of Alabama System; University of Alabama Tuscaloosa; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University System of Ohio; University of Cincinnati; Jefferson University; University of Southern California; Utah System of Higher Education; University of Utah; University System of Ohio; Miami University; University of Oklahoma System; University of Oklahoma - Norman; University of Texas System; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.		/AAO-2076-2020; Varner, Michael/K-9890-2013	Varner, Michael/0000-0001-9455-3973; Wise, Robert/0000-0002-8353-2349; caritis, steve/0000-0002-2169-0712	NICHD NIH HHS [HD34116, HD27917, HD27889, HD27905, HD27915, HD19897, HD21410, HD21414, HD21434, HD27860, HD27861, HD34208, HD34136, HD34122, HD27869, HD27883] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027869, U10HD021410, U10HD027915, U10HD027917, U10HD034116, U10HD034208] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD027889, U01HD019897, U10HD027861, U01HD021410, U01HD021434, U10HD034122, U10HD021434, U10HD021414, U01HD021414, U10HD034136, U10HD027860, U10HD027905, U10HD027883] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Global Initiative for Asthma, 2002, NIH PUBL; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Juniper Elizabeth F., 1993, V7, P223; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NAT ASTHM ED PROG, 1993, NIH PUBL; *NAT ASTHM ED PROG, 1991, NIH PUBL; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188	10	193	200	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					283	288		10.1067/mai.2003.1516	http://dx.doi.org/10.1067/mai.2003.1516			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897733				2022-12-18	WOS:000184650600011
J	Cisternas, MG; Blanc, PD; Yen, IH; Katz, PP; Earnest, G; Eisner, MD; Shiboski, S; Yelin, EH				Cisternas, MG; Blanc, PD; Yen, IH; Katz, PP; Earnest, G; Eisner, MD; Shiboski, S; Yelin, EH			A comprehensive study of the direct and indirect costs of adult asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; direct costs; indirect costs; health care use; work losses	HEALTH-CARE UTILIZATION; SEVERITY; CHILDREN; DETERMINANTS; RISK	Background: Asthma is a common and costly health condition, but most estimates of its economic effect have relied on secondary sources with limited condition-specific detail. Objective: We sought to estimate the magnitude of direct and indirect costs of adult asthma from the perspective of society. Methods: We used cross-sectional survey data from an ongoing community-based panel study of 401 adults with asthma originally derived from random samples of northern California pulmonologists, allergist-immunologists, and family practitioners to assess health care use for asthma, to assess purchase of items to assist with asthma care, and to measure work and other productivity losses. Unit costs derived from public-use and proprietary data sources were then assigned to the survey items. Results: Total per-person annual costs of asthma averaged $4912, with direct and indirect costs accounting for $3180 (65%) and $1732 (35%), respectively. The largest components within direct costs were pharmaceuticals ($1605 [50%]), hospital admissions ($463 [15%]), and non-emergency department ambulatory visits ($342 [11%]). Within indirect costs, total cessation of work accounted for $1062 (61%), and the loss of entire work days among those remaining employed accounted for another $486 (28%). Total per-person costs were $2646, $4530, and $12,813 for persons self-reporting mild, moderate, and severe asthma, respectively (P < .0001, 1-way ANOVA). Conclusion: Asthma-related costs are substantial and are driven largely by pharmaceuticals and work loss.	Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA; MGC Data Serv, Carlsbad, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yelin, EH (corresponding author), Univ Calif San Francisco, Dept Biostat & Epidemiol, Box 0920, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH003480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010906] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 56538] Funding Source: Medline; NIEHS NIH HHS [R01 ES 10906] Funding Source: Medline; NIOSH CDC HHS [R01 OH 03480] Funding Source: Medline	NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS		*AG HLTH CAR QUAL, 1999, AG HLTH CAR QUAL RES; Awadh Behbehani N, 1999, Can Respir J, V6, P521; Birnbaum HG, 2002, J ALLERGY CLIN IMMUN, V109, P264, DOI 10.1067/mai.2002.121310; Blanc P, 2000, CHEST, V118, P564, DOI 10.1378/chest.118.2.564; Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; BLANC PD, 1999, ASTHMAS IMPACT SOC S, P55; *BUR CENS, 1992, 1990 CENS POP HOUS A; CAVAZOS G, 2000, REV ALERG MEX, V47, P96; Chew FT, 1999, AUST NZ J MED, V29, P228, DOI 10.1111/j.1445-5994.1999.tb00688.x; COHEN S, 1996, AHCPR PUBL; COHEN SB, 2000, AHRQ PUBLICATION; Dranove D, 1998, J HEALTH ECON, V17, P729, DOI 10.1016/S0167-6296(97)00045-3; DRUMMOND MF, 1997, METHODS EVALUATION H; Eisner MD, 1998, MED CARE, V36, P1567, DOI 10.1097/00005650-199811000-00006; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; FEENSTRA T, 1999, ANN M INT SOC TECH A, V15, P57; Fleiss JL, 1981, STAT METHODS RATES P; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Grupp-Phelan J, 2001, J ASTHMA, V38, P363, DOI 10.1081/JAS-100001492; Hoskins G, 2000, THORAX, V55, P19, DOI 10.1136/thorax.55.1.19; JANSONBJERKLIE S, 1992, HEART LUNG, V21, P265; KATZ P, 2002, AM J RESP CRIT CARE, V165, pA122; Kiivet RA, 2001, EUR J PUBLIC HEALTH, V11, P89, DOI 10.1093/eurpub/11.1.89; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Leigh JP, 2002, CHEST, V121, P264, DOI 10.1378/chest.121.1.264; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957, DOI 10.1016/S0091-6749(99)70075-8; Malone D C, 2000, Pharm Pract Manag Q, V20, P12; *MED EC COMP, 1999, 1999 RED BOOK; *MED LETT INC, 1996, MED LETT DRUGS THER, V38, P21; *MED LETT INC, 1998, MED LETT DRUGS THER, V40, P85; *MED LETT INC, 1994, MED LETT DRUGS THER, V36, P78; *MED LETT INC, 1997, MED LETT DRUGS THER, V39, P86; *MED LETT INC, 2000, MED LETT DRUGS THER, V42, P19; *MED LETT INC, 1999, MED LETT DRUGS THER, V41, P16; MELLIS CM, 1991, MED J AUSTRALIA, V155, P522, DOI 10.5694/j.1326-5377.1991.tb93888.x; Piecoro LT, 2001, HEALTH SERV RES, V36, P357; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; STOUPE K, 1999, J ASTHMA, V36, P645; Szucs TD, 2000, SCHWEIZ MED WSCHR, V130, P305; Ungar WJ, 2001, PEDIATR PULM, V32, P101, DOI 10.1002/ppul.1095; *US BUR CENS, 2002, STAT ABSTR US 2001; *US DEP LAB BUR LA, 1999, NAT COMP SURV OCC WA; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Weissflog D, 2001, DEUT MED WOCHENSCHR, V126, P803, DOI 10.1055/s-2001-15705; Yelin E, 2002, EUR RESPIR J, V19, P414, DOI 10.1183/09031936.02.00522001; 2001, HEALTHCARE CONSULTAN; 2002, MMWR MORB MORTAL WKL, V51, P1	52	193	195	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1212	1218		10.1067/mai.2003.1449	http://dx.doi.org/10.1067/mai.2003.1449			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	688FZ	12789219	Bronze			2022-12-18	WOS:000183424700007
J	BOCHNER, BS; SCHLEIMER, RP				BOCHNER, BS; SCHLEIMER, RP			THE ROLE OF ADHESION MOLECULES IN HUMAN EOSINOPHIL AND BASOPHIL RECRUITMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; INFLAMMATORY PROTEIN 1-ALPHA; PLATELET-ACTIVATING-FACTOR; LEUKOCYTE ADHESION; L-SELECTIN; TRANSENDOTHELIAL MIGRATION; POLYMORPHONUCLEAR LEUKOCYTES; NEUTROPHIL ADHESION; CHEMOTACTIC FACTORS; ALLERGIC REACTIONS				BOCHNER, BS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NHLBI NIH HHS [HL49545] Funding Source: Medline; NIAID NIH HHS [AI21036, AI27429] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027429] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; BAROODY FM, 1994, IN PRESS EUR ARCH OT; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BOCHNER BS, 1991, J IMMUNOL, V146, P2367; BOCHNER BS, 1992, FASEB J, V6, pA1435; BOCHNER BS, 1994, IN PRESS J ALLERGY C; BOCHNER BS, 1994, IN PRESS SAMTERS IMM; BOCHNER BS, 1990, LATE PHASE ALLERGIC, P221; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN KR, 1994, IN PRESS ARCH DERMAT; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P3783; COHNHEIM J, 1989, INFLAMMATION LECTURE; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DUNN CJ, 1984, EUR J RHEUMATOL INFL, V7, P80; EBISAWA M, 1992, J IMMUNOL, V149, P4021; EBISAWA M, 1993, J ALLERGY CLIN IMMUN, V91, P313; EBISAWA M, 1994, IN PRESS LEUKOCYTE T, V5; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GEORAS SN, 1993, BLOOD, V82, P2872; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HANSEL TT, 1992, CLIN EXP ALLERGY, V22, P345, DOI 10.1111/j.1365-2222.1992.tb03096.x; HASKARD DO, 1992, AM REV RESPIR DIS, V145, pS10, DOI 10.1164/ajrccm/145.2_Pt_2.S10; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HENOCQ E, 1986, LANCET, V1, P1378; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KNOL EF, 1993, J ALLERGY CLIN IMMUN, V91, P334; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V93, P183; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MACDONALD SM, 1993, ASTHMA, P99; MENGELERS HJJ, 1993, CLIN EXP ALLERGY, V23, P196, DOI 10.1111/j.1365-2222.1993.tb00882.x; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MOSER R, 1992, BLOOD, V79, P2937; MULLARKEY MF, 1994, J IMMUNOL, V152, P2033; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Schleimer R P, 1991, J Immunol, V147, P380; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SCHLEIMER RP, 1993, EOSINOPHILS ALLERGY, P99; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEHMI R, 1992, BLOOD, V79, P2952; SMITH CH, 1993, J IMMUNOL, V151, P3274; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUR S, 1993, ALLERGY PRINCIPLES P, P169; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANIMOTO Y, 1992, CLIN EXP ALLERGY, V22, P1020, DOI 10.1111/j.1365-2222.1992.tb03031.x; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TIDSWELL M, 1993, AM REV RESPIR DIS, V147, pA542; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; VADAS MA, 1993, EOSINOPHILS ALLERGY, P69; WALKER C, 1993, J IMMUNOL, V150, P4061; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, BLOOD, V79, P1836; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEGNER C D, 1991, American Review of Respiratory Disease, V143, pA418; WEGNER CD, 1992, CHEST, V101, pS34, DOI 10.1378/chest.101.3.34S; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEIN M, 1993, EUR RESPIR J, V6, P1239; WEIN M, 1994, J ALLERGY CLIN IMMUN, V93, P268; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; YAMADA T, 1993, J ALLERGY CLIN IMMUN, V91, P314; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	111	193	196	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				427	438		10.1016/0091-6749(94)90195-3	http://dx.doi.org/10.1016/0091-6749(94)90195-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083447				2022-12-18	WOS:A1994PG90700001
J	KUEHR, J; FRISCHER, T; MEINERT, R; BARTH, R; FORSTER, J; SCHRAUB, S; URBANEK, R; KARMAUS, W				KUEHR, J; FRISCHER, T; MEINERT, R; BARTH, R; FORSTER, J; SCHRAUB, S; URBANEK, R; KARMAUS, W			MITE ALLERGEN EXPOSURE IS A RISK FOR THE INCIDENCE OF SPECIFIC SENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DUST MITE; EXPOSURE; SENSITIZATION; INCIDENCE; CHILDHOOD; RISK FACTOR; POPULATION-BASED STUDY	DER-P-I; DERMATOPHAGOIDES-PTERONYSSINUS; ASTHMA; CHILDHOOD; CHILDREN	Background: Mite allergen exposure is essential for the process of specific allergic sensitization. However; it is not clear whether incidence of specific sensitization at school age depends on the level of mite antigen exposure. Therefore the relationship between mite allergen exposure and incidence of specific sensitization was investigated. Methods: Eighteen hundred twelve primary school children were enrolled in a population-based 2-year follow-up study. In three consecutive skin prick tests (SPTs), each 12 months apart, sensitization to Dermatophagoides pteronyssinus (Dpt) and sir non-Dpt allergens was ascertained. To assess exposure to Der p I between the first and second SPTs (period I) and the second and third SPTs (period II), the amount of antigen per gram of dust (taken from the children's mattresses was measured. By using the SPT reactions to Dpt as a basis, conversions after ''no wheal'' were classified as doubtful incidence (average yearly incidence = 6.7%) or definite incidence (average yearly incidence = 3.2%). Then with the use of multiple logistic regression, the risk of exposure to Der p I (medians: 1.4 mu g/gm in period L 1.6 mu g/gm in period II) was analyzed with adjustment being made for gender, low gestational age, parental atopy, and initial sensitization to non-Dpt allergens. Results: Regarding doubtful incidence, the analysis failed to identify a reliable cutoff point of exposure. For definite incidence, the Der p I exposure represents a significant risk in the total population, starting from a concentration of 9 mu g/gm. This effect is modified by an initial sensitization to non-Dpt allergens: for these children exposure to concentrations above 2 mu g/gm poses a significant risk, whereas for the population without other initial sensitizations, only an extremely high cutoff limit (> 80 mu g/gm) gains significance. Conclusion: Our data suggest that a concentration limit of 2 mu g Der p I antigen per grain of dust should be regarded as minimal avoidance level for primary prevention in children with sensitization to other inhalant allergens.	UNIV VIENNA,CHILDRENS HOSP,VIENNA,AUSTRIA; NORDIG,INST HLTH RES & PREVENT,HAMBURG,GERMANY	University of Vienna	KUEHR, J (corresponding author), UNIV FREIBURG,CHILDRENS HOSP,MATHILDENSTR 1,D-79106 FREIBURG,GERMANY.							ANDERSEN PK, 1988, STAT MED, V7, P661, DOI 10.1002/sim.4780070605; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; JUBLINDANNFELDT C, 1948, ACTA MED SCAND, V26, P563; KUEHR J, 1992, CLIN EXP ALLERGY, V22, P839, DOI 10.1111/j.1365-2222.1992.tb02829.x; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LAU S, 1988, N ENGL REG ALLERGY P, V9, P282; LIND P, 1988, J IMMUNOL, V140, P4256; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; 1990, P200 SAS I INC TECHN	18	193	196	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					44	52		10.1016/0091-6749(94)90070-1	http://dx.doi.org/10.1016/0091-6749(94)90070-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027498				2022-12-18	WOS:A1994NX39300007
J	Abonia, JP; Blanchard, C; Butz, BB; Rainey, HF; Collins, MH; Stringer, K; Putnam, PE; Rothenberg, ME				Abonia, J. Pablo; Blanchard, Carine; Butz, Bridget Buckmeier; Rainey, Heather F.; Collins, Margaret H.; Stringer, Keith; Putnam, Philip E.; Rothenberg, Marc E.			Involvement of mast cells in eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells/basophils; eosinophils; human	C-KIT RECEPTOR; GASTROESOPHAGEAL-REFLUX; GASTROINTESTINAL DISORDERS; ALLERGIC ESOPHAGITIS; PEDIATRIC-PATIENTS; MEDIATOR RELEASE; ELIMINATION DIET; SKIN PRICK; ACTIVATION; LIGAND	Background: Eosinophilic esophagitis (EE) is an emerging disorder with poorly understood pathogenesis. Objective: Whereas prior studies have primarily focused on the role of eosinophils in disease diagnosis and pathogenesis, this study investigates the involvement of mast cells. Methods: Total and degranulated mast cell counts were correlated to microarray and RT-PCR data to generate transcriptome expression profiles related to mast cell number and degranulation in patients with EE and healthy control subjects. Results: Esophageal mastocytosis and mast cell degranulation were readily apparent in patients with EE compared with control subjects (P<.01), as assessed by staining for total mast cells and the presence of extracellular mast cell tryptase (P<.01). Microarray analysis revealed that mast cell levels correlated with the dysregulation of 0.8% (301 genes) of the genome, which was partially distinct from the genes that correlated with tissue eosinophilia. The expression of transcripts for the mast cell proteases carboxypeptidase A3 and tryptase, but not chymase, correlated with mast cell levels and distinguished patients with EE from control subjects. Suprabasilar mast cell counts (P<.01) and degranulation (P<.01) were proportional with KIT ligand mRNA expression. Treatment of patients with EE with swallowed fluticasone propionate normalized levels of mast cells and the mast cell related transcriptome in responder patients. Conclusion: Herein we have identified local mastocytosis and mast cell degranulation in the esophagi of patients with EE; identified an esophageal mast cell associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, with carboxypeptidase A3 mRNA levels serving as the best mast cell surrogate marker; and provided evidence for the involvement of KIT ligand in the pathogenesis of EE. (J Allergy Clin Immunol 2010;126:140-9.)	[Abonia, J. Pablo; Blanchard, Carine; Butz, Bridget Buckmeier; Rainey, Heather F.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Putnam, Philip E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Pediat Gastroenterol & Nutr, Cincinnati, OH 45229 USA; [Collins, Margaret H.; Stringer, Keith] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Pathol & Lab Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org		Abonia, Juan/0000-0003-3788-6485	National Institutes of Health [12HD028827, AI057991, AI070235, AI045898, P30 DK078392, DK076893]; Food Allergy Project; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundations; National Institutes of Health; Ception Therapeutics; Children's Digestive Health; Nutrition Foundation; Food Allergy and Anaphylaxis Network; Dana Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045898, K08AI057991, U19AI070235, R01AI083450, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893, P30DK078392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Project; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundations; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ception Therapeutics; Children's Digestive Health; Nutrition Foundation; Food Allergy and Anaphylaxis Network; Dana Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grants 12HD028827 and AI057991 to J.P.A. and grants AI070235, AI045898, P30 DK078392, and DK076893; the Food Allergy Project; the Campaign Urging Research for Eosinophilic Disorders (CURED); and the Buckeye Foundations to M.E.R.; J. P. Abonia has received research support from the National Institutes of Health, Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. M. H. Collins has consulted for GlaxoSmithKline, Ception Therapeutics, and Meritage Pharma. M. E. Rothenberg has consulted for and is a speaker for Merck; has consulted for Centocor, Ception Therapeutics, Nycomed, Array Biopharma, Biocrystal Pharmaceuticals, Endo Pharmaceuticals, and Pieres A; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation; is on the medical advisory board of the American Partnership for Eosinophilic Disorders; and is on the executive council of the International Eosinophil Society. The rest of the authors have declared they have no conflict of interest.	Abonia JP, 2005, BLOOD, V105, P4308, DOI 10.1182/blood-2004-09-3578; Aceves SS, 2007, J CLIN GASTROENTEROL, V41, P252, DOI 10.1097/01.mcg.0000212639.52359.f1; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; BECKSTEAD JH, 1981, BLOOD, V57, P1088; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; COLUMBO M, 1992, J IMMUNOL, V149, P599; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Feldweg AM, 2003, EUR J IMMUNOL, V33, P2262, DOI 10.1002/eji.200323978; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Friend DS, 2000, J IMMUNOL, V165, P344, DOI 10.4049/jimmunol.165.1.344; GEISSLER EN, 1991, SOMAT CELL MOLEC GEN, V17, P207, DOI 10.1007/BF01232978; Gill R, 2007, AM J GASTROENTEROL, V102, P2281, DOI 10.1111/j.1572-0241.2007.01352.x; Hammerberg B, 2001, VET DERMATOL, V12, P339, DOI 10.1046/j.0959-4493.2001.00273.x; HOSACK DA, 2003, GENOME BIOL, V4, pP4, DOI DOI 10.1186/GB-2003-4-6-P4; Jyonouchi S, 2009, IMMUNOL ALLERGY CLIN, V29, P85, DOI 10.1016/j.iac.2008.09.008; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kirsch R, 2007, J PEDIATR GASTR NUTR, V44, P20, DOI 10.1097/MPG.0b013e31802c0d06; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; Lim JR, 2004, GASTROINTEST ENDOSC, V59, P835, DOI 10.1016/S0016-5107(04)00364-5; Lucendo AJ, 2007, AM J SURG PATHOL, V31, P598, DOI 10.1097/01.pas.0000213392.49698.8c; Lucendo AJ, 2009, PEDIAT ALLERG IMM-UK, V20, P512, DOI 10.1111/j.1399-3038.2008.00798.x; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; MURAKAMI M, 1992, NEUROBIOLOGY ESSENTI, V318, P27; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Pejler G, 2009, TRENDS IMMUNOL, V30, P401, DOI 10.1016/j.it.2009.04.008; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; Rolland AMGASAS, 2004, J PEDIATR GASTR NUTR, V39, P373, DOI 10.1097/00005176-200410000-00013; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; Sheth PD, 2003, BIOCHEM PHARMACOL, V66, P2251, DOI 10.1016/j.bcp.2003.08.002; Simon D, 2005, J ALLERGY CLIN IMMUN, V115, P1090, DOI 10.1016/j.jaci.2005.01.017; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; URATA H, 1991, J BIOL CHEM, V266, P17173; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	63	192	197	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					140	149		10.1016/j.jaci.2010.04.009	http://dx.doi.org/10.1016/j.jaci.2010.04.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20538331	Green Accepted, Bronze			2022-12-18	WOS:000280061800025
J	Barnes, KC				Barnes, Kathleen C.			An update on the genetics of atopic dermatitis: Scratching the surface in 2009	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; genetics; IgE-mediated response; innate immunity; skin barrier dysfunction; genetic association; gene-environment interaction; ethnicity	FILAGGRIN NULL MUTATIONS; INNATE IMMUNE-RESPONSE; OF-FUNCTION MUTATIONS; GENOME-WIDE; STAPHYLOCOCCUS-AUREUS; ICHTHYOSIS VULGARIS; LIPOPOLYSACCHARIDE RECEPTOR; SUSCEPTIBILITY LOCI; FUNCTION VARIANTS; CYTOKINE MILIEU	A genetic basis for atopic dermatitis (AD) has long been recognized. Historic documents allude to family history of disease as a risk factor. Before characterization of the human genome, heritability studies combined with family-based linkage studies supported the definition of AD as a complex trait in that interactions between genes and environmental factors and the interplay between multiple genes contribute to disease manifestation. A summary of more than 100 published reports on genetic association studies through mid-2009 implicates 81 genes, in 46 of which at least I positive association with AD has been demonstrated. Of these, the gene encoding filaggrin (FLG) has been most consistently replicated. Most candidate gene studies to date have focused on adaptive and innate immune response genes, but there is increasing interest in skin barrier dysfunction genes. This review examines the methods that have been used to identify susceptibility genes for AD and bow the underlying pathology of this disease has been used to select candidate genes. Current challenges and the potential effect of new technologies are discussed. (J Allergy Clin Immunol 2010;125:16-29.)	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu			National Institute of Health (National Institute of Allergy and Infectious Diseases) [HSN266200400029C]	National Institute of Health (National Institute of Allergy and Infectious Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Health (National Institute of Allergy and Infectious Diseases: HSN266200400029C).	Aijaz S, 2005, DEV CELL, V8, P777, DOI 10.1016/j.devcel.2005.03.003; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; BESNIER E, 1892, ANN DERMATOL SYPHIL, V3, P634; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Callard RE, 2007, TRENDS IMMUNOL, V28, P294, DOI 10.1016/j.it.2007.05.003; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chen QX, 2007, GENES IMMUN, V8, P439, DOI 10.1038/sj.gene.6364401; Christensen U, 2009, HUM GENET, V126, P549, DOI 10.1007/s00439-009-0692-z; Coca AF, 1934, J AMER MED ASSOC, V103, P1275, DOI 10.1001/jama.1934.02750430007002; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; de Jongh CM, 2008, BRIT J DERMATOL, V159, P621, DOI 10.1111/j.1365-2133.2008.08730.x; Diepgen TL, 1996, J INVEST DERMATOL, V106, P977, DOI 10.1111/1523-1747.ep12338475; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; DURIEUX JJ, 1994, EUR J IMMUNOL, V24, P2006, DOI 10.1002/eji.1830240911; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Ekelund E, 2008, ACTA DERM-VENEREOL, V88, P15, DOI 10.2340/00015555-0383; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Enomoto H, 2007, BMC DERMATOL, V7, DOI 10.1186/1471-5945-7-5; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Ferraris A, 2006, INFLAMM BOWEL DIS, V12, P355, DOI 10.1097/01.MIB.0000217338.23065.58; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; Gao L, 2007, J ALLERGY CLIN IMMUN, V119, P1111, DOI 10.1016/j.jaci.2007.03.019; Gayan J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-360; Gazouli M, 2006, SARCOIDOSIS VASC DIF, V23, P23; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Giardina E, 2008, DERMATOLOGY, V216, P83, DOI 10.1159/000109365; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Guilloud-Bataille M, 2008, HUM GENET, V122, P605, DOI 10.1007/s00439-007-0439-7; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HIRSCHHORN JN, 2005, NATURE REV GENETICS, V6, P108; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Janumpally SR, 2002, ARCH DERMATOL, V138, P634, DOI 10.1001/archderm.138.5.634; Kabesch M, 2009, THORAX, V64, P370, DOI 10.1136/thx.2008.105197; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; LABETA MO, 1993, EUR J IMMUNOL, V23, P2144, DOI 10.1002/eji.1830230915; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LARSEN FVS, 1985, ACTA DERM-VENEREOL, P159; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Levy H, 2005, J ALLERGY CLIN IMMUN, V115, P252, DOI 10.1016/j.jaci.2004.11.013; Lue ZR, 2009, J DERMATOL SCI, V54, P126, DOI 10.1016/j.jdermsci.2008.12.006; Matsushita I, 2002, BIOCHEM BIOPH RES CO, V291, P17, DOI 10.1006/bbrc.2002.6395; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MORGAN JK, 1953, OCCUP MED LONDON, V3, P274; Morris AP, 2006, AM J HUM GENET, V79, P679, DOI 10.1086/508264; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Raulet D. H., 2003, FUNDAMENTAL IMMUNOLO, P365; Ricci G, 2003, PEDIATR DERMATOL, V20, P389, DOI 10.1046/j.1525-1470.2003.20503.x; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sawada Norimasa, 2003, Medical Electron Microscopy, V36, P147, DOI 10.1007/s00795-003-0219-y; Schaffer N, 1966, J Asthma Res, V3, P189, DOI 10.3109/02770906609106918; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; Segat L, 2006, J MATERN-FETAL NEO M, V19, P13, DOI 10.1080/14767050500381123; Sherriff A, 2002, ARCH DIS CHILD, V87, P26, DOI 10.1136/adc.87.1.26; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith W. W., 1994, HIPPOCRATES; SNEDDON I B, 1951, Med Press, V226, P329; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Sugimoto K, 2006, DERMATOLOGY, V212, P26, DOI 10.1159/000089196; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Toulza E, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r107; Travers JB, 2001, J INVEST DERM SYMP P, V6, P225, DOI 10.1046/j.0022-202x.2001.00045.x; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Warner JA, 2009, BRIT J DERMATOL, V160, P183, DOI 10.1111/j.1365-2133.2008.08905.x; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014	106	192	203	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					16	29		10.1016/j.jaci.2009.11.008	http://dx.doi.org/10.1016/j.jaci.2009.11.008			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109730	Bronze, Green Accepted			2022-12-18	WOS:000273660500002
J	Eyerich, K; Pennino, D; Scarponi, C; Foerster, S; Nasorri, F; Behrendt, H; Ring, J; Traidl-Hoffmann, C; Albanesi, C; Cavani, A				Eyerich, Kilian; Pennino, Davide; Scarponi, Claudia; Foerster, Stefanie; Nasorri, Francesca; Behrendt, Heidrun; Ring, Johannes; Traidl-Hoffmann, Claudia; Albanesi, Cristina; Cavani, Andrea			IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema/dermatitis; T(H)17; IL-17; superantigen; defensin	PATCH TEST REACTIONS; ANTIMICROBIAL PEPTIDES; HUMAN KERATINOCYTES; DENDRITIC CELLS; BETA-DEFENSINS; TH17 CELLS; DERMATITIS; EXPRESSION; SUSCEPTIBILITY; SUPERANTIGENS	Background: Patients with atopic eczema (AE) regularly experience colonization with Staphylococcus aureus that is directly correlated with the severity of eczema. Recent studies show that an impaired IL-17 immune response results in diseases associated with chronic skin infections. Objective: We sought to elucidate the effect of IL-17 on antimicrobial immune responses in AE skin. Methods: T cells infiltrating atopy patch test (APT) reactions were characterized for IL-17 secretion to varying stimuli. IL-17-dependent induction of the antimicrobial peptide human beta-defensin 2 (HBD-2) in keratinocytes was investigated. Results: Approximately 10% of APT-infiltrating T cells secreted IL-17 after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation. Among these, 33% belonged to the newly characterized subtype T(H)2/IL-17. Despite the capacity to secrete IL-17, specific T-cell clones released only low amounts of IL-17 on cognate allergen stimulation, whereas IL-4, IFN-gamma, or both were efficiently induced. IL-17 secretion was not enhanced by IL-23, IL-1 beta, or IL-6 but was enhanced by the S aureus-derived superantigen staphylococcal enterotoxin B. Both healthy and AE keratinocytes upregulated HBD-2 in response to IL-17, but coexpressed IL-4/IL-13 partially inhibited this effect. fit vivo, additional application of staphylococcal enterotoxin B induced IL-17 in APT reactions, whereas IL-4, IFN-gamma, and IL-10 were marginally regulated. Induced IL-17 upregulated HBD-2 in human keratinocytes in vivo. Conclusion: IL-17-capable T cells, in particular T(H)2/IL-17 cells, infiltrate acute AE reactions. Although IL-17 secretion by specific T cells is tightly regulated, it can he triggered by bacteria-derived superantigens. The ineffective IL-17-dependent upregulation of HBD-2 in patients with AE is due to a partial inhibition by the type 2 microenvironment, which could partially explain why patients with AE do not clear S aureus. (J Allergy Clin Immunol 2009;123:59-66.)	[Eyerich, Kilian; Pennino, Davide; Scarponi, Claudia; Nasorri, Francesca; Albanesi, Cristina; Cavani, Andrea] IDIIRCCS, Immunol Lab, Via Monti Creta 104, I-00167 Rome, Italy; [Foerster, Stefanie; Behrendt, Heidrun; Traidl-Hoffmann, Claudia] TUM, ZAUM Ctr Allergy & Environm, Div Environm Dermatol & Allergy Helmholtz, Munich, Germany; [Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany	Technical University of Munich; Technical University of Munich	Eyerich, K (corresponding author), IDIIRCCS, Immunol Lab, Via Monti Creta 104, I-00167 Rome, Italy.	kilian.eyerich@gmx.de	Albanesi, Cristina/K-4699-2016; Pennino, Davide/D-7519-2013; Ring, Johannes/GLN-4341-2022	Albanesi, Cristina/0000-0002-7537-6833; Pennino, Davide/0000-0002-5834-1049; Ring, Johannes/0000-0001-8236-3152; Traidl-Hoffmann, Claudia/0000-0001-5085-5179	Bayerische Forschungsstiftung (BFS); European Community [UE-LSHB-CT-2005-018681]; Italian minister of health	Bayerische Forschungsstiftung (BFS); European Community(European Commission); Italian minister of health	K, Eyerich was supported by a grant of the "Bayerische Forschungsstiftung" (BFS). This work was supported by a grant of the European Community (UE-LSHB-CT-2005-018681) and by the Italian minister of health.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; ANDERNJONES MR, 2007, P NATL ACAD SCI USA, V104, P5556; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Eyerich K, 2008, INT ARCH ALLERGY IMM, V145, P213, DOI 10.1159/000109290; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Langer K, 2007, EXP DERMATOL, V16, P124, DOI 10.1111/j.1600-0625.2006.00523.x; Leung Alexander K C, 2007, Adv Pediatr, V54, P241, DOI 10.1016/j.yapd.2007.03.013; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mempel M, 2003, EUR J CLIN MICROBIOL, V22, P306, DOI 10.1007/s10096-003-0928-0; Midorikawa K, 2003, INFECT IMMUN, V71, P3730, DOI 10.1128/IAI.71.7.3730-3739.2003; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379, DOI 10.1159/000237609; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	33	192	198	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					59	66		10.1016/j.jaci.2008.10.031	http://dx.doi.org/10.1016/j.jaci.2008.10.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19056110				2022-12-18	WOS:000262793900009
J	Stoloff, SW; Stempel, DA; Meyer, J; Stanford, RH; Rosenzweig, JRC				Stoloff, SW; Stempel, DA; Meyer, J; Stanford, RH; Rosenzweig, JRC			Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; fluticasone propionate; salmeterol; montelukast; refill persistence; long-acting bronchodilator; oral leukotriene modifier; inhaled corticosteroid; adherence	DOUBLE-BLIND; CHILDHOOD ASTHMA; ELDERLY-PATIENTS; MU-G; RISK; CORTICOSTEROIDS; BUDESONIDE; HOSPITALIZATION; READMISSION; COMBINATION	Background: Improved adherence to inhaled corticosteroids (ICSs) has also been associated with decreased asthma-associated morbidity and mortality. Objective: The purpose of this study was to assess patient medication refill persistence with fluticasone propionate (FP) and salmeterol combination in a single inhaler (FSC), FP and salmeterol in combination from 2 separate inhalers, FP and montelukast in combination, FP as monotherapy, and montelukast as monotherapy. Methods: We performed a retrospective, observational, 24-month (12-month baseline and 12-month follow-up) database study using medical and pharmacy claims from a large managed care organization. We identified 2511 subjects 12 years of age or older with a claim for asthma (International Classification of Diseases, Ninth Revision: 493.XX): 563 patients receiving FSC, 224 receiving FP plus salmeterol, 75 receiving FP plus montelukast, 798 receiving FP only, and 776 receiving montelukast only. Refill rates of FP, as a measure of adherence, were compared for each FP-containing cohort during the 12-month follow-up period. In addition, refill rates were compared between FSC, an inhaler, and montelukast, an oral medication. Results: Twelve-month baseline asthma medication use and patient demographics were comparable among cohorts. Patients in the FSC cohort obtained significantly more refills compared with the number of FP refills in the other FP-containing cohorts (4.06 for FSC vs 2.35 for FP plus salmeterol, 1.83 for FP plus montelukast, and 2.27 for FP alone) over the 12-month follow-up period. In addition, patients taking FSC had similar refill persistence compared with patients taking the oral leukotriene modifier montelukast (4.51). Conclusion: FSC might increase ICS refill persistence compared with FP alone in a single inhaler, FP in combination with salmeterol from 2 separate inhalers, and FP in combination with montelukast. In addition, FSC in a dry powdered inhaler had similar refill rates compared with an oral asthma agent, montelukast. Use of a single inhaler containing both an ICS (FP) and a long-acting bronchodilator (salmeterol) might increase the likelihood that patients are getting more optimal ICS therapy, as well as the benefits from the long-acting bronchodilator, with patient adherence comparable to an oral agent.	Univ Nevada, Sch Med, Reno, NV 89557 USA; Informed NW, Seattle, WA 98195 USA; Univ Washington, Seattle, WA 98195 USA; Ingenix Inc, Eden Prairie, Res Triangle Pk, NC USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Washington; University of Washington Seattle; GlaxoSmithKline	Stoloff, SW (corresponding author), 1200 N Mt St Suite 220, Carson City, NV 89703 USA.							Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; Balkrishnan R, 2000, CLIN THER, V22, P452, DOI 10.1016/S0149-2918(00)89013-X; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; Calhoun WJ, 2001, AM J RESP CRIT CARE, V164, P759, DOI 10.1164/ajrccm.164.5.2012124; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Ducharme FM, 2003, BMJ-BRIT MED J, V326, P621, DOI 10.1136/bmj.326.7390.621; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; Global Initiative for Asthma, 2002, NIH PUBL; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; Gray SL, 2001, ANN PHARMACOTHER, V35, P539, DOI 10.1345/aph.10295; Johnson FR, 2002, VALUE HEALTH, V5, P62; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kiortsis DN, 2000, J CLIN PHARM THER, V25, P445, DOI 10.1046/j.1365-2710.2000.00315.x; Lanes SF, 2002, THORAX, V57, P683, DOI 10.1136/thorax.57.8.683; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; *NAEPP, 2002, NIH PUBL; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; Nelson HS, 2001, J ALLERGY CLIN IMMUN, V107, P397, DOI 10.1067/mai.2001.112939; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Price JF, 1997, PEDIATR PULM, V24, P178; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; Ringdal N, 2003, RESP MED, V97, P234, DOI 10.1053/rmed.2003.1436; Ringdal N, 2002, RESP MED, V96, P851, DOI 10.1053/rmed.2002.1416; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Sin DD, 2002, ARCH INTERN MED, V162, P1591, DOI 10.1001/archinte.162.14.1591; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3	40	192	193	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					245	251		10.1016/j.jaci.2003.10.011	http://dx.doi.org/10.1016/j.jaci.2003.10.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767437				2022-12-18	WOS:000188885700010
J	Bielory, L				Bielory, L			Allergic and immunologic disorders of the eye. Part II: Ocular allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						ocular allergy; conjunctiva; seasonal allergic conjunctivitis; perennial allergic conjunctivitis; atopic keratoconjunctivitis; giant papillary conjunctivitis; vernal keratoconjunctivitis	GIANT PAPILLARY CONJUNCTIVITIS; MAJOR BASIC-PROTEIN; 2-PERCENT OPHTHALMIC SOLUTION; EOSINOPHIL CATIONIC PROTEIN; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; LATE-PHASE REACTION; QUALITY-OF-LIFE; NEDOCROMIL SODIUM; DOUBLE-BLIND; ATOPIC-DERMATITIS	Allergy affects more than 15% of the world population, and some studies have shown that up 30% of the US population has some form of allergy. Most of these patients have various target organs for their allergies, and most have ocular involvement, The ocular component may be the most prominent and sometimes disabling feature of their allergy, Some are affected for only a few weeks to months, whereas others have symptoms that last throughout the year, The seasonal forms may present to clinical allergists, whereas the more chronic forms may present to ophthalmologists. Thus, in the second: of this 2-part review series (Part I: Ocular Immunology appeared in the November issue of the Journal), an overview is provided of the spectrum of ocular allergy that ranges from acute seasonal allergic conjunctivitis to chronic variants of atopic keratoconjunctivitis. With a better understanding of the immunologic mechanisms, we now can develop better treatment approaches and design further research in intervention of allergic eye diseases.	Univ Med & Dent New Jersey, Asthma & Allergy Res Ctr, New Jersey Med Sch, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bielory, L (corresponding author), Univ Med & Dent New Jersey, Asthma & Allergy Res Ctr, New Jersey Med Sch, 90 Bergen St,DOC Suite 4700, Newark, NJ 07103 USA.							ABELSON MB, 1980, OPHTHALMOLOGY, V87, P812; ABELSON MB, 1981, ARCH OPHTHALMOL-CHIC, V99, P302; Abelson MB, 1998, ANN ALLERG ASTHMA IM, V81, P211, DOI 10.1016/S1081-1206(10)62814-1; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P520, DOI 10.1001/archopht.1990.01070060068051; Abelson MB, 1998, AM J OPHTHALMOL, V125, P797, DOI 10.1016/S0002-9394(98)00044-0; Akman A, 1998, EYE, V12, P291, DOI 10.1038/eye.1998.67; ALLANSMITH MR, 1988, INT OPHTHALMOL CLIN, V28, P309, DOI 10.1097/00004397-198802840-00010; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; AMEMIYA T, 1980, OPHTHALMOLOGICA, V180, P129, DOI 10.1159/000308965; ARRIAGA F, 1990, ALLERGY, V45, P552, DOI 10.1111/j.1398-9995.1990.tb00531.x; Avunduk AM, 1997, EXP EYE RES, V65, P803, DOI 10.1006/exer.1997.0398; AZEVEDO M, 1991, CLIN EXP ALLERGY, V21, P689, DOI 10.1111/j.1365-2222.1991.tb03197.x; BALLAS Z, 1993, SURV OPHTHALMOL, V38, P141, DOI 10.1016/0039-6257(93)90038-9; Beetham WP, 1940, ARCH OPHTHALMOL-CHIC, V24, P21; BENEZRA D, 1986, AM J OPHTHALMOL, V101, P278, DOI 10.1016/0002-9394(86)90819-6; BISHOP K, 1990, Investigative Ophthalmology and Visual Science, V31, P487; BLEIK JH, 1991, OPHTHALMOLOGY, V98, P1679; BLOCHMICHEL E, 1990, REV FR ALLERGOL, V30, P163, DOI 10.1016/S0335-7457(05)80231-X; BLUMENTHAL M, 1992, AM J OPHTHALMOL, V113, P56, DOI 10.1016/S0002-9394(14)75754-X; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; Bonini S, 1997, OPHTHALMOLOGY, V104, P849, DOI 10.1016/S0161-6420(97)30223-1; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; Bonini S, 1993, Ocul Immunol Inflamm, V1, P323, DOI 10.3109/09273949309057059; BONNET M, 1985, J FR OPHTALMOL, V8, P573; Bourcier T, 1998, J FR OPHTALMOL, V21, P209; BRUNSTING LA, 1955, ARCH DERMATOL, V72, P237, DOI 10.1001/archderm.1955.03730330017003; CARLSON AN, 1987, AM J OPHTHALMOL, V104, P437, DOI 10.1016/0002-9394(87)90249-2; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; COHEN GA, 1985, ANN ALLERGY, V55, P38; COLES RS, 1952, AMA ARCH OPHTHALMOL, V48, P30; COPEMAN PWM, 1965, BRIT MED J, V2, P977, DOI 10.1136/bmj.2.5468.977; Coursaux G, 1989, Bull Soc Ophtalmol Fr, V89, P1371; DART JKG, 1986, T OPHTHAL SOC UK, V105, P513; Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; Dell SJ, 1997, AM J OPHTHALMOL, V123, P791, DOI 10.1016/S0002-9394(14)71128-6; Denis D, 1998, BRIT J OPHTHALMOL, V82, P1135, DOI 10.1136/bjo.82.10.1135; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; DICK AD, 1993, BRIT J OPHTHALMOL, V77, P171, DOI 10.1136/bjo.77.3.171; Dogru M, 1999, JPN J OPHTHALMOL, V43, P53, DOI 10.1016/S0021-5155(98)00061-6; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; DONSHIK PC, 1991, INT OPHTHALMOL CLIN, V31, P133, DOI 10.1097/00004397-199103120-00015; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DRIEBE WT, 1989, SURV OPHTHALMOL, V34, P44, DOI 10.1016/0039-6257(89)90128-8; Dua H S, 1994, Ocul Immunol Inflamm, V2, P29, DOI 10.3109/09273949409057799; DUNN JP, 1990, CORNEA, V9, P357; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; EASTY D, 1975, T OPHTHAL SOC UK, V95, P267; ELGEBALY SA, 1991, INVEST OPHTH VIS SCI, V32, P208; Ellis AK, 1999, ANN ALLERG ASTHMA IM, V83, P33, DOI 10.1016/S1081-1206(10)63510-7; FLOYD R, 1988, Investigative Ophthalmology and Visual Science, V29, P45; FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; FRIEDLAENDER MH, 1991, ANN ALLERGY, V67, P5; Friedlaender MH, 1997, AM J OPHTHALMOL, V123, P455, DOI 10.1016/S0002-9394(14)70171-0; FRIEDLAENDER MH, 2000, IN PRESS OPHTHALMOLO; Fukagawa K, 2000, INT ARCH ALLERGY IMM, V121, P144, DOI 10.1159/000024310; GARRITY JA, 1984, CAN J OPHTHALMOL, V19, P21; GEORGE M A, 1990, Investigative Ophthalmology and Visual Science, V31, P63; Goldberg A, 1998, J ALLERGY CLIN IMMUN, V102, P210, DOI 10.1016/S0091-6749(98)70088-0; GONZALEZ JP, 1987, DRUGS, V34, P560, DOI 10.2165/00003495-198734050-00004; HALLBERG CK, 1994, INVEST OPHTHALMOL VI, V35; HEIDEMANN DG, 1993, CORNEA, V12, P78, DOI 10.1097/00003226-199301000-00014; HENRIQUEZ AS, 1979, ARCH OPHTHALMOL-CHIC, V97, P473; HIRSCH SR, 1988, J ALLERGY CLIN IMMUN, V81, P173, DOI 10.1016/0091-6749(88)90257-6; HJEM A, 2000, CLIN EXP ALLERGY, V30, P521; HoangXuan T, 1997, OPHTHALMOLOGY, V104, P1300, DOI 10.1016/S0161-6420(97)30144-4; HOGAN MJ, 1953, AM J OPHTHALMOL, V36, P937, DOI 10.1016/0002-9394(53)92176-X; HOGAN MJ, 1952, T AM OPHTHAL SOC, V50, P265; Howes JF, 2000, PHARMAZIE, V55, P178; HURLBUT WB, 1954, AMA ARCH OPHTHALMOL, V52, P852; HYAMS SW, 1975, J PEDIATR OPHTHALMOL, V12, P116; INGRAM RM, 1965, BRIT J OPHTHALMOL, V49, P96, DOI 10.1136/bjo.49.2.96; IRANI AMA, 1990, J ALLERGY CLIN IMMUN, V86, P34, DOI 10.1016/S0091-6749(05)80120-4; Irkec M, 1995, Ocul Immunol Inflamm, V3, P107, DOI 10.3109/09273949509085038; Irkec MT, 1999, OCUL IMMUNOL INFLAMM, V7, P35, DOI 10.1076/ocii.7.1.35.8107; Ito Yukiko, 1997, Auris Nasus Larynx, V24, P163, DOI 10.1016/S0385-8146(96)00028-4; Jacq PL, 1997, J FR OPHTALMOL, V20, P97; JARMOSZUK I, 1988, J ALLERGY CLIN IMMUN, V81, P174, DOI 10.1016/0091-6749(88)90258-8; JOHNSON HG, 1978, INT ARCH ALLER A IMM, V56, P416, DOI 10.1159/000232051; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; KAREL I, 1965, ACTA DERM-VENEREOL, V45, P381; Keane-Myers AM, 1999, INVEST OPHTH VIS SCI, V40, P3041; KIMATA H, 1991, CLIN EXP IMMUNOL, V84, P395; Koizumi T, 1995, Ocul Immunol Inflamm, V3, P113, DOI 10.3109/09273949509085039; KOMERUP T, 1959, ACTA OPHTHALMOL, V37, P508; Lambiase A, 1998, INVEST OPHTH VIS SCI, V39, P1272; LEINO M, 1990, ANN ALLERGY, V64, P398; Leino M., 1993, OCUL IMMUNOL INFLAMM, V1, P21; Leonardi A, 2000, AM J OPHTHALMOL, V129, P151, DOI 10.1016/S0002-9394(99)00295-0; LEONARDI A, 1990, OPHTHALMIC RES, V22, P209, DOI 10.1159/000267025; LEONARDI A, 1990, OPHTHALMIC RES, V22, P95, DOI 10.1159/000267007; Leonardi A, 1997, BRIT J OPHTHALMOL, V81, P23, DOI 10.1136/bjo.81.1.23; LEONARDI A, 1995, ALLERGY, V50, P610, DOI 10.1111/j.1398-9995.1995.tb01209.x; LEYSEN JE, 1986, DRUG DEVELOP RES, V8, P119, DOI 10.1002/ddr.430080115; LOH RKS, 1994, J EXP MED, V180, P663, DOI 10.1084/jem.180.2.663; MAGGI E, 1991, J IMMUNOL, V146, P1169; Magone MT, 2000, J ALLERGY CLIN IMMUN, V105, P299, DOI 10.1016/S0091-6749(00)90080-0; MARRACHE F, 1978, REV FR ALLERGOL, V18, P151, DOI 10.1016/S0335-7457(78)80018-5; McNeely W, 1998, DRUGS, V56, P91, DOI 10.2165/00003495-199856010-00011; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MELAMED J, 1994, ANN ALLERGY, V73, P57; Metz DP, 1997, J ALLERGY CLIN IMMUN, V100, P817, DOI 10.1016/S0091-6749(97)70279-3; Montan PG, 1999, ACTA OPHTHALMOL SCAN, V77, P559; Montan PG, 1996, BRIT J OPHTHALMOL, V80, P556, DOI 10.1136/bjo.80.6.556; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nimmagadda S R, 1999, Pediatr Rev, V20, P111; Noon L, 1911, LANCET, V1, P1572; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; OSHINSKIE L, 1982, J AM OPTOM ASSOC, V53, P889; PECOUD A, 1987, INT ARCH ALLER A IMM, V82, P541, DOI 10.1159/000234274; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; PLEYER U, 1993, INVEST OPHTH VIS SCI, V34, P2737; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; RICH LF, 1985, INT OPHTHALMOL CLIN, V25, P61, DOI 10.1097/00004397-198502510-00005; ROBIN JB, 1987, ARCH OPHTHALMOL-CHIC, V105, P619; ROMAGNANI S, 1991, INT ARCH ALLER A IMM, V94, P133, DOI 10.1159/000235344; SAIGA T, 1991, INVEST OPHTHALMOL VI, V32; Sall K, 2000, OPHTHALMOLOGY, V107, P631, DOI 10.1016/S0161-6420(99)00176-1; Sasabe Tetsuo, 1997, Nippon Ganka Gakkai Zasshi, V101, P389; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUDEL P, 1985, Z HAUTKRANKHEITEN, V60, P479; Secchi A, 1995, Ocul Immunol Inflamm, V3, P23, DOI 10.3109/09273949509057807; SECCHI AG, 1990, AM J OPHTHALMOL, V110, P641, DOI 10.1016/S0002-9394(14)77061-8; Sharif NA, 1996, J PHARMACOL EXP THER, V278, P1252; SHARIF NA, 1995, INVEST OPHTH VIS SCI, V36, pS135; SHARIF NA, 1996, INVEST OPHTH VIS SCI, V37, pS1027; SMITH L M, 1989, Investigative Ophthalmology and Visual Science, V30, P502; SORKIN EM, 1986, DRUGS, V31, P131, DOI 10.2165/00003495-198631020-00003; SPECTOR SL, 1994, J ALLERGY CLIN IMMUN, V94, P134, DOI 10.1016/0091-6749(94)90081-7; SRINIVASAN BD, 1979, ARCH OPHTHALMOL-CHIC, V97, P892; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; STENSON SM, 1987, CONTACT LENSES, P215; STOCKWELL A, 1988, Investigative Ophthalmology and Visual Science, V29, P229; Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336; SUGAR A, 1981, AM J OPHTHALMOL, V92, P368; Tabbara KF, 1999, CAN J OPHTHALMOL, V34, P88; TAKANO T, 1992, ACTA SOC OPHTHALMOL, V96, P834; TANAKA H, 1987, TRANSPLANT P, V19, P11; Taniguchi Hiroko, 1999, Journal of Dermatology (Tokyo), V26, P658; Tauber J, 1998, J OCUL PHARMACOL TH, V14, P137, DOI 10.1089/jop.1998.14.137; TINKELMAN DG, 1993, SURV OPHTHALMOL, V38, P133, DOI 10.1016/0039-6257(93)90037-8; Tomioka H, 1979, Monogr Allergy, V14, P313; Toshitani A, 1999, J DERMATOL SCI, V19, P134, DOI 10.1016/S0923-1811(98)00056-5; TRIPATHI PC, 1992, INVEST OPHTH VIS SCI, V33, P121; TROCME SD, 1993, AM J OPHTHALMOL, V115, P640, DOI 10.1016/S0002-9394(14)71463-1; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57, DOI 10.1016/S0002-9394(14)73261-1; TROCME SD, 1991, INVEST OPHTH VIS SCI, V32, P1161; TROCME SD, 1988, CURR EYE RES, V7, P437, DOI 10.3109/02713688809031795; TROCME SD, 1994, INVEST OPHTH VIS SCI, V35, P3051; TUFT SJ, 1991, OPHTHALMOLOGY, V98, P150; TUFT SJ, 1992, OPHTHALMOLOGY, V99, P180; Uchio E, 1999, ALLERGY, V54, P135, DOI 10.1034/j.1398-9995.1999.00738.x; Uchio E, 1998, BRIT J OPHTHALMOL, V82, P82, DOI 10.1136/bjo.82.1.82; Uchio E, 2000, CLIN EXP ALLERGY, V30, P103; UDELL IJ, 1981, AM J OPHTHALMOL, V92, P824, DOI 10.1016/S0002-9394(14)75637-5; UEHARA M, 1985, DERMATOLOGICA, V170, P180, DOI 10.1159/000249527; Van Bijsterveld O P, 1994, Ocul Immunol Inflamm, V2, P177, DOI 10.3109/09273949409057074; VANBIJSTERVELD OP, 1986, KLIN MONATSBL AUGENH, V188, P625, DOI 10.1055/s-2008-1050733; Verin P, 1998, CLIN EXP ALLERGY, V28, P44; VERSTAPPEN AA, 1988, ALCON REPORT, P1287; VERSURA P, 1988, CURR EYE RES, V7, P277, DOI 10.3109/02713688809047033; VRABEC TR, 1992, AUTOIMMUNITY, V12, P175, DOI 10.3109/08916939209148457; WEEKE ER, 1987, MONOGR ALLERGY, V21, P1; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; WESTON J H, 1981, Investigative Ophthalmology and Visual Science, V20, P32; Whitcup SM, 1999, CLIN IMMUNOL, V93, P107, DOI 10.1006/clim.1999.4775; Whitcup SM, 1996, INVEST OPHTH VIS SCI, V37, P2686; WOODWARD DF, 1995, J ALLERGY CLIN IMMUN, V95, P360; Yanni JM, 1999, ARCH OPHTHALMOL-CHIC, V117, P643; Yanni JM, 1997, ANN ALLERG ASTHMA IM, V79, P541, DOI 10.1016/S1081-1206(10)63063-3; Yokoi K, 1998, BRIT J OPHTHALMOL, V82, P797, DOI 10.1136/bjo.82.7.797; Yoshida A, 1997, BRIT J OPHTHALMOL, V81, P402, DOI 10.1136/bjo.81.5.402; ZUBLER P, 1988, J ALLERGY CLIN IMMUN, V82, P590	177	192	208	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1019	1032		10.1067/mai.2000.111238	http://dx.doi.org/10.1067/mai.2000.111238			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112882				2022-12-18	WOS:000165930300002
J	GWALTNEY, JM; SCHELD, WM; SANDE, MA; SYDNOR, A				GWALTNEY, JM; SCHELD, WM; SANDE, MA; SYDNOR, A			THE MICROBIAL ETIOLOGY AND ANTIMICROBIAL THERAPY OF ADULTS WITH ACUTE COMMUNITY-ACQUIRED SINUSITIS - A 15-YEAR EXPERIENCE AT THE UNIVERSITY-OF-VIRGINIA AND REVIEW OF OTHER SELECTED STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		ACUTE SINUSITIS; MICROBIAL ETIOLOGY; ANTIMICROBIAL THERAPY	ACUTE MAXILLARY SINUSITIS; CEFACLOR; SINUSES	Pretreatment sinus puncture was performed on 339 patients with acute community-acquired sinusitis (ACAS) between 1975 and 1990. Bacterial species recovered in titers of greater-than-or-equal-to 10(4) colony-forming units per milliliter (CFU/ml) from 383 sinus aspirates included Streptococcus pneumoniae, 92 (41%); Haemophilus influenzae, 79 (35%); anaerobes, 17 (7%); streptococcal species, 16 (7%); Moraxella catarrhalis, 8 (4%); Staphylococcus aureus, 7 (33%); and other, 8 (4%). Viruses (rhinovirus, parainfluenza virus, and influenza virus) and fungi (Aspergillus, zygomycoses, Phaeohyphomycis, Pseudallescheria, and Hyalohyphomycis) have also been reported to cause ACAS. Posttreatment sinus puncture was performed on 220 of the 339 patients in six studies to evaluate efficacy of selected antimicrobial agents in producing bacteriologic cure. Ampicillin, 500 mg four times daily; amoxicillin, 500 mg three times daily; trimethoprim-sulfamethoxazole, twice a day; cefaclor, 500 mg four times daily: bacampicillin, 800 mg twice a day; cyclacillin, 500 mg three times a day; cefuroxime axetil, 250 mg twice daily; amoxicillin-clavulanate, 500/125 three times daily; and loracarbef 400 mg twice daily, given in 10-day courses, produced bacteriologic cure in more than 90% of patients. Early studies were done before beta-lactamase-producing strains of H. influenzae were a frequent cause of ACAS in Charlottesville. Management of therapeutic failures is a difficult problem for which diagnostic and therapeutic sinus puncture and lavage, prolonged antimicrobial therapy, steroid therapy, and evaluation of allergy, immunodeficiency, and surgically correctable lesions of the osteomeatal complex are recommended.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center	GWALTNEY, JM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908, USA.							AVIV J, 1990, ARCH OTOLARYNGOL, V116, P210; AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; BJORKWALL T, 1950, ACTA OTO-LARYNGOL, V83, P33; CARENFELT C, 1990, ACTA OTO-LARYNGOL, V110, P128, DOI 10.3109/00016489009122527; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FARR B, 1983, B NEW YORK ACAD MED, V59, P477; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; GWALTNEY JM, 1983, AM J OTOLARYNG, V4, P422, DOI 10.1016/S0196-0709(83)80053-2; GWALTNEY JM, 1978, CURR CHEMOTHER, P120; GWALTNEY JM, 1980, J RESPIR DIS, V1, P40; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, P1919; KARMA P, 1979, ARCH OTOLARYNGOL, V105, P386; LEW D, 1983, NEW ENGL J MED, V309, P1149, DOI 10.1056/NEJM198311103091904; MORGAN MA, 1984, AM J CLIN PATHOL, V82, P597, DOI 10.1093/ajcp/82.5.597; MORRISS FH, 1970, AM J DIS CHILD, V119, P357, DOI 10.1001/archpedi.1970.02100050359017; PADHYE AA, 1986, J CLIN MICROBIOL, V24, P245, DOI 10.1128/JCM.24.2.245-249.1986; RANTANEN T, 1973, ACTA OTO-LARYNGOL, V76, P58, DOI 10.3109/00016487309121483; SCHELD WM, 1986, ANTIMICROB AGENTS CH, V30, P350, DOI 10.1128/AAC.30.3.350; SHAPIRO ED, 1982, ANN OTO RHINOL LARYN, V91, P150, DOI 10.1177/000348948209100205; SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430; SYDNOR T A JR, 1992, Ear Nose and Throat Journal, V71, P225; TURNER BW, IN PRESS J ALLERGY C; URDAL KNUT, 1949, ACTA OTO LARYNGOL [STOCKHOLM], V37, P20, DOI 10.3109/00016484909120210; [No title captured]	27	192	196	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			457	462		10.1016/0091-6749(92)90169-3	http://dx.doi.org/10.1016/0091-6749(92)90169-3			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527337				2022-12-18	WOS:A1992JP52100010
J	Jones, SM; Sicherer, SH; Burks, AW; Leung, DYM; Lindblad, RW; Dawson, P; Henning, AK; Berin, MC; Chiang, D; Vickery, BP; Pesek, RD; Cho, CB; Davidson, WF; Plaut, M; Sampson, HA; Wood, RA				Jones, Stacie M.; Sicherer, Scott H.; Burks, A. Wesley; Leung, Donald Y. M.; Lindblad, Robert W.; Dawson, Peter; Henning, Alice K.; Berin, M. Cecilia; Chiang, David; Vickery, Brian P.; Pesek, Robbie D.; Cho, Christine B.; Davidson, Wendy F.; Plaut, Marshall; Sampson, Hugh A.; Wood, Robert A.		Consortium Food Allergy Res	Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut hypersensitivity; food allergy; immunotherapy; IgE; desensitization; epicutaneous	ORAL IMMUNOTHERAPY; DOUBLE-BLIND; FOOD ALLERGY; SUSTAINED UNRESPONSIVENESS; SUBLINGUAL IMMUNOTHERAPY; IMPACT; CELLS; DESENSITIZATION; ASTHMA; SAFETY	Background: Peanut allergy is common, life-threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment. Objective: We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy. Methods: In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 mu g (VP100; n = 24) or Viaskin Peanut 250 mu g (VP250; n = 25; DBV Technologies, Montrouge, France). The primary outcome was treatment success after 52 weeks, which was defined as passing a 5044-mg protein oral food challenge or achieving a 10-fold or greater increase in successfully consumed dose from baseline to week 52. Adverse reactions and mechanistic changes were assessed. Results: At week 52, treatment success was achieved in 3 (12%) placebo-treated participants, 11 (46%) VP100 participants, and 12 (48%) VP250 participants (P = .005 and P = .003, respectively, compared with placebo; VP100 vs VP250, P = .48). Median change in successfully consumed doses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003). Treatment success was higher among younger children (P = .03; age, 4-11 vs >11 years). Overall, 14.4% of placebo doses and 79.8% of VP100 and VP250 doses resulted in reactions, predominantly local patch-site and mild reactions (P = .003). Increases in peanut-specific IgG(4) levels and IgG(4)/IgE ratios were observed in peanut EPIT-treated participants, along with trends toward reduced basophil activation and peanut-specific T(H)2 cytokines. Conclusions: Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children. This, when coupled with a high adherence and retention rate and	[Jones, Stacie M.; Pesek, Robbie D.] Univ Arkansas Med Sci, Dept Pediat, 13 Childrens Way,Slot 512-13, Little Rock, AR 72205 USA; [Jones, Stacie M.; Pesek, Robbie D.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Sicherer, Scott H.; Berin, M. Cecilia; Chiang, David; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Burks, A. Wesley; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Lindblad, Robert W.; Dawson, Peter; Henning, Alice K.; Cho, Christine B.] EMMES Corp, Rockville, MD USA; [Davidson, Wendy F.; Plaut, Marshall] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; National Jewish Health; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Jones, SM (corresponding author), Univ Arkansas Med Sci, Dept Pediat, 13 Childrens Way,Slot 512-13, Little Rock, AR 72205 USA.	JonesStacieM@uams.edu		Vickery, Brian/0000-0002-7243-5543; berin, cecilia/0000-0002-9051-9249	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; NIH/National Center for Advancing Translational Sciences (NCATS) from the National Center for Research Resources (NCRR) of the NIH [UL1 TR0001082, UL1 TR000067, UL1 TR000039, UL1 TR000083, UL1 TR000424]	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Advancing Translational Sciences (NCATS) from the National Center for Research Resources (NCRR) of the NIH	This study is registered with ClinicalTrials.gov with ID NCT01904604. The study is supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants U19AI066738 and U01AI066560. The project was also supported by NIH/National Center for Advancing Translational Sciences (NCATS) grant nos. UL1 TR0001082 (Colorado), UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL1 TR000083 (North Carolina), and UL1 TR000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH. Support for this trial was also provided by DBV Technologies (Montrouge, France) through funds provided to the Consortium of Food Allergy Research (CoFAR). Protocol development, study conduct, data analysis, and manuscript development were conducted independently of DBV.	Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dioszeghy V, 2014, J ALLERGY CLIN IMMUN, V133, pAB48, DOI 10.1016/j.jaci.2013.12.196; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1258, DOI 10.1016/j.jaci.2016.01.008; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Sampson HA, 2015, J ALLERGY CLIN IMMUN, V135, pAB390, DOI 10.1016/j.jaci.2014.12.1901; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P129; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2015, J ALLERGY CLIN IMMUN, V135, pAB155, DOI 10.1016/j.jaci.2014.12.1446; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Walkner M, 2015, PEDIATR CLIN N AM, V62, P1453, DOI 10.1016/j.pcl.2015.07.003; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	36	191	195	0	48	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1242	+		10.1016/j.jaci.2016.08.017	http://dx.doi.org/10.1016/j.jaci.2016.08.017			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	28091362	Bronze, Green Accepted			2022-12-18	WOS:000398771800019
J	Blaiss, M; Maloney, J; Nolte, H; Gawchik, S; Yao, R; Skoner, DP				Blaiss, Michael; Maloney, Jennifer; Nolte, Hendrik; Gawchik, Sandra; Yao, Ruji; Skoner, David P.			Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy tablet; allergic rhinoconjunctivitis; specific immunotherapy; grass pollen; children; sublingual immunotherapy	QUALITY-OF-LIFE; TERM CLINICAL-EFFICACY; SUBLINGUAL IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; POLLEN IMMUNOTHERAPY; RHINOCONJUNCTIVITIS; RHINITIS; ASTHMA; AEROALLERGENS; PREVALENCE	Background: Allergy immunotherapy tablet (AIT) treatment might be a safe and convenient form of specific immunotherapy but it has not been investigated in North American children and adolescents. Objective: We sought to investigate the efficacy and safety of timothy grass AIT treatment in North American children/adolescents with grass pollen-induced allergic rhinoconjunctivitis (ARC) with or without asthma. Methods: Three hundred forty-five subjects (5-17 years old) were randomized to once-daily grass AIT treatment (2,800 bioequivalent allergen units, 75,000 standardized quality tablet, approximately 15 mu g of Phl p 5) or placebo approximately 16 weeks before the 2009 grass pollen season (GPS). Treatment continued through the GPS. Daily symptoms and allergy rescue medication use were recorded. The primary end point was the total combined score (TCS) of the daily symptom score (DSS) and daily medication score (DMS) for the entire GPS. DSS, DMS, Rhinoconjunctivitis Quality of Life Questionnaire score, and Phl p 5-specific IgG4 and IgE-blocking factor levels were secondary end points. Safety was assessed through adverse events. Results: Eighty-nine percent of subjects were multisensitized. TCS, DSS, DMS, and Rhinoconjunctivitis Quality of Life Questionnaire score versus placebo improved 26% (P = .001), 25% (P = .005), 81% (P = .006), and 18% (P = .04). Phl p 5-specific IgG4 and IgE-blocking factor levels were significantly higher at the peak and end of the GPS (P < .001). Treatment was well tolerated. Adverse events were generally mild and transient. Although no investigator-assessed systemic allergic reactions were reported, 1 grass AIT-treated subject experienced an event indicating a systemic reaction (lip angioedema, dysphagia, and cough). Conclusions: Use of once-daily timothy grass AIT treatment effectively treats timothy grass (cross-reactive with Festucoideae grasses) pollen-induced ARC in North American children 5 years and older. Given its convenient administration, lack of dose build-up requirement, safety profile, and efficacy, AIT treatment might become an important addition to the North American ARC treatment armamentarium. (J Allergy Clin Immunol 2011;127:64-71.)	[Blaiss, Michael] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; [Blaiss, Michael] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; [Maloney, Jennifer; Nolte, Hendrik; Yao, Ruji] Merck Res Labs, Kenilworth, NJ USA; [Maloney, Jennifer] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Nolte, Hendrik] Bispebjerg Copenhagen Univ Hosp, Resp Res Unit, Copenhagen, Denmark; [Gawchik, Sandra] Asthma & Allergy Associates, Upland, PA USA; [Skoner, David P.] Allegheny Gen Hosp, Div Allergy Asthma & Immunol, Pittsburgh, PA 15212 USA; [Skoner, David P.] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Merck & Company; Icahn School of Medicine at Mount Sinai; University of Copenhagen; Allegheny General Hospital; Drexel University	Blaiss, M (corresponding author), 7205 Wolf River Blvd, Germantown, TN 38120 USA.	michael.blaiss@gmail.com			Merck Co.; Alcon; ALK-Abello; AstraZeneca; Curalogic; GlaxoSmithKline; Greer; Johnson Johnson; MAP; MEDA; Merck; Novartis; PDZ Biopharm; Sanofi-Aventis; Sepracor; Skye Pharma; Symbio; Schering-Plough	Merck Co.(Merck & Company); Alcon(Novartis); ALK-Abello; AstraZeneca(AstraZeneca); Curalogic; GlaxoSmithKline(GlaxoSmithKline); Greer; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); MAP; MEDA; Merck(Merck & Company); Novartis(Novartis); PDZ Biopharm; Sanofi-Aventis(Sanofi-Aventis); Sepracor; Skye Pharma; Symbio; Schering-Plough(Merck & CompanySchering Plough Corporation)	Medical writing and editorial assistance was provided by Erin P. Scott, PhD, of Complete Publication Solutions and was funded by Merck & Co.; M. Blaiss has provided consultant and speaker services for Alcon, AstraZeneca, Genentech, GlaxoSmithKline, ISTA, Merck, Nycomed, Proctor & Gamble, Sanofi-Aventis, Sepracor, Teva, UCB, and Vectura and has provided legal consultation and expert witness testimony in rhinitis and asthma-related cases. J. Maloney, H. Nolte, and R. Yao are employees of Merck Research Laboratories. S. Gawchik has received grant support from Alcon, ALK-Abello , AstraZeneca, Curalogic, GlaxoSmithKline, Greer, Johnson & Johnson, MAP, MEDA, Merck, Novartis, PDZ Biopharm, Sanofi-Aventis, Sepracor, Skye Pharma, Symbio, and Teva; has served as a consultant for AstraZeneca, Merck, and Teva; and has provided speaker services for AstraZeneca, GlaxoSmithKline, Merck, Sepracor, and Teva. D. P. Skoner is on the speakers' bureau for AstraZeneca, GlaxoSmithKline, Merck, Novartis, and Teva; has consulted for Merck; and has received research support from Novartis and Schering-Plough.	Acquistapace F, 2009, PEDIAT ALLERG IMM-UK, V20, P660, DOI 10.1111/j.1399-3038.2009.00860.x; Ait-Khaled N, 2009, ALLERGY, V64, P123, DOI 10.1111/j.1398-9995.2008.01884.x; Altintas Derya Ufuk, 2004, Clin Dev Immunol, V11, P87, DOI 10.1080/10446670410001670544; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernstein DI, 2010, ANN ALLERG ASTHMA IM, V104, P530, DOI 10.1016/j.anai.2010.04.008; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Frolund L, 2010, ALLERGY, V65, P753, DOI 10.1111/j.1398-9995.2009.02238.x; Galant S, 1998, ANN ALLERG ASTHMA IM, V81, P203, DOI 10.1016/S1081-1206(10)62813-X; Ibanez MD, 2007, PEDIAT ALLERG IMM-UK, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; MARTIN BG, 1985, ANN ALLERGY, V54, P99; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; van den Nieuwenhof L, 2010, ALLERGY, V65, P1049, DOI 10.1111/j.1398-9995.2009.02316.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Wu LYF, 1999, ANN ALLERG ASTHMA IM, V83, P137, DOI 10.1016/S1081-1206(10)62625-7	39	191	193	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					64	U127		10.1016/j.jaci.2010.11.034	http://dx.doi.org/10.1016/j.jaci.2010.11.034			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211642				2022-12-18	WOS:000285917300010
J	Maloney, JM; Rudengren, M; Ahlstedt, S; Bock, SA; Sampson, HA				Maloney, Jennifer M.; Rudengren, Magnus; Ahlstedt, Staffan; Bock, S. A.; Sampson, Hugh A.			The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut allergy; tree nut allergy; serum-specific IgE	DIAL TELEPHONE SURVEY; ANAPHYLACTIC REACTIONS; NATURAL-HISTORY; FOOD CHALLENGES; QUESTIONNAIRE SURVEY; FOLLOW-UP; CHILDREN; PREVALENCE; SENSITIZATION; ADOLESCENTS	Background: The gold standard for diagnosing food allergy is the double-blind, placebo-controlled food challenge. Diagnostic food-specific IgE levels might assist in diagnosing food allergies and circumventing the need for food challenges. Objectives: The purpose of this study was to determine the utility of food-specific IgE measurements for identifying symptomatic peanut, tree nut, and seed allergies and to augment what is known about the relationships among these foods. Methods: Patients referred for suspected peanut or tree nut allergies answered a questionnaire about their perceived food allergies. Allergen-specific diagnoses were based on questionnaire, medical history, and, when relevant, skin prick tests and serum specific IgE levels. Sera from the patients were analyzed for specific IgE antibodies to peanuts, tree nuts, and seeds by using ImmunoCAP Specific IgE (Phadia, Inc, Uppsala, Sweden). Results: Three hundred twenty-four patients (61% male; median age, 6.1 years; range, 0.2-40.2 years) were evaluated. The patients were highly atopic (57% with atopic dermatitis and 58% with asthma.). The majority of patients with peanut allergy were sensitized to tree nuts (86%), and 34% had documented clinical allergy. The relationship between diagnosis and allergen-specific IgE levels were estimated by using logistic regression. Diagnostic decision points are suggested for peanut and walnut. Probability curves were drawn for peanut, sesame, and several tree nuts. High correlations were found between cashew and pistachio and between pecan and walnut. Conclusions: Quantification of food-specific IgE is a valuable tool that will aid in the diagnosis of symptomatic food allergy and might decrease the need for double-blind, placebo-controlled food challenges.	[Maloney, Jennifer M.; Sampson, Hugh A.] Mt Sinai Hosp, Div Allergy & Immunol, Dept Pediat, Mt Sinai Sch Med, New York, NY 10029 USA; [Rudengren, Magnus; Ahlstedt, Staffan] Phadia AB, Uppsala, Sweden; [Ahlstedt, Staffan] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Bock, S. A.] Boulder Valley Asthma & Allergy Clin, Boulder, CO USA	Icahn School of Medicine at Mount Sinai; Thermo Fisher Scientific; Phadia; Karolinska Institutet	Maloney, JM (corresponding author), Mt Sinai Hosp, Div Allergy & Immunol, Dept Pediat, Mt Sinai Sch Med, Box 1198,1 G Levy Pl, New York, NY 10029 USA.	jennifer.maloney@mssm.edu						Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Cohen A, 2007, PEDIAT ALLERG IMM-UK, V18, P217, DOI 10.1111/j.1399-3038.2006.00506.x; de Leon MP, 2005, CLIN EXP ALLERGY, V35, P1056, DOI 10.1111/j.1365-2222.2005.02310.x; de Leon MP, 2003, CLIN EXP ALLERGY, V33, P1273, DOI 10.1046/j.1365-2222.2003.01761.x; Derby CJ, 2005, PEDIAT ALLERG IMM-UK, V16, P171, DOI 10.1111/j.1399-3038.2005.00232.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Lemerdy P, 2003, CICBAA DATABANK ALIM, V8, P5; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	27	191	195	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					145	151		10.1016/j.jaci.2008.04.014	http://dx.doi.org/10.1016/j.jaci.2008.04.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18502490				2022-12-18	WOS:000257605100024
J	Jaakkola, JJK; Ahmed, P; Ieromnimon, A; Goepfert, P; Laiou, E; Quansah, R; Jaakkola, MS				Jaakkola, Jouni J. K.; Ahmed, Parvez; Ieromnimon, Antonia; Goepfert, Petra; Laiou, Elpiniki; Quansah, Reginald; Jaakkola, Maritta S.			Preterm delivery and asthma: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; preterm delivery; gestational age; fetal development; meta-analysis	ENVIRONMENTAL TOBACCO-SMOKE; PERINATAL RISK-FACTORS; LOW-BIRTH-WEIGHT; MATERNAL SMOKING; FETAL-GROWTH; IN-UTERO; RESPIRATORY HEALTH; ATOPIC DISEASE; CHILDHOOD; EXPOSURE	Background: Accumulating evidence suggests that reduced duration of pregnancy predicts increased risk of asthma, but the studies published have been inconsistent. Objective: We sought to synthesize the evidence on the relation between preterm delivery and the risk of asthma later in life and to assess differences between the studies as potential sources for heterogeneity of the results. Methods: We conducted a MEDLINE search (until the end of May 2005). The outcome was asthma. The determinant of interest was preterm delivery defined as a gestational age of less than 37 weeks. Results: We identified 19 articles that provided estimates for the meta-analysis. The summary effect estimates for asthma (fixed-effects odds ratio, 1.074 [95% CI, 1.072-1.075]; heterogeneity P=.000; random-effects odds ratio, 1.366 [95% CI, 1.303-1.4321]) showed an increased risk in relation to preterm delivery, with substantial heterogeneity between studyspecific estimates. The effect of preterm delivery on asthma was stronger in cross-sectional studies; studies with broad outcome criteria, a small sample size, and a younger study population; and studies conducted in English-speaking populations, outside Europe, and published more recently. In metaregression, adjusting for other determinants, the effect estimate was significantly associated only with the mean age of the study population. Conclusions: The weight of evidence shows that preterm babies have an increased risk of asthma compared with term babies. Clinical implications: Recognition of prematurity as a determinant of asthma emphasizes the importance of active treatment of physiologic airflow obstruction and a need for special preventive measures against known environmental determinants of asthma in preterm babies.	Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jaakkola, JJK (corresponding author), Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England.	j.jaakkola@bham.ac.uk	Quansah, Reginald/AAZ-4015-2020; Jaakkola, Jouni J.K./G-4314-2012	Quansah, Reginald/0000-0002-7318-4192; Jaakkola, Jouni/0000-0003-4168-4683; Jaakkola, Maritta S./0000-0003-1373-7784				Alati R, 2006, EPIDEMIOLOGY, V17, P138, DOI 10.1097/01.ede.0000198148.02347.33; Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Barker DJP, 1992, FETAL INFANT ORIGINS; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218, DOI 10.1164/ajrccm.153.1.8542119; Debley JS, 2005, ANN ALLERG ASTHMA IM, V94, P228, DOI 10.1016/S1081-1206(10)61300-2; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P557, DOI 10.2307/3455027; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jaakkola JJK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-48; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; MANTEL N, 1959, J NATL CANCER I, V22, P719; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Mutitts E, 1994, AM J RESP CRIT CARE, V149, P358; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; PETITTI DB, 1994, META ANAL DECISION A, P102; Poole C, 1999, AM J EPIDEMIOL, V150, P469, DOI 10.1093/oxfordjournals.aje.a010035; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Spahr JE, 2005, ANN ALLERG ASTHMA IM, V94, P211, DOI 10.1016/S1081-1206(10)61296-3; Steffensen FH, 2000, EPIDEMIOLOGY, V11, P185, DOI 10.1097/00001648-200003000-00018; Sterne JAC, 2001, SYSTEMATIC REV HLTH, P347, DOI [DOI 10.1002/9780470693926.CH18, 10.1002/9780470693926.ch18]; Svanes C, 1998, EUR RESPIR J, V12, P1366, DOI 10.1183/09031936.98.12061366; United Nations Children's Fund and WHO, 2004, LOW BIRTH WEIGHT COU; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011; Yuan W, 2003, EUR J EPIDEMIOL, V18, P763, DOI 10.1023/A:1025390420122	42	191	194	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					823	830		10.1016/j.jaci.2006.06.043	http://dx.doi.org/10.1016/j.jaci.2006.06.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030233				2022-12-18	WOS:000241434200007
J	Fleischer, DM; Conover-Walker, MK; Matsui, EC; Wood, RA				Fleischer, DM; Conover-Walker, MK; Matsui, EC; Wood, RA			The natural history of tree nut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tree nut allergy; peanut allergy; food challenge; CAPRAST; food hypersensitivity	PEANUT ALLERGY; FEATURES	Background: Although 20% of children outgrow peanut allergy the natural history of tree nut (TN) allergy has not been well studied. Objective: The goals of the study were to estimate the proportion of children who outgrow TN allergy and examine predictors of outgrowing it. Methods: Patients with TN allergy, defined as a history of reaction on ingestion and evidence of TN-specific IgE (TN-IgE) or positive TN-specific IgE level but no history of ingestion, were evaluated. If all current TN-IgE levels were less than 10 kilounits of antibody (W,)[L, double-blind, placebo-controlled food challenges were offered. Patients who had undergone open TN challenges as part of routine clinical care were also included. Results: Two hundred seventy-eight patients with TN allergy were identified. One hundred one (36%) had a history of acute reactions, 12 (12%) of whom had reactions to multiple TNs and 73 (63 %) of whom had a history of moderate-to-severe reactions. Nine of 20 patients who had previously reacted to a TN passed challenges, so that 9 (8.9%; 95% CL 4% to 16%) of 101 patients with a history of prior TN reactions outgrew TN allergy. Fourteen of 19 who had never ingested TNs but had detectable TN-specific IgE levels passed challenges. One hundred sixty-one did not meet the challenge criteria, and 78 met the criteria but declined challenges. Looking at specific TN-IgE cutoffs, 58% with TN-IgE levels of 5 kU(A)/L or less and 63% with TN-IgE levels of 2 kUA/L or less passed challenges. Conclusions: Approximately, 9% of patients outgrow TN allergy, including some who had prior severe reactions. Although ideal cutoffs for challenge cannot be firmly recommended on the basis of these data, patients aged 4 years or older with all TN-IgE levels of 5 kU(A)/L or less should be considered for challenge.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.			Matsui, Elizabeth/0000-0001-8134-5593	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR000052] Funding Source: Medline; NIAID NIH HHS [T32 AI 07007] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; de Leon MP, 2003, CLIN EXP ALLERGY, V33, P1273, DOI 10.1046/j.1365-2222.2003.01761.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129	12	191	201	2	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1087	1093		10.1016/j.jaci.2005.09.002	http://dx.doi.org/10.1016/j.jaci.2005.09.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275381				2022-12-18	WOS:000235686700022
J	Perez-Novo, CA; Watelet, JB; Claeys, C; Van Cauwenberge, P; Bachert, C				Perez-Novo, CA; Watelet, JB; Claeys, C; Van Cauwenberge, P; Bachert, C			Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; nasal polyposis; aspirin sensitivity; inflammation; leukotrienes; lipoxins; prostaglandins; cyclooxygenase; lipoxygenase	ASPIRIN-INDUCED ASTHMA; ARACHIDONIC-ACID; EPIDEMIOLOGY; POLYMORPHISM; SENSITIVITY; GENERATION; METABOLISM; EXPRESSION; DIAGNOSIS; CELLS	Background: Upper airway diseases and especially the aspirin hypersensitivity syndrome have been linked to changes in the arachidonic acid cascade; however, the specificity of these changes and their relation to inflammatory reactions in these diseases still remain controversial. Objective: We aimed to study the tissue eicosanoid production in 3 subgroups of patients with chronic rhinosinusitis (CRS) and control subjects and to correlate it with the severity of inflammation and clinical manifestation of aspirin sensitivity. Methods: Samples were prepared from sinonasal tissue of patients with CRS with (CRS-NP group, n = 13) and without nasal polyposis (CRS group, n = 11), sinonasal tissue of patients with nasal polyposis and aspirin sensitivity (CRS-ASNP group, n = 13), and normal nasal mucosa from healthy subjects (NM group, n = 8). Real-time PCR was applied for mRNA quantification of COX-2, 5-lipoxygenase, leukotriene C-4 synthase, and 15-lipoxygenase. Enzyme immunoassays were used to measure IL-5, eosinophil cationic protein, and eicosanoid (leukotriene [1,T] C-4, LTD4, and LTE4; lipoxin A(4); and prostaglandin E-2 [PGE(2)]) concentrations. Results: COX-2 mRNA and PGE(2) concentrations were similar in the CRS and NM groups but significantly decreased in nasal polyp tissue, especially in the CRS-ASNP group. LTC4 synthase, 5-lipoxygenase mRNA, LTC4, LTD4, and LTE4 concentrations increased with disease severity among the patient groups. 15-Lipoxygenase and lipoxin A(4) concentrations were increased in all CRS groups compared with in the NM group but were significantly downregulated in the CRS-ASNP group when compared with the CRS-NP group. IL-5 and eosinophil cationic protein were increased in both groups of nasal polyp tissue compared with in the NM and CRS groups and correlated directly with LTC4, LTD4, and LTE4 concentrations and inversely with PGE2 concentrations. Conclusion: Changes of tissue eicosanoid metabolism do occur in CRS, even in the absence of clinical aspirin sensitivity, and these changes appear to be related to the severity of eosinophilic inflammation.	Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Perez-Novo, CA (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, Pintelaan 185, B-9000 Ghent, Belgium.	claudina.Pereznovo@UGent.be	Bachert, Claus/J-8825-2012; Novo, Claudina A Perez/E-6098-2011; Novo, Claudina Angela Perez/H-9697-2016	Novo, Claudina A Perez/0000-0003-4562-4346; 				BACHERT C, 2003, ALLERGY PRINCIPLES P, P1421; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Bonnans C, 2003, J BIOL CHEM, V278, P10879, DOI 10.1074/jbc.M210294200; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; EDENIUS C, 1990, FEBS LETT, V272, P25, DOI 10.1016/0014-5793(90)80440-T; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gosepath J, 2004, J INVEST ALLERG CLIN, V14, P114; Gosepath J, 1999, ORL J OTO-RHINO-LARY, V61, P146, DOI 10.1159/000027660; HOLGATE ST, 2003, J ALLERGY CLIN IMM S, V1111, pS18; JUNG TTK, 1987, LARYNGOSCOPE, V97, P184; Kantarci A, 2003, CRIT REV ORAL BIOL M, V14, P4, DOI 10.1177/154411130301400102; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kedda MA, 2004, J ALLERGY CLIN IMMUN, V113, P889, DOI 10.1016/j.jaci.2004.02.008; Kowalski ML, 2003, J ALLERGY CLIN IMMUN, V112, P505, DOI 10.1067/mai.2003.1678; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Parsons, 1986, VITAL HLTH STAT; Pereira M D, 2001, BMC Microbiol, V1, P11, DOI 10.1186/1471-2180-1-11; Perez-Novo CA, 2004, INT ARCH ALLERGY IMM, V133, P255, DOI 10.1159/000076832; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Pinto S, 1997, PROSTAG LEUKOTR ESS, V57, P533, DOI 10.1016/S0952-3278(97)90556-1; Rubinsztajn Renata, 2003, Pol Arch Med Wewn, V110, P849; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Sanak M, 2001, J ALLERGY CLIN IMMUN, V107, P561, DOI 10.1067/mai.2001.112853; Schmid M, 1999, ACTA OTO-LARYNGOL, V119, P277; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SETTIPANE GA, 1988, BIOMED PHARMACOTHER, V42, P493; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; van den Hove S, 2002, CLIM POLICY, V2, P3, DOI 10.1016/S1469-3062(02)00008-6; Vignola A Maurizio, 2003, Drugs, V63 Suppl 2, P35, DOI 10.2165/00003495-200363002-00004; Ziroli NE, 2002, OTOLARYNG HEAD NECK, V126, P141, DOI 10.1067/mhn.2002.121913	39	191	198	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1189	1196		10.1016/j.jaci.2005.02.029	http://dx.doi.org/10.1016/j.jaci.2005.02.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940133	Bronze			2022-12-18	WOS:000229815400013
J	Hijnen, DJ; de Bruin-Weller, M; Oosting, B; Lebre, C; de Jong, E; Bruijnzeel-Koomen, C; Knol, E				Hijnen, DJ; de Bruin-Weller, M; Oosting, B; Lebre, C; de Jong, E; Bruijnzeel-Koomen, C; Knol, E			Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic disease; asthma; atopic dermatitis; rhinitis; T(H)2; chemokines; TARC; CTACK; cyclosporin A	MACROPHAGE-DERIVED CHEMOKINE; BRONCHIAL EPITHELIAL-CELLS; SKIN-ASSOCIATED CHEMOKINE; IN-VITRO; DOUBLE-BLIND; HACAT CELLS; RECEPTOR 4; TNF-ALPHA; IFN-GAMMA; KERATINOCYTES	Background: Tissue infiltration of CD4(+) T cells plays an important role in the pathogenesis of allergic diseases. T-cell trafficking is mediated by specific chemokines and their receptors. Objective: The purpose of this study was to investigate the participation of the chemokines; thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) in a large population of patients with allergic diseases. Methods: Serum TARC and CTACK levels were measured in 455 patients with allergic disease. Patients were characterized as having atopic dermatitis (AD), allergic asthma, allergic rhinitis, or combinations or as healthy control subjects. Serum TARC and CTACK levels were correlated with disease activity in patients with AD. Furthermore, in 7 patients with AD, serum TARC and CTACK levels were studied after the start of systemic cyclosporin A treatment. Finally, TARC and CTACK localization was checked by immunohistochemistry in lesional skin biopsy specimens of patients with AD. Results: Both TARC and CTACK serum levels in patients with AD were significantly higher than those in healthy control subjects and patients with allergic respiratory disease. Furthermore, serum TARC and CTACK levels significantly correlated with disease activity in patients with AD. Serum TARC levels paralleled clinical improvement in patients treated with cyclosporin A. Immunoreactive TARC was found in infiltrating cells and endothelial cells of the dermis but not in epidermal cells. Conclusions: The serum TARC level is an objective parameter for disease severity specific for AD. Furthermore, it is a promising tool for treatment monitoring.	Univ Utrecht, Ctr Med, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Acad Med Ctr, Dept Cell Biol & Histol, Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Hijnen, DJ (corresponding author), Univ Utrecht, Ctr Med, Dept Dermatol Allergol, Heidelberglaan 100,Room G02-124, NL-3508 GA Utrecht, Netherlands.		Hijnen, DirkJan/L-1387-2015	Hijnen, DirkJan/0000-0003-3379-3425; Knol, Edward/0000-0001-7368-9820				Albanesi C, 2001, J LEUKOCYTE BIOL, V70, P617; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Charman C, 2003, J INVEST DERMATOL, V120, P932, DOI 10.1046/j.1523-1747.2003.12251.x; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; D'Ambrosio D, 2002, J IMMUNOL, V169, P2303, DOI 10.4049/jimmunol.169.5.2303; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Gutgesell C, 2002, BRIT J DERMATOL, V147, P914, DOI 10.1046/j.1365-2133.2002.04938.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Oosting AJ, 2002, J ALLERGY CLIN IMMUN, V110, P500, DOI 10.1067/mai.2002.126791; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.1s3256.x; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Sugawara N, 2002, ALLERGY, V57, P180, DOI 10.1034/j.1398-9995.2002.1n3503.x; Terada N, 2001, CLIN EXP ALLERGY, V31, P1923, DOI 10.1046/j.1365-2222.2001.01152.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Tsuda T, 2003, J DERMATOL SCI, V31, P37, DOI 10.1016/S0923-1811(02)00138-X; Uchida T, 2002, INT IMMUNOL, V14, P1431, DOI 10.1093/intimm/dxf109; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Vestergaard C, 2000, MOL MED TODAY, V6, P209, DOI 10.1016/S1357-4310(00)01683-X; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Vestergaard C, 2001, J DERMATOL SCI, V26, P46, DOI 10.1016/S0923-1811(00)00160-2; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; Yu B, 2002, J DERMATOL SCI, V30, P29, DOI 10.1016/S0923-1811(02)00046-4; Zheng XY, 2002, J DERMATOL SCI, V30, P154, DOI 10.1016/S0923-1811(02)00071-3	38	191	215	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					334	340		10.1016/j.jaci.2003.12.007	http://dx.doi.org/10.1016/j.jaci.2003.12.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767451	Bronze			2022-12-18	WOS:000188885700024
J	Zock, JP; Jarvis, D; Luczynska, C; Sunyer, J; Burney, P				Zock, JP; Jarvis, D; Luczynska, C; Sunyer, J; Burney, P		European Community Resp Hlth Surv	Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; housing; dampness; mold; carpeting; European Community Respiratory Health Survey	HOME DAMPNESS; DUST MITES; FUNGAL PROPAGULES; INDOOR AIR; SYMPTOMS; ADULTS; CHILDREN; (1->3)-BETA-D-GLUCAN; INFECTIONS; ALLERGENS	Background: The effects of home dampness and mold exposure on adult asthma are not clear. Objective: We aimed to investigate the associations between housing characteristics related to dampness, mold exposure, and house dust mite levels and adult asthma in 38 study centers from the European Community Respiratory Health Survey. Methods: Data about the present home, heating and ventilation systems, double glazing, floor covers, recent water damage, and mold exposure were obtained by means of an interviewer-led questionnaire. The associations between these factors and asthma, as defined on the basis of symptoms in the last year, and of bronchial responsiveness, as determined with methacholine challenge, were evaluated. Odds ratios (ORs) were obtained by using random-effects meta-analyses adjusted within study centers for sex, age group, and smoking status. Results: Fitted carpets and rugs in the bedroom were related to fewer asthma symptoms and bronchial responsiveness (OR range, 0.69-0.91). This effect was consistent across centers and more pronounced among house dust mite-sensitized individuals. Reported mold exposure in the last year was associated with asthma symptoms and bronchial responsiveness (OR range, 1.14-1.44). This effect was homogeneous among centers and stronger in subjects sensitized to Cladosporium species. In centers with a higher prevalence of asthma, the prevalence of reported indoor mold exposure was also high. This association was observed for reported mold exposure by asthmatic subjects (Spearman r(s) = 0.46), as well as reported mold exposure by nonasthmatic subjects (r(s) = 0.54). Reported mold exposure was highest in older houses with recent water damage. Conclusion: We conclude that indoor mold growth has an adverse effect on adult asthma.	Municipal Inst Med Res, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England	University of London; King's College London	Zock, JP (corresponding author), Municipal Inst Med Res, Resp & Environm Hlth Res Unit, Dr Aiguader 80, E-08003 Barcelona, Spain.		Soriano, Joan B/O-1215-2017; Zock, Jan-Paul/P-5034-2018; Sunyer, Jordi/G-6909-2014; Svanes, Cecilie/N-7556-2017; Jarvis, Deborah/E-6494-2011; Sánchez-Ramos, José Luis/G-1259-2011; Allwright, Shane/A-1537-2012; Heinrich, Joachim/N-1720-2013	Soriano, Joan B/0000-0001-9740-2994; Zock, Jan-Paul/0000-0002-2941-6259; Sunyer, Jordi/0000-0002-2602-4110; Svanes, Cecilie/0000-0001-8512-5192; Sánchez-Ramos, José Luis/0000-0001-7187-9989; ROMANO, Canzio/0000-0001-5294-9793; Allwright, Shane/0000-0003-1841-4781; Heinrich, Joachim/0000-0002-9620-1629; Cerveri, Isa/0000-0003-0337-043X; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678; Abramson, Michael/0000-0002-9954-0538; Tobias, Aurelio/0000-0001-6428-6755	NCRR NIH HHS [2SO7 RR 05521-28] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARMSTRONG BG, 1990, AM J EPIDEMIOL, V132, P1176, DOI 10.1093/oxfordjournals.aje.a115761; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DALES RE, 1991, AM REV RESPIR DIS, V143, P505, DOI 10.1164/ajrccm/143.3.505; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65, DOI 10.1164/ajrccm.164.1.9911066; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Evans J, 2000, J EPIDEMIOL COMMUN H, V54, P677, DOI 10.1136/jech.54.9.677; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Rylander R, 1997, MEDIAT INFLAMM, V6, P275, DOI 10.1080/09629359791613; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544, DOI 10.1016/S1081-1206(10)63214-0; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; Williamson IJ, 1997, THORAX, V52, P229, DOI 10.1136/thx.52.3.229	31	191	196	1	29	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					285	292	UNSP 1/81/126383	10.1067/mai.2002.126383	http://dx.doi.org/10.1067/mai.2002.126383			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170270				2022-12-18	WOS:000177509800014
J	Patel, AM; Ryu, JH; Reed, CE				Patel, AM; Ryu, JH; Reed, CE			Hypersensitivity pneumonitis: Current concepts and future questions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						hypersensitivity pneumonitis; immunopathogenesis; lymphocytes; antibody; cytokines; chemokines; adhesion molecules; causative agents; diagnosis; prognosis; high-resolution computed tomography; bronchoalveolar lavage; pathology	EXTRINSIC ALLERGIC ALVEOLITIS; BRONCHOALVEOLAR LAVAGE FLUID; PIGEON-BREEDERS DISEASE; IMMUNOLOGICAL LUNG-DISEASE; BIRD FANCIERS LUNG; MAST-CELL TRYPTASE; HIGH-RESOLUTION CT; ACUTE FARMERS LUNG; PULMONARY FIBROSIS; AIRWAY LESIONS	Hypersensitivity pneumonitis (extrinsic allergic alveolitis) caused by inhaled allergens can progress to disabling or even fatal end-stage lung disease. The only truly effective treatment is early recognition and control of exposure. Although patients produce antibody exuberantly, the immunopathogenesis involves cellular immunity-notably, CD8(+) cytotoxic lymphocytes, multinucleate giant cell granulomas, and ultimately interstitial fibrosis. Many causative agents have been recognized in occupational dusts or mists, but most current new cases arise from residential exposure to pet birds (pigeons and parakeets), contaminated humidifiers, and indoor molds. The symptoms and physical findings are nonspecific. Serum IgG containing high titers of specific antibody to the offending antigen is elevated, Pulmonary function tests show restrictive and diffusion defects with hypoxemia, especially after exercise. Occasionally, small airways disease causes obstruction. Radiographic changes vary according to the stage of the disease and are best evaluated by means of high-resolution computed tomography. In typical cases, the history of a known exposure and the presence of a characteristic interstitial lung disease with serologic confirmation of IgG antibody to the offending antigen suffice for diagnosis. In more obscure cases, observation of changes after a natural environmental exposure, bronchoalveolar lavage, and lung biopsy might be indicated. Among the many questions that remain are the following: What is the prevalence of hypersensitivity pneumonitis and how often is it the cause of chronic interstitial fibrosis? What is the long-term prognosis? Why do most individuals exposed to these antigens develop a vigorous antibody response whereas only a few develop the disease? How does exposure to endotoxin and cigarette smoking affect the disease? To answer these questions, standardized and validated clinical laboratory immunochemical tests are needed, in addition to a systematic approach to diagnosis, classification of disease severity, risk assessment, and management. This review is limited to the disease caused by airborne allergens and focuses on its immunopathogenesis, eliciting agents, clinical manifestations, diagnosis, management, and prognosis.	Mayo Clin, Dept Internal Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Patel, AM (corresponding author), Mayo Clin, Dept Internal Med, Div Pulm & Crit Care Med, Mayo Bldg E 18,200 1st St SW, Rochester, MN 55905 USA.			Ryu, Jay/0000-0002-9576-2272				Adawi A, 1998, CLIN IMMUNOL IMMUNOP, V89, P222, DOI 10.1006/clin.1998.4606; ADLER BD, 1992, RADIOLOGY, V185, P91, DOI 10.1148/radiology.185.1.1523340; AGOSTINI C, 1987, J CLIN IMMUNOL, V7, P64, DOI 10.1007/BF00915427; Agostini C, 1996, AM J RESP CRIT CARE, V153, P1359, DOI 10.1164/ajrccm.153.4.8616567; ANDO M, 1991, J ALLERGY CLIN IMMUN, V87, P1002, DOI 10.1016/0091-6749(91)90423-L; ANDO M, 1991, AM REV RESPIR DIS, V144, P765, DOI 10.1164/ajrccm/144.4.765; Baldwin CI, 1999, CLIN EXP IMMUNOL, V117, P230; BARBEE RA, 1968, AM REV RESPIR DIS, V97, P223; BJERMER L, 1988, ARCH INTERN MED, V148, P1362, DOI 10.1001/archinte.148.6.1362; Blackwell TS, 2001, AM J RESP CRIT CARE, V163, P1516, DOI 10.1164/ajrccm.163.7.2103055d; BOST TW, 1994, AM J RESP CRIT CARE, V10, P596; BOUCHARD S, 1995, AM J RESP CRIT CARE, V152, P997, DOI 10.1164/ajrccm.152.3.7663816; BRAUN SR, 1979, AM REV RESPIR DIS, V119, P185; CAMPBELL AR, 1989, AM REV RESPIR DIS, V140, P317, DOI 10.1164/ajrccm/140.2.317; Cormier Y, 2000, EUR RESPIR J, V16, P56, DOI 10.1034/j.1399-3003.2000.16a10.x; CORMIER Y, 1985, CHEST, V87, P796, DOI 10.1378/chest.87.6.796; COSTABEL U, 1988, EUR RESPIR J, V1, P5; Dai H, 1999, CLIN EXP ALLERGY, V29, P1209; DENIS M, 1995, AM J RESP CRIT CARE, V151, P164, DOI 10.1164/ajrccm.151.1.7812548; DENIS M, 1995, INFLAMMATION, V19, P157, DOI 10.1007/BF01534459; Drent M, 1997, SARCOIDOSIS VASC DIF, V14, P31; DRENT M, 1993, EUR RESPIR J, V6, P1276; Erkinjuntti-Pekkanen R, 1998, AM J RESP CRIT CARE, V158, P662, DOI 10.1164/ajrccm.158.2.9710012; FINK JN, 1986, CHEST, V89, pS193, DOI 10.1378/chest.89.3_Supplement.193S; FINK JN, 1992, CLIN CHEST MED, V13, P303; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, 1987, MONOGR ALLERGY, V21, P59; FLAHERTY DK, 1980, AM REV RESPIR DIS, V122, P437; FOURNIER E, 1985, CHEST, V88, P563, DOI 10.1378/chest.88.4.563; Garcia JEL, 1999, MEDIAT INFLAMM, V8, P43, DOI 10.1080/09629359990711; GRAMMER LC, 1987, ANN ALLERGY, V58, P151; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; Gudmundsson G, 1997, J CLIN INVEST, V99, P2386, DOI 10.1172/JCI119420; Gudmundsson G, 1999, EXP LUNG RES, V25, P217; GURNEY JW, 1992, RADIOL CLIN N AM, V30, P1219; HALEY PJ, 1991, INT ARCH ALLER A IMM, V96, P168, DOI 10.1159/000235489; Hansell DM, 1996, RADIOLOGY, V199, P123, DOI 10.1148/radiology.199.1.8633133; Hisauchi-Kojima K, 1999, J ALLERGY CLIN IMMUN, V103, P1158, DOI 10.1016/S0091-6749(99)70193-4; HUNT LW, 1992, MAYO CLIN PROC, V67, P941, DOI 10.1016/S0025-6196(12)60924-0; Israel-Assayag E, 1999, J IMMUNOL, V163, P6794; Israel-Assayag E, 1999, AM J RESP CRIT CARE, V159, P1830, DOI 10.1164/ajrccm.159.6.9810087; KALTREIDER HB, 1993, WESTERN J MED, V159, P570; KANE GC, 1993, CHEST, V104, P627, DOI 10.1378/chest.104.2.627; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; KOKKARINEN J, 1994, CHEST, V106, P509, DOI 10.1378/chest.106.2.509; KURUP VP, 1987, MYCOPATHOLOGIA, V98, P91, DOI 10.1007/BF00437294; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; LOPEZ M, 1987, MONOGR ALLERGY, V21, P70; MALMBERG P, 1990, AM J IND MED, V17, P7, DOI 10.1002/ajim.4700170104; MARX JJ, 1990, AM J IND MED, V18, P263, DOI 10.1002/ajim.4700180304; McSharry C, 2000, CLIN EXP ALLERGY, V30, P1221; Miyagawa T, 2000, AM J RESP CRIT CARE, V161, P961, DOI 10.1164/ajrccm.161.3.9802013; MORELL F, 1986, THORAX, V41, P538, DOI 10.1136/thx.41.7.538; Mori S, 1998, OCCUP MED-OXFORD, V48, P465, DOI 10.1093/occmed/48.7.465; Ohtani Y, 1999, INTERNAL MED, V38, P896, DOI 10.2169/internalmedicine.38.896; Oshima M, 1999, LUNG, V177, P229, DOI 10.1007/PL00007643; Pan LH, 2000, AM J RESP CRIT CARE, V161, P1689, DOI 10.1164/ajrccm.161.5.9812016; Pardo A, 2000, AM J RESP CRIT CARE, V161, P1698, DOI 10.1164/ajrccm.161.5.9907065; Patel RA, 2000, J COMPUT ASSIST TOMO, V24, P965, DOI 10.1097/00004728-200011000-00025; Patterson R, 1998, CHEST, V114, P931, DOI 10.1378/chest.114.3.931; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P103, DOI 10.1016/0091-6749(78)90086-6; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1113; PerezPadilla R, 1996, CHEST, V110, P371, DOI 10.1378/chest.110.2.371; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; PESCI A, 1991, CHEST, V100, P1197, DOI 10.1378/chest.100.5.1197; Ramirez-Venegas A, 1998, AM J RESP CRIT CARE, V158, P862, DOI 10.1164/ajrccm.158.3.9710036; REED CE, 1983, J OCCUP ENVIRON MED, V25, P207, DOI 10.1097/00043764-198303000-00014; REIJULA K, 1986, PATHOL RES PRACT, V181, P418, DOI 10.1016/S0344-0338(86)80077-2; REMYJARDIN M, 1993, RADIOLOGY, V189, P111, DOI 10.1148/radiology.189.1.8372179; RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7; Rodrigo MJ, 2000, OCCUP ENVIRON MED, V57, P159, DOI 10.1136/oem.57.3.159; Schaaf BM, 2001, AM J RESP CRIT CARE, V163, P379, DOI 10.1164/ajrccm.163.2.2002062; Schuyler M, 2000, J LAB CLIN MED, V136, P29, DOI 10.1067/mlc.2000.107694; Schuyler M, 1997, CHEST, V111, P534, DOI 10.1378/chest.111.3.534; SELMANLAMA M, 1993, CLIN CHEST MED, V14, P699; Shanley TP, 1996, J CLIN INVEST, V97, P963, DOI 10.1172/JCI118520; Sharma O P, 1995, Semin Respir Infect, V10, P96; Shigematsu M, 1998, SARCOIDOSIS VASC DIF, V15, P173; SHIJUBO N, 1995, CLIN EXP IMMUNOL, V102, P91; SOLER P, 1987, THORAX, V42, P565, DOI 10.1136/thx.42.8.565; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V78, P411, DOI 10.1016/0091-6749(86)90026-6; Suga M, 1997, SARCOIDOSIS VASC DIF, V14, P131; SUGIYAMA Y, 1995, EUR RESPIR J, V8, P1084, DOI 10.1183/09031936.95.08071084; TAKIZAWA H, 1989, J IMMUNOL, V143, P1982; TESCHLER H, 1993, EUR RESPIR J, V6, P709; TRENTIN L, 1990, J IMMUNOL, V145, P2147; Wahlstrom J, 1997, EUR RESPIR J, V10, P772; WALLS AF, 1991, CLIN SCI, V81, P183, DOI 10.1042/cs0810183; WALLS AF, 1990, INT ARCH ALLER A IMM, V92, P233, DOI 10.1159/000235183; Yamasaki H, 1999, J IMMUNOL, V163, P3516; Yoshizawa Y, 1999, J ALLERGY CLIN IMMUN, V103, P315, DOI 10.1016/S0091-6749(99)70507-5	91	191	210	0	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					661	670						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692086				2022-12-18	WOS:000172523800001
J	HORST, M; HEJJAOUI, A; HORST, V; MICHEL, FB; BOUSQUET, J				HORST, M; HEJJAOUI, A; HORST, V; MICHEL, FB; BOUSQUET, J			DOUBLE-BLIND, PLACEBO-CONTROLLED RUSH IMMUNOTHERAPY WITH A STANDARDIZED ALTERNARIA EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE				Bousquet, Jean/O-4221-2019					AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437, DOI 10.1016/0091-6749(82)90006-9; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; AUKRUST L, 1978, ALLERGY, V33, P24, DOI 10.1111/j.1398-9995.1978.tb01503.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; AUKRUST L, 1980, ADV ALLERGOLOGY APPL, P475; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1984, 3RD P INT P EHRL SEM, P291; Brighton W D, 1975, Dev Biol Stand, V29, P362; BRILL N, 1981, ALLERGOLOGIE, V3, P151; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V57, P367, DOI 10.1016/0091-6749(76)90094-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; Domson, 1984, MOULD ALLERGY, P66; Domson JF, 1984, MOULD ALLERGY, P187; DREBOORG S, 1987, THESIS LINKOPING U L; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GOLDSTEIN GL, 1981, ANN ALLERGY, V47, P333; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; HOWARD WA, 1984, MOULD ALLERGY, P147; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KAAD PH, 1982, CLIN ALLERGY, V12, P317, DOI 10.1111/j.1365-2222.1982.tb02534.x; KARLKSSON R, 1986, ALLERGY, V41, P131; KOIVIKKO A, 1984, MOULD ALLERGY WORKSH, P35; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; LOPEZ M, 1987, HIGHLIGHTS ASTHMOLOG, P322; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MALLING H-J, 1988, Allergy (Copenhagen), V43, P1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1987, ALLERGY, V42, P305, DOI 10.1111/j.1398-9995.1987.tb02214.x; MOSBECH H, 1986, CLIN ALLERGY, V16, P11; MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P219, DOI 10.3109/00016487609120888; Nilsson S., 1984, MOULD ALLERGY WORKSH, P13; NORMAN PS, 1981, PROG ALLERGY, V32, P318; OSTERBALLE O, 1983, THESIS UNISATS APS N; PUTONEN F, 1981, INT ARCH ALLER A IMM, V64, P157; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P773, DOI 10.1016/0091-6749(85)90746-8; ROLFSEN W, 1986, IMPORTANT MOULDS ALL; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, P1327; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325, DOI 10.1159/000234316; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WILKENJENSEN K, 1984, ATLAS MOULDS EUROPE, P12; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; 1962, AM REV RESPIR DIS, V85, P762; 1985, BIOL PRODUCTS ALLERG	68	191	199	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					460	472		10.1016/0091-6749(90)90156-X	http://dx.doi.org/10.1016/0091-6749(90)90156-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406323				2022-12-18	WOS:A1990CP51100007
J	Weller, K; Groffik, A; Church, MK; Hawro, T; Krause, K; Metz, M; Martus, P; Casale, TB; Staubach, P; Maurer, M				Weller, Karsten; Groffik, Adriane; Church, Martin K.; Hawro, Tomasz; Krause, Karoline; Metz, Martin; Martus, Peter; Casale, Thomas B.; Staubach, Petra; Maurer, Marcus			Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Disease control; disease activity; urticaria; development; validation	QUALITY-OF-LIFE; ASTHMA CONTROL; QUESTIONNAIRE; VERSION; CARE	Background: Chronic urticaria is a frequent and debilitating skin disease. Its symptoms commonly fluctuate considerably from day to day. As of yet, the only reliable tool to assess disease activity is the Urticaria Activity Score, which prospectively documents the signs and symptoms of urticaria for several days. Objective: We sought to develop and validate a novel patient-reported outcome instrument to retrospectively assess urticaria control, the Urticaria Control Test (UCT). Methods: Potential UCT items were developed by using established methods (literature research and expert and patient involvement). Subsequently, item reduction was performed by using a combined approach, applying impact and regression analysis. The resulting UCT instrument was then tested for its validity, reliability, and screening accuracy. Results: A 4-item UCT with a recall period of 4 weeks was developed based on 25 potential UCT items tested in 508 patients with chronic urticaria. A subsequent validation study with the 4-item UCT in 120 patients with chronic urticaria demonstrated that this new tool exhibits good convergent and known-groups validity, as well as excellent test-retest reliability. In addition, the screening accuracy to identify patients with urticaria with insufficiently controlled disease was found to be high. Conclusions: The UCT is the first valid and reliable tool to assess disease control in patients with chronic urticaria (spontaneous and inducible). Its retrospective approach and simple scoring system make it an ideal instrument for the management of patients with chronic urticaria in clinical practice.	[Weller, Karsten; Church, Martin K.; Hawro, Tomasz; Krause, Karoline; Metz, Martin; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Allergie Centrum Charite, D-10117 Berlin, Germany; [Groffik, Adriane; Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany; [Casale, Thomas B.] Creighton Univ, Div Allergy & Immunol, Omaha, NE 68178 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen; Creighton University	Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Allergie Centrum Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Krause, Karoline/G-5218-2018; Casale, Thomas B/K-4334-2013; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Krause, Karoline/0000-0001-9711-9654; Casale, Thomas B/0000-0002-3149-7377; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313; Hawro, Tomasz/0000-0001-9990-1332	Urtikaria Network e.V. (UNEV); Novartis Germany	Urtikaria Network e.V. (UNEV); Novartis Germany(Novartis)	Supported in part by the Urtikaria Network e.V. (UNEV) and Novartis Germany.	Allen Michael H, 2012, Innov Clin Neurosci, V9, P15; Baiardini I, 2005, ALLERGY, V60, P1073, DOI 10.1111/j.1398-9995.2005.00833.x; Baiardini I, 2010, ALLERGY, V65, P290, DOI 10.1111/j.1398-9995.2009.02263.x; European Medicines Agency (EMA), REFL PAP REG GUID US; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; Jia CE, 2013, J ALLERGY CLIN IMMUN, V131, P695, DOI 10.1016/j.jaci.2012.08.023; Kocaturk E, 2012, ACTA DERM-VENEREOL, V92, P419, DOI 10.2340/00015555-1199; Maurer M, 2011, ALLERGY, V66, P317, DOI 10.1111/j.1398-9995.2010.02496.x; Mlynek A, 2008, ALLERGY, V63, P777, DOI 10.1111/j.1398-9995.2008.01726.x; Mlynek A, 2009, ALLERGY, V64, P927, DOI 10.1111/j.1398-9995.2008.01920.x; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Weller K, 2013, J EUR ACAD DERMATOL, V27, pe8, DOI 10.1111/j.1468-3083.2011.04387.x; Weller K, 2012, J DTSCH DERMATOL GES, V10, P341, DOI 10.1111/j.1610-0387.2011.07822.x; Zuberbier T, 2009, ALLERGY, V64, P1427, DOI 10.1111/j.1398-9995.2009.02178.x	14	190	201	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1365	U604		10.1016/j.jaci.2013.12.1076	http://dx.doi.org/10.1016/j.jaci.2013.12.1076			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24522090				2022-12-18	WOS:000335450700019
J	Bianchi, M; Niemiec, MJ; Siler, U; Urban, CF; Reichenbach, J				Bianchi, Matteo; Niemiec, Maria J.; Siler, Ulrich; Urban, Constantin F.; Reichenbach, Janine			Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; gene therapy; neutrophil extracellular trap; calprotectin; Aspergillus infection	REVERSIBLE ANTIMICROBIAL ACTIVITY; ZINC; FUMIGATUS; INFECTION; MIGRATION; COMPLEX; PROTEIN; ABSENCE; GROWTH; S100A8	Background: Aspergillus spp infection is a potentially lethal disease in patients with neutropenia or impaired neutrophil function. We showed previously that Aspergillus hyphae, too large for neutrophil phagocytosis, are inhibited by reactive oxygen species-dependent neutrophil extracellular trap (NET) formation. This process is defective in chronic granulomatous disease (CGD) because of impaired phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function. Objective: To determine the antifungal agent and mechanism responsible for reconstitution of Aspergillus growth inhibition within NETs after complementation of NADPH oxidase function by gene therapy (GT) for CGD. Methods: Antifungal activity of free and NET-released calprotectin was assessed by incubation of Aspergillus nidulans with purified calprotectin, induced NETs from human controls, and CGD neutrophils after GT in the presence or absence of Zn2+ or alpha-S100A9 antibody, and with induced NETs from wildtype or S100A9(-/-) mouse neutrophils. Results: We identified the host Zn2+ chelator calprotectin as a neutrophil-associated antifungal agent expressed within NETs, reversibly preventing A nidulans growth at low concentrations, and leading to irreversible fungal starvation at higher concentrations. Specific antibody-blocking and Zn2+ addition abolished calprotectin-mediated inhibition of A nidulans proliferation in vitro. The role of calprotectin in anti-Aspergillus defense was confirmed in calprotectin knockout mice. Conclusion: Reconstituted NET formation by GT for human CGD was associated with rapid cure of pre-existing therapy-refractory invasive pulmonary aspergillosis in vivo, underlining the role of functional NADPH oxidase in NET formation and calprotectin release for antifungal activity. These results demonstrate the critical role of calprotectin in human innate immune defense against Aspergillus infection. (J Allergy Clin Immunol 2011;127:1243-52.)	[Bianchi, Matteo; Siler, Ulrich; Reichenbach, Janine] Univ Childrens Hosp Zurich, Div Immunol Hematol BMT, Steinwiesstr 75, CH-8032 Zurich, Switzerland; [Niemiec, Maria J.; Urban, Constantin F.] Umea Univ, Antifungal Immun Grp, Dept Mol Biol, Lab Mol Infect Med Sweden, Umea, Sweden	University Children's Hospital Zurich; Umea University	Reichenbach, J (corresponding author), Univ Childrens Hosp Zurich, Div Immunol Hematol BMT, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	constantin.urban@molbiol.umu.se; janine.reichenbach@kispi.uzh.ch	Urban, Constantin/H-5121-2019; Reichenbach, Janine/U-2171-2018	Urban, Constantin/0000-0003-1438-1134; Reichenbach, Janine/0000-0002-9008-1312; Niemiec, Maria Joanna/0000-0001-5667-6032; Siler, Ulrich/0000-0002-2458-2629; Bianchi, Matteo/0000-0003-0517-8599	Chronic Granulomatous Disorder Research Trust, United Kingdom [J4G/08/ 01]; GEBERT RUF STIF-TUNG, Switzerland [GRS-046/10]; EU; Swiss National Science Foundation [320000-121983]; MIMS; Stiftelsen J. C. Kempes Minnes Stipendiefond; Medicinska Fakulteten Umea Universitet	Chronic Granulomatous Disorder Research Trust, United Kingdom; GEBERT RUF STIF-TUNG, Switzerland; EU(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MIMS; Stiftelsen J. C. Kempes Minnes Stipendiefond; Medicinska Fakulteten Umea Universitet	Supported by a grant of the Chronic Granulomatous Disorder Research Trust, United Kingdom (grant no. J4G/08/ 01 to J.R. and M. B.), a grant of GEBERT RUF STIF-TUNG, Switzerland (grant number GRS-046/10 to J.R.), a grant of the EU FP7 CELL-PID programme (J.R. and U. S.), and a grant of the Swiss National Science Foundation (grant no. 320000-121983 to U. S.). M.J.N. and C. F. U. were supported by a starting grant from MIMS, a stipend from Stiftelsen J. C. Kempes Minnes Stipendiefond, and a travel financing grant from Medicinska Fakulteten Umea Universitet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.r Disclosure of potential conflict of interest: M. Bianchi and J. Reichenbach have received research support from the CGD Research Trust. M. J. Niemiec has received research support from the Stiftelsen J. C. Kempes Minnes. U. Siler has received research support from the Swiss National Science Foundation. C. F. Urban has received research support from Molecular Infection Medicines Sweden, Stiftelsen J. C. Kempes Minnes, and Med/Cinska Fakuleten Umea University.	Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; Behnsen J, 2007, PLOS PATHOG, V3, P138, DOI 10.1371/journal.ppat.0030013; Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606; Bonnett CR, 2006, INFECT IMMUN, V74, P6528, DOI 10.1128/IAI.00909-06; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bruns S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000873; CLOHESSY PA, 1995, SCAND J IMMUNOL, V42, P551, DOI 10.1111/j.1365-3083.1995.tb03695.x; Corbin BD, 2008, SCIENCE, V319, P962, DOI 10.1126/science.1152449; Decleva E, 2006, J LEUKOCYTE BIOL, V79, P87, DOI 10.1189/jlb.0605338; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Ermert D, 2009, J INNATE IMMUN, V1, P181, DOI 10.1159/000205281; Essin K, 2007, AM J PHYSIOL-CELL PH, V293, pC45, DOI 10.1152/ajpcell.00450.2006; Femling JK, 2006, J GEN PHYSIOL, V127, P659, DOI 10.1085/jgp.200609504; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106; Hakkim A, 2009, BLOOD, V114, P3498, DOI 10.1182/blood-2009-08-234054; Hsu Kenneth, 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P290; Jurgens B, 2010, CLIN IMMUNOL, V137, P1, DOI 10.1016/j.clim.2010.05.007; Korndorfer IP, 2007, J MOL BIOL, V370, P887, DOI 10.1016/j.jmb.2007.04.065; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; LEVITZ SM, 1986, J INFECT DIS, V154, P483, DOI 10.1093/infdis/154.3.483; Lulloff SJ, 2004, J LAB CLIN MED, V144, P208, DOI 10.1016/j.lab.2004.07.007; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; McCormick A, 2010, MICROBES INFECT, V12, P928, DOI 10.1016/j.micinf.2010.06.009; Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171; Mizgerd JP, 2008, NEW ENGL J MED, V358, P716, DOI 10.1056/NEJMra074111; Moroz OV, 2009, J MOL BIOL, V391, P536, DOI 10.1016/j.jmb.2009.06.004; MURTHY ARK, 1993, J IMMUNOL, V151, P6291; Nacken W, 2007, FEBS LETT, V581, P5127, DOI 10.1016/j.febslet.2007.09.060; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Raquil MA, 2008, J IMMUNOL, V180, P3366, DOI 10.4049/jimmunol.180.5.3366; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Segal BH, 1998, MEDICINE, V77, P345, DOI 10.1097/00005792-199809000-00004; Segal BH, 2009, MED MYCOL, V47, pS282, DOI 10.1080/13693780902736620; Seger RA, 2008, BRIT J HAEMATOL, V140, P255, DOI 10.1111/j.1365-2141.2007.06880.x; SOHNLE PG, 1991, J INFECT DIS, V164, P137, DOI 10.1093/infdis/164.1.137; Sohnle PG, 1996, J INFECT DIS, V174, P1369, DOI 10.1093/infdis/174.6.1369; Sohnle PG, 2000, J INFECT DIS, V182, P1272, DOI 10.1086/315810; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; SUGARMAN B, 1983, REV INFECT DIS, V5, P137; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	49	190	197	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1243	+		10.1016/j.jaci.2011.01.021	http://dx.doi.org/10.1016/j.jaci.2011.01.021			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21376380				2022-12-18	WOS:000290018600020
J	Sherrill, JD; Gao, PS; Stucke, EM; Blanchard, C; Collins, MH; Putnam, PE; Franciosi, JP; Kushner, JP; Abonia, JP; Assa'ad, AH; Kovacic, MB; Myers, JMB; Bochner, BS; He, H; Hershey, GK; Martin, LJ; Rothenberg, ME				Sherrill, Joseph D.; Gao, Pei-Song; Stucke, Emily M.; Blanchard, Carine; Collins, Margaret H.; Putnam, Phil E.; Franciosi, James P.; Kushner, Jonathan P.; Abonia, J. Pablo; Assa'ad, Amal H.; Kovacic, Melinda Butsch; Myers, Jocelyn M. Biagini; Bochner, Bruce S.; He, Hua; Hershey, Gurjit Khurana; Martin, Lisa J.; Rothenberg, Marc E.			Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; thymic stromal lymphopoietin; single nucleotide polymorphism; allergy; cytokine receptor-like factor 2; Toll-like receptor 3	EPITHELIAL-CELLS; IL-13	Background: The genetic cause of eosinophilic esophagitis (EE) has been largely unexplored until a recent genome-wide association study identified a disease susceptibility locus on 5q22, a region that harbors the thymic stromal lymphopoietin (TSLP) gene. However, it is unclear whether the observed genetic associations with EE are disease-specific or confounded by the high rate of allergy in patients with EE. In addition, the genetic contributions of other allergy-associated genes to EE risk have not been explored. Objective: We aimed to delineate single nucleotide polymorphisms (SNPs) that associated with EE apart from allergy. Methods: We used a custom array containing 738 SNPs in 53 genes implicated in allergic responses, immune responses, or both to genotype 220 allergic or 246 nonallergic control subjects and a discovery cohort of 170 patients with EE. We replicated a statistically significant SNP association in an independent case-control cohort and examined the induction of the candidate gene in primary esophageal epithelial cells. Results: A single SNP residing in the TSLP gene reached Bonferroni linkage disequilibrium adjusted significance but only when patients with EE were compared with allergic control subjects (rs10062929; P = 4.11 x 10(-5); odds ratio, 0.35). A nonsynonymous polymorphism in the thymic stromal lymphopoietin receptor (TSLPR) gene on Xp22.3 and Yp11.3 was significantly associated with disease only in male patients with EE. Primary esophageal epithelial cells expressed TSLP mRNA after Toll-like receptor 3 stimulation. Conclusion: These data collectively identify TSLP as a candidate gene critically involved in EE susceptibility beyond its role in promoting T(H)2 responses. (J Allergy Clin Immunol 2010;126:160-5.)	[Sherrill, Joseph D.; Stucke, Emily M.; Blanchard, Carine; Abonia, J. Pablo; Assa'ad, Amal H.; Hershey, Gurjit Khurana; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Gao, Pei-Song; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Collins, Margaret H.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Pathol & Lab Med,Dept Pediat, Cincinnati, OH 45229 USA; [Putnam, Phil E.; Franciosi, James P.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Gastroenterol Hepatol & Nutr,Dept Pediat, Cincinnati, OH 45229 USA; [Kushner, Jonathan P.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Gastroenterol,Dept Pediat, Cincinnati, OH 45229 USA; [Kovacic, Melinda Butsch; Myers, Jocelyn M. Biagini; Hershey, Gurjit Khurana] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Asthma Res,Dept Pediat, Cincinnati, OH 45229 USA; [He, Hua; Martin, Lisa J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Biostat & Epidemiol,Dept Pediat, Cincinnati, OH 45229 USA; [Martin, Lisa J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Human Genet,Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Sherrill, Joseph/B-6662-2014; Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Biagini, Jocelyn/0000-0002-4378-6133; Abonia, Juan/0000-0003-3788-6485	National Institutes of Health [U19 AI070235, R01 DK076893, HL091805]; Public Health Service [P30 DK0789392]; Department of Defense; Food Allergy Project; Buckeye Foundation; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation; Dana Foundation Human Immunology Consortium; Ception Therapeutics,; Children's Digestive Health and Nutrition Foundation; GlaxoSmithKline; Food Allergy and Anaphylaxis Network; Dana Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083450, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Department of Defense(United States Department of Defense); Food Allergy Project; Buckeye Foundation; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation; Dana Foundation Human Immunology Consortium; Ception Therapeutics,; Children's Digestive Health and Nutrition Foundation; GlaxoSmithKline(GlaxoSmithKline); Food Allergy and Anaphylaxis Network; Dana Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grant U19 AI070235, National Institutes of Health grant R01 DK076893, Public Health Service grant P30 DK0789392, the Department of Defense, the Food Allergy Project, the Buckeye Foundation, and the Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation. J.D.S. is supported by a T32 National Institutes of Health training grant (HL091805). PG., B.S.B., and M.E.R. were supported by a Dana Foundation Human Immunology Consortium Grant.; M. H. Collins has consultant and reviewer arrangements with GlaxoSmithKline, Ception Therapeutics, and Meritage Pharma. J. P. Abonia receives research support from the National Institutes of Health, Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. A. H. Assa'ad receives research support from GlaxoSmithKline and is a volunteer member of the medical board of directors for the American Partnership for Eosinophilic Disorders. L. J. Martin receives research support from the National Institutes of Health. M. E. Rothenberg is on the speakers' bureau for Merck; has consultant arrangements with Merck, Centocor, Ception Therapeutics, Nycomed, Array Biopharma, Biocrystal Pharmaceuticals, Endo Pharmaceuticals, and Pieres AG; receives research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation; is on the Medical Advisory Board for American Partnership for Eosinophilic Disorders; and is on the Executive Council for the International Eosinophil Society. The rest of the authors have declared that they have no conflict of interest.	ASAKAWA M, 1990, CELL MOL BIOL, V36, P265; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Cheng JL, 2006, PROTEINS, V62, P1125, DOI 10.1002/prot.20810; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Fisher R., 1970, STAT METHODS RES WOR; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Knisz J, 2009, CLIN IMMUNOL, V132, P277, DOI 10.1016/j.clim.2009.04.003; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Mullighan CG, 2009, NAT GENET, V41, P1243, DOI 10.1038/ng.469; Nicodemus KK, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-S1-S78; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Okayama Y, 2009, EUR RESPIR J, V34, P425, DOI 10.1183/09031936.00121008; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Roy-Ghanta S, 2008, CLIN GASTROENTEROL H, V6, P531, DOI 10.1016/j.cgh.2007.12.045; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941	25	190	199	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					160	165		10.1016/j.jaci.2010.04.037	http://dx.doi.org/10.1016/j.jaci.2010.04.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20620568	Green Accepted			2022-12-18	WOS:000280061800029
J	Guttman-Yassky, E; Suarez-Farinas, M; Chiricozzi, A; Nograles, KE; Shemer, A; Fuentes-Duculan, J; Cardinale, I; Lin, P; Bergman, R; Bowcock, AM; Krueger, JG				Guttman-Yassky, Emma; Suarez-Farinas, Mayte; Chiricozzi, Andrea; Nograles, Kristine E.; Shemer, Avner; Fuentes-Duculan, Judilyn; Cardinale, Irma; Lin, Peng; Bergman, Reuven; Bowcock, Anne M.; Krueger, James G.			Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; cornified envelope; terminal differentiation; altered barrier	GENE-EXPRESSION; PSORIASIS SUSCEPTIBILITY; CORNIFIED ENVELOPE; CHROMOSOME 1Q21; PATHOGENIC MECHANISMS; ALTERNATIVE PATHWAY; BARRIER FUNCTION; DENDRITIC CELLS; TH2 CYTOKINES; SKIN-DISEASE	Background: Psoriasis and atopic dermatitis (AD) are common, complex inflammatory skin diseases. Both diseases display immune infiltrates in lesions and epidermal growth/differentiation alterations associated with a defective skin barrier. An incomplete understanding of differences between these diseases makes it difficult to compare human disease pathology to animal disease models. Objective: To characterize differences between these diseases in expression of genes related to epidermal growth/differentiation and inflammatory circuits. Methods: We performed genomic profiling of mRNA in chronic psoriasis (n = 15) and AD (it = 18) skin lesions compared with normal human skin (it = 15). Results: As expected, clear disease classifications could he constructed on the basis of expected immune polarity (T(H)1, T(H)2, T(H)17) differences. However, even more striking differences were identified in epidermal differentiation programs that could be used for precise disease classifications. Although both psoriasis and AD skin lesions displayed regenerative epidermal hyperplasia, which is a general alteration in epidermal growth, keratinocyte terminal differentiation was differentially polarized. In AD, we found selective defects in expression of multiple genes encoding the cornified envelope, with the largest alteration in loricrin (expressed at 2% of the level of normal skin). At the ultrastructural level, the cornified envelope in AD was broadly defective with highly decreased compaction of corneocytes and reduced intercellular lipids. Hence, the entire keratinocyte terminal differentiation program (cytoplasmic compaction, cornification, and lipid release) is defective in AD, potentially underlying the immune differences. Conclusion: Our study shows that although alterations in barrier responses exist in both diseases, epidermal differentiation is differentially polarized, with major implications for primary disease pathogenesis. (J Allergy Clin Immunol 2009;124:1235-44.)	[Guttman-Yassky, Emma; Suarez-Farinas, Mayte; Chiricozzi, Andrea; Nograles, Kristine E.; Fuentes-Duculan, Judilyn; Cardinale, Irma; Krueger, James G.] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Guttman-Yassky, Emma] Cornell Univ, Weill Cornell Med Coll, Dept Dermatol, New York, NY 10021 USA; [Chiricozzi, Andrea] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; [Shemer, Avner] Tel Hashomer Hosp, Tel Aviv, Israel; [Shemer, Avner] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Lin, Peng; Bowcock, Anne M.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Bergman, Reuven] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel; [Bergman, Reuven] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Rockefeller University; Cornell University; University of Rome Tor Vergata; Tel Aviv University; Washington University (WUSTL); Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Krueger, JG (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10065 USA.	jgk@rockefeller.edu	Lin, P/G-7702-2014; Suarez-Farinas, Mayte/I-3558-2012; Nograles, Kristine/V-3648-2019	Suarez-Farinas, Mayte/0000-0001-8712-3553; Bowcock, Anne/0000-0001-8691-9090	National Institutes of Health [5ULIRR024143-02]; National Institutes of Health Roadmap for Medical Research [5ULIRR024143-02]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by grant number 5ULIRR024143-02 from the National Center for Research Resources, a component of the National Institutes of Health, and the National Institutes of Health Roadmap for Medical Research.	Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Capon F, 2001, J INVEST DERMATOL, V116, P728, DOI 10.1046/j.1523-1747.2001.01311.x; de Cid R, 2009, NAT GENET, V41, P211, DOI 10.1038/ng.313; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Elias Peter M, 2008, Drug Discov Today Dis Mech, V5, pe33, DOI 10.1016/j.ddmec.2008.05.006; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fartasch M, 1997, MICROSC RES TECHNIQ, V38, P361, DOI 10.1002/(SICI)1097-0029(19970815)38:4<361::AID-JEMT4>3.0.CO;2-M; FARTASCH M, 1994, J INVEST DERMATOL, V102, P366, DOI 10.1111/1523-1747.ep12371797; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Giardina E, 2004, ANN HUM GENET, V68, P639, DOI 10.1046/j.1529-8817.2004.00118.x; Giardina E, 2006, HUM HERED, V61, P229, DOI 10.1159/000095059; Gudjonsson JE, 2007, J INVEST DERMATOL, V127, P1292, DOI 10.1038/sj.jid.5700807; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Haider AS, 2006, J INVEST DERMATOL, V126, P912, DOI 10.1038/sj.jid.5700183; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Jackson B, 2005, J INVEST DERMATOL, V124, P1062, DOI 10.1111/j.0022-202X.2005.23699.x; Kess D, 2006, J IMMUNOL, V177, P4612, DOI 10.4049/jimmunol.177.7.4612; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Lee JH, 2007, J EUR ACAD DERMATOL, V21, P1360, DOI 10.1111/j.1468-3083.2007.02277.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Madison KC, 2003, J INVEST DERMATOL, V121, P231, DOI 10.1046/j.1523-1747.2003.12359.x; MANSBRIDGE JN, 1984, J INVEST DERMATOL, V83, P296, DOI 10.1111/1523-1747.ep12340429; Matsumoto M, 2008, P NATL ACAD SCI USA, V105, P6720, DOI 10.1073/pnas.0709345105; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; MCNUTT NS, 1981, CANCER, V47, P698, DOI 10.1002/1097-0142(19810215)47:4<698::AID-CNCR2820470413>3.0.CO;2-Z; Nair RP, 2006, AM J HUM GENET, V78, P827, DOI 10.1086/503821; Nickoloff BJ, 2006, J INVEST DERM SYMP P, V11, P16, DOI 10.1038/sj.jidsymp.5650010; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Plager DA, 2007, EXP DERMATOL, V16, P28, DOI 10.1111/j.1600-0625.2006.00504.x; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Saaf AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004017; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Scharschmidt TC, 2008, J INVEST DERMATOL, V128, P1061, DOI 10.1038/sj.jid.5701201; Semprini S, 2002, HUM GENET, V111, P310, DOI 10.1007/s00439-002-0812-5; Semprini S, 1999, HUM GENET, V104, P130, DOI 10.1007/s004390050925; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Sun C, 2006, HUM GENET, V119, P113, DOI 10.1007/s00439-005-0115-8; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Wenzel J, 2008, J INVEST DERMATOL, V128, P67, DOI 10.1038/sj.jid.5700945; Wilsmann-Theis D, 2008, EUR J DERMATOL, V18, P172, DOI 10.1684/ejd.2008.0357; Yao YH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002737; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zheng T, 2005, CURR ALLERGY ASTHM R, V5, P291, DOI 10.1007/s11882-005-0069-x; Zhou XH, 2003, PHYSIOL GENOMICS, V13, P69, DOI 10.1152/physiolgenomics.00157.2002	65	190	197	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1235	1244		10.1016/j.jaci.2009.09.031	http://dx.doi.org/10.1016/j.jaci.2009.09.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004782				2022-12-18	WOS:000273071500015
J	Scharschmidt, TC; Man, MQ; Hatano, Y; Crumrine, D; Gunathilake, R; Sundberg, JP; Silva, KA; Mauro, TM; Hupe, M; Cho, SY; Wu, Y; Celli, A; Schmuth, M; Feingold, KR; Elias, PM				Scharschmidt, Tiffany C.; Man, Mao-Qiang; Hatano, Yutaka; Crumrine, Debra; Gunathilake, Roshan; Sundberg, John P.; Silva, Kathleen A.; Mauro, Theodora M.; Hupe, Melanie; Cho, Soyun; Wu, Yan; Celli, Anna; Schmuth, Matthias; Feingold, Kenneth R.; Elias, Peter M.			Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; barrier function; contact dermatitis; filaggrin; flaky-tail mouse; lamellar body	HAIRLESS MOUSE SKIN; EPIDERMAL PERMEABILITY BARRIER; STRATUM-CORNEUM ACIDIFICATION; CONTACT-DERMATITIS MODELS; OF-FUNCTION MUTATIONS; ATOPIC-DERMATITIS; ICHTHYOSIS-VULGARIS; PATHOGENIC MECHANISMS; LAMELLAR BODIES; MURINE MODEL	Background: Mutations in the human filaggrin gene (FLG) are associated with atopic dermatitis (AD) and are presumed to provoke a barrier abnormality. Yet additional acquired stressors might be necessary because the same mutations can result in a noninflammatory disorder, ichthyosis vulgaris. Objective: We examined here whether FLG deficiency alone suffices to produce a barrier abnormality, the basis for the putative abnormality, and its proinflammatory consequences. Methods: By using the flaky-tail mouse, which lacks processed murine filaggrin because of a frameshift mutation in the gene encoding profilaggrin that mimics some mutations in human AD, we assessed whether FLG deficiency provokes a barrier abnormality, further localized the defect, identified its subcellular basis, and assessed thresholds to irritant- and hapten-induced dermatitis. Results: Flaky-tail mice exhibit low-grade inflammation with increased bidirectional, paracellular permeability of water-soluble xenobiotes caused by impaired lamellar body secretion and altered stratum corneum extracellular membranes. This barrier abnormality correlates with reduced inflammatory thresholds to both topical irritants and haptens. Moreover, when exposed repeatedly to topical haptens at doses that produce no inflammation in wild-type mice, flaky-tail mice experience a severe AD-like dermatosis with a further deterioration in barrier function and features of a T(H)2 immunophenotype (increased CRTH levels plus inflammation, increased serum IgE levels, and reduced antimicrobial peptide [mBD3] expression). Conclusions: FLG deficiency alone provokes a paracellular barrier abnormality in mice that reduces inflammatory thresholds to topical irritants/haptens, likely accounting for enhanced antigen penetration in FLG-associated AD. (J Allergy Clin Immunol 2009;124:496-506.)	[Scharschmidt, Tiffany C.; Man, Mao-Qiang; Hatano, Yutaka; Crumrine, Debra; Gunathilake, Roshan; Mauro, Theodora M.; Hupe, Melanie; Celli, Anna; Schmuth, Matthias; Feingold, Kenneth R.; Elias, Peter M.] Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; [Scharschmidt, Tiffany C.; Man, Mao-Qiang; Hatano, Yutaka; Crumrine, Debra; Gunathilake, Roshan; Mauro, Theodora M.; Hupe, Melanie; Celli, Anna; Schmuth, Matthias; Feingold, Kenneth R.; Elias, Peter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Sundberg, John P.; Silva, Kathleen A.] Jackson Lab, Bar Harbor, ME 04609 USA; [Cho, Soyun] Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Cho, Soyun] Boramae Hosp, Seoul, South Korea; [Wu, Yan] Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Jackson Laboratory; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Peking University	Elias, PM (corresponding author), VA Med Ctr, Dermatol Serv 190, 4150 Clement St, San Francisco, CA 94121 USA.	eliasp@derm.ucsf.edu	Man, Mao-Qiang/V-5266-2019; Cho, Soyun/B-7359-2013; Cho, Soyun/J-5666-2012	man, mao-qiang/0000-0002-0957-4903; Schmuth, Matthias/0000-0002-4064-1334; Scharschmidt, Tiffany/0000-0001-5517-089X; Gunathilake, Roshan/0000-0002-3241-0974; Cho, Soyun/0000-0003-2468-485X	National Institutes of Health [AR019098, AG028492, AI059311]; Medical Research Service, Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028492] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Service, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by National Institutes of Health grants AR019098, AG028492, AI059311 and the Medical Research Service, Department of Veterans Affairs.	Aberg KM, 2007, J CLIN INVEST, V117, P3339, DOI 10.1172/JCI31726; Behne MJ, 2002, J BIOL CHEM, V277, P47399, DOI 10.1074/jbc.M204759200; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; BOND JR, 1988, J INVEST DERMATOL, V90, P486, DOI 10.1111/1523-1747.ep12460958; BOND JR, 1988, J INVEST DERMATOL, V90, P810, DOI 10.1111/1523-1747.ep12462031; Brown SJ, 2008, J INVEST DERMATOL, V128, P1591, DOI 10.1038/sj.jid.5701206; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; Choi EH, 2007, J INVEST DERMATOL, V127, P2847, DOI 10.1038/sj.jid.5700913; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Demerjian M, 2006, EXP DERMATOL, V15, P154, DOI 10.1111/j.1600-0625.2006.00402.x; Demerjian M, 2006, J INVEST DERMATOL, V126, P2032, DOI 10.1038/sj.jid.5700332; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Elias PM, 2009, CURR ALLERGY ASTHM R, V9, P265, DOI [10.1007/s11882-009-0037-y, 10.1097/ACI.0b013e32832e7d36]; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Elias PM, 2002, EXP DERMATOL, V11, P248, DOI 10.1034/j.1600-0625.2001.110308.x; ELIAS PM, 2005, COSMECEUTICALS; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; FARTASCH M, 1992, BRIT J DERMATOL, V127, P221, DOI 10.1111/j.1365-2133.1992.tb00118.x; Fluhr JW, 2001, BRIT J DERMATOL, V145, P696, DOI 10.1046/j.1365-2133.2001.04431.x; Fluhr JW, 2001, J INVEST DERMATOL, V117, P44, DOI 10.1046/j.0022-202x.2001.01399.x; Fowler AJ, 2003, J INVEST DERMATOL, V120, P246, DOI 10.1046/j.1523-1747.2003.12033.x; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gruber R, 2007, J INVEST DERMATOL, V127, pS87; Gunathilake R, 2009, J INVEST DERMATOL, V129, P1719, DOI 10.1038/jid.2008.442; Hachem JP, 2005, J INVEST DERMATOL, V125, P510, DOI 10.1111/j.0022-202X.2005.23838.x; HINZ RS, 1989, J INVEST DERMATOL, V93, P87, DOI 10.1111/1523-1747.ep12277361; HOCHULI E, 1987, J ANTIBIOT, V40, P1086, DOI 10.7164/antibiotics.40.1086; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Man MQ, 2008, J INVEST DERMATOL, V128, P370, DOI 10.1038/sj.jid.5701026; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; MENON GK, 1992, BRIT J DERMATOL, V126, P337, DOI 10.1111/j.1365-2133.1992.tb00675.x; Menon GK, 1997, SKIN PHARMACOL, V10, P235; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland R. B., 2006, SKIN BARRIER, P111; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rassner UA, 1997, HISTOCHEM J, V29, P387, DOI 10.1023/A:1026438917856; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Scharschmidt TC, 2008, J INVEST DERMATOL, V128, P1061, DOI 10.1038/sj.jid.5701201; Schmuth M, 2005, J INVEST DERMATOL, V124, pA72; Schmuth M, 2004, J INVEST DERMATOL, V122, P909, DOI 10.1111/j.0022-202X.2004.22431.x; Schmuth M, 2001, J INVEST DERMATOL, V117, P837, DOI 10.1046/j.0022-202x.2001.01471.x; Schmuth Matthias, 2007, Adv Dermatol, V23, P231, DOI 10.1016/j.yadr.2007.07.011; Schmuth M, 2008, J LIPID RES, V49, P499, DOI 10.1194/jlr.R800001-JLR200; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Sheu Hamm-Ming, 1998, Journal of Dermatology (Tokyo), V25, P281; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Sundberg JP, 1994, HDB MOUSE MUTATIONS, P345; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630	65	190	195	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					496	U164		10.1016/j.jaci.2009.06.046	http://dx.doi.org/10.1016/j.jaci.2009.06.046			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733297	Green Accepted			2022-12-18	WOS:000274315900015
J	Jenkins, JA; Griffiths-Jones, S; Shewry, PR; Breiteneder, H; Mills, ENC				Jenkins, JA; Griffiths-Jones, S; Shewry, PR; Breiteneder, H; Mills, ENC			Structural relatedness of plant food allergens with specific reference to cross-reactive allergens: An in silico analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen bioinformatics; distribution of plant food allergens across protein families; plant food allergen structures; Bet v 1 family cross-reactivity; nsLTP family cross-reactivity	LIPID TRANSFER PROTEIN; BIRCH POLLEN ALLERGEN; MAJOR ALLERGEN; EPITOPE ANALYSIS; 2S ALBUMIN; IGE; DATABASE; BET-V-1; CLASSIFICATION; IDENTIFICATION	Background: The body of sequence and structural information on allergens and the sequence analysis of whole plant genomes are facilitating the application of bioinformatic approaches to identifying and defining plant allergens. Objective: An in silico approach was used to quantify the distribution of plant food allergen sequences across protein families and to develop and apply a novel means of assessing conserved surface features important for IgE cross-reactivity. Methods: Plant food allergen sequences were classified into Pfam families on the basis of sequence homology. Contact surface areas of selected proteins were calculated with MOLMOL by using a 1.4-Angstrom probe, corrected by removing contributions from IgE inaccessible main chains and side chains forming the ligand binding sites. Results: A set of 129 food allergen sequences were classified into only 20 of 3849 possible Pfam families, with 4 families accounting for more than 65% of food allergens. Structural bioinformatic analysis of conserved exterior main chains and amino acid side chains in cross-reactive homologues of Bet v I and nonspecific lipid transfer proteins showed higher levels of similarity than shown by simple sequence comparisons. Thus, 75% of the Mal d 1 surface is likely to bind anti-Bet v 1 antibodies, compared with a sequence identity of similar to56%. Conclusion: Most plant food allergens belong to only 4 structural families, indicating that conserved structures and biological activities may play a role in determining or promoting allergenic properties. Structural bioinformatic analysis shows that conservation of 3-dimensional structure should be included in any assessment of potential IgE cross-reactivity in, for example, novel proteins.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Inst Food Res, Inst Food Res, Norwich NR4 7UA, Norfolk, England; Wellcome Trust Sanger Inst, Cambridge, England; Rothamsted Res, Harpenden, Herts, England	Medical University of Vienna; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Wellcome Trust Sanger Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol, AKH EBO-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Heimo.Breiteneder@meduniwien.ac.at	Griffiths-Jones, Sam/H-2998-2014	Griffiths-Jones, Sam/0000-0001-6043-807X				Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Hileman RE, 2002, INT ARCH ALLERGY IMM, V128, P280, DOI 10.1159/000063861; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; MENENDEZARIAS L, 1990, MOL IMMUNOL, V27, P143, DOI 10.1016/0161-5890(90)90109-D; Midoro-Horiuti T, 2003, MOL IMMUNOL, V40, P555, DOI 10.1016/S0161-5890(03)00168-8; Mills ENC, 2004, CRIT REV FOOD SCI, V44, P379, DOI 10.1080/10408690490489224; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pantoja-Uceda D, 2004, BIOCHEMISTRY-US, V43, P6976, DOI 10.1021/bi0496900; Pantoja-Uceda D, 2003, BIOCHEMISTRY-US, V42, P13839, DOI 10.1021/bi0352217; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Pruess M, 2003, NUCLEIC ACIDS RES, V31, P414, DOI 10.1093/nar/gkg105; Robotham JM, 2002, J ALLERGY CLIN IMMUN, V109, P143, DOI 10.1067/mai.2002.120558; San Miguel-Moncin M, 2003, ALLERGY, V58, P511, DOI 10.1034/j.1398-9995.2003.00097.x; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Soeria-Atmadja D, 2004, INT ARCH ALLERGY IMM, V133, P101, DOI 10.1159/000076382; Stadler MB, 2003, FASEB J, V17, P1141, DOI 10.1096/fj.02-1052fje; Taylor SL, 2002, CURR OPIN ALLERGY CL, V2, P249, DOI 10.1097/00130832-200206000-00015; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	33	190	199	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					163	170		10.1016/j.jaci.2004.10.026	http://dx.doi.org/10.1016/j.jaci.2004.10.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637564	Green Published			2022-12-18	WOS:000226267000024
J	Gardulf, A; Nicolay, U; Asensio, O; Bernatowska, E; Bock, A; Costa-Carvalho, BT; Granert, C; Haag, S; Hernandez, D; Kiessling, P; Kus, J; Matamoros, N; Niehues, T; Schmidt, S; Schulze, I; Borte, M				Gardulf, A; Nicolay, U; Asensio, O; Bernatowska, E; Bock, A; Costa-Carvalho, BT; Granert, C; Haag, S; Hernandez, D; Kiessling, P; Kus, J; Matamoros, N; Niehues, T; Schmidt, S; Schulze, I; Borte, M			Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiencies; subcutaneous IgG therapy; intravenous IgG therapy; quality of life; home care; patient satisfaction; self-care; nursing	GAMMA-GLOBULIN; IMMUNOGLOBULIN REPLACEMENT; THERAPY; SAFETY; HYPOGAMMAGLOBULINEMIA; COSTS	Background: A large number of children and adults with primary antibody deficiencies need lifelong IgG replacement therapy. It is mostly unknown what effect the choice of replacement therapy has on the patients' health-related quality of life (HRQOL) and treatment satisfaction (TS). Objective: To investigate whether a switch from hospital-based intravenous IgG (IVIG) to home-based subcutaneous IgG (SCIG) therapy would improve the HRQOL and TS. Methods: Fifteen children (<14 years; hospital-based IVIG therapy at enrollment) and 32 adults (greater than or equal to14 years; 22 on hospital-based IVIG and 10 on home-based SCIG therapy at enrollment) were included. Questionnaires were completed at baseline and at 6 and 10 months: the Child Health Questionnaire-Parental Form 50 (children) or Short Form 36 (adults), the Life Quality Index, and questions regarding therapy preferences. Results: The SCIG home therapy was reported to give better health (P = .001) and improved school/social functioning (P = .02) for the children, reduced emotional distress (P = .02) and limitations on personal time for the parents (P = .004), and fewer limitations on family activities (P = .002). Adults switching therapy reported improved vitality (P = .04), mental health (P = .05), and social functioning (P = .01). Adults already on SCIG home therapy at enrollment retained high HRQOL and TS scores. The SCIG home therapy improved TS because it led to greater independence and better therapy convenience (P <.05). The patients preferred the SCIG administration route and having the treatment at home. Conclusions: Home-based SCIG therapy improves several important aspects of HRQOL and provides the patients with primary antibody deficiencies and their families with greater independence and better control of the therapy situation and daily life. SCIG home therapy is an appreciated therapeutic alternative for adults and children in need of lifelong IgG replacement therapy.	Karolinska Univ Hosp, Swedish Ctr Immunodeficiencies, Div Clin Immunol, Dept Lab Med, SE-14186 Stockholm, Sweden; Consorcio Hosp Parc Tauli, Serv Immunol Clin, Sabadell, Spain; Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; Univ Vienna, Klin Kinder & Jugendheilkunde, Vienna, Austria; Univ Fed Sao Paulo, Dept Pediat, Div Rheumatol Allergy & Clin Immunol, Sao Paulo, Brazil; Karolinska Univ Hosp, Clin Immunol Sect, Immunodeficiency Unit, SE-14186 Stockholm, Sweden; ZLB Behring GMBH, Marburg, Germany; Hosp Univ La Fe, Dept Allergy, Valencia, Spain; Natl Res Inst TB & Lung Dis, Warsaw, Poland; Hosp Univ Son Dureta, Serv Immunol, Palma de Mallorca, Spain; Univ Klinikum Dusseldorf, Klin Kinder Onkol Hamatol & Immunol, Dusseldorf, Germany; Univ Freiburg, Med Klin, Abt Rheumatol & Klin Immunol, D-7800 Freiburg, Germany; Humboldt Univ, Charite Berlin, Klin Padiat, Schwerpunkt Pneumol Immunol, Berlin, Germany; Univ Leipzig, Akad Lehrkrankenhaus, Stadt Klinikum St Georg Leipzig, Klin Kinder & Jugendmed, Leipzig, Germany	Karolinska Institutet; Karolinska University Hospital; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Children's Memorial Health Institute; University of Vienna; Universidade Federal de Sao Paulo (UNIFESP); Karolinska Institutet; Karolinska University Hospital; Hospital Universitari i Politecnic La Fe; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leipzig University	Gardulf, A (corresponding author), Karolinska Univ Hosp, Swedish Ctr Immunodeficiencies, Div Clin Immunol, Dept Lab Med, M96, SE-14186 Stockholm, Sweden.	ann.gardulf@labmed.ki.se		Bernatowska, Ewa/0000-0002-0125-266X				Abrahamsen TG, 1996, PEDIATRICS, V98, P1127; Acquadro C., 1996, QUALITY LIFE PHARMAC, P575; ANDERSON RT, 1993, QUAL LIFE RES, V2, P369, DOI 10.1007/BF00422215; Brennan V, 1993, Immunodeficiency, V4, P79; Brown H., 1999, APPL MIXED MODELS ME; Chapel HM, 2000, J CLIN IMMUNOL, V20, P94, DOI 10.1023/A:1006678312925; Conley ME, 2002, CLIN IMMUNOL, V104, P201, DOI 10.1006/clim.2002.5252; DALY PB, 1991, ANN ALLERGY, V67, P504; *EUR AG EV MED PRO, 1999, NOT GUID CLIN IN HUM; *EUR AG EV MED PRO, 2002, NOT GUID CLIN IN HUM; Fairclough DL, 2002, DESIGN ANAL QUALITY; Fayers P. M., 2007, QUALITY LIFE ASSESSM; GARDULF A, 1993, CLIN EXP IMMUNOL, V92, P200; GARDULF A, 1995, LANCET, V345, P365; GARDULF A, 1991, LANCET, V338, P162; GARDULF A, 1995, INT J TECHNOL ASSESS, V11, P345, DOI 10.1017/S0266462300006942; GARDULF A, 1995, J ADV NURS, V21, P917, DOI 10.1046/j.1365-2648.1995.21050917.x; Gaspar J, 1998, ARCH DIS CHILD, V79, P48, DOI 10.1136/adc.79.1.48; Gustafson R, 1997, LANCET, V350, P865, DOI 10.1016/S0140-6736(05)62034-X; Gustafson R, 2002, ELLIPSE, V18, P45; Hansen S, 2002, CLIN IMMUNOL, V104, P237, DOI 10.1006/clim.2002.5215; Henderson Karen, 2003, Nurs Times, V99, P28; Landgraf JM, 1999, CHILD HLTH QUESTIONN; Radinsky S, 2003, J ALLERGY CLIN IMMUN, V112, P630, DOI 10.1067/mai.2003.1688; Rosenzweig ML, 1999, EVOL ECOL RES, V1, P1; THOMAS MJ, 1993, LANCET, V342, P1432, DOI 10.1016/0140-6736(93)92798-X; WANIEWSKI J, 1994, J CLIN IMMUNOL, V14, P90, DOI 10.1007/BF01541341; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 2000, SF 36 HLTH SUVEY MAN	29	190	194	0	15	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					936	942		10.1016/j.jaci.2004.06.053	http://dx.doi.org/10.1016/j.jaci.2004.06.053			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480339				2022-12-18	WOS:000224439100033
J	Matheu, V; Back, O; Mondoc, E; Issazadeh-Navikas, S				Matheu, V; Back, O; Mondoc, E; Issazadeh-Navikas, S			Dual effects of vitamin D-induced alteration of T(H)1/T(H)2 cytokine expression: Enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vitamin D; eosinophils; cytokines; IL-4; IL-5; IL-13; allergy; costimulation; inflammation; knockout; lung	NONOBESE DIABETIC MICE; 1,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; ASTHMA; ENCEPHALOMYELITIS; PROLIFERATION; INDUCTION; PREVENTS	Background: Vitamin D, a common food additive, has been shown to prevent the induction of experimental autoimmune diseases in mice. A possible immune deviation from T(H)1 to T(H)2 responses has been postulated. Although there is no doubt about the beneficial effects of vitamin D, its role in allergy has not been investigated. Objective: To define the role of vitamin D in modulating the development of a T(H)2-mediated disease, we used a murine model of pulmonary eosinophilic inflammation. Methods: Five-week-old mice were primed on day 0 with oval-bumin intraperitoneally. Then they were nasally challenged with ovalbumin on days 7, 8, 9, and 10, and on day 11, samples were studied. Some mice received subcutaneous injections of vitamin D every second day as follows: days -3, -1, 1, 3, 5, 7, and 9. The control groups received PBS on the same days. Results: Early treatment with vitamin D augmented allergen-induced T-cell proliferation along with TH2 cytokine (IL-4 and IL-13) and IgE production. Surprisingly, the local inflammatory response in bronchoalveolar lavage fluid and lung, tissue was significantly ameliorated with impaired recruitment of eosinophils and inferior levels of IL-5. These findings were attributed to late treatment with vitamin D after establishment of an early immune response. Conclusion: We suggest that excess supplementation of vitamin D could influence the development of a sustained TH2 response, leading to an increasing prevalence of allergy, whereas vitamin D might hold promising beneficial effects in airway eosinophitia.	Lund Univ, Inst Cell & Mol Biol, Sect Med Inflammat Res, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Lund Univ, Dept Med Microbiol Dermatol & Infect, Div Dermatol & Venerol, Lund, Sweden	Lund University; Lund University	Matheu, V (corresponding author), Lund Univ, Inst Cell & Mol Biol, Sect Med Inflammat Res, Dept Cell & Mol Biol, BMC 111, S-22184 Lund, Sweden.		Issazadeh-Navikas, Shohreh/AAI-7900-2021; Matheu, Victor/AAU-3043-2020	Matheu, Victor/0000-0002-0469-800X				Adorini L, 2001, TRANSPLANT P, V33, P58, DOI 10.1016/S0041-1345(00)02262-4; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Cantorna MT, 1998, TRANSPLANTATION, V66, P828, DOI 10.1097/00007890-199810150-00003; Cantorna MT, 2000, ARCH BIOCHEM BIOPHYS, V377, P135, DOI 10.1006/abbi.2000.1765; Cantorna MT, 1998, J NUTR, V128, P68, DOI 10.1093/jn/128.1.68; Cantorna MT, 1998, J IMMUNOL, V160, P5314; Casteels K, 1998, TRANSPLANTATION, V65, P1225, DOI 10.1097/00007890-199805150-00014; Casteels KM, 1998, ENDOCRINOLOGY, V139, P95, DOI 10.1210/en.139.1.95; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Ferlin WG, 1996, EUR J IMMUNOL, V26, P2911, DOI 10.1002/eji.1830261216; Gijbels MJJ, 2000, EXP DERMATOL, V9, P351, DOI 10.1034/j.1600-0625.2000.009005351.x; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; IHO S, 1985, IMMUNOL LETT, V11, P331, DOI 10.1016/0165-2478(85)90116-6; Jabara HH, 2001, J CLIN INVEST, V107, P371, DOI 10.1172/JCI10168; Jirapongsananuruk O, 2000, J ALLERGY CLIN IMMUN, V106, P981, DOI 10.1067/mai.2000.110101; LEMIRE JM, 1992, J BONE MINER RES, V7, P171; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; LEMIRE JM, 1984, J CLIN INVEST, V74, P657, DOI 10.1172/JCI111465; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MATHEU V, 2001, ALLERGOL IMMUNOL CLI, V16, P282; MATHIEU C, 1994, TRANSPLANT P, V26, P3130; MATHIEU C, 1992, DIABETES, V41, P1491, DOI 10.2337/diabetes.41.11.1491; Matricardi PM, 2001, ANN ALLERG ASTHMA IM, V87, P24, DOI 10.1016/S1081-1206(10)62336-8; Mattner F, 2000, EUR J IMMUNOL, V30, P498, DOI 10.1002/1521-4141(200002)30:2<498::AID-IMMU498>3.0.CO;2-Q; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; Meehan TF, 2002, P NATL ACAD SCI USA, V99, P5557, DOI 10.1073/pnas.082100699; Morawetz RA, 1996, J EXP MED, V184, P1651, DOI 10.1084/jem.184.5.1651; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; Obase Y, 2001, ANN ALLERG ASTHMA IM, V86, P304, DOI 10.1016/S1081-1206(10)63303-0; Overbergh L, 2000, DIABETES, V49, P1301, DOI 10.2337/diabetes.49.8.1301; PAKKALA S, 1995, LEUKEMIA RES, V19, P65, DOI 10.1016/0145-2126(94)00065-I; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; REICHEL H, 1987, P NATL ACAD SCI USA, V84, P3385, DOI 10.1073/pnas.84.10.3385; Smith EA, 2000, J ENDOCRINOL, V165, P163, DOI 10.1677/joe.0.1650163; Steerenberg PA, 1999, CLIN EXP ALLERGY, V29, P1304, DOI 10.1046/j.1365-2222.1999.00658.x; Sullivan S, 1996, J ALLERGY CLIN IMMUN, V97, P966, DOI 10.1016/S0091-6749(96)80072-8; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; YANG SL, 1993, BIOCHIM BIOPHYS ACTA, V1158, P279, DOI 10.1016/0304-4165(93)90026-5; Zhang DH, 1998, J IMMUNOL, V161, P3817; ZHOU JY, 1990, P NATL ACAD SCI USA, V87, P3929, DOI 10.1073/pnas.87.10.3929	49	190	224	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					585	592		10.1037/mai.2003.1703	http://dx.doi.org/10.1037/mai.2003.1703			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679819				2022-12-18	WOS:000185231200019
J	DESHAZO, RD; SWAIN, RE				DESHAZO, RD; SWAIN, RE			DIAGNOSTIC-CRITERIA FOR ALLERGIC FUNGAL SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUSITIS; FUNGUS; ALLERGIC MUCIN	ASPERGILLUS SINUSITIS; CURVULARIA-LUNATA; BIPOLARIS SINUSITIS; DRECHSLERA; PHAEOHYPHOMYCOSIS	Diagnostic criteria for allergic fungal sinusitis have not been established, and clinical information consists primarily of isolated case reports. We proposed five diagnostic criteria for allergic fungal sinusitis including: (1) the demonstration of the characteristic eosinophil-rich allergic mucin visually or histopathologically (2) a positive fungal stain or culture from the sinus at surgery, and (3) the absence of immunodeficiency or diabetes. With these criteria, seven patients in our metropolitan area with allergic fungal sinusitis were identified in a short period. Initial symptoms in our seven patients reflected those in 99 case reports in that two children were first seen with proptosis, one child and three adults with nasal congestion and one adult with symptoms of chronic sinusitis, All had pansinusitis as shown on x-ray films. Six patients were atopic, five had nasal polyposis, and five had Curvularia species cultured from the sinuses. Infections with Bipolaris species, asthma, and chronic sinusitis were less common in our patients than in those previously reported. Recurrent symptoms and additional surgery sometimes resulted when the diagnosis was delayed by failure to obtain silver stains for fungus on surgical material sent for histopathologic review. Sinus tomography showed that the fungal material in the sinuses was of high density, which distinguished it from polyps or bacterial exudate. Bony compression, erosion, and rupture of the sinus walls were common. Results of IgE levels, precipitin determinations and eosinophil counts were variable in both our patients and those in the literature. On the basis of our review, we believe that the simple diagnostic criteria proposed are appropriate for both research and clinical purposes.	UNIV SO ALABAMA,DIV ALLERGY IMMUNOL,MOBILE,AL 36688; UNIV SO ALABAMA,DEPT PEDIAT,MOBILE,AL 36688; UNIV SO ALABAMA,COLL MED,DEPT SURG,MOBILE,AL 36688	University of South Alabama; University of South Alabama; University of South Alabama	DESHAZO, RD (corresponding author), UNIV SO ALABAMA,DEPT MED,2451 FILLINGIM ST,SUITE 400-A,MOBILE,AL 36617, USA.							ADAM RD, 1986, MEDICINE, V65, P203, DOI 10.1097/00005792-198607000-00001; ALLPHIN AL, 1991, LARYNGOSCOPE, V101, P815, DOI 10.1288/00005537-199108000-00003; BARTYNSKI JM, 1990, OTOLARYNG HEAD NECK, V103, P32, DOI 10.1177/019459989010300105; BERRY AJ, 1984, J PEDIAT INFECT DIS, V3, P150; BHAGAT R, 1991, J ALLERGY CLIN IMMUN, V91, P1094; BRUMMUND W, 1986, JAMA-J AM MED ASSOC, V256, P3249; DEJUAN E, 1983, AM J OPHTHALMOL, V96, P299, DOI 10.1016/S0002-9394(14)77818-3; DELBALSO AM, 1990, MAXILLOFACIAL IMAGIN, P177; ENCE BK, 1990, AM J RHINOL, V4, P169; FRENKEL L, 1987, PEDIATR INFECT DIS J, V6, P1130, DOI 10.1097/00006454-198706120-00012; FRIEDMAN GC, 1991, AM J CLIN PATHOL, V96, P368, DOI 10.1093/ajcp/96.3.368; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; GREENBERGER PA, 1993, ALLERGY PRINCIPLES P, P1395; GUMMA SA, 1991, T R SOC TROP MED HYG, V86, P93; Handley GH, 1990, AM J RHINOL, V4, P149; HARPSTER WH, 1985, OTOLARYNG HEAD NECK, V93, P683; JACKSON IT, 1987, PLAST RECONSTR SURG, V79, P804, DOI 10.1097/00006534-198705000-00022; JAY WM, 1988, AM J OPHTHALMOL, V105, P366, DOI 10.1016/0002-9394(88)90299-1; JONATHAN D, 1989, J LARYNGOL OTOL, V103, P1181, DOI 10.1017/S0022215100111296; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KILLINGSWORTH SM, 1990, LARYNGOSCOPE, V100, P932, DOI 10.1288/00005537-199009000-00004; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; MACMILLAN RH, 1987, HUM PATHOL, V18, P960, DOI 10.1016/S0046-8177(87)80276-9; MANNING SC, 1991, ARCH OTOLARYNGOL, V117, P174; MCCAFFREY TV, 1991, MAYO CLIN P, V68, P571; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; NISHIOKA G, 1987, ARCH OTOLARYNGOL, V113, P665; Platts-Mills TA, 1993, ALLERGY PRINCIPLES P, P469; ROBSON JMB, 1989, AUST NZ J MED, V19, P351, DOI 10.1111/j.1445-5994.1989.tb00278.x; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; SCULLY RE, 1991, NEW ENGL J MED, V324, P1424; SHAH A, 1990, ANN ALLERGY, V64, P507; SHER TH, 1988, J ALLERGY CLIN IMMUN, V81, P844, DOI 10.1016/0091-6749(88)90940-2; SLAVIN RG, 1993, ALLERGY PRINCIPLES P, P1455; SOBOL SM, 1984, LARYNGOSCOPE, V94, P620; TRAVIS WD, 1991, HUM PATHOL, V22, P1240, DOI 10.1016/0046-8177(91)90106-Y; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; WICKERN GM, 1993, J ALLERGY CLIN IMMUN, V92, P624, DOI 10.1016/0091-6749(93)90087-V; YOUNG CN, 1978, J LARYNGOL OTOL, V92, P137, DOI 10.1017/S0022215100085145; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	42	190	203	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					24	35		10.1016/S0091-6749(95)70029-3	http://dx.doi.org/10.1016/S0091-6749(95)70029-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622760	Bronze			2022-12-18	WOS:A1995RK38300004
J	OHMAN, JL; FINDLAY, SR; LEITERMANN, KM				OHMAN, JL; FINDLAY, SR; LEITERMANN, KM			IMMUNOTHERAPY IN CAT-INDUCED ASTHMA - DOUBLE-BLIND TRIAL WITH EVALUATION OF INVIVO AND INVITRO RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA	Tufts University	OHMAN, JL (corresponding author), VET ADM OUTPATIENT CLIN, ALLERGY LAB, 17 COURT ST, BOSTON, MA 02108 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI018023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BRUUN EGON, 1949, ACTA ALLERGOL, V2, P122, DOI 10.1111/j.1398-9995.1949.tb03295.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FORGACS P, 1968, BRIT MED J, V3, P774; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LEITERMANN K, 1982, Journal of Allergy and Clinical Immunology, V69, P104; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; WARNER JO, 1978, LANCET, V2, P912; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269	25	190	193	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					230	239		10.1016/0091-6749(84)90251-3	http://dx.doi.org/10.1016/0091-6749(84)90251-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6206105	Bronze			2022-12-18	WOS:A1984TJ80800003
J	GREEN, GR; ROSENBLUM, AH; SWEET, LC				GREEN, GR; ROSENBLUM, AH; SWEET, LC			EVALUATION OF PENICILLIN HYPERSENSITIVITY - VALUE OF CLINICAL HISTORY AND SKIN TESTING WITH PENICILLOYL-POLYLYSINE AND PENICILLIN-G	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP UNIV PENN,PHILADELPHIA,PA 19104; HENRY FORD HOSP,DIV ALLERGY,DETROIT,MI 48202; MICHAEL REESE HOSP & MED CTR,DEPT PEDIAT,CHICAGO,IL 60616	University of Pennsylvania; Pennsylvania Medicine; Henry Ford Health System; Henry Ford Hospital; Michael Reese Hospital & Medical Center								BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; GRIECO MH, 1967, ARCH INTERN MED, V119, P141, DOI 10.1001/archinte.119.2.141; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1960, J EXP MED, V112, P1131, DOI 10.1084/jem.112.6.1131; PARKER CW, 1965, FED PROC, V24, P51; PARKER CW, 1975, NEW ENGL J MED, V292, P957, DOI 10.1056/NEJM197505012921806; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; THOBURN R, 1966, J AMER MED ASSOC, V198, P345, DOI 10.1001/jama.198.4.345	10	190	192	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					339	345		10.1016/0091-6749(77)90064-1	http://dx.doi.org/10.1016/0091-6749(77)90064-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	925260	Bronze			2022-12-18	WOS:A1977ED83400002
J	Hartmann, K; Escribano, L; Grattan, C; Brockow, K; Carter, MC; Alvarez-Twose, I; Matito, A; Broesby-Olsen, S; Siebenhaar, F; Lange, M; Niedoszytko, M; Castells, M; Oude Elberink, JNG; Bonadonna, P; Zanotti, R; Hornick, JL; Torrelo, A; Grabbe, J; Rabenhorst, A; Nedoszytko, B; Butterfield, JH; Gotlib, J; Reiter, A; Radia, D; Hermine, O; Sotlar, K; George, TI; Kristensen, TK; Kluin-Nelemans, HC; Yavuz, S; Hagglund, H; Sperr, WR; Schwartz, LB; Triggiani, M; Maurer, M; Nilsson, G; Horny, HP; Arock, M; Orfao, A; Metcalfe, DD; Akin, C; Valent, P				Hartmann, Karin; Escribano, Luis; Grattan, Clive; Brockow, Knut; Carter, Melody C.; Alvarez-Twose, Ivan; Matito, Almudena; Broesby-Olsen, Sigurd; Siebenhaar, Frank; Lange, Magdalena; Niedoszytko, Marek; Castells, Mariana; Oude Elberink, Joanna N. G.; Bonadonna, Patrizia; Zanotti, Roberta; Hornick, Jason L.; Torrelo, Antonio; Grabbe, Juergen; Rabenhorst, Anja; Nedoszytko, Boguslaw; Butterfield, Joseph H.; Gotlib, Jason; Reiter, Andreas; Radia, Deepti; Hermine, Olivier; Sotlar, Karl; George, Tracy I.; Kristensen, Thomas K.; Kluin-Nelemans, Hanneke C.; Yavuz, Selim; Hagglund, Hans; Sperr, Wolfgang R.; Schwartz, Lawrence B.; Triggiani, Massimo; Maurer, Marcus; Nilsson, Gunnar; Horny, Hans-Peter; Arock, Michel; Orfao, Alberto; Metcalfe, Dean D.; Akin, Cem; Valent, Peter			Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Classification; cutaneous mastocytosis; diagnostic criteria; mast cell; mastocytosis; standardization; urticaria pigmentosa	MAST-CELLS; PEDIATRIC MASTOCYTOSIS; URTICARIA PIGMENTOSA; SYSTEMIC MASTOCYTOSIS; ONSET MASTOCYTOSIS; DIAGNOSTIC-CRITERIA; GERMLINE MUTATION; TRYPTASE LEVELS; ADULT PATIENTS; RISK-FACTORS	Cutaneous lesions in patients with mastocytosis are highly heterogeneous and encompass localized and disseminated forms. Although a classification and criteria for cutaneous mastocytosis (CM) have been proposed, there remains a need to better define subforms of cutaneous manifestations in patients with mastocytosis. To address this unmet need, an international task force involving experts from different organizations (including the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology) met several times between 2010 and 2014 to discuss the classification and criteria for diagnosis of cutaneous manifestations in patients with mastocytosis. This article provides the major outcomes of these meetings and a proposal for a revised definition and criteria. In particular, we recommend that the typical maculopapular cutaneous lesions (urticaria pigmentosa) should be subdivided into 2 variants, namely a monomorphic variant with small maculopapular lesions, which is typically seen in adult patients, and a polymorphic variant with larger lesions of variable size and shape, which is typically seen in pediatric patients. Clinical observations suggest that the monomorphic variant, if it develops in children, often persists into adulthood, whereas the polymorphic variant may resolve around puberty. This delineationmight have important prognostic implications, and its implementation in diagnostic algorithms and future mastocytosis classifications is recommended. Refinements are also suggested for the diagnostic criteria of CM, removal of telangiectasia macularis eruptiva perstans from the current classification of CM, and removal of the adjunct solitary from the term solitary mastocytoma.	[Hartmann, Karin; Rabenhorst, Anja] Univ Cologne, Dept Dermatol, Cologne, Germany; [Hartmann, Karin] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Escribano, Luis; Orfao, Alberto] Univ Salamanca, Serv Cent Citometria NUCLEUS, Ctr Invest Canc IBMCC, CSIC USAL, E-37008 Salamanca, Spain; [Escribano, Luis; Orfao, Alberto] Univ Salamanca, Dept Med, E-37008 Salamanca, Spain; [Escribano, Luis; Orfao, Alberto] Univ Salamanca, IBSAL, E-37008 Salamanca, Spain; [Grattan, Clive] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England; [Brockow, Knut] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80290 Munich, Germany; [Carter, Melody C.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Alvarez-Twose, Ivan; Matito, Almudena] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Kristensen, Thomas K.] Odense Univ Hosp, Dept Pathol, Odense, Denmark; [Siebenhaar, Frank; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Interdisciplinary Mastocytosis Ctr Charite, Berlin, Germany; [Lange, Magdalena; Nedoszytko, Boguslaw] Med Univ Gdansk, Dept Dermatol Venereol & Allergol, Gdansk, Poland; [Niedoszytko, Marek] Med Univ Gdansk, Dept Allergol, Gdansk, Poland; [Castells, Mariana; Akin, Cem] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Oude Elberink, Joanna N. G.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Dept Allergol, NL-9700 AB Groningen, Netherlands; [Bonadonna, Patrizia] Verona Univ Hosp, Allergy Unit, Verona, Italy; [Zanotti, Roberta] Verona Univ Hosp, Dept Med, Sect Hematol, Verona, Italy; [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; [Torrelo, Antonio] Hosp Nino Jesus, Dept Dermatol, Madrid, Spain; [Grabbe, Juergen] Cantonal Hosp Aarau, Dept Dermatol, Aarau, Switzerland; [Butterfield, Joseph H.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Gotlib, Jason] Stanford Univ, Sch Med, Div Hematol, Dept Med, Stanford, CA 94305 USA; [Reiter, Andreas] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany; [Radia, Deepti] Guys & St Thomas NHS Fdn Trust, Guys Hosp, Dept Haematol, London, England; [Hermine, Olivier] Univ Paris 05, Sorbonne Paris Cite, Natl Reference Ctr Mastocytosis,Imaging Inst, Dept Hematol,INSERM U1163,CNRS ERL8564, Paris, France; [Sotlar, Karl; Horny, Hans-Peter] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [George, Tracy I.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Kluin-Nelemans, Hanneke C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9700 AB Groningen, Netherlands; [Yavuz, Selim] Istanbul Univ, Dept Internal Med, Div Hematol, Istanbul, Turkey; [Hagglund, Hans] Karolinska Univ Hosp, Hematol Ctr Karolinska, Stockholm, Sweden; [Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; [Triggiani, Massimo] Univ Salerno, Div Clin Immunol & Allergy, Salerno, Italy; [Nilsson, Gunnar] Karolinska Inst, Dept Med, Clin Immunol & Allergy, Stockholm, Sweden; [Arock, Michel] Ecole Normale Super, Mol Oncol & Pharmacol, LBPA CNRS UMR8113, Cachan, France	University of Cologne; University of Lubeck; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Complejo Hospitalario de Toledo; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Groningen; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kantonsspital Aarau AG (KSA); Mayo Clinic; Stanford University; Ruprecht Karls University Heidelberg; Guy's & St Thomas' NHS Foundation Trust; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munich; University of New Mexico; University of Groningen; Istanbul University; Karolinska Institutet; Karolinska University Hospital; Medical University of Vienna; Virginia Commonwealth University; University of Salerno; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Hartmann, K (corresponding author), Med Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	karin.hartmann@uksh.de	Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Triggiani, Massimo/K-8271-2016; Nedoszytko, Boguslaw/AAY-5079-2020; Hartmann, Karin/N-4865-2015; Lange, Magdalena/AAI-1466-2019; Maurer, Marcus/ABG-2174-2020; Niedoszytko, Marek/U-1250-2018; Rabenhorst, Anja/J-3217-2016; Test, PV/U-9451-2019; Test, Test/Y-7921-2019; George, Tracy I./GRY-0951-2022; Gamperl, Susi/V-2715-2019; Hermine, Olivier/Q-7072-2018; Kluin-Nelemans, Johanna C/F-8658-2018; Orfao, Alberto/B-5801-2017	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Triggiani, Massimo/0000-0001-7318-2093; Hartmann, Karin/0000-0002-4595-8226; Lange, Magdalena/0000-0002-6967-1393; Maurer, Marcus/0000-0002-4121-481X; Niedoszytko, Marek/0000-0003-1089-1911; Gamperl, Susi/0000-0003-0456-5095; Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Siebenhaar, Frank/0000-0003-4532-1644; Hornick, Jason/0000-0001-6475-8345; Akin, Cem/0000-0001-6301-4520; Sperr, Wolfgang/0000-0003-3288-8027; Alvarez-Twose, Ivan/0000-0002-1190-4473; Hermine, Olivier/0000-0003-2574-3874; Matito, Almudena/0000-0002-9547-4844; Nedoszytko, Boguslaw/0000-0002-6286-0693; George, Tracy/0000-0001-5478-7847	German Research Council (DFG) [HA 2393/6-1, CRC/SFB832]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases; Austrian Science Funds (FWF) [SFB F4611, SFB F4707-B20]; American Academy of Allergy, Asthma Immunology; European Academy of Allergy and Clinical Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249] Funding Source: NIH RePORTER	German Research Council (DFG)(German Research Foundation (DFG)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Austrian Science Funds (FWF)(Austrian Science Fund (FWF)); American Academy of Allergy, Asthma Immunology; European Academy of Allergy and Clinical Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by research grants from the German Research Council (DFG; HA 2393/6-1; CRC/SFB832, project A14; to K.H.); from the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (to D.D.M.); and from the Austrian Science Funds (FWF; projects SFB F4611 and SFB F4707-B20; to P.V.). The Consensus Conference on Mastocytosis in Boston, Massachusetts (October 2012), was supported by the American Academy of Allergy, Asthma & Immunology. A task force/consensus panel on mastocytosis between 2010 and 2012 was supported by the European Academy of Allergy and Clinical Immunology.	Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C., 2004, Journal of Allergy and Clinical Immunology, V113, pS327, DOI 10.1016/j.jaci.2004.01.683; Akin C, 2014, IMMUNOL ALLERGY CLIN, V34, P207, DOI 10.1016/j.iac.2014.02.003; Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; Alvarez-Twose I, 2015, J ALLERGY CLIN IMMUN; Alvarez-Twose I, 2012, J CLIN ONCOL, V30, pE126, DOI 10.1200/JCO.2011.38.9973; Barnes M, 2014, PEDIATR DERMATOL, V31, P271, DOI 10.1111/pde.12291; Ben-Amitai D, 2005, ISR MED ASSOC J, V7, P320; Berezowska S, 2014, MODERN PATHOL, V27, P19, DOI 10.1038/modpathol.2013.117; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2003, J AM ACAD DERMATOL, V48, P508, DOI 10.1067/mjd.2003.98; Brockow K, 2002, ARCH DERMATOL, V138, P785, DOI 10.1001/archderm.138.6.785; Brockow K, 2002, J ALLERGY CLIN IMMUN, V109, P82, DOI 10.1067/mai.2002.120524; Buttner C, 1999, INT ARCH ALLERGY IMM, V118, P206, DOI 10.1159/000024069; CAPLAN RM, 1963, ARCH DERMATOL, V87, P146, DOI 10.1001/archderm.1963.01590140008002; Carter MC, 2002, ARCH DIS CHILD, V86, P315, DOI 10.1136/adc.86.5.315; Carter MC, 2015, J ALLERGY CLIN IMMUN; Chan EC, 2014, J ALLERGY CLIN IMMUN, V134, P178, DOI 10.1016/j.jaci.2013.12.1090; CZARNETZKI BM, 1981, BRIT J DERMATOL, V105, P563, DOI 10.1111/j.1365-2133.1981.tb00800.x; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Galen BT, 2014, BLOOD, V123, P1127, DOI 10.1182/blood-2013-11-538355; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; Georgin-Lavialle S, 2013, BLOOD, V121, P1285, DOI 10.1182/blood-2012-07-442400; Gulen T, 2014, CLIN EXP ALLERGY, V44, P121, DOI 10.1111/cea.12225; Hartmann K, 2000, HEMATOL ONCOL CLIN N, V14, P625, DOI 10.1016/S0889-8588(05)70299-9; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; Hartmann K, 2002, LEUKEMIA RES, V26, P483, DOI 10.1016/S0145-2126(01)00157-6; Hartmann K, 2002, INT ARCH ALLERGY IMM, V127, P143, DOI 10.1159/000048187; Hartmann K, 2001, BRIT J DERMATOL, V144, P682, DOI 10.1046/j.1365-2133.2001.04123.x; Hollmann TJ, 2008, AM J SURG PATHOL, V32, P139, DOI 10.1097/PAS.0b013e3180ca9a02; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Husak R, 2001, BRIT J DERMATOL, V144, P355, DOI 10.1046/j.1365-2133.2001.04026.x; IRANI AA, 1990, CLIN EXP ALLERGY, V20, P53, DOI 10.1111/j.1365-2222.1990.tb02775.x; KETTELHUT BV, 1994, ANN ALLERGY, V73, P197; Lange M, 2013, J EUR ACAD DERMATOL, V27, P97, DOI 10.1111/j.1468-3083.2011.04365.x; Lange M, 2012, J EUR ACAD DERMATOL, V26, P1565, DOI 10.1111/j.1468-3083.2011.04350.x; Lange M, 2014, INT ARCH ALLERGY IMM, V165, P104, DOI 10.1159/000368799; Lange M, 2012, ARCH MED SCI, V8, P533, DOI 10.5114/aoms.2012.29409; Lanternier F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001906; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Ma DQ, 2014, HISTOPATHOLOGY, V64, P218, DOI 10.1111/his.12212; Marrouche N, 2014, J AM ACAD DERMATOL, V70, P581, DOI 10.1016/j.jaad.2013.09.006; Matito A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0450-8; Meni C, 2015, BRIT J DERMATOL, V172, P642, DOI 10.1111/bjd.13567; Metcalfe DD, 1991, J INVEST DERMATOL, V96, p2S; Morgado JM, 2014, J CONT IMMUNOL, V1, P44; Neri I, 2013, ARCH DIS CHILD, V98, P607, DOI 10.1136/archdischild-2013-303839; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; REVERT A, 1991, PEDIATR DERMATOL, V8, P152, DOI 10.1111/j.1525-1470.1991.tb00307.x; Ribatti D, 2009, CANCER LETT, V279, P209, DOI 10.1016/j.canlet.2009.01.039; Sagher F, 1967, MASTOCYTOSIS MAST CE, P14; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84; Sangster A., 1878, T CLIN SOC LOND, V11, P161; Skrabs CC, 2002, ARCH DERMATOL, V138, P1253, DOI 10.1001/archderm.138.9.1253; Soter NA, 2000, HEMATOL ONCOL CLIN N, V14, P537, DOI 10.1016/S0889-8588(05)70295-1; SOTER NA, 1991, J INVEST DERMATOL, V96, pS32, DOI 10.1111/1523-1747.ep12468973; Soucie E, 2015, MOL IMMUNOL, V63, P55, DOI 10.1016/j.molimm.2014.03.013; Tang X, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015156; Teodosio C, 2010, J ALLERGY CLIN IMMUN, V125, P719, DOI 10.1016/j.jaci.2009.10.020; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Torrelo A, 2012, CURR OPIN PEDIATR, V24, P480, DOI 10.1097/MOP.0b013e328355b248; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; Uzzaman A, 2009, PEDIATR BLOOD CANCER, V53, P629, DOI 10.1002/pbc.22125; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2014, CLIN EXP ALLERGY, V44, P914, DOI 10.1111/cea.12318; Valent P, 2001, WHO CLASSIFICATION T, P291; Valent P, 2013, AM J CANCER RES, V3, P159; Wang HJ, 2014, CLIN EXP DERMATOL, V39, P146, DOI 10.1111/ced.12225; Wawrzycki B, 2013, DERMATOL THER, V26, P176, DOI 10.1111/j.1529-8019.2013.01544.x; Webber NK, 2008, CLIN EXP DERMATOL, V33, P198, DOI 10.1111/j.1365-2230.2007.02585.x; Weber A, 2003, BRIT J DERMATOL, V148, P224, DOI 10.1046/j.1365-2133.2003.05090.x; Wiechers T, 2015, J ALLERGY CLIN IMMUN; Williams KW, 2014, J ALLER CL IMM-PRACT, V2, P813, DOI 10.1016/j.jaip.2014.07.002; Wolff K, 2001, LEUKEMIA RES, V25, P519, DOI 10.1016/S0145-2126(01)00044-3; Yanagihori H, 2005, J MOL DIAGN, V7, P252, DOI 10.1016/S1525-1578(10)60552-1; Yang Y, 2010, BLOOD, V116, P1114, DOI 10.1182/blood-2009-06-226027; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	80	189	193	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					35	45		10.1016/j.jaci.2015.08.034	http://dx.doi.org/10.1016/j.jaci.2015.08.034			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26476479				2022-12-18	WOS:000367724300041
J	Saglani, S; Lui, S; Ullmann, N; Campbell, GA; Sherburn, RT; Mathie, SA; Denney, L; Bossley, CJ; Oates, T; Walker, SA; Bush, A; Lloyd, CM				Saglani, Sejal; Lui, Stephen; Ullmann, Nicola; Campbell, Gaynor A.; Sherburn, Rebekah T.; Mathie, Sara A.; Denney, Laura; Bossley, Cara J.; Oates, Timothy; Walker, Simone A.; Bush, Andrew; Lloyd, Clare M.			IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pediatric; airway remodeling; steroid resistance; IL-33; therapy	RETICULAR BASEMENT-MEMBRANE; INNATE; CHILDREN; INFLAMMATION; CELLS; INTERLEUKIN-13; EXPRESSION; ADULTS	Background: T(H)2 cytokines are not responsible for the ongoing symptoms and pathology in children with severe therapy-resistant asthma (STRA). IL-33 induces airway hyperresponsiveness, but its role in airway remodeling and steroid resistance is unknown. Objective: We sought to investigate the relationship between IL-33 and airway remodeling in pediatric patients with STRA. Methods: IL-33 levels were quantified in neonatal mice given inhaled house dust mite (HDM), and the effect of blocking IL-13 on remodeling and IL-33 levels was assessed. HDM-induced allergic airways disease (AAD) in neonatal ST2(-/-) mice lacking the IL-33 receptor was assessed, together with collagen production after IL-33 administration. The effect of steroid therapy on IL-33 levels in patients with neonatal AAD was explored. IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified. Results: Blocking IL-13 after AAD was established in neonatal mice and did not reduce remodeling or IL-33 levels; airway hyperresponsiveness was only partially reduced. IL-33 promoted collagen synthesis both from asthmatic fibroblasts from pediatric patients and after intranasal administration in mice. Increased cellular expression of IL-33, but not IL-13, was associated with increased reticular basement membrane thickness in EB specimens from children with STRA, whereas remodeling was absent in HDM-exposed ST2(-/-) mice. IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA. Conclusion: IL-33 is a relatively steroid-resistant mediator that promotes airway remodeling in patients with STRA and is an important therapeutic target.	[Saglani, Sejal; Lui, Stephen; Ullmann, Nicola; Campbell, Gaynor A.; Sherburn, Rebekah T.; Mathie, Sara A.; Denney, Laura; Oates, Timothy; Walker, Simone A.; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England; [Saglani, Sejal; Ullmann, Nicola; Bossley, Cara J.; Bush, Andrew] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London SW7 2AZ, England; [Saglani, Sejal; Ullmann, Nicola; Bossley, Cara J.; Bush, Andrew] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London; Imperial College London; Royal Brompton Hospital; Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Immunol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk	ULLMANN, NICOLA/K-6140-2016; Saglani, Sejal/AAE-5072-2019; Sherburn, Rebekah/AAB-5414-2022	Ullmann, Nicola/0000-0003-1111-5690; Lloyd, Clare/0000-0001-8977-6726; Saglani, Sejal/0000-0001-5192-6418; Sherburn, Rebekah/0000-0002-1683-3977	Intermediate Clinical Fellowship from the Wellcome Trust, United Kingdom; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London; Wellcome Trust; MRC [MR/J010529/1] Funding Source: UKRI; Medical Research Council [MR/J010529/1, G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, 10/058] Funding Source: researchfish	Intermediate Clinical Fellowship from the Wellcome Trust, United Kingdom; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London(General Electric); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	S.S. was supported by an Intermediate Clinical Fellowship from the Wellcome Trust, United Kingdom. C.M.L. is a Wellcome Senior Fellow in Basic Biomedical Sciences, and A.B. is a National Institute for Health Research (NIHR) Senior Clinical Investigator. The project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.; S. Saglani has received grants from the Wellcome Trust. L. Denney has received grants and travel support from the Wellcome Trust. C. M. Lloyd has received grants from the Wellcome Trust and has consultant arrangements from MedImmune. The rest of the authors declare that they have no relevant conflicts of interest.	Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barlow JL, 2011, J LEUKOCYTE BIOL, V90, P867, DOI 10.1189/jlb.0311160; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bourdin A, 2012, CHEST, V141, P1504, DOI 10.1378/chest.11-0232; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Choi Inseon S., 2008, Korean Journal of Internal Medicine, V23, P176, DOI 10.3904/kjim.2008.23.4.176; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Durrani SR, 2011, J ALLERGY CLIN IMMUN, V128, P439, DOI 10.1016/j.jaci.2011.06.002; Gregory LG, 2009, CLIN EXP ALLERGY, V39, P1597, DOI 10.1111/j.1365-2222.2009.03302.x; Halwani R, 2010, CURR OPIN PHARMACOL, V10, P236, DOI 10.1016/j.coph.2010.06.004; Heijink IH, 2008, INT ARCH ALLERGY IMM, V145, P111, DOI 10.1159/000108136; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kunisch E, 2012, INT J MOL MED, V29, P530, DOI 10.3892/ijmm.2012.883; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Liew FY, 2012, ANN RHEUM DIS, V71, P101, DOI 10.1136/annrheumdis-2011-200589; Liou CJ, 2011, J CLIN IMMUNOL, V31, P656, DOI 10.1007/s10875-011-9529-3; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Sharples J, 2012, EUR RESPIR J, V40, P264, DOI 10.1183/09031936.00209511; Stolarski B, 2010, J IMMUNOL, V185, P3472, DOI 10.4049/jimmunol.1000730; Szefler SJ, 2011, ANN ALLERG ASTHMA IM, V107, P110, DOI 10.1016/j.anai.2011.04.008; Tomlinson KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013136; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Yanaba K, 2011, CLIN RHEUMATOL, V30, P825, DOI 10.1007/s10067-011-1686-5; Zhu JY, 2012, CYTOKINE, V58, P368, DOI 10.1016/j.cyto.2012.02.008	37	189	197	5	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					676	+		10.1016/j.jaci.2013.04.012	http://dx.doi.org/10.1016/j.jaci.2013.04.012			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23759184	Green Accepted			2022-12-18	WOS:000323612000020
J	Ingram, JL; Kraft, M				Ingram, Jennifer L.; Kraft, Monica			IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IL-13; asthma; phenotypes; biomarkers; periostin; IgE; eosinophils; fraction of exhaled nitric oxide; T(H)2 inflammation	EXHALED NITRIC-OXIDE; AIRWAY EPITHELIAL-CELLS; TOTAL SERUM IGE; RECEPTOR-ALPHA POLYMORPHISMS; SPUTUM EOSINOPHIL COUNTS; EARLY GROWTH RESPONSE-1; IL-13-INDUCED INFLAMMATION; CLUSTER-ANALYSIS; LYMPHOID-CELLS; TH2 CYTOKINES	Decades of research in animal models have provided abundant evidence to show that IL-13 is a key T(H)2 cytokine that directs many of the important features of airway inflammation and remodeling in patients with allergic asthma. Several promising focused therapies for asthma that target the IL-13/IL-4/signal transducer and activator of transcription 6 pathway are in development, including anti-IL-13 mAbs and IL-4 receptor antagonists. The efficacy of these new potential asthma therapies depends on the responsiveness of patients. However, an understanding of how IL-13-directed therapies might benefit asthmatic patients is confounded by the complex heterogeneity of the disease. Recent efforts to classify subphenotypes of asthma have focused on sputum cellular inflammation profiles, as well as cluster analyses of clinical variables and molecular and genetic signatures. Researchers and clinicians can now evaluate biomarkers of T(H)2-driven airway inflammation in asthmatic patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels, to aid decision making in clinical trials and drug development and to identify subsets of patients who might benefit from therapies. Although it is unlikely that these therapies will benefit all asthmatic patients with this heterogeneous disease, advances in understanding asthma subphenotypes in relation to clinical variables and T(H)2 cytokine responses offer the opportunity to improve the efficacy and safety of proposed therapies for asthma. (J Allergy Clin Immunol 2012; 130:829-42.)	[Ingram, Jennifer L.] Duke Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Med Center, Durham, NC 27710 USA	Duke University	Ingram, JL (corresponding author), Duke Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Med Center, Box 2641, Durham, NC 27710 USA.	Jennifer.ingram@duke.edu			National Institutes of Health; Genentech; GlaxoSmithKline; Merck; Asthmatx; Scientic; Eurmedics; Novartis; American Thoracic Society	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Asthmatx; Scientic; Eurmedics; Novartis(Novartis); American Thoracic Society	M. Kraft has received research support from the National Institutes of Health, Genentech, GlaxoSmithKline, Merck, Asthmatx, Scientic, Eurmedics, and Novartis and has received other financial assistance from the American Thoracic Society. J.L. Ingram declares that she has no relevant conflicts of interest.	Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Al Obaidi AHA, 2008, J ASTHMA, V45, P654, DOI 10.1080/02770900802126958; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Booth BW, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-51; Bosse Y, 2008, INT ARCH ALLERGY IMM, V146, P138, DOI 10.1159/000113517; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bottema RWB, 2010, INT ARCH ALLERGY IMM, V153, P259, DOI 10.1159/000314366; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Brightling CE, 2010, CLIN EXP ALLERGY, V40, P42, DOI 10.1111/j.1365-2222.2009.03383.x; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen QS, 2005, J IMMUNOL, V174, P2305, DOI 10.4049/jimmunol.174.4.2305; Chen WG, 2009, J IMMUNOL, V183, P7870, DOI 10.4049/jimmunol.0901028; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Chlumsky J, 2006, J INT MED RES, V34, P129, DOI 10.1177/147323000603400202; Cho SJ, 2006, J BIOL CHEM, V281, P8161, DOI 10.1074/jbc.M506770200; Chow S, 2012, J BREATH RES, V6, DOI 10.1088/1752-7155/6/1/016004; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Darcan-Nicolaisen Y, 2009, J IMMUNOL, V182, P7501, DOI 10.4049/jimmunol.0713433; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fleming L, 2012, THORAX, V67, P193, DOI 10.1136/thx.2010.156836; Fujisawa T, 2009, CANCER RES, V69, P8678, DOI 10.1158/0008-5472.CAN-09-2100; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Gelb AF, 2012, J ALLERGY CLIN IMMUN, V129, P1491, DOI 10.1016/j.jaci.2012.03.036; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hecker M, 2010, AM J RESP CRIT CARE, V182, P805, DOI 10.1164/rccm.200909-1367OC; Hodsman GP, 2012, BR J CLIN PHARM; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Horie S, 1997, INTERNAL MED, V36, P179, DOI 10.2169/internalmedicine.36.179; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; HOWARTH PH, 1995, ALLERGY, V50, P13, DOI 10.1111/j.1398-9995.1995.tb02730.x; HUANG SK, 1995, J IMMUNOL, V155, P2688; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Ingram JL, 2006, J IMMUNOL, V177, P4141, DOI 10.4049/jimmunol.177.6.4141; Ingram JL, 2011, AM J RESP CRIT CARE, V183, P1625, DOI 10.1164/rccm.201009-1452OC; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917, DOI 10.1164/ajrccm.158.3.9802066; Kasaian MT, 2011, J IMMUNOL, V187, P561, DOI 10.4049/jimmunol.1100467; Kaur D, 2006, ALLERGY, V61, P1047, DOI 10.1111/j.1398-9995.2006.01139.x; Keen C, 2010, PEDIATR PULM, V45, P241, DOI 10.1002/ppul.21137; KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Konstantinidis AK, 2007, EUR RESPIR J, V30, P40, DOI 10.1183/09031936.00025706; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; Kraft M, 2011, NEW ENGL J MED, V365, P1141, DOI 10.1056/NEJMe1108666; Kuhl K, 2012, CURR OPIN PULM MED, V18, P1, DOI 10.1097/MCP.0b013e32834deebb; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kuperman DA, 2008, CURR MOL MED, V8, P384, DOI 10.2174/156652408785161032; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee PJ, 2006, J CLIN INVEST, V116, P163, DOI 10.1172/JCI25711; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Levesque MC, 2008, J ALLERGY CLIN IMMUN, V121, P396, DOI 10.1016/j.jaci.2007.09.031; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Lordan JL, 2002, J IMMUNOL, V169, P407, DOI 10.4049/jimmunol.169.1.407; Loughlin CE, 2010, RESP MED, V104, P29, DOI 10.1016/j.rmed.2009.07.002; Mandal D, 2010, INFLAMM BOWEL DIS, V16, P753, DOI 10.1002/ibd.21133; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755, DOI 10.1165/ajrcmb.24.6.4351; May RD, 2012, BRIT J PHARMACOL, V166, P177, DOI 10.1111/j.1476-5381.2011.01659.x; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; O'Byrne PM, 2009, CLIN EXP ALLERGY, V39, P181, DOI 10.1111/j.1365-2222.2008.03172.x; O'Toole M, 2008, CLIN EXP ALLERGY, V38, P594, DOI 10.1111/j.1365-2222.2007.02921.x; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Parameswaran K, 2007, AM J RESP CELL MOL, V37, P240, DOI 10.1165/rcmb.2006-0172OC; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Porsbjerg C, 2009, J ASTHMA, V46, P606, DOI 10.1080/02770900903015654; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Ramirez-Icaza G, 2004, J CLIN IMMUNOL, V24, P426, DOI 10.1023/B:JOCI.0000029111.27168.c6; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Schleich FN, 2010, THORAX, V65, P1039, DOI 10.1136/thx.2009.124925; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Shim YM, 2006, J IMMUNOL, V177, P1918, DOI 10.4049/jimmunol.177.3.1918; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Singh D, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-3; Slager RE, 2012, J ALLERGY CLIN IMMUN; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tan RA, 2011, EXPERT OPIN DRUG SAF, V10, P463, DOI 10.1517/14740338.2011.563840; Temann UA, 2007, INT IMMUNOL, V19, P1, DOI 10.1093/intimm/dxl117; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; van der Pouw Kraan TCTM, 1998, CLIN EXP IMMUNOL, V111, P129; Wallace J, 2011, CAN RESPIR J, V18, P13, DOI 10.1155/2011/920734; Wang IM, 2004, MOL IMMUNOL, V41, P873, DOI 10.1016/j.molimm.2004.04.027; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yap E, 2011, INTERN MED J; Yates DH, 2011, J BREATH RES, V5, DOI 10.1088/1752-7155/5/2/024001; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zheng T, 2008, J IMMUNOL, V180, P522, DOI 10.4049/jimmunol.180.1.522; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953; Zitnik SE, 2009, PEDIAT ALLERG IMM-UK, V20, P551, DOI 10.1111/j.1399-3038.2008.00815.x	152	189	207	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					829	842		10.1016/j.jaci.2012.06.034	http://dx.doi.org/10.1016/j.jaci.2012.06.034			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22951057				2022-12-18	WOS:000309594800001
J	Henderson, CJ; Abonia, JP; King, EC; Putnam, PE; Collins, MH; Franciosi, JP; Rothenberg, ME				Henderson, Carol J.; Abonia, J. Pablo; King, Eileen C.; Putnam, Philip E.; Collins, Margaret H.; Franciosi, James P.; Rothenberg, Marc E.			Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; eosinophils; histologic remission; pediatric; dietary therapy; food allergy; negative predictive values; elemental diet; 6-food elimination diet; skin test-directed elimination diet	SKIN PRICK TESTS; ATOPY PATCH TEST; FOOD ALLERGY; CONSENSUS RECOMMENDATIONS; EXPRESSION PROFILE; IGE CONCENTRATIONS; ELIMINATION DIET; CHILDREN; FLUTICASONE; MANAGEMENT	Background: Eosinophilic esophagitis is a chronic, immune-mediated inflammatory disorder that responds to dietary therapy; however, data evaluating the effectiveness of dietary therapeutic strategies are limited. Objective: This study compared the effectiveness of 3 frequently prescribed dietary therapies (elemental, 6-food elimination, and skin prick and atopy patch-directed elimination diets) and assessed the remission predictability of skin tests and their utility in directing dietary planning. Methods: A retrospective cohort of proton-pump inhibitor-unresponsive, non-glucocorticoid-treated patients with eosinophilic esophagitis who had 2 consecutive endoscopic biopsy specimens associated with dietary intervention was identified. Biopsy histology and remissions (<15 eosinophils/high-power field) after dietary therapy and food reintroductions were evaluated. Results: Ninety-eight of 513 patients met the eligibility criteria. Of these 98 patients, 50% (n = 49), 27% (n = 26), and 23% (n = 23) received elemental, 6-food elimination, and directed diets, respectively. Remission occurred in 96%, 81%, and 65% of patients on elemental, 6-food elimination, and directed diets, respectively. The odds of postdiet remission versus nonremission were 5.6-fold higher (P = .05) on elemental versus 6-food elimination diets and 12.5-fold higher (P = .003) on elemental versus directed diets and were not significantly different (P = .22) on 6-food elimination versus directed diets. After 116 single-food reintroductions, the negative predictive value of skin testing for remission was 40% to 67% (milk, 40%; egg, 56%; soy, 64%; and wheat, 67%). Conclusion: All 3 dietary therapies are effective; however, an elemental diet is superior at inducing histologic remission compared with 6-food elimination and skin test-directed diets. Notably, an empiric 6-food elimination diet is as effective as a skin test-directed diet. The negative predictive values of foods most commonly reintroduced in single-food challenges are not sufficient to support the development of dietary advancement plans solely based on skin test results. (J Allergy Clin Immunol 2012;129:1570-8.)	[Henderson, Carol J.; Abonia, J. Pablo; Rothenberg, Marc E.] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA; [King, Eileen C.] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Dept Pediat, Cincinnati, OH 45229 USA; [Putnam, Philip E.; Franciosi, James P.] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Pathol, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Dept Pediat, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	King, Eileen/Q-1815-2015	Abonia, Juan/0000-0003-3788-6485	Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); Institutional Clinical and Translational Science Award; National Institutes of Health (NIH)/National Center for Research Resources [5UL1RR026314]; National Institutes of Health (NIH); Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER	Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); Institutional Clinical and Translational Science Award; National Institutes of Health (NIH)/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by the Campaign Urging Research for Eosinophilic Disease (CURED), the Buckeye Foundation, the International Group of Eosinophilic Researchers (TIGER), an Institutional Clinical and Translational Science Award, and National Institutes of Health (NIH)/National Center for Research Resources grant no. 5UL1RR026314. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.; J. P. Abonia has received research support from the National Institutes of Health (NIH), Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. M. E. Rothenberg has an equity interest in Teva Pharmaceutical Industries' reslizumab; is Chief Scientific Officer of Immune Pharmaceuticals; is inventor of several patents related to EoE that are being considered for commercial development; is on the American Partnership for Eosinophilic Disorders Medical Advisory Board; and is on the Steering Committee of the International Eosinophil Society (IES) and the International Group of Eosinophilic Researchers (TIGER). The rest of the others declare that they have no relevant conflicts of interest.	Aceves SS, 2007, AM J GASTROENTEROL, V102, P2271, DOI 10.1111/j.1572-0241.2007.01379.x; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Feuling MB, 2010, NUTR CLIN PRACT, V25, P166, DOI 10.1177/0884533610361608; Franciosi JP, 2011, CHILD CARE HLTH DEV; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Heine RG, 2011, J GASTROEN HEPATOL, V26, P1106, DOI 10.1111/j.1440-1746.2011.06757.x; Heine RG, 2006, PEDIAT ALLERG IMM-UK, V17, P213, DOI 10.1111/j.1399-3038.2005.00368.x; Hommel K. A., 2011, J PEDIAT PSYCHOL; Hong S, 2010, CLEV CLIN J MED, V77, P51, DOI 10.3949/ccjm.77a.09018; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Miles MV, 2011, MITOCHONDRION, V11, P127, DOI 10.1016/j.mito.2010.08.010; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2007, J LEUKOCYTE BIOL, V81, P916, DOI 10.1189/jlb.1106653; Nielsen RG, 2007, J PEDIATR GASTR NUTR, V45, P281, DOI 10.1097/MPG.0b013e31806210c8; Rocha R, 2011, EUR J PEDIATR, V170, P1471, DOI 10.1007/s00431-011-1540-4; Rothenberg ME, 2009, GASTROENTEROLOGY, V137, P1238, DOI 10.1053/j.gastro.2009.07.007; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Wang FY, 2007, J CLIN GASTROENTEROL, V41, P451, DOI 10.1097/01.mcg.0000248019.16139.67	40	189	193	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1570	1578		10.1016/j.jaci.2012.03.023	http://dx.doi.org/10.1016/j.jaci.2012.03.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22541246	Green Accepted			2022-12-18	WOS:000304764600018
J	Ursell, LK; Clemente, JC; Rideout, JR; Gevers, D; Caporaso, JG; Knight, R				Ursell, Luke K.; Clemente, Jose C.; Rideout, Jai Ram; Gevers, Dirk; Caporaso, J. Gregory; Knight, Rob			The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human microbiome; microbial diversity; temporal variation; 16S rRNA sequencing	MOLECULAR ANALYSIS; HUMAN SKIN; INTESTINAL MICROBIOTA; GUT MICROBIOME; COMMUNITIES; HABITATS; PATTERNS; DATABASE; ECOLOGY; PROJECT	The human body harbors 10 to 100 trillion microbes, mainly bacteria in our gut, which greatly outnumber our own human cells. This bacterial assemblage, referred to as the human microbiota, plays a fundamental role in our well-being. Deviations from healthy microbial compositions (dysbiosis) have been linked with important human diseases, including inflammation-linked disorders, such as allergies, obesity, and inflammatory bowel disease. Characterizing the temporal variations and community membership of the healthy human microbiome is critical to accurately identify the significant deviations from normality that could be associated with disease states. However, the diversity of the human microbiome varies between body sites, between patients, and over time. Environmental differences have also been shown to play a role in shaping the human microbiome in different cultures, requiring that the healthy human microbiome be characterized across life spans, ethnicities, nationalities, cultures, and geographic locales. In this article we summarize our knowledge on the microbial composition of the 5 best-characterized body sites (gut, skin, oral, airways, and vagina), focusing on interpersonal and intrapersonal variations and our current understanding of the sources of this variation. (J Allergy Clin Immunol 2012;129:1204-8.)	[Knight, Rob] Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; [Rideout, Jai Ram; Caporaso, J. Gregory] No Arizona Univ, Dept Comp Sci, Flagstaff, AZ 86011 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Northern Arizona University	Knight, R (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, 215 UCB, Boulder, CO 80309 USA.	rob.knight@colorado.edu	Gevers, Dirk/C-1451-2009; Knight, Rob/D-1299-2010	Knight, Rob/0000-0002-0975-9019; Caporaso, Greg/0000-0002-8865-1670	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004872, U01HG004866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHGRI NIH HHS [R01 HG004872, U01 HG004866-01, U01 HG004866, R01 HG004872-01] Funding Source: Medline; NIGMS NIH HHS [T32 GM142607, T32 GM008759-01, T32 GM008759] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bik EM, 2010, ISME J, V4, P962, DOI 10.1038/ismej.2010.30; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Cox MJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011044, 10.1371/journal.pone.0008745]; Crielaard W, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-22; de Carcer DA, 2011, ISME J, V5, P801, DOI 10.1038/ismej.2010.177; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Dominguez-Bello MG, 2011, GASTROENTEROLOGY, V140, P1713, DOI 10.1053/j.gastro.2011.02.011; Donders GGG, 2000, AM J OBSTET GYNECOL, V182, P872, DOI 10.1016/S0002-9378(00)70338-3; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; Flint HJ, 2011, J CLIN GASTROENTEROL, V45, pS128, DOI 10.1097/MCG.0b013e31821f44c4; Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104; Glass EM, 2010, COLD SPRING HARB PRO, V2010; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Gupta K, 1998, J INFECT DIS, V178, P446, DOI 10.1086/515635; Hamady M, 2008, NAT METHODS, V5, P235, DOI 10.1038/NMETH.1184; Hartman AL, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-317; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Huber JA, 2007, SCIENCE, V318, P97, DOI 10.1126/science.1146689; Jarchum I, 2011, CURR OPIN IMMUNOL, V23, P353, DOI 10.1016/j.coi.2011.03.001; Kallus SJ, 2012, J CLIN GASTROENTEROL, V46, P16, DOI 10.1097/MCG.0b013e31823711fd; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Lee S, 2011, APPL ENVIRON MICROB, V77, P7433, DOI 10.1128/AEM.05490-11; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Ley RE, 2010, CURR OPIN GASTROEN, V26, P5, DOI 10.1097/MOG.0b013e328333d751; Ling ZX, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-488; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Nasidze I, 2009, GENOME RES, V19, P636, DOI 10.1101/gr.084616.108; Paulino LC, 2006, J CLIN MICROBIOL, V44, P2933, DOI 10.1128/JCM.00785-06; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Proctor LM, 2011, CELL HOST MICROBE, V10, P287, DOI 10.1016/j.chom.2011.10.001; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Reibman J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004060; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stearns JC, 2011, SCI REP-UK, V1, DOI 10.1038/srep00170; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Watts DH, 2005, J INFECT DIS, V191, P1129, DOI 10.1086/427777; Willner D, 2012, ISME J, V6, P471, DOI 10.1038/ismej.2011.104; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Young VB, 2012, CURR OPIN GASTROEN, V28, P63, DOI 10.1097/MOG.0b013e32834d61e9; Zaura E, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-259; Zhou X, 2007, ISME J, V1, P121, DOI 10.1038/ismej.2007.12	59	189	203	2	94	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1204	1208		10.1016/j.jaci.2012.03.010	http://dx.doi.org/10.1016/j.jaci.2012.03.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22541361	Green Accepted			2022-12-18	WOS:000303418000005
J	Wollenberg, A; Wetzel, S; Burgdorf, WHC; Haas, J				Wollenberg, A; Wetzel, S; Burgdorf, WHC; Haas, J			Viral infections in atopic dermatitis: Pathogenic aspects and clinical management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; cowpox; smallpox; eczema herpeticum; eczema molluscatum; eczema vaccinatum	HERPES-SIMPLEX VIRUS; MOLLUSCUM-CONTAGIOSUM VIRUS; ECZEMA HERPETICUM; THERAPEUTIC-EFFICACY; VARICELLIFORM ERUPTION; SMALLPOX VACCINATION; CUTANEOUS HERPES; CONTROLLED TRIAL; DENDRITIC CELLS; ACYCLOVIR	A number of different widespread and disseminated viral infections can occur in patients with atopic dermatitis. Eczema molluscatum is troublesome but not dangerous. Although eczema vaccinatum is rare, it is life-threatening and of increased concern as smallpox vaccinations are reintroduced as a response to possible bioterrorism. There is little information on the course of smallpox itself in atopic dermatitis. Eczema herpeticum is the most common member of this group; recent advances in understanding its pathogenesis might contribute to a more successful management of this serious complication.	Univ Munich, Dept Dermatol & Allergy, D-80337 Munich, Germany; Univ Munich, Max von Pettenkofer Inst, D-80337 Munich, Germany	University of Munich; University of Munich	Wollenberg, A (corresponding author), Univ Munich, Dept Dermatol & Allergy, Frauenlobstr 9-11, D-80337 Munich, Germany.							Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; BLACKFORD S, 1993, BRIT J DERMATOL, V129, P628, DOI 10.1111/j.1365-2133.1993.tb00500.x; Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159; BORK K, 1988, J AM ACAD DERMATOL, V19, P1024, DOI 10.1016/S0190-9622(88)70267-4; BRION N, 1981, ANN DERMATOL VENER, V108, P517; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Charatan Fred, 2003, BMJ, V326, P1350, DOI 10.1136/bmj.326.7403.1350-b; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; Drazen JM, 2002, NEW ENGL J MED, V346, P1262, DOI 10.1056/NEJM2e020038; EISHUBINGER AM, 1990, LANCET, V336, P880, DOI 10.1016/0140-6736(90)92387-W; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; FENERF, 1988, SMALLPOX ITS ERADICA, P122; FORGHANI B, 1992, MOL CELL PROBE, V6, P67, DOI 10.1016/0890-8508(92)90073-7; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; Gruchalla RS, 2003, J ALLERGY CLIN IMMUN, V112, P675, DOI 10.1016/j.jaci.2003.08.001; Hackett CJ, 2003, J ALLERGY CLIN IMMUN, V112, P686, DOI 10.1016/S0091-6749(03)02025-6; Haim M, 2000, MIL MED, V165, P287, DOI 10.1093/milmed/165.4.287; Harrison CJ, 2001, VACCINE, V19, P1820, DOI 10.1016/S0264-410X(00)00387-X; HENG MCY, 1989, AM J DERMATOPATH, V11, P248, DOI 10.1097/00000372-198906000-00009; HIGGINS CR, 1993, J MED VIROL, P22; Highet AS, 1992, TXB DERMATOLOGY, P872; Jones JF, 2003, J ALLERGY CLIN IMMUN, V111, P908; KAPOSI M, 1987, PATHOLOGIE THERAPIE, V3; KEMPE CH, 1960, PEDIATRICS, V26, P176; Kessler HA, 1996, J ACQ IMMUN DEF SYND, V12, P147, DOI 10.1097/00042560-199606010-00007; LANE JM, 1971, AM J EPIDEMIOL, V93, P238, DOI 10.1093/oxfordjournals.aje.a121252; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Lazarus HM, 1999, ANTIMICROB AGENTS CH, V43, P1192, DOI 10.1128/AAC.43.5.1192; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lin L, 2002, J DERMATOL TREAT, V13, P67, DOI 10.1080/095466302317584412; MARTINSCASTRO R, 1974, INT J DERMATOL, V13, P271, DOI 10.1111/j.1365-4362.1974.tb05080.x; MASESSA JM, 1989, J AM ACAD DERMATOL, V21, P133, DOI 10.1016/S0190-9622(89)80352-4; McGrath N, 1997, J NEUROL NEUROSUR PS, V63, P321, DOI 10.1136/jnnp.63.3.321; Mikloska Z, 2001, J VIROL, V75, P11821, DOI 10.1128/JVI.75.23.11821-11826.2001; MODIANO P, 1995, BRIT J DERMATOL, V133, P475, DOI 10.1111/j.1365-2133.1995.tb02682.x; NIIMURA M, 1988, AM J MED, V85, P49; NISHIMURA M, 1984, ARCH DERMATOL, V120, P799, DOI 10.1001/archderm.120.6.799; Noisakran S, 2000, CURR EYE RES, V20, P405, DOI 10.1076/0271-3683(200005)20:5;1-1;FT405; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; PANDA A, 1995, CAN J OPHTHALMOL, V30, P256; PERRY CM, 1995, DRUGS, V50, P396, DOI 10.2165/00003495-199550020-00011; Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009; Rappersberger K, 1999, HAUTARZT, V50, P706; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; SANDERSON IR, 1987, BMJ-BRIT MED J, V294, P693, DOI 10.1136/bmj.294.6573.693; SCHIRREN H, 1995, HAUTARZT, V46, P494, DOI 10.1007/s001050050289; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SOLOMON LM, 1966, CAN MED ASSOC J, V95, P978; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309; Tabery HM, 2001, ACTA OPHTHALMOL SCAN, V79, P256, DOI 10.1034/j.1600-0420.2001.790309.x; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; VERBOV J, 1972, BRIT J DERMATOL, V86, P438, DOI 10.1111/j.1365-2133.1972.tb05062.x; Virella-Lowell I, 2000, GENE THER, V7, P1783, DOI 10.1038/sj.gt.3301268; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; WHEELER CE, 1966, ARCH DERMATOL, V93, P162, DOI 10.1001/archderm.93.2.162; Wienecke R, 2000, J AM ACAD DERMATOL, V42, P892, DOI 10.1016/S0190-9622(00)90265-2; Wilhelmus K R, 2000, Trans Am Ophthalmol Soc, V98, P505; Wollenberg A, 2000, ALLERGY, V55, P205, DOI 10.1034/j.1398-9995.2000.00115.x; WOLLENBERG A, 1995, DEUT MED WOCHENSCHR, V120, P1395, DOI 10.1055/s-2008-1055490; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wollenberg A, 2000, ALLERGO J, V9, P96; Xiang Y, 2003, J VIROL, V77, P2623, DOI 10.1128/JVI.77.4.2623-2630.2003; Yoon M, 2002, J VIROL, V76, P7203, DOI 10.1128/JVI.76.14.7203-7208.2002	66	189	199	4	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					667	674		10.1016/j.jaci.2003.07.001	http://dx.doi.org/10.1016/j.jaci.2003.07.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564342	Bronze			2022-12-18	WOS:000185831200003
J	Lambiase, A; BracciLaudiero, L; Bonini, S; Bonini, S; Starace, G; DElios, MM; DeCarli, M; Aloe, L				Lambiase, A; BracciLaudiero, L; Bonini, S; Bonini, S; Starace, G; DElios, MM; DeCarli, M; Aloe, L			Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nerve growth factor; tyrosine kinase receptor; lymphocyte; CD4+ T cells; T-H2 clones	SYSTEMIC LUPUS-ERYTHEMATOSUS; HUMAN LYMPHOCYTES-B; TRK PROTOONCOGENE; MAST-CELLS; NGF RECEPTOR; DIFFERENTIATION; HELPER; COEXPRESSION; IMMUNITY; DISEASES	Background: Increasing evidence shows that nerve growth factor (NGF) plays a role in the complex and fascinating linkage between the nervous and the immune systems due to its ability to modulate functions of several inflammatory cells. Objective: To investigate NGF receptor expression and NGF production and release by human CD4+ cells clones, which have primary relevance in modulating inflammatory events through their different subsets of functional phenotypes. Methods: The expression of NGF and a transmembrane tyrosine kinase (TrkA) was evaluated by immunohistochemistry and flow cytometry analysis in five T-H0, six T-H1, and five T-H2 cell clones derived from human circulating mononuclear blood cells. Moreover, the amount of NGF protein was assessed by measuring the NGF levels in culture supernatants of the T cell clones before stimulation and 48 hours after phytohemagglutinin (PHA) activation by use of an immunoenzymatic assay. Results: Our data have shown that in unstimulated conditions, human CD4+ T cell clones express both immunoreactivity for NGF and the TrkA NGF receptor irrespective of their cytokine profile. Moreover, T-H1 and T-H2 clones, but not T-H0 clones, secrete NGF in basal conditions. PHA activation induces NGF secretion in T-H0 clones and a significant increase of NGF levels in T-H2 (p < 0.05), but not in T-H1 culture supernatants. Conclusions: Results obtained represent the first evidence of TrkA expression and NGF production and release in human CD4+ cell clones and suggest a possible functional role of NGF in modulating the immune and inflammatory network.	CNR, INST NEUROBIOL, I-00168 ROME, ITALY; CNR, INST EXPT MED, I-00168 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT OPHTHALMOL, I-00173 ROME, ITALY; GB BIETTI FDN, ROME, ITALY; UNIV FLORENCE, INST INTERNAL MED & IMMUNOALLERGOL, I-50121 FLORENCE, ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia; University of Florence			Bonini, Sergio/T-6594-2019; Bracci Laudiero, Luisa/AAC-3521-2022; D'Elios, Mario Milco/Y-9573-2019; Bonini, Stefano/A-2250-2012; Bracci-Laudiero, Luisa/H-1541-2013; Lambiase, Alessandro/K-3902-2016	Bonini, Sergio/0000-0003-0079-3031; D'Elios, Mario Milco/0000-0001-9160-0930; Bonini, Stefano/0000-0002-7787-2144; Bracci-Laudiero, Luisa/0000-0002-1682-6371; Lambiase, Alessandro/0000-0002-8974-991X				ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; ALOE L, 1986, P NATL ACAD SCI USA, V83, P6184, DOI 10.1073/pnas.83.16.6184; ALOE L, 1992, ARTHRITIS RHEUM, V35, P351, DOI 10.1002/art.1780350315; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1994, NEUROREPORT, V5, P1030, DOI 10.1097/00001756-199405000-00003; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BISCHOFF SC, 1992, BLOOD, V79, P2662; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BOYLE MDP, 1985, J IMMUNOL, V134, P564; BRACCI-LAUDIERO L, 1992, NEUROSCI LETT, V147, P9; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRODIE C, 1992, J IMMUNOL, V148, P3492; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Fitch Frank W., 1993, P733; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LAMBIASE A, 1995, INVEST OPHTH VIS SCI, V36, P2127; LAUTERBORN JC, 1991, J COMP NEUROL, V306, P439, DOI 10.1002/cne.903060308; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVITZKI A, 1990, MOL PHARM CELL REGUL, V1, P1; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LU B, 1989, EXP NEUROL, V104, P191, DOI 10.1016/0014-4886(89)90029-0; MAGGI E, 1991, J IMMUNOL, V146, P1169; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; TAKAFUJI S, 1992, EUR J IMMUNOL, V22, P969, DOI 10.1002/eji.1830220414; THORPE LW, 1987, ANN NY ACAD SCI, V496, P310, DOI 10.1111/j.1749-6632.1987.tb35781.x; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; TUVERI MA, 1993, CLIN EXP RHEUMATOL, V11, P319; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VIA CS, 1993, J IMMUNOL, V151, P3914	47	189	194	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					408	414		10.1016/S0091-6749(97)70256-2	http://dx.doi.org/10.1016/S0091-6749(97)70256-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314355	Bronze			2022-12-18	WOS:A1997XX47900020
J	LEUNG, PSC; CHU, KH; CHOW, WK; ANSARI, A; BANDEA, CI; KWAN, HS; NAGY, SM; GERSHWIN, ME				LEUNG, PSC; CHU, KH; CHOW, WK; ANSARI, A; BANDEA, CI; KWAN, HS; NAGY, SM; GERSHWIN, ME			CLONING, EXPRESSION, AND PRIMARY STRUCTURE OF METAPENAEUS-ENSIS TROPOMYOSIN, THE MAJOR HEAT-STABLE SHRIMP ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SHRIMP ALLERGY; METAPENAEUS ENSIS; IGE REACTIVITY; CDNA CLONE; TROPOMYOSIN; RECOMBINANT PROTEIN; EPITOPE	MUSCLE ALPHA-TROPOMYOSIN; RYE-GRASS POLLEN; SENSITIVE INDIVIDUALS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CROSS-REACTIVITY; VENOM ALLERGEN; AMINO TERMINUS; IGE ANTIBODIES; MITE ALLERGEN	Shrimp is a common cause of seafood hypersensitivity. To study the mechanism of seafood hypersensitivity at the molecular level, we have determined the primary structure of the major heat-stable allergen of shrimp by cloning, expression, nucleotide sequencing, and amino acid sequence determination of an IgE-reactive cDNA clone, Met e I, isolated from a Metapenaeus ensis expression library in lambda gt 11. We first constructed a cDNA library from the shrimp M. ensis in lambda gt 11. We then screened the library with sera from patients with hypersensitivity reactions to shrimp and identified a positive IgE-reactive clone, designated as Met e I. This cDNA was purified to homogeneity and subsequently expressed in the plasmid pGEX. Serum antibodies from patients with shrimp allergy demonstrated positive IgE reactivity by immunoblotting to a protein encoded by the clone Met e I; sera from nonallergic control subjects were not reactive. The nucleotide sequence of this cDNA clone revealed art open reading frame of 281 amino acid residues, coding for a protein of 34 kd. Comparison of the Met e I amino acid sequence with the Genbank database showed that Met e I is highly homologous to multiple isoforms of tropomyosin.	CHINESE UNIV HONG KONG, DEPT BIOL, SHA TIN, HONG KONG; EMORY UNIV, SCH MED, DEPT PATHOL, ATLANTA, GA 30322 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA	Chinese University of Hong Kong; Emory University; Centers for Disease Control & Prevention - USA	LEUNG, PSC (corresponding author), UNIV CALIF DAVIS, SCH MED, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, TB192, DAVIS, CA 95616 USA.		Kwan, Hoi Shan/F-3048-2010; Chu, Ka Hou/B-8010-2011	Chu, Ka Hou/0000-0001-8107-5415; Kwan, Hoi Shan/0000-0002-7943-2513				CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHU KH, 1993, FISH RES, V18, P187, DOI 10.1016/0165-7836(93)90152-W; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1990, J ALLERGY CLIN IMMUN, V86, P88, DOI 10.1016/S0091-6749(05)80127-7; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FORRYSCHAUDIES S, 1991, J BIOL CHEM, V266, P13821; GHOSH B, 1993, J IMMUNOL, V150, P5391; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; HAN X, 1989, EXP PARASITOL, V69, P373, DOI 10.1016/0014-4894(89)90087-8; HANKE PD, 1986, GENE, V45, P211, DOI 10.1016/0378-1119(86)90256-8; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; Holthuis LB., 1980, FAO SPECIES CATALOGU, V1; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LEHRER SB, 1990, J ALLERGY CLIN IMMUN, V85, P1005, DOI 10.1016/0091-6749(90)90044-5; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; LU G, 1993, J IMMUNOL, V150, P2823; MARSH DG, 1988, INT ARCH ALLER A IMM, V85, P194; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MORGAN JE, 1989, J ALLERGY CLIN IMMUN, V83, P1112, DOI 10.1016/0091-6749(89)90454-5; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; ONEIL CE, 1985, ANN ALLERGY, V55, P374; OWNBY DR, 1991, IMMUNOL ALLERGY CLIN, V11, P851; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; RACEK AA, 1972, COASTAL AQUACULTURE, P153; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RUIZOPAZO N, 1985, NATURE, V315, P67, DOI 10.1038/315067a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPSON HA, 1991, FOOD ALLERGY ADVERSE, P99; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANSEY T, 1991, MOL CELL BIOL, V11, P6337, DOI 10.1128/MCB.11.12.6337; THIEBAUD P, 1991, EUR J BIOCHEM, V202, P431; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WARING NP, 1983, J ALLERGY CLIN IMMUN, V71, P111, DOI 10.1016/0091-6749(83)90213-0; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; 1986, FDA AD HOC COMMITTEE	53	189	224	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					882	890		10.1016/0091-6749(94)90156-2	http://dx.doi.org/10.1016/0091-6749(94)90156-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963157				2022-12-18	WOS:A1994PR24000013
J	MATTOLI, S; SOLOPERTO, M; MARINI, M; FASOLI, A				MATTOLI, S; SOLOPERTO, M; MARINI, M; FASOLI, A			LEVELS OF ENDOTHELIN IN THE BRONCHOALVEOLAR LAVAGE FLUID OF PATIENTS WITH SYMPTOMATIC ASTHMA AND REVERSIBLE AIR-FLOW OBSTRUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHOSPASM; ENDOTHELIN	GUINEA-PIG; EPITHELIAL-CELLS; BRONCHOCONSTRICTOR; MODULATION; MECHANISMS; PEPTIDE	We have previously demonstrated that human bronchial smooth muscle cells possess a single class of specific binding sites for the potent bronchoconstrictive peptide, endothelin 1, and that human bronchial epithelial cells constitutively release an endothelin-like material in culture, which binds to smooth muscle cell receptors with a kinetic analogous to that observed with the authentic peptide. To evaluate the potential role of endothelin in the pathogenesis of asthma, we examined in this study the release of endothelin in the airways of six patients with asthma, both at the time when they were symptomatic and had reversible airflow obstruction and during the remission phase of the disease induced by treatment. Five normal volunteers and five patients with chronic bronchitis and airflow obstruction unaffected by bronchodilators were tested as control subjects. The release of endothelin in airway mucosa was assessed by RIA with the bronchoalveolar lavage fluid recovered during bronchoscopy. Patients with asthma had increased amounts of immunoreactive endothelin in bronchoalveolar lavage fluid than normal control subjects or subjects with chronic bronchitis (p < 0.05) in absence of any significant alteration in the levels of circulating peptide. Treatment of patients with asthma with oral corticosteroids and inhaled beta-agonists for 15 days resulted in improvement of airflow obstruction and in more than threefold reduction in the contents of endothelin in lavage fluid. Our findings indicate that the potent bronchoconstrictive substance, endothelin, may contribute to the pathogenesis of airflow obstruction in asthma.	DEPT INTERNAL MED,LUNG CELLULAR & MOLEC BIOL SECT,MILAN,ITALY		MATTOLI, S (corresponding author), DIAGNOST CTR RESP DIS,VIA ALESSANDRIA 4,I-20144 MILAN,ITALY.		Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				ADVENIER C, 1990, BRIT J PHARMACOL, V100, P168, DOI 10.1111/j.1476-5381.1990.tb12071.x; Allegra L, 1989, Eur Respir J Suppl, V6, p460s; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BROFMAN JD, 1989, J APPL PHYSIOL, V66, P1867, DOI 10.1152/jappl.1989.66.4.1867; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CORBO GM, 1988, J ALLERGY CLIN IMMUN, V81, P41, DOI 10.1016/0091-6749(88)90218-7; FROSSARD N, 1986, J APPL PHYSIOL, V61, P1449, DOI 10.1152/jappl.1986.61.4.1449; LAGENTE V, 1989, BIOCHEM BIOPH RES CO, V158, P625, DOI 10.1016/0006-291X(89)92767-8; MACQUINMAVIER I, 1989, J PHARMACOL EXP THER, V250, P740; MARINI M, IN PRESS AM J RESPIR; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; PAYNE AN, 1988, EUR J PHARMACOL, V158, P303, DOI 10.1016/0014-2999(88)90085-4; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; UCHIDA Y, 1988, EUR J PHARMACOL, V154, P227, DOI 10.1016/0014-2999(88)90106-9; VANE JR, 1990, NEW ENGL J MED, V323, P27; 1985, AM REV RESPIR DIS, V132, P180	17	189	193	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				376	384		10.1016/0091-6749(91)90100-3	http://dx.doi.org/10.1016/0091-6749(91)90100-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890266				2022-12-18	WOS:A1991GG12600032
J	Mattoo, H; Mahajan, VS; Maehara, T; Deshpande, V; Della-Torre, E; Wallace, ZS; Kulikova, M; Drijvers, JM; Daccache, J; Carruthers, MN; Castelino, FV; Stone, JR; Stone, JH; Pillai, S				Mattoo, Hamid; Mahajan, Vinay S.; Maehara, Takashi; Deshpande, Vikram; Della-Torre, Emanuel; Wallace, Zachary S.; Kulikova, Maria; Drijvers, Jefte M.; Daccache, Joe; Carruthers, Mollie N.; Castelino, Flavia V.; Stone, James R.; Stone, John H.; Pillai, Shiv			Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fibrosis; IgG(4)-related disease; IgG4; CD4(+) cytotoxic T cells; T(H)2 cells; rituximab; IL-1 beta	REGULATORY IMMUNE-REACTIONS; IGG4-RELATED DISEASE; ANTIGEN PRESENTATION; PERIPHERAL-BLOOD; LUNG FIBROBLASTS; CELLS; FIBROSIS; TH2; IL-13; PANCREATITIS	Background: IgG(4)-related disease (IgG(4)-RD) is a systemic condition of unknowncause characterized by highly fibrotic lesions with dense lymphoplasmacytic infiltrates. CD4(+) T cells constitute the major inflammatory cell population in IgG(4)-RD lesions. Objective: We used an unbiased approach to characterize CD4(+) T-cell subsets in patients with IgG(4)-RD based on their clonal expansion and ability to infiltrate affected tissue sites. Methods: We used flow cytometry to identify CD4(+) effector/memory T cells in a cohort of 101 patients with IgG(4)-RD. These expanded cells were characterized by means of gene expression analysis and flow cytometry. Next-generation sequencing of the T-cell receptor beta chain gene was performed on CD4(+) SLAMF7(+) cytotoxic T lymphocytes (CTLs) and CD4(+) GATA3(+) T(H)2 cells in a subset of patients to identify their clonality. Tissue infiltration by specific T cells was examined by using quantitative multicolor imaging. Results: CD4(+) effector/memory T cells with a cytolytic phenotype were expanded in patients with IgG4-RD. Next-generation sequencing revealed prominent clonal expansions of these CD4(+) CTLs but not CD4(+) GATA3(+) memory TH2 cells in patients with IgG4-RD. The dominantTcells infiltrating a range of inflamed IgG(4)-RD tissue sites were clonally expanded CD4(+) CTLs that expressed SLAMF7, granzyme A, IL-1 beta, and TGF-beta 1. Clinical remission induced by rituximab-mediated B-cell depletion was associated with a reduction in numbers of disease-associated CD4(+) CTLs. Conclusions: IgG(4)-RD is prominently linked to clonally expanded IL-1 beta- and TGF-beta 1-secreting CD4(+) CTLs in both peripheral blood and inflammatory tissue lesions. These active, terminally differentiated, cytokine-secreting effector CD4(+) T cells are now linked to a human disease characterized by chronic inflammation and fibrosis.	[Mattoo, Hamid; Mahajan, Vinay S.; Maehara, Takashi; Deshpande, Vikram; Della-Torre, Emanuel; Wallace, Zachary S.; Kulikova, Maria; Drijvers, Jefte M.; Daccache, Joe; Carruthers, Mollie N.; Castelino, Flavia V.; Stone, James R.; Stone, John H.; Pillai, Shiv] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA; [Maehara, Takashi] Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Oncol, Fukuoka, Japan	Harvard University; Harvard Medical School; Massachusetts General Hospital	Pillai, S (corresponding author), MIT & Harvard, Ragon Inst, Massachusetts Gen Hosp, 400 Tech Sq, Cambridge, MA 02139 USA.; Stone, JH (corresponding author), Massachusetts Gen Hosp, Rheumatol Unit, Yawkey 2,55 Fruit St, Boston, MA 02114 USA.	jhstone@partners.org; pillai@helix.mgh.harvard.edu	Della Torre, Emanuel/AAB-5024-2022; Mahajan, Vinay S/AAF-3303-2019	Mahajan, Vinay/0000-0003-0814-2989; Della Torre, Emanuel/0000-0002-9192-4270	National Institutes of Health (NIH) [U19-AI110495, AI 113163]; NIH [S10RR023440]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI113163, U19AI110495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants U19-AI110495 and AI 113163 from the National Institutes of Health (NIH). The Massachusetts General Hospital flow core is supported by grant S10RR023440 from the NIH.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Aoki S, 2005, HISTOPATHOLOGY, V47, P147, DOI 10.1111/j.1365-2559.2005.02204.x; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; Carruthers MN, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/259408; Chakraborty Abhijit, 2012, Clin Pharmacokinet, V51, pe1, DOI 10.2165/11599820-000000000-00000; Chen K, 2005, J LEUKOCYTE BIOL, V77, P166, DOI 10.1189/jlb.0904538; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; De Calisto J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00186; DEJONG R, 1992, EUR J IMMUNOL, V22, P993, DOI 10.1002/eji.1830220418; Della Torre E, 2014, ALLERGY, V69, P269, DOI 10.1111/all.12320; Della-Torre E, 2014, ANN RHEUM DIS, V73, P1434, DOI 10.1136/annrheumdis-2014-205187; Deshpande V, 2012, SEMIN DIAGN PATHOL, V29, P191, DOI 10.1053/j.semdp.2012.08.001; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Fuschiotti P, 2011, CYTOKINE, V56, P544, DOI 10.1016/j.cyto.2011.08.030; Gasse P, 2007, J CLIN INVEST, V117, P3786, DOI 10.1172/JCI32285; Gilani SR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008959; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johnson S, 2015, J VIROL, V89, P7494, DOI 10.1128/JVI.00438-15; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Kanari H, 2010, INT ARCH ALLERGY IMM, V152, P47, DOI 10.1159/000312125; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Khosroshahi A, 2010, ARTHRITIS RHEUM-US, V62, P1755, DOI 10.1002/art.27435; Kim JR, 2010, CLIN EXP IMMUNOL, V160, P348, DOI 10.1111/j.1365-2249.2010.04116.x; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; Kolodsick JE, 2004, J IMMUNOL, V172, P4068, DOI 10.4049/jimmunol.172.7.4068; Komocsi A, 2002, AM J PATHOL, V160, P1717, DOI 10.1016/S0002-9440(10)61118-2; Koyabu M, 2010, J GASTROENTEROL, V45, P732, DOI 10.1007/s00535-010-0199-3; Larimore K, 2012, J IMMUNOL, V189, P3221, DOI 10.4049/jimmunol.1201303; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Marrache F, 2008, GASTROENTEROLOGY, V135, P1277, DOI 10.1053/j.gastro.2008.06.078; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Mattoo H, 2014, ALLERGY, V69, P399, DOI 10.1111/all.12342; Mattoo H, 2014, J ALLERGY CLIN IMMUN, V134, P679, DOI 10.1016/j.jaci.2014.03.034; Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x; Mucida D, 2013, NAT IMMUNOL, V14, P281, DOI 10.1038/ni.2523; Murray LA, 2008, INT J BIOCHEM CELL B, V40, P2174, DOI 10.1016/j.biocel.2008.02.016; Oh MH, 2011, J IMMUNOL, V186, P7232, DOI 10.4049/jimmunol.1100504; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SEMPOWSKI GD, 1994, J IMMUNOL, V152, P3606; Soghoian DZ, 2010, EXPERT REV VACCINES, V9, P1453, DOI [10.1586/erv.10.132, 10.1586/ERV.10.132]; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Stone JH, 2009, ARTHRITIS RHEUM-US, V60, P3139, DOI 10.1002/art.24798; Tanaka A, 2012, ARTHRITIS RHEUM-US, V64, P254, DOI 10.1002/art.33320; Veillette A, 2013, CRIT REV ONCOL HEMAT, V88, P168, DOI 10.1016/j.critrevonc.2013.04.003; Weng HL, 2009, HEPATOLOGY, V50, P230, DOI 10.1002/hep.22934; Wick G, 2010, TRENDS IMMUNOL, V31, P110, DOI 10.1016/j.it.2009.12.001; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697; Zonder JA, 2012, BLOOD, V120, P552, DOI 10.1182/blood-2011-06-360552	60	188	204	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					825	838		10.1016/j.jaci.2015.12.1330	http://dx.doi.org/10.1016/j.jaci.2015.12.1330			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	26971690	Green Accepted, Bronze			2022-12-18	WOS:000385496000019
J	Rothenberg, ME; Wen, T; Greenberg, A; Alpan, O; Enav, B; Hirano, I; Nadeau, K; Kaiser, S; Peters, T; Perez, A; Jones, I; Arm, JP; Strieter, RM; Sabo, R; Gunawardena, KA				Rothenberg, Marc E.; Wen, Ting; Greenberg, Allison; Alpan, Oral; Enav, Benjamin; Hirano, Ikuo; Nadeau, Kari; Kaiser, Sergio; Peters, Thomas; Perez, Antonio; Jones, Ieuan; Arm, Jonathan P.; Strieter, Robert M.; Sabo, Ronald; Gunawardena, Kulasiri A.			Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						QAX576; mAb; cytokine; T(H)2 cells; IL-13; eosinophilic esophagitis; randomized clinical trial; targeted therapy; mast cell; barrier function; transcriptome	ALLERGIC INFLAMMATION; CONSENSUS RECOMMENDATIONS; GENE-EXPRESSION; CHILDREN; PERIOSTIN; ADULTS; PREVALENCE; ASSOCIATE; DIAGNOSIS; VARIANTS	Background: Eosinophilic esophagitis (EoE) is a chronic allergic disease with limited treatment options. Objective: We evaluated QAX576, an mAb against IL-13, in the treatment of patients with EoE. Methods: Patients (18-50 years) with proton pump inhibitor-resistant esophageal eosinophilia received intravenous QAX576 (6 mg/kg) or placebo (2: 1) at weeks 0, 4, and 8 and were followed for 6 months. The primary end point was the responder rate for a greater than 75% decrease in peak eosinophil counts at week 12. Efficacy was to be declared if the lower 90% confidence limit for the proportion of responders on QAX576 was 35% or greater. Secondary end points included changes in esophageal eosinophil counts, symptoms assessed by questionnaire scores, and quantification of a series of biomarkers. Results: Twenty-three patients completed the study up to week 12, and 18 continued to the end of the study. For the proximal and distal esophageal biopsies combined, the responder rate was 12.5% (90% confidence limit, 1% to 43%) with placebo, compared to 40.0% (90% confidence limit, 22% to 61%) with QAX576. Although the primary end point was not met, the mean esophageal eosinophil count decreased by 60% with QAX576 versus an increase of 23% with placebo (P = .004), and the decrease was sustained up to 6 months. There was a trend for improved symptoms, particularly dysphagia. QAX576 improved expression of EoE-relevant esophageal transcripts, including eotaxin-3, periostin, and markers of mast cells and barrier function, for up to 6 months after treatment. QAX576 was well tolerated. Conclusions: QAX576 significantly improved intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts in adults with EoE in a sustained manner.	[Rothenberg, Marc E.; Wen, Ting; Greenberg, Allison] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Coll Med, Cincinnati, OH 45221 USA; [Greenberg, Allison] Cincinnati Childrens Hosp Med Ctr, Off Clin & Translat Res, Cincinnati, OH 45229 USA; [Alpan, Oral; Enav, Benjamin] O&O Alpan LLC, Fairfax, VA USA; [Enav, Benjamin] Pediat Gastroenterol Northern Virginia, Fairfax, VA USA; [Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Nadeau, Kari] Stanford Univ, Med Ctr, Div Immunol & Allergy, Stanford, CA 94305 USA; [Kaiser, Sergio; Peters, Thomas; Perez, Antonio; Jones, Ieuan; Arm, Jonathan P.] Novartis Inst Biomed Res, Basel, Switzerland; [Strieter, Robert M.; Sabo, Ronald] Novartis Inst Biomed Res, Cambridge, England; [Gunawardena, Kulasiri A.] Novartis Inst Biomed Res, Horsham, W Sussex, England	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Northwestern University; Feinberg School of Medicine; Stanford University; Novartis; Novartis; University of London; University College London; Novartis	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org	Peters, Thomas/GQB-3622-2022		Novartis Pharma AG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	Novartis Pharma AG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Novartis Pharma AG (ClinicalTrials.gov Identifier:NCT01022970).	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Andersson CK, 2008, AM J RESP CELL MOL, V39, P648, DOI 10.1165/rcmb.2007-0443OC; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bochner BS, 2012, J ALLERGY CLIN IMMUN, V130, P587, DOI 10.1016/j.jaci.2012.07.024; Butz BK, 2014, GASTROENTEROLOGY, V147, P324, DOI 10.1053/j.gastro.2014.04.019; Cai YP, 2009, J IMMUNOL, V182, P5393, DOI 10.4049/jimmunol.0803874; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai TK, 2005, GASTROINTEST ENDOSC, V61, P795, DOI 10.1016/S0016-5107(05)00313-5; Fiorentino R, 2012, J ALLERGY CLIN IMMUN, V130, P613, DOI 10.1016/j.jaci.2012.07.011; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Grudell ABM, 2007, DIS ESOPHAGUS, V20, P202, DOI 10.1111/j.1442-2050.2007.00670.x; Ingerski LM, 2010, J PEDIATR-US, V156, P639, DOI 10.1016/j.jpeds.2009.11.008; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Soon IS, 2013, J PEDIATR GASTR NUTR, V57, P72, DOI 10.1097/MPG.0b013e318291fee2; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Veerappan GR, 2009, CLIN GASTROENTEROL H, V7, P420, DOI 10.1016/j.cgh.2008.10.009; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	36	188	209	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					500	507		10.1016/j.jaci.2014.07.049	http://dx.doi.org/10.1016/j.jaci.2014.07.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25226850				2022-12-18	WOS:000349372300024
J	Penders, J; Gerhold, K; Stobberingh, EE; Thijs, C; Zimmermann, K; Lau, S; Hamelmann, E				Penders, John; Gerhold, Kerstin; Stobberingh, Ellen E.; Thijs, Carel; Zimmermann, Kurt; Lau, Susanne; Hamelmann, Eckard			Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiota; atopic dermatitis; birth mode; siblings; mediation analysis	REAL-TIME PCR; GUT MICROBIOTA; ESCHERICHIA-COLI; ORAL TOLERANCE; FECAL SAMPLES; INFANTS; MICROFLORA; QUANTIFICATION; CHILDREN; BACTERIA	Background: Perturbations in the intestinal microbiota may disrupt mechanisms involved in the development of immunologic tolerance. The present study aimed to examine the establishment of the infant microbiota and its association to the development of atopic dermatitis (AD). Methods: Within a randomized, placebo-controlled trial on the prevention of AD by oral supplementation of a bacterial lysate between week 5 and the end of month 7, feces was collected at the ages of 5 weeks (n = 571), 13 weeks (n = 332), and 31 weeks (n = 499) and subjected to quantitative PCRs to detect bifidobacteria, bacteroides, lactobacilli, Escherichia coli, Clostridium difficile, and Clostridium cluster I. Results: Birth mode, breast-feeding but also birth order had a strong effect on the microbiota composition. With increasing number of older siblings the colonization rates at age 5 weeks of lactobacilli (P < .001) and bacteroides (P = .02) increased, whereas rates of clostridia decreased (P < .001). Colonization with clostridia, at the age of 5 and 13 weeks was also associated with an increased risk of developing AD in the subsequent 6 months of life (odds ratio(adjusted) = 2.35; 95% CI, 1.36-3.94 and 2.51; 1.30-4.86, respectively). Mediation analyses demonstrated that there was a statistically significant indirect effect via Clostridium cluster I colonization for both birth mode and birth order in association to AD. Conclusion: The results of this study are supportive for a role of the microbiota in the development of AD. Moreover, the "beneficial'' influence of older siblings on the microbiota composition suggests that this microbiota may be one of the biological mechanisms underlying the sibling effect.	[Penders, John; Stobberingh, Ellen E.] Maastricht Univ, Med Ctr, Sch Nutr Toxicol & Metab, Dept Med Microbiol, NL-6200 MD Maastricht, Netherlands; [Penders, John; Thijs, Carel] Maastricht Univ, Sch Publ Hlth & Primary Care, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands; [Gerhold, Kerstin; Lau, Susanne] Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Zimmermann, Kurt] SymbioPharm, Herborn, Germany; [Hamelmann, Eckard] Ruhr Univ Bochum, Univ Childrens Hosp, Bochum, Germany	Maastricht University; Maastricht University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruhr University Bochum; University of Hamburg; University Medical Center Hamburg-Eppendorf	Penders, J (corresponding author), Maastricht Univ, Dept Epidemiol, POB 616, NL-6200 MD Maastricht, Netherlands.	j.penders@maastrichtuniversity.nl	Thijs, Carel/H-8340-2019; Hamelmann, Eckard/AAJ-9124-2021; Penders, John/A-1280-2011	Thijs, Carel/0000-0001-6646-5458; Penders, John/0000-0001-9146-5919	German Research Foundation DFG [DFG HA 2162/4-1]; SymbioPharm Herborn; German Research Foundation (DFG); AbbVie; Bristol-Myers Squibb; MSD Sharp Dohme; Pfizer; Roche; UCB; BMS; Symbiopharm; Nestle; DFG	German Research Foundation DFG(German Research Foundation (DFG)); SymbioPharm Herborn; German Research Foundation (DFG)(German Research Foundation (DFG)); AbbVie(AbbVie); Bristol-Myers Squibb(Bristol-Myers Squibb); MSD Sharp Dohme; Pfizer(Pfizer); Roche(Roche Holding); UCB(UCB Pharma SA); BMS(Bristol-Myers Squibb); Symbiopharm; Nestle(Nestle SA); DFG(German Research Foundation (DFG))	Supported by the German Research Foundation DFG (DFG HA 2162/4-1 to E. H.) and SymbioPharm Herborn.; K. Gerhold has received grants from the German Research Foundation (DFG); is employed by the biologics register RABBIT which is supported by joint, unconditional grants from AbbVie, Bristol-Myers Squibb, MSD Sharp & Dohme, Pfizer, Roche, and UCB; has received payment for lectures, including service on speakers bureaus from BMS; has received payment for a case report and review article manuscript preparation for "Arthritis und Rheuma,'' schattaur Verlag. S. Lau has received grants and consulting fees or honoraria from Symbiopharm, is a board member for Merck DMC, has consultant arrangements and grants pending with Allergopharma, has received payment for lectures, including service on speakers' bureaus from Nestle. E. Hamelmann has received grants from DFG. The rest of the authors declare that they have no relevant conflicts of interest.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Fanaro S, 2003, ACTA PAEDIATR, V92, P48; Goossens D, 2003, SCAND J GASTROENTERO, V38, P15, DOI 10.1080/00855920310002645; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Heilig HGHJ, 2002, APPL ENVIRON MICROB, V68, P114, DOI 10.1128/AEM.68.1.114-123.2002; Huijsdens XW, 2002, J CLIN MICROBIOL, V40, P4423, DOI 10.1128/JCM.40.12.4423-4427.2002; Johnke H, 2006, PEDIAT ALLERG IMM-UK, V17, P591, DOI 10.1111/j.1399-3038.2006.00453.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; KIM JH, 1995, BIOL PHARM BULL, V18, P854; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Liu CX, 2003, FEMS MICROBIOL LETT, V222, P9, DOI 10.1016/S0378-1097(03)00296-9; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI 10.1177/0193841X9301700202; Mah KW, 2006, INT ARCH ALLERGY IMM, V140, P157, DOI 10.1159/000092555; Nakayama J, 2011, FEMS IMMUNOL MED MIC, V63, P397, DOI 10.1111/j.1574-695X.2011.00872.x; Noverr MC, 2005, CLIN EXP ALLERGY, V35, P1511, DOI 10.1111/j.1365-2222.2005.02379.x; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Penders J, 2005, FEMS MICROBIOL LETT, V243, P141, DOI 10.1016/j.femsle.2004.11.052; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Rask C, 2005, SCAND J IMMUNOL, V61, P529, DOI 10.1111/j.1365-3083.2005.01598.x; Rinttila T, 2004, J APPL MICROBIOL, V97, P1166, DOI 10.1111/j.1365-2672.2004.02409.x; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Song YL, 2004, APPL ENVIRON MICROB, V70, P6459, DOI 10.1128/AEM.70.11.6459-6465.2004; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Walter J, 2001, APPL ENVIRON MICROB, V67, P2578, DOI 10.1128/AEM.67.6.2578-2585.2001; Yap GC, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-193	33	188	199	0	60	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					601	+		10.1016/j.jaci.2013.05.043	http://dx.doi.org/10.1016/j.jaci.2013.05.043			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23900058	Green Submitted			2022-12-18	WOS:000323612000011
J	Tulic, MK; Fiset, PO; Christodoulopoulos, P; Vaillancourt, P; Desrosiers, M; Lavigne, F; Eiden, J; Hamid, Q				Tulic, MK; Fiset, PO; Christodoulopoulos, P; Vaillancourt, P; Desrosiers, M; Lavigne, F; Eiden, J; Hamid, Q			Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						amb a 1-immunostimulatory phosphorothioate; oligonucleotide conjugate; immunotherapy; rhinitis; ragweed	MESSENGER-RNA; ALLERGEN; EOSINOPHILS; LYMPHOCYTES; EXPRESSION; INCREASES; MUCOSA; DNA	Background: Amb a 1-immunostimulatory phosphorothioate oligonucleotide conjugate (AIC) is a novel immunotherapeutic compound consisting of purified Amb a 1 from short ragweed proteins covalently linked to an immunostimulatory phosphorothioate oligodeoxyribonucleotide. In sensitized animals AIC can stimulate an Amb a 1-specific T(H)1 response and decrease pulmonary reactivity to ragweed challenge. Clinical trials have documented reduced allergic response to AIC in comparison with licensed ragweed extract. Objectives: We sought to determine the in vivo effect,of shortcourse immunotherapy with AIC on eosinophilia and cytokine mRNA expression in the nasal mucosa of ragweed-sensitive patients. Methods: Ragweed-sensitive patients with allergic rhinitis were treated with 6 escalating doses of AIC (0.06-12 mug, n 28) or placebo (n = 29) at weekly intervals immediately before the 2001 ragweed season. Symptom scores and medication use were recorded for the 2001 and 2002 ragweed seasons for all patients. A subset of patients (12 receiving AIC and 7 receiving placebo) consented to have nasal biopsy specimens taken before immunization and before and after the first ragweed season. The preseason and postseason biopsy specimens were taken 24 hours after ragweed allergen challenge and compared with the initial unchallenged biopsy specimen to assess cytokine and inflammatory cell responses by using immunocytochemistry and in situ hybridization. Results: AIC was safe and well tolerated by all patients. There was no difference between the AIC and placebo groups in the number of allergen-induced major basic protein-, IL-4-, IL-5-, or IFN-gamma-positive cells in the mucosa in the first weeksafter AIC immunization. On rechallenge and rebiopsy after the end of the 2001 ragweed season, however, AIC-treated patients had a significantly reduced increase in eosinophils and IL-4 mRNA-positive cells and an increased number of IFN-gamma mRNA-positive cells compared with placebo-treated patients. No difference between treatment groups was observed in symptom scores or medication use during the first ragweed season. During the second ragweed season, however, there was a significant decrease in chest symptoms and a trend toward reduced nasal symptoms in the AIC-treated group. Conclusion: Short-course immunotherapy with AIC can modify the response of nasal mucosa to allergen challenge by increasing T(H)1 cytokine production and decreasing T(H)2 cytokine production and eosinophilia. This modification was not immediate but was observed 4 to 5 months after completion of immunotherapy and seasonal ragweed-pollen exposure. The T-cell subset shift after immunization and seasonal exposure was followed by evidence of clinical efficacy in the second ragweed season without additional AIC immunizations.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Ctr Hosp, Montreal, PQ, Canada; Dynavax Technol Corp, Berkeley, CA USA	McGill University; Universite de Montreal	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Tulic, Meri/P-6613-2016; Tulic, Meri K/ABB-5138-2020	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369				Christodoulopoulos P, 2002, J ALLERGY CLIN IMMUN, V109, pS316, DOI 10.1016/S0091-6749(02)82108-X; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282, DOI 10.1159/000237003; DURHAM SR, 1997, ARB P EHRLICH I BUND, V91, P33; FREW AJ, 1988, J IMMUNOL, V141, P4158; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170	15	188	216	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					235	241		10.1016/j.jaci.2003.11.001	http://dx.doi.org/10.1016/j.jaci.2003.11.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767435	Bronze			2022-12-18	WOS:000188885700008
J	Ponikau, JU; Sherris, DA; Kephart, GM; Kern, EB; Gaffey, TA; Tarara, JE; Kita, H				Ponikau, JU; Sherris, DA; Kephart, GM; Kern, EB; Gaffey, TA; Tarara, JE; Kita, H			Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: Is the histopathology similar to asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; histopathology; eosinophil; remodeling; sinusitis	MAJOR BASIC-PROTEIN; CHRONIC SINUSITIS	Background: Asthma and chronic rhinosinusitis (CRS) coexist clinically in >50% of patients with CRS. Although epithelial damage and basement membrane thickening are well-known features of airway remodeling in asthma, they have not been described in CRS. Objective: In this study, we tested the hypothesis that histopathologic features of asthma, namely, the chronic eosinophilic inflammation, epithelial damage, and basement membrane thickening of the airway mucosa, are also present in sinonasal specimens from patients with CRS. Methods: We examined histologic specimens from 22 randomly selected patients with refractory CRS undergoing endoscopic sinus surgery and 4 healthy control subjects. The shedding of the epithelium and basement membrane thickening were evaluated by 3 independent observers' scores of hematoxylin-and-eosin staining. Eosinophilic inflammation was monitored with immunohistochemistry for eosinophil major basic protein. A novel, computerized method objectively analyzed confocal microscopic images of major basic protein immunufluorescence to determine areas with the least and most inflammation per specimen. Results: Specimens from all patients with CRS (22/22) revealed epithelial damage (shedding) and basement membrane thickening. Strikingly heterogeneous eosinophilic inflammation, which did not differ between allergic and nonallergic patients, was detected in all patients with CRS and was absent in all healthy control subjects. Conclusion: The histopathologic findings of asthma, namely, heterogeneous eosinophilic inflammation and features of airway remodeling, are also present in CRS. These findings, coupled with the common clinical coexistence of both diseases, suggest that the same pathologic disease process is manifest as CRS in the sinonasal tissue and as asthma in the lower airway.	Mayo Clin, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Div Allergy & Infect Dis, Rochester, MN 55905 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Ponikau, JU (corresponding author), Mayo Clin, Dept Otorhinolaryngol Head & Neck Surg, 200 1st St SW, Rochester, MN 55905 USA.				NIAID NIH HHS [AI 50494-P3, AI 49235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235, P01AI050494] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhattacharyya N, 2001, ARCH OTOLARYNGOL, V127, P1102, DOI 10.1001/archotol.127.9.1102; BLACKWELL DL, 2002, NAT CTR HLTH STAT VI, P10; Carter PM, 1997, J INVEST ALLERG CLIN, V7, P566; Chiappara G, 2001, CURR OPIN ALLERGY CL, V1, P85, DOI 10.1097/00130832-200102000-00015; FILLEY WV, 1982, LANCET, V2, P11; FILLEY WV, 1981, J IMMUNOL METHODS, V47, P227, DOI 10.1016/0022-1759(81)90123-X; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; Nadel DM, 1998, AM J RHINOL, V12, P233, DOI 10.2500/105065898781390000; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309	18	188	215	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					877	882		10.1016/j.jaci.2003.08.009	http://dx.doi.org/10.1016/j.jaci.2003.08.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610473				2022-12-18	WOS:000186553300008
J	Fernandez-Rivas, M; Gonzalez-Mancebo, E; Rodriguez-Perez, R; Benito, C; Sanchez-Monge, R; Salcedo, G; Alonso, D; Rosado, A; Tejedor, MA; Vila, C; Casas, ML				Fernandez-Rivas, M; Gonzalez-Mancebo, E; Rodriguez-Perez, R; Benito, C; Sanchez-Monge, R; Salcedo, G; Alonso, D; Rosado, A; Tejedor, MA; Vila, C; Casas, ML			Clinically relevant peach allergy is related to peach lipid transfer protein, Pru p 3, in the Spanish population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						double-blind placebo-controlled food challenge; food allergy; lipid transfer protein; peach; Pru p 3; rBet vl; rBet v2; Rosaceae fruits; skin prick tests	PLANT-DERIVED FOODS; CROSS-REACTIVITY; BIRCH POLLEN; MAJOR ALLERGEN; ROSACEAE FRUITS; ARTEMISIA POLLEN; PROFILIN; BET-V-1; CHERRY; APPLE	Background: Sensitization to peach and related Rosaceae fruits without clinical expression is commonly observed as the result of the extensive cross-reactivity of IgE antibodies directed toward lipid transfer proteins (LTPs), Bet v 1 homologues, profilins, and carbohydrate determinants. Objective: We aimed to study whether there are any clinical or immunologic differences between patients allergic to peach and those who have a current clinically irrelevant sensitization to this fruit. Methods: One hundred subjects with adverse reactions to peach were evaluated by medical history, skin prick tests with fresh peach and purified peach UP (Pro p 3), and specific IgE determinations to peach, rBet v 1, and rBet v 2 (birch profilin). Clinical reactivity to peach was established by double-blind, placebo-controlled food challenges. The clinical characteristics and the in vivo and in vitro tests were compared between allergic and nonallergic patients. Results: Peach allergy was confirmed in 76 patients and ruled out in 16; 2 patients dropped out, and the study was not conclusive in 6 individuals (placebo reactors). Pollen allergy was found in 76% of the allergic patients and in 100% of the nonallergic patients. Positive responses to Pro p 3, rBet v 1, and rBet v 2 were observed in 62%, 7%, and 34% of patients allergic to peach, respectively. The sensitization rate to Pru p 3 was significantly higher among subjects allergic than nonallergic to peach (62% vs 31%, P = .02). IgE responses to rBet v 2 were more frequent among subjects allergic to pollen, but no difference was observed in the presence or absence of peach allergy. Conclusions: Pro p 3 is the major allergen of peach in our population, and the IgE response to this allergen is related to the clinical expression of peach allergy. Sensitization to profilin is observed in those patients with an associated pollen allergy but does not appear to be related to the clinical reactivity to peach.	Fdn Hosp Alcorcon, Unidad Alergia, Madrid 28922, Spain; ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid, Spain; Fdn Hosp Alcorcon, Area Lab, Madrid, Spain	Alcorcon Foundation University Hospital; Alcorcon Foundation University Hospital	Fernandez-Rivas, M (corresponding author), Fdn Hosp Alcorcon, Unidad Alergia, C Budapest 1, Madrid 28922, Spain.		Alonso, Miguel Angel Tejedor/AAM-8217-2021; Perez, Rosa Rodriguez/F-2634-2013; alonso, miguel angel tejedor/I-6682-2019; alonso, miguel angel tejedor/J-1703-2019	Perez, Rosa Rodriguez/0000-0003-0771-7103; alonso, miguel angel tejedor/0000-0003-3618-8220; alonso, miguel angel tejedor/0000-0003-3618-8220; Rosado, Ana/0000-0002-4862-9006; ALONSO-DIAZ DE DURANA, MARIA DOLORES/0000-0001-5869-6790				Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; BOCK SA, 1997, FOOD ALLERGY ADVERSE, P151; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Cuesta-Herranz J, 1999, J ALLERGY CLIN IMMUN, V104, P688, DOI 10.1016/S0091-6749(99)70343-X; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Drebotg S, 1989, ALLERGY S10, V44, P22; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Fernandez-Rivas M, 1999, CLIN EXP ALLERGY, V29, P1239, DOI 10.1046/j.1365-2222.1999.00628.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; HERNANDEZ J, 1985, ALLERGOL IMMUNOPATH, V13, P197; Karamloo F, 2001, J CHROMATOGR B, V756, P281, DOI 10.1016/S0378-4347(01)00087-1; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; MALLING HJ, 1993, ALLERGY, V48, P9; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P183, DOI 10.1067/mai.2000.106927; Rodriguez-Perez R, 2003, ALLERGY, V58, P635, DOI 10.1034/j.1398-9995.2003.00198.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380	39	188	190	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					789	795		10.1016/S0091-6749(03)02016-5	http://dx.doi.org/10.1016/S0091-6749(03)02016-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564363				2022-12-18	WOS:000185831200021
J	MATTOLI, S; MATTOSO, VL; SOLOPERTO, M; ALLEGRA, L; FASOLI, A				MATTOLI, S; MATTOSO, VL; SOLOPERTO, M; ALLEGRA, L; FASOLI, A			CELLULAR AND BIOCHEMICAL CHARACTERISTICS OF BRONCHOALVEOLAR LAVAGE FLUID IN SYMPTOMATIC NONALLERGIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; MAST-CELLS; EOSINOPHIL FUNCTION; MILD ASTHMA; T-CELLS; EXPRESSION; ANTIGEN; HYPERREACTIVITY	We have undertaken cellular and biochemical examination of bronchoalveolar lavage fluid from nonallergic patients with asthma to determine the nature and degree of inflammatory process in symptomatic asthma. Six patients with asthma (mean methacholine provocative concentration causing a 20% fall in FEV1 was 0.26 mg/ml) and six control subjects underwent fiberoptic bronchoscopy with bronchoalveolar wash. The patients with asthma shed a higher number of epithelial cells into lavage fluid than normal control subjects (p < 0.05). Their lavage fluid also contained increased numbers of neutrophils (p < 0.025), eosinophils (p < 0.025), and basophilic cells (p < 0.025), and increased proportion of activated T cells (p < 0.05). The basophilic cells were mast cells, as indicated by positive labeling with the monoclonal antibody MCG35. Biochemical analysis of lavage fluid demonstrated exudation of protein molecules in airways of patients with asthma with increased contents of albumin (p < 0.05) and fibronectin (p < 0.05). In the lavage fluid of patients with asthma, there were also increased amounts of interleukin-1-beta (IL-1-beta) (p < 0.025), interleukin-6 (IL-6) (p < 0.025), and granulocyte-macrophage, colony-stimulating factor (GM-CSF) (p < 0.05), as compared with lavage fluid of normal control subjects. Immunocytochemical evaluation of lavage cells demonstrated that IL-1-beta, IL-6, and GM-CSF were mostly produced by nonciliated epithelial cells and/or monocytes. IL-1, IL-6, and GM-CSF can prime granulocytes to respond to other stimuli and can promote T cell activation. The production of these cytokines by bronchial resident cells may have a role in the perpetuation of the inflammatory responses in asthma.	UNIV MILAN, SCH MED, DEPT INTERNAL MED, I-20122 MILAN, ITALY; UNIV MILAN, SCH MED, LUNG CELLULAR & MOLEC BIOL SECT, I-20122 MILAN, ITALY	University of Milan; University of Milan			Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BITTERMAN PB, 1983, J CELL BIOL, V97, P1925, DOI 10.1083/jcb.97.6.1925; Cardell BS, 1959, THORAX, V14, P341; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CHANEZ P, 1988, CLIN SCI, V75, pP5; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; DALEY SF, 1985, J IMMUNOL, V134, P330; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EARLE BV, 1953, THORAX, V8, P195, DOI 10.1136/thx.8.3.195; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GILLIS S, 1987, INFECTION IMMUNITY B, P375; GINNS LC, 1982, CLIN IMMUNOL IMMUNOP, V25, P11, DOI 10.1016/0090-1229(82)90160-X; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; HOGG N, 1984, IMMUNOLOGY, V53, P753; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNIG T, 1985, J EXP MED, V162, P890, DOI 10.1084/jem.162.3.890; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KIRNBAUER R, 1989, J IMMUNOL, V142, P1922; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; LAM S, 1985, CHEST, V87, P740, DOI 10.1378/chest.87.6.740; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MATTOLI S, 1990, J CELL PHYSIOL, V142, P379, DOI 10.1002/jcp.1041420222; MATTOLI S, 1990, CELLULAR COMMUNICATI, V25, P35; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; METCALF D, 1989, LANCET, V1, P825; MICHEL FB, 1989, INT ARCH ALLER A IMM, V88, P101, DOI 10.1159/000234756; MOIR DJ, 1983, BRIT J HAEMATOL, V55, P395, DOI 10.1111/j.1365-2141.1983.tb02154.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; RENNARD SI, 1982, J CLIN INVEST, V69, P113, DOI 10.1172/JCI110421; RIMMER EF, 1984, J CLIN PATHOL, V37, P1249, DOI 10.1136/jcp.37.11.1249; ROCHE WR, 1989, LANCET, V1, P520; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALVATO G, 1960, THORAX, V15, P142; SCHWARTING R, 1985, BLOOD, V65, P974; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; VANDAMME J, 1988, J IMMUNOL, V140, P1534; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	51	188	190	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					794	802		10.1016/0091-6749(91)90125-8	http://dx.doi.org/10.1016/0091-6749(91)90125-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013675				2022-12-18	WOS:A1991FG05900008
J	GODARD, P; CHAINTREUIL, J; DAMON, M; COUPE, M; FLANDRE, O; DEPAULET, AC; MICHEL, FB				GODARD, P; CHAINTREUIL, J; DAMON, M; COUPE, M; FLANDRE, O; DEPAULET, AC; MICHEL, FB			FUNCTIONAL ASSESSMENT OF ALVEOLAR MACROPHAGES - COMPARISON OF CELLS FROM ASTHMATICS AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST ELOI,BIOCHIM LAB A,F-34059 MONTPELLIER,FRANCE; INSERM,U58,F-34100 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	GODARD, P (corresponding author), HOP AIGUELONGUE,CHU,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.							ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; ARNOUX B, 1981, RESPIRATION S1, V42, P4; BOCKMAN RS, 1981, PROSTAGLANDINS, V21, P9, DOI 10.1016/0090-6980(81)90192-1; BURSTON BC, 1965, HISTOPATHOLOGIC TECH, P342; CAPRON A, 1981, RESPIRATION S1, V42, P20; COHEN AB, 1971, J CLIN INVEST, V50, P1390, DOI 10.1172/JCI106622; DESSAINT JP, 1980, PATHOL BIOL, V28, P605; DRAY F, 1975, EUR J CLIN INVEST, V5, P311, DOI 10.1111/j.1365-2362.1975.tb02363.x; Gemsa D, 1979, Monogr Allergy, V14, P194; GODARD P, 1981, CHEST, V80, P447, DOI 10.1378/chest.80.4.447; GREEN GM, 1977, AM REV RESPIR DIS, V115, P479; HSUEH W, 1980, NATURE, V283, P80, DOI 10.1038/283080a0; HSUEH W, 1979, AM J PATHOL, V97, P137; HSUEH W, 1979, BIOCHEM J, V184, P345, DOI 10.1042/bj1840345; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; KENNEDY MS, 1980, PROSTAGLANDINS, V20, P135; KOHLER CA, 1973, J IMMUNOL, V111, P1610; LAVIOLETTE M, 1981, AM REV RESPIR DIS, V124, P397; LEVINE L, 1979, PROSTAG LEUKOTR ESS, V3, P295, DOI 10.1016/0161-4630(79)90071-5; MORLEY J, 1979, Prostaglandins, V17, P730; PATERSON NAM, 1981, J ALLERGY CLIN IMMUN, V67, P435, DOI 10.1016/0091-6749(81)90096-8; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; SCHWARTZ D, 1980, METHODES STATISTIQUE; STENSON WF, 1980, J IMMUNOL, V125, P1; WELLER PF, 1980, AM J PATHOL, V100, P793	27	188	189	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					88	93		10.1016/0091-6749(82)90234-2	http://dx.doi.org/10.1016/0091-6749(82)90234-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	7096825	Bronze			2022-12-18	WOS:A1982PB59100003
J	SOLLEY, GO; GLEICH, GJ; VANDELLEN, RG				SOLLEY, GO; GLEICH, GJ; VANDELLEN, RG			PENICILLIN ALLERGY - CLINICAL-EXPERIENCE WITH A BATTERY OF SKIN-TEST REAGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,DEPT INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; BIERMAN CW, 1969, J ALLERGY, V43, P267, DOI 10.1016/0021-8707(69)90147-6; DOGLIOTTI M, 1968, DERMATOLOGICA, V136, P489, DOI 10.1159/000254145; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1964, J MED CHEM, V7, P675, DOI 10.1021/jm00335a030; PETZ LD, 1971, POSTGRAD MED J, V47, P64; ROSENBLU.AH, 1968, J ALLERGY, V42, P309, DOI 10.1016/0021-8707(68)90093-2; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; VANDELLEN RG, 1970, MED CLIN N AM, V54, P997, DOI 10.1016/S0025-7125(16)32617-7; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; VOSS HE, 1966, J AMER MED ASSOC, V196, P679, DOI 10.1001/jama.1966.03100210049014; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x	16	188	191	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					238	244		10.1016/0091-6749(82)90105-1	http://dx.doi.org/10.1016/0091-6749(82)90105-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056954				2022-12-18	WOS:A1982NC58100011
J	Wen, WP; Liu, WL; Zhang, L; Bai, J; Fan, YP; Xia, WT; Luo, Q; Zheng, J; Wang, HT; Li, ZW; Xia, JH; Jiang, HY; Liu, Z; Shi, JB; Li, HB; Xu, G				Wen, Weiping; Liu, Wenlong; Zhang, Luo; Bai, Jing; Fan, Yunping; Xia, Wentong; Luo, Qing; Zheng, Jing; Wang, Hongtian; Li, Zuwang; Xia, Jiahong; Jiang, Hongyan; Liu, Zheng; Shi, Jianbo; Li, Huabin; Xu, Geng		NHGC	Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nose; inflammatory response; prognostic factor; response to therapy	CHRONIC RHINOSINUSITIS; INFLAMMATION; ASTHMA; CELLS; STEROIDS; SPRAY	Background: Nasal polyps (NPs) are characterized by eosinophilic inflammation, which is generally considered sensitive to corticosteroid treatment. Objectives: We evaluated levels of neutrophilia in NPs and investigated whether increased neutrophilia in polyp tissue affected the response to corticosteroid treatment. Methods: We studied 3 independent cross-sectional groups of patients with NPs. Levels of infiltration by different types of inflammatory cells were determined by using immunohistochemical analyses and compared with those seen in control nasal tissues from subjects without NPs. Levels of inflammatory mediators were measured by using real-time PCR, ELISA, and FlowCytomix analyses. Patients with NPs received oral corticosteroid therapy (30 mg of prednisone once daily for 7 days); clinical parameters of efficacy were associated with NP phenotypes. Results: Among patients with NPs, 76.5% had an eosinophilic phenotype, 46.0% had a neutrophilic phenotype, and 35.8% had a mixed phenotype (indicated by double staining). Overall, patients' symptoms improved after corticosteroid treatment; numbers of eosinophils and levels of their mediators (IL-4 and IL-5), but not numbers of neutrophils or levels of their mediators (IL-8 and interferon-inducible protein 10), were reduced (P < .05). After corticosteroid treatment, patients with the nonneutrophilic phenotype (neutrophil negative) had significantly greater reductions in bilateral polyp size scores, nasal congestion scores, total nasal symptom scores, and nasal resistance than patients with the neutrophilic phenotype (neutrophil positive, P < .05). Conclusions: There are different phenotypes of NPs based on the type of immune cell infiltrate and cytokines produced (eosinophilic or neutrophilic). Patients with the neutrophilic phenotype have less response to treatment with corticosteroids based on symptom scores. (J Allergy Clin Immunol 2012;129:1522-8.)	[Wen, Weiping; Liu, Wenlong; Bai, Jing; Xia, Wentong; Luo, Qing; Zheng, Jing; Li, Zuwang; Jiang, Hongyan; Shi, Jianbo; Li, Huabin; Xu, Geng] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolarygol Hosp, Allergy & Canc Ctr, Guangzhou 510080, Guangdong, Peoples R China; [Wen, Weiping; Liu, Wenlong; Bai, Jing; Xia, Wentong; Luo, Qing; Zheng, Jing; Li, Zuwang; Jiang, Hongyan; Shi, Jianbo; Li, Huabin; Xu, Geng] Sun Yat Sen Univ, Otorhinolaryngol Inst, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Luo] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Fan, Yunping] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Otolaryngol, Zhuhai, Peoples R China; [Wang, Hongtian] Peoples Liberat Army Gen Hosp, Dept Otolaryngol, Beijing, Peoples R China; [Xia, Jiahong] Huazhong Univ Sci & Technol, Union Hosp, Dept Surg, Wuhan 430074, Peoples R China; [Liu, Zheng] Huazhong Univ Sci & Technol, Dept Otolaryngol, Tongji Hosp, Wuhan 430074, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Capital Medical University; Sun Yat Sen University; Chinese People's Liberation Army General Hospital; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Li, HB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolarygol Hosp, Allergy & Canc Ctr, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	allergyli@163.com; entxgfess@163.com	温, 家琦/GYV-3177-2022	Zhang, Luo/0000-0002-0910-9884	National Natural Science grants of China [30872845, 81070771, 81070772, U0832007]; Ministry of Hygiene [201202005]; Guangdong Province Natural Science grants [9151006001000014, S2011010004634, S2011020002295]; Program for New Century Excellent Talents in University [NCET-10-0851]	National Natural Science grants of China; Ministry of Hygiene; Guangdong Province Natural Science grants; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	Supported by National Natural Science grants of China (no. 30872845, 81070771, 81070772, and U0832007), a grant from the Ministry of Hygiene (no. 201202005), Guangdong Province Natural Science grants (no. 9151006001000014, S2011010004634, and S2011020002295), and the Program for New Century Excellent Talents in University (no. NCET-10-0851).	Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Fan YP, 2011, J ALLERGY CLIN IMMUN, V127, P1312, DOI 10.1016/j.jaci.2011.01.059; Fokkens W, 2007, RHINOLOGY, P1; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Ito K, 2008, AM J RESP CELL MOL, V39, P543, DOI 10.1165/rcmb.2008-0028OC; Jankowski R, 2009, ALLERGY, V64, P944, DOI 10.1111/j.1398-9995.2009.01938.x; Kim JW, 2007, OTOLARYNG HEAD NECK, V137, P925, DOI 10.1016/j.otohns.2007.07.036; Kowalski ML, 2011, CURR ALLERGY ASTHM R, V11, P187, DOI 10.1007/s11882-011-0192-9; Maneechotesuwan K, 2007, CHEST, V132, P98, DOI 10.1378/chest.06-2982; Mullol J, 2009, IMMUNOL ALLERGY CLIN, V29, P657, DOI 10.1016/j.iac.2009.07.001; Rowe-Jones Jilian M., 1997, Rhinology (Utrecht), V35, P113; Small CB, 2008, J ALLERGY CLIN IMMUN, V121, P928, DOI 10.1016/j.jaci.2007.11.018; STOOP AE, 1991, J ALLERGY CLIN IMMUN, V87, P470, DOI 10.1016/0091-6749(91)90004-8; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; van Drunen CM, 2009, IMMUNOL ALLERGY CLIN, V29, P621, DOI 10.1016/j.iac.2009.07.003; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	22	187	210	2	48	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1522	+		10.1016/j.jaci.2012.01.079	http://dx.doi.org/10.1016/j.jaci.2012.01.079			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22460066				2022-12-18	WOS:000304764600012
J	Miller, EK; Edwards, KM; Weinberg, GA; Lwane, MK; Griffin, MR; Hall, CB; Zhu, YW; Szilagyi, PG; Morin, LL; Heil, LH; Lu, XY; Williams, JV				Miller, E. Kathryn; Edwards, Kathryn M.; Weinberg, Geoffrey A.; Lwane, Marika K.; Griffin, Marie R.; Hall, Caroline B.; Zhu, Yuwei; Szilagyi, Peter G.; Morin, Laura-Lee; Heil, Luke H.; Lu, Xiaoyan; Williams, John V.		New Vaccine Surveillance Network	A novel group of rhinoviruses is associated with asthma hospitalizations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinoviruses; asthma; children; wheezing; hospitalized; genetic diversity	RESPIRATORY-TRACT INFECTIONS; POLYMERASE-CHAIN-REACTION; TRANSCRIPTION-PCR ASSAY; HUMAN METAPNEUMOVIRUS; SYNCYTIAL VIRUS; CHILDREN; ILLNESS; ENTEROVIRUS-68; EXACERBATIONS; EPIDEMIC	Background: Although recent studies have identified new group C human rhinoviruses (HRVCs), their spectrum of pediatric disease is unknown. Objective: We sought to determine the presentation and burden of disease caused by HRVCs among young hospitalized children. Methods: We conducted prospective population-based surveillance in 2 US counties among children less than 5 years of age hospitalized with acute respiratory illness or fever from October 2001 through September 2003. Nasal/throat swabs were obtained and tested for HRVs, as determined by means of RT-PCR and then characterized by means of partial sequencing. Results: Of 1052 children enrolled and tested during the 2-year period, 167 (16%) had HRVs detected. Of 147 samples successfully sequenced, 64 were group A HRVs, 6 were group B HRVs, and 77 were HRVCs. Children with HRVCs were significantly more likely than those with group A HRVs to have underlying high-risk conditions, such as asthma (42% vs 23%, P = .023) and to have had a discharge diagnosis of asthma (55% vs 36%, P = .022). Conclusions: Overall, HRVCs were detected in 7% of children hospitalized for fever or respiratory conditions and constituted almost half of all rhinovirus-associated hospitalizations, suggesting that this novel group causes a substantial burden of pediatric disease. (J Allergy Clin Immunol 2009;123:98-104.)	[Lwane, Marika K.; Lu, Xiaoyan] Ctr Dis Control & Prevent, Natl Immunizat Program, Resp & Enter Viruses Branch, Atlanta, GA USA; [Weinberg, Geoffrey A.; Hall, Caroline B.; Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14627 USA; [Miller, E. Kathryn; Edwards, Kathryn M.; Morin, Laura-Lee; Heil, Luke H.; Williams, John V.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Williams, John V.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; [Zhu, Yuwei] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37232 USA	Centers for Disease Control & Prevention - USA; University of Rochester; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Miller, EK (corresponding author), Vanderbilt Childrens Hosp, 2200 Childrens Way,11215 Doctors Off Tower, Nashville, TN 37232 USA.	eva.k.miller@vanderbilt.edu	Weinberg, Geoffrey A./W-7510-2019; Williams, John/ABE-3227-2020	Weinberg, Geoffrey A./0000-0002-3900-379X; Williams, John/0000-0001-8377-5175	Centers for Disease Control and Prevention [U38/CCU417958, U01/IP000022, U38/CCU217969, U01/IP000017]; MedImmune; Agency for Healthcare Quality and Research [T32 HS 13833-02]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS013833] Funding Source: NIH RePORTER; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [U01IP000017, U01IP000022] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); MedImmune(AstraZenecaMedimmune); Agency for Healthcare Quality and Research(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This project was supported in part by cooperative agreement nos. U38/CCU417958, U01/IP000022, U38/CCU217969, and U01/IP000017 from the Centers for Disease Control and Prevention, by MedImmune (provided funding for PCR and DNA sequencing supplies to EKM), and by the Agency for Healthcare Quality and Research (T32 HS 13833-02 to EKM). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.	Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689; Bertino JS, 2002, AM J MED, V112, p42S; Blomqvist S, 2002, J CLIN MICROBIOL, V40, P4218, DOI 10.1128/JCM.40.11.4218-4223.2002; Calvo C, 2007, PEDIATR INFECT DIS J, V26, P904, DOI 10.1097/INF.0b013e31812e52e6; *CDCP CTR DIS CONT, 2006, PUBL CDCP, V15; COONEY MK, 1982, INFECT IMMUN, V37, P642, DOI 10.1128/IAI.37.2.642-647.1982; Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003; Felsenstein J, 2005, PHYLIP PHYLOGENY INF; Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487; Ferreira A, 2002, RESPIRATION, V69, P136, DOI 10.1159/000056316; Gern JE, 2002, AM J MED, V112, p19S; Griffin MR, 2004, PEDIATR INFECT DIS J, V23, DOI [DOI 10.1097/01.INF.0000144660.53024.64, 10.1097/01.inf.0000144660.53024.64]; HAMPARIAN VV, 1987, VIROLOGY, V159, P191; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Ishiko H, 2002, INTERVIROLOGY, V45, P136, DOI 10.1159/000065866; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Jennings LC, 2004, PEDIATR INFECT DIS J, V23, P1003, DOI 10.1097/01.inf.0000143648.04673.6c; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; KAPIKIAN A Z, 1971, Virology, V43, P524, DOI 10.1016/0042-6822(71)90329-1; KAPIKIAN A Z, 1967, Nature (London), V213, P761; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Monto AS, 2002, CLIN THER, V24, P1987, DOI 10.1016/S0149-2918(02)80093-5; Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555; Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002; PELON W, 1957, P SOC EXP BIOL MED, V94, P262; Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832; Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312; Rust K F, 1996, Stat Methods Med Res, V5, P283, DOI 10.1177/096228029600500305; Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3; Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; West JV, 2002, BRIT MED BULL, V61, P215, DOI 10.1093/bmb/61.1.215; Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274; [No title captured]; [No title captured]	56	187	195	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					98	104		10.1016/j.jaci.2008.10.007	http://dx.doi.org/10.1016/j.jaci.2008.10.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19027147	Green Published, Bronze			2022-12-18	WOS:000262793900015
J	Arruda, LK; Vailes, LD; Ferriani, VPL; Santos, BR; Pomes, A; Chapman, MD				Arruda, LK; Vailes, LD; Ferriani, VPL; Santos, BR; Pomes, A; Chapman, MD			Cockroach allergens and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR, 2000	SAN DIEGO, CALIFORNIA	Amer Acad Allergy Asthma & Immunol		cockroach; asthma; indoor allergens; public health; risk factors; environment	HOUSE-DUST MITE; IMMUNOSTIMULATORY DNA-SEQUENCES; INNER-CITY CHILDREN; HIGH-LEVEL EXPRESSION; AMERICAN COCKROACH; RISK-FACTORS; AIRWAY HYPERRESPONSIVENESS; BLATTELLA-GERMANICA; INHALANT ALLERGENS; SHRIMP ALLERGEN	Asthma and allergy are the most common diseases associated with cockroach infestation of houses in the United States and other parts of the world. Sensitization and exposure to cockroach allergens is associated with increased asthma morbidity in the United States, especially among lower socioeconomic groups, including African American and Hispanic populations. Exposure to cockroach allergens in the first 3 months of life has been associated with repeated wheezing and asthma. The principal domestic cockroach species are Blattella germanica and Periplaneta americana. Both species produce several potent allergens, including Bla g 2 (inactive aspartic proteinase), Bla g 4 (calycin), Bla g 5 (glutathione-S-transferase), the group 1 cross-reactive allergens Bla g 1 and Per a 1, and tropomyosin. Structural homology between tropomyosins from cockroaches, mites, and shrimp may explain clinical cases of the oral allergy syndrome. The 3-dimensional structures of several cockroach allergens are known, and biologically active recombinant allergens have been produced in high-level expression vectors. The use of recombinant cockroach allergens should allow mechanisms of cockroach-induced asthma to be investigated and may lead to the development of new approaches to asthma treatment. Environmental allergen measurements of Bla g 1 and Bla g 2 have allowed exposure levels that cause allergic sensitization to be established. Abatement studies have shown that a sustained decrease in cockroach allergen levels is difficult but can be accomplished by professional application of insecticides, together with rigorous household cleaning. Cockroach asthma is an important public health problem that affects patients who are the least likely to be compliant with treatment with asthma medications or environmental control. Patient education, improvements in the housing stock, and improvements in environmental and immunologic treatment strategies are likely to be the most successful approaches to reduce the prevalence of cockroach-induced asthma.	Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, BR-14049 Ribeirao Preto, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Cell & Mol Biol, BR-14049 Ribeirao Preto, Brazil; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Universidade de Sao Paulo; Universidade de Sao Paulo; University of Virginia	Chapman, MD (corresponding author), UVA Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.		Pomés, Anna/H-7010-2019; Arruda, L. Karla/D-5845-2013; Ferriani, Virginia PL/E-2209-2012	Pomés, Anna/0000-0002-8729-1829; Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, R01AI032557, U01AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34607, AI32557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; ARRUDA LK, 1995, J BIOL CHEM, V270, P3116; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Broide D, 1998, J IMMUNOL, V161, P7054; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Camara AA, 2000, J ALLERGY CLIN IMMUN, V105, pS80, DOI 10.1016/S0091-6749(00)91578-1; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Chapman MD, 1998, REV FR ALLERGOL, V38, P842, DOI 10.1016/S0335-7457(98)80153-6; Chapman MD, 1996, ALLERGY ALLERGIC DIS, P942; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; Creticos P. S., 1997, Journal of Allergy and Clinical Immunology, V99, pS401; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS559, DOI 10.1016/S0091-6749(00)90060-5; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; DUFF AL, 1993, PEDIATRICS, V92, P535; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; Henderson CE, 2000, J REPROD MED, V45, P341; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; KANG BC, 1992, ANN ALLERGY, V68, P23744; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Lima RC, 1999, J ALLERGY CLIN IMMUN, V103, pS29; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; MENDOZA J, 1970, ANN ALLERGY, V28, P159; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; O'Connor GT, 1999, ENVIRON HEALTH PERSP, V107, P243, DOI 10.2307/3434516; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90938-2; Prescott SL, 1998, J IMMUNOL, V160, P4730; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Santos ABR, 2000, J ALLERGY CLIN IMMUN, V105, pS325, DOI 10.1016/S0091-6749(00)91383-6; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHULANER FA, 1970, PEDIATRICS, V45, P465; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMITH A, 1998, IMMUNOTHERAPY ASTHMA; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4; Zhou DH, 1998, J ALLERGY CLIN IMMUN, V101, P653, DOI 10.1016/S0091-6749(98)70174-5	79	187	207	4	38	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					419	428		10.1067/mai.2001.112854	http://dx.doi.org/10.1067/mai.2001.112854			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240940				2022-12-18	WOS:000167793300001
J	Ouyang, Y; Virasch, N; Hao, P; Aubrey, MT; Mukerjee, N; Bierer, BE; Freed, BM				Ouyang, Y; Virasch, N; Hao, P; Aubrey, MT; Mukerjee, N; Bierer, BE; Freed, BM			Suppression of human IL-1 beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cigarette smoking; hydroquinone; catechol; nicotine; cytokine; IL-1 beta; IL-2; IFN-gamma; TNF-alpha; immunosuppression	NECROSIS-FACTOR-ALPHA; HUMAN ALVEOLAR MACROPHAGES; TOBACCO CARCINOGENESIS; INTERFERON-GAMMA; T-LYMPHOCYTES; REACTIVE METABOLITE; MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; TUMOR PROMOTERS; P-BENZOQUINONE	Background: Although cigarette smoking is known to have detrimental effects on the immune system, the nature of the immunosuppressive agent or agents is poorly understood. Objective: The purpose of the current study was to evaluate the effects of cigarette smoke extracts from high-tar (unfiltered Camel), medium-tar (Marlboro), and low-tar (Carlton) cigarettes on the in vitro production of IL-1 beta, IL-2, IFN-gamma, and TNF-alpha. Methods: The concentrations of hydroquinone and catechol in cigarette smoke extracts were determined by using HPLC. Human PBMCs were treated with cigarette smoke extracts, hydroquinone, or catechol, and stimulated with anti-CDS and phorbol-12-myristate-13-acetate. Cytokine levels in the supernatants were quantified by ELISA. Results: Pretreatment of PBMCs with cigarette smoke extracts derived from a single high- or low-tar cigarette suppressed the production of IL-1 beta, IL-2, IFN-gamma, and TNF-alpha by greater than 90% without significant loss of cell viability. Nicotine, at a concentration comparable with that found in the highest-tar cigarettes (200 mu g/mL), suppressed the production of IL-2, IFN-gamma, and TNF-alpha by only 21% to 38%. Catechol (50 mu mol/L) inhibited production of IL-2 and IL-1 beta by 62% to 73% but had little effect on TNF-alpha or IFN-gamma production. In contrast, hydroquinone inhibited the production of all 4 cytokines with IC50 values ranging from 3 mu mol/L(IL-1 beta) to 29 mu mol/L (IFN-gamma). However, HPLC determination of the hydroquinone concentrations in cigarette smoke extracts from single Camel (33 +/- 4 mu mol/L), Marlboro (13 +/- 2 mu mol/L), and Carlton (<1 mu mol/L) cigarettes clearly demonstrated that the potent inhibitory effects of the low-tar cigarettes could not be accounted for by either hydroquinone or catechol. Conclusion: These studies indicate that cigarette smoke contains potent inhibitors of cytokine production, at least one of which is present even in low-tar cigarettes.	Univ Colorado, Dep Med,Hlth Sci Ctr, Div Clin Immunol & Allergy, Clin Immunol & Histocompatibil Lab, Denver, CO 80262 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Dana-Farber Cancer Institute	Freed, BM (corresponding author), Univ Colorado, Dep Med,Hlth Sci Ctr, Div Clin Immunol & Allergy, Clin Immunol & Histocompatibil Lab, Campus Box B164,4200 E 9th Ave, Denver, CO 80262 USA.			Bierer, Barbara/0000-0001-6448-8170	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL060538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60538] Funding Source: Medline; NIEHS NIH HHS [ES05673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBUD RA, 1995, J INFECT DIS, V172, P859, DOI 10.1093/infdis/172.3.859; BROWN GP, 1989, AM J PHYSIOL, V256, pC260, DOI 10.1152/ajpcell.1989.256.2.C260; CARBONNELLE P, 1995, TOXICOL APPL PHARM, V132, P220, DOI 10.1006/taap.1995.1102; CHEUNG SC, 1988, J NATL CANCER I, V80, P1069, DOI 10.1093/jnci/80.13.1069; CLARKE JR, 1993, AIDS, V7, P555, DOI 10.1097/00002030-199304000-00015; Conley LJ, 1996, AIDS, V10, P1121, DOI 10.1097/00002030-199609000-00010; Dale LC, 1998, POSTGRAD MED, V104, P75, DOI 10.3810/pgm.1998.12.390; DANIELE RP, 1977, AM REV RESPIR DIS, V116, P997; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Geiselhart LA, 1997, TOXICOL APPL PHARM, V143, P30, DOI 10.1006/taap.1996.8071; GHOSH P, 1995, JNCI-J NATL CANCER I, V87, P1478, DOI 10.1093/jnci/87.19.1478; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Hays JT, 1998, POSTGRAD MED, V104, P56, DOI 10.3810/pgm.1998.12.389; HAYS JT, 1998, POSTGRAD MED, V104, P65; HECHT SS, 1981, J NATL CANCER I, V66, P163; HOFFMANN D, 1983, ENVIRON HEALTH PERSP, V50, P247, DOI 10.2307/3429556; Kalf GF, 1996, ENVIRON HEALTH PERSP, V104, P1251, DOI 10.2307/3433171; Kobayashi M, 1998, J IMMUNOL, V160, P5869; Lauwerys BR, 1999, CYTOKINE, V11, P822, DOI 10.1006/cyto.1999.0501; LeCam L, 1996, INT ARCH ALLERGY IMM, V111, P372, DOI 10.1159/000237395; Li Q, 1997, FUND APPL TOXICOL, V38, P158, DOI 10.1006/faat.1997.2346; Li Q, 1996, TOXICOL APPL PHARM, V139, P317, DOI 10.1006/taap.1996.0171; LUNTE SM, 1983, CHEM-BIOL INTERACT, V47, P195, DOI 10.1016/0009-2797(83)90157-6; Luster MI, 1999, CRIT REV TOXICOL, V29, P491, DOI 10.1080/10408449991349258; Madretsma GS, 1996, IMMUNOPHARMACOLOGY, V35, P47, DOI 10.1016/0162-3109(96)00122-1; Martin F, 1999, CYTOKINE, V11, P80, DOI 10.1006/cyto.1998.0398; MCADAM AJ, 1995, INT J CANCER, V61, P628, DOI 10.1002/ijc.2910610508; MCCREA KA, 1994, AM J RESP CRIT CARE, V150, P696, DOI 10.1164/ajrccm.150.3.8087340; NIEMAN RB, 1993, AIDS, V7, P705, DOI 10.1097/00002030-199305000-00015; Pyatt DW, 1998, TOXICOL APPL PHARM, V149, P178, DOI 10.1006/taap.1998.8369; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; Sadanaga N, 1999, J IMMUNOTHER, V22, P315, DOI 10.1097/00002371-199907000-00005; Saijo Y, 1999, CLIN CANCER RES, V5, P1203; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P2268, DOI 10.1073/pnas.96.5.2268; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOLIMAN DM, 1992, AM J PHYSIOL, V263, pL471, DOI 10.1152/ajplung.1992.263.4.L471; STEDMAN RL, 1968, CHEM REV, V68, P153, DOI 10.1021/cr60252a002; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; VANDUUREN BL, 1976, JNCI-J NATL CANCER I, V56, P1237, DOI 10.1093/jnci/56.6.1237; WEISS GR, 1992, J CLIN ONCOL, V10, P275, DOI 10.1200/JCO.1992.10.2.275; YAMAGUCHI E, 1993, CHEST, V103, P479, DOI 10.1378/chest.103.2.479; YAMAGUCHI E, 1989, AM REV RESPIR DIS, V140, P397, DOI 10.1164/ajrccm/140.2.397; YAMAMURA M, 1993, J CLIN INVEST, V91, P1005, DOI 10.1172/JCI116256; YONEDA K, 1993, CLIN EXP IMMUNOL, V93, P229; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; Zhang SB, 1996, INT J IMMUNOPHARMACO, V18, P467, DOI 10.1016/S0192-0561(96)00054-9	48	187	195	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					280	287		10.1067/mai.2000.107751	http://dx.doi.org/10.1067/mai.2000.107751			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932071				2022-12-18	WOS:000088708100010
J	Corren, J; Harris, AG; Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, RD; Chervinsky, P; Cohen, R; Fourre, J; Grossman, J; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A				Corren, J; Harris, AG; Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, RD; Chervinsky, P; Cohen, R; Fourre, J; Grossman, J; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A			Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						loratadine; pseudoephedrine; rhinitis; asthma; peak expiratory flow rate; spirometry; albuterol; quality of life; nasal obstruction	BRONCHIAL RESPONSIVENESS; AIRWAY-OBSTRUCTION; CONTROLLED TRIAL; DOUBLE-BLIND; CETIRIZINE; TERFENADINE; PLACEBO; ANTIHISTAMINES; ANTAGONIST; MANAGEMENT	Background: Antihistamines have been shown to have a variety of therapeutic effects in asthma. Although nasal obstruction may play an important role in modulating lower airway function, no prior trial has used a decongestant in combination with an antihistamine in patients with allergic rhinitis and concomitant asthma. Objective: We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma. Methods: We conducted a randomized, double-blind, placebo-controlled trial of L/P in 193 subjects during the fall allergy season. Nasal and chest symptoms, albuterol use, and peak expiratory pow rates were recorded daily for 6 weeks. Spirometry was measured at baseline and after 1, 2, 4, and 6 weeks of therapy, and health-related quality of life was rated at the beginning and end of the study. Results: Total rhinitis and asthma symptom severity scores were significantly reduced in patients receiving active therapy compared with those receiving placebo throughout the 6-week study. Peak expiratory flow rates improved significantly in patients treated with L/P during weeks 2 through 6 (peak effect [mean +/- SEM]: L/P, 26.23 +/- 4.64 L/min vs placebo, 8.52 +/- 3.53 L/min, p = 0.002) as did FEV1 (peak effect [mean +/- SEM]: L/P, 170 +/- 53 ml vs placebo, 20 +/- 40 ml, p = 0.01) at all clinic visits. In addition, select measures of asthma-specific quality of life improved significantly relative to placebo. Conclusions: L/P significantly improved nasal and asthma symptoms, pulmonary function, and quality of life in patients with seasonal allergic rhinitis and concomitant mild asthma.	Allergy Res Fdn Inc, Los Angeles, CA 90025 USA; Schering Plough Corp, Kenilworth, NJ 07033 USA; Drug Study Ctr, Des Plaines, IL USA; Certified Allergy Consultants, Chelmsford, MA USA; Atlanta Allergy & Immunol Res Fdn, Atlanta, GA USA; Intermediate Clin Res, Salt Lake City, UT USA; Allergy & Asthma Associates, N Dartmouth, MA USA; Ctr Asthma & Allergy, Lawrenceville, GA USA; Allergy Care Consultants Ltd, Tucson, AZ USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Princeton Allergy & Asthma Associates, Princeton, NJ USA; Clin Res Ctr Ozarks, Rolla, MO USA; Clin Res Grp Colorado, Englewood, CO USA	Merck & Company; Schering Plough Corporation	Corren, J (corresponding author), Allergy Res Fdn Inc, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.			Harris, Alan/0000-0002-6618-2092				Aaronson DW, 1996, ANN ALLERG ASTHMA IM, V76, P440, DOI 10.1016/S1081-1206(10)63461-8; *AM AC ALL IMM, 1988, J ALLERGY CLIN IMMUN, V82, P481; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BOUSQUET J, 1992, EUR RESPIR J, V5, P1137; BRONSKY E, 1995, J ALLERGY CLIN IMMUN, V96, P139, DOI 10.1016/S0091-6749(95)70001-3; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; DEJONG JW, 1994, AM J RESP CRIT CARE, V149, P91, DOI 10.1164/ajrccm.149.1.8111606; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; DIRKSEN A, 1989, ALLERGY, V44, P566, DOI 10.1111/j.1398-9995.1989.tb04201.x; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; KARLIN JM, 1972, ANN ALLERGY, V30, P342; LAITINEN LA, 1982, EUR J CLIN PHARMACOL, V23, P107, DOI 10.1007/BF00545963; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PROCTOR DF, 1977, AM REV RESPIR DIS, V115, P97; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; SMITH JM, 1988, ALLERGY PRINCIPLES P, P893; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; Ware J.E., 1993, LINC RI QUAL METR IN; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WOODBAKER R, 1995, BRIT J CLIN PHARMACO, V39, P671, DOI 10.1111/j.1365-2125.1995.tb05727.x; YAN K, 1983, EUR J RESPIR DIS, V64, P105	33	187	192	1	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				781	788		10.1016/S0091-6749(97)70274-4	http://dx.doi.org/10.1016/S0091-6749(97)70274-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438487	Bronze			2022-12-18	WOS:000071353600011
J	Schatz, M; Zeiger, RS; Harden, K; Hoffman, CC; Chilingar, L; Petitti, D				Schatz, M; Zeiger, RS; Harden, K; Hoffman, CC; Chilingar, L; Petitti, D			The safety of asthma and allergy medications during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pregnancy; medications; corticosteroids; preeclampsia; asthma; allergy	BRONCHIAL-ASTHMA; GASTROSCHISIS; THEOPHYLLINE; WOMEN	Background: Although no asthma or allergy medications can be considered proven safe for use during pregnancy, these medications are often used to prevent the potential direct and indirect consequences of uncontrolled asthma or allergy. Objective: The safety of asthma medications, antihistamines, and decongestants was assessed in a prospectively monitored cohort of 824 pregnant women with and 678 pregnant women without asthma. Methods: Medications used since conception were recorded on each subject's initial visit (< 28 weeks' gestation). Thereafter, diary cards for medications were completed by the patient through the time of delivery. Perinatal outcomes were compared in exposed versus unexposed individuals. A multivariate analysis accounted for the potential effects of age, parity, smoking, race, weight gain during pregnancy, maternal pulmonary function, acute asthmatic episodes, and multiple medication exposure. Results: No significant relationships were identified between major congenital malformations and first trimester or any exposure to beta-agonists, theophylline, cromolyn, corticosteroids, antihistamines, or decongestants. In the multivariate analyses, oral corticosteroids were independently associated with preeclampsia (odds ratio = 2.0, p = 0.027), but no other independent associations were observed between asthma or allergy medications and adverse perinatal outcomes. Conclusion: Use of most common asthma and allergy medications during pregnancy was not associated with increased perinatal risks. Maternal use of oral corticosteroids was independently associated with the occurrence of preeclampsia in this study, although the mechanism of this association is not clear. However, because prior observations suggest that severe asthma may be associated with maternal and/or fetal mortality, risk-benefit considerations still favor the use of oral corticosteroids when indicated for the treatment of asthma during pregnancy.	KAISER PERMANENTE MED CTR,DEPT OBSTET & GYNECOL,SAN DIEGO,CA 92111; KAISER PERMANENTE MED CTR,DEPT RES & EVALUAT,SAN DIEGO,CA 92111	Kaiser Permanente; Kaiser Permanente	Schatz, M (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020426] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20426] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams Richard S., 1993, V7, P109; ASELTON P, 1985, OBSTET GYNECOL, V65, P451; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; DOMBROWSKI MP, 1986, AM J OBSTET GYNECOL, V155, P265, DOI 10.1016/0002-9378(86)90804-5; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; LAO TT, 1990, EUR J OBSTET GYN R B, V35, P183, DOI 10.1016/0028-2243(90)90160-3; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LEHRER S, 1993, AM J OBSTET GYNECOL, V168, P1463, DOI 10.1016/S0002-9378(11)90782-0; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; MABIE WC, 1992, J MATERNAL FETAL MED, V1, P45; MARDEN PM, 1964, J PEDIATR, V64, P358; MILLAR EA, 1995, EUR RESPIR J, V8, P1938; *NAT ASTHM ED PROG, 1993, NIH PUBL; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; SCHATZ M, 1988, J ALLERGY CLIN IMMUN, V82, P686, DOI 10.1016/0091-6749(88)90984-0; SCHATZ M, 1988, ALLERGY PRINCIPLES P, P1124; SCHATZ M, 1993, ALLERGY PRINCIPLES P, P1301; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; Wilson J, 1982, ACTA THERAP, V8, P45	27	187	193	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					301	306		10.1016/S0091-6749(97)70241-0	http://dx.doi.org/10.1016/S0091-6749(97)70241-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314340				2022-12-18	WOS:A1997XX47900005
J	HIDE, DW; MATTHEWS, S; MATTHEWS, L; STEVENS, M; RIDOUT, S; TWISELTON, R; GANT, C; ARSHAD, SH				HIDE, DW; MATTHEWS, S; MATTHEWS, L; STEVENS, M; RIDOUT, S; TWISELTON, R; GANT, C; ARSHAD, SH			EFFECT OF ALLERGEN AVOIDANCE IN INFANCY ON ALLERGIC MANIFESTATIONS AT AGE 2 YEARS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; PREVENTION; ASTHMA; ECZEMA; FOOD INTOLERANCE; SKIN PRICK TESTS		Background: One hundred twenty children, identified before birth as being at high risk for atopy, were prenatally assigned to prophylactic or control groups. Methods: The infants in the prophylactic group either received breast milk from mothers on an exclusion diet or an extensively hydrolyzed formula. Their bedrooms and living rooms were treated repeatedly with an acaricide, and they used polyvinyl-covered mattresses with vented head areas. The infants in the control group were fed conventionally, and no environmental control was recommended. Results: A significant advantage first demonstrated at I year of age, persists for children in the prophylactic group. They have less of any allergy or eczema, bur the reduced prevalence of asthma is no longer significant. Only three children in the prophylactic group had positive skin prick test results compared with 16 in the control group, suggesting a significant reduction in sensitization. Conclusion: A dual approach to allergen avoidance, focusing on foods and aeroallergens, appears to be beneficial in selected high-risk infants. Avoidance of potent allergens in early life increases the threshold for sensitization in these high-risk infants. Whether sensitization has been avoided or merely deferred has yet to be proved.			HIDE, DW (corresponding author), ST MARYS HOSP,CLIN ALLERGY RES UNIT,NEWPORT PO30 5TG,WIGHT,ENGLAND.							ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]	4	187	189	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					842	846		10.1016/0091-6749(94)90375-1	http://dx.doi.org/10.1016/0091-6749(94)90375-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182225				2022-12-18	WOS:A1994NL91900006
J	MCGEADY, SJ; BUCKLEY, RH				MCGEADY, SJ; BUCKLEY, RH			DEPRESSION OF CELL-MEDIATED-IMMUNITY IN ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,SCH MED,DEPT MICROBIOL,DURHAM,NC; DUKE UNIV,SCH MED,DEPT IMMUNOL,DURHAM,NC; DUKE UNIV,SCH MED,DEPT PEDIAT,BOX 2898,DURHAM,NC 27710	Duke University; Duke University; Duke University			Buckley, Rebecca/AAB-1578-2019					BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BOVORNKITTI S, 1960, DIS CHEST, V38, P51, DOI 10.1378/chest.38.1.51; BROSTOFF J, 1969, LANCET, V2, P1269; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BUCKLEY RH, 1974, PRACTICE PEDIATRICS, V2, pCH64; FEIVEL M, 1969, LANCET, V1, P485; FULGINITI VA, 1973, IMMUNOLOGIC DISORDER, P551; Gabrielsen A E, 1967, Adv Immunol, V6, P91, DOI 10.1016/S0065-2776(08)60522-2; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HAMAOKA T, 1973, J EXP MED, V138, P538, DOI 10.1084/jem.138.3.538; HARTZMAN RJ, 1971, TRANSPLANTATION, V11, P268, DOI 10.1097/00007890-197103000-00005; ISHIZAKA K, 1973, Journal of Immunology, V110, P1067; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; KIKKAWA Y, 1973, PEDIATRICS, V51, P690; KINCADE PW, 1971, J IMMUNOL, V106, P1421; KIND LS, 1973, INT ARCH ALLER A IMM, V45, P780, DOI 10.1159/000231077; KISHIMOTO T, 1973, J IMMUNOL, V111, P720; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MENDES NF, 1973, J IMMUNOL, V111, P860; OKUMURA K, 1974, J IMMUNOL, V112, P783; OKUMURA K, 1971, J IMMUNOL, V107, P1682; OKUMURA K, 1971, J IMMUNOL, V106, P1019; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PINCKARD RN, 1972, J ALLERGY CLIN IMMUN, V49, P301; POLMAR SH, 1972, AM J PATHOL, V69, P499; ROWE DS, 1973, J EXP MED, V138, P965, DOI 10.1084/jem.138.4.965; SCHIFF RI, 1974, J IMMUNOL, V112, P376; TADA T, 1971, J IMMUNOL, V107, P1137; TADA T, 1971, J IMMUNOL, V106, P1012; TADA T, 1973, J IMMUNOL, V111, P952; TANIGUCH.M, 1971, J IMMUNOL, V107, P579; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; TO BH, 1973, CLIN EXP IMMUNOL, V14, P193; WILSON L, 1973, BRIT J DERMATOL, V88, P373	39	187	187	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					393	406		10.1016/0091-6749(75)90133-5	http://dx.doi.org/10.1016/0091-6749(75)90133-5			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	810508				2022-12-18	WOS:A1975AW33000009
J	Huang, YJ; Marsland, BJ; Bunyavanich, S; O'Mahony, L; Leung, DYM; Muraro, A; Fleisher, TA				Huang, Yvonne J.; Marsland, Benjamin J.; Bunyavanich, Supinda; O'Mahony, Liam; Leung, Donald Y. M.; Muraro, Antonella; Fleisher, Thomas A.			The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; microbiota; dysbiosis; asthma; atopic dermatitis; food allergy; systems biology; probiotic; prebiotic	EARLY-LIFE; ATOPIC-DERMATITIS; SKIN MICROBIOME; GUT MICROBIOTA; COWS MILK; AIRWAY INFLAMMATION; COMMUNITY STRUCTURE; FECAL MICROBIOTA; FOOD ALLERGY; 1ST YEAR	PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and immunology. PRACTALL 2017 is focused on what has been established regarding the role of the microbiome in patients with asthma, atopic dermatitis, and food allergy. This is complemented by outlining important knowledge gaps regarding its role in allergic disease and delineating strategies necessary to fill these gaps. In addition, a review of progress in approaches used to manipulate the microbiome will be addressed, identifying what has and has not worked to serve as a baseline for future directions to intervene in allergic disease development, progression, or both.	[Huang, Yvonne J.] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; [Marsland, Benjamin J.] Univ Lausanne, Fac Biol & Med, Serv Pneumol, CH-1015 Lausanne, Switzerland; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genom Sci, New York, NY 10029 USA; [O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res, Mol Immunol, Davos, Switzerland; [Leung, Donald Y. M.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO USA; [Muraro, Antonella] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Fleisher, Thomas A.] NIH, Dept Lab Med, Ctr Clin, 10 Ctr Dr,MSC 1508, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Lausanne; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Swiss Institute of Allergy & Asthma Research; University of Zurich; National Jewish Health; University of Padua; Azienda Ospedaliera - Universita di Padova; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Fleisher, TA (corresponding author), NIH, Dept Lab Med, Ctr Clin, 10 Ctr Dr,MSC 1508, Bethesda, MD 20892 USA.	tfleishe@mail.nih.gov	O'Mahony, Liam/AAG-5838-2019	O'Mahony, Liam/0000-0003-4705-3583; Huang, Yvonne/0000-0002-7497-6597	National Institutes of Health (NIH) Intramural Program of the NIH Clinical Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL105572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118833] Funding Source: NIH RePORTER	National Institutes of Health (NIH) Intramural Program of the NIH Clinical Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the National Institutes of Health (NIH) Intramural Program of the NIH Clinical Center.	Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Barcik W, 2016, J ALLERGY CLIN IMMUN, V138, P1491, DOI 10.1016/j.jaci.2016.05.049; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Berin MC, 2013, CURR BIOL, V23, pR389, DOI 10.1016/j.cub.2013.02.043; Bernasconi E, 2016, AM J RESP CRIT CARE, V194, P1252, DOI 10.1164/rccm.201512-2424OC; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Bokulich NA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7121; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Byrd AL, 2016, SCIENCE, V351, P224, DOI 10.1126/science.aad6753; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; CARPENTER L, 1989, BRIT MED J, V299, P357, DOI 10.1136/bmj.299.6695.357; Casadevall A, 2014, NATURE, V516, P165, DOI 10.1038/516165a; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Clavel T, 2014, GUT MICROBES, V5, P544, DOI 10.4161/gmic.29331; Cui LJ, 2013, GENOME MED, V5, DOI 10.1186/gm467; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Dobrin R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r55; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Durack J, 2016, J ALLERGY CLIN IMMUN; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Frei R, 2015, CURR OPIN GASTROEN, V31, P153, DOI 10.1097/MOG.0000000000000151; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gao L, 2015, J ALLERGY CLIN IMMUN, V136, P1591, DOI 10.1016/j.jaci.2015.06.047; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Goodrich JK, 2016, CELL HOST MICROBE, V19, P731, DOI 10.1016/j.chom.2016.04.017; Green BJ, 2014, PLOS ONE, V9; Grice EA, 2015, GENOME RES, V25, P1514, DOI 10.1101/gr.191320.115; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hannigan GD, 2015, MBIO, V6, DOI 10.1128/mBio.01578-15; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Hollingsworth JW, 2006, J IMMUNOL, V176, P5856, DOI 10.4049/jimmunol.176.10.5856; Hua X, 2016, EBIOMEDICINE, V3, P172, DOI 10.1016/j.ebiom.2015.11.038; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Jung WH, 2015, MYCOSES, V58, P167, DOI 10.1111/myc.12296; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kramer R, 2015, J CLIN MICROBIOL, V53, P2900, DOI 10.1128/JCM.01094-15; Leung DYM, 2013, ANTIVIR RES, V98, P153, DOI 10.1016/j.antiviral.2013.02.010; Lim ES, 2015, NAT MED, V21, P1228, DOI 10.1038/nm.3950; Loza MJ, 2016, ANN AM THORAC SOC, V13, pS102, DOI 10.1513/AnnalsATS.201508-519MG; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Lynde CW, 2016, J CUTAN MED SURG, V20, P21, DOI 10.1177/1203475415605498; Lyons A, 2010, CLIN EXP ALLERGY, V40, P811, DOI 10.1111/j.1365-2222.2009.03437.x; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Marsland BJ, 2014, NAT REV IMMUNOL, V14, P827, DOI 10.1038/nri3769; McCutcheon JP, 2012, NAT REV MICROBIOL, V10, P13, DOI 10.1038/nrmicro2670; Miller CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12092; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Moore Wendy C, 2013, Ann Am Thorac Soc, V10 Suppl, pS118, DOI 10.1513/AnnalsATS.201309-307AW; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nembrini C, 2011, THORAX, V66, P755, DOI 10.1136/thx.2010.152512; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Otto Michael, 2010, Expert Rev Dermatol, V5, P183, DOI 10.1586/edm.10.6; Oyoshi MK, 2016, J ALLERGY CLIN IMMUN, V138, P283, DOI 10.1016/j.jaci.2015.12.1304; Perez GIP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151990; Raciborski F, 2012, INT J OCCUP MED ENV, V25, P470, DOI 10.2478/S13382-012-0056-0; Rivas MN, 2016, CURR OPIN PEDIATR, V28, P764, DOI 10.1097/MOP.0000000000000419; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Roduit C, 2009, THORAX, V64, P107, DOI 10.1136/thx.2008.100875; Roduit C, 2014, J ALLERGY CLIN IMMUN, V133, P1056, DOI 10.1016/j.jaci.2013.12.1044; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Schadt EE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002132; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Shi BC, 2016, J ALLERGY CLIN IMMUN, V138, P1233, DOI 10.1016/j.jaci.2016.04.053; Silvers KM, 2012, J PEDIATR-US, V160, DOI 10.1016/j.jpeds.2011.11.055; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Smits HH, 2016, J ALLERGY CLIN IMMUN, V137, P690, DOI 10.1016/j.jaci.2016.01.004; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Sugimoto S, 2013, J BACTERIOL, V195, P1645, DOI 10.1128/JB.01672-12; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tauber M, 2016, J ALLERGY CLIN IMMUN, V137, P1272, DOI 10.1016/j.jaci.2015.07.052; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thompson-Chagoyan OC, 2010, PEDIAT ALLERG IMM-UK, V21, pE394, DOI 10.1111/j.1399-3038.2009.00961.x; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; van Neerven RJJ, 2012, J ALLERGY CLIN IMMUN, V130, P853, DOI 10.1016/j.jaci.2012.06.050; Van Schooneveld TC, 2013, NEW ENGL J MED, V368, P2143, DOI 10.1056/NEJMc1303919; van Woerden HC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-69; Verheijden KAT, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0171-0; Virgin HW, 2011, CELL, V147, P44, DOI 10.1016/j.cell.2011.09.009; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Vos AP, 2007, CRIT REV IMMUNOL, V27, P97, DOI 10.1615/CritRevImmunol.v27.i2.10; Waldor MK, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002050; Weinstock GM, 2012, NATURE, V489, P250, DOI 10.1038/nature11553; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4; Yadava K, 2016, AM J RESP CRIT CARE, V193, P975, DOI 10.1164/rccm.201504-0779OC; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875; Yuki T, 2011, J IMMUNOL, V187, P3230, DOI 10.4049/jimmunol.1100058; Zelante T, 2016, SEMIN IMMUNOPATHOL, V38, P239, DOI 10.1007/s00281-015-0523-3; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030	117	186	198	2	60	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1099	1110		10.1016/j.jaci.2017.02.007	http://dx.doi.org/10.1016/j.jaci.2017.02.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	28257972	Green Accepted, Bronze			2022-12-18	WOS:000398771800004
J	Tsakok, T; Marrs, T; Mohsin, M; Baron, S; du Toit, G; Till, S; Flohr, C				Tsakok, Teresa; Marrs, Tom; Mohsin, Mahrose; Baron, Susannah; du Toit, George; Till, Stephen; Flohr, Carsten			Does atopic dermatitis cause food allergy? A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; eczema; food allergy; food sensitization	OF-FUNCTION MUTATIONS; RISK-FACTORS; SENSITIZATION; ASSOCIATION; ECZEMA; CHILDHOOD; INFANTS; ONSET; BIRTH; AGE	Background: The association between atopic dermatitis (AD) and food allergy (FA) is not fully understood, although a causal relationship has been suggested. This has important implications for prevention and treatment. Objective: We aimed to review the association between AD and FA, the effect of FA on AD severity, chronicity, and age of onset, and the temporal relationship between the two. Methods: Medline and Embase were systematically searched from inception to November 2014 for studies investigating both AD and FA. Results: Sixty-six studies were identified. Eighteen were population-based, 8 used high-risk cohorts, and the rest comprised patients with either established AD or FA. In population-based studies, the likelihood of food sensitization was up to 6 times higher in patients with AD versus healthy control subjects at 3 months of age (odds ratio, 6.18; 95% CI, 2.94-12.98; P < .001). Other population-based studies reported that up to 53% of subjects with AD were food sensitized, and up to 15% demonstrated signs of FA on challenge. Meanwhile, studies including only patients with established AD have reported food sensitization prevalences up to 66%, with challenge-proven FA prevalences reaching up to 81%. Sixteen studies suggested that FA is associated with a more severe AD phenotype. Six studies indicated that AD of earlier onset or increased persistence is particularly associated with FA. Finally, one study found that AD preceded the development of FA. Conclusions: This systematic review confirms a strong and dose-dependent association between AD, food sensitization, and FA. AD of increased severity and chronicity is particularly associated with FA. There is also evidence that AD precedes the development of food sensitization and allergy, in keeping with a causal relationship.	[Tsakok, Teresa; Flohr, Carsten] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England; [Tsakok, Teresa; Flohr, Carsten] Kings Coll London, London WC2R 2LS, England; [Marrs, Tom; du Toit, George] Guys & St Thomas NHS Fdn Trust, Dept Childrens Allergies, London, England; [Marrs, Tom; du Toit, George; Till, Stephen] Kings Coll London, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Mohsin, Mahrose; Baron, Susannah] East Kent Hosp Univ NHS Fdn Trust, Dept Dermatol, Canterbury, Kent, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Flohr, C (corresponding author), St Thomas Hosp, St Johns Inst Dermatol, Westminster Bridge Rd, London SE1 7EH, England.	carsten.flohr@kcl.ac.uk	Baron, Susannah/S-5336-2019	Till, Stephen/0000-0003-4518-3093; Du Toit, George/0000-0002-0321-2928	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy & Research Education (FARE); MRC & Asthma UK Centre; UK Department of Health through the NIHR; National Peanut Board (NPB); Osem; UK Food Standards Agency (FSA); ALK-Abello; Nutricia; Abbvie	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy & Research Education (FARE); MRC & Asthma UK Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health through the NIHR; National Peanut Board (NPB); Osem; UK Food Standards Agency (FSA); ALK-Abello; Nutricia(Danone Nutricia); Abbvie(AbbVie)	S. Baron has served as a consultant for Abbvie, receives payment for lectures regarding psychodermatology training and also received travel support from Abbvie. G. du Toit receives research funding from National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy & Research Education (FARE), the MRC & Asthma UK Centre, the UK Department of Health through the NIHR, the National Peanut Board (NPB), and Osem and received grants from UK Food Standards Agency (FSA) during the conduct of the study. S. Till serves as a consultant for ALK-Abello, receives payment for lectures for Thermo Fisher, and receives unrestricted research funding from ALK-Abello. C. Flohr serves as a consultant for Roche/Regeneron and has received payments for lecture from Nutricia. The rest of the authors declare that they have no relevant conflicts of interest.	Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bohme M, 2001, ACTA DERM-VENEREOL, V81, P193, DOI 10.1080/000155501750376294; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Burr ML, 2013, BRIT J DERMATOL, V168, P1339, DOI 10.1111/bjd.12216; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Eller E, 2009, ALLERGY, V64, P1023, DOI 10.1111/j.1398-9995.2009.01952.x; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Gray CL, 2014, PEDIAT ALLERG IMM-UK, V25, P572, DOI 10.1111/pai.12270; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Johnke H, 2006, PEDIAT ALLERG IMM-UK, V17, P591, DOI 10.1111/j.1399-3038.2006.00453.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Mortz CG, 2003, ACTA DERM-VENEREOL, V83, P194, DOI 10.1080/00015550310007201; Peroni DG, 2008, BRIT J DERMATOL, V158, P539, DOI 10.1111/j.1365-2133.2007.08344.x; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Schmitt J, 2008, HAUTARZT, V59, P841, DOI 10.1007/s00105-008-1503-5; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Soderstrom L, 2011, ALLERGY, V66, P1058, DOI 10.1111/j.1398-9995.2011.02578.x; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Wells GA, NEWCASTLE OTTAWA SCA; Werfel T, 2004, CURR OPIN ALLERGY CL, V4, P379, DOI 10.1097/00130832-200410000-00009; Wolkerstorfer A, 2002, CLIN EXP ALLERGY, V32, P70, DOI 10.1046/j.0022-0477.2001.01265.x	40	186	191	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1071	1078		10.1016/j.jaci.2015.10.049	http://dx.doi.org/10.1016/j.jaci.2015.10.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26897122	Green Submitted, Bronze			2022-12-18	WOS:000373351200013
J	Du Toit, G; Roberts, G; Sayre, PH; Plaut, M; Bahnson, HT; Mitchell, H; Radulovic, S; Chan, S; Fox, A; Turcanu, V; Lack, G				Du Toit, George; Roberts, Graham; Sayre, Peter H.; Plaut, Marshall; Bahnson, Henry T.; Mitchell, Herman; Radulovic, Suzana; Chan, Susan; Fox, Adam; Turcanu, Victor; Lack, Gideon		Learning Early Peanut Allergy LEAP	Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut sensitization; peanut allergy; allergy risk factors; eczema; egg allergy; patient recruitment; allergy prevention; LEAP study	MEDIATED FOOD ALLERGY; SKIN PRICK; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; CHILDREN; PREVALENCE; SENSITIZATION; CHALLENGES; PREDICTION; DIAGNOSIS	Background: Peanut allergy (PA) is rare in countries in which peanuts are introduced early into infants' diets. Learning Early About Peanut Allergy (LEAP) is an interventional study aiming to assess whether PA can be prevented by oral tolerance induction. Objective: We sought to characterize a population screened for the risk of PA. Methods: Subjects screened for the LEAP interventional trial comprise the LEAP screening study cohort. Infants were aged 4 to 10 months and passed a prescreening questionnaire. Results: This analysis includes 834 infants (mean age, 7.8 months). They were split into the following: group I, patients with mild eczema and no egg allergy (n = 118); group II, patients with severe eczema, egg allergy, or both but 0-mm peanut skin prick test (SPT) wheal responses (n = 542); group III, patients with severe eczema, egg allergy, or both and 1- to 4-mm peanut wheal responses (n = 98); and group IV, patients with greater than 4-mm peanut wheal responses (n = 76). Unexpectedly, many (17%) in group II had peanut-specific IgE sensitization (>= 0.35 kU/L); 56% of group III were similarly sensitized. In contrast, none of the patients in group I and 91% of those in group IV had peanut-specific IgE sensitization. Sensitization on skin testing to peanut (SPT response of 1- 4 mm vs 0 mm) was associated with egg allergy and severe eczema (odds ratio [OR], 2.31 [95% CI, 1.39-3.86] and 2.47 [95% CI, 1.14-5.34], respectively). Similar associations were observed with specific IgE sensitization. Black race was associated with a significantly higher risk of peanut-specific IgE sensitization (OR, 5.30 [95% CI, 2.85-9.86]). Paradoxically, for a given specific IgE level, black race was protective against cutaneous sensitization (OR, 0.15 [95% CI, 0.04-0.61]). Conclusion: Egg allergy, severe eczema, or both appear to be useful criteria for identifying high-risk infants with an intermediate level of peanut sensitization for entry into a PA prevention study. The relationship between specific IgE level and SPT sensitization needs to be considered within the context of race. (J Allergy Clin Immunol 2013;131:135-43.)	[Du Toit, George; Radulovic, Suzana; Chan, Susan; Fox, Adam; Turcanu, Victor; Lack, Gideon] Kings Coll London, Kings Hlth Partners, MRC & Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England; [Du Toit, George; Radulovic, Suzana; Chan, Susan; Fox, Adam; Turcanu, Victor; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Dept Paediat Allergy, London, England; [Roberts, Graham] Univ Southampton, Southampton SO9 5NH, Hants, England; [Sayre, Peter H.] Immune Tolerance Network, San Francisco, CA USA; [Sayre, Peter H.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Plaut, Marshall] NIAID, Bethesda, MD 20892 USA; [Bahnson, Henry T.; Mitchell, Herman] Rho Fed Syst, Chapel Hill, NC USA	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Southampton; Immune Tolerance Network; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lack, G (corresponding author), St Thomas Hosp, 2nd Floor,South Wing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Fox, Adam/O-3547-2015	Fox, Adam/0000-0002-3533-9798; Caballero, Maria Rosario/0000-0002-0702-043X; Roberts, Graham/0000-0003-2252-1248; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases; Food Allergy Initiative, New York, NY; Food Standards Agency, United Kingdom; Food Allergy and Anaphylaxis Network, Fairfax, Va; MRC & Asthma UK Centre; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board, Atlanta, Ga; Immune Tolerance Network (ITN); National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health; ITN/NIAID; Food Allergy Initiative; National Peanut Board; Food Standards Agency; Food Allergy & Anaphylaxis Network; Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award; ITN; Food Allergy and Anaphylaxis Network; Sodilac; Novartis; Nestle Nutrition; GlaxoSmithKline; Serono Symposia International Foundation	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Initiative, New York, NY; Food Standards Agency, United Kingdom; Food Allergy and Anaphylaxis Network, Fairfax, Va; MRC & Asthma UK Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board, Atlanta, Ga; Immune Tolerance Network (ITN); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ITN/NIAID; Food Allergy Initiative; National Peanut Board; Food Standards Agency; Food Allergy & Anaphylaxis Network; Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award; ITN; Food Allergy and Anaphylaxis Network; Sodilac; Novartis(Novartis); Nestle Nutrition(Nestle SA); GlaxoSmithKline(GlaxoSmithKline); Serono Symposia International Foundation	This study was supported by the Immune Tolerance Network (funded by the National Institute of Allergy and Infectious Diseases); the Food Allergy Initiative, New York, NY; the Food Standards Agency, United Kingdom; the Food Allergy and Anaphylaxis Network, Fairfax, Va; the MRC & Asthma UK Centre; and the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board, Atlanta, Ga.; G. Roberts has received research support from the Immune Tolerance Network (ITN). P. H. Sayre has received travel support from the National Institute of Allergy and Infectious Diseases (NIAID). H. T. Bahnson and H. Mitchell have received research support from the National Institutes of Health. S. Radulovic has received research support from the ITN/NIAID, the Food Allergy Initiative, and the National Peanut Board and has received travel support from Stallergenes and the Allergy Academy. S. Chan has received research support from the ITN/NIAID, the Food Allergy Initiative, the National Peanut Board, the Food Standards Agency, the Food Allergy & Anaphylaxis Network, MRC & Asthma UK Centre, and the Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award to the Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. V. Turcanu has received research support from the ITN. G. Lack has received research support from the ITN/NIAID, the Food Allergy Initiative, the National Peanut Board, the Food Standards Agency, the Food Allergy and Anaphylaxis Network, MRC Asthma UK Centre, and the Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award to the Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; is on the DBV Technologies advisory board; is a voluntary scientific advisor for the Anaphylaxis Campaign and the National Peanut Board; has received lecture fees from Sodilac, Novartis, Nestle Nutrition, GlaxoSmithKline, and the Serono Symposia International Foundation; and has stock/stock options in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Du Toit G, 2009, PEDIAT ALLERG IMM-UK, V20, P309, DOI 10.1111/j.1399-3038.2009.00887.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, pe1; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Kumar R, 2011, PEDIATRICS, V128, pE821, DOI 10.1542/peds.2011-0691; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LEAP Study Team, 2010, ITN032AD LEARN EARL; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	35	186	188	20	73	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					135	U215		10.1016/j.jaci.2012.09.015	http://dx.doi.org/10.1016/j.jaci.2012.09.015			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23174658	Bronze			2022-12-18	WOS:000312961200017
J	Prescott, SL				Prescott, Susan L.			Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic disease; early immune development; inflammation; pregnancy and early life; diet and nutrition; microbiome; environmental pollutants and irritants; gene-environmental interactions; developmental origins of health and disease; noncommunicable diseases; obesity; disease prevention	FISH-OIL SUPPLEMENTATION; DIET-INDUCED OBESITY; CHAIN GALACTO-OLIGOSACCHARIDES; FATTY-ACID SUPPLEMENTATION; GUT MICROBIOTA; HIGH-RISK; ATOPIC-DERMATITIS; DNA METHYLATION; DEVELOPMENTAL ORIGINS; MEDITERRANEAN DIET	The unparalleled burden of a diverse range of chronic noncommunicable diseases (NCDs) is a major global challenge in the 21st century. Chronic low-grade inflammation is a common feature of virtually all NCDs, indicating a central role of the immune system. Furthermore, as the most common and earliest-onset NCD, the epidemic of allergic diseases points to specific vulnerability of the developing immune system to modern environmental change. Indeed, many environmental risk factors implicated in the rise of other NCDs have been shown to mediate their effects through immune pathways. The innate immune system provides a clear example of this convergence, with evidence that physical activity, nutrition, pollutants, and the microbiome all influence systemic inflammation through Toll-like receptor pathways (notably Toll-like receptor 4), with downstream effects on the risk of insulin resistance, obesity, cardiovascular risk, immune diseases, and even mood and behavior. Common risk factors will likely mean common solutions, and interdisciplinary strategies to promote immune health should be an integral part of NCD prevention, with a greater focus early in the life course before disease processes are established. In this context allergic disease provides a very important early target to assess the effectiveness of environmental strategies to reduce immune dysregulation. (J Allergy Clin Immunol 2013;131:23-30.)	[Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6001, Australia; [Prescott, Susan L.] Dev Origins Hlth & Dis DOHaD Consortium, Perth, WA, Australia; [Prescott, Susan L.] WUN, Int Inflammat In FLAME Network, Perth, WA, Australia	University of Western Australia	Prescott, SL (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Princess Margaret Hosp, POB D184, Perth, WA 6001, Australia.	susan.prescott@uwa.edu.au	Prescott, Susan/H-5665-2014		National Health and Medical Research Council (NHMRC) of Australia; National Health and Medical Research Council	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by a Practitioner Fellowship from the National Health and Medical Research Council (NHMRC) of Australia.; S. L. Prescott has received grants from the National Health and Medical Research Council and is a board member for Nestle, Danone, and ALK-Abello.	Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Barden AE, 2004, FREE RADICAL RES, V38, P233, DOI 10.1080/10715760310001656722; Bercik P, 2012, NEUROGASTROENT MOTIL, V24, P405, DOI 10.1111/j.1365-2982.2012.01906.x; Bercik P, 2011, GASTROENTEROLOGY, V141, P599, DOI 10.1053/j.gastro.2011.04.052; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Boehm G, 2002, ARCH DIS CHILD-FETAL, V86, P178, DOI 10.1136/fn.86.3.F178; Boeke CE, 2012, EPIGENETICS-US, V7, P253, DOI 10.4161/epi.7.3.19082; Boerner BP, 2011, ANN NY ACAD SCI, V1243, P103, DOI 10.1111/j.1749-6632.2011.06340.x; Bonaccio M, 2012, THROMB RES, V129, P401, DOI 10.1016/j.thromres.2011.10.018; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708; D'Vaz N, 2012, PEDIATRICS, V130, P674, DOI 10.1542/peds.2011-3104; D'Vaz N, 2012, CLIN EXP ALLERGY, V42, P1206, DOI 10.1111/j.1365-2222.2012.04031.x; Dinan TG, 2012, PSYCHONEUROENDOCRINO, V37, P1369, DOI 10.1016/j.psyneuen.2012.03.007; Doege K, 2012, BRIT J NUTR, V107, P1, DOI 10.1017/S0007114511003400; Dunstan JA, 2008, ARCH DIS CHILD-FETAL, V93, pF45, DOI 10.1136/adc.2006.099085; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Erkkola M, 2012, PEDIAT ALLERG IMM-UK, V23, P186, DOI 10.1111/j.1399-3038.2012.01272.x; Forsyth JS, 2003, BRIT MED J, V326, P953, DOI 10.1136/bmj.326.7396.953; Francaux M, 2009, APPL PHYSIOL NUTR ME, V34, P454, DOI 10.1139/H09-036; Granell R, 2008, CLIN EXP ALLERGY, V38, P320, DOI 10.1111/j.1365-2222.2007.02902.x; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Hanson M, 2011, AM J CLIN NUTR, V94, p1754S, DOI 10.3945/ajcn.110.001206; Hanson M, 2011, LANCET, V378, P566, DOI 10.1016/S0140-6736(11)61286-5; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Huang RC, 2009, DIABETES CARE, V32, P695, DOI 10.2337/dc08-1917; Innis SM, 2011, MATERN CHILD NUTR, V7, P112, DOI 10.1111/j.1740-8709.2011.00318.x; Jones AP, 2012, NUTRIENTS, V4, P13, DOI 10.3390/nu4010013; Kawasaki J, 2011, J DERMATOL SCI, V62, P131, DOI 10.1016/j.jdermsci.2011.02.005; Klemens CM, 2011, BJOG-INT J OBSTET GY, V118, P916, DOI 10.1111/j.1471-0528.2010.02846.x; Knoflach M, 2005, ARCH INTERN MED, V165, P2521, DOI 10.1001/archinte.165.21.2521; Lazinski M, 2008, ARCH WOMEN MENT HLTH, V11, P363, DOI 10.1007/s00737-008-0035-4; Li MC, 2009, CURR MOL MED, V9, P365, DOI 10.2174/156652409787847137; Liu L, 2011, BRAIN BEHAV IMMUN, V25, P1223, DOI 10.1016/j.bbi.2011.03.016; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matheson EM, 2008, J AM BOARD FAM MED, V21, P179, DOI 10.3122/jabfm.2008.03.070273; Matzinger P, 2011, NAT REV IMMUNOL, V11, P221, DOI 10.1038/nri2940; Meldrum SJ, 2011, CONTEMP CLIN TRIALS, V32, P771, DOI 10.1016/j.cct.2011.05.019; Meldrum SJ, 2012, BRIT J NUTR, V108, P1443, DOI 10.1017/S0007114511006878; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056; Morita T, 2004, J GASTROEN HEPATOL, V19, P303, DOI 10.1111/j.1440-1746.2003.03208.x; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nakamura Y, 2008, J ALLERGY CLIN IMMUN, V122, P1208, DOI 10.1016/j.jaci.2008.09.022; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Oliveira AG, 2011, DIABETES, V60, P784, DOI 10.2337/db09-1907; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Palmer DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e184; Pawankar R., 2011, WORLD ALLERGY ORG WA; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Prescott SL, PREBIOTICS PROBIOTIC; Prescott S, 2011, CLIN EPIGENETICS, V2, P223, DOI 10.1007/s13148-011-0028-4; Prescott Susan, 2011, Ann Nutr Metab, V59 Suppl 1, P28, DOI 10.1159/000334150; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Prescott SL, 2007, CLIN SCI, V113, P409, DOI 10.1042/CS20070111; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Renz H, 2011, NAT IMMUNOL, V12, P273, DOI 10.1038/ni0411-273; Rzehak P, 2009, BRIT J NUTR, V101, P20, DOI 10.1017/S0007114508992564; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Scholtens PAMJ, 2008, J NUTR, V138, P1141, DOI 10.1093/jn/138.6.1141; Shaheen SO, 2008, THORAX, V63, P483, DOI 10.1136/thx.2007.090019; Shi L, 2012, BR J NUTR; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Skilton MR, 2012, PEDIATRICS, V129, pE698, DOI 10.1542/peds.2011-2472; Stenius F, 2011, J ALLERGY CLIN IMMUN, V128, P1335, DOI 10.1016/j.jaci.2011.07.038; Sudo N, 1997, J IMMUNOL, V159, P1739; Thacher TD, 2011, MAYO CLIN PROC, V86, P50, DOI 10.4065/mcp.2010.0567; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Uauy R, 2011, AM J CLIN NUTR, V94, p1759S, DOI 10.3945/ajcn.110.000562; Valdivielso JM, 2006, CLIN CHIM ACTA, V371, P1, DOI 10.1016/j.cca.2006.02.016; van Hoffen E, 2009, ALLERGY, V64, P484, DOI 10.1111/j.1398-9995.2008.01765.x; Weise C, 2011, PEDIAT ALLERG IMM-UK, V22, P497, DOI 10.1111/j.1399-3038.2010.01133.x; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015	91	186	192	2	88	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					23	30		10.1016/j.jaci.2012.11.019	http://dx.doi.org/10.1016/j.jaci.2012.11.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23265694				2022-12-18	WOS:000312961200003
J	Fiocchi, A; Schunemann, HJ; Brozek, J; Restani, P; Beyer, K; Troncone, R; Martelli, A; Terracciano, L; Bahna, SL; Rance, F; Ebisawa, M; Heine, RG; Assa'ad, A; Sampson, H; Verduci, E; Bouygue, GR; Baena-Cagnani, C; Canonica, W; Lockey, RF				Fiocchi, Alessandro; Schuenemann, Holger J.; Brozek, Jan; Restani, Patrizia; Beyer, Kirsten; Troncone, Riccardo; Martelli, Alberto; Terracciano, Luigi; Bahna, Sami L.; Rance, Fabienne; Ebisawa, Motohiro; Heine, Ralf G.; Assa'ad, Amal; Sampson, Hugh; Verduci, Elvira; Bouygue, G. R.; Baena-Cagnani, Carlos; Canonica, Walter; Lockey, Richard F.			Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA): A summary report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; epidemiology; amino acid formula; hydrolyzed milk formula; soy formula; hydrolyzed rice formula; skin prick test; specific IgE; oral immunotherapy; Grading of Recommendations; Assessments; Development; Evaluation approach	ORAL TOLERANCE INDUCTION; REGULATORY T-CELLS; 1ST 3 YEARS; FOOD ALLERGY; ADVERSE-REACTIONS; NATURAL-HISTORY; CLINICAL-COURSE; FOLLOW-UP; ANAPHYLACTIC REACTIONS; ATOPIC-DERMATITIS	The 2nd Milan Meeting on Adverse Reactions to Bovine Proteins was the venue for the presentation of the first consensus-based approach to the management of cow's milk allergy. It was also the first time that the Grading of Recommendations, Assessments, Development, and Evaluation approach for formulating guidelines and recommendations was applied to the field of food allergy. In this report we present the contributions in allergen science, epidemiology, natural history, evidence-based diagnosis, and therapy synthesized in the World Allergy Organization Diagnosis and Rationale for Action against Cow's Milk Allergy guidelines and presented during the meeting. A consensus emerged between discussants that cow's milk allergy management should reflect not only basic research but also a newer and better appraisal of the literature in the light of the values and preferences shared by patients and their caregivers in partnership. In the field of diagnosis, atopy patch testing and microarray technology have not yet evolved for use outside the research setting. With foreseeable breakthroughs (eg, immunotherapy and molecular diagnosis) in the offing, the step ahead in leadership can only stem from a worldwide organization implementing consensus-based clinical practice guidelines to diffuse and share clinical knowledge. (J Allergy Clin Immunol 2010;126:1119-28.)	[Fiocchi, Alessandro; Martelli, Alberto; Terracciano, Luigi; Bouygue, G. R.] Univ Milan, Dept Child & Maternal Med, Sch Med, Paediat Div,Melloni Hosp, I-20123 Milan, Italy; [Schuenemann, Holger J.; Brozek, Jan] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Schuenemann, Holger J.; Brozek, Jan] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Restani, Patrizia] Univ Milan, Dept Pharmacol Sci, I-20123 Milan, Italy; [Beyer, Kirsten] Charite Klin Padiatrie MS Pneumol & Immunol, Berlin, Germany; [Troncone, Riccardo] Univ Naples Federico II, Federico II Hosp, Dept Pediat, I-80138 Naples, Italy; [Bahna, Sami L.] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA; [Rance, Fabienne] Hop Enfants, Toulouse, France; [Ebisawa, Motohiro] Sagamihara Natl Hosp, Dept Allergy, Clin Res Ctr Allergy & Rheumatol, Kanagawa, Japan; [Heine, Ralf G.] Univ Melbourne, Dept Allergy & Immunol, Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3010, Australia; [Assa'ad, Amal] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Sampson, Hugh] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA; [Verduci, Elvira] Univ Milan, Dept Pediat, I-20123 Milan, Italy; [Baena-Cagnani, Carlos] Infantile Hosp Cordoba, Dept Pediat, Div Immunol & Resp Med, Cordoba, Spain; [Canonica, Walter] Univ Genoa, Dept Internal Med, Allergy & Resp Dis Clin, I-16126 Genoa, Italy; [Lockey, Richard F.] Univ S Florida, Coll Med, Div Allergy & Immunol, Tampa, FL USA	University of Milan; McMaster University; McMaster University; University of Milan; University of Naples Federico II; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; CHU de Toulouse; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Icahn School of Medicine at Mount Sinai; University of Milan; University of Genoa; State University System of Florida; University of South Florida	Fiocchi, A (corresponding author), Univ Milan, Dept Child & Maternal Med, Sch Med, Paediat Div,Melloni Hosp, Via Melloni 52, I-20123 Milan, Italy.	allerg@tin.it	Verduci, Elvira/D-7338-2014; Terracciano, Luigi M./AAB-5335-2022; canonica, giorgio walter/ABF-2037-2020; Fiocchi, Alessandro/K-9235-2016	Terracciano, Luigi M./0000-0002-9393-9660; canonica, giorgio walter/0000-0001-8467-2557; Fiocchi, Alessandro/0000-0002-2549-0523; Schunemann, Holger/0000-0003-3211-8479; Heine, Ralf Gunter/0000-0002-3343-0379; Verduci, Elvira/0000-0003-2111-3111; Ebisawa, Motohiro/0000-0003-4117-558X	World Allergy Organization (WAO); European Union; Food Allergy and Anaphylaxis Network (FAAN); Phadia; Paul Ehrlich Institute; German Research Foundation; Pharming; Food Allergy Initiative (FAI); National Institutes of Health / National Institute of Allergy and Infectious Diseases	World Allergy Organization (WAO); European Union(European Commission); Food Allergy and Anaphylaxis Network (FAAN); Phadia(Phadia); Paul Ehrlich Institute; German Research Foundation(German Research Foundation (DFG)); Pharming; Food Allergy Initiative (FAI); National Institutes of Health / National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: A. Fiocchi has received support from the World Allergy Organization (WAO); he is chairman of the American College of Allergy, Asthma, and Immunology's (ACAAI) adverse reactions to foods committee and the WAO's food allergy special committee. H. J. Schunemann and J. Brozek have received research support from the WAO. K. Beyer has received research support from the European Union, Food Allergy and Anaphylaxis Network (FAAN), Phadia, Paul Ehrlich Institute, and the German Research Foundation. S. L. Bahna has received research support from Pharming and speaker's honoraria from Abbott, and is president of the ACAAI. R. G. Heine is on scientific advisory boards for Nutricia Australia and Nestle Nutrition Institute Australia, and has received lecture honoraria from Nutricia Australia. H. A. Sampson has consulted for Allertein Therapeutics, LLC; has received research support from the Food Allergy Initiative (FAI) and the National Institutes of Health / National Institute of Allergy and Infectious Diseases; is a consultant/scientific advisor for FAI; and is part-owner of Herbal Springs, LLC. The remaining authors declare that they have no relevant conflicts of interest to disclose.	Agostoni C, 2007, PEDIAT ALLERG IMM-UK, V18, P599, DOI 10.1111/j.1399-3038.2007.00566.x; ALTINTAS D, 1995, ACTA PAEDIATR, V84, P1320, DOI 10.1111/j.1651-2227.1995.tb13559.x; Altman DR, 1996, J ALLERGY CLIN IMMUN, V97, P1247, DOI 10.1016/S0091-6749(96)70192-6; ARA CG, 2003, J ALLERGY CLIN IMMUN, V111, P647; ARA MCG, 2003, AN PEDIATR, V58, P100; Bahna SL, 2001, ANN ALLERG ASTHMA IM, V86, P414, DOI 10.1016/S1081-1206(10)62487-8; BAHNA SL, 1994, ALLERGY, V49, P129, DOI 10.1111/j.1398-9995.1994.tb00812.x; Baker SS, 2000, PEDIATRICS, V106, P346; BIVALKEVICH VG, 1990, VESTN DERMATOL VENER, P49; Black RE, 2002, AM J CLIN NUTR, V76, P675, DOI 10.1093/ajcn/76.3.675; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1992, PEDIATR ALLERGY IMMU, V3, P188, DOI DOI 10.1111/J.1399-3038.1992.TB00048.X; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Bonadonna P, 2003, OCCUP ENVIRON MED, V60, P609, DOI 10.1136/oem.60.8.609; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Brugman E, 1998, EUR J CLIN NUTR, V52, P577, DOI 10.1038/sj.ejcn.1600609; Bruni FM, 2009, ACTA PAEDIATR, V98, P321, DOI 10.1111/j.1651-2227.2008.01064.x; Calvani M, 1998, EUR J PEDIATR, V157, P17, DOI 10.1007/s004310050759; Caminiti L, 2007, ALLERGY, V62, P335, DOI 10.1111/j.1398-9995.2006.01289.x; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Dean T, 2007, J ALLERGY CLIN IMMUN, V120, P1166, DOI 10.1016/j.jaci.2007.06.042; deBoissieu D, 1997, ACTA PAEDIATR, V86, P1042, DOI 10.1111/j.1651-2227.1997.tb14803.x; Eda Asuka, 2009, Allergology International, V58, P137, DOI 10.2332/allergolint.C-07-59; Eggesbo M, 1999, PEDIATR ALLERGY IMMU, V10, P122, DOI 10.1034/j.1399-3038.1999.00022.x; Falcao H, 2004, EUR J CLIN NUTR, V58, P1621, DOI 10.1038/sj.ejcn.1602017; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fiocchi A, 2004, ALLERGY, V59, P78, DOI 10.1111/j.1398-9995.2004.00653.x; Fiocchi A, 1999, ALLERGY, V54, P401, DOI 10.1034/j.1398-9995.1999.00977.x; Fiocchi A, 2008, ANN ALLERG ASTHMA IM, V101, P166, DOI 10.1016/S1081-1206(10)60205-0; Fiocchi A, 2006, PEDIATR ANN, V35, P755, DOI 10.3928/0090-4481-20061001-13; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI [10.1111/j.1399-3038.2010.01068.x, 10.1097/WOX.0b013e3181defeb9]; Fossati G, 1992, Pediatr Med Chir, V14, P203; Garcia C, 2007, ALLERGOL IMMUNOPATH, V35, P15, DOI 10.1157/13099090; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; GISLASON D, 2000, ICELANDIC MED J, V86, P851; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Halken S, 2004, PEDIAT ALLERG IMM-UK, V15, P9, DOI 10.1111/j.1399-3038.2004.0148b.x; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Heine RG, 2008, PEDIAT ALLERG IMM-UK, V19, P383, DOI 10.1111/j.1399-3038.2008.00785.x; Henriksen C, 2000, ACTA PAEDIATR, V89, P272, DOI 10.1080/080352500750028393; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Host A, 1994, Pediatr Allergy Immunol, V5, P1; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Hu Y, 2010, PEDIATR INT, V52, P820, DOI 10.1111/j.1442-200X.2010.03166.x; Huang SW, 2007, PEDIAT ALLERG IMM-UK, V18, P81, DOI 10.1111/j.1399-3038.2006.00476.x; Iacono G, 1998, NEW ENGL J MED, V339, P1100, DOI 10.1056/NEJM199810153391602; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; *INT UN IMM SOC AL, ALL NOM 2009; Isolauri E, 2004, CLIN EXP ALLERGY, V34, P1007, DOI 10.1111/j.1365-2222.2004.01999.x; ISOLAURI E, 1995, J PEDIATR-US, V127, P550, DOI 10.1016/S0022-3476(95)70111-7; James JM, 1996, AM J RESP CRIT CARE, V153, P597, DOI 10.1164/ajrccm.153.2.8564104; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; James JM, 2003, PEDIATRICS, V111, P1625; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, CLIN EXP ALLERGY, V31, P978, DOI 10.1046/j.1365-2222.2001.01151.x; Jarvinen KM, 1999, J PEDIATR-US, V135, P506, DOI 10.1016/S0022-3476(99)70175-7; Jesenak M, 2009, INT J DERMATOL, V48, P941, DOI 10.1111/j.1365-4632.2008.04037.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, pS91, DOI 10.1016/S0091-6749(02)81377-X; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Killig C, 2008, CURR ALLERGY ASTHM R, V8, P209, DOI 10.1007/s11882-008-0035-5; Kim JS, 2010, CURR OPIN ALLERGY CL, V10, P252, DOI 10.1097/ACI.0b013e328337bd3a; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Kristjansson I, 1999, SCAND J PRIM HEALTH, V17, P30, DOI 10.1080/028134399750002863; Kunz R, 2008, INTERNIST, V49, P673, DOI 10.1007/s00108-008-2141-9; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Lake AM, 1999, IMMUNOL ALLERGY CLIN, V19, P553, DOI 10.1016/S0889-8561(05)70107-7; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; Larramendi CH, 2006, PEDIAT ALLERG IMM-UK, V17, P230, DOI 10.1111/j.1399-3038.2005.00373.x; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Levy Y, 2007, PEDIAT ALLERG IMM-UK, V18, P589, DOI 10.1111/j.1399-3038.2007.00562.x; Liccardi G, 2004, J INVEST ALLERG CLIN, V14, P168; Liccardi G, 2007, ANN ALLERG ASTHMA IM, V99, P394, DOI 10.1016/S1081-1206(10)60562-5; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; Madrigal B I, 1996, Rev Alerg Mex, V43, P41; Marklund Birgitta, 2004, Health Qual Life Outcomes, V2, P65, DOI 10.1186/1477-7525-2-65; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Mazon A, 2008, PEDIATR ALLERGY IMMU, V19, P180, DOI 10.1111/j.1399-3038.2007.00591.x; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; Miyazawa T, 2009, PEDIATR INT, V51, P544, DOI 10.1111/j.1442-200X.2009.02811.x; Moissidis I, 2005, PEDIAT ALLERG IMM-UK, V16, P545, DOI 10.1111/j.1399-3038.2005.00291.x; Moneret-Vautrin DA, 2006, ALLERGY, V61, P507, DOI 10.1111/j.1398-9995.2006.01050.x; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Munoz-Furlong A, 2009, CURR ALLERGY ASTHM R, V9, P57, DOI 10.1007/s11882-009-0009-2; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nguyen J, 2001, PRESSE MED, V30, P1496; Nielsen RG, 2004, J PEDIATR GASTR NUTR, V39, P383, DOI 10.1097/00005176-200410000-00015; Noh G, 2009, J INTERF CYTOK RES, V29, P667, DOI 10.1089/jir.2009.0001; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Nowak-Wegrzyn A, 2004, J ALLERGY CLIN IMMUN, V113, P558, DOI 10.1016/j.jaci.2003.11.015; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Patriarca G, 2002, INT J IMMUNOPATH PH, V15, P53, DOI 10.1177/039463200201500107; Penard-Morand C, 2005, ALLERGY, V60, P1165, DOI 10.1111/j.1398-9995.2005.00860.x; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Prescott SL, 2010, CURR OPIN ALLERGY CL, V10, P258, DOI 10.1097/ACI.0b013e328339ab25; Ramirez Daniel A Jr, 2009, Clin Mol Allergy, V7, P4, DOI 10.1186/1476-7961-7-4; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; REINHARDT MC, 1983, ADV PEDIAT ALLERGY, P155; Restani P, 2009, ANAL BIOANAL CHEM, V395, P47, DOI 10.1007/s00216-009-2909-3; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAPS M, 2010, J PEDIAT GASTRO 1020; Savilahti EM, 2010, CLIN EXP ALLERGY, V40, P251, DOI 10.1111/j.1365-2222.2009.03409.x; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; SCHUNEMANN H, 2008, USERS GUIDE MED LIT; Schunemann HJ, 2011, COCHRANE HDB SYSTEMA; Schunemann HJ, 2009, GRADE HDB GRADING QU; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2009, CURR OPIN ALLERGY CL, V9, P259, DOI 10.1097/ACI.0b013e32832b2218; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Sletten GBG, 2007, PEDIAT ALLERG IMM-UK, V18, P71, DOI 10.1111/j.1399-3038.2006.00489.x; Spergel JM, 2005, IMMUNOL ALLERGY CLIN, V25, P149, DOI 10.1016/j.iac.2004.09.012; Sprikkelman AB, 2000, CLIN EXP ALLERGY, V30, P1358, DOI 10.1046/j.1365-2222.2000.00846.x; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Steinke M, 2007, INT ARCH ALLERGY IMM, V143, P290, DOI 10.1159/000100575; Sugii Kyoko, 2006, Arerugi, V55, P1400; *SWISS I BIOINF, EXPASY PROT SERV BIN; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Terracciano L, 2010, CLIN EXP ALLERGY, V40, P637, DOI 10.1111/j.1365-2222.2009.03427.x; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Tsuge I, 2006, CLIN EXP ALLERGY, V36, P1538, DOI 10.1111/j.1365-2222.2006.02600.x; van Bockel-Geelkerken M, 1992, Ned Tijdschr Geneeskd, V136, P1351; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; VARGIU A, 1994, ALLERGY, V49, P386, DOI 10.1111/j.1398-9995.1994.tb02287.x; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wal JM, 2002, ANN ALLERG ASTHMA IM, V89, P3, DOI 10.1016/S1081-1206(10)62115-1; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Werfel T, 2007, ALLERGY, V62, P723, DOI 10.1111/j.1398-9995.2007.01429.x; WHITING P, 2006, BMC MED RES METHODOL, V6, P6; Wickman M, 2004, ALLERGY, V59, P30, DOI 10.1111/j.1398-9995.2004.00572.x; Woods RK, 2002, ANN ALLERG ASTHMA IM, V88, P183, DOI 10.1016/S1081-1206(10)61994-1; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x	168	186	205	3	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1119	U97		10.1016/j.jaci.2010.10.011	http://dx.doi.org/10.1016/j.jaci.2010.10.011			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21134569				2022-12-18	WOS:000284947800006
J	Cookson, H; Granell, R; Joinson, C; Ben-Shlomo, Y; Henderson, AJ				Cookson, Hannah; Granell, Raquel; Joinson, Carol; Ben-Shlomo, Yoav; Henderson, A. John			Mothers' anxiety during pregnancy is associated with asthma in their children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anxiety; pregnancy; prenatal programming; asthma; child	DAY-CARE ATTENDANCE; MATERNAL ANTENATAL ANXIETY; POSTNATAL DEPRESSION; COMORBID ANXIETY; INCREASED RISK; BIRTH-COHORT; EARLY-LIFE; STRESS; DISORDERS; CHILDHOOD	Background: Maternal stress in early life has been associated with the development of asthma in children, although it is unclear whether there are any critical periods of exposure. The association of asthma with prenatal exposure to maternal stress has not been reported. Objective: We tested whether prenatal and postnatal anxiety and/or depression in pregnant women predicted the risk of their offspring developing asthma in childhood. Methods: The Avon Longitudinal Study of Parents and Children is a population-based birth cohort recruited during pregnancy. Data were available on maternal anxiety scores and asthma at age 71/2 years in 5810 children. Anxiety was assessed at 18 and 32 weeks of gestation by using the validated Crown-Crisp Experiential Index. Asthma was defined at age 71/2 years as doctor-diagnosed asthma with current symptoms or treatment in the previous 12 months. Multivariable logistic regression was used to determine the association of prenatal anxiety with asthma (odds ratio; 95% CI). Results: Independent of postnatal anxiety and adjusted for a number of likely confounders, there was a higher likelihood of asthma at age 71/2 years (odds ratio, 1.64; 95% CI, 1.25-2.17) in children of mothers in the highest compared with lowest quartile of anxiety scores at 32 weeks of gestation, with evidence for a dose-response (P value for trend <0.001). Conclusions: Maternal anxiety symptoms as an indicator of stress during fetal life may program the development of asthma during childhood. (J Allergy Clin Immunol 2009;123:847-853.)	[Henderson, A. John] Univ Bristol, ALSPAC, Dept Community Based Med, Bristol BS8 2BN, Avon, England; [Cookson, Hannah] Sir Charles Gairdner Hosp, Dept Internal Med, Perth, WA, Australia; [Granell, Raquel; Ben-Shlomo, Yoav] Univ Bristol, Dept Social Med, Bristol BS8 2BN, Avon, England	University of Bristol; University of Western Australia; University of Bristol	Henderson, AJ (corresponding author), Univ Bristol, ALSPAC, Dept Community Based Med, Oakfield House,Oakfield Grove, Bristol BS8 2BN, Avon, England.	a.j.henderson@bris.ac.uk	Granell, Raquel/AAY-4846-2020; Granell, Raquel/AAB-5256-2022; Ben-Shlomo, Yoav/ABD-2004-2021	Granell, Raquel/0000-0002-4890-4012; Ben-Shlomo, Yoav/0000-0001-6648-3007; Henderson, Alexander John/0000-0001-9650-231X; Joinson, Carol/0000-0002-5651-097X	UK Medical Research Council; Wellcome Trust; University of Bristol; Asthma UK; Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish; Medical Research Council [G9815508, G0401540] Funding Source: researchfish; ESRC [ES/G007543/1] Funding Source: UKRI; MRC [G0401540] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Bristol; Asthma UK; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. R.G. wits supported by a project grant from Asthma UK.	Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bardi M, 2004, BIOL PSYCHIAT, V55, P724, DOI 10.1016/j.biopsych.2004.01.002; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; BIRTCHNELL J, 1988, BRIT J MED PSYCHOL, V61, P255, DOI 10.1111/j.2044-8341.1988.tb02787.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Deshmukh VM, 2008, RESPIROLOGY, V13, P695, DOI 10.1111/j.1440-1843.2008.01310.x; Glover V, 2004, EARLY HUM DEV, V79, P107, DOI 10.1016/j.earlhumdev.2004.04.012; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Goodwin Renee D, 2003, Adv Psychosom Med, V24, P51, DOI 10.1159/000073780; Gunnar MR, 1998, PREV MED, V27, P208, DOI 10.1006/pmed.1998.0276; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; Hobel CJ, 2008, CLIN OBSTET GYNECOL, V51, P333, DOI 10.1097/GRF.0b013e31816f2709; Kaplan LA, 2008, EARLY HUM DEV, V84, P249, DOI 10.1016/j.earlhumdev.2007.06.004; Katon WJ, 2004, PSYCHOSOM MED, V66, P349, DOI 10.1097/01.psy.0000126202.89941.ea; Kay G, 1998, PHYSIOL BEHAV, V63, P397, DOI 10.1016/S0031-9384(97)00456-3; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; LEVENSON RW, 1979, PSYCHOSOM MED, V41, P28, DOI 10.1097/00006842-197902000-00004; O'Connor TG, 2005, BIOL PSYCHIAT, V58, P211, DOI 10.1016/j.biopsych.2005.03.032; O'Connor TG, 2003, J CHILD PSYCHOL PSYC, V44, P1025, DOI 10.1111/1469-7610.00187; O'Connor TG, 2002, J AM ACAD CHILD PSY, V41, P1470, DOI 10.1097/00004583-200212000-00019; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484; Richardson LP, 2008, GEN HOSP PSYCHIAT, V30, P398, DOI 10.1016/j.genhosppsych.2008.06.004; Rietveld S, 2000, CLIN EXP ALLERGY, V30, P1058; Risbrough VB, 2006, HORM BEHAV, V50, P550, DOI 10.1016/j.yhbeh.2006.06.019; Ritz T, 2000, PSYCHOSOM MED, V62, P401, DOI 10.1097/00006842-200005000-00014; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Sarkar P, 2008, J NEUROENDOCRINOL, V20, P489, DOI 10.1111/j.1365-2826.2008.01659.x; Scott KM, 2008, PSYCHOSOM MED, V70, P1035, DOI 10.1097/PSY.0b013e318187a2fb; Smith GD, 2008, BASIC CLIN PHARMACOL, V102, P245, DOI 10.1111/j.1742-7843.2007.00191.x; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Young AF, 2006, AUST NZ J PUBL HEAL, V30, P353, DOI 10.1111/j.1467-842X.2006.tb00849.x	40	186	189	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					847	853		10.1016/j.jaci.2009.01.042	http://dx.doi.org/10.1016/j.jaci.2009.01.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	431JW	19348924	Green Published, hybrid			2022-12-18	WOS:000265058600010
J	Simon, D; Hosli, S; Kostylina, G; Yawalkar, N; Simon, HU				Simon, Dagmar; Hosli, Susanne; Kostylina, Ganna; Yawalkar, Nikhil; Simon, Hans-Uwe			Anti-CD20 (rituximab) treatment improves atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; B cells; biologics; cytokines; inflamation; rituximab; T cells	SYSTEMIC-LUPUS-ERYTHEMATOSUS; REFRACTORY PEMPHIGUS-VULGARIS; B-LYMPHOCYTE DEPLETION; AUTOIMMUNE-DISEASE; T-CELLS; RHEUMATOID-ARTHRITIS; INFLAMMATORY CELLS; SYNDROME AEDS; PLASMA-CELLS; THERAPY	Background: Atopic eczema (AE) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus, and typical histopathologic features. Objective: We asked whether depletion of B cells by monoclonal anti-CD20 antibody therapy (rituximab) would improve severe AE. Methods: Six patients (4 women and 2 men) with severe AE received 2 intravenous applications of rituximab, each 1000 mg, 2 weeks apart. To evaluate the efficacy of rituximab, we monitored clinical parameters (eczema area and severity index, pruritus), total and allergen-specific IgE levels, skin histology, and inflammatory cells and cytokine expression in the skin and peripheral blood before and after therapy (ClinicalTrials.gov Identifier: NCT00267826). Results: All patients showed an improvement of their skin symptoms within 4 to 8 weeks. The eczema area and severity index significantly decreased (before therapy, 29.4 +/- 4.3; week 8, 8.4 +/- 3.6; P <.001). Histologic alterations such as spongiosis, acanthosis, and dermal infiltrate, including T and B cell numbers, also dramatically improved. However, whereas blood B cells were below detectable levels as a consequence of rituximab administration, skin B cells were reduced by approximately 50% only. Expression of IL-5 and IL-13 was reduced after therapy. Moreover, whereas allergen-specific IgE levels were not altered, we observed a slight reduction in total IgE concentrations in blood. Conclusions: B cells play a major role in AE pathogenesis. Treatment with an anti-CD20 antibody leads to an impressive improvement of AE in patients with severe disease.	[Hosli, Susanne; Kostylina, Ganna; Simon, Hans-Uwe] Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; [Simon, Dagmar; Yawalkar, Nikhil] Univ Bern, Dept Dermatol, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Ahmed AR, 2006, NEW ENGL J MED, V355, P1772, DOI 10.1056/NEJMoa062930; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Arin MJ, 2005, BRIT J DERMATOL, V153, P620, DOI 10.1111/j.1365-2133.2005.06651.x; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; Cambridge G, 2003, ARTHRITIS RHEUM-US, V48, P2146, DOI 10.1002/art.11181; Cancro MP, 1998, IMMUNOL RES, V17, P3, DOI 10.1007/BF02786425; Clark R, 2005, J INVEST DERMATOL, V125, P629, DOI 10.1111/j.0022-202X.2005.23856.x; Cooper HL, 2003, CLIN EXP DERMATOL, V28, P366, DOI 10.1046/j.1365-2230.2003.01283.x; De Vita S, 2002, ARTHRITIS RHEUM, V46, P2029, DOI 10.1002/art.10467; Dupuy A, 2004, ARCH DERMATOL, V140, P91, DOI 10.1001/archderm.140.1.91; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Eisenberg R, 2005, CLIN IMMUNOL, V117, P207, DOI 10.1016/j.clim.2005.08.006; Frezzolini A, 2002, ALLERGY, V57, P815, DOI 10.1034/j.1398-9995.2002.23687.x; Grillo-Lopez AJ, 1999, SEMIN ONCOL, V26, P66; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HARADA H, 1993, BLOOD, V81, P2658; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jirapongsananuruk O, 1998, J IMMUNOL, V160, P4622; Joly P, 2007, NEW ENGL J MED, V356, P521; Kaser A, 2000, J IMMUNOL, V165, P2474, DOI 10.4049/jimmunol.165.5.2474; Leandro MJ, 2002, ARTHRITIS RHEUM-US, V46, P2673, DOI 10.1002/art.10541; Leandro MJ, 2002, ANN RHEUM DIS, V61, P883, DOI 10.1136/ard.61.10.883; Levesque MC, 2008, J ALLERGY CLIN IMMUN, V121, P13, DOI 10.1016/j.jaci.2007.11.030; Lin Lin, 2003, Journal of Medical and Dental Sciences, V50, P27; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Lugovic L, 2001, INT J DERMATOL, V40, P489, DOI 10.1046/j.1365-4362.2001.01203.x; Macaulay AE, 1997, J IMMUNOL, V158, P4171; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Masuda K, 2003, ACTA DERM-VENEREOL, V83, P249, DOI 10.1080/00015550310016472; Morrison LH, 2004, J AM ACAD DERMATOL, V51, P817, DOI 10.1016/j.jaad.2004.06.007; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Sfikakis PP, 2005, CURR OPIN RHEUMATOL, V17, P550, DOI 10.1097/01.bor.0000172798.26249.fc; Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P501, DOI 10.1002/art.20858; Silverman GJ, 2003, ARTHRITIS RHEUM-US, V48, P1484, DOI 10.1002/art.10947; Silverman GJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2194, DOI 10.2741/2222; Simon D, 2007, BRIT J DERMATOL, V157, P583, DOI 10.1111/j.1365-2133.2007.08050.x; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Simon D, 2002, ALLERGY, V57, P431, DOI 10.1034/j.1398-9995.2002.13506.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Stockinger B, 1996, J EXP MED, V183, P891, DOI 10.1084/jem.183.3.891; Takemura S, 2001, J IMMUNOL, V167, P4710, DOI 10.4049/jimmunol.167.8.4710; Vallerskog T, 2007, CLIN IMMUNOL, V122, P62, DOI 10.1016/j.clim.2006.08.016; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034	49	186	197	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					122	128		10.1016/j.jaci.2007.11.016	http://dx.doi.org/10.1016/j.jaci.2007.11.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206507	Bronze			2022-12-18	WOS:000252372000018
J	Chapman, MD; Pomes, A; Breiteneder, H; Ferreira, F				Chapman, Martin D.; Pomes, Anna; Breiteneder, Heimo; Ferreira, Fatima			Nomenclature and structural biology of allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; nomenclature; IgE; asthma; protein families; allergic disease; protein structure; biologic function	SEED STORAGE PROTEINS; CRYSTAL-STRUCTURE; CROSS-REACTIVITY; POLLEN ALLERGEN; FOOD ALLERGENS; CAT ALLERGEN; BINDING; COCKROACH; IMMUNOTHERAPY; EVOLUTION	Purified allergens are named using the systematic nomenclature of the Allergen Nomenclature Sub-Committee of the World Health Organization and International Union of Immunological Societies. The system uses abbreviated Linnean genus and species names and an Arabic number to indicate the chronology of allergen purification. Most major allergens from mites, animal dander, pollens, insects, and foods have been cloned, and more than 40 three-dimensional allergen structures are in the Protein Database. Allergens are derived from proteins with a variety of biologic functions, including proteases, ligand-binding proteins, structural proteins, pathogenesis-related proteins, lipid transfer proteins, profilins, and calcium-binding proteins. Biologic function, such as the proteolytic enzyme allergens of dust mites, might directly influence the development of IgE responses and might initiate inflammatory responses in the lung that are associated with asthma. Intrinsic structural or biologic properties might also influence the extent to which allergens persist in indoor and outdoor environments or retain their allergenicity in the digestive tract. Analyses of the protein family database suggest that the universe of allergens comprises more than 120 distinct protein families. Structural biology and proteomics define recombinant allergen targets for diagnostic and therapeutic purposes and identify motifs, patterns, and structures of immunologic significance.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; Med Univ Vienna, Vienna, Austria; Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria	INDOOR Biotechnologies; Medical University of Vienna; Salzburg University	Chapman, MD (corresponding author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	mdc@inbio.com	Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Pomés, Anna/H-7010-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632				Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Breiteneder H, 2006, WOODHEAD PUBL FOOD S, P21, DOI 10.1533/9781845690057.1.21; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; CHAPMAN MD, 2003, ALLERGENS ALLERGEN I, P51; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Czerwinski EW, 2005, J BIOL CHEM, V280, P3740, DOI 10.1074/jbc.M409655200; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Ferreira F, 2004, ADV IMMUNOL, V84, P79, DOI 10.1016/S0065-2776(04)84003-3; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gadermaier G, 2004, CURR ALLERGY ASTHM R, V4, P391, DOI 10.1007/s11882-004-0090-5; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Ivanciuc O, 2003, NUCLEIC ACIDS RES, V31, P359, DOI 10.1093/nar/gkg010; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KREIS M, 1985, J MOL BIOL, V183, P499, DOI 10.1016/0022-2836(85)90017-8; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MARSH DG, 1975, ANTIGENS, V3, P271; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; Piboonpocanun S, 2006, CLIN EXP ALLERGY, V36, P510, DOI 10.1111/j.1365-2222.2006.02464.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Schenk MF, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-168; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Smith AM, 2001, J ALLERGY CLIN IMMUN, V107, P977, DOI 10.1067/mai.2001.115629; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wopfner N, 2005, INT ARCH ALLERGY IMM, V138, P337, DOI 10.1159/000089188; Wunschmann S, 2005, J ALLERGY CLIN IMMUN, V116, P140, DOI 10.1016/j.jaci.2005.04.024	44	186	200	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					414	420		10.1016/j.jaci.2006.11.001	http://dx.doi.org/10.1016/j.jaci.2006.11.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17166572				2022-12-18	WOS:000244327900020
J	Verhagen, J; Akdis, M; Traidl-Hoffmann, C; Schmid-Grendelmeier, P; Hijnen, D; Knol, EF; Behrendt, H; Blaser, K; Akdis, CA				Verhagen, J; Akdis, M; Traidl-Hoffmann, C; Schmid-Grendelmeier, P; Hijnen, D; Knol, EF; Behrendt, H; Blaser, K; Akdis, CA			Absence of T-regulatory cell expression and function in atopic dermatitis skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						regulatory T cell; atopic dermatitis; apoptosis; suppression; regulation; skin; human; inflammation	KERATINOCYTE APOPTOSIS; RECEPTORS; IL-10; STIMULATION; INDUCTION; RESPONSES; DRUGS; IGE	Background: The role of regulatory T cells has been widely reported in the suppression of T-cell activation. A dysfunction in CD4(+)CD25(+) T-regulatory cell-specific transcription factor FoxP3 leads to immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome, often associated with atopic dermatitis. Increasing the number and activity of regulatory T cells in affected organs has been suggested as a remedy in various inflammatory diseases, including allergy. Objective: To determine the presence and function of regulatory T cells in atopic dermatitis. Methods: Immunohistochemistry of lesional atopic dermatitis skin and control skin conditions was used to demonstrate regulatory cells and cytokines in situ. The role of effector and regulatory T cells as well as their specific cytokines in apoptosis in human keratinocyte cultures and artificial skin equivalents was investigated. Results: Human T-regulatory type 1 cells, their suppressive cytokines, IL-10 and TGF-beta, as well as receptors for these cytokines were significantly expressed, whereas CD4(+)CD25(+)FoxP3(+) T-regulatory cells were not found in lesional and atopy patch test atopic dermatitis or psoriasis skin. Both subsets of regulatory T cells suppress the allergen-specific activation of T(H)1 and T(H)2 cells. In coculture and artificial skin equivalent experiments, subsets of T-regulatory cells neither induced keratinocyte death nor suppressed apoptosis induced by skin T cells, TH1 cells, IFN-gamma, or TNF-alpha. Conclusion: A dysregulation of disease-causing effector T cells is observed in atopic dermatitis lesions, in association with an impaired CD4+CD25+FoxP3+ T-cell infiltration, despite the expression of type 1 regulatory cells in the dermis.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Tech Univ, Natl Res Ctr Environm & Hlth, ZAUM Ctr Allergy & Environm, Munich, Germany; Univ Zurich, Dept Dermatol, CH-8006 Zurich, Switzerland; Univ Utrecht, Ctr Med, NL-3508 TC Utrecht, Netherlands	Swiss Institute of Allergy & Asthma Research; Technical University of Munich; University of Munich; University of Zurich; Utrecht University	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; Hijnen, DirkJan/L-1387-2015	Akdis, Cezmi/0000-0001-8020-019X; Hijnen, DirkJan/0000-0003-3379-3425; Knol, Edward/0000-0001-7368-9820; Verhagen, Johan/0000-0001-8414-1342; Traidl-Hoffmann, Claudia/0000-0001-5085-5179				Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gold LI, 1997, AM J PATHOL, V150, P209; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Joss A, 2000, EUR J IMMUNOL, V30, P1683, DOI 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Michel G, 1997, J IMMUNOL, V159, P6291; MULLER G, 1994, J CLIN INVEST, V94, P1799, DOI 10.1172/JCI117528; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; Saha B, 1996, J EXP MED, V183, P2675, DOI 10.1084/jem.183.6.2675; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Taylor A, 2004, INT ARCH ALLERGY IMM, V135, P73, DOI 10.1159/000080523; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Traidl C, 2000, J IMMUNOL, V165, P3058, DOI 10.4049/jimmunol.165.6.3058; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796	35	186	211	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					176	183		10.1016/j.jaci.2005.10.040	http://dx.doi.org/10.1016/j.jaci.2005.10.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387603	Bronze			2022-12-18	WOS:000235687100028
J	Broide, DH				Broide, DH			Molecular and cellular mechanisms of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; mast cell; eosinophil; IgE; IL-4; IL-5; T(H)2 cell	ANTI-IGE ANTIBODY; EPSILON-RI EXPRESSION; LOW-AFFINITY RECEPTOR; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; EOSINOPHILIC INFLAMMATION; CD23-DEFICIENT MICE; DOWN-REGULATION; HUMAN BASOPHILS; ASTHMA	The molecular and cellular mechanisms mediating the allergic inflammatory cascade involve multiple mediators, cell types, and pathways. Of particular interest are the pathways regulated by the T(H)2 lymphocyte, which result in release of IL-4 (important to IgE synthesis) and IL-5 (important to eosinophil proliferation). IL-4 regulates differentiation of naive THO cells to develop a T(H)2 phenotype and stimulates B cells to produce IgE. Cross-linking by allergen of IgE affixed to high-affinity receptors on mast cells and basophils triggers degranulation and the release of preformed inflammatory mediators (important to the early phase response), and subsequently initiates synthesis and the release of lipid mediators and cytokines (which may contribute to the late phase response). Eosinophils may also play a prominent role in the development of bronchial hyperreactivity. IL-5, which is a lineage-specific eosinophil grow th factor, increases the formation of eosinophils from progenitor cells and, in concert with CCR3 active chemokines, increases their trafficking to sites of allergic inflammation. An improved understanding of the basic mechanisms of allergic inflammation has led to the discovery of molecular targets involved in the initial events of the inflammatory cascade. Potential targets for the development of novel therapies for allergic disease include IgE, the T(H)2 lymphocyte, and T(H)2-derived cytokines, IL-4 and IL-5.	Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Div Allergy & Immunol, Basic Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.			Broide, David/0000-0001-8405-9090				ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; BARNES PJ, 1998, ALLERGY PRINCIPLES P, P356; Blumenthal MN, 1998, ALLERGY PRINCIPLES P, P28; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; Broide DH, 2001, AM J RESP CELL MOL, V24, P304, DOI 10.1165/ajrcmb.24.3.4071; Broide DH, 2000, BLOOD, V95, P263; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; GRANT JA, 1998, ALLERGY PRINCIPLES P, P277; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gustavsson S, 2000, J IMMUNOL, V164, P3990, DOI 10.4049/jimmunol.164.8.3990; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; Huang SK, 1998, J ALLERGY CLIN IMMUN, V102, P887, DOI 10.1016/S0091-6749(98)70323-9; Kay AB, 1997, ALLERGY ALLERGIC DIS, P23; Kisselgof AB, 1998, INT IMMUNOL, V10, P1377, DOI 10.1093/intimm/10.9.1377; Kita H, 1998, ALLERGY PRINCIPLES P, P242; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Ober C, 1998, J ALLERGY CLIN IMMUN, V101, pS417, DOI 10.1016/S0091-6749(98)70234-9; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132, DOI 10.1016/S0091-6749(99)70308-8; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Saini SS, 1999, J IMMUNOL, V162, P5624; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Sriramarao P, 1996, J IMMUNOL, V157, P4672; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; Sung KLP, 1997, J IMMUNOL, V158, P919; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; WALDSCHMIDT TJ, 1992, ADV EXP MED BIOL, V323, P149; WEIN M, 1995, AM J RESP CELL MOL, V12, P315, DOI 10.1165/ajrcmb.12.3.7532979; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3	55	186	192	0	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2		S			S65	S71		10.1067/mai.2001.116436	http://dx.doi.org/10.1067/mai.2001.116436			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	466VB	11498675				2022-12-18	WOS:000170665900001
J	Sicherer, SH; Morrow, EH; Sampson, HA				Sicherer, SH; Morrow, EH; Sampson, HA			Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; double-blind; placebo-controlled food challenge	HYPERSENSITIVITY REACTIONS; NATURAL-HISTORY; MILK ALLERGY; INFANTS; ANAPHYLAXIS; ADOLESCENTS; MANAGEMENT; DIAGNOSIS; SYMPTOMS; PROTEIN	Background: Double-blind, placebo-controlled oral food challenges (DBPCFCs) are considered the "gold standard" for diagnosing food hypersensitivity, but the dose that elicits positive challenges, or determinants that may predict dose-response relationships, have not been reported. Objective: Our purpose was to determine the quantity of food that elicits reactions during DBPCFCs and to evaluate parameters that may predict the provocative dose and severity of reaction. Methods: We reviewed challenge data for all positive challenges to 6 common allergenic foods in children with atopic dermatitis evaluated for food allergy over a 13-year period. Challenge food was generally administered in 6 doses at 10- to 15-minute intervals beginning with 400 to 500 mg and completing with a total of 8 to 10 g of food, An open feeding of a larger portion followed negative challenges. At the physician's discretion, a lower starting dose was occasionally used (100 mg, 250 mg), Food-specific IgE antibody concentrations (radioallergosorbent test [RAST]) were determined on stored sera of 20 % of the challenges selected randomly and 99.6 % had prick skin tests (PSTs) performed to the challenged food. Results: A total of 196 children (45% male; median age 5 y 9 mo; atopic dermatitis 98%, asthma 62%) had 513 positive challenges distributed as follows: egg 267, milk 117, soy 53, wheat 40, peanut 24, fish 12. The percentage of children reacting at the first dose (500 mg or less) was as follows: egg 49%, milk 55%, soy 28%, wheat 25%, peanut 26%, and fish 17%. Twenty-six milk challenges and 22 egg challenges were positive at a first dose of 250 mg; 3 milk challenges and 7 egg challenges were positive at a first dose of 100 mg, Eleven pel cent of the reactions that occurred on the first dose were severe. The percentage reacting after the final dose of the DBPCFC (or during open challenge) a ere egg 11%, milk 12%, soy 19%, wheat 12.5%, peanut 8.7%, and fish 25%. There was not a strong correlation between PST absolute wheal size or score (adjusted for histamine controls) and dose at reaction or severity of reaction (R-s range -0.22 to 0.39 for particular foods), Serum concentration of food-specific IgE did not correlate well with the dose causing a reaction or with severity (R-s range -0.40 to 0.55 for particular foods). Conclusions: This food-allergic population may react to as little as 100 mg of food, possibly less, and the dose causing a reaction and the severity of reaction is not predicted by PST or PAST Lower doses (100 mg or less) should he investigated for their appropriateness in initiating DBPCFCs.	CUNY Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCRR NIH HHS [RR 00071, RR 00052] Funding Source: Medline; NIAID NIH HHS [R01 AI24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; FUKUTOMI O, 1994, INT ARCH ALLERGY IMM, V104, P352, DOI 10.1159/000236691; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Laoprasert N, 1998, J FOOD PROTECT, V61, P1522, DOI 10.4315/0362-028X-61.11.1522; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Rance F, 1997, PEDIATR ALLERGY IMMU, V8, P41; Rance F, 1999, PEDIAT ALLERG IMM-UK, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Vanderhoof JA, 1997, J PEDIATR-US, V131, P741, DOI 10.1016/S0022-3476(97)70103-3; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	24	186	189	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					582	586		10.1067/mai.2000.104941	http://dx.doi.org/10.1067/mai.2000.104941			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719311	Bronze			2022-12-18	WOS:000088946700028
J	LAUFER, P; FINK, JN; BRUNS, WT; UNGER, GF; KALBFLEISCH, JH; GREENBERGER, PA; PATTERSON, R				LAUFER, P; FINK, JN; BRUNS, WT; UNGER, GF; KALBFLEISCH, JH; GREENBERGER, PA; PATTERSON, R			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,ALLERGY & IMMUNOL SECT,MILWAUKEE,WI 53226; MED COLL WISCONSIN,RADIOL SECT,MILWAUKEE,WI 53226; VET ADM MED CTR,MARCUS CTR IMMUNOL & ALLERGY RES,WOOD,WI 53193; MILWAUKEE CHILDRENS HOSP,CYST FIBROSIS CLIN,MILWAUKEE,WI 53233; NORTHWESTERN UNIV,SCH MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NHLBI NIH HHS [HL 29319] Funding Source: Medline; NIAID NIH HHS [AI 19104, AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403, P50AI019104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDANA EJ, 1975, AM J DIS CHILD, V129, P1164, DOI 10.1001/archpedi.1975.02120470020005; BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P99; BATTEN J. C., 1967, MOD PROBL PAEDIATR, V10, P227; BRUETON MJ, 1980, ARCH DIS CHILD, V55, P348, DOI 10.1136/adc.55.5.348; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; KURUP VP, 1978, AM J CLIN PATHOL, V69, P414; KURUP VP, 1978, MICROBIOS, V19, P191; LEWISTON NJ, 1973, CYSTIC FIBROSIS Q S, P47; MEARNS M, 1967, LANCET, V1, P53; MINTZER RA, 1978, RADIOLOGY, V127, P301, DOI 10.1148/127.2.301; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; ORES CN, 1975, CF CLUB ABSTR, P20; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; RIMM AA, 1980, BASIC BIOSTATISTICS, P226; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SCHWARTZ RH, 1970, AM J DIS CHILD, V120, P432, DOI 10.1001/archpedi.1970.02100100096009; STEINBERG AG, 1960, AM J HUM GENET, V12, P416; VANSELOW NA, 1968, MANUAL CLIN ALLERGY, P55; VOSS MJ, 1982, J ALLERGY CLIN IMMUN, V69, P539; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WARNER JO, 1976, ARCH DIS CHILD, V51, P507, DOI 10.1136/adc.51.7.507; WARREN C P W, 1975, Clinical Allergy, V5, P1, DOI 10.1111/j.1365-2222.1975.tb01831.x	22	186	190	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					44	48		10.1016/0091-6749(84)90482-2	http://dx.doi.org/10.1016/0091-6749(84)90482-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693666				2022-12-18	WOS:A1984SB99000006
J	FIELDS, T; GHEBREHIWET, B; KAPLAN, AP				FIELDS, T; GHEBREHIWET, B; KAPLAN, AP			KININ FORMATION IN HEREDITARY ANGIOEDEMA PLASMA - EVIDENCE AGAINST KININ DERIVATION FROM C2 AND IN SUPPORT OF SPONTANEOUS FORMATION OF BRADYKININ	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK, HLTH SCI CTR, DIV ALLERGY RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Fields, Theodore Robert/ABA-4821-2021	Fields, Theodore Robert/0000-0003-4026-1267	NHLBI NIH HHS [5R01-HL23714-02] Funding Source: Medline; PHS HHS [P50AL 16337-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARLAUD GJ, 1980, BIOCHIM BIOPHYS ACTA, V616, P116, DOI 10.1016/0005-2744(80)90269-7; AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; COLLEN D, 1976, BIOCHEM J, V159, P545; COOPER NR, 1982, FED PROC, V41, P374; COOPER NR, 1980, J IMMUNOL, V124, P1517; CURD JG, 1982, MOL IMMUNOL, V19, P1365, DOI 10.1016/0161-5890(82)90035-9; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONALDSON VH, 1968, J EXP MED, V127, P411, DOI 10.1084/jem.127.3.411; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FIELDS TR, 1982, CLIN RES, V30, pA348; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1979, J CLIN INVEST, V64, P280, DOI 10.1172/JCI109449; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GIGLI I, 1970, J IMMUNOL, V104, P574; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P20; KAPLAN AP, 1970, J IMMUNOL, V105, P802; KAPLAN AP, 1981, CRITICAL REV IMMUNOL, P75; KLEMPERER MR, 1967, J CLIN INVEST, V46, P1079; LOPEZTRASCASA M, 1982, MOL IMMUNOL, V19, P1403, DOI 10.1016/0161-5890(82)90154-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER G, 1980, BIOCHEM BIOPH RES CO, V92, P803, DOI 10.1016/0006-291X(80)90774-3; MOROI M, 1976, J BIOL CHEM, V251, P5956; MULLEREBERHARD HJ, 1963, J EXP MED, V118, P447, DOI 10.1084/jem.118.3.447; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; RATNOFF OD, 1967, J EXP MED, V125, P337, DOI 10.1084/jem.125.2.337; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; RUDDY S, 1968, ALLERGOLOGIE, P351; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SOTER NA, 1975, J IMMUNOL, V114, P928; SPRAGG J, 1966, J IMMUNOL, V96, P865; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; VALET G, 1974, J IMMUNOL, V112, P339	41	186	187	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					54	60		10.1016/0091-6749(83)90052-0	http://dx.doi.org/10.1016/0091-6749(83)90052-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6222104				2022-12-18	WOS:A1983QZ19800007
J	ARLIAN, LG; BERNSTEIN, IL; GALLAGHER, JS				ARLIAN, LG; BERNSTEIN, IL; GALLAGHER, JS			THE PREVALENCE OF HOUSE DUST MITES, DERMATOPHAGOIDES SPP, AND ASSOCIATED ENVIRONMENTAL-CONDITIONS IN HOMES IN OHIO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WRIGHT STATE UNIV,SCH MED,DEPT PHYSIOL,DAYTON,OH 45435; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; Wright State University Dayton; University System of Ohio; University of Cincinnati	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,SCH MED,DEPT BIOL SCI,DAYTON,OH 45435, USA.				PHS HHS [1 R01 A1 13702] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARLIAN L G, 1977, Journal of Medical Entomology, V14, P484, DOI 10.1093/jmedent/14.4.484; ARLIAN LG, 1976, J ASTHMA RES, V13, P165, DOI 10.3109/02770907609104172; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437, DOI 10.1093/jmedent/12.4.437; ARLIAN LG, 1974, J INSECT PHYSIOL, V20, P1063, DOI 10.1016/0022-1910(74)90148-6; ARLIAN LG, 1978, J MED ENTOMOL, V15, P35, DOI 10.1093/jmedent/15.1.35; ARLIAN LG, 1979, COMP BIOCHEM PHYS A, V64, P191, DOI 10.1016/0300-9629(79)90650-9; ARLIAN LG, UNPUB SEASONAL POPUL; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; BRONSWIJK JEM, 1971, RES POPUL ECOL, V13, P67; DUSBABEK F, 1975, Folia Parasitologica (Ceske Budejovice), V22, P219; Furumizo R.T., 1978, CALIFORNIA VECTOR VIEWS, V25, P13; HUGHES A M, 1973, Clinical Allergy, V3, P127, DOI 10.1111/j.1365-2222.1973.tb01316.x; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LANG JD, 1977, ENVIRON ENTOMOL, V6, P643, DOI 10.1093/ee/6.5.643; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; SESAY H R, 1972, Acarologia (Paris), V14, P384; WOODFORD PJ, 1978, REC ADV ACAROLOGY, V2, P197; [No title captured]	19	186	194	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					527	532		10.1016/0091-6749(82)90178-6	http://dx.doi.org/10.1016/0091-6749(82)90178-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076994				2022-12-18	WOS:A1982NT02500009
J	VANE, JR				VANE, JR			MODE OF ACTION OF ASPIRIN AND SIMILAR COMPOUNDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories								ADAMS SS, 1958, NATURE, V181, P773, DOI 10.1038/181773b0; AMBACHE N, 1957, J PHYSIOL-LONDON, V135, P114, DOI 10.1113/jphysiol.1957.sp005699; ANGGARD E, 1971, ACTA PHYSIOL SCAND, V81, P440, DOI 10.1111/j.1748-1716.1971.tb04921.x; BERGSTROM S, 1959, ACTA PHYSIOL SCAND, V45, P145, DOI 10.1111/j.1748-1716.1959.tb01686.x; BERRY PA, 1966, THESIS CNAA LONDON, P90; CHANG J, 1976, BRIT J PHARMACOL, V56, pP342; CLARK WG, 1972, J PHARMACOL-PARIS, V181, P183; COLLIER HOJ, 1968, NATURE, V219, P864, DOI 10.1038/219864a0; COLLIER HOJ, 1972, NATURE-NEW BIOL, V236, P141, DOI 10.1038/newbio236141a0; COLLIER HOJ, 1969, ADV PHARMACOL CHEMOT, V7, P333; COLLIER HOJ, 1963, ASPIRIN SCI AM, V209, P96; COLLIER JG, 1972, BRIT J PHARMACOL, V44, pP374; CUTHBERT MF, 1971, P ROY SOC MED, V64, P15, DOI 10.1177/003591577106400108; DAWSON W, 1974, BRIT J PHARMACOL, V52, pP107; DENKO CW, 1975, PHARMACOLOGY, V13, P219, DOI 10.1159/000136907; DIPASQUA.G, 1973, PROSTAG OTH LIPID M, V3, P741, DOI 10.1016/0090-6980(73)90001-4; DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103; DIROSA M, 1972, J PATHOL, V105, P239; DOEGLAS HMG, 1975, BRIT J DERMATOL, V93, P135, DOI 10.1111/j.1365-2133.1975.tb06732.x; EAKINS KE, 1972, NATURE-NEW BIOL, V239, P248, DOI 10.1038/newbio239248a0; EAKINS KE, 1972, BMJ-BRIT MED J, V3, P452, DOI 10.1136/bmj.3.5824.452; EAKINS KE, 1974, PROSTAGLANDIN SYNTHE, P343; FARMER JB, 1972, BRIT J PHARMACOL, V46, pP536; FELDBERG W, 1973, J PHYSIOL-LONDON, V228, P41, DOI 10.1113/jphysiol.1973.sp010071; FELDBERG W, 1971, J PHYSIOL-LONDON, V217, P547, DOI 10.1113/jphysiol.1971.sp009585; FELDBERG W, 1976, INFLAMMATORY ANTI IN; FERREIRA S H, 1973, Biorheology, V10, P288; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P86, DOI 10.1111/j.1476-5381.1973.tb08270.x; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; FERREIRA SH, 1973, BRIT J PHARMACOL, V47, P48, DOI 10.1111/j.1476-5381.1973.tb08157.x; FERREIRA SH, 1974, ANNU REV PHARMACOL, V14, P57, DOI 10.1146/annurev.pa.14.040174.000421; FERREIRA SH, 1973, PROSTAGLANDINS, P345; FERREIRA SH, 1973, BRIT J PHARMACOL, V47, P429; FERREIRA SH, 1976, FUTURE TRENDS INFLAM; FISHERMAN EW, 1973, ANN ALLERGY, V31, P476; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; GLATT M, 1974, EXPERIENTIA, V30, P1257, DOI 10.1007/BF01945171; GLENN EM, 1972, P SOC EXP BIOL MED, V139, P290; GLENN EM, 1972, PROSTAGLANDINS CELLU, V1, P329; GREAVES MW, 1970, J INVEST DERMATOL, V54, P365, DOI 10.1111/1523-1747.ep12259058; GREAVES MW, 1971, BMJ-BRIT MED J, V2, P258, DOI 10.1136/bmj.2.5756.258; GREAVES MW, 1972, BMJ-BRIT MED J, V2, P83, DOI 10.1136/bmj.2.5805.83; GREAVES MW, 1973, BRIT MED J, V3, P608, DOI 10.1136/bmj.3.5881.608; GREAVES MW, 1975, IMMUNOLOGY MEDICAL P; GRYGLEWSKI R, 1972, BRIT J PHARMACOL, V45, P37, DOI 10.1111/j.1476-5381.1972.tb09574.x; GRYGLEWSKI RJ, 1975, ANN INTERN MED, V82, P286, DOI 10.7326/0003-4819-82-2-286; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; GUZMAN F, 1964, ARCH INT PHARMACOD T, V149, P571; GUZMAN F, 1962, ARCH INT PHARMACOD T, V136, P353; HAMBERG M, 1972, BIOCHEM BIOPH RES CO, V49, P720, DOI 10.1016/0006-291X(72)90470-6; HAMBERG M, 1975, LIFE SCI, V16, P451, DOI 10.1016/0024-3205(75)90266-0; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1974, BIOCHEM BIOPH RES CO, V61, P942, DOI 10.1016/0006-291X(74)90246-0; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3824, DOI 10.1073/pnas.71.10.3824; HAMBERG M, 1976, ADV PROSTAG THROMB R, V1, P19; HEDQVIST P, 1974, PROSTAGLANDIN SYNTHE, P303; HENDRICKS CH, 1971, AM J OBSTET GYNECOL, V111, P564, DOI 10.1016/0002-9378(71)90473-X; HERMAN PS, 1973, Z IMMUNITATSFORSCH, V146, P93; HIGGS GA, 1975, BRIT J PHARMACOL, V53, P539, DOI 10.1111/j.1476-5381.1975.tb07392.x; HIGGS GA, 1972, BRIT J PHARMACOL, V44, pP330; HIGGS GA, 1975, ADV PROSTAGLANDIN TH, V1, P105; HIGGS GA, 1974, PROSTAGLANDIN SYNTHE, P165; HORTON EW, 1963, NATURE, V200, P892, DOI 10.1038/200892b0; HSIA SL, 1974, PROSTAGLANDIN SYNTHE, P353; JUAN H, 1974, N-S ARCH PHARMACOL, V283, P151, DOI 10.1007/BF00501142; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P251; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; KADOWITZ P, 1976, PROSTAGLANDINS, V11, P437; KALEY G, 1971, ANN NY ACAD SCI, V180, P338, DOI 10.1111/j.1749-6632.1971.tb53203.x; KANTROWITZ F, 1975, NATURE, V258, P737, DOI 10.1038/258737a0; KARIM S, 1971, ANN NY ACAD SCI, V180, P483, DOI 10.1111/j.1749-6632.1971.tb53216.x; KOOPMAN WJ, 1970, J IMMUNOL, V105, P1096; KUBBA R, 1975, BRIT J DERMATOL, V93, P61, DOI 10.1111/j.1365-2133.1975.tb06802.x; KURTI M, 1974, POL J PHARMACOL PHAR, V26, P109; LEWIS AJ, 1974, BRIT J PHARMACOL, V50, pP468; LEWIS GP, 1975, NATURE, V254, P308, DOI 10.1038/254308a0; LICHTENSTEIN LM, 1971, BIOCH ACUTE ALLERGIC, P161; LIM RKS, 1964, ARCH INT PHARMACOD T, V152, P25; MAJNO G, 1972, INFLAMMATION MECHANI, P13; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MCARTHUR JN, 1971, BRIT MED J, V4, P230, DOI 10.1136/bmj.4.5781.230-b; MILTON AS, 1973, ADV BIOSCI, V9, P495; MILTON AS, 1971, J PHYSIOL-LONDON, V218, P235; MONCADA S, 1975, EUR J PHARMACOL, V31, P250, DOI 10.1016/0014-2999(75)90047-3; MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0; MONCADA S, 1974, PROSTAGLANDIN SYNTHE, P189; MONCADA S, 1972, 5 P INT C PHARM, P160; NEEDLEMAN P, 1976, NATURE, V261, P558, DOI 10.1038/261558a0; NORTHOVER BJ, 1967, BRIT J PHARM CHEMOTH, V31, P483, DOI 10.1111/j.1476-5381.1967.tb00413.x; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; PACEASCIAK C, 1976, BIOCHIM BIOPHYS ACTA, V424, P323, DOI 10.1016/0005-2760(76)90200-9; PACEASCIAK C, 1971, BIOCHEMISTRY-US, V10, P3657, DOI 10.1021/bi00796a004; PALMER MA, 1970, BRIT J PHARMACOL, V40, pP547; PALMER MA, 1973, BRIT J PHARMACOL, V49, P226, DOI 10.1111/j.1476-5381.1973.tb08368.x; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; PIPER PJ, 1973, BRIT J PHARMACOL, V47, P291, DOI 10.1111/j.1476-5381.1973.tb08327.x; PIPER PJ, 1969, NATURE, V223, P29, DOI 10.1038/223029a0; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; ROBINSON DR, 1974, PROSTAGLANDIN SYNTHE, P223; ROSENTHALE ME, 1972, J PHARM PHARMACOL, V24, P149, DOI 10.1111/j.2042-7158.1972.tb08948.x; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMUELSSON B, 1974, PROSTAGLANDIN SYNTHE, P99; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SMITH AP, 1976, ADV PROSTAG THROMB R, V1, P449; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH M. J. H., 1966, P203; SOLOMON LM, 1968, J INVEST DERMATOL, V51, P280, DOI 10.1038/jid.1968.128; STASZEWSKABARCZAK J, 1976, CARDIOVASC RES, V10, P314, DOI 10.1093/cvr/10.3.314; Stone E., 1763, PHILOS T, V53, P195; SVENSSON J, 1975, ACTA PHYSIOL SCAND, V94, P222, DOI 10.1111/j.1748-1716.1975.tb05881.x; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TAUBER AI, 1973, J IMMUNOL, V111, P27; TAVEIRADASILVA AM, 1976, PROSTAGLANDINS, V11, P71, DOI 10.1016/0090-6980(76)90174-X; TOLMAN EL, 1975, PROSTAGLANDINS, V9, P349, DOI 10.1016/0090-6980(75)90139-2; TURNER SR, 1975, NATURE, V257, P680, DOI 10.1038/257680a0; VANE J R, 1972, Hospital Practice, V7, P61; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1975, ADV MEDICINE TOPICS, P64; VANE JR, 1973, ADV BIOSCI, V9, P395; VARGAFTIG BB, 1972, EUR J PHARMACOL, V18, P43; WALKER JL, 1973, ADV BIOSCI, V9, P235; WEINER R, 1969, AM J PHYSIOL, V217, P563, DOI 10.1152/ajplegacy.1969.217.2.563; WHITEHOUSE MW, 1962, NATURE, V194, P984, DOI 10.1038/194984a0; WHITEHOUSE MW, 1964, NATURE, V201, P629, DOI 10.1038/201629a0; WHITEHOUSE MW, 1965, PROGRESS DRUG RESEAR, V8, P321; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; WILLIS AL, 1974, PROSTAGLANDINS, V5, P1, DOI 10.1016/S0090-6980(74)80126-7; WILLIS AL, 1973, PROSTAG OTH LIPID M, V3, P353, DOI 10.1016/0090-6980(73)90073-7; WILLIS AL, 1969, PROSTAGLANDINS PEPTI, P33; ZURIER RB, 1971, NATURE, V234, P304, DOI 10.1038/234304a0	134	186	189	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					691	712		10.1016/0091-6749(76)90181-0	http://dx.doi.org/10.1016/0091-6749(76)90181-0			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	791988	Bronze			2022-12-18	WOS:A1976CP07700008
J	Kennedy, EA; Connolly, J; Hourihane, JO; Fallon, PG; McLean, WHI; Murray, D; Jo, JH; Segre, JA; Kong, HH; Irvine, AD				Kennedy, Elizabeth A.; Connolly, Jennifer; Hourihane, Jonathan O'B.; Fallon, Padraic G.; McLean, W. H. Irwin; Murray, Deirdre; Jo, Jay-Hyun; Segre, Julia A.; Kong, Heidi H.; Irvine, Alan D.			Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; atopic dermatitis; skin; microbiome; longitudinal birth cohort; 16S sequencing	PARTY DIAGNOSTIC-CRITERIA; HAY-FEVER; ALLERGIC SENSITIZATION; CESAREAN DELIVERY; BODY HABITATS; CHILDREN; CELLS; DISEASE; AUREUS; LIFE	Background: Disease flares of established atopic dermatitis (AD) are generally associated with a low-diversity skin microbiota and Staphylococcus aureus dominance. The temporal transition of the skin microbiome between early infancy and the dysbiosis of established AD is unknown. Methods: We randomly selected 50 children from the Cork Babies After SCOPE: Evaluating the Longitudinal Impact Using Neurological andNutritional Endpoints (BASELINE) longitudinal birth cohort for microbiome sampling at 3 points in the first 6 months of life at 4 skin sites relevant to AD: the antecubital and popliteal fossae, nasal tip, and cheek. We identified 10 infants with AD and compared them with 10 randomly selected control infants with no AD. We performed bacterial 16S ribosomal RNA sequencing and analysis directly from clinical samples. Results: Bacterial community structures and diversity shifted over time, suggesting that age strongly affects the skin microbiome in infants. Unlike established AD, these patients with infantile AD did not have noticeably dysbiotic communities before or with disease and were not colonized by S aureus. In comparing patients and control subjects, infants who had affected skin at month 12 had statistically significant differences in bacterial communities on the antecubital fossa at month 2 compared with infants who were unaffected at month 12. In particular, commensal staphylococci were significantly less abundant in infants affected at month 12, suggesting that this genus might protect against the later development of AD. Conclusions: This study suggests that 12-month-old infants with AD were not colonized with S aureus before having AD. Additional studies are needed to confirm whether colonization with commensal staphylococci modulates skin immunity and attenuates development of AD.	[Kennedy, Elizabeth A.; Jo, Jay-Hyun; Kong, Heidi H.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Connolly, Jennifer; Hourihane, Jonathan O'B.; Murray, Deirdre] Univ Coll, Paediat & Child Hlth, Cork, Ireland; [Fallon, Padraic G.; Irvine, Alan D.] Cork Univ Matern Hosp, Irish Ctr Fetal & Neonatal Translat INFANT Res, Cork, Ireland; [Fallon, Padraic G.; Irvine, Alan D.] Trin Coll Dublin, Med Clin, Dublin, Ireland; [Irvine, Alan D.] Univ Dundee, Natl Childrens Res Ctr, Dundee DD1 4HN, Scotland; [Irvine, Alan D.] Univ Dundee, Paediat Dermatol, Our Ladys Childrens Hosp Crumlin, Dundee DD1 4HN, Scotland; [McLean, W. H. Irwin] Univ Dundee, Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Segre, Julia A.] NHGRI, Translat & Funct Genom Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University College Cork; Trinity College Dublin; University of Dundee; University of Dundee; University of Dundee; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Irvine, AD (corresponding author), Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin 12, Ireland.; Kong, HH (corresponding author), NCI, Dermatol Branch, CCR, NIH, 10 Ctr Dr,Bldg 10-MSC 1908, Bethesda, MD 20892 USA.	konghe@mail.nih.gov; irvinea@tcd.ie	Fallon, Padraic/Y-2711-2019; Irvine, Alan D/A-3982-2008; Kong, Heidi H/L-4856-2018	Fallon, Padraic/0000-0002-8401-7293; Irvine, Alan D/0000-0002-9048-2044; Kong, Heidi H/0000-0003-4424-064X; Murray, Deirdre/0000-0002-2201-9912; Kennedy, Elizabeth/0000-0001-7934-1307	National Children's Research Centre (NCRC), Dublin, Ireland; NCRC; UK Food Standards Agency (FSA); Intramural Research Program of the National Institutes of Health's National Cancer Institute; National Human Genome Research Institute; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI15C1095]; NATIONAL CANCER INSTITUTE [ZIABC010938, ZIABC011558] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000180] Funding Source: NIH RePORTER; MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: researchfish	National Children's Research Centre (NCRC), Dublin, Ireland; NCRC; UK Food Standards Agency (FSA); Intramural Research Program of the National Institutes of Health's National Cancer Institute; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	A.D.I. is funded by the National Children's Research Centre (NCRC), Dublin, Ireland. The NCRC is the primary funding source for the ongoing Cork BASELINE birth cohort. Additional support came from the UK Food Standards Agency (FSA). The work was also supported by the Intramural Research Program of the National Institutes of Health's National Cancer Institute (to E.A.K., J.-H.J., and H.H.K.) and the National Human Genome Research Institute (to J.A.S.). J.-H.J. is also supported by a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI15C1095).	AGACHE P, 1980, BRIT J DERMATOL, V103, P643, DOI 10.1111/j.1365-2133.1980.tb01686.x; [Anonymous], 2008, WELCOME BASELINE STU; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Capone KA, 2011, J INVEST DERMATOL, V131, P2026, DOI 10.1038/jid.2011.168; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Fluhr JW, 2010, EXP DERMATOL, V19, P483, DOI 10.1111/j.1600-0625.2009.01023.x; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Grimbaldeston MA, 2003, BRIT J DERMATOL, V148, P300, DOI 10.1046/j.1365-2133.2003.05113.x; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Madan JC, 2016, JAMA PEDIATR, V170, P212, DOI 10.1001/jamapediatrics.2015.3732; Matsen FA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-538; Nagao K, 2015, IMMUNITY, V43, P842, DOI 10.1016/j.immuni.2015.10.020; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Oh J, 2013, GENOME RES, V23, P2103, DOI 10.1101/gr.159467.113; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Omine Y, 2015, ANAT CELL BIOL, V48, P177, DOI 10.5115/acb.2015.48.3.177; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sanford JA, 2013, SEMIN IMMUNOL, V25, P370, DOI 10.1016/j.smim.2013.09.005; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Skov L, 2009, BRIT J DERMATOL, V160, P1286, DOI 10.1111/j.1365-2133.2009.09051.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; THOMAS JA, 1984, HISTOCHEM J, V16, P507, DOI 10.1007/BF01041351; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Weber A, 2003, BRIT J DERMATOL, V148, P224, DOI 10.1046/j.1365-2133.2003.05090.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Yue JC, 2005, COMMUN STAT-THEOR M, V34, P2123, DOI 10.1080/STA-200066418	44	185	192	3	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					166	172		10.1016/j.jaci.2016.07.029	http://dx.doi.org/10.1016/j.jaci.2016.07.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27609659	Green Published, hybrid			2022-12-18	WOS:000393996800018
J	Song, H; Yoo, Y; Hwang, J; Na, YC; Kim, HS				Song, Han; Yoo, Young; Hwang, Junghyun; Na, Yun-Cheol; Kim, Heenam Stanley			Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; gut microbiota; microbiome; dysbiosis; Faecalibacterium prausnitzii	ESCHERICHIA-COLI; INTESTINAL MICROBIOTA; OXIDATIVE STRESS; IRRITABLE-BOWEL; HIGH-THROUGHPUT; DISEASE; CLASSIFICATION; DYSFUNCTION; METABOLISM; PREBIOTICS	Background: Atopic dermatitis (AD) is a serious global epidemic associated with a modern lifestyle. Objective: Although aberrant interactions between gut microbes and the intestinal immune system have been implicated in this skin disease, the nature of the microbiome dysfunction underlying the disease remains unclear. Methods: The gut microbiome from 132 subjects, including 90 patients with AD, was analyzed by using 16S rRNA gene and metagenome sequence analyses. Reference genomes from the Human Microbiome Project and the KEGG Orthology database were used for metagenome analyses. Short-chain fatty acids in fecal samples were compared by using gas chromatographic-mass spectrometric analyses. Results: We show that enrichment of a subspecies of the major gut species Faecalibacterium prausnitzii is strongly associated with AD. In addition, the AD microbiome was enriched in genes encoding the use of various nutrients that could be released from damaged gut epithelium, reflecting a bloom of auxotrophic bacteria. Fecal samples from patients with AD showed decreased levels of butyrate and propionate, which have anti-inflammatory effects. This is likely a consequence of an intraspecies compositional change in F prausnitzii that reduces the number of high butyrate and propionate producers, including those related to the strain A2-165, a lack of which has been implicated in patients with Crohn disease. Conclusions: The data suggest that feedback interactions between dysbiosis in F prausnitzii and dysregulation of gut epithelial inflammation might underlie the chronic progression of AD by resulting in impairment of the gut epithelial barrier, which ultimately leads to aberrant T(H)2-type immune responses to allergens in the skin.	[Song, Han; Hwang, Junghyun; Kim, Heenam Stanley] Korea Univ, Dept Biomed Sci, Seoul 136713, South Korea; [Yoo, Young] Korea Univ, Dept Pediat, Seoul 136713, South Korea; [Na, Yun-Cheol] Korea Basic Sci Inst, Western Seoul Ctr, Seoul, South Korea	Korea University; Korea University; Korea University Medicine (KU Medicine); Korea Basic Science Institute (KBSI)	Kim, HS (corresponding author), Korea Univ, 145 Anam Ro, Seoul 136713, South Korea.	hstanleykim@korea.ac.kr	Kim, Heenam Stanley/L-2279-2016	Kim, Heenam Stanley/0000-0003-4856-3518; Na, Yun-Cheol/0000-0002-8045-3784	National Research Foundation (NRF) of the Republic of Korea [2011-0016847, 2015R1A2A2A01004007, 2015M3C9A-4053393]	National Research Foundation (NRF) of the Republic of Korea	Supported by grants 2011-0016847, 2015R1A2A2A01004007, and 2015M3C9A-4053393 from the National Research Foundation (NRF) of the Republic of Korea (to H.S.K.).	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Alhasawi A, 2015, MICROBIOL RES, V171, P26, DOI 10.1016/j.micres.2014.12.001; Arrieta MC, 2006, GUT, V55, DOI 10.1136/gut.2005.085373; Baker BS, 2006, CLIN EXP IMMUNOL, V144, P1, DOI 10.1111/j.1365-2249.2005.02980.x; Barcenilla A, 2000, APPL ENVIRON MICROB, V66, P1654, DOI 10.1128/AEM.66.4.1654-1661.2000; Bearson BL, 2009, MICROBIOL-SGM, V155, P805, DOI 10.1099/mic.0.022905-0; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Brandt Eric B, 2011, J Clin Cell Immunol, V2; Candela M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-95; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Duncan SH, 2002, INT J SYST EVOL MICR, V52, P2141, DOI 10.1099/00207713-52-6-2141; Dziva F, 2004, MICROBIOL-SGM, V150, P3631, DOI 10.1099/mic.0.27448-0; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Endres DM, 2003, IEEE T INFORM THEORY, V49, P1858, DOI 10.1109/TIT.2003.813506; Ewaschuk JB, 2005, J NUTR, V135, P1619, DOI 10.1093/jn/135.7.1619; Ezraty B, 2005, J BACTERIOL, V187, P231, DOI 10.1128/JB.187.1.231-237.2005; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66; Hood MI, 2012, NAT REV MICROBIOL, V10, P525, DOI 10.1038/nrmicro2836; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kiefer D, 2004, ALTERN THER HEALTH M, V10, P22; Knights D, 2014, CELL HOST MICROBE, V16, P433, DOI 10.1016/j.chom.2014.09.013; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Lopez-Siles M, 2012, APPL ENVIRON MICROB, V78, P420, DOI 10.1128/AEM.06858-11; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; Moreau NM, 2003, J CHROMATOGR B, V784, P395, DOI 10.1016/S1570-0232(02)00827-9; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Parsonage D, 2008, P NATL ACAD SCI USA, V105, P8209, DOI 10.1073/pnas.0708308105; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; PIKE MG, 1986, J INVEST DERMATOL, V86, P101, DOI 10.1111/1523-1747.ep12284035; Ploger S, 2012, ANN NY ACAD SCI, V1258, P52, DOI 10.1111/j.1749-6632.2012.06553.x; Reynolds AP., 2006, J MATH MODEL ALGORIT, V5, P475, DOI [DOI 10.1007/S10852-005-9022-1, 10.1007/s10852-005-9022-1]; Romagnani S, 2006, ALLERGY, V61, P3, DOI 10.1111/j.1398-9995.2006.01005; Rook Graham A. W., 2013, Evolution Medicine and Public Health, P46, DOI 10.1093/emph/eot004; Sambrook J, 2001, MOL CLONING LAB MANU; Sandoval JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025573; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Stecher B, 2013, NAT REV MICROBIOL, V11, P277, DOI 10.1038/nrmicro2989; Sun YJ, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp285; The_HMP_Consortium, 2012, NATURE, V486, P207; TIEDEMAN AA, 1988, NUCLEIC ACIDS RES, V16, P3587, DOI 10.1093/nar/16.8.3587; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Whelan K, 2011, CURR OPIN CLIN NUTR, V14, P581, DOI 10.1097/MCO.0b013e32834b8082; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Zaneveld JRR, 2011, TRENDS MICROBIOL, V19, P472, DOI 10.1016/j.tim.2011.07.006	58	185	200	4	52	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					852	860		10.1016/j.jaci.2015.08.021	http://dx.doi.org/10.1016/j.jaci.2015.08.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26431583	hybrid			2022-12-18	WOS:000371897500029
J	Ko, TM; Chung, WH; Wei, CY; Shih, HY; Chen, JK; Lin, CH; Chen, YT; Hung, SI				Ko, Tai-Ming; Chung, Wen-Hung; Wei, Chun-Yu; Shih, Han-Yu; Chen, Jung-Kuei; Lin, Chia-Hsien; Chen, Yuan-Tsong; Hung, Shuen-Iu			Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug hypersensitivity; T-cell receptor; HLA; third complementarity-determining region; Stevens-Johnson syndrome; toxic epidermal necrolysis	TOXIC EPIDERMAL NECROLYSIS; HLA-B-ASTERISK-1502 ALLELE; RISK; ASSOCIATION; HYPERSENSITIVITY; ACTIVATION; CLONES; MARKER; CD8(+)	Background: Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN), are life-threatening drug hypersensitivities with robust immune responses to drugs. Despite the strong HLA predisposition to drug hypersensitivities, such as HLA-B*1502 to carbamazepine (CBZ)-induced SJS/TEN, it remains unknown whether particular T-cell receptors (TCRs) participate in recognition of small drug/peptide-HLA complexes. Objective: Using the strong HLA predisposition in patients with CBZ-induced SJS/TEN as a model, we aimed to study the use of TCR repertoire in patients with drug hypersensitivity. Method: We enrolled patients with CBZ-SJS/TEN, tolerant control subjects, and healthy subjects who had no history of CBZ exposure. We isolated PBMCs from the subjects, cultured CBZ-specific T cells, and globally investigated the expression level and third complementarity-determining region length distribution of the TCR profile. We further assessed the pathogenic role of the disease-specific clonotype using real-time PCR-based tests and functional analysis. Results: On drug stimulation, CBZ-specific CD8(+) T cells were expanded in vitro and activated to release granulysin. Notably, VB-11-ISGSY was identified as the most predominant clonotype and shared among different subjects. This clonotype was present in 16 (84%) of 19 patients with SJS/TEN, absent in all 17 tolerant patients, and present at a low frequency in healthy subjects (4/29 [14%]). CBZ-specific cytotoxicity could be primed in vitro in the PBMCs of healthy subjects who are carriers of HLA-B*1502 and VB-11-ISGSY; this cytotoxicity could be blocked by an anti-TCR-VB-11 antibody. Furthermore, a single T-cell clone expressing VA-22-FISGTY/VB-11-ISGSY showed significant cytotoxicity against HLA-B*1502-positive antigen-presenting cells and CBZ. Conclusion: This study establishes the key role of the TCR in the pathogenic mechanism of SJS/TEN, explains why some HLA-B*1502 carriers are tolerant to CBZ, and provides a biomarker profile for drug hypersensitivity. (J Allergy Clin Immunol 2011;128:1266-76.)	[Hung, Shuen-Iu] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 11221, Taiwan; [Ko, Tai-Ming; Shih, Han-Yu; Chen, Yuan-Tsong] Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan; [Ko, Tai-Ming; Wei, Chun-Yu; Shih, Han-Yu; Chen, Jung-Kuei; Lin, Chia-Hsien; Chen, Yuan-Tsong; Hung, Shuen-Iu] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Taipei 10591, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Infect & Immun Res Ctr, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; National Taiwan University; Academia Sinica - Taiwan; Chang Gung Memorial Hospital; National Yang Ming Chiao Tung University	Hung, SI (corresponding author), Natl Yang Ming Univ, Inst Pharmacol, Sch Med, 155 Linong St,Sect 2, Taipei 11221, Taiwan.	chen0010@ibms.sinica.edu.tw; sihung@ym.edu.tw	Ko, Tai-Ming/ABB-3384-2020; Hung, Shuen-Iu/ABB-2139-2021	Hung, Shuen-Iu/0000-0001-6531-5538; Shih, Han-Yu/0000-0002-7525-5433	National Science Council, Taiwan [NSC95-2314-B-010-096, 95-2314-B-182A-048, 95-3112-B-001-010, 95-3112-B-001-011, 96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, NSC 97-2745-B-010-001, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3]; Taiwanese Ministry of Education; Academia Sinica Thematic Research Program [AS 99 TP B12]; Chang-Gung Memorial Hospital	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Taiwanese Ministry of Education; Academia Sinica Thematic Research Program(Academia Sinica - Taiwan); Chang-Gung Memorial Hospital(Chang Gung Memorial Hospital)	Supported by grants from the National Science Council, Taiwan (NSC95-2314-B-010-096, 95-2314-B-182A-048, 95-3112-B-001-010, 95-3112-B-001-011, 96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, NSC 97-2745-B-010-001, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3); the Taiwanese Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); the Academia Sinica Thematic Research Program (AS 99 TP B12); and Chang-Gung Memorial Hospital.	BERAN RG, 1993, EPILEPSIA, V34, P163, DOI 10.1111/j.1528-1157.1993.tb02392.x; Bousso P, 1998, IMMUNITY, V9, P169, DOI 10.1016/S1074-7613(00)80599-3; Buggy Y, 2010, EPILEPSIA, V51, P818, DOI 10.1111/j.1528-1167.2009.02489.x; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Currier Jeffrey R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1028s38; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Dogan EA, 2008, EPILEPSY BEHAV, V13, P156, DOI 10.1016/j.yebeh.2008.02.001; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; Guglielmi L, 2006, CURR PHARM DESIGN, V12, P3309, DOI 10.2174/138161206778194088; Hallmayer J, 2009, NAT GENET, V41, P708, DOI 10.1038/ng.372; Hermansson A, 2010, J EXP MED, V207, P1081, DOI 10.1084/jem.20092243; Hirsch LJ, 2008, NEUROLOGY, V71, P1527, DOI 10.1212/01.wnl.0000334295.50403.4c; Hovhannisyan Z, 2008, NATURE, V456, P534, DOI 10.1038/nature07524; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Aceves-Avila FJ, 2008, JCR-J CLIN RHEUMATOL, V14, P261, DOI 10.1097/RHU.0b013e31817a241a; Le Louet H, 2008, EUR J NEUROL, V15, pE43, DOI 10.1111/j.1468-1331.2008.02111.x; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; May TW, 2003, CLIN PHARMACOKINET, V42, P1023, DOI 10.2165/00003088-200342120-00002; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Morel E, 2010, J ALLERGY CLIN IMMUN, V125, P703, DOI 10.1016/j.jaci.2009.10.030; Mueller DL, 2010, NAT IMMUNOL, V11, P21, DOI 10.1038/ni.1817; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Ochsenreither S, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-34; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; Risitano AM, 2004, LANCET, V364, P355, DOI 10.1016/S0140-6736(04)16724-X; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Roujeau Jean-Claude, 2006, Allergol Int, V55, P27, DOI 10.2332/allergolint.55.27; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017	39	185	194	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1266	U624		10.1016/j.jaci.2011.08.013	http://dx.doi.org/10.1016/j.jaci.2011.08.013			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21924464				2022-12-18	WOS:000298342700016
J	Allakhverdi, Z; Comeau, MR; Smith, DE; Toy, D; Endam, LM; Desrosiers, M; Liu, YJ; Howie, KJ; Denburg, JA; Gauvreau, GM; Delespesse, G				Allakhverdi, Zoulfia; Comeau, Michael R.; Smith, Dirk E.; Toy, Dean; Endam, Leandra Mfuna; Desrosiers, Martin; Liu, Yong-Jun; Howie, Karen J.; Denburg, Judah A.; Gauvreau, Gail M.; Delespesse, Guy			CD34(+) hemopoietic progenitor cells are potent effectors of allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blood CD34(+) cells; TSLP; IL-33; T(H)2 cytokines; chemokines; asthma; rhinosinusitis; airway epithelial cells; allergen inhalation challenge	THYMIC STROMAL LYMPHOPOIETIN; AIRWAY EPITHELIAL-CELLS; BONE-MARROW; MAST-CELLS; EOSINOPHIL PROGENITORS; ATOPIC-DERMATITIS; IL-5 RECEPTOR; NASAL-MUCOSA; DIFFERENTIATION; ASTHMA	Background: In steady state, hemopoietic progenitors constantly egress from the bone marrow (BM) into the blood and circulate through the peripheral tissues. In allergic diseases, the BM releases increased numbers of CD34(+) progenitor cells that migrate to the site of allergic inflammation, where they differentiate into tissue-dwelling and classic effector cells of allergy, such as mast cells, eosinophils, and basophils. Objective: To examine whether peripheral blood CD34(+) cells in addition to being progenitors may also directly function as inflammatory effector cells. Methods: Highly purified neonatal or adult blood CD34(+) cells were examined for the expression of thymic stromal lymphopoietin (TSLP) and IL-33 receptors and for their response to these cytokines as well as to supernatants of primary small airway epithelial cells and nasal explants from rhinosinusitis and control subjects. Sputum of patients with asthma was examined before and after allergen inhalation for the presence of IL-5 and IL-13-containing CD34(+) cells. Results: Circulating CD34(+) cells expressed receptors for TSLP and IL-33 and responded to these cytokines by rapidly releasing high levels of proinflammatory T(H)2-like cytokines and chemokines. These cells were activated in a TSLP-dependent manner by the supernatant fluids from activated primary human small airway epithelial cells and from nasal explants of patients with chronic rhinosinusitis. Moreover, activated CD34(+) cells containing IL-5 and IL-13 could be detected in the sputum of individuals with allergic asthma, with numbers increasing in response to specific allergen inhalation challenge. Conclusion: Blood CD34(+) cells, in addition to being progenitors, may act as proinflammatory effector cells by themselves and directly contribute to the allergic inflammation. (J Allergy Clin Immunol 2009;123:472-8.)	[Allakhverdi, Zoulfia; Delespesse, Guy] Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, Montreal, PQ H2L 4M1, Canada; [Comeau, Michael R.; Smith, Dirk E.; Toy, Dean] Amgen Inc, Inflammat Res, Seattle, WA USA; [Endam, Leandra Mfuna; Desrosiers, Martin] Hop Hotel Dieu, CHUM, Dept Otorhinolaryngol, Montreal, PQ, Canada; [Liu, Yong-Jun] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Howie, Karen J.; Denburg, Judah A.; Gauvreau, Gail M.] McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON L8S 4L8, Canada; [Denburg, Judah A.] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON L8S 4L8, Canada	Universite de Montreal; Amgen; Universite de Montreal; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; McMaster University; McMaster University	Delespesse, G (corresponding author), Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, 1560 Sherbrooke E St,Pav Mailloux,M4211-K, Montreal, PQ H2L 4M1, Canada.	guy.delespesse@sympatico.ca	Allakhverdi, Zoulfia/AAG-1379-2019		Amgen Inc.; Parker B. Francis fellowship	Amgen Inc.(Amgen); Parker B. Francis fellowship	Supported by a grant from Amgen Inc. Z.A. is a recipient of the Parker B. Francis fellowship.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Asosingh K, 2007, J IMMUNOL, V178, P6482, DOI 10.4049/jimmunol.178.10.6482; Baatjes AJ, 2002, PHARMACOL THERAPEUT, V95, P63, DOI 10.1016/S0163-7258(02)00233-4; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; Cancelas JA, 2006, NAT MED, V12, P278, DOI 10.1038/nm0306-278; Chackerian AA, 2007, J IMMUNOL, V179, P2551, DOI 10.4049/jimmunol.179.4.2551; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; Da Silva CA, 2006, FUND CLIN PHARMACOL, V20, P21, DOI 10.1111/j.1472-8206.2005.00390.x; DENBURG JA, 1985, BLOOD, V66, P312; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P573, DOI 10.1164/rccm.200307-1004OC; Godot V, 2007, J ALLERGY CLIN IMMUN, V120, P827, DOI 10.1016/j.jaci.2007.05.046; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Massberg S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047; Mastrandrea F, 1999, J INVEST ALLERG CLIN, V9, P386; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Spiegel A, 2007, NAT IMMUNOL, V8, P1123, DOI 10.1038/ni1509; Von Luttichau I, 2005, STEM CELLS DEV, V14, P329, DOI 10.1089/scd.2005.14.329	31	185	192	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					472	478		10.1016/j.jaci.2008.10.022	http://dx.doi.org/10.1016/j.jaci.2008.10.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19064280				2022-12-18	WOS:000263495000028
J	Zeiger, RS; Szefler, SJ; Phillips, BR; Schatz, M; Martinez, FD; Chinchilli, VM; Lemanske, RF; Strunk, RC; Larsen, G; Spahn, JD; Bacharier, LB; Bloomberg, GR; Guilbert, TW; Heldt, G; Morgan, WJ; Moss, MH; Sorkness, CA; Taussig, LM				Zeiger, RS; Szefler, SJ; Phillips, BR; Schatz, M; Martinez, FD; Chinchilli, VM; Lemanske, RF; Strunk, RC; Larsen, G; Spahn, JD; Bacharier, LB; Bloomberg, GR; Guilbert, TW; Heldt, G; Morgan, WJ; Moss, MH; Sorkness, CA; Taussig, LM		Childhood Asthma Res Educ Network	Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma control days; asthma control outcomes; Asthma Control Questionnaire; exhaled nitric oxide; fluticasone propionate; inhaled corticosteroids; leukotriene receptor antagonists; montelukast; pulmonary response	EXHALED NITRIC-OXIDE; LEUKOTRIENE RECEPTOR ANTAGONIST; INHALED BECLOMETHASONE; IMPULSE OSCILLOMETRY; COMPARATIVE EFFICACY; ORAL MONTELUKAST; END-POINTS; CHILDREN; CORTICOSTEROIDS; VARIABILITY	Background: Outcome data are needed to base recommendations for controller asthma medication use in school-aged children. Objective: We sought to determine intraindividual and interindividual response profiles and predictors of response to an inhaled corticosteroid (ICS) and a leukotriene receptor antagonist (LTRA). Methods: An ICS, fluticasone propionate (100 mu g twice daily), and an LTRA, montelukast (5-10 mg nightly, age dependent), were administered to children ages 6 to 17 years with mild-to-moderate persistent asthma using only as-needed bronchodilators in a multicenter, double-masked, 2-sequence, 16-week crossover trial. Clinical. pulmonary, and inflammatory responses to these controllers were evaluated. Results: Improvements in most clinical asthma control measures occurred with both controllers. However, clinical outcomes (asthma control days [ACDs], the validated Asthma Control Questionnaire, and albuterol use), pulmonary responses (FEV1/forced vital capacity, peak expiratory flow variability, morning peak expiratory flow, and measures of impedance), and inflammatory biomarkers (exhaled nitric oxide [eNO]) improved significantly more with fluticasone than with montelukast treatment. eNO was both a predictor of ACDs (P = .011) and a response indicator (P = .003) in discriminating the difference in ACD response between fluticasone and montelukast. Conclusions: The more favorable clinical, pulmonary, and inflammatory responses to an ICS than to an LTRA provide pediatric-based group evidence to support ICSs as the preferred first-line therapy for mild-to-moderate persistent asthma in children. eNO, as a predictor of response, might help to identify individual children not receiving controller medication who achieve a greater improvement in ACDs with an ICS compared with an LTRA.	Univ Calif San Diego, Dept Pediat, San Diego, CA 92111 USA; Kaiser Permanente, Dept Allergy, San Diego, CA USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA; Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; Univ Wisconsin, Ctr Clin Sci, Madison, WI USA; Washington Univ, Dept Pediat, St Louis, MO 63130 USA	University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Arizona; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)	Zeiger, RS (corresponding author), Univ Calif San Diego, Dept Pediat, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	robert.s.zeiger@kp.org		Guilbert, Theresa/0000-0002-6932-712X; Zeiger, Robert/0000-0001-5788-5063; Bacharier, Leonard/0000-0003-0432-2704	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064307, U10HL064305, U10HL064288, U10HL064295, U10HL064313, U10HL064287] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00036, M01RR00051] Funding Source: Medline; NHLBI NIH HHS [5U10HL064288, 5U10HL064295, 5U10HL064313, 5U10HL064305, 5U10HL064307, 5U10HL064287] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227, DOI 10.1164/ajrccm.160.4.9903004; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Carra S, 2001, RESP MED, V95, P734, DOI 10.1053/rmed.2001.1130; Dempsey OJ, 2002, J ALLERGY CLIN IMMUN, V109, P68, DOI 10.1067/mai.2002.120559; Ducharme FM, 2003, BMJ-BRIT MED J, V326, P621, DOI 10.1136/bmj.326.7390.621; Ducharme Francine M, 2004, Treat Respir Med, V3, P399, DOI 10.2165/00151829-200403060-00006; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; Gershman NH, 2000, EUR RESPIR J, V15, P11, DOI 10.1183/09031936.00.15101100; *GLOB IN ASTHM, 2002, 023659 NIH NHLBI; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kissoon N, 1999, PEDIATR PULM, V28, P282, DOI 10.1002/(SICI)1099-0496(199910)28:4<282::AID-PPUL8>3.0.CO;2-2; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Malmberg LP, 2004, J ASTHMA, V41, P511, DOI 10.1081/JAS-120037652; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Marotta A, 2003, J ALLERGY CLIN IMMUN, V112, P317, DOI 10.1067/mai.2003.1627; Maspero JF, 2001, CURR MED RES OPIN, V17, P96, DOI 10.1185/0300799039117037; Meyer KA, 2003, J ALLERGY CLIN IMMUN, V111, P757, DOI 10.1067/mai.2003.1391; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Ostrom NK, 2005, J PEDIATR-US, V147, P213, DOI 10.1016/j.jpeds.2005.03.052; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Stelmach I, 2002, CLIN EXP ALLERGY, V32, P264, DOI 10.1046/j.1365-2222.2002.01286.x; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P466, DOI 10.1016/j.jaci.2004.12.1113; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; Wilson AM, 2000, AM J RESP CRIT CARE, V162, P1297, DOI 10.1164/ajrccm.162.4.9912046; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	41	185	196	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					45	52		10.1016/j.jaci.2005.10.012	http://dx.doi.org/10.1016/j.jaci.2005.10.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387583				2022-12-18	WOS:000235687100008
J	Perry, TT; Matsui, EC; Conover-Walker, MK; Wood, RA				Perry, TT; Matsui, EC; Conover-Walker, MK; Wood, RA			Risk of oral food challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; oralfbod challenge; risk; severity	IMMEDIATE HYPERSENSITIVITY; IGE CONCENTRATIONS; DOUBLE-BLIND; CHILDREN; PEANUT; PROTEIN; MILK	Background: Oral food challenges are essential to the diagnosis of food allergy; however, little has been reported regarding the risks of performing food challenges in children with suspected food allergy. Objective: To examine the risk and reaction severity of failed oral food challenges. Methods: A retrospective chart review was performed on children who underwent food challenges to milk, egg, peanut, soy, and/or wheat in a university-based pediatric allergy clinic over a 7-year period. Results: Of the 584 challenges completed, 253 (43%) resulted in an allergic reaction. There were 90 milk, 56 egg, 71 peanut, 21 soy, and 15 wheat failed challenges. Of patients who failed, there were 197 (78%) cutaneous, 108 (43%) gastrointestinal, 66 (26%) oral, 67 (26%) lower respiratory, and 62 (25%) upper respiratory reactions. No patients had cardiovascular symptoms. There was no difference between foods in the severity of failed challenges or the type of treatment required to reverse symptoms. All reactions were reversible with shortacting antihistamines epinephrine, beta-agonists, and/or corticosteroids. No children required hospitalization, and there were no deaths. Conclusions: There are risks associated with food challenges, and the risks are similar for each of the foods studied. Given the benefits that result from a negative challenge, these risks are reasonable when challenges are performed under the guidance of an experienced practitioner in a properly equipped setting.	Johns Hopkins Univ, Dept Pediat, Div Allergy Immunol, Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University	Wood, RA (corresponding author), 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593				BOCK SA, 1987, PEDIATRICS, V79, P683; Burks A. Wesley, 1998, Current Opinion in Pediatrics, V10, P588; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	16	185	189	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1164	1168		10.1016/j.jaci.2004.07.063	http://dx.doi.org/10.1016/j.jaci.2004.07.063			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536426				2022-12-18	WOS:000225047800026
J	Martinez-Moczygemba, M; Huston, DP				Martinez-Moczygemba, M; Huston, DP			Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IL-3; IL-5; GM-CSF; beta c; allergic inflammation; asthma; hematopoiesis; cytokine physiology	COLONY-STIMULATING FACTOR; COMPLETE EXTRACELLULAR DOMAIN; N-TERMINAL KINASE; INTERLEUKIN-5 RECEPTOR; DEFICIENT MICE; ALPHA-SUBUNIT; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; NEGATIVE REGULATION; HUMAN EOSINOPHILS	IL-3, IL-5, and GM-CSF are related hematopoietic cytokines that are important for allergic inflammation. The receptors for human IL-5, IL-3, and GM-CSF are members of the hematopoietin receptor superfamily and are comprised of a cytokine-specific a chain and the common beta chain that is shared among these cytokines for signaling. Each of these cytokines contributes to the differentiation and function of leukocyte subpopulations and have clinical importance in protective immunity and in the pathophysiology of a spectrum of immunologic diseases that are as diverse as allergy and asthma, pulmonary alveolar proteinosis, neurodegenerative diseases, and malignancies. Delineating the biology of these cytokines is enabling the development of new strategies for diagnosing and treating these diseases and modulating immune responses.	Baylor Coll Med, Biol Inflammat Ctr, BCM 285, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Immunol Allergy & Rheumatol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Immunol Allergy & Rheumatol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Huston, DP (corresponding author), Baylor Coll Med, Biol Inflammat Ctr, BCM 285, 1 Baylor Plaza, Houston, TX 77030 USA.			Huston, David/0000-0002-2332-0010	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI050686, R01AI036936] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50686, AI 36936] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; APPEL K, 1995, J NEUROSCI, V15, P5800; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ARAUJO DM, 1994, NEUROSCIENCE, V61, P745, DOI 10.1016/0306-4522(94)90398-0; Armitage JO, 1998, BLOOD, V92, P4491, DOI 10.1182/blood.V92.12.4491; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bagley CJ, 2001, INT J HEMATOL, V73, P299, DOI 10.1007/BF02981954; BAIRD PN, 1995, LEUKEMIA LYMPHOMA, V18, P373, DOI 10.3109/10428199509059635; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Bernard F, 2002, BLOOD, V99, P2615, DOI 10.1182/blood.V99.7.2615; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bonfield TL, 2002, CLIN IMMUNOL, V105, P342, DOI 10.1006/clim.2002.5301; Bonfield TL, 2002, AM J RESP CELL MOL, V27, P481, DOI 10.1165/rcmb.2002-0023OC; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; delPeso L, 1997, SCIENCE, V278, P687; Dickason RR, 1996, J MOL MED-JMM, V74, P535; Dickason RR, 1996, J IMMUNOL, V156, P1030; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; Ebner S, 2002, J IMMUNOL, V168, P6199, DOI 10.4049/jimmunol.168.12.6199; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Evans CA, 2002, BLOOD, V100, P3164, DOI 10.1182/blood-2001-12-0235; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gauvreau GM, 1998, AM J RESP CELL MOL, V19, P55, DOI 10.1165/ajrcmb.19.1.2871; Gebhardt T, 2002, EUR J IMMUNOL, V32, P2308, DOI 10.1002/1521-4141(200208)32:8<2308::AID-IMMU2308>3.0.CO;2-X; GEBICKEHAERTER PJ, 1994, J NEUROSCI RES, V38, P32, DOI 10.1002/jnr.490380106; Geijsen N, 2001, CYTOKINE GROWTH F R, V12, P19, DOI 10.1016/S1359-6101(00)00019-8; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; Gustin SE, 2001, EUR J BIOCHEM, V268, P2905, DOI 10.1046/j.1432-1327.2001.02178.x; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Herbert DR, 2000, J IMMUNOL, V165, P4544, DOI 10.4049/jimmunol.165.8.4544; HU XT, 1994, BBA-MOL CELL RES, V1223, P306, DOI 10.1016/0167-4889(94)90241-0; HUANG JC, 2003, THERAPEUTIC TARGETS, P495; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LEE TT, 1993, GLIA, V8, P51, DOI 10.1002/glia.440080107; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu R, 1997, BIOCHEM BIOPH RES CO, V234, P611, DOI 10.1006/bbrc.1997.6643; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; Martinez-Moczygemba M, 2001, J CLIN INVEST, V108, P1797, DOI 10.1172/JCI13877; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Munoz L, 2001, HAEMATOLOGICA, V86, P1261; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NICOLA NA, 1994, GUIDEBOOK CYTOKINES, P171; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; Ogata M, 1998, AM J HEMATOL, V59, P242, DOI 10.1002/(SICI)1096-8652(199811)59:3<242::AID-AJH11>3.3.CO;2-F; OSHEA JJ, 2001, CLIN IMMUNOLOGY PRIN; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; Robertson SA, 2000, J REPROD FERTIL, V120, P423, DOI 10.1530/reprod/120.2.423; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Scott CL, 1999, INT J BIOCHEM CELL B, V31, P1011, DOI 10.1016/S1357-2725(99)00077-1; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sferruzzi-Perri AN, 2003, BIOL REPROD, V69, P224, DOI 10.1095/biolreprod.102.010611; Shardonofsky FR, 1999, J ALLERGY CLIN IMMUN, V104, P215, DOI 10.1016/S0091-6749(99)70138-7; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stomski FC, 1999, BLOOD, V94, P1933; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Strobl H, 2003, INT ARCH ALLERGY IMM, V131, P73, DOI 10.1159/000070921; Szabolcs P, 2003, STEM CELLS, V21, P296, DOI 10.1634/stemcells.21-3-296; TAKATSU K, 1997, GROW FACT CYTOK  A&B, V2, P143; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Testa U, 2002, BLOOD, V100, P2980, DOI 10.1182/blood-2002-03-0852; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Vallance BA, 2000, PARASITE IMMUNOL, V22, P487, DOI 10.1046/j.1365-3024.2000.00328.x; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALSH GM, 1990, IMMUNOLOGY, V71, P258; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Welker P, 2001, ARCH DERMATOL RES, V293, P249, DOI 10.1007/s004030100225; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Yamada K, 1997, BLOOD, V90, P4832, DOI 10.1182/blood.V90.12.4832.4832_4832_4841; Yamada T, 1998, J ALLERGY CLIN IMMUN, V101, P677, DOI 10.1016/S0091-6749(98)70177-0; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng XY, 2002, IMMUNOLOGY, V107, P306, DOI 10.1046/j.1365-2567.2002.01517.x; Zuberbier T, 2001, BRIT J DERMATOL, V145, P661, DOI 10.1046/j.1365-2133.2001.04435.x	117	185	194	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					653	665		10.1067/mai.2003.1796	http://dx.doi.org/10.1067/mai.2003.1796			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564341				2022-12-18	WOS:000185831200002
J	Ono, SJ; Nakamura, T; Miyazaki, D; Ohbayashi, M; Dawson, M; Toda, M				Ono, SJ; Nakamura, T; Miyazaki, D; Ohbayashi, M; Dawson, M; Toda, M			Chemokines: Roles in leukocyte development, trafficking, and effector function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chemokines; receptors; allergy; asthma; signal transduction	HUMAN MAST-CELLS; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; EOTAXIN RECEPTOR CCR3; CD4(+) T-CELLS; FC-EPSILON-RI; LATE-PHASE; AIRWAY INFLAMMATION; SURFACE EXPRESSION; GENE-EXPRESSION; ACTIVATION	Chemokines, representing a large superfamily of 8- to 15-kd proteins, were originally discovered through their ability to recruit various cell types into sites of inflammation. It is now clear that these molecules play a much wider role in immune homeostasis, playing key roles in driving the maturation, homing, and activation of leukocytes. In this review we analyze the roles chemokines play in the development, recruitment, and activation of leukocytes. Because signaling from the receptors drives these processes, signal transduction from chemokine receptors will also be reviewed. Taken together, we highlight the various points at which chemokines contribute to allergic inflammation and at which their targeting might contribute to new therapies for type I hypersensitivity reactions.	UCL, Univ London, Inst Ophthalmol, Dept Immunol, London EC1V 9EL, England; UCL, Univ London, Inst Child Hlth, Dept Immunol, London EC1V 9EL, England; Moorfields Eye Hosp, London, England	University of London; University College London; University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Ono, SJ (corresponding author), UCL, Univ London, Inst Ophthalmol, Dept Immunol, 11-43 Bath St, London EC1V 9EL, England.		Toda, Masako/S-9810-2019					AGRAWAL L, 2003, EXPERT OPIN INV DRUG, V12, P185; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alexander JM, 2002, CELL, V111, P343, DOI 10.1016/S0092-8674(02)01007-3; Anders HJ, 2002, J CLIN INVEST, V109, P251, DOI 10.1172/JCI14040; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barnes PJ, 2001, NOVART FDN SYMP, V234, P255; Beil WJ, 2000, HISTOL HISTOPATHOL, V15, P937, DOI 10.14670/HH-15.937; Bertrand CP, 2000, EXPERT OPIN INV DRUG, V9, P43, DOI 10.1517/13543784.9.1.43; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Brown V, 2003, THORAX, V58, P311, DOI 10.1136/thorax.58.4.311; Campbell JD, 2002, INT IMMUNOL, V14, P1255, DOI 10.1093/intimm/dxf098; Carollo M, 2001, BRIT J PHARMACOL, V134, P1166, DOI 10.1038/sj.bjp.0704371; CHAPOVAL SP, 2001, J ALLERGY CLIN IMMUN, V168, P245; Clemetson KJ, 2000, BLOOD, V96, P4046; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Cosmi L, 2001, INT ARCH ALLERGY IMM, V125, P273, DOI 10.1159/000053827; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Curnock AP, 2003, J IMMUNOL METHODS, V273, P29, DOI 10.1016/S0022-1759(02)00416-7; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Paulis A, 2000, J IMMUNOL, V165, P7171, DOI 10.4049/jimmunol.165.12.7171; Dombrowicz D, 2000, J IMMUNOL, V165, P1266, DOI 10.4049/jimmunol.165.3.1266; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd1034; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Furue M, 2003, BRIT J DERMATOL, V148, P128, DOI 10.1046/j.1365-2133.2003.04934.x; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guo J, 2003, ARTERIOSCL THROM VAS, V23, P447, DOI 10.1161/01.ATV.0000058431.78833.F5; Gurish MF, 2002, J IMMUNOL, V168, P5730, DOI 10.4049/jimmunol.168.11.5730; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Han KH, 1999, J BIOL CHEM, V274, P32055, DOI 10.1074/jbc.274.45.32055; HANDY RLC, 2002, P INT S OC IMM INFL, P18; Hirata H, 2003, J CLIN IMMUNOL, V23, P34, DOI 10.1023/A:1021948214742; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Inamura H, 2002, INT ARCH ALLERGY IMM, V128, P142, DOI 10.1159/000059405; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; JUREMALM M, 2001, J ALLERGY CLIN IMMUN, V50, P168; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Khan IA, 2001, J IMMUNOL, V166, P1930, DOI 10.4049/jimmunol.166.3.1930; Kim Y, 2001, J IMMUNOL, V166, P5183, DOI 10.4049/jimmunol.166.8.5183; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Lahn M, 2002, P NATL ACAD SCI USA, V99, P8850, DOI 10.1073/pnas.132519299; Lang K, 2003, SCAND J IMMUNOL, V57, P350, DOI 10.1046/j.1365-3083.2003.01247.x; Langenkamp A, 2003, EUR J IMMUNOL, V33, P474, DOI 10.1002/immu.200310023; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEPIDI H, 1995, J CELL SCI, V108, P1771; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Lewis DB, 2002, CURR OPIN IMMUNOL, V14, P644, DOI 10.1016/S0952-7915(02)00388-6; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Lippert U, 1998, J IMMUNOL, V161, P2600; Liu ZJ, 2001, P NATL ACAD SCI USA, V98, P7289, DOI 10.1073/pnas.121171998; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Mariani M, 2003, J IMMUNOL METHODS, V273, P103, DOI 10.1016/S0022-1759(02)00503-3; Marone G, 2001, INT ARCH ALLERGY IMM, V125, P89, DOI 10.1159/000053802; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Miyazaki D, 2000, INVEST OPHTH VIS SCI, V41, P3850; Miyazaki D, 1999, INVEST OPHTH VIS SCI, V40, pS687; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Nardelli B, 1999, J IMMUNOL, V162, P435; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Ohkubo Kimihiro, 1998, Rhinology (Utrecht), V36, P156; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Oliveira SHP, 2001, INFLAMM RES, V50, P168, DOI 10.1007/s000110050741; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Ono SJ, 2003, CLIN EXP ALLERGY, V33, P279, DOI 10.1046/j.1365-2745.2003.01616.x; Osbourn JK, 1998, NAT BIOTECHNOL, V16, P778, DOI 10.1038/nbt0898-778; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; Pinco KA, 2002, MOL BIOL CELL, V13, P3203, DOI 10.1091/mbc.02-05-0086; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Pribila JT, 2003, IMMUNOL RES, V27, P107, DOI 10.1385/IR:27:1:107; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Proudfoot AEI, 2003, SEMIN IMMUNOL, V15, P57, DOI 10.1016/S1044-5323(02)00128-8; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Root Allen W., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P27, DOI 10.2174/1568008024606293; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Salazar-Mather TP, 2002, J CLIN INVEST, V110, P321, DOI 10.1172/JCI200215376; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; SAYAMA K, 2002, BMC IMMUNOL, V3, P1; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Schier AF, 2003, CURR BIOL, V13, pR192, DOI 10.1016/S0960-9822(03)00122-2; Schuh JM, 2002, J IMMUNOL, V168, P1447, DOI 10.4049/jimmunol.168.3.1447; Schultz A, 2003, CURR OPIN ALLERGY CL, V3, P21, DOI 10.1097/01.all.0000053263.39029.e8; Senechal S, 2002, LAB INVEST, V82, P929, DOI 10.1097/01.LAB.0000020417.13757.05; Shapiro SD, 2003, NATURE, V421, P223, DOI 10.1038/421223a; Shlomchik, 2002, IMMUNOBIOLOGY; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Toda M, 2002, IMMUNOLOGY, V106, P1, DOI 10.1046/j.1365-2567.2002.01407.x; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Vulcano M, 2003, J IMMUNOL, V170, P3843, DOI 10.4049/jimmunol.170.7.3843; Wakahara S, 2001, CYTOKINE, V16, P143, DOI 10.1006/cyto.2001.0958; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Woo CH, 2002, BIOCHEM BIOPH RES CO, V298, P392, DOI 10.1016/S0006-291X(02)02432-4; Wuyts A, 2003, LAB INVEST, V83, P23, DOI 10.1097/01.LAB.0000048719.53282.00; Yano K, 1997, LAB INVEST, V77, P185; Ying S, 2001, CLIN EXP ALLERGY, V31, P1724, DOI 10.1046/j.1365-2222.2001.01232.x; Youn BS, 2001, BIOCHEM BIOPH RES CO, V281, P627, DOI 10.1006/bbrc.2001.4393; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139; Zingoni A, 1998, J IMMUNOL, V161, P547	129	185	191	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1185	1199		10.1067/mai.2003.1594	http://dx.doi.org/10.1067/mai.2003.1594			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789214				2022-12-18	WOS:000183424700002
J	Leung, DYM				Leung, DYM			Pathogenesis of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NY			atopic dermatitis; allergies; cytokines; skin; T cells	EPIDERMAL LANGERHANS CELLS; COLONY-STIMULATING FACTOR; IN-VIVO EXPRESSION; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; STAPHYLOCOCCUS-AUREUS; GENE-EXPRESSION; T-CELLS; CONTACT SENSITIVITY; ADHESION MOLECULE-1	Atopic dermatitis (AD) is a common inflammatory skin disease with increasing prevalence since World War II, Recent studies have shed light on how the complex interrelation of genetic, environmental, immunologic, and pharmacologic factors contributes to the development of AD. The current review will examine the cellular and immunologic mechanisms underlying AD as well as the potential role of microbial superantigens in the pathogenesis of AD. An understanding of the relative contributions of allergens, IgE, T cells with skin homing capability, Langerhans cells, keratinocytes, eosinophils, and mast cells to the inflammatory process in AD may lead to improved treatments for this potentially debilitating disease.	Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, 1400 Jackson St,Room K926, Denver, CO 80206 USA.	leungd@njc.org			NHLBI NIH HHS [HL37260, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, P01HL036577, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; Akdis M, 1997, J IMMUNOL, V159, P4611; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BACK O, 1995, ARCH DERMATOL RES, V287, P448, DOI 10.1007/BF00373427; Bieber T, 1998, J ALLERGY CLIN IMMUN, V102, P555, DOI 10.1016/S0091-6749(98)70270-2; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; CHAN SC, 1993, J IMMUNOL, V151, P3345; CHAN SC, 1993, J LAB CLIN MED, V121, P44; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; ENGMAN MF, 1936, MED CLIN N AM, V20, P651; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hauk PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS236; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; HILL LW, 1933, YB DERMATOLOGY SYPHI; Hofer MF, 1998, J ALLERGY CLIN IMMUN, V101, P96, DOI 10.1016/S0091-6749(98)70199-X; Jirapongsananuruk O, 1998, J IMMUNOL, V160, P4622; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; Klubal R, 1997, J INVEST DERMATOL, V108, P336, DOI 10.1111/1523-1747.ep12286482; Kolmer HL, 1996, J ALLERGY CLIN IMMUN, V98, P702, DOI 10.1016/S0091-6749(96)70106-9; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kupper T S, 1988, Adv Dermatol, V3, P293; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Leung DYM, 1993, DERMATOLOGY GEN MED, P1543; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; NASSIF A, 1994, ARCH DERMATOL, V130, P1402, DOI 10.1001/archderm.130.11.1402; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Nissen D, 1997, ANN ALLERG ASTHMA IM, V79, P403, DOI 10.1016/S1081-1206(10)63033-5; OHMEN JD, 1995, J IMMUNOL, V154, P1956; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; RAJKA G, 1968, ACTA DERM-VENEREOL, V48, P320; Rattis FM, 1996, EUR J IMMUNOL, V26, P449, DOI 10.1002/eji.1830260227; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROKUGO M, 1990, ARCH DERMATOL, V126, P627, DOI 10.1001/archderm.126.5.627; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SAURAT JH, 1985, ACTA DERM-VENEREOL, P125; SAWAI T, 1995, BRIT J DERMATOL, V132, P22, DOI 10.1111/j.1365-2133.1995.tb08619.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Taha RA, 1998, J ALLERGY CLIN IMMUN, V102, P245, DOI 10.1016/S0091-6749(98)70093-4; TAHA RA, 1998, J ALLERGY CLIN IMMUN, V101, pA946; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VERCELLI D, 1990, J IMMUNOL, V144, P570; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x	93	185	221	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S99	S108		10.1016/S0091-6749(99)70051-5	http://dx.doi.org/10.1016/S0091-6749(99)70051-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	242FP	10482860				2022-12-18	WOS:000082928500003
J	Juniper, EF; Howland, WC; Roberts, NB; Thompson, AK; King, DR				Juniper, EF; Howland, WC; Roberts, NB; Thompson, AK; King, DR			Measuring quality of life in children with rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; rhinoconjunctivitis; pediatrics	OF-LIFE; CLINICAL-TRIALS; HEALTH-STATUS; QUESTIONNAIRE; ASTHMA	Objective: The objective of this study was to develop, pretest, and validate a questionnaire to measure quality of life in children with seasonal allergic rhinoconjunctivitis (SAR). Methods (development study): Thirty-four children with SAR were enrolled from summer camps, notices in the media, and an allergy clinic (Southern Ontario). After generating a pool of 48 potentially important quality of life items, the children identified the ones that they experienced with their SAR and scored each for bother (1 = a little bothered to 4 = extremely bothered). Items identified most frequently and with the highest bother score were included in the Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ). The PRQLQ was pretested for ease completion and accuracy of understanding. Results (development study): The PRQLQ has 23 items in five domains (nose symptoms, eye symptoms, practical problems, other symptoms, and activities). Responses are given on a seven-point scale, and children are asked to score their experiences during the previous 7 days. Methods (validation study): Seventy-five children with symptomatic SAR mere enrolled from notices in the media and a pediatric allergy clinic (Austin, Tex.). A single cohort design was used, with children assessed at 0, 1, and 3 weeks. The PRQLQ was administered to the children by a trained interviewer at 1 and 3 weeks. A conventional nasal symptom daily diary was completed for 1 week before each of these clinic visits. Global ratings were completed at the final visit. Results (validation study): In patients who were stable between clinic visits, the PRQLQ demonstrated good reliability (intraclass correlation coefficient = 0.93). The questionnaire was very responsive to change (p < 0.001) and was able to differentiate between patients who were in a stable clinical state and those whose clinical state changed between visits (p = 0.005). Correlations between the PRQLQ and diary scores were close to predicted and supported both the cross-sectional and longitudinal validity of the PRQLQ. Conclusions: The PRQLQ measures the quality of life impairments important to children with SAR. Children provide reliable and accurate responses, the measurement properties are strong, and the questionnaire can be used with confidence in clinical trials, clinical practice, and surveys.	McMaster Univ, Fac Hlth Sci, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Healthquest Therapy & Res Inst Inc, Austin, TX USA; Hoechst Marion Roussel Inc, Hlth Outcomes Res, Kansas City, MO USA	McMaster University	Juniper, EF (corresponding author), McMaster Univ, Fac Hlth Sci, Med Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; FLEISS LJ, 1981, STAT METHODS RATES P, P222; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Juniper EF, 1997, EUR RESPIR J, V10, P2285, DOI 10.1183/09031936.97.10102285; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; ROSENBAUM PL, 1996, QUALITY LIFE PHARMAC, P785	11	185	207	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				163	170		10.1016/S0091-6749(98)70380-X	http://dx.doi.org/10.1016/S0091-6749(98)70380-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500748	Bronze			2022-12-18	WOS:000072244800004
J	PEDERSEN, S; HANSEN, OR				PEDERSEN, S; HANSEN, OR			BUDESONIDE TREATMENT OF MODERATE AND SEVERE ASTHMA IN CHILDREN - A DOSE-RESPONSE STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; CHILDREN; CORTICOSTEROIDS; DOSE-RESPONSE; EXERCISE-INDUCED ASTHMA		Objective: The purpose of the study was to evaluate the dose-response relationships of the inhaled corticosteroid budesonide in a double blind crossover study in 19 children with moderate and severe asthma. Methods: A 2-week placebo treatment period (run-in) was followed by three 4-week treatment periods during which 100, 200, and 400 mu g of budesonide were given per day in randomized order. Urinary cortisol excretion, lung functions, and protection against exercise-induced asthma were assessed at the end of run-in and each treatment period. Furthermore, morning and evening peak expiratory pow rates, day and night symptoms, and use of rescue beta(2)-agonists were recorded throughout the study. Results: One hundred micrograms of budesonide per day markedly improved symptoms, morning and evening peak expiratory pow rates, and use of rescue beta(2)-agonists (p < 0.01). No further improvement was seen in these parameters with increasing doses of budesonide. In contrast, a significant dose-response effect was found on lung functions measured at the hospital and fall in lung functions after exercise (p < 0.001); 200 mu g was significantly better than 100 mu g, and 400 mu g was significantly better than 200 mu g. About 53% of the maximum effect against exercise-induced asthma was achieved by the lowest budesonide dose (p < 0.001), and about 83% by the highest dose. No significant differences were seen in urinary cortisol excretion between run-in and the various budesonide doses. Conclusions: Low doses of budesonide, which are not associated with any systemic side effects, have a marked antiasthma effect in children. Protection against exercise-induced asthma requires higher doses than achievement of symptom control.			PEDERSEN, S (corresponding author), KOLDING CTY HOSP,DEPT PEDIAT,DK-6000 KOLDING,DENMARK.							BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1993, AM REV RESPIR DIS, V148, P1; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HENRIKSEN JM, 1986, ALLERGY, V41, P499, DOI 10.1111/j.1398-9995.1986.tb00335.x; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; Pedersen S., 1994, EUR RESPIR REV, V4, P33	8	185	193	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				29	33		10.1016/S0091-6749(95)70149-4	http://dx.doi.org/10.1016/S0091-6749(95)70149-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822661				2022-12-18	WOS:A1995QC31200005
J	HANIFIN, JM				HANIFIN, JM			ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											HANIFIN, JM (corresponding author), OREGON HLTH SCI UNIV, SCH MED, DEPT DERMATOL, PORTLAND, OR 97201 USA.							ABRAMSON JS, 1982, J AM ACAD DERMATOL, V7, P105, DOI 10.1016/S0190-9622(82)80017-0; ALY R, 1980, ACTA DERM-VENEREOL, P16; ATHERTON DJ, 1978, LANCET, V1, P401; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BERRENS L, 1980, ACTA DERM-VENEREOL, P106; BESNIER E, 1892, ANN DERMATOL SYPHIL, V3, P634; BLUMENTHAL MN, 1980, J ALLERGY CLIN IMMUN, V65, P403, DOI 10.1016/0091-6749(80)90231-6; BRASHER GW, 1971, ANN ALLERGY, V29, P422; BROCQ L, 1902, PRATIQUE DERMATOLOGI, V3, P158; BROSTOFF J, 1977, LANCET, V2, P741; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; BYROM NA, 1979, BRIT J DERMATOL, V100, P499, DOI 10.1111/j.1365-2133.1979.tb05575.x; CARR RH, 1973, J ALLERGY CLIN IMMUN, V51, P255, DOI 10.1016/0091-6749(73)90127-9; CHAI H, 1976, J ALLERGY CLIN IMMUN, V58, P308; CHAMPION RH, 1971, BRIT J DERMATOL, V85, P551, DOI 10.1111/j.1365-2133.1971.tb14081.x; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; COOPER KD, 1983, J INVEST DERMATOL, V80, P139, DOI 10.1111/1523-1747.ep12533078; COOPER KD, 1982, CLIN RES, V30, pA580; CRONIN E, 1970, ACTA DERM-VENEREOL, V50, P183; CURRIE JM, 1971, CUTIS, V8, P244; DEWECK AL, 1977, HLA ALLERGY; Ebbecke U, 1917, PFLUG ARCH GES PHYS, V169, P1, DOI 10.1007/BF01681264; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P1424, DOI 10.1001/archderm.115.12.1424; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; ELLISTON WL, 1982, ARCH DERMATOL, V118, P26, DOI 10.1001/archderm.118.1.26; Feinberg SM, 1939, ARCH DERMATOL SYPH, V40, P200, DOI 10.1001/archderm.1939.01490020027004; FISER PM, 1979, J IMMUNOL, V123, P1788; FRITZ KA, 1980, J AM ACAD DERMATOL, V3, P167, DOI 10.1016/S0190-9622(80)80255-6; GALANT SP, 1979, J INVEST DERMATOL, V72, P330, DOI 10.1111/1523-1747.ep12531768; GRAHAM DT, 1953, J LAB CLIN MED, V42, P238; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; GUREVITCH AW, 1973, ARCH DERMATOL, V107, P712, DOI 10.1001/archderm.107.5.712; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HAMMAR H, 1977, ACTA DERM-VENEREOL, V57, P159; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P52; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HANIFIN JM, 1974, BRIT J DERMATOL, V90, P1, DOI 10.1111/j.1365-2133.1974.tb06355.x; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HESKEL N, 1983, CLIN RES, V31, pA573; HILL HR, 1974, LANCET, V1, P183; HIRSHMAN CA, 1980, J APPL PHYSIOL, V49, P953, DOI 10.1152/jappl.1980.49.6.953; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HOLLA SWJ, 1972, BRIT J DERMATOL, V86, P147, DOI 10.1111/j.1365-2133.1972.tb16077.x; HORSMANHEIMO M, 1979, J INVEST DERMATOL, V72, P128, DOI 10.1111/1523-1747.ep12530530; HOVMARK A, 1977, ACTA DERM-VENEREOL, V57, P237; INGRAM JT, 1955, BRIT J DERMATOL, V67, P43, DOI 10.1111/j.1365-2133.1955.tb12685.x; ISHIZAKA T, 1973, MECHANISMS ALLERGY, P221; JACKSON PG, 1981, LANCET, V1, P1285; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JOHNSON MT, 1977, 4 NAT CTR HLTH STAT; JONES HE, 1973, ARCH DERMATOL, V108, P61, DOI 10.1001/archderm.108.1.61; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; JUHLIN L, 1967, ACTA DERM-VENEREOL, V47, P255; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KANG K, 1983, J AM ACAD DERMATOL, V8, P372, DOI 10.1016/S0190-9622(83)70042-3; KANG K, 1983, SEMIN DERMATOL, V2, P20; Kaposi M, 1895, PATHOLOGY TREATMENT; KAUFMAN HS, 1968, J ALLERGY, V42, P1, DOI 10.1016/0021-8707(68)90126-3; KAUFMAN HS, 1970, LANCET, V2, P1061; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KRAGBALLE K, 1981, ACTA DERM-VENEREOL, V61, P11; KRAMER MS, 1981, J PEDIATR-US, V98, P546, DOI 10.1016/S0022-3476(81)80757-3; LEBEL B, 1980, ACTA DERM-VENEREOL, P57; LEUNG DYM, 1983, CLIN RES, V31, pA164; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; LEVI L., 1959, ACTA ALLERGOL, V13, P332, DOI 10.1111/j.1398-9995.1959.tb02779.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; LUCKASEN JR, 1974, ARCH DERMATOL, V110, P375, DOI 10.1001/archderm.110.3.375; MATTHEW DJ, 1977, LANCET, V1, P321; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MIKHAIL GR, 1964, J INVEST DERMATOL, V43, P249, DOI 10.1038/jid.1964.152; MITCHELL EB, 1982, LANCET, V1, P127; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OHMAN S, 1974, ACTA DERM-VENEREOL, V54, P283; OHMAN S, 1974, ACTA DERM-VENEREOL, V54, P193; OLOUGHLIN S, 1977, ARCH DERMATOL, V113, P309; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PETERSEN HO, 1979, ARCH DERMATOL RES, V264, P193, DOI 10.1007/BF00431131; PETERSON RD, 1962, J ALLERGY, V33, P406, DOI 10.1016/0021-8707(62)90045-X; PROSE PH, 1960, J INVEST DERMATOL, V34, P149, DOI 10.1038/jid.1960.21; RACHELEFSKY GS, 1976, J ALLERGY CLIN IMMUN, V57, P569, DOI 10.1016/0091-6749(76)90008-7; RAJKA G, 1960, Acta Derm Venereol, V40, P285; RAJKA G, 1974, ACTA DERM-VENEREOL, V54, P193; Rajka G, 1975, ATOPIC DERMATITIS; RAJKA G, 1963, ACTA DERM-VENEREOL, V13, P54; RAMSAY C, 1969, BRIT J DERMATOL, V81, P37, DOI 10.1111/j.1365-2133.1969.tb15917.x; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; REED WB, 1958, ARCH DERMATOL, V77, P91, DOI 10.1001/archderm.1958.01560010093012; RING J, 1978, BRIT J DERMATOL, V99, P495, DOI 10.1111/j.1365-2133.1978.tb02016.x; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; Rostenberg A, 1937, ARCH DERMATOL SYPH, V35, P433, DOI 10.1001/archderm.1937.01470210059006; ROTH HL, 1964, ARCH DERMATOL, V89, P209, DOI 10.1001/archderm.1964.01590260047008; RUOHO AE, 1980, J ALLERGY CLIN IMMUN, V66, P46, DOI 10.1016/0091-6749(80)90137-2; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P129, DOI 10.1016/0091-6749(83)90285-3; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SCHUSTER DL, 1976, J IMMUNOL, V117, P2171; SCHWARTZMAN RM, 1983, INT ARCH ALLER A IMM, V72, P97, DOI 10.1159/000234849; SECHER L, 1978, ACTA DERM-VENEREOL, V58, P117; SHMUNES E, 1983, J AM ACAD DERMATOL, V9, P861, DOI 10.1016/S0190-9622(83)70199-4; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; SOLOMON LM, 1966, CAN MED ASSOC J, V95, P978; STORCK H, 1960, DERMATOLOGICA, V121, P150; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAYLOR B, 1973, LANCET, V2, P111; THESTRUPPEDERSEN K, 1977, CLIN EXP IMMUNOL, V27, P118; THUNE P, 1980, ACTA DERM-VENEREOL, P30; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; TURNER KJ, 1981, CLIN EXP IMMUNOL, V43, P458; UEHARA M, 1978, ARCH DERMATOL, V114, P1097; UEHARA M, 1977, ARCH DERMATOL, V113, P627, DOI 10.1001/archderm.113.5.627; UEHARA M, 1976, ARCH DERMATOL, V112, P951, DOI 10.1001/archderm.112.7.951; UNO H, 1980, J INVEST DERMATOL, V75, P52, DOI 10.1111/1523-1747.ep12521130; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; VICKERS CFH, 1980, ACTA DERM-VENEREOL, P113; WALKER RB, 1956, BRIT J DERMATOL, V68, P182, DOI 10.1111/j.1365-2133.1956.tb12805.x; WHITE CR, 1983, SEMIN DERMATOL, V2, P34; Whitfield A, 1938, BRIT J DERMATOL SYPH, V50, P71, DOI 10.1111/j.1365-2133.1938.tb10475.x; Williams DH, 1938, J INVEST DERMATOL, V1, P119; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; WISE F, 1933, YB DERMATOLOGY SYPHI, P59	141	185	185	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					211	222		10.1016/S0091-6749(84)80008-1	http://dx.doi.org/10.1016/S0091-6749(84)80008-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6321581				2022-12-18	WOS:A1984SF02000001
J	GOLDEN, DBK; MEYERS, DA; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; MEYERS, DA; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			CLINICAL RELEVANCE OF THE VENOM-SPECIFIC IMMUNOGLOBULIN-G ANTIBODY LEVEL DURING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; FRANKLAND AW, 1954, LANCET, V1, P1055; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1981, 37TH P ANN M AM AC A, P57; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LOCKEY R, 1981, 37TH P ANN M AM AC A, P56; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PARKER JL, 1980, J ALLERGY CLIN IMMUN, V65, P198; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	27	185	189	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					489	493		10.1016/0091-6749(82)90172-5	http://dx.doi.org/10.1016/0091-6749(82)90172-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076990				2022-12-18	WOS:A1982NT02500003
J	Kiel, MA; Roder, E; van Wijk, RG; Al, MJ; Hop, WCJ; Rutten-van Molken, MPMH				Kiel, Menno A.; Roder, Esther; van Wijk, Roy Gerth; Al, Maiwenn J.; Hop, Wim C. J.; Rutten-van Molken, Maureen P. M. H.			Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; specific allergen immunotherapy; subcutaneous; sublingual; subcutaneous allergen immunotherapy; sublingual allergen immunotherapy; persistence; compliance; adherence; cost	TERM CLINICAL-EFFICACY; QUANTITATIVE ASSESSMENT; SLIT FORMULATION; EASY PROJECT; RHINITIS; ADHERENCE; ASTHMA; MEDICATION; CHILDREN; IMPACT	Background: Subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) are safe and effective treatments of allergic rhinitis, but high levels of compliance and persistence are crucial to achieving the desired clinical effects. Objective: Our objective was to assess levels and predictors of compliance and persistence among grass pollen, tree pollen, and house dust mite immunotherapy users in real life and to estimate the costs of premature discontinuation. Methods: We performed a retrospective analysis of a community pharmacy database from The Netherlands containing data from 6486 patients starting immunotherapy for 1 or more of the allergens of interest between 1994 and 2009. Two thousand seven hundred ninety-six patients received SCIT, and 3690 received SLIT. Time to treatment discontinuation was analyzed and included Cox proportional hazard models with time-dependent covariates, where appropriate. Results: Overall, only 18% of users reached the minimally required duration of treatment of 3 years (SCIT, 23%; SLIT, 7%). Median durations for SCIT and SLIT users were 1.7 and 0.6 years, respectively (P < .001). Other independent predictors of premature discontinuation were prescriber, with patients of general practitioners demonstrating longer persistence than those of allergologists and other medical specialists; single-allergen immunotherapy, lower socioeconomic status; and younger age. Of the persistent patients, 56% were never late in picking up their medication from the pharmacy. Direct medication costs per nonpersistent patient discontinuing in the third year of treatment were (sic)3800, an amount that was largely misspent. Conclusion: Real-life persistence is better in SCIT users than in SLIT users, although it is low overall. There is an urgent need for further identification of potential barriers and measures that will enhance persistence and compliance.	[Kiel, Menno A.; Al, Maiwenn J.; Rutten-van Molken, Maureen P. M. H.] Erasmus Univ, Inst Med Technol Assessment, Dept Hlth Econ iMTA, NL-3000 DR Rotterdam, Netherlands; [Kiel, Menno A.; Roder, Esther; van Wijk, Roy Gerth] Erasmus MC Univ Med Ctr, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands; [Hop, Wim C. J.] Erasmus MC Univ Med Ctr, Dept Biostat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Kiel, MA (corresponding author), Inst Med Technol Assessment iMTA, Dept Hlth Econ, Rm W-J5-69,50 Burg Oudlaan,POB 1738, NL-3000 DR Rotterdam, Netherlands.	kiel@bmg.eur.nl	Al, Maiwenn J/E-3272-2014; Molken, Maureen Rutten-van/X-8712-2019; Molken, Maureen PMH Rutten-van/G-8481-2014	Al, Maiwenn J/0000-0001-9763-0436; Molken, Maureen Rutten-van/0000-0001-8706-3159; Molken, Maureen PMH Rutten-van/0000-0001-8706-3159; Kiel, Menno/0000-0002-5440-2123	ZonMw (NWO); ALK-Abello; GlaxoSmithKline; HAL; Meda Pharma; Novartis; Phadia; Stallergenes; Allergopharma	ZonMw (NWO)(Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development); ALK-Abello; GlaxoSmithKline(GlaxoSmithKline); HAL(Horticulture Australia Limited); Meda Pharma; Novartis(Novartis); Phadia(Phadia); Stallergenes; Allergopharma	E. Roder has received research support from ZonMw (NWO), and her thesis was financially supported by ALK-Abello, GlaxoSmithKline, HAL, Meda Pharma, Novartis, Phadia, and Stallergenes. R. Gerth van Wijk has received consultancy fees from Allergopharma, has received research support from ZonMw (NWO), and has participated in European Academy of Allergology and Clinical Immunology immunotherapy task forces. The rest of the authors declare they have no relevant conflicts of interest.	Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Calderon MA, 2010, EVID BASED CHILD HLT, V5, P1279; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; de Bot CMA, 2012, PEDIAT ALLERG IMM-UK, V23, P151, DOI 10.1111/j.1399-3038.2011.01219.x; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339, DOI 10.1016/S1081-1206(10)63282-6; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Hakkaart-van Roijen L, 2010, HANDLEIDING KOSTENON; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Herings R., 2012, PHARMACOEPIDEM DR S, P270, DOI [10.1002/9781119959946.ch18, DOI 10.1002/9781119959946.CH18]; Incorvaia Cristoforo, 2008, Patient Prefer Adherence, V2, P247; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Passalacqua G, 2007, PEDIAT ALLERG IMM-UK, V18, P58, DOI 10.1111/j.1399-3038.2006.00471.x; Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312; Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524-4733.2006.00139.x; PHARMO, PHARMO I HOM COMM PH; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Sachs A, 2009, NHG STANDAARDEN HUIS, P980; Senna G, 2009, CURR OPIN ALLERGY CL, V9, P544, DOI 10.1097/ACI.0b013e328332b8df; Sieber J, 2011, CURR MED RES OPIN, V27, P855, DOI 10.1185/03007995.2011.559538; Sociaal & Cultureel Planbureau (SCP), RANG NAAR SOC STAT P, P20133; TINKELMAN D, 1995, ANN ALLERG ASTHMA IM, V74, P241; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Vita D, 2010, ALLERGY, V65, P668, DOI 10.1111/j.1398-9995.2009.02223.x	27	184	192	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					353	+		10.1016/j.jaci.2013.03.013	http://dx.doi.org/10.1016/j.jaci.2013.03.013			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23651609				2022-12-18	WOS:000322631700012
J	Kelso, JM; Greenhawt, MJ; Li, JT; Nicklas, RA; Bernstein, DI; Blessing-Moore, J; Cox, L; Khan, D; Lang, DM; Oppenheimer, J; Portnoy, JM; Randolph, CR; Schuller, DE; Spector, SL; Tilles, SA; Wallace, D				Kelso, John M.; Greenhawt, Matthew J.; Li, James T.; Nicklas, Richard A.; Bernstein, David I.; Blessing-Moore, Joann; Cox, Linda; Khan, David; Lang, David M.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher R.; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen A.; Wallace, Dana			Adverse reactions to vaccines practice parameter 2012 update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vaccine; immunization; adverse reaction; allergy; influenza vaccine; egg allergy	GUILLAIN-BARRE-SYNDROME; EVENT-REPORTING-SYSTEM; ACELLULAR PERTUSSIS-VACCINE; HYPOTONIC-HYPORESPONSIVE EPISODES; IMMUNIZATION PRACTICES ACIP; WHOLE-CELL PERTUSSIS; ADVISORY-COMMITTEE; INFLUENZA VACCINE; DELAYED-HYPERSENSITIVITY; PREVENTING TETANUS	Mild local reactions and fever after vaccinations are common and do not contraindicate future doses. Anaphylactic reactions to vaccines are rare and should be evaluated with skin tests to the vaccine and its components. If the skin test results are negative, subsequent doses can be administered in the usual manner but under observation. If the skin test results are positive and the patient requires subsequent doses, the vaccine can be administered in graded doses under observation. Some nonanaphylactic reactions to vaccines might also require evaluation, but only a few are contraindications to future doses. Pregnant women and persons who are immune compromised should generally not receive live vaccines. Purported long-term sequelae of vaccination, such as autism, are not supported by epidemiologic studies. Patients with egg allergy of any severity should receive annual influenza vaccinations because studies have demonstrated a very low rate of reactions. Studies to date have evaluated the injectable trivalent influenza vaccine (TIV), and thus TIV, rather than the live attenuated influenza vaccine (LAIV), should be used for recipients with egg allergy. All influenza vaccines available in the United States contain low amounts of ovalbumin. Neither skin testing with the vaccine nor dividing the dose is required; however, the vaccine should be administered in a setting in which anaphylaxis can be recognized and treated.	[Kelso, John M.] Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA USA; [Greenhawt, Matthew J.] Univ Michigan Hlth Syst, Univ Michigan Med Sch, Div Allergy & Clin Immunol, Dept Internal Med, Ann Arbor, MI USA; [Li, James T.] Mayo Clin, Coll Med, Dept Med, Rochester, MN USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Dept Med & Environm Hlth, Div Immunol Allergy & Rheumatol, Cincinnati, OH USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Palo Alto, CA 94304 USA; [Cox, Linda; Wallace, Dana] Nova SE Univ, Dept Med, Davie, FL USA; [Khan, David] Univ Texas SW Med Ctr Dallas, Dept Med, Div Allergy & Immunol, Dallas, TX 75390 USA; [Lang, David M.] Cleveland Clin Fdn, Resp Inst, Allergy Immunol Sect, Cleveland, OH 44195 USA; [Nicklas, Richard A.] George Washington Med Ctr, Dept Med, Washington, DC USA; [Oppenheimer, John] Univ Med & Dent New Jersey, Dept Internal Med, Morristown, NJ USA; [Portnoy, Jay M.] Univ Missouri, Sch Med, Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Randolph, Christopher R.] Yale Hosp, Ctr Allergy Asthma & Immunol, Waterbury, CT USA; [Schuller, Diane E.] Penn State Univ, Milton S Hershey Med Coll, Dept Pediat, Hershey, PA USA; [Spector, Sheldon L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Tilles, Stephen A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Scripps Research Institute; University of Michigan System; University of Michigan; Mayo Clinic; University System of Ohio; University of Cincinnati; Stanford University; Nova Southeastern University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; George Washington University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle	Kelso, JM (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St,3-3, Palatine, IL 60067 USA.	info@jcaai.org	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870	American College of Allergy, Asthma & Immunology (ACAAI); National Institutes of Health (NIH)/Clinical and Translational Science Awards (CTSA)	American College of Allergy, Asthma & Immunology (ACAAI); National Institutes of Health (NIH)/Clinical and Translational Science Awards (CTSA)	M. Greenhawt is on the Phadia/Thermo Fisher Scientific specialty advisory board and speakers' bureau; is on the advisory boards for Nutricia and Sunovion; has received research support from the American College of Allergy, Asthma & Immunology (ACAAI), a private foundation, and from the National Institutes of Health (NIH)/Clinical and Translational Science Awards (CTSA); is a medical advisor for the Kids with Food Allergies Foundation; is on the American Academy of Allergy, Asthma & Immunology's (AAAAI) Adverse Reactions to Foods Committee, Anaphylaxis Committee, and EGID Committee; and has received nonfinancial support from the Food Allergy & Anaphylaxis Network (FAAN). J. T. Li has stock shares in Abbott, Novartis, and Johnson & Johnson. J. M. Kelso declares that he has no relevant conflicts of interest.	AALBERSE RC, 1995, INT ARCH ALLERGY IMM, V107, P169, DOI 10.1159/000236967; ABERER W, 1991, CONTACT DERMATITIS, V24, P6, DOI 10.1111/j.1600-0536.1991.tb01621.x; ANOLIK R, 1992, ANN ALLERGY, V68, P69; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P13; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 2011, CLIMBING OUT DEPRESS; [Anonymous], REC IMM SCHED PERS A; [Anonymous], 2008, VACCINES-BASEL, DOI DOI 10.1016/B978-1-4160-3611-1.50022-2; [Anonymous], 2009, RED BOOK REP COMM IN; [Anonymous], 2010, YF VAX PACKAGE INSER; Audicana Maria Teresa, 2002, Am J Contact Dermat, V13, P3, DOI 10.1053/ajcd.2002.29945; Barlow WE, 2001, NEW ENGL J MED, V345, P656, DOI 10.1056/NEJMoa003077; Baxter DN, 1996, VACCINE, V14, P131, DOI 10.1016/0264-410X(95)00154-S; Beeler J, 1996, PEDIATR INFECT DIS J, V15, P88, DOI 10.1097/00006454-199601000-00020; Bergfors E, 2003, VACCINE, V22, P64, DOI 10.1016/S0264-410X(03)00531-0; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Beytout J, 2009, HUM VACCINES, V5, P315, DOI 10.4161/hv.5.5.6911; Bogdanovic J, 2009, J ALLERGY CLIN IMMUN, V124, P1108, DOI 10.1016/j.jaci.2009.06.021; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Bradyd MT, 2011, PEDIATRICS, V128, P813, DOI 10.1542/peds.2011-2295; Broder Karen R., 2006, Morbidity and Mortality Weekly Report, V55, P1; CAREY AB, 1992, ANN ALLERGY, V69, P336; CDC, 2007, GUID VACC PREGN WOM; Centers for Disease Control and Prevention, 2014, REC AD IMM SCHED US; Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT, V13th; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P855; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; CODY CL, 1981, PEDIATRICS, V68, P650; Committee on Infectious Diseases, 2011, PEDIATRICS; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; COX NH, 1988, CONTACT DERMATITIS, V18, P229, DOI 10.1111/j.1600-0536.1988.tb02809.x; Danovaro-Holliday MC, 2000, JAMA-J AM MED ASSOC, V284, P2733, DOI 10.1001/jama.284.21.2733; DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504; DiMiceli L, 2006, VACCINE, V24, P703, DOI 10.1016/j.vaccine.2005.07.069; DuVernoy TS, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.4.e52; Edelman K, 1999, EUR J PEDIATR, V158, P989, DOI 10.1007/s004310051264; EDWARDS KM, 2008, VACCINES; ELLIMAN D, 1991, LANCET, V337, P365, DOI 10.1016/0140-6736(91)90995-2; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; Fiore AE, 2008, VACCINES; Fischer Marc, 2010, Morbidity and Mortality Weekly Report, V59, P1; Food and Drug Administration, THIM VACC; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Gershon A, 2008, VACCINES, P915; Goulleret N, 2010, VACCINE, V28, P5878, DOI 10.1016/j.vaccine.2010.06.056; Greenhawt MJ, 2011, ANN ALLERG ASTHMA IM, V106, P11, DOI 10.1016/j.anai.2010.11.015; Greenhawt MJ, 2010, ANN ALLERG ASTHMA IM, V105, P387, DOI 10.1016/j.anai.2010.08.015; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Grohskopf Lisa, 2011, Morbidity and Mortality Weekly Report, V60, P1128; Haber P, 2004, JAMA-J AM MED ASSOC, V292, P2478, DOI 10.1001/jama.292.20.2478; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Heijbel H, 1997, DEV BIOL STAND, V89, P101; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392; Jadavji T, 2003, PEDIATR INFECT DIS J, V22, P119; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; KAABER K, 1992, CONTACT DERMATITIS, V26, P304, DOI 10.1111/j.1600-0536.1992.tb00123.x; Kattan JD, 2011, J ALLERGY CLIN IMMUN, V128, P215, DOI 10.1016/j.jaci.2011.04.046; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V104, P202, DOI 10.1016/S0091-6749(99)70136-3; Kelso JM, 2000, J ALLERGY CLIN IMMUN, V106, P990, DOI 10.1067/mai.2000.110800; Kelso JM, 2008, MIDDLETONS ALLERGY P, P1189; Koppen S, 2004, VACCINE, V22, P3375, DOI 10.1016/j.vaccine.2004.02.033; Kreth HW, 2006, EUR J PEDIATR, V165, P677, DOI 10.1007/s00431-006-0103-6; Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1; KWITTKEN PL, 1993, AM J DIS CHILD, V147, P128, DOI 10.1001/archpedi.1993.02160260018005; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; Le Saux N, 2003, PEDIATRICS, V112, pE348, DOI 10.1542/peds.112.5.e348; LEAR JT, 1995, LANCET, V345, P1249, DOI 10.1016/S0140-6736(95)92039-0; Lee-Wong M, 2005, ANN ALLERG ASTHMA IM, V94, P90, DOI 10.1016/S1081-1206(10)61292-6; Lehman HK, 2008, J PEDIATR-US, V152, P133, DOI 10.1016/j.jpeds.2007.08.039; Lehmann HC, 2010, LANCET INFECT DIS, V10, P643, DOI 10.1016/S1473-3099(10)70140-7; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Liang XF, 2011, NEW ENGL J MED, V364, P638, DOI 10.1056/NEJMoa1008553; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; Marin Mona, 2010, Morbidity and Mortality Weekly Report, V59, P1; Matheson MC, 2010, PEDIAT ALLERG IMM-UK, V21, P301, DOI 10.1111/j.1399-3038.2009.00950.x; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; McKinney KK, 2011, J ALLERGY CLIN IMMUN, V127, P1629, DOI 10.1016/j.jaci.2011.02.003; Monath T. P., 2008, VACCINES, P959; Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303; Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61; MURPHY KR, 1985, J PEDIATR-US, V106, P931, DOI 10.1016/S0022-3476(85)80241-9; NAGEL JE, 1979, J ALLERGY CLIN IMMUN, V63, P308, DOI 10.1016/0091-6749(79)90124-6; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; NOEL I, 1991, LANCET, V338, P705, DOI 10.1016/0140-6736(91)91289-7; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; Owens G, 2011, J ALLERGY CLIN IMMUN, V127, P264, DOI 10.1016/j.jaci.2010.10.005; Parker AA, 2006, NEW ENGL J MED, V355, P447, DOI 10.1056/NEJMoa060775; Parker SK, 2004, PEDIATRICS, V114, P793, DOI 10.1542/peds.2004-0434; Patrizi A, 1999, CONTACT DERMATITIS, V40, P94, DOI 10.1111/j.1600-0536.1999.tb05998.x; Plotkin S., 2008, VACCINES-BASEL; Plotkin SA, 2001, PEDIATR INFECT DIS J, V20, P63, DOI 10.1097/00006454-200101000-00013; RIETSCHEL RL, 1990, DERMATOL CLIN, V8, P161, DOI 10.1016/S0733-8635(18)30543-6; RIETSCHEL RL, 1981, JAMA-J AM MED ASSOC, V245, P571; Rosenthal S, 1996, ARCH PEDIAT ADOL MED, V150, P457, DOI 10.1001/archpedi.1996.02170300011001; Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155; Russell M, 2004, VACCINE, V23, P664, DOI 10.1016/j.vaccine.2004.06.042; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakaguchi M, 2001, ALLERGY, V56, P536, DOI 10.1034/j.1398-9995.2001.056006536.x; Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47; Schneider L, 2010, J ALLERGY CLIN IMMUN, V126, P1306, DOI 10.1016/j.jaci.2010.08.010; Sharrar RG, 2000, VACCINE, V19, P916, DOI 10.1016/S0264-410X(00)00297-8; Sivadon-Tardy V, 2009, CLIN INFECT DIS, V48, P48, DOI 10.1086/594124; Slater JE, 2011, J ALLERGY CLIN IMMUN, V128, P434, DOI 10.1016/j.jaci.2011.06.028; Souayah N, 2007, VACCINE, V25, P5253, DOI 10.1016/j.vaccine.2007.03.053; Staples J. Erin, 2010, Morbidity and Mortality Weekly Report, V59, P1; Stratton K, 2001, IMMUNIZATION SAFETY; Stratton K.R., 1994, ADVERSE EVENTS ASS C; Talbot EA, 2010, VACCINE, V28, P8001, DOI 10.1016/j.vaccine.2010.09.034; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Thompson WW, 2007, NEW ENGL J MED, V357, P1281, DOI 10.1056/NEJMoa071434; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Vellozzi C, 2010, VACCINE, V28, P7248, DOI 10.1016/j.vaccine.2010.09.021; Vestergaard M, 2004, JAMA-J AM MED ASSOC, V292, P351, DOI 10.1001/jama.292.3.351; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Wassilak SG, 2008, VACCINES, P805; Webb L, 2011, J ALLERGY CLIN IMMUN, V128, P218, DOI 10.1016/j.jaci.2011.02.013; Wise RP, 2000, JAMA-J AM MED ASSOC, V284, P1271, DOI 10.1001/jama.284.10.1271; Wood RA, 2008, PEDIATRICS, V122, pE771, DOI 10.1542/peds.2008-1002; Wood RA, 2007, J ALLERGY CLIN IMMUN, V120, P478, DOI 10.1016/j.jaci.2007.04.035; Zent O, 2004, VACCINE, V23, P579, DOI 10.1016/j.vaccine.2004.07.016; Zheng W, 2007, ANN ALLERG ASTHMA IM, V99, P574, DOI 10.1016/S1081-1206(10)60391-2; Zielinski Andrzej, 2008, Przegl Epidemiol, V62, P589; 2001, MMWR MORB MORTAL WKL, V50, P553	131	184	185	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					25	43		10.1016/j.jaci.2012.04.003	http://dx.doi.org/10.1016/j.jaci.2012.04.003			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22608573				2022-12-18	WOS:000306644800005
J	Oyoshi, MK; Larson, RP; Ziegler, SF; Geha, RS				Oyoshi, Michiko K.; Larson, Ryan P.; Ziegler, Steven F.; Geha, Raif S.			Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; scratching; mechanical injury; thymic stromal lymphopoietin; IL-10; T(H)2 cytokines	T-HELPER-CELL; ANTIGEN-PRESENTING CELLS; HUMAN EPITHELIAL-CELLS; ATOPIC-DERMATITIS; ALLERGIC DERMATITIS; IN-VIVO; TRANSCRIPTION FACTOR; MOUSE KERATINOCYTES; GATA3 EXPRESSION; GENE-EXPRESSION	Background: Atopic dermatitis is characterized by scratching and by T(H)2-dominated immune response to cutaneously introduced antigens. Antigen application to skin mechanically injured by tape stripping results in T(H)2-dominated skin inflammation. Objective: To examine the effect of tape stripping on the capacity of skin dendritic cells (DCs) to polarize T cells toward a T(H)2 phenotype. Methods: CD11c(+) DCs were isolated from skin of BALB/c or C57BL/6 mice. Fluorescein isothiocyanate (FITC)(+) and FITC- DCs were isolated from draining lymph nodes (DLNs) 24 hours after painting the skin with FITC. DCs were assessed for their ability to induce cytokine secretion by ovalbumin-stimulated naive CD4(+) T cells from T cell receptor-ovalbumin transgenic DO11.10 mice. Cytokine mRNA levels were examined by quantitative PCR. Results: Dendritic cells isolated from the skin of wild-type, but not thymic stromal lymphopoietin (TSLP) receptor(-/-) or IL-10(-/-), mice 6 hours after tape stripping elicited significantly more IL-4 and IL-13 and significantly less IFN-gamma production by CD4(+) cells than DCs isolated from unmanipulated skin, and expressed significantly more mRNA for the T(H)2 skewing molecules IL-10, Jagged1, and Jagged2, but significantly less mRNA for the T(H)1 skewing cytokine IL-12. CD11c(+)FITC(+) cells isolated from DLNs of shaved and tape stripped skin of wildtype, but not TSLP receptor(-/-) or IL-10(-/-), mice polarized T cells significantly more toward T(H)2 and expressed significantly more IL-10, Jagged1, and Jagged2 mRNA than CD11c(+)FITC(+) cells isolated from DLNs of shaved skin. Tape stripping significantly increased TSLP levels in the skin, and TSLP was shown to play an essential role in the T(H)2 polarization of skin DCs by tape stripping. Conclusions: Tape stripping upregulates TSLP levels in the skin, which polarizes skin DCs to elicit a T(H)2 response via the induction of IL-10. (J Allergy Clin Immunol 2010; 126:976-84.)	[Oyoshi, Michiko K.; Geha, Raif S.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Oyoshi, Michiko K.; Geha, Raif S.] Harvard Univ, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Larson, Ryan P.; Ziegler, Steven F.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; [Larson, Ryan P.; Ziegler, Steven F.] Benaroya Res Inst Virginia Mason, Program Immunol, Seattle, WA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle; Benaroya Research Institute; Virginia Mason Medical Center	Geha, RS (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			NIH [AR-047417, N01-AI-40030, AI068731, AR055695, AR056113]; Howard Hughes Institute Med into Grad initiative;  [CA009537];  [T32-GM007270]; NATIONAL CANCER INSTITUTE [T32CA009537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417, R01AR055695, R01AR056113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Institute Med into Grad initiative; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by NIH grants AR-047417, N01-AI-40030, AI068731, AR055695, and AR056113. R.P.L. was supported by training grant CA009537, T32-GM007270, and the Howard Hughes Institute Med into Grad initiative through a grant to the University of Washington.	Akei HS, 2006, J ALLERGY CLIN IMMUN, V118, P62, DOI 10.1016/j.jaci.2006.04.046; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; Guo PF, 2010, BLOOD, V116, P2061, DOI 10.1182/blood-2009-11-252940; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Imai Y, 2006, CLIN EXP ALLERGY, V36, P1462, DOI 10.1111/j.1365-2222.2006.02574.x; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Krawczyk CM, 2008, J IMMUNOL, V180, P7931, DOI 10.4049/jimmunol.180.12.7931; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; MITCHELL EB, 1982, LANCET, V1, P127; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Okamoto M, 2009, J IMMUNOL, V183, P2995, DOI 10.4049/jimmunol.0900692; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Ranger AM, 1996, INT IMMUNOL, V8, P1549, DOI 10.1093/intimm/8.10.1549; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Salomon B, 1998, J IMMUNOL, V160, P708; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Shigeno T, 2009, IMMUNOLOGY, V128, pe849, DOI 10.1111/j.1365-2567.2009.03094.x; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soroosh P, 2009, IMMUNOLOGY, V127, P450, DOI 10.1111/j.1365-2567.2009.03114.x; Soumelis V, 2004, SPRINGER SEMIN IMMUN, V25, P325, DOI 10.1007/s00281-003-0152-0; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Wahlgren Carl-Fredrik, 1999, Journal of Dermatology (Tokyo), V26, P770; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; Wood LC, 1997, EXP DERMATOL, V6, P98, DOI 10.1111/j.1600-0625.1997.tb00154.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Worsley AGF, 2008, EUR J IMMUNOL, V38, P1043, DOI 10.1002/eji.200737335; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	55	184	188	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					976	U133		10.1016/j.jaci.2010.08.041	http://dx.doi.org/10.1016/j.jaci.2010.08.041			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050944	Green Accepted			2022-12-18	WOS:000283727100013
J	Bacharier, LB; Phillips, BR; Zeiger, RS; Szefler, SJ; Martinez, FD; Lemanske, RF; Sorkness, CA; Bloomberg, GR; Morgan, WJ; Paul, IM; Guilbert, T; Krawiec, M; Covar, R; Larsen, G; Mellon, M; Moss, MH; Chinchilli, VM; Taussig, LM; Strunk, RC				Bacharier, Leonard B.; Phillips, Brenda R.; Zeiger, Robert S.; Szefler, Stanley J.; Martinez, Fernando D.; Lemanske, Robert F., Jr.; Sorkness, Christine A.; Bloomberg, Gordon R.; Morgan, Wayne J.; Paul, Ian M.; Guilbert, Theresa; Krawiec, Marzena; Covar, Ronina; Larsen, Gary; Mellon, Michael; Moss, Mark H.; Chinchilli, Vernon M.; Taussig, Lynn M.; Strunk, Robert C.		Natl Heart Lung & Blood Inst	Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheezing; preschool children; montelukast; budesonide	CHILDHOOD ASTHMA; VIRAL WHEEZE; DOUBLE-BLIND; SHORT-TERM; MONTELUKAST; PREVENTION; ATTACKS; EXACERBATIONS; EFFICACY; STEROIDS	Background: Acute wheezing illnesses in preschoolers require better management strategies to reduce morbidity. Objectives: We sought to examine the effectiveness of episodic use of an inhaled corticosteroid and a leukotriene receptor antagonist in preschoolers with intermittent wheezing. Methods: In a randomized, double-blind, placebo-controlled 12-month trial, 238 children aged 12 to 59 months with moderate-to-severe intermittent wheezing received 7 days of either budesonide inhalation suspension (1 mg twice daily), montelukast (4 mg daily), or placebo in addition to albuterol with each identified respiratory tract illness (RTI). Proportion of episode-free days (EFDs) during the 12-month trial was the primary outcome. Results: The 3 treatment groups did not differ in proportions of EFDs, with adjusted mean EFDs of 76% (95% CI, 70% to 81%)for budesonide, 73% (95% CI, 66% to 79%) for montelukast, and 74% (95% CI, 65% to 81%) for conventional therapy (P = .66). The 3 groups did not differ in oral corticosteroid use, health care use, quality of life, or linear growth. However, during RTIs, budesonide and montelukast therapy led to modest reductions in trouble breathing (38% [P = .003] and 37% [P = .003], respectively) and interference with activity scores (32% [P =.01] and 40% [P =.001], respectively) that were most evident in those with positive asthma predictive indices. Conclusions: In preschool children with moderate-to-severe intermittent wheezing, episodic use of either budesonide or montelukast early in RTIs, when added to albuterol, did not increase the proportion of EFDs or decrease oral corticosteroid use over a 12-month period. However, indicators of severity of acute illnesses were reduced, particularly in children with positive asthma predictive indices. (J Allergy Clin Immunol 2008; 122:1127-35.)	[Bacharier, Leonard B.] Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Phillips, Brenda R.; Paul, Ian M.; Chinchilli, Vernon M.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Zeiger, Robert S.; Mellon, Michael] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.; Mellon, Michael] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Szefler, Stanley J.; Krawiec, Marzena; Covar, Ronina; Larsen, Gary; Taussig, Lynn M.] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; [Martinez, Fernando D.; Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Lemanske, Robert F., Jr.; Moss, Mark H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Lemanske, Robert F., Jr.; Moss, Mark H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Guilbert, Theresa] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA	St. Louis Children's Hospital; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health; University of Arizona; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bacharier, LB (corresponding author), Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	bacharier@kids.wustl.edu	Paul, Ian/AAD-9813-2020	Paul, Ian/0000-0002-6344-8609; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063; Guilbert, Theresa/0000-0002-6932-712X	Sanofi-Aventis; Teva Pharmaceuticals; Merck; AstraZeneca; GlaxoSmithKline; Genentech; National Institutes of Health (NIH); National Heart, Lung. and Blood Institute (NHLBI); Ross Pharmaceuticals; Pharmaxis; National Honey Board; Altus Pharmaceuticals; Inspire Pharmaceuticals; American Lung Association; Ross Abbott Laboratories; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064287, U10HL064305, U10HL064313, U10HL064288, U10HL064307, U10HL064295] Funding Source: NIH RePORTER	Sanofi-Aventis(Sanofi-Aventis); Teva Pharmaceuticals(Teva Pharmaceutical Industries); Merck(Merck & Company); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung. and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Ross Pharmaceuticals; Pharmaxis; National Honey Board; Altus Pharmaceuticals; Inspire Pharmaceuticals; American Lung Association; Ross Abbott Laboratories(Abbott Laboratories); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	L. B. Bacharier has received honoraria from AstraZeneca, Genentech. GlaxoSmithKIine, Merck, and Acrocrine and has served on an advisory board for Schering-Plough. R. S. Zeiger has served as a consultant for Aerocrine. AstraZeneca, Dynavax, Genentech, Merck, Novartis, and GlaxoSmithKline and has received research support from Sanofi-Aventis. Teva Pharmaceuticals, Merck, AstraZeneca, GlaxoSmithKline. and Genentech. S. J. Szefler has served as a consultant for AstraZeneca, GlaxoSmithKline, Aventis. Genentech, and Merck and hits received research support from the National Institutes of Health (NIH), the National Heart, Lung. and Blood Institute (NHLBI), and Ross Pharmaceuticals. F. 1). Martinez has received lecture fees from Merck and Pfizer; hits served on an advisory board for Merck and MedImmune: and has served as a consultant for GlaxoSmithKline and Pfizer. R. F Lemanske has received speaker honoraria from Merck: has served as it consultant for GlaxoSmithKline and hits received research support front the NHLBI. C. A. Sorkness has served on the speakers' bureau and as a consultant for GlaxoSmithKline and has received research support from GlaxoSmithKline and Pharmaxis. W. J. Morgan has served as a consultant for the Cystic Fibrosis Foundation and Genentech. has served as a speaker for Aerocrine, and has received research support from the NIH. I. NI. Paul hits served as a consultant for the Consumer Healthcare Products Association, McNeil Consumer Healthcare,and Reckitt Benckiser Healthcare International and has received research support front GlaxoSmithKline and the National Honey Board. T. Guilbert hits served as it consultant, speaker, or both for GlaxoSmithKline, AstraZeneca, Peerpoint Medical Education Institute. Merck, Scheing-Plough. Genentech/Novartis, and Antidote (formerly World Medical Conferences CME programs) and has received research support from Altus Pharmaceuticals. Inspire Pharmaceuticals, and the NIH. M. Krawiec has served on the speakers' bureau of Merck and GlaxoSmithKline, has,served its a consultant for Novartis and Parexel. and hits received research support fromthe American Lung Association. R. Covar has received honoraria from Aerocrine and has received research support from Ross Abbott Laboratories. G. Larsen has served on an asthma advisory board for Genentech and has received research support from the NIH. M. Mellon has served as a speaker, consultant, or both for AstraZeneca and Schering-Plough. V. M. Chinehilli hits received research support from the NHLBI. The rest of the authors have declared that they have no conflict of interest.	Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P929; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; Dawson KL, 1998, PEDIATR PULM, V26, P362, DOI 10.1002/(SICI)1099-0496(199811)26:5<362::AID-PPUL10>3.0.CO;2-G; DOLAN LM, 1987, J ALLERGY CLIN IMMUN, V80, P81, DOI 10.1016/S0091-6749(87)80195-1; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Fox GF, 1996, EUR J PEDIATR, V155, P512, DOI 10.1007/BF01955192; Georgitis John W., 2001, Pediatric Asthma Allergy and Immunology, V15, P3, DOI 10.1089/088318701750314527; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; GRANT CC, 1995, PEDIATRICS, V96, P224; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Kayani S, 2002, CHEST, V122, P624, DOI 10.1378/chest.122.2.624; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; MCKEAN M, 2001, COCHRANE LIB; Mellon M, 2000, AM J RESP CRIT CARE, V162, P593, DOI 10.1164/ajrccm.162.2.9909030; *NAT ASTHM ED PREV, 1997, 2 US DEP HLTH HUM SE; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913; WEBB MSC, 1986, ARCH DIS CHILD, V61, P15, DOI 10.1136/adc.61.1.15; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407	32	184	193	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1127	1135		10.1016/j.jaci.2008.09.029	http://dx.doi.org/10.1016/j.jaci.2008.09.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18973936	Green Accepted			2022-12-18	WOS:000261711800009
J	Cox, L; Platts-Mills, TAE; Finegold, I; Schwartz, LB; Simons, FER; Wallace, DV				Cox, Linda; Platts-Mills, Thomas A. E.; Finegold, Ira; Schwartz, Lawrence B.; Simons, F. Estelle R.; Wallace, Dana V.			American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology joint task force report on omalizumab-associated anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						omalizumab; Xolair; anaphylaxis; recombinant monoclonal antibodies; hypersensitivity; IgE antibody	INFUSION REACTIONS; ANTIBODIES; MANAGEMENT	The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.	[Cox, Linda] Nova SE Univ, Coll Osteopath Med, Dept Clin Med, Davie, FL USA; [Platts-Mills, Thomas A. E.] Univ Virginia, Dept Internal Med, Div Clin Immunol & Allergy, Charlottesville, VA USA; [Platts-Mills, Thomas A. E.] Univ Virginia, Dept Microbiol, Div Clin Immunol & Allergy, Charlottesville, VA USA; [Finegold, Ira] RA Cooke Inst Allergy, St Lukes Roosevelt Hosp Ctr, Dept Allergy, New York, NY USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; [Wallace, Dana V.] Nova SE Univ, Coll Osteopath Med, Dept Clin Med, Ft Lauderdale, FL 33334 USA	Nova Southeastern University; University of Virginia; University of Virginia; Mount Sinai St. Luke's; Mount Sinai West; Virginia Commonwealth University; University of Manitoba; Nova Southeastern University	Cox, L (corresponding author), Nova SE Univ, Coll Osteopath Med, Dept Clin Med, 5333 N Dixie Highway,Suite 210, Ft Lauderdale, FL 33334 USA.	lindaswolfcox@msn.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870; Platts-Mills, Thomas/0000-0002-1263-329X				[Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, pS483; Baudouin V, 2003, TRANSPLANTATION, V76, P459, DOI 10.1097/01.TP.0000073809.65502.8F; California Department of Corrections and Rehabilitation, 2007, EXP PAN REP EXP PAN; Castells M, 2006, CURR OPIN ALLERGY CL, V6, P476, DOI 10.1097/ACI.0b013e3280108716; Cheifetz A, 2005, MT SINAI J MED, V72, P250; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; *GEN INC, 2007, XOL OM; Johnson TL, 2006, ANN ALLERG ASTHMA IM, V97, P694, DOI 10.1016/S1081-1206(10)61102-7; Klastersky J, 2006, CURR OPIN ONCOL, V18, P316, DOI 10.1097/01.cco.0000228734.32261.62; Kozutsumi D, 2006, IMMUNOLOGY, V118, P392, DOI 10.1111/j.1365-2567.2006.02390.x; Leonard PA, 2002, TRANSPLANTATION, V74, P1697, DOI 10.1097/01.TP.0000038316.61592.28; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Steele RH, 2005, NEPHROLOGY, V10, P317, DOI 10.1111/j.1440-1797.2005.00389.x	15	184	193	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1373	1377		10.1016/j.jaci.2007.09.032	http://dx.doi.org/10.1016/j.jaci.2007.09.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17996286				2022-12-18	WOS:000251653800019
J	Camargo, CA; Clark, S; Kaplan, MS; Lieberman, P; Wood, RA				Camargo, Carlos A., Jr.; Clark, Sunday; Kaplan, Michael S.; Lieberman, Philip; Wood, Robert A.			Regional differences in EpiPen prescriptions in the United States: The potential role of vitamin D	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; epidemiology; EpiPen; vitamin D	REGULATORY T-CELLS; SUN EXPOSURE; ANAPHYLAXIS; EPIDEMIOLOGY; POPULATION; ALLERGY; MELANOMA; CHILDREN; RISK; D-3	Background: The epidemiology of anaphylaxis is uncertain, especially its geographic distribution. Objective: To address this deficit, we examined regional rates of EpiPen prescriptions in the United States. Methods: EpiPen prescriptions in 2004 were obtained for all 50 states and Washington, DC, from NDCHealth, Pharmaceutical Audit Suite (Alpharetta, Ga). Data included the number of total filled prescriptions, including refills, and the actual number of EpiPens prescribed. Several data sets were used to obtain state-specific populations, as well as multiple demographic, health, and weather characteristics. State population was used to calculate the average number of prescriptions written per person. Results: Overall, there were 1,511,534 EpiPen prescriptions filled during 2004. These prescriptions accounted for 2,495,188 EpiPens. On average, there were 5.71 EpiPens prescribed per 1000 persons. Massachusetts had the highest number of prescriptions per 1000 persons (11.8), whereas Hawaii had the lowest (2.7). In addition to state-to-state variation, there was an obvious regional difference: New England (Connecticut, Rhode Island, Massachusetts, Vermont, New Hampshire, Maine) had the highest values, with 8 to 12 EpiPen prescriptions per 1000 persons, whereas the southern states (between and including California and Mississippi) had only 3 prescriptions per 1000 persons. The New England finding persisted even when controlling for all available factors (eg, population demographic characteristics, number of health care providers, prescriptions for other medications). Conclusion: A strong north-south gradient was observed for the prescription of EpiPens in the United States, with the highest rates found in New England. Clinical implications: The regional differences in EpiPen prescribing may provide important etiologic clues (vitamin D status) and merit further investigation.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr D Receptor Activat Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Kaiser Permanente, Dept Allergy, Los Angeles, CA USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA; Johns Hopkins Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaiser Permanente; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine	Camargo, CA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr D Receptor Activat Res, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Camargo, Carlos A./C-2145-2008; Clark, Sunday/AAA-5458-2021	Camargo, Carlos A./0000-0002-5071-7654; 				Annesi-Maesano I, 2002, PEDIATR RES, V52, P3, DOI 10.1023/01.PDR/0000017228.29635.EF; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown SJ, 2006, ANN PHARMACOTHER, V40, P1158, DOI 10.1345/aph.1G513; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; *CDCP, 2006, BEH RISK FACT SURV S; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Feldman D, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hernan MA, 1999, NEUROLOGY, V53, P1711, DOI 10.1212/WNL.53.8.1711; Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317; Ivry GB, 2006, DERMATOL SURG, V32, P481, DOI 10.1111/j.1524-4725.2006.32101.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; MEEHAN MA, 1992, CELL IMMUNOL, V140, P400, DOI 10.1016/0008-8749(92)90206-5; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1203/01.PDR.0000017267.23950.48; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 2006, US CENSUS BUREAU WEB; 2006, NOAA WEB SITE	29	184	188	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					131	136		10.1016/j.jaci.2007.03.049	http://dx.doi.org/10.1016/j.jaci.2007.03.049			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17559916				2022-12-18	WOS:000248066400019
J	Morar, N; Willis-Owen, SAG; Moffatt, MF; Cookson, WOCM				Morar, Nilesh; Willis-Owen, Saffron A. G.; Moffatt, Miriam F.; Cookson, William O. C. M.			The genetics of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; genetics; candidate gene; linkage; microarray	MAST-CELL CHYMASE; EPSILON-RI-BETA; SINGLE NUCLEOTIDE POLYMORPHISMS; IMMUNOGLOBULIN-E CONCENTRATIONS; HIGHLY EXPRESSED GENES; SERUM IGE LEVELS; IN-VIVO; PROMOTER REGION; LESIONAL SKIN; SUSCEPTIBILITY LOCUS	Atopic dermatitis (AD) is a chronic itching (pruritic) skin disease. It results from a complex interplay between strong genetic and environmental factors. Genome screens of families with AD have implicated chromosomal regions that overlap with other skin diseases and with inflammatory and autoimmune diseases. These, together with candidate gene studies, provide novel insights into the pathogenesis of AD. The findings suggest a common theme of generalized epidermal dysfunction manifesting as a compromised skin barrier and failure to protect against, or aberrant responses to, microbial insults and antigens. Recent genetic advances with high-throughput methods for gene identification, such as DNA microarrays and whole-genome genotyping, will help further dissect this complex trait. This will aid disease-defining criteria and focused therapies for AD.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England	Imperial College London; University of Oxford; Wellcome Centre for Human Genetics	Morar, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	nilesh.morar@well.ox.ac.uk	Cookson, William/HHC-1790-2022	Willis-Owen, Saffron/0000-0003-2633-1150	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Alam R, 1997, J ALLERGY CLIN IMMUN, V99, P273, DOI 10.1016/S0091-6749(97)70042-3; Andrasfalvy M, 2005, J IMMUNOL, V175, P2801, DOI 10.4049/jimmunol.175.5.2801; Arakawa S, 2006, ARCH DERMATOL RES, V297, P377, DOI 10.1007/s00403-005-0620-6; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V108, P281, DOI 10.1067/mai.2001.117259; Badertscher K, 2005, ARCH DERMATOL RES, V296, P503, DOI 10.1007/s00403-005-0542-3; Bai BX, 2005, J DERMATOL SCI, V39, P189, DOI 10.1016/j.jdermsci.2005.06.003; Beyer K, 2000, J INVEST DERMATOL, V115, P906, DOI 10.1046/j.1523-1747.2000.00096.x; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; Chae SC, 2003, BIOCHEM BIOPH RES CO, V312, P346, DOI 10.1016/j.bbrc.2003.10.125; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Cheng SS, 2002, EXP MOL PATHOL, V73, P1, DOI 10.1006/exmp.2002.2439; Cheng SS, 2002, J IMMUNOL, V168, P2887, DOI 10.4049/jimmunol.168.6.2887; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Cox HE, 1999, CLIN GENETIC ASPECTS; DARVASI A, 1993, GENETICS, V134, P943; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Diepgen TL, 1996, J INVEST DERMATOL, V106, P977, DOI 10.1111/1523-1747.ep12338475; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Folster-Holst R, 2005, BRIT J DERMATOL, V152, P1365, DOI 10.1111/j.1365-2133.2005.06602.x; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066, DOI 10.1016/S0091-6749(99)70090-4; Gaffney PM, 2000, AM J HUM GENET, V66, P547, DOI 10.1086/302767; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 1998, EUR J PHARMACOL, V352, P91, DOI 10.1016/S0014-2999(98)00343-4; Heishi M, 2002, INT ARCH ALLERGY IMM, V129, P57, DOI 10.1159/000065174; Hijnen D, 2005, J INVEST DERMATOL, V125, P1149, DOI 10.1111/j.0022-202X.2005.23932.x; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Hosomi N, 2004, J INVEST DERMATOL, V122, P843, DOI 10.1111/j.0022-202X.2004.22338.x; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Imada T, 2002, JPN J PHARMACOL, V90, P214, DOI 10.1254/jjp.90.214; Iwanaga T, 2004, CLIN EXP ALLERGY, V34, P1037, DOI 10.1111/j.1365-2222.2004.02000.x; Jang N, 2005, GENES IMMUN, V6, P262, DOI 10.1038/sj.gene.6364169; Jeong CW, 2003, CLIN EXP ALLERGY, V33, P1717, DOI 10.1111/j.1365-2222.2003.01782.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jones G, 2006, BRIT J DERMATOL, V154, P467, DOI 10.1111/j.1365-2133.2005.07080.x; Jongepier H, 2005, J ALLERGY CLIN IMMUN, V115, P486, DOI 10.1016/j.jaci.2004.12.013; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kaburagi Y, 2001, ARCH DERMATOL RES, V293, P350, DOI 10.1007/s004030100230; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kawashima T, 1998, HUM HERED, V48, P271, DOI 10.1159/000022815; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Kootiratrakarn T, 2005, EUR J IMMUNOL, V35, P3277, DOI 10.1002/eji.200526274; Kozma GT, 2002, ALLERGY, V57, P160, DOI 10.1034/j.1398-9995.2002.1s3361.x; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Lange J, 2005, PEDIAT ALLERG IMM-UK, V16, P456, DOI 10.1111/j.1399-3038.2005.00277.x; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; Mao XQ, 1998, HUM HERED, V48, P38, DOI 10.1159/000022782; Mao XQ, 1996, LANCET, V348, P581, DOI 10.1016/S0140-6736(95)10244-2; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Matsumoto Y, 2002, INT ARCH ALLERGY IMM, V129, P327, DOI 10.1159/000067589; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MOFFATT MF, 2005, 35 ANN EUR SOC DERM, pA22; Nagata N, 2003, INT ARCH ALLERGY IMM, V132, P156, DOI 10.1159/000073717; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Nishio Y, 2001, J HUM GENET, V46, P664, DOI 10.1007/s100380170018; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Ogawa K, 2003, CLIN EXP IMMUNOL, V131, P436, DOI 10.1046/j.1365-2249.2003.02090.x; Ogawa K, 2005, J DERMATOL SCI, V40, P35, DOI 10.1016/j.jdermsci.2005.06.001; Oiso N, 2000, BRIT J DERMATOL, V142, P1003, DOI 10.1046/j.1365-2133.2000.03485.x; On M, 2004, J BIOL CHEM, V279, P45782, DOI 10.1074/jbc.M404890200; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Park CW, 2005, BRIT J DERMATOL, V152, P1173, DOI 10.1111/j.1365-2133.2005.06474.x; Pascale E, 2001, HUM HERED, V51, P177, DOI 10.1159/000053339; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Rafatpanah H, 2003, J ALLERGY CLIN IMMUN, V112, P593, DOI 10.1067/mai.2003.1699; Rho NK, 2004, BRIT J DERMATOL, V151, P119, DOI 10.1111/j.1365-2133.2004.06027.x; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soderhall C, 2001, HUM GENET, V109, P129, DOI 10.1007/s004390100556; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Suzuki K, 2006, BIOCHEM BIOPH RES CO, V339, P1217, DOI 10.1016/j.bbrc.2005.11.141; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Tanaka K, 1999, CLIN EXP ALLERGY, V29, P800; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Tazawa T, 2004, ARCH DERMATOL RES, V295, P459, DOI 10.1007/s00403-004-0455-6; Tosh K, 2002, J INFECT DIS, V186, P1190, DOI 10.1086/343806; Traherne JA, 2003, HUM MOL GENET, V12, P2577, DOI 10.1093/hmg/ddg290; Tsunemi Y, 2002, J DERMATOL SCI, V30, P100, DOI 10.1016/S0923-1811(02)00065-8; Tsunemi Y, 2002, J DERMATOL SCI, V29, P222, DOI 10.1016/S0923-1811(02)00038-5; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Vavilin VA, 2003, B EXP BIOL MED+, V136, P388, DOI 10.1023/B:BEBM.0000010960.06583.20; WACHTER AM, 1992, ANN ALLERGY, V69, P407; Wadonda-Kabondo N, 2004, ARCH DIS CHILD, V89, P917, DOI 10.1136/adc.2003.034033; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Watanabe N, 2002, INT ARCH ALLERGY IMM, V128, P229, DOI 10.1159/000064256; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2005, ALLERGY, V60, P1256, DOI 10.1111/j.1398-9995.2005.00879.x; Weidinger S, 2005, CLIN EXP ALLERGY, V35, P866, DOI 10.1111/j.1365-2222.2005.02269.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; WISE F, 1993, FOOTNOTE PROBLEMS EC; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	128	184	195	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					24	34		10.1016/j.jaci.2006.03.037	http://dx.doi.org/10.1016/j.jaci.2006.03.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815134				2022-12-18	WOS:000239184800002
J	Liu, MC; Dube, LM; Lancaster, J				Liu, MC; Dube, LM; Lancaster, J			Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse effects; antiinflammatory agents; asthma; beta-agonists; bronchial diseases; corticosteroids; leukotrienes; 5-lipolygenase inhibitors; pulmonary function tests; zileuton	MAST-CELLS; BRONCHOALVEOLAR LAVAGE; LEUKOTRIENE SYNTHESIS; EOSINOPHIL COUNTS; HUMAN-LUNG; INFLAMMATION; GLYCOPROTEIN; METABOLISM; GENERATION; MECHANISM	Background: Leukotrienes produced by the 5-lipoxygenase pathway of arachidonic acid metabolism may mediate bronchoconstriction and inflammatory changes important in the pathophysiology of asthma. Leukotriene inhibition may be effective in asthma management. Objective: This clinical trial was performed to assess the long-term efficacy and safety of zileuton, an inhibitor of 5-lipoxygenase. Methods: In this multicenter, double-blind parallel-group, placebo-controlled trial, 600 mg of zileuton, 400 mg of zileuton, or placebo was given orally, each four times daily for 6 months. Patients with mild to moderate asthma (n = 373), 18 to 62 years of age, being managed with regularly inhaled beta-agonist alone, were randomized to the zileuton or placebo groups (n = 122 to 126). Outcome measures included serial spirometry, daily peak expiratory flow rates, daytime and nocturnal symptoms, frequency of beta-agonist use, and number of asthma exacerbations treated with systemic corticosteroids. Results: An acute bronchodilatory effect was observed 2 to 5 hours after the initial dose of medication in both 400 mg zileuton and 600 mg zileuton groups compared to the placebo group. Both zileuton groups had significantly greater improvements in FEV(1) than did the placebo group by day 8. On day 36, FEV(1) improved 16% and 12% from baseline for patients treated with 600 mg zileuton and 400 mg zileuton, respectively, compared with an improvement of 6% for the placebo-treated group (p < 0.01, zileuton 600 mg vs placebo). Blood eosinophil levels were significantly reduced in both zileuton-treated groups compared with the placebo group. In the group receiving 600 mg zileuton, morning peak expiratory flow rate improved by 7% to 10%; daytime and nocturnal symptoms decreased by 37% and 31%, respectively; beta-agonist use decreased by 31%; and the proportion of patients requiring steroid rescue medication during the study was reduced by 62% (p < 0.05 for all comparisons of zileuton, 600 mg, vs placebo). Improvements were sustained over 6 months. Adverse events were similar in the three groups with no apparent dose-related side effects. Conclusion: Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated.	ABBOTT LABS, ABBOTT PK, IL 60064 USA	Abbott Laboratories	Liu, MC (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED, 5501 HOPKINS BAYVIEW CIRCLE, BALTIMORE, MD 21224 USA.							BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; *DIV DRUG BIOL PRO, 1989, COSTART COD SYMB THE; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JORIS I, 1987, AM J PATHOL, V126, P19; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; MILLER AM, 1986, EXP HEMATOL, V14, P760; REID GK, 1990, J BIOL CHEM, V265, P19818; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SORENSEN LS, 1988, INT ARCH ALLER A IMM, V86, P267, DOI 10.1159/000234584; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; UNDERWOOD DC, 1994, J PHARMACOL EXP THER, V270, P250; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	36	184	185	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				859	871		10.1016/S0091-6749(96)80002-9	http://dx.doi.org/10.1016/S0091-6749(96)80002-9			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939149	hybrid			2022-12-18	WOS:A1996VU76400002
J	BENTLEY, AM; MAESTRELLI, P; SAETTA, M; FABBRI, LM; ROBINSON, DS; BRADLEY, BL; JEFFERY, PK; DURHAM, SR; KAY, AB				BENTLEY, AM; MAESTRELLI, P; SAETTA, M; FABBRI, LM; ROBINSON, DS; BRADLEY, BL; JEFFERY, PK; DURHAM, SR; KAY, AB			ACTIVATED LYMPHOCYTES-T AND EOSINOPHILS IN THE BRONCHIAL-MUCOSA IN ISOCYANATE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; LYMPHOCYTES-T; NEUTROPHILS; MACROPHAGES; BRONCHIAL BIOPSIES; SUBJECTS WITH ASTHMA, ISOCYANATES		We have studied the phenotype and activation status of leukocytes in the bronchial mucosa in patients with isocyanate-induced asthma. Fiberoptic bronchial biopsy specimens were obtained from nine subjects with occupational (five toluene- and four methylene diisocyanate-sensitive) asthma, 10 subjects with extrinsic asthma, and 12 nonatopic healthy control subjects. Bronchial biopsy specimens were examined by immunohistology with a panel of monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase method. There was a significant increase in the number of CD25+ cells (interleukin-2 receptor-bearing cells, presumed "activated" T-lymphocytes; p < 0.01) in isocyanate-induced asthma compared with that of control subjects. There were also significant increases in major basic protein (BMK-13)-positive (p < 0.02) and EG2-positive (p < 0.01) cells that represent total and "activated" eosinophil cationic protein-secreting eosinophils, respectively. In agreement with our previous findings, CD25+ (p < 0.01), BMK-13 (p < 0.03), and EG2+ (p < 0.01) cells were also elevated in extrinsic asthma. No significant differences were observed in the numbers of T-lymphocyte phenotypic markers (CD3, CD4, and CD8) between subjects with asthma (isocyanate-induced and extrinsic) and control subjects. Similarly, no significant differences in immunostaining for neutrophil elastase (neutrophils) or CD68 (macrophages) were observed. The results suggest that isocyanate-induced occupational asthma and atopic (extrinsic) asthma have a similar pattern of inflammatory cell infiltrate. The results support the view that T-lymphocyte activation and eosinophil recruitment may be important in asthma of diverse etiology.	NATL HEART & LUNG INST, DEPT ALLERGY & CLIN IMMUNOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND; NATL HEART & LUNG INST, DEPT LUNG PATHOL, LONDON SW3 6LY, ENGLAND; UNIV PADUA, IST MED LAVORO, I-35100 PADUA, ITALY	Imperial College London; Imperial College London; University of Padua			Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689; SAETTA, MARINA/0000-0002-1547-2102; Bentley, Andrew/0000-0002-6883-9246				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOSCHETTO P, 1987, J ALLERGY CLIN IMMUN, V80, P261, DOI 10.1016/0091-6749(87)90028-5; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cardell BS, 1959, THORAX, V14, P341; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P688; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FREW AJ, 1988, J IMMUNOL, V141, P4158; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLYNN A. A., 1960, THORAX, V15, P142, DOI 10.1136/thx.15.2.142; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; HERRMANN F, 1985, J EXP MED, V162, P1111, DOI 10.1084/jem.162.3.1111; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; INGLEFINGER JA, 1983, BIOSTATISTICS CLIN M, P170; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, IN PRESS AM REV RESP; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; MAPP CE, 1986, EUR J RESPIR DIS, V68, P89; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MAPP CE, 1985, ANN ALLERGY, V54, P424; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MOQBEL R, IN PRESS CLIN EXP AL; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; RAMAZZINNI B, 1940, T DISEASE WORKERS; ROBINSON D S, 1991, Journal of Allergy and Clinical Immunology, V87, P208, DOI 10.1016/0091-6749(91)91558-B; SALVATO G, 1968, THORAX, V23, P168, DOI 10.1136/thx.23.2.168; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; STAIN C, 1987, BLOOD, V70, P1872; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TOPPING MD, 1986, J ALLERGY CLIN IMMUN, V77, P834, DOI 10.1016/0091-6749(86)90381-7; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	48	184	185	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					821	829		10.1016/0091-6749(92)90437-7	http://dx.doi.org/10.1016/0091-6749(92)90437-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1532807				2022-12-18	WOS:A1992HN86000007
J	BERNHISELBROADBENT, J; SCANLON, SM; SAMPSON, HA				BERNHISELBROADBENT, J; SCANLON, SM; SAMPSON, HA			FISH HYPERSENSITIVITY .1. INVITRO AND ORAL CHALLENGE RESULTS IN FISH-ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FISH ALLERGY; FOOD HYPERSENSITIVITY; DOUBLE-BLIND PLACEBO-CONTROLLED ORAL FOOD CHALLENGES; IMMUNOBLOT	LEGUME BOTANICAL FAMILY; FOOD HYPERSENSITIVITY; CROSS-ALLERGENICITY; ATOPIC-DERMATITIS; DOUBLE-BLIND; CHILDREN; CONSUMPTION	The purpose of this study was to determine whether patients allergic to one fish species can safely eat other fish species. Eleven atopic, food-allergic children and young adults with histories consistent with IgE-mediated fish hypersensitivity were skin prick tested to 10 fish species. Skin prick tests (SPTs) were positive to all 10 fish in eight of the 11 patients, and the remaining three patients had at least two positive fish SPTs. Positive oral challenges occurred to only one fish in seven of the patients, to two fish species in one patient, and to three fish species in two patients. One patient did not react to any of the fish tested. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analyses were performed on raw and cooked protein extracts from nine of the 10 fish species used in SPTs. Several protein bands in the raw-fish extracts appeared to denature with cooking and form high molecular weight conglomerates. Immunoblot analyses with sera from documented fish-allergic patients demonstrated specific IgE binding to protein bands from fish to which patients were not clinically allergic, as determined by oral challenge. In ELISA-inhibition assays, the concentration of fish antigen required to achieve 50% inhibition was similar for fish to which the patients were clinically allergic as compared to fish to which they were clinically tolerant. SPT and in vitro evidence of IgE-specific cross-reactivity does not necessarily correlate with symptomatic fish allergy. In addition, these fish-hypersensitive patients were able to consume one or more other fish species without adverse allergic reactions.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV ALLERGY IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University					NCI NIH HHS [CA 16754] Funding Source: Medline; NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI 24439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; Aas K., 1987, FOOD ALLERGY INTOLER, P356; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURR ML, 1989, LANCET, V2, P757; de Besche A, 1938, ACTA MED SCAND, V92, P237; DEMARTINO M, 1990, J ALLERGY CLIN IMMUN, V86, P909, DOI 10.1016/S0091-6749(05)80154-X; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DYBENDAL T, 1989, ALLERGY, V44, P401, DOI 10.1111/j.1398-9995.1989.tb04171.x; EASTAUGH J, 1989, ARCH INTERN MED, V149, P1735, DOI 10.1001/archinte.149.8.1735; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; HENDRICKSON WA, 1973, J BIOL CHEM, V248, P3327; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; SAARINEN UM, 1980, LANCET, V1, P166; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; TAYLOR SL, 1984, ACS SYM SER, V262, P417; TUFT L, 1946, J ALLERGY, V17, P329, DOI 10.1016/0021-8707(46)90155-4; WENDEROTH H, 1956, DEUT MED WOCHENSCHR, V81, P1274, DOI 10.1055/s-0028-1115831	22	184	188	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					730	737		10.1016/0091-6749(92)90381-B	http://dx.doi.org/10.1016/0091-6749(92)90381-B			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545094				2022-12-18	WOS:A1992HJ34000013
J	BOCK, SA				BOCK, SA			THE NATURAL-HISTORY OF FOOD SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,BOULDER,CO 80309	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	BOCK, SA (corresponding author), NATL JEWISH HOSP & RES CTR,NATL ASTHMA CTR,DEPT PEDIAT,DENVER,CO 80206, USA.							BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1980, AM J DIS CHILD, V134, P973, DOI 10.1001/archpedi.1980.02130220049015; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1980, ALLERGY, V35, P301, DOI 10.1111/j.1398-9995.1980.tb01771.x; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x	7	184	190	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					173	177		10.1016/0091-6749(82)90096-3	http://dx.doi.org/10.1016/0091-6749(82)90096-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	6895758				2022-12-18	WOS:A1982NC58100002
J	Kelleher, M; Dunn-Galvin, A; Hourihane, JO; Murray, D; Campbell, LE; McLean, WHI; Irvine, AD				Kelleher, Maeve; Dunn-Galvin, Audrey; Hourihane, Jonathan O'B.; Murray, Deirdre; Campbell, Linda E.; McLean, W. H. Irwin; Irvine, Alan D.			RETRACTED: Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year (Retracted article. See vol. 147, pg. 1526, 2021)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Retracted Publication						Infant; skin barrier; TEWL; atopic dermatitis; filaggrin; predictor; biomarker	PARTY DIAGNOSTIC-CRITERIA; EUROPEAN TASK-FORCE; RISK-FACTORS; CONFOUNDER-SELECTION; ALLERGIC RHINITIS; CONSENSUS REPORT; STRATUM-CORNEUM; ECZEMA SEVERITY; SCORAD INDEX; FILAGGRIN	Background: Loss-of-function mutations in the skin barrier protein filaggrin (FLG) are a major risk for atopic dermatitis (AD). The pathogenic sequence of disturbances in skin barrier function before or during the early development of AD is not fully understood. A more detailed understanding of these events is needed to develop a clearer picture of disease pathogenesis. A robust, noninvasive test to identify babies at high risk of AD would be important in planning early intervention and/or prevention studies. Objectives: To ascertain whether a noninvasive measurement of skin barrier function at day 2 after birth and at 2 months predicts the development of AD at 1 year. Furthermore, to determine whether increases in transepidermal water loss (TEWL) predate the development of clinical AD. Methods: A total of 1903 infants were enrolled in the Cork Babies After Scope: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints Birth Cohort study from July 2009 to October 2011. Measurements of TEWL were made at birth (day 2) and at 2 and 6 months. The presence of AD was ascertained at 6 and 12 months, and disease severity was assessed by using the SCORing Atopic Dermatitis clinical tool at 6 months and by using both the SCORing Atopic Dermatitis clinical tool and Nottingham Severity Score at 12 months. A total of 1300 infants were genotyped for FLG mutations. Results: At 6 months, 18.7% of the children had AD, and at 12 months, 15.53%. In a logistic regression model, day 2 upper quartile TEWL measurement was significantly predictive of AD at 12 months (area under the receiver operating characteristic curve, 0.81; P < .05). Lowest quartile day 2 TEWL was protective against AD at 12 months. An upper quartile 2 month TEWL was also strongly predictive of AD at 12 months (area under the receiver operating characteristic curve, 0.84; P <. 05). At both ages, this effect was independent of parental atopy, FLG status, or report of an itchy flexural rash at 2 months. Associations were increased when parental atopy status or child FLG mutation status was added into the linear regression model. Conclusions: Impairment of skin barrier function at birth and at 2 months precedes clinical AD. In addition to providing important mechanistic insights into disease pathogenesis, these findings have implications for the optimal timing of interventions for the prevention of AD.	[Kelleher, Maeve; Dunn-Galvin, Audrey; Hourihane, Jonathan O'B.; Murray, Deirdre] Natl Univ Ireland Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland; [Hourihane, Jonathan O'B.; Murray, Deirdre; Irvine, Alan D.] Natl Childrens Res Ctr, Dublin, Ireland; [Campbell, Linda E.; McLean, W. H. Irwin] Univ Dundee, Dermatol & Genet Med, Dundee, Scotland; [Irvine, Alan D.] Our Ladys Childrens Hosp, Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Med Clin, Dublin, Ireland	University College Cork; National Children's Research Centre (NCRC); Trinity College Dublin; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Hosp Sick Children, Dublin D12, Ireland.	IRVINEA@tcd.ie	Irvine, Alan D/A-3982-2008; DunnGalvin, Audrey/G-1741-2012	Irvine, Alan D/0000-0002-9048-2044; Murray, Deirdre/0000-0002-2201-9912	Food Standards Agency of the United Kingdom [TO7060]; National Children's Research Centre, Dublin, Ireland; Wellcome Trust [090066/B/09/Z, 092530/Z/10/Z, 098439/Z/12/Z]; Wellcome Trust Strategic Award [098439/Z/12/Z]; National Children's Research Centre; Food Standards Agency; National Children's Research Centre (Ireland); Thermo Fisher; MRC [G0700314, G0802780] Funding Source: UKRI; Medical Research Council [G0802780, G0700314] Funding Source: researchfish	Food Standards Agency of the United Kingdom; National Children's Research Centre, Dublin, Ireland; Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust Strategic Award(Wellcome Trust); National Children's Research Centre; Food Standards Agency; National Children's Research Centre (Ireland); Thermo Fisher; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Food Standards Agency of the United Kingdom (grant no. TO7060). The BASELINE cohort was supported by the National Children's Research Centre, Dublin, Ireland. A.D.I. and W.H.I.M. were supported by the Wellcome Trust (grant nos. 090066/B/09/Z and 092530/Z/10/Z). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (grant no. 098439/Z/12/Z to W.H.I.M.).; Disclosure of potential conflict of interest: J.O'B. Hourihane has received research support from the Food Standards Agency and the National Children's Research Centre (Ireland) and has received lecture fees from Thermo Fisher. W.H. Irwin McLean has received research support from the Wellcome Trust (098439/Z/12/Z). A.D. Irvine has received research support from the National Children's Research Centre. The rest of the authors declare that they have no relevant conflicts of interest.	AB, 2008, WELC BASELINE STUD; ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Boralevi F, 2008, ALLERGY, V63, P205, DOI 10.1111/j.1398-9995.2007.01556.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Budtz-Jorgensen E, 2007, ANN EPIDEMIOL, V17, P27, DOI 10.1016/j.annepidem.2006.05.007; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Duggan EM, 2012, PEDIAT ALLERG IMM-UK, V23, P464, DOI 10.1111/j.1399-3038.2012.01291.x; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Nikolovski J, 2008, J INVEST DERMATOL, V128, P1728, DOI 10.1038/sj.jid.5701239; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Portelli MA, 2015, CLIN EXP ALLERGY, V45, P21, DOI 10.1111/cea.12327; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	35	183	188	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					930	+		10.1016/j.jaci.2014.12.013	http://dx.doi.org/10.1016/j.jaci.2014.12.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25618747	Green Published, hybrid			2022-12-18	WOS:000352238600014
J	Brough, HA; Simpson, A; Makinson, K; Hankinson, J; Brown, S; Douiri, A; Belgrave, DCM; Penagos, M; Stephens, AC; McLean, WHI; Turcanu, V; Nicolaou, N; Custovic, A; Lack, G				Brough, Helen A.; Simpson, Angela; Makinson, Kerry; Hankinson, Jenny; Brown, Sara; Douiri, Abdel; Belgrave, Danielle C. M.; Penagos, Martin; Stephens, Alick C.; McLean, W. H. Irwin; Turcanu, Victor; Nicolaou, Nicolaos; Custovic, Adnan; Lack, Gideon			Peanut allergy: Effect of environmental peanut exposure in children with filaggrin loss-of-function mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FLG loss-of-function mutations; filaggrin; skin barrier; peanut sensitization; peanut allergy; environmental peanut exposure; dust; threshold	ATOPIC-DERMATITIS; RISK-FACTOR; GENE; SENSITIZATION; PROTEIN; ECZEMA; CONSUMPTION; EXPRESSION; CONTACT; INFANCY	Background: Filaggrin (FLG) loss-of-function mutations lead to an impaired skin barrier associated with peanut allergy. Household peanut consumption is associated with peanut allergy, and peanut allergen in household dust correlates with household peanut consumption. Objective: We sought to determine whether environmental peanut exposure increases the odds of peanut allergy and whether FLG mutations modulate these odds. Methods: Exposure to peanut antigen in dust within the first year of life was measured in a population-based birth cohort. Peanut sensitization and peanut allergy (defined by using oral food challenges or component-resolved diagnostics [CRD]) were assessed at 8 and 11 years. Genotyping was performed for 6 FLG mutations. Results: After adjustment for infantile atopic dermatitis and preceding egg skin prick test (SPT) sensitization, we found a strong and significant interaction between natural log (ln[loge]) peanut dust levels and FLG mutations on peanut sensitization and peanut allergy. Among children with FLG mutations, for each ln unit increase in the house dust peanut protein level, there was a more than 6-fold increased odds of peanut SPT sensitization, CRD sensitization, or both in children at ages 8 years, 11 years, or both and a greater than 3-fold increased odds of peanut allergy compared with odds seen in children with wild-type FLG. There was no significant effect of exposure in children without FLG mutations. In children carrying an FLG mutation, the threshold level for peanut SPT sensitization was 0.92 mu g of peanut protein per gram (95% CI, 0.70-1.22 mu g/g), that for CRD sensitization was 1.03 mu g/g (95% CI, 0.90-1.82 mu g/g), and that for peanut allergy was 1.17 mu g/g (95% CI, 0.01-163.83 mu g/g). Conclusion: Early-life environmental peanut exposure is associated with an increased risk of peanut sensitization and allergy in children who carry an FLG mutation. These data support the hypothesis that peanut allergy develops through transcutaneous sensitization in children with an impaired skin barrier.	[Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London SE1 7EH, England; [Simpson, Angela; Hankinson, Jenny; Belgrave, Danielle C. M.; Nicolaou, Nicolaos; Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England; [Simpson, Angela; Hankinson, Jenny; Belgrave, Danielle C. M.; Nicolaou, Nicolaos; Custovic, Adnan] Univ S Manchester Hosp, NHS Fdn Trust, Manchester M20 8LR, Lancs, England; [Belgrave, Danielle C. M.] Univ Manchester, Ctr Hlth Informat, Inst Populat Hlth, Manchester M13 9PL, Lancs, England; [Brown, Sara; McLean, W. H. Irwin] Univ Dundee, Coll Life Sci, Ctr Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Brown, Sara; McLean, W. H. Irwin] Univ Dundee, Coll Med Dent & Nursing, Dundee DD1 4HN, Scotland; [Douiri, Abdel] Kings Coll London, Sch Med, Dept Publ Hlth Sci, London WC2R 2LS, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Manchester; Oxford University Hospitals NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; University of Dundee; University of Dundee; University of London; King's College London	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Floor,Stairwell B,South Wing, London SE1 7EH, England.	Gideon.lack@kcl.ac.uk	Brown, Sara J/AAF-7095-2019; Custovic, Adnan/A-2435-2012	Brown, Sara J/0000-0002-3232-5251; Custovic, Adnan/0000-0001-5218-7071; Douiri, Abdel/0000-0002-4354-4433; Simpson, Angela/0000-0003-2733-6666; Penagos, Martin/0000-0002-9488-194X; Brough, Helen/0000-0001-7203-0813; Lack, Gideon/0000-0001-7350-4021	Action Medical Research [S/P/4529]; National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre; Kings College London; Medical Research Council [G0601361, MR/K002449/1]; JP Moulton Charitable Foundation; North West Lung Centre Charity; National Institute for Health Research Clinical Research Facility at the University Hospital of South Manchester NHS Foundation Trust; Wellcome Trust Strategic Award [098439/Z/12/Z]; MRC [MR/K002449/1, G0700314, G0601361] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: researchfish	Action Medical Research; National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Kings College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); JP Moulton Charitable Foundation; North West Lung Centre Charity; National Institute for Health Research Clinical Research Facility at the University Hospital of South Manchester NHS Foundation Trust; Wellcome Trust Strategic Award(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The research was funded by Action Medical Research (S/P/4529) and supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and Kings College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Manchester Asthma and Allergy Study is supported by Medical Research Council grants G0601361 and MR/K002449/1, the JP Moulton Charitable Foundation, North West Lung Centre Charity, and the National Institute for Health Research Clinical Research Facility at the University Hospital of South Manchester NHS Foundation Trust. The Centre for Dermatology and Genetic Medicine, University of Dundee, is funded by a Wellcome Trust Strategic Award (098439/Z/12/Z; to W.H.I.M.). S.B. holds a Wellcome Intermediate Clinical Fellowship (086398/Z/08/Z).	Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Bertelsen RJ, 2014, CLIN EXP ALLERGY, V44, P142, DOI 10.1111/cea.12231; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Brown S, 2008, TLS-TIMES LIT SUPPL, P27; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; Dodge Y, 2003, OXFORD DICT STAT TER; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park DL, 2005, J AOAC INT, V88, P156; Park MY, 2008, BIOSTATISTICS, V9, P30, DOI 10.1093/biostatistics/kxm010; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Poms RE, 2005, FOOD ADDIT CONTAM A, V22, P104, DOI 10.1080/02652030400027953; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Shults J, 1998, BIOMETRICS, V54, P1622, DOI 10.2307/2533686; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Simpson A, 2002, CLIN EXP ALLERGY, V32, P1413, DOI 10.1046/j.1365-2745.2002.01496.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Succop PA, 2004, J OCCUP ENVIRON HYG, V1, P436, DOI 10.1080/15459620490462797; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030	45	183	185	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					867	U472		10.1016/j.jaci.2014.08.011	http://dx.doi.org/10.1016/j.jaci.2014.08.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282568	Green Published, hybrid			2022-12-18	WOS:000343155700013
J	Wu, W; Bleecker, E; Moore, W; Busse, WW; Castro, M; Chung, KF; Calhoun, WJ; Erzurum, S; Gaston, B; Israel, E; Curran-Everett, D; Wenzel, SE				Wu, Wei; Bleecker, Eugene; Moore, Wendy; Busse, William W.; Castro, Mario; Chung, Kian Fan; Calhoun, William J.; Erzurum, Serpil; Gaston, Benjamin; Israel, Elliot; Curran-Everett, Douglas; Wenzel, Sally E.			Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma phenotyping; variable analysis; unsupervised approaches; supervised machine learning approaches	CLUSTER-ANALYSIS; YOUNG-CHILDREN	Background: Previous studies have identified asthma phenotypes based on small numbers of clinical, physiologic, or inflammatory characteristics. However, no studies have used a wide range of variables using machine learning approaches. Objectives: We sought to identify subphenotypes of asthma by using blood, bronchoscopic, exhaled nitric oxide, and clinical data from the Severe Asthma Research Program with unsupervised clustering and then characterize them by using supervised learning approaches. Methods: Unsupervised clustering approaches were applied to 112 clinical, physiologic, and inflammatory variables from 378 subjects. Variable selection and supervised learning techniques were used to select relevant and nonredundant variables and address their predictive values, as well as the predictive value of the full variable set. Results: Ten variable clusters and 6 subject clusters were identified, which differed and overlapped with previous clusters. Patients with traditionally defined severe asthma were distributed through subject clusters 3 to 6. Cluster 4 identified patients with early-onset allergic asthma with low lung function and eosinophilic inflammation. Patients with later-onset, mostly severe asthma with nasal polyps and eosinophilia characterized cluster 5. Cluster 6 asthmatic patients manifested persistent inflammation in blood and bronchoalveolar lavage fluid and exacerbations despite high systemic corticosteroid use and side effects. Age of asthma onset, quality of life, symptoms, medications, and health care use were some of the 51 nonredundant variables distinguishing subject clusters. These 51 variables classified test cases with 88% accuracy compared with 93% accuracy with all 112 variables. Conclusion: The unsupervised machine learning approaches used here provide unique insights into disease, confirming other approaches while revealing novel additional phenotypes.	[Wu, Wei] Carnegie Mellon Univ, Sch Comp Sci, Lane Ctr Computat Biol, Pittsburgh, PA 15213 USA; [Bleecker, Eugene; Moore, Wendy] Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27109 USA; [Busse, William W.] Univ Wisconsin, Div Allergy & Immunol, Madison, WI USA; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Calhoun, William J.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Erzurum, Serpil] Cleveland Clin, Dept Pulm Allergy & Crit Care Med, Cleveland, OH 44106 USA; [Gaston, Benjamin] Case Western Reserve Univ, Sch Med, Dept Pediat, Div Pediat Pulmonol & Allergy Immunol, Cleveland, OH 44106 USA; [Israel, Elliot] Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; [Curran-Everett, Douglas; Wenzel, Sally E.] Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO USA; [Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA	Carnegie Mellon University; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Imperial College London; University of Texas System; University of Texas Medical Branch Galveston; Cleveland Clinic Foundation; Case Western Reserve University; Harvard University; Brigham & Women's Hospital; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, W (corresponding author), Carnegie Mellon Univ, Sch Comp Sci, Lane Ctr Computat Biol, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.	weiwu2@cs.cmu.edu; wenzelse@upmc.edu	Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Calhoun, William/0000-0001-7075-712X; Wenzel, Sally/0000-0002-4242-0164; Curran-Everett, Douglas/0000-0001-5992-4839	National Institutes of Health [R01GM087694, RO1-HL69174, HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, M01 RR018390, M01RR07122, M01 RR03186, HL087665]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122, M01RR018390, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069174, R01HL087665, R01HL069155, R01HL069170, U10HL109257, R01HL069167, R01HL069149, R01HL069130, U10HL109172, R01HL069116, R01HL069349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA035778] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by National Institutes of Health grants R01GM087694, RO1-HL69174, HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, M01 RR018390, M01RR07122, M01 RR03186, and HL087665.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Dudoit S, 2002, STAT SINICA, V12, P111; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Gouvis-Echraghi R, 2012, J ALLERGY CLIN IMMUN, V130, P1005, DOI 10.1016/j.jaci.2012.07.007; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Koller D., 1996, Machine Learning. Proceedings of the Thirteenth International Conference (ICML '96), P284; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; MITCHELL TOM M., 1997, MACH LEARN, P2; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Saffar AS, 2011, CURR DRUG TARGETS, V12, P556; Siroux V, 2011, CURR OPIN ALLERGY CL, V11, P393, DOI 10.1097/ACI.0b013e32834a955a; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Xing E.-P., 2001, 18 INT C MACH LEARN, P601; Yu L, 2004, J MACH LEARN RES, V5, P1205	21	183	187	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1280	1288		10.1016/j.jaci.2013.11.042	http://dx.doi.org/10.1016/j.jaci.2013.11.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24589344	Green Accepted			2022-12-18	WOS:000335450700007
J	Dang, TD; Tang, MM; Choo, S; Licciardi, PV; Koplin, JJ; Martin, PE; Tan, T; Gurrin, LC; Ponsonby, AL; Tey, D; Robinson, M; Dharmage, SC; Allen, KJ				Dang, Thanh D.; Tang, Mimi; Choo, Sharon; Licciardi, Paul V.; Koplin, Jennifer J.; Martin, Pamela E.; Tan, Tina; Gurrin, Lyle C.; Ponsonby, Anne-Louise; Tey, Dean; Robinson, Marnie; Dharmage, Shyamali C.; Allen, Katrina J.		HealthNuts Study	Increasing the accuracy of peanut allergy diagnosis by using Ara h 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; diagnosis; diagnostic testing; Ara h 1; Ara h 2; Ara h 3; skin prick tests; ImmunoCAP; HealthNuts; IgE; oral food challenge	FOOD ALLERGY; RECOMBINANT ALLERGENS; CHILDREN; IGE; PREVALENCE	Background: Measurement of whole peanut-specific IgE (sIgE) is often used to confirm sensitization but does not reliably predict allergy. Ara h 2 is the dominant peanut allergen detected in 90% to 100% of patients with peanut allergy and could help improve diagnosis. Objectives: We sought to determine whether Ara h 2 testing might improve the accuracy of diagnosing peanut allergy and therefore circumvent the need for an oral food challenge (OFC). Methods: Infants from the population-based HealthNuts study underwent skin prick tests to determine peanut sensitization and subsequently underwent a peanut OFC to confirm allergy status. In a stratified random sample of 200 infants (100 with peanut allergy and 100 with peanut tolerance), whole peanut sIgE and Ara h 2 sIgE levels were quantified by using fluorescence enzyme immunoassay. Results: By using the previously published 95% positive predictive value of 15 kU(A)/L for whole peanut sIgE, a corresponding specificity of 98% (95% CI, 93% to 100%) was found in this study cohort. At the equivalent specificity of 98%, the sensitivity of Ara h 2 sIgE is 60% (95% CI, 50% to 70%), correctly identifying 60% of subjects with true peanut allergy compared with only 26% correctly identified by using whole peanut sIgE. We report that when using a combined approach of plasma sIgE testing for whole peanut followed by Ara h 2 for the diagnosis of peanut allergy, the number of OFCs required is reduced by almost two thirds. Conclusion: Ara h 2 plasma sIgE test levels provide higher diagnostic accuracy than whole peanut plasma sIgE levels and could be considered a new diagnostic tool to distinguish peanut allergy from peanut tolerance, which might reduce the need for an OFC. (J Allergy Clin Immunol 2012;129:1056-63.)	[Tang, Mimi; Choo, Sharon; Tey, Dean; Robinson, Marnie; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Dang, Thanh D.; Tang, Mimi; Licciardi, Paul V.; Koplin, Jennifer J.; Martin, Pamela E.; Tan, Tina; Gurrin, Lyle C.; Ponsonby, Anne-Louise; Tey, Dean; Robinson, Marnie; Dharmage, Shyamali C.; Allen, Katrina J.] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Dang, Thanh D.; Tang, Mimi; Licciardi, Paul V.; Koplin, Jennifer J.; Martin, Pamela E.; Tan, Tina; Ponsonby, Anne-Louise; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Gurrin, Lyle C.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia; [Choo, Sharon] Royal Childrens Hosp, Dept Lab Serv, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne	Allen, KJ (corresponding author), Royal Childrens Hosp, Dept Allergy & Immunol, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Wake, Melissa/J-1396-2012; Allen, Katrina/I-4361-2018; Matheson, Melanie C/O-4721-2015; Tey, Dean/U-4525-2019; Dang, Thanh/AAK-1608-2021; Ponsonby, Anne-Louise/AAE-4351-2019; Osborne, Nicholas/D-2086-2011	Wake, Melissa/0000-0001-7501-9257; Allen, Katrina/0000-0002-1921-4493; Matheson, Melanie C/0000-0002-5822-3499; Dang, Thanh/0000-0003-2010-5582; Osborne, Nicholas/0000-0002-6700-2284; Tan, Hern-Tze Tina/0000-0002-8289-7573; Tang, Mimi/0000-0002-3839-5293; Gurrin, Lyle/0000-0001-7052-1969; Ponsonby, Anne-Louise/0000-0002-6581-3657; Koplin, Jennifer/0000-0002-7576-5142	Australian National Health & Medical Research Council; Ilhan Food Allergy Foundation; AnaphylaxiStop; Victorian Government; NHMRC; Malaysian Government; Phadia; Abacus ALS; Abbott; Wyeth; Nutricia	Australian National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Victorian Government; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Malaysian Government; Phadia(Phadia); Abacus ALS; Abbott(Abbott Laboratories); Wyeth(Wyeth); Nutricia(Danone Nutricia)	Funding for this project was obtained from the Australian National Health & Medical Research Council, the Ilhan Food Allergy Foundation, AnaphylaxiStop, and the Victorian Government's Operational Infrastructure Support Program. K.J.A. is a Viertel Senior Medical Research Fellow, J.J.K. is supported by an NHMRC Capacity Building Grant in Population Health postdoctoral fellowship, and L.C.G., A.-L.P., and S.C.D. hold National Health & Medical Research Council Awards. J.J.K., P.E.M., and T.D.D. are Australian Postgraduate Award scholars. T.T. is a recipient of a Malaysian Government Scholarship.; M. Tang receives research support from Phadia. S. Choo receives research support from Abacus ALS. A.-L. Ponsonby receives research support from the National Health and Medical Research Council. K. J. Allen receives speaker's fees from Abbott, Wyeth, and Nutricia. The rest of the authors declare that they have no relevant conflicts of interest.	Allen KJ, 2006, MED J AUSTRALIA, V185, P394, DOI 10.5694/j.1326-5377.2006.tb00618.x; [Anonymous], 2010, OFF LIST ALL; ASCIA, IS IT ALL; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Chiang WC, 2010, PEDIAT ALLERG IMM-UK, V21, pE429, DOI 10.1111/j.1399-3038.2009.00930.x; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618, DOI 10.5694/j.1326-5377.2007.tb01077.x; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010	18	183	185	0	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1056	1063		10.1016/j.jaci.2012.01.056	http://dx.doi.org/10.1016/j.jaci.2012.01.056			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22385632				2022-12-18	WOS:000302144600022
J	Cornelissen, C; Marquardt, Y; Czaja, K; Wenzel, J; Frank, J; Luscher-Firzlaff, J; Luscher, B; Baron, JM				Cornelissen, Christian; Marquardt, Yvonne; Czaja, Katharina; Wenzel, Joerg; Frank, Jorge; Luescher-Firzlaff, Juliane; Luescher, Bernhard; Baron, Jens M.			IL-31 regulates differentiation and filaggrin expression in human organotypic skin models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; differentiation; filaggrin; HaCaT; IL-20; IL-24; IL-31; keratinocyte; organotypic skin model; proliferation	ATOPIC-DERMATITIS; EPIDERMAL-KERATINOCYTES; EPITHELIAL-CELLS; ICHTHYOSIS VULGARIS; PROFILAGGRIN GENE; BARRIER FUNCTION; MAST-CELLS; T-CELLS; INTERLEUKIN-31; CYTOKINE	Background: Atopic dermatitis (AD) is an inflammatory skin disease affecting 10% to 20% of children and 1% to 3% of adults in industrialized countries. Enhanced expression of IL-31 is detected in skin samples of patients with AD, but its physiological relevance is not known. Objective: We sought to determine the role of IL-31 in skin differentiation. Methods: We used human 3-dimensional organotypic skin models with either primary keratinocytes or HaCaT keratinocytes with inducible IL-31 receptor alpha to evaluate the effect of IL-31. The consequences were studied by using histology, the expression of markers analyzed by immunofluoresence and quantitative RT-PCR, and gene expression arrays. Results: We observed that IL-31 interferes with keratinocyte differentiation. Gene expression analysis revealed a limited set of genes deregulated in response to IL-31, including IL20 and IL24. In HaCaT keratinocytes with inducible IL-31 receptor alpha, IL-31 inhibited proliferation upon induction of IL-31 receptor alpha by inducing cell cycle arrest. As in primary cells, IL-31-treated HaCaT cells elicited a differentiation defect in organotypic skin models, associated with reduced epidermal thickness, disturbed epidermal constitution, altered alignment of the stratum basale, and poor development of the stratum granulosum. The differentiation defect was associated with a profound repression of terminal differentiation markers, including filaggrin, an essential factor for skin barrier formation, and a reduced lipid envelope. The highly induced proinflammatory cytokines IL-20 and IL-24 were responsible for part of the effect on FLG expression and thus for terminal differentiation. Conclusion: Our study suggests that IL-31 is an important regulator of keratinocyte differentiation and demonstrates a link between the presence of IL-31 in skin, as found in patients with AD, and filaggrin expression. (J Allergy Clin Immunol 2012;129:426-33.)	[Cornelissen, Christian; Luescher-Firzlaff, Juliane; Luescher, Bernhard] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, D-52074 Aachen, Germany; [Marquardt, Yvonne; Czaja, Katharina; Baron, Jens M.] Rhein Westfal TH Aachen, Dept Dermatol & Allergol, D-52074 Aachen, Germany; [Wenzel, Joerg] Univ Bonn, Dept Dermatol, Bonn, Germany; [Frank, Jorge] Univ Dusseldorf, Dept Dermatol, Dusseldorf, Germany; [Frank, Jorge] Maastricht Univ, GROW Sch Oncol & Dev Biol, Med Ctr, Maastricht, Netherlands	RWTH Aachen University; RWTH Aachen University; University of Bonn; Heinrich Heine University Dusseldorf; Maastricht University	Luscher, B (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Pauwelsstr 30, D-52074 Aachen, Germany.	luescher@RWTH-aachen.de; JensMalte.Baron@post.rwth-aachen.de	Wenzel, Jörg/AAX-2644-2020; Baron, Jens/N-2934-2016; Luscher, Bernhard/A-7330-2011	Wenzel, Jörg/0000-0002-4744-5993; Baron, Jens/0000-0002-1174-6946; Luscher, Bernhard/0000-0002-9622-8709	Deutsche Forschungsgemeinschaft [SFB 542]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft Grant SFB 542, project C11, to J.B. and B.L.	Aasen T, 2010, NAT PROTOC, V5, P371, DOI 10.1038/nprot.2009.241; Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Carmi-Levy I, 2011, CLIN REV ALLERG IMMU, V41, P245, DOI 10.1007/s12016-010-8239-6; Chattopadhyay S, 2007, J BIOL CHEM, V282, P3014, DOI 10.1074/jbc.M609655200; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Cornelissen C, 2011, BRIT J DERMATOL, V165, P966, DOI 10.1111/j.1365-2133.2011.10487.x; Cornelissen C, 2011, EUR J CELL BIOL 1005; Dambacher J, 2007, GUT, V56, P1257, DOI 10.1136/gut.2006.118679; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; Ezzat MHM, 2011, J EUR ACAD DERMATOL, V25, P334, DOI 10.1111/j.1468-3083.2010.03794.x; Gutzmer R, 2009, J ALLERGY CLIN IMMUN, V123, P619, DOI 10.1016/j.jaci.2008.12.1110; Heise R, 2009, J INVEST DERMATOL, V129, P240, DOI 10.1038/jid.2008.183; Houben E, 2007, SKIN PHARMACOL PHYS, V20, P122, DOI 10.1159/000098163; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Ishii T, 2009, BLOOD, V113, P5942, DOI 10.1182/blood-2008-09-179416; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jiang K, 2008, NUCLEIC ACIDS RES, V36, P1517, DOI 10.1093/nar/gkn002; Kasraie S, 2010, ALLERGY, V65, P712, DOI 10.1111/j.1398-9995.2009.02255.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Neis MM, 2010, SKIN PHARMACOL PHYS, V23, P29, DOI 10.1159/000257261; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Osawa Rinko, 2011, Allergology International, V60, P1, DOI 10.2332/allergolint.10-RAI-0270; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P315, DOI 10.1016/j.cytogfr.2010.11.001; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Schulz F, 2007, J ALLERGY CLIN IMMUN, V120, P1097, DOI 10.1016/j.jaci.2007.07.065; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Takaoka A, 2006, EXP DERMATOL, V15, P161, DOI 10.1111/j.1600-0625.2006.00405.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Wenzel J, 2005, J PATHOL, V205, P435, DOI 10.1002/path.1721; Wiederholt T, 2009, EXP DERMATOL, V18, P969, DOI 10.1111/j.1600-0625.2009.00884.x; Yamaoka K, 2009, INT ARCH ALLERGY IMM, V149, P73, DOI 10.1159/000211376	48	183	195	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					426	U235		10.1016/j.jaci.2011.10.042	http://dx.doi.org/10.1016/j.jaci.2011.10.042			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22177328				2022-12-18	WOS:000299951700020
J	Majak, P; Olszowiec-Chlebna, M; Smejda, K; Stelmach, I				Majak, Pawel; Olszowiec-Chlebna, Malgorzata; Smejda, Katarzyna; Stelmach, Iwona			Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Majak, Pawel; Olszowiec-Chlebna, Malgorzata; Smejda, Katarzyna; Stelmach, Iwona] Med Univ Lodz, Dept Pediat & Allergy, Lodz, Poland	Medical University Lodz	Majak, P (corresponding author), Med Univ Lodz, Dept Pediat & Allergy, Lodz, Poland.	alergol@kopernik.lodz.pl	Stelmach, Iwona/S-9796-2016	Smejda, Katarzyna/0000-0001-9504-2673; Majak, Pawel/0000-0002-2532-9983; Stelmach, Iwona/0000-0002-1475-8221				Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Ginde AA, 2010, J ALLERGY CLIN IMMUN, V126, P59, DOI 10.1016/j.jaci.2010.05.030; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Kleinman R., 1998, PEDIAT NUTR HDB, V4th; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305	7	183	198	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1294	1296		10.1016/j.jaci.2010.12.016	http://dx.doi.org/10.1016/j.jaci.2010.12.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21315433				2022-12-18	WOS:000290018600026
J	Dougherty, RH; Sidhu, SS; Raman, K; Solon, M; Solberg, OD; Caughey, GH; Woodruff, PG; Fahy, JV				Dougherty, Ryan H.; Sidhu, Sukhvinder S.; Raman, Kavita; Solon, Margaret; Solberg, Owen D.; Caughey, George H.; Woodruff, Prescott G.; Fahy, John V.			Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; mast cells; tryptase; chymase; carboxypeptidase A3; stem cell factor	EPITHELIAL-CELLS; CARBOXYPEPTIDASE-A; ATOPIC ASTHMATICS; ANGIOTENSIN-II; HUMAN AIRWAY; EXPRESSION; CHYMASE; INFLAMMATION; BASOPHILS; ADHESION	Background: Previously, we found that mast cell tryptases and carboxypeptidase A3 (CPA3) are differentially expressed in the airway epithelium in asthmatic subjects. We also found that asthmatic subjects can be divided into 2 subgroups ("T(H)2 high" and "T(H)2 low" asthma) based on epithelial cell gene signatures for the activity of T(H)2 cytokines. Objectives: We sought to characterize intraepithelial mast cells (IEMCs) in asthma. Methods: We performed gene expression profiling in epithelial brushings and stereology-based quantification of mast cell numbers in endobronchial biopsy specimens from healthy control and asthmatic subjects before and after treatment with inhaled corticosteroids (ICSs). We also performed gene expression and protein quantification studies in cultured airway epithelial cells and mast cells. Results: By means of unsupervised clustering, mast cell gene expression in the airway epithelium related closely to the expression of IL-13 signature genes. The levels of expression of mast cell genes correlate positively with lung function improvements with ICSs. IEMC density was 2-fold higher than normal in subjects with T(H)2-high asthma compared with that seen in subjects with T(H)2-low asthma or healthy control subjects (P = .015 for both comparisons), and these cells were characterized by expression of tryptases and CPA3 but not chymase. IL-13 induced expression of stem cell factor in cultured airway epithelial cells, and mast cells exposed to conditioned media from IL-13 activated epithelial cells showed downregulation of chymase but no change in tryptase or CPA3 expression. Conclusion: IEMC numbers are increased in subjects with T(H)2-high asthma, have an unusual protease phenotype (tryptase and CPA3 high and chymase low), and predict responsiveness to ICSs. IL-13 stimulated production of stem cell factor by epithelial cells potentially explains mast cell accumulation in TH2-high asthmatic epithelium. (J Allergy Clin Immunol 2010;125:1046-53.)	[Dougherty, Ryan H.; Sidhu, Sukhvinder S.; Solon, Margaret; Solberg, Owen D.; Caughey, George H.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Dougherty, Ryan H.; Solon, Margaret; Solberg, Owen D.; Caughey, George H.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Dougherty, Ryan H.] Calif Pacific Med Ctr, San Francisco Crit Care Med Grp, San Francisco, CA USA; [Raman, Kavita; Caughey, George H.] San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Fahy, JV (corresponding author), 513 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.	john.fahy@ucsf.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	National Institutes of Health [F32HL093999-01, A1077439-025, R01 HL080414, R01 HL095372, P01 HL024136]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL093999, P01HL024136, R01HL080414, R01HL095372] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Institutes of Health National Research Service Award F32HL093999-01 (R.H.D.), A1077439-025 and R01 HL080414 (J.V.F.), R01 HL095372 (P.G.W.), and P01 HL024136 (G.H.C.).	Agis H, 1996, IMMUNOLOGY, V87, P535, DOI 10.1046/j.1365-2567.1996.493578.x; Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Cairns JA, 1996, J IMMUNOL, V156, P275; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Ferrando RE, 2003, J ALLERGY CLIN IMMUN, V112, P1243, DOI 10.1016/j.jaci.2003.09.038; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; GOLD WM, 1991, AM REV RESPIR DIS, V143, pS61, DOI 10.1164/ajrccm/143.3_Pt_2.S61; Hsieh FH, 2005, P NATL ACAD SCI USA, V102, P14380, DOI 10.1073/pnas.0503948102; Innes AL, 2006, CHEST, V130, P1102, DOI 10.1378/chest.130.4.1102; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JOHNSON HG, 1983, INT J IMMUNOPHARMACO, V5, P391, DOI 10.1016/0192-0561(83)90013-9; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lundequist A, 2004, J BIOL CHEM, V279, P32339, DOI 10.1074/jbc.M405576200; Makowska Joanna S, 2009, BMC Pulm Med, V9, P27, DOI 10.1186/1471-2466-9-27; MATIN R, 1992, J HISTOCHEM CYTOCHEM, V40, P781, DOI 10.1177/40.6.1588024; Mayhew TM, 1996, J ANAT, V188, P1; McEuen AR, 1999, LAB INVEST, V79, P27; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; MILLAR E, 1995, EUR RESPIR J, V8, P1838, DOI 10.1183/09031936.95.08111838; NILSSON G, 1994, J IMMUNOL, V153, P3717; Pejler G, 2009, TRENDS IMMUNOL, V30, P401, DOI 10.1016/j.it.2009.04.008; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; Schneider LA, 2007, J EXP MED, V204, P2629, DOI 10.1084/jem.20071262; Schwartz Lawrence B, 2006, Methods Mol Biol, V315, P53; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Weber S, 1997, SCAND J IMMUNOL, V45, P471, DOI 10.1046/j.1365-3083.1997.d01-420.x; Weibel ER, 2007, J APPL PHYSIOL, V102, P459, DOI 10.1152/japplphysiol.00808.2006; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	43	183	187	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1046	1053		10.1016/j.jaci.2010.03.003	http://dx.doi.org/10.1016/j.jaci.2010.03.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451039	Green Accepted			2022-12-18	WOS:000277686700013
J	Elias, JA; Homer, RJ; Hamid, Q; Lee, CG				Elias, JA; Homer, RJ; Hamid, Q; Lee, CG			Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; acidic mammalian chitinase; chitinase; breast regression protein 39; T(H)2 inflammation	ACIDIC MAMMALIAN CHITINASE; SERUM YKL-40; PARASITE CHITINASE; GENE; IDENTIFICATION; MARKER; FLUID; YM1	Chitin is the second most abundant biopolymer in nature, where it protects crustaceans, parasites, fungi, and other pathogens from the adverse effects of their environments, hosts, or both. Because chitin does not exist in mammals, it had been assumed that the chitinases that degrade it are also restricted to lower life forms. However, chitinases and chitinase-like proteins have recently been noted in mice and human subjects. The prototypic chitinase, acidic mammalian chitinase, was also noted to be induced during T(H)2 inflammation through an IL-13-dependent mechanism. It was also shown to play an important role in the pathogenesis of TH2 inflammation and IL-13 effector pathway activation and demonstrated to be expressed in an exaggerated fashion in human asthmatic tissues. The finding that chitinases contribute to host antiparasite responses and asthmatic T(H)2 inflammation support the concept that asthma might be a parasiteindependent antiparasite response.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Pathol & Lab Med Serv, VA CT Hlth Care Syst, West Haven, CT USA; McGill Univ, Dept Pathol & Med, Meakins Christie Labs, Montreal, PQ, Canada	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; McGill University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 300 Cedar St-441C TAC, New Haven, CT 06520 USA.	jack.elias@yale.edu	Lee, Chun Geun/AAC-2838-2021; homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658				ARAUJO ACG, 1993, J HISTOCHEM CYTOCHEM, V41, P571, DOI 10.1177/41.4.8450196; Bleau G, 1999, EXS, V87, P211; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Cai GP, 1997, J CELL BIOCHEM, V67, P257, DOI 10.1002/(SICI)1097-4644(19971101)67:2<257::AID-JCB11>3.0.CO;2-C; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; FUHRMAN JA, 1985, MOL BIOCHEM PARASIT, V17, P93, DOI 10.1016/0166-6851(85)90130-6; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; McCall C, 2001, VET IMMUNOL IMMUNOP, V78, P231, DOI 10.1016/S0165-2427(00)00258-0; MORRISON BW, 1994, ONCOGENE, V9, P3417; NEVILLE AC, 1976, J CELL SCI, V21, P73; Nordenbaek C, 1999, J INFECT DIS, V180, P1722, DOI 10.1086/315050; Ostergaard C, 2002, CLIN DIAGN LAB IMMUN, V9, P598, DOI 10.1128/CDLI.9.3.598-604.2002; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Perkin JE, 2000, J AM DIET ASSOC, V100, P1381, DOI 10.1016/S0002-8223(00)00384-9; Saito A, 1999, GENE, V239, P325, DOI 10.1016/S0378-1119(99)00394-7; SEIBOLD MA, 2005, P AM THOR SOC, V2, pA79; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shahabuddin M, 1999, EXS, V87, P223; SHAHABUDDIN M, 1994, EXP PARASITOL, V79, P85, DOI 10.1006/expr.1994.1066; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Ward JM, 2001, AM J PATHOL, V158, P323, DOI 10.1016/S0002-9440(10)63972-7; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	32	183	192	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					497	500		10.1016/j.jaci.2005.06.028	http://dx.doi.org/10.1016/j.jaci.2005.06.028			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159614				2022-12-18	WOS:000235686500003
J	Guler, N; Kirerleri, E; Ones, U; Tamay, Z; Salmayenli, N; Darendeliler, F				Guler, N; Kirerleri, E; Ones, U; Tamay, Z; Salmayenli, N; Darendeliler, F			Leptin: Does it have any role in childhood asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leptin; atopy; asthma; children	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; SERUM LEPTIN; BIRTH-WEIGHT; FAT MASS; CHILDREN; OBESITY; ASSOCIATION; EXPRESSION; GENDER	Background: Although there is evidence of a positive association between asthma and obesity in adults and children, very little is known about the role of leptin in asthmatic children. Objectives: The aims of this study were to evaluate the relation between leptin and parameters of atopy and asthma in children. Methods: Body mass index (BMI) and serum leptin levels were measured in 102 (37 female, 65 male; mean age, 5.9 +/- 3.4 years) asthmatic and 33 (14 female, 19 male; mean age, 6.1 3.4 years) healthy children. Skin prick tests, total serum IgE, and pulmonary function tests were performed and were completed. Results: A significant difference was observed in serum leptin levels between asthmatic and healthy children. Median (interquartile range) levels were 3.53 (2.06-7.24) ng/mL and 2.26 (1.26-4.71) ng/mL, respectively (P = .008). Subgroup analysis revealed that this difference in leptin levels was confined entirely to boys: 3.09 (1.99-7.51) ng/mL in boys with asthma versus 1.52 (1.06-3.17) ng/mL in boys without asthma (P = .003). By logistic regression analysis, we found that leptin was a predictive factor for having asthma (odds ratio, 1.98; CI, 1.10-3.55; P = .021), whereas sex, age, or BMI were not. In a stepwise multiple regression analysis including sex (P = .001), age (P = .016), BMI (P < .001), and asthma (P = .022), all of these variables were found to affect log leptin levels (R-2 = 0.404). There was no significant sex difference in serum leptin levels among asthmatic children, whereas healthy boys had significantly lower leptin levels than healthy girls (P = .019). Atopic asthmatic subjects had significantly higher leptin levels than nonatopic asthmatic subjects (P = .038) with similar BMI. A significant, but weak, correlation was observed between leptin levels and IgE in the overall group of asthmatic children (r = 0.231; P = .019). Again, this correlation was confined entirely to boys (r = 0.319; P = .010). There was no relation between leptin levels and skin prick tests, pulmonary function tests, passive smoking, birth weight, and duration of breast-feeding. Conclusion: Our findings suggest that leptin may play a role in atopic asthma. High serum leptin levels in asthmatic boys may partly explain the higher prevalence of childhood asthma in male sex.	Istanbul Fac Med, Dept Pediat, Div Allergy & Chest Dis, Istanbul, Turkey; Istanbul Fac Med, Dept Biochem, Istanbul, Turkey; Istanbul Fac Med, Dept Pediat, Div Endocrinol, Istanbul, Turkey	Istanbul University; Istanbul University; Istanbul University	Guler, N (corresponding author), Hasirci Veli Sok 16, Istanbul, Turkey.	eztamay@yahoo.com	Tamay, Zeynep/AAE-5668-2020; Darendeliler, Feyza/AAH-1013-2020; Salmayenli, Nihal/AAD-9599-2020					Asher MI, 1998, EUR RESPIR J, V12, P315; Bastard JP, 1999, CIRCULATION, V99, P2221; Blum WF, 1997, J CLIN ENDOCR METAB, V82, P2904, DOI 10.1210/jc.82.9.2904; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; CLOUGH JB, 1993, CLIN EXP ALLERGY, V23, P883, DOI 10.1111/j.1365-2222.1993.tb00272.x; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P2849, DOI 10.1210/jc.82.9.2849; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Gibson G. J., 2000, Thorax, V55, pS41, DOI 10.1136/thorax.55.suppl_1.S41; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; Guler N., 2003, Journal of Allergy and Clinical Immunology, V111, pS268, DOI 10.1016/S0091-6749(03)80962-4; Hassink SG, 1996, PEDIATRICS, V98, P201; Hediger ML, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e60; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; LARSSON H, 1998, J CLIN ENDOCR METAB, V83, P1821; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; *NAT HEART LUNG BL, 1995, 953659 NHLBI WHO; Savino F, 2002, ACTA PAEDIATR, V91, P897, DOI 10.1080/080352502760272551; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; Shekhawat PS, 1998, PEDIATR RES, V43, P338, DOI 10.1203/00006450-199803000-00005; Shimizu H, 1997, INT J OBESITY, V21, P536, DOI 10.1038/sj.ijo.0800437; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; Tantisira KG, 2001, THORAX, V56, P64; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; Visser M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e13; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	39	183	196	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					254	259		10.1016/j.jaci.2004.03.053	http://dx.doi.org/10.1016/j.jaci.2004.03.053			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316499				2022-12-18	WOS:000223405600006
J	Ying, S; Kikuchi, Y; Meng, Q; Kay, AB; Kaplan, AP				Ying, S; Kikuchi, Y; Meng, Q; Kay, AB; Kaplan, AP			T(H)1/T(H)2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TH1/TH2-type cytokines; chronic urticaria; inflammatory cells	EXPRESSING MESSENGER-RNA; AFFINITY IGE RECEPTOR; FC-EPSILON-RI; HISTAMINE-RELEASE; T-CELLS; BRONCHIAL BIOPSIES; ANTI-IGE; AUTOANTIBODIES; EOSINOPHILS; AUTOIMMUNITY	Background: Previous studies have demonstrated infiltration of eosinophils, neutrophils, monocytes, and T cells in the skin of patients with chronic idiopathic urticaria (CIU), suggesting a possible T(H)2-type cytokine pathology analogous to the allergen-induced skin late-phase reaction (LPR). Objective: We sought to compare skin biopsy specimens from patients with CIU and the allergen-induced skin LPR for mRNA(+) cells for IL-4, IL-5, and IFN-gamma and inflammatory cell infiltration. Methods: Skin biopsy specimens were obtained from 13 patients with CIU (6 had positive results for FcepsilonRI autoantibodies), 6 nonatopic control subjects, and 6 atopic subjects (before and after cutaneous allergen challenge). Cryostat sections were processed for immunohistochemistry and in situ hybridization by using the S-35-riboprobes. Results: There were significant increases in the numbers of intradermal CD3(+) (P = .007), CD4(+) (P = .004), CD8(+) (P = .012), and CD25(+) (P = .018) T cells, as well as eosinophils (P = .02), neutrophils (P = .01), basophils (P = .004), and macrophages (P = .0014) in patients with CIU compared with numbers in nonatopic control subjects. There A ere lower numbers of tryptase-positive mast cells (P = .048). In the epidermis of patients with CIU, but not in that of normal subjects or in allergen-challenged biopsy specimens, there were increased numbers of CD3(+) T cells (P = .039). The profile of inflammatory cell infiltration in the allergen-induced skin LPR was similar to that in patients with CIU. In patients with CIU there was a T(H)0 cytokine profile, with significant increases in IL-4 (P = .0029), IL-5 (P = .0025), and IFN-gamma (P = .037) mRNA(+) cells. As expected, in the skin LPR there was an increase in IL-4 (P = .0082) and IL-5 (P = .0051), but not IFN-gamma, mRNA(+) cells. There were no significant differences in either the numbers of inflammatory cells or the cytokine pattern between patients with and without autoantibody. Conclusion: The molecular immuno pathology of CIU is that of an eosinophil and basophil cell-mediated hypersensitivity reaction. Thus it is similar to the allergic skin LPR but has a T(H)0 rather than a T(H)2 cytokine profile.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Allergy & Clin Immunol, London SW3 6LY, England; Med Univ S Carolina, Div Pulm & Crit Care, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Konishi Inst Inflammat Res, Charleston, SC 29425 USA	Imperial College London; Medical University of South Carolina; Medical University of South Carolina	Ying, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.							Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; COLLET E, 1995, ANN DERMATOL VENER, V122, P413; DELEURAN B, 1991, BRIT J DERMATOL, V125, P14, DOI 10.1111/j.1365-2133.1991.tb06031.x; Drugarin D, 2000, IMMUNOL LETT, V71, P73, DOI 10.1016/S0165-2478(99)00156-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; FREW AJ, 1988, J IMMUNOL, V141, P4158; Gerli R, 2001, TRENDS IMMUNOL, V22, P72, DOI 10.1016/S1471-4906(00)01829-9; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; HAMID Q, 1992, IMMUNOLOGY, V75, P659; Heuer M, 1996, THYROID, V6, P97, DOI 10.1089/thy.1996.6.97; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kaplan AP, 1999, CAN J ALLERGY CLIN I, V4, P286; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Kukreja A, 2000, CELL MOL LIFE SCI, V57, P534, DOI 10.1007/PL00000715; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Olsen JK, 2001, J CLIN INVEST, V108, P311; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Singh VK, 1999, IMMUNOL RES, V20, P147, DOI 10.1007/BF02786470; SMITH CH, 1995, J ALLERGY CLIN IMMUN, V96, P360, DOI 10.1016/S0091-6749(95)70055-2; Tejada-Simon MV, 2001, EUR J IMMUNOL, V31, P907, DOI 10.1002/1521-4141(200103)31:3<907::AID-IMMU907>3.0.CO;2-1; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Turktas I, 1997, INT J DERMATOL, V36, P187, DOI 10.1046/j.1365-4362.1997.00187.x; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 1997, J IMMUNOL, V158, P3539	34	183	201	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					694	700		10.1067/mai.2002.123236	http://dx.doi.org/10.1067/mai.2002.123236			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941321	Bronze			2022-12-18	WOS:000175132600020
J	La Rosa, M; Ranno, C; Andre, C; Carat, F; Tosca, MA; Canonica, GW				La Rosa, M; Ranno, C; Andre, C; Carat, F; Tosca, MA; Canonica, GW			Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal rhinoconjunctivitis; Parietaria; children; sublingual-swallow immunotherapy	HOUSE-DUST MITE; CONTROLLED TRIAL; POLLEN EXTRACT; RESPIRATORY ALLERGY; ORAL IMMUNOTHERAPY; EFFICACY; RHINITIS; ASTHMA	Background: Sublingual-swallow immunotherapy was recently recognized in the World Health Organization Position Paper (Allergen immunotherapy: therapeutic vaccines for allergic diseases) "as a viable alternative to parenteral injection therapy to treat allergic diseases" in adults. More controlled studies were required to assess the efficacy and safety of this treatment in children. Objective: This study was carried out to assess the clinical efficacy and safety profile of sublingual-swallow immunotherapy with high-dose allergen in children with allergies. Methods: We used a double-blind placebo-controlled design. Forty-one children with Parietaria-induced rhinoconjunctivitis were randomized to receive sublingual standardized Parietaria judaica extract (n = 20) or placebo (n = 21) for 2 years. The cumulative dose of allergen was 375 times higher than that used in parenteral immunotherapy and the cumulative dose of Par j 1 major allergen was 52.5 mg over 2 years. The main efficacy assessment criteria were symptoms and rescue medication scores recorded on the patients' diary cards, Secondary criteria were changes in skin and conjunctival specific reactivity as well as blood parameters, analyzed after 1 and 2 years of immunotherapy: The safety of the treatment was assessed by evaluating the frequency and severity of adverse effects. Results: A significant reduction in rhinitis symptoms was observed in the active treatment group during the second season (P = .02), with no difference in medication scores. A significant decrease in skin reactivity (P = .002 after 2 years of treatment) and an increase in the threshold dose for conjunctival allergen provocation test (P = .02) were observed in the active treatment group compared with the group receiving placebo, A significant increase in specific IgG(4) levels (P = .02) was also observed in the active group. Immunotherapy was well tolerated. Conclusion: Sublingual-swallow immunotherapy in Parietaria-allergic children provided a clinical benefit and a decreased specific reactivity to the allergen, The safety profile of this treatment, which constitutes an important issue, indicated good tolerance and compliance.	Stallergenes, F-92183 Antony, France; Clin Pediat 1, Catania, Italy; Univ Genoa, Dept Internal Med, Allergy & Clin Immunol Unit, I-16126 Genoa, Italy	Stallergenes Greer; University of Genoa	Andre, C (corresponding author), Stallergenes, 6 Rue Alexis Tocqueville, F-92183 Antony, France.		canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557				ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Ariano R, 1998, J INVEST ALLERG CLIN, V8, P155; BASS D, 1984, MED J AUSTRALIA, V140, P511, DOI 10.5694/j.1326-5377.1984.tb108213.x; Bousquet J, 1998, ALLERGY, V53, P4; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; KAUFMAN HS, 1990, ANN ALLERGY, V64, P293; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Malling HJ, 1998, ALLERGY, V53, P461; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 1998, ALLERGY, V53, P477, DOI 10.1111/j.1398-9995.1998.tb04084.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	25	183	190	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				425	432		10.1016/S0091-6749(99)70388-X	http://dx.doi.org/10.1016/S0091-6749(99)70388-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452766				2022-12-18	WOS:000082364800037
J	JAEGER, D; KLEINHANS, D; CZUPPON, AB; BAUR, X				JAEGER, D; KLEINHANS, D; CZUPPON, AB; BAUR, X			LATEX-SPECIFIC PROTEINS CAUSING IMMEDIATE-TYPE CUTANEOUS, NASAL, BRONCHIAL, AND SYSTEMIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; RUBBER GLOVES; GLOVE POWDER; LATEX ASTHMA; IMMEDIATE-TYPE HYPERSENSITIVITY; SPECIFIC IGE ANTIBODIES; PAGE; IMMUNOBLOT; INHALATIVE PROVOCATION TEST	CONTACT URTICARIA; RUBBER GLOVES; NATURAL LATEX; HYPERSENSITIVITY; DERMATITIS; POWDER; ASTHMA	We examined 70 patients reporting hypersensitivity reactions caused by latex articles. All patients suffered from urticaria, 36 from rhinitis, 31 from conjunctivitis, 22 from dyspnea, and 17 from systemic reactions, and four patients developed severe systemic complications during surgery. By means of inhalative challenge tests with powdered latex gloves, it could be demonstrated that the glove powder (cornstarch) obviously functions as a carrier for latex allergens, which then become airborne. Five of 18 patients undergoing such challenge tests demonstrated a significant increase of specific airway resistance; 17, acute rhinitis and/or conjunctivitis; and two, a systemic reaction. Sixty-two percent of the patients demonstrated specific IgE antibodies to natural latex, 58% to an irradiatively cross-linked, so-called, "hypoallergenic" latex preparation, and 46% to commercial-latex RAST disks (Pharmacia). No specific antibodies to cornstarch or a mixture of rubber chemicals were found. A good correlation (82%) exists between latex IgE RAST and latex skin prick test, as revealed in a subgroup of 45 subjects. By means of sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the latex allergen appears to be a mixture of proteins in a molecular weight range from 10 to 67 kd.	CLIN DERMATOL,DEPT ALLERGOL,STUTTGART,GERMANY; OCCUPAT MED INST,DEPT ALLERGOL,BOCHUM,GERMANY									ARCHER BL, 1955, BIOCHEM J, V61, P503, DOI 10.1042/bj0610503; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BELSITO DV, 1990, DERMATOL CLIN, V8, P61, DOI 10.1016/S0733-8635(18)30523-0; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CRONIN E, 1990, CONTACT DERMATITIS, P714; CZUPPON AB, 1991, ALLERGY CLIN IMMUN S, P201; EHL W, 1988, ALLERGOLOGIE, V11, P182; FISHER AA, 1987, CONTACT DERMATITIS, V16, P224, DOI 10.1111/j.1600-0536.1987.tb01430.x; FOERSTROEM L, 1980, CONTACT DERMATITIS, V6, P33; FRANKE W, 1989, NUTZPFLANZENKUNDE, P414; FROSCH PI, 1987, HAUTARZT, V38, P1; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; GEIER J, 1990, Z HAUTKRANKHEITEN, V65, P267; HEESE A, 1989, DTSCH ARZTEBL, V86, P2409; HELANDER I, 1983, CONTACT DERMATITIS, V9, P326; KLEINHANS D, 1984, CONTACT DERMATITIS, V10, P124, DOI 10.1111/j.1600-0536.1984.tb00363.x; KLEINHANS D, 1984, Aktuelle Dermatologie, V10, P227; LEKLAR BC, 1951, J RUBBER RES I MALAY, V13, P146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIBACH HI, 1975, ARCH DERMATOL, V111, P726, DOI 10.1001/archderm.111.6.726; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; ROE CP, 1942, J AM CHEM SOC, V64, P2074; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; Seifert H U, 1987, Derm Beruf Umwelt, V35, P137; SOTO J, 1989, ALLERGOL IMMUNOPATH, V17, P263; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1986, CONTACT DERMATITIS, P603; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1984, ALLERGY S, V2, P35; TURJANMAA K, 1989, CURRENT TOPICS CONTA, P460; VANDERMEEREN HLM, 1986, CONTACT DERMATITIS, V14, P190, DOI 10.1111/j.1600-0536.1986.tb01213.x; VANKETEL WG, 1984, CONTACT DERMATITIS, V11, P323, DOI 10.1111/j.1600-0536.1984.tb01026.x; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x	38	183	189	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					759	768		10.1016/0091-6749(92)90385-F	http://dx.doi.org/10.1016/0091-6749(92)90385-F			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545097				2022-12-18	WOS:A1992HJ34000017
J	Schmitt, J; Spuls, PI; Thomas, KS; Simpson, E; Furue, M; Deckert, S; Dohil, M; Apfelbacher, C; Singh, JA; Chalmers, J; Williams, HC				Schmitt, Jochen; Spuls, Phyllis I.; Thomas, Kim S.; Simpson, Eric; Furue, Masutaka; Deckert, Stefanie; Dohil, Magdalene; Apfelbacher, Christian; Singh, Jasvinder A.; Chalmers, Joanne; Williams, Hywel C.		HOME Initiative Collaborators	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; clinical trials; eczema; Eczema Area and Severity Index; evidence-based medicine; outcomes research	SEVERITY INDEX EASI; QUALITY-OF-LIFE; DISEASE-ACTIVITY; ADULT PATIENTS; DERMATITIS; CONSENSUS; SCORE; OMERACT; AREA; VALIDATION	The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) initiative has already defined clinical signs, symptoms, quality of life, and long-term control of flares as core outcome domains for AE trials. This article deals with the standardization of measurement instruments to assess clinical signs of AE. To resolve the current lack of standardization of the assessment of clinical signs of AE, we followed a structured process of systematic reviews and international consensus sessions to identify 1 core outcome measurement instrument for assessment of clinical signs in all future AE trials. Systematic reviews indicated that from 16 different instruments identified to assess clinical signs of AE, only the Eczema Area and Severity Index (EASI) and the objective Scoring Atopic Dermatitis (SCORAD) index were identified as extensively validated. The EASI has adequate validity, responsiveness, internal consistency, and intraobserver reliability. The objective SCORAD index has adequate validity, responsiveness, and interobserver reliability but unclear intraobserver reliability to measure clinical signs of AE. In an international consensus study, patients, physicians, nurses, methodologists, and pharmaceutical industry representatives agreed that the EASI is the preferred core instrument to measure clinical signs in all future AE trials. All stakeholders involved in designing, reporting, and using clinical trials on AE are asked to comply with this consensus to enable better evidence-based decision making, clearer scientific communication, and improved patient care.	[Schmitt, Jochen; Deckert, Stefanie] Tech Univ Dresden, Med Fac Carl Gustav Carus, Ctr Evidence Based Healthcare, D-01307 Dresden, Germany; [Spuls, Phyllis I.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1012 WX Amsterdam, Netherlands; [Thomas, Kim S.; Chalmers, Joanne; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England; [Simpson, Eric] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Furue, Masutaka] Kyushu Univ, Dept Dermatol, Fukuoka 812, Japan; [Dohil, Magdalene] Univ Calif San Diego, San Diego, CA 92103 USA; [Dohil, Magdalene] Rady Childrens Hosp, San Diego, CA USA; [Apfelbacher, Christian] Univ Regensburg, Dept Epidemiol & Prevent Med, D-93053 Regensburg, Germany; [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL 35487 USA	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Nottingham; Oregon Health & Science University; Kyushu University; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of Regensburg; University of Alabama System; University of Alabama Tuscaloosa	Schmitt, J (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Ctr Evidence Based Healthcare, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de	Apfelbacher, Christian/X-1051-2019; Singh, Jasvinder/R-6172-2019	Apfelbacher, Christian/0000-0003-3805-8219; Singh, Jasvinder/0000-0003-3485-0006; Chalmers, Joanne/0000-0002-2281-7367; Deckert, MPH, Stefanie/0000-0002-4889-3632; Thomas, Kim/0000-0001-7785-7465; Spuls, Phyllis/0000-0002-6035-2863; williams, hywel/0000-0002-5646-3093	National Institute for Health Research (NIHR) [RP-PG-0407-10177]; National Institute for Health Research [RP-PG-0407-10177] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This publication describes work conducted on behalf of the Harmonising Outcome Measures for Eczema (HOME) initiative that is supported through an independent research grant funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme funding scheme (RP-PG-0407-10177). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Angelova-Fischer I, 2005, BRIT J DERMATOL, V153, P767, DOI 10.1111/j.1365-2133.2005.06697.x; Barbier N, 2004, BRIT J DERMATOL, V150, P96, DOI 10.1111/j.1365-2133.2004.05696.x; Bellamy N, 1997, J RHEUMATOL, V24, P799; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Boers M, 1998, J RHEUMATOL, V25, P198; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Chalmers JR, 2014, BRIT J DERMATOL, V170, pE10; Chalmers JR, 2014, BR J DERMATOL; Charman C, 2003, J INVEST DERMATOL, V120, P932, DOI 10.1046/j.1523-1747.2003.12251.x; Charman CR, 2005, ARCH DERMATOL, V141, P1146, DOI 10.1001/archderm.141.9.1146; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Hachisuka J, 2009, INT J DERMATOL, V48, P374, DOI 10.1111/j.1365-4632.2009.03906.x; Haeck IM, 2012, J EUR ACAD DERMATOL, V26, P236, DOI 10.1111/j.1468-3083.2011.04043.x; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hon KLE, 2006, INT J DERMATOL, V45, P728, DOI 10.1111/j.1365-4632.2005.02703.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leshem Y, 2014, BRIT J DERMATOL, V170, pE50; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Nankervis H, 2011, BMC DERMATOL, V11, DOI 10.1186/1471-5945-11-10; Pucci N, 2005, ALLERGY, V60, P113, DOI 10.1111/j.1398-9995.2004.00622.x; Rehal B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017520; Rullo VEV, 2008, ALLERGOL IMMUNOPATH, V36, P205, DOI 10.1016/S0301-0546(08)72551-5; Ruperto N, 2003, RHEUMATOLOGY, V42, P1452, DOI 10.1093/rheumatology/keg403; Schmitt J, 2010, Br J Dermatol, V163, P1166, DOI 10.1111/j.1365-2133.2010.10054.x; Schmitt J, 2011, ECZEMA CLIN EVID ONL, V2011; Schmitt J, 2014, J INVEST DE IN PRESS; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schmitt J, 2013, J ALLERGY CLIN IMMUN, V132, P1337, DOI 10.1016/j.jaci.2013.07.008; Schmitt J, 2012, ALLERGY, V67, P1111, DOI 10.1111/j.1398-9995.2012.02874.x; Schmitt J, 2011, J INVEST DERMATOL, V131, P623, DOI 10.1038/jid.2010.303; Schram ME, 2012, ALLERGY, V67, P99, DOI 10.1111/j.1398-9995.2011.02719.x; Shim WH, 2011, ANN ALLERG ASTHMA IM, V106, P540, DOI 10.1016/j.anai.2011.02.005; Sinha IP, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-103; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tofte S., 1998, J EUR ACAD DERMAT S2, V11, pS197; TUGWELL P, 1993, J RHEUMATOL, V20, P528; Tugwell P, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-38; Weisshaar E, 2008, ACTA DERM-VENEREOL, V88, P234, DOI 10.2340/00015555-0432; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356; Yang HJ, 2010, ASIAN PAC J ALLERGY, V28, P130	42	182	185	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					800	807		10.1016/j.jaci.2014.07.043	http://dx.doi.org/10.1016/j.jaci.2014.07.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282560				2022-12-18	WOS:000343155700004
J	Sharief, S; Jariwala, S; Kumar, J; Muntner, P; Melamed, ML				Sharief, Shimi; Jariwala, Sunit; Kumar, Juhi; Muntner, Paul; Melamed, Michal L.			Vitamin D levels and food and environmental allergies in the United States: Results from the National Health and Nutrition Examination Survey 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; allergic sensitization; vitamin D	SERUM 25-HYDROXYVITAMIN D; D DEFICIENCY; 1,25-DIHYDROXYVITAMIN D-3; CHILDHOOD ASTHMA; US POPULATION; CHILDREN; IGE; SUPPLEMENTATION; SENSITIZATION; PREVALENCE	Background: Previous research supports a possible link between low vitamin D levels and atopic disease. However, the association between low vitamin D levels and total and allergen-specific IgE levels has not been studied. Objective: We sought to test the association between serum 25-hydroxyvitamin D (25[OH] D) deficiency (<15 ng/mL) and insufficiency (15-29 ng/mL) and allergic sensitization measured by serum IgE levels in a US nationally representative sample of 3136 children and adolescents and 3454 adults in the National Health and Nutrition Examination Survey 2005-2006. Methods: The association of 25(OH) D deficiency with 17 different allergens was assessed after adjustment for potential confounders, including age; sex; race/ethnicity; obesity, low socioeconomic status; frequency of milk intake; daily hours spent watching television, playing videogames, or using a computer; serum cotinine levels; and vitamin D supplement use. Results: In children and adolescents allergic sensitization to 11 of 17 allergens was more common in those with 25(OH) D deficiency. Compared with sufficient vitamin D levels of greater than 30 ng/mL, after multivariate adjustment, 25(OH) D levels of less than 15 ng/mL were associated with peanut (odds ratio [OR], 2.39; 95% CI, 1.29-4.45), ragweed (OR, 1.83; 95% CI, 1.20-2.80), and oak (OR, 4.75; 95% CI, 1.53-4.94) allergies (P < .01 for all). Eight other allergens were associated with 25 (OH) D deficiency, with P values of less than .05 but greater than .01. There were no consistent associations seen between 25(OH) D levels and allergic sensitization in adults. Conclusion: Vitamin D deficiency is associated with higher levels of IgE sensitization in children and adolescents. Further research is needed to confirm these findings. (J Allergy Clin Immunol 2011;127:1195-202.)	[Sharief, Shimi] Rush Univ, Dept Med, Med Ctr, Chicago, IL 60612 USA; [Jariwala, Sunit] Montefiore Med Ctr, Dept Allergy & Immunol, Bronx, NY 10467 USA; [Kumar, Juhi] Weill Cornell Med Coll, Dept Pediat, New York, NY USA; [Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; [Melamed, Michal L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Melamed, Michal L.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA	Rush University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Cornell University; University of Alabama System; University of Alabama Birmingham; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Melamed, ML (corresponding author), 1300 Morris Pk Ave,Ullmann 615, Bronx, NY 10461 USA.	michal.melamed@einstein.yu.edu	Kumar, Juhi/CAF-8743-2022		National Institutes of Health [K23-DK078774, K23 DK084339]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK078774, K23DK084339] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	M. L. M. is supported by K23-DK078774 and J. K. is supported by K23 DK084339 from the National Institutes of Health.	Andjelkovic Z, 1999, CLIN EXP RHEUMATOL, V17, P453; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Chang Jei-Wen, 2006, Journal of Microbiology Immunology and Infection, V39, P316; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Correale J, 2009, BRAIN, V132, P1146, DOI 10.1093/brain/awp033; Di Gioacchino M, 2000, ALLERGY, V55, P1030, DOI 10.1034/j.1398-9995.2000.00676.x; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Ezzati T M, 1992, Vital Health Stat 2, P1; Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Gordon CM, 2004, ARCH PEDIAT ADOL MED, V158, P531, DOI 10.1001/archpedi.158.6.531; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; Hernan MA, 1999, NEUROLOGY, V53, P1711, DOI 10.1212/WNL.53.8.1711; Holick MF, 2006, J CLIN INVEST, V116, P2062, DOI 10.1172/JCI29449; Hypponen E, 2009, ALLERGY, V64, P613, DOI 10.1111/j.1398-9995.2008.01865.x; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; LEMIRE JM, 1992, TRANSPLANTATION, V54, P762, DOI 10.1097/00007890-199210000-00046; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd; Long KZ, 1999, PEDIATR INFECT DIS J, V18, P283, DOI 10.1097/00006454-199903000-00018; Looker AC, 2008, AM J CLIN NUTR, V88, P1519, DOI 10.3945/ajcn.2008.26182; Mansbach JM, 2009, PEDIATRICS, V124, P1404, DOI 10.1542/peds.2008-2041; Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3; McKeever TM, 2004, J ALLERGY CLIN IMMUN, V114, P1398, DOI 10.1016/j.jaci.2004.08.006; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Oren E, 2008, J ALLERGY CLIN IMMUN, V121, P533, DOI 10.1016/j.jaci.2007.11.005; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Storaas T, 2005, ACTA OTO-LARYNGOL, V125, P1211, DOI 10.1080/00016480510044205; Vassallo MF, 2010, ANN ALLERG ASTHMA IM, V104, P307, DOI 10.1016/j.anai.2010.01.019; Weisberg P, 2004, AM J CLIN NUTR, V80, p1697S, DOI 10.1093/ajcn/80.6.1697S; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	40	182	185	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1195	1202		10.1016/j.jaci.2011.01.017	http://dx.doi.org/10.1016/j.jaci.2011.01.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21329969	Green Accepted, Bronze			2022-12-18	WOS:000290018600014
J	Wenzel, SE; Busse, WW				Wenzel, Sally E.; Busse, William W.		Natl Heart, Lung Blood Inst Severe	Severe asthma: Lessons from the Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergy; phenotypes; corticosteroids	AIRWAY WALL THICKNESS; LUNG-FUNCTION; RISK-FACTORS; INFLAMMATION; EXACERBATIONS; SINUSITIS; CHILDREN; CELLS; ONSET; AGE	Severe asthma affects only a small percentage of the asthma population. However, these patients remain poorly understood and difficult to treat. Because the numbers are relatively small (10% or less of the asthma population), a network approach with shared protocols, samples, and data provides a unique opportunity to recruit the numbers of subjects necessary to perform adequately powered studies. The Severe Asthma Network (Severe Asthma Research Program) was established by the National Heart, Lung, and Blood Institute in 2001 to advance collectively the study of severe asthma to determine factors that differentiated these patients or subjects from those with milder asthma. Nearly 800 subjects have been recruited in less than 4 years to begin to address these differences. Future studies will specifically evaluate the role of inflammatory/oxidative processes, infection, genetics, and the distal lung in the pathogenesis of severe asthma.	Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Univ Wisconsin, Med Ctr, Madison, WI 53706 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison	Wenzel, SE (corresponding author), Univ Pittsburgh, Med Ctr, NW 628 Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.	wenzelse@upmc.edu						Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Castro M, 2004, AM J RESP CRIT CARE, V169, P842, DOI 10.1164/rccm.200208-960OC; CHANEZ P, 2007, IN PRESS J ALLERGY C; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; HALLOUM AM, 2005, P AM THORAC SOC, V2, P101; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Jarvis D, 2000, ASTHMA RHINITIS, P17; KOTARU C, 2006, P AM THORACIC SOC, V3, pA16; Kotaru C, 2006, AM J RESP CRIT CARE, V173, P1208, DOI 10.1164/rccm.200508-1218OC; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; MOORE BB, 1996, SEVERE ASTHMA PATHOG, P1; MOORE W, 2006, P AM THORACIC SOC, V3, pA16; MOORE WC, 2007, IN PRESS J ALLERGY C; *NIH NAT HEART LUN, 2002, GLOB IN ASTHM GLOB S; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; SIMPSON JL, 2006, THORAX          0714; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; *US DEP HHS NAEPP, 1997, PUBL US DEP HHS NAEP; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; WENZEL S, 2007, IN PRESS AM J RESP C; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605	43	182	188	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					14	21		10.1016/j.jaci.2006.10.025	http://dx.doi.org/10.1016/j.jaci.2006.10.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208583				2022-12-18	WOS:000243622200002
J	Pereira, B; Venter, C; Grundy, J; Clayton, B; Arshad, SH; Dean, T				Pereira, B; Venter, C; Grundy, J; Clayton, B; Arshad, SH; Dean, T			Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; teenagers; fbod challenges; skin prick testing	COWS MILK ALLERGY; SKIN PRICK; DIAGNOSTIC-ACCURACY; ATOPIC-DERMATITIS; PATCH TESTS; CHILDREN; POPULATION; IGE; PEANUT; INTOLERANCE	Background: There is a paucity of information on food hypersensitivity (FHS) among teenagers. Objectives: We sought to investigate the sensitization rates, perception of FHS, food avoidance, and FHS assessed by means of food challenges among teenagers. Methods: This cohort study recruited 757 eleven-year-olds and 775 fifteen-year-olds in the United Kingdom. Sensitization rates, reported rates of FHS, and rates of food avoidance were measured. The prevalence of FHS was established by using food challenges. Results: The prevalence of reported FHS among the 11- and 15-year-old cohorts was 11.6% (90/775) and 12.4% (94/757), respectively. One hundred twenty-two (15.7%) and 142 (18.7%) of the 11- and 15-year-olds reported they were avoiding some food. The rates of sensitization to the food allergens were 5.1% (36/699) and 4.9% (32/649) for the 11- and 15-year-olds, respectively. FHS was confirmed in 8 (1.0%) 11-year-old children and 8 (1.0%) 15-year-old children by means of open food challenge and in 1 (0.1%) 11-year-old and 4 (0.5%) 15-year-olds by means of double-blind, placebo-controlled food challenge. The prevalence of FHS, as confirmed by using open food challenges and positive skin prick test responses plus a history of adverse reactions, was 18 (2.3%) of 775 in the 11-year-old cohort and 17 (2.3%) of 757 in the 15-year-old cohort. Conclusions: The rate of reported FHS was significantly more than sensitization to the predetermined allergens (odds ratio, 2.17; 95% Cl, 1.47-3.18; P < .001 in the 11-year-olds; odds ratio, 2.73; 95% CI, 1.81-4.13; P < .001 in the 15-year-olds). By means of objective assessment, 2.3% of both 11 and 15-year-old children had FHS, with the majority showing immediate reactions.	Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth Inst Med Hlth & Social Care, Portsmouth PO1 2HY, Hants, England; St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England	University of Portsmouth	Dean, T (corresponding author), Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth Inst Med Hlth & Social Care, St Georges Bldg,141 High St, Portsmouth PO1 2HY, Hants, England.	tara.dean@port.ac.uk		Dean, Taraneh/0000-0002-0123-7646	Department of Health [PDF/01/055] Funding Source: Medline	Department of Health		ADLER BR, 1991, CLIN EXP ALLERGY, V21, P683, DOI 10.1111/j.1365-2222.1991.tb03196.x; Altman DR, 1996, J ALLERGY CLIN IMMUN, V97, P1247, DOI 10.1016/S0091-6749(96)70192-6; Baehler P, 1996, CLIN EXP ALLERGY, V26, P254, DOI [10.1046/j.1365-2222.1996.d01-310.x, 10.1111/j.1365-2222.1996.tb00089.x]; Barraclough R, 2002, EUR RESPIR J, V20, P826, DOI 10.1183/09031936.02.00822002; Bhat K, 2002, ALIMENT PHARM THERAP, V16, P969, DOI 10.1046/j.1365-2036.2002.01256.x; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; BOCCAFOGLI A, 1994, ANN ALLERGY, V73, P301; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; GREGORY J, 2000, NATL DIET NUTR SURVE, V1; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hansen TK, 2004, PEDIAT ALLERG IMM-UK, V15, P428, DOI 10.1111/j.1399-3038.2004.00193.x; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; Holland B., 2000, MCCANCE WIDDOWSONS C; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kokkonen J, 2001, J PEDIATR-US, V139, P797, DOI 10.1067/mpd.2001.118882; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x; Mosges R., 2002, CLIN EXP ALLERGY REV, V2, DOI [10.1046/j.1472-9725.2002.00029.x, DOI 10.1046/J.1472-9725.2002.00029.X]; Niggemann B, 2005, ALLERGY, V60, P104, DOI 10.1111/j.1398-9995.2004.00591.x; OSLO KA, 1997, EUROPEAN ALLERGY WHI; PausJenssen ES, 2003, ANN ALLERG ASTHMA IM, V91, P34, DOI 10.1016/S1081-1206(10)62055-8; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2001, LANCET, V358, P1832, DOI 10.1016/S0140-6736(01)06881-7; SAMPSON HA, 1998, ALLERGY PRINCIPLES P, P1162; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Woods RK, 2002, EUR J CLIN NUTR, V56, P31, DOI 10.1038/sj.ejcn.1601306; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; 1999, MMWR MORB MORTAL WKL, V48, P918	39	182	184	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					884	892		10.1016/j.jaci.2005.05.047	http://dx.doi.org/10.1016/j.jaci.2005.05.047			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210065	Bronze			2022-12-18	WOS:000235686600025
J	Carsetti, R; Rosado, MM; Donnanno, S; Guazzi, V; Soresina, A; Meini, M; Plebani, A; Aiuti, F; Quinti, I				Carsetti, R; Rosado, MM; Donnanno, S; Guazzi, V; Soresina, A; Meini, M; Plebani, A; Aiuti, F; Quinti, I			The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						common variable immunodeficiency; IgM memory B cells; bacterial pneumonia; bronchiectasis; natural antibodies; capsular polysaccharide; pneumococcal vaccine	AGAMMAGLOBULINEMIA; ABNORMALITIES; EXPRESSION	Background: Recurrent lower respiratory tract infections caused by encapsulated bacteria might cause permanent organ damage in patients with common variable immunodeficiency (CVID). Despite the profound hypogammaglobulinemia, some patients do not experience bacterial pneumonia. We have shown that IgM memory B cells and natural antibodies play an important role in the defense against encapsulated bacteria. Objective: In this study we addressed the question of whether the apparent paradox of patients with severe hypogammaglobulinemia but no increased frequency of respiratory infections can be explained by the presence of IgM memory B cells and anti-pneumococcal polysaccharide (anti-PnPS) IgM. Methods: We measured the frequency of memory B cells and the levels of anti-PnPS IgM antibodies in 26 patients with CVID with recurrent bacterial pneumonia and bronchiectasis (group 1) and 22 who never had pneumonia and showed no lung lesions (group 2). An additional 6 patients had a clinical history of recurrent pneumonia without lung abnormalities at computed tomographic scanning. Results: Patients of group 1 lacked IgM memory B cells and failed to produce anti-PnPS IgM antibodies, and those of group 2 had a normal frequency of IgM memory B cells and produced anti-PnPS IgM antibodies. Conclusions: IgM memory B cells and anti-PnPS IgM antibodies protect patients with CVID from bacterial pneumonia. Evaluation of these 2 parameters discriminates patients with low or high risk of recurrent infections caused by encapsulated bacteria and low or high risk of bronchiectasis. Identification of high-risk individuals at diagnosis might help in the planning of a more effective therapeutic strategy and prevent permanent organ damage.	IRCCS, Osped Pediat Bambino Gesu, Res Ctr, I-00165 Rome, Italy; Univ Roma La Sapienza, Dept Clin Med, Div Clin Immunol & Allergy, Rome, Italy; Univ Brescia, Dept Pediat, I-25121 Brescia, Italy; Univ Brescia, Inst Mol Med Angelo Nocivelli, I-25121 Brescia, Italy	IRCCS Bambino Gesu; Sapienza University Rome; University of Brescia; University of Brescia	Carsetti, R (corresponding author), IRCCS, Osped Pediat Bambino Gesu, Res Ctr, Piazza S Onofrio 4, I-00165 Rome, Italy.	Rita.Carsetti@uniroma2.it	Plebani, Alessandro/C-8593-2011; Rosado, Maria Manuela/AAX-6495-2020; Carsetti, Rita/K-7616-2016	Carsetti, Rita/0000-0002-2632-1078				Agematsu K, 2002, CLIN IMMUNOL, V103, P34, DOI 10.1006/clim.2001.5197; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Casali P, 1996, CURR TOP MICROBIOL, V210, P167; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Kainulainen L, 1999, J ALLERGY CLIN IMMUN, V104, P1031, DOI 10.1016/S0091-6749(99)70085-0; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Oliva A, 1997, SCAND J IMMUNOL, V46, P86, DOI 10.1046/j.1365-3083.1997.d01-95.x; PANDOLFI F, 1992, CLIN EXP IMMUNOL, V89, P198; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655; THON V, 1987, LANCET, V1, P1075; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166	20	182	184	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					412	417		10.1016/j.jaci.2004.10.048	http://dx.doi.org/10.1016/j.jaci.2004.10.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696104				2022-12-18	WOS:000227043600032
J	Ahmad-Nejad, P; Mrabet-Dahbi, S; Breuer, K; Klotz, M; Werfel, T; Herz, U; Heeg, K; Neumaier, M; Renz, H				Ahmad-Nejad, P; Mrabet-Dahbi, S; Breuer, K; Klotz, M; Werfel, T; Herz, U; Heeg, K; Neumaier, M; Renz, H			The Toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STAPHYLOCOCCUS-AUREUS; MUTATIONS; ASTHMA; GENE		Univ Heidelberg, Inst Clin Chem, Univ Hosp Mannheim, Heidelberg, Germany; Univ Marburg, Cent Lab, Dept Clin Chem & Mol Diagnost, D-3550 Marburg, Germany; Hannover Med Sch, Dept Dermatol, D-3000 Hannover, Germany; Univ Marburg, Inst Med Microbiol & Hyg, Marburg, Germany	Ruprecht Karls University Heidelberg; Philipps University Marburg; Hannover Medical School; Philipps University Marburg	Ahmad-Nejad, P (corresponding author), Univ Heidelberg, Inst Clin Chem, Univ Hosp Mannheim, Bergheimer Str 58, Heidelberg, Germany.		Werfel, Thomas/B-6921-2012					Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Kang TJ, 2001, FEMS IMMUNOL MED MIC, V31, P53, DOI 10.1111/j.1574-695X.2001.tb01586.x; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648	10	182	190	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					565	567		10.1016/j.jaci.2003.12.583	http://dx.doi.org/10.1016/j.jaci.2003.12.583			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007364				2022-12-18	WOS:000220144200034
J	Lin, RY; Schwartz, LB; Curry, A; Pesola, GR; Knight, RJ; Lee, HS; Bakalchuk, L; Tenenbaum, C; Westfal, RE				Lin, RY; Schwartz, LB; Curry, A; Pesola, GR; Knight, RJ; Lee, HS; Bakalchuk, L; Tenenbaum, C; Westfal, RE			Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; tryptase; emergency department; beta-tryptase; hypersensitivity	MAST-CELL TRYPTASE; ANAPHYLACTOID REACTIONS; PLASMA HISTAMINE; TIME-COURSE; CHILDREN; MARKERS; BLOOD; FOOD	Background: Emergency department visits for acute allergic reactions are common. Although the diagnosis and classification of these allergic reactions is primarily empiric, it is not always clear whether certain signs and symptoms constitute systemic mediator release syndromes, such as anaphylaxis, and thus may warrant more aggressive therapy or follow-up. Objective: We sought to determine associations between various clinical signs and symptoms with both plasma histamine levels and serum tryptase levels in adult patients presenting to an emergency department with acute allergic syndromes. The clinical correlates of raised beta-tryptase levels were also investigated. Methods: Ninety-seven adult emergency department patients were prospectively studied by using a questionnaire, physical examination, and serum-plasma sampling. Plasma histamine and serum total and beta-tryptase levels were determined. Clinical groupings were compared for mediator levels by using simple and multivariate analysis. Results: Elevated levels of plasma histamine (>10 nmol/L) and serum total tryptase (>15 ng/mL) were observed in 42 and 20 patients, respectively. Detectable P-tryptase (greater than or equal to 1 ng/mL) was observed in 23 patients, including 15 of the patients with elevated total tryptase levels. Suspected food allergy incidences and the duration of reaction were similar in patients with increased histamine levels and in patients with increased tryptase levels. Increased total tryptase levels, histamine Levels, or both were observed in some patients who did not have airway, cardiovascular, or abdominal signs. Histamine levels correlated better with clinical signs than tryptase levels. Histamine elevations (>10 nmol/L) were observed more frequently in patients characterized by the following clinical signs in univariate analysis: the presence of urticaria, more extensive erythema, abnormal abdominal findings, and wheezing. Total tryptase increases were observed more Frequently only in patients with urticaria. Histamine levels correlated with initial heart rates. In multivariate analysis the extent of urticaria was the best single predictor of plasma histamine levels and of either an elevated histamine or tryptase Level. Detectable beta-tryptase levels were observed in some patients who had neither elevated total tryptase nor elevated histamine levels. Unlike patients without detectable beta-tryptase levels, patients who had detectable beta-tryptase levels had a significant correlation between total tryptase and histamine levels (P < .05). Conclusions: Raised histamine and, less commonly, raised tryptase levels are observed in almost 50% of patients presenting to emergency departments with acute allergic reactions. Some cases associated with systemic mediator release do not have classical features of severe anaphylaxis, such as hypotension or tachycardia. The lack of total tryptase elevations in many patients with elevated plasma histamine levels suggests basophil involvement. The clinical utility of beta-tryptase determinations in the evaluation of acute allergic reactions needs further study.	St Vincents Hosp & Med Ctr, New York Med Coll, Dept Med, New York, NY 10011 USA; St Vincents Hosp & Med Ctr, New York Med Coll, Dept Emergency Med, New York, NY 10011 USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23284 USA	New York Medical College; Saint Vincents Hospital Manhattan; New York Medical College; Saint Vincents Hospital Manhattan; Virginia Commonwealth University	Lin, RY (corresponding author), St Vincents Hosp & Med Ctr, New York Med Coll, Dept Med, 153 W 11th St, New York, NY 10011 USA.			Pesola, Gene/0000-0002-3909-8039	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI020487, R01AI020487, R37AI020487] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20487] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bengtsson U, 1996, CLIN EXP ALLERGY, V26, P1387, DOI 10.1111/j.1365-2222.1996.tb00540.x; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; Cottineau C, 1996, Allerg Immunol (Paris), V28, P273; Cottineau C, 1996, ALLERG IMMUNOL PARIS, V28, P273; DOENICKE A, 1997, THERAPEUTICS, V38, P140; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Kanthawatana S, 1999, J ALLERGY CLIN IMMUN, V103, P1092, DOI 10.1016/S0091-6749(99)70184-3; KNIGHT R, 1999, ANN EMERG MED S, V34, pS18; Laporte JR, 1998, EPIDEMIOLOGY, V9, P141, DOI 10.1097/00001648-199803000-00007; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; Laroche D, 1998, RADIOLOGY, V209, P183, DOI 10.1148/radiology.209.1.9769830; LAROCHE D, 1992, ANN FR ANESTH, V11, P613, DOI 10.1016/S0750-7658(05)80779-8; Lorenz W, 1982, Ann Fr Anesth Reanim, V1, P271, DOI 10.1016/S0750-7658(82)80040-3; MOREL A, 1990, AGENTS ACTIONS, V30, P291, DOI 10.1007/BF01969064; OHTSUKA T, 1993, ANN ALLERGY, V71, P139; Renz CL, 1998, ANESTHESIOLOGY, V89, P620, DOI 10.1097/00000542-199809000-00010; RING J, 1985, INT ANESTHESIOL CLIN, V23, P67; Sainte-Laudy J, 1998, Allerg Immunol (Paris), V30, P209; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1988, ALLERGY PRINCIPLES P, P1162; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5	23	182	190	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				65	71		10.1067/mai.2000.107600	http://dx.doi.org/10.1067/mai.2000.107600			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887307				2022-12-18	WOS:000088393300009
J	Kavuru, M; Melamed, J; Gross, G; LaForce, C; House, K; Prillaman, B; Baitinger, L; Woodring, A; Shah, T				Kavuru, M; Melamed, J; Gross, G; LaForce, C; House, K; Prillaman, B; Baitinger, L; Woodring, A; Shah, T			Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	APR 24-29, 1998	CHICAGO, IL	Amer Thorac Soc		asthma; fluticasone; salmeterol; inhaled corticosteroid; long-acting bronchodilator; Diskus dry powder inhaler	PITUITARY-ADRENAL AXIS; LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS; TRIAMCINOLONE ACETONIDE; MEDICATIONS; PREDNISONE; FORMOTEROL; BUDESONIDE; RECEPTORS; THERAPY	Background: Many patients with persistent asthma need both long-acting bronchodilators and inhaled corticosteroids for optimal asthma control. Objective: Our purpose was to compare the efficacy and safety of salmeterol 50 mu g combined with fluticasone 100 mu g (in a combination dry powder product) with that of placebo, fluticasone, or salmeterol alone. Methods: A 12-week randomized, double-blind, multicenter study was conducted in 356 patients aged 12 years or older with asthma. After a 14-day screening period, patients were randomized to treatment with salmeterol 50 mu g combined with fluticasone 100 mu g (combination product), salmeterol 50 mu g, fluticasone 100 mu g, or placebo administered in the Diskus dry powder inhaler (GlaxoWellcome, UK) twice daily. Results: Mean change in FEV1 at end point was significantly (P less than or equal to .003) greater with the combination product (0.51 L) compared with placebo (0.01 L), salmeterol (0.11 L), and fluticasone (0.28 L), The combination product significantly increased (P less than or equal to .013) area under the curve compared with placebo and fluticasone on day 1 and compared with placebo, salmeterol, and fluticasone at week 1 and week 12. Patients in the combination product group were less likely to withdraw from the study because of worsening asthma compared with those in the other groups (P less than or equal to .020). The combination product significantly increased (P less than or equal to .012) morning PEF (combination, 52.5 L/min; placebo, -23.7 L/min; salmeterol, -1.7 L/min; fluticasone, 17.3 L/min) and evening PEF at end point compared with the other groups. The combination product significantly (P less than or equal to .025) reduced symptom scores and albuterol use compared with the other treatments and increased the percentage of nights with no awakenings and the percentage of days with no symptoms compared with placebo and salmeterol. All treatments were equally well tolerated. Conclusion: Salmeterol 50 mu g and fluticasone 100 mu g combined in the Diskus powder delivery device offers significant clinical advantages over salmeterol or fluticasone alone at the same doses.	Cleveland Clin Fdn, Cleveland, OH 44195 USA; Certified Allergy Consultants, Chelmsford, MA USA; Dallas Allergy & Asthma Ctr, Dallas, TX USA; Carolina Allergy & Asthma Res Grp, Raleigh, NC USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Cleveland Clinic Foundation; GlaxoSmithKline	Kavuru, M (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,Desk A90, Cleveland, OH 44195 USA.							American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P77; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Chambers CV, 1999, RESP MED, V93, P88, DOI 10.1016/S0954-6111(99)90296-2; CHAPMAN KR, 1998, EUR RESPIR REV, V8, P275; Chung KF, 1998, ALLERGY, V53, P7, DOI 10.1111/j.1398-9995.1998.tb04887.x; COCHRANE GM, 1998, EUR RESPIR REV, V8, P239; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; CRAPO R O, 1989, Respiratory Care, V34, P626; DAVIES AO, 1984, ANNU REV PHYSIOL, V46, P119; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Lee E, 1980, STAT METHODS SURVIVA; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P622, DOI 10.1016/S0091-6749(99)70234-4; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; *NIH, 1997, NIH PUBL, P250; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; Polgar G, 1971, PULMONARY FUNCTION T; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Sorkness CA, 1999, CLIN THER, V21, P353, DOI 10.1016/S0149-2918(00)88292-2; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; 1983, CLIN RESP PHYSL S, V19, P1	29	182	184	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1108	1116		10.1067/mai.2000.105711	http://dx.doi.org/10.1067/mai.2000.105711			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	327EX	10856143				2022-12-18	WOS:000087781800010
J	Hoshino, M; Takahashi, M; Takai, Y; Sim, J				Hoshino, M; Takahashi, M; Takai, Y; Sim, J			Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						subepithelial basement membrane; matrix metalloproteinase; tissue inhibitors of metalloproteinase; airway wall remodeling; airway inflammation	EOSINOPHIL CATIONIC PROTEIN; AIRWAY INFLAMMATION; MONOCLONAL-ANTIBODIES; BASEMENT-MEMBRANE; BRONCHIAL-ASTHMA; BUDESONIDE; FIBROSIS; MYOFIBROBLASTS; BETA-2-AGONIST; TERBUTALINE	Background: Bronchial asthma is characterized by airway wall remodeling. Matrix metalloproteinases (MMPs) are members of a family of proteolytic enzymes that degrade the extracellular matrix and that restrain the effects of their tissue inhibitors (TIMPs). Treatment with inhaled corticosteroids may prevent airway remodeling in asthma. However, the effects of corticosteroid treatment on MMPs and TIMPs in asthma are unknown. Objective: We examined the effects of inhaled beclomethasone dipropionate (BDP) on the expression of MMP-9 and TIMP-1 and subepithelial collagen deposition in bronchial biopsy specimens from 30 subjects with asthma. Methods: Inhaled BDP, 800 mu g daily, or placebo was administered for 6 months in a double-blind, parallel-group study, and bronchial biopsies were performed before and after treatment. Biopsy specimens were examined for extent of collagen type III in the subepithelial basement membrane by means of immunohistochemistry, and expression of both epithelial and submucosal MMP-9 and TIMP-1 was quantitated. Numbers of inflammatory cells were also determined. Results: We observed significant decreases in collagen type III deposition (P < .01) and the expression of submucosal MMP-9 (P < .01) and a significant increase in the expression of submucosal TIMP-1 (P < .05) In the BDP group. Significant correlations were found between the subepithelial collagen type III deposition and epithelial (r(s) = 0.37, P < 0.5) and submucosal expression of MMP-9 (r(s) = 0.47, P < .01). Additionally, the number of many inflammatory cells and myofibroblasts in airway mucosa were significantly decreased in the BDP group. Conclusion: Our findings suggest that corticosteroid treatment of asthma can reduce subepithelial collagen deposition by downregulation of MMP-9 expression and upregulation of TIMP-1 expression.	Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, Tokyo, Japan		Hoshino, M (corresponding author), Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, 6-11-1 Omori-nishi, Tokyo, Japan.							*AM THOR SOC, 1988, AM REV RESPIR DIS, V136, P225; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Cataldo D., 1998, AM J RESP CRIT CARE, V157, pA502; Cheung N. T., 1996, British Journal of Rheumatology, V35, P120; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KODAMA S, 1987, COLLAGEN REL RES, V7, P341; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; *NAT ASTHM ED PROG, 1991, PUBL NIH; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; ROCHE WR, 1989, LANCET, V1, P520; SKALLI O, 1989, LAB INVEST, V60, P275; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WARNKE RA, 1989, AM J PATHOL, V135, P1089; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZUCKER S, 1993, CANCER RES, V53, P140	42	182	195	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				356	363		10.1016/S0091-6749(99)70379-9	http://dx.doi.org/10.1016/S0091-6749(99)70379-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452757				2022-12-18	WOS:000082364800028
J	Meyts, I; Bucciol, G; Quinti, I; Neven, B; Fischer, A; Seoane, E; Lopez-Grandos, E; Gianelli, C; Robles-Marhuenda, A; Jeandel, PY; Paillard, C; Sankaran, VG; Demirdag, YY; Lougaris, V; Aiuti, A; Plebani, A; Milito, C; Dalm, VASH; Guevara-Hoyer, K; Sanchez-Ramon, S; Bezrodnik, L; Barzaghi, F; Gonzalez-Granado, LI; Hayman, GR; Uzel, G; Mendonca, LO; Agostini, C; Spadaro, G; Badolato, R; Soresina, A; Vermeulen, F; Bosteels, C; Lambrecht, BN; Keller, M; Mustillo, PJ; Abraham, RS; Gupta, S; Ozen, A; Karakoc-Aydiner, E; Baris, S; Freeman, AF; Yamazaki-Nakashimada, M; Scheffler-Mendoza, S; Espinosa-Padilla, S; Gennery, AR; Jolles, S; Espinosa, Y; Poli, MC; Fieschi, C; Hauck, F; Cunningham-Rundles, C; Mahlaoui, N; Warnatz, K; Sullivan, KE; Tangye, SG				Meyts, Isabelle; Bucciol, Giorgia; Quinti, Isabella; Neven, Benedicte; Fischer, Alain; Seoane, Elena; Lopez-Grandos, Eduardo; Gianelli, Carla; Robles-Marhuenda, Angel; Jeandel, Pierre-Yves; Paillard, Catherine; Sankaran, Vijay G.; Demirdag, Yesim Yilmaz; Lougaris, Vassilios; Aiuti, Alessandro; Plebani, Alessandro; Milito, Cinzia; Dalm, Virgil A. S. H.; Guevara-Hoyer, Kissy; Sanchez-Ramon, Silvia; Bezrodnik, Liliana; Barzaghi, Federica; Ignacio Gonzalez-Granado, Luis; Hayman, Grant R.; Uzel, Gulbu; Mendonca, Leonardo Oliveira; Agostini, Carlo; Spadaro, Giuseppe; Badolato, Raffaele; Soresina, Annarosa; Vermeulen, Francois; Bosteels, Cedric; Lambrecht, Bart N.; Keller, Michael; Mustillo, Peter J.; Abraham, Roshini S.; Gupta, Sudhir; Ozen, Ahmet; Karakoc-Aydiner, Elif; Baris, Safa; Freeman, Alexandra F.; Yamazaki-Nakashimada, Marco; Scheffler-Mendoza, Selma; Espinosa-Padilla, Sara; Gennery, Andrew R.; Jolles, Stephen; Espinosa, Yazmin; Poli, M. Cecilia; Fieschi, Claire; Hauck, Fabian; Cunningham-Rundles, Charlotte; Mahlaoui, Nizar; Warnatz, Klaus; Sullivan, Kathleen E.; Tangye, Stuart G.		IUIS Comm Inborn Errors Immunity	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; primary immunodeficiencies; inborn errors of immunity; hypogammaglobulinemia; immune dysregulation		Background: There is uncertainty about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI), a population at risk of developing severe coronavirus disease 2019. This is relevant not only for these patients but also for the general population, because studies of IEIs can unveil key requirements for host defense. Objective: We sought to describe the presentation, manifestations, and outcome of SARS-CoV-2 infection in IEI to inform physicians and enhance understanding of host defense against SARS-CoV-2. Methods: An invitation to participate in a retrospective study was distributed globally to scientific, medical, and patient societies involved in the care and advocacy for patients with IEI. Results: We gathered information on 94 patients with IEI with SARS-CoV-2 infection. Their median age was 25 to 34 years. Fifty-three patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had immune dysregulation syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) an autoinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2 (2%) bone marrow failure. Ten were asymptomatic, 25 were treated as outpatients, 28 required admission without intensive care or ventilation, 13 required noninvasive ventilation or oxygen administration, 18 were admitted to intensive care units, 12 required invasive ventilation, and 3 required extracorporeal membrane oxygenation. Nine patients (7 adults and 2 children) died. Conclusions: This study demonstrates that (1) more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID19) and (2) risk factors predisposing to severe disease/mortality in the general population also seemed to affect patients with IEI, including more younger patients. Further studies will identify pathways that are associated with increased risk of severe disease and are nonredundant or redundant for protection against SARS-CoV-2.	[Meyts, Isabelle; Bucciol, Giorgia] Univ Hosp Leuven, Dept Immunol & Microbiol, Inborn Errors Immun, Dept Pediat, Leuven, Belgium; [Meyts, Isabelle; Bucciol, Giorgia] Katholieke Univ Leuven, Leuven, Belgium; [Quinti, Isabella; Milito, Cinzia] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Neven, Benedicte; Fischer, Alain; Fieschi, Claire; Mahlaoui, Nizar] Necker Hosp Sick Children, AP HP, Pediat Hematol & Immunol Unit, Paris, France; [Neven, Benedicte; Fischer, Alain] Univ Paris, Paris, France; [Neven, Benedicte; Fischer, Alain] Inst Imagine, Paris, France; [Fischer, Alain] Inst Natl Sante & Rech Med INSERM UMR 1163, Paris, France; [Fischer, Alain] Coll France, Paris, France; [Seoane, Elena] Dept Pediat Allergy & Immunol, Madrid, Spain; [Seoane, Elena] IISGM Gregorio Maranon Univ Hosp, Madrid, Spain; [Lopez-Grandos, Eduardo; Gianelli, Carla; Robles-Marhuenda, Angel] Univ Hosp La Paz, Madrid, Spain; [Lopez-Grandos, Eduardo; Gianelli, Carla; Robles-Marhuenda, Angel] Rare Dis Network Res Ctr CIBERER, IdiPAZ Inst Hlth Res, Lymphocyte Pathophysiol Immunodeficiencies Grp, Madrid, Spain; [Jeandel, Pierre-Yves] Ctr Hosp Univ Nice, Serv Med Interne, Nice, France; [Paillard, Catherine] CHRU, Hop Hautepierre, Pediat Oncohematol & Bone Marrow Transplantat Uni, Strasbourg, France; [Sankaran, Vijay G.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Sankaran, Vijay G.] Harvard Med Sch, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; [Demirdag, Yesim Yilmaz; Gupta, Sudhir] Univ Calif Irvine, Dept Med, Div Basic & Clin Immunol, Irvine, CA 92717 USA; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Pediat Clin, Dept Clin & Expt Sci, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Aiuti, Alessandro; Barzaghi, Federica] IRCCS San Raffaele Sci Inst Milan, San Raffaele Telethon Inst Gene Therapy TIGET, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy; [Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Dalm, Virgil A. S. H.] Erasmus MC, Dept Internal Med, Div Clin Immunol, Rotterdam, Netherlands; [Guevara-Hoyer, Kissy; Sanchez-Ramon, Silvia] Univ Complutense Madrid, Hosp Clin San Carlos, Dept Immunol, IML & IDISSC, Madrid, Spain; [Bezrodnik, Liliana] Immunol Grp Childrens Hosp Ricardo Gutierrez, Ctr Clin Immunol, Buenos Aires, DF, Argentina; [Ignacio Gonzalez-Granado, Luis] Hosp 12 Octubre, Pediat, Primary Immunodeficiencies Unit, Madrid, Spain; [Ignacio Gonzalez-Granado, Luis] Res Inst Hosp 12 Octubre i 12, Madrid, Spain; [Ignacio Gonzalez-Granado, Luis] Univ Complutense Madrid, Sch Med, Madrid, Spain; [Hayman, Grant R.] Epsom & St Helier Univ Hosp NHS Trust, Immunol Dept, Carshalton, Surrey, England; [Uzel, Gulbu; Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Mendonca, Leonardo Oliveira] Univ Sao Paulo, Dept Internal Med, Discipline Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil; [Agostini, Carlo] Univ Padua, Dept Med, Div Internal Med 1, Ca Foncello Treviso Hosp, Padua, Italy; [Agostini, Carlo] Univ Padua, Ctr Immunol Rare Dis, Ca Foncello Treviso Hosp, Padua, Italy; [Spadaro, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Ctr Basic & Clin Immunol Res, Naples, Italy; [Badolato, Raffaele; Soresina, Annarosa] Univ Brescia & Asst Spedali Civili, Dept Expt & Clin Sci, Inst Mol A Nocivelli, Brescia, Italy; [Vermeulen, Francois] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Bosteels, Cedric; Lambrecht, Bart N.] VIB UGent Ctr Inflammat Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium; [Bosteels, Cedric; Lambrecht, Bart N.] Univ Ghent, Dept Internal Med & Pediat, Ghent, Belgium; [Keller, Michael] Childrens Natl Hosp, Div Allergy & Immunol, Washington, DC USA; [Mustillo, Peter J.] Nationwide Childrens Hosp, Div Allerg Dis & Immunol, Columbus, OH USA; [Abraham, Roshini S.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA; [Ozen, Ahmet; Karakoc-Aydiner, Elif; Baris, Safa] Marmara Univ, Div Allergy & Immunol, Istanbul, Turkey; [Ozen, Ahmet; Karakoc-Aydiner, Elif; Baris, Safa] Isil Berat Barlan Ctr Translat Med, Istanbul, Turkey; [Ozen, Ahmet; Karakoc-Aydiner, Elif; Baris, Safa] Istanbul Jeffrey Modell Diagnost & Res Ctr Primar, Istanbul, Turkey; [Yamazaki-Nakashimada, Marco; Scheffler-Mendoza, Selma; Espinosa-Padilla, Sara] Natl Inst Pediat, Immunodeficiencies Res Unit, Mexico City, DF, Mexico; [Gennery, Andrew R.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Gennery, Andrew R.] Great North Childrens Hosp, Paediat Immunol & Haematopoiet Stem Cell Transpla, Newcastle Upon Tyne, Tyne & Wear, England; [Jolles, Stephen] Univ Hosp Wales, Immunodeficiency Ctr Wales, Cardiff, Wales; [Espinosa, Yazmin; Poli, M. Cecilia] Univ Desarrollo, Clin Alemana Santiago, Santiago, Chile; [Fieschi, Claire; Mahlaoui, Nizar] Necker Univ, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Fieschi, Claire] St Louis Hosp, AP HP, Dept Clin Immunol, Paris, France; [Hauck, Fabian] Ludwig Maximilians Univ Munchen, Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Warnatz, Klaus] Univ Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Warnatz, Klaus] Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany; [Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Div Allergy Immunol, Dept Pediat,Perelman Sch Med, Philadelphia, PA 19104 USA; [Tangye, Stuart G.] Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Tangye, Stuart G.] UNSW Sydney, St Vincents Clin Sch, Darlinghurst, NSW, Australia; [Espinosa, Yazmin; Poli, M. Cecilia] Hosp Roberto Del Rio, Santiago, Chile	KU Leuven; University Hospital Leuven; KU Leuven; Sapienza University Rome; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France; Hospital Universitario La Paz; CHU Nice; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of California System; University of California Irvine; University of Brescia; University of Brescia; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; Erasmus University Rotterdam; Erasmus MC; Complutense University of Madrid; Hospital Clinico San Carlos; Hospital Universitario 12 de Octubre; Complutense University of Madrid; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidade de Sao Paulo; University of Padua; University of Padua; University of Naples Federico II; KU Leuven; University Hospital Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Children's National Health System; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Marmara University; Newcastle University - UK; Cardiff University; Clinica Alemana; Universidad del Desarrollo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munich; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Freiburg; University of Freiburg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Garvan Institute of Medical Research; University of New South Wales Sydney; Universidad de Chile	Tangye, SG (corresponding author), Garvan Inst Med Res, Immun & Inflammat Theme, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	isabelle.meyts@uzleuven.be; s.tangye@garvan.org.au	Guevara-Hoyer, Kissy/AAC-7207-2021; Lambrecht, Bart N/K-2484-2014; Yamazaki-Nakashimada, Marco Antonio/Y-7129-2019; Ozen, Ahmet/R-6749-2017; Badolato, Raffaele/A-8081-2010; Sanchez-Ramon, Silvia/AAZ-7670-2020; Warnatz, Klaus/AAD-3464-2022; Guevara-Hoyer, Kissy/ADZ-6574-2022; Sanchez-Ramon, Silvia/I-8242-2019	Guevara-Hoyer, Kissy/0000-0003-3568-8821; Lambrecht, Bart N/0000-0003-4376-6834; Yamazaki-Nakashimada, Marco Antonio/0000-0002-7609-3923; Ozen, Ahmet/0000-0002-9065-1901; Badolato, Raffaele/0000-0001-7375-5410; Sanchez-Ramon, Silvia/0000-0001-9585-6167; Sanchez-Ramon, Silvia/0000-0001-9585-6167; Ziyadullaev, Shukhrat/0000-0002-9309-3933; Poli, Maria Cecilia/0000-0001-6817-0573; VERMEULEN, Francois/0000-0003-2303-2470; paillard, catherine/0000-0003-1662-5446; Bosteels, Cedric/0000-0003-3230-0879; Bucciol, Giorgia/0000-0001-5004-0738; Seoane Reula, M Elena/0000-0002-2845-9492	Fonds Wetenschappelijk Onderzoek Vlaanderen [GCG0C8517N]; VIB Grand Challenges PID; Fonds Wetenschappelijk Onderzoek Vlaanderen; National Health and Medical Research Council of Australia; UNSW Sydney	Fonds Wetenschappelijk Onderzoek Vlaanderen(FWO); VIB Grand Challenges PID; Fonds Wetenschappelijk Onderzoek Vlaanderen(FWO); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); UNSW Sydney	I.M. is supported by the Fonds Wetenschappelijk Onderzoek Vlaanderen (grant no. GCG0C8517N) as a senior clinical researcher and by the VIB Grand Challenges PID. G.B. is supported by the Fonds Wetenschappelijk Onderzoek Vlaanderen. S.G.T. is supported by a Leadership 3 Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a COVID19 Rapid Response Grant awarded by UNSW Sydney.	[Anonymous], 2020, OFFICIAL REGISTRY CO; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Bunders MJ, 2020, IMMUNITY, V53, P487, DOI 10.1016/j.immuni.2020.08.003; Casanova JL, 2020, CELL, V181, P1194, DOI 10.1016/j.cell.2020.05.016; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Gomez C, 2020, J ALLERGY CLIN IMMUN; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Gu X., 2020, LANCET, V395, P506, DOI [10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30183-5]; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Ito T, 2006, BLOOD, V107, P2423, DOI 10.1182/blood-2005-07-2709; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Kong XF, 2020, J CLIN IMMUNOL, V40, P807, DOI 10.1007/s10875-020-00803-9; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu T, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012421; Lougaris V, 2014, J ALLERGY CLIN IMMUN, V133, P1644, DOI 10.1016/j.jaci.2013.12.1085; Castano-Jaramillo LM, 2021, PEDIAT ALLERG IMM-UK, V32, P199, DOI 10.1111/pai.13322; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Moens L, 2020, CURR OPIN IMMUNOL, V62, P79, DOI 10.1016/j.coi.2019.12.002; Notarangelo LD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1662; Quartuccio L, 2020, J MED VIROL, V92, P2852, DOI 10.1002/jmv.26149; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Russell Timothy W, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.12.2000256; Sologuren I, 2018, J CLIN IMMUNOL, V38, P513, DOI 10.1007/s10875-018-0512-0; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Verstegen RHJ, 2020, J CLIN IMMUNOL, V40, P791, DOI 10.1007/s10875-020-00805-7; Wahlster L, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28382; Wang D, 2020, J AEROSPACE ENG, V33, DOI 10.1061/(ASCE)AS.1943-5525.0001149; World Health Organization, 2020, WHO TIMELINE COVID 1; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhang Q, 2020, HUM GENET, V139, P941, DOI 10.1007/s00439-019-02108-3; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou Y, 2020, J ALLERGY CLIN IMMUN; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	43	181	185	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					520	531		10.1016/j.jaci.2020.09.010	http://dx.doi.org/10.1016/j.jaci.2020.09.010		FEB 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32980424	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000616665800013
J	Canna, SW; Girard, C; Malle, L; de Jesus, A; Romberg, N; Kelsen, J; Surrey, LF; Russo, P; Sleight, A; Schiffrin, E; Gabay, C; Goldbach-Mansky, R; Behrens, EM				Canna, Scott W.; Girard, Charlotte; Malle, Louise; de Jesus, Adriana; Romberg, Neil; Kelsen, Judith; Surrey, Lea F.; Russo, Pierre; Sleight, Andrew; Schiffrin, Eduardo; Gabay, Cem; Goldbach-Mansky, Raphaela; Behrens, Edward M.			Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							JUVENILE IDIOPATHIC ARTHRITIS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; INTERFERON-GAMMA; AUTOINFLAMMATION; MUTATION		[Canna, Scott W.; Malle, Louise; de Jesus, Adriana; Goldbach-Mansky, Raphaela] Natl Inst Arthrit & Musculoskeletal & Skin Dis, Intramural Res Program, Bethesda, MD 20892 USA; [Girard, Charlotte; Gabay, Cem] Univ Hosp Geneva, Div Rheumatol, Dept Internal Med Specialties, Geneva, Switzerland; [Romberg, Neil; Kelsen, Judith; Surrey, Lea F.; Russo, Pierre; Behrens, Edward M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Sleight, Andrew; Schiffrin, Eduardo] AB2Bio Ltd, Lausanne, Switzerland; [Canna, Scott W.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [de Jesus, Adriana; Goldbach-Mansky, Raphaela] IRP Natl Inst Allergy & Infect Dis, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Geneva; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Canna, SW (corresponding author), Natl Inst Arthrit & Musculoskeletal & Skin Dis, Intramural Res Program, Bethesda, MD 20892 USA.; Canna, SW (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.	scott.canna@chp.edu	Surrey, Lea/HHS-2541-2022; Goldbach-Mansky, Raphaela/N-5917-2017	Romberg, Neil/0000-0002-1881-5318; Girard-Guyonvarc'h, Charlotte/0000-0002-4901-2059	Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases; National Institutes of Health [R01 HL112836-A1]; Nancy Taylor Foundation; Sean Fischel Connect; Swiss National Science Foundation [10030_152638]; Rheumasearch Foundation; Institute of Arthritis Research.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041138] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nancy Taylor Foundation; Sean Fischel Connect; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Rheumasearch Foundation; Institute of Arthritis Research.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	S.W.C., L.M., A.de.J., and R.G.-M. were supported by the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases. E.M.B. was supported by the National Institutes of Health (grant no. R01 HL112836-A1), the Nancy Taylor Foundation, and Sean Fischel Connect. C.G. is supported by Swiss National Science Foundation (grant no. 10030_152638), the Rheumasearch Foundation, and the Institute of Arthritis Research.	Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; de Jager W, 2009, ARTHRITIS RHEUM-US, V60, P2782, DOI 10.1002/art.24750; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Nowarski R, 2015, CELL, V163, P1444, DOI 10.1016/j.cell.2015.10.072; Quartier P, 2011, ANN RHEUM DIS, V70, P747, DOI 10.1136/ard.2010.134254; Romberg N, 2014, NAT GENET, V46, P1135, DOI 10.1038/ng.3066; Takada H, 2003, CLIN EXP IMMUNOL, V133, P448, DOI 10.1046/j.1365-2249.2003.02237.x	9	181	193	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1698	1701		10.1016/j.jaci.2016.10.022	http://dx.doi.org/10.1016/j.jaci.2016.10.022			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27876626	Green Accepted, Bronze			2022-12-18	WOS:000400465300037
J	Noti, M; Kim, BS; Siracusa, MC; Rak, GD; Kubo, M; Moghaddam, AE; Sattentau, QA; Comeau, MR; Spergel, JM; Artis, D				Noti, Mario; Kim, Brian S.; Siracusa, Mark C.; Rak, Gregory D.; Kubo, Masato; Moghaddam, Amin E.; Sattentau, Quentin A.; Comeau, Michael R.; Spergel, Jonathan M.; Artis, David			Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; atopic dermatitis; epicutaneous sensitization; thymic stromal lymphopoietin; basophils; mast cells; IgE	EPICUTANEOUS SENSITIZATION; MAST-CELLS; MURINE MODEL; RESPONSES; TSLP; INFLAMMATION; KERATINOCYTES; ANAPHYLAXIS; MECHANISMS; GUIDELINES	Background: Exposure to food allergens through a disrupted skin barrier has been recognized as a potential factor in the increasing prevalence of food allergy. Objective: We sought to test the immunologic mechanisms by which epicutaneous sensitization to food allergens predisposes to intestinal food allergy. Methods: Mice were epicutaneously sensitized with ovalbumin or peanut on an atopic dermatitis-like skin lesion, followed by intragastric antigen challenge. Antigen-specific serum IgE levels and T(H)2 cytokine responses were measured by ELISA. Expression of type 2 cytokines and mast cell proteases in the intestine were measured by using real-time PCR. Accumulation of basophils in the skin and mast cells in the intestine was examined by using flow cytometry. In vivo basophil depletion was achieved by using diphtheria toxin treatment of Baso-DTR mice. For cell-transfer studies, the basophil population was expanded in vivo by means of hydrodynamic tail vein injection of thymic stromal lymphopoietin ( TSLP) cDNA plasmid. Results: Sensitization to food allergens through an atopic dermatitis-like skin lesion is associated with an expansion of TSLP-elicited basophils in the skin that promote antigen-specific T(H)2 cytokine responses, increased antigen-specific serum IgE levels, and accumulation of mast cells in the intestine, promoting the development of intestinal food allergy. Critically, disruption of TSLP responses or depletion of basophils reduced the susceptibility to intestinal food allergy, whereas transfer of TSLP-elicited basophils into intact skin promoted disease. Conclusion: Epicutaneous sensitization on a disrupted skin barrier is associated with accumulation of TSLP-elicited basophils, which are necessary and sufficient to promote antigen-induced intestinal food allergy.	[Noti, Mario; Kim, Brian S.; Siracusa, Mark C.; Rak, Gregory D.; Artis, David] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; [Noti, Mario; Kim, Brian S.; Siracusa, Mark C.; Rak, Gregory D.; Artis, David] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA; [Artis, David] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Kim, Brian S.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; [Noti, Mario] Univ Bern, Inst Pathol, Div Expt Pathol, CH-3012 Bern, Switzerland; [Kubo, Masato] RIKEN, Yokohama Inst, Res Ctr Integrat Med Sci, Lab Cytokine Regulat, Yokohama, Kanagawa, Japan; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Chiba, Japan; [Moghaddam, Amin E.; Sattentau, Quentin A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Comeau, Michael R.] Amgen Inc, Inflammat Res, Seattle, WA USA; [Spergel, Jonathan M.] Childrens Hosp Philadelphia, Dept Pediat, Div Allergy & Immunol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Bern; RIKEN; Tokyo University of Science; University of Oxford; Amgen; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Artis, D (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Dept Microbiol, 421 Curie Blvd,BRB 2-3,Rm 356, Philadelphia, PA 19104 USA.	dartis@mail.med.upenn.edu	Kubo, Masato/A-5918-2016; Moghaddam, Amin/N-2300-2014; Noti, Mario/I-6581-2019; Kim, Brian/GZK-6649-2022	Moghaddam, Amin/0000-0001-8668-1609; Noti, Mario/0000-0001-9386-1245; Kim, Brian/0000-0002-8100-7161; Artis, David/0000-0002-1753-4100; Spergel, Jonathan/0000-0002-4658-5353	National Institutes of Health [AI061570, AI087990, AI074878, AI106679, AI095466, AI095608, AI102942, AI097333]; Crohn's and Colitis Foundation of America; Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; Swiss National Science Foundation Prospective and Advanced Research Fellowships [PBBEP3_130438, PA00P3_136468]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI083480, F32AI085828, R01AI074878, U01AI095608, R01AI095466, R01AI061570, R21AI087990, P01AI106697, R01AI102942, R01AI097333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057217, T32AR007465, K08AR065577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; Medical Research Council [G0000635] Funding Source: researchfish; MRC [G0000635] Funding Source: UKRI	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; Swiss National Science Foundation Prospective and Advanced Research Fellowships; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research in the Artis laboratory is supported by the National Institutes of Health (AI061570, AI087990, AI074878, AI106679, AI095466, AI095608, AI102942, and AI097333 to D. A.); the Crohn's and Colitis Foundation of America ( to D. A.); the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award ( to D. A.); the Swiss National Science Foundation Prospective and Advanced Research Fellowships (PBBEP3_130438 and PA00P3_136468 to M. N.); T32-AR007465 and KL2-RR024132 to B. S. K.; and F32-AI085828 to M. C. S. The ACC Flow Cytometry and Cell Sorting Shared Resource is partially supported by an NCI Comprehensive Cancer Center Support Grant (2-P30-CA016520). This work was supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases P30 Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), its pilot grant program, and scientific core facilities (Molecular Pathology and Imaging, Molecular Biology, Cell Culture and Mouse).	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; Berin MC, 2011, CURR OPIN IMMUNOL, V23, P794, DOI 10.1016/j.coi.2011.08.010; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Boyce JA, 2011, J AM ACAD DERMATOL, V64, P175, DOI [10.1016/j.jaad.2010.11.020, 10.1016/j.nutres.2011.01.001]; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Burks AW, 2011, PEDIATRICS, V128, P955, DOI 10.1542/peds.2011-0539; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Comeau MR, 2010, MUCOSAL IMMUNOL, V3, P138, DOI 10.1038/mi.2009.134; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Fiocchi A, 2010, J ALLERGY CLIN IMMUN, V126, P1119, DOI 10.1016/j.jaci.2010.10.011; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Han H, 2012, MUCOSAL IMMUNOL, V5, P342, DOI 10.1038/mi.2012.14; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Helm RM, 2002, CURR OPIN ALLERGY CL, V2, P541, DOI 10.1097/00130832-200212000-00011; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Jiang H, 2012, ALLERGY, V67, P1078, DOI 10.1111/j.1398-9995.2012.02857.x; Khoriaty E, 2013, ALLERGY ASTHMA IMMUN, V5, P3, DOI 10.4168/aair.2013.5.1.3; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Lemon-Mule H, 2008, CURR ALLERGY ASTHM R, V8, P201, DOI 10.1007/s11882-008-0034-6; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Rance F, 2008, PEDIATR ALLERGY IMMU, V19, P279, DOI 10.1111/j.1399-3038.2008.00719.x; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Simpson E, 2013, ANN M AM AC DERM AAD; Siracusa MC, 2012, ADV IMMUNOL, V115, P141, DOI 10.1016/B978-0-12-394299-9.00005-9; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Vaali K, 2006, SCAND J GASTROENTERO, V41, P1405, DOI 10.1080/00365520600815639; Wang JL, 2012, IMMUNOL RES, V54, P83, DOI 10.1007/s12026-012-8309-3; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	51	181	186	3	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1390	U643		10.1016/j.jaci.2014.01.021	http://dx.doi.org/10.1016/j.jaci.2014.01.021			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24560412	Green Accepted			2022-12-18	WOS:000335450700022
J	Broide, DH				Broide, David H.			Immunologic and inflammatory mechanisms that drive asthma progression to remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophil; TGF-beta; MMP-9; VEGF ADAM-33	THYMIC STROMAL LYMPHOPOIETIN; ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; SUBEPITHELIAL COLLAGEN DEPOSITION; LUNG-FUNCTION DECLINE; AIRWAY SMOOTH-MUSCLE; POSITIVE MAST-CELLS; FACTOR-BETA 1; BASEMENT-MEMBRANE; GENE-EXPRESSION	Although histologic features of airway remodeling have been well characterized in asthma, the immunologic and inflammatory mechanisms that drive progression of asthma to remodeling are still incompletely understood. Conceptually, airway remodeling may be a result of persistent inflammation and/or aberrant tissue repair mechanisms. It is likely that several immune and inflammatory cell types and mediators are involved in mediating airway remodeling. In addition, different features of airway remodeling are likely mediated by different inflammatory pathways. Several important candidate mediators of remodeling have been identified, including TGF-beta and T(H)2 cytokines (including IL-5 and IL-13), as well as vascular endothelial growth factor, a disintegrin and metalloproteinase 33, and matrix metalloproteinase 9. Mouse models of airway remodeling have provided important insight into potential mechanisms by which TGF-beta activation of the Smad-2/3 signaling pathway may contribute to airway remodeling. Human studies have demonstrated that anti-IL-5 reduces levels of airway eosinophils expressing TGF-beta, as well as levels of airway remodeling as assessed by bronchial biopsies. Further such studies confirming these observations, as well as alternate studies targeting additional individual cell types, cytokines, and mediators, are needed in human subjects with asthma to determine the role of candidate mediators of inflammation on the development and progression of airway remodeling.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072115, R37AI038425, U19AI070535] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI038425, U19 AI070535, R01 AI072115, U19 AI070535-029001, U19 AI070535-01, U19 AI070535-02, R01 AI072115-01A1, U19 AI070535-010001, U19 AI070535-020001, R37 AI038425-12, R37 AI038425-11A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bergeron C, 2007, EUR RESPIR J, V29, P596, DOI 10.1183/09031936.00019906; Bhandari V, 2006, P NATL ACAD SCI USA, V103, P11021, DOI 10.1073/pnas.0601057103; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Boulet LP, 2007, EUR RESPIR J, V30, P831, DOI 10.1183/09031936.00110107; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen C, 2006, MOL CELL BIOL, V26, P6950, DOI 10.1128/MCB.00646-06; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Holtzman Michael J, 2005, Proc Am Thorac Soc, V2, P132, DOI 10.1513/pats.200502-015AW; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kelly MM, 2006, CHEST, V130, P741, DOI 10.1378/chest.130.3.741; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kotaru C, 2006, AM J RESP CRIT CARE, V173, P1208, DOI 10.1164/rccm.200508-1218OC; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Le AV, 2007, J IMMUNOL, V178, P7310, DOI 10.4049/jimmunol.178.11.7310; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee SY, 2006, J ALLERGY CLIN IMMUN, V117, P597, DOI 10.1016/j.jaci.2005.11.008; Lee YC, 2001, CLIN EXP ALLERGY, V31, P1623, DOI 10.1046/j.1365-2222.2001.01211.x; Lim DH, 2006, AM J PHYSIOL-LUNG C, V291, pL265, DOI 10.1152/ajplung.00305.2005; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Min MG, 2007, J IMMUNOL, V178, P5321, DOI 10.4049/jimmunol.178.8.5321; Munitz A, 2006, J ALLERGY CLIN IMMUN, V118, P1082, DOI 10.1016/j.jaci.2006.07.041; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Okayama Y, 2007, CURR OPIN IMMUNOL, V19, P687, DOI 10.1016/j.coi.2007.07.018; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Pare PD, 2003, AM J RESP CRIT CARE, V168, P913, DOI 10.1164/rccm.2307005; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Seroogy CM, 2005, J ALLERGY CLIN IMMUN, V116, P996, DOI 10.1016/j.jaci.2005.07.015; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Tournoy KG, 2006, CLIN EXP ALLERGY, V36, P8, DOI 10.1111/j.1365-2222.2005.02385.x; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Oosterhout AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wegmann M, 2007, AM J RESP CELL MOL, V36, P61, DOI 10.1165/rcmb.2006-0188OC; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Xie SP, 2007, AM J PHYSIOL-LUNG C, V293, pL245, DOI 10.1152/ajplung.00068.2007; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	105	181	192	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					560	570		10.1016/j.jaci.2008.01.031	http://dx.doi.org/10.1016/j.jaci.2008.01.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328887	Green Accepted, Bronze			2022-12-18	WOS:000253918900002
J	Meltzer, EO; Hamilos, DL; Hadley, JA; Lanza, DC; Marple, BF; Nicklas, RA; Adinoff, AD; Bachert, C; Borish, L; Chinchilli, VM; Danzig, MR; Ferguson, BJ; Fokkens, WJ; Jenkins, SG; Lund, VJ; Mafee, MF; Naclerio, RM; Pawankar, RR; Ponikau, JU; Schubert, MS; Slavin, RG; Stewart, MG; Togias, A; Wald, ER; Winther, B				Meltzer, Eli O.; Hamilos, Daniel L.; Hadley, James A.; Lanza, Donald C.; Marple, Bradley F.; Nicklas, Richard A.; Adinoff, Allen D.; Bachert, Claus; Borish, Larry; Chinchilli, Vernon M.; Danzig, Melvyn R.; Ferguson, Berrylin J.; Fokkens, Wytske J.; Jenkins, Stephen G.; Lund, Valerie J.; Mafee, Mahmood F.; Naclerio, Robert M.; Pawankar, Ruby R.; Ponikau, Jens U.; Schubert, Mark S.; Slavin, Raymond G.; Stewart, Michael G.; Togias, Alkis; Wald, Ellen R.; Winther, Birgit			Rhinosinusitis: Developing guidance for clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						acute bacterial rhinosinusitis; chronic rhinosinusitis with or without polyps; allergic fungal rhinosinusitis; clinical trials	ALLERGIC FUNGAL SINUSITIS; FUROATE NASAL SPRAY; QUALITY-OF-LIFE; ACUTE BACTERIAL RHINOSINUSITIS; ORAL ANTIBIOTIC-THERAPY; NEWLY RECOGNIZED FORM; MAXILLARY SINUSITIS; DOUBLE-BLIND; AMPHOTERICIN-B; BACTERIOLOGICAL FINDINGS	Rhinosinusitis Initiative was developed by 5 national clinical research and patient care" and provides templates for societies. The current guidance document is an expansion of the clinical trials in antimicrobial, anti-inflammatory, and 2004 publication "Rhinosinusitis: Establishing definitions for symptom-relieving therapies for the following: (1) acute presumed bacterial rhinosinusitis, (2) chronic rhinosinusitis (CRS) without nasal polyps, (3) CRS with nasal polyps, and (4) classic allergic fungal rhinosinusitis. In addition to the templates for clinical trials and proposed study designs, the Rhinosinusitis Initiative has developed 6 appendices, which address (1) health outcomes, (2) nasal endoscopy and staging of CRS, (3) radiologic imaging, (4) microbiology, (5) laboratory measures, and (6) biostatistical methods.					Fokkens, Wytske WJ/ABF-2185-2020; Bachert, Claus/J-8825-2012					Anderson ER, 1999, OTOLARYNG HEAD NECK, V121, P702, DOI 10.1053/hn.1999.v121.a100114; Anon JB, 2004, OTOLARYNG HEAD NECK, V130, P1, DOI 10.1016/j.otohns.2003.12.003; Aral M, 2003, AM J OTOLARYNG, V24, P163, DOI 10.1016/S0196-0709(02)32420-7; Arango P, 2001, LARYNGOSCOPE, V111, P1779, DOI 10.1097/00005537-200110000-00022; Atlas SJ, 2005, QUAL LIFE RES, V14, P1375, DOI 10.1007/s11136-004-6674-7; Atlas SJ, 2005, LARYNGOSCOPE, V115, P846, DOI 10.1097/01.MLG.0000157693.92975.02; Aukema Albertien A C, 2004, Treat Respir Med, V3, P97, DOI 10.2165/00151829-200403020-00004; BACHERT C, 2005, J ALLERGEY CLIN IMMU, V107, P607; Baraniuk JN, 2005, AM J RESP CRIT CARE, V171, P5, DOI 10.1164/rccm.200403-357OC; Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; Baron E.J., 1999, MANUAL CLIN MICROBIO, V7th; Bende M, 1996, ANN OTO RHINOL LARYN, V105, P222, DOI 10.1177/000348949610500309; Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Berger G, 2005, EUR ARCH OTO-RHINO-L, V262, P416, DOI 10.1007/s00405-004-0830-0; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Brook I, 1997, J MED MICROBIOL, V46, P430, DOI 10.1099/00222615-46-5-430; Brook I, 2005, J MED MICROBIOL, V54, P595, DOI 10.1099/jmm.0.45767-0; Brook I, 2005, J CLIN MICROBIOL, V43, P3479, DOI 10.1128/JCM.43.7.3479-3480.2005; Chen Hubert, 2005, Health Qual Life Outcomes, V3, P68, DOI 10.1186/1477-7525-3-68; Chinchilli VM, 1996, STAT MED, V15, P1619, DOI 10.1002/(SICI)1097-0258(19960815)15:15<1619::AID-SIM326>3.0.CO;2-N; Clement S, 2005, J INFECT DIS, V192, P1023, DOI 10.1086/432735; Curtin HD, 1998, RADIOL CLIN N AM, V36, P1201, DOI 10.1016/S0033-8389(05)70240-2; Deal RT, 2004, LARYNGOSCOPE, V114, P1932, DOI 10.1097/01.mlg.0000147922.12228.1f; Deja M, 2003, AM J RESP CRIT CARE, V168, P281, DOI 10.1164/rccm.200207-640OC; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; Dolor RJ, 2001, JAMA-J AM MED ASSOC, V286, P3097, DOI 10.1001/jama.286.24.3097; ENCE BK, 1990, AM J RHINOL, V4, P169; Eustis HS, 1998, RADIOL CLIN N AM, V36, P1165, DOI 10.1016/S0033-8389(05)70238-4; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Finegold SM, 2002, CLIN INFECT DIS, V35, P428, DOI 10.1086/341899; Fisher LD, 1990, STAT ISSUES DRUG RES, P331, DOI DOI 10.1201/9780203738610; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens W, 2005, RHINOLOGY, V43, P1; FROLUND L, 1987, ACTA OTO-LARYNGOL, V104, P175, DOI 10.3109/00016488709109064; Gillespie MB, 2004, CURR ALLERGY ASTHM R, V4, P478, DOI 10.1007/s11882-004-0015-3; GLIKLICH RE, 1995, LARYNGOSCOPE, V105, P387, DOI 10.1288/00005537-199504000-00010; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; Hoover GE, 1997, J ALLERGY CLIN IMMUN, V100, P185, DOI 10.1016/S0091-6749(97)70223-9; Hwang PH, 2003, OTOLARYNG HEAD NECK, V128, P489, DOI 10.1016/S0194-5998(02)23295-7; Inanli S, 2002, LARYNGOSCOPE, V112, P320; Johansson L, 2000, ACTA OTO-LARYNGOL, V120, P72; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Jornot L, 2005, J CELL PHYSIOL, V204, P859, DOI 10.1002/jcp.20347; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; Katz Russell, 2004, NeuroRx, V1, P307, DOI 10.1007/BF03206615; Katz Russell, 2004, NeuroRx, V1, P189, DOI 10.1007/BF03206602; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; Klossek JM, 1998, J LARYNGOL OTOL, V112, P1162, DOI 10.1017/S0022215100142732; Kupferberg SB, 1996, ARCH OTOLARYNGOL, V122, P1381, DOI 10.1001/archotol.1996.01890240087019; Lacroix JS, 2002, ACTA OTO-LARYNGOL, V122, P192, DOI 10.1080/00016480252814216; LAGAKOS SW, 1984, BIOMETRICS, V40, P1037, DOI 10.2307/2531154; LEE JW, 1991, J AM STAT ASSOC, V86, P757, DOI 10.2307/2290409; LEE JW, 1992, J AM STAT ASSOC, V87, P136, DOI 10.2307/2290461; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; Linder JA, 2003, J GEN INTERN MED, V18, P390, DOI 10.1046/j.1525-1497.2003.20744.x; Lockwood D, 2006, CLEV CLIN J MED, V73, P583, DOI 10.3949/ccjm.73.6.583; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Mafee M F, 1994, Ear Nose Throat J, V73, P532; MAFEE MF, 1993, RADIOL CLIN N AM, V31, P1; MAFEE MF, 1993, AM J ROENTGENOL, V160, P735, DOI 10.2214/ajr.160.4.8456654; MAFEE MF, 1991, AM J NEURORADIOL, V12, P855; MAFEE MF, 1993, JAMA-J AM MED ASSOC, V269, P2608; MAFEE MF, 1996, OTOLARYNGOLOGY, V2, P11; MAFEE MF, 1994, ENT-EAR NOSE THROAT, V73, P540; MAFEE MF, 2005, IMAGING HEAD NECK, P353; MAKUCH RW, 1990, STAT ISSUES DRUG RES, P225; Malm L, 2000, RHINOLOGY, V38, P1; MANNING SC, 1989, LARYNGOSCOPE, V99, P681; Marple BF, 2001, LARYNGOSCOPE, V111, P1006, DOI 10.1097/00005537-200106000-00015; Marple BF, 2000, AM J RHINOL, V14, P223, DOI 10.2500/105065800779954482; Meinert CL, 1986, CLIN TRIALS DESIGN C; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V106, P630, DOI 10.1067/mai.2000.109056; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V116, P1289, DOI 10.1016/j.jaci.2005.08.044; MILOSHEV B, 1966, LANCET, V1, P746; Mukherji SK, 1998, RADIOLOGY, V207, P417, DOI 10.1148/radiology.207.2.9577490; MULLER KE, 1992, J AM STAT ASSOC, V87, P1209, DOI 10.2307/2290663; Nathan Robert A, 2005, J Allergy Clin Immunol, V115, pS442, DOI 10.1016/j.jaci.2004.12.015; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V89, P271, DOI 10.1016/S1081-1206(10)61954-0; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V272, P852; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; NORD CE, 1995, CLIN INFECT DIS, V20, P1512, DOI 10.1093/clinids/20.6.1512; Nussenbaum B, 2001, OTOLARYNG HEAD NECK, V124, P150, DOI 10.1067/mhn.2001.112573; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Osguthorpe JD, 2001, AM FAM PHYSICIAN, V63, P69; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Peterson LR, 1999, INFECT DIS CLIN N AM, V13, P775, DOI 10.1016/S0891-5520(05)70108-2; Piantadosi S, 2005, WILEY SER PROBAB ST, P515; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Ponikau JU, 2006, CLIN REV ALLERG IMMU, V30, P187, DOI 10.1385/CRIAI:30:3:187; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; POOLE MD, 1992, OTOLARYNGOL HEAD NEC, V107, P272; Prasad M, 2004, PHARMACOECONOMICS, V22, P225, DOI 10.2165/00019053-200422040-00002; Rabago D, 2005, OTOLARYNG HEAD NECK, V133, P3, DOI 10.1016/j.otohns.2005.03.002; Ragab SM, 2004, LARYNGOSCOPE, V114, P923, DOI 10.1097/00005537-200405000-00027; Ramadan HH, 2005, OTOLARYNG HEAD NECK, V132, P414, DOI 10.1016/j.otohns.2004.11.011; RAMADAN HH, 1995, AM J OTOLARYNG, V16, P303, DOI 10.1016/0196-0709(95)90057-8; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Rontal M, 1999, AM J RHINOL, V13, P91, DOI 10.2500/105065899782106788; SALMAN SD, 1990, NEW ENGL J MED, V322, P116; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Schubert MS, 2000, ANN ALLERG ASTHMA IM, V85, P90, DOI 10.1016/S1081-1206(10)62445-3; Schubert MS, 2004, DRUGS, V64, P363, DOI 10.2165/00003495-200464040-00002; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Senn S, 1993, CROSS OVER TRIALS CL, V2nd; Sharp HR, 1999, CLIN OTOLARYNGOL, V24, P39, DOI 10.1046/j.1365-2273.1999.00199.x; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; SOM PM, 1993, RADIOL CLIN N AM, V31, P33; SOM PM, 1996, HEAD NECK IMAGING, P126; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stewart MG, 2004, OTOLARYNG HEAD NECK, V130, P157, DOI 10.1016/j.otohns.2003.09.016; Stjarne P, 2006, ARCH OTOLARYNGOL, V132, P179, DOI 10.1001/archotol.132.2.179; Stringer SP, 2000, OTOLARYNG CLIN N AM, V33, P375, DOI 10.1016/S0030-6665(00)80012-2; Subramanian HN, 2002, AM J RHINOL, V16, P303, DOI 10.1177/194589240201600605; SUMMANEN P, 1993, CLIN INFECT DIS, V16, P606, DOI 10.1093/clind/16.5.606; Tantilipikorn P, 2002, AM J RHINOL, V16, P255, DOI 10.1177/194589240201600507; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; Turnidge J, 2001, DRUGS, V61, P2065, DOI 10.2165/00003495-200161140-00004; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vogan JC, 2000, OTOLARYNG HEAD NECK, V122, P370, DOI 10.1016/S0194-5998(00)70051-9; Vonesh E.F., 1997, LINEAR NONLINEAR MOD; Wallwork B, 2006, LARYNGOSCOPE, V116, P189, DOI 10.1097/01.mlg.0000191560.53555.08; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watkins DN, 1998, CLIN EXP ALLERGY, V28, P211; Werk LN, 1998, DRUGS, V55, P779, DOI 10.2165/00003495-199855060-00005; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; WILLIAMS JW, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000243; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990; ZINREICH SJ, 2003, HEAD NECK IMAGING, V1, P149	145	181	188	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5		S			S17	S61		10.1016/j.jaci.2006.09.005	http://dx.doi.org/10.1016/j.jaci.2006.09.005			45	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	138WD	17084217				2022-12-18	WOS:000244393100001
J	Astier, C; Morisset, M; Roitel, O; Codreanu, F; Jacquenet, S; Franck, P; Ogier, V; Petit, N; Proust, B; Moneret-Vautrin, DA; Burks, AW; Bihain, B; Sampson, HA; Kanny, G				Astier, Catherine; Morisset, Martine; Roitel, Olivier; Codreanu, Fanny; Jacquenet, Sandrine; Franck, Patricia; Ogier, Virginie; Petit, Nicolas; Proust, Barbara; Moneret-Vautrin, Denise-Anne; Burks, A. Wesley; Bihain, Bernard; Sampson, Hugh A.; Kanny, Gisele			Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut; diagnosis; recombinant allergens	IGE-BINDING EPITOPES; ARA H 3; FOOD ALLERGY; ANAPHYLACTIC REACTIONS; CLINICAL REACTIVITY; MUTATIONAL ANALYSIS; MAJOR ALLERGEN; NUT ALLERGY; IMMUNOTHERAPY; HYPERSENSITIVITY	Background: Current diagnosis of peanut allergy relies on natural extracts that lack standardization. Recombinant DNA technology allows production of pure biochemically characterized proteins. Their usefulness for peanut allergy diagnosis is not established. Objective: This study aimed to evaluate the diagnostic value of the 3 major recombinant peanut allergens. Methods: Recombinant (r) Ara h1, rAra h2, and rAra h3 were produced according to the recommendations of good manufacturing practice for recombinant allergens. Skin prick tests (SPTs) and IgE ELISA assays were performed in 30 patients with peanut allergy and 30 control subjects without food allergy: 15 nonatopic and 15 sensitized to birch pollen. Disease severity was graded by clinical scoring. Results: All patients with peanut allergy showed positive SPT results to rAra h 2; 40% reacted with rAra h 1 and 27% with rAra h 3. No control subjects reacted with any of the recombinant allergens. Monosensitization to rAra h 2 was observed in 53% of patients. Neither SPT size nor levels of specific IgE were correlated with the disease severity. However, patients with monosensitization to rAra h 2 had a significantly lower severity score than polysensitized subjects and a lower level of specific IgE against peanut extract and rAra h2. Conclusion: Skin prick tests to individual recombinant peanut allergens appear to be a safe and effective diagnostic tool. Cosensitization to rAra h2 and rArah I and/or rAra h3 is predictive of more severe reactions. Clinical implications: Recombinant peanut allergens can be used by SPTs for diagnosis and evaluation of allergy severity.	United Hosp, Cent Hosp, Dept Internal Med, Nancy, France; Lipidomix, Lab Mol Med & Therapeut, Nancy, France; Duke Univ, Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Durham, NC USA; Mt Sinai Hosp, Dept Pediat, Div Allergy & Immunol, New York, NY USA	CHU de Nancy; Duke University; Icahn School of Medicine at Mount Sinai	Kanny, G (corresponding author), Lab Med & Therapeut Mol, EA 3999,15 Rue Bois Champelle, F-54500 Vandoeuvre Les Nancy, France.	gisele.kanny@mtm.nancy.inserm.fr	Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Morisset, Martine/0000-0002-4028-703X				Akkerdaas JH, 2003, INT ARCH ALLERGY IMM, V132, P132, DOI 10.1159/000073714; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Cromwell O, 2004, METHODS, V32, P300, DOI 10.1016/j.ymeth.2003.08.009; DREBORG S, 1991, ALLERGY PROC, V12, P251, DOI 10.2500/108854191778879278; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P837, DOI 10.1016/S0091-6749(95)70127-3; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; Moneret-Vautrin DA, 2004, CURR OPIN ALLERGY CL, V4, P215, DOI 10.1097/01.all.0000129454.42340.23; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Mortz CG, 2005, PEDIAT ALLERG IMM-UK, V16, P501, DOI 10.1111/j.1399-3038.2005.00302.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Pons L, 2005, CURR OPIN ALLERGY CL, V5, P558; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Rance F, 1997, ALLERGY, V52, P1031, DOI 10.1111/j.1398-9995.1997.tb02427.x; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; *WHO IUIS ALL NOM, 2006, ALL NOM OFF LIST ALL	39	181	184	1	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					250	256		10.1016/j.jaci.2006.04.053	http://dx.doi.org/10.1016/j.jaci.2006.04.053			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815163				2022-12-18	WOS:000239184800031
J	Kelly, EAB; Busse, WW; Jarjour, NN				Kelly, EAB; Busse, WW; Jarjour, NN			A comparison of the airway response to segmental antigen bronchoprovocation in atopic asthma and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; airway inflammation; bronchoalveolar lavage; segmental bronchoprovocation; cytokines	CHALLENGE; INFLAMMATION; MILD	Background: Patients with allergic asthma and those with allergic rhinitis (without asthma) share many immunopathologic features but differ in the presence of lower airway symptoms in response to antigen. Objectives: We sought to compare the airway inflammatory response to antigen in patients with atopic asthma and allergic rhinitis. Methods: Segmental bronchoprovocation with saline or ragweed antigen was performed in 9 patients with atopic asthma and 9 patients with allergic rhinitis without asthma. The antigen dose used in segmental bronchoprovocation was 10% of the dose that caused a 20% decrease in FEV1 in response to inhalation challenge. Bronchoalveolar lavage (BAL) was performed from the saline- and antigen-challenged segments at 5 minutes and 48 hours after challenge. BAL fluid was analyzed for cell count and differential, distribution of lymphocytes, and concentration of soluble factors (histamine, IL-5, matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1, and fibronectin). In addition, BAL cells were cultured ex vivo, and IL-5, IFN-gamma, and IL-10 generation was measured. Results: Antigen challenge led to similar patterns of cellular recruitment, mediator levels, and BAL cell cytokine generation in both groups; however, the dose of antigen required to promote comparable responses in the airway was significantly less in patients with asthma. Conclusion: These data suggest that the pattern of acute airway inflammation in response to allergen does not by itself explain antigen-induced lower airway obstruction and asthma symptoms. We speculate that other factors, such as increased airway sensitivity to allergen or preexisting airway injury and remodeling, might explain why patients with asthma and rhinitis differ in their clinical and physiologic response to antigen exposure.	Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Dept Med, Madison, WI 53792 USA; Univ Wisconsin, Allergy & Immunol Sect, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kelly, EAB (corresponding author), Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Dept Med, 600 Highland Ave,CSC K4-928, Madison, WI 53792 USA.			Kelly, Elizabeth/0000-0001-7335-6698	NHLBI NIH HHS [HL56396] Funding Source: Medline; PHS HHS [R01 64066] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alvarez MJ, 2000, ALLERGY, V55, P531, DOI 10.1034/j.1398-9995.2000.00534.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1999, AM J RESP CRIT CARE, V160, P1778; [Anonymous], 1999, AM J RESP CRIT CARE, V161, P309; Bolos AM, 2000, J ALLERGY CLIN IMMUN, V105, pS259, DOI 10.1016/S0091-6749(00)91198-9; BOWSHER RR, 1983, J BIOL CHEM, V258, P2215; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Crimi E, 2001, J APPL PHYSIOL, V91, P1029, DOI 10.1152/jappl.2001.91.3.1029; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Moore WC, 2001, J ALLERGY CLIN IMMUN, V108, P908, DOI 10.1067/mai.2001.119413; Ndukwu IM, 1999, AM J RESP CRIT CARE, V160, P1516, DOI 10.1164/ajrccm.160.5.9812126; SHAVER JR, 1995, AM J RESP CRIT CARE, V152, P1189, DOI 10.1164/ajrccm.152.4.7551369; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586	17	181	188	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					79	86		10.1067/mai.2003.28	http://dx.doi.org/10.1067/mai.2003.28			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532100				2022-12-18	WOS:000180465500012
J	Gehring, U; Bolte, G; Borte, M; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J				Gehring, U; Bolte, G; Borte, M; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J		LISA Study Grp	Exposure to endotoxin decreases the risk of atopic eczema in infancy: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; house dust; atopic eczema; infections; wheezing; infancy	HOUSE-DUST ENDOTOXIN; HAY-FEVER; INFECTIOUS-DISEASES; CHILDHOOD; ASTHMA; DERMATITIS; CHILDREN; ALLERGY; SENSITIZATION; ENVIRONMENT	Background: Previous studies have shown a protective effect of early exposure to cats and dogs on the development of atopic eczema, asthma, allergic rhinitis, and atopic sensitization in later life. In particular, a higher microbial exposure to endotoxin in early childhood might contribute to this effect. Objective: We examined the associations between bacterial endotoxin in house dust and atopic eczema, infections, and wheezing during the first year of life in an ongoing birth cohort study (LISA). Methods: Data of 1884 term and normal-weight neonates with complete information on exposure to biocontaminants and confounding variables were analyzed. House dust from the mothers' and the children's mattresses was sampled 3 months after birth. Endotoxin content was quantified by using a chromogenic kinetic limulus amoebocyte lysate test. Results: During the first 6 months of life, the risk of atopic eczema was significantly decreased by endotoxin exposure in dust from mothers' mattresses in the fifth quintile (odds ratio [OR], 0.50; 95% CI, 0.28-0.88), whereas the risk was increased for respiratory infections (OR, 1.69; 95% CI, 1.25-2.28) and cough with respiratory infection, bronchitis, or both (OR, 1.73; 95% CI, 1.28-2.33). The risk of wheezing was also significantly increased during the first 6 months of life (OR, 2.37; 95% CI, 1.40-4.03). For the entire first year of life, these associations attenuated, except for the risk of wheezing, which remained significant (OR, 1.60; 95% CI, 1.10-2.30). Conclusion: Our findings support the hygiene hypothesis that exposure to high concentrations of endotoxin very early in life might protect against the development of atopic eczema within the first 6 months of life, along with an increased prevalence of nonspecific respiratory diseases.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Chair Epidemiol, Munich, Germany; Univ Leipzig, Dept Pediat, D-7010 Leipzig, Germany; Univ Jena, Inst Clin Immunol, D-6900 Jena, Germany; Univ Jena, Inst Occupat Social & Enviornm Med, Dept Indoor Climatol Ark, Erfurt, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Leipzig University; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Gehring, U (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Wichmann, Heinz Erich/AAA-5695-2022; Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629; Bolte, Gabriele/0000-0002-0269-5059; Gehring, Ulrike/0000-0003-3612-5780				Asher MI, 1998, EUR RESPIR J, V12, P315; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bischof W, 2000, P HLTH BUILDINGS, V1, P251; Bjorksten B, 1999, P NUTR SOC, V58, P729, DOI 10.1017/S0029665199000956; BONIFAZI E, 1989, ACTA DERM-VENEREOL, V144, P20; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burney P, 1996, EUR RESPIR J, V9, P687; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HEINRICH J, IN PRESS CLIN EXP AL; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kimpen JLL, 2000, AM J RESP CRIT CARE, V162, pS108, DOI 10.1164/ajrccm.162.supplement_2.ras-11; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P229, DOI 10.1111/j.1651-2227.1994.tb13057.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; QUEILLEROUSSEL C, 1985, ACTA DERM-VENEREOL, V114, P87; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; YATES VM, 1983, BRIT J DERMATOL, V108, P633, DOI 10.1111/j.1365-2133.1983.tb01074.x	36	181	182	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					847	854		10.1067/mai.2001.119026	http://dx.doi.org/10.1067/mai.2001.119026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692114				2022-12-18	WOS:000172523800029
J	Cho, SH; Strickland, I; Boguniewicz, M; Leung, DYM				Cho, SH; Strickland, I; Boguniewicz, M; Leung, DYM			Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; collagen; fibrinogen; fibronectin; Staphylococcus aureus	CLUMPING FACTOR; IGE ANTIBODIES; CELL-SURFACE; DERMATITIS; EXPRESSION; PROTEINS; MSCRAMM; EXOTOXINS; KERATINOCYTES; COLONIZATION	Background: Staphylococcus aureus colonizes the skin lesions of more than 90% of patients with atopic dermatitis (AD). The mechanism for increased S aureas colonization in AD is unknown. However, the initial event in colonization requires adherence of S aureus to the skin. Objective: The purpose of this study was to examine the roles of various bacterial adhesins on S aureus binding to AD skin. Methods: In an attempt to delineate the mechanism behind this adherence process, an in vitro bacterial binding assay was developed to quantitate the adherence of various S aureus strains to AD, psoriatic, and normal skin sections. S aureus strains used in this study were obtained either from cultures of AD skin lesions or from genetically manipulated strains of S aureus that lacked specific microbial surface components recognizing adhesive matrix molecules (MSCRAMMs)-namely, fibronectin-binding protein (Fnbp), fibrinogen-binding protein (CIf), collagen-binding protein (Cna), and their parent strains. In addition, S aureus strains from patients with AD were pretreated with fibronectin or fibrinogen to block MSCRAMM receptors and interfere with binding. Results: Under all experimental conditions, binding of S aureus was localized primarily to the stratum corneum. Immunocytochemical staining of AD skin sections showed a redistribution of fibronectin to the cornified layer, an observation not seen in normal skin. S aureus binding to uninvolved AD skin was significantly greater than the binding to uninvolved psoriatic skin (P <.0001) and normal skin (P <.0005). The Fnbp-negative S aureus showed a significant reduction in binding to the AD skin (P <.0001) but not to the psoriatic and normal skin. In the AD skin, a significant reduction in the binding of S aureus was also observed in the Clf-negative strain (P <.0001) but not in the Cna-negative S aureus. Preincubation of S aureus with either fibronectin or fibrinogen also inhibited bacterial binding to AD skin (P <.0001). Conclusion: These data suggest that fibronectin and fibrinogen-but not collagen-play a major role in the enhanced binding of S aureus to the skin of patients with AD.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [RR00051] Funding Source: Medline; NHLBI NIH HHS [HL37260, HL-36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, P01HL036577, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Mempel M, 1998, J INVEST DERMATOL, V111, P452, DOI 10.1046/j.1523-1747.1998.00293.x; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; TOMPKINS DC, 1990, J CLIN INVEST, V85, P1248, DOI 10.1172/JCI114560; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; WIKNER NE, 1988, J INVEST DERMATOL, V91, P207, DOI 10.1111/1523-1747.ep12464997; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1	30	181	187	4	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					269	274		10.1067/mai.2001.117455	http://dx.doi.org/10.1067/mai.2001.117455			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496245				2022-12-18	WOS:000170584600017
J	Gold, MS; Sainsbury, R				Gold, MS; Sainsbury, R			First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; children; EpiPen autoinjector device	FOOD; SCHOOL	Background: Epinephrine for first aid use by parents and other caregivers and in the form of an autoinjector device (EpiPen, Center Laboratories) is often prescribed for children who have had previous anaphylactic reactions. It is not known whether the EpiPen device is used appropriately during subsequent reactions and whether its use is able to prevent the complications of anaphylaxis. Objective: Our purpose was to determine parental knowledge and practice concerning first aid anaphylaxis management, the frequency of recurrent generalized allergic reactions, the first aid measures taken, and the subsequent outcome of these reactions. Methods: A retrospective survey was performed with a telephone questionnaire of all children with a history of anaphylaxis who attended a specialist allergy service and were prescribed an EpiPen autoinjector device. Results: Recurrent generalized allergic reactions occurred with a frequency of 0.98 episodes per patient per year and were more common in those with food compared with insect venom anaphylaxis, The EpiPen device was only used in 29% of recurrent anaphylactic reactions. Parental knowledge was deficient in recognition of the symptoms of anaphylaxis and use of the EpiPen device, and adequate first aid measures were not in place for the majority of children attending school. Those children in whom the EpiPen device was used were less likely to be given epinephrine in hospital and to require subsequent hospital admission. Conclusion: The EpiPen autoinjector device is infrequently used in children with recurrent episodes of anaphylaxis; the reasons for this require further research. It is likely that parents and other caregivers will require continuing education and support in first aid anaphylaxis management. When the EpiPen device is used appropriately, it appears to reduce subsequent morbidity from anaphylaxis.	Univ Adelaide, Womens & Childrens Hosp, Dept Pediat, Adelaide, SA 5006, Australia	University of Adelaide; Womens & Childrens Hospital Australia	Gold, MS (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Dept Pediat, 72 King William Rd, Adelaide, SA 5006, Australia.							AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; AAAI Board of Directos, 1994, J ALLERGY CLIN IMMUN, V94, P666; Bannon MJ, 1998, BRIT MED J, V316, P1591, DOI 10.1136/bmj.316.7144.1591; Boros CA, 2000, J PAEDIATR CHILD H, V36, P36, DOI 10.1046/j.1440-1754.2000.00444.x; DELAGE C, 1972, Journal of Forensic Sciences, V17, P525; Dibs SD, 1997, PEDIATRICS, V99, pE71; GRABENSTEIN JD, 1989, ANN ALLERGY, V63, P184; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; HAY GH, 1994, J SCHOOL HEALTH, V64, P119, DOI 10.1111/j.1746-1561.1994.tb03274.x; Huang SW, 1998, J ALLERGY CLIN IMMUN, V102, P525, DOI 10.1016/S0091-6749(98)70145-9; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; PATEL L, 1994, ARCH DIS CHILD, V71, P370, DOI 10.1136/adc.71.4.370; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; USHKOW MC, 1990, PEDIATRICS, V86, P999; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; 1994, CAN MED ASS J, V150, P337	18	181	184	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				171	176		10.1067/mai.2000.106041	http://dx.doi.org/10.1067/mai.2000.106041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887321				2022-12-18	WOS:000088393300023
